<SEC-DOCUMENT>0001125345-22-000013.txt : 20220224
<SEC-HEADER>0001125345-22-000013.hdr.sgml : 20220224
<ACCEPTANCE-DATETIME>20220224160603
ACCESSION NUMBER:		0001125345-22-000013
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220224
DATE AS OF CHANGE:		20220224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		22670884

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336,d:42ef1f69451b4aa1b71984b2e3189d12--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:mgnx="http://macrogenics.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8xLTEtMS0xLTE3ODUz_33f7fa5c-18c0-49e3-ac70-2bdfcc57948f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8yLTEtMS0xLTE3ODUz_23927c59-f961-41b1-b4c9-dff2279a3121">2021</ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8zLTEtMS0xLTE3ODUz_85b0df74-93dd-479d-9542-d5213cc096d5">FY</ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV80LTEtMS0xLTE3ODUz_30a5cf89-d430-4362-a1e6-b926c697119c">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i9a11109968df48d4832bc46bd0626e2d_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Nzk_1f9bb43e-2188-4db1-a2dd-eef9b62cc89b">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_14efbc58-6be4-43f5-936e-e2b8c4ab192a">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_b4c5924c-e837-4d82-8676-20ffc42a5e51">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i37eeac76fe9a4ee09f98fe9eb786de75_I20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0476cd5394264601b79261912eab342d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fec438d9ae4646875042505289ee11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5089e1becc4a40a38b3b484eab37d9b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42358bb227514ae49d829ac1733ef857_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c530cb42694976a0a5d52af3aafa8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3974741d1c498b99f8a988e3a436a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc526fcd5c54d52a90d55d37856964c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e2b21a437348b598121ecfdc9b9df4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d45dc278504512b2a1022987fc80b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c75130354f448cb0610b16a488d692_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7daedbbfe1d34ee1bdc1e20516be6dae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7e57f295ae49d897b71843458bab53_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ecb39d5f42493faf2bf88fe9d7478d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef0bb29d42b4d0eaa2df5672eae4ae7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09cc8fc3b9ea4814b48196d223df5899_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602de41a128f4eaa954138a4f48a76d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd003024ad64612a490d329efe545b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3f288834b84b7bb3fb22cda39b1f12_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6a99969335484aafa2c3d650cc7be2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b98867374514f4084ff535c13783e98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cccb6db34994ec2825d89e1e8e9e5d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0eddd478eb64a50be4d0792a14a3d43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cae1bdacdfc4c09bfd62025b0041738_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4291d4100d2946dc9a44dc34ce540d33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88b7c32e47a4e3fb38db1475b81d73d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ceff59a3256484e8c5aec6dccf28729_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf4328b36c34fe98d0cd1ccb2e9a7fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffbb346889914074ba3ec066de2f190b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73cc242d37df4e43ad348da2cdcc8786_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce9c21295c045d299c67921090a0e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i984196a6f9894e27b6e2c7d801d41348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f72f227590e4d73b71a3cd5eb786ac8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i3a42b204c7ac4b96b2efdd29380bcefb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0993f3d52a4ea094ec1edb6598a865_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf781227292741cca6941ae8752cdc90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aaf64ab813e4d7abb51d05d48d5cd9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia72da0fc0ac74829bfab2bfa1b6a4295_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e20ca944414c688558e0c138dab25f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0b50f677364cfda16e92a9660b911d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c082935f9bb4e5786832ef1a7cec74f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia780b693775f41f2b9d2b93f91aeb2c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07cde9d1e0dc435e983217063f27a631_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2c0b6722614803b9f9e8801058dcf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7342585a6dde49dc9e30b562abc13e18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363eb5f7afb94ce287279a79e80834b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d8cefe777d48e3a76bd2b84fe5dcb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1304d0f8356e4abbae5d98d9f4fa3f56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093a88a4bbf74bd3b948328faaf3d256_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94a07f241b54f1691ed49732b3c0ae1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef087b39eeb4d259811e54d29f775db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1534796b1ba49499aaf26bbdce2e184_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icca4ce8fba5d48eb8625c2cc87e156f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1fc07cd6f74785bf5181914a299bfa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacf461f8bd8944e2a1b163c0f85cfed0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a458f53b4d483d806f635005a4289f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1743997f4174cf3b7ce02d8d189ecbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e0af088a8b485681a6a2cfd9025765_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9984b5de6d4f54918b58b5fe6cf688_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dec97d172754754841a40dd976b4e22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9442a64247474df8b1461add74aaacda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i90ff6ac23bd34894869aca014c7b476d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53501799fb3d4cbf8748227063b31e3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5feac2025e8d48bf8cd74e582995d13e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51bb3e3b4fc40308c8090fc4154ddae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic810e0c6d6cc456284b6df45e6ab5613_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf78a63b685442e7a6b074034658ca90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb8128eb5c64ebb87cdd3c2321b0d5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5477c51959420fb6ada04c4079057a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaebcf345af04995bc12d851fe3ad345_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib886448527284148a9cd4abc404044c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5be726a5b24402b410d091823c143f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa3401fe2864c42a216e6ff8b3f73c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cc50a482614599917ddedb148b766e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da65abefa7a47aaa53a42be5b560258_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509383488634405f80d7cbfb16dfbcfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14aaa6274a1f4698a0529bccda6863f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7512c174d93d4b40bd56c7de25b4cc65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482c81605c314f92b439395729ec9358_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5c8da8f19745d6898a617604443be6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c95d46b9e34932876caa0130763aca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib144434d1fac45d38bcdaf750b51e786_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf993cac6f64ab8ae585d3a0284bff8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18071c232bf4c1f8935ca41ff645bb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e329af75a644cc48324b311a1c967cf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a0b84a19744f28ab6571e422cc21ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e9b541c7d14da4b142d7261904ce4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268a3aae59a84907bef761d5aed331fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48a351150ac4a5eb9e5e9dda3c114b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e6d9783b92432ea33daf8eb921627f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28a044d1dfe4d36a71c069813f7c53c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcef9e6df6fc49d8aacf159f30ee4514_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7c22c8312a430ca1abd6f404d03919_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8206a542994cf6ae5a0d5d787ddd83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045caf1d0b3b47e9a583b3518ce82462_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9141e7bbac044ed0b92ea1beb2676495_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8238c19ee74d50b77649fc0430ae5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ecd57bb740432882d856e06fb03953_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd4ac0aa4f84f12b9173dabcc85a1e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf50eeea4f84d868f237bb8d23137a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f03cac289bf4ae48981b949d7420242_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a11109968df48d4832bc46bd0626e2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02618b2ea51d4cd3af3550dd4354387c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf7adc47c73485eb154e973b4a0c805_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e033b068624ccd94d4101edb79e5d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82158f1c3e8248488d95c8b5bd40b59b_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba492058a73347a0a5489e85e2e14c17_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c67b59b55c4ed49bb7327fa669d24b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b85187757a14127bf72d33a7726047d_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35cfb96164647f3ab6265a6387a0ad6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9ef449adad42c281b17649822997df_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd4d20af737483f900bfdde13332313_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a04d0404924490b3850604be6a89bd_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia806a05d835e448d9a55bdd709901742_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc03fb113394648b6bdf6152f7f62a0_I20170518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c715158e6064e159bcab21034af9af4_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9275d7191a54f6c8cef0a06cd60f348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf57af4d358745b3b61d2a28c3928667_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b8363a661845b8b88668665eb30137_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida585248332d440d8b323582780c5460_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40eceed5a1a4f0bbac51e606900df93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd525d4970a470494f9448eb7781e63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f4b23a571a4c828aa3564e2cf02b6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6003a2136a8f46d480f8bb29b428b7cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72620f596efb4d87830df652d48d868b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a79b00742544d54ace1cbe572cc95e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15761487f3c647019105907db9a09b9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd7737654fe4891a7d522515d8d2f96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137fc423fc124b71bb9d9d0ea218086f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f48a736a74a46c48d9e72e00bec62fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95796e3e505f42ce851397ea0c19f8d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6da34d58144c65bd270cebe6dfb2e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d5f2f6af1b44ea983621a977a1a87a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6308c33e7e5b4be5b26db9579c7deaa2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b4bb09dae64bad959730c0f8dc14d8_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2378ab796454164a230b9cc2d7faa0f_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if421d26f11f845ee931133022aca115d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cd8e55dd2e43a6b2c8992d16bc68e1_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1a228424a64a95a007cd7763fe9af6_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4888039d1b4ab7aa399c1ee0fb212c_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51aa661b71304203b27532bef5a74fda_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d11f08a9b004f7386c9c4c263eb7355_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe770ef261ed4f4a9306a45bca01f142_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95774cf1200470694fcafd3bf7ec9ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if911c7bcddb24ab59739871990c63da1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5513c4a35d44bd7aa7138877117d5e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ccfbfd141f41db8e5179255ee74463_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01efa0761354d62a3103622dabffb96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ba3c13ff3547468eb072c96419c534_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf0564421e9468ba07b3edabd65d7c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d501e4822e04d958b40b530762460c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792d3a81b74946ddad05c545e411fb39_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a760482c5564290aeaf43f8d43b77eb_D20220101-20220224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5612ac4f2da44022b008ed9b0154cf3c_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90aa1101cc4c45c0970ae75b5e31eda7_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d46c300f18a459cb051be0f2ec1b59e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56a1c317b0c4eb380a90f7cf2d2edd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2e893ab41645da9ad74d3d817f1e4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc661c7a12847b8a62549a312da1610_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie768d1a8776c43debb1629980a72e2b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i190bb429937844f9815169af38df6990_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44996a78ebbc4831af9aa001839a44eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57a28be4be44c419ffec77b716c5c4f_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20708ad0030840aea94ffda954ec8390_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a115baa21f04453b29af91ceecedbd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba60bca18874586a933ffcf1f9ec4d5_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379c6fe0225946f5bfd1ba393f064bbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862de472d0f64045b43008af95f4bb59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bbffe268d44dd5869451d63139c197_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0b205b720243ee89a12573c7a8fe9d_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a1dcf4a9df4c959ddbb1934d1a6bf6_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8662ec0dbc144632a584c73f4938b548_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbbd3ca3757470f9bc0909619e0664d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0a8985fef04a7bafcbb4cc03c35452_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576f9279609e4017a60567b1d894e7c6_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="productcandidate"><xbrli:measure>mgnx:productCandidate</xbrli:measure></xbrli:unit><xbrli:context id="i3acefd7dc96d408ab172307350cf602c_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d998ab8e404b8194f6c63d78bb64bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d006afd97914c30b1c39b119a8f1fff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197aeb0afffc4bdaa28739f0f1fc2ca8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6a818854f941c79c5bc2d50e4f7fc4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafca778c80146dc9c099099f62a8ac1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cda7295203d408e87a17554ea99f6dc_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF84Ng_eca75ccf-e02e-4e35-a204-b21ad6e9da17">10-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6ODI4Y2IxZDcwMTM1NGRjZGI3ZGFjNzgxMWIyMjg1ZmIvdGFibGVyYW5nZTo4MjhjYjFkNzAxMzU0ZGNkYjdkYWM3ODExYjIyODVmYl8wLTAtMS0xLTE3ODUz_f1b9b2b3-2a47-4364-a4c5-d0ab3331b95c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjY2_e89c506a-dc7c-4210-a4fc-5c45270efaff"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjY2_c769ce5d-fd10-4478-b99d-c044e6dab483">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6YjJmMzhiZGQ1MGRkNGUyOTgzYmYwZTE2MzZkODhlZjYvdGFibGVyYW5nZTpiMmYzOGJkZDUwZGQ0ZTI5ODNiZjBlMTYzNmQ4OGVmNl8wLTAtMS0xLTE3ODUz_59062949-9d37-4fc3-bd9b-f8fee06856e9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yMTI_c012990d-f713-415f-b60d-dffeebbf2ce7">001-36112</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yMTY_0d0b0fa7-c4c1-4d4e-8b0e-a96042e32b49">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6MWIyZmUyNWM1ZGExNGIyZThhMjU4MzYwMDVmZjA4ZDAvdGFibGVyYW5nZToxYjJmZTI1YzVkYTE0YjJlOGEyNTgzNjAwNWZmMDhkMF8wLTAtMS0xLTE3ODUz_ca7f536f-f4c3-4868-af07-ca6cbcbf9d0c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6MWIyZmUyNWM1ZGExNGIyZThhMjU4MzYwMDVmZjA4ZDAvdGFibGVyYW5nZToxYjJmZTI1YzVkYTE0YjJlOGEyNTgzNjAwNWZmMDhkMF8wLTItMS0xLTE3ODUz_5c62a569-5b4f-49c2-8f83-c88b25612397">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTA_9fd5c299-3375-45bd-b937-158bd1470c24">9704 Medical Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTQ_056c871d-db0e-433f-b8ce-bac8d11c7521">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTg_9c0b4c32-145e-4e89-9687-28b29d99ea03">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNjE_bc5de91f-2025-4355-a50a-df4a49a84ea5">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjE_fd3efedc-0779-4acc-8b3f-13e8f53a4481">301</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjY_ef239f09-1091-4761-ae36-0c074e143cb0">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:37.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTAtMS0xLTE3ODUz_2ae965dc-a0f0-4e73-ab43-0e4eda72e20a">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTEtMS0xLTE3ODUz_adce99bd-e271-4230-af35-6f179e3fddec">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTItMS0xLTE3ODUz_dfe5a981-4fe5-4cc9-80db-910c30ef3064">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF82MTQ_173a87d5-1c73-436f-b446-5a27338409e4">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF83NjU_d9baa839-c747-4596-88a2-2f79ad6ff558">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMTE3_df29e8d0-28fd-4c08-aa3e-7a6b7063c598">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xNDE1_23a02177-d3e1-4cca-8ac8-26448674179d">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company"  in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:22.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM18wLTAtMS0xLTE3ODUz_9dcf8cbf-120c-4909-92ba-083b600b735d">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM18yLTQtMS0xLTE3ODUz_73f77f3a-228c-444b-8e43-89e3265a6a45">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM180LTEtMS0xLTE3ODUz_79831253-4915-44dd-b54e-47751a82a13a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zNDUz_c440217b-a9fd-4fb9-aadd-7d23e5441871">&#9745;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNDk2_c704b491-7ff4-4a98-bc50-f4d2ad49607c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF80Mzk4MDQ2NTE0NTgw_23927c59-f961-41b1-b4c9-dff2279a3121">2021</ix:nonNumeric>, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjMz_1d62b58a-6c1a-418a-bd7b-03e34049fbbd">1.6</ix:nonFraction> billion based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant's common stock outstanding on February&#160;22, 2022 was <ix:nonFraction unitRef="shares" contextRef="i37eeac76fe9a4ee09f98fe9eb786de75_I20220222" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjQz_dff2e13b-b2ba-427c-9ffc-e450d658e9da">61,324,258</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zNDU0_726adae1-7617-4a75-8c2d-07d9834d5c94" escape="true">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2022 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_16">Business</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_19">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_22">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_25">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_28">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_31">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_40">Reserved</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_70">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_73">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_76">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_79">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_82">Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_872">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_88">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_91">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_94">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_97">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_100">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_103">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_106">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_109">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_112">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_115">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_16"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MacroGenics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, the MacroGenics logo, DART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, TRIDENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and the phrases Breakthrough Biologics, Life-Changing Medicines&#174; and Developing Breakthrough Biologics, Life-Changing Medicines&#174; are our trademark</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators. These product candidates include six immuno-oncology programs, many of which were created using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Our lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is widely expressed by several different tumor types.  We are also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system&#8217;s response to cancer. Our clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and LAG-3, or lymphocyte-activation gene 3 (tebotelimab), and PD-1 and CTLA-4, or cytotoxic T-lymphocyte-associated protein 4 (lorigerlimab). In addition, we are developing MGD024, a next-generation bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML). Finally, we and our collaboration partners are developing product candidates for which we retain certain economic rights. These product candidates include IMGC936, a clinical-stage ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types; retifanlimab, an anti-PD-1 mAb that we out-licensed and teplizumab, an anti-CD3 monoclonal antibody, sold to a partner.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created our product candidates based on the following antibody-based technologies:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specific platforms, which enable us to design antibodies that can bind to two (in the case of our bispecific DART product candidates) or more distinct targets;</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fc Optimization platform, which introduces certain mutations into the Fc domain of a monoclonal antibody in order to modulate antibody interaction with immune effector cells to enhance the killing of cancer cells; and</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ADC platforms, which we have licensed from collaboration partners, and which link monoclonal antibodies that specifically target cancer cells with cytotoxins that are designed to trigger cell death in the cancer cell.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to be a fully-integrated biotechnology company leading in the discovery, development, manufacturing and commercialization of breakthrough antibody-based biologics for the treatment of patients with cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline of Immuno-Oncology Clinical Product Candidates for Which We Retain Commercial Rights</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below depicts the status of our immuno-oncology product candidates that are in clinical development and for which we retain all or some commercial rights:</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><img src="mgnx-20211231_g1.jpg" alt="mgnx-20211231_g1.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B7-H3 Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have two clinical-stage programs, MGC018 and enoblituzumab, that target B7-H3 (CD276), an immune checkpoint molecule that is overexpressed in cancer tissues while showing limited expression in normal tissues. B7-H3 belongs to the B7 family of immune regulator proteins that is widely expressed by different tumor types and may play a key role in regulating the immune response to various cancers. There are no currently approved therapeutic agents directed against B7-H3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC018 </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MGC018 is an investigational ADC with a cleavable peptide linker designed to deliver a DNA-alkylating duocarmycin payload to dividing and non-dividing cells on solid tumors that express B7-H3. The underlying ADC technology was licensed from Byondis B.V. After completing a dose escalation study in 2020, we commenced the ongoi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ng Phase 1/2 dose expansion study of MGC018 in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">metastatic castration-resistant prostate cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mCRPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">non-small cell lung cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, melanoma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">squamous cell carcinoma of the head and neck (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SCCHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">triple negative breast cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TNBC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The purpose of this ongoing study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of the molecule. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Phase 1/2 study dose expansion cohorts are fully enrolled for patients with mCRPC (n=40), and smaller cohorts (n=approximately 20 each) of patients with NSCLC, melanoma, and TNBC, while we continue to recruit patients for the SCCHN cohort.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We expect to provide details regarding further development plans in mCRPC, including a potential registration-directed study, in the first half of 2022, following interaction with regulatory agencies in the first quarter of 2022. We also plan to present additional data from the ongoing Phase 1/2 study of MGC018 in the second half of 2022. In addition, we expect to initiate a Phase 1/2 dose escalation study of MGC018 in combination with lorigerlimab </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(formerly MDG019), a bispecific monoclonal antibody designed to block PD-1 and CTLA-4, in patients with solid tumors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dose Escalation Study Results (as of May 2020)<br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, data from the dose escalation study of MGC018 was initially presented. At the May 6, 2020 data cut-off, 23 evaluable patients with advanced solid tumors had been enrolled in four dose escalation cohorts of 0.5 mg/kg to 3 mg/kg given intravenously every three weeks. Treatment was ongoing in an expanded fifth cohort of patients at 4 mg/kg every three weeks at the data cut-off date.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 6, 2020 data cut off, preliminary evidence of anti-tumor activity by MGC018 was observed in the dose escalation portion of the study, particularly in patients with advanced mCRPC. Reductions in prostate-specific antigen (PSA) levels of &#8805; 50% were observed in five of seven mCRPC patients treated, including one with substantial regression of bone disease. Six mCRPC patients had bone-only disease, and one patient with measurable peripheral disease had a 29% reduction in target lesions that did not qualify as a response per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST). Four PSA responders remained on therapy as of the data cut-off. Patients with mCRPC had received a median of four therapies prior to MGC018, including taxane chemotherapy (six patients) and next-generation hormonal agents (six patients were treated with both abiraterone and enzalutamide, and one with abiraterone only).</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through dose escalation, the safety profile of MGC018, which had included hematologic and skin toxicities, was generally manageable as of the data cut-off. At least one treatment-related adverse event (TRAE) occurred in 22 of 23 patients (96%), including Grade &#8805; 3 reported in 14 of 23 patients (61%). Three treatment-related serious adverse events occurred in one patient each: pneumonitis in a patient with concurrent bacterial pneumonia; non-infectious gastroenteritis; and stasis dermatitis in a patient with chronic venous insufficiency. One dose-limiting toxicity of Grade 4 neutropenia that resolved to baseline was reported. No febrile neutropenia was observed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 Dose Expansion Study Results (as of May 2021)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1/2 dose expansion study of MGC018 in patients with mCRPC, TNBC and NSCLC was initiated in the fourth quarter of 2020. As of the May 3, 2021 cut-off, updated clinical data from the Phase 1 study of MGC018 was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating anti-tumor activity in patients with melanoma and mCRPC. Preliminary results in the mCRPC cohort expansion showed 11 of 22 patients (50%) had a PSA reduction of 50% or greater, with anti-tumor activity observed in four of seven patients with measurable disease who had their first 9-week imaging results available, including one unconfirmed partial response. Anti-tumor activity was also reported in all three melanoma patients who received 4 mg/kg in dose escalation, with one patient achieving a confirmed partial response. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 Dose Expansion Study Results (as of August 2021)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary clinical results from the ongoing Phase 1/2 study of MGC018 in patients with solid tumors was presented at the 2021 European Society for Medical Oncology (ESMO) Meeting. As of the August 16, 2021 data cut-off, a total of 86 patients with advanced solid tumors were enrolled in the cohort expansion of MGC018 at the recommended Phase 2 dose (RP2D) of 3.0 mg/kg, administered intravenously every three weeks. The enrollment included 40 patients with mCRPC, 21 patients with NSCLC, 16 patients with TNBC and nine patients with melanoma. In addition, enrollment of patients with SCCHN had been initiated. The safety analysis included all enrolled patients, whereas the efficacy analysis was limited to mCRPC and NSCLC patients; enrollment was ongoing in the other tumor cohorts. In the cohort expansion, tumor response by investigator per RECIST was evaluated every nine weeks for all patients and PSA was assessed every three weeks in mCRPC.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the August 16, 2021 data cut-off, all 40 patients in the mCRPC cohort expansion had been enrolled. Patients had previously received a median of three prior therapies for advanced disease, with all 40 patients having received both chemotherapy and next-generation hormonal therapy. Based on an immunohistochemistry assessment of patient tumor samples, the median B7-H3 H-score (a combined score of the intensity and the proportion of B7-H3 expression, comprising values between 0 and 300) for all mCRPC patients was 223. A total of 39 mCRPC patients were evaluable for PSA response. Reductions in PSA levels of &#8805; 50% were observed in 21 of 39 patients (54%). Twenty-four of the 39 patients (62%) remained on treatment as of the data cut-off. Of the 40 patients in the mCRPC cohort, 16 of the 23 patients with measurable disease were evaluable for tumor response by RECIST as of the data cut-off. Ten of these 16 patients (63%) had reductions in their target lesion sums from baseline. Four patients (25%) demonstrated a partial response (PR), consisting of two confirmed and two unconfirmed PRs. Treatment was ongoing in six of 16 patients with evaluable tumor response as of the data cut-off.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the August 16, 2021 data cut-off, the NSCLC cohort expansion had been fully enrolled with 21 patients. Patients had previously received a median of two prior therapies for advanced disease, with 15 (71%) having previously received anti-PD-1/PD-L1 therapy. The median B7-H3 H-score for these patients was 139. A total of 16 NSCLC patients were evaluable for tumor response by RECIST. Thirteen of 16 (81%) patients had reductions in their target lesion sums from baseline. Four of these 16 patients (25%) experienced unconfirmed partial responses. Another one of these 16 patients experienced a 30% reduction in target lesions; however, the patient&#8217;s non-target lesions were not evaluated due to an obstruction of the bronchus and overall response was not evaluable. Treatment was ongoing in seven of 16 patients as of the data cut-off.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety analysis includes all 86 patients enrolled in the cohort expansion as of the August 16, 2021 data cut-off. The median number of doses received by mCRPC patients was 3.5 (range: 1-8); those with NSCLC received 3.0 (range: 1-7). Adverse events for the dose expansion cohorts of 3 mg/kg were generally consistent with those previously reported at ASCO 2021. TRAEs included hematologic and skin toxicities that have been clinically manageable to date. In the cohort expansion study overall, at least one TRAE of any grade was experienced by 78 of 86 patients (91%), with 43 of 86 patients (50%) experiencing a Grade &#8805;3 TRAE.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were two Grade 5 fatal events: one from an unknown cause and one due to SARS-CoV-2.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common TRAEs were fatigue (37% all grades; 1% Grade &#8805;3), neutropenia (34% all grades; 22% Grade &#8805;3), palmar plantar erythrodysesthesia syndrome (31% all grades; 4% Grade &#8805;3), pleural effusion (23% all grades; 1% Grade &#8805;3), nausea (22% all grades; 1% Grade &#8805;3), asthenia (20% all grades; 5% Grade &#8805;3) and thrombocytopenia (14% all grades; 7% </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grade &#8805;3). The overall results demonstrated a manageable safety profile with a low rate of treatment discontinuation due to TRAEs: only six of 86 (7%) patients had discontinued therapy in the cohort expansion as of the data cut-off date due to TRAEs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enoblituzumab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 that has been engineered using our Fc Optimization platform. We are currently evaluating enoblituzumab in combination with checkpoint molecules in patients with SCCHN in an ongoing Phase 2 study. The combination of enoblituzumab and immune checkpoint blockade is designed to engage innate and adaptive immunity to enhance tumor cell killing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We had initially conducted a Phase 1b/2 clinical study combining enoblituzumab and pembrolizumab, an anti-PD-1 monoclonal antibody, in patients with B7-H3-expressing melanoma, SCCHN, NSCLC and urothelial cancer. A total of 133 patients were treated in the study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As presented in November 2018 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, in the SCCHN dose expansion cohort, confirmed PRs were observed in 6 of 18 (33%) patients evaluable for response who had not previously received anti-PD-1 or anti-PD-L1 therapy. For the subset of patients with B7-H3 tumor expression &#8805; 10%, 6 of 15 (40%) had confirmed PRs. Objective response rates (ORRs) ranging from 13% to 16% have previously been reported in SCCHN patients treated with anti-PD-1 agents alone. The combination of enoblituzumab and an anti-PD-1 monoclonal antibody demonstrated acceptable tolerability, with any adverse event &#8805; Grade 3 occurring in 27.1% of patients as of the October 12, 2018 data cut-off date. The rate of immune-related adverse events experienced in the trial was comparable to that historically observed by others in patients who received pembrolizumab as monotherapy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further inform the development of enoblituzumab, we initiated a Phase 2 study of this agent in patients with relapsed or metastatic SCCHN not curable by local therapy in the first quarter of 2021. This trial includes enoblituzumab in a chemotherapy-free regimen in combination with either retifanlimab, an anti-PD-1 antibody, in patients who are programmed death-ligand 1 (PD-L1) positive or with tebotelimab, a bispecific checkpoint targeting both PD-1 and LAG-3, in patients who are PD-L1 negative. We expect to complete enrollment of the PD-L1 positive patient cohort during the first half of 2022 and provide an update on this cohort during the second half of 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we licensed the right to develop and commercialize enoblituzumab in mainland China, Hong Kong, Macau and Taiwan to I-Mab Biopharma (I-Mab). I-Mab plans to both lead regional studies in its territories as well as participate in global studies conducted by us. In December 2021, I-Mab announced that the Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) approved its Investigational New Drug (IND) submission for the initiation of a Phase 2 trial in China for enoblituzumab in combination with pembrolizumab in patients with solid tumors, including NSCLC, urothelial carcinoma and other selected cancers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">T-cell Redirected Bispecific DART Molecules</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a bispecific DART molecule that can simultaneously target T-cells and tumor cell surface antigens to engage and promote redirected T-cell killing of cancer cells. CD123, the interleukin-3 receptor alpha chain, is widely overexpressed in various hematologic malignancies, including AML and myelodysplastic syndrome (MDS), making it an attractive therapeutic target. Various drugs have been developed to target CD123, but none have received U.S. Food and Drug Administration (FDA) approval. We have created two bispecific DART molecules that engage CD3 expressed on immune effector cells, such as T cells, to kill CD123-expressing cancer cells for the potential treatment of certain hematologic malignancies, including AML. One of these DART molecules, flotetuzumab, is being discontinued due to reprioritization to more efficiently utilize our financial and human resources to focus on the next-generation version of the molecule, MGD024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MGD024</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGD024 is an investigational, next-generation, bispecific CD123 &#215; CD3 DART molecule designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. In December 2021, we presented preclinical MGD024 data at the American Society of Hematology (ASH) Annual Meeting that showed the potential for anti-tumor activity from the combination of MGD024 with standard of care agents used to treat AML. We submitted an IND to the FDA for MGD024 in the fourth quarter of 2021, and plan to initiate a Phase 1 study of MG024 in patients with hematologic malignancies, pending IND clearance by the FDA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Flotetuzumab</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flotetuzumab is an investigational bispecific, humanized DART molecule that recognizes both CD123 and CD3. In a single-arm study evaluating flotetuzumab, our first generation, continuous infusion CD123 x CD3 DART molecule, in AML patients who were refractory to induction therapy, activity looked promising with manageable safety. Nonetheless, we recently decided to prioritize the development of MGD024 and discontinue development of flotetuzumab, in view of our belief that MGD024 may offer certain advantages over flotetuzumab, including easier dose administration and the ability to be combined with other agents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immune Checkpoint Inhibitors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Checkpoint inhibition has become an important staple of oncology. Our clinical pipeline includes three product candidates in clinical development that target checkpoint molecules for the potential treatment of a broad range of solid tumors. These candidates include two bispecific DART product candidates that co-engage PD-1 and other checkpoint molecules and an anti-PD-1 monoclonal antibody that we have out-licensed to a partner.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lorigerlimab (formerly MGD019)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved monoclonal antibodies that target the immune checkpoints PD-1 and CTLA-4 have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and NSCLC with high tumor mutational burden. Lorigerlimab is an investigational, bispecific tetravalent DART molecule designed to enable simultaneous and/or independent blockade of PD-1 and CTLA-4, with potentially enhanced CTLA-4 blockade on T cells co-expressing these immune checkpoint molecules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are conducting a Phase 1/2 clinical trial of lorigerlimab in patients with advanced solid tumors. The study is designed to enroll patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no approved therapy with demonstrated clinical benefit is available or patients who are intolerant to standard therapy. Forty-three patients were enrolled in the 3+3+3 dose escalation study within a dose range of 0.03 &#8211; 10.0 mg/kg, administered every three weeks initially, in a population of heavily pre-treated patients representing a broad range of different types (23) of solid tumors. A total of 28 patients were treated at doses &#8805; 3.0 mg/kg administered every three weeks initially. Of the 18 evaluable patients who received doses &#8805; 3.0 mg/kg as of the July 21, 2020 cut-off date, four objective responses were reported, including a confirmed complete response in mCRPC, confirmed PRs in microsatellite stable colorectal cancer (MSS CRC) and metastatic type AB thymoma, and an unconfirmed PR in serous fallopian tube carcinoma. Lorigerlimab was well-tolerated in patients who received less than 10 mg/kg. The most common TRAEs observed were pruritus (23.3%), arthralgia (18.6%), fatigue (18.6%), rash (18.6%), nausea (16.3%) and infusion-related reaction (16.3%) as of the data cut-off. Several Grade 3 adverse events were observed at the 10.0 mg/kg level; however, none were considered dose limiting.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this study, full and sustained peripheral PD-1 blockade was evident at doses &#8805; 1.0 mg/kg over a 3-week dosing interval. In addition, dose-dependent upregulation of the inducible costimulator (ICOS) molecule was evident in treated patients, including those who responded to lorigerlimab therapy. This is consistent with an observation previously reported in the literature that anti-CTLA-4 therapy increases the frequency of CD4 T cells expressing the ICOS molecule.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating lorigerlimab in a Phase 1/2 dose expansion study in patients with MSS CRC, mCRPC, melanoma and checkpoint-naive NSCLC at a dose of 6.0 mg/kg, based on data from dose escalation, and expect to provide an update on this study in the second half of 2022. We also expect to initiate a Phase 1 dose escalation study of MGC018 and lorigerlimab in patients with solid tumors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tebotelimab</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tebotelimab is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. We have engineered tebotelimab to concomitantly or independently bind to PD-1 and LAG-3 and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. Tebotelimab was evaluated in a Phase 1/2 dose expansion study in several tumor types and is currently being studied in combination with enoblituzumab in SCCHN. We expect to provide an update on potential future development plans for tebotelimab in the second half of 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, initial data was presented from a Phase 1 study in which 53 patients with advanced tumors were treated with tebotelimab given intravenously in cohorts of escalating flat doses of 1-1200 mg every two weeks. A maximum tolerated dose was not identified. A flat dose of 600 mg every two weeks was selected for tumor-specific expansion cohorts. At the April 25, 2020 data cut-off, 205 patients with advanced solid and hematologic neoplasms had been treated with tebotelimab monotherapy in the ongoing dose-expansion part of the study, of which 152 were evaluable for response. Anti-tumor activity was assessed by RECIST.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Anti-tumor activity of tebotelimab as monotherapy was observed in evaluable patients across several of the tumor types in the selected dose expansion cohorts. ORRs, including both confirmed and unconfirmed responses, and disease control rate (DCR), comprising both confirmed objective responses and stable disease, were observed as follows: TNBC (17% ORR, 4 of 23 patients; 39% DCR, 9 of 23 patients), epithelial ovarian cancer (9% ORR, 2 of 23 patients; 52% DCR, 12 of 23 patients) and NSCLC (checkpoint inhibitor na&#239;ve: 21% ORR, 3 of 14 patients; 64% DCR, 9 of 14 patients; and post anti-PD-1: 13% ORR, 2 of 15 patients; 53% DCR, 8 of 15 patients). Response to tebotelimab monotherapy was associated with LAG-3 expression and an IFN-&#947; gene signature at baseline. The overall safety profile of tebotelimab in the Phase 1 study, including the incidence of immune-mediated adverse events, appeared generally consistent with anti-PD-1 antibody monotherapy with respect to event type and frequency.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immune effector cell activation and LAG-3, PD-1 and PD-L1 expression has been shown to be enhanced in vitro by Fc-engineered margetuximab. An expansion cohort of patients with advanced HER2-positive tumors was treated with margetuximab plus tebotelimab to evaluate whether Fc-engineering can enhance tumor responsiveness to checkpoint blockade and improve clinical outcomes in patients.  In November 2020, updated data was presented from the combination study of tebotelimab and margetuximab in patients with advanced HER2-positive neoplasms.  In this study, 41 patients had been enrolled. As of the October 5, 2020 data cut-off, there were 28 response-evaluable patients. Evidence of antitumor activity was observed among refractory patients with various HER2-positive tumor types, including eight objective responses (six confirmed) observed in multiple advanced HER2-positive tumor types. The ORR (including unconfirmed responses) was 28.6%, while 64.3% of response-evaluable patients experienced a decrease in target lesion tumor burden. The duration of response for confirmed responders was 4.21&#8211;8.97 months, with three patients remaining on treatment as of the data cut-off. Of particular interest, a majority of responding patients had a baseline PD-L1 combined positive score (CPS) &#8804; 1.  All responding patients carried the less favorable CD16A-158F allotype (i.e., V/F or F/F). Evaluation of baseline LAG-3 and PD-1 mRNA expression and potential association with clinical response analyses are ongoing, and will be important for defining patient enrichment biomarker strategies for further development. The combination of tebotelimab and margetuximab was generally well tolerated, with a safety profile consistent with that of tebotelimab monotherapy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, data was presented from the ongoing tebotelimab Phase 1/2 dose expansion study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). LAG-3 has been shown to be highly expressed in DLBCL and has emerged as a therapeutic target of interest in this population, while PD-1-targeted therapy has yielded modest efficacy. There remains significant unmet need for patients with relapsed/refractory (R/R) DLBCL. In this study, 20 DLBCL patients were enrolled, half of whom were chimeric antigen receptor (CAR) T cell therapy experienced. As of the October 23, 2020 data cut-off, there were 13 response-evaluable patients. A preliminary ORR of 53.8% (7 of 13 patients) was observed, including responses in five of seven CAR T cell-na&#239;ve patients and in two of six CAR T cell experienced patients, the latter of whom both had complete responses. A preliminary duration of response of up to 168 days was observed, with six of seven ongoing responses as of the cut-off date. In the study, baseline LAG-3 expression appeared to associate with clinical response, with additional analyses ongoing. Tebotelimab was generally well-tolerated among heavily pre-treated R/R DLBCL patients, with manageable infusion-related reactions and no evidence of tumor lysis syndrome. The most common TRAE was pyrexia, which occurred in three (15%) patients. A single Grade 3 TRAE of anemia was observed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our November 2018 license and collaboration agreement with Zai Lab Limited (Zai Lab), we licensed to them the right to develop and commercialize tebotelimab in mainland China, Hong Kong, Macau and Taiwan. Zai Lab has led regional studies evaluating tebotelimab in various indications in its territory. Zai lab recently informed us that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Margetuximab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our commercial partner, Eversana Life Science Services, LLC (Eversana), are currently marketing MARGENZA (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Margetuximab is an Fc-engineered, mAb that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our November 2018 license and collaboration agreement, Zai Lab has the rights to develop  margetuximab in mainland China, Hong Kong, Macau and Taiwan. On January 6, 2022, Zai Lab announced that the China NMPA had accepted the New Drug Application (NDA) for margetuximab for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease, in combination with chemotherapy.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on results from an earlier study combining margetuximab and pembrolizumab, an anti-PD-1 mAb, in patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) who had previously been treated with chemotherapy and trastuzumab, we initiated the MAHOGANY study in September 2019. This was a Phase 2/3 registration-directed clinical trial to evaluate, in Module A, margetuximab in combination with retifanlimab, an anti-PD-1 mAb, in patients with tumors that were both HER2 IHC3-positive and PD-L1 positive. This approach was designed as a chemotherapy-free regimen intended to engage both innate and adaptive immunity for the treatment of patients with gastric cancer (GC) or gastroesophageal junction (GEJ) cancer in the first-line setting.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we presented data from Part 1, Module A of the Phase 2/3 MAHOGANY clinical trial of margetuximab at the 2021 ESMO Virtual Conference. The efficacy data and safety cutoff dates were July 19 and August 3, 2021, respectively. Tumor shrinkage was observed in 32 of 41 patients (78%) with at least one post-baseline target lesion measurement. Twenty-one of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for the trial. Median duration of response was 10.3 months as of data cutoff. Margetuximab plus retifanlimab was well tolerated with Grade 3 TRAEs in 19% of patients; no Grade 4 TRAEs or treatment-related deaths. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the results from the initial portion of Module A of this trial were encouraging, we subsequently decided and announced in November 2021 to prioritize other pipeline product candidates and not proceed with the next phase of this trial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Zai Lab has decided to discontinue enrollment of Module B of the MAHOGANY study based on their review of both the clinical data and the changing treatment landscape.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Partnered Programs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retifanlimab</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retifanlimab is an investigational mAb targeting PD-1. Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" of the immune system and helping to restore the immune system's ability to detect and kill tumor cells. In 2017, we licensed retifanlimab to Incyte Corporation (Incyte) under a global collaboration and license agreement, although we retain the right to develop the molecule in combination with product candidates from our pipeline. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its BLA for retifanlimab. Incyte&#8217;s announcement indicated that the FDA determined that additional data were needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of SCAC. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond SCAC, including in patients with microsatellite instability-high, or MSI-high, endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we&#8239;initiated a Phase 2 study of enoblituzumab in a chemotherapy-free regimen in combination with retifanlimab in front-line SCCHN patients who are PD-L1 positive and with tebotelimab in SCCHN patients who are PD-L1 negative.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">IMGC936</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMGC936 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types. IMGC936 is being advanced under a co-development agreement with ImmunoGen, Inc. (ImmunoGen).  Under the 50/50 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration, ImmunoGen is leading clinical development and the Phase 1 dose escalation study is currently enrolling patients with select advanced solid tumors and ImmunoGen has indicated they anticipate disclosing initial data in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teplizumab </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an asset purchase agreement with Provention Bio, Inc. (Provention) pursuant to which they acquired our interest in teplizumab, a monoclonal antibody we had been developing for the treatment of type 1 diabetes. Teplizumab has been granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines (PRIME) designation by the European Medicines Agency. We are entitled to received future milestones payments and royalties on net sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Provention announced that a BLA for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals had been filed by the FDA, which granted Provention's request for Priority Review. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D in the Phase 3 PROTECT study, which has been fully recruited. Provention has indicated that it expects to report top line data from the Phase 3 PROTECT study in the second half of 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2021, the FDA issued a CRL for teplizumab&#8217;s BLA for the delay of clinical T1D in at-risk individuals. The CRL did not cite any clinical deficiencies related to the efficacy and safety data packages submitted to the BLA. However, pharmacokinetic (PK) drug product comparability considerations remain outstanding, according to a statement released by Provention. In September 2021, Prevention disclosed that it had completed the collection of data from a PK/pharmacodynamic (PD) sub-study in the ongoing PROTECT Phase 3 trial in newly diagnosed T1D patients. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Provention announced that teplizumab was awarded an Innovation Passport for the delay of clinical T1D in at-risk individuals. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, Provention announced that it had resubmitted the BLA for teplizumab for the delay of clinical T1D in at-risk individuals. Provention indicated that the purpose of the resubmission was to address the FDA's PK comparability considerations contained in the CRL, as well as the CRL's Chemical, Manufacturing, and Controls (CMC) and product quality considerations. The BLA resubmission followed Provention&#8217;s Type B meeting with the FDA earlier in the year.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRV-3279 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we also entered into a license agreement with Provention pursuant to which we granted them exclusive global rights for the purpose of developing and commercializing PRV-3279 (formerly MGD010), a CD32B &#215; CD79B DART molecule being developed for the treatment of autoimmune indications. Provention is initially developing PRV-3279 for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder characterized by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies. Provention has disclosed that it believes PRV-3279 also has the potential to prevent or reduce the immunogenicity of biotherapeutics, including but not limited to gene therapy vectors and transgenes. In January 2022, Provention announced the initiation of the Phase 2a PREVAIL-2 study of PRV-3279 in SLE patients. Provention has indicated that it expects to report data from PREVAIL-2 in the first half of 2024.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIV DART Molecules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing MGD014 and MGD020 under a contract awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. These bispecific DART molecules are designed to target the viral envelope (Env) protein of human immunodeficiency virus (HIV) infected cells and CD3 on T cells to redirect the immune system's T cells to kill HIV-infected cells. These molecules may become a key part of a strategy to reduce or eliminate latent HIV reservoirs in conjunction with latency-reversing agents currently under development. MGD014 and MGD020 target the gp120 and gp41 subunits of HIV Env, respectively. A Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy has been completed and a Phase 1 study of MGD020 alone and combined with MGD014 will initiate in 2022. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Therapeutic Area Focus: Cancer</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell division or proliferation that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. An increasing number of people are also living longer with cancer. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platforms and Technology Expertise</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets: (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined to address the complex biology of cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule from our DART platform is illustrated below:</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20211231_g2.jpg" alt="mgnx-20211231_g2.jpg" style="height:208px;margin-bottom:5pt;vertical-align:text-bottom;width:466px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms of action, including those set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:10pt">Redirected T cell activation and killing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In this version of the DART molecule, we are engaging the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to proteins expressed on a cancer cell, or tumor associated antigens (e.g., CD123), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, given the design of a DART molecule, since any T cell could be recruited for this killing process, relatively small amounts of a DART molecule may be required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Our DART molecules that redirect T cells against cancer or other targets, including MGD024, are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as CAR T cells. We have continued to evolve our bispecific platform with the introduction of a next-generation CD3-engaging DART technology designed to recruit, engage and activate T cells to kill tumor target cells with reduced release of pro-inflammatory cytokines. This next-generation CD3 DART platform is aimed at addressing cytokine-release syndrome, the most frequent and often dose-limiting adverse event associated with CD3-engaging molecules. We believe the next-generation CD3 DART platform could expand the therapeutic window of CD3-engaing DART molecules and further increase their potential application in oncology.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mgnx-20211231_g3.jpg" alt="mgnx-20211231_g3.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="mgnx-20211231_g4.jpg" alt="mgnx-20211231_g4.jpg" style="height:334px;margin-bottom:5pt;vertical-align:text-bottom;width:183px"/></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing specific product candidates using this technology, including lorigerlimab, MGD024, tebotelimab, and MGD014 in clinical trials, as well as others in preclinical development. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens. Product candidates using this technology are currently in preclinical development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity (ADCC).</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADCC</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><img src="mgnx-20211231_g5.jpg" alt="mgnx-20211231_g5.jpg" style="height:185px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have successfully incorporated our Fc variants in two of our antibody-based molecules, margetuximab and enoblituzumab. In vitro, the modified Fc region of margetuximab increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitor Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation. The clinical significance of in vitro data is unknown.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and plan to continue to do so. We enter into collaborations when there is a strategic advantage to us and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.  In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (USPTO) filings for any applications by third parties that may infringe on our patents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Patent Protection</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we held 88 patents in the United States with 46 patent applications pending and 814 patents in other countries of the world with 569 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or Product Candidate</span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">margetuximab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">enoblituzumab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">retifanlimab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tebotelimab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lorigerlimab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039*</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* pending</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension and Reference Product Exclusivity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we have applied or expect to apply for patent term extensions on patents covering those products. We intend to seek, and are seeking, patent term extensions to our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect these provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Intellectual Property</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our clinical product candidates. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture drug substance for most of our clinical trials at our manufacturing facilities located in Rockville, Maryland. We also rely on contract manufacturers, primarily Byondis, for production components of one of our ADC candidates. We have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc. (AGC, formerly CMC Biologics, Inc.), a contract manufacturing organization, and commercially produced initial margetuximab commercial supply and inventory at AGC. In October 2021, the FDA approved the BLA supplement to add our commercial manufacturing site at 9704 Medical Center Drive in Rockville, Maryland as a licensed manufacturing site for margetuximab drug substance. We intend to commercially produce material for MARGENZA, as well as our and partner&#8217;s product candidates when and if approved by the FDA. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Bio-Pharma Services and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier or general national supply chain disruption, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA is currently our only approved product in the U.S. In November 2020, we partnered with Eversana, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the U.S. by leveraging their integrated commercial services. Under the terms of the agreement, we maintain ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. Eversana received a co-exclusive right to conduct approved commercialization activities. Eversana utilizes its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services; we book MARGENZA sales. We and Eversana equally share in funding Eversana&#8217;s commercialization expenses. In exchange for co-funding these expenses, Eversana is eligible to earn future revenue share payments which shall be capped at 125% of Eversana&#8217;s cumulative service fees. The term of the agreement is five years following the date of FDA approval, subject to predefined termination provisions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market through arrangements with third-party commercial partners. Other than through our arrangement with Eversana for MARGENZA, we have not established a sales, marketing or distribution capabilities. If we are unable to enter into third-party commercial arrangements for other product candidates with respect to the United States, we believe that we could potentially put in place an appropriately sized organization to commercialize our approved product or products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">particular, MARGENZA is directed against HER2 and many companies have cancer therapeutics directed against HER2 that are either currently approved and on the market or may be in development, such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo Company, Limited and AstraZeneca plc. (AstraZeneca), Seagen Inc., Zymeworks, Inc., </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shanghai Hengrui Pharmaceutical, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and Byondis, many of which have significantly greater resources than we do. Market competition has limited the utilization of MARGENZA as a therapeutic, and these competitors as well as biosimilar trastuzumab competition may limit such utilization in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the immuno-oncology field is competitive, with treatments currently approved and, on the market, or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc. (Merck), The Bristol-Myers Squibb Company (BMS), and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing PD-1-directed product candidates, including a monoclonal antibody that we have outlicensed and two DART molecules. Merck, BMS, Roche, AstraZeneca, Pfizer Inc., Merck KGaA, and Regeneron Pharmaceuticals, Inc. all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs. In addition, these and other companies are developing product candidates directed against other immuno-oncology targets that we are pursuing through our bispecific approaches.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie Inc., Affimed N.V., Eli Lilly and Company, Genmab A/S, Merus B.V., Regeneron, Roche, AstraZeneca, Xencor, Inc. and Zymeworks, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, trastuzumab biosimilars have been approved in the U.S. by the FDA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, pricing, reimbursement, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA as biological products (biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practice (GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND application is cleared and the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials involve the administration of the investigational drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and the FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board (IRB) and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual program user fees also apply. These fees are typically increased annually.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the PDUFA begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. The FDA's current performance goals call for the FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of filing and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline. In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally gives significant deference to such recommendations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect one or more clinical sites and possibly the sponsor itself  to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current Good Manufacturing Practices (cGMPs) is satisfactory. The FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when deficiencies outlined in a complete response letter have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Post-Marketing Regulatory Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMPs, as well as registration, listing, and inspection. There also are continuing, annual program user fee requirements for marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. The FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with post-marketing requirements can result in one or more of the following consequences:</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation,  and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products. There are regular legislative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposals to rescind or reduce the biologics exclusivity provisions of the ACA and it is uncertain whether or if any of those proposals may be approved, and if approved, how exclusivity for biologics would be affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations,guidance or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such anti-kickback laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third party payers (including Medicare and Medicaid) that are false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and/or exclusion from federal health care programs (including Medicare and Medicaid).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures.  Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalty provisions of the pertinent laws and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union (EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements. A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, we must submit a marketing authorisation application (MAA). The content of the MAA is similar to that of a New Drug Application or BLA filed in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorisation applications either under a centralised or decentralised procedure. Under the centralised procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorisation by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPharmaceutical Coverage, Pricing, and Reimbursement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available or optimal for our products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain government or Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the marketplace that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 427 full-time employees, 355 of whom were primarily engaged in research, development and manufacturing activities, and 77 of whom had an M.D. and/or Ph.D.   Our employees are critically important to the achievement of our company&#8217;s mission and goals. We periodically conduct employee engagement surveys to understand our employees&#8217; perspectives and endeavor to listen, change and improve on how we work together in response to these perspectives. We face significant competition for experienced and talented individuals in our area due to the growth of local companies. We monitor our compensation, benefits, and exit interview data and make changes as needed to enable the ongoing recruitment and selection of talented new employees, as well as to retain existing talent. We strive to offer our employees an intellectually challenging and diverse work environment, opportunities to expand their knowledge and skills, to  receive feedback on performance, and for career advancement. Our Living Values, which focus on patients, honest and transparent communications, innovation, ethics, collaboration, our sense of urgency, getting results, and valuing diversity and striving for inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set the tone for how we work together.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We empowered a cross-functional team in the early days of the ongoing pandemic to recommend safety protocols, ensure timely communications, and make decisions related to the effect of COVID-19 on our employees and work environment. We believe management&#8217;s relationships with our employees is very positive and they are not subject to a collective bargaining agreement or represented by a trade or labor union.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The discussion below addresses material factors, of which we are currently aware, that could have a material and adverse effect on our business, results of operations and financial condition. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. These risk factors and other forward-looking statements that relate to future events, expectations, trends and operating periods involve certain factors that are subject to change, and important risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties should not be considered a complete discussion of all the risks and uncertainties we may face and although the risks are organized by headings and each risk is discussed separately, many are interrelated. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors Affecting Our Business </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following summary highlights some of the risks you should consider with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. You should review and consider carefully the risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, which includes a more complete discussion of the risks summarized below as well as a discussion of other risks related to our business and an investment in our common stock, as well as our other SEC filings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including MGC018. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of MGC018 and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and to date has not resulted in revenues sufficient for us to reach profitability.  Accordingly, we may never achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials for our product candidates are prolonged, delayed or stopped for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current or planned clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration (FDA) or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved or may not approve products that utilize these technologies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MGC018, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of MGC018, MARGENZA and our product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production.  There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture  commercial quantities of MARGENZA, or other products or product candidates, if and when approved. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The current or future impact of the COVID-19 (or any variant thereof) pandemic may have significant negative impact on our clinical trials, preclinical studies, development, manufacturing and commercialization of our product and product candidates and other aspects of our business, staff, and operations. The extent to which the COVID-19 pandemic, both now and in the future, adversely affects our financial condition, results of operations, and liquidity, will depend on future developments, including but not limited to the measures taken by public and private entities in response to the pandemic, which remain highly uncertain and cannot be predicted. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing our internally developed products. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of health care items and services. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement decisions by third-party payors, including government payors, may have an adverse effect on pricing and market acceptance. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with, and may in the future contract with, third parties for the distribution and commercialization of MARGENZA and our other product candidates. Failure of third-party contractors to successfully perform their obligations for commercialization, distribution, or other services could harm out ability to commercialize our product or product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including MGC018. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on the successful development, regulatory approval and commercialization of our products and product candidates, including MGC018. We have invested and will continue to invest a significant portion of our efforts and financial resources in the development of our product candidates, including MGC018. The success of our products and product candidates depends on many factors, including but not limited to: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in, and completion of, clinical trials, as well as completion of preclinical studies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and favorable efficacy and acceptable safety data from our clinical trials and other studies</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our financial resources and ability to obtain additional funding for the development of our products and product candidates;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance by clinical research organizations (CROs) or other third parties we may retain of their duties to us in a manner that complies with our protocols and applicable laws and that protects the integrity of the resulting data; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual property rights of third parties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching our product candidates, including MGC018, if and when approved; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining commercial manufacturing capabilities, either by utilizing our current manufacturing facilities or making arrangements with third-party manufacturers; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or obtaining sufficient supplies of our products and product candidates that may be necessary for use in clinical trials for evaluation of our product candidates and commercialization of our products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable reimbursement from third-party payors for products and product candidates;  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments to regulatory agencies following regulatory approval; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile following regulatory approval.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of MGC018 and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. For example, in November 2021, we announced the discontinuation of Cohort A of the MAHOGANY trial for margetuxumab in gastric cancer, </span><span style="color:#293849;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on a number of factors, including the prioritization of&#160;our other product candidates given the competition in this indication, and the FDA&#8217;s approval of competing combination therapy with pembrolizumab. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborator Incyte submitted a BLA for retifanlimab in January 2021 and in July 2021, received a Complete Response Letter (CRL) from the FDA regarding its BLA. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in October 2021, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier preclinical studies or clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from preclinical studies and clinical trials sufficient or meaningful; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our collaborators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, or designing clinical trials for molecules that include MGC018, lorigerlimab, enoblituzumab, retifanlimab, tebotelimab, IMGC936 and MGD024 as monotherapies or in combination with other product candidates. In addition, Incyte is currently enrolling patients in clinical trials for retifanlimab, and other collaborators outside the United States are developing our product candidates. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain institutional review board (IRB) approval to conduct a clinical trial at a prospective site; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition of product candidates that are expected to be more effective or have a more favorable safety profile; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of potential combination therapies by competitors.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials could also be substantially delayed or prevented by many factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict;</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time. For example, the Investigational New Drug (IND) submission for MGD024 announced in November 2021 has not yet been accepted by the FDA while we address their comments on the submission. The trial start is on hold, pending alignment with the FDA. We believe we are able to address the FDA&#8217;s comments and the MGD024 IND submission will be accepted for filing. A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of MARGENZA and our product candidates in the U.S. or in other jurisdictions. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products in development are based on our technology platforms, including Fc Optimization, DART and TRIDENT technologies. Given the novelty of these technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. Even though MARGENZA, which incorporates an Fc variation created using our Fc Optimization platform, was approved by the FDA, there is no assurance that the FDA will approve future product candidates using such technology. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our technology platforms to continue to build a pipeline of product candidates and progress several of these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for initial or continued clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC018, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC018, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. For example, revenues from MARGENZA are unlikely to enable us to reach profitability.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If product candidates that we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance  of any product candidates that we develop will depend on a number of factors, including but not limited to: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; any safety events that may have occurred in connection with the development of the product candidate; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe the product or other new therapies, and of the patient population to try the product or these therapies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales, and distribution support; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product&#8217;s market acceptance depends significantly on the medical community&#8217;s determination of clinical benefit and safety compared to alternative therapies available both now and in the future. For example. several new therapies for the treatment of HER2-positive breast cancer have recently been approved. Certain of these therapies may have or may be perceived to have greater efficacy benefits than MARGENZA in clinical trials. Competition from recently approved therapies has and may adversely impact the market acceptance of MARGENZA. In particular, final overall survival (OS) endpoint data from the SOPHIA trial analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab.  This OS data may adversely affect the market acceptance of MARGENZA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential market opportunities for our product candidates  are difficult to precisely estimate. Our internal estimates of the potential market opportunities for MGC018 and our other product candidates include several key assumptions based on a variety of factors, which may include our industry knowledge, industry publications, third-party research reports, assessment of competition, and other surveys. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of these assumptions proves to be inaccurate, then the actual market for MGC018, our other product candidates could be smaller than our estimates of our potential market opportunity.  </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8239;Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or preclinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others later identify undesirable or unacceptable side effects caused by such products: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity. Further, based on the identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA&#8217;s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA&#8217;s acceptance in the market. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the FDA&#8217;s current Good Manufacturing Practices (cGMP) requirements, as set out in statute, regulations and interpreted through guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product or product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product or product candidates, including leading to significant delays in the availability of drug product for sale and our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation or negatively impact a product&#8217;s commercial success. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of MGC018, MARGENZA and our other product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of MARGENZA, or other products or product candidates, if and when approved.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture  product and  product candidates for ourselves and our collaborators in our in-house manufacturing facilities, and we anticipate manufacturing both commercial product as well as product candidates in the future, including for example commercial manufacturing of MARGENZA.  We have limited experience in manufacturing at commercial scale. The process of commercial or clinical biotechnology manufacturing for ourselves and our collaborators is highly susceptible to delays or product loss due to a variety of factors, including but not limited to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, difficulties in scaling the production process, and vendor supply chain disruptions or fluctuations. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in MARGENZA and our product candidates or in the manufacturing facilities in which MARGENZA and our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for MARGENZA and our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, if we fail to supply required quantities of MARGENZA or a product candidate for one of our collaborators, our collaborator may terminate our agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on third parties to manufacture certain components of our products or product candidates.  See risk factor &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with, and may in the future contract with, third parties for components of the manufacturing of MARGENZA and our other product candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. If there were to be a catastrophic event or failure of our manufacturing facilities or processes, we may be unable to meet our requirements for supply of MARGENZA and our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The current or future impact of the COVID-19 (or any variant thereof) pandemic has had, and may continue to have, significant negative impact on our clinical trials, preclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations. The extent to which the COVID-19 pandemic, both now and in the future, adversely affects our financial condition, results of operations, and liquidity, will depend on future developments, including but not limited to the measures taken by public and private entities in response to the pandemic, which remain highly uncertain and cannot be predicted. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks has, and may continue to have, a material impact our business. The COVID-19 pandemic and its variants continue to evolve, and to date have led to the implementation of various responses, including government-imposed quarantines, work and travel restrictions and other public health safety measures at the federal, state and local levels. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of the COVID-19 pandemic has had, and may continue to have, a material impact on our clinical trials, preclinical studies, commercialization efforts, manufacturing and development of our product candidates and other aspects of our business, staff, and operations, which in turn may impact our financial condition, results of operations and liquidity. For instance, the COVID-19 pandemic impaired our ability to enroll patients in clinical trials, continue ongoing clinical trials or activate clinical trial sites, and MARGENZA commercialization, due to, for example, heightened exposure to COVID-19 if an outbreak occurs in a specific geography, the shifting of healthcare resources toward the pandemic or the closing of or limiting of access to clinical facilities, and reduced or eliminated in-person access to physicians and health care centers. Furthermore, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial protocols if COVID-19 related restrictions impede patient movement or interrupt healthcare services. Government-imposed quarantines and other restrictions may also require us to temporarily suspend activity at our clinical sites. The COVID-19 pandemic may also negatively affect the operations of third-party CROs that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact the COVID-19 pandemic has had, or will have, on patient enrollment or treatment or the timing and execution of our clinical trials could cause delays to our clinical trial activities, which could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the COVID-19 pandemic has increased the risk that a portion of the workforce, including ours, may suffer illness or otherwise be unable or unwilling to work due to close contact related precautions or due to choosing not to comply with vaccine mandates for healthcare workers. To date, we have seen limited business impact from COVID-19 related absences, but there can be no assurance that there will not be additional or significant employee COVID-19 related absences with negative business impact in the future. We have maintained an on-site workforce and implemented stay-at-home orders consistent with the requirements of the jurisdictions in which we operate, with arrangements such as remote work and flexible schedules for certain functions, as well as other measures intended to reduce the risks to our employees from the impact of the pandemic while maintaining our operations. Re-opening our offices could expose our employees to health risks, and us to associated liability, and could create additional risks and operational challenges that require us to make additional investments in the design, implementation and enforcement of new workplace health and safety protocols. We expect many employees to continue to work remotely or a hybrid of in-person and remote work, which presents risks, uncertainties and costs that could affect our performance, including operational and workplace culture challenges and uncertainty regarding office space needs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we implemented a company-wide vaccination requirement by the end of 2021, with certain exceptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we do not believe our vaccination requirement has resulted in workforce attrition nor will it result in material difficulty securing future labor needs. If employee attrition is significant, our business could be adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to the shifting of a majority of our corporate functions operating remotely in regions impacted the virus. Increased levels of remote access may create additional opportunities for cybercriminals to attempt to exploit vulnerabilities, and our employees may be more susceptible to phishing and social engineering attempts. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic impacts our business, staff, operations, financial condition, results of operations and liquidity, or those of our collaborators, will largely depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, new information that may emerge concerning the severity of COVID-19 and its variants or the effectiveness of actions to contain COVID-19 or treat its impact, an extended period of global supply chain and economic disruption as a result of the pandemic, among others. We cannot presently predict the scope and severity of any potential government or business shutdowns or disruptions. If we or any of the third parties with whom we engage experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in launching and marketing products. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the FDA approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We launched MARGENZA in March 2021. In conjunction with Eversana Life Science Services, LLC (Eversana), we continue to build commercialization support in United States to commercialize MARGENZA in a manner we believe to be appropriate in light of the modest size of the market opportunity. We have limited internal commercialization capabilities, and any additional products or product candidates that we may develop or in-license, will require significant capital expenditures, management resources and time. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in commercializing our products. For example, we have limited experience in building and managing a commercial team, conducting a comprehensive market analysis, and reimbursement, or managing distributors and a field force for our products. We compete with many companies that currently have extensive and well-funded sales and marketing operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercialization of any or all of our product candidates, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our products, we will likely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursue additional collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties. We would have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our products ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts for our products. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that we will be able to further develop or successfully maintain internal sales and commercial capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate substantial product sales revenue.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed, or may have succeeded, in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there are a large number of companies developing or marketing potential treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity for MARGENZA is limited, and the commercial opportunity for future product candidates including MGC018 may be reduced or limited if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs through lowering prescription drug prices, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA), which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases the likelihood of downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider additional reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been executive, judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (Tax Act) included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, on November 20, 2020, the Centers for Medicare&#8239;&amp; Medicaid Services (CMS) issued an interim final rule implementing former President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. However, it is unclear whether these or similar policy initiatives will be implemented in the future. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of various and evolving payor models and additional legislative proposals.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our products and product candidates, if approved for sale by the appropriate regulatory authorities, may depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for our products or any products that we develop . Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available or is available on a limited basis, or if the reimbursement amount for our products is inadequate to support a product&#8217;s price, we may not be able to successfully commercialize any of our approved products. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often time-consuming and costly. This process may require us to provide scientific and clinical information to support the coverage or reimbursement of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that MARGENZA and our product candidates, if approved, will be covered, or remain covered, by private or public payors, and if covered, whether the reimbursement will be perceived by product purchasers as adequate. Health reform actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for MARGENZA and our product candidates, if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that biopharmaceutical manufacturers provide them with discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products . There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific products and product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our products may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any approved product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates where appropriate. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates in, seriously ill patients. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory scrutiny; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to or costly settlement with patients or other claimants; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which they may be used; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to MGC018, MARGENZA and any of our other product candidates that are approved for commercial sale, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive ongoing obligations and continued regulatory review from applicable regulatory agencies with respect to any product obtaining regulatory approval, including MGC018 and MARGENZA, such as continued adverse event reporting requirements and post-marketing commitments, all of which may result in significant expense and limit our and our collaborators' ability to commercialize our current and any future approved products. For example, the FDA's approval of MARGENZA included a requirement that we provide to the FDA the data from the final overall survival endpoint from our SOPHIA study, which we reported in September 2021.  Moreover, in connection with MARGENZA&#8217;s approval, the labeling and advertising and promotion of MARGENZA are subject to additional regulatory requirements, which could entail significant expense and could negatively impact the potential commercialization of MARGENZA. To the extent other product candidates or those of our partners are approved by the FDA, we or our collaborators may be subject to similar post-marketing obligations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with cGMP regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products and product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject an approved product, its manufacturer and the manufacturer&#8217;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with our current or any future approved products, including adverse events of unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and including withdrawal of the affected product from the market. If our manufacturing facilities, our collaborators' manufacturing facilities, or those of our respective suppliers, fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of fines and other civil penalties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, suspensions or revocations of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of manufacturing; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in commercialization; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusals to permit drugs to be imported into or exported from the United States; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of MGC018, our other product candidates or of MARGENZA in any additional indications or territories, or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to market our current or any future approved products and our business would suffer.  </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we and our current and potential collaboration partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional preclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Although we obtained FDA approval of MARGENZA in December 2020, we do not have any product candidates approved for sale in any international market. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA, and other government employees and pause or stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#8239;makes us a government contractor. Laws and regulations affecting government contracts&#8239;may&#8239;make it more costly and difficult for us to successfully conduct our business.&#8239; </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. Failure to comply with these laws could result in significant civil and criminal penalties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the most significant government contracting regulations that may affect our business are: the Federal Acquisition Regulation (FAR) and NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts; business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, and the False Claims Act; export and import control laws and regulations; and laws, regulations and executive orders restricting the use and dissemination of sensitive information we may receive pursuant to our performance of the government contract, and vaccination mandates. U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, financial conditions and results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government may seek to implement more protective trade measures with countries in which we plan to conduct business in, with great deal of uncertainty regarding trade policies, tariffs and government regulations, which if altered could have the potential to create a significant adverse effect on trade between the United States and other countries. Overall, changes in international trade relations, such as the imposition of or increase in tariffs or other trade barriers, could materially and adversely impact our costs, the ability to make sales of our product candidates to any of our significant customers in other countries, and reduce the competitiveness of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and to date has not resulted in revenues sufficient for us to reach profitability. Accordingly, we may never achieve or sustain profitability. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of December&#8239;31, 2021, our accumulated deficit was approximately $974&#160;million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, manufacture product and product candidate inventory, prepare for and begin to commercialize any future approved products, and add infrastructure and personnel if needed to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales force and other commercially relevant functions to support the commercialization of any of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. For example, revenues from MARGENZA are unlikely to be sufficient to enable us to reach profitability. In order to commercialize any additional product candidates, we will need to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are advancing our product candidates through clinical development and have commercialized MARGENZA in collaboration with Eversana. Developing and commercializing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval of product candidates, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of December 31, 2021, combined with anticipated and potential collaboration payments and product revenues, will enable us to fund our operations through 2023. Such guidance does not reflect anticipated expenditures related to the potential late-stage development of MGC018 in mCRPC or further expansion of studies currently ongoing. Because development of our product candidates is uncertain, we are unable to estimate accurately the actual funds we will require to complete research, development and clinical testing to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including but not limited to: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of other product candidates and indications that we pursue; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, cost and results of research, preclinical development, and clinical trials, in particular, our planned potential registrational path trial for MCG018; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with manufacturing our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management, scientific, and medical personnel; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing products that may limit market penetration of our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, MARGENZA, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market MARGENZA or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our federal net operating losses (NOLs) and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#8239;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#8239;382 limitations due to acquisitions we made in 2002 and 2008.&#8239;As of December 31, 2021, we had federal and state NOL carryforwards of approximately $837 million and federal research and development tax credits of approximately $81 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#8239;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug development and have little to no internal capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our agreements with, for example, Incyte Corporation, Zai Lab Limited, I-Mab Biopharma and Janssen Biotech, Inc. These current collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our program collaborators. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For MGC018 and our other product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of MGC018 or our other product candidates, reduce or delay one or more of our other development programs, delay the commercialization of a product candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop MGC018 or  our other product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into additional agreements on certain terms with potential collaborators. Most of our existing therapeutic collaborations contain a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials, including future trials for MGC018 and other product candidates.  CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop, or engage third parties to develop,  companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may terminate their relationship with us. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with, and may in the future contract with, third parties for components of the manufacturing of MARGENZA and our other product candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two cGMP manufacturing facilities located in Rockville, Maryland in compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates. We manufacture drug substance lots at these facilities that we use for clinical trials of our and our collaborators&#8217; product candidates. We also manufacture commercial supply of MARGENZA. Although we believe we currently have capacity to produce most of the material required for our and our collaborators&#8217; clinical trials and for the commercial supply of MARGENZA, we may not be able to do so in the future, and may continue to rely on arrangements with third parties. We will continue to rely on third parties for bioconjugation to produce ADCs and for fill finish activities, neither of which our cGMP manufacturing facilities can currently accommodate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with contract manufacturing organizations in the past to supplement our clinical supply and internal capacity as we commercialize MARGENZA and advance MGC018 and other product candidates in our pipeline. Current MARGENZA inventory was manufactured by a third party. In the future, we plan to manufacture MARGENZA utilizing our internal facility.  In addition, in the future, we may use third parties for the manufacture of some or all components of our product candidates for clinical testing, including anti-body drug conjugates, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by us or one of our third party collaborators.. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured MARGENZA or the product candidates ourselves, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could cause adversely impact the commercialization of MARGENZA and the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for MARGENZA or our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization collaborations will be important to our business. If we are unable to maintain commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug commercialization, with little to no internal capability for sales, marketing or distribution.  For example, we have entered into a collaboration with Eversana for the commercialization of MARGENZA in the United States that we believe can provide such capabilities, and may enter into commercial collaborations in the future for MARGENZA or our product candidates. Our existing commercialization collaboration, and any future commercialization collaborations we enter into, may pose a number of risks, including the following: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization of MARGENZA or any product candidates that achieve regulatory approval or may elect not to continue commercialization based on clinical trial results, changes in the collaborators' strategic focus or other factors that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently commercialize products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to MARGENZA or our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements on contract interpretation, commercialization strategy or tactics, might cause delays or termination of the commercialization of MARGENZA or product candidates, might lead to additional responsibilities for us with respect to MARGENZA or product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly utilize our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may violate, or be investigated for potentially violating, health care compliance and related laws and regulations, which may expose us to litigation, enforcement actions or inquiries, or other potential liability; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further commercialization of MARGNEZA or applicable product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the risks relating to commercialization, and health care legal compliance described in this Annual Report on Form 10-K also apply to the commercialization activities of our collaborators. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. We may also be restricted under commercialization collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, our collaboration with Eversana contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time among other conditions </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the commercialization of MARGENZA or a product candidate, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake or commercialization activities at our own expense. If in the future we elect to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations to commercialize our product candidates and do not have sufficient funds or expertise to undertake the necessary commercialization activities, we may not be able to commercialize our product candidates or bring them to market or continue and our business may be materially and adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Cybersecurity</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in our computer networks, including those related to cybersecurity, could adversely affect our financial performance as well as our research, development and commercialization efforts. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches continue to increase generally and can create system disruptions or shutdowns or the unauthorized disclosure of confidential information. In addition, due to the COVID-19 pandemic a significant portion of our employees have been working remotely, either from home or elsewhere. If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of federal, state, or other laws protecting confidential personal information. In addition, a cybersecurity breach could hurt our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a material adverse effect on our business, financial condition and results of operations. In order to reduce such risks, our information security program employs a policy-driven information systems security architecture based on National Institute of Standards and Technology (NIST) Cybersecurity Framework and references the NIST 800-53 guidelines for risk-based assessments and implementation of information security controls. The program is managed by dedicated Information Security personnel with the primary mission to implement, maintain, and improve the capabilities and practices to ensure the confidentiality, integrity, and availability of the sensitive information it maintains. &#8239; </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover MARGENZA or enoblituzumab and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our approved products and product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by patents or pending patent applications; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications for these inventions; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel or our agents to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially, </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal Compliance Matters </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our operations, and those of our collaborators, are subject to regulation by various local, state, federal authorities in addition to the FDA, including but not limited to, CMS, other divisions of HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. We and our collaborators are or may be subject to broadly applicable &#8220;fraud and abuse&#8221; laws, such as false claims, anti-kickback laws, transparency laws, and privacy and security laws. Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices, or those of our collaborators, may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal anti-kickback statute and the criminal healthcare fraud statutes (discussed below) was amended by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">case law that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil false claims act. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Sunshine Act provisions of the ACA, covered manufacturers of drugs, devices, biological and medical supplies for which payment is available under a federal health care program (with certain exceptions) are subject to annual federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as information regarding certain ownership and investment interests held by physicians and their immediate family members.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time as we or our collaborators market MARGENZA or any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#8220;fraud and abuse&#8221; laws. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business, as well as foreign jurisdictions. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and its implementing regulations, impose requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information. We are subject to other state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the General Data Protection Regulation (EU) 2016/679 (GDPR) which went into effect on May 25, 2018, imposes privacy and security obligations on any entity that collects and/or processes health data from individuals located in the European Union. Under the GDPR, fines of up to 20&#160;million Euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance. In addition, on June 28, 2018, California enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely affect our business. As well as complicating our compliance efforts, non-compliance with these laws could result in penalties or significant legal liability.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to distribute products commercially in the United States, we or our collaborators must also comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers, and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track, and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations, or those of our collaborators marketing, distributing or commercializing any of our products on our behalf, are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations and those of our collaborators may be subject to analogous foreign health care laws in the jurisdictions in which we operate. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Employee Matters and Managing Growth </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and other personnel will also be critical to our success.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have experienced increased employee turnover, consistent with high numbers of employee resignations across the broader American economy, and we may continue to experience employee turnover in the future that may have an adverse effect on our business strategy. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. In addition, the foregoing may be exacerbated by employees unwilling to work due to choosing not to comply with vaccine mandates for healthcare workers or for government contractors. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Such competition may increase due to the recent move by companies to offer a remote or hybrid work environment. In addition, we rely on consultants and advisors, including scientific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, motivate existing employees, or maintain our corporate culture in a hybrid or remote work environment and in the midst of higher turnover, our ability to pursue our growth strategy will be limited. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide meaningful equity incentives to our key employees, it could adversely affect our ability to retain these key employees, which in turn could affect our ability to implement our business strategies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon the members of our senior management team and other key employees. In our industry, it is common to attract and retain executive and other key employees with compensation packages that include a significant equity component. As a result, we may have difficulty retaining key personnel, which would have a material adverse effect on our ability to execute our business strategy. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had 427 full-time employees. As our development and commercialization plans and strategies develop, we may choose to expand our employee base for managerial, operational, manufacturing, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Any such growth could require significant capital expenditures and may divert financial resources from other projects, such as the commercialization of MARGENZA and the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize MARGENZA, our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Common Stock </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, on September 13, 2019, a securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal, and on January 18, 2022 the Lead Plaintiff filed its opening brief.  The case is now pending in the Fourth Circuit. This or any future securities litigation brought by private parties or government enforcement agencies could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance. The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of our clinical trials and clinical trials of our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing our product candidates or future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing products or new products that may emerge; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of technological innovations or new commercial products by us or our competitors; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts, if any cover our common stock; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our product candidates or any future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">threatened or actual litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future or anticipated sales of our common stock; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems in the United States or overseas; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of MARGENZA or our product candidates, if approved, to achieve commercial success; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and market conditions for biopharmaceutical stocks; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall fluctuations in U.S. equity markets; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic as well as mandatory and voluntary actions taken to mitigate the evolving public health impact of the pandemic. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. For example, we currently have one such securities class action lawsuit brought against us. We could incur substantial costs defending this or similar lawsuits, as well as diversion of the time and attention of our management, any or all of which could seriously harm our business </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of directors to be changed only by resolution of our board of directors; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#8239;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_22"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160; UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_25"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160; PROPERTIES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a total of approximately 235,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland and California. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical and commercial quantities and scale. This location is occupied under a lease that expires in 2027. We also lease another space supporting smaller-scale manufacturing operations in Rockville. The lease of that space expires in December 2024. These leases and all of the leases on our other properties include one or more options to renew, with those renewal periods ranging from five to fourteen years. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_28"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See note 11, Commitments and Contingencies, to the consolidated financial statements for more information. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_31"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_37"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;As of February&#160;22, 2022, we had 61,324,258 shares of common stock outstanding held by approximately 62 holders of record, which include shares held by a broker, bank or other nominee.&#160;We have never declared or paid any cash dividends.&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the five-year cumulative total return of our common stock with the  Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;The comparison assumes a $100 investment on December 31, 2016 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20211231_g6.jpg" alt="mgnx-20211231_g6.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading "Performance Graph" shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to liabilities of Section 18 of the Exchange Act, except to the extent that we specifically request that such information be treated as soliciting material or specifically be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_40"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_43"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the discussion of our financial condition and results of operations for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the SEC on February&#160;25, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer.  We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators.  These product candidates include six immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2021, combined with anticipated and potential collaboration payments and product revenues, should enable us to fund our operations through 2023. Our guidance does not reflect expenditures relating to the potential late-stage development of MGC018 in metastatic castration-resistant prostate cancer (mCRPC) or further expansion of studies currently ongoing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2021, we had an accumulated deficit of $973.9 million.&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic and its variants are evolving and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies, commercialization activities, and on clinical trial enrollment. Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. We are classified as a government contractor because of our contract with National Institute of Allergy and Infectious Diseases (NIAID), and our government contract includes provisions to comply with Executive Order 14042. The contract terms include the requirement that all our employees that may be on site at the same location as any employee supporting the government contract be fully vaccinated against COVID-19, unless legally entitled to an accommodation due to a disability or religious </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">belief, practice or observance.  In anticipation of deadlines associated with the contract terms and Executive Order 14042, we implemented a company-wide vaccination requirement by the end of 2021, with certain exceptions.  To date, we do not believe our vaccination requirement  has resulted in workforce attrition nor will it result in material difficulty securing future labor needs. If attrition is significant, our business could be adversely affected.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. In July 2021, Incyte announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data were needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA.  Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones. We received $70.0 million of the total development milestones through December 31, 2021. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones, of which we have already received $4.0 million ($3.6 million net of foreign withholding tax). Subsequent to December&#160;31, 2021, we earned $5.0 million upon Zai Lab&#8217;s achievement of a regulatory milestone. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay us $85.0 million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs under the 2021 Zai Lab Agreement, we could receive up to $1.4 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of low double-digit teens on annual net sales of certain specified products and of mid-single digits to low double-digit teens on annual net sales of other specified products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/><br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay us tiered royalties ranging from mid teens to 20% on annual net sales in its territories.</span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an agreement under which we are to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_52"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, amounts earned by performing development and manufacturing services, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. During 2021 we launched MARGENZA and began generating revenue from product sales.  However, revenues from MARGENZA are unlikely to enable us to reach profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of MARGENZA. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, such as salaries and benefits;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation of laboratory and manufacturing equipment, computers and leasehold improvements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal and third party costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval.  The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions.  Selling, general and administrative expense also includes costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC, and other legal and professional fees.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of realized and unrealized gains and losses on equity securities and interest income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_55"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. We did not make any material changes to these assumptions during the year ended December&#160;31, 2021, and do not expect any material changes in the near term to the underlying assumptions.  If we were to adjust our assumptions, the results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. Management considers an accounting estimate to be critical if:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it requires a significant level of estimation uncertainty; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the estimate are reasonably likely to have a material effect on our financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe regulatory approval is probable and expect future economic benefit from the sales of a product candidate to be realized, we capitalize manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving our first approval from the FDA in December 2020, we expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for us of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, we began capitalizing our third-party contract manufacturing MARGENZA inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, (ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. We may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we grant a license to our intellectual property, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to our intellectual property.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under our agreements may include research and development or manufacturing services to be performed by us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of our product represents a single performance obligation for these transactions and we record net product revenue when control is transferred to the customer, generally upon receipt by the customer.  The transaction price for net product revenue represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.Sales deductions are based on management's estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment, in particular, for government-mandated rebates and chargebacks, such as for the Medicaid and 340B programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MARGENZA. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs we incur for our own research and development activities and costs incurred by our collaborators under cost sharing arrangements. Research and development costs consist of salaries and benefits, including related stock-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs, and the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract manufacturing organizations (CMOs). Research and development costs are expensed as incurred. We receive estimates from our collaborators when we are sharing development expenses, and use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and we outsource a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expense as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recently Adopted Accounting Standards."</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_58"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the years ended December&#160;31, 2021 and 2020 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:43.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $34.5 million in revenue from collaborative and other agreements for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 was primarily due to:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $25.0 million in development milestones recognized under the</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Incyte License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $18.5 million recognized under the Janssen research collaboration and global license agreement;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $12.0 million payment from Boehringer Ingelheim International GmbH (BII) for retention of rights to two DART molecules during 2020;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $8.6 million recognized under the 2018 Zai Lab Agreement; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $7.1 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognit</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion of $20.3 million in revenue from the 2021 Zai Lab Agreement executed in June 2021;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $9.2 million in revenue recognized under the I-Mab License Agreement; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $6.4 million in revenue recognized under the Incyte Commercial Supply Agreement which was executed in late 2020.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $5.3 million in revenue from government agreements for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 was primarily due to decreased development costs related to the second DART molecule.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks and discounts, distribution-related fees and other sales-related deductions.  The table below includes a reconciliation of the accounts associated with these deductions (in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Rebates and chargebacks </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Distribution fees, product returns and other </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current year sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits for current year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the year ended December&#160;31, 2021 consisted primarily of reserves for unsaleable inventory, as well as product royalties. Product sold during the year ended December&#160;31, 2021 consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin for the year ended December&#160;31, 2021. No similar cost of product sales was recognized during the year ended December&#160;31, 2020, as there were no sales of MARGENZA during those periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the years ended December&#160;31, 2021 and 2020 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:43.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab (formerly MGD019)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December&#160;31, 2021 increased by $21.4 million compared to the year ended December&#160;31, 2020. This increase was primarily attributable to:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">increased MGC018 development, manufacturing and clinical trial costs related to our Phase 1/2 dose expansion study;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to enoblituzumab;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to our lorigerlimab Phase 1 dose expansion study; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to IND preparation and clinical trial initiation for MGD024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte under the Incyte supply agreements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial and BLA support costs for margetuximab; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to tebotelimab.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our general and administrative expenses for the years ended December&#160;31, 2021 and 2020 (dollars in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased for the year ended December&#160;31, 2021 by $20.3 million compared to 2020 primarily due to due to costs related to the launch of MARGENZA, as well as increased labor-related costs and legal expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decrease of $0.6 million in other income for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 is primarily due to decreased investment income. </span></div><div><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the years ended December&#160;31, 2021 and 2020 (dollars in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(112.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was primarily the result of our net loss, adjusted for non-cash items, with the year ended December&#160;31, 2021 benefiting from the $25.0 million upfront payment under the 2021 Zai Lab Agreement, $15.0 million milestone payment received from Incyte, and $4.5 million milestone payment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from I-Mab.  The year ended December&#160;31, 2020 benefited from the $40.0 million in milestone payments received from Incyte, the $20.0 million upfront payment from Janssen, and the $12.0 million received from BII. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the years ended December&#160;31, 2021 and 2020 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the years ended December&#160;31, 2021 and 2020 reflects net cash proceeds from our securities offerings of approximately $117.8 million and $170.5 million, respectively, and cash from stock option exercises and the purchase of shares under our employee stock purchase plan.&#160; Net cash provided by financing activities for the year ended December&#160;31, 2021 also reflects approximately $19.6 million from Zai Lab under the Stock Purchase Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2021, as well as anticipated and potential collaboration payments, and product revenues should enable us to fund our operations through 2023, assuming our programs and collaborations advance as currently contemplated.  </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term material cash requirements consist of operational and capital expenditures, some of which contain contractual obligations. Our primary uses of cash relate to paying salaries and benefits, administering clinical trials, marketing our product, and providing the technology and facilities necessary to support our operations.  The most significant contractual obligations are the operating leases at our facilities in Maryland and California. Our future minimum lease payments as of December&#160;31, 2021 totaled $6.9&#160;million related to short-term lease liabilities, and $25.5&#160;million related to long-term lease liabilities.  See Note 6, Leases, in the Notes to the Financial Statements in this Annual Report on Form 10-K for additional information about our lease liabilities. We also have short-term commitments for ongoing capital improvement projects totaling approximately $1.7 million as of December&#160;31, 2021.  We expect to fund these requirements with current cash, cash equivalents and marketable securities as well as anticipated and potential collaboration payments, and product revenues. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_70"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;As of December&#160;31, 2021, we had cash, cash equivalents and marketable securities of $243.6 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_73"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth beginning on page F-1 in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_76"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_79"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2021. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Annual Report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has concluded that there was no change that occurred during the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2021.&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160;Based on our assessment, management believes that, as of December&#160;31, 2021, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2021 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on page 68.</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_82"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric Risser, the Company&#8217;s current</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Business Development and Portfolio Management and Chief Business Officer, was promoted to the position of Chief Operating Officer. M</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r. Risser will continue to receive compensation in connection with such appointment pursuant to his current Employment Agreement with the Company, dated March 8, 2016. </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Risser&#8217;s biography is included in the Company&#8217;s definitive proxy statement on Schedule 14A, filed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the Securities and Exchange Commission on April 2, 2021, in the section titled &#8220;Executive Officers&#8221; and is incorporated herein by reference.</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_872"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2021, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes and our report dated February&#160;24, 2022, expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_91"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2022 annual meeting of stockholders (the 2022 Proxy Statement).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_94"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2022 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_97"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2022 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_100"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2022 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_103"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2022 Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_109"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Consolidated Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:71.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_136">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i42ef1f69451b4aa1b71984b2e3189d12_136">7</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_112"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and CEO and Director</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:29.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and CEO and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer and Secretary (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller and Treasurer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paulo Costa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paulo Costa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_121"> (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMTgvZnJhZzpjMTk3YmM3MWViMWY0ODU0YjUxZTkzYWRkMjIxNjZiMC90YWJsZTpkNTNiNzk2NGY5NWI0Nzg1OWQ3MmM5N2Y1NWMwMTdmNC90YWJsZXJhbmdlOmQ1M2I3OTY0Zjk1YjQ3ODU5ZDcyYzk3ZjU1YzAxN2Y0XzItMC0xLTEtMzMzMjcvdGV4dHJlZ2lvbjo3MzZlZmE0YWVhN2E0OGU0YWY4ZDk3YTMzZGM5NGU4MF8xMDk5NTExNjI4MjMx_050d34af-2f46-40c0-9eaf-793f83cd731f">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_121">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">Consolidated Balance Sheets at December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124"> and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_124">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_127">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">Consolidated Statements of Stockholders' Equity for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_130">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_133">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_136">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i42ef1f69451b4aa1b71984b2e3189d12_136">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;24, 2022 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated</span><span style="background-color:#f4f4f4;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Collaboration and Licensing Agreement with Zai Lab</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note 10 of the consolidated financial statements, in June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (&#8220;Zai Agreement&#8221;). As part of the consideration for the rights granted to Zai Lab US LLC under the Zai Agreement, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;).  The Zai Agreement and Stock Purchase Agreement are referred to collectively as the Agreements.  The Agreements resulted in the recognition of $20.3 million of revenue from collaborative and other agreements and $16.1 million of deferred revenue for the year ended December 31, 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounting for the Zai Agreement required the Company to make significant judgments, including but not limited to the identification of performance obligations and the estimation of the standalone selling price of each identified performance obligation. The standalone selling price of the performance obligation was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the estimated amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each program under the agreement. Changes to these assumptions can have a material effect on the allocation of the transaction price to the performance obligations as well as the amount and timing of revenue recognized. As a result, auditing the identification of performance obligations and estimates of standalone selling price for performance obligations required especially complex auditor judgment.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s collaboration revenue process. For example, we tested controls over management's process to determine the significant assumptions described above with respect to the identification of the performance obligations and the related estimation of the standalone selling price of each performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To audit the Company&#8217;s revenue recognition related to the Zai Agreement, we performed audit procedures that included, among others, inspecting the executed Agreements and accounting assessment and evaluating whether the promised services and performance obligations were properly identified.  In addition, we evaluated management&#8217;s estimates of the standalone selling price of the identified performance obligations. For example, we evaluated the market values of other preclinical collaboration arrangements and the probability of success assumptions used by the Company in developing the estimates of standalone selling price by comparing the significant assumptions described above to current industry trends using available information from other guideline companies within the same industry and other relevant factors. We also performed a sensitivity analysis of the significant assumptions to evaluate the impact that the change in the estimated standalone selling price of certain performance obligations resulting from changes in the significant assumptions would have on the allocation of transaction price to each performance obligation, as well as revenue recognized during the period. </span></div></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjEvZnJhZzphODNiNjEzMDNjNWM0ODQ5YWI2NTVlMjRhNzM2Y2RhOC90YWJsZTo0ZWZjNGJmYTk2OGQ0OTI4YTFiMTlmNjNjNDYzZTk2YS90YWJsZXJhbmdlOjRlZmM0YmZhOTY4ZDQ5MjhhMWIxOWY2M2M0NjNlOTZhXzAtMC0xLTEtMzMzMjEvdGV4dHJlZ2lvbjo5YzlmNGYxYjJiYzQ0ZWYxOTYzOGYzMzViNDllOGM1Yl8xMDk5NTExNjI3ODE4_702c1ee0-06a3-4dcf-8898-81ae13e78362">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjEvZnJhZzphODNiNjEzMDNjNWM0ODQ5YWI2NTVlMjRhNzM2Y2RhOC90YWJsZTo0ZWZjNGJmYTk2OGQ0OTI4YTFiMTlmNjNjNDYzZTk2YS90YWJsZXJhbmdlOjRlZmM0YmZhOTY4ZDQ5MjhhMWIxOWY2M2M0NjNlOTZhXzQtMC0xLTEtMzMzMTUvdGV4dHJlZ2lvbjplMTYzOTY3Y2M5ZTk0MmIwYThkYWQzZTMwM2M3OWEyMl8xMDk5NTExNjI3ODEy_913523bd-4a1f-4cc9-bf67-c325e1a9f992">Tysons, Virginia</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzQtMS0xLTEtMTc4NTM_01350a3f-7b75-465c-825a-2a268a5876d2">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzQtMy0xLTEtMTc4NTM_eeaabd77-282a-4754-b9b4-d72558d0929b">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzUtMS0xLTEtMTc4NTM_09448c34-8b52-409e-a740-1722bd19daa5">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzUtMy0xLTEtMTc4NTM_941fc583-1ef8-4c70-838f-d5f6f8f43f50">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzYtMS0xLTEtMTc4NTM_7beb98fa-53b5-4876-86c8-a9346c9834dc">10,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzYtMy0xLTEtMTc4NTM_5dc5eed6-2051-4afc-b22e-d4f70e5e6d91">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzctMS0xLTEtMTc4NTM_868d30d7-1895-4c23-aab9-08197f5655e6">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzctMy0xLTEtMTc4NTM_d208c4b9-7d87-4781-90db-732450e6a438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzgtMS0xLTEtMTc4NTM_d0820dec-0c34-46e1-ab91-b6836127e0c1">21,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzgtMy0xLTEtMTc4NTM_2dc3322d-350c-44ac-a91a-9580bfa179fe">16,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzktMS0xLTEtMTc4NTM_a5b64134-a0f3-4a21-a578-25274f734b6b">279,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzktMy0xLTEtMTc4NTM_3d3c2d52-5f75-4061-b815-fb68d6016fc0">312,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEwLTEtMS0xLTE3ODUz_a15d650a-d0f8-4c25-ac82-eeba193a5ae2">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEwLTMtMS0xLTE3ODUz_7d8827d1-434c-4368-8f61-616d13267831">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEyLTEtMS0xLTE3ODUz_86ccdebc-1c84-4ef2-8647-42a16d5ed0e0">18,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEyLTMtMS0xLTE3ODUz_29e60a61-1851-4cf7-82a3-81c724d881e3">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEzLTEtMS0xLTE3ODUz_e20753b9-a0bb-4581-87f6-15c9508980b4">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEzLTMtMS0xLTE3ODUz_54943b25-dc0e-460b-893f-8539754aabc6">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE3LTEtMS0xLTE3ODUz_dcda4cc8-5b71-4166-a0aa-8b9b83be5d74">15,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE3LTMtMS0xLTE3ODUz_2906e6a0-42c3-4f09-8856-25cbd9fb6636">8,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE4LTEtMS0xLTE3ODUz_3a17001b-45fe-4bd6-b12e-8344c85308ed">33,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE4LTMtMS0xLTE3ODUz_eeb0a193-ec4e-4aa9-b6f2-d76f0f701888">34,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE5LTEtMS0xLTE3ODUz_2c2bc77f-4780-4352-9c5b-d83c032e7478">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE5LTMtMS0xLTE3ODUz_6cc2b06e-dac0-4e2c-ad25-fe33f3546ac5">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIwLTEtMS0xLTE3ODUz_8bed324c-1eb8-48f0-a574-d06fe1b64991">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIwLTMtMS0xLTE3ODUz_5100ec3f-8470-4a77-a0d5-0e6a4b2dec53">3,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIxLTEtMS0xLTE3ODUz_48b8cd95-d233-460e-b4c1-73cd8e729c18">74,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIxLTMtMS0xLTE3ODUz_c8f174b6-a035-42a8-8098-0a8a675a394f">50,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIyLTEtMS0xLTE3ODUz_a2df4e84-138e-45b4-961b-2b9e7ee1fc64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIyLTMtMS0xLTE3ODUz_426c5ceb-0e7c-484c-ad67-beb4f09d1094">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIzLTEtMS0xLTE3ODUz_b83bf5b4-af91-4b0b-979e-4c1d622388a4">20,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIzLTMtMS0xLTE3ODUz_c80a771b-809a-4dcb-8750-c6742a80aa2c">25,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI0LTEtMS0xLTE3ODUz_16a7caf0-9802-4687-a366-2f5eafed8fe1">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI0LTMtMS0xLTE3ODUz_c435c413-09d3-4b05-9e27-b322c890b7af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI1LTEtMS0xLTE3ODUz_e7d445ac-315b-4abb-a734-ae8f946f0ad5">95,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI1LTMtMS0xLTE3ODUz_8070a188-8d0c-4f2b-b2f1-d6ddfeef550e">82,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzg5Ng_27c1174c-1fdf-4b64-b64d-b798a67eb3ad"><ix:nonFraction unitRef="usdPerShare" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzg5Ng_d95a9d02-a52b-40f1-a750-e2ae6b9a17e3">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwMA_6deac4a7-2bcd-45cc-85b9-9cf22b56c1c9"><ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwMA_804d36d4-7bd2-4acb-a1b0-87a3d4c2d142">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwOA_adb17c3e-d503-4165-9aae-cc1a158e9acc">61,307,428</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwNA_abb26143-bb7c-4e59-b7cb-17014135c4c6">56,244,771</ix:nonFraction> shares outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTEtMS0xLTE3ODUz_e5532352-3b50-4ea8-b099-227aa0445617">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTMtMS0xLTE3ODUz_37c25852-0c60-4497-855c-9886bfed702c">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI5LTEtMS0xLTE3ODUz_b3a18cfa-4254-4459-bf01-04e97c4da704">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI5LTMtMS0xLTE3ODUz_067c9240-20fc-4e3a-8906-121c80ae8207">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMwLTEtMS0xLTE3ODUz_63eabe6c-1397-4f29-b203-50541348bf7c">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMwLTMtMS0xLTE3ODUz_4cbe3831-ce14-4010-a8c7-f3fdceff560f">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMxLTEtMS0xLTE3ODUz_a135740d-e195-49ef-ac65-6e8854429c51">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMxLTMtMS0xLTE3ODUz_15f82155-115b-4d13-9286-e68478e1765a">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMyLTEtMS0xLTE3ODUz_671d1448-b09c-4e58-97ff-9d43ea84426f">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMyLTMtMS0xLTE3ODUz_e3d513d5-a7fd-460a-a915-cd5b386edf47">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMzLTEtMS0xLTE3ODUz_efbacef4-556c-4a18-80e3-7e1fdf09bb76">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMzLTMtMS0xLTE3ODUz_fb2fdbca-7a70-4363-b743-0fed6c31ff37">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0476cd5394264601b79261912eab342d_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtMS0xLTEtMTc4NTM_a7ea8d1d-bf59-46e7-8c06-552ae8078152">63,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fec438d9ae4646875042505289ee11_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtMy0xLTEtMTc4NTM_68665cc8-9aac-4042-8bac-a85a01ca4cfc">97,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5089e1becc4a40a38b3b484eab37d9b2_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtNS0xLTEtMTc4NTM_efdf3b7d-3ff9-484f-8838-69fa71927ea6">62,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42358bb227514ae49d829ac1733ef857_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtMS0xLTEtMTc4NTM_0ef5a1f0-f5c4-447a-ac42-e48f816b4899">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c530cb42694976a0a5d52af3aafa8c_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtMy0xLTEtMTc4NTM_94ea00ae-178f-4504-98a9-85a73503b6e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3974741d1c498b99f8a988e3a436a8_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtNS0xLTEtMTc4NTM_4551de0e-97d9-4830-91a0-ee09d689ae6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc526fcd5c54d52a90d55d37856964c_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtMS0xLTEtMTc4NTM_600c3a6a-bdf9-4f40-a374-c725bee830f0">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8e2b21a437348b598121ecfdc9b9df4_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtMy0xLTEtMTc4NTM_cab6690f-c307-463a-bb40-85749b35f75a">7,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d45dc278504512b2a1022987fc80b5_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtNS0xLTEtMTc4NTM_3b40fb02-e0b6-47dd-a79f-c8d410c71089">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtMS0xLTEtMTc4NTM_4266b89a-416e-4991-ab73-2caf37052c29">77,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtMy0xLTEtMTc4NTM_ae8193a6-591b-47bf-9ba7-ccb827879113">104,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtNS0xLTEtMTc4NTM_81e26e57-53e9-43b9-9429-61f90de33a7f">64,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtMS0xLTEtMTc4NTM_04f11c25-2f4f-4210-947f-a7bfc51dbec5">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtMy0xLTEtMTc4NTM_44382697-f212-4e0a-bdf1-1b5665050a41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtNS0xLTEtMTc4NTM_99af1193-f107-4871-9a6f-0a08c10af2ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktMS0xLTEtMTc4NTM_70cc04a2-7c56-471a-b47a-bbd92d94eb1e">214,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktMy0xLTEtMTc4NTM_97060c60-64b2-4113-a7c0-9c54d76d2bad">193,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktNS0xLTEtMTc4NTM_2debd325-deba-49f8-8af4-c27f6831527d">195,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTEtMS0xLTE3ODUz_5e099ed6-e472-40b8-a4f0-a745087bb652">63,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTMtMS0xLTE3ODUz_ba986c35-3ad7-4c84-87eb-b5a658856e44">42,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTUtMS0xLTE3ODUz_63b48e1f-dba5-458a-8f31-fb7fae5c5a13">46,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTEtMS0xLTE3ODUz_36d68cd8-4147-479a-bb80-7c09910d197f">280,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTMtMS0xLTE3ODUz_ec4fb255-3e8c-48a4-b122-d866ec5ea37e">235,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTUtMS0xLTE3ODUz_d98e6bd6-4639-4b0e-9165-2afeaefe2fe9">241,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTEtMS0xLTE3ODUz_bc8ddf30-362e-4161-9908-eaa6c436a6f5">202,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTMtMS0xLTE3ODUz_10146399-c84b-494b-b48b-29045da38dce">131,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTUtMS0xLTE3ODUz_dee251f7-dd9d-412c-b37d-888bb5deca1b">177,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTEtMS0xLTE3ODUz_24b7d3c8-bfe1-4731-9c8b-4aab63cea56f">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTMtMS0xLTE3ODUz_39ae9db4-4bad-4132-83c0-dac8aed4e959">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTUtMS0xLTE3ODUz_b5069d9d-bdff-40dd-a029-9b4c6a2666d6">25,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTEtMS0xLTE3ODUz_91892d8f-518c-4903-bb30-38c27907d3fa">202,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTMtMS0xLTE3ODUz_48255d1d-ba67-493e-aff7-7b6352e1f554">129,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTUtMS0xLTE3ODUz_51c41a09-ccf3-44d3-b500-cf877b223a3a">151,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTEtMS0xLTE3ODUz_2b623693-9c24-41ae-905f-c487a6530239">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTMtMS0xLTE3ODUz_924ec158-73f2-4003-b908-846d59f07e7d">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTUtMS0xLTE3ODUz_1ac4fdd3-7243-4919-b9be-2692d7e9e35f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTEtMS0xLTE3ODUz_963923cf-870d-4943-a8d4-699cef141736">202,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTMtMS0xLTE3ODUz_ce141035-66e1-40bd-8fdf-35079152ff9b">129,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTUtMS0xLTE3ODUz_9294810c-e95a-4f53-9917-aca70589b791">151,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTEtMS0xLTE3ODUz_a4345912-47b7-4d8a-bcd5-4b4f488f401f"><ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTEtMS0xLTE3ODUz_cded2eb3-eb5b-4620-85e9-97a285c89128">3.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTMtMS0xLTE3ODUz_1df9657c-52af-442e-9a2f-ed33fe45c579"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTMtMS0xLTE3ODUz_602240a4-9e3c-470b-9231-e568e3f550ff">2.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTUtMS0xLTE3ODUz_ead972ab-1fae-45b2-b518-026f88a464f8"><ix:nonFraction unitRef="usdPerShare" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTUtMS0xLTE3ODUz_f9a952de-1a05-4cf9-a08e-0ecf32e63461">3.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTEtMS0xLTE3ODUz_619f1f0f-db6d-4ec1-b0d7-29e934f6d183"><ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTEtMS0xLTE3ODUz_f5ee067f-018d-417b-a80a-e3644c309b4b">59,944,717</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTMtMS0xLTE3ODUz_07d3385a-8a7d-424a-80ed-5184f918fa83"><ix:nonFraction unitRef="shares" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTMtMS0xLTE3ODUz_94438ccb-9b59-4d90-adec-b07781faa13d">52,442,389</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTUtMS0xLTE3ODUz_4d6674c8-9f5b-455c-b42d-73acd53ac6ce"><ix:nonFraction unitRef="shares" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTUtMS0xLTE3ODUz_841d6806-8ae5-4918-bca2-9e9a2470b373">48,082,728</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.482%"></td><td style="width:0.1%"></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMS0xLTEtMTc4NTM_7d46e8c3-c9b1-4601-a463-0d9707636e6b">42,353,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMy0xLTEtMTc4NTM_0a9a6e22-2f1c-4460-ab77-6b2668a7c1b4">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c75130354f448cb0610b16a488d692_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtOS0xLTEtMTc4NTM_78eeed2b-ea72-4bae-8745-cc685a9b4e5b">732,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7daedbbfe1d34ee1bdc1e20516be6dae_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTEtMS0xLTE3ODUz_bc12169d-ed0f-48ac-a68f-808af55026bc">490,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida7e57f295ae49d897b71843458bab53_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTMtMS0xLTE3ODUz_24ccb330-24db-4d18-8b7e-cd9e510ae0cb">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTUtMS0xLTE3ODUz_894f5fc6-0591-4749-ae7a-bcda1c798386">242,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzUtOS0xLTEtMTc4NTM_3edb3c31-b8a4-45f3-848f-5ad7d15ae2f0">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzUtMTUtMS0xLTE3ODUz_73ab81a4-6e4f-484c-88d7-ae9d1e5d3fd6">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMS0xLTEtMTc4NTM_50aa40db-df02-4fd4-a4f7-0e2af0322533">6,325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMy0xLTEtMTc4NTM_a7447f97-1ad2-450c-a673-e00eca51631f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtOS0xLTEtMTc4NTM_03cb0472-e8e6-4ac1-b132-f31fd3bdabea">118,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMTUtMS0xLTE3ODUz_e1689ac1-12f8-4356-8381-18c543744dd0">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMS0xLTEtMTc4NTM_bdc90b06-e313-4189-b96b-64e88f8adcb5">280,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMy0xLTEtMTc4NTM_49360609-37fe-4015-90d7-2a9a57226c3e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctOS0xLTEtMTc4NTM_55dda248-ac50-42cc-a630-96057ddc5d9b">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMTUtMS0xLTE3ODUz_0b8f5325-e0c3-49d5-b411-d338d0f94435">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecb39d5f42493faf2bf88fe9d7478d_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzktMTMtMS0xLTE3ODUz_a780698b-8763-4d56-912d-5a474f0700da">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzktMTUtMS0xLTE3ODUz_421d2e18-2b4d-433d-8079-edd8a45c8080">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibef0bb29d42b4d0eaa2df5672eae4ae7_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEwLTExLTEtMS0xNzg1Mw_95a282f1-840f-4a71-87d0-39c42c14b6e2">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEwLTE1LTEtMS0xNzg1Mw_4258fd88-7b5c-43a7-af85-67a4876b7eef">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09cc8fc3b9ea4814b48196d223df5899_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTEtMS0xLTE3ODUz_d7d9b198-c03f-4f7c-9ce0-ab6b51f7fefc">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cc8fc3b9ea4814b48196d223df5899_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTMtMS0xLTE3ODUz_fe1ecfce-6a8f-4c68-badd-cb6ad548d081">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602de41a128f4eaa954138a4f48a76d8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTktMS0xLTE3ODUz_9edb0a06-40ce-439f-9a4f-45f732dfcfec">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd003024ad64612a490d329efe545b2_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTExLTEtMS0xNzg1Mw_78e5464c-41e8-463a-913e-e72ae77e2983">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3f288834b84b7bb3fb22cda39b1f12_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTEzLTEtMS0xNzg1Mw_5e82caff-f056-4be0-872f-69b40ced44ba">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTE1LTEtMS0xNzg1Mw_c0605e2a-8375-43b1-942b-5968e7e843c5">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEzLTktMS0xLTE3ODUz_dd5bcbab-ac73-4886-b022-f3e63e9d629e">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEzLTE1LTEtMS0xNzg1Mw_3a0c16a0-ce0e-41df-b637-8c638b0bf65a">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTEtMS0xLTE3ODUz_356febd4-9fc6-4793-9adf-b71d3c9f3d8b">6,612,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTMtMS0xLTE3ODUz_4e713d73-996a-4d3a-baa0-205d5a4a313b">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTktMS0xLTE3ODUz_e93626d0-a080-4207-8829-f6b2be5437e9">170,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTE1LTEtMS0xNzg1Mw_3478f76e-140c-416d-bb9d-4f1ae550e387">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTEtMS0xLTE3ODUz_57c9716b-d698-458c-b47a-f35187fbdc6c">673,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTMtMS0xLTE3ODUz_b1d8f025-0575-47b3-840a-e655a729217f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTktMS0xLTE3ODUz_fa737823-d4ad-4497-8d7c-2288c9db130b">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTE1LTEtMS0xNzg1Mw_9b2e526c-7577-40a9-9b45-9495abfbd0af">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cccb6db34994ec2825d89e1e8e9e5d5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE3LTEzLTEtMS0xNzg1Mw_80809913-9823-428a-99c2-e88d96c04c49">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE3LTE1LTEtMS0xNzg1Mw_aa0ae4ab-d99b-494f-a55b-f737fd350b16">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0eddd478eb64a50be4d0792a14a3d43_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE4LTExLTEtMS0xNzg1Mw_7b1e061f-fc1f-4083-8ed8-7093539e0ecd">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE4LTE1LTEtMS0xNzg1Mw_e1402629-dcbb-4df1-bca0-648e7d4fb53f">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cae1bdacdfc4c09bfd62025b0041738_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTEtMS0xLTE3ODUz_df6f570c-9333-4e47-9de5-77f31b3fc7b0">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cae1bdacdfc4c09bfd62025b0041738_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTMtMS0xLTE3ODUz_c0095d65-7abb-4154-9e15-3257353f0796">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4291d4100d2946dc9a44dc34ce540d33_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTktMS0xLTE3ODUz_6ccc39cd-fa03-49ce-bef8-7c17953f4eb6">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia88b7c32e47a4e3fb38db1475b81d73d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTExLTEtMS0xNzg1Mw_84b1fc03-c60e-4364-b2c8-ca4fce321d0e">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ceff59a3256484e8c5aec6dccf28729_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTEzLTEtMS0xNzg1Mw_c8dbc470-b90e-497f-972c-cc948a98f6dd">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTE1LTEtMS0xNzg1Mw_ae550fd8-88a3-4cef-b5d3-a2524f75a67c">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIwLTktMS0xLTE3ODUz_74795a32-689f-4cb3-91f5-368b60331b9e">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIwLTE1LTEtMS0xNzg1Mw_77169898-44f1-4211-9a1e-e8c07a472afd">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTEtMS0xLTE3ODUz_a9851b68-8b6f-44ca-88fd-996c7788a87f">4,580,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTMtMS0xLTE3ODUz_fd9a6175-4243-4833-90ec-10dbadb2dd20">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTktMS0xLTE3ODUz_91b88f8a-dc45-48c7-926e-2e0c0f60bdb8">117,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTE1LTEtMS0xNzg1Mw_22345af1-570f-45d6-8c1e-9c03eabd326e">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTEtMS0xLTE3ODUz_e4d14534-18b1-441b-b63f-c2770584b469">482,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTMtMS0xLTE3ODUz_323d285d-374e-4dc2-a212-be4116602783">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTktMS0xLTE3ODUz_48ff79ee-a8f0-4a75-a36f-1480a974cdc5">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTE1LTEtMS0xNzg1Mw_cf50c1ea-4440-4b46-b7fc-4a214e0634a2">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaf4328b36c34fe98d0cd1ccb2e9a7fe_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI0LTEzLTEtMS0xNzg1Mw_74712f4a-1973-4731-874c-3917e63d3629">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI0LTE1LTEtMS0xNzg1Mw_938b9b2f-ea05-4908-8593-d48489e7827a">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffbb346889914074ba3ec066de2f190b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI1LTExLTEtMS0xNzg1Mw_d56e009f-185f-4353-bd18-851bd8e57763">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI1LTE1LTEtMS0xNzg1Mw_ac34e87d-8582-425b-9bf6-2795ca277d32">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73cc242d37df4e43ad348da2cdcc8786_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTEtMS0xLTE3ODUz_f8749328-27b9-44c8-b096-1b9a48cd1ad0">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73cc242d37df4e43ad348da2cdcc8786_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTMtMS0xLTE3ODUz_ba87562e-6a11-44d1-bd1f-9be7a5fefbdc">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce9c21295c045d299c67921090a0e2c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTktMS0xLTE3ODUz_46f42e4f-7381-4930-8544-c7b657d0c4f5">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i984196a6f9894e27b6e2c7d801d41348_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTExLTEtMS0xNzg1Mw_6b26cdd9-fd4f-4b24-91f6-e422f38e1b15">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f72f227590e4d73b71a3cd5eb786ac8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTEzLTEtMS0xNzg1Mw_acb6fb45-2d2b-4135-812c-cab5627a443c">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTE1LTEtMS0xNzg1Mw_25e44965-f2a1-4010-a8b9-465a64c6fe83">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtMS0xLTEtMTc4NTM_d250e5d5-e155-4207-9c67-043c0234eed4">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtMy0xLTEtMTc4NTM_a3ca9767-1bca-46c2-92f7-220cc975d7ef">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtNS0xLTEtMTc4NTM_889ad9ab-162b-43c2-a46f-9989167742aa">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtMS0xLTEtMTc4NTM_b97721af-8840-49bc-9bdd-7ff3ae62d93a">11,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtMy0xLTEtMTc4NTM_10fbef98-2a06-4d33-9e4c-8a2845972bdf">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtNS0xLTEtMTc4NTM_59b63134-8940-4c50-87cc-199cae789229">12,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtMS0xLTEtMTc4NTM_cf85e5e3-128c-43c0-a759-110331ae377c">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtMy0xLTEtMTc4NTM_8ae78dfa-e615-4150-bfc2-f771eae51a5b">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtNS0xLTEtMTc4NTM_24a98108-ee31-4add-92cd-6e33ccd1e44d">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctMS0xLTEtMTc4NTM_2832d6d3-ddde-419f-b6d0-75e67847a579">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctMy0xLTEtMTc4NTM_45018e45-2e7d-4dfd-95ff-4593780763c4">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctNS0xLTEtMTc4NTM_8e7e33b1-9560-48c4-94d2-b936fbb72893">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtMS0xLTEtMTg3NzM_0b63e654-c96e-403c-aaa5-4ffaf0ce8a8c">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtMy0xLTEtMTg4MDU_eaf86794-6097-42b9-965d-269ef0c8ffa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtNS0xLTEtMTkwMzA_b68af16e-62ee-4556-a9d3-25600844cfcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktMS0xLTEtMTc4NTM_538cffd7-ac89-43f0-a343-4db7178251da">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktMy0xLTEtMTc4NTM_6ac88e84-f9e7-4c26-bfa4-f78e05c50461">10,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktNS0xLTEtMTc4NTM_c1cf3554-ce79-4270-a9fa-f1e99bf98006">16,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTEtMS0xLTE4Nzg3_d40ab6b9-e5e3-41b1-8fc5-74586d02ea1f">6,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTMtMS0xLTE4ODA1_9aec686c-6f41-42cf-81b6-8087d2959a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTUtMS0xLTE5MDQw_d1b7ba3e-1b77-4e0d-b89b-da4f71ae59bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTEtMS0xLTE3ODUz_745d5d29-61cd-48d3-a438-cda1d9a6917b">4,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTMtMS0xLTE3ODUz_08d36e77-7c91-4b1e-a19e-eac3f9411d09">5,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTUtMS0xLTE3ODUz_205db515-2b50-4af7-8151-920dbe5c16ee">4,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTEtMS0xLTE3ODUz_23b7f07b-f021-4f12-a55e-fd90ec6ac0ca">5,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTMtMS0xLTE3ODUz_d64b3a25-db50-44c4-b640-eead7b439523">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTUtMS0xLTE3ODUz_eba49369-0501-4cf5-8f85-d1f630e327d6">1,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTEtMS0xLTE3ODUz_35574ffa-2d96-492e-a2e5-0a5ce1b12dc1">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTMtMS0xLTE3ODUz_656ae482-d54f-4506-8425-dd8adbb36a18">3,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTUtMS0xLTE3ODUz_32c234fd-af53-4404-9b81-549763bf21ff">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTEtMS0xLTE3ODUz_81665951-7203-48d7-8768-5df36b076403">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTMtMS0xLTE3ODUz_28b3ffdc-472f-4a9b-8e38-18efe4eb8ed3">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTUtMS0xLTE3ODUz_9ddc7c2b-963e-4b21-af4c-c26561d6367b">6,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTEtMS0xLTE3ODUz_d8e57d7b-8822-4556-aa1f-a547e3e57001">3,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTMtMS0xLTE3ODUz_599ccd8c-3cb0-4117-b2ed-785237fecffe">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTUtMS0xLTE3ODUz_87b86730-0b71-4604-ae0f-37b2ba7149f9">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTEtMS0xLTE3ODUz_2fcd2f49-a7d3-419b-93b6-f75d59475890">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTMtMS0xLTE3ODUz_920faf62-260b-4e66-85ce-9d85882a0c23">8,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTUtMS0xLTE3ODUz_d344535b-72d6-4baa-8a44-615af6cee5dc">20,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTEtMS0xLTE3ODUz_cc0e46e2-fb30-4300-947d-4bdf9dbc12e4">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTMtMS0xLTE3ODUz_c09d0789-2735-4f29-880b-d7973ac83085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTUtMS0xLTE3ODUz_227c2a3c-247e-4234-b8d5-fbf1fed45dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTEtMS0xLTE3ODUz_10d2ea00-c6f5-421f-9c65-90536ea9e8ba">143,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTMtMS0xLTE3ODUz_571e7ec1-f251-4434-928e-24c0a7c02f98">111,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTUtMS0xLTE3ODUz_75f32682-6633-4fd6-a25b-d78b5c854e26">134,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTEtMS0xLTE3ODUz_eca0ce3a-6884-46bf-9f9c-11093492f20e">231,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTMtMS0xLTE3ODUz_37b995be-f194-41e8-a6c5-2c5f1f434ca9">223,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTUtMS0xLTE3ODUz_e5ce845e-bc6e-474e-a5eb-97344e2f6c8c">264,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTEtMS0xLTE3ODUz_7091391a-f508-40fc-a64f-35d72441f56a">200,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTMtMS0xLTE3ODUz_a2b6126b-4779-4823-a950-4f1f55dc25fc">221,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTUtMS0xLTE3ODUz_003521e8-560a-4657-9fcc-670ce695d168">189,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTEtMS0xLTE3ODUz_17b2e6ed-512f-4721-936b-de9c16fb94d3">6,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTMtMS0xLTE3ODUz_d8e8a99d-0910-4de9-96df-4994d891f508">5,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTUtMS0xLTE3ODUz_89a7c94f-a3f1-486e-ae53-a38e772150f2">4,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTEtMS0xLTE3ODUz_f7b9148d-f465-4322-8792-873f59b4ac1c">36,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTMtMS0xLTE3ODUz_5936e500-a091-4a14-b637-45ee410a8e4e">7,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTUtMS0xLTE3ODUz_de586f1f-b883-4b75-aed9-5fde0875cc90">79,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTEtMS0xLTE3ODUz_2149050f-894b-4ccf-b1b4-efbbb23103f3">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTMtMS0xLTE3ODUz_3827ca22-4464-4d1e-8f9a-9a3c0fd2cbc0">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTUtMS0xLTE3ODUz_4e1649f2-45c9-4099-a0a5-0a9ba6bf41d4">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTEtMS0xLTE3ODUz_f8aa4136-2996-4fc6-972c-d2b2c93841db">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTMtMS0xLTE3ODUz_54fd1d41-5871-47be-8594-6d64f44e5fc3">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTUtMS0xLTE3ODUz_8aed6713-9614-48eb-a2ef-f5c1ac759b9c">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing  activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTEtMS0xLTE3ODUz_dc9ccef4-2a5c-424e-834a-cf2345518187">122,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTMtMS0xLTE3ODUz_67dbfa8f-1387-4732-94ff-13ceb4adcc34">174,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTUtMS0xLTE3ODUz_166f5e11-db94-40ed-85e5-383ff3a4fa08">119,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTEtMS0xLTE3ODUz_0a02d1da-ba04-4d07-878f-3eab0744f631">57,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTMtMS0xLTE3ODUz_bec85aac-02f8-43d4-b4fc-d66376465647">54,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTUtMS0xLTE3ODUz_ff2ba7af-d601-42ad-967b-fd2888e97ca8">93,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTEtMS0xLTE3ODUz_54ff6f03-11fa-4c43-81a0-a563ce349a86">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTMtMS0xLTE3ODUz_392d3e3b-6660-4e56-9e28-899f285d5774">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTUtMS0xLTE3ODUz_313466af-a4aa-4971-a690-a6548561b3fe">220,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTEtMS0xLTE3ODUz_cf5acd55-8cd2-49cd-86f0-bd82798639b8">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTMtMS0xLTE3ODUz_e6fba544-f19a-49e4-9126-c4a086d2e59e">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTUtMS0xLTE3ODUz_b2785f05-bc39-43f6-afe6-1d6e7b85fead">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating and investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets modified in exchange for operating lease obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTEtMS0xLTE3ODUz_6c2aa29d-cfc0-4ebe-94b0-72a572f7700c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTMtMS0xLTE3ODUz_cb8d4320-cb5f-4715-afce-85d5ab5a186f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTUtMS0xLTE3ODUz_488eb22a-feb0-488a-8f54-24e07fad7470">6,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable or accruals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTEtMS0xLTE3ODUz_7c4ff7cf-5a10-4f26-82bf-df263832c731">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTMtMS0xLTE3ODUz_268e7362-8f85-43c0-a13b-8dd61cfb3f0f">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTUtMS0xLTE3ODUz_188050af-e774-4488-b3de-72f0750b838c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzkvZnJhZzpkOTg1ZDM0NDFiZjg0MWYzYTVlOTIzNDFmNDJjNDA4ZC90ZXh0cmVnaW9uOmQ5ODVkMzQ0MWJmODQxZjNhNWU5MjM0MWY0MmM0MDhkXzgxNQ_6faf6516-644b-41ad-8dc2-e5c7cada9c7b" continuedAt="i47c9e08b70904988923093a515271177" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i47c9e08b70904988923093a515271177"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include six immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report was filed. In the longer term, the Company plans to meet its operating requirements by generating revenue from current and future strategic collaborations or other arrangements, as well as MARGENZA product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_142"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk3_19e55e44-1329-4388-8426-665b5718ca21" continuedAt="i4761899c42c24527be4e8b74182a5e1f" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4761899c42c24527be4e8b74182a5e1f" continuedAt="i6f2504e967164a3fa86bf677fb844bc7"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDkx_7dc88dc7-fd73-4233-a13f-f22639fbe3a8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTI5ODk_feefbde5-82b8-42db-9b7b-1f32490fd858">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTMwMDM_feefbde5-82b8-42db-9b7b-1f32490fd858">one</ix:nonFraction> segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk4_8904166a-80fc-4513-be25-c8035a75791d" continuedAt="i381032a5fa874cbd8eb9a55f1455265d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i6f2504e967164a3fa86bf677fb844bc7" continuedAt="i8fb4eb70aa7a4bdf9915cc13c7e0c0ae"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i381032a5fa874cbd8eb9a55f1455265d">contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</ix:continuation></span></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg1_30703a1b-2c93-48b4-ac73-c665f68a2359" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg4_0fbfe9bf-7ca2-4b9a-bd64-ea574588f0b3" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. <ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzU2MDU_5baae835-bf56-4b8b-a0cf-d4ebce20edb0"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzU2MDU_955afa8e-5dd3-426d-a024-3065a7811ca4">No</ix:nonFraction></ix:nonFraction> allowance was recorded as of December&#160;31, 2021 or 2020, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg2_b415b283-e3b1-4842-95d3-7c208c8ced5e" continuedAt="if1212ff5f50b42d9807e4ee6e72ba85f" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if1212ff5f50b42d9807e4ee6e72ba85f" continuedAt="i980d8e5cd73a4e7f921fb5b9d4e42efd">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </ix:continuation></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i980d8e5cd73a4e7f921fb5b9d4e42efd">There were no transfers between levels during the periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i8fb4eb70aa7a4bdf9915cc13c7e0c0ae" continuedAt="i0f31162a4bcc40a2b0d51e644c63cef3"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAx_f8347aa9-658e-49d9-83c8-79bf318eb118" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a42b204c7ac4b96b2efdd29380bcefb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtMS0xLTEtMTc4NTM_d5def750-1c47-4461-a695-56201d9058fd">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0993f3d52a4ea094ec1edb6598a865_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtMy0xLTEtMTc4NTM_31cca62c-b100-4434-af71-cecd9bf69c1f">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf781227292741cca6941ae8752cdc90_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtNS0xLTEtMTc4NTM_1706bebf-2d8b-4009-b602-396113df66cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aaf64ab813e4d7abb51d05d48d5cd9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtMS0xLTEtMTc4NTM_06424caa-7242-4354-8346-383d0671730e">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72da0fc0ac74829bfab2bfa1b6a4295_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtMy0xLTEtMTc4NTM_9c7431c0-c5a2-4b50-b1fb-13f5fc426595">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e20ca944414c688558e0c138dab25f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtNS0xLTEtMTc4NTM_8969ec64-636f-47cb-b262-102851f49c8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0b50f677364cfda16e92a9660b911d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtMS0xLTEtMTc4NTM_dd1fb4d2-5eb0-4356-a36f-b6d62ec9a942">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c082935f9bb4e5786832ef1a7cec74f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtMy0xLTEtMTc4NTM_73f77fd2-f8bd-4f71-8729-6babef7b7784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia780b693775f41f2b9d2b93f91aeb2c3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtNS0xLTEtMTc4NTM_f6447b1e-98d0-4d73-88c7-4386b651570d">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07cde9d1e0dc435e983217063f27a631_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctMS0xLTEtMTc4NTM_80c472f7-4175-4dca-9824-2900b7ccaa2a">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2c0b6722614803b9f9e8801058dcf7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctMy0xLTEtMTc4NTM_231a5c85-f0c2-4a16-b6a3-1e3b587b7f56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7342585a6dde49dc9e30b562abc13e18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctNS0xLTEtMTc4NTM_236ab365-d604-4e87-b244-c15f0e75c15c">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363eb5f7afb94ce287279a79e80834b7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktMS0xLTEtMTc4NTM_5cc3e3c0-b0f5-4aef-92bc-b0fef3feb09e">143,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d8cefe777d48e3a76bd2b84fe5dcb9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktMy0xLTEtMTc4NTM_74a41264-999b-4624-92b0-b98aa1f414f3">98,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d0f8356e4abbae5d98d9f4fa3f56_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktNS0xLTEtMTc4NTM_dfd9b66d-794b-4c6b-a684-002cb1b89e25">45,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093a88a4bbf74bd3b948328faaf3d256_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtMS0xLTEtMTc4NTM_31765cdb-a6ae-47e0-a2f7-9d6ab857360d">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94a07f241b54f1691ed49732b3c0ae1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtMy0xLTEtMTc4NTM_19ae4b0d-a5e7-42f6-b683-d8573ce3f652">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef087b39eeb4d259811e54d29f775db_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtNS0xLTEtMTc4NTM_597740af-778d-4c46-8720-a1eb4c1f81d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1534796b1ba49499aaf26bbdce2e184_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtMS0xLTEtMTc4NTM_f686ad06-70b1-4b66-ad0c-f79242593773">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca4ce8fba5d48eb8625c2cc87e156f0_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtMy0xLTEtMTc4NTM_b6686c07-564c-4bde-90aa-4fe89b03b04f">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1fc07cd6f74785bf5181914a299bfa_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtNS0xLTEtMTc4NTM_f1a6cfad-7fd6-4ba8-87b6-b56df2e275c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf461f8bd8944e2a1b163c0f85cfed0_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctMS0xLTEtMTc4NTM_669ecb0c-5a74-4f4a-8931-1b49d0c6a453">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a458f53b4d483d806f635005a4289f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctMy0xLTEtMTc4NTM_25c39f31-4130-433b-af8c-bc70a1840a7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1743997f4174cf3b7ce02d8d189ecbd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctNS0xLTEtMTc4NTM_cbcf0943-bb9c-4053-98ab-30a6c3fb9b64">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e0af088a8b485681a6a2cfd9025765_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktMS0xLTEtMTc4NTM_302de439-a43a-4db7-bc5e-721867ebc43e">143,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9984b5de6d4f54918b58b5fe6cf688_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktMy0xLTEtMTc4NTM_662b6605-6d9b-419d-940f-059f7510cc38">109,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dec97d172754754841a40dd976b4e22_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktNS0xLTEtMTc4NTM_0212633c-12da-41fc-9d5f-d0f2bd4ff4a7">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzE2NDkyNjc0NzY3ODA_27d4a1fa-6ef8-4947-b547-f62bbf823fb7">23.2</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTgyNjU_db5ad63c-99da-4baa-b23f-2787d4a38fef">120.1</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzE2NDkyNjc0NzY3ODg_03714334-d314-4c6a-80bb-7ac92ec1a9cf">52.0</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTgyODE_fb1a658e-3b2f-4fe7-ae37-de743a2d2e82">91.4</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDc3_ad65e104-42ae-41f0-bee2-e61effde3f6d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDky_25fb8c60-260c-43b8-8a0d-021d2a924ee2" continuedAt="i393fab7b93e142ccb1679e5a5e524e07" escape="true">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:</ix:nonNumeric></span><ix:continuation id="i393fab7b93e142ccb1679e5a5e524e07" continuedAt="i9e00455267f7416098432d1dce2b9fb4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9442a64247474df8b1461add74aaacda_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItMS0xLTEtMTc4NTM_93d7078d-f834-46b5-9b73-f1c8251f2381">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90ff6ac23bd34894869aca014c7b476d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItMy0xLTEtMTc4NTM_ffd2463d-dd5c-42bf-9968-019e6195a2c6">47</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53501799fb3d4cbf8748227063b31e3f_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItNS0xLTEtMTc4NTM_81b84e70-437d-4346-aef6-49f168857cbb">35</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5feac2025e8d48bf8cd74e582995d13e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzMtMy0xLTEtMTc4NTM_d7e0efb0-e220-41a2-a13c-84ad7f787629">19</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia51bb3e3b4fc40308c8090fc4154ddae_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzMtNS0xLTEtMTc4NTM_96d1ccdb-e60d-4d41-b877-869c611af01f">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic810e0c6d6cc456284b6df45e6ab5613_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtMS0xLTEtMTc4NTM_a081d56e-f36a-429c-8675-b472ccdbbd5e">30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf78a63b685442e7a6b074034658ca90_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtMy0xLTEtMTc4NTM_41f7770a-5a04-4268-9901-f34c1a81eae5">11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bb8128eb5c64ebb87cdd3c2321b0d5d_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtNS0xLTEtMTc4NTM_d40b2e93-bbd1-450d-9c00-7e22cc6135aa">29</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c5477c51959420fb6ada04c4079057a_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzUtMS0xLTEtMTc4NTM_4604e8d9-f596-454e-9824-c1fab5aae4ce">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idaebcf345af04995bc12d851fe3ad345_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzUtNS0xLTEtMTc4NTM_d74f2fcf-c314-4d2d-a091-f8753749b985">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib886448527284148a9cd4abc404044c2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzYtMS0xLTEtMjQxNjQ_88b4585d-3558-49f8-92a1-ab5bbbd61d20">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9e00455267f7416098432d1dce2b9fb4" continuedAt="i1c6d214824fe4fd388a889c7b1f8aa10">* Amount is less than 10% for the period indicated.</ix:continuation></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0f31162a4bcc40a2b0d51e644c63cef3" continuedAt="ibf406225d70f4b6eaf791000979815fb"><ix:continuation id="i1c6d214824fe4fd388a889c7b1f8aa10"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b5be726a5b24402b410d091823c143f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzItMy0xLTEtMTc4NTM_15c93e36-47f2-4243-92d0-010b5a3fe55b">87</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fa3401fe2864c42a216e6ff8b3f73c5_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzMtMS0xLTEtMTc4NTM_247499fe-2a70-4a39-aa56-418e9d777ac8">23</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81cc50a482614599917ddedb148b766e_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzQtMS0xLTEtMTc4NTM_6bfe80fc-ed1b-4eb0-a225-284a797cacfe">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da65abefa7a47aaa53a42be5b560258_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzQtMy0xLTEtMTc4NTM_aa0a12e6-aedd-416b-badf-0f146e087402">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i509383488634405f80d7cbfb16dfbcfd_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzUtMS0xLTEtMzEwNjE_32e59ccb-1d90-4695-bc7e-c5607ac922e6">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14aaa6274a1f4698a0529bccda6863f1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzUtMy0xLTEtMzEwNjE_67d44c02-02f1-41c6-a8fd-001e54b629b1">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7512c174d93d4b40bd56c7de25b4cc65_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzYtMS0xLTEtMzEwNjE_814c1e29-e1a9-4d85-a238-2373b80a6946">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i482c81605c314f92b439395729ec9358_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzYtMy0xLTEtMzEwNjE_0fb01839-9f99-4ab6-8a8a-60c24fb29ae1">&#8212;</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div></ix:continuation><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA0_dba3e348-15e4-4a25-a1f6-90a3c962213c" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDkz_bd3ec05c-218e-4c3c-a454-c76c47011738" continuedAt="i11023f4dcd2d4a33a3a99abe7d2ccd9d" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i11023f4dcd2d4a33a3a99abe7d2ccd9d">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk2_03a4f917-82fb-4bcb-bb87-42bd46964e6f" continuedAt="ie2995ea9e3824797a144b78eaf635839" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ie2995ea9e3824797a144b78eaf635839"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b5c8da8f19745d6898a617604443be6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzAtMS0xLTEtMTc4NTM_12580f66-3316-49f9-a704-5c5f12424632">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6c95d46b9e34932876caa0130763aca_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzEtMS0xLTEtMTc4NTM_ad81f4d8-d9e8-4b36-b2c4-df9b41f9d242">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib144434d1fac45d38bcdaf750b51e786_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzItMS0xLTEtMTc4NTM_0adbbb8c-8e51-414c-8bd6-f85b045c3d66">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3bf993cac6f64ab8ae585d3a0284bff8_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzMtMS0xLTEtMTc4NTM_056765ab-1a3c-445c-ba52-5833e587dc9e">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDc4_07084372-4be2-4e60-a94a-5142dd4a90f8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2021, and 2020, the Company determined that there were <ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_307a51de-784e-40a7-b4dd-e19ae278eba1"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_d15dd22b-3f8e-4bad-80d9-718405defef9"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="INF" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_f9716d51-e60d-4dd6-ac6c-373d358e3c20">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impaired assets.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAw_666ed3c1-b9f2-4444-afa6-fe85fb78ca14" continuedAt="i9e35324337a945dfb0cc9ab48b2a133b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ibf406225d70f4b6eaf791000979815fb" continuedAt="i2e20c80cbd41440fb0f03affadc78690"><ix:continuation id="i9e35324337a945dfb0cc9ab48b2a133b" continuedAt="i16cf5103208b443a893550f7bec59f50"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i2e20c80cbd41440fb0f03affadc78690" continuedAt="i81816616ff36492590d81a60a1d8b72c"><ix:continuation id="i16cf5103208b443a893550f7bec59f50" continuedAt="i72d7031d0f3546d4a4d04c566356c185"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 10, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product revenue, net</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i81816616ff36492590d81a60a1d8b72c" continuedAt="ife6b98bf4bd04993a2b6b0d261fe5463"><ix:continuation id="i72d7031d0f3546d4a4d04c566356c185"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the year ended December 31, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA5_cf44da2c-ccbc-432c-ab5b-8ead43991027" continuedAt="i55c50c1d5ae04342838cecedd04e5d02" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ife6b98bf4bd04993a2b6b0d261fe5463" continuedAt="i346d02bdb8c84f4ebc0c120876fe026e"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55c50c1d5ae04342838cecedd04e5d02">approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</ix:continuation></span></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAz_7d610699-4107-48cb-b3aa-a539062cf195" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA2_4885b5eb-7bf7-4269-8013-87bd4384c6a1" continuedAt="iab9045d0392d4cc59c6a25ad3f0a0de0" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="iab9045d0392d4cc59c6a25ad3f0a0de0" continuedAt="i7a24f3dbbefe40b7a83aaf8dc8b57ac3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a24f3dbbefe40b7a83aaf8dc8b57ac3">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTA0_5b20ae02-8bbc-49b5-a52e-9442391d11e8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk0_4ea77a91-f7e9-4fe2-9f31-b66099391b19" continuedAt="ib9658cacb24f41459adf2f6d67b747d7" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9658cacb24f41459adf2f6d67b747d7">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</ix:continuation> <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDgy_97791a1b-5587-49ca-a4a9-49c753f51b00" continuedAt="i248d605c50224ef091cfd44f32fb3fd9" escape="true">The following table presents the number of </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i346d02bdb8c84f4ebc0c120876fe026e"><div style="margin-bottom:9pt"><ix:continuation id="i248d605c50224ef091cfd44f32fb3fd9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItMS0xLTEtMTc4NTM_e198e66d-c761-4e40-8217-66275d085e3e">8,395,421</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib18071c232bf4c1f8935ca41ff645bb8_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItMy0xLTEtMTc4NTM_a3ca2c8a-4cb3-4320-9b00-9065d26e766a">7,467,603</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e329af75a644cc48324b311a1c967cf_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItNS0xLTEtMTc4NTM_51872199-8c0c-41a9-8dfa-8eb7710993a9">7,159,494</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDgz_4ac6d4f6-8dfe-4005-aa3c-47174ab4937a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (ASU)  2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses, (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13),which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative effect adjustment was required. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Issued But Not Yet Adopted </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs.  ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_145"></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzE0NDI_dc89f9d6-afa3-41f8-9f84-27285611c710" continuedAt="iceca1c718cea47c69cc5aa3960e1acc0" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:31.5pt"><ix:continuation id="iceca1c718cea47c69cc5aa3960e1acc0" continuedAt="i608aebcc352440e5a097c4af235cb6cb"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzE0NDM_646b43a7-e402-4ffe-a73e-48e2e1254a74" continuedAt="i5c2d1b7a121942a4ac36722fe453283a" escape="true"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2021 and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItMS0xLTEtMTc4NTM_a9791b4a-b8f3-4e63-84c9-e847109fe296">81,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItMy0xLTEtMTc4NTM_3a8e1768-60b9-4ff8-bd8d-d3f6ea421673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItNS0xLTEtMTc4NTM_34363f5f-bde5-4d84-98f2-6fc7956bf1d4">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItNy0xLTEtMTc4NTM_d9dd09bf-c3e8-46ef-acd8-ce53d0361322">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtMS0xLTEtMTc4NTM_83298619-0689-4c50-af7d-3ad227601bd7">7,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtMy0xLTEtMTc4NTM_ad1565bf-044f-407d-b7c5-eb4e4b15c6d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtNS0xLTEtMTc4NTM_522ec135-a7c4-46f5-b784-3a0f324075b1">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtNy0xLTEtMTc4NTM_f75e6e65-ced7-444f-9b0a-8eb8d5af64da">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtMS0xLTEtMTc4NTM_210891c1-eb74-4aaa-b0b2-f13f1ee1da05">31,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtMy0xLTEtMTc4NTM_df92033b-0b5b-467a-856e-5776df669d89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtNS0xLTEtMTc4NTM_7054dea2-c0a8-4087-b359-4c92acb791e0">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtNy0xLTEtMTc4NTM_ff641242-a29b-4893-a0d6-03597e605a19">31,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtMS0xLTEtMTc4NTM_37004661-bed1-4caa-b907-56f409876f35">120,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtMy0xLTEtMTc4NTM_6f57b8c8-1671-46de-a14b-25888121dda9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtNS0xLTEtMTc4NTM_246ec051-f724-4159-bdcd-3a69bfe0b724">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtNy0xLTEtMTc4NTM_bc0649d0-3755-4930-9c9b-50a30c38ba44">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i608aebcc352440e5a097c4af235cb6cb"><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i5c2d1b7a121942a4ac36722fe453283a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItMS0xLTEtMTc4NTM_ad8fbe98-ad7d-4baa-bd35-4e4caf0331ed">60,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItMy0xLTEtMTc4NTM_814660c8-9666-4f39-bb08-502ad5871528">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItNS0xLTEtMTc4NTM_4b9ab093-6ad2-4d7f-97ab-9619416e0d09">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItNy0xLTEtMTc4NTM_e367b6d0-8d98-4797-abdb-9eb3fb5987b7">60,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtMS0xLTEtMTc4NTM_594c6571-2b13-4970-b90d-df9196c2bc5a">30,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtMy0xLTEtMTc4NTM_2849894a-7e51-4a9e-acc0-d4ad2dfb4f4c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtNS0xLTEtMTc4NTM_22074d10-fd37-4907-8856-7914629ebe9c">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtNy0xLTEtMTc4NTM_d550c9b7-a27d-4e2f-8846-c8ec9372f9f0">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtMS0xLTEtMTc4NTM_e03825a0-c9a2-48fe-b9e0-a24ea3fe8191">91,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtMy0xLTEtMTc4NTM_1f9bd564-ec63-4f80-9a89-155865af5c34">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtNS0xLTEtMTc4NTM_23979b21-b267-4466-8e2c-2d165935fe24">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtNy0xLTEtMTc4NTM_58e35f40-17ce-42ea-b1f0-61926c0b033f">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2021 and 2020 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2Mjk3Nzc_e8baa312-9602-49f0-810e-dc9173d0449e">no</ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyNjg_f18a3bed-9c6c-479f-96e3-79eab24582c2">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyNzY_8b258676-d2d7-4b6e-a74e-63ac6cf85a2d">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyODQ_da97363a-fbe1-4f8d-a489-e209b3ec7cc3">3.4</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020 and 2019, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_823"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjgzOTQ_f489f2a0-9f75-4a63-b888-cc5369023142" continuedAt="i61deb68258984a92a974884a46c8c85a" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="i61deb68258984a92a974884a46c8c85a"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxODY_b5086174-19fc-4cd4-9408-2a59b39c2b04" continuedAt="id7a97fe475914a1ea7ddb648c1a59190" escape="true">The following table sets forth the Company's inventory, net of reserves (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt"><ix:continuation id="id7a97fe475914a1ea7ddb648c1a59190"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzMtMS0xLTEtMjAzMDM_a3d0330b-303f-4a64-b2cc-f090e6623149">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzQtMS0xLTEtMjAzMDM_b2533a99-50d5-471f-9bb4-047c1b5c3d14">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzUtMS0xLTEtMjAzMDM_cf182360-122b-467b-8060-53674c2c405c">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2021 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxOTA_49632b8d-31f0-484d-b9cf-a4c669f78e08">2.0</ix:nonFraction> million for unsaleable inventory which is reflected in cost of product sales for the year ended December 31, 2021.  </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="mgnx:ScheduleOfInventoryReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxODc_4f49834d-f66c-4585-b125-0988742b3054" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e9b541c7d14da4b142d7261904ce4e_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItMS0xLTEtMzI1OTc_61f09d4a-14b4-48bf-9e2b-a7401a726c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItMy0xLTEtMjkyNDY_456c4798-dbec-4dbd-84be-d748517f3e4c">2,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268a3aae59a84907bef761d5aed331fb_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItNS0xLTEtMzI1OTk_ed4ed42d-4dfe-430c-abb4-6b507e25afd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia48a351150ac4a5eb9e5e9dda3c114b5_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItNy0xLTEtMzI1ODY_3de90328-7732-4093-823f-6b167e5bfc6e">2,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_148"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzI2Ng_5740fb24-550e-46f8-bc5b-b59d51f1d80b" continuedAt="i69241561a1e1478bba2b2ee672c36d1d" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i69241561a1e1478bba2b2ee672c36d1d"><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzI2NQ_5069ebaa-f578-4708-89eb-31364cdb3901" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e6d9783b92432ea33daf8eb921627f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzItMS0xLTEtMTc4NTM_b607d2b2-c47c-4917-a506-28735e704496">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28a044d1dfe4d36a71c069813f7c53c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzItMy0xLTEtMTc4NTM_8a1aabf6-29ed-407d-b6ba-fdadfc1484e5">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcef9e6df6fc49d8aacf159f30ee4514_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzMtMS0xLTEtMTc4NTM_17424128-0cb5-4fab-8422-09b3ef80e852">9,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7c22c8312a430ca1abd6f404d03919_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzMtMy0xLTEtMTc4NTM_74e64142-9aae-4b8f-9d49-b5814a9e337f">8,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8206a542994cf6ae5a0d5d787ddd83_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzQtMS0xLTEtMTc4NTM_d73809ff-36d2-422e-bf28-86b7ff61f882">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045caf1d0b3b47e9a583b3518ce82462_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzQtMy0xLTEtMTc4NTM_565f2bed-430a-42e4-9097-05f6136a425d">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9141e7bbac044ed0b92ea1beb2676495_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzUtMS0xLTEtMTc4NTM_2b12de51-69e1-4e6c-9562-400d54a65155">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa8238c19ee74d50b77649fc0430ae5c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzUtMy0xLTEtMTc4NTM_2ee85ba7-5e94-4bd1-8ee5-84664f2901c8">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ecd57bb740432882d856e06fb03953_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzYtMS0xLTEtMTc4NTM_7ff46ec9-88d9-44bc-ba6d-540619ea2ccb">45,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4ac0aa4f84f12b9173dabcc85a1e8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzYtMy0xLTEtMTc4NTM_e3922bf2-6219-446a-806f-5b22bdceb6fb">41,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf50eeea4f84d868f237bb8d23137a1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzctMS0xLTEtMTc4NTM_bb2219ef-357d-4651-b1c5-4efc8d88e4f6">51,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f03cac289bf4ae48981b949d7420242_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzctMy0xLTEtMTc4NTM_7ef7cf21-4b66-47aa-9ca5-0f5cc2ddbe39">48,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzgtMS0xLTEtMTc4NTM_50089e08-9d39-44f3-a915-3db712a8b1dc">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzgtMy0xLTEtMTc4NTM_b822b94d-8c75-4d25-a007-6fa2c322bb78">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzktMS0xLTEtMTc4NTM_c4b71da8-dbf8-4d06-b39c-39ad3e958b72">110,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzktMy0xLTEtMTc4NTM_7de3633c-affe-4755-be3b-34a5ba51d4cd">103,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzEwLTEtMS0xLTE3ODUz_c9312072-5eaf-42dc-b23f-7e39663b8895">72,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzEwLTMtMS0xLTE3ODUz_06c2c3de-6ff7-445b-8acc-f48fb8468fdc">61,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzExLTEtMS0xLTE3ODUz_251dd911-7652-4b5d-a12a-91772f13f50b">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzExLTMtMS0xLTE3ODUz_770e9a6a-8011-46e4-a82b-e6d05920e273">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNDY_c7b50fe0-674a-49fb-ba8d-b3d4507cda61">11.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNTQ_f9d109bb-e9f7-4485-9f02-75ea1591e78c">12.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNjI_ae7e6ff8-78bd-4871-a547-a00925fdc226">12.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i42ef1f69451b4aa1b71984b2e3189d12_151"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3Mjk_ada498cb-5252-43c1-b75d-c0ef23d2aaf4" continuedAt="i55c0f2bc01b747c5a0a49aad8c3388dd" escape="true">Leases</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:continuation id="i55c0f2bc01b747c5a0a49aad8c3388dd" continuedAt="ia3e9731009eb40e09779175c2c170e10">&#160;&#160;&#160;&#160;</ix:continuation></span></div><ix:continuation id="ia3e9731009eb40e09779175c2c170e10" continuedAt="i43472aa3c9124493b74f7c712ca5ddbb"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Nzk_1f9bb43e-2188-4db1-a2dd-eef9b62cc89b">five</span> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="i02618b2ea51d4cd3af3550dd4354387c_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0ODM_0b3a8cdb-65b4-475e-8501-010cc64bf16d">fourteen years</ix:nonNumeric>.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njg_2cdc2ade-999e-4cbc-a863-d5bd8d5584df" continuedAt="i6373a398e4b1444c9a8df0810d879fcb" escape="true">The table below presents supplemental balance sheet information related to operating leases:</ix:nonNumeric></span></div><div><ix:continuation id="i6373a398e4b1444c9a8df0810d879fcb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzItMS0xLTEtMTc4NTM_855b13ce-4cc0-4c67-bb09-fb61b8417c70">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzItMy0xLTEtMTc4NTM_804f8da7-4ed1-4287-9438-12fd09861123">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzMtMS0xLTEtMTc4NTM_57126d55-f75e-437a-b7d9-8eac26bc588e">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzMtMy0xLTEtMTc4NTM_8ac24f93-475b-45a1-aa14-1e47cd11dbae">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2020, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MTE_7b780f49-660e-445f-8522-2dae8606d881">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MTU_e2ebb90c-2a69-4695-9737-c2f8f27e4b65">5.9</ix:nonFraction> million, respectively. As of December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2020,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Mjc_020ca73b-aba2-4895-816f-eebaa407285e">16.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MzE_227b4bf4-8663-4921-8381-16bd8d25b5d5">19.3</ix:nonFraction> million, respectively, and are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_14efbc58-6be4-43f5-936e-e2b8c4ab192a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_b4c5924c-e837-4d82-8676-20ffc42a5e51">other non current assets</span></span> on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3MzI_955cb2cb-c515-4f9c-9dcf-9e730bdfd3c8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzItMS0xLTEtMTc4NTM_51acc162-ec28-4d80-a6f2-3790e3a407ed">5,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzItMy0xLTEtMTc4NTM_eb1cffcb-172a-41bb-9962-b5d4689276ab">5,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzMtMS0xLTEtMTc4NTM_2445a8e8-7059-45b9-a4ef-5c63e95f98c3">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzMtMy0xLTEtMTc4NTM_0d70a3d4-9cb4-4771-badd-db35341144af">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzQtMS0xLTEtMTc4NTM_3b37607b-5ea6-4488-b0a9-1151a9c7040d">814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzQtMy0xLTEtMTc4NTM_155509af-0533-47a2-93c5-7738a59e4397">770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzUtMS0xLTEtMTc4NTM_a6700f04-18c5-4eca-a095-aab6fa021c87">5,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzUtMy0xLTEtMTc4NTM_72b587f3-3fd6-4b8c-93c8-50fc1b8f37c4">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3MzM_0ef09791-518a-4d33-be64-8e8dce9399e8" continuedAt="ic939345c2e3845f2865911fbdbfe2aa0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><ix:continuation id="i43472aa3c9124493b74f7c712ca5ddbb"><ix:continuation id="ic939345c2e3845f2865911fbdbfe2aa0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzAtMS0xLTEtMTc4NTM_88566d3d-7916-4495-8d3b-937b53703d87">6,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzEtMS0xLTEtMTc4NTM_3d944c66-8ce6-428d-a0f3-a6b85faf2f07">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzItMS0xLTEtMTc4NTM_5a5569f9-d57b-4fbe-8731-26bcc0d19627">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzMtMS0xLTEtMTc4NTM_ef21941b-1bdd-4f3c-84bb-5ac862be6721">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzQtMS0xLTEtMTc4NTM_53693cd2-f644-4e1f-ba25-7ca6348ac6fe">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzUtMS0xLTEtMTc4NTM_a4f77860-72ba-4fca-9a0f-99a5e29c9255">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzYtMS0xLTEtMTc4NTM_0097a1be-2e95-41c2-9717-d5fc706cb7a5">32,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzctMS0xLTEtMTc4NTM_04d787b1-4370-4310-a1b2-2454b51b1acc">6,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzgtMS0xLTEtMTc4NTM_69fd7244-995b-40ef-a36b-90c1a911ceed">25,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_154"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzIyMTY_6343a291-83cd-47cd-ab69-6d1e680ef334" continuedAt="icbe0cecdd81c42399a75a0ab8cce9a99" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="icbe0cecdd81c42399a75a0ab8cce9a99"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5Mzg_1ef05942-6491-4db7-903a-1cb27934764a">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTE_893e3f0c-e26e-4917-9f01-802ae84b6123">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NjM_688ecd06-b808-4d68-a74a-08352ab98cf7"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NjM_9d71d7d7-7bb0-4898-a241-10f2fe3ee793">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_21df1928-a818-4ea8-9f57-703bfd0a1eab"><ix:nonFraction unitRef="shares" contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_43c48df2-ecf4-4c46-9a6e-75259181501c"><ix:nonFraction unitRef="shares" contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_7e7ce95d-5753-4b4b-a19e-bdd93c4d0692"><ix:nonFraction unitRef="shares" contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_d31c4272-42af-4fef-b94c-19e4057b81d1">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2021 or 2020. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i82158f1c3e8248488d95c8b5bd40b59b_D20191201-20191231" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1NTY_0f8654a0-3c33-4a03-bcc6-06692293af97">50.0</ix:nonFraction>&#160;million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $<ix:nonFraction unitRef="usd" contextRef="iba492058a73347a0a5489e85e2e14c17_D20200601-20200630" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1Nzc_3637a0c6-e04c-45de-8a3c-a7dd8a65f246">175.0</ix:nonFraction>&#160;million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on December 23, 2019. During the year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1OTM_d8a120e6-6698-4071-b2d6-c58e23089575">6,612,815</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="id4c67b59b55c4ed49bb7327fa669d24b_I20201231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MDI_cf7bc1ef-8d2d-4005-a78f-22579b3c9b4d">26.46</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MTk_9e99dadc-71be-4817-97ad-2cd9cdd402b1">170.5</ix:nonFraction>&#160;million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i2b85187757a14127bf72d33a7726047d_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1MjA_2fe1ec5e-6e03-4593-ab48-3a5270e4526a">100.0</ix:nonFraction> million through an ATM Offering. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December&#160;31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1MzY_455c5fd3-90f6-41b9-92cb-3b0cae6254c3">3,622,186</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia35cfb96164647f3ab6265a6387a0ad6_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1NDA_5a996506-699a-46e5-b72f-ec226f0012b9">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1Mjg_bce930f4-a7c2-4879-8759-4348673a6345">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i2b85187757a14127bf72d33a7726047d_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2Mjc_1c0faacf-33fd-451e-9f7a-57093762f6b8">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i1b9ef449adad42c281b17649822997df_D20210401-20210430" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MzU_74b24564-887f-41dd-b8ad-61e7c894d441">300.0</ix:nonFraction>&#160;million.  During the year ended December&#160;31, 2021, the Company did not sell any shares of common stock related to Amendment No. 1 to the Sales Agreement.  </span></div><div style="margin-bottom:21pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 10, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA3ODQ_7f36304f-5c84-4ecd-8f77-6bf7410a942d">30.0</ix:nonFraction> million to purchase <ix:nonFraction unitRef="shares" contextRef="ia1a04d0404924490b3850604be6a89bd_D20210601-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA4MDA_737fd7b9-63f0-41ed-8dcd-758769250686">958,467</ix:nonFraction> newly issued shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2NDM_9827dc00-7e91-47dc-b1b1-dc9ad41acfa1">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA4OTA_fbd685b8-f239-4152-a142-196baf642d26">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA5MjU_099f9206-7d31-4edc-84f4-50f65fc2f62e">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date.</span></div></ix:continuation><div id="i42ef1f69451b4aa1b71984b2e3189d12_157"></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzU_eb08dc01-904a-4b54-9389-82b14bcf447c" continuedAt="i1920cbc08633404c836cb4fe1cb1bc7f" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i1920cbc08633404c836cb4fe1cb1bc7f" continuedAt="i8270ef4387c44c238e0ee13b4e7a4a6a"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="i4cc03fb113394648b6bdf6152f7f62a0_I20170518" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NTk_33c256e8-f72c-4deb-a609-5a187b03f7c5">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NjM_653b6537-9045-4875-b651-2e511773ac3e">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="i6c715158e6064e159bcab21034af9af4_D20170501-20170531" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzc2OTY1ODE0MDI2NTY_1662d3e6-4d83-4ce8-abbe-0289b3e9552b">six-month</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4Njc_3b2180f7-ee3d-4620-babc-c3b192911450">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2021, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i8270ef4387c44c238e0ee13b4e7a4a6a" continuedAt="i343caa2992e54788b925a75550a0e61f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees purchased <ix:nonFraction unitRef="shares" contextRef="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NzE_09171b69-8711-4d3b-a521-4c9c7ee00a8f">34,922</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NzU_8c29d42f-8c9e-4021-b82c-e47a9007ac43">0.7</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2021, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="id9275d7191a54f6c8cef0a06cd60f348_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MjM_fa301d1d-3b07-4a84-8ffd-e353a4071640">187,543</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id9275d7191a54f6c8cef0a06cd60f348_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MTg_e721778c-6805-4a2c-8e08-446c7a7ed5c6">2.96</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="idf57af4d358745b3b61d2a28c3928667_I20131031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Mjc_33323c50-611a-4773-b6b6-e874bf603c9c">1,960,168</ix:nonFraction> shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="idf57af4d358745b3b61d2a28c3928667_I20131031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MzE_33323c50-611a-4773-b6b6-e874bf603c9c">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MzU_75878768-897a-4e83-820f-74ca2f5153d7">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231" decimals="INF" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Mzk_ece7c1c4-ba46-4298-93a9-171f7212fbf0">13,856,781</ix:nonFraction>.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2021, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NDM_f1400b9a-fa30-416e-bbb1-b3845a815e43">8,186,378</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NDc_4d0edcc9-73e4-46d1-9408-6a3d985a6779">21.90</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzM_289d948d-d7da-4044-88d1-17e054b7087c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17b8363a661845b8b88668665eb30137_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtMS0xLTEtMTc4NTM_238d8ca1-188d-4d52-9cc6-15b09e215bfe">11,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida585248332d440d8b323582780c5460_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtMy0xLTEtMTc4NTM_e6e43eda-7c27-4253-8010-717a1f63e145">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40eceed5a1a4f0bbac51e606900df93_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtNS0xLTEtMTc4NTM_24e5558a-1103-4db0-92f3-90bd39e36a21">10,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd525d4970a470494f9448eb7781e63_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtMS0xLTEtMTc4NTM_f9137d06-38ba-4aed-80e1-9572d8f489e7">11,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f4b23a571a4c828aa3564e2cf02b6c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtMy0xLTEtMTc4NTM_fabb2154-bcc0-4562-a1e1-ebaf7003c025">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6003a2136a8f46d480f8bb29b428b7cb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtNS0xLTEtMTc4NTM_9e1793d7-ec50-4428-816b-5d3d577fdb5d">9,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtMS0xLTEtMTc4NTM_6d379a7f-90ee-4280-8c9e-9ec2795a3cd3">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtMy0xLTEtMTc4NTM_9cf5be6e-284b-4aed-b2ff-687c632ef469">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtNS0xLTEtMTc4NTM_d0309b02-3f12-4ba8-a547-730438fd8cc9">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Options</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxODA_ebcfb7f8-2d21-4fe2-b264-4fed70aec59f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItMS0xLTEtMTc4NTM_60faa58d-e189-4312-b024-f5d618f121bb">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItMy0xLTEtMTc4NTM_dcce8933-e0dd-4c55-9367-aa90c640d9bf">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItNS0xLTEtMTc4NTM_354fdde5-b092-4b71-8d35-da2cb9256917">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpjOWIxZjU1Mjc1MDQ0ODgwYWY4M2Q3Y2Q2YTI5Mzc1N180_464b4bff-603d-4b13-b733-0867091249af">86.2</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpjOWIxZjU1Mjc1MDQ0ODgwYWY4M2Q3Y2Q2YTI5Mzc1N184_0dc2b975-a4a4-418f-8798-f3cdcacbc4de">87.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72620f596efb4d87830df652d48d868b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjozNGYwZWMxNGY2MWQ0ZmQ0YWQ5MjBmY2NjM2Y5MzYyOF80_29e43f37-0f30-4039-82a7-07a8c85e1ca3">67.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjozNGYwZWMxNGY2MWQ0ZmQ0YWQ5MjBmY2NjM2Y5MzYyOF85_7a108162-2f24-49c9-8205-f3a135758f5d">109</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo2NTE3MjAwYTExYTM0NzhhODFhMjNmODM1ZGY2OWQ3Nl8xNjQ5MjY3NDQxNjc2_dc9183b1-9507-4323-977e-35d8d4ef71ff">74</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo2NTE3MjAwYTExYTM0NzhhODFhMjNmODM1ZGY2OWQ3Nl8xNjQ5MjY3NDQxNjgw_8e4aacb7-97fe-4984-95f1-06d6db9ebfbe">76</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpiZjI5ZTE1NjFmNWE0NmQ1YmRmMzFiZTZlMWFkMjUwNV80_5ddf14b6-52b9-4250-8b47-01f95240c38b">0.64</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpiZjI5ZTE1NjFmNWE0NmQ1YmRmMzFiZTZlMWFkMjUwNV85_a5577e96-d3aa-4115-91d2-e80e391b01ea">1.55</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72620f596efb4d87830df652d48d868b_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpkYzhlMjM0OTY0ZDU0MDFhYWYwNGRlNDg0NTg5ZjJhMl80_a837d028-3ed6-4237-a007-1f1eb67d79a7">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpkYzhlMjM0OTY0ZDU0MDFhYWYwNGRlNDg0NTg5ZjJhMl85_fbcd1c89-d607-458f-8a7a-09336f16b91f">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo3NmY3OWIyNTc2M2M0MjljOGUwYjc3YzJkMzZmNTg3Zl8xNjQ5MjY3NDQxNjc2_1195e9e0-41e2-4eb8-91d0-71f88a0eb3a7">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo3NmY3OWIyNTc2M2M0MjljOGUwYjc3YzJkMzZmNTg3Zl8xNjQ5MjY3NDQxNjgw_0517a1b3-f719-4aba-906c-4fc7aa0caae5">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtMS0xLTEtMTc4NTM_fd15ff85-7bd4-4ff4-b963-f1e09f2491c3">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtMy0xLTEtMTc4NTM_50b6a16b-dbce-48c9-a587-fdee359ecf68">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtNS0xLTEtMTc4NTM_24fbaf77-e3a3-4e71-affd-523e1d6bf59f">6.25</ix:nonNumeric> years</span></div></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i343caa2992e54788b925a75550a0e61f"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of <ix:nonNumeric contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxNDc_349c3937-1225-4705-ab95-7655eba87fbe">ten years</ix:nonNumeric>. The Company uses a simplified method to calculate the average expected term.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzQ_7a042386-24a1-4d0a-9c78-1a79b6ff02cd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtMS0xLTEtMTc4NTM_2bd78c51-8f01-40ca-a124-a688de9e133b">7,258,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtMy0xLTEtMTc4NTM_b8767258-62ad-4ba9-a7ef-942e03ba092b">21.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtNS0xLTEtMTc4NTM_f1476ec3-f126-4e7a-83c1-ff7c3d520d48">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzItMS0xLTEtMTc4NTM_0f84c6f9-2060-4fe3-952a-c3cda567178a">1,941,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzItMy0xLTEtMTc4NTM_e1666157-3a0b-4f03-bf7e-6d38ace02ce7">20.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzMtMS0xLTEtMTc4NTM_674622c4-2014-4460-b1a9-4b31938f533f">332,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzMtMy0xLTEtMTc4NTM_4248f2bc-9493-4b67-b093-6ac01d093440">17.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzQtMS0xLTEtMTc4NTM_05bede74-dc71-40ae-9997-3810ac2c1680">493,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzQtMy0xLTEtMTc4NTM_786a68d3-9b27-4c5e-9cdc-3913a620b875">21.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtMS0xLTEtMTc4NTM_ca3ee6dd-3606-415d-b6c7-09f7332c0a26">8,373,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtMy0xLTEtMTc4NTM_d7004c28-4ce3-435d-9705-f1ed6a20071b">21.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtNS0xLTEtMTc4NTM_c49d7041-d4c0-4954-86eb-689b7b98c4cb">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtNy0xLTEtMTc4NTM_efc16498-29ca-4c47-b516-4360c274cdef">7,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtMS0xLTEtMTc4NTM_7ef57826-71ba-48ea-9446-c46600ed6de3">5,546,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtMy0xLTEtMTc4NTM_5fe0fdf3-067c-4611-aa85-36757efe8e96">22.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtNS0xLTEtMTc4NTM_8e64e686-df0c-4469-833d-3d1e1e18bb9c">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtNy0xLTEtMTc4NTM_989d2953-0df1-4edc-b45a-bd79f10c2113">4,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktMS0xLTEtMTc4NTM_4f247898-e64d-40a2-b7ac-12c7abe93567">8,010,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktMy0xLTEtMTc4NTM_56cd8837-40e5-4362-bb0c-199d08af0914">21.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktNS0xLTEtMTc4NTM_f56a6294-570c-4ec1-a81a-4ec8904dce5e">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktNy0xLTEtMTc4NTM_c3cd2db2-66b8-4613-bc2d-c68f30ab5b08">7,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019 the Company issued <ix:nonFraction unitRef="shares" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTA_75a31af2-e5c7-4616-afe8-bb41a0a191a3">332,767</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTQ_767ef965-302a-4ea6-8584-308c70beaec6">504,445</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTg_958a0af5-59c1-4498-8a1e-85c0581f6d96">219,045</ix:nonFraction> net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNjI_5535829b-7b04-4660-8796-0ed5dbc24b77">5.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNjY_beb39add-6521-4973-b862-2423cacccb80">5.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNzA_b1cc898e-9df7-4980-9791-22c300e8cdcb">0.7</ix:nonFraction> million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwODU_8e68f03a-7dfd-4b02-b1ad-438efa90873e">15.20</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwODk_1ecaee5a-9dc7-41ca-af1f-c1ed00c14a08">10.68</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwOTM_dd95968c-6a1a-4f34-a5e1-477443f12a44">13.98</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwOTc_c259f627-d4f5-4317-b132-aef1adbc7bb3">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMDE_56b64bc0-7e50-4636-9c97-4b21af9fec13">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMTM_cf3aa70a-dd1e-4900-8679-b64cd0dd38a2">2.9</ix:nonFraction> million, respectively.&#160;The total fair value of stock options which vested during 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjE_1839352c-0a49-4e5b-b1b0-52fa6e294230">20.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjU_40d6101e-565a-48a2-b28c-2c81a14cee5d">16.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjk_d673a347-c95d-4f7f-838a-84f55f02ed76">17.7</ix:nonFraction> million, respectively.&#160;As of December&#160;31, 2021, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Njk_6751b80d-6a32-48c9-9e23-49487c8d4951">31.1</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NzM_0344c758-aeee-4fdb-ab8d-2770b674a3bc">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded RSUs under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of December&#160;31, 2021. The Company also grants RSUs to employees from time to time as a component of their compensation. Compensation expense related to RSUs is recognized on a straight-line basis. </span></div><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzk_0aa42e60-56e6-4d5b-a298-471a6eb78062" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a79b00742544d54ace1cbe572cc95e9_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzEtMS0xLTEtMTc4NTM_15431485-5b75-4f07-8196-9e136cf1662d">209,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a79b00742544d54ace1cbe572cc95e9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzEtMy0xLTEtMTc4NTM_79d83da0-38c7-4f64-9150-a98fe4d295c8">15.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzItMS0xLTEtMTc4NTM_5cc66006-de36-449d-914a-112dbbfabc2b">16,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzItMy0xLTEtMTc4NTM_c5c247f7-815d-4397-aeba-99c0cae34f62">26.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzMtMS0xLTEtMTc4NTM_8a9c0566-c4de-4158-a7b4-fedf3e02a121">184,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzMtMy0xLTEtMTc4NTM_7c723a92-1a26-4e24-978a-cb906b1c6ac0">15.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzQtMS0xLTEtMTc4NTM_83112e03-585d-4e2a-9936-5919db904bcd">20,150</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzQtMy0xLTEtMTc4NTM_f0a166a2-b209-419f-9c42-e9e4ad9ec2d7">16.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzUtMS0xLTEtMTc4NTM_895d3a0d-4b8b-45d9-ae63-c12575cf2344">21,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzUtMy0xLTEtMTc4NTM_020e2b92-f390-4733-865a-16c93fb5f6a4">25.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NTI_25ba2fe9-bd88-44bb-ad65-222d9533cab3">0.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NTU_915fc564-4bc7-4f6c-9949-c9ae21cf4636">2.3</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;<ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzg_682a9291-9868-4767-86e9-50655e21cff7" continuedAt="i7f1c78baea66438a8f2fd7b893cd60b5" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i7f1c78baea66438a8f2fd7b893cd60b5" continuedAt="i6bcf0a06b283444288b7eaabce28b174"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019 there was <ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_78f01a23-31b3-4fec-a222-f4cf82ec3e42"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_bb9b772d-dfb1-4a64-a69b-4dd385e57a6a"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_ce983365-6269-4770-b367-fa56e6909220">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzk_47cac2c2-c287-4fa5-bee4-18e43426dd28" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzMtMS0xLTEtMTc4NTM_dfc28c9e-a4f7-481d-b4e6-3f58ec8e0646">175,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzMtMy0xLTEtMTc4NTM_d581c89d-22a4-4a7d-8645-2f5aa51bf7a3">136,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzQtMS0xLTEtMTc4NTM_b55e7319-1537-416d-94e4-ccb5616bd361">49,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzQtMy0xLTEtMTc4NTM_aef4c2cd-bb42-4aec-aa5d-f6eec21473f7">37,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzUtMS0xLTEtMTc4NTM_396d7cd9-49bb-4b31-8ffc-51906dc818aa">60,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzUtMy0xLTEtMTc4NTM_372e8552-b465-47c1-84db-4d3a22d17cc0">50,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzYtMS0xLTEtMTc4NTM_447e675a-d697-4d25-8f1a-ea697ab21b23">24,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzYtMy0xLTEtMTc4NTM_2f9d26ad-bd96-42fd-85a5-a433189c01d4">23,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzctMS0xLTEtMTc4NTM_0c8d008e-8fc4-45ce-911c-d3dab85efc06">7,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzctMy0xLTEtMTc4NTM_3e2fa569-9aa1-4973-aa01-5ef478bcec32">8,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzgtMS0xLTEtMTc4NTM_59f1b008-4093-4681-8760-8b8f9a473423">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzgtMy0xLTEtMTc4NTM_61a30283-d8f2-4daa-9a8f-35e328ddc415">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEwLTEtMS0xLTE3ODUz_68827eb9-46e2-43a0-a7f3-747c58d8c431">16,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEwLTMtMS0xLTE3ODUz_e03c31f6-ef8c-42d2-a83d-ba47cf928469">14,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzExLTEtMS0xLTE3ODUz_12cf00b4-81f1-42bd-87b2-661e2736751f">336,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzExLTMtMS0xLTE3ODUz_d4c29bf1-f5e7-4135-a417-e668b998a1dc">272,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEyLTEtMS0xLTE3ODUz_3d4244c0-6d45-4483-9e2c-4a83c4237cd7">327,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEyLTMtMS0xLTE3ODUz_7cca9073-1a15-4ac1-a688-2dc142b0625a">263,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEzLTEtMS0xLTE3ODUz_41c9d123-ae9d-4254-82d3-e3c715eb3411">8,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEzLTMtMS0xLTE3ODUz_cd50a11b-2fd7-46db-821f-55985f8b098d">9,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE2LTEtMS0xLTE3ODUz_2006dfe4-8e6a-4a5c-972c-778987a85874">1,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE2LTMtMS0xLTE3ODUz_440f6b8e-19ac-41ee-8bcc-b7ee1111a595">2,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE3LTEtMS0xLTE3ODUz_befbc240-f413-4e84-ab7e-c5deed72a17f">4,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE3LTMtMS0xLTE3ODUz_f2b1765f-7b30-4c70-80f0-41508f616f31">5,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE4LTEtMS0xLTE3ODUz_93d5dfb1-b96e-432a-8153-2b37b09c75a5">2,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE4LTMtMS0xLTE3ODUz_03e90169-3753-42b3-b7dc-dca0686cf316">1,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE5LTEtMS0xLTE3ODUz_ff496856-c456-4a44-a2f3-9602ef3791e9">8,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE5LTMtMS0xLTE3ODUz_21f6a913-2d58-457d-9bb2-dff93ddd2211">9,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzIwLTEtMS0xLTE3ODUz_567da834-f9ac-4e2d-ae5d-5bd7789f6dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzIwLTMtMS0xLTE3ODUz_0798f0e6-9a58-4241-b73d-65ba0d9269de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="iccd7737654fe4891a7d522515d8d2f96_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzExNjA_d8bfb76a-1ebf-49c7-8579-944ba48018ff">837.0</ix:nonFraction> million. Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="i137fc423fc124b71bb9d9d0ea218086f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMDA_070e2efa-dc09-46f0-ba58-07728a458e22">238.0</ix:nonFraction> million will expire in various years beginning in 2025 through 2037. $<ix:nonFraction unitRef="usd" contextRef="i9f48a736a74a46c48d9e72e00bec62fd_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMTY_263aa141-f61b-416d-a56e-a8743d5f1bdc">599.0</ix:nonFraction> million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="i95796e3e505f42ce851397ea0c19f8d0_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMjQ_6c56e493-aab5-4fdb-99b0-a800b643547d">81.0</ix:nonFraction> million which will expire in various years beginning in 2022 through 2041.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i7f6da34d58144c65bd270cebe6dfb2e5_D20210101-20211231" decimals="-5" name="mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNDA_3bec84f0-9b65-4e5e-a988-8fd5b72516f9">13.5</ix:nonFraction> million of the Company's U.S. Federal NOLs are limited for use over the years 2022 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $<ix:nonFraction unitRef="usd" contextRef="i0d5f2f6af1b44ea983621a977a1a87a1_I20211231" decimals="-5" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNTY_c76b7af9-e6e7-4d16-b3a6-20cdfbc3381c">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i6308c33e7e5b4be5b26db9579c7deaa2_I20211231" decimals="-5" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNjQ_85cf41f0-2cea-40ad-85dd-7db182062048">1.4</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="mgnx:OperatingLossCarryforwardsNotSubjectToLimitation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNzI_1b742876-f80c-440d-bd6e-5d966708152b">824.0</ix:nonFraction> million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i6bcf0a06b283444288b7eaabce28b174"><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzODE_6d5e1bc5-0a9b-4e9c-b4f6-a619256251dd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtMS0xLTEtMTc4NTM_971328fb-df82-4fae-b31a-61a6a5852e6d">42,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtMy0xLTEtMTc4NTM_cf74fde4-58e6-42dd-bacb-2cee26e4ec71">27,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtNS0xLTEtMTc4NTM_1e6792e3-39df-4edc-8ab4-dcc091beabf9">31,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtMS0xLTEtMTc4NTM_6593085a-0ad2-4a8c-9b62-a0b2de0e3d3d">12,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtMy0xLTEtMTc4NTM_7df02c46-43e0-4122-a47b-843bee517f40">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtNS0xLTEtMTc4NTM_1933bcfa-5d31-4fae-959d-34f0a710eb6c">9,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtMS0xLTEtMTc4NTM_22c84817-f96e-4e70-9339-a5e894db27e5">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtMy0xLTEtMTc4NTM_83f47495-5fa2-4e48-b5f4-ded907c3e88f">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtNS0xLTEtMTc4NTM_cbc70a33-aff3-4ba4-b162-b64f8b1f9192">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtMS0xLTEtMTc4NTM_9b0aff6e-1fee-42c8-820c-cef74ede2854">10,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtMy0xLTEtMTc4NTM_f0071340-0cb3-49ca-9496-4087c421770b">14,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtNS0xLTEtMTc4NTM_13aa20a6-d762-479c-ab6b-ec07afacc37e">5,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktMS0xLTEtMTc4NTM_577691cd-68e8-405e-8338-db6ce15ef47f">1,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktMy0xLTEtMTc4NTM_bb55d437-bae3-488e-b35e-309f6d2ba212">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktNS0xLTEtMTc4NTM_8d289cdd-9ce0-40e4-930b-24ee77f13440">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTEtMS0xLTE3ODUz_7e7b5273-5b83-4110-8d5f-e4f20d06a28d">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTMtMS0xLTE3ODUz_14278c0c-4fe3-4bc3-8a82-b938bc4ef343">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTUtMS0xLTE3ODUz_3ee57187-3a12-417a-a60a-9f047e131bfd">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTEtMS0xLTE3ODUz_7a8fc76c-8c35-4bf7-a5c2-cee8ae65d728">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTMtMS0xLTE3ODUz_e46a730f-4c23-407d-822d-17727f660a03">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTUtMS0xLTE3ODUz_aaedfe65-9a86-4502-8cba-2367252090e4">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTEtMS0xLTE3ODUz_9186c49c-087a-4180-b9c2-8fd9619c8d1f">64,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTMtMS0xLTE3ODUz_fc2d7db9-84ae-4ba2-858c-a58a2e7c4142">48,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTUtMS0xLTE3ODUz_9e667034-ff86-46df-a78c-9928e992206d">42,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTEtMS0xLTE3ODUz_35a4fbed-2521-4460-b5e7-241e7a3f529d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTMtMS0xLTE3ODUz_aa524ed8-8d62-4997-bccd-652f3323c2b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTUtMS0xLTE3ODUz_dab83a2f-e86d-470d-b769-be2b5b1260cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzc_e5f3bf9d-b033-41dd-896b-62dd5a0f6f9f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItMS0xLTEtMTc4NTM_99710d00-0f95-4334-86a0-a56a4f0cbce9">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItMy0xLTEtMTc4NTM_13713dc7-7d71-43ba-9ab9-e333e8c3359b">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItNS0xLTEtMTc4NTM_384f0bb8-ba7c-40ed-8e71-b5acc81a1908">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtMS0xLTEtMTc4NTM_f44e7499-54af-40ae-816c-eaaa07d0d8d1">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtMy0xLTEtMTc4NTM_bcecd84a-9b8c-4c2f-a154-115bdaa39dc6">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtNS0xLTEtMTc4NTM_70747f10-e64a-4535-a51e-f1859706a9dc">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtMS0xLTEtMTc4NTM_1c283908-8283-4ffa-b614-fb38e6023cac">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtMy0xLTEtMTc4NTM_19fbc7af-d738-412d-bb75-d94378da70a8">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtNS0xLTEtMTc4NTM_e2ee7206-d152-4d5e-ae8f-c0c8585ffa54">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtMS0xLTEtMTc4NTM_31028463-2d26-476a-a21b-bd659a1485be">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtMy0xLTEtMTc4NTM_deec74be-252a-4b0b-abd4-2239ebc89e6f">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtNS0xLTEtMTc4NTM_8ea3b2d6-a8e2-4687-9f75-d4ca483708d0">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxODA_4c8d9c9d-42a8-43bd-9ff4-0c7f2d927d46">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxODg_bcb44ac0-4e22-4905-8ebb-6931ed62a9ae">6.1</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the Company has <ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_71329f13-3974-491a-9e19-356b867c8d22"><ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_758c83be-1125-4626-96d0-2d636acde066"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_ab851fa4-0430-4e65-9968-312dede23421">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">The Company's U.S. Federal and state income tax returns from 2002 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_163"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzIxOTkwMjMyNjU0MTA2_f9b34cb1-719b-4c0f-8448-214c07e270ec" continuedAt="i69a7a812a62e473b8f89138c84d4822e" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="i69a7a812a62e473b8f89138c84d4822e" continuedAt="i5471c968d53449a18ae37d304a6f09e0"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i93b4bb09dae64bad959730c0f8dc14d8_D20180101-20180331" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ3MjQ_a40e9416-b6e2-44ce-9830-68bd928735db">150.0</ix:nonFraction> million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA.  Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i5471c968d53449a18ae37d304a6f09e0" continuedAt="i77cadb3f15ce461fafb334d6587481ae"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic2378ab796454164a230b9cc2d7faa0f_I20171031" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0MTk_4e33ccca-112d-4cca-9b61-8393d94870c9">420.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="ic2378ab796454164a230b9cc2d7faa0f_I20171031" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0MzQ_cf9ad1d1-3deb-4d70-bfb9-d519e701c9f7">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="if421d26f11f845ee931133022aca115d_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODMzOTI_11ebe134-b67f-4ee3-95bc-cfca9db59879">70.0</ix:nonFraction> million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="if9cd8e55dd2e43a6b2c8992d16bc68e1_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0Mzg_a324b88f-3cef-4d1d-8b59-70f8c9aadee1">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifa1a228424a64a95a007cd7763fe9af6_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NDI_b86d433d-d174-4d18-b8be-4e926a314505">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="iea4888039d1b4ab7aa399c1ee0fb212c_I20171031" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NDc_813761e2-ba6e-4aca-9fae-036b37206465">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="if421d26f11f845ee931133022aca115d_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NTU_11ebe134-b67f-4ee3-95bc-cfca9db59879">70.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i51aa661b71304203b27532bef5a74fda_D20171001-20171031" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NjM_fe7039cf-bc95-47be-bd94-a1d5b5de3018">150.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="i3d11f08a9b004f7386c9c4c263eb7355_D20170101-20181231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0Njc_23666a6d-9bfd-47b8-958d-ea4fe703b2c7">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ibe770ef261ed4f4a9306a45bca01f142_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MDg_715fd441-f1d9-484d-8a4d-caefc5220cdb">15.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia95774cf1200470694fcafd3bf7ec9ba_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MTY_8f80b1f8-861e-4237-9dcb-d75d723f867b">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if911c7bcddb24ab59739871990c63da1_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MjQ_8b61c953-7b74-45b5-9ba3-31d0def37255">0.1</ix:nonFraction> million under the Incyte Agreement during the years ended December&#160;31, 2021, 2020 and 2019, respectively.  All of the revenue recognized during the years ended December&#160;31, 2021 and 2020 was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being  recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib5513c4a35d44bd7aa7138877117d5e8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MzM_111da07e-8c16-4691-89eb-77d687fbee27">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia9ccfbfd141f41db8e5179255ee74463_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NDE_bad67b04-6600-48fd-8a33-3fc17d3a7821">8.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id01efa0761354d62a3103622dabffb96_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NDk_a8f3e7d4-8c52-4f39-89b0-75df060d1dae">22.1</ix:nonFraction> million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i77cadb3f15ce461fafb334d6587481ae" continuedAt="i55789b1423a743989ceb787c92a1a3f9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.   During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i36ba3c13ff3547468eb072c96419c534_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NTc_ff5793c3-717c-4078-b9a5-cc1aeb1cb14c">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iacf0564421e9468ba07b3edabd65d7c6_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjI5OTY_ee207fdd-ba7c-497a-8723-565081bc3cc8">1.4</ix:nonFraction>&#160;million, respectively, for services performed under this agreement. </span></div><div style="text-indent:42pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0ODI_01a4ceae-0481-4944-a8bb-5c5d33c21897">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0ODY_e984bdbe-ef9b-47c5-833a-fe8a826c12a2">22.5</ix:nonFraction> million after netting value-added tax withholdings of  $<ix:nonFraction unitRef="usd" contextRef="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130" decimals="-5" name="mgnx:NonrefundablePaymentTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTA_72037843-49db-4ded-9d2e-15526ba8d86d">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i2d501e4822e04d958b40b530762460c8_I20211231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTQ_b1b860c0-1577-4e09-a271-35642db62182">140.0</ix:nonFraction> million in development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTg_86fabc8a-ad6b-4ffc-b5e3-86d0f38332be">4.0</ix:nonFraction> million of which ($<ix:nonFraction unitRef="usd" contextRef="i792d3a81b74946ddad05c545e411fb39_I20200229" decimals="-5" name="mgnx:EntitledMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MDI_44412d62-ff47-4210-9463-9ec7aaa05e94">3.6</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231" decimals="-5" name="mgnx:RevenuesTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MDY_59ae3bbd-82df-47ce-aa18-46c563c8c124">0.4</ix:nonFraction> million) was earned during the year ended December 31, 2020. Subsequent to December&#160;31, 2021, the Company earned $<ix:nonFraction unitRef="usd" contextRef="i3a760482c5564290aeaf43f8d43b77eb_D20220101-20220224" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwMTQ_fe1fddb7-da38-479b-93a0-adc5b76513ad">5.0</ix:nonFraction> million upon Zai Lab&#8217;s achievement of a regulatory milestone.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="i5612ac4f2da44022b008ed9b0154cf3c_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTA_3dacb753-8f06-4612-be77-f1f9d702ff77">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="i90aa1101cc4c45c0970ae75b5e31eda7_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTQ_bc9ae60e-0d19-448a-9cb6-42c3e66c5ecd">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTk_e984bdbe-ef9b-47c5-833a-fe8a826c12a2">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the year ended </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i55789b1423a743989ceb787c92a1a3f9" continuedAt="id98ce20999224fc2a79ef1a2ff3be7b6"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i5d46c300f18a459cb051be0f2ec1b59e_D20200101-20201231" decimals="-5" name="mgnx:RevenuesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1ODg_92c6740b-842a-4f5f-b63e-98c8991aa331">8.6</ix:nonFraction>&#160;million related to the 2018 Zai Lab Agreement.  <ix:nonFraction unitRef="usd" contextRef="id56a1c317b0c4eb380a90f7cf2d2edd3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwMzE_2af11429-f23b-4788-99dc-9ba95cce8fea">No</ix:nonFraction> revenue was recognized under the 2018 Zai Lab Agreement during the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service.  During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i2f2e893ab41645da9ad74d3d817f1e4d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2MjQ_fbbb47d4-08e3-49d3-bac1-e3cc956c8c8b">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1cc661c7a12847b8a62549a312da1610_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2MzI_cabaee94-9c1b-4285-a6e3-e4183242bd1e">2.7</ix:nonFraction>&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $<ix:nonFraction unitRef="usd" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="-5" name="mgnx:OptInFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NjkwOTQ_5ca262bf-7d49-4b6b-9ca5-ed9c47383bfd">85.0</ix:nonFraction>&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2Njk4NTU_e6abc386-b4c2-4fa3-aace-a3f43167cfce">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAwODQ_7f36304f-5c84-4ecd-8f77-6bf7410a942d">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAxNzM_fbd685b8-f239-4152-a142-196baf642d26">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAxOTc_099f9206-7d31-4edc-84f4-50f65fc2f62e">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAzODY_1e76d5b1-01af-4528-8055-d23cb3cdc6a0">800.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzA0MzU_b92e3f41-bdef-4317-bb0c-f108012bfdc8">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="id98ce20999224fc2a79ef1a2ff3be7b6" continuedAt="ie9983cb97ba047cdb092042f1e7384f2"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIxODk_e8b21c40-fdaa-457f-a8df-996fae323527">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIyMTI_5e3b50e4-4a6a-4717-b769-05db8f85eb15">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIyMzc_067cefe0-0815-4111-8a6a-e006f36594ef">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231" decimals="-5" name="mgnx:EstimatedReimbursementForResearchAndDevelopmentT" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIzMjI_574aa662-17fc-44fb-a939-d905d81549ec">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ia806a05d835e448d9a55bdd709901742_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzMxOTc_cdd8ef0e-5075-4356-8dae-6832f329fa4d">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized revenue of  $<ix:nonFraction unitRef="usd" contextRef="ie768d1a8776c43debb1629980a72e2b4_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ1MTM_829ed820-609d-482a-85ec-f2005b6285f4">20.3</ix:nonFraction> million under the 2021 Zai Lab Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ1ODg_28f81be7-4569-4a49-9d30-0b23f1d69567">16.1</ix:nonFraction> million in deferred revenue under the agreements, all of which is current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MjM_db05c760-2729-4adb-839e-2d89479aa25c">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i44996a78ebbc4831af9aa001839a44eb_I20211231" decimals="-5" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1Mjc_abb6452b-bd28-4155-af26-74ce8444bfc3">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MzE_6b2f41d0-7ede-404f-a535-6269c2909d1e">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i44996a78ebbc4831af9aa001839a44eb_I20211231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MzU_e4071385-f3db-4f15-a9ee-13214972255e">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ie9983cb97ba047cdb092042f1e7384f2" continuedAt="i5637537016cf494b8047ee7b15d691ea"><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ib57a28be4be44c419ffec77b716c5c4f_D20201201-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1NDA_fed29520-bcb8-4a48-94d5-35140a1c1427">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1NDQ_4c75a71c-f3c1-4989-a75e-77761b9c0180">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  During the year ended December&#160;31, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i20708ad0030840aea94ffda954ec8390_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODI1NzI_9dff37be-9331-4117-bb7a-c0456c662267">1.5</ix:nonFraction>&#160;million for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">I-Mab License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MTQ_c74d602d-8918-4c96-8b8e-41351ec693a9">15.0</ix:nonFraction> million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MzE_bc1a6195-e94f-4df8-9a04-ba2180230038">135.0</ix:nonFraction> million in development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNjY_d159da2a-12cd-48b7-bc01-e3a862c601b1">5.0</ix:nonFraction>&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="i5ba60bca18874586a933ffcf1f9ec4d5_D20190701-20190731" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MzU_3f5b9f2a-9522-4cf7-b3bf-454721ae2636">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4MzI_c74d602d-8918-4c96-8b8e-41351ec693a9">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231" decimals="-5" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4MzY_a60dedf8-4950-485f-a7c5-a6b47bce8f05">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNzU_d159da2a-12cd-48b7-bc01-e3a862c601b1">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231" decimals="-5" name="mgnx:OneTimeMillstoneCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNzk_f2361ca0-107d-44cb-ba62-19c005fbb60d">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NDg_b101d465-6634-4e29-93b2-c6ca9916b3aa">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i379c6fe0225946f5bfd1ba393f064bbb_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NTI_4faeea74-9841-4dd8-a40a-7d3684729f5e">2.2</ix:nonFraction> million, respectively, related to the I-Mab License Agreement. At December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NjA_dedb6e82-2337-4bcc-b737-70726dc5bdc4">4.5</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current. At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i862de472d0f64045b43008af95f4bb59_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NDA_5231bd8b-34aa-4130-ae0c-b09eb23c5441">11.4</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, $<ix:nonFraction unitRef="usd" contextRef="i862de472d0f64045b43008af95f4bb59_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NDg_e1eb41ab-55fe-40e2-8912-5c6dee1bc190">4.5</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i862de472d0f64045b43008af95f4bb59_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NTY_b01d6a23-6d23-4ac9-b538-0d15c6d9314d">6.9</ix:nonFraction> million of which was non-current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">I-Mab Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i5637537016cf494b8047ee7b15d691ea" continuedAt="iffac280ae29043b28305c34ab8afeac7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the year ended December&#160;31, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i32bbffe268d44dd5869451d63139c197_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwOTg_ef374f1e-900c-495d-a991-cc790f38897b">1.3</ix:nonFraction> million for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icd0b205b720243ee89a12573c7a8fe9d_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTE_8853c31e-6d6d-4db7-89c9-4c4513207310">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTU_fba72d29-6ccd-47e5-9695-57785c3d805d">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTk_7a04cf27-6079-4d9f-8625-52f016c8b458">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if2a1dcf4a9df4c959ddbb1934d1a6bf6_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MzE_6133c540-8bbe-4954-a9ee-6f3ce831eb5b">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MzU_6aa2d383-ecdb-4934-9e45-f69b57cede6d">170.0</ix:nonFraction> million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5Mzk_3ea84f41-7f00-4b77-a12d-310552286b26">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531" decimals="-5" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5NDM_d6d897f0-3a8f-42da-a8cf-de8c29009a3f">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="iefbbd3ca3757470f9bc0909619e0664d_I20180531" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5Njk_76735466-b9f6-4ffa-897b-4ab2ba6d1f9e">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="iefbbd3ca3757470f9bc0909619e0664d_I20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5NzM_6098c151-9ceb-47ab-a51c-7ebb2fb04ad8">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8e0a8985fef04a7bafcbb4cc03c35452_D20180501-20180531" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5ODE_7bd7d953-58c7-4b84-b1f5-c4ebf7280af9">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in other income on the 2019 consolidated statement of operations and comprehensive loss.  In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a <ix:nonNumeric contextRef="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031" name="mgnx:CollaborationAndLicenseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzM5NTc0_72235157-e789-43f5-8ba0-cde3a47476dd">five-year</ix:nonNumeric> period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="iffac280ae29043b28305c34ab8afeac7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the agreement.  During the evaluation period, BII selected <ix:nonFraction unitRef="productcandidate" contextRef="i576f9279609e4017a60567b1d894e7c6_I20151031" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzYzMzQ_249ce37d-5268-47b8-995b-a1333ad76381">two</ix:nonFraction> product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMDY_daf10685-a6b7-4724-8116-c1e30cca0b3b">15.0</ix:nonFraction>&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $<ix:nonFraction unitRef="usd" contextRef="i3acefd7dc96d408ab172307350cf602c_D20200601-20200630" decimals="-5" name="mgnx:DevelopmentMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMTM_fa8d136b-934a-417a-946b-ad3e19de1861">12.0</ix:nonFraction>&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="ic8d998ab8e404b8194f6c63d78bb64bf_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMjE_a6e30dfb-69ab-409e-ae55-f3127880262f">12.0</ix:nonFraction>&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="productcandidate" contextRef="i576f9279609e4017a60567b1d894e7c6_I20151031" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMjk_01036d1e-cc7d-4ac6-b8b4-0a2e488c066b">two</ix:nonFraction> DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i7d006afd97914c30b1c39b119a8f1fff_D20210101-20211231" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMzQ_2972ad65-0667-40b8-8c7d-c5abeeaa1d10">25.1</ix:nonFraction> million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i197aeb0afffc4bdaa28739f0f1fc2ca8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzcyODk_ac958b02-5b1b-463c-a9af-3157cf81602f">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0b6a818854f941c79c5bc2d50e4f7fc4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzcyOTQ_5f597c95-85fe-4809-a937-be31733e2a75">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieafca778c80146dc9c099099f62a8ac1_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzczMDI_9e68338e-18f0-4095-8c50-31c1ef8a26f4">2.2</ix:nonFraction> million under the NIAID contract during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i42ef1f69451b4aa1b71984b2e3189d12_166"></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjYvZnJhZzpkNDNmYjZiNDI1YTQ0ZjRkYjhjZjBjNmRjZTlhNjEzNi90ZXh0cmVnaW9uOmQ0M2ZiNmI0MjVhNDRmNGRiOGNmMGM2ZGNlOWE2MTM2XzExNzg_53dd986d-eb9b-495b-81ee-8f15c26358e1" continuedAt="ic1d19d5c7e4346e29c5fd07f3df0aece" escape="true">Commitments and Contingencies</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1d19d5c7e4346e29c5fd07f3df0aece" continuedAt="i3d0c28f859c74f17955f011315de2676">&#160;</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3d0c28f859c74f17955f011315de2676">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal, and on January 18, 2022, the Lead Plaintiff filed its opening brief.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_169"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzY1Mg_75c5eb69-f5c4-43e2-a81e-d1a13091e097" continuedAt="if2205d903acb40179357a1ca8e57825a" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="if2205d903acb40179357a1ca8e57825a"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMTk_caf5ca27-5279-4eb4-b6b0-2ab25c65dcf4">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMjM_cbe78a41-8ec3-44f9-8193-3068214cb675">100</ix:nonFraction>% of their salary, subject to government maximums.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees are <ix:nonFraction unitRef="number" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMjc_258d7ec6-e98d-4d18-a7f8-90086f787537">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMzE_84b3351c-3d2c-47f1-bbac-e5b19cb097e7">1.6</ix:nonFraction> million for the year ended December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzEwOTk1MTE2Mjg1NzY_59a4ffd0-0f0b-4b48-9d96-22a276402662"><ix:nonFraction unitRef="usd" contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzEwOTk1MTE2Mjg1NzY_74bc328a-6121-464d-8925-f8a4c384a455">1.4</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2020 and December&#160;31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_842"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84NDIvZnJhZzozNWIxMzA5OGRjZGQ0M2NjOThhYmM2NThkNmY0Y2Y1ZC90ZXh0cmVnaW9uOjM1YjEzMDk4ZGNkZDQzY2M5OGFiYzY1OGQ2ZjRjZjVkXzEwOTk1MTE2Mjg4Mjc_f3d949c4-a0fa-486f-bd5d-78d0eeff4551" continuedAt="i0385cc592d3f4a31a9332e7e4234c74d" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0385cc592d3f4a31a9332e7e4234c74d">In January 2022, the Company entered into an agreement with Incyte under which Incyte reserved capacity at one of the Company&#8217;s GMP manufacturing facilities where the Company will manufacture certain bulk drug substance for Incyte.  This agreement is unrelated to the Incyte agreements described in Note 10, Collaboration and Other Agreements. Under the terms of the agreement, Incyte will pay the Company an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i7cda7295203d408e87a17554ea99f6dc_D20220101-20220131" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84NDIvZnJhZzozNWIxMzA5OGRjZGQ0M2NjOThhYmM2NThkNmY0Y2Y1ZC90ZXh0cmVnaW9uOjM1YjEzMDk4ZGNkZDQzY2M5OGFiYzY1OGQ2ZjRjZjVkXzEwOTk1MTE2Mjg4MTM_7794929b-9ac4-43c7-8179-bd5957bfb3e3">10.0</ix:nonFraction>&#160;million.</ix:continuation>  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 29</span></div></div></div><div id="i42ef1f69451b4aa1b71984b2e3189d12_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">1 to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">s Cur</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">rent Report on Form 8-K (File No. 001-36112) filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">pril 2, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534521000035/mgnxexhibit4-2202010xk.htm">Description of Common Stock (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312515075224/d838054dex43.htm">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed on February 27, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex103.htm">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex104.htm">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000060/exhibit101stepheneckemploy.htm">Employment Agreement between the Company and Stephen Eck, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2017)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1016incytecommercia.htm">Commercial Supply Agreement by and between Incyte Corporation and the Company, dated October 13, 2020 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1017eversanaagreeme.htm">Product Commercialization Agreement by and between the Company and Eversana Life Science Services, LLC, dated November 13, 2020 (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000099/exhibit101collabliczairdct.htm">Collaboration and License Agreement by and between the Company and Zai Lab US LLC, dated June 15, 2021 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on July 29, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000099/exhibit102stckprchsagrmntz.htm">Stock Purchase Agreement by and between the Company and Zai Lab Limited, dated June 14, 2021 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on July 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1* </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit23-1202110xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-1202110xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-2202110xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-1202110xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-2202110xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#&#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>mgnxexhibit23-1202110xk.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i40bece323a07483da99052463a325867_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option and Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-202470, Form S-8 No. 333-209812, Form S-8 No. 333-217620, Form S-8 No. 333-223682, Form S-8 No. 333-230292, Form S-8 No. 333-237127, and Form S-8 No. 333-253502) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc., and</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-249851) of MacroGenics, Inc.&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;24, 2022, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended December&#160;31, 2021.</font></div><div style="margin-top:18pt"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2022&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>mgnxexhibit31-1202110xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id6cc77d162a846f3a26b9de40774148e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;February&#160;24, 2022&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>mgnxexhibit31-2202110xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1c1e440f26eb4c2ead684b7477b8bc80_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;February&#160;24, 2022&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>mgnxexhibit32-1202110xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifddb8851c1bc4484ad287a29c297047b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2021 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig </font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February&#160;24, 2022 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>mgnxexhibit32-2202110xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieca447d98afb4c9882a141a3152771ac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2021 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels&#160;&#160;&#160;&#160;</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2022 </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgnx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://macrogenics.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>2101101 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2110103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2311302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2412406 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://macrogenics.com/role/Inventory">
        <link:definition>2114104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>2315303 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetScheduleofInventoryDetails" roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails">
        <link:definition>2416408 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>2417409 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>2118105 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>2319304 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>2420410 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://macrogenics.com/role/Leases">
        <link:definition>2121106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://macrogenics.com/role/LeasesTables">
        <link:definition>2322305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://macrogenics.com/role/LeasesNarrativeDetails">
        <link:definition>2423411 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2424412 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCostsDetails" roleURI="http://macrogenics.com/role/LeasesCostsDetails">
        <link:definition>2425413 - Disclosure - Leases - Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2426414 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2426414 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2127107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>2129108 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>2330306 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2431416 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2432417 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2433418 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>2434419 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>2135109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>2336307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2437420 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2438421 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>2439422 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2440423 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2141110 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2442424 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2443425 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2444426 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2445427 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsProventionDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails">
        <link:definition>2446428 - Disclosure - Collaboration and Other Agreements - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
        <link:definition>2447429 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2448430 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2149111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>2150112 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2451431 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://macrogenics.com/role/SubsequentEvents">
        <link:definition>2152113 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://macrogenics.com/role/SubsequentEventsDetails">
        <link:definition>2453432 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_EquityIncentivePlan2003Member" abstract="true" name="EquityIncentivePlan2003Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TaxYear2025To2037Member" abstract="true" name="TaxYear2025To2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EntitledMilestonePaymentsUnderAgreement" abstract="false" name="EntitledMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ScheduleOfInventoryReservesTableTextBlock" abstract="false" name="ScheduleOfInventoryReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteClinicalSupplyAgreementMember" abstract="true" name="IncyteClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ImabMember" abstract="true" name="ImabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsMember" abstract="true" name="ZaiLabsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ASDHealthcareAndOncologySupplyMember" abstract="true" name="ASDHealthcareAndOncologySupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" abstract="true" name="LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" abstract="false" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EstimatedReimbursementForResearchAndDevelopmentT" abstract="false" name="EstimatedReimbursementForResearchAndDevelopmentT" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" abstract="true" name="BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DevelopmentMilestonesAmount" abstract="false" name="DevelopmentMilestonesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementTerm" abstract="false" name="CollaborationAndLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_RevenuesTaxWithholding" abstract="false" name="RevenuesTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" abstract="false" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteCommercialSupplyAgreementMember" abstract="true" name="IncyteCommercialSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHMember" abstract="true" name="BoehringerIngelheimInternationalGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" abstract="false" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OneTimeMillstoneCredit" abstract="false" name="OneTimeMillstoneCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" abstract="true" name="McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesNetOfTaxWithholding" abstract="false" name="RevenuesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgnx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_079f9a3b-fa87-4310-9f89-e3a7635f6265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7abafe69-3ffc-4f4a-941b-3f5840d0074e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079f9a3b-fa87-4310-9f89-e3a7635f6265" xlink:to="loc_us-gaap_CommonStockValue_7abafe69-3ffc-4f4a-941b-3f5840d0074e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a1194a5-7e31-482a-b345-e1dab201d611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079f9a3b-fa87-4310-9f89-e3a7635f6265" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a1194a5-7e31-482a-b345-e1dab201d611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c811d04d-0617-4b11-848b-2ad1a3514afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079f9a3b-fa87-4310-9f89-e3a7635f6265" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c811d04d-0617-4b11-848b-2ad1a3514afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77490c6b-ca3c-4339-b33b-9c7281233f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079f9a3b-fa87-4310-9f89-e3a7635f6265" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77490c6b-ca3c-4339-b33b-9c7281233f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4bea977b-3f7b-4553-b51f-c14dc1e0d362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fc656351-4ba8-4954-bed6-8528fd75f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4bea977b-3f7b-4553-b51f-c14dc1e0d362" xlink:to="loc_us-gaap_AccountsPayableCurrent_fc656351-4ba8-4954-bed6-8528fd75f1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fe542d95-3795-4d97-a942-bfedef5a8994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4bea977b-3f7b-4553-b51f-c14dc1e0d362" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fe542d95-3795-4d97-a942-bfedef5a8994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_da0906a3-4f9b-47f3-9205-9efd999b51ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4bea977b-3f7b-4553-b51f-c14dc1e0d362" xlink:to="loc_us-gaap_DeferredRevenueCurrent_da0906a3-4f9b-47f3-9205-9efd999b51ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17c8b087-4216-4a88-88ba-b08c0effa35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4bea977b-3f7b-4553-b51f-c14dc1e0d362" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_17c8b087-4216-4a88-88ba-b08c0effa35a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_94df61bb-d83d-4eb4-aab5-6a927b9597c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_385a0a94-dab9-4356-a6ba-098515d86754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94df61bb-d83d-4eb4-aab5-6a927b9597c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_385a0a94-dab9-4356-a6ba-098515d86754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3235e7cd-e3f1-4592-b36b-4aacdcdbd945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94df61bb-d83d-4eb4-aab5-6a927b9597c0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3235e7cd-e3f1-4592-b36b-4aacdcdbd945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_89fae407-c632-4cfb-a408-59fda977851a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94df61bb-d83d-4eb4-aab5-6a927b9597c0" xlink:to="loc_us-gaap_LiabilitiesCurrent_89fae407-c632-4cfb-a408-59fda977851a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_e5f299f5-b649-42b9-bae3-2e9367434d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94df61bb-d83d-4eb4-aab5-6a927b9597c0" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_e5f299f5-b649-42b9-bae3-2e9367434d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26dc3c89-ca21-46b5-9748-068ad83357f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44fbfbae-07ed-41e6-a48c-0d13304083bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dc3c89-ca21-46b5-9748-068ad83357f5" xlink:to="loc_us-gaap_AssetsCurrent_44fbfbae-07ed-41e6-a48c-0d13304083bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fe42199-88e3-42b6-8ff7-560b234f75f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dc3c89-ca21-46b5-9748-068ad83357f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fe42199-88e3-42b6-8ff7-560b234f75f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_08e848f1-371d-4b53-908a-7e3116fbb15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dc3c89-ca21-46b5-9748-068ad83357f5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_08e848f1-371d-4b53-908a-7e3116fbb15d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd9995b-550b-487c-b790-7562c69001e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fb3bebc2-958b-4103-a5d7-a6b8810b6294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd9995b-550b-487c-b790-7562c69001e9" xlink:to="loc_us-gaap_Liabilities_fb3bebc2-958b-4103-a5d7-a6b8810b6294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e45f01d-7bdc-4171-804c-8d5d76c12a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd9995b-550b-487c-b790-7562c69001e9" xlink:to="loc_us-gaap_StockholdersEquity_4e45f01d-7bdc-4171-804c-8d5d76c12a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2427ad46-c490-41a4-a952-b74d32474847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2427ad46-c490-41a4-a952-b74d32474847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e08fcfe7-6c4d-41fb-853a-474a8c13185b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:to="loc_us-gaap_InventoryNet_e08fcfe7-6c4d-41fb-853a-474a8c13185b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_e63824ec-7bc8-4fb8-af8d-110dd153dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:to="loc_us-gaap_Investments_e63824ec-7bc8-4fb8-af8d-110dd153dea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6ccb1d8b-c010-4926-8c4c-93507d9a6cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6ccb1d8b-c010-4926-8c4c-93507d9a6cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8934744-0e7d-4e6d-a05c-4194773b0ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ba58eb1-f7ee-40ab-b6f4-2b709c9f1f38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8934744-0e7d-4e6d-a05c-4194773b0ce0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b095caf-304f-4e3d-a843-1b4a66a22206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50992bcd-ddb2-4163-963b-157704ee50dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b095caf-304f-4e3d-a843-1b4a66a22206" xlink:to="loc_us-gaap_NetIncomeLoss_50992bcd-ddb2-4163-963b-157704ee50dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bc8e299c-6eb2-4d50-91b3-43f65e4e53ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b095caf-304f-4e3d-a843-1b4a66a22206" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bc8e299c-6eb2-4d50-91b3-43f65e4e53ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_34727b7e-9aa4-497a-b1c8-bff13b5ff7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2f3d2eb0-cb19-4605-ba36-20546df3521d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_34727b7e-9aa4-497a-b1c8-bff13b5ff7b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2f3d2eb0-cb19-4605-ba36-20546df3521d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_12de3b9a-944b-45ec-b1a0-43dfa740926d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_34727b7e-9aa4-497a-b1c8-bff13b5ff7b5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_12de3b9a-944b-45ec-b1a0-43dfa740926d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b97ffc13-d8e6-42ae-b5e3-2ba9cb777a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_34727b7e-9aa4-497a-b1c8-bff13b5ff7b5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b97ffc13-d8e6-42ae-b5e3-2ba9cb777a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9bd74ecf-ad15-457b-aa31-3394f01b475a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2769bf68-1054-44e4-a871-0e575b5eba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9bd74ecf-ad15-457b-aa31-3394f01b475a" xlink:to="loc_us-gaap_Revenues_2769bf68-1054-44e4-a871-0e575b5eba2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6ce9600d-437f-4765-8b14-825f8a5ea915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9bd74ecf-ad15-457b-aa31-3394f01b475a" xlink:to="loc_us-gaap_CostsAndExpenses_6ce9600d-437f-4765-8b14-825f8a5ea915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_56b4a03c-a6ae-4abb-9be3-a0a8eee67083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a63edf0-be3b-4673-a930-3c460579fab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_56b4a03c-a6ae-4abb-9be3-a0a8eee67083" xlink:to="loc_us-gaap_OperatingIncomeLoss_5a63edf0-be3b-4673-a930-3c460579fab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5b0320c5-6f90-4a19-a52e-421c6ca0ad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_56b4a03c-a6ae-4abb-9be3-a0a8eee67083" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5b0320c5-6f90-4a19-a52e-421c6ca0ad7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d494535-3adb-431b-a8b5-60b3e96155fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_68caefd3-2a8a-44a2-8dbc-19e6b3e5b67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d494535-3adb-431b-a8b5-60b3e96155fc" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_68caefd3-2a8a-44a2-8dbc-19e6b3e5b67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5d33b815-235c-42af-8a65-560a45fcb91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d494535-3adb-431b-a8b5-60b3e96155fc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5d33b815-235c-42af-8a65-560a45fcb91c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed4a7d39-870c-4360-9e2e-818f11009db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d494535-3adb-431b-a8b5-60b3e96155fc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed4a7d39-870c-4360-9e2e-818f11009db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3249bc78-d7d8-41e8-ad0e-3d139a06172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0fe1e8c7-eb07-49b7-92fb-8c6c0b715434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3249bc78-d7d8-41e8-ad0e-3d139a06172a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0fe1e8c7-eb07-49b7-92fb-8c6c0b715434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_5223960a-68d4-4143-93dd-79a4685517a9" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3249bc78-d7d8-41e8-ad0e-3d139a06172a" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_5223960a-68d4-4143-93dd-79a4685517a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_49882487-ccb9-41e8-9dbf-e206a3ae507e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_49882487-ccb9-41e8-9dbf-e206a3ae507e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b14e558-bdcb-4e8a-b89c-c4056676ad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b14e558-bdcb-4e8a-b89c-c4056676ad2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2d67d45b-6c2d-4f4f-8a57-7e78fb36f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2d67d45b-6c2d-4f4f-8a57-7e78fb36f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8789883f-ce69-4bdd-90f5-0427340713ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_ShareBasedCompensation_8789883f-ce69-4bdd-90f5-0427340713ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7aa322b3-6bcc-4a62-a16f-70512ea8846a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7aa322b3-6bcc-4a62-a16f-70512ea8846a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0200e9be-d4f5-4a6f-80c7-ad156204764f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0200e9be-d4f5-4a6f-80c7-ad156204764f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e1afd178-0ff1-4bd7-9ccc-c8a170e6b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_NetIncomeLoss_e1afd178-0ff1-4bd7-9ccc-c8a170e6b1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_d3901fb9-12e8-4519-b893-22555e690ddc" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_d3901fb9-12e8-4519-b893-22555e690ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fba75107-1191-4db1-a179-0c10ca424ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fba75107-1191-4db1-a179-0c10ca424ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1c62ec57-7b1f-403b-a76f-84deaea05b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1c62ec57-7b1f-403b-a76f-84deaea05b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_751bc818-7655-4eb0-a0cb-f1cd7f457ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_751bc818-7655-4eb0-a0cb-f1cd7f457ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2df5249-8ac1-4622-954e-365d5c5193da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2df5249-8ac1-4622-954e-365d5c5193da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2d8e62d9-a8cf-4d9c-b943-8ee6b9d2b503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2d8e62d9-a8cf-4d9c-b943-8ee6b9d2b503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_9b052dea-ee56-40ce-aadc-24fb04a087e1" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a417bb44-53f7-4285-8430-e8693e098b84" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_9b052dea-ee56-40ce-aadc-24fb04a087e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf3f4185-cdf5-4491-99ca-d8f88ab7a5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08396d94-4df1-4c81-9dee-18d49ad0f3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf3f4185-cdf5-4491-99ca-d8f88ab7a5e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08396d94-4df1-4c81-9dee-18d49ad0f3da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65172ec6-c025-433f-a6e5-3f67f4109532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf3f4185-cdf5-4491-99ca-d8f88ab7a5e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65172ec6-c025-433f-a6e5-3f67f4109532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d866f97b-75e6-40e3-bb02-a4ff6aa2494c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf3f4185-cdf5-4491-99ca-d8f88ab7a5e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d866f97b-75e6-40e3-bb02-a4ff6aa2494c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_51b9c7bf-3e52-4619-978e-e9f14a979cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6378ae5a-d203-4193-ae86-dc9f5bf874b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_51b9c7bf-3e52-4619-978e-e9f14a979cfa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6378ae5a-d203-4193-ae86-dc9f5bf874b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_19b74b31-3d15-4f9b-b210-fb2cb90893af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_51b9c7bf-3e52-4619-978e-e9f14a979cfa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_19b74b31-3d15-4f9b-b210-fb2cb90893af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b095e59e-d15c-4e3c-8935-cf43fb38a088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b9d061fe-f619-474f-ba7e-1d60bf5c5fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b095e59e-d15c-4e3c-8935-cf43fb38a088" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b9d061fe-f619-474f-ba7e-1d60bf5c5fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c024c7dd-fcad-4910-bbeb-f22e63904218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b095e59e-d15c-4e3c-8935-cf43fb38a088" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c024c7dd-fcad-4910-bbeb-f22e63904218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a94b6738-cde2-492a-aa18-ea3515458e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b095e59e-d15c-4e3c-8935-cf43fb38a088" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a94b6738-cde2-492a-aa18-ea3515458e42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc1603f1-8fed-47e8-9eca-a57e8fcd20c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8b25ebec-e82a-4413-9a5e-269b8673bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cc1603f1-8fed-47e8-9eca-a57e8fcd20c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8b25ebec-e82a-4413-9a5e-269b8673bebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ddb8181-87e0-4e53-9002-0173ab8036a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cc1603f1-8fed-47e8-9eca-a57e8fcd20c0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ddb8181-87e0-4e53-9002-0173ab8036a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesCostsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesCostsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_796311e6-d666-43b3-9f80-4c0618e4e00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_d63c7991-4589-4ccb-bf7f-f177fcbb7766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_796311e6-d666-43b3-9f80-4c0618e4e00a" xlink:to="loc_us-gaap_SubleaseIncome_d63c7991-4589-4ccb-bf7f-f177fcbb7766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2d25aab6-1f6f-4fb0-8db5-baa4adebe6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_796311e6-d666-43b3-9f80-4c0618e4e00a" xlink:to="loc_us-gaap_OperatingLeaseCost_2d25aab6-1f6f-4fb0-8db5-baa4adebe6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_df4d904e-e7eb-46f7-a92a-9968f6653bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_796311e6-d666-43b3-9f80-4c0618e4e00a" xlink:to="loc_us-gaap_VariableLeaseCost_df4d904e-e7eb-46f7-a92a-9968f6653bc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_62eccfb6-78fb-4a3d-910c-57da5644bf20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_62eccfb6-78fb-4a3d-910c-57da5644bf20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8d977aed-a04b-4f13-914a-560b2073d251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8d977aed-a04b-4f13-914a-560b2073d251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ab814b5-4198-461b-95a1-2fe09a4521b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ab814b5-4198-461b-95a1-2fe09a4521b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d1504091-48ba-4e5f-99ad-4a087ae5a169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d1504091-48ba-4e5f-99ad-4a087ae5a169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b49096c2-729c-496c-b1ba-8e5da1a57b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b49096c2-729c-496c-b1ba-8e5da1a57b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4424a211-3b5a-47ed-a5e5-5cf20604a892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c27d400-9ad1-4c1b-a8d5-14bb3a02b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4424a211-3b5a-47ed-a5e5-5cf20604a892" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f1be14-1a65-4c5d-8fab-295ba6d3a043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ca3d3f98-8dec-47bc-aa15-de8f24fa80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f1be14-1a65-4c5d-8fab-295ba6d3a043" xlink:to="loc_us-gaap_OperatingLeaseLiability_ca3d3f98-8dec-47bc-aa15-de8f24fa80cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b9a7f63-e17d-4b5d-8fae-7afd892ba0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f1be14-1a65-4c5d-8fab-295ba6d3a043" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b9a7f63-e17d-4b5d-8fae-7afd892ba0e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b21e123-e380-4844-8190-a7cb0a100683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4d6c26b7-db6b-4b2d-a2dd-76ce5c33fff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b21e123-e380-4844-8190-a7cb0a100683" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4d6c26b7-db6b-4b2d-a2dd-76ce5c33fff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_6ee0db37-b846-48e6-b1b3-a7b77e736547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b21e123-e380-4844-8190-a7cb0a100683" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_6ee0db37-b846-48e6-b1b3-a7b77e736547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_e4b62f23-2ae4-45c5-99b3-43a4346bd695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_e4b62f23-2ae4-45c5-99b3-43a4346bd695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e98cbf-6cf3-4445-ae50-eefabacf8fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e98cbf-6cf3-4445-ae50-eefabacf8fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_996c93e0-c939-402c-b4f3-9141cd219662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_996c93e0-c939-402c-b4f3-9141cd219662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_c2412b23-ad1d-492f-9bd8-b558733ed83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_c2412b23-ad1d-492f-9bd8-b558733ed83d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d7be34b-4da3-4900-a24a-302f950f16fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d7be34b-4da3-4900-a24a-302f950f16fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_536ff34f-7eba-49d9-bf86-2b588f7cf3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_536ff34f-7eba-49d9-bf86-2b588f7cf3ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_93ac7be7-2a7c-440e-aac6-9d603b82cfa7" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0158fdfb-cb01-4f62-87b9-558712dd9660" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_93ac7be7-2a7c-440e-aac6-9d603b82cfa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1db352-8e96-45c3-88ff-fd7190110c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3bd31a6d-ab3f-4ed6-88ee-f3c7949e95ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1db352-8e96-45c3-88ff-fd7190110c88" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3bd31a6d-ab3f-4ed6-88ee-f3c7949e95ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_28b3af9d-2e0b-49ba-9843-e9a4e3fa16dc" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1db352-8e96-45c3-88ff-fd7190110c88" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_28b3af9d-2e0b-49ba-9843-e9a4e3fa16dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e0b5bb19-c901-474e-864c-e6fc65e0ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1db352-8e96-45c3-88ff-fd7190110c88" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e0b5bb19-c901-474e-864c-e6fc65e0ef5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_46493518-cb78-4554-953b-24c2ef482430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_30459dcf-341b-401e-9029-a91ce2efd105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_46493518-cb78-4554-953b-24c2ef482430" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_30459dcf-341b-401e-9029-a91ce2efd105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c26ff603-bae9-444b-bf9d-d45ba15b7d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_46493518-cb78-4554-953b-24c2ef482430" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c26ff603-bae9-444b-bf9d-d45ba15b7d65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_01733506-b298-4bf2-88a3-fecc49203f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_01733506-b298-4bf2-88a3-fecc49203f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_45b75b96-bfff-47f4-a49e-ef6c6df29a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_45b75b96-bfff-47f4-a49e-ef6c6df29a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_e3811d76-f63d-4da2-9154-d5d396de523d" xlink:href="mgnx-20211231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_e3811d76-f63d-4da2-9154-d5d396de523d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c873d784-043f-41bf-9af6-001a3d9f3141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c873d784-043f-41bf-9af6-001a3d9f3141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_8c548d12-75c8-4918-8d6c-d264ed017a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_8c548d12-75c8-4918-8d6c-d264ed017a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_52e6914f-dc65-490e-88d0-3363e142a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_52e6914f-dc65-490e-88d0-3363e142a2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a7960191-9cc2-42f9-b6af-d4281f0aa410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a7960191-9cc2-42f9-b6af-d4281f0aa410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d775f3b-77f1-4826-b353-10995d0c3be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae2f4a30-21c6-4dfd-9bf4-4f63bf8b9026" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d775f3b-77f1-4826-b353-10995d0c3be8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgnx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i3bb79320e16d4ad1921c75ca02f09a26_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e730fca5-5c75-47d1-b96e-286233a3f267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:to="loc_us-gaap_Revenues_e730fca5-5c75-47d1-b96e-286233a3f267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_02e43b2a-354c-490e-a053-f776894e4382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_02e43b2a-354c-490e-a053-f776894e4382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f825d6e9-044c-46d7-b56a-ab461856ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f825d6e9-044c-46d7-b56a-ab461856ff14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_98a1c8a9-0548-411e-a3a4-0daa885e53eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_98a1c8a9-0548-411e-a3a4-0daa885e53eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_76c23776-7bf4-4f7f-b8f1-98a00b072036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_CostsAndExpenses_76c23776-7bf4-4f7f-b8f1-98a00b072036" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_847cad5d-ff90-42a3-85f3-7c9a22e096c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OperatingIncomeLoss_847cad5d-ff90-42a3-85f3-7c9a22e096c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7673b261-70c9-444d-bca2-6f72fe869716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7673b261-70c9-444d-bca2-6f72fe869716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe2e7d34-576d-4fac-899d-31e132eea8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_NetIncomeLoss_fe2e7d34-576d-4fac-899d-31e132eea8e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d82a35-0b5e-4e6d-80c6-2bd8890172ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d82a35-0b5e-4e6d-80c6-2bd8890172ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f18a503-df89-4b8a-a850-2455a1d08960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f18a503-df89-4b8a-a850-2455a1d08960" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bfaff9f4-2aa8-41c1-99bd-c0018b4a2be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bfaff9f4-2aa8-41c1-99bd-c0018b4a2be7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aa974cf8-4a96-4fc3-aae6-148a681895c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aa974cf8-4a96-4fc3-aae6-148a681895c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ead730aa-f8f6-4bc9-a2e0-e3b3e3aee33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ead730aa-f8f6-4bc9-a2e0-e3b3e3aee33a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b2826c1-92bb-4fa4-8405-1235b06ed86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b2826c1-92bb-4fa4-8405-1235b06ed86d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:to="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa220027-b554-4556-a25a-e2dd2f0823db_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:to="loc_srt_ProductsAndServicesDomain_aa220027-b554-4556-a25a-e2dd2f0823db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:to="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_96271585-8ba2-49c8-aaae-df2d7ec9ba90" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_96271585-8ba2-49c8-aaae-df2d7ec9ba90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_e6730bef-27c7-4f67-8401-214b4050dbf2" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_e6730bef-27c7-4f67-8401-214b4050dbf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f9193848-d2b4-481e-b6bb-cd5f314ed6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_us-gaap_ProductMember_f9193848-d2b4-481e-b6bb-cd5f314ed6c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i1c4163ada40e4591ba5ea5cba621f9ae_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_29c0f8db-268f-4ab3-8390-e523bf24489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_SharesIssued_29c0f8db-268f-4ab3-8390-e523bf24489d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efd01f7f-6467-45ec-8120-00d52c97e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockholdersEquity_efd01f7f-6467-45ec-8120-00d52c97e7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0d57478-6498-4c5d-b133-e660977c655d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0d57478-6498-4c5d-b133-e660977c655d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee78158-c0e6-47f9-bb7c-83c4d6bfe6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee78158-c0e6-47f9-bb7c-83c4d6bfe6ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52ecee40-768b-4216-83c7-a5796c57d029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52ecee40-768b-4216-83c7-a5796c57d029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_f3cd7959-1eaa-462c-a769-923a57c5c691" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_f3cd7959-1eaa-462c-a769-923a57c5c691" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e4d040ab-a2a9-455d-8444-001776d6cbc4" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e4d040ab-a2a9-455d-8444-001776d6cbc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_843aec3a-e72f-475c-ae8b-c76f6cfd2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_843aec3a-e72f-475c-ae8b-c76f6cfd2c7b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1da39d3-bc46-406b-9111-22e085145b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_NetIncomeLoss_a1da39d3-bc46-406b-9111-22e085145b56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ecdf04fb-9c9d-4184-bf93-975dc539eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3276460-e156-4061-a98f-88d12a368de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_66eab89c-b28e-4e57-bcc9-9b4a53e86f86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:to="loc_us-gaap_EquityComponentDomain_66eab89c-b28e-4e57-bcc9-9b4a53e86f86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:to="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d18cb68f-2cc6-48e2-a3ab-3e5f0eb51b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_CommonStockMember_d18cb68f-2cc6-48e2-a3ab-3e5f0eb51b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_406a0d39-40a9-493f-97e9-a5d2dac319d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_406a0d39-40a9-493f-97e9-a5d2dac319d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b6abee75-aaa3-46c5-a0de-bf60cbda88ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_RetainedEarningsMember_b6abee75-aaa3-46c5-a0de-bf60cbda88ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc33e89a-ec4c-418d-a406-fe69316b87ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc33e89a-ec4c-418d-a406-fe69316b87ba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended" id="i494d5707dad7466f8422e2ff993156d3_SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aab34db-a936-426e-8bbd-e111c57c54ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aab34db-a936-426e-8bbd-e111c57c54ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a8b0238-07f4-490c-b7eb-add6ab6090e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a8b0238-07f4-490c-b7eb-add6ab6090e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c89df882-89c8-4046-92b5-da8c2a695d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c89df882-89c8-4046-92b5-da8c2a695d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1fbade3e-1ad5-43d6-afdb-d9443620d3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:to="loc_us-gaap_Investments_1fbade3e-1ad5-43d6-afdb-d9443620d3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af203137-4301-4731-b8d3-012ce8bfbe88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af203137-4301-4731-b8d3-012ce8bfbe88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_79ee7eb1-7627-4957-8d40-e0187d60736d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_79ee7eb1-7627-4957-8d40-e0187d60736d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2b38b835-630f-49e3-8579-f3e83cabbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2b38b835-630f-49e3-8579-f3e83cabbf7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8a1b06e8-a408-4797-8cc2-dcc736d5ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8a1b06e8-a408-4797-8cc2-dcc736d5ee8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c8a35d97-85e2-4cce-960d-02e76c8f3c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c8a35d97-85e2-4cce-960d-02e76c8f3c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_4dba85d5-1b0a-4c66-b348-5511410d07c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_4dba85d5-1b0a-4c66-b348-5511410d07c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_933af1c4-d502-4607-a091-f18ac34e3dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_933af1c4-d502-4607-a091-f18ac34e3dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6d683d6-87d7-4900-a8a1-072d3b626e9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6d683d6-87d7-4900-a8a1-072d3b626e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_69bd36d8-ca17-4d36-a6e5-e66b595a90bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_69bd36d8-ca17-4d36-a6e5-e66b595a90bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended" id="i81eb33541fdd4ab087cb4cc20c42a2d0_SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f446ca04-a223-466b-86e1-7b9ab10fcae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f446ca04-a223-466b-86e1-7b9ab10fcae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:to="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_57861b74-59ec-45be-a16d-3736cfeecf10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_57861b74-59ec-45be-a16d-3736cfeecf10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_66f5bf41-a4c9-4460-94f6-c94c95b0921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_66f5bf41-a4c9-4460-94f6-c94c95b0921c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3cb25d1f-ebae-486e-a4b7-60cb502d5435_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3cb25d1f-ebae-486e-a4b7-60cb502d5435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_53e07db0-5b18-4fc1-acdd-763a8d26c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:to="loc_us-gaap_SalesRevenueNetMember_53e07db0-5b18-4fc1-acdd-763a8d26c2d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1a843b79-edc0-4a3f-9e04-f537eebb9ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:to="loc_us-gaap_AccountsReceivableMember_1a843b79-edc0-4a3f-9e04-f537eebb9ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e0edeefc-a573-4a8d-8687-6f2a25d8880f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:to="loc_srt_NameOfMajorCustomerDomain_e0edeefc-a573-4a8d-8687-6f2a25d8880f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:to="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_7f53eab7-3f60-4b7d-8fbd-61fdcc08b4d9" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_IncyteCorporationMember_7f53eab7-3f60-4b7d-8fbd-61fdcc08b4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_c7775a1f-8d89-4780-9c3a-3f80403700fb" xlink:href="mgnx-20211231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_JanssenBiotechIncMember_c7775a1f-8d89-4780-9c3a-3f80403700fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_468e44a4-27ea-41af-aaf1-51c85eb5359b" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ZaiLabLimitedMember_468e44a4-27ea-41af-aaf1-51c85eb5359b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_83db62e7-4832-4d72-a690-0e30403b0c4d" xlink:href="mgnx-20211231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_83db62e7-4832-4d72-a690-0e30403b0c4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_37d1655c-4d54-4211-b5c1-8ec13f72d131" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ZaiLabMember_37d1655c-4d54-4211-b5c1-8ec13f72d131" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember_6de67e3c-1e2c-475e-b856-b1f4f8c98c44" xlink:href="mgnx-20211231.xsd#mgnx_ImabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ImabMember_6de67e3c-1e2c-475e-b856-b1f4f8c98c44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_d2f480f9-3bd6-45af-87d9-552a3a49db94" xlink:href="mgnx-20211231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_d2f480f9-3bd6-45af-87d9-552a3a49db94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_91bc0ae7-9d95-4598-9616-63ba957d5721" xlink:href="mgnx-20211231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_91bc0ae7-9d95-4598-9616-63ba957d5721" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" id="i8a0e9187317c49eda30190a0aad7bae5_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5c6c7ec-e653-4e09-9824-174cdd315c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5c6c7ec-e653-4e09-9824-174cdd315c86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_390fde69-7913-45b7-9e72-2af1ba1fff76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_390fde69-7913-45b7-9e72-2af1ba1fff76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ebb382af-2184-4c80-918e-d1c2ef85d85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_ComputerEquipmentMember_ebb382af-2184-4c80-918e-d1c2ef85d85d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6ac9e710-887b-474b-9a4f-f47303331698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6ac9e710-887b-474b-9a4f-f47303331698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3bc0ae2f-cd22-49f7-970c-d4910c2957f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3bc0ae2f-cd22-49f7-970c-d4910c2957f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_73541272-95a6-4332-a59a-51c67963020f" xlink:href="mgnx-20211231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_73541272-95a6-4332-a59a-51c67963020f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended" id="i430f58a72c9143f3aeea462fd7655ebd_SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d94d0ace-3846-4ea7-815c-c832e17e14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d94d0ace-3846-4ea7-815c-c832e17e14b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a64b380-793d-470d-bcfa-57c6462b8301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a64b380-793d-470d-bcfa-57c6462b8301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a0ee97b0-a382-4069-9b9a-2e854091d2a4" xlink:href="mgnx-20211231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a0ee97b0-a382-4069-9b9a-2e854091d2a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="if744ee817ac44d7f83850d2cd08860e7_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_607c747f-8c2c-45da-8bf9-e87e8048cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_607c747f-8c2c-45da-8bf9-e87e8048cc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5870f1c0-ce12-4f3d-9033-e6dca1d8fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5870f1c0-ce12-4f3d-9033-e6dca1d8fa82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_54dc9e88-2cd0-4778-80fa-5b355770bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_54dc9e88-2cd0-4778-80fa-5b355770bb63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c32593f8-f058-43b2-beb0-12b6a36cc89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c32593f8-f058-43b2-beb0-12b6a36cc89f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a72ec70b-657f-48f4-a1b9-d799c5347946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a72ec70b-657f-48f4-a1b9-d799c5347946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d7ea805a-c3e1-4f92-b776-a3a7af48fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d7ea805a-c3e1-4f92-b776-a3a7af48fc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3c478b60-4e91-44b5-9c6a-2759b2f514f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3c478b60-4e91-44b5-9c6a-2759b2f514f2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#InventoryNetDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended" id="i4523844503ae478fa3ce7fafdd078941_InventoryNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_347de9dd-efd7-48f6-b327-ce49d055c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_347de9dd-efd7-48f6-b327-ce49d055c788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d78b0fa0-e4f8-4365-89cc-ce74c436bd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d78b0fa0-e4f8-4365-89cc-ce74c436bd37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_f79402fe-3c53-475a-b031-9c58b6f8f280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_f79402fe-3c53-475a-b031-9c58b6f8f280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f45addd4-c6f8-4cd6-a490-2640a7bc4460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_93baa28b-cb58-4379-82d6-83023eed9674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_93baa28b-cb58-4379-82d6-83023eed9674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_9dc0fdf5-7fb2-446f-9ba9-795bf2eacfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:to="loc_us-gaap_InventoryValuationReserveMember_9dc0fdf5-7fb2-446f-9ba9-795bf2eacfc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended" id="ia30b8337de3644c8b7f715738b28ee8e_PropertyEquipmentandSoftwareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b24a56d9-dd61-4017-9508-5266130cf032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b24a56d9-dd61-4017-9508-5266130cf032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7e3371e3-b0d0-49cd-8ca9-9691a26233c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_ConstructionInProgressGross_7e3371e3-b0d0-49cd-8ca9-9691a26233c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ca459659-08ad-43e3-9e74-98ed950756a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ca459659-08ad-43e3-9e74-98ed950756a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d7497b07-e638-44ea-8984-9bed98249cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d7497b07-e638-44ea-8984-9bed98249cc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d4304307-ed32-40d7-a4cb-be34de652eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_Depreciation_d4304307-ed32-40d7-a4cb-be34de652eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e92acb0c-144a-4f00-b6e2-c04c4a23adda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e92acb0c-144a-4f00-b6e2-c04c4a23adda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2f0a0d1c-a857-442d-8e18-b8b893a2ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_ComputerEquipmentMember_2f0a0d1c-a857-442d-8e18-b8b893a2ff9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6423f479-7002-4f10-b802-27a1c9a0cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6423f479-7002-4f10-b802-27a1c9a0cac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_e090359d-6bbb-423d-be2f-43c2f1e017e5" xlink:href="mgnx-20211231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_e090359d-6bbb-423d-be2f-43c2f1e017e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_6b551272-52d3-4efd-8147-5f3126e008c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_VehiclesMember_6b551272-52d3-4efd-8147-5f3126e008c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_65a230e2-dc99-498f-9b42-fa23f727561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_EquipmentMember_65a230e2-dc99-498f-9b42-fa23f727561e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4c8d6e11-ae5c-4087-a91d-d7d018a693c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4c8d6e11-ae5c-4087-a91d-d7d018a693c9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i83b9f93cafba4ac59168901bc04e9f12_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2ecd22ed-2952-4af1-904a-85275740387e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2ecd22ed-2952-4af1-904a-85275740387e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8ab3ea65-d52c-46fd-991a-ce9e72067fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeasePayments_8ab3ea65-d52c-46fd-991a-ce9e72067fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52724f43-b7ad-42a1-897d-cf0ffea7a9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52724f43-b7ad-42a1-897d-cf0ffea7a9f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68ed9b88-4edb-4ccb-9a11-38937433c979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68ed9b88-4edb-4ccb-9a11-38937433c979" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:to="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a57f92cc-f71f-496e-a601-d804809b55b9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:to="loc_srt_RangeMember_a57f92cc-f71f-496e-a601-d804809b55b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:to="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6985a959-9de7-4f36-9c43-ff37ba05f643" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:to="loc_srt_MinimumMember_6985a959-9de7-4f36-9c43-ff37ba05f643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd51dc68-5c9a-456e-96bb-d6e58202bfb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:to="loc_srt_MaximumMember_bd51dc68-5c9a-456e-96bb-d6e58202bfb2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i4737a2038cb844669e755de8eec9135a_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cc09e013-3e1f-433c-ba61-378650e523f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cc09e013-3e1f-433c-ba61-378650e523f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_84019d7e-7b96-4001-83ec-6f417df98bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_84019d7e-7b96-4001-83ec-6f417df98bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f890bed-0b32-4faa-8ada-916f151622a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f890bed-0b32-4faa-8ada-916f151622a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_928c019b-5fd1-439c-8774-fc3a3ab3b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_928c019b-5fd1-439c-8774-fc3a3ab3b874" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4a215101-d108-47a8-833e-8a6b928daeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4a215101-d108-47a8-833e-8a6b928daeb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb25b644-46ae-4cee-b8cc-68c23bf59d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb25b644-46ae-4cee-b8cc-68c23bf59d05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf590b8b-fc18-42a4-a035-2d6ef5df3b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf590b8b-fc18-42a4-a035-2d6ef5df3b94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f7f16c3c-f925-4192-a3ff-30d815015635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90fbabf3-ca55-42f5-91b1-4bc4b0563456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90fbabf3-ca55-42f5-91b1-4bc4b0563456" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f8bd5713-bd14-41a5-9676-1937ccde8e81" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f8bd5713-bd14-41a5-9676-1937ccde8e81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9c9e1b1c-dd31-4e9e-8c08-39a942557cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9c9e1b1c-dd31-4e9e-8c08-39a942557cb9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_89f8c5c3-bf44-46de-bc4b-5b5535480097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_89f8c5c3-bf44-46de-bc4b-5b5535480097" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_49c4fc2d-a5f6-45b0-a373-2022684c858a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_49c4fc2d-a5f6-45b0-a373-2022684c858a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c91ba9bc-4701-4a0c-a5f9-53a6f9108a93" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c91ba9bc-4701-4a0c-a5f9-53a6f9108a93" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf9031b-ebad-4365-a834-35fbf47ce2b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf9031b-ebad-4365-a834-35fbf47ce2b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_b724b065-ad9d-4329-ba4c-629c9332b141" xlink:href="mgnx-20211231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:to="loc_mgnx_AtTheMarketOfferingMember_b724b065-ad9d-4329-ba4c-629c9332b141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_729f1ca4-6bcf-417a-9917-d05e0c26016a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:to="loc_us-gaap_ClassOfStockDomain_729f1ca4-6bcf-417a-9917-d05e0c26016a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:to="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_6ed446f9-776d-4842-81cc-776cbc123710" xlink:href="mgnx-20211231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_6ed446f9-776d-4842-81cc-776cbc123710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cb9d727-d31c-4488-9e2f-f176e3237217_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cb9d727-d31c-4488-9e2f-f176e3237217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_4a3ceed5-a8f8-4e13-9d7c-cf9044ca0c08" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:to="loc_mgnx_IncyteCorporationMember_4a3ceed5-a8f8-4e13-9d7c-cf9044ca0c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_32dca00c-6f19-41c0-9a07-e825334980b6" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:to="loc_mgnx_ZaiLabMember_32dca00c-6f19-41c0-9a07-e825334980b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_befa1e97-98d5-4539-9995-82dbe2fe970f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:to="loc_srt_RangeMember_befa1e97-98d5-4539-9995-82dbe2fe970f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:to="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c60997d2-7e56-4251-b542-4a74db123948" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:to="loc_srt_MaximumMember_c60997d2-7e56-4251-b542-4a74db123948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adca45b9-20f7-4afe-91d7-6ddb309d0166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adca45b9-20f7-4afe-91d7-6ddb309d0166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_97f2c473-e0c3-4728-8503-963b11623c06" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_97f2c473-e0c3-4728-8503-963b11623c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_3c69fc62-956d-4c33-bebe-b9e435f7ff3f" xlink:href="mgnx-20211231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_3c69fc62-956d-4c33-bebe-b9e435f7ff3f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ic4612c3e800b41149b8859848b308313_StockbasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2f0f7c0-9ed7-410d-8804-0a814e5720b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2f0f7c0-9ed7-410d-8804-0a814e5720b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8aa28db4-7bf5-4779-a365-a604b42f3425" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8aa28db4-7bf5-4779-a365-a604b42f3425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c45ccb42-83c1-4736-ac71-2ce613cd78b2" xlink:href="mgnx-20211231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c45ccb42-83c1-4736-ac71-2ce613cd78b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_945f2f31-62c1-4548-b478-8a1d3bcaf093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_945f2f31-62c1-4548-b478-8a1d3bcaf093" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d9151110-1f2d-4285-9080-a403512b5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d9151110-1f2d-4285-9080-a403512b5c99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f0a9e4d-44a3-40aa-8d32-855b19aea3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f0a9e4d-44a3-40aa-8d32-855b19aea3d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:to="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:to="loc_us-gaap_PlanNameDomain_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:to="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e8cff5aa-8128-49a5-af18-5100636d76cf" xlink:href="mgnx-20211231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e8cff5aa-8128-49a5-af18-5100636d76cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:to="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87e75280-ee2f-40df-8ac8-0d24926d5ff2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87e75280-ee2f-40df-8ac8-0d24926d5ff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e0b57a7b-2c8e-46c1-a4ee-613feea69cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:to="loc_us-gaap_EmployeeStockMember_e0b57a7b-2c8e-46c1-a4ee-613feea69cbd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ib5c86a08b8b7492e9e00f5e548a37248_StockbasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30d567ae-2ea7-4271-83a7-a5f2c5fe2cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30d567ae-2ea7-4271-83a7-a5f2c5fe2cdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_8dd74205-9563-4d97-b9b8-f9c8350ea5d4" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_8dd74205-9563-4d97-b9b8-f9c8350ea5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a305a85-7b04-4fe1-ab9e-bace69a9c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a305a85-7b04-4fe1-ab9e-bace69a9c4ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b75ff361-d013-489d-bef7-40147a4da816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b75ff361-d013-489d-bef7-40147a4da816" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f469263a-cb48-417d-af14-80c7f7797b51" xlink:href="mgnx-20211231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f469263a-cb48-417d-af14-80c7f7797b51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:to="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9e2d3960-dea8-4f3d-a033-5b78ebada7a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:to="loc_us-gaap_PlanNameDomain_9e2d3960-dea8-4f3d-a033-5b78ebada7a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:to="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_9adf5919-0389-4a57-a81f-2da946a0102d" xlink:href="mgnx-20211231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_9adf5919-0389-4a57-a81f-2da946a0102d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_77156d0f-cb56-4f9b-98cf-6dbfb95855e1" xlink:href="mgnx-20211231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:to="loc_mgnx_StockIncentivePlan2013Member_77156d0f-cb56-4f9b-98cf-6dbfb95855e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_538e0115-491d-4bc5-a185-4994b1a73906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_538e0115-491d-4bc5-a185-4994b1a73906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dd257ea4-8f92-4fb9-b50e-f37df74701cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dd257ea4-8f92-4fb9-b50e-f37df74701cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e1d8e90-bc47-4b60-99a2-4b3b12bd6ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e1d8e90-bc47-4b60-99a2-4b3b12bd6ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c285ea00-1fa9-418d-8cf1-a08e321b8d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c285ea00-1fa9-418d-8cf1-a08e321b8d73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i9e9a986023794ec19915d189e08998f4_StockbasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af949b46-0c56-4152-b037-4638e3a4793d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af949b46-0c56-4152-b037-4638e3a4793d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa77cbc-23f4-4312-b99e-374cd9bc1132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa77cbc-23f4-4312-b99e-374cd9bc1132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02fefeb0-a18c-4736-bfa0-d6df12bed839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02fefeb0-a18c-4736-bfa0-d6df12bed839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f684a0ff-531c-45f6-ab92-f6a8ef96fe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f684a0ff-531c-45f6-ab92-f6a8ef96fe7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6c9fcdc-467d-491d-8579-c931c9b491da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6c9fcdc-467d-491d-8579-c931c9b491da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:to="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:to="loc_srt_RangeMember_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:to="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_49fa2126-1409-46b8-b5fe-e9b02cac8468" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:to="loc_srt_MinimumMember_49fa2126-1409-46b8-b5fe-e9b02cac8468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3193177c-a147-4497-a158-481dbec54351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:to="loc_srt_MaximumMember_3193177c-a147-4497-a158-481dbec54351" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended" id="i99c8639b78324832bb20cc60046730fe_StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09e20bdb-037d-4cdd-b51d-aaa13ab1aaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09e20bdb-037d-4cdd-b51d-aaa13ab1aaae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6f92a5d8-b5e8-4952-a5dd-1750f0cfb5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6f92a5d8-b5e8-4952-a5dd-1750f0cfb5b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09921b1e-742b-4c6d-a777-b805fd2e3883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09921b1e-742b-4c6d-a777-b805fd2e3883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11e9f613-9315-49c3-90f9-d42b81418bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11e9f613-9315-49c3-90f9-d42b81418bdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d81428b7-64da-4a94-86d6-3806cc559ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c04de56b-0fea-45d4-a420-a59ee5801efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c04de56b-0fea-45d4-a420-a59ee5801efe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_804b6ddb-421d-467c-9369-51efbafa56aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_804b6ddb-421d-467c-9369-51efbafa56aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd389cdc-959b-4bb5-ad75-32f98a9107b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd389cdc-959b-4bb5-ad75-32f98a9107b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5621392-0667-4c01-96f9-7236c9cdaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5621392-0667-4c01-96f9-7236c9cdaaef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bffc579d-5166-4344-b9e2-082e94075c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bffc579d-5166-4344-b9e2-082e94075c8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1bf13f4b-b15b-46e6-9cdc-4cf0c9cfc33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1bf13f4b-b15b-46e6-9cdc-4cf0c9cfc33d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec1afa38-034d-4e4f-b0a8-32b4d0c2e522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c51b1efe-38c3-4326-b115-b6c937806d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c51b1efe-38c3-4326-b115-b6c937806d9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09e23cd5-99ec-4d4c-a46f-dbcc6e977b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09e23cd5-99ec-4d4c-a46f-dbcc6e977b1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_053b18ce-b0af-473f-a7f5-e5e05f0c3ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_053b18ce-b0af-473f-a7f5-e5e05f0c3ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348c9347-cf0d-40b7-a4d6-039c72892062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348c9347-cf0d-40b7-a4d6-039c72892062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd3b9e5d-55ab-4d24-b421-335551759552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd3b9e5d-55ab-4d24-b421-335551759552" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_46a261d7-b83c-4eb7-a2c3-0a50e5d1b9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_46a261d7-b83c-4eb7-a2c3-0a50e5d1b9f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3c12cb0-69f9-4733-bf52-763843d060e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3c12cb0-69f9-4733-bf52-763843d060e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_87758e35-5dfd-4980-9cfd-c106aaf1d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_87758e35-5dfd-4980-9cfd-c106aaf1d2e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_576de9fe-816b-47b6-8a6e-559c2f161e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_576de9fe-816b-47b6-8a6e-559c2f161e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e30b7b3-342a-41a1-90b6-343ee6c6aeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e30b7b3-342a-41a1-90b6-343ee6c6aeb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_b217f641-29ff-4597-82a7-2585d2b5cc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_b217f641-29ff-4597-82a7-2585d2b5cc53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe740467-7aa0-4f35-8833-1c295c734312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe740467-7aa0-4f35-8833-1c295c734312" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ecf9ec1-dfe8-4440-8091-55f6b80b30af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cece1fd3-273f-4f0f-8c0f-75b49ad20089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cece1fd3-273f-4f0f-8c0f-75b49ad20089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0589a5dd-9539-46fa-80fa-4c1f8a4dc30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0589a5dd-9539-46fa-80fa-4c1f8a4dc30c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7a8f4a46-b1d9-4d6f-9b3b-4e6013e9fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7a8f4a46-b1d9-4d6f-9b3b-4e6013e9fa86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_accef57c-2220-48e6-9ff3-435816ad50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_accef57c-2220-48e6-9ff3-435816ad50aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0d87ab0-0280-46cc-8685-5e1b4419639e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_848e2adc-d59a-453f-bffe-0f31d6edecff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_848e2adc-d59a-453f-bffe-0f31d6edecff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3c6c5b29-28eb-4592-9e79-1ada003874f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3c6c5b29-28eb-4592-9e79-1ada003874f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bddfd2d3-2dc9-4d09-9bc3-12584ebff36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bddfd2d3-2dc9-4d09-9bc3-12584ebff36e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bd91480e-c6f5-473c-84a8-5de9d01bbb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bd91480e-c6f5-473c-84a8-5de9d01bbb59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_cfdb74b4-e03d-4a67-8e10-221e5cce68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_cfdb74b4-e03d-4a67-8e10-221e5cce68fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5304f7f0-769f-464e-8488-4312bbf747f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5304f7f0-769f-464e-8488-4312bbf747f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f9e0fe8d-03da-43f2-9732-12268936647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f9e0fe8d-03da-43f2-9732-12268936647a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_818731c9-3a60-49d3-95f5-9eab8b28fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_892ed1c2-7579-4f4a-8f68-8a0b1ecc19cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_892ed1c2-7579-4f4a-8f68-8a0b1ecc19cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79e1a90d-19b2-4310-a560-ca03fa11d786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:to="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67fd9612-299d-4831-bb3a-74236cd777b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67fd9612-299d-4831-bb3a-74236cd777b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d7e4c32-a48e-4820-a04f-dc39bd964f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d7e4c32-a48e-4820-a04f-dc39bd964f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:to="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9850cc92-b8fe-4020-bdc1-516436066924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:to="loc_us-gaap_PlanNameDomain_9850cc92-b8fe-4020-bdc1-516436066924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:to="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_4eb7232e-a967-425d-aa52-90535d9ba62a" xlink:href="mgnx-20211231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:to="loc_mgnx_StockIncentivePlan2013Member_4eb7232e-a967-425d-aa52-90535d9ba62a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i2297e65ad81d4879ac1bb1c993c65364_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4b5b0dbb-97b1-4534-8e1d-44672582f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4b5b0dbb-97b1-4534-8e1d-44672582f41a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ed39c4d7-0aae-4a89-a33b-0fa2de243903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ed39c4d7-0aae-4a89-a33b-0fa2de243903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5175cee8-23fd-4f8b-bbcb-25e8e33104c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_5175cee8-23fd-4f8b-bbcb-25e8e33104c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_d14c227f-d5ab-4aa3-b99b-7a301efccaae" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_d14c227f-d5ab-4aa3-b99b-7a301efccaae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_acf5e831-2d9e-48ad-89f0-29ff37f3a9a9" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_acf5e831-2d9e-48ad-89f0-29ff37f3a9a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b8e3aaed-8039-41c7-9848-bc382bb0679d" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b8e3aaed-8039-41c7-9848-bc382bb0679d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7fc9e281-db8f-4add-a63f-3bda4a0978a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7fc9e281-db8f-4add-a63f-3bda4a0978a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_72476362-b2ed-4470-982b-4cc174f17baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_72476362-b2ed-4470-982b-4cc174f17baa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ee591894-b44d-4f29-b1d2-a79599b13255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ee591894-b44d-4f29-b1d2-a79599b13255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_c8029ddc-1852-40de-a560-f5b9ead07c8c" xlink:href="mgnx-20211231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_c8029ddc-1852-40de-a560-f5b9ead07c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c8b9cc7a-4f33-4497-ad93-809f949fe70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:to="loc_us-gaap_DomesticCountryMember_c8b9cc7a-4f33-4497-ad93-809f949fe70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_65cffb6d-b1b9-4243-8346-6819faf4ab95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:to="loc_us-gaap_TaxPeriodDomain_65cffb6d-b1b9-4243-8346-6819faf4ab95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:to="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_a33bb3ac-1cee-4ac2-a60e-14f4ea0dd3d2" xlink:href="mgnx-20211231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:to="loc_mgnx_TaxYear2025To2037Member_a33bb3ac-1cee-4ac2-a60e-14f4ea0dd3d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_0b1c4419-ac1b-4500-840d-4bd1b2ecffc6" xlink:href="mgnx-20211231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:to="loc_mgnx_IndefiniteMember_0b1c4419-ac1b-4500-840d-4bd1b2ecffc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d830ebe5-0a64-4366-8ea9-06a67582fd14_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:to="loc_srt_RangeMember_d830ebe5-0a64-4366-8ea9-06a67582fd14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:to="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a60c6438-28aa-4662-985b-3b8926c98b07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:to="loc_srt_MinimumMember_a60c6438-28aa-4662-985b-3b8926c98b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_deec69c1-31c1-4db4-a5d5-8cccf155836e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:to="loc_srt_MaximumMember_deec69c1-31c1-4db4-a5d5-8cccf155836e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i0d05ff1dff734962858fbdf4858e38ed_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_e81eb883-a377-4d18-b1ec-9549d421926e" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_e81eb883-a377-4d18-b1ec-9549d421926e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4abb9bdc-7053-4955-899d-45b17cfeae6b" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4abb9bdc-7053-4955-899d-45b17cfeae6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_709a7c63-b4f7-47d4-9fb4-f91debd3642b" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_709a7c63-b4f7-47d4-9fb4-f91debd3642b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d35d35df-65a6-4a5e-b4bc-2a0660b4a7e0" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d35d35df-65a6-4a5e-b4bc-2a0660b4a7e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_5a820b71-b86a-41d8-83bc-97fa89468877" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_5a820b71-b86a-41d8-83bc-97fa89468877" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_b2c4ae31-45fa-4da8-bd0c-9fbc025cc58e" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_b2c4ae31-45fa-4da8-bd0c-9fbc025cc58e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_70fb011c-b60f-4e16-87a5-bc115292ab8a" xlink:href="mgnx-20211231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_70fb011c-b60f-4e16-87a5-bc115292ab8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_84955091-e7ed-466c-8a09-813603ead9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_us-gaap_Revenues_84955091-e7ed-466c-8a09-813603ead9c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab41aaec-b324-4831-af84-96866d35d3fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:to="loc_srt_ProductsAndServicesDomain_ab41aaec-b324-4831-af84-96866d35d3fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:to="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_f49c6c2e-c376-412e-87a0-f6871521761d" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_f49c6c2e-c376-412e-87a0-f6871521761d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17748b35-abe9-48fd-90f2-190029accb13_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:to="loc_srt_RangeMember_17748b35-abe9-48fd-90f2-190029accb13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:to="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a562b4f6-7ea1-448d-b905-f4f43fe863f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:to="loc_srt_MinimumMember_a562b4f6-7ea1-448d-b905-f4f43fe863f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40df28c0-fede-4254-b940-c26eb8a5f33b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:to="loc_srt_MaximumMember_40df28c0-fede-4254-b940-c26eb8a5f33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f43addf2-5648-4d41-ae1f-b55c893b92d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f43addf2-5648-4d41-ae1f-b55c893b92d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_b93806b0-7977-4e15-adae-b54343b874ae" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_b93806b0-7977-4e15-adae-b54343b874ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_b7dc22f6-69bb-497d-8344-fd1ceee34051" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_b7dc22f6-69bb-497d-8344-fd1ceee34051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_e56acf2b-4301-4750-afc7-becaab5dba13" xlink:href="mgnx-20211231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_e56acf2b-4301-4750-afc7-becaab5dba13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f2f7b55-da07-428e-ba34-85ec7dd596ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f2f7b55-da07-428e-ba34-85ec7dd596ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8713c37b-1a7b-4c1c-84a6-067e07840509" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:to="loc_mgnx_IncyteCorporationMember_8713c37b-1a7b-4c1c-84a6-067e07840509" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i1267a35a6e8b464d8d037af6aa3ff193_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_d40bc127-f0de-4ce4-ab46-ab67c8473ee6" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonRefundableUpfrontFees_d40bc127-f0de-4ce4-ab46-ab67c8473ee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_1b447f3c-0f7b-4c60-b835-2b4ccf51fd31" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_1b447f3c-0f7b-4c60-b835-2b4ccf51fd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_e8886649-085a-476b-851d-9251d6237aee" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_e8886649-085a-476b-851d-9251d6237aee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4a3e582e-7cf7-4ddd-9e6b-5ece9b79aeb7" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4a3e582e-7cf7-4ddd-9e6b-5ece9b79aeb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a0952537-d2c9-4204-8a4c-be33bbcd935a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_us-gaap_Revenues_a0952537-d2c9-4204-8a4c-be33bbcd935a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_23a7d35b-44fe-4196-829f-10463817c863" xlink:href="mgnx-20211231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_23a7d35b-44fe-4196-829f-10463817c863" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_7067c8da-db17-448b-b9ff-52714f87dacb" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_RevenuesTaxWithholding_7067c8da-db17-448b-b9ff-52714f87dacb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_48636ab9-dbdd-4054-bf18-96322a0cc96b" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_48636ab9-dbdd-4054-bf18-96322a0cc96b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_deaae9ac-1c45-48cb-a401-a03086262cd5" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_deaae9ac-1c45-48cb-a401-a03086262cd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_25e8b281-4154-42ec-a17a-aa103032b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_us-gaap_ContractWithCustomerLiability_25e8b281-4154-42ec-a17a-aa103032b44d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_1a1e989c-4d2b-4935-b1f9-8b7812b94724" xlink:href="mgnx-20211231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_1a1e989c-4d2b-4935-b1f9-8b7812b94724" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_92a09241-5ed6-4bcc-a869-9a5cac9e77f7" xlink:href="mgnx-20211231.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_OptInFee_92a09241-5ed6-4bcc-a869-9a5cac9e77f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_fec91c66-6abf-40cf-9175-0e00b7878a1e" xlink:href="mgnx-20211231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_fec91c66-6abf-40cf-9175-0e00b7878a1e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_f440aa52-539b-478a-832f-b9caab5c8c94" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_f440aa52-539b-478a-832f-b9caab5c8c94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_abd59a3e-a1b9-4c5d-8f7a-e2dc07e4109f" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_abd59a3e-a1b9-4c5d-8f7a-e2dc07e4109f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acb31287-70db-40e2-94c5-2e291699d842_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acb31287-70db-40e2-94c5-2e291699d842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_48c9b254-ac27-4320-a8fa-2be0253a1c3c" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_48c9b254-ac27-4320-a8fa-2be0253a1c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_77fe27d1-5d83-48dc-9398-9bcf65633bda" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_77fe27d1-5d83-48dc-9398-9bcf65633bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f3a54423-5ebe-4b64-8ea9-e3209b32704d" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f3a54423-5ebe-4b64-8ea9-e3209b32704d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_aef20d00-00eb-4db7-8602-0c3286f49420" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_aef20d00-00eb-4db7-8602-0c3286f49420" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_6f48804f-49fd-49a3-aa87-917917a8ddde" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_6f48804f-49fd-49a3-aa87-917917a8ddde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_e34ce826-bc81-4bab-879b-98d559fe5bdf" xlink:href="mgnx-20211231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_e34ce826-bc81-4bab-879b-98d559fe5bdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_0609194b-99ff-4872-8e40-1895cbe7c608" xlink:href="mgnx-20211231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_0609194b-99ff-4872-8e40-1895cbe7c608" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3311fdd-10ce-49e1-80a7-f399c3b5e02c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3311fdd-10ce-49e1-80a7-f399c3b5e02c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_16b0357b-f47c-4ade-b3c7-2eb729734aca" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:to="loc_mgnx_ZaiLabsMember_16b0357b-f47c-4ade-b3c7-2eb729734aca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_127cbe9b-d97e-4495-b0d4-ed2af029ea16" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:to="loc_mgnx_ZaiLabMember_127cbe9b-d97e-4495-b0d4-ed2af029ea16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:to="loc_srt_RangeMember_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:to="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8045497-978f-4851-b1e8-4aba49dad441" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:to="loc_srt_MaximumMember_f8045497-978f-4851-b1e8-4aba49dad441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f0b29db1-83f7-4bd6-b278-ec266dc69c13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:to="loc_us-gaap_EquityComponentDomain_f0b29db1-83f7-4bd6-b278-ec266dc69c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:to="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3de74aaf-3097-468c-a376-417a5e8f2f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3de74aaf-3097-468c-a376-417a5e8f2f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fda66539-c27a-4015-b661-19a645130fb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fda66539-c27a-4015-b661-19a645130fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_678c942d-5e84-40dd-a5cb-8b070b472430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:to="loc_us-gaap_SubsequentEventMember_678c942d-5e84-40dd-a5cb-8b070b472430" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="i18676339cbd8463ea9267a0a0a2aa8a7_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2af72b62-e816-4be0-9a6b-c539fdf5efc9" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2af72b62-e816-4be0-9a6b-c539fdf5efc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_b5c9325e-aeee-45ed-9cd4-64249671ab8d" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_b5c9325e-aeee-45ed-9cd4-64249671ab8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_9180a4da-4f2a-4bd8-8d1f-cdfead177ad2" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_9180a4da-4f2a-4bd8-8d1f-cdfead177ad2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_2a3b0fdc-5b5c-4d30-9a4c-dfb4e6801c5b" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_2a3b0fdc-5b5c-4d30-9a4c-dfb4e6801c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3823400b-ca6e-46e8-96b2-3e4febc734ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_us-gaap_Revenues_3823400b-ca6e-46e8-96b2-3e4febc734ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_bf734b71-f0bd-431e-9999-f8fe80a7711d" xlink:href="mgnx-20211231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_bf734b71-f0bd-431e-9999-f8fe80a7711d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268001f6-9e24-4620-9c11-537f37cfc1e0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268001f6-9e24-4620-9c11-537f37cfc1e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_1a7aaeb2-85f6-4649-8e3a-c89ad25cdb67" xlink:href="mgnx-20211231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:to="loc_mgnx_JanssenBiotechIncMember_1a7aaeb2-85f6-4649-8e3a-c89ad25cdb67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ade561e7-0b1f-42ed-9ef2-f73adbafda65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ade561e7-0b1f-42ed-9ef2-f73adbafda65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_8488d2ac-ec4e-4cd0-9c6b-d62a95b9a883" xlink:href="mgnx-20211231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_8488d2ac-ec4e-4cd0-9c6b-d62a95b9a883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64aa6ec4-cf32-4246-adec-9b5202f5e4d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:to="loc_srt_ProductsAndServicesDomain_64aa6ec4-cf32-4246-adec-9b5202f5e4d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:to="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_bab441b1-f207-4079-a4d1-6a62f2d920ad" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_bab441b1-f207-4079-a4d1-6a62f2d920ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_8e4a0d1d-43af-4000-a2b7-250adebdca71" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_8e4a0d1d-43af-4000-a2b7-250adebdca71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="icc2a91c211ce4deb8acb070554371715_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2d5ad563-4638-4cb2-abf9-86b950da718c" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2d5ad563-4638-4cb2-abf9-86b950da718c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e8c6c2ed-5b3b-4f07-a368-f77cd8b0051e" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e8c6c2ed-5b3b-4f07-a368-f77cd8b0051e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9232cb50-751a-41b1-b9a6-769d661a4211" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9232cb50-751a-41b1-b9a6-769d661a4211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_51344e69-0394-4ec9-9d85-7cf94da7644d" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_51344e69-0394-4ec9-9d85-7cf94da7644d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_eddcbda2-6192-43d4-8cbb-7901d64f2d30" xlink:href="mgnx-20211231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_eddcbda2-6192-43d4-8cbb-7901d64f2d30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_87cfefb2-a689-4b65-ba4d-3c0875421c44" xlink:href="mgnx-20211231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_OneTimeMillstoneCredit_87cfefb2-a689-4b65-ba4d-3c0875421c44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a1fc742-87f5-4852-8bf8-76dffe140ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_Revenues_4a1fc742-87f5-4852-8bf8-76dffe140ef0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e3fb80a2-d954-41bf-b14f-67fb03f2bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e3fb80a2-d954-41bf-b14f-67fb03f2bd96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_940f14b2-aa3b-483d-aa77-86796dd16a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_940f14b2-aa3b-483d-aa77-86796dd16a32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_acd47aee-8ae0-4550-90fb-c7b9944a79d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_acd47aee-8ae0-4550-90fb-c7b9944a79d9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_87739383-9679-48e8-a5d2-d7f07e1f862b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_87739383-9679-48e8-a5d2-d7f07e1f862b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_269fdb64-af25-4b8b-b144-0e146e684577" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_269fdb64-af25-4b8b-b144-0e146e684577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_979e3de7-acd4-40ab-97ae-30113322656c" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_979e3de7-acd4-40ab-97ae-30113322656c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c29a540e-c495-4fc5-b42f-01a6c706febc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c29a540e-c495-4fc5-b42f-01a6c706febc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_4a81d3ef-f285-41be-b040-80b981e0e032" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:to="loc_mgnx_IMabBiopharmaMember_4a81d3ef-f285-41be-b040-80b981e0e032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04998979-3609-46c3-8e26-bef588de2b85_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:to="loc_srt_RangeMember_04998979-3609-46c3-8e26-bef588de2b85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:to="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b1688a0-3cdc-466b-bcd4-d55f685a721d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:to="loc_srt_MaximumMember_5b1688a0-3cdc-466b-bcd4-d55f685a721d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended" id="if213a9a838f74e2d92c6956156192d26_CollaborationandOtherAgreementsProventionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9d01c47d-66dd-4f63-8b99-76f52cc4d04c" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9d01c47d-66dd-4f63-8b99-76f52cc4d04c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_39a66730-9cf7-4b9e-a685-59f38afd3ad9" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_39a66730-9cf7-4b9e-a685-59f38afd3ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_260e1d25-23bb-46e6-ba21-697e4fb1c117" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_260e1d25-23bb-46e6-ba21-697e4fb1c117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_9d5d86ae-406f-4f22-baec-c693b929157a" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_9d5d86ae-406f-4f22-baec-c693b929157a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_8bcf5f51-a4e3-4b36-812c-bbf674f7a432" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_8bcf5f51-a4e3-4b36-812c-bbf674f7a432" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_01177c12-3fb4-4a74-a65a-07bb43165a11" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_01177c12-3fb4-4a74-a65a-07bb43165a11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_12643b48-125f-42ca-9c6d-80f57d2c20df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_us-gaap_Revenues_12643b48-125f-42ca-9c6d-80f57d2c20df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1dc6cce-d1a9-4597-8e88-90c695368c5f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:to="loc_srt_ProductsAndServicesDomain_f1dc6cce-d1a9-4597-8e88-90c695368c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:to="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_6a519e51-4a7e-4a81-8a14-ca0a7d1b24d9" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_6a519e51-4a7e-4a81-8a14-ca0a7d1b24d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3ab1405-679c-4356-a905-8b3d4aad1357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3ab1405-679c-4356-a905-8b3d4aad1357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_af377995-bb4f-4a1d-8b84-173c8323d18b" xlink:href="mgnx-20211231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_af377995-bb4f-4a1d-8b84-173c8323d18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_eef50039-c75d-4292-9247-66eda3fa06b9" xlink:href="mgnx-20211231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_eef50039-c75d-4292-9247-66eda3fa06b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bdd2f757-6ef6-4079-b294-852bb93bc613_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bdd2f757-6ef6-4079-b294-852bb93bc613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_11e98c30-284d-4f87-a64b-affbee701ca5" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:to="loc_mgnx_ProventionPRV3279Member_11e98c30-284d-4f87-a64b-affbee701ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_f0daea49-936b-4b9c-893e-ce4bd54ea912" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:to="loc_mgnx_ProventionPRV031Member_f0daea49-936b-4b9c-893e-ce4bd54ea912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a91b6a5-ac6d-4d9c-8e81-8a994df25e73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a91b6a5-ac6d-4d9c-8e81-8a994df25e73_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c32260e-99fe-482e-a046-e6e27165654f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_514e9900-2ef2-4273-9f4c-c39c8c23a4b5" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3945655-6793-43d1-b49c-64c22f94a8f6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3945655-6793-43d1-b49c-64c22f94a8f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_ad1d9ca0-1411-4219-b883-66ec2cd35c44" xlink:href="mgnx-20211231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:to="loc_mgnx_ProventionBioMember_ad1d9ca0-1411-4219-b883-66ec2cd35c44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended" id="i579c327eabd848a191853f5520adfb43_CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_67d4d05d-441f-438d-80fa-c15ab050229d" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_67d4d05d-441f-438d-80fa-c15ab050229d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_d2184bc3-2059-4236-806c-6bd16cde9f4a" xlink:href="mgnx-20211231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_NumberOfProductCandidates_d2184bc3-2059-4236-806c-6bd16cde9f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ab65fa8f-a1b7-45e2-ba54-6d6a6c05bde6" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ab65fa8f-a1b7-45e2-ba54-6d6a6c05bde6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_3c87974f-a916-41b1-84b0-0c71ad53c49d" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_3c87974f-a916-41b1-84b0-0c71ad53c49d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_6c17384b-89b8-43aa-adaa-e7ea4ef34083" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_6c17384b-89b8-43aa-adaa-e7ea4ef34083" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b8296a64-f2c2-41b9-a24e-f6cdb3e688de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b8296a64-f2c2-41b9-a24e-f6cdb3e688de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_56081388-0220-4b13-9739-4ab498f0367f" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_56081388-0220-4b13-9739-4ab498f0367f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:to="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50d41fc3-6dee-435e-8f6c-e3142eb1199d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50d41fc3-6dee-435e-8f6c-e3142eb1199d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_8e0b9cf8-1bd6-44f4-a965-27187aa22805" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_8e0b9cf8-1bd6-44f4-a965-27187aa22805" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="i861f00f8a90b49619a82ae57f1341d0d_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_ac6da671-470b-4625-9efb-0e54d37ef234" xlink:href="mgnx-20211231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_mgnx_NumberOfProductCandidates_ac6da671-470b-4625-9efb-0e54d37ef234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_870b541d-94f6-4c3e-8a69-5535c6f4919a" xlink:href="mgnx-20211231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_870b541d-94f6-4c3e-8a69-5535c6f4919a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_73236d18-ec1f-4d6e-b8ed-748ae4851eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_us-gaap_Revenues_73236d18-ec1f-4d6e-b8ed-748ae4851eb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b3efeed-6212-4eff-9293-21203d4923af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:to="loc_srt_ProductsAndServicesDomain_9b3efeed-6212-4eff-9293-21203d4923af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:to="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_db038b8e-4b2b-4679-9315-344a037931e2" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:to="loc_mgnx_RevenuesFromGrantsMember_db038b8e-4b2b-4679-9315-344a037931e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_8a42ab9c-cf12-425c-b3df-5f42cfbc9e3a" xlink:href="mgnx-20211231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_8a42ab9c-cf12-425c-b3df-5f42cfbc9e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_70f21e1c-6908-45c5-929b-0d95dac5b3f1" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_70f21e1c-6908-45c5-929b-0d95dac5b3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_16e9385d-e3a4-4d1d-92a5-0db49429437a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_16e9385d-e3a4-4d1d-92a5-0db49429437a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_b7651f72-5999-4bc3-b0f1-f1f3f2f2f053" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_b7651f72-5999-4bc3-b0f1-f1f3f2f2f053" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended" id="i845bbfb62d6a4c27a9968d71fcd94767_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_8cc53867-e1f7-49dd-a210-592ffad37b8b" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:to="loc_mgnx_NonRefundableUpfrontFees_8cc53867-e1f7-49dd-a210-592ffad37b8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:to="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9800f122-701e-47bd-89ce-1f1f044f7136_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9800f122-701e-47bd-89ce-1f1f044f7136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_c5c7b35a-81ed-4d23-a7f5-04e0e49f6d87" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:to="loc_mgnx_IncyteCorporationMember_c5c7b35a-81ed-4d23-a7f5-04e0e49f6d87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b835fcd3-7f35-4a6f-8360-fcc26ba29d60_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:to="loc_srt_ProductsAndServicesDomain_b835fcd3-7f35-4a6f-8360-fcc26ba29d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:to="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_4f4883ac-da2f-4d38-95cf-1cd2e81918db" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_4f4883ac-da2f-4d38-95cf-1cd2e81918db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_57278ef2-459b-4d63-9609-1fa6808998b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_57278ef2-459b-4d63-9609-1fa6808998b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_d20a6cda-d8d4-4e0c-ac14-c34e1c859f11" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_d20a6cda-d8d4-4e0c-ac14-c34e1c859f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_64f9a2b0-16ef-492f-8944-6ddab6f94b93_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:to="loc_srt_ScenarioUnspecifiedDomain_64f9a2b0-16ef-492f-8944-6ddab6f94b93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:to="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b558e71e-7f7c-4771-9ad3-7299075507a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:to="loc_srt_ScenarioForecastMember_b558e71e-7f7c-4771-9ad3-7299075507a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgnx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_NameOfMajorCustomerDomain_1ea945f1-f7f6-4d0c-9aea-d59b2e83008d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_ea6d2c11-5c0a-4752-96db-af762781c802_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8c7508a8-591a-4962-b82e-862c3920cf4b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_dea52298-bb15-4893-893c-e4a1894afad6_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20211231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_57e04540-7147-4e21-845d-a67a3ab0234c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa8a984c-6253-4b8a-9b8e-72c772f39506_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_470f999e-4dfe-49bc-bf38-142af7971317_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_927ad54b-beae-4619-be7c-854dedc94390_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_18118f01-1ef7-47e9-939d-d83864f3dcf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, ROU Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4e6363db-66c3-4c76-aa12-bd77687d0e7b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b0d72cec-345b-45ef-af20-bc3ed833af81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2cec5209-2dfe-4e64-a24c-55553cb3a10d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ad8bbf3f-cac5-497b-831a-7138fe76628f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_47cf6e4e-ec64-4c76-a184-4e96467cc5f5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_7a132920-78f4-4a1b-aadf-19e6b4d56f3d_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8b0953ca-d697-498f-91f9-14dbb1e9b6a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c9e9fe2b-c455-4072-89b4-1afdda16bae5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bc935a75-dcb9-4e5d-ae20-61830faba149_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_a373d91c-e219-4cff-8033-4dc43d346c2f_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e3356be4-4cb7-4258-98db-ad215a4c8dce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2d9ee125-1ed0-4527-9b74-ca3bd1b99a29_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20211231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_3c193174-bbc1-4cc9-82b6-cb5f670d8709_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6cc9f3c4-cc81-4c4f-bf4c-f2c2e0710f18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_343423e0-4d93-4507-8fef-05a45ccb2887_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_9b7c25eb-52f4-4115-87ad-bc26b224d5d7_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5843e827-2167-4a9c-bec8-a7ddb9a7f047_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fbe2dcd5-ce83-4efb-84e9-5e464f0e252b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5aa7eb2f-1ee2-4bed-b937-cbdb18e52e23_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_224ac00e-a8a9-4724-8196-7642267f759f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eacf99bc-ebe1-4d2e-8819-8712abca46ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c77a82c6-bf3a-46ac-9105-91bc08c20743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_c01df0be-c7e3-4600-91c4-2a2e9e76a91f_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Table Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:href="mgnx-20211231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8584856e-9297-4c80-bdeb-7ecb5852c8d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_56b24e52-2627-4aac-b2bb-a493b35083c7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_7691afcf-9fff-487a-91a0-b998bfa837af_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_101d4a2d-eb94-47b7-9e58-d87c85875c31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions Charged to Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e9daecb2-0b4a-40f3-b0d1-b49939c713ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_009f1941-d5e6-4d4e-8d13-d47adcb6c3ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_5da4538f-6f4b-4c62-ab72-e4a39bf7c43c_terseLabel_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_label_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_documentation_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:href="mgnx-20211231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:to="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ff5168b1-a3b5-4a72-94dd-0ff18bfff37f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_62c93a12-dd76-46ea-856f-034d7ca4de13_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5a56b103-a262-49a1-8e5a-f07897e00dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_812490d9-bce3-44be-b448-c62ad959ad08_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9c4ce664-3671-4a33-b49b-acb9cd09a9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9d9b5173-ce8c-4940-bf5d-b43175b1dd21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a62b1266-0409-4659-a442-e50ce1ca0c1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_378369c1-477d-4b29-856c-b12e45fa0b9b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6a2f3a8-6fa9-42a8-95a1-a8b9f5628aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_a7311254-5aff-4b6a-8eaa-3410459bc68c_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_761b3d9f-56a2-480c-bab7-d6957eed1607_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ce426c31-e3a2-4752-a9fd-b7b9e80b9550_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_855fcb5b-1851-4aee-b9d3-67b0a91e3a55_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1344668a-1c61-4533-8735-4e254c16679a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_96bd6115-4acc-46a7-914a-24d3a28bf871_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4c207e87-e1bc-479b-858f-f400dd1b1992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_29221995-6bb6-4b6c-86ed-242eeb8047db_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_53142497-a1bb-431b-847d-760dc9194948_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1d8b50df-99a6-49b4-bebc-cca7e680b583_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12541647-0040-4f56-94c7-23d4722d0b09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2b761d52-bb34-47dd-a32c-64b1fc70c0df_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_21ff5401-bea1-4e2c-b8f7-37a05c1cca67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6af4f056-b390-434f-a6f5-1e756ac2d481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_601effc1-b2b7-4e61-93c6-a7d88f365192_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39685534-3dad-497f-b805-413bc481f418_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fc4ef19f-2c3f-4594-8cae-494b3646e618_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b3384acb-d3c0-43db-a092-0f1da1d4bca7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_cdfe225e-92c8-494b-89aa-21d70d52e3de_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in years)</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a08ad45f-df6f-4184-a7e6-94033ac8c840_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_6a55e8a8-6ac0-4962-8695-f7b9f9d45245_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_3b5509a1-0466-4af0-81d5-6d144db73397_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9b4f8afb-293f-48c1-9bf8-da53077ab740_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_ac49e75b-0858-48cd-a7a5-1fc74b75cc52_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20211231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4c36468b-3962-4d4b-9eda-a6dcc319a9d0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2f5836db-04d2-4fb5-9e7d-86d651469ed7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets modified in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2c50c29f-7a66-43a6-a1f4-13448d119163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_cee7b13a-bc9b-4455-86c9-722215c77a07_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20211231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_123eb672-47a9-4e6c-bdee-f5e139c67513_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9b116d11-ab8c-43b1-87b8-a8213aa001aa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a11a466b-1368-44c6-9e0b-614c33210e57_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_8892561e-7fdd-49d5-be1e-52a2e7a8e598_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_270b903a-cbf4-4edb-982d-3506b30257f3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bbc34834-8b84-4d6c-8745-584d9d030b70_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_041aad9a-6472-487f-9aeb-33141b2e39c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f39cd95c-4aa3-4e53-a4e8-a8f8b5f94d75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_056e7b5a-40a3-4b09-8b73-18edf72ee678_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20211231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_22e2a2c8-824e-4844-ba9a-ba0d80680b48_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_a219b62e-1283-42ae-8896-5e9c48a319fe_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4aa6f666-a956-4673-ae3e-5f2558170669_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c7288b21-ae95-49b4-a0ad-5a5d84c95312_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_5fbae83c-ef10-4741-add6-bfa3938e0d49_terseLabel_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases/(decreases) for prior year tax positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="mgnx-20211231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5de183a8-dc61-413e-8b26-362ebd96044d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_29067b3e-87ec-4beb-8496-2b7db113856d_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20211231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d86e6c29-9a49-4f60-8877-1a92ee6741d5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ImabMember_64182938-6f6c-4b3d-83c5-8060b6ef1b98_terseLabel_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab</link:label>
    <link:label id="lab_mgnx_ImabMember_label_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab [Member]</link:label>
    <link:label id="lab_mgnx_ImabMember_documentation_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember" xlink:href="mgnx-20211231.xsd#mgnx_ImabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ImabMember" xlink:to="lab_mgnx_ImabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9cdd671c-6a22-4f14-bc9c-18590fba520d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_03cc5a3b-510a-43d9-9dac-662f58b71714_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_f0bbc76d-d716-40d6-8852-857ba0e9d103_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserveMember" xlink:to="lab_us-gaap_InventoryValuationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3b3f43c0-491b-414a-a4be-c2f64f3e0550_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a9758a12-73f8-4470-a750-830aa799f39e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_bb8b2f91-3edb-4a0a-96a7-468baaec5b37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d25bb5a2-b0c5-4ca1-986f-5a8544f5dd9d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_df7542f8-7deb-4d3a-b86a-9bb420f83727_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Including Clinical Trial Accruals/Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_7709b1e0-7e10-4fe7-b30f-6bbf2299086d_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0a896367-ad24-4885-a3f9-f6d1af3d89d1_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20211231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fe659944-a023-4845-8c38-b5f2f0bed3ee_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_301171c8-2fa8-497a-9024-ce4ce3748b7a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6423913e-a3a4-43d1-a6f0-1c6ccaa231a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_f8aa15c2-9f2f-4596-9c3c-385c4d654d1e_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_9cce0db7-164a-45b0-a760-4d429bc22833_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_df98af79-0402-4052-a5cf-c936fffd80aa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ffd3dd45-adc4-454d-b0ca-6a9931c17df3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_93ac767c-8344-42b3-bd52-8ef43cd363f6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a78e293a-658d-484d-b367-a4d6495073c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8d484574-739f-4d6a-b28a-94d244332ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_8962f3e4-4453-444e-8a5c-e72fd35ad239_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6c8d3f76-cfc8-4ffc-8acd-0d82203ba215_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ea342583-129c-44d0-a276-fa018e9857a3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_4a615f89-3731-4507-ac2f-a76f2d9b8eb5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_122af1a5-1c80-42fc-93df-cd0a374cb1e3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0c5c78ef-6c1a-4a30-898c-9019f75b6ad0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_576dcf73-b020-487b-84a2-f853fd775cff_negatedLabel_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_73d68b9a-8e9f-455c-bc6f-0bdf1df0bf6e_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_label_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member" xlink:href="mgnx-20211231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2025To2037Member" xlink:to="lab_mgnx_TaxYear2025To2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ee0b41e7-c95b-41ec-a4d3-84d1538f9396_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_6be3b08e-8312-457c-af51-30c54539c68d_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Commercial Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Commercial Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:to="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_9b54e3cd-db97-4cb8-89b6-9cd8bdf33667_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d9ffb19a-ce02-4106-84d6-c5d81606a631_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_562d8ff1-4328-4869-a407-c2282b17ca67_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_466507dc-7ed0-4427-890d-7c40bac42e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a39b2a52-472e-4dcc-a473-ab1ba657bb17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_c2cab21f-66bd-4b73-be73-8c9b0bfdef8f_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_label_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_documentation_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentMilestonesAmount" xlink:to="lab_mgnx_DevelopmentMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_27473036-a9ab-478d-9462-bef7e63ab87e_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_787d8baa-bce7-4b31-8847-1ca50264af1b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06b4a43b-d050-4609-9607-adf1ec3d3d60_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ee82eaaa-4da0-42cc-acb2-115bd3cbcd07_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_2469bda3-1494-40bf-bbae-ab75661c65f9_terseLabel_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply [Member]</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_label_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply [Member]</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_documentation_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:href="mgnx-20211231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:to="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AuditorInformationAbstract_label_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_mgnx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract" xlink:href="mgnx-20211231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AuditorInformationAbstract" xlink:to="lab_mgnx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9d557147-4959-4789-a190-559aa1d7bd9d_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_73584566-c2bd-44b8-a0b0-3e854df14719_verboseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1fc0c687-6769-4377-8718-a09f2781064b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_71ce1b77-5f4d-47f2-b560-95f151d507db_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_02c00665-5835-4755-9892-e036886ae276_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_c65adf8e-ee49-4653-882c-3e3cc0316314_terseLabel_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Clinical Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:to="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e7824424-2360-4a16-a0b1-3a370fd1c65a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7b05f7e7-9b12-4675-9dd0-73556504bddf_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_326ed7c0-b80a-489e-9639-1567c5a0ceee_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_fcc58f94-27f6-4beb-9db1-d3f9de1c4102_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0e88bffd-8801-4f98-aaf9-b6a495e468b8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_25dab608-96e5-4b33-8764-6a741fe6acfe_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20211231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_1836b471-d1a8-4e0e-8d50-c73a5eb0c822_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20211231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_757de83d-0afb-4e1d-8612-0001c57d7d6f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f1d7ce57-39de-4394-a458-a3c2f88e2afa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_af1b03c6-2a3b-4199-abd8-7a3c57b93882_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_432a511d-b75b-4853-8bb9-f28b4ed70f42_terseLabel_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_label_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_documentation_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit" xlink:href="mgnx-20211231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OneTimeMillstoneCredit" xlink:to="lab_mgnx_OneTimeMillstoneCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_48ce6ac0-72e0-4b03-b5b6-aa004ef4af8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f522974e-43e4-4d28-bd2e-ffaabe1ce5fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_332c1d97-043a-4602-9dac-12706b5dbbf7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ed2239ed-4eec-4014-9253-214c16df53aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d72c31d4-58d6-4196-abfe-27f3efd154d1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_eb2b780b-e911-48ab-af96-53abeea3b0bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_beed00b6-c278-44a8-a6ad-c90b78088637_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_21dabfa9-7797-415c-882d-80b27d3f44a5_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_6b076ecf-f905-4cdb-ba94-bb66d98a09aa_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:to="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3f764dee-b324-4a7e-bb30-619a2bcb16cc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_78aba77a-bc64-414d-aa5d-b8290fdbe501_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_81a405d8-3cfb-4465-8e3f-f816760335a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_4ecbda14-3458-4eb5-ae6d-6386f5e4017a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_51156e32-9df9-4423-bc67-2baafd1024cb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b7f00b87-e89f-4755-bd9d-c3b2df738c29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f5e543d0-45e1-4b60-9a93-aab447a58673_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_cc5e60a7-34f4-4675-aaf4-5c09b6222fd8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5969dbf5-d8f4-4c3d-b33c-d6f1f2927b86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_68f732f6-4013-4dca-8306-dddbfbd0d60a_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20211231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_69b065d0-9be7-44fa-85a6-e41296f43e6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c79e530c-00c5-417c-9e4b-fcd2cea55c76_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1f95e927-965e-47d8-848a-ab12c6fa3991_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ed7b3e5-02b1-4313-aa97-e8f2b398dba4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6bdc5ce-47c1-4c9e-b560-919ee3741cd3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7ca736e8-8052-4db4-b7c4-82e3b4df54cb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_70a51bc7-0c1a-41b8-8e10-faa0294104d4_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fa65508e-9472-44f1-a85d-4d0e88dee28e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7531fd49-e397-4a63-a5b1-756e2ed0c367_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,307,428 and 56,244,771 shares outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2859b315-e5a0-4c3b-a325-48cafaf6c26f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04c89776-e9fc-45ee-902f-fdd88d10fdfa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5bae0e1-d30b-4fb1-8db3-84c25f1e3c08_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_feff6c4e-deb4-47c9-8def-7cb31a1ae760_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d49e2c07-8f22-49d5-9428-42d9e53f9d7e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_28b80a64-32ad-4ecd-81c4-0f0490a0dc6a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d4f148be-640f-47f7-804c-37680ced83c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_66550b17-9e01-458e-a1d6-8371b990b682_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1fc328b1-5632-411c-b4e6-85f83149414d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_da500fc7-56a0-4916-a64f-8fc04796a088_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c66f0358-b74c-4fc0-88e2-b2ea75a48114_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_bdae0bdd-f79c-43ea-a97f-153800db9784_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0636d46d-e447-489b-957b-819d20226951_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_37de4156-c81a-46ce-9c54-eaacdbd25c01_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_dfab9262-92b4-424e-aa85-90831b1adcff_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2c83e6b2-758d-4251-ab2e-4b7e0e02ebc1_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_89ab0f1a-38fa-4513-88b2-bce4fd730b50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7cb84165-5dda-455d-bd8d-51eb3e74af16_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9f9578f5-516c-4916-80e4-f7a8b6b07cd1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a91148a3-e22f-4b28-91a5-bee7540ee35b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_36fafcb6-63c8-4984-9c27-27fba3c3be37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_de50c73c-eb3e-465f-9932-8e924fc52860_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b035ec92-a017-4d2e-8a06-a8c8801fed2b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4e7d2aa3-4ed0-4aaa-9109-4fbd56891657_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_f00ee5c3-0c81-4c63-aaa2-0f14c8174fe8_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_6270a5e7-4615-43e3-9f23-f7de306e8640_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_e229f290-8862-4f16-b9c4-2286708a814a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad498a01-051b-4a58-a43e-45b23b633e6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ea62b586-3dd9-47be-afc0-21b54b651908_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_243cee82-6d19-4f28-9759-231bde39fab8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ce0f8700-a6e9-45cd-b89a-48505f9bd857_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_8db51b09-8394-40ee-9659-e58fe3c63b27_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a94daf69-4ea8-4c36-88d6-45931e6fe0b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9521c859-651f-4857-ac08-10ccbcc8adaa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1c32a62-d3b2-4745-8b83-97de93474354_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ed15538c-c649-4780-8eb1-a9f7622ed9c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e1a960ce-5373-47de-941c-b98275a6395c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_56d0dd67-c8f4-43e0-a9ac-9acf136aa921_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_0fd81eac-ab87-40ff-a168-d6a57f97fddb_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5725318c-d220-4e0d-954a-e141dc5f132a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_da34a1bf-b021-4301-a1e6-089b0bdfd3b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_93d575c7-cee5-46cf-9d8c-c278afad3ec8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d7d447c-acbd-4bc3-8b1a-ad9e6d2d9759_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a4bb3c87-275d-4985-a929-8442767e8e37_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_1630680d-894f-4783-b596-57976c688337_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_3c547d82-12f0-4b6d-abab-084eefb2975a_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ac0f78ca-0fe1-4e75-99ce-2a3e04d46793_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b9928bfc-07d2-4ec5-92d4-9530b5af8cad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e3bb2e4-6380-4525-aa4c-4d2fb04016d0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_cfd564de-0d57-46aa-85c4-44ce28ac39fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_aace9b75-6f6e-4bec-8fd9-ef0641c0b651_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0fb3d884-941b-4ed2-8fb3-94ddeb5c10be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1d42abd0-8f8b-4e61-970e-0aa583534a9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e45c6a6b-63e6-4092-b056-5d1c766a6f6f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d7ff673-05f6-48e3-912d-4a3540b300e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_18325f90-8b88-45c6-99f4-be62559572b3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_ba03fdc6-98f7-4cbb-a2d9-fdf3e0dcbbd2_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20211231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_cc10ef73-a018-4f4a-a825-d7061f179723_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20211231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6fa56df6-6a7f-495c-b651-c12011592c93_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b68589f9-a18e-4d65-abfe-987a862ca72a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ff229aa2-79af-41bd-be96-840c4b2d4957_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_74c51e7e-b19f-40c0-b77f-d2fa204ba69c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_09ec9d68-3afc-4667-a437-ac41c55af46a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1d78db22-7826-4155-9c9c-d4a0a52983c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b21bed0b-773e-488f-8bd9-e87af1463448_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d7a7e9bd-b6e4-4e92-8e7b-144765e5736b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6bba13f9-9ef4-4014-8648-66f796748c50_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_24d782db-58fe-4adf-892e-00cc29c057c9_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:href="mgnx-20211231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_169b26fd-849c-4a36-8dde-02a6c4f04288_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5aee546a-d50a-4bed-bac3-02ebbcb2c8cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_6d150d7d-8185-4b93-9975-9da06320ef8a_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5a1a0898-58ad-489c-bbfb-527714faf3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_0c23b872-0d47-419d-ac8c-f126cc3c8d73_terseLabel_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_label_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_documentation_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:href="mgnx-20211231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:to="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_f8c803e6-8eca-437f-9b8f-19fef1718253_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20211231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6ee55f77-629f-4892-9d20-eba5443f46bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_53209e05-01f7-47bf-90b6-99b0406f45bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2d694aee-c8a0-461e-95f0-76fd8b699501_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating and investing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0171fe76-bd32-4d16-9d0a-a36087a136ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a6e9f473-def0-425e-adb0-a18a78ee4147_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_45214c7a-86ea-432c-b7f8-433bb049fa61_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_bf18cbc4-6870-4fd4-8e6e-06565ec35abc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2d11ba44-62eb-4238-8103-f0e0f478db70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_e27946cf-735b-45e5-90a5-ec1d1680e9fe_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_3ea0db84-9196-43b6-b037-e095f3f3a18a_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fb41f226-e877-4880-bac3-133eb9012bf8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_888ab335-6a57-4212-acbc-f483dd15452f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8ec8b18-b698-4a31-86b6-832a44209cef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d79318da-4c66-4e01-a28e-2da2e86ebed0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6190223e-c7db-4aca-b693-fd524afde5d5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d18b0f0f-724c-4d49-a546-36fcdca66443_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0ef2a1b8-60a2-4a25-b806-4136bebf21cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_ec9b503f-a46d-421c-9afd-13d795c13123_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2abbec65-54b5-4019-8d46-39ee0db1893b_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7c8e9089-eaf4-4b9f-ab7d-5486b62c4142_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_2904b171-0e85-45ca-90fa-6963adb02035_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f3dac46b-d78a-412f-8c08-27f88b4865e7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d0c6bb75-06f1-402b-a790-73d132f1f771_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_32ed6b82-c2d6-45ed-9c9d-5d17c8fb7858_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_c1a1be25-03c8-4510-a653-258ae55cd02c_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member" xlink:href="mgnx-20211231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member" xlink:to="lab_mgnx_EquityIncentivePlan2003Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_23bcc1f8-69fe-4b71-8672-c137ad9a4911_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_91dbb5c3-13d8-4c18-90ce-b5a1735fad03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4cb94576-4cb0-45bb-9937-183344362093_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_88793d90-547b-411a-85af-9e285ff6a634_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_65caba05-0581-4f33-9b21-3c831ed6f516_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c7f3d092-2813-4fb5-a688-d1eff98a9f47_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a3da887a-27fe-4458-ad6b-28438c1437f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_35b41555-56d7-41dc-afde-e9d42ff12503_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_2daa0d87-7eed-47e9-b4b7-96d64dca5190_terseLabel_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled milestone payments</link:label>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:href="mgnx-20211231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fef10bc4-3b1a-4640-b844-05766b22acac_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_85cf20b7-7475-4f7a-b082-fdf4bc16f51e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_97661b98-cff3-4bbd-b5cb-b91510eb3403_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d23c8de1-4561-4068-ab89-3545c7e9291a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4cf3128c-a3a5-49ef-89ff-bccefcd4bfb7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_466fef0f-8941-4e1e-89fa-a24e5572c58f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ffec911e-94e4-4fe2-9156-e53a2f3a5261_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c9697f7d-3982-45b9-8b1b-3bb0abd7a43a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8cf0deb8-e6cd-4d2c-a10a-317dca8cde55_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_dc470f7e-ff82-4665-9888-1bc0ac128995_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesTaxWithholding" xlink:to="lab_mgnx_RevenuesTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_74be3471-46c5-41f7-a69d-b032d2eaa380_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c050d24e-b81f-4e2e-b454-cce8e058b83c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_70d1c7fa-aa7b-4c78-93a5-ab9e945f869c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_1eb95d26-4a79-4b82-8067-0644ae867138_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d865a9c-bb3e-4adb-985a-6a573e9f860a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2487b404-854b-4d12-b1b6-990f3517f73e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b879cb29-d2ac-4c51-a016-18ce533b9948_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e387c87b-a8f9-4624-a8f3-c10b92a5ec45_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f63d6eb6-93f9-4a7a-a13e-775ddef2fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cb2b4166-6e58-46a9-9824-43fa9ae437e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0fd76759-c0dc-43f7-b803-22de009e393a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d8949f09-c645-4568-91d8-31051230220d_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1579cf50-8cc3-4d81-aabd-75f8ad4f8fd6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_42f5b4b3-8cf5-4d44-8178-053b67e41cdc_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9db4adc7-15f0-45f7-8970-d5e302da2c35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_02a88b7c-f1c3-4acb-bb70-31c13c4b87f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8f2767a6-dd01-473f-a046-c428b0acf114_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ae33f45-b5ca-4b9a-b837-e22223daddbf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_02cb252f-5f93-439c-bb04-5248aef57e17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abc4d06e-4dff-4c02-b805-7b0b316c9595_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2dc22627-57eb-4da3-8503-6ea1edcde550_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_1afbb463-0355-4616-b2e4-35699fd64378_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20211231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e691772e-c55b-434e-8803-617c78f919e4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_1b761904-68c9-4cc9-b8b1-c7d9e7b05082_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motor vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e178358c-e39c-4a69-8dfb-c27112c1148b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7361088e-c4ea-4a35-89e9-f689ebaef792_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1148a63f-4783-4add-ae8e-7df1886917ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_f286372c-efbd-4a5a-a655-597f5559a3f6_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_48ed3a0b-a191-45f8-918f-73c6ae6ce78a_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_4c387f80-4d55-4852-b2da-7bd86d84c3c3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_38e5971e-689a-41e6-a780-3b91f7957437_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3670e4de-6a2c-4109-b828-d3d100ef3a57_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1953e5bc-382d-49f4-8d24-64be05c9853c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_26136a21-1ae4-41d7-8771-f79e7b2f94c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_ed3f05bc-17d3-4065-b9ed-6008e22538fe_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_d4ab8924-655c-4bc7-97ab-52457db3145c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7ac01047-2324-440b-a3e4-b57b0cb66ebe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_32770cca-09f8-4704-acf3-ec8ddda592af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a1a3a093-1779-4f45-9fba-0512e6d2e7b4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7216820-844f-44a5-bc98-b2da2ad7ed1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fb943f42-f570-49be-8093-c1bc8ac54f76_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_944d746f-5fb0-4b25-b675-7c35c05a7db7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6eb7bd95-6e1c-4d4a-9839-16b49ec5c502_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_87de0a84-9cb5-48b0-9583-5f4eeb9132dd_terseLabel_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:href="mgnx-20211231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_455f5ec1-bb1c-44d2-8ac5-e2a0c5064779_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20211231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe3d8ddd-85d5-4ee1-9987-a4b781aab2fb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_4bca8abb-6764-47f7-aca6-a2110af1dde3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2202851b-e374-433d-a801-3fd016012b88_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a0b05b37-8074-476f-a601-5a384714e97a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_643cc9fb-a3c9-4f81-b7ba-bfabe046dbe7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e1dc0820-2f48-45bf-af3d-d3defdc7870b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_5719e274-f0c4-4699-ae92-0f265ea20740_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5e746b45-d46b-4921-875c-c0144768c05a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_1ffb865b-180d-4626-a53a-5d0eb3fb280e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4c07d37d-f820-4c48-9a8b-6519ffc7e076_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6c1a1a2f-1cac-4f83-a985-2856f0e66fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5fa6aacd-5931-4667-9d1b-2489c7245411_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_7099f2a0-de11-460c-a434-1039a5d471b7_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_68a472f5-8318-489b-a64b-8f2e92ae9987_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f8235699-b2b9-4748-ae51-655eab90cdf2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3df6295d-9a6a-4072-bf59-6d5d41de80a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_15f57e9b-6965-4bed-b9e6-9f459489043b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_62a15aac-acf4-4788-8685-6fc0200421e6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3b4e2ba4-8068-4042-b384-6f7fa277e3a8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b9e2e244-6841-4d2b-8cc6-9c7d5a661271_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_ec2eae1f-924a-4e4b-ab65-137ac6fddd0f_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8a9bfc3-034a-451d-8ac0-e233d39eb727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6e2cbd6f-a3b0-4212-8d80-2471f7664573_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_985c82ec-ba74-4f9b-a80c-bec2c234f6d4_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20211231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_10701e35-16d1-42d2-898c-0cb4a6fff7f2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0cb80f03-63c8-4700-80dc-ac576864b07b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_960e7857-54b8-43c8-83d8-dda107ea8f18_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_83528da8-eebd-41ed-bc46-092a3ab9820d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_aa03d833-e9d5-40c1-87d2-0c9f11692784_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_340e69d8-3ad4-47ba-963f-0eba113331fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_656e7514-3ce4-4587-8bdd-bca881ce5410_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_009a25a7-59dd-4aa0-850e-e4af52c85b8a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c27a506-dfd5-4724-91ac-b5637f64aa90_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d6d04b3e-c02b-4f6a-a5ad-e605bd6dd905_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_48d4d6e9-0ff1-4a6d-b2da-7911efd50806_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_79fb40ac-55d4-4980-90fd-704626eac27a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_98120a1c-4404-4432-aabd-1690de58199c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d1ded8a9-6e71-4264-a824-2d299f72c5a5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_0df56e9a-413e-4dea-a7b3-3d697a1d9de4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_06a5ff5e-78a7-4681-aaea-1609ba93d6f2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30678eba-c41b-4058-ad69-4cb5c70d61de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_eba7c01a-7346-48fe-9c73-41b3705c2339_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d8030989-ae8f-4d01-9186-85946a730c28_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6cc142ac-c7a7-4789-99ee-21c21e0cd863_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3d95c73a-49cf-4106-bd74-002c7ebad968_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b326d0d3-6aa3-4635-ae5c-49a5afd48c13_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_885a7036-5314-426c-a422-0d9fe3b54057_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c69ebaf1-c16b-4182-974b-d507fdd5c428_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1fe123e1-c0a9-454a-9823-e3f1bdddbff8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3062d284-6cb1-4d19-9c69-381279cf465e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_62605ca5-78ba-43b9-9d80-2b2df6dddf86_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_a6914056-60c9-499a-889e-3c747f1e6663_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_11b2ddb4-3c58-4296-9844-e20198a7a100_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5a86ab50-b9b0-4138-a15f-e29627f787ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25682cf9-2bca-424f-aedd-92e3157a9487_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_492ef673-3463-476e-9977-e858f6f4e411_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa1ebde6-5f27-4bdb-b88a-e0ba9e55c1be_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_68a00cae-617c-4a48-84b9-9dc86dd8f484_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_42ee9655-b215-47aa-ac6c-51b6e2e01be9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dda72ce7-68b5-40c7-b1d3-e5dcc72469b6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f5068249-fde6-4eef-bf56-22e38579b9db_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d8415a70-3e70-4426-8720-8b7f52cb8b68_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7bae36c0-0588-4b69-a921-3f78b543e56a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e149a2ad-5129-40fc-a362-a3993443ea97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_652062b5-7db2-4e03-b648-4d671029762f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0832142b-caf5-4e2b-8366-f030da5a4968_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6df22354-f98d-4034-87e4-c36f65dabf9c_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_83107062-7988-4b30-8e23-37245d345c2c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_56550fcb-86d7-441b-b140-7047e92cfd43_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a4c7b676-efb0-472b-a679-1446087fe90e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ab24a8a2-1d8c-4e12-9838-9635c47245be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7466a11b-201b-4463-9184-e92be47f3a4b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d4ca7597-dfb8-4c25-9b58-3916bb4d14ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_03538f56-269e-478a-9414-75496f5657c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_372e96b6-fc1a-4247-bf99-1c6bb5ef4622_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65e2440f-831e-42f5-bea4-5b0b792ad6e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_99c9e3c5-da72-4c0c-9424-e1bafd13a449_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20211231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_32ffa46b-9930-480a-a9d6-d1ca317ecc9a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_8ebaa74c-78d8-4378-9ee2-e96ca7a622df_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee contribution percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20211231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8a5bfbb4-6054-4e06-ae4e-94f334a01576_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_ae3d43f7-fa7e-446e-a343-54a548b536ee_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance recorded</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4af0a74c-9811-4d40-ad3f-3120b3189a71_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e2a2dc6f-7f85-4d34-9869-14e48389e73e_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_cdac897b-527a-465b-ba48-187341f9d486_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_4a97f0d6-ac38-424f-9088-51b4406f8c53_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_03351e6e-cf3e-4db8-ab96-e06b682a94f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_673f4c51-db17-4b74-a624-da482a730073_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6b71c762-9ea0-49b4-9ec0-f1a5a532c061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2f2cdc8b-1a27-4606-8947-97ecf6909d9d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9d777373-de1f-4de8-a60a-cb099b2fd501_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_81240ba0-b9ae-435a-8109-233259c93976_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a02c00cf-8402-41fe-9473-3d9da44b4b37_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_ea08f20c-c552-443a-842e-004ba20503f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_df22fba2-1f21-484f-8f68-28abafa7b2d9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsMember_bb5d333b-6481-4715-8b6b-d528b659e7b3_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsMember" xlink:to="lab_mgnx_ZaiLabsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_088d260e-c177-48ed-b036-1a942e312893_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7e5aea9c-63a3-4b61-8cde-e3d1c2f1fd28_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eac71218-c6a6-4d84-a9ac-640b5b8a0ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1b9840fd-beaa-4935-b17b-1290af012d02_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9698b034-82cd-476b-a028-5c5ef43504f1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_88892167-4c31-4858-93b1-e756c49c0be5_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ed391b37-9019-48ae-8c6e-9b0ec3d2614c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_85cb486c-28e1-4863-8c95-1a83c02db486_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_caa73ef5-e3a4-40a6-be1f-2f50dd48092e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_066ecd97-ea75-4f04-a6ab-e39afdd170fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_d0e5ae4c-c385-47b8-bab4-64dc12a3def7_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_5089ce0c-a322-48f6-ae4c-89a2231e0717_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_320ca824-8f01-4959-9fd6-1ab1b9c2c729_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c00fc468-f960-4b53-8135-076475843f4a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_543e0cba-7e3e-442d-b525-61576c7624b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_27b220d4-020b-4c3d-b2b1-72efc4b8b109_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cd0d95d6-7ec3-4b81-a490-0127299f6617_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4b429ab3-b6b2-4f8e-8106-46efb281ae66_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8cf773cd-78fe-4f48-8ea0-377584a56564_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_b1e99751-b9cc-4b22-9916-dcc39664eef6_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_c5e0fa19-56d8-42e1-b84b-64c40cb86d8a_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f7e310f6-8dc4-4f83-9c35-15921acc5a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_482ff654-ec2f-405e-8aa0-06534588a5d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_36f9f600-ce72-4f81-8656-83553d7caf97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2ccc8201-0fa9-4057-b27c-c7fe8d7cd0ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0da4d64d-f9bb-4070-a59e-9310f16d82a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8000f6fb-5592-40e7-8d47-6db516cf1240_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60894a1d-7c89-41cf-8a75-ba88107a430a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_fc887084-2b3d-4b7e-9bf0-8b62fa0a41c9_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_375c4e9b-2bf8-4a4a-baf2-a20d0045cf35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_214406cb-0fd0-46bc-8b46-1446f60eb607_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_422d1560-278f-4ac3-9d67-d77eab4e5204_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_564ba20d-0cd0-4612-8029-e1fbaeedea3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_adda8a72-0835-4cba-a2b7-3602284aee00_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_documentation_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:href="mgnx-20211231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:to="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7832e546-285d-4eb9-a2f8-b1d34161006d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_de8a3ea4-22b3-498c-a344-026c11bccae7_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_3fd74b5a-0599-40b6-9d2f-ce9d3ac7a8a1_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20211231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_f53c4fc9-5095-45f2-bff0-a97743a364dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_87db7c25-8f7f-4069-90c8-84d1153e51bd_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_e15323b0-1ed6-4d4c-bce1-14d25b46b52b_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_090b473a-c207-484e-b9f9-dffa79159c83_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_519b584c-819e-4baa-a377-7d69359e3537_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_02e1aea2-6ebf-4066-a350-ec67e134934c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_42bf2924-bc10-47c5-95f5-2d6fdd7e506a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bef1931-d54d-454d-a648-1402be9eba41_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93853acc-0171-491e-a212-0a06dd00837c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92ea60ef-e4b4-4a91-95d0-412aa6d69ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_046c8af0-16fe-4af8-9942-38d2bdc2df21_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42e3ae1d-438b-41d9-8276-cd2d58d03d15_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c158c4a9-6985-4f99-87d4-755759076d79_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9745d558-3ac1-4cf3-af23-a44597572fc5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_5b26dd33-ac10-4b38-9ad1-33160f774f13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3acb0b76-d933-488a-876a-ddb24df86dec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_94de439e-6a61-4493-9e9d-c07b1678f2b4_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_674b3ab7-0f9c-4144-81b1-5527d0552628_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d06b448b-78c3-4b32-876b-6b4011845146_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_4f07de15-7bdd-4b7d-91d3-57a256cf4ee5_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1b3bba8c-040f-4429-8e3b-107ac0c6a5d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_05e969c0-8f60-43bc-865c-985e59558afd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_67320a68-4e0b-4a0d-98d1-4a672a38037e_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_0bfa4aae-b5b5-48f9-b91b-5963a0b777de_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20211231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_c049493a-c034-40a7-9312-962cb40bd4e3_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20211231.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4d3a46e1-335b-4afa-b6ff-7c64ed7be5a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_179c0c35-ba3b-43f6-86c2-0fda13b824d4_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20211231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_331445e3-f37d-4d40-8882-d9fc3c5b798c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80452b1e-9da5-448c-bff9-2df17fb1401c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e1618a73-c6b7-4065-81fa-c0b541ae5d33_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5b67cdbc-6eeb-4dbd-9ca5-657be173a328_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cfe3c32-9bbc-42f8-bf9f-b8633291ace1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9fb1c98c-ae59-4337-8d67-224d5bc7c1f5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_010ac7a7-8073-4ae9-94b3-354dff89ac44_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:href="mgnx-20211231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_c2591375-2477-4573-ad5e-754c101055ae_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a9894e6c-487c-48f6-97ad-914dda679a27_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0503d387-f611-476a-97f7-bae87abba2bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4827d276-a8a8-4415-91db-f325ff4c0935_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_83d517d1-a9ed-4b34-86eb-d30849cb9819_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_096a438b-a3da-407f-9b03-508db6e39f12_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_957129d0-b7d2-493a-84b6-7b21b31d5c7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_499999e3-5d99-4151-bdc8-1f69c2705c8a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_4fe4f6ac-c826-43f7-9902-05521285fd54_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20211231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a85ec48e-f993-4bc1-b6cd-30892011b476_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_9a8829a9-e016-42a1-bfd3-693c834b9a6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ddd4148b-194e-4fe0-be5f-5a557b0c4508_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cc6b9797-b4af-4cda-9bbb-dad2de398c21_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_d5b0032f-1b4e-4755-9e88-79092ba2dc32_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_d1396f64-9c46-4ecc-a5e0-b02c76be6ed2_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20211231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4431074d-26f1-4186-8b2f-fa0b86b534df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f1fb3035-aec9-446a-9535-14fcc153ad42_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9aa4b78d-5192-4f33-ab81-e419ece2a3d1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_eba4ee12-ae7c-449b-8a81-f9bf0de80109_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_644d81dd-320c-4038-921a-f7adb1a9678b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d4bbdacd-4701-478b-8d53-c41f896767a7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgnx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:09172e5e-8198-46c4-9363-bae551b683dc,g:ffdc8ac5-1c37-4010-88ac-e0714458a336-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1a3dc84c-8044-479a-a091-28137a406323" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentType_1a3dc84c-8044-479a-a091-28137a406323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c57e1d4f-d690-41f5-a8a9-124278592e8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentAnnualReport_c57e1d4f-d690-41f5-a8a9-124278592e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_54623b2b-b33e-4a25-8aef-ce1953105443" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentPeriodEndDate_54623b2b-b33e-4a25-8aef-ce1953105443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_61747476-a8b9-4259-ba77-20a738a33fd6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_CurrentFiscalYearEndDate_61747476-a8b9-4259-ba77-20a738a33fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_dbe3e0d2-9509-4da7-940f-845b2d036670" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentTransitionReport_dbe3e0d2-9509-4da7-940f-845b2d036670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eb5071f9-c744-44ec-93fa-33d29dd8891b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityFileNumber_eb5071f9-c744-44ec-93fa-33d29dd8891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7bf15c6e-ddcc-4bd0-b86a-8152db21e6fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityRegistrantName_7bf15c6e-ddcc-4bd0-b86a-8152db21e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_78eb8cad-47f7-4054-9c20-dc17081e1282" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityIncorporationStateCountryCode_78eb8cad-47f7-4054-9c20-dc17081e1282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_89b9fadf-7b9f-4478-ad29-f9e2db6987bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityTaxIdentificationNumber_89b9fadf-7b9f-4478-ad29-f9e2db6987bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46e4078d-60bc-44fc-b3be-c186cb4c044b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityAddressAddressLine1_46e4078d-60bc-44fc-b3be-c186cb4c044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f73ce3c-35ad-43c4-8868-3c5df674b7f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityAddressCityOrTown_8f73ce3c-35ad-43c4-8868-3c5df674b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_632c40d0-f6f5-438f-84a7-ca2ce7b4d801" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityAddressStateOrProvince_632c40d0-f6f5-438f-84a7-ca2ce7b4d801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a6bb7b12-2a09-4a6e-afd2-ece4c45a164f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityAddressPostalZipCode_a6bb7b12-2a09-4a6e-afd2-ece4c45a164f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b80a09d1-3b75-412a-8f84-fda7bfc425c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_CityAreaCode_b80a09d1-3b75-412a-8f84-fda7bfc425c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2e23159f-ddf2-484b-8eef-51897eeb01e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_LocalPhoneNumber_2e23159f-ddf2-484b-8eef-51897eeb01e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8ca6a42d-cd99-486b-92a2-28c2c1557f6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_Security12bTitle_8ca6a42d-cd99-486b-92a2-28c2c1557f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b105f5e2-17f8-4d47-96a0-c02ec3d89d82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_TradingSymbol_b105f5e2-17f8-4d47-96a0-c02ec3d89d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cf1ac12c-8cd7-442b-98d8-e2c86a52e09d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_SecurityExchangeName_cf1ac12c-8cd7-442b-98d8-e2c86a52e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6a8dec1f-9f7d-45eb-99ff-52bc323e5c25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6a8dec1f-9f7d-45eb-99ff-52bc323e5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_daac98d1-70a7-4b62-80d8-c355a0f8b68f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityVoluntaryFilers_daac98d1-70a7-4b62-80d8-c355a0f8b68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2a91e319-1997-4310-be63-11ca5a649208" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityCurrentReportingStatus_2a91e319-1997-4310-be63-11ca5a649208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_37f2345d-d9b7-45c2-b701-6724b06de7b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityInteractiveDataCurrent_37f2345d-d9b7-45c2-b701-6724b06de7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f218768d-0b50-42a6-95eb-244989d9048c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityFilerCategory_f218768d-0b50-42a6-95eb-244989d9048c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d2f4eca8-b581-456b-bbbb-fcd4ffca9c9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntitySmallBusiness_d2f4eca8-b581-456b-bbbb-fcd4ffca9c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_61703294-92b6-45bd-84d4-e218df93f551" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityEmergingGrowthCompany_61703294-92b6-45bd-84d4-e218df93f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1dda4001-0c42-4a03-ac99-8a844e5e3911" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1dda4001-0c42-4a03-ac99-8a844e5e3911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_de2b3d6f-6294-4ca5-9774-a871966a2ed3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityShellCompany_de2b3d6f-6294-4ca5-9774-a871966a2ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_fb654b36-5e98-491b-a602-9502d1d8299a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityPublicFloat_fb654b36-5e98-491b-a602-9502d1d8299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_66264576-f5a9-468e-89af-2d16c179790d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_66264576-f5a9-468e-89af-2d16c179790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_54e14a66-3d69-4eeb-b2ab-be54157ecad2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_54e14a66-3d69-4eeb-b2ab-be54157ecad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ca2fdad7-43a2-47c2-94b5-f2db1846a0ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_AmendmentFlag_ca2fdad7-43a2-47c2-94b5-f2db1846a0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1c53d143-2078-4940-ad7e-b6e05c437afe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentFiscalYearFocus_1c53d143-2078-4940-ad7e-b6e05c437afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_921cae37-3115-410e-8345-9fd508407761" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_DocumentFiscalPeriodFocus_921cae37-3115-410e-8345-9fd508407761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1aba675e-d1bf-4163-b48e-a758e56beddf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb8833d8-69c6-43b0-89a7-67341273aa41" xlink:to="loc_dei_EntityCentralIndexKey_1aba675e-d1bf-4163-b48e-a758e56beddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/AuditInformation" xlink:type="simple" xlink:href="mgnx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract_390740c8-5415-4af8-bcac-862ae02dd3a6" xlink:href="mgnx-20211231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_446a480a-cebb-4a59-bfdf-16b5fc43b5a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_390740c8-5415-4af8-bcac-862ae02dd3a6" xlink:to="loc_dei_AuditorFirmId_446a480a-cebb-4a59-bfdf-16b5fc43b5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_54a3f4dd-e0c4-4264-9612-cfb15eba41b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_390740c8-5415-4af8-bcac-862ae02dd3a6" xlink:to="loc_dei_AuditorName_54a3f4dd-e0c4-4264-9612-cfb15eba41b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_10879a0d-b0b7-4fed-b478-ec4fe609790d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_390740c8-5415-4af8-bcac-862ae02dd3a6" xlink:to="loc_dei_AuditorLocation_10879a0d-b0b7-4fed-b478-ec4fe609790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_37240098-52ed-4c38-813b-0b25dcfdacf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_37240098-52ed-4c38-813b-0b25dcfdacf2" xlink:to="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_45a73977-ed34-4311-a4b9-47cf10a7c09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_45a73977-ed34-4311-a4b9-47cf10a7c09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_2c6707fd-2a40-4053-af08-fc1a87905f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_Investments_2c6707fd-2a40-4053-af08-fc1a87905f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c86e92a7-40b1-4c55-a222-aa230b92563f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c86e92a7-40b1-4c55-a222-aa230b92563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_94eb447f-35f1-4bd4-9e2d-42f2810443e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_InventoryNet_94eb447f-35f1-4bd4-9e2d-42f2810443e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b8d1555b-8937-4d1c-a718-443c0277010c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b8d1555b-8937-4d1c-a718-443c0277010c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b1f448ee-0ce0-460b-ad2d-500f3754b475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4e354869-cb21-41fa-bdc7-c58a3372bb45" xlink:to="loc_us-gaap_AssetsCurrent_b1f448ee-0ce0-460b-ad2d-500f3754b475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3ebac033-c61a-47d1-a90c-d2eb538795aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3ebac033-c61a-47d1-a90c-d2eb538795aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6a9ca623-5753-4a61-a972-8cca284637cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6a9ca623-5753-4a61-a972-8cca284637cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05910e06-1e4f-4e4c-947d-61c313ffd465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869f08d3-a751-4c0a-bf5d-b2f9488a1c29" xlink:to="loc_us-gaap_Assets_05910e06-1e4f-4e4c-947d-61c313ffd465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_37240098-52ed-4c38-813b-0b25dcfdacf2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2e5cdd16-4294-48f0-ade7-b3f87c438489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:to="loc_us-gaap_AccountsPayableCurrent_2e5cdd16-4294-48f0-ade7-b3f87c438489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1317d1f0-cf16-47fe-864e-6979c3f197f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1317d1f0-cf16-47fe-864e-6979c3f197f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_22a0026b-1f24-4dca-b8a1-3ccec125d85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:to="loc_us-gaap_DeferredRevenueCurrent_22a0026b-1f24-4dca-b8a1-3ccec125d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2f460e4-5822-4679-a1f9-16a53fbf7388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2f460e4-5822-4679-a1f9-16a53fbf7388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b2ac278-03ee-4676-8d79-a13ee2bce890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e88e9e26-ee48-4aa0-b598-84becf01e34a" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b2ac278-03ee-4676-8d79-a13ee2bce890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_5e30e1f0-0423-451c-ad86-d999384cbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_5e30e1f0-0423-451c-ad86-d999384cbd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1fa91e39-239a-4d6e-82b2-201aeb304a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1fa91e39-239a-4d6e-82b2-201aeb304a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bbc7b0a3-9a77-4f09-90a7-85a774d20dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bbc7b0a3-9a77-4f09-90a7-85a774d20dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d39553e9-4907-4ad6-9291-649ad2281635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_Liabilities_d39553e9-4907-4ad6-9291-649ad2281635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9be1b102-cded-4358-b5f3-0d23499cd036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:to="loc_us-gaap_CommonStockValue_9be1b102-cded-4358-b5f3-0d23499cd036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7d0590de-73e2-48e4-97d1-f04fd76e4db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7d0590de-73e2-48e4-97d1-f04fd76e4db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c0412547-4b9a-4c55-9963-3e4c958f881b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c0412547-4b9a-4c55-9963-3e4c958f881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad9a8cfc-f27f-406d-a88f-c0fdb42ae513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad9a8cfc-f27f-406d-a88f-c0fdb42ae513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb58fa38-79c1-4bdf-82f3-05cbdc977bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9564d196-2c03-403e-bd07-4a2e70c1dc93" xlink:to="loc_us-gaap_StockholdersEquity_eb58fa38-79c1-4bdf-82f3-05cbdc977bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a91bb00-934d-4f52-a154-77e90ef9f074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0beb88a-3f22-40d2-bca2-f1519bf4a916" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a91bb00-934d-4f52-a154-77e90ef9f074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_834f738d-f202-431b-ac6a-1fc41ae4bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dda884a0-fe33-4f0c-bd82-d1fe6b14d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_834f738d-f202-431b-ac6a-1fc41ae4bf7e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dda884a0-fe33-4f0c-bd82-d1fe6b14d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2b0a66d4-7329-4563-8d8c-c41bc7299e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_834f738d-f202-431b-ac6a-1fc41ae4bf7e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2b0a66d4-7329-4563-8d8c-c41bc7299e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a90db04d-7fbf-4ff1-8e76-5c925cf9ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_834f738d-f202-431b-ac6a-1fc41ae4bf7e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a90db04d-7fbf-4ff1-8e76-5c925cf9ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f3b2d20c-5f25-41de-b1df-fe8c6ec469e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3b2d20c-5f25-41de-b1df-fe8c6ec469e2" xlink:to="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:to="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aa220027-b554-4556-a25a-e2dd2f0823db" xlink:to="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_96271585-8ba2-49c8-aaae-df2d7ec9ba90" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_96271585-8ba2-49c8-aaae-df2d7ec9ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_e6730bef-27c7-4f67-8401-214b4050dbf2" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_e6730bef-27c7-4f67-8401-214b4050dbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f9193848-d2b4-481e-b6bb-cd5f314ed6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc80c6b7-c56b-48fe-ae15-909b822a531f" xlink:to="loc_us-gaap_ProductMember_f9193848-d2b4-481e-b6bb-cd5f314ed6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8abad42-586b-4d24-9257-4774cd35a277" xlink:to="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e730fca5-5c75-47d1-b96e-286233a3f267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c95fc056-8824-443b-9148-74ce65f2f2fe" xlink:to="loc_us-gaap_Revenues_e730fca5-5c75-47d1-b96e-286233a3f267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_02e43b2a-354c-490e-a053-f776894e4382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_02e43b2a-354c-490e-a053-f776894e4382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f825d6e9-044c-46d7-b56a-ab461856ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f825d6e9-044c-46d7-b56a-ab461856ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_98a1c8a9-0548-411e-a3a4-0daa885e53eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_98a1c8a9-0548-411e-a3a4-0daa885e53eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_76c23776-7bf4-4f7f-b8f1-98a00b072036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e6ef4e24-288b-47cf-b773-ac65a87cda1b" xlink:to="loc_us-gaap_CostsAndExpenses_76c23776-7bf4-4f7f-b8f1-98a00b072036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_847cad5d-ff90-42a3-85f3-7c9a22e096c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OperatingIncomeLoss_847cad5d-ff90-42a3-85f3-7c9a22e096c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7673b261-70c9-444d-bca2-6f72fe869716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7673b261-70c9-444d-bca2-6f72fe869716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe2e7d34-576d-4fac-899d-31e132eea8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_NetIncomeLoss_fe2e7d34-576d-4fac-899d-31e132eea8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d82a35-0b5e-4e6d-80c6-2bd8890172ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cc531fb-95d1-4b7e-9090-9332ba83d94d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d82a35-0b5e-4e6d-80c6-2bd8890172ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f18a503-df89-4b8a-a850-2455a1d08960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f18a503-df89-4b8a-a850-2455a1d08960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bfaff9f4-2aa8-41c1-99bd-c0018b4a2be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bfaff9f4-2aa8-41c1-99bd-c0018b4a2be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aa974cf8-4a96-4fc3-aae6-148a681895c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aa974cf8-4a96-4fc3-aae6-148a681895c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ead730aa-f8f6-4bc9-a2e0-e3b3e3aee33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ead730aa-f8f6-4bc9-a2e0-e3b3e3aee33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b2826c1-92bb-4fa4-8405-1235b06ed86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ac8fd93-721e-4f47-aece-a5616f2de549" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b2826c1-92bb-4fa4-8405-1235b06ed86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3c9b8d20-48a1-410e-a09e-90a8863ce39a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3c9b8d20-48a1-410e-a09e-90a8863ce39a" xlink:to="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66eab89c-b28e-4e57-bcc9-9b4a53e86f86" xlink:to="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d18cb68f-2cc6-48e2-a3ab-3e5f0eb51b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_CommonStockMember_d18cb68f-2cc6-48e2-a3ab-3e5f0eb51b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_406a0d39-40a9-493f-97e9-a5d2dac319d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_406a0d39-40a9-493f-97e9-a5d2dac319d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b6abee75-aaa3-46c5-a0de-bf60cbda88ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_RetainedEarningsMember_b6abee75-aaa3-46c5-a0de-bf60cbda88ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc33e89a-ec4c-418d-a406-fe69316b87ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f96e354e-3dd0-4acb-9d39-30e78361457f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc33e89a-ec4c-418d-a406-fe69316b87ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_817ed441-e8ed-43ae-afde-9d9b7cf22fa3" xlink:to="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_29c0f8db-268f-4ab3-8390-e523bf24489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_SharesIssued_29c0f8db-268f-4ab3-8390-e523bf24489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efd01f7f-6467-45ec-8120-00d52c97e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockholdersEquity_efd01f7f-6467-45ec-8120-00d52c97e7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0d57478-6498-4c5d-b133-e660977c655d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0d57478-6498-4c5d-b133-e660977c655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee78158-c0e6-47f9-bb7c-83c4d6bfe6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee78158-c0e6-47f9-bb7c-83c4d6bfe6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52ecee40-768b-4216-83c7-a5796c57d029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52ecee40-768b-4216-83c7-a5796c57d029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_f3cd7959-1eaa-462c-a769-923a57c5c691" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_f3cd7959-1eaa-462c-a769-923a57c5c691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e4d040ab-a2a9-455d-8444-001776d6cbc4" xlink:href="mgnx-20211231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e4d040ab-a2a9-455d-8444-001776d6cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_843aec3a-e72f-475c-ae8b-c76f6cfd2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_843aec3a-e72f-475c-ae8b-c76f6cfd2c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1da39d3-bc46-406b-9111-22e085145b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_NetIncomeLoss_a1da39d3-bc46-406b-9111-22e085145b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ecdf04fb-9c9d-4184-bf93-975dc539eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_SharesIssued_ecdf04fb-9c9d-4184-bf93-975dc539eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3276460-e156-4061-a98f-88d12a368de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e06c74-44e5-46ea-a6f5-1067371076ae" xlink:to="loc_us-gaap_StockholdersEquity_a3276460-e156-4061-a98f-88d12a368de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_81f724ac-bcde-4f12-a172-f38c13667368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_81f724ac-bcde-4f12-a172-f38c13667368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aaf07474-e6b8-4d86-af62-abef8689f2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_81f724ac-bcde-4f12-a172-f38c13667368" xlink:to="loc_us-gaap_NetIncomeLoss_aaf07474-e6b8-4d86-af62-abef8689f2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_81f724ac-bcde-4f12-a172-f38c13667368" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a2ef0830-700f-4fc4-9508-649b53f592be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a2ef0830-700f-4fc4-9508-649b53f592be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_43e21cf7-21d1-41f5-a161-5f821fd86bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_43e21cf7-21d1-41f5-a161-5f821fd86bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6e5095c8-9cf7-428d-9877-2119fdb58847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:to="loc_us-gaap_ShareBasedCompensation_6e5095c8-9cf7-428d-9877-2119fdb58847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c4e339eb-ea46-497f-8fbf-3be86af04ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c4e339eb-ea46-497f-8fbf-3be86af04ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff3ace17-77e2-44e9-a587-8fcd8bfa2afd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccf7961a-d2ba-4028-a557-8f30678cf28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccf7961a-d2ba-4028-a557-8f30678cf28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_438c897f-6626-4122-835e-89a964022c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_438c897f-6626-4122-835e-89a964022c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_b30e8080-e266-40f0-b42b-b4de10dba089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_b30e8080-e266-40f0-b42b-b4de10dba089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32cd9c97-f841-4448-bbe7-a08f5d150aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32cd9c97-f841-4448-bbe7-a08f5d150aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2933e45f-9d93-4736-9974-c602f6a1776a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2933e45f-9d93-4736-9974-c602f6a1776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_744b5b2d-1b7f-48e1-bf63-1493519281f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_744b5b2d-1b7f-48e1-bf63-1493519281f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_1934907b-f9bf-4b64-bb25-2de4cc6a21ee" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_1934907b-f9bf-4b64-bb25-2de4cc6a21ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d1a6e19b-0053-4148-af27-dc81efdb106e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d1a6e19b-0053-4148-af27-dc81efdb106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_44f8989e-eb64-4f26-9bf4-b308129d7830" xlink:href="mgnx-20211231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0aaf1d33-a670-48bb-ac13-33c971794de1" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_44f8989e-eb64-4f26-9bf4-b308129d7830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fe03969-7b08-4a42-9a74-cccac1f3065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_81f724ac-bcde-4f12-a172-f38c13667368" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fe03969-7b08-4a42-9a74-cccac1f3065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0d415e78-e1d8-4250-a170-d8072da218d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0d415e78-e1d8-4250-a170-d8072da218d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3ae0bcf9-4431-4922-a943-f4320c316ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3ae0bcf9-4431-4922-a943-f4320c316ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_706a0549-8248-41bf-b5ae-0ae9dab95fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_706a0549-8248-41bf-b5ae-0ae9dab95fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d76ace11-27cc-4211-b5a3-2a2870e4d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7329c08b-07bf-4dca-a2b0-2677eed62f86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d76ace11-27cc-4211-b5a3-2a2870e4d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_be654539-93ec-4100-80e3-ee5df978fef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_be654539-93ec-4100-80e3-ee5df978fef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f7a4ccb4-da1a-430e-a297-0bfbc6ce1326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_be654539-93ec-4100-80e3-ee5df978fef9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f7a4ccb4-da1a-430e-a297-0bfbc6ce1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_b9aca04b-d551-40b6-bd79-39d236f10b80" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_be654539-93ec-4100-80e3-ee5df978fef9" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_b9aca04b-d551-40b6-bd79-39d236f10b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_efe3d20a-5e20-4b99-874b-4914ebe646b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_be654539-93ec-4100-80e3-ee5df978fef9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_efe3d20a-5e20-4b99-874b-4914ebe646b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50460150-182a-4e44-87c4-75fdfa93fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50460150-182a-4e44-87c4-75fdfa93fe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_557c9d31-8411-46a2-a381-71c9b8ef38d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_557c9d31-8411-46a2-a381-71c9b8ef38d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3183cdba-4a5e-4211-ae21-4745890ad03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3183cdba-4a5e-4211-ae21-4745890ad03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2136c776-0130-4d49-96c3-12c3deb20d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_56030bd3-7986-4ecc-a7e6-d66fe97f639c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2136c776-0130-4d49-96c3-12c3deb20d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_854724f3-3bf7-4e61-8bce-8fc1d66a548a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2136c776-0130-4d49-96c3-12c3deb20d23" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_854724f3-3bf7-4e61-8bce-8fc1d66a548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c9fdf8c6-15f6-4e0c-a16f-ef79001c57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2136c776-0130-4d49-96c3-12c3deb20d23" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c9fdf8c6-15f6-4e0c-a16f-ef79001c57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20211231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82fc1d7d-c462-4a94-bd90-f719d1643320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8c309ebd-cf9a-4a26-973d-6b34538dd0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82fc1d7d-c462-4a94-bd90-f719d1643320" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8c309ebd-cf9a-4a26-973d-6b34538dd0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f2a602a-ab44-4f8a-b156-7693cdf5f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_80bee94e-8dec-4b43-9392-97d5203466e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f2a602a-ab44-4f8a-b156-7693cdf5f6ff" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_80bee94e-8dec-4b43-9392-97d5203466e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4fdb47a2-3e1d-4eec-9c09-fbd3d227bc59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4fdb47a2-3e1d-4eec-9c09-fbd3d227bc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e745832f-bdd8-40f4-a006-7d224d195742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_UseOfEstimates_e745832f-bdd8-40f4-a006-7d224d195742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4cdd9e6e-b21f-4d4f-9938-fa789a0541bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4cdd9e6e-b21f-4d4f-9938-fa789a0541bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6b08b65b-b05d-41ab-897a-8e5469398806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6b08b65b-b05d-41ab-897a-8e5469398806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_422b6fee-a8b8-42dd-8be8-2f89ee9baeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_422b6fee-a8b8-42dd-8be8-2f89ee9baeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_8083c569-dc19-4895-ac19-b8a875a9c389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_8083c569-dc19-4895-ac19-b8a875a9c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2b84239c-eca2-4c9e-9c38-de076432d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2b84239c-eca2-4c9e-9c38-de076432d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_09d69225-5801-44f3-8794-c3642088d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_09d69225-5801-44f3-8794-c3642088d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_92c46ea0-1f56-47a7-8468-9a62014bc420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_92c46ea0-1f56-47a7-8468-9a62014bc420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_43d55e76-5fc5-4be1-b8ad-ac511d3781d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_43d55e76-5fc5-4be1-b8ad-ac511d3781d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_2e8d97e4-1c98-4867-be15-82f77047990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_2e8d97e4-1c98-4867-be15-82f77047990f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_59bf7245-0788-46d7-b053-f5bc26bc9ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_59bf7245-0788-46d7-b053-f5bc26bc9ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8168a14a-3e68-4dc3-aadc-77739682a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8168a14a-3e68-4dc3-aadc-77739682a3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a07f7ae7-04d9-4b3f-982f-7291b3f88476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a07f7ae7-04d9-4b3f-982f-7291b3f88476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8258997f-4489-45cf-a11b-adb6612caabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8258997f-4489-45cf-a11b-adb6612caabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0357b0a-2664-49d9-97b6-05428a6aa1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df8713d0-add9-4a88-a02a-ecb8b53183b3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0357b0a-2664-49d9-97b6-05428a6aa1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9dca10ca-f285-4bfc-9dbe-dcd42c1ddea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c0010fe6-bced-4745-afa5-19220d4230eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dca10ca-f285-4bfc-9dbe-dcd42c1ddea8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c0010fe6-bced-4745-afa5-19220d4230eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6fa34b35-cb0a-45ac-95c3-1306c610ed88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dca10ca-f285-4bfc-9dbe-dcd42c1ddea8" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6fa34b35-cb0a-45ac-95c3-1306c610ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_0ec7e7c1-9117-446c-8b1a-1c63daaf2016" xlink:href="mgnx-20211231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dca10ca-f285-4bfc-9dbe-dcd42c1ddea8" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_0ec7e7c1-9117-446c-8b1a-1c63daaf2016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c9a6e907-923e-442a-8ecf-0ca9e207dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dca10ca-f285-4bfc-9dbe-dcd42c1ddea8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c9a6e907-923e-442a-8ecf-0ca9e207dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a21005d-545a-415e-84ef-dbc8425a8d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24257070-9217-4412-9dc9-5be2105cf623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a21005d-545a-415e-84ef-dbc8425a8d67" xlink:to="loc_us-gaap_NumberOfOperatingSegments_24257070-9217-4412-9dc9-5be2105cf623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0a29f63f-0161-4c26-b6b3-c2405e30be8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a21005d-545a-415e-84ef-dbc8425a8d67" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0a29f63f-0161-4c26-b6b3-c2405e30be8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_2d66cb8d-0ab8-43c0-8385-c3e2a3868e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a21005d-545a-415e-84ef-dbc8425a8d67" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_2d66cb8d-0ab8-43c0-8385-c3e2a3868e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_418b8ad0-4215-45e2-9d58-9d8cc10f895c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_418b8ad0-4215-45e2-9d58-9d8cc10f895c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af203137-4301-4731-b8d3-012ce8bfbe88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_79ee7eb1-7627-4957-8d40-e0187d60736d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_79ee7eb1-7627-4957-8d40-e0187d60736d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2b38b835-630f-49e3-8579-f3e83cabbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5981350b-f1cc-4e6e-983d-556d868a8b39" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2b38b835-630f-49e3-8579-f3e83cabbf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c0a267a-e66c-4c7d-baf2-d5a2fc8a245d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8a1b06e8-a408-4797-8cc2-dcc736d5ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8a1b06e8-a408-4797-8cc2-dcc736d5ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c8a35d97-85e2-4cce-960d-02e76c8f3c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c8a35d97-85e2-4cce-960d-02e76c8f3c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_4dba85d5-1b0a-4c66-b348-5511410d07c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_4dba85d5-1b0a-4c66-b348-5511410d07c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_933af1c4-d502-4607-a091-f18ac34e3dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c49c882-a71f-48a9-a4dc-ac4d5cf38dce" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_933af1c4-d502-4607-a091-f18ac34e3dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6d683d6-87d7-4900-a8a1-072d3b626e9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_69bd36d8-ca17-4d36-a6e5-e66b595a90bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af03d54b-6b8e-46c4-a0d1-d2fd4a4fa565" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_69bd36d8-ca17-4d36-a6e5-e66b595a90bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f4689bf-cfd4-4c5e-91fa-05b8e537aacc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aab34db-a936-426e-8bbd-e111c57c54ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aab34db-a936-426e-8bbd-e111c57c54ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a8b0238-07f4-490c-b7eb-add6ab6090e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a8b0238-07f4-490c-b7eb-add6ab6090e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c89df882-89c8-4046-92b5-da8c2a695d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10021050-bf3e-4f27-a94d-0f18b82e10aa" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c89df882-89c8-4046-92b5-da8c2a695d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1fbade3e-1ad5-43d6-afdb-d9443620d3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e99a756-fa3c-41a0-9198-df9d847c770c" xlink:to="loc_us-gaap_Investments_1fbade3e-1ad5-43d6-afdb-d9443620d3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_202c3ed5-1059-40d1-ae57-58cd43f30a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_202c3ed5-1059-40d1-ae57-58cd43f30a17" xlink:to="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57861b74-59ec-45be-a16d-3736cfeecf10" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_66f5bf41-a4c9-4460-94f6-c94c95b0921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1a372500-8c01-43a6-85e8-3e331c67846c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_66f5bf41-a4c9-4460-94f6-c94c95b0921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3cb25d1f-ebae-486e-a4b7-60cb502d5435" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_53e07db0-5b18-4fc1-acdd-763a8d26c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:to="loc_us-gaap_SalesRevenueNetMember_53e07db0-5b18-4fc1-acdd-763a8d26c2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1a843b79-edc0-4a3f-9e04-f537eebb9ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47719335-7ebc-4367-b092-6df11d55484f" xlink:to="loc_us-gaap_AccountsReceivableMember_1a843b79-edc0-4a3f-9e04-f537eebb9ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e0edeefc-a573-4a8d-8687-6f2a25d8880f" xlink:to="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_7f53eab7-3f60-4b7d-8fbd-61fdcc08b4d9" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_IncyteCorporationMember_7f53eab7-3f60-4b7d-8fbd-61fdcc08b4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_c7775a1f-8d89-4780-9c3a-3f80403700fb" xlink:href="mgnx-20211231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_JanssenBiotechIncMember_c7775a1f-8d89-4780-9c3a-3f80403700fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_468e44a4-27ea-41af-aaf1-51c85eb5359b" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ZaiLabLimitedMember_468e44a4-27ea-41af-aaf1-51c85eb5359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_83db62e7-4832-4d72-a690-0e30403b0c4d" xlink:href="mgnx-20211231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_83db62e7-4832-4d72-a690-0e30403b0c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_37d1655c-4d54-4211-b5c1-8ec13f72d131" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ZaiLabMember_37d1655c-4d54-4211-b5c1-8ec13f72d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember_6de67e3c-1e2c-475e-b856-b1f4f8c98c44" xlink:href="mgnx-20211231.xsd#mgnx_ImabMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ImabMember_6de67e3c-1e2c-475e-b856-b1f4f8c98c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_d2f480f9-3bd6-45af-87d9-552a3a49db94" xlink:href="mgnx-20211231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_d2f480f9-3bd6-45af-87d9-552a3a49db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_91bc0ae7-9d95-4598-9616-63ba957d5721" xlink:href="mgnx-20211231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8d055fec-40a4-49eb-9ab2-ef10fdd5e19d" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_91bc0ae7-9d95-4598-9616-63ba957d5721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2e91874c-330b-4c81-826d-ee8684c53e38" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f446ca04-a223-466b-86e1-7b9ab10fcae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e02c77d6-5e8d-45e7-bd36-21ec16c61214" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f446ca04-a223-466b-86e1-7b9ab10fcae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d50b4aa2-d903-4ea3-a598-dc7dbf22b446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d50b4aa2-d903-4ea3-a598-dc7dbf22b446" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_390fde69-7913-45b7-9e72-2af1ba1fff76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ebb382af-2184-4c80-918e-d1c2ef85d85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_ComputerEquipmentMember_ebb382af-2184-4c80-918e-d1c2ef85d85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6ac9e710-887b-474b-9a4f-f47303331698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6ac9e710-887b-474b-9a4f-f47303331698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3bc0ae2f-cd22-49f7-970c-d4910c2957f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3bc0ae2f-cd22-49f7-970c-d4910c2957f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_73541272-95a6-4332-a59a-51c67963020f" xlink:href="mgnx-20211231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8a7602b6-0ad9-4caa-8f18-3904fb495532" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_73541272-95a6-4332-a59a-51c67963020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_481075c5-65cb-405a-bc9e-2ed06d65651c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5c6c7ec-e653-4e09-9824-174cdd315c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d5d3252c-f378-4c17-a0a7-e6c0bb42e767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5c6c7ec-e653-4e09-9824-174cdd315c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c5ed7ec-41f1-4bd1-9ada-6da6c0ba4478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c5ed7ec-41f1-4bd1-9ada-6da6c0ba4478" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a64b380-793d-470d-bcfa-57c6462b8301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a0ee97b0-a382-4069-9b9a-2e854091d2a4" xlink:href="mgnx-20211231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_014fe774-dd41-4768-8f9c-d54a1f29d4fa" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a0ee97b0-a382-4069-9b9a-2e854091d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98f56df7-cfc5-47b5-8672-7b3764b273df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d94d0ace-3846-4ea7-815c-c832e17e14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa0186d5-a140-4c8a-b341-9328faedb0a2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d94d0ace-3846-4ea7-815c-c832e17e14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_65ceabd8-ad67-4af2-89b7-7f90de6cfc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ba582ad2-9640-45c6-997e-5bfde5f86d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_65ceabd8-ad67-4af2-89b7-7f90de6cfc6d" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ba582ad2-9640-45c6-997e-5bfde5f86d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_045fdd79-c8ce-44a8-8984-9f39281213f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cdec57a0-1a83-4549-b17d-16924d05335e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_045fdd79-c8ce-44a8-8984-9f39281213f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cdec57a0-1a83-4549-b17d-16924d05335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c41fe77c-b1bc-479a-a844-14cd0dff6d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c41fe77c-b1bc-479a-a844-14cd0dff6d59" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e3d7cc1-6ea2-46b6-8c17-f01cd3bd06b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a72ec70b-657f-48f4-a1b9-d799c5347946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a72ec70b-657f-48f4-a1b9-d799c5347946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d7ea805a-c3e1-4f92-b776-a3a7af48fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d7ea805a-c3e1-4f92-b776-a3a7af48fc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3c478b60-4e91-44b5-9c6a-2759b2f514f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2059fd9-aaca-4046-8683-1e9f77021aa5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3c478b60-4e91-44b5-9c6a-2759b2f514f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89a7f356-04ab-4a6c-8810-35d7a957886c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_607c747f-8c2c-45da-8bf9-e87e8048cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_607c747f-8c2c-45da-8bf9-e87e8048cc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5870f1c0-ce12-4f3d-9033-e6dca1d8fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5870f1c0-ce12-4f3d-9033-e6dca1d8fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_54dc9e88-2cd0-4778-80fa-5b355770bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_54dc9e88-2cd0-4778-80fa-5b355770bb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c32593f8-f058-43b2-beb0-12b6a36cc89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94559efe-b6cc-485e-9827-7e1b5c2456f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c32593f8-f058-43b2-beb0-12b6a36cc89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_840d33a0-5e9f-40b1-89d2-7e6cfc0e3bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4585469b-9277-4b0e-b6a6-f4a5b50b7f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_840d33a0-5e9f-40b1-89d2-7e6cfc0e3bbc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4585469b-9277-4b0e-b6a6-f4a5b50b7f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_804eb5ce-6c7b-48e1-b7c6-8168b7370426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_840d33a0-5e9f-40b1-89d2-7e6cfc0e3bbc" xlink:to="loc_us-gaap_InterestIncomeOther_804eb5ce-6c7b-48e1-b7c6-8168b7370426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Inventory" xlink:type="simple" xlink:href="mgnx-20211231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_93063a6c-cac1-45d6-b82e-e6d54d38df94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_632fa6d2-7e60-47f5-8637-a2e5dc979f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_93063a6c-cac1-45d6-b82e-e6d54d38df94" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_632fa6d2-7e60-47f5-8637-a2e5dc979f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_54ae4bbe-cf45-48bd-a8d2-6ec562eedd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_481429dd-d4a7-4306-9ee9-2504270805f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_54ae4bbe-cf45-48bd-a8d2-6ec562eedd52" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_481429dd-d4a7-4306-9ee9-2504270805f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_2d627cc5-ed80-4810-a9fb-93016dfe97ed" xlink:href="mgnx-20211231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_54ae4bbe-cf45-48bd-a8d2-6ec562eedd52" xlink:to="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_2d627cc5-ed80-4810-a9fb-93016dfe97ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#InventoryNetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_37d94923-1f88-450d-aa3f-b7a570e6c131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_db3340da-3ebc-4964-8e04-3914d48ec52a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37d94923-1f88-450d-aa3f-b7a570e6c131" xlink:to="loc_us-gaap_InventoryWorkInProcess_db3340da-3ebc-4964-8e04-3914d48ec52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c3814c6a-d3e9-4abb-99eb-962b23517a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37d94923-1f88-450d-aa3f-b7a570e6c131" xlink:to="loc_us-gaap_InventoryFinishedGoods_c3814c6a-d3e9-4abb-99eb-962b23517a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_18b65229-b34c-4de1-991a-36a1f1485e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37d94923-1f88-450d-aa3f-b7a570e6c131" xlink:to="loc_us-gaap_InventoryNet_18b65229-b34c-4de1-991a-36a1f1485e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_1378ae9f-7f63-4811-a278-6e4d1788e392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37d94923-1f88-450d-aa3f-b7a570e6c131" xlink:to="loc_us-gaap_InventoryValuationReserves_1378ae9f-7f63-4811-a278-6e4d1788e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a90009ca-344b-4db6-93d3-ae0aeb32751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a90009ca-344b-4db6-93d3-ae0aeb32751f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_93baa28b-cb58-4379-82d6-83023eed9674" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_9dc0fdf5-7fb2-446f-9ba9-795bf2eacfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cbc77324-7bc2-453e-99e7-13b3cc6b5a76" xlink:to="loc_us-gaap_InventoryValuationReserveMember_9dc0fdf5-7fb2-446f-9ba9-795bf2eacfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_2577ed12-d88b-439f-bba0-c970585fa2d7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_347de9dd-efd7-48f6-b327-ce49d055c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_347de9dd-efd7-48f6-b327-ce49d055c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d78b0fa0-e4f8-4365-89cc-ce74c436bd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d78b0fa0-e4f8-4365-89cc-ce74c436bd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_f79402fe-3c53-475a-b031-9c58b6f8f280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_f79402fe-3c53-475a-b031-9c58b6f8f280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f45addd4-c6f8-4cd6-a490-2640a7bc4460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4d9539fc-d43e-4556-a29a-7e5d98c085c0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f45addd4-c6f8-4cd6-a490-2640a7bc4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20211231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06d1fd67-5c01-4bc8-8293-23ac601844cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5746b2f3-0aa7-42d7-8b18-22d5da13fa25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06d1fd67-5c01-4bc8-8293-23ac601844cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5746b2f3-0aa7-42d7-8b18-22d5da13fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43b70098-8e19-44e4-acb0-3516291c2722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef2cb9bc-e346-4c04-9323-e0cda3d41c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43b70098-8e19-44e4-acb0-3516291c2722" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef2cb9bc-e346-4c04-9323-e0cda3d41c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e50467b4-3537-45bd-9ced-89ec49e422ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e50467b4-3537-45bd-9ced-89ec49e422ba" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e92acb0c-144a-4f00-b6e2-c04c4a23adda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2f0a0d1c-a857-442d-8e18-b8b893a2ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_ComputerEquipmentMember_2f0a0d1c-a857-442d-8e18-b8b893a2ff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6423f479-7002-4f10-b802-27a1c9a0cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6423f479-7002-4f10-b802-27a1c9a0cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_e090359d-6bbb-423d-be2f-43c2f1e017e5" xlink:href="mgnx-20211231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_e090359d-6bbb-423d-be2f-43c2f1e017e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_6b551272-52d3-4efd-8147-5f3126e008c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_VehiclesMember_6b551272-52d3-4efd-8147-5f3126e008c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_65a230e2-dc99-498f-9b42-fa23f727561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_EquipmentMember_65a230e2-dc99-498f-9b42-fa23f727561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4c8d6e11-ae5c-4087-a91d-d7d018a693c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ecf650b-1f51-4f07-93d4-08a3671308cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4c8d6e11-ae5c-4087-a91d-d7d018a693c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01dab991-70cc-42fe-bc95-b8578da44fe8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b24a56d9-dd61-4017-9508-5266130cf032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b24a56d9-dd61-4017-9508-5266130cf032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7e3371e3-b0d0-49cd-8ca9-9691a26233c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_ConstructionInProgressGross_7e3371e3-b0d0-49cd-8ca9-9691a26233c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ca459659-08ad-43e3-9e74-98ed950756a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ca459659-08ad-43e3-9e74-98ed950756a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d7497b07-e638-44ea-8984-9bed98249cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d7497b07-e638-44ea-8984-9bed98249cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d4304307-ed32-40d7-a4cb-be34de652eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bbaa491c-01e7-437d-942b-318da718dfd6" xlink:to="loc_us-gaap_Depreciation_d4304307-ed32-40d7-a4cb-be34de652eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_37eaab86-c38d-4fea-a963-bbfec2a5a065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0ef6402c-7cfa-4c77-ba65-44b007af5f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37eaab86-c38d-4fea-a963-bbfec2a5a065" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0ef6402c-7cfa-4c77-ba65-44b007af5f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a26d31da-356c-497c-9a7e-6a63a0d4b7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_a15c0248-81fb-406d-9938-e901163537aa" xlink:href="mgnx-20211231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a26d31da-356c-497c-9a7e-6a63a0d4b7db" xlink:to="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_a15c0248-81fb-406d-9938-e901163537aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2a1adb27-ff95-47e2-adde-7b4de4583acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a26d31da-356c-497c-9a7e-6a63a0d4b7db" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2a1adb27-ff95-47e2-adde-7b4de4583acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_495b755e-cc13-4208-9d28-0a1b05bd4ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a26d31da-356c-497c-9a7e-6a63a0d4b7db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_495b755e-cc13-4208-9d28-0a1b05bd4ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0ee7d505-d0fd-44c1-818f-b2c3e569001f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ee7d505-d0fd-44c1-818f-b2c3e569001f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:to="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a57f92cc-f71f-496e-a601-d804809b55b9" xlink:to="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6985a959-9de7-4f36-9c43-ff37ba05f643" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:to="loc_srt_MinimumMember_6985a959-9de7-4f36-9c43-ff37ba05f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd51dc68-5c9a-456e-96bb-d6e58202bfb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eb9251a-1e27-4204-a4aa-79b2765ee4b8" xlink:to="loc_srt_MaximumMember_bd51dc68-5c9a-456e-96bb-d6e58202bfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74408716-dba9-4fc7-800c-0a630523417e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2ecd22ed-2952-4af1-904a-85275740387e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2ecd22ed-2952-4af1-904a-85275740387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8ab3ea65-d52c-46fd-991a-ce9e72067fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeasePayments_8ab3ea65-d52c-46fd-991a-ce9e72067fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52724f43-b7ad-42a1-897d-cf0ffea7a9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52724f43-b7ad-42a1-897d-cf0ffea7a9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68ed9b88-4edb-4ccb-9a11-38937433c979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a7eac5fb-7011-454e-a3a9-a17260bab282" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68ed9b88-4edb-4ccb-9a11-38937433c979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9745310f-6741-4b4c-9159-c6ca07787012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d764bae1-791b-4cd3-87a4-87bd4cb154bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9745310f-6741-4b4c-9159-c6ca07787012" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d764bae1-791b-4cd3-87a4-87bd4cb154bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c183cad6-a2e6-4e32-a817-812f5696d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9745310f-6741-4b4c-9159-c6ca07787012" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c183cad6-a2e6-4e32-a817-812f5696d51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesCostsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesCostsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f0f9c48e-a36f-4c19-b6f4-952b0d42a0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8872de1e-ca91-4e5c-b02d-c99afda5c0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0f9c48e-a36f-4c19-b6f4-952b0d42a0da" xlink:to="loc_us-gaap_OperatingLeaseCost_8872de1e-ca91-4e5c-b02d-c99afda5c0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8d435001-58ac-4772-913f-7ccb48cad323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0f9c48e-a36f-4c19-b6f4-952b0d42a0da" xlink:to="loc_us-gaap_VariableLeaseCost_8d435001-58ac-4772-913f-7ccb48cad323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_4fdc9ea4-630a-4c9b-906a-d8d24621ebe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0f9c48e-a36f-4c19-b6f4-952b0d42a0da" xlink:to="loc_us-gaap_SubleaseIncome_4fdc9ea4-630a-4c9b-906a-d8d24621ebe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c23e14dc-abb8-4902-b33d-2dc4c74fcc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0f9c48e-a36f-4c19-b6f4-952b0d42a0da" xlink:to="loc_us-gaap_LeaseCost_c23e14dc-abb8-4902-b33d-2dc4c74fcc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c086c8ef-679e-499c-9dc9-e70011cf66b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c086c8ef-679e-499c-9dc9-e70011cf66b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_26438311-de0c-448d-9344-6627705097cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_26438311-de0c-448d-9344-6627705097cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6bea8237-0771-42f1-a922-6aaad0eeeedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6bea8237-0771-42f1-a922-6aaad0eeeedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_676820fe-5ee9-45a3-8456-879d7bfc77a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_676820fe-5ee9-45a3-8456-879d7bfc77a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a4fe2436-7a51-4977-99db-5275042fc035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a4fe2436-7a51-4977-99db-5275042fc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_21f32af9-f976-452d-add2-679be5e96307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_21f32af9-f976-452d-add2-679be5e96307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df61a0b5-bacb-482d-b5e5-b120b6d8f7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df61a0b5-bacb-482d-b5e5-b120b6d8f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c09871f3-beb5-4fd2-b387-ac2e2a9fb9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c09871f3-beb5-4fd2-b387-ac2e2a9fb9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b683ac8a-da24-4501-9c1f-11197819d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2e205d3-724e-4963-b4d1-031f0be8f6af" xlink:to="loc_us-gaap_OperatingLeaseLiability_b683ac8a-da24-4501-9c1f-11197819d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mgnx-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d151752a-e838-4c2a-b301-225f85f56fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fdd2bfdb-c164-4292-ab5b-de77e34bed73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d151752a-e838-4c2a-b301-225f85f56fd5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fdd2bfdb-c164-4292-ab5b-de77e34bed73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c5be4a96-5edc-4c1c-ba76-499423f8d208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c5be4a96-5edc-4c1c-ba76-499423f8d208" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bf9031b-ebad-4365-a834-35fbf47ce2b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_b724b065-ad9d-4329-ba4c-629c9332b141" xlink:href="mgnx-20211231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_79ca9f75-3074-4b90-b83a-6e1804fa674c" xlink:to="loc_mgnx_AtTheMarketOfferingMember_b724b065-ad9d-4329-ba4c-629c9332b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_729f1ca4-6bcf-417a-9917-d05e0c26016a" xlink:to="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_6ed446f9-776d-4842-81cc-776cbc123710" xlink:href="mgnx-20211231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e123fca-0ff7-4e67-a25d-7ce01e5d713e" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_6ed446f9-776d-4842-81cc-776cbc123710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0cb9d727-d31c-4488-9e2f-f176e3237217" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_4a3ceed5-a8f8-4e13-9d7c-cf9044ca0c08" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:to="loc_mgnx_IncyteCorporationMember_4a3ceed5-a8f8-4e13-9d7c-cf9044ca0c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_32dca00c-6f19-41c0-9a07-e825334980b6" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722bf802-aad8-4ccf-b477-8a366bcaa292" xlink:to="loc_mgnx_ZaiLabMember_32dca00c-6f19-41c0-9a07-e825334980b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_befa1e97-98d5-4539-9995-82dbe2fe970f" xlink:to="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c60997d2-7e56-4251-b542-4a74db123948" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a1e6b13a-920a-4090-8942-871fc9d9a442" xlink:to="loc_srt_MaximumMember_c60997d2-7e56-4251-b542-4a74db123948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adca45b9-20f7-4afe-91d7-6ddb309d0166" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_97f2c473-e0c3-4728-8503-963b11623c06" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_97f2c473-e0c3-4728-8503-963b11623c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_3c69fc62-956d-4c33-bebe-b9e435f7ff3f" xlink:href="mgnx-20211231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e23fe034-91a3-40d1-83be-913f2faf92be" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_3c69fc62-956d-4c33-bebe-b9e435f7ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66dc9fb6-5191-4672-8c16-fccfe728d35a" xlink:to="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cc09e013-3e1f-433c-ba61-378650e523f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cc09e013-3e1f-433c-ba61-378650e523f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_84019d7e-7b96-4001-83ec-6f417df98bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_84019d7e-7b96-4001-83ec-6f417df98bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f890bed-0b32-4faa-8ada-916f151622a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f890bed-0b32-4faa-8ada-916f151622a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_928c019b-5fd1-439c-8774-fc3a3ab3b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_928c019b-5fd1-439c-8774-fc3a3ab3b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4a215101-d108-47a8-833e-8a6b928daeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4a215101-d108-47a8-833e-8a6b928daeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb25b644-46ae-4cee-b8cc-68c23bf59d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb25b644-46ae-4cee-b8cc-68c23bf59d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf590b8b-fc18-42a4-a035-2d6ef5df3b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf590b8b-fc18-42a4-a035-2d6ef5df3b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f7f16c3c-f925-4192-a3ff-30d815015635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f7f16c3c-f925-4192-a3ff-30d815015635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90fbabf3-ca55-42f5-91b1-4bc4b0563456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90fbabf3-ca55-42f5-91b1-4bc4b0563456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f8bd5713-bd14-41a5-9676-1937ccde8e81" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f8bd5713-bd14-41a5-9676-1937ccde8e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9c9e1b1c-dd31-4e9e-8c08-39a942557cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9c9e1b1c-dd31-4e9e-8c08-39a942557cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_89f8c5c3-bf44-46de-bc4b-5b5535480097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_89f8c5c3-bf44-46de-bc4b-5b5535480097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_49c4fc2d-a5f6-45b0-a373-2022684c858a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_49c4fc2d-a5f6-45b0-a373-2022684c858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c91ba9bc-4701-4a0c-a5f9-53a6f9108a93" xlink:href="mgnx-20211231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01122049-9a14-403a-960e-d642c0f10807" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c91ba9bc-4701-4a0c-a5f9-53a6f9108a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8aaa156-4f35-4229-b611-8f15a450acc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0669e83a-faa5-4ba7-b7d4-7936a5cd0932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8aaa156-4f35-4229-b611-8f15a450acc4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0669e83a-faa5-4ba7-b7d4-7936a5cd0932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e634ecc1-ca1d-4788-84f5-70118b2f79d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c821c128-b0c0-4fae-b0c6-ec24790fcc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e634ecc1-ca1d-4788-84f5-70118b2f79d5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c821c128-b0c0-4fae-b0c6-ec24790fcc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8a83653-a2a8-415c-b9c1-aaad4e356b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e634ecc1-ca1d-4788-84f5-70118b2f79d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8a83653-a2a8-415c-b9c1-aaad4e356b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e6fe756e-c962-4d82-9c45-8ba42dfc1957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e634ecc1-ca1d-4788-84f5-70118b2f79d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e6fe756e-c962-4d82-9c45-8ba42dfc1957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c08204f9-ec9c-4104-9628-4f14781d3f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e634ecc1-ca1d-4788-84f5-70118b2f79d5" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c08204f9-ec9c-4104-9628-4f14781d3f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d11b59a-6d4e-43ba-8ef8-836ac3b0c92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d11b59a-6d4e-43ba-8ef8-836ac3b0c92f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:to="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_345950f3-1edb-4a71-8bdd-2e0fa94ca4b3" xlink:to="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e8cff5aa-8128-49a5-af18-5100636d76cf" xlink:href="mgnx-20211231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aa7f0ad9-fa39-4f6d-a3fa-1975fba9bb4f" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e8cff5aa-8128-49a5-af18-5100636d76cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:to="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_87e75280-ee2f-40df-8ac8-0d24926d5ff2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e0b57a7b-2c8e-46c1-a4ee-613feea69cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cc1f25-d0b4-4ecc-975a-cfa89ee14b9a" xlink:to="loc_us-gaap_EmployeeStockMember_e0b57a7b-2c8e-46c1-a4ee-613feea69cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84bf3b33-fa1d-4be0-99f5-bc887d06fde9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2f0f7c0-9ed7-410d-8804-0a814e5720b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2f0f7c0-9ed7-410d-8804-0a814e5720b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8aa28db4-7bf5-4779-a365-a604b42f3425" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8aa28db4-7bf5-4779-a365-a604b42f3425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c45ccb42-83c1-4736-ac71-2ce613cd78b2" xlink:href="mgnx-20211231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c45ccb42-83c1-4736-ac71-2ce613cd78b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_945f2f31-62c1-4548-b478-8a1d3bcaf093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_945f2f31-62c1-4548-b478-8a1d3bcaf093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d9151110-1f2d-4285-9080-a403512b5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d9151110-1f2d-4285-9080-a403512b5c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f0a9e4d-44a3-40aa-8d32-855b19aea3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed77a051-34df-4fbe-a4fe-68da7206a5e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f0a9e4d-44a3-40aa-8d32-855b19aea3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b10b6a0c-df78-43db-9e47-f25649813d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b10b6a0c-df78-43db-9e47-f25649813d59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:to="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9e2d3960-dea8-4f3d-a033-5b78ebada7a6" xlink:to="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_9adf5919-0389-4a57-a81f-2da946a0102d" xlink:href="mgnx-20211231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_9adf5919-0389-4a57-a81f-2da946a0102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_77156d0f-cb56-4f9b-98cf-6dbfb95855e1" xlink:href="mgnx-20211231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f0e2c0ca-84fd-49a0-af80-e417f24a8350" xlink:to="loc_mgnx_StockIncentivePlan2013Member_77156d0f-cb56-4f9b-98cf-6dbfb95855e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c78c124e-c591-44a4-9352-7e884f35e94c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30d567ae-2ea7-4271-83a7-a5f2c5fe2cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30d567ae-2ea7-4271-83a7-a5f2c5fe2cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_8dd74205-9563-4d97-b9b8-f9c8350ea5d4" xlink:href="mgnx-20211231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_8dd74205-9563-4d97-b9b8-f9c8350ea5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a305a85-7b04-4fe1-ab9e-bace69a9c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a305a85-7b04-4fe1-ab9e-bace69a9c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b75ff361-d013-489d-bef7-40147a4da816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b75ff361-d013-489d-bef7-40147a4da816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f469263a-cb48-417d-af14-80c7f7797b51" xlink:href="mgnx-20211231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_107ac330-9abf-42c5-9151-351ed0217fe7" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f469263a-cb48-417d-af14-80c7f7797b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b10b6a0c-df78-43db-9e47-f25649813d59" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd257ea4-8f92-4fb9-b50e-f37df74701cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e1d8e90-bc47-4b60-99a2-4b3b12bd6ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e1d8e90-bc47-4b60-99a2-4b3b12bd6ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c285ea00-1fa9-418d-8cf1-a08e321b8d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13483d0-245b-49dd-8fb0-ab1408e53a18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c285ea00-1fa9-418d-8cf1-a08e321b8d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96d72966-452c-4bd9-b52c-a2aff1d505d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_538e0115-491d-4bc5-a185-4994b1a73906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25158529-a5d1-4892-863f-26fe4096c620" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_538e0115-491d-4bc5-a185-4994b1a73906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c936d7b3-21ea-4f67-81ef-27a859a44807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c936d7b3-21ea-4f67-81ef-27a859a44807" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:to="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0ca6ef4-cf5e-4cbd-8492-34a2ef1f7328" xlink:to="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_49fa2126-1409-46b8-b5fe-e9b02cac8468" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:to="loc_srt_MinimumMember_49fa2126-1409-46b8-b5fe-e9b02cac8468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3193177c-a147-4497-a158-481dbec54351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5b4f6bd-8f73-4a03-9c13-bc7e4785f84a" xlink:to="loc_srt_MaximumMember_3193177c-a147-4497-a158-481dbec54351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c7cdab-fa1c-4516-a48c-0a67536ad883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af949b46-0c56-4152-b037-4638e3a4793d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af949b46-0c56-4152-b037-4638e3a4793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa77cbc-23f4-4312-b99e-374cd9bc1132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa77cbc-23f4-4312-b99e-374cd9bc1132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02fefeb0-a18c-4736-bfa0-d6df12bed839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02fefeb0-a18c-4736-bfa0-d6df12bed839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f684a0ff-531c-45f6-ab92-f6a8ef96fe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f684a0ff-531c-45f6-ab92-f6a8ef96fe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6c9fcdc-467d-491d-8579-c931c9b491da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb8c9f2b-ac3e-46aa-bd2b-85f7055c59db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6c9fcdc-467d-491d-8579-c931c9b491da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46ff7a79-16d2-4ba6-ab64-59948d61045b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46ff7a79-16d2-4ba6-ab64-59948d61045b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:to="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_67fd9612-299d-4831-bb3a-74236cd777b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d7e4c32-a48e-4820-a04f-dc39bd964f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7cbe35a-cf8b-4248-8294-7a84e0ee5289" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d7e4c32-a48e-4820-a04f-dc39bd964f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:to="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9850cc92-b8fe-4020-bdc1-516436066924" xlink:to="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_4eb7232e-a967-425d-aa52-90535d9ba62a" xlink:href="mgnx-20211231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9cd8d911-0e8f-4117-b09f-8c1c1aff3a70" xlink:to="loc_mgnx_StockIncentivePlan2013Member_4eb7232e-a967-425d-aa52-90535d9ba62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e3bab0-8877-4f42-926a-2d0bd122fdb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09e20bdb-037d-4cdd-b51d-aaa13ab1aaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09e20bdb-037d-4cdd-b51d-aaa13ab1aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6f92a5d8-b5e8-4952-a5dd-1750f0cfb5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6f92a5d8-b5e8-4952-a5dd-1750f0cfb5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09921b1e-742b-4c6d-a777-b805fd2e3883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09921b1e-742b-4c6d-a777-b805fd2e3883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11e9f613-9315-49c3-90f9-d42b81418bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11e9f613-9315-49c3-90f9-d42b81418bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d81428b7-64da-4a94-86d6-3806cc559ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d81428b7-64da-4a94-86d6-3806cc559ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c04de56b-0fea-45d4-a420-a59ee5801efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c04de56b-0fea-45d4-a420-a59ee5801efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_804b6ddb-421d-467c-9369-51efbafa56aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cdb3f645-4f74-4734-b738-a81c7e0dbe5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_804b6ddb-421d-467c-9369-51efbafa56aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd389cdc-959b-4bb5-ad75-32f98a9107b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd389cdc-959b-4bb5-ad75-32f98a9107b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5621392-0667-4c01-96f9-7236c9cdaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5621392-0667-4c01-96f9-7236c9cdaaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bffc579d-5166-4344-b9e2-082e94075c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bffc579d-5166-4344-b9e2-082e94075c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1bf13f4b-b15b-46e6-9cdc-4cf0c9cfc33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1bf13f4b-b15b-46e6-9cdc-4cf0c9cfc33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec1afa38-034d-4e4f-b0a8-32b4d0c2e522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec1afa38-034d-4e4f-b0a8-32b4d0c2e522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c51b1efe-38c3-4326-b115-b6c937806d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c51b1efe-38c3-4326-b115-b6c937806d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09e23cd5-99ec-4d4c-a46f-dbcc6e977b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_93964a10-44ae-4c2c-9aa2-fe8475df5d34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09e23cd5-99ec-4d4c-a46f-dbcc6e977b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_053b18ce-b0af-473f-a7f5-e5e05f0c3ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_053b18ce-b0af-473f-a7f5-e5e05f0c3ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348c9347-cf0d-40b7-a4d6-039c72892062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348c9347-cf0d-40b7-a4d6-039c72892062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd3b9e5d-55ab-4d24-b421-335551759552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd3b9e5d-55ab-4d24-b421-335551759552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_46a261d7-b83c-4eb7-a2c3-0a50e5d1b9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_46a261d7-b83c-4eb7-a2c3-0a50e5d1b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3c12cb0-69f9-4733-bf52-763843d060e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3c12cb0-69f9-4733-bf52-763843d060e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_87758e35-5dfd-4980-9cfd-c106aaf1d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd66e3c-8f40-4e06-8281-b435b5f41e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_87758e35-5dfd-4980-9cfd-c106aaf1d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_576de9fe-816b-47b6-8a6e-559c2f161e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_576de9fe-816b-47b6-8a6e-559c2f161e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e30b7b3-342a-41a1-90b6-343ee6c6aeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e30b7b3-342a-41a1-90b6-343ee6c6aeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_b217f641-29ff-4597-82a7-2585d2b5cc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_b217f641-29ff-4597-82a7-2585d2b5cc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe740467-7aa0-4f35-8833-1c295c734312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe740467-7aa0-4f35-8833-1c295c734312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ecf9ec1-dfe8-4440-8091-55f6b80b30af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ba1d909-ba40-478d-b69b-c7b2f54bca3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ecf9ec1-dfe8-4440-8091-55f6b80b30af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cece1fd3-273f-4f0f-8c0f-75b49ad20089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cece1fd3-273f-4f0f-8c0f-75b49ad20089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0589a5dd-9539-46fa-80fa-4c1f8a4dc30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0589a5dd-9539-46fa-80fa-4c1f8a4dc30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7a8f4a46-b1d9-4d6f-9b3b-4e6013e9fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7a8f4a46-b1d9-4d6f-9b3b-4e6013e9fa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_accef57c-2220-48e6-9ff3-435816ad50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_accef57c-2220-48e6-9ff3-435816ad50aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0d87ab0-0280-46cc-8685-5e1b4419639e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a00d0b8-8630-448f-a979-92446710e61d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0d87ab0-0280-46cc-8685-5e1b4419639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_848e2adc-d59a-453f-bffe-0f31d6edecff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_848e2adc-d59a-453f-bffe-0f31d6edecff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3c6c5b29-28eb-4592-9e79-1ada003874f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3c6c5b29-28eb-4592-9e79-1ada003874f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bddfd2d3-2dc9-4d09-9bc3-12584ebff36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bddfd2d3-2dc9-4d09-9bc3-12584ebff36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bd91480e-c6f5-473c-84a8-5de9d01bbb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bd91480e-c6f5-473c-84a8-5de9d01bbb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_cfdb74b4-e03d-4a67-8e10-221e5cce68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_cfdb74b4-e03d-4a67-8e10-221e5cce68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5304f7f0-769f-464e-8488-4312bbf747f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5304f7f0-769f-464e-8488-4312bbf747f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f9e0fe8d-03da-43f2-9732-12268936647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f9e0fe8d-03da-43f2-9732-12268936647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_818731c9-3a60-49d3-95f5-9eab8b28fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_818731c9-3a60-49d3-95f5-9eab8b28fd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_892ed1c2-7579-4f4a-8f68-8a0b1ecc19cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f025ec6-d3de-4366-829a-4adfca12a945" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_892ed1c2-7579-4f4a-8f68-8a0b1ecc19cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79e1a90d-19b2-4310-a560-ca03fa11d786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96db1bb3-d69d-41a7-91aa-963900cf66e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_20120076-5bb6-47c9-b292-13cd088b15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96db1bb3-d69d-41a7-91aa-963900cf66e3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_20120076-5bb6-47c9-b292-13cd088b15f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_35308b0e-7653-4437-8800-44e71dfae90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_342ef348-6c98-48e9-86a2-9312e4d58095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_35308b0e-7653-4437-8800-44e71dfae90d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_342ef348-6c98-48e9-86a2-9312e4d58095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cfac5509-9d1a-4550-83f0-ced6a413d080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_35308b0e-7653-4437-8800-44e71dfae90d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cfac5509-9d1a-4550-83f0-ced6a413d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_624e86ef-9d85-4d10-a816-de1fd8033160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_35308b0e-7653-4437-8800-44e71dfae90d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_624e86ef-9d85-4d10-a816-de1fd8033160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eaf34140-a70f-41e2-81cf-ca6992746aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eaf34140-a70f-41e2-81cf-ca6992746aac" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ee591894-b44d-4f29-b1d2-a79599b13255" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_c8029ddc-1852-40de-a560-f5b9ead07c8c" xlink:href="mgnx-20211231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_c8029ddc-1852-40de-a560-f5b9ead07c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c8b9cc7a-4f33-4497-ad93-809f949fe70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e879fcac-e7cb-4cb6-9ae8-43aded62e6fd" xlink:to="loc_us-gaap_DomesticCountryMember_c8b9cc7a-4f33-4497-ad93-809f949fe70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_65cffb6d-b1b9-4243-8346-6819faf4ab95" xlink:to="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_a33bb3ac-1cee-4ac2-a60e-14f4ea0dd3d2" xlink:href="mgnx-20211231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:to="loc_mgnx_TaxYear2025To2037Member_a33bb3ac-1cee-4ac2-a60e-14f4ea0dd3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_0b1c4419-ac1b-4500-840d-4bd1b2ecffc6" xlink:href="mgnx-20211231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_fc6dd626-4767-410b-a26d-e8cd186a2e49" xlink:to="loc_mgnx_IndefiniteMember_0b1c4419-ac1b-4500-840d-4bd1b2ecffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d830ebe5-0a64-4366-8ea9-06a67582fd14" xlink:to="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a60c6438-28aa-4662-985b-3b8926c98b07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:to="loc_srt_MinimumMember_a60c6438-28aa-4662-985b-3b8926c98b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_deec69c1-31c1-4db4-a5d5-8cccf155836e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65ca4e40-4df5-42d5-935b-20ba71f6d1da" xlink:to="loc_srt_MaximumMember_deec69c1-31c1-4db4-a5d5-8cccf155836e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6458f82a-fcb8-46f9-8ee1-aaf5e3944fc8" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4b5b0dbb-97b1-4534-8e1d-44672582f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4b5b0dbb-97b1-4534-8e1d-44672582f41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ed39c4d7-0aae-4a89-a33b-0fa2de243903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ed39c4d7-0aae-4a89-a33b-0fa2de243903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5175cee8-23fd-4f8b-bbcb-25e8e33104c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_5175cee8-23fd-4f8b-bbcb-25e8e33104c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_d14c227f-d5ab-4aa3-b99b-7a301efccaae" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_d14c227f-d5ab-4aa3-b99b-7a301efccaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_acf5e831-2d9e-48ad-89f0-29ff37f3a9a9" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_acf5e831-2d9e-48ad-89f0-29ff37f3a9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b8e3aaed-8039-41c7-9848-bc382bb0679d" xlink:href="mgnx-20211231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b8e3aaed-8039-41c7-9848-bc382bb0679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7fc9e281-db8f-4add-a63f-3bda4a0978a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7fc9e281-db8f-4add-a63f-3bda4a0978a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_72476362-b2ed-4470-982b-4cc174f17baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_304baba6-cf7f-40b9-82eb-555589b5a93e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_72476362-b2ed-4470-982b-4cc174f17baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_845d4f62-3af0-4ade-92da-0d2723756cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845d4f62-3af0-4ade-92da-0d2723756cab" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fc187991-68b8-46ad-a991-b037cdcb3a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fc187991-68b8-46ad-a991-b037cdcb3a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_8917b589-0cca-463f-b012-37b46017ab15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_8917b589-0cca-463f-b012-37b46017ab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1ee94ed8-a75e-4692-8be5-85446a6c078f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1ee94ed8-a75e-4692-8be5-85446a6c078f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6fa6c765-3f0e-4ff7-bdd9-32e6546a6d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6fa6c765-3f0e-4ff7-bdd9-32e6546a6d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_aa84ef65-f038-413d-8314-44bf8ff4a1c8" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_aa84ef65-f038-413d-8314-44bf8ff4a1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_48842bb5-ef6e-4da0-bc18-cdaf049c0eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_48842bb5-ef6e-4da0-bc18-cdaf049c0eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b143f125-1fe5-4132-ae29-5e1b9eff1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b143f125-1fe5-4132-ae29-5e1b9eff1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b187ff79-92f0-472f-a95e-a76e5d51a9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b187ff79-92f0-472f-a95e-a76e5d51a9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c78dcf2e-7a90-42b6-9c55-e0578bdc4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c78dcf2e-7a90-42b6-9c55-e0578bdc4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_65fd4180-a812-48d3-a568-5f710f6167ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ada52d56-2781-481f-a4d7-891e802216de" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_65fd4180-a812-48d3-a568-5f710f6167ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845d4f62-3af0-4ade-92da-0d2723756cab" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_86fdccea-0de5-4e99-a9c1-f91e429565a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_86fdccea-0de5-4e99-a9c1-f91e429565a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_75c0bead-6a0a-4781-acca-d8b2f9ba35ce" xlink:href="mgnx-20211231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_75c0bead-6a0a-4781-acca-d8b2f9ba35ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_b6121fb6-b69f-4ed2-999e-a91867ff1e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_b6121fb6-b69f-4ed2-999e-a91867ff1e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cdd09ef5-d8c5-4f83-9cc8-7d81248d9190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_cdd09ef5-d8c5-4f83-9cc8-7d81248d9190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0c9a228e-cf83-4a04-898f-8f83d3ff31df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_22842458-24a1-4638-96df-8da2ab9ff8f3" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0c9a228e-cf83-4a04-898f-8f83d3ff31df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5393b01b-b246-40d1-95a4-f9423b014735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5393b01b-b246-40d1-95a4-f9423b014735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6330ece2-66a5-4159-a95e-44477ac83632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6330ece2-66a5-4159-a95e-44477ac83632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_dbfd0270-f4ad-4dd0-88de-3d301fc7e280" xlink:href="mgnx-20211231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_dbfd0270-f4ad-4dd0-88de-3d301fc7e280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_b37b8b66-67e5-41de-a54f-cce1bd8fcb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_b37b8b66-67e5-41de-a54f-cce1bd8fcb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_304a9bc5-9c7b-41e8-82df-7ceaefb3e481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_304a9bc5-9c7b-41e8-82df-7ceaefb3e481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_62ff949e-a1f0-4567-af99-3cac55064313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_62ff949e-a1f0-4567-af99-3cac55064313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_66d1ac28-df95-4f10-ba38-cbccf340abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_66d1ac28-df95-4f10-ba38-cbccf340abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6cfec9b1-30f2-45de-bef3-d6783266266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6cfec9b1-30f2-45de-bef3-d6783266266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_32c9f396-4d7c-4aaa-bccc-b8bd4b0f272d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe3fbd27-1a41-426f-ad1a-8c7134ab3316" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_32c9f396-4d7c-4aaa-bccc-b8bd4b0f272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e5c3539-98af-484a-828c-f95032eae6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e5c3539-98af-484a-828c-f95032eae6c2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fed66552-1c35-4a4d-996d-c912ad1e42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fed66552-1c35-4a4d-996d-c912ad1e42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6a8bb55d-6005-4b76-8b91-092c338b282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6a8bb55d-6005-4b76-8b91-092c338b282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_9547673b-89f1-4e40-88a6-509a967eebb7" xlink:href="mgnx-20211231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_9547673b-89f1-4e40-88a6-509a967eebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a226312e-18b2-4b67-bbaa-919701a69571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_feba0ed2-5083-4cfe-8476-c6bd5f09de51" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a226312e-18b2-4b67-bbaa-919701a69571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b7ddfdd0-59eb-40ab-b955-f939c28e6e40" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_6745a3ea-5528-4854-a67a-5bc18f86d572" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b7ddfdd0-59eb-40ab-b955-f939c28e6e40" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_6745a3ea-5528-4854-a67a-5bc18f86d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_84c0a72f-37aa-4693-8158-d3a7e5937524" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_84c0a72f-37aa-4693-8158-d3a7e5937524" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab41aaec-b324-4831-af84-96866d35d3fb" xlink:to="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_f49c6c2e-c376-412e-87a0-f6871521761d" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2122dcb6-d6f8-44e1-a035-82e9737aebac" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_f49c6c2e-c376-412e-87a0-f6871521761d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17748b35-abe9-48fd-90f2-190029accb13" xlink:to="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a562b4f6-7ea1-448d-b905-f4f43fe863f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:to="loc_srt_MinimumMember_a562b4f6-7ea1-448d-b905-f4f43fe863f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40df28c0-fede-4254-b940-c26eb8a5f33b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a21dfeb5-86ae-4edc-8973-563a37e57bb6" xlink:to="loc_srt_MaximumMember_40df28c0-fede-4254-b940-c26eb8a5f33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f43addf2-5648-4d41-ae1f-b55c893b92d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_b93806b0-7977-4e15-adae-b54343b874ae" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_b93806b0-7977-4e15-adae-b54343b874ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_b7dc22f6-69bb-497d-8344-fd1ceee34051" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_b7dc22f6-69bb-497d-8344-fd1ceee34051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_e56acf2b-4301-4750-afc7-becaab5dba13" xlink:href="mgnx-20211231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e1b799c2-5d58-4e12-ade0-caaaff59f120" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_e56acf2b-4301-4750-afc7-becaab5dba13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8f2f7b55-da07-428e-ba34-85ec7dd596ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8713c37b-1a7b-4c1c-84a6-067e07840509" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_033b4d77-39a0-47e4-84fd-fca3fa407016" xlink:to="loc_mgnx_IncyteCorporationMember_8713c37b-1a7b-4c1c-84a6-067e07840509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a00788d5-0fc2-4585-9f26-f99eac39419e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_e81eb883-a377-4d18-b1ec-9549d421926e" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_e81eb883-a377-4d18-b1ec-9549d421926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4abb9bdc-7053-4955-899d-45b17cfeae6b" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4abb9bdc-7053-4955-899d-45b17cfeae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_709a7c63-b4f7-47d4-9fb4-f91debd3642b" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_709a7c63-b4f7-47d4-9fb4-f91debd3642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d35d35df-65a6-4a5e-b4bc-2a0660b4a7e0" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d35d35df-65a6-4a5e-b4bc-2a0660b4a7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_5a820b71-b86a-41d8-83bc-97fa89468877" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_5a820b71-b86a-41d8-83bc-97fa89468877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_b2c4ae31-45fa-4da8-bd0c-9fbc025cc58e" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_b2c4ae31-45fa-4da8-bd0c-9fbc025cc58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_70fb011c-b60f-4e16-87a5-bc115292ab8a" xlink:href="mgnx-20211231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_70fb011c-b60f-4e16-87a5-bc115292ab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_84955091-e7ed-466c-8a09-813603ead9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deba45cd-209a-4da6-a98a-29389c04db6c" xlink:to="loc_us-gaap_Revenues_84955091-e7ed-466c-8a09-813603ead9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_afcb0785-6715-42d6-a2ee-7ac34d702e11" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_afcb0785-6715-42d6-a2ee-7ac34d702e11" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_acb31287-70db-40e2-94c5-2e291699d842" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_48c9b254-ac27-4320-a8fa-2be0253a1c3c" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_48c9b254-ac27-4320-a8fa-2be0253a1c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_77fe27d1-5d83-48dc-9398-9bcf65633bda" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_77fe27d1-5d83-48dc-9398-9bcf65633bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f3a54423-5ebe-4b64-8ea9-e3209b32704d" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f3a54423-5ebe-4b64-8ea9-e3209b32704d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_aef20d00-00eb-4db7-8602-0c3286f49420" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_aef20d00-00eb-4db7-8602-0c3286f49420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_6f48804f-49fd-49a3-aa87-917917a8ddde" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_6f48804f-49fd-49a3-aa87-917917a8ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_e34ce826-bc81-4bab-879b-98d559fe5bdf" xlink:href="mgnx-20211231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_e34ce826-bc81-4bab-879b-98d559fe5bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_0609194b-99ff-4872-8e40-1895cbe7c608" xlink:href="mgnx-20211231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b7617b36-ffbb-43ec-b2a2-a9a00b4e7bec" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_0609194b-99ff-4872-8e40-1895cbe7c608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3311fdd-10ce-49e1-80a7-f399c3b5e02c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_16b0357b-f47c-4ade-b3c7-2eb729734aca" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:to="loc_mgnx_ZaiLabsMember_16b0357b-f47c-4ade-b3c7-2eb729734aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_127cbe9b-d97e-4495-b0d4-ed2af029ea16" xlink:href="mgnx-20211231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efe2d138-3069-447a-88d7-e1733ad4c469" xlink:to="loc_mgnx_ZaiLabMember_127cbe9b-d97e-4495-b0d4-ed2af029ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b2ea320e-5ae2-4f8d-a81c-44c1c0c07db1" xlink:to="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8045497-978f-4851-b1e8-4aba49dad441" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a0eca434-79d1-4e2c-a8bd-2520251f66fb" xlink:to="loc_srt_MaximumMember_f8045497-978f-4851-b1e8-4aba49dad441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0b29db1-83f7-4bd6-b278-ec266dc69c13" xlink:to="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3de74aaf-3097-468c-a376-417a5e8f2f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39e33092-d32c-4436-a0c2-a8cb4ec299ea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3de74aaf-3097-468c-a376-417a5e8f2f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fda66539-c27a-4015-b661-19a645130fb5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_678c942d-5e84-40dd-a5cb-8b070b472430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f455e2bc-0101-4010-8aa3-aa2837b2be5b" xlink:to="loc_us-gaap_SubsequentEventMember_678c942d-5e84-40dd-a5cb-8b070b472430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a792bcd-8241-4cb1-899a-7a71350a146f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_d40bc127-f0de-4ce4-ab46-ab67c8473ee6" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonRefundableUpfrontFees_d40bc127-f0de-4ce4-ab46-ab67c8473ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_1b447f3c-0f7b-4c60-b835-2b4ccf51fd31" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_1b447f3c-0f7b-4c60-b835-2b4ccf51fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_e8886649-085a-476b-851d-9251d6237aee" xlink:href="mgnx-20211231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_e8886649-085a-476b-851d-9251d6237aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4a3e582e-7cf7-4ddd-9e6b-5ece9b79aeb7" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4a3e582e-7cf7-4ddd-9e6b-5ece9b79aeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a0952537-d2c9-4204-8a4c-be33bbcd935a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_us-gaap_Revenues_a0952537-d2c9-4204-8a4c-be33bbcd935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_23a7d35b-44fe-4196-829f-10463817c863" xlink:href="mgnx-20211231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_23a7d35b-44fe-4196-829f-10463817c863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_7067c8da-db17-448b-b9ff-52714f87dacb" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_RevenuesTaxWithholding_7067c8da-db17-448b-b9ff-52714f87dacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_48636ab9-dbdd-4054-bf18-96322a0cc96b" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_48636ab9-dbdd-4054-bf18-96322a0cc96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_deaae9ac-1c45-48cb-a401-a03086262cd5" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_deaae9ac-1c45-48cb-a401-a03086262cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_25e8b281-4154-42ec-a17a-aa103032b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_us-gaap_ContractWithCustomerLiability_25e8b281-4154-42ec-a17a-aa103032b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_1a1e989c-4d2b-4935-b1f9-8b7812b94724" xlink:href="mgnx-20211231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_1a1e989c-4d2b-4935-b1f9-8b7812b94724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_92a09241-5ed6-4bcc-a869-9a5cac9e77f7" xlink:href="mgnx-20211231.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_OptInFee_92a09241-5ed6-4bcc-a869-9a5cac9e77f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_fec91c66-6abf-40cf-9175-0e00b7878a1e" xlink:href="mgnx-20211231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_fec91c66-6abf-40cf-9175-0e00b7878a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_f440aa52-539b-478a-832f-b9caab5c8c94" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_f440aa52-539b-478a-832f-b9caab5c8c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_abd59a3e-a1b9-4c5d-8f7a-e2dc07e4109f" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0bcc832b-2b2c-4223-b281-ba802a6ce655" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_abd59a3e-a1b9-4c5d-8f7a-e2dc07e4109f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_43baa343-303a-4a02-84b7-9d37c63a8ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_43baa343-303a-4a02-84b7-9d37c63a8ac6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_268001f6-9e24-4620-9c11-537f37cfc1e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_1a7aaeb2-85f6-4649-8e3a-c89ad25cdb67" xlink:href="mgnx-20211231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152ae7a1-a52f-4329-b1e2-9aae235f95d0" xlink:to="loc_mgnx_JanssenBiotechIncMember_1a7aaeb2-85f6-4649-8e3a-c89ad25cdb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ade561e7-0b1f-42ed-9ef2-f73adbafda65" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_8488d2ac-ec4e-4cd0-9c6b-d62a95b9a883" xlink:href="mgnx-20211231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2a3a00bd-0150-4034-b73f-be9ef3739cdc" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_8488d2ac-ec4e-4cd0-9c6b-d62a95b9a883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_64aa6ec4-cf32-4246-adec-9b5202f5e4d2" xlink:to="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_bab441b1-f207-4079-a4d1-6a62f2d920ad" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_bab441b1-f207-4079-a4d1-6a62f2d920ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_8e4a0d1d-43af-4000-a2b7-250adebdca71" xlink:href="mgnx-20211231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0947b1e-640e-43ed-8a4d-ff8d097a00bd" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_8e4a0d1d-43af-4000-a2b7-250adebdca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfd431d8-e63a-47a7-83ba-44386a5637d8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2af72b62-e816-4be0-9a6b-c539fdf5efc9" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2af72b62-e816-4be0-9a6b-c539fdf5efc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_b5c9325e-aeee-45ed-9cd4-64249671ab8d" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_b5c9325e-aeee-45ed-9cd4-64249671ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_9180a4da-4f2a-4bd8-8d1f-cdfead177ad2" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_9180a4da-4f2a-4bd8-8d1f-cdfead177ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_2a3b0fdc-5b5c-4d30-9a4c-dfb4e6801c5b" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_2a3b0fdc-5b5c-4d30-9a4c-dfb4e6801c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3823400b-ca6e-46e8-96b2-3e4febc734ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_us-gaap_Revenues_3823400b-ca6e-46e8-96b2-3e4febc734ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_bf734b71-f0bd-431e-9999-f8fe80a7711d" xlink:href="mgnx-20211231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_df119d55-2de2-49c8-a419-62dcd827fffb" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_bf734b71-f0bd-431e-9999-f8fe80a7711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_cc5d974c-4b26-4b30-8360-dac026c796c7" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_cc5d974c-4b26-4b30-8360-dac026c796c7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_87739383-9679-48e8-a5d2-d7f07e1f862b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_269fdb64-af25-4b8b-b144-0e146e684577" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_269fdb64-af25-4b8b-b144-0e146e684577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_979e3de7-acd4-40ab-97ae-30113322656c" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0a5b0548-bd13-4f58-b9c7-928c3383f56e" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_979e3de7-acd4-40ab-97ae-30113322656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c29a540e-c495-4fc5-b42f-01a6c706febc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_4a81d3ef-f285-41be-b040-80b981e0e032" xlink:href="mgnx-20211231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4e3cf5c-dcda-443e-9f1b-b96d94f25ea0" xlink:to="loc_mgnx_IMabBiopharmaMember_4a81d3ef-f285-41be-b040-80b981e0e032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04998979-3609-46c3-8e26-bef588de2b85" xlink:to="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b1688a0-3cdc-466b-bcd4-d55f685a721d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5337f8cd-243d-450d-8fef-d953e024e87d" xlink:to="loc_srt_MaximumMember_5b1688a0-3cdc-466b-bcd4-d55f685a721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f107854d-05b6-45ab-9914-5ea1743f8657" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2d5ad563-4638-4cb2-abf9-86b950da718c" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2d5ad563-4638-4cb2-abf9-86b950da718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e8c6c2ed-5b3b-4f07-a368-f77cd8b0051e" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e8c6c2ed-5b3b-4f07-a368-f77cd8b0051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9232cb50-751a-41b1-b9a6-769d661a4211" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9232cb50-751a-41b1-b9a6-769d661a4211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_51344e69-0394-4ec9-9d85-7cf94da7644d" xlink:href="mgnx-20211231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_51344e69-0394-4ec9-9d85-7cf94da7644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_eddcbda2-6192-43d4-8cbb-7901d64f2d30" xlink:href="mgnx-20211231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_eddcbda2-6192-43d4-8cbb-7901d64f2d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_87cfefb2-a689-4b65-ba4d-3c0875421c44" xlink:href="mgnx-20211231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_mgnx_OneTimeMillstoneCredit_87cfefb2-a689-4b65-ba4d-3c0875421c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a1fc742-87f5-4852-8bf8-76dffe140ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_Revenues_4a1fc742-87f5-4852-8bf8-76dffe140ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e3fb80a2-d954-41bf-b14f-67fb03f2bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e3fb80a2-d954-41bf-b14f-67fb03f2bd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_940f14b2-aa3b-483d-aa77-86796dd16a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_940f14b2-aa3b-483d-aa77-86796dd16a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_acd47aee-8ae0-4550-90fb-c7b9944a79d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_152b4fc6-aa58-43ef-9269-1d8d9ca34933" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_acd47aee-8ae0-4550-90fb-c7b9944a79d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_826a5297-46b8-4bd2-9780-5d3fe382c195" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_826a5297-46b8-4bd2-9780-5d3fe382c195" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f1dc6cce-d1a9-4597-8e88-90c695368c5f" xlink:to="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_6a519e51-4a7e-4a81-8a14-ca0a7d1b24d9" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cfaea6d-7b87-4d3f-a948-95632d8ef71a" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_6a519e51-4a7e-4a81-8a14-ca0a7d1b24d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3ab1405-679c-4356-a905-8b3d4aad1357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_af377995-bb4f-4a1d-8b84-173c8323d18b" xlink:href="mgnx-20211231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_af377995-bb4f-4a1d-8b84-173c8323d18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_eef50039-c75d-4292-9247-66eda3fa06b9" xlink:href="mgnx-20211231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b143dbb6-013a-4b74-82f6-1ad76069bc47" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_eef50039-c75d-4292-9247-66eda3fa06b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdd2f757-6ef6-4079-b294-852bb93bc613" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_11e98c30-284d-4f87-a64b-affbee701ca5" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:to="loc_mgnx_ProventionPRV3279Member_11e98c30-284d-4f87-a64b-affbee701ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_f0daea49-936b-4b9c-893e-ce4bd54ea912" xlink:href="mgnx-20211231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ed494ec-a36b-4e5b-905b-4eb27cfde292" xlink:to="loc_mgnx_ProventionPRV031Member_f0daea49-936b-4b9c-893e-ce4bd54ea912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a91b6a5-ac6d-4d9c-8e81-8a994df25e73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c32260e-99fe-482e-a046-e6e27165654f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_514e9900-2ef2-4273-9f4c-c39c8c23a4b5" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a3945655-6793-43d1-b49c-64c22f94a8f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_ad1d9ca0-1411-4219-b883-66ec2cd35c44" xlink:href="mgnx-20211231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d3da770-b1e3-45df-a30b-606d205ce128" xlink:to="loc_mgnx_ProventionBioMember_ad1d9ca0-1411-4219-b883-66ec2cd35c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23ade606-8ef3-409e-8f13-f2301077736a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9d01c47d-66dd-4f63-8b99-76f52cc4d04c" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9d01c47d-66dd-4f63-8b99-76f52cc4d04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_39a66730-9cf7-4b9e-a685-59f38afd3ad9" xlink:href="mgnx-20211231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_39a66730-9cf7-4b9e-a685-59f38afd3ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_260e1d25-23bb-46e6-ba21-697e4fb1c117" xlink:href="mgnx-20211231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_260e1d25-23bb-46e6-ba21-697e4fb1c117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_9d5d86ae-406f-4f22-baec-c693b929157a" xlink:href="mgnx-20211231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_9d5d86ae-406f-4f22-baec-c693b929157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_8bcf5f51-a4e3-4b36-812c-bbf674f7a432" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_8bcf5f51-a4e3-4b36-812c-bbf674f7a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_01177c12-3fb4-4a74-a65a-07bb43165a11" xlink:href="mgnx-20211231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_01177c12-3fb4-4a74-a65a-07bb43165a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_12643b48-125f-42ca-9c6d-80f57d2c20df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_95c35efc-1c01-40ed-bd8c-2683695aa78e" xlink:to="loc_us-gaap_Revenues_12643b48-125f-42ca-9c6d-80f57d2c20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_780b148e-aa0b-4f96-b8a8-311f43eb41d8" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_780b148e-aa0b-4f96-b8a8-311f43eb41d8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8296a64-f2c2-41b9-a24e-f6cdb3e688de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_56081388-0220-4b13-9739-4ab498f0367f" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_51d37e9e-99ec-4012-98f1-31888b549b07" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_56081388-0220-4b13-9739-4ab498f0367f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:to="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_50d41fc3-6dee-435e-8f6c-e3142eb1199d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_8e0b9cf8-1bd6-44f4-a965-27187aa22805" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5969c42f-aa09-457f-9055-a561812cfaf3" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_8e0b9cf8-1bd6-44f4-a965-27187aa22805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7af5a6b-776b-413f-b849-67cff41c8ac8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_67d4d05d-441f-438d-80fa-c15ab050229d" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_67d4d05d-441f-438d-80fa-c15ab050229d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_d2184bc3-2059-4236-806c-6bd16cde9f4a" xlink:href="mgnx-20211231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_NumberOfProductCandidates_d2184bc3-2059-4236-806c-6bd16cde9f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ab65fa8f-a1b7-45e2-ba54-6d6a6c05bde6" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ab65fa8f-a1b7-45e2-ba54-6d6a6c05bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_3c87974f-a916-41b1-84b0-0c71ad53c49d" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_3c87974f-a916-41b1-84b0-0c71ad53c49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_6c17384b-89b8-43aa-adaa-e7ea4ef34083" xlink:href="mgnx-20211231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5a8a4f7-d6ed-4d7c-bcef-ee1efeb7621b" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_6c17384b-89b8-43aa-adaa-e7ea4ef34083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_216716d6-53c9-45a7-a7db-1b09ea83459b" xlink:href="mgnx-20211231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_216716d6-53c9-45a7-a7db-1b09ea83459b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b3efeed-6212-4eff-9293-21203d4923af" xlink:to="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_db038b8e-4b2b-4679-9315-344a037931e2" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_253ee2dc-337b-462c-84e2-018589daf3d5" xlink:to="loc_mgnx_RevenuesFromGrantsMember_db038b8e-4b2b-4679-9315-344a037931e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b7d6294b-ebe7-4108-8e6f-cafb68dd82e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_8a42ab9c-cf12-425c-b3df-5f42cfbc9e3a" xlink:href="mgnx-20211231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_8a42ab9c-cf12-425c-b3df-5f42cfbc9e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_70f21e1c-6908-45c5-929b-0d95dac5b3f1" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eff84914-c728-4ac1-b46a-ff4fcbc29b23" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_70f21e1c-6908-45c5-929b-0d95dac5b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_16e9385d-e3a4-4d1d-92a5-0db49429437a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_b7651f72-5999-4bc3-b0f1-f1f3f2f2f053" xlink:href="mgnx-20211231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_305c02b5-bbda-4955-84c5-020ea2aa12c9" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_b7651f72-5999-4bc3-b0f1-f1f3f2f2f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b38df95d-497b-4433-a7d7-e40fe943adfd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_ac6da671-470b-4625-9efb-0e54d37ef234" xlink:href="mgnx-20211231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_mgnx_NumberOfProductCandidates_ac6da671-470b-4625-9efb-0e54d37ef234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_870b541d-94f6-4c3e-8a69-5535c6f4919a" xlink:href="mgnx-20211231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_870b541d-94f6-4c3e-8a69-5535c6f4919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_73236d18-ec1f-4d6e-b8ed-748ae4851eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7d6b5d6-1e4c-4e8a-9f72-8dfd3c5695c0" xlink:to="loc_us-gaap_Revenues_73236d18-ec1f-4d6e-b8ed-748ae4851eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f874692-7c68-445d-a7d4-332668a03e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35b3bcd5-0802-460e-baaa-298965c1f972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f874692-7c68-445d-a7d4-332668a03e8a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35b3bcd5-0802-460e-baaa-298965c1f972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4998e3d-ec2d-4d3b-be0b-67de21377d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9e067801-cb04-4813-80e7-e7064cec5f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4998e3d-ec2d-4d3b-be0b-67de21377d9f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9e067801-cb04-4813-80e7-e7064cec5f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5cd5f769-9fee-4a23-8524-bfe2d64c4064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_cfb6ff9b-5e2e-4c95-9bb6-93f8b4b53966" xlink:href="mgnx-20211231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5cd5f769-9fee-4a23-8524-bfe2d64c4064" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_cfb6ff9b-5e2e-4c95-9bb6-93f8b4b53966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_984353f7-d96d-4975-952a-db0ac16e45ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5cd5f769-9fee-4a23-8524-bfe2d64c4064" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_984353f7-d96d-4975-952a-db0ac16e45ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_ad6e1da5-515f-420f-91f5-f074cd379040" xlink:href="mgnx-20211231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5cd5f769-9fee-4a23-8524-bfe2d64c4064" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_ad6e1da5-515f-420f-91f5-f074cd379040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9ceffe37-c231-4b8a-a225-98d5c4697aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5cd5f769-9fee-4a23-8524-bfe2d64c4064" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9ceffe37-c231-4b8a-a225-98d5c4697aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f0812ecb-a487-4541-80f4-5ec444f488c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_560cdd1a-97e5-4d9d-8422-10029e3412c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f0812ecb-a487-4541-80f4-5ec444f488c2" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_560cdd1a-97e5-4d9d-8422-10029e3412c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d1926f1c-a5a8-47ae-aec8-392c3f952b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d1926f1c-a5a8-47ae-aec8-392c3f952b0b" xlink:to="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9800f122-701e-47bd-89ce-1f1f044f7136" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_c5c7b35a-81ed-4d23-a7f5-04e0e49f6d87" xlink:href="mgnx-20211231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b218ff8-d09f-415c-9624-3afc333f014d" xlink:to="loc_mgnx_IncyteCorporationMember_c5c7b35a-81ed-4d23-a7f5-04e0e49f6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b835fcd3-7f35-4a6f-8360-fcc26ba29d60" xlink:to="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_4f4883ac-da2f-4d38-95cf-1cd2e81918db" xlink:href="mgnx-20211231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fea42020-d6c4-4f56-877a-448757dfc8da" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_4f4883ac-da2f-4d38-95cf-1cd2e81918db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57278ef2-459b-4d63-9609-1fa6808998b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_d20a6cda-d8d4-4e0c-ac14-c34e1c859f11" xlink:href="mgnx-20211231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_da7e3511-71ab-491c-a80e-237c178372b1" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_d20a6cda-d8d4-4e0c-ac14-c34e1c859f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_64f9a2b0-16ef-492f-8944-6ddab6f94b93" xlink:to="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b558e71e-7f7c-4771-9ad3-7299075507a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_564f0a07-8fec-4d29-a32f-73092487d37a" xlink:to="loc_srt_ScenarioForecastMember_b558e71e-7f7c-4771-9ad3-7299075507a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fbea944c-410b-4cae-ac47-7a294c4b6b09" xlink:to="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_8cc53867-e1f7-49dd-a210-592ffad37b8b" xlink:href="mgnx-20211231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9cd01957-6e91-46e0-ae9c-bf912928b132" xlink:to="loc_mgnx_NonRefundableUpfrontFees_8cc53867-e1f7-49dd-a210-592ffad37b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mgnx-20211231_g1.jpg
<TEXT>
begin 644 mgnx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!217AI9@  34T *@    @ ! ,"  (
M   ,    /E$0  $    ! 0   %$1  0    !   6)5$2  0    !   6)0
M  !)0T,@4')O9FEL90#_X@U824-#7U!23T9)3$4  0$   U(87!P; (0  !M
M;G1R4D="(%A96B 'Y@ ! !P #  [ !EA8W-P05!03     !!4%!,
M                ]M8  0    #3+6%P<&P
M                                     !)D97-C   !7    &)D<V-M
M   !P    >IC<')T   #K    "-W='!T   #T    !1R6%E:   #Y    !1G
M6%E:   #^    !1B6%E:   $#    !1R5%)#   $(   " QA87)G   ,+
M "!V8V=T   ,3    #!N9&EN   ,?    #YC:&%D   ,O    "QM;6]D   ,
MZ    "AV8V=P   -$    #AB5%)#   $(   " QG5%)#   $(   " QA86)G
M   ,+    "!A86=G   ,+    "!D97-C          A$:7-P;&%Y
M
M                                        ;6QU8P         F
M#&AR2%(    2   !V&MO2U(    2   !V&YB3D\    2   !V&ED       2
M   !V&AU2%4    2   !V&-S0UH    2   !V&1A1$L    2   !V&YL3DP
M   2   !V&9I1DD    2   !V&ET250    2   !V&5S15,    2   !V')O
M4D\    2   !V&9R0T$    2   !V&%R       2   !V'5K54$    2   !
MV&AE24P    2   !V'IH5%<    2   !V'9I5DX    2   !V'-K4TL    2
M   !V'IH0TX    2   !V')U4E4    2   !V&5N1T(    2   !V&9R1E(
M   2   !V&US       2   !V&AI24X    2   !V'1H5$@    2   !V&-A
M15,    2   !V&5N054    2   !V&5S6$P    2   !V&1E1$4    2   !
MV&5N55,    2   !V'!T0E(    2   !V'!L4$P    2   !V&5L1U(    2
M   !V'-V4T4    2   !V'1R5%(    2   !V'!T4%0    2   !V&IA2E
M   2   !V !, $< ( !( $0 4@ @ #0 2P  =&5X=     !#;W!Y<FEG:'0@
M07!P;&4@26YC+BP@,C R,@  6%E:(        /,6  $    !%LI865H@
M    ?M0  #G?    P%A96B        !1T0  N80  !"L6%E:(        "8Q
M   ,G0  P<%C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8
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M.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1
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M<F$       ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M         0    $          0    $          0  ;F1I;@         V
M  "N0   3\   $2   "IP   )H    R   !0    5$   C,S  (S,P ",S,
M         '-F,S(       $,<@  !?C___,=   'N@  _7+___N=___]I
M ]D  ,!Q;6UO9        !YM  !W4  *CR;:A*
M '9C9W        ,    "9F8  P    )F9@ #     F9F     C,S       "
M,S,       (S,P  _]L 0P " 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&
M!P<'!@<'" D+"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(#
M P,& P,&# @'" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@)>A73 P$B  (1 0,1 ?_$ !\   $% 0$!
M 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$"
M P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G
M*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%
MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35
MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M**^V.,**.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
M**.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':
M@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
M !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH
M[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!H
MHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.
MU':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H
M-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !1
M1VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4
M%!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
M**.U':@ H-%% !7ZL?\ !G__ ,I+/''_ &3._P#_ $ZZ37Y3]J_5C_@S_P#^
M4E?CC_LF=_\ ^G72:X,S_P!UGZ%T_B1_1]7\[O\ P>(_\GP_#'_L1A_Z<+JO
MZ(J_G=_X/$/^3X?AC_V(P_\ 2^ZKYC)/]Z7HSIK?"?D711VH[5]L<84&BB@
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MCM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %?LE_P9O\
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MC&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH
M!1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.*
M**  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !
M1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q
M10 48XHHH !1THQBB@ K]._^#2P?\;2M0_[$;4O_ $HLZ_,2OT[_ .#2S_E*
M7J'_ &(VI?\ I19UPYC_ +M/T+I_$C^ENOYWO^#Q#C]N'X8_]B,/_2^ZK^B&
MOYW?^#Q ?\9P_#'_ +$9?_2^ZKY?)/\ >EZ,Z:WPGY%T8XHHK[8XP%'2C&**
M "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1TH
MQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***
M4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBB
MB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 4
M8XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,4
M4 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI
M1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444
M HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%
M%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@
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MU7R^2?[TO1G36^$_(L4=*,8HK[8XPHQQ110 "CI1C%% !1CBBB@ %'2C&**
M"C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQ
MBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4
M=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB
M@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48
MXHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44
M %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !7ZZ_P#!G?Q^W#\3O^Q&
M/_I?:U^16,5^NO\ P9W_ /)\/Q._[$8_^E]I7GYI_NL_3]32G\2/Z(:_G!_X
M/ ?^4EG@?_LF=A_Z==6K^CZOYP?^#P#_ )26>!_^R9V'_IUU:OF\C_WI>C-Z
MWPGY3BCI1C%%?:'(%&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQ
MBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4
M=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB
M@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48
MXHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44
M %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1
MC%% !1CBBB@ %'2C&** "C'%%%  *_77_@SOX_;A^)W_ &(Q_P#2^UK\BL8K
M]=?^#.__ )/A^)W_ &(Q_P#2^TKS\T_W6?I^II3^)']$-?S2?\':8_XVEZ?_
M -B-IO\ Z47E?TMU_-)_P=I_\I2]/_[$;3?_ $HO*^<R+_>ODS>M\)^8@HZ4
M8Q17V9R!1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<44
M4  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C
M'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB
M@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*
M,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@
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M H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
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M?T15_.[_ ,'B'_)\/PQ_[$8?^E]U7S&2?[TO1G36^$_(NBCM1VK[8XPH-%%
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MX/\ P> ?\I+/ _\ V3*P_P#3KJU?-Y'_ +TO1F];X3\IZ*.U':OM#D"@T44
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M[3_Y2EZ?_P!B-IO_ *47E?.9%_O7R9O6^$_,2BCM1VK[,Y H-%% !11VH[4
M%!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
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M^4M6L?\ 8LZ5_P"BWKY[(?\ >?D_T-JWPGYPT4=J.U?9'*%!HHH **.U':@
MH-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !
M11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4
M %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
M **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U'
M:@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%
M% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11V
MH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH _LC_P""8/\ RC3_ &>/^R9^
M&_\ TU6U>YUX9_P3!_Y1I_L\?]DS\-_^FJVKW.OS>M_$EZL[X[!BBDSCUHK,
M8M?E/_P> <?\$U/ _P#V4VP_]-6K5^K%?E/_ ,'@ _XUJ>!_^RFV'_IJU:N[
M+?\ >H>I%3X6?S@T8XHHK[XX@%'2C&** /Z5O^#27_E%SJW_ &/FH_\ I+8U
M^H!K\O\ _@TE_P"47.K?]CYJ7_I+8UF?\';WC;6O O[ G@"XT35]4T>XF^(%
MO')+8W4EN[K_ &=J!VDH02,@'!XXKX?$4?;8Z5.]KL[(RM"Y^I]S;1WD+1S1
MQRQMP4==RGZ@UX[\??\ @G;\"_VH=)N+3QY\)_ OB W2>6UW)I,4-]&/^F=U
M&%GC/NCJ:_D4\*?M@?%KP)?_ &K0_BE\1=&NO^>UCXDO;=_^^DD!K]@/^#>K
M_@O?\1/BO^T)HWP+^-6N3>+K?Q+"UMX9\0748;4;>[C0N+>YE&#,DB*P$CAI
M X4%F#97IKY/7H1=6G*]NVC)C54G9GD/_!;7_@W#E_8P\&:E\6?@O<:IKWP[
MT\^=K6A79\^^\.1=[A)>L]LIX;<-\8PS%UW.GY,8XK^XKQ%X>L?%WA^^TG5+
M2WU#3=4MY+2[M9T$D5S#(I1XW4\,K*2"#U!K^,C]N+X"Q_LN_MB_$[X=P,SV
M?@_Q-?Z7:.22SVT<[B%CGN8]A/N3UKT\EQ\ZT73J:M=?(SK02U1Y8*.E&,45
M[AB%&.*O:'X9U+Q--)'INGWVH21+O=;:!IF1?4A0<#W-470QN592K*<$'J/K
M0 "CI1C%7M \,ZEXKOOLNEZ??:E<XSY5I TTF.GW5!- %&C'%=9KOP#\=>%K
M'[5J?@OQ9IUKM+^==:/<0Q[?7<R 8]ZY.DI)[  HZ48Q13 *,<45M>$/AOXB
M^(,QCT'0-:UN13M*Z?8RW+ ^F$4TKVW Q11TK5\5^!-<\!7HMM<T;5=%N&SB
M*^M)+=SCK\K@&LJB]]4 48XHHI@ HZ48Q10 48XJ]I?A;4];L[BYL].OKRWM
M!F>6"W>1(1URQ ('XU1H !1THQBNH\+? [QKXZM([C0_!_BC6()!E);'2I[A
M&'L44@TG)+<#EZ,<5J^*_ FN> [Q;?7-'U71;A\[8[ZTDMW;'7 < \5E4;[
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M[8XP%'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10
M48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,
M44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "C
MI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444
M  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'
M%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@
M HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,
M8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %
M'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHH
MH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&
M.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%%
M !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  K]6
M/^#/\X_X*6>./^R97_\ Z==)K\I\8K]6/^#/[_E)9XX_[)G?_P#IUTFN',_]
MUGZ%T_B1_1]7\[W_  >(_P#)\'PQ_P"Q&'_I?=U_1#7\[O\ P>(?\GP_#'_L
M1A_Z7W5?+Y)_O2]&=-;X3\BQ1THQBBOMCC"C'%%%  *.E&,44 %&.***  4=
M*,8HH *,<444  HZ48Q10 48XK[R_P"",G_!$I?^"N6@?$"^;XF'X?\ _""W
M%C!L'A[^U?MOVE9VSG[3#LV^3T^;.[MCG[;_ .(,"/\ Z.0;_P (#_[Y5P5L
MRPU*;IU)6:\G_D:*G)JZ/PR%'2OW-'_!F!'_ -'(-_X0'_WRH_X@P$S_ ,G(
M-_X0'_WRK+^V,'_/^#_R#V4NQ^&5&.*^P?\ @L;_ ,$H?^'3/QB\)^%?^$\_
MX3Y?%&CMJPN_[%_LLVQ6=XO+V>?-N^Z#NW#KC'&3]F_\&R7_  2!^%G[8WPS
M\6_%_P"*NBP^,+71]=;P[H^AW,C"RCDCMX9YKB9%8>:2+F-41OE&UR0Q*E>B
MKCJ4*'UC>/02@W+E/QQ%'2OZ)O\ @N[_ ,$,_@;IW[#GC+XG?#;P;I/P[\8?
M#VS_ +6/]C)]GLM4MD91-#+ #Y8(0LRNBAMR@'(.*_G9HP>,AB8<\/04HN+L
MPHQQ11782 HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2
MC&*_3#_@VJ_X);> ?^"AWQO\<^(/B9:MK7A7X9V]BRZ()FACU.[NVG\HS,A#
MF)%MI"4!&]F7)VAE;'$5XT:;JSV148MNR/S/HQQ7]0O_  4=_P"#?_\ 9W^,
M7[*OBQ_!GP]T'X=^--!TFXO]%U70H?L@\Z&)G6*>-2(Y8Y"NUBP+#.X,".?Y
M>JY\#CH8F+E#2PY0<=P%'2C&**[B HQQ110 "CI1C%% !1CBBB@ %'2C&**
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M_@SO_P"3X?B=_P!B,?\ TOM*\_-/]UGZ?J:4_B1_1#7\X/\ P> _\I+/ _\
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MQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***
M4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBB
MB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 4
M8XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,4
M4 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI
M1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444
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MUJ_X)#?MEWG[>O\ P3V^'?Q&U<JWB.]LWT_6V$:QK+?6LC032A5PJB4QB4*
M HD XQBK'_!6#]NB#_@G9^PQXR^)""WFUZWA73?#MM,NY+G4Y\I &7C<J?-*
MPR,I"X!SBN'#XC$T)O#TWJW;YWW14HQ:YF>B?!3X._"C]D#P]8^"/ NB^#?
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M4=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U
M!0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:**
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M#?2YX=6:$R3.T[R[E\MF&W# <\Y%._X(Z_\ !;[Q9_P2=O=?T?\ X1NV\<>
M?%$ZWMYH[WALKBUNU3R_M$$VQP"R!%=60AA&F"I!)^&Z^W/^"1__  12\0?\
M%9O#OCC4=$\=:/X/7P3<VEM*E]I\ET;HW"RL"I1EV[?*.<YSFNBK1P]+#^SJ
M_ O7_A]R5*3E=;GL_P#P5?\ ^#EKQ)_P4"^ E]\+O!O@9?A]X4UQD_MNZN=2
M%]J&IQ(ZR+ NV-$AC+JI;&]G"@952P;\O*_2+_@I3_P;D>*_^";_ .RMJ7Q3
MU3XF>'O%%EI=]:V;V%KI<UO*_GR",,&9V'!()&.F:_-WM3P*PZI_[-\-_/?Y
MA/FO[P4&OUW^"G_!I)XV^-'P;\)>,;?XR>%K&#Q9HMGK,=M)HL[O;K<0),$+
M"3!*AP,CKBOESX_?\$-?BI\,?^"ANG_LX^#[FQ^(GBS4-(@UO[=:PM96=G:O
MNWRSM(2(XX]O+$G)954%F52Z>88><G&,MOT%[.2/BNBOW(\ ?\&:+S>$4?Q1
M\>5MM>EB!:'2O"_GV=K)CD"22Y1Y5![[(R1V';\=?VHO@3/^S-^TMX\^&\VH
M)K-QX&\07N@->Q0F);UK>=X?,"9)7=MSMR<9QDT\/CJ->3C2=VO4)0<=S@:#
M7Z0?L,?\&P_[0'[6>E6.O>+!I_P?\*WT2SPSZY&T^J7",,JR6*$,OTG>(]P#
M7VEX:_X,U?!EKI3)K'QS\47U]CY9;/P[!:Q ^Z--(3]-PK*KFN%IOEE+7RU_
M(I4Y,_ VBOVB_:._X,]O$'@GP=J&L?#_ .-&CZU)I]O)<O9>(-$DT]2J*6.)
MX9)LD@8P8ASW]/SB_P""9'_!/O5/^"F'[3T7PQTGQ)8^%;R32[G4_MUY:O<1
MA8=F4VJ0<G?USVK2ECJ%2#J0EHM]R7"2=CZG_P"#;;_@F;\)_P#@HS\6/B0O
MQ6TO5-;T_P $V6GW-G86VHR64%PT\DZOYK1;9" (EQM=>IZ]OT^_X+._L)_!
MO]E'_@B_\:(_AS\,O!?A&2*RTT?:['2XEO7_ .)K9CY[A@9GXXRSDUO?\$0/
M^"*/B#_@DSXM^(>I:UXZT?QBOC:TL;:)++3Y+4VIMWF8EB[-NSYH''3%?37_
M  4J_9%O?V\/V(O'GPGT[6K7P]>^,(+:*+4+F!IXK<PW<%QED4@G(A*\'C=G
MM7S6*QW/C%*,_<37>W2^AT1A:'F?QNT5^S5Q_P &;GCR*WD9?C;X19E4D Z'
M< $CW\ROQE[5]1A\72KW]D[V.>46MPH-%%=)(5]3_P#!)_\ X*L>,/\ @E+\
M<=0\3:!I5GXF\/\ B2V2RU_0KJ<VZW\<;%HWCF 8Q3(6<*Q5UQ(X*G((^6.U
M?5'_  2>_P""6^L?\%6?C)XD\&Z+XMTWP?<>'=%.LO<WMF]TDR^?%#L"HRD'
M,H.?:N?$^R]D_;?#U*C>^A]L?M\_\'7^O_M)?L\:[X#^''PW;P'<>*K&33M2
MUN_U@7UQ!;RH4FCMXUB15=E)7S68D G"!L,OX_FOU6_:_P#^#6/QG^R/^S'X
MX^)EY\6O#&M6O@G2I=5FL8=(GADNDCP2BN7(!(Z9%?E37/EZPR@_JVW7?]2J
MG-?W@HK]0_V%?^#8CQ=^W+^R=X-^*VF_%;PWX?LO&-M+<Q:?<Z1--);".>6$
MAG5P#DQ$\#O7C7_!17_@AE\1/V$?CG\-OAWI.K1_%3Q-\3XKA]+L]#TR6.8/
M"Z*RE&+<8?<6R JJQ; !-:1QU"53V:EKK^&Y/)*USXAH-?M'^S'_ ,&>7BOQ
M1X6M]1^+7Q4T[PGJ,ZJYT;0-._M-X 1DK)<R/&@<="$1UST<CKVGQ@_X,VM/
M/AV>7X?_ !LO5U:-28;;Q!HBM;SMCA6FAD#1C/\ $(W^AK%YQA%+EYOP97LI
M'X445ZE^V'^QE\0_V$?C7?> ?B5H,FBZY9J)H75O-M=1@8D)<6\H^62-L$9'
M((96"LK*/+>U>A&2DN:+NC/8*#115 %%':CM0!^\?_!F;_R('Q__ .PAH?\
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M 2#M1% QEB?SPNO&VM7WA.UT&;5M4FT.RG>ZM].>ZD:T@F88:1(B=BNP !8
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M=9VTT]3JJ)M61^"]SXVUJ]\)VN@S:OJDVAV,[75OISW4C6D$SC#2)$3L5V
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M%':CM0 4&BB@ HH[4=J "@T44 ?M9_P9H?\ )4?CU_V"]'_]&W=?O57X*_\
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M_P#TJ->=FW^Z3_KJC2G\2/Z!*_F'_P"#J?\ Y2U:Q_V+.E?^BWK^GBOYA_\
M@ZF_Y2U:Q_V+.E?^BWKY[(?]Y^3_ $-JWPGYPT4=J.U?9'*%!HHH **.U':@
M H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
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MU]A?\%$O^"C_ ( _X)D?"#2/&OQ$M?$EYI.M:PFB6Z:+:1W,XG>":8%EDDC
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M_P 'F/CR0W_P"\,1LRQ)'K6J3K_"[$V441^HQ+_WU7Z$_P#!OO\ \H=_@?\
M]@R[_P#3A=5^:/\ P>4_\EN^!W_8#U/_ -'P5\C@5?,GZR_4ZI_PS\7Z_:S_
M (,T-%MY_B;\>M09E^U6NEZ-;1@]2DDMXSD>V8D_,5^*=?J[_P &B_Q]L_AW
M^WKXM\#WTT4'_"Q/##_82S8::[LY1,L8'?,#73>O[OZU]!FL6\)-+^M48T_B
M1^QO_!<;Q?<>"/\ @DK\=[RU5FDF\,R:>0O79<R1VS_^.2M^%?R*]*_M._;#
M_9ZM?VLOV5OB%\-;R9+>/QMH-WI*7#+N%K+)$PBFQWV2;'Q_LU_&O\9O@[XD
M_9^^*NO^"?%^EW&B^)O#-[)8:A9S##0RH<'!Z,IX96&596# D$&O-X?J1]G*
M'6]_D:5]T<S7[-?\&;6O7EM\?_C9I<<;?V?>>'M/NIG_ (5EBN9%C'XK-+^1
MK\9:_H@_X-'_ -C#5O@[^S!XT^+NN0R6K?%2ZM[71H)$VM]@L3,IN/7$LTT@
M'M;JPR&%=V<5%'"R3ZV7XF='XC[D_P""P]C;ZA_P2R^/T=TP6-? ^IRJ2/XT
M@9T'XL%%?AI_P:8:!'K'_!4Z\N)%C+:3X'U*[C+=0QGM(<CWQ*WX$U^M?_!R
M5^T39_ 3_@D[X^LWN(8]6\?R6WAC3HG;F8S2K)/@=3BVBG.>QQ7XR_\ !K_\
M6[3X8?\ !6_PI97DBQ1^,]&U+04D9MJK(8?M* _[S6P0#N7%>3E].7]GU6NM
M_P $:U/C1_2M^TMXJN/ O[.7Q URS622[T?PWJ-] J?>9XK61U ]R5%?Q/XX
MK^XCQ+H%MXL\.ZAI=XOF6>I6TEK.O]Z.12K#\B:_C)_;6_91\0?L1?M1^,OA
M?XECD_M#PKJ#VT5P8RBZA;'YH+E!_=EB*./3=@\@UIP[./OPZZ,5?HSRT5^\
M7_!F;-<'P#\?XV:3[*NH:&T8/W0YCOMY'N0$S]!7X.XQ7].W_!L%^Q9KG[*7
M_!//_A(/$UNUGK/Q8U(>(XK5T*2VMAY*1V@?/=U5YAZ+.HX.:[L\J*.%<7UM
M^=R*/Q&I_P '1/\ RB!\9?\ 8:TC_P!+(Z_EUQQ7]17_  =$_P#*('QE_P!A
MK2/_ $LCK^76HR'_ '9^K_)#K?$?V@?L)?\ )D'P;_[$;1/_ $@@K\$?^#NS
MQY)XA_X*1>%=%5F^S>'? MFNPGCS9KR\D=A]4\H?\!K][OV$O^3(/@W_ -B-
MHG_I!!7\]O\ P=?_ /*5EO\ L3]+_P#0KBO*R=7QK^9I5^ _-&O4/V-?V0/&
MG[=?[0_A_P"&?@*SANM?UYV/F7$GEVMC"BEY;B9\';&B@DX!).%4,S*I\OK]
MO/\ @S5^%%C>>)OCIXXN+:W?4M/MM)T2RG(!DABF:ZFN%!Z@,8+8^^SVKZ7'
M8AT*$JJW7_#'/"-Y6/LC]BC_ (-F?V;_ -E_P_9W'B_0F^+GBSRD^U7WB+YM
M/63 W"&R4B(1D]!+YK#^]R17TIK7CO\ 9?\ V$6%O>:E\#/A'-;C"6WF:9HL
MPXZ+&-CDX[ 9KQG_ (.)?VF_&G[*W_!+_P 5ZYX#U"]T;7-8U"ST-]4LV*7&
MFV]PY$LD;CF-V5?+#CYE,H*D, 1_*GJ&H7&KW\UU=3S75U<2&6::5R\DKL<E
MF8\DDG))Y-?/8/!U<;%U:M1VO;^NB.B4E#1(_L0_9Z_X*E_ ']J_XQR> ?AS
M\2M'\8>*H;&74GM-/M[EXQ;Q,BN_GF,0\-(@P'R<\ X.*_\ P5O_ .47O[0/
M_8@:S_Z1RU^1/_!GS^R_K6J?M ?$;XQ7.GR)X:T?0V\+6=VXPL]]//;W$BQ_
MWC'%"N[T^T)Z\?KM_P %;O\ E%[^T%_V(&L_^D<E<6(P\*&+5*F[V:^\J,FX
MW9_'B*_M _82X_8@^#?_ &(VB?\ I!!7\7^,5_:!^PC_ ,F0?!O_ +$;1/\
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M&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110
M"CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<4
M44  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "
MC'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQB
MB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=
M*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@
M %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48X
MHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44
M%&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !7ZL?\&?YQ_P4L\<?]DRO
M_P#TZZ37Y3XQ7ZL?\&?W_*2SQQ_V3.__ /3KI-<.9_[K/T+I_$C^CZOYWO\
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M^+'BC1;WQII*:E-8V^DP2Q6K,6&U69P6''4BO7?^(-KX?_\ 1;/&'_@DMO\
MXNNF6<86,G%RU7DR?92W/P$%'2OWVO\ _@S@\ VMA/(GQL\7[XXV9<Z);D9
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MGQ8_ZX:+_P"F>RK2_P"#84?\;A_ /_8+UC_TW3UF_P#!R]_RF<^+'_7#1?\
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M9_M$^ ?C!HMG#:GXC6<^F:X(DVK+>V8B\N=_]N2"54^EJ#U))_'K'%?T3?\
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M#O@[X<?#V;X*ZX\]C9Z9X=>]3Q'%L9D2*W,H0P XR-VW/MFOV^-?Q)_ D?\
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M/",6L/;Y_=M):7L4*OCU O&&?1C7["_\%=M-CU7_ ()<_M 1R#Y5\!:O,/\
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M]F;3?!NA06M[XEO(TN?$VOB$+/K5YCYCNQN$,9)6*/HJ\\LSLWR;_P %>O\
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MZ\T*2^C\110I=M;S-$9 A@)4-MS@DXSUK];:_CM_X*T_\I/_ -H+_LH&M?\
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M5]F<@48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%
M*.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ1
M10!^UG_!F?\ \E0^/7_8*T;_ -&W=?O5TK\%?^#- 8^*'QZ_[!>C_P#HZ[K]
MZJ^'SG_>Y?+\D=E+X3^4S_@X%\#:WJ__  6.^-#6FCZI="XO]/\ *,5I(XDS
MIEGC;@<_A67_ ,$W_P#@A]\:OV[OC%HUI>^"_$_@WX>QWD9UWQ)JMBUC';VV
M<R"V$P4SS%>%6,, S*7VKDU_6/172L\J1HJG"-FDE>Y/L5>[*^E:9;Z)IEM9
MVL:PVMG$L,,:CB-% 50/H !7Q#_P<9?M&V'[/7_!)_XBPS7"Q:IX\6'PII<1
MZW$ERX,P_"UCN&SZJ!WKZ6_:P_;.^&?[$/PPN?%WQ-\6:7X9TJ%6,*32;KK4
M''_+*W@7,DTAX^5 <=3@ D?R^_\ !97_ (*U:]_P54_:!AU)+6XT'X>>%?-M
MO#&BR/F5$<C?=7&"5-Q+M3(4E4550%L,[X95@9UJJFU[J=[_ *%5))*Q])?\
M&@7_ "DO\:?]DTO_ /TZ:57](!K^;_\ X- Q_P ;+O&G_9-+_P#].FE5_2!5
M9Y_O3]$*C\)_+=_P<_?\IAO'G_8*T?\ ]((:_8/_ (-D_P!KK_AIC_@F/H.@
MWUUYVO\ PINY/"UT';YVM5 ELWQV40.(1ZFW:OQ\_P"#G[_E,-X[_P"P5H__
M *;X:[__ (-1?VNO^%'?\% [_P"'=_=>3HOQ<TIK.-6;:@U*T#W%LQ[<Q_:H
MP.[2J/8^IB</[7+8M;Q2?X:_@9QE:H?T<?$7P)IOQ3^'VO>&-8A^T:1XCT^X
MTN^B_P">L$\;12+^*L17\5?QP^$VI? ;XS^+? ^L+MU3P?K-WHMY\NW,MO,\
M3D#T)0D>U?VW5_+W_P '07[-?_"A_P#@J=KNN6UOY.E_$[2K3Q+#M'R";:;6
MX&?[QEMVD/\ UV![BN/A^M:K*D^JO]Q=9:7/:O\ @T _9J_X3?\ :Q^(7Q2N
M[?S+/P'H,>E63LO"WE^Y^93ZK!;S*<=!./45_0UTK\[/^#7[]FG_ (4)_P $
MLM"URYM_)U3XG:K=^)9]R_.(-PMK89_NF*W60?\ 78^IKZC_ ."D?[6-O^P_
M^P[\2/B;))$MYX=T>3^RUDP1-J$Q$-HA'<&>2//^SN/:N+,JCKXQQCWLOR_,
MJGI$_G1_X.#OVHK[]N3_ (*N^(M%\/>?J^G^"9X? F@VML#(UU/%(5GV*/O,
M]Y),H(SN58_:OW>_X(Y?\$I/"_\ P3#_ &;;"P%G9WWQ+\16T=SXKUPHK2R3
MLH8VD3]1;0GY5 .'(+D9; _G_P#^#?\ ^%T?[0'_  6*^$JZWYFH1Z?J5WXE
MNI)3O=I[2UGNH9&)ZG[2D))-?U@5VYQ4=*$,)#9+7S_K<FDKWDRGXB\1:?X1
MT&\U75KZSTO2]-A>YN[R[F6&"UB0%GD=V(554 DDD  5\:WO_!Q)^QOI_BXZ
M+)\:-/:X5MAGCT34Y+/=Z>>ML8R/]H-MYZU\1_\ !X!^V!KGA;PO\-_@GI-U
M)9Z7XE27Q+KOER%6O4B?RK6%@.L8?SG(.062,]4K\&Z,OR>%:E[6JWKM852J
MT[(_N \">/-%^*'@[3?$/AO5M.UW0=8@6ZL=0L+A;BVNXFY5TD4E64^H-?.?
M_!5__@F+X1_X*>?LSZAX7U6WM+'QCI<3W7A;7S$//TN[ R$9L;C;R$!9$Z$8
M8#>B,/S/_P"#/']J;6KS6/BE\&;ZZ:YT.ULX_%NE1.Y)LI/-2VN@@_NOOMVP
M, ,A/5S7[I5YN(I3PF(Y8O5;,UBU*.I_(G_P2M\::9^QA_P5A^'>I?%"Z_X0
MZQ\!>(;JVU^2]C<_V9)'#<0.CJ@9LK)\I !YK^G3]E[_ (*<? ?]M'Q]>>%_
MA?\ $?1_%^O:?I[ZK<6=K!<1O%;))'$TI,D:C >:->N?G''6OYR?^#D#X36?
MPF_X*^?$Y=/A\BU\1K8Z[LQQYMQ:1&=O^!3"5OJQKW+_ (,_O^4E/CG_ +)G
M??\ ITTJO>S'#PQ&'6+=[\J]/ZU,*<G&7*?T>5\Z?M"?\%:?V=?V5/BE?>"?
MB%\4M#\,^*M-CBENM/N+>YDDA66-9(R3'$R_,C*W7H:^BZ_EE_X.</\ E,?\
M2/\ KPT;_P!-EM7AY9@XXFJZ<VTK7T^1K4DXJZ.X_P"#G/\ ;8^%O[;7[2'P
MWU;X5^,+'QCINB^&I;.]N+2&:-8)6NG<(?,1<G:<\9ZU^I'_  0D_:'\"_LQ
M_P#!!WX0^*/B%XLT'P;H%N^MH;W5;Q+>-W_MO4"$3<<NYP<(H+'L#7\P>,5]
M,?L8_P#!.;]HC_@IA8:?I/P_T+6]>\)^%9'LH=0U34#;Z'H1E<S2QQO*VU26
M<R/' K.2^XJ=V3]+BLOI_5HT92M&+O=_/_,PC4?-<_;[XR_\'9_[,WP[U>6S
M\.:;\1?'OEL5%YIVE16EF^.X-U+%+SV_=5ZM_P $\/\ @X0^!/\ P44^*,'@
M314\4>#?&U\CM8:9XAM8D752B,[K;S0R2(S*JD[7V,0#M#8./S[^%'_!FQXL
MU&VBD\<?'#P[H\V 9+?0] FU)3Z@2S2V_P"9C/TKZL_9'_X-7?A#^RY\9O"'
MQ D^(WQ*USQ)X)U>UUJP$;V=C9R3V\JRH)(_)=VC)4!E$@R"1FO&K4\MC!J$
MFY=]?\K&L74OJ?J!+$MQ$T<BJ\;@JRL,A@>H(K^4/_@X!_88TK]@W_@HWXAT
M7PS9Q:=X/\86<7BG1+.)=L=C%</(DL"]@J7$,VU1]U#&*_J^K\"?^#RC18H/
MC=\#M151YUUH>IVS'')6.X@9?UE:HR.K*.)Y%LT_\QUE[MSS7_@T"_Y27^-/
M^R:7_P#Z=-*K^D U_-__ ,&@8_XV7>-/^R:7_P#Z=-*K^D"EGG^]/T04?A/Y
M;O\ @Y^_Y3#>//\ L%:/_P"D$-?GUTK]!?\ @Y^_Y3#>._\ L%:/_P"F^&OS
MZKZG _[M3]%^1S5/B848XHHKK) 4=*,8HH *,<444  HZ48Q10 48XHHH !1
MTHQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***
M  4=*,8HH *,<444  K]DO\ @S?X_:6^,O\ V+-G_P"E1K\;<8K]DO\ @S?_
M .3EOC+_ -BS9_\ I4:\[-O]TG_75&E/XD?T"5_,/_P=3_\ *6K6/^Q9TK_T
M6]?T\5_,/_P=3?\ *6K6/^Q9TK_T6]?/9#_O/R?Z&U;X3\X11THQBBOLCE"C
M'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB
M@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*
M,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@
M%'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XH
MHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %
M&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%
M% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ
M48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%
M']D?_!,#_E&G^SO_ -DR\-_^FJVKW/I7AG_!,#_E&G^SQ_V3/PW_ .FJVKW.
MOS>M_$EZL[X["9HH_.BLQBU^4_\ P> _\HT_ _\ V4RP_P#35JU?JQ7Y3_\
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M'P5MM6T&]M=+\<:9;1_\))X8DE_TK2YL ,\8/,MLS?<E&1@@-M<%1H?MX?\
M!(KX$_\ !1EH;SXD>$?,\16D(M[?Q!I4[6.J11C.$,J\2J,G"RJZJ2< 9-?R
M-?#_ .(GB#X3^+['Q#X6UO5O#NO:9)YMIJ.F7;VMU;/ZI(A#*?H:^\_@Y_P=
M!?M:_"?1X[&^\3^&?'$<.!')XAT*-YE4=C);F%G^KEF]Z^:K9+5IU/:865OP
M?WG1&LFK2/UP^"'_  :U?LI_!SQG;ZU?:;XT\>&UD$L5EXEUA);,,#D;H[>&
M'S%_V9"RD<$$9K[L^)'Q,\%?LN?""\\0>)=4T3P7X*\*V:^9/,5MK2P@0!4C
M10,= %2-!DG:J@D@5_.;XP_X.R_VJ/$NGR0V5M\+_#TDBE5GT_0)I)(S_> N
M+B5<CW4CVKXC_:J_;N^+_P"V[X@AU+XJ?$#7_&,MJ2UM!=2K%9VA/4Q6T86&
M,G."40$CUP*G^R,57DGB9Z>M_NZ![2*^%'T)_P %R_\ @K3=?\%1_P!I"W?0
MUNK#X7^"/-M/#-I.NR:[+E?.O9E[/*44*I^XB*/O%R?D'X4?$_6O@I\3_#OC
M#P[=-8Z]X5U*WU;3K@<^3<02+)&V.XW*,CN.*Y_M1VKZ*E1A3IJE%:(P<FW<
M_L,_X)E_\%'O!7_!2_\ 9LTWQIX9NK6WURWBC@\2:%YF;C0KXK\T; \F)B&,
M<F,.H[,&55_;Q_X)7?!/_@H_I-G'\3O"HO-6TN,PV&N:?.UGJEDA).Q9E^_'
MDL1'('0$DA<G-?R5?L^_M*>/?V4_B/:^+OASXKUKP?XBM1M6\TZ<QF1#R8Y%
MY22,X&4<,IP,@U]]>"O^#L3]JKPKH4=G?+\,_$MQ&@0WVI>'Y([B0C^(BWGA
MCR?9 /:OG:V2UJ=3GPTM/6S1O&LFK2/UD_9H_P"#:/\ 99_9I\?VOB7_ (1_
MQ!XZU#3Y1/:1^+-12\M+=QR&\B..**3'I*KCH<9 -?2G[,O[=_@7]K?XS?%#
MPCX#O8=<L_A3+86.H:Q:S++9W5W<+.SPPLN0PA$*AG!(+LR@?)EOYH?VN?\
M@OK^T]^V3X5NO#^O>//^$=\-WT30W>E^&;5=,AO$;ADED4F9T93@HTA0CJIY
MK]<O^#2#]G?4OAA^P-XH\<:G;RVO_"R/$CRZ<''^OLK2,0+*/K.;E?I&#WK#
M'8&K"BZV)G>6B2_KR*A--VBCTK_@Z*8+_P $@O&'^UK>D >_^F)7\NYK^D[_
M (.V_B=:^$?^":FB^'VD_P!.\6>,K*&*('DQ00W$\C_0,L0^KK7\V->KD,6L
M-?S?Z&=;XC^T#]A+_DR#X-_]B-HG_I!!7\]O_!U__P I66_[$[3/_0KBO(?
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M]F[WNWUZ"]LK:GQ[7]H'["7_ "9!\&_^Q&T3_P!((*_B_P"U?9_@+_@X3_;
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M4=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U
M!0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:**
M"BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1V
MH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#11
M0 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J
M.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:
M** "BCM1VH *#110 5^K'_!G_P#\I+/''_9,[_\ ].NDU^4_:OU8_P"#/_\
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M52..21F2V\%Z9'$#_ IEN6P/^!,Q_&OZ#OV$O^3(/@W_ -B-HG_I!!7\]O\
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M^"M'QPUC19H;C3UUY=.$L)RCR6EM#:2D'O\ O8'Y'!ZC(KCX?K3YY4_LVO\
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M3]N[]IWQ1\5_%UCH>F^(O%C6S7=MI$4L5E'Y%K#;)Y:RR2.,I"I.7.6)Q@8
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MH>&_^PI:_P#HU:_MXK^(?X5_\E0\-_\ 84M?_1RU_;Q6?$6\/G^@4.I_)/\
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M7?\ )3/#O_84MO\ T:M=.0_[K+U?Y(FM\1_;Q7\E/_!?7_E+_P#'+_L,P?\
MI%;U_6M7\E/_  7T_P"4P'QR_P"PS!_Z16]>=P__ !Y>GZHTK['Q_7]('_!H
M'_RC0\:?]E+O_P#TV:57\W_:OZ0/^#0/_E&AXT_[*7?_ /ILTJO6SS_=?FC*
MC\1F_P#!X3_RC\^'?_90H/\ TVZA7\Z)K^B[_@\)_P"4?GP[_P"RA6__ *;=
M0K^=&C(_]U7JPK?$%%':CM7L&04&BB@ HH[4=J "@T44 %%':CM0 4&BB@ K
M]=?^#.__ )/@^)W_ &(Q_P#2^UK\BNU?KI_P9W_\GP_$[_L1F_\ 2^UKS\T_
MW6?H:4_B1_1%7\X/_!X#_P I+/ __9,K#_TZZM7]'U?S@_\ !X!_RDL\#_\
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M;_\ X+ ?'*2:1I'768(P3_=2RME4?@H _"OC^OKS_@O5_P I>OCG_P!AR/\
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MC_F1?@?_ ."C5/\ Y85^4M%9_P!F87^1#]I+N>_?\%'?^"C7C;_@I[\==/\
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M2AB)^6*YM%_>>8O0M&K(V,Y4G8OFY'C:<8.C-V=[HTK0;=T?G77]#7_!G?\
M#ZXTC]C;XI>)I8YHX=<\8)8PE@0L@M;.)BR^HS<D9'=2.U?EO^RO_P &_P#^
MU'^T]XZL],D^&.O?#_27E O-9\76KZ5;V4>>7\J4":4XZ+&C$GJ5&2/Z<?V*
M?V3/#O[#?[+O@[X6^%]TFE^$[$6[73QB.34+AB7GN7 R TLK.Y&2!NP. *US
MO&4W2]C!W;["HQ=[L^/O^#I3QG;^%O\ @D3XHL9I8XY/$FOZ3IT"L>976Y%T
M5'OMMG/T4U_-/\">/CAX-_[#ME_Z4)7ZL?\ !V7_ ,%!],^,_P :?#/P+\+W
M\%_IOPYE?4_$4T#[T_M:13&EMGIN@A+[L9PUPRG#(PK\I_@1_P EP\&_]ARR
M_P#2A*Z<HHRIX3WNMV35E>1_;97\B_\ P7*_Y2V?';_L97_]%1U_717\B_\
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MI?"]Y<2:EX4OI,LE_IDCDQ?/_%)'_JI!UWQDXPRD_,]?V2_M[?\ !//X9?\
M!1[X,R>#?B1H[7,<):72]5M"L6I:).0 9;>4@[<X&Y&#(X W*<#'X<?M0?\
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M[3_Y2EZ?_P!B-IO_ *47E?.9%_O7R9O6^$_,2BCM1VK[,Y H-%% !11VH[4
M%!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
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M]/%?S#_\'4W_ "EJUC_L6=*_]%O7SV0_[S\G^AM6^$_.&BCM1VK[(Y0H-%%
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M#%%)G'K168Q:_*?_ (/ ./\ @FIX'_[*;8?^FK5J_5BORG_X/ !_QK4\#_\
M93;#_P!-6K5W9;_O4/4BI\+/YP:,<445]\<0"CI1C%% !1CBBB@ %'2C&**
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MW=@*.E&,45L2%&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@
MHQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8
MHH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'
M2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *_3O\ X-+!_P ;2M0_[$;4
MO_2BSK\Q*_3O_@TL_P"4I>H?]B-J7_I19UPYC_NT_0NG\2/Z6Z_G>_X/$./V
MX?AC_P!B,/\ TONJ_HAK^=W_ (/$!_QG#\,?^Q&7_P!+[JOE\D_WI>C.FM\)
M^1=&.***^V.,!1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%
M*.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ1
M10 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *
M,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&*
M* "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1T
MHQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***
M 4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CB
MBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10
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M@ %'2C&** "C'%%%  *.E&,44 ?K5_P;,_\ !3;X'_\ !/GPC\8+7XO>-O\
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MP"3SG& 37XNXXHHIX7"QP]/V<+V\PE)R=V HZ48Q1722%&.***  4=*,8HH
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MOA\+3H1Y*:L92DWJS?\ A1KEKX7^*7AK4[R3R;/3M5M;J=]I;9&DR,QP.3@
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M_!)7_@YR^&?B;X(:#X(_:!UJ\\'^-?#=C%8GQ+=02W=AXB6/")+(T2,\-P5
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MC&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH
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M /!U/_REJUC_ +%G2O\ T6]?T\5_,/\ \'4W_*6K6/\ L6=*_P#1;U\]D/\
MO/R?Z&U;X3\X11THQBBOLCE"C'%%%  *.E&,44 %&.***  4=*,8HH *,<44
M4  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C
M'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB
M@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*
M,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@
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M H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
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M?T15_.[_ ,'B'_)\/PQ_[$8?^E]U7S&2?[TO1G36^$_(NBCM1VK[8XPH-%%
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MX/\ P> ?\I+/ _\ V3*P_P#3KJU?-Y'_ +TO1F];X3\IZ*.U':OM#D"@T44
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MH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J
M"@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44
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M[=/);.<=17YR5]#@76=%>W^+K]_D<\[7]T!1THQBBNPD*,<444  HZ48Q10
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M8Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%
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MFBCI1C%%?6G*%&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@
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M(JI32]Z.Q\CBCI1C%%>X8A1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***
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MO^46-G_V.^F_^B+NOYHJ[<CDWAM>[(K?$ HZ48Q17L&048XHHH !1THQBB@
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M$YCDC8=F5E(/N*K*\=]8I^]\2W_S%4ARO0S:,<445ZAF HZ48Q10 48XHHH
M!1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.*
M**  4=*,8HH *,<444  K]DO^#-_C]I;XR_]BS9_^E1K\;<8K]DO^#-__DY;
MXR_]BS9_^E1KSLV_W2?]=4:4_B1_0)7\P_\ P=3_ /*6K6/^Q9TK_P!%O7]/
M%?S#_P#!U-_REJUC_L6=*_\ 1;U\]D/^\_)_H;5OA/SA%'2C&**^R.4*,<44
M4  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% 'T!_P3$_897_@HW^V3
MX;^$I\4'P</$%O>3_P!JC3O[0\C[/;23X\GS8MV[R]N=XQG/.,5^IO\ Q!@1
MC_FY!O\ P@/_ +Y5\8?\&QH_XW&_#G_L'ZS_ .FVYK^IBOFLWS"O1KJ%*5E;
MLO/NCHI0BU=G\N7_  6,_P""!FL?\$H?A3X3\:6OQ ;XC:#K^IR:1?3?V!_9
M1TJ?RO,@!'VB?>)%2?GY=IC ^;=Q^>W2O[&O^"GW[($/[=G["7Q&^&IBCDU3
M6=+>?1G? \G4H")K4[OX09456(_@=QT-?QU7]A-I=]-:W,,EO<VTC12Q2*5>
M)U."K \@@@@@]*[\HQLL12?M'>2?_#$58\KT(J,<445ZQD?0G_!+_P#X)]:U
M_P %,_VN-(^%^DZL?#MO<6ESJ.J:R;+[8NE6L*<RF+>F_=(T40&]?FE7G%?J
M5_Q!@H/^;D&_\(#_ .^5>H?\&CW[%?\ PJ_]EOQ5\:=6M-FJ_$J].F:0[K\R
M:99NRNZGJ!+<^8"._P!EC-?KQ7RF99M6C7<*,K):;+?KNCIITTU=G\J/_!9_
M_@BW_P .B$^'+CXD?\+!7X@'4ASH']DFP-G]D_Z>9O,W_:O]G;L[YX^%\<5^
MZ'_!Y[_QX_LX_P#73Q)_+2J_"^O<RVM.KAHU*CNW?\V8U$E*R 4=*,8HKO("
MC'%%%  *_I,_X(Q_\$(O@'HG[#?P_P#''Q \#Z)\1O&7Q$T.U\175UK<?VJV
MLHKN(30V\,))C79%(H9R"[/N.0-JK_-GC%?J[_P3$_X.A-?_ &)_V<M&^&/C
MOX??\+ TGPK +/0]3LM5%C>6UJN=EO*K1NLJID*K H510"&(S7EYK1Q%2DEA
M][ZZV-*<DGJ6?^#FC_@DK\-OV&+CP/\ $CX5Z8/#&B>,;R?2=3T*.5I+6WN4
MC$L<T&]BR*ZB0,@.T%%*@9(K\F<<5]C?\%>O^"Q_C#_@K'X_T.;4=#M/!W@S
MPF)?['T*WN3=.DDNWS)YYRJ>;(P10,(JHHP!DLS?'-=&!IU84(QK/WB9M.6@
M"CI1C%%=A(48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@#ZY_X(Z_\$LA
M_P %8OCOXF\%-XZ;P#_PCN@MK?VP:+_:GVC%Q##Y6SSX=O\ KMV[<?NXQSD?
MHK_Q!@H/^;D&_P#" _\ OE7D/_!GB,?MV?$O_L0Y/_3A9U_1-7R^:9CB*.(<
M*<K+3HO\CHITXN-V?R<?\%D?^".FL?\ !)#QYX-LI/%O_">>'_&EA-/:ZO\
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M[\:-'T'2=-T32++6(5M['3[5+:V@!M(&(2- %7+,3P!R2:^4>E?8'_!?0?\
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M0;_P@/\ [Y5]]?\ !O9_RAQ^"/\ V#[[_P!.=W5/_@K[_P %HM'_ ."25_X
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M_@G2O=IGXJ44=J.U?5',%?UO?\$'_P#E$3\"_P#L -_Z4S5_)#7];W_!!_\
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MA.-L9S@?EQ-$T$K1R*R2(2K*PPRD<8(K^Q__ ()V_P#!0#P7_P %*/V:]/\
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M\2;+>?4OGO7YQ]J]S"UO:THU.Z1C)6=@H-%%=!(44=J.U !0:** "BCM1VH
M*#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110
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M!X;\2:-\3O!5CJVEW=AKGA_Q!91W5I<PNL]K?VTR!D=3RKHZ,"#T(-?S+_\
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M\^.A;&U$!X,DD8) .:_KA_9K_9J\%_LB_!G1? /P_P!#M/#_ (:T.$10P0H
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M/]DCX<_#:]U*#6+OP/H%KH\U[#$8X[IH8PA=5))4'&<$U^!W_!)K_@XXT/\
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M H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
M!11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH *_5C_@S_P#^4EGCC_LF
M=_\ ^G72:_*?M7ZL?\&?_P#RDK\<?]DSO_\ TZZ37!F?^ZS]"Z?Q(_H^K^=W
M_@\1_P"3X?AC_P!B,/\ TX75?T15_.[_ ,'B'_)\/PQ_[$8?^E]U7S&2?[TO
M1G36^$_(NBCM1VK[8XPH-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %
M!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%  J-(X51N9C@ #DU
M_8U_P3#_ &0;']A?]A;X=_#FUMQ#?:7I<=SK+E</<:E./.NG8]3^]=E7.<(B
M+T K^6?_ ()1_ ZW_:._X*0?!?P?>*LFGZEXIM)[V-AD36UNWVF:/_@4<+K_
M ,"K^N;X_P#Q6M_@/\"/&WCB\C\VT\&:#?:[,G]]+6WDG8?B$-?,\056W"BO
M7]%^IT4%NS^8'_@XH_;.N_VN_P#@IIXRM(YV;PW\,9G\'Z3"'R@:VD874O'!
M+W/F_,.J)&.=HKX5-7O$_B2]\8^)=0UC4IWNM0U6YDO+J9OO2RR.7=C]6)/X
MU1KZ"A25*FJ:Z(PD[NY_2M_P:2_\HN=6_P"Q\U+_ -);&N8_X/"?^4?'P\_[
M*';_ /IMU"NG_P"#27_E%SJW_8^:E_Z2V-<S_P 'A/\ RCX^'G_90[?_ --N
MH5\K'_D:?]O'3_R[/YSZ^O/^"$'QWUCX"?\ !5GX.W&E7MU:V_BC7(?#&I0P
MD[;VVO6$!CD7HRB1HY.>C1*W50:^0Z_73_@V^_X(U_$+QC^U#X7^.WQ \-:E
MX7\ ^#,ZIH2ZG ;>X\07I1E@>*)@'\B,MYOFD ,RQA-P+%?I,=5A"A)U-K/Y
MG/33<M#^B*OY!_\ @M)X3M?!?_!5CX\V-FD<<,GBZ[O-L8PH><B=_P#QZ0Y]
MZ_KJ\3^)M/\ !?AK4-8U:\M].TK2;:6]O;N=PD-K#&I>21V/ 554DD] #7\8
MG[:7QY_X:B_:X^)?Q$2-X;?QGXEO]6MHG^]#!+.[1(?=8RB_A7@\/1?M)RZ6
M-Z^R/Z\_V$O^3(/@W_V(VB?^D$%?AI_P<2_LJ>/OVS/^"VND^!/AOX=O?$GB
M+4O!NF$0P#;';1B6X#332'"11+D9=R ,@=2 ?W+_ &$O^3(/@W_V(VB?^D$%
M<S^UW\<_A!_P3D\&^,OCYXXABTV^U*VL]*N[NWC\W4M:,/FFTL(%8@%LO,P4
M%5&7=B%4L//PF(E1Q#E!7;NDO-LTE&\;,_*?X#?\&;]U>>&[6Z^)WQFCL=6D
MYGT[PUH_VB&'V%S.Z%S_ -L0/K3?V@/^#.*ZL/"]U=_"_P",BZCJT*,T.F^)
M-(^SQ71[+]IA=MA[<PD'/44V/_@\LU ?$:1F^!%FWA$R;8XU\3,NI*F<;RWV
M<QEL<[-H&>-_\5?LC^R7^U5X-_;7_9_\._$KP%?R7_AOQ)"TD!FB\J>VD1S'
M+#*G\,D<BLI&2#C*EE(8]F(Q694+3JNR?I;T(C&F]$?QR?M!_L]>,OV5OB_K
M7@/Q]H5YX=\4^'YO)N[.X R.ZNC#Y9(W4AE=2592""0:XLU^_O\ P=__ +)6
MF:[\"?A_\:K&SCCU[P_JP\+ZG-&GSW-E<1RS0EV[B*:)@OO=-7X!5]%@<5]8
MHJIUZ^ISSCRNQ]B?L!?\$+?V@O\ @HAH=KX@\*^'K/P[X)NF(B\2>(YVL[&Y
M 8JQ@55>:< JPW1QE-RD%@:_13X;_P#!FGIL>G*_C#X[7TUVP!>'1_#2QQQ^
MH$DL[%OKL7Z5ZY^PI_P5T^#'_!-#_@BO\"9?'FN27WB2^T6ZDT_PSHZK<ZI>
M 7]T-Y0L%ACR"/,E902"%W$$5\L_%W_@\:^)^IZ[(W@/X1^ ]#TQ3B-=?N[O
M59V'J3"]LJY';!QZFO)J5LQK5)*BK13:OIT]?T-E&"6IZ]X[_P"#-;PK=:7+
M_P (Q\<O$-C?!<Q_VIX?ANHF;T/ES1D ^HSCT/2OR_\ ^"E'_!'/XQ?\$P=8
MMIO&VGV>L>$=3F-OI_B?1V>;3YY.2(I-RJ\,Q4$[' #8;8SA6(_93_@C_P#\
M'*MG^WM\<+'X5_$KPCIO@OQCKP?^P]0TRY9M,U*5$+FV9)27BE(5BAWN'/R_
M*VW?^B/[6?[-'AW]L3]G'QA\-?%5M'<:/XNTV6R=VC#M:2D9BN$!Z212!)%/
M9D%<L<RQ>&JJ&)U7RV[IHKV<9*\3^*ZO7OV.?V#OBM^WS\09/#?PK\(7WB:]
MM%62^N ZP6>FQL<!YYY"L<8.#@$[FVG:&(Q7F?C'PI>>!/%NJ:'J47DZAHUY
M+8W4?7RY8G*.OX,IK^O;_@E#^QAX>_86_86\!^#=%L8;?4+C3(-5U^Z6/;+J
M.I3Q(\\KGJ<,=B@_=2-%[5[.99A]6IIQU;V[&-.',S\JO@E_P9MZ[J>@V=U\
M1/C9INCZE(H:YTW0- >^CB/HMU--%DC_ *XXSZ]3WWBC_@S4\&W=JPT7XY^)
MK&;;@->^'8+M=WT2:(XSVS7M/_!:+_@XDA_X)M?%U?A?X'\&V?B[QY#917VI
M7>JW#Q:;I*R@/%'Y<>))I&3#$!XPH9.6)(7XK^&7_!XO\6M-UB%O&7PG^'6M
M:?YH\U-%N+S3)O+SR%:62X&['<KC/:O*IRS2K'VL7H]MC3]VG8^*_P#@K#_P
M2/\ %O\ P2=\?^&=)\2>*/#OBRQ\807-SIEUIJ30RA(&C5_.BD7",?,7 5W!
MYY&.?DVOT8_X. _^"IGPW_X*DW/P;U[P##KVGW7AW3=1AUG3=5M!%-82RR6Y
M10ZLT<BD1N0R-T R%)Q7QG^QQ^RWX@_;5_:=\%_"[PR-NK>,-12S$[(72QA
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ML5!KQ\R_V?'1KQZV?Z/\#:G[T+,_BGHITD;1.RLI5E."".AIO:OJSE"@T44
M%%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM
M0 4&BB@ HH[4=J "@T44 %?KK_P9W_\ )\'Q._[$8_\ I?:U^17:OUT_X,[_
M /D^'XG?]B,W_I?:UY^:?[K/T-*?Q(_HBK^<'_@\!_Y26>!_^R96'_IUU:OZ
M/J_G!_X/ /\ E)9X'_[)E8?^G75J^;R/_>EZ,WK?"?E/11VH[5]H<@4&BB@
MHH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J
M "@T44 %%':CM0 4&BB@#^C;_@TL_8_LOA7^Q+K7Q<NK;/B#XI:I+;VT[KS'
MIME(T*JO<;K@7!;'#;(_[H->,_\ !X%^V;=6*?#OX":7,T=O>1?\)AKVQO\
M7*'EM[.(X_A#)<N5/4B(]A7ZQ?\ !/7X'6_[-O[#/PE\#VZJI\/>%K""X*C
MEN3"KSOC_:F:1O\ @5?S)_\ !?CX]2_M!?\ !6?XP7V]C9^&M5'A:UC/2%=/
M1;:0#V,\<S_5S7RN7_[1CY5GLKO]$=,_=A8^.:_>3_@S-X\ ?'__ +"&A_\
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M8::-P&89)D7C) [5Z9IO_!X?\<XO$+27GPQ^$\^DD_+;0QZA%< >\QN64_\
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MGBR1TXB(]"1U[3X@_P#!FKX;N-'F/A7XY:Y9WZIF)=6\/17$+MZ,8YHRH/J
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MV'A/06DD:STW2]-MRS,Q6&WM88UY)/"HBJ/8 #TK^17_ (+'?MOK_P % ?\
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M  =3?\I:M8_[%G2O_1;U\]D/^\_)_H;5OA/SAHH[4=J^R.4*#110 44=J.U
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MBKXY^*E_:I>C2S/Y-CI%NY(62ZD7+;F )6)1N*_,2@*EN3$9I7K5O8X/[_\
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M+_[*7Q!_;-^+5EX'^&OAG4/%'B.]4R>1;X6.WB! :::1B$BB4LH+N0 2!G)
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M+R5;>Y1AT/[N1F7/ =$;JHK^P<U_%S^Q+\/KCXL?MD_"?PS;1S23:]XPTJQ
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M444  HZ48Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&**
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M/;_@O[X MOAM_P %@_CAI]I#Y,-SJUMJI'8R7EC;7<C?C).Q_&OCO'%>[?\
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MBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10
M48XHHH !7ZZ_\&=_'[</Q._[$8_^E]K7Y%8Q7ZZ_\&=__)\/Q._[$8_^E]I7
MGYI_NL_3]32G\2/Z(:_G!_X/ ?\ E)9X'_[)G8?^G75J_H^K^<'_ (/ /^4E
MG@?_ +)G8?\ IUU:OF\C_P!Z7HS>M\)^4XHZ48Q17VAR!1CBBB@ %'2C&**
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M?^EE_7'DR:QC3WLRJOP'V]_P:/\ [7^@^.?V0_$/P:N+X1^+? ^K3ZO;6<A
M-QIMT4/F1]VV7'FAP!\OFQ_WZ^Y/^"FW_!,GP'_P5%^!,/@[QE/J&DWNDW)O
MM$UJPP;C2K@KM8[&^62-UX=&QD $%6"L/Y&_A)\7?%'P&^(FE^+O!NO:GX:\
M2:+,)[+4;"<PS0./0CJI&05.58$@@@D5^R7[#G_!WKJFAV=KHO[0'@=M;6/;
M&?$OA54ANF'3=-9R,L;,>I:*2,#'$9KJQ^65U6^L8;U\TR85%;ED?,_[:?\
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M110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH
M*,<444  HZ48Q10 48XHHH !7ZZ_\&=_'[</Q._[$8_^E]K7Y%8Q7ZZ_\&=_
M_)\/Q._[$8_^E]I7GYI_NL_3]32G\2/Z(:_FD_X.TQ_QM+T__L1M-_\ 2B\K
M^ENOYI/^#M/_ )2EZ?\ ]B-IO_I1>5\YD7^]?)F];X3\Q!1THQBBOLSD"C'%
M%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@
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MVP$LYD>.!6<E]Q4[LGSO]A[]F:X_;(_:Z^'OPPM[HV'_  FFM0:?/=*NYK6
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M/]6Q )"2A'(!.W K^MKX'?M#>!?VF/!$?B3X>^+O#WC+0Y&V?;-(OH[J.-\
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M:_%7['G[#7P\^&/C36]/\1>(?!EC+I\M_8O*UO+"+B5K=4,BJ^$@:),$#&S
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MC%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444
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M&=SU8U^#%?M1_P &:_P^N+OXN?'#Q48Y5M=/T?3-)5\$1N\\TTI /0D"V'N
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MVH1$PW<8'8">.3;GJI4]"*USVBX5(XB']-;?UY$T977*?Q^#X/\ B3_A</\
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M_!+'X_1R<JO@C4Y1]4@9Q^JBOQ?_ .#/C_E(9\0O^R=W/_ISTZOVF_X*\_\
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MFYTW5OBEXX,;ZQ<V>7@TNVCR8K*&1@"P#,SNX"AV*C!$:L?LWXU_\D:\7?\
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M4=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U
M!0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:**
M"BCM1VH *_3O_@TLX_X*F:A_V(VI?^E%G7YB5^G7_!I9_P I2]0_[$;4O_2B
MSKAS'_=I^A5/XD?TN5_.[_P>(_\ )\/PQ_[$8?\ I?=5_1%7\[W_  >(_P#)
M\'PQ_P"Q&'_I?=U\ODG^]+T9U5OA/R*H-%%?;'&%?UD?\&]G_*''X(_]@^^_
M].=W7\F_:OZ%O^".'_!<G]EO]E;_ ()J?"WX?^/OBA_8'B[PW9W<6HV!\-ZM
M=?9V>^N95_>06KQME)$/RL<9P<$$#Q<\I3J44H)MWZ*_1FU%I/4\F_X/./\
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M_P#X(C^++;QI_P $F_@/>6O,</A6"P;G/SVS/;O_ ./Q-7\B':OU?_X(!?\
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M\@FGCJ>,Q%JM2#\DD]/^'"#A'1'X8_\ !PY_RF2^-O\ U_:?_P"FNSK]%_\
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MGNM_^D,M?SX?\&WW[;_PO_8(_;;\5^+OBQXF_P"$4\.ZGX'NM'MKO^SKN_\
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M3;)!YDB$"0*3)&J@C.['-?ICH'_!83]EGQ)9M/;_ !_^%,:*,D77B&WM'/\
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M\5>#=3W?V;XMT>[T:[(&3Y5S"\+_ /CKFOXC:_L!_P""1?[:%G^WE^P#\/\
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M;?L%U99GC><NGEW$<<G&]>=N#G@FOE<IP]6&+<IQ:6NK3.FI).-D?#5?NO\
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M/^"0O_!SY>?LV>!='^&?QZL-7\4>%])CCL])\46 $VI:9;J J0W$1Q]HC0
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M(_\ !5CX-Z*T3266D:VOB.\/\*Q:>K7@W?[+20QQ_60#O7]3/[8OQX@_9?\
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M._MH67Q$_9:\3?!&_N NO?#N^DUC3(F?_7Z9=R;GV#_IE=%RQZ?Z3'[UR?\
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M4^%6M6GAOXG^&]1OF\NQT_5+6YN&V%]L:3*S':,D_*#P!DU_4E_Q$E_L5_\
M19__ "T==_\ D*OG\^IU:BA&G%M:WLF^QO1:5[GAW_!?[_@G)^U1_P %*OB/
MX>\._#N;PS!\(_#MHET+*\UK[))J.J,7#SRIL.X1QE4C!)VYD(^^:_.;_B%,
M_:Q/_+E\/?\ PHA_\;K]BO\ B),_8K_Z+/\ ^6CKO_R%1_Q$F?L5_P#1:/\
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M!0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:**
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M#?P[^'[ZU<:3)X,LM4N[G5+H7%S>7<ES>1O*Q555<K"GRHH48Z<FOWL^-/\
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M]/%?S#_\'4W_ "EJUC_L6=*_]%O7SV0_[S\G^AM6^$_.&BCM1VK[(Y0H-%%
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M&&(!8BD\8?\ !8_]E?P/I\EU>_'WX7S1Q*7*Z?KD.HR$#T2W+LQ]@":_/_\
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M/_3A9U^JW_!PQ_RAO^-W_7A8?^G.SK\3?^#;7]NSX5?L"_M9>./$WQ:\4?\
M")Z'K'A%],M+K^S;N_\ -N3>6T@CV6T4KCY(W.2H7Y<9R0#^@'_!93_@N/\
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MP!V-E$='P=KQJ2& *G586=3+U1M:5NOD[AS)3N?TO?\ !<+]A?Q+_P %"?\
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MS\[E<<1AJ[IS@^5Z/1V]3>IRR5T=3_P9G_\ ),_CW_V%-&_]%7E?3W_!T?\
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M?\%7?^"EWQ0\::Y:?V#X)\)^#!IF@Z!;RM+!I@N+^%]\KG DN)%M_F?"@B,
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M8?:NK*X2AA81DK/7?U9-1WE='ZR?\&?'_*0SXA?]D[N?_3EIU?M-_P %>?\
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M"K,I!#$'\^:WP2K*DHU]U^),[7T"C'%%%=A("CI1C%% !1CBBB@ %'2C&**
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MOO 7PJ^'OA#4%R!>Z5H-M;7>",$><J"3&,C&[N:\S_6*%O@=_4T]@^Y^>/\
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M110 "CI1C%% !1CBBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH
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MJN4AF?/"QRJWE.W8B%B0J,:_,?&**PQ%"-:FZ<]F5&5G=']9W_!<'_@FBO\
MP4R_8PO=!TE88O'_ (1E;6_"TSD*LUPJ%9+1F/W4G3Y<Y #K$QX0@_R=Z]H-
M]X6UR\TO4K.YT_4=-G>UNK6XC,<UM,C%71U/*LK @@\@@BOTB_9[_P"#J/\
M:._9^^"OAOP5_8_PU\71>&;-;"'5=?L+Z;4KJ),B/SI(KN-794VINV!F"@L6
M8EC\4_ML?M:ZI^W)^T;KWQ.UWPWX3\+ZYXD,<FH6WAVVFM[.>94"&<I++(WF
M/M!<AL,V6QDDGS\KP^(PZ=*I;EZ?UYEU)1EJCRD4=*,8HKUS(*,<444  HZ4
M8Q10 48XHHH !1THQBB@ HQQ110 "CI1C%% !1CBBB@ %'2C&** "C'%%%
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M7'Q!7F97ETJ+=6M\3_K\32I4OH@%'2C&**]DQ"C'%%%  *.E&,44 %&.***
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M?KK_ ,&=_P#R?#\3O^Q&/_I?:5Y^:?[K/T_4TI_$C^B&OYI/^#M,?\;2]/\
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MBB@ %'2C&** "C'%%%  *.E&,44 %&.***  4=*,8HH *,<444  HZ48Q10
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MY5]P^9EK6=:O/$6IS7VH7=U?WEPV^6XN)6EEE/JS,<D^Y-53116H@HH[4=J
M"@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44
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M1VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4
M%!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
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M1VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4
M%!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH
M**.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':
M@ H-%% !11VH[4 %!HHH **.U':@ H-%% !11VH[4 %!HHH **.U':@ H-%%
M !11VH[4 %!HHH **.U':@ H-%% !7ZZ_P#!G?\ \GP?$[_L1C_Z7VM?D5VK
M]=/^#.__ )/A^)W_ &(S?^E]K7GYI_NL_0TI_$C^B*OYP?\ @\!_Y26>!_\
MLF5A_P"G75J_H^K^<'_@\ _Y26>!_P#LF5A_Z==6KYO(_P#>EZ,WK?"?E/11
MVH[5]H<@4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM
M0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB
M@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4
M=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T
M44 %%':CM0 4&BB@ HH[4=J "@T44 %%':CM0 4&BB@ HH[4=J "@T44 %%'
M:CM0 4&BB@ HH[4=J "@T44 %?KK_P &=_\ R?!\3O\ L1C_ .E]K7Y%=J_7
M3_@SO_Y/A^)W_8C-_P"E]K7GYI_NL_0TI_$C^B*OYH_^#M3_ )2EZ?\ ]B-I
MO_I1>5_2Y7\TG_!VG_RE+T__ +$;3?\ THO*^<R+_>ODS>M\)^8E%':CM7V9
MR!0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:**
M "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1
MVH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#1
M10 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=
MJ.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0
M:** "BCM1VH *#110 5^R7_!F_\ \G+?&7_L6;/_ -*C7XV]J_9+_@S?_P"3
MEOC+_P!BS9_^E1KSLV_W2?\ 75&E/XD?T"5_,/\ \'4__*6K6/\ L6=*_P#1
M;U_3Q7\P_P#P=3?\I:M8_P"Q9TK_ -%O7SV0_P"\_)_H;5OA/SAHH[4=J^R.
M4*#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110
M 44=J.U !0:** "BCM1VH *UO _Q U[X7^)K;6O#.MZOX=UFS.ZWO],O)+2Z
M@/JDD9#+^!K)HI;[@>_:K_P5:_::UK1?[/N?C_\ &"2UVE"H\67JM(IZAG60
M,V?]HFO"M9UF\\1:I<7VH75U?7MTYDGN+B5I99G/5F9B2Q/J:K=J.U1&G&/P
MJP784&BBM "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0
M:** "BCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "B
MCM1VH *#110 44=J.U !0:** "BCM1VH *#110 44=J.U !0:** "BCM1VH
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M@)P.YKNRW_>H>I%3X6?S848XKNO^&7_B7_T3OQU_X(;K_P"(I/\ AE_XE_\
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M?_$4G_#+_P 2_P#HG?CK_P $-U_\;I^TCW#4X84=*[G_ (9?^)0_YIWXZ_\
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MB=^.O_!#=?\ Q%)_PR_\2_\ HG?CK_P0W7_QNG[2/<-3AA1TKN?^&7_B4/\
MFG?CK_P0W7_Q%'_#,'Q+_P"B=^.O_!#=?_&Z7M(]P.&HQQ7=?\,O_$O_ *)W
MXZ_\$-U_\12?\,O_ !+_ .B=^.O_  0W7_QNG[2/<-3AA1TKN?\ AE_XE#_F
MG?CK_P $-U_\11_PS!\2_P#HG?CK_P $-U_\;I>TCW X:C'%=U_PR_\ $O\
MZ)WXZ_\ !#=?_$4G_#+_ ,2_^B=^.O\ P0W7_P ;I^TCW#4X84=*[G_AE_XE
M#_FG?CK_ ,$-U_\ $4?\,P?$O_HG?CK_ ,$-U_\ &Z7M(]P.&HQQ7=?\,O\
MQ+_Z)WXZ_P#!#=?_ !%)_P ,O_$O_HG?CK_P0W7_ ,;I^TCW#4X84=*[G_AE
M_P")0_YIWXZ_\$-U_P#$4?\ #,'Q+_Z)WXZ_\$-U_P#&Z7M(]P.&HQQ7=?\
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MI'N&IPPHZ5W/_#+_ ,2A_P T[\=?^"&Z_P#B*/\ AF#XE_\ 1._'7_@ANO\
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M_C=+VD>X'#48XKNO^&7_ (E_]$[\=?\ @ANO_B*3_AE_XE_]$[\=?^"&Z_\
MC=/VD>X:G#"CI7<_\,O_ !*'_-._'7_@ANO_ (BC_AF#XE_]$[\=?^"&Z_\
MC=+VD>X'#48XKNO^&7_B7_T3OQU_X(;K_P"(I/\ AE_XE_\ 1._'7_@ANO\
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M *)WXZ_\$-U_\;I^TCW#4X84=*[G_AE_XE#_ )IWXZ_\$-U_\11_PS!\2_\
MHG?CK_P0W7_QNE[2/<#AJ,<5W7_#+_Q+_P"B=^.O_!#=?_$4G_#+_P 2_P#H
MG?CK_P $-U_\;I^TCW#4X84=*[G_ (9?^)0_YIWXZ_\ !#=?_$4?\,P?$O\
MZ)WXZ_\ !#=?_&Z7M(]P.&HQQ7=?\,O_ !+_ .B=^.O_  0W7_Q%)_PR_P#$
MO_HG?CK_ ,$-U_\ &Z?M(]PU.&%'2NY_X9?^)0_YIWXZ_P#!#=?_ !%'_#,'
MQ+_Z)WXZ_P#!#=?_ !NE[2/<#AJ,<5W7_#+_ ,2_^B=^.O\ P0W7_P 12?\
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M_#+_ ,2_^B=^.O\ P0W7_P ;I^TCW#4X84=*[G_AE_XE#_FG?CK_ ,$-U_\
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M-U_\12?\,O\ Q+_Z)WXZ_P#!#=?_ !NG[2/<-3AA1TKN?^&7_B4/^:=^.O\
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M^B=^.O\ P0W7_P 12?\ #+_Q+_Z)WXZ_\$-U_P#&Z?M(]PU.&%'2NY_X9?\
MB4/^:=^.O_!#=?\ Q%'_  S!\2_^B=^.O_!#=?\ QNE[2/<#AJ,<5W7_  R_
M\2_^B=^.O_!#=?\ Q%)_PR_\2_\ HG?CK_P0W7_QNG[2/<-3AA1TKN?^&7_B
M4/\ FG?CK_P0W7_Q%'_#,'Q+_P"B=^.O_!#=?_&Z7M(]P.&HQQ7=?\,O_$O_
M *)WXZ_\$-U_\12?\,O_ !+_ .B=^.O_  0W7_QNG[2/<-3AA1TKN?\ AE_X
ME#_FG?CK_P $-U_\11_PS!\2_P#HG?CK_P $-U_\;I>TCW X:C'%=U_PR_\
M$O\ Z)WXZ_\ !#=?_$4G_#+_ ,2_^B=^.O\ P0W7_P ;I^TCW#4X84=*[G_A
ME_XE#_FG?CK_ ,$-U_\ $4?\,P?$O_HG?CK_ ,$-U_\ &Z7M(]P.&HQQ7=?\
M,O\ Q+_Z)WXZ_P#!#=?_ !%)_P ,O_$O_HG?CK_P0W7_ ,;I^TCW#4X84=*[
MG_AE_P")0_YIWXZ_\$-U_P#$4?\ #,'Q+_Z)WXZ_\$-U_P#&Z7M(]P.&HQQ7
M=?\ #+_Q+_Z)WXZ_\$-U_P#$4G_#+_Q+_P"B=^.O_!#=?_&Z?M(]PU.&%'2N
MY_X9?^)0_P":=^.O_!#=?_$4?\,P?$O_ *)WXZ_\$-U_\;I>TCW X:C'%=U_
MPR_\2_\ HG?CK_P0W7_Q%)_PR_\ $O\ Z)WXZ_\ !#=?_&Z?M(]PU.&%'2NY
M_P"&7_B4/^:=^.O_  0W7_Q%'_#,'Q+_ .B=^.O_  0W7_QNE[2/<#AJ,<5W
M7_#+_P 2_P#HG?CK_P $-U_\12?\,O\ Q+_Z)WXZ_P#!#=?_ !NG[2/<-3AA
M7ZZ_\&=_'[</Q._[$8_^E]K7YA_\,O\ Q*'_ #3OQU_X(;K_ .(K]7_^#1_X
M.>+OAY^V=\2[WQ!X5\2:'9R^"O(2?4-,FM8WD-];$(&=0"Q"L<=<*?2O/S2<
M7A9V?3]32G\2/W^K^<'_ (/ ?^4EG@?_ +)G8?\ IUU:OZ/J_GE_X.T/@WXN
M^(?_  49\%WOA_PKXDURSC^&]C \^GZ9-=1)(-3U5BA9%(# ,IQG.&![U\YD
MC2Q2OV9T5OA/R#%'2NY_X9?^)0_YIWXZ_P#!#=?_ !%'_#,'Q+_Z)WXZ_P#!
M#=?_ !NOLO:1[G&<-1CBNZ_X9?\ B7_T3OQU_P""&Z_^(I/^&7_B7_T3OQU_
MX(;K_P"-T_:1[AJ<,*.E=S_PR_\ $H?\T[\=?^"&Z_\ B*/^&8/B7_T3OQU_
MX(;K_P"-TO:1[@<-1CBNZ_X9?^)?_1._'7_@ANO_ (BD_P"&7_B7_P!$[\=?
M^"&Z_P#C=/VD>X:G#"CI7<_\,O\ Q*'_ #3OQU_X(;K_ .(H_P"&8/B7_P!$
M[\=?^"&Z_P#C=+VD>X'#48XKNO\ AE_XE_\ 1._'7_@ANO\ XBD_X9?^)?\
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M7_@ANO\ XW3]I'N&IPPHZ5W/_#+_ ,2A_P T[\=?^"&Z_P#B*/\ AF#XE_\
M1._'7_@ANO\ XW2]I'N!PU&.*[K_ (9?^)?_ $3OQU_X(;K_ .(I/^&7_B7_
M -$[\=?^"&Z_^-T_:1[AJ<,*.E=S_P ,O_$H?\T[\=?^"&Z_^(H_X9@^)?\
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M$[\=?^"&Z_\ C=+VD>X'#48XKNO^&7_B7_T3OQU_X(;K_P"(I/\ AE_XE_\
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M/B7_ -$[\=?^"&Z_^-TO:1[@<-1CBNZ_X9?^)?\ T3OQU_X(;K_XBD_X9?\
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MQU_X(;K_ .(H_P"&8/B7_P!$[\=?^"&Z_P#C=+VD>X'#48XKNO\ AE_XE_\
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M?^"&Z_\ B*3_ (9?^)?_ $3OQU_X(;K_ .-T_:1[AJ<,*.E=S_PR_P#$H?\
M-._'7_@ANO\ XBC_ (9@^)?_ $3OQU_X(;K_ .-TO:1[@<-1CBNZ_P"&7_B7
M_P!$[\=?^"&Z_P#B*3_AE_XE_P#1._'7_@ANO_C=/VD>X:G#"CI7<_\ #+_Q
M*'_-._'7_@ANO_B*/^&8/B7_ -$[\=?^"&Z_^-TO:1[@<-1CBNZ_X9?^)?\
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M&,44 %&.***  4=*,8HH *,<444  HZ48Q10 48XHHH !1THQBB@ HQQ110
M"CI1C%% !1CBBB@ %'2C&** "C'%%% ']D?_  3 _P"4:?[._P#V3+PW_P"F
MJVKW/I7AG_!,#_E&G^SQ_P!DS\-_^FJVKW.OS>M_$EZL[X["9HH_.BLQBU0U
M?1/[4U#2Y_,\O^S;IKG;MSYF898L9SQ_K,YY^[COD7Z* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_,/_@JI_P &X?\ P\T_:UO/BE_PN3_A"?M6F6FG?V9_PB7]I;?(4KO\[[;#
MG=GILX]37Z>45MA\14HRYZ3L_P"NY,HIZ,_#/_B"_P#^KDO_ #'W_P!\J4_\
M&7__ %<E_P"8^_\ OE7[ET5V_P!L8S^?\%_D3[*)^&G_ !!?_P#5R7_F/O\
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M^8^_^^5*?^#+_P#ZN2_\Q]_]\J_<NBC^V,9_/^"_R#V43\-/^(+_ /ZN2_\
M,??_ 'RI/^(+[/\ S<E_YC[_ .^5?N911_;&,_G_  7^0>RCV/PS_P"(+_\
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MY5^Y=%']L8S^?\%_D'LHGX:?\07_ /U<E_YC[_[Y4G_$%]G_ )N2_P#,??\
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ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 )FBC\Z* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\M_:3_:3_P"&>?[%_P")+_;']L>?_P OGV?RO+\O
M_8;.?,]L8[YKU*OEW_@I/_S)?_;]_P"V]?)<=9GB<OR.OC,'+EJ1Y;.R=KSB
MGHTULWT/H>%<#0QF:4L-B8\T)<UU=K:+:U33W0#_ (*3?]27_P"5?_[11_P\
MF_ZDO_RK_P#VBOERDK^>/^(F\2_]!/\ Y)3_ /D#]C_U'R3_ )\?^33_ /DC
MZD_X>3?]27_Y5_\ [32?\/)O^I+_ /*O_P#:*^7:*/\ B)G$O_03_P"24_\
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M)O$O_03_ .24_P#Y /\ 4?)/^?'_ )-/_P"2/J3_ (>3?]27_P"5?_[32?\
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M'R3_ )\?^33_ /DCZD_X>3?]27_Y5_\ [32?\/)O^I+_ /*O_P#:*^7:*/\
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M_P#*O_\ :*/^'DW_ %)?_E7_ /M%?+E)1_Q$WB7_ *"?_)*?_P @'^H^2?\
M/C_R:?\ \D?4G_#R;_J2_P#RK_\ VFD_X>3?]27_ .5?_P"T5\NT4?\ $3.)
M?^@G_P DI_\ R ?ZCY)_SX_\FG_\D?48_P""DW_4E_\ E7_^T4?\/)O^I+_\
MJ_\ ]HKY<I*/^(F\2_\ 03_Y)3_^0#_4?)/^?'_DT_\ Y(^I/^'DW_4E_P#E
M7_\ M-)_P\F_ZDO_ ,J__P!HKY=HH_XB9Q+_ -!/_DE/_P"0#_4?)/\ GQ_Y
M-/\ ^2/J,?\ !2;_ *DO_P J_P#]HH_X>3?]27_Y5_\ [17RY24?\1-XE_Z"
M?_)*?_R ?ZCY)_SX_P#)I_\ R1]2?\/)O^I+_P#*O_\ ::3_ (>3?]27_P"5
M?_[17R[11_Q$SB7_ *"?_)*?_P @'^H^2?\ /C_R:?\ \D?48_X*3?\ 4E_^
M5?\ ^T4?\/)O^I+_ /*O_P#:*^7*2C_B)O$O_03_ .24_P#Y /\ 4?)/^?'_
M )-/_P"2/J3_ (>3?]27_P"5?_[32?\ #R;_ *DO_P J_P#]HKY=HH_XB9Q+
M_P!!/_DE/_Y /]1\D_Y\?^33_P#DCZC'_!2;_J2__*O_ /:*/^'DW_4E_P#E
M7_\ M%?+E)1_Q$WB7_H)_P#)*?\ \@'^H^2?\^/_ ":?_P D?4G_  \F_P"I
M+_\ *O\ _::3_AY-_P!27_Y5_P#[17R[11_Q$SB7_H)_\DI__(!_J/DG_/C_
M ,FG_P#)'U&/^"DW_4E_^5?_ .T4?\/)O^I+_P#*O_\ :*^7*2C_ (B;Q+_T
M$_\ DE/_ .0#_4?)/^?'_DT__DCZD_X>3?\ 4E_^5?\ ^TTG_#R;_J2__*O_
M /:*^7:*/^(F<2_]!/\ Y)3_ /D _P!1\D_Y\?\ DT__ )(^HQ_P4F_ZDO\
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M_P"T5\NT4?\ $3.)?^@G_P DI_\ R ?ZCY)_SX_\FG_\D?48_P""DW_4E_\
ME7_^T4?\/)O^I+_\J_\ ]HKY<I*/^(F\2_\ 03_Y)3_^0#_4?)/^?'_DT_\
MY(^I/^'DW_4E_P#E7_\ M-)_P\F_ZDO_ ,J__P!HKY=HH_XB9Q+_ -!/_DE/
M_P"0#_4?)/\ GQ_Y-/\ ^2/J,?\ !2;_ *DO_P J_P#]HH_X>3?]27_Y5_\
M[17RY24?\1-XE_Z"?_)*?_R ?ZCY)_SX_P#)I_\ R1]2?\/)O^I+_P#*O_\
M::3_ (>3?]27_P"5?_[17R[11_Q$SB7_ *"?_)*?_P @'^H^2?\ /C_R:?\
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M\DI__(!_J/DG_/C_ ,FG_P#)'U&/^"DW_4E_^5?_ .T4?\/)O^I+_P#*O_\
M:*^7*2C_ (B;Q+_T$_\ DE/_ .0#_4?)/^?'_DT__DCZD_X>3?\ 4E_^5?\
M^TTG_#R;_J2__*O_ /:*^7:*/^(F<2_]!/\ Y)3_ /D _P!1\D_Y\?\ DT__
M )(^HQ_P4F_ZDO\ \J__ -HH_P"'DW_4E_\ E7_^T5\N4E'_ !$WB7_H)_\
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M?+E)1_Q$WB7_ *"?_)*?_P @'^H^2?\ /C_R:?\ \D?4G_#R;_J2_P#RK_\
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M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %?+O_!2;_F2_P#M^_\ ;>OJ*OES_@I-_P R7_V_?^V]?!^)
MO_)-8G_MS_TY ^LX'_Y'=#_M[_TB1\N]*#THI.U?R6?T(+11G-)0 O2@]**3
MM0 M%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<
MTE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE "]*#
MTHI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE "]*#THI.U "
MT49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE "]*#THI.U "T49S24
M+TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE "]*#THI.U "T49S24 +TH/2BD
M[4 +11G-)0 O2@]**3M0 M%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G
M-)0 O2@]**3M0 M%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@
M]**3M0 M%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0
MM%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE
M"]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0 M%&<TE "]*#THI
M.U "T49S24 +TH/2BD[4 +11G-)0!^COP._Y(KX/_P"P)9?^B$KJ37+? _\
MY(KX/_[ EE_Z(2NIK^X<J_W*C_@C^2/Y:Q_^]5/\3_-A1THHKO.0*#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@!,T4?G10 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_@3K_P#9_B_R2GC3Q-9/^_T174%;"UD'W+@J<R2+\T0954B3<8_S1_X(Z?\
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MGA/Q9#%!J,-K<M;3.L<T<R[9%Y7YXU/';(H _%[_ (CC]!_Z-OU?_P +:/\
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MEK_B./T'_HV_5_\ PMH__D*OD#_@\5_Y2\Q?]B+I7_HVZK[J_P""3G_!M/\
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M?#\_#Z#3YW>?7%U+[=]J:X4  01;-OV?WSN[8Y\J_P"#Q'_E$&O_ &/&E?\
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MUQXI\?>(#+=0I<2'>ZAB=]U=ONW; P^\"[(&!(!^D?QF_P"#X"\_MR>'X>_
M.V_LU.(;OQ%XB)GE]V@@BVI]!*WUK@/#O_![I\7K;4]VK?!7X;WUGGF*TU"]
MM9<?[[-(/_':_0K]F+_@TF_9'^!OA^W7Q;H/B/XL:V(U\^^U[6)[6 R<;C%;
MV;1*J$]%D,A _B)YKTKQW_P;,?L1^/K79-\$;'3)57:DVEZ]JEFR>^$N0C'_
M 'E- 'A'_!,C_@[(^'_[>_Q]\+_"WQ%\+?%7@'QEXQO!8:7+9ZA#K&F22[2P
M\V4K!+'D*<8B< ]3WK]5O&?B1/!O@_5M8DB:>/2;.:\:-3AI!&A<J#[[<5^3
M/P3_ .#3_P *_L?_ /!0[X9_&;X4_$G54\,^#=<&IWOAKQ%:K=7'EA'&V"[B
MV9P6 "R1YQR9"1S^I_QR_P"2*>,/^P)>_P#HAZ /R=_81_X.Y=&_;?\ VP/
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MULV/O5\T_P#!!#_E,=^SS_V-L'_H#T ?V@4444 %%%% !1110!_+!_P<&_\
M!2_]H?X$?\%A/C-X3\%_'#XJ>$_#&D76FK8Z5I/B>\L[.T#Z592.(XHY J[G
M=V.!R6)ZFOZ9?V7M>O/%7[,_P[U34KJ:]U#4O#&FW5U<3-NDGE>UB9W8]V9B
M23W)K^2O_@YD_P"4XGQX_P"OS2O_ $S6%?UD?L??\FD_"W_L4=)_](X: /1J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEW_@I-Q_PA?_;]_P"V
M]?45?+O_  4G_P"9+_[?O_;>O@_$W_DFL3_VY_Z<@?6<#_\ ([H?]O?^D2/E
MP4=J*2OY+/Z$%HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1V
MHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHH
MH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI*
M %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !
M1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %H
MHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VH
MI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH
M !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI*
M%HHHH _1SX'?\D5\'_\ 8$LO_1"5U-<M\#_^2*^#_P#L"67_ *(2NIK^X<J_
MW*C_ ((_DC^6L?\ [S4_Q/\ -A1117><@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 &**3./6B@!:.E%% !0:**
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MFSPEH/C&/2YC!)XQ\1-,VFW;@X?[+:Q-')(@_AF>50Q&0C+AF_ ?PMX_\7?
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M_P $1_A2=062/^T[K6+ZU1Q@K ^J704@>C;2X]0X/>OP$_X)T?\ !+'XZ_\
M!=W]K/5/&.M2:M'X:UC5VU3QGX]U*(K 3)(6ECMB1MFN",JD48V1X7=L0"OZ
MY_A+\*] ^!OPO\/^#?"NFP:/X;\+:=!I6F64(PEM;PH(XT'<X51R>2<DY)H
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M_"?XM74MU;QP1XAT'5CF2XLL#A(WYFB' VF1%&(<D _JVKRO]NGC]B3XQ_\
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M.NY(;ORPUY>A3_$B2QQ1MR 7G_B52/Z&C7Q'_P &Y7PSM/A;_P $7/@5:6L
MA;5-(GUJX;^*62[NY[@L3WXD4#T"@=J^W* "CI110 4&BB@ HZ444 %!HHH
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M5?'W_!CAQXY_:1_Z\/#W_HS4J^P/^#Q'G_@D&O\ V/&E?^B[JOC_ /X,;_\
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MO[/?Q.\%Z7]H^*_PE\%?:8HX(]T^O:0)99+BSP.7DC^::(<G(E11F7(^4_\
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MXX5&@'&10!^OU?.O_!5[]N:R_P""<_[ WQ#^*DTD!U71]/-KH-O+@B[U2?\
M=6B;?XE$C!W _P"6<;GM7T57\VO_  >7_P#!0;_A:7[1OA/]GO0;[S-'^&\*
MZYXB6-_EEU:YB_<1L/6"U?<#ZWK@_=H ^5?^#>S]BS4/V^/^"B=WXT\3+<ZM
MX?\ A7:7/CWQ!=W!,GVZ^0L]G&['[SR76)2&SO2"45YG_P $$./^"QO[//\
MV-L'_H$E?O\ ?\&Z/_!/[_AB7_@CC>:]J]C]E\:?&/2Y_%>J%TVRPVCVSC3[
M<]\+;GS<$95[J0=J_ '_ (((?\IC?V>?^QM@_P#0)* /[0*XW]H#]H'P;^RS
M\(-<\>?$#Q!I_A?PGX=MS<W^H7C[4B7H%4#+/(S$*J*"SLP5020*[*OY</\
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MO@6^TVZMOLL4]OH\%I?:>O\ "UM<1*LL#+V*,/0Y!((!\M_\$9O^#CKX:_\
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M6-O<L6",%&&F*C Z**_<"OX\?^#F3_E.)\>/^OS2O_3-84 ?ME_P4N_X.E/
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MQT?Q'HTDBZ/>73D+';SPRL[V[.Q"K)YCH68 A!\Q_:8U_%;_ ,%F/^">S_\
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M>E%)VH 6BC.:2@!>E!Z44G:@!:*,YI* %Z4'I12=J %HHSFDH 7I0>E%)VH
M6BC.:2@!>E!Z44G:@!:*,YI* %Z4'I12=J %HHSFDH 7I0>E%)VH 6BC.:2@
M!>E!Z44G:@!:*,YI* %Z4'I12=J %HHSFDH 7I0>E%)VH 6BC.:2@!>E!Z44
MG:@!:*,YI* %Z4'I12=J %HHSFDH 7I0>E%)VH 6BC.:2@!>E!Z44G:@!:*,
MYI* %Z4'I12=J %HHSFDH 7I0>E%)VH 6BC.:2@!>E!Z44G:@!:*,YI* %Z4
M'I12=J %HHSFDH 7I0>E%)VH 6BC.:2@!>E!Z44G:@!:*,YI* %Z4'I12=J
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MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH 3-%'YT4 +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q,?MC>%K?QS_ ,%A
M?BIHEWG[+K'QCU:QFQUV2ZW,C?HQK^V>OXJ_VD/^4V_CW_LN&H?^GZ2@#^U-
M$"*%4!57@ #I2T44 ?Q%_M _#C3M>_X*Q^-O"+1^7I-Y\6[_ $=D ^[ ^L21
M8_[Y-?VYJH1< 8"C  [5_%9\8O\ E-MXJ_[+A=_^GYZ_M4H *_BFURS70O\
M@M1>6]M^[CL_C8\<07C8%UT@8^F!7]K-?Q5^-.?^"VVK?]EPF_\ 3\U ']BG
M[6'@:;XG_LL_$OPS;PM<7'B+PKJFF1Q*,M*TUI+&% ]26Q7\;?\ P1M^+5G\
M#?\ @JI\ O$FI2?9]/M/&NGVUU*3@017$HMG=O\ 95923[ U_;)7\7__  7
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M^R9XO^$_C*(#3?$MJ1:WJQAYM)O$^:WNXL_QQR -C(#+N0_*Q!\C_P"" O\
MRAL_9[_[%:/_ -&R5]@T ?Q6_";XA?%C_@A!_P %/UNKFU:Q\;?"K6FL=7T\
MR,MKKMBV/,BSCYH+FW8.CXX#QR !E&/ZP/B/^TGX3_;"_P""4'C;XF>![\:E
MX7\9?#?5]0LI>!)&&L)P\4@!.V6-PT;KGY71AVKX%_X.S?\ @D3_ ,-1_L_K
M^T'X%TOS?'WPPLF3Q!;V\?[S6=#4EVD('WI+4EI >IB:4$G8BU^;?_! #_@K
M0WP ^$?QB_9M\;:EL\&_$_PMK+>%9YW^32M<>PE06X)^['=@*H':98\#]ZYH
M \=_X-I?^4W_ ,!_^O\ U/\ ]-%]7]B5?QV_\&TW_*;_ . __7_J7_IHOJ_L
M2H _E9_X/%?^4O,7_8C:5_Z-NJ_6C_@B?_P2M_9L^,O_  2H^!_BGQ9\"_A=
MXD\2:WX<2YU#4]1\.VUQ=7DIED!>21D+,V !DGM7Y+_\'BO_ "EYB_[$72O_
M $;=5^\O_! 7_E#9^SW_ -BK'_Z-EH S_B]_P;R?L:_&?09K&^^!/A'1VE4A
M+K0/.T>X@;LRFV= 2/1@R^H(XK^=S_@O?_P10O?^".?QR\.W_A?7-3U[X9^-
MC-+X>U&[*KJ&F7,!0R6L[1A59U#HZ2JJ;P3\H*,3_7I7X5_\'N/QZT&#X(_!
MGX8I=V4WB>[UVX\3S6RN&N+2TBMWMD=EZJDLD[A2?O&W;'W30!]2?\&MO_!2
MWQ'_ ,%!/V"K[1_'6J7&M>//A-J$>B7NI7$GF7.J6,D>^SN)F/+2X6:)F/+^
M0&)+,QK\<_\ @[Q\"S>$?^"R.M:A)"\4?BCPKI&IPNPP)E6)[0L/7YK9E^JF
MOMC_ (,<_!6H6/P]_:.\121S+I6J:CH&G6[D?NWGMX]0DE /]X+=0D^S"M__
M (/1_P!A:^^('P2^'_Q^T6W:8^ 97\.>(PB99+&ZD#6LY/9([C?&?5KQ/0T
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M\,R*YW^3%?.MH0W7.U8SGKFO[E/B)X#T[XJ?#S7/#&M0_:-)\2:=<:7?1?\
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M/=8AUKPOXGM5N;>5&'F6[X^>"903Y<T;91T/*LI'O0!Z)1110 4444 %%%%
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M!))=NH6NH:5KT,9/^MBDCG@D9?\ =:*('_KHM?H]_P %[/V&;W_@H)_P2_\
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M_P &TW_*;_X#_P#7_J?_ *:+ZO[$J "BBB@ HHHH Y7XX_\ )%/&'_8$O?\
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M8<&@#];/BE:0Z?\ !SQ';V\4<$$&C7,<<<:A4C40, H X  XP*_CE_X((_\
M*8[]GK_L;8/_ $!Z_L>^+W_))_%'_8)N_P#T2]?QP_\ !!#_ )3'?L\_]C;!
M_P"@/0!_:!7\)W[47Q*NO'?[87Q$\87RQZC>:QXQU+5YUNU+I<O)>R2L)!P2
M&)P1QP37]V-?P^_ME>#KO]DO_@I=\2-)OK*&ZF\"?$.^86\\0:&[C@OW>/*,
M"#')&%.",%7YH ^YD_X/(OVMHD55TKX.JJC  \.W( '_ (%T?\1DO[6__0+^
M#W_A/77_ ,EU_1Q\)O@W\"?CG\+_  _XR\*^ _AKK'AOQ3I\&J:9>P^';,I<
MV\R!XW'[OC*L,@\@Y!P170_\,C_"C_HF/P]_\)RS_P#C= '\8W_!1[_@I#X_
M_P""HWQXL?B-\2+3PS9^(;#18="4:'9/:020133RHSJ\DA,F9V!;(&U5&.,G
M^HC_ (-C=9EUW_@AK\"9IB2T=OK%N,G/RQ:WJ$2_^.H*^L?^&1_A1_T3'X>_
M^$Y9_P#QNNS\,>%=+\$Z%;Z7HNFV&D:9:@B"TLK=+>"$$ECM1 %7+$G@=230
M!_(#_P ',G'_  7$^/'_ %^:5_Z9K"OZR/V/O^32OA;_ -BCI/\ Z1PU_)O_
M ,',G_*<3X\?]?FE?^F:PK^LC]C[_DTGX6_]BCI/_I'#0!Y7_P %-/\ @K/\
M(?\ @E+\*K?Q%\2M4N;C5-6+)HWAS2E2;5M89?O&.-F55B3(W2NRHN0,EF56
M_$7]H;_@]<^-'BG6;J+X8_"_X>^#](9R()-<:YUF_"]F+))!$&/7!C8#IDXR
M?C7_ (.*OVF=9_:;_P""OWQBFU.^:ZL?!.L2>#=)@S^[L;:P9H6C0?[4XGD/
MJTK'@8 _I._X)C?\$0?@7_P3U^"'AFTM? /AKQ!\0H[&&36_%6K:?'>ZA=WA
M4-*8GDW?9X@Q(6.+:-JKNW-ER ?@>W_!>#_@I)^UX3%X+UGQS>6MS]RW\%>
M(9<Y_NR16LDWY25\(Z._BEOVR[5O'$>K0^-3XT0Z_'JL3PW\>H?;A]I$Z, R
MS";>'5@"&R" :_NFU+4K70=+N+R\N+>SLK.)IIYYG$<4$:C+,S'A54 DD\ "
MOX@?BM\6+?X]?\%,O$GCJU96M?&GQ.NM=A*_=*76JO.N/;#B@#^X:OX\?^#F
M3_E.)\>/^OS2O_3-85_8=7\>/_!S)_RG#^/'_7YI7_IFL* /ZL?^"?W@RU^'
M7["'P5T"Q7;9Z-X$T2SAXY*QV$"@GW.,GW->NUYS^Q__ ,FE?"W_ +%'2?\
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M6+QMX19-FDWGQ;O]'*#^&!M8DBQ_WR:_MTK^*OXQ?\IM?%7_ &7"[_\ 3\]
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M\)7?ANU65PIN)]13[$J(#]YL3EL#G"$] :_GI_X-+O\ E-1X(_[ 6M?^D,E
M']:5%%% !1110 4444 %%%% !1110 5\N_\ !2;C_A"_^W[_ -MZ^HJ^7?\
M@I/_ ,R7_P!OW_MO7P?B;_R36)_[<_\ 3D#ZS@?_ )'=#_M[_P!(D?+@H[44
ME?R6?T(+1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +
M1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM
M124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +111
M0 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124
M +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "
MCM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1
M110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM1
M24 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110
M!^CGP._Y(KX/_P"P)9?^B$KJ:Y;X'_\ )%?!_P#V!++_ -$)74U_<.5?[E1_
MP1_)'\M8_P#WFI_B?YL****[SD"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB[XXW_Q(U#X/K<>,]4UV3Q+<ZA_PE6MJ)=0DN#</-Y2W@B&926V! G.-N.*
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M[X=V>D2/H'P'\::E?X^2+4-?MK&$GWD2.8C_ +X-?(?Q)_X.J/VE/VU_VBO
M/A?PZ^C_  C\(:EXJTV">R\.J\NHWT+7<0,4UY+EBIS@B%(=P)# @D5^GO@C
M_@S^_8[\*LOV^S^)7B;;U&I>)O+W?7[-%#^E?8_[('_!*G]GG]@Z*-OA9\*/
M"OAO48QM_M=H#?:LP/4&\N#)/@_W0X7VH ^@J_C9_P"#BS_E-7\?O^PW;_\
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MV<?!,7AOX?\ @_PSX)\/PL773]#TV&PM]QZN4B506/=CDGN30!Y!_P $J/\
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ML:;\']/\1ZI;X\N7Q1?7&M0J1SG[/.[6Y/?)CR,<8H R/^#:3]IWX@?M??\
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M01'<(,C<I!*.F1O1V&5.UE^C** /XH/VMOV)/C]_P1?_ &J+)=?M]<\'>(=
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M1YD;J59<C!Y!(XYKY!_9O_X-_P#]D?\ 9'^-F@?$;X>_"7_A'_&7A>5Y],U
M^*-9N_LSO&\3'RI[MXFRCL/F0XSD<@&@#[(KY)_X+?\ [ <?_!1[_@F_X^\
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M:^"?^"QW_!U'XN_X*!_"C5/A;\+/#%Y\-?A[KJ&WUJ]O+I9M:UVW.<VY\O\
M=V\+C =$9V<#:7"%D;],=4_X,XOV1;_5/M$-Y\7+&+.?LT'B*!HA[9>U9_\
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M_-A1THHKO.0*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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MWWGQTJ3C",WUO^!]^_\ !!K_ )'3XD?]>5C_ .C)J_2:OS9_X(-?\CI\2/\
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M .C5K^@FOY]OAM_R470/^PE;_P#HU:_H)KP_$+XZ'I+]#NX=^&?R_4*_'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF^,+KQYK/CR\M9;K4[C2ET]H+>V1Q% J"63(#S3,6W#.\#'R@G[@HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *_,7Q#_P;4>'_ !Y_P5N_X:H\3?%;5-=D7Q;%XK3PO-H$
M:Q*]N%^RP&Y\\DI$T4."8OF6, CG-?IU10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH !1VHI* %HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*G&&_D?TKU8'(_E38!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ,44F<>M% "T=*** "@T44 %'2BB@#\=_^"O7_
M "?5XD_Z\[#_ -)HZXG_ ()Z_P#)ZOPW_P"PNG_H+5VW_!7OC]NKQ)_UYV/_
M *2QUQ/_  3T_P"3UOAQ_P!AA/\ T%J_<<-_R(H_]>O_ &T^%J_[^_\ '^I[
M-_P6L^"/_""?M&:?XOMH=MCXUL@9F X^UVX6-_89C,)]SN-?*?PL^(-Y\)OB
M3H/B;3S_ *;H-_#?Q#. YC<-M/LV"#Z@FOUN_P""L/P1_P"%Q?L?ZS=6\/F:
MEX/D77+<@?,8XP5G&?3R6=L=S&M?CCVKFX3QBQ>6*G/5Q]U^G3\-#3-Z+HXI
MRCUU7]>I^['QK_:*TWX>_LJ:Q\2K*9);-=$74=-9ONS/,B_9@?\ >DDC'XU^
M%MW>2ZA=2W$\CS33N9)'<[F=B<DD^I-?37Q8_:H?Q-_P3/\ ASX#2Y9KZ#6[
MNVOOF^8V]IMDA5A_=Q=Q8_ZX>QKP7X._#:[^,7Q6\.^%;'(NM?U"&R5P,^4'
M<!G/LJY8^P-3PSE:RZC6G4_F>O\ =C=)_FRLTQ3Q,X1CV7WO^D?H=^RA\%/^
M%5?\$C?B#JUQ#Y>I>-/#VJZM(6'S"#[+)' N?0HOF#_KJ:_,S'%?N7^U-X>M
M/"/[$?C_ $G3X5@L-+\&7UI;1#I'%'9NBK^"@#\*_#/M6/!^+EBOK&(E]J=_
MPT7R6A><452]G371'W]_P0;_ .1T^(__ %Y6/_HR:OI#_@KI<S0?L)>*EB^Y
M-<V"2^R_:XF_]""U\W_\$&_^1T^)'_7E8_\ HR:OKK_@HSX%G^(O[$WQ"T^V
M7=-#IRZ@!C)(M98[E@/<K$1^-?,9U44.)(RELI4_RB>I@8N66M+M+]3\2*_0
M[_@@E%#]I^*3G_7JNE*O^Z3>9_4#]*_/$U]<_P#!&KXWVOPP_:@FT'4)E@L_
M&UD;")F;:HNT;S(<_P"\/,0>K2*.]?><449U<KK0AO9/[FF_P1X&5U%#%0<O
MZNK'ZSS_ .I?Z&OYX.U?T0LNY2OK7R9_PY>^"_\ <\5?^#0?_$5^=\)Y[ALN
M]K]8O[W+:ROM>_7S/H\VP-7$\GL[:7W\['Y(48XKZ?\ ^"H'[)?A/]DKXA>&
M--\)#4A:ZMITES/]LN?.;>LA48.!@8KY?[5^KX'&4\70CB*5^66U]^Q\E7HR
MHU'3GNC]TOV9KR33_P!BKX?7$*[IH?!.G21@=V%A&1^M?A?G-?NY^R*@D_9)
M^&"L-RMX1TH$'N/L<5?AY\2/!=Q\-_B)KWAZ\&VZT+4)]/E_WHI&0_\ H-?$
M\%37UG%PZW3_ !D>YG<7[*D_+_(]K_X)5QPR?M[> ?.^Z'OBN?[PL+DK^N*_
M9[I7X&_L]_%>3X'?'#PKXNC225=!U*&ZEC0X::(-B5 ?]J,LOXU^\7A;Q/I_
MC7PW8:QI5U#?:;JD"75K<1-N2:-P&5@?<&O+X_P\UBJ=?[+C;YIM_J=7#]1>
MRE#K>_WI?Y&A0:**^!/H K\1?^"BTKS?MM_$9I!AO[5*_@(T _0"OVZK\7?^
M"I7AZ3PY^W5XZ61<)>2VUW&?[RO:PG_T+</J#7W7 ,E]>FO[GZH\'B!?N(OS
M_1G!_L?JK?M9_"\-]W_A+-*_]+(J_=XU^ GP/\41^"/C5X/UJ1O+CTC6[*]=
MO[HCG1R?PVU^_=='B#%^WHRZ6?YK_,SX>E[DUYH\ _X*D;?^&#?B!NZ>1:?G
M]MM\5^+>.*_87_@L!XHC\/\ [#>OVK-M?6KZQLH_]HB=9R/^^86_*OQY[5[?
M <6LOD^\W^43AS^2>(2\E^;/TL_X(/)(/AY\0F/^J;4;0+_O>5)G^:U]\&OB
MO_@ASX4DTK]FCQ%JT@*_VMX@=(QCJD4$0S_WTSC_ (#7VI7P/%$U+-:S7=+[
MDD?097&V$@O+]0K\?_\ @L3_ ,GOZQ_V#;+_ -$BOV K\?\ _@L3_P GOZQ_
MV#;'_P!$BO5X$_Y&+_PO\T<N??[LO5?J?.WPW_Y*+X?_ .PC;_\ HU:_H)-?
MS[?#?_DHN@?]A*W_ /1JU_037I>(7QT/27Z'+P[\,_E^H5XI^VG^V;X._9*\
M";O$$*ZYJ6L1M'::$A7S+Y#D,9-P(6'J"S YZ ,<BO:Z_"7]KKXW7W[0O[1'
MBCQ/>2;H[J\>"S0-E8+6,E(4'_  "?5BQ[UX'"V21S'$OVOP0LW;K?9>77[C
MT,UQSP]+W=WL<O\ %3QE8_$'X@ZGK&F^']-\*V-_-YL6EV#.;>U''"[R3SU(
M&%R3A5& .?[5] ?\$V?V6-/_ &K?VBX]+US>WAW0[1]5U&)69#=JKHB0AEP5
MW,X)((.U6P0<&OV T7X1>%?#OA==%L?#>A6NCH@C^QQV,8A*@8&5Q@_4U]_G
M7%%'*ZD<+&#DTE?6UETU=VW_ %<^?P65U,5%U7*R]/\ AC\"="U--%UNSO)+
M.UU".UF29K6Z#&&X"D'8X5E;:<8(!!P3R*_7#_@GI_P4(\'_ +1.CV_@]='T
MWP/XBTR#;:Z1;$+9W<2C)-MP,8Y)C(R!R"P#$?)G_!7/]C/0?V>/%^A^*?"-
MG'I>A^*&EAN-/B!$-I=)ALQCHJ.K'Y!PI0XX( ^3/ WC34?ASXQTO7M(N&M=
M4T>ZCO+64?P2(P9?J..1T(R*TQF#PV?8"-:%T[/E?9[--;;_ / 9-&M5R_$.
M$OGYKR/Z#J#6!\*_'"?$WX8>'/$D:+''X@TNVU)44[@@FB63&?;=C\*WZ_%Y
MQ<9.,MT?:QDFKH*.E%%2,*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %?./_!0+P/K7C/_
M (1+^Q]'U35OLWVSS?L=I)/Y6[R-N[:#C.TXSUP?2OHZBO%XBR6&;9?4R^I)
MQ4[:K=6DI?H>ID^9RR_&0QD(\SC?1^::_4_./_A1_C4?\R?XH_\ !5/_ /$4
M'X'^-O\ H3_%'_@JG_\ B:_1RBOS#_B"^"_Z"9_<C[G_ (B9BO\ GS'[V?G'
M_P *.\:_]"?XI_\ !5/_ /$T?\*/\:?]"?XH_P#!3/\ _$U^CE%'_$%\%_T$
MS^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\ P53_ /Q%!^!_C;_H3_%'_@JG
M_P#B:_1RBC_B"^"_Z"9_<@_XB9BO^?,?O9^<?_"CO&O_ $)_BG_P53__ !-'
M_"C_ !I_T)_BC_P4S_\ Q-?HY11_Q!?!?]!,_N0?\1,Q7_/F/WL_./\ X4?X
MU'_,G^*/_!5/_P#$4'X'^-O^A/\ %'_@JG_^)K]'**/^(+X+_H)G]R#_ (B9
MBO\ GS'[V?G'_P *.\:_]"?XI_\ !5/_ /$T?\*/\:?]"?XH_P#!3/\ _$U^
MCE%'_$%\%_T$S^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\ P53_ /Q%!^!_
MC;_H3_%'_@JG_P#B:_1RBC_B"^"_Z"9_<@_XB9BO^?,?O9^<?_"CO&O_ $)_
MBG_P53__ !-'_"C_ !I_T)_BC_P4S_\ Q-?HY11_Q!?!?]!,_N0?\1,Q7_/F
M/WL_./\ X4?XU'_,G^*/_!5/_P#$4'X'^-O^A/\ %'_@JG_^)K]'**/^(+X+
M_H)G]R#_ (B9BO\ GS'[V?G'_P *.\:_]"?XI_\ !5/_ /$T?\*/\:?]"?XH
M_P#!3/\ _$U^CE%'_$%\%_T$S^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\
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M_P#!3/\ _$U^CE%'_$%\%_T$S^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\
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M_P#!3/\ _$U^CE%'_$%\%_T$S^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\
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M_P#!3/\ _$U^CE%'_$%\%_T$S^Y!_P 1,Q7_ #YC][/SC_X4?XU'_,G^*/\
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 ?*_P"W7^R)_P )'#<>-O#-J/[0B!DU2TC'
M_'RHZS(!_&.2W]X#/7.:7["7[7/VI;7P+XFN-LR@1:3>2M]_L+=R>_0)_P!\
M_P!T5]:U\4?MQ?LEOX$U&;QMX7@,>E32"2_MHA@V,I;_ %B =(V)Z#[IZ<$
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M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 )FBC\Z* %HHHH ****
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M5O/W5\]_PT^9XN38?VF)3>T=?\CTK]LO_DT;XG_]BKJ7_I+)7X2U^[7[9?\
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M3+ @D'X-D5W5%%?A]:HZDW4ENVW]Y]U&/+%170****S*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%P-3$0K-RA%O96T5_5?>?;]%%8/Q"^)NA_"S1X[_ %Z^2QMI)!%&Q1G+M@G
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M)   ))( YKQP?\%,O@F?^9S7_P %EW_\:K]$Q>:8+"R4,36C!O5*4DG;YL^
MPN68S$Q<\/2E-+2\8MJ_R1[S17@W_#S'X)_]#FO_ (++O_XU7I/P:^//A/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX9"^$W_1+_AW_P"$W9__ !NN_L;&'2[&&UMH8K>VMT6***) B1(HP%51P
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M9KGK991K.]7'1EZ\S_,TIXJ</@H->EC]$J#7YV_\.\_VLO\ HN7_ )>>L?\
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M9)KUF91FD[K#?@C]"M+TFUT.PBM+*UM[.UA&V.&",1QQCT"C 'X58Z5^=O\
MP[S_ &LS_P UR_\ +SUG_P",T?\ #O+]K/\ Z+E_Y>>L_P#QFN#^Q,(]7C(?
MB;_7JW_/F7X'Z >*_!ND>/-&DT[7-+T[6-/F^_;7ULEQ"_U5P1^E>,ZS_P $
MR/@5KET9IOA[IT;L2<6]Y=6ZY/\ LQRJOX8KYE_X=Y_M9?\ 1<O_ "\]8_\
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M=RN#R"#W!HN)X[2"265TCBC4N[NVU5 Y))[ >M #Z#61_P )]H7_ $&M)_\
M R/_ !H_X3[0?^@UI/\ X&1_XT :]'2H;#4(-4M5GM9H;B&3.V2)PZ-@X.".
M.H(_"IJ "@UD?\)]H7_0:TG_ ,#(_P#&C_A/M!_Z#6D_^!D?^- &O1TJOIFK
MVNM0&6SNK>[B5MA>&02*#P<9!Z\C\ZL4 %!K+N/&VBVD\D,NKZ7'+&Q5T>Z1
M60C@@C/!%,_X3[0?^@UI/_@9'_C0!KT=*IZ5K]CKGF?8KVTO/*QO\B99-F<X
MS@G&<'\JN4 %!K.O_%^DZ7=/;W6J:?;SQXW1RW*(ZY&1D$YZ<U#_ ,)]H/\
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M@#7HZ5D_\)]H7_0:TG_P,C_QJ[IFKVFM0-+9W5O=Q*VPO#*)%#<'&1WY'YT
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M:0X1([E&9C[ ')K2H *.E5=3UNST2-6O+RULUD.%::58PQ]LFJ7_  GV@_\
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MDCS(9 ZDCKR*GH *#63)XZT2*1D;6-*5E)!!NXP0?IFD_P"$^T'_ *#6D_\
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M_P#01G\J_0?&C-I0P%'**&LZ\E=>46K+YR:MZ,^4\.<!&6*J8^K\-*._F_\
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MI9_^ED%?F!^S_P#!^;X^?%[1?"-O>PZ?-K$CQI<2H72/;&S\@<\[<?C7Z?\
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ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 F:*/SHH 6BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#C_ (\_#"3XR_"C5O#4=XFGOJ7DXG>/S FR9)/NY&<[,=>]?./_  ["OO\
MH<+3_P %S?\ QROKZB@#Y"_X=A7W_0X6O_@N;_XY7U+\/?##>"/ .AZ*TRW#
M:/I\%D90NT2F.-4W8YQG;G%;%% &/\0?##>-_ 6N:*LRV[:QI]Q9"4KN$1DC
M9-V,C.-V<9KY9_X=A7W_ $.%I_X+F_\ CE?7U% 'R%_P["OO^APM?_!<W_QR
MOI/X)_#N3X3?"[2/#LETMZ^EQM&9U0H),NS="3C[V.O:NJHH *^0?^'85]_T
M.%I_X+F_^.5]?44 ?(7_  ["OO\ H<+7_P %S?\ QRO?/V:O@G-\ _AW)H<V
MH1ZDS7DET)DB,8PRH,8)/3;ZUZ#10 5\J>,O^"<%YXI\7ZMJB^++6%=1O)KH
M1FP9B@=RV,^9SC-?5=% 'R%_P["OO^APM?\ P7-_\<KVG]EK]G6?]G70M6LI
MM4AU7^TITG#I 8MF%*XP2<_6O5** "OFOXV?L$7?Q9^*.K^(H_$UO91ZG(CB
M!K)I&CQ&J8W;QG[N>E?2E% 'R%_P["OO^APM?_!<W_QRO4OV6OV3;G]G7Q#J
ME[-K4.JKJ5NL 5+8PF,JV<\L<U[710 5\^_M&?L2W/QT^)4GB"'Q%!IRR6\<
M)@>S,A!0$9W!QU^E?05% 'R%_P .PK[_ *'"U_\ !<W_ ,<KT']FG]B^Y^ 7
MQ#DUR;Q!!J:O9R6HA2T,1!9D.<ESTV^G>O?** "O%?VI?V3)_P!HG7=*O8=<
MATO^S;=X&1[4S;\MNR"&'Y8KVJB@#Y"_X=A7W_0X6O\ X+F_^.5U/P2_8(N_
MA+\4=(\12>)K>^CTR1W,"V3(9,HRXW%SC[WI7TI10 5Y-^U1^S7/^T98:+!#
MJT.E?V5)+(S/;F;S-X08&&&,;:]9HH ^0O\ AV%??]#A:_\ @N;_ ..5I>#?
M^"<%YX6\7Z5JC>++69=-O(;HQBP8%PCAL ^9WQBOJNB@ KSW]I7X)R_'SX=Q
MZ'#J$>FLMY'=&9XC*,*KC& 1UW>O:O0J* /D+_AV%??]#A:_^"YO_CE'_#L.
M^_Z'"T_\%S?_ !ROKVB@ KE?C7\.I/BS\+M7\.QW2V4FIQJ@G9#((\.K=,C/
MW?6NJHH ^0O^'85]_P!#A:_^"YO_ (Y1_P .P[[_ *'"T_\ !<W_ ,<KZ]HH
M Q_A]X8;P1X"T/16F6X;2-/@LC*%VB4QQJFX#MG;G%'Q"\+MXW\ ZYHJS"W;
M5]/GLA*5W"(R1LF['&<9SC-;%% 'R%_P["OO^APM?_!<W_QRC_AV'??]#A:?
M^"YO_CE?7M% '*_!3X=R?";X7:3X=DNDO9-,C=#.J;!)EV;.W)Q]['6NJHHH
M ^0O^'85]_T.%K_X+F_^.4?\.P[[_H<+3_P7-_\ '*^O:* //?V:O@G-\ _A
MW)H4VH1ZDS7DET)DA,0PRH,8R>FWU[UZ%110!\J>,O\ @G!>>*?%^K:HOBRV
MA74KR:Z$9L&)0.[-@G?SC.,UF_\ #L.^_P"APM/_  7-_P#'*^O:* /)OV5_
MV;+C]G.PUJ";5H=5_M62*162W,/E[ PQ@L<YW5ZS110!\U_&S]@BZ^+7Q1U?
MQ%'XFM[%-3D1Q UD7,>(U3&=XS]WTKEO^'8=]_T.%I_X+F_^.5]>T4 >)_LM
M_LFW/[.OB'5+V;6H-574K=8 J6QA,95MV?O'->V444 >!_M*_L7W/Q]^(<>N
M0^((=,5;..U,+VAE.59SG(8==WIVKS[_ (=AWW_0X6G_ (+F_P#CE?7M% 'S
MY^SK^Q-=_ KXF0Z_)X@M]22."6 PK:&(_.,9SN/3TQ7T'110!XK^U+^R9/\
MM%:[I5]#KD6E?V= \#(]J9=^6SG(85Y9_P .P[[_ *'"T_\ !<W_ ,<KZ]HH
M ^:_@G^P1=_"7XI:3XBD\36]\FF2.Y@6R*&3,;+UWG'WO3M7TI110!Y;^U)^
MSI-^T5X?TNSAU:/2FTVX:<L]N9A(&7;CAAC%>*?\.P[[_H<+3_P7-_\ '*^O
M:* /E3P;_P $X+WPMXPTK4V\66LRZ=>0W1C%@P+A'#8!\SC.,5]5T44 >>_M
M*_!.;X^?#N/0X=0CTUEO([HS/"9!A5<8P".N[U[5X)_P[#OO^APM/_!<W_QR
MOKVB@#Y!_P"'8=]G_D<+/_P7-_\ '*^N+"U^PV,,.[=Y,:INQC.!C^E344 <
MK\:_AU)\6?A=J_AV.Z6QDU2-4$[)O$>'5LXR,_=QUKYL_P"'8=]_T.%I_P""
MYO\ XY7U[10!\@_\.P[[/_(X6?\ X+F_^.5]3?#[PNW@CP#H>BM,+AM'T^"R
M,H7:)3'&J;@.<9VYQFMBB@#-\8Z$WBGPAJNF+(L+:C9S6HD(R$+H5SCOC-?*
MG_#L.^_Z'"T_\%S?_'*^O:* /D'_ (=AWV?^1PL__!<W_P <KZ.^ WPPD^#/
MPHTKPW)>+J$FF^=F=8S&)-\SR?=R<8WXZ]J["B@ KY"_X=AWW_0X6G_@N;_X
MY7U[10!\@_\ #L.^S_R.%G_X+F_^.5[Y^S5\$IO@%\.Y-#FU"/4F:\DNA,D1
MC&&5!C!)Z;?7O7H5% !7RS\0O^"=5YXW\?:YK2^*K6W76-0GO1$U@S&(22,^
MW.\9QNQG%?4U% 'R#_P[#OL_\CA9_P#@N;_XY7LO[*_[-<_[.5AK4$VK1:M_
M:LD4BLD!B\O8'&.6.<[OTKUFB@ KYK^-G[!%W\6OBCJ_B*/Q-;V4>J2(X@>R
M9S'A%7KO&?N^E?2E% 'R#_P[#OL_\CA9_P#@N;_XY7IW[+O[(=S^SOXNU#4Y
MM<AU1;ZS^RB-+8Q%#O5LY+'/W>E>X44 %>!_M*_L7W/Q]^(<>N0^((--5;..
MU\E[0RG*LYSD..N[T[5[Y10!\@_\.P[[/_(X6?\ X+F_^.5W?[.O[$MW\"OB
M7#K\OB"WU*.."2 PK:-$WSC&<[CTQTQ7T'10 5XK^U+^R;<?M%:[I5[#KD.E
M?V= \!1[4R[\MNSD,/RQ7M5% 'R#_P .P[[/_(X6?_@N;_XY72?"/_@G]>?#
M#XE:/K[>)K6\72[@3F$63(9!R,!MYQU]*^FJ* "O+?VI/V=)OVBO#VEV<.K1
MZ4VFW#3;GMS,) RXQPPQ7J5% 'R#_P .P[[/_(X6?_@N;_XY6GX,_P""<%YX
M5\7Z5JC>++69=-O(;HQBP8%PCAL ^9WQ7U710 5PO[1?P<D^.OPTFT"+4$TV
M22>.<3/"91\ASC&1US7=44 ?(/\ P[#OL_\ (X6?_@N;_P".4?\ #L*^_P"A
MPM/_  7-_P#'*^OJ* (;"U^PV,,.[=Y**F[&,X&*YOXU_#J3XL_"[5_#L5TM
MC)JD:H)V0N(\.K9QD9^[ZUU5% 'R#_P[#OL_\CA9_P#@N;_XY1_P["OO^APM
M/_!<W_QROKZB@#'^'OA=O!'@+0]%:9;AM'T^"R,H7:)3'&J;L=L[<XJ;QCH3
M>*/"&JZ8LBPMJ-G-:B0C(0NA7..^,UI44 ?(/_#L.^S_ ,CA9_\ @N;_ ..4
M?\.PK[_H<+3_ ,%S?_'*^OJ* ./^ WPPD^#7PHTKPW)>+J#Z;YV9UC\L2;YG
MD^[DXQOQU[5V%%% 'R#_ ,.P[[/_ ".%G_X+F_\ CE'_  ["OO\ H<+3_P %
MS?\ QROKZB@#SC]F'X$3?L]^ KS19M2CU1KK4'O1*D)B"AHXTVX)/_//.?>O
M1Z** /EGX@_\$ZKSQOX^US6E\56MNNL:A/>B)K!F,0DD9]N=XSC=C/M6/_P[
M"OO^APM/_!<W_P <KZ^HH \F_97_ &:Y_P!G*PUJ&;5H=6_M62*162W,/E[
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M\@S*FP28).<<XZ^M;&OZ7_;FA7UCYGE?;()(-^W=LW*5SCC.,]*N44 ?(/\
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M'UGK4.O0:6MKIZ61B>U,I8K)*^[(8?\ /3&,=J\W_P"'85]_T.%I_P""YO\
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M_'*]Q_9=_9_F_9X\(:AI<VJ1ZHU]>?:A(D!B"#8JXP6.?NUZ910 5\S?%_\
MX)^W?Q-^)>L:_'XHM[2/5)S.(6L6=H\@#&=XST]*^F:* /D+_AV%??\ 0X6O
M_@N;_P".5ZS^RO\ LKW'[.5]K4TVM0ZM_:L<2!4MC%Y>PN>I8YSN_2O9** "
MOG?]H+]AR[^-OQ1OO$4?B*WT^.ZCB00-9M(R[$5<[MXZXSTKZ(HH ^0O^'85
M]_T.%K_X+F_^.5Z/^S#^QS<_L]^/KS6IM>AU1;K3WLA$EJ8BI:2-]V2Q_P">
M>,8[U[M10 5X?^U#^R)<_M#^+]/U.'7(=+6QL_LIC>U,Q<[V;.0PQ]ZO<**
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M_57OB!_W^_\ LJ^P** /C_\ X=-?]5>^('_?W_[*O3OV6_V*$_9G\7ZAJ_\
MPFWB;Q1)?6?V,0ZE)NC@!=7++R?F^0#Z9KW*B@#E?C;\,V^,?PMUCPRFK7VA
M-JT:QF^LSB> !U8[>1U"E>O0GK7S3_PZ:_ZJ]\0/^_W_ -E7V!10!\?_ /#I
MK_JKWQ _[^__ &5:7@W_ ()<IX3\7Z5JDGQ3\=7\>FWD-VUM-+^[N CAC&WS
M'Y6Q@\'@U]744 %?*/C+_@E\WC+Q?JVL2?%?QU:R:K>37C0Q2XCA,CERJ_/]
MT9P/85]744 ?'_\ PZ:_ZJ]\0/\ O[_]E1_PZ:_ZJ]\0/^_W_P!E7V!10!RO
MP2^%R_!?X6Z1X834K[6%TF-T^VWAW3W!9V<LQ^K$?0"O,?VH/V(/^&EO']GK
MO_"=>*/"_P!DT]+#[+IK[8I-LDK^8?F'S'S,?117O%% 'Q__ ,.FO^JO?$#_
M +^__94?\.FO^JO?$#_O]_\ 95]@44 >,_LJ?L?K^S#J&M7'_"8>(O%4FL1Q
M1@:F^X6P0N3MY/WMPST^Z.M=5^T;\#_^&A/AG+X;_M[5/#OF7$<_VS3VVS+L
M).WJ.#WKO** /C__ (=-?]5>^('_ ']_^RH_X=-?]5>^('_?[_[*OL"B@#Y=
M^%W_  3/7X;?$71?$#_$[QMJRZ->1WGV.YE_<W!1MP5^3\I(&:^HJ** /C__
M (=-?]5>^('_ ']_^RH_X=-?]5>^('_?[_[*OL"B@#X__P"'37_57OB!_P!_
MO_LJ^J/AYX2_X0'P!H>A?;+C4/[%T^"P^U3G,MSY4:IYC_[3;<GW-;%% 'SW
M^T=^P5_PT)\3)?$?_"P/%GAWS+>.#['I\FV$;!C=C<.3GFN#_P"'37_57OB!
M_P!_O_LJ^P** /C_ /X=-?\ 57OB!_W^_P#LJ]L_98_9C_X9CT#5K'_A*=<\
M4_VI<+/YNIMN>#:NW:O)X/6O5** /-_VH?V>?^&EO -GH/\ PDFL>%_LFH)?
M_:M-;;+)MCE3RSR/E/F9^JBO!_\ ATU_U5[X@?\ ?[_[*OL"B@#X_P#^'37_
M %5[X@?]_O\ [*NP^ G_  3S_P"%&_%G2?%7_"QO&&O?V7YW^@WTFZ"?S(7B
M^8;C]W?N'NHKZ0HH I^(=)_M_0+ZQ\Z2W^VV\D'FI]Z/>I7</<9S7R7_ ,.F
MO^JO?$#_ +_?_95]@44 ?'__  Z:_P"JO?$#_O\ ?_94?\.FO^JO?$#_ +_?
M_95]@44 4_#VD_V!H%C8^=)<?8K>.#S9/O2[5"[C[G&:^>_CW_P3S_X7E\6-
M6\4_\+&\8:#_ &IY/^@V,F((/+ACB^4;A][9N/NQKZ0HH ^/_P#ATU_U5[X@
M?]_O_LJ/^'37_57OB!_W^_\ LJ^P** /-_V7OV>?^&:? -YH/_"2:QXH^UZ@
M]_\ :M2;=+'NCB3RQR?E'EY^K&LW]JO]EEOVGM/T6W_X2[7O"L>CR2RDZ8VU
MKDN$ W<C[NTXZ_>/X^M44 ?'_P#PZ:_ZJ]\0/^_W_P!E1_PZ:_ZJ]\0/^_W_
M -E7V!10!\]_LX_L%?\ #/?Q,B\1_P#"P/%GB+R[>6#['J$FZ%MX W8W'D=J
M]F^*/@EOB1\.M:\/IJ%UI+:S9R6?VRV/[ZW#J5+)R/F )QS6]10!\?\ _#IK
M_JKWQ _[_?\ V5'_  Z:_P"JO?$#_O\ ?_95]@44 ?'_ /PZ:_ZJ]\0/^_O_
M -E7V!110!\N_%#_ ()J-\3OB+K7B%_BCXVTUM8O)+O[+;2XAM@S$B-!N^ZH
MP!]*P?\ ATU_U5[X@?\ ?[_[*OL"B@#X_P#^'37_ %5[X@?]_?\ [*OHK]GO
MX,)\ OA;9>&5UC4M?:TDEE:^OVW3S%W+<GV!"CD\"NVHH \9_:J_9#;]I^_T
M6;_A-/$7A6/1HY4$>F/M$YD*$LWS#IL 'XUY+_PZ:_ZJ]\0/^_W_ -E7V!10
M!\?_ /#IK_JKWQ _[^__ &5>G?LM_L4)^S/XOU#5_P#A-O$WBB2^L_L8AU*3
M=' "ZN67D_-\@'TS7N5% '*_&WX9M\8_A;K'AE-6OM";5HUC-]9G$\ #JQV\
MCJ%*]>A/6OFG_ATU_P!5>^('_?[_ .RK[ HH ^/_ /ATU_U5[X@?]_?_ +*M
M+P;_ ,$N4\)^+]*U23XI^.K^/3;R&[:VFE_=W 1PQC;YC\K8P>#P:^KJ* "O
ME'QE_P $OF\9>+]6UB3XK^.K635;R:\:&*7$<)D<N57Y_NC.!["OJZB@#X__
M .'37_57OB!_W]_^RH_X=-?]5>^('_?[_P"RK[ HH Y7X)?"Y?@O\+=(\,)J
M5]K"Z3&Z?;;P[I[@L[.68_5B/H!7F_[4G[%K?M,^+]/U3_A.O$WA>/3[/[*+
M;37VQR'>S&1OF'S'<!TZ*/P]RHH ^/\ _ATU_P!5>^('_?W_ .RH_P"'37_5
M7OB!_P!_O_LJ^P** /&?V5/V/U_9AU#6KC_A,/$7BJ36(XHP-3?<+8(7)V\G
M[VX9Z?='6NJ_:-^!_P#PT)\,Y?#?]O:IX=\RXCG^V:>VV9=A)V]1P>]=Y10!
M\?\ _#IK_JKWQ _[^_\ V5'_  Z:_P"JO?$#_O\ ?_95]@44 ?+OPN_X)GK\
M-OB+HOB!_B=XVU9=&O([S['<R_N;@HVX*_)^4D#-?45%% 'Q_P#\.FO^JO?$
M#_O[_P#94?\ #IK_ *J]\0/^_P!_]E7V!10!\?\ _#IK_JKWQ _[_?\ V5?4
M7PN\"K\,?AUHOA]+RZU)='LX[7[7<G,UR54 NY]6.3^/>MZB@#Y[_:._8*_X
M:$^)DOB/_A8'BSP[YEO'!]CT^3;"-@QNQN')SS7!_P##IK_JKWQ _P"_W_V5
M?8%% 'Q__P .FO\ JKWQ _[_ '_V5>V?LL?LQ_\ #,>@:M8_\)3KGBG^U+A9
M_-U-MSP;5V[5Y/!ZUZI10!YO^U#^SS_PTMX!L]!_X236/"_V34$O_M6FMMED
MVQRIY9Y'RGS,_517@_\ PZ:_ZJ]\0/\ O]_]E7V!10!\?_\ #IK_ *J]\0/^
M_P!_]E78? 3_ ()Y_P#"C?BSI/BK_A8WC#7O[+\[_0;Z3=!/YD+Q?,-Q^[OW
M#W45](44 4_$.D_V_H%]8^=);_;;>2#S4^]'O4KN'N,YKY+_ .'37_57OB!_
MW^_^RK[ HH ^/_\ ATU_U5[X@?\ ?[_[*C_ATU_U5[X@?]_O_LJ^P** *?A[
M2?[ T"QL?.DN/L5O'!YLGWI=JA=Q]SC-?/?Q[_X)Y_\ "\OBQJWBG_A8WC#0
M?[4\G_0;&3$$'EPQQ?*-P^]LW'W8U](44 ?'_P#PZ:_ZJ]\0/^_W_P!E1_PZ
M:_ZJ]\0/^_W_ -E7V!10!YO^R]^SS_PS3X!O-!_X236/%'VO4'O_ +5J3;I8
M]T<2>6.3\H\O/U8U3_:G_9B_X:;T#2K'_A*=<\+?V7<-<>;IC;7GW+MVMR.!
MUKU2B@#RO]EC]F+_ (9CT#5;'_A*=<\4_P!J7"W'FZFVYX-J[=J\G@]:]4HH
MH **** "BBB@ HHHH **** "O(OVWX@_[/NHMSF.>%A^+8_K7KM>2_MM1-+^
MSSJVU6;;+ 3@=/W@'^%?+\;?\D_C?^O4_P#TEGM<.?\ (UPW^./YH^<_V&?^
M3@M-_P"N,_\ Z)>O>OV[/A__ ,)9\'#J44>Z[T&=9@0,L8G(5Q^>P_\  :\(
M_8:M94_: T_,<@"P3DY4\#RF&?S('XBOM?Q#HD'B;0;W3KI=]O?P/;R@CJK*
M5/\ .ORWPSRF.9\'8K 2_P"7DYI>3Y8<K^4DG\C[;C+'RP7$-'%1^S&+?IS2
MNOFM#\Y?!'Q*U+P#I^M6]C)L37+)K&;GHC,I)'O@%?HQKT3]AOX>_P#"9?&F
M&^FCW6N@Q->'(X,G"QCZACN_X!]:\O\ %WA"]\'^*-0TJZA<7&GW#P284XRI
MQQ['J#W'-?8W["7PZ;P=\(6U.>/R[KQ!-YXR,-Y*96//XEV'J&!K\W\.<GKY
MEG]##8B_)A[R:?V>5WM;SFU=>I]EQ?F%+!Y54K4;<U:T4UUNK7_\!3M\BQ^W
M7_R0.X_Z_(O_ &:O _V$/^2]VO\ U[3?^@&O?OVYXFF^ =UM5FVW<).!G'4?
MS('XUX'^PC:RK\>K=C'( MK,3\IX&PC/YD#\:^XXSO\ \1!P/_<+_P!+9\QP
MZU_JIB?^W_\ TE'M_P"WA\0QX3^$2Z3#-LN]>G$>T'#>2A#.?SV#W#&OD3X:
M_$&\^%WC"UUNPAM9KRSW>4+A"Z*64KG (Y&>/?!KTS]N/QE<>+_C7<6*QR?9
M=#B6UC !P6(#LV/7+8^BBO7OV./@+H[_  =AU+7=%T^^NM6G:XA-W:K(\<0P
MJCY@>"59ACJ&%>7G&'QO%7&=6E@*G)]7TC)W]WV;W]7-NW_ ._+ZV&R/AV%3
M%0YO:ZM=^=;?^ I7/$?B#^V3XI^)7A"]T/4[71VL[Y0LFR!E888,"#NZ@@&O
M.O!/BFX\$^+M-U:U;;<:?<).GU4@X^GUZU^A/_"C_!O_ $*OA_\ \ (_\*^(
M?VD_AFWPV^,FL:?;V[+922_:;4*F%$;_ #!1[+DK_P !KS?$#A7/,KC2S;,,
M5[9IJ*EK>+5Y1WZ7O;L_4[.%,\RS&NI@,+0]FFFVM+/9/\+?(^E/VU$3X@?L
MU6NKZ>?.M%N;;458=XG1E!_\BK7S#^SMXWA^'?QHT'5KIECMX+CRY7;I&DBF
M-F_!7-?4'['.L1_$_P#9ZN/#^JPM)'8M+I\@?/[V%QN')[C<P'H%4U\[?'C]
MF'7O@WK%Q(MK/J&A%BT%]$A953L),?=;IUX/;->EQQ1QF*E@N,L!'FBXP<K*
M_).#OK_=OI?;35ZHXN&:F'HK$\.XJ5GS22OIS1DK:>=M?GY,^^+>XCNX$EB=
M)(Y%#HZG<K \@@]P?6F7-_!9-$LTT,)G<1QAW"^8YR=HSU/!X'I7YZ^$OV@_
M&W@/2UT_3]<U""UCXCA<^8L8]%#9P/85UWP,N/&GQJ^.V@:E>S:IJD>EWL=Q
M/-*S&&UC5@Y'/RKG' '4]*^TP/C-AL;.CA<+A9RK3E%-77*KM)M-7;MO\*^1
M\YBO#NMAHU*U>O%4XIN^MW9:)IV2OZL]._X*.?\ (L^&?^N\_P#*.O(?V3O@
MMI/QN\::AIVK27L,-O8O<(ULZJP821K_ !*>,.?TKV#_ (*,PM+X9\-;59OW
M\_09[1UR/_!.^VDC^*&KLT;JHTMQDJ< F6''\C^1KY'/L#0Q?B.L-B8J4).%
MT]FO9(]_*\54P_"#K49<LHJ5FMU[YPG[3O[/[? 3Q=;PVT\UUI.H1^9:S2@!
MP1PR-C )'!R .&%>^_L-?'B[^(6@W7AW5KC[1J&CQB6WE8_O)K?(4AO782HS
MZ,!VR=K]N#X>?\)K\%YKV*,O=:#*+M JY9HS\KCZ8(8^R5\K_L[>.9OA?\7M
M'U1UF6U\[R;H8.#$_P K<=\ Y ]0*SQEN#>,X_5_<PU7E;5].26C_P# )7:Z
MI)+KK="_$/#LO:^]6IWL^O,M5_X$K)]+^AZA_P %&M%D@\>^']0V_N;FP:W!
M]620L?TD%6O^"='C*VL=>\0:',X6XU".*YMP3C=Y>X.!ZG#@X'937NW[0WP6
MA^.7P^DTWS([>_@?S[*=ER$D ^ZW?:PX..G!P<8KX;\1^!_%'P:\4*MY::AI
M&H6K[H9DRN2/XD=>"/<$BM^,J&,X;XM7$4*;E1D[W6VL>646^CW:OW5KV9GP
M[5P^<9"\HE-1J)6\]'S1:75=';]4?I!7R/\ \%$O'-KJOBG1="MY%DGTJ*2:
MYP<[&EV[5/OM4'Z,*\_?]L'XC2Z;]C_M^;:1MW"WB$G_ 'V%W9]\YK$^'OP=
M\5?'#Q$?L=K=737$A:XO[C=Y49)RS/(>_?')/H:?&7B53XBP/]C9/0FY56KW
M2O9-.T5%ROJE=Z67KI/#O!T\HQ/]HYC5BHP3M9NVJM=MI=&]-=3V3_@G+X6>
M77O$&M,I5(;=+-"1PQ=@YP?;RQ_WU7)?\%8/",7Q=^$-OXITF.26X^'^L3Z5
MJ2*,^7')L^<^P=8P/^NAKZP^$7PPT_X(_#NWTFV=66V4S75R5V^?(1\\A_(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@!,T4?G10 M
M%%% !1110 4444 ?RQ_\'2_QGUK]M'_@M39?"70;B2^C\%P:7X-TFT5LPMJ-
M]Y<\S ?WVDN8HF/_ $[J.U?TS?LW? 70?V6_@%X-^'/A>W6U\/\ @G2+;1[)
M,89DAC";V]7<@LQZEF).2:_E[_8+L8_VH?\ @Z]AO-27^T8[KXO>(]?B\P[M
MOV)[^]MR/:/[/'CTV"OZNJ /GG_@KE_RBK_:4_[)?XD_]-=Q7\_/_!F#_P I
M7?%7_9--2_\ 3AIE?T"_\%<O^45?[2G_ &2_Q)_Z:[BOX]OV"6_:!3XTW9_9
MM_X67_PGW]DS?:?^$&%R=2_L_P R+S=_V?Y_)\SR,Y^7=L[XH _N/9@BEF("
MKR2>U?R\?\'>7_!0/P5^V!^V'X'\!^ ]6L_$EA\(=/O+;4=3LI$FM9=0O'@:
M6"*121)Y26\*L0<!RZ]5-?/7[0'@K_@I1X\\*W%E\1-*_;&UG0+J)H;FUO[;
M7KBPD0\,LD8!B((X.X<BN-_X)+_MA?!W_@GS^U)9^*OC3\#M0^)E]HM^GV5I
MM3%NWAB5&&Z==/DB\NYN(R"56:1 K $;64-0!_3E_P &_?[(FM?L3_\ !)SX
M5>#_ !/:?8/%%[:W&OZK;,I62UEOIY+E(9 >1)'"\,;CLZ,*^S:\Y_91_:P\
M _MM_ K1?B1\-/$%OXC\)Z\C&"YC1HY(I%.V2&6-@&CE1@0R, 1UY!!/HU !
M7QA_P7M_X**_\.UO^"<7B[Q;I=XMKXX\2 >&O"8!_>)?W"MFX4?],(5EF!(Q
MNC13]X5]GU_+#_P=I_MS77[6O_!26W^%/A^XFO\ PY\&X!HL5O;YD%WK-QL>
M\90.2R_N+?;C(:W?'WJ /0/^#//_ ()V?\+^_:L\1?M!>*+-KK0?A7FRT-YU
MW+=ZY<(2TF3D,;>W8L<\A[F%@<K7]+U?-?\ P2+_ &&;/_@G7_P3X^'/PQ2W
MABUK3].6_P#$4J8/VG5KC$MTQ;^(+(WEJ3_RSB0=J^E* "BO-_%7[8WPB\">
M(KS1]<^*GPWT;5M/D,5U8WWB6RM[BV<?PO&\@93ST(!K/_X;S^!O_19_A/\
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MU>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_11_ ?\ X4%I_P#'*3_AJ?X7_P#11_ ?_A06G_QROQ8HH_XBABO^?$?O8?\
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MG_QROQ7HH_XBABO^?$?O8?\ $,<-_P _I?<C]J/^&J/AC_T4?P'_ .%!:?\
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M\!_^%!:?_'*_%BBC_B*&*_Y\1^]A_P 0QPO_ #^E]R/VG_X:H^&'_11_ ?\
MX4%I_P#'*7_AJCX8?]%'\!_^%!:?_'*_%>BC_B*&*_Y\1^]A_P 0QPW_ #^E
M]R/VH_X:H^&/_11_ ?\ X4%I_P#'*3_AJ?X7_P#11_ ?_A06G_QROQ8HH_XB
MABO^?$?O8?\ $,<+_P _I?<C]I_^&J/AA_T4?P'_ .%!:?\ QRE_X:H^&'_1
M1_ ?_A06G_QROQ7HH_XBABO^?$?O8?\ $,<-_P _I?<C]J/^&J/AC_T4?P'_
M .%!:?\ QRD_X:G^%_\ T4?P'_X4%I_\<K\6**/^(H8K_GQ'[V'_ !#'"_\
M/Z7W(_:_2OVD_AUKNJ6UC8^/O!5Y>WDJP6]O!KEM)+/(Q"JB*')9B2  .22!
M7:U^*_[+'_)SWPX_[&C3/_2N*OVHK[OA+B.IF]&I4J04>5I:7['P_%G#M/**
MM.G3FY<R;U]0HHHKZT^3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?VC_ /DA7BG_ *\'KMJX
MG]H__DA7BC_KP>O)S[_D68C_ *]S_P#26=V5_P"^4O\ %'\T> _\$XO^1J\2
M?]>D?_H=?6E?)?\ P3B_Y&CQ)_UZQ_\ H=?6E?%^$?\ R3%#UG_Z7(^CX]_Y
M'=7TC_Z2@HHHK]*/C@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR8_X.RO^"<_@/XS_ /!/;Q)\;H-#L=/^)7PPDM+I-5M8DAGU6RFNH+6:WN6
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M0)/&)%!(5]DBY ) .>3UH ZBCI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *^#?^"VW_-,
MO^XK_P"V=?>5?!O_  6V_P":9_\ <5_]LZ^1X[_Y$=?_ +=_]+B?6<#?\CNA
M_P!O?^D2/@WO1117\ZG]#!1THHH .]%%% !1THHH .]%%% !1THHH .]%%%
M!1THHH .]%%% !1THHH .]%%% !1THHH .]%%% !1THHH .]%%% !1THHH .
M]%%% !1THHH .]%%% !1THHH .]%%% !1THHH .]%%% !1THHH [S]EC_DY_
MX<?]C1IG_I7%7[4&OQ7_ &5_^3GOAQ_V-&F?^E<5?M17[1X7_P"ZU_\ $OR/
MQOQ._P!ZH_X7^84=***_4#\Q"@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %<3^T?_R0KQ3_ ->$E=M7$_M'\? KQ3_U
MX/7DY]_R+,1_U[G_ .DL[LK_ -\I?XH_FCP'_@G'_P C3XC_ .O6/_T.OK0U
M\E_\$XO^1I\2?]>L?_H=?6E?%^$?_),4/6?_ *7(^CX]_P"1W5](_P#I*"CI
M117Z4?'!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI16+X_\
M'VE_#'PG>:UK-TEK8V:%F8GYG/9%'\3'H!WH Y_]H3XXZ?\  /X=7.L7>R6[
M?]S8VI/-S,1P/]T=6/H/4@'\V=;UG5/B7XSGO+EIM0U;6+G<>-SRR.W"@?B
M /85U'[1OQ]U']H'X@2ZI=;H+"WS%86@;*V\6?\ T)NK'N?8 #Z%_P""?_[+
M+::L/CS7[<K-(I.D6\BD% <@W!'N.$]B6_NFM?A0'M'[*OP&A^ ?PNM[!T0Z
MQ?8N=2E'.Z4CA ?[J#@8XSN/>O2^E%%9 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 F:*/SHH 6BBB@ HHHH **** /YT?^#T;]A*\\*_&;P'
M^T3I$$C:1XHM$\)Z^R+Q;7]N));65C_TU@\Q/;[(/[PK]>_^"(_[?T/_  4A
M_P""<G@/Q_<7,<WBJRM_[!\4Q@_-%JMJJI,Y';SE,=P!V6X4=0:]3_;R_8M\
M)?\ !0C]E'QA\)?&D<BZ/XJM?+CNXE!GTRZ1A)!=19_CBE56QT8 J<JQ!_G@
M_P""0O[2OQ._X-[/^"I/B;X(?%K3=4_X5WXFU2+2/$$EO;2S6=NY/^A:W;''
MS1,CKOQ\QBD.Y3)$J@ _HK_;E^!VJ_M-_L6?%SX;Z%<Z?9ZUX^\&ZOX=T^>_
M=TM8;B[LY8(VE9%=A&&D!8JK$#. 3P?YU?\ B"J_:F_Z'[X ?^#S5_\ Y65_
M3]UHH _F%M?^#*C]J)YU$WQ!^ D<6?F9-9U9V ]@=-&?S%?5O[#'_!EMX4\
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M8>'?"FG3:GJ$ZQF1EBB4L0J#EW.,*HY9B .2* /S!_X.[OV_X?V:?^"?UO\
M"72;I%\6?&RY-E*JGY[72+9DENI/;S',,(!'S+)-@Y2L7_@SM_8.O/V>_P!A
MSQ%\7]<MWM]8^-5[$^G12)AHM)LC+'"_/(,TTEP_HR+"W.17YN_#[X0_%C_@
MZ-_X+#WWB+Q1I^N>%_ACI3*UW))$RQ^&?#\,A\FQA=AM:[G+-R,YDEEDV[$*
MC^HKX>?#_1OA/X!T/POX=T^WTGP_X;L(-+TRR@&([.VAC6.*)?9450,^E &Q
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %1W=Y#I]I+<7$L<%O ADDDD8*D:@9+$G@ #G)J2ODO
M_@NW\2=4^$W_  2!_: UK1IKBWU#_A%)K!)8#MDB2Z=+61@>V$F<Y'(QD<T
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MM<\X-?T4UGGPKI;>*%US^S;#^VEM38B_^SI]J%N7#F$28W>67 ;;G&0#C(H
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M;N7.,XR/6KO@?XB^'_B=H U;PUKNC>(=++M$+S3+V.[MRZ_>7?&Q7(SR,Y%
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M&)9)?*E9F=PX5%3HC$L/E#?H7!"EM"D<:+''&H5$4850.@ ]!7Q5_P %=_\
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MPBO['GQ<^)$T/ES>,O%4&BPLPYD@T^V$@8?[)DOI%^J'TK]KZ "LSQIXLM?
M7@[5M<OENGL=%LIK^X6VMWN)VCB0NP2- 7D;"G"*"S'  )-:=% 'R?\ L+?\
M%L_V</\ @H[\4]0\%_"?QS/K?B;3=.;59+*[TB[T]Y+='2-WC,\:!]K2)D*2
M0#G& 2/K"OY0_P#@H3X>O/\ @@[_ ,'$J^,O!]M-I?A:WURU\::9:6XV)<Z-
M?DB^LT7H(\F^ME'8(IX(X_JN\-^(K'Q?X>L-6TRZBO=-U2VCN[2XB.8[B&10
MZ.I]&4@CV- %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O@W_@MM_P TR_[BO_MG7WE7P;_P6W_YIE_W
M%?\ VRKY'CO_ )$=?_MW_P!+B?6<#?\ (\H?]O?^D2/@VBBBOYU/Z&"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [S]
ME?\ Y.?^''_8TZ9_Z5Q5^U%?BO\ LL?\G/?#C_L:-,_]*XJ_:BOVCPO_ -UK
M_P")?D?C?B=_O5'_  O\PHHHK]0/S$**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)_:/_Y(5XI_
MZ\'KMJXG]H__ )(5XH_Z\'KR<^_Y%F(_Z]S_ /26=V5_[Y2_Q1_-'@/_  3B
M_P"1J\2?]>D?_H=?6E?)?_!.+_D:/$G_ %ZQ_P#H=?6E?%^$?_),4/6?_I<C
MZ/CW_D=U?2/_ *2@HHHK]*/C@HHHH **** "BBB@ HHHH **** "BBB@ HHK
MR_\ :"_:O\-? &PDCN9EU+7&7,6FP./,Z9!D//EKR.O)!X!YHW [3XB_$?1_
MA5X5N-8UR\CL[*WXR>6E;LB#^)CCI^/ !-?GG^TS^T]JW[0_B7=)YECH5FY^
MQ6 ;A?\ IH_]Z0COV' [YP_C)\</$7Q]\6?;M8G:3!*6MG"#Y-L#CY47U.!D
MGDX&3Q7OW[*/[ TE_):^(O'5NT-NI$MMI#C#2^C3C^%>^SJ>^!D'1)1U8&'^
MQ=^QG)\0[FW\5>*;9H]!B8/:6D@VMJ##HS#_ )Y?^A?3-?<$<:Q1JJJJJHP
M!@ 4D$$=K D4<:1QQJ%1%&U5 X  [ 4^IE*X!1114@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !BBDSCUHH 6CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 5YU^UU^SAI/[8'[+_ (^^%VN2M;Z7X\T*ZT:6
MX1-[V9FC94G520"T;[9 "<$H*]%HH _B#^*'PX^,'_!'/]O:33YIKSPA\3/A
M;K N=.U&W4^5=*"?*N82PQ+;3QD\,,.CLC#[RU_1A_P2I_X.GO@K^VWI.F^&
M?BI>:;\&_B=)M@:+4;C9H.KR=-UM=O\ +$6/_+*<J06"J\IR:^O_ /@HY_P2
MN^#O_!4GX5IX;^*'A]IKVP#'2/$&GLMOJ^B.W4P3%6^4_P 43JT;8!*DA2/Y
MS/\ @IG_ ,&L?Q^_8<DU#Q%X#M9?C1\.[?=+]MT.U8:Q81#G_2+ %G.!G+P&
M1< LWEC@ ']7L$Z7,*21NLD<@#*RG*L#R"#W!IYK^.W_ ()A?\' ?Q^_X)?Z
MOI^BV.LS>-OAK9RA+GP9X@F>2"",'YEM)CF2S<#=@)F/<<M$]?U'_P#!-W_@
MI?\ #'_@J/\  &/QY\-=1G9;61;36='O4$>H:%=%0WDSH"0<@Y61"R. <'(8
M  ^@995@B:21E2- 69F. H'4DU_,!_P7N_X.3_&W[6?Q0UWX6_ OQ-J'A3X0
M:/</8SZQI-P]M?\ C)U^220S*0Z69.X)&I'F*=TF=P1/VC_X.+?VG;[]E/\
MX(__ !>UO1[J:SUS7[*'PQ831':\;7\Z6\S*W56%N\[!AR"HQ@X-?@Q_P:D?
ML(Z/^V/_ ,%,8=>\46$.I>&?A#IA\4-:S)OANM0\U(K)''HKL\X!X)M@"""1
M0!K?L)_\&EO[1G[7OP^T_P 7^++[P[\']!U>);BS@U]9I]8N(V 99#:1C]TI
M!Z32))_L8(-=?^U=_P &;7[07P3\#7FN_#_Q9X.^+!L(C++I-LDNEZI.!R?(
MCEW12$#)VF96/10Q(%?U 44 ?R%_\$=_^"YOQ8_X)(_'"S\*^*+KQ!KGPE2_
M_L_Q'X/U,R--H0$A66:RCD(-O<1'<6B^5)""K@-M=/ZW/A]X^T?XJ^ ]%\4>
M'=0M]6\/^(["#4]-OH#F*\MIHUDBE4_W61E89[&OYJ_^#RS]BG2/@;^VAX(^
M+6@V,5C;_&#3+B/5XX4VI+J=@T2O<'' :6"XMP>.6A=N2S&OTT_X-(_VA[[X
MZ_\ !('1])U&XFNKCX9^)-0\*1R2MN<P*(;V%<_W42]$:^@C Z"@#XG_ .#Y
M+_D;OV:_^O/Q'_Z'IE?9G_!H+_RASTW_ +&[5_\ T**OC/\ X/DO^1N_9K_Z
M]/$?_H>F5]F?\&@O_*'/3?\ L;M7_P#0HJ .T_X.J?\ E!W\6O\ K\T+_P!/
M-E7YE_\ !D5Q^UK\;/\ L4;3_P!+!7Z:?\'5'_*#OXM?]?FA?^GFRK\R_P#@
MR)_Y.U^-G_8HVG_I:* /Z09[B.U@>65UCCC4L[L=JH!R23Z5_*[_ ,' 7_!P
MCXR_;S^+VO?"[X4>(+_0O@?HMQ)IN_3)WBE\<,IVO/.RX+6K$'RH?NLN'<%B
MJQ_N7_P<3?M-WW[*G_!'_P",&N:3=26>MZY80^&;"6,X=6OYTMI2I_A9;=YV
M##D%1C!P:_ ?_@U7_8<TG]L;_@J-IFL>(HX[C0/A#IS>,7M9$W)>7D<T45FA
M[86:03<]?L^.A- ':_L0_P#!H=^T-^U'\.;#Q9XUUKPW\'=-U:%9[/3]8BFO
M-9:-@"KRVT8"P@@YVR2"0=&1:P/VU?\ @VS_ &IO^"5>D0_%[P7KEGXTT_PA
M,=0;6O!,]U;ZSX>6,;OM;PE5=449)>%Y-@#%]J@FOZO*9/;QW4+Q21I)'(I5
MU8;E<'@@CN#0!_#)^W!^VAXL_;\^/,GQ)\=?99?%E_I.G:=J5U @C6_DM+2*
MV^TE  J/(L2NP4!=S-M"C"C^RS_@F'_RC5_9Y_[)GX;_ /35;5_)/_P7)_9/
MT7]BC_@JK\8/A]X9L%TOPS8ZI%J.D6B?ZNUMKVVAO$B3_8C\\Q@=@F.<9K^M
MC_@F'_RC5_9Y_P"R9^&__37;4 >Y4=*** "@T44 ?SD?\'OG_)RWP*_[%G4/
M_2I*_0?_ (-)N/\ @BYX/_[&#6?_ $K:OSW_ .#WS_DY;X%?]BSJ'_I4E?H1
M_P &DO\ RA=\'_\ 8P:S_P"E;4 ?IA7\5_\ P4!_Y3<_&;_LM>L_^GR:O[4*
M_BO_ ."@7_*;CXS?]EKUG_T^34 ?VH4=*** /Y0O^#O'G_@LEK7_ &*FC_\
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M<\=:]JD\ESI7A;3I3;Z%X=@'!=(W<0V\:*55IY6W-E=SLQ&?M;_@]-_:=O\
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M_!=7_@X"A\1>,;>2\T+Q%XENO&NO6\HWI#I-F=\%DP_YY%4M+3KPKCG-?UQ
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MM;_"GP%_P1]^!6CZ[\3OA[HNK6.A2)<V5_XCL[:YMV^USG#QO(&4X(.".A%
M'Z)4&O-M"_;)^$/BC6[/3--^*WPWU'4M1G2VM+2V\364T]S*[!4CC19"S,S$
M * 220!7I- 'QW_P7[^/G_#./_!'OX\:\DWDW6I>''\.VQ!PYDU*1+#Y?]I5
MN&;(Z!2>U?C7_P &47P$_P"$O_;9^*?Q&FA\RV\#^$X]*B8CB*YU"Y#*P/KY
M5E.OT<U]>?\ !ZO\?/\ A"_V%OAG\/(9O+NO'?BYM1E4'F:UT^V;>N/3SKNV
M;ZJ*W?\ @S%^ ?\ PK[_ ()N^+O'5Q#Y=Y\0_&,_DR8_UMG90QP1_E.UV/\
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MJ_8?PK\$?!?@;X<Q>#]%\(^&=)\)PP_9X]%L]+@@T](_[@@51'M]MM?RR?\
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MVR#_ +]FOZ6_AI\*?"_P7\(VOA_P?X;T'PKH5BH2WT[2+"*RM8%'98HE51^
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M_P""3/Q.U3XI6>@MJ.GZ:R>#[NZC3[?#K3D?94M'_P!9N9P-ZH<&)92P*!J
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MJ#_@MY\/=6U;=J"^&Y=2\9ZI*PRS2102&.0^_P!KF@.?>@#^NROR+_X+O?\
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MX?\ V>OA_%XV6S=HO^$G\322VFG7##@-!:1[9Y(SUW2/"W'W.<UX)_P=P_\
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
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MT4?G10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_\ !.']G?6/B)\1=:M+"UL8)/[-TWS@+W7KL+E+2VCZO(S;02!M0$NQ55)
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M[,R@GHJJ.  !_/O_ ,'A'PEU+P)_P5O?Q#<V\BZ=XX\):9?V4^#Y;F$26DB
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M^,.M?M,?\%N/'F@I)]KA\)?V9X.T2#=_JU6".1T].;NYN#_P+VK^J?\ 9:^
M&C_LJ?LW^!?AMH,4<6D^!]#M-&@V#'F^3$J-(?5G8,[$\EF)/)K^2C_@N!:S
M_L[_ /!>KXO:A=I)<-I?C>U\2!&&3)'-';7RJ,\8VR #MBOZ^/AK\1M%^+_P
M\T/Q7X<OX-4T#Q)80ZGIUY"VZ.YMYD#QN#[JP- %SQ5XHT_P/X7U+6M6NX=/
MTG1[66^O;J8[8[:&)"\DC'LJJI)/H*_CY_8VN9_^"I'_  <%^$M<NK>2:W^(
MOQ5?Q5<6KC.RPANGU!X#[+:P%/8+7ZZ?\'77_!9O0_@I\ M6_9L^'VMP7WQ
M\=0BV\6S6,ZO_P (]I;<R6LA4G;/<CY#&>5A9RP'F1D_"O\ P9J? 7_A8_\
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MTR9_U5Y?3R22#'O!%:'\:_INT^_AU6PANK>19;>YC66)QT=6&0?Q!%?QZ_\
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M?"OX=Z_XGU63RM+\-Z;<:I>/_<A@B:5S^"J:_CS_ .".?P&N?^"EW_!9_P
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M#OBA\2]#^#/PWU[Q=XFU"WTGP[X8T^?5-2O9CB.UMX8S))(?8*I/K0!_-_\
M\'JG[1=OX]_;=^&?PWL[CSU^'?AB6_O$4\6]UJ,P)0C^]Y%K;/\ 21:_>+_@
MEA\!Y_V9/^";_P $/ MY:M9ZEH'@W38]1@(P8KUX%EN5_">22OYF_P!C#P9K
MG_!?G_@OY_PDVO6<S:#X@\2OXOUZ)QO73]"L2GDVCGD8,4=K:!O[TJFOZX*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O@W_@MM_P TR_[BO_MG7WE7P;_P6W_YIE_W%?\ VRKY'CO_
M )$=?_MW_P!+B?6<#?\ (\H?]O?^D2/@VBBBOYU/Z&"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [S]E?\ Y.?^''_8
MTZ9_Z5Q5^U%?BO\ LL?\G/?#C_L:-,_]*XJ_:BOVCPO_ -UK_P")?D?C?B=_
MO5'_  O\PHHHK]0/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&4
M,I!&0>"#WI:* .0\8? /P9X]5O[4\-Z5<.^=TJP^3*?^!IAOUKSS6_\ @GG\
M.=7/[F'6M.7^[;7QP/\ OX&KW*BGS,#YGNO^"8GA5A_H_B#7HSG_ ):"-_Y!
M:@/_  3$T-OO>*=7(]/(7_&OI^BGS,#YML/^"8W@R)U-QK/B*90#N"211Y/_
M 'P:ZSPY^P1\,_#\BNVCW.H.AR#=7DA_12H/XCO7LU%',P,7PM\.?#_@B-5T
M?1=+TW:,9M[9(V/U8#)_$UM445(!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &**3./
M6B@!:.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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MI(UN+H>7=!'80KR8MSN$"@-P*_J>HH _-/\ X.?OV,/CM^WW^QIX,^'/P/\
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MQOX@N=-TI8!U-SYK^;<Q+@$*$F)P-JFOZJJ* /YR?^"D_P#P:Q?%+X;?LU_
MOP+^SWX+C^)NN:7_ &OJ?Q"\1'5].TN2^U"<6*P*JWD\1^SQK#,L2)NV[I&;
M#2$G]8O^#?3]C/QK^P;_ ,$M/ _P_P#B-H*^&?'5O?:K?:OIPO+>\\AY;^<P
MYEMY)(FW6XA;Y7.-V#@@@?:E% 'Q1_P7H_X)D>,/^"KO[$MO\./!7B_2/">K
MZ7K\'B!5U2"1K/5C#!<1+;221Y:%=TX?>(Y.8U&WG(_GWM?^"+W_  43_P""
M<?Q NM3^'_@_XDZ/>/\ NCJ_P\UX7":A&,XW+:R^:4Y/RS1CK]VOZWZ* /Y.
M_%O[)_\ P53_ &]['_A$_%FD_M%:QHNH((;C3_$>IR:+I,Z@C_7)<20P/C&<
MN"3VR:_2;_@C1_P:>:+^R3X\\/\ Q3^/FL:7XU\<:*ZWNF>%["/S-%TBX'*2
MSR. UU+&<%0%6-'7/[S"L/V>HH *_ G_ (.Z?^"PL$^GG]E'X=ZDMS<3R0WG
MQ O+63=Y>UA);Z4".K%@DTH[8B3/,BCZ_P#^#C#_ (+B-_P3.^$L?P]^'>Z\
M^-GCBP::SF$/F0^%[%BT9OG!!5IF976&,Y&Y&=QM4))\??\ !L]_P05O_&?B
M#3OVK?V@M/N]0OM0N#K'@S1=8W2SWD[L9/[:O!)EF9F.^$/DL3YQ_P"69(!]
MF?\ !LS_ ,$C[C_@FY^Q[)XI\::>+7XL?%9(-1U:&6/$VAV*J6M; YY60;VD
ME''SN$(/E G]+#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M5\&_\%MO^:9?]Q7_ -LZ^\J^#?\ @MM_S3/_ +BO_MG7R/'?_(CK_P#;O_I<
M3ZS@;_D=T/\ M[_TB1\&]Z***_G4_H8*.E%% !WHHHH *.E%% !WHHHH *.E
M%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHH
MH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%%
M'>?LL?\ )S_PX_[&C3/_ $KBK]J#7XK_ +*__)SWPX_[&C3/_2N*OVHK]H\+
M_P#=:_\ B7Y'XWXG?[U1_P +_,*.E%%?J!^8A0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% "9HH_.B@!:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^<_^"K?[!$W_!3+]A[Q9\&X?&$W@?\ X2:2TF.I)8B]7-M<1W"1R1;T
M+(TD29PP(P#ST/T910!_+#XS_P"#4S]M_P#9K\77-]\.9_#OB22)F2WU#PMX
MN72;J://&?M)MRI/&5W$ ]SUI-$_X-<?V\_VGO%5F?B/-I6CJ@/_ !,?%WC=
M=5-LIQD*+9KE\GT P2.2.M?U/T4 ?G=_P1H_X-V/AC_P2CNE\97^H'XB_%VX
MMS"?$%U:B&VT9'4K)'8098Q[@2K2LQD9<@>6K,A_1&BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^#?^"VW_ #3+_N*_^V=?>5?!O_!;?_FF7_<5
M_P#;*OD>._\ D1U_^W?_ $N)]9P-_P CRA_V]_Z1(^#:***_G4_H8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#O/V5
M_P#DY_X<?]C3IG_I7%7[45^*_P"RQ_R<]\./^QHTS_TKBK]J*_:/"_\ W6O_
M (E^1^-^)W^]4?\ "_S"BBBOU _,0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M Q129QZT4 +1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
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MY3^^7_R ?\1*RS_GW4^Z/_R1^2O>BOUJ_P"'9/P/'_,D_P#E8O\ _P"/T?\
M#LGX'_\ 0D_^5B__ /C]'_$,LT_Y^4_OE_\ (!_Q$K+/^?=3[H__ "9^2M'2
MOUJ_X=D_ _\ Z$G_ ,K%_P#_ !^C_AV3\#\_\B3_ .5B_P#_ (_1_P 0RS3_
M )^4_OE_\@'_ !$K+/\ GW4^Z/\ \D?DKWHK]:O^'9/P/'_,D_\ E8O_ /X_
M1_P[)^!__0D_^5B__P#C]'_$,LT_Y^4_OE_\@'_$2LL_Y]U/NC_\F?DK1TK]
M:O\ AV3\#_\ H2?_ "L7_P#\?H_X=D_ _/\ R)/_ )6+_P#^/T?\0RS3_GY3
M^^7_ ,@'_$2LL_Y]U/NC_P#)'Y*]Z*_6K_AV3\#Q_P R3_Y6+_\ ^/T?\.R?
M@?\ ]"3_ .5B_P#_ (_1_P 0RS3_ )^4_OE_\@'_ !$K+/\ GW4^Z/\ \F?D
MK1TK]:O^'9/P/_Z$G_RL7_\ \?H_X=D_ _/_ ")/_E8O_P#X_1_Q#+-/^?E/
M[Y?_ " ?\1*RS_GW4^Z/_P D?DKWHK]:O^'9/P/'_,D_^5B__P#C]'_#LGX'
M_P#0D_\ E8O_ /X_1_Q#+-/^?E/[Y?\ R ?\1*RS_GW4^Z/_ ,F?DK1TK]:O
M^'9/P/\ ^A)_\K%__P#'Z/\ AV3\#\_\B3_Y6+__ ./T?\0RS3_GY3^^7_R
M?\1*RS_GW4^Z/_R1^2O>BOUJ_P"'9/P/'_,D_P#E8O\ _P"/T?\ #LGX'_\
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M\1*RS_GW4^Z/_P D?DKWHK]:O^'9/P/'_,D_^5B__P#C]'_#LGX'_P#0D_\
ME8O_ /X_1_Q#+-/^?E/[Y?\ R ?\1*RS_GW4^Z/_ ,F?DK1TK]:O^'9/P/\
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% "9HH_.B@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #
M%%)G'K10 M'2BOF__@J/^PUXJ_X*"_LUV_@7P?\ %WQ!\$]7M]:M]5_X2+1K
M>:>Y:.*.9&M]L5S;MM?S02?,Q\@^4]@#Z0H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\ !3J/
M_P NJ/\ B%L^/H_YR)?&#_P4ZC_\NJ /V>H-?C#_ ,0MGQ]_Z2)?&#_P4ZC_
M /+JC_B%L^/G_21+XP?^"G4?_EU0!^SU'2OQA_XA;?CZ?^<B7Q@_\%.H_P#R
MZH_XA;/CZ/\ G(E\8/\ P4ZC_P#+J@#]GJ#7XP_\0MGQ]_Z2)?&#_P %.H__
M "ZH_P"(6SX^?])$OC!_X*=1_P#EU0!^SU'2N+_9O^%NH? W]GCP%X)U;Q%>
M>,-4\'^'=/T2\UZ[1DN-;FMK:.&2[D5GD8/*R&0AI'(+G+,>3VE "9HH_.B@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY+BUN9[?57DMX9(HV1W0%(UV*P)"@9K[W_XB[/VUO^B3?"G_ ,)#6?\ Y/H
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MG^*OV,_;;\/6_B[]C#XNZ3=+NM=3\%:S:3#'5)+&9&_0FOYS_P#@RPO)8?\
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M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1TK\V6_P""\>N*W_).=*_\&TG_ ,;KV3]A?_@J!J/[7OQJD\)W?@^Q
MT2-=-FOA<PW[3-F-HQMVE!P=_7/:OH,3PMF5"E*M5A:,5=ZK_,\ZGFN&J34(
M2U?DS["H-%%?/GHA1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M5N00>#3C7/QZA)X5OQ;W'S6<S?NG[H3V_P __KWP=RY['O0 M'2BB@ H-%%
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MW[%!';23S79CV[PJHIZ;TY8@?,.:^1?BS_P76TJS\R#P/X)O;YN0EWK-P+=
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MV/  &[DFNED=8D9F9551DD\ "B5.4?B5A*2>PZBN5_X7GX)_Z'#PK_X-H/\
MXNC_ (7GX)_Z'#PM_P"#6#_XNM/J]7^5_<Q>TCW1U5%<K_PO+P2?^9P\*_\
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MMY.O_ 7X.ZH NQ7F\':>9(Q_LN(MR_@10!^4/_!(C_@[(^('[8W[5_@;X/\
MQ-^%OA(W_CK4AIMMKWAN\GL4LF*,P:2UG,_F9VX)65,9SCM7[H5^=OA+_@V;
M_9Y^#/[;G@/XX?#%?$7P]U3P7JXU5] M;O[9H]\=CC:$GW2P\MGY)-@ P$'&
M/OCXB_$+1?A+X USQ5XDU"WTCP_X;L)]3U.^G.(K.VAC:265N^%16)QSQ0!G
M_&KXW>$?V<OACJWC3QWXBTGPKX5T*'S[[4]1G$,%NN0!R>K,Q"JHRS,0 "2!
M7XJ_MQ?\'J'A?P5XBOM$^ 'PW;QG%;Y2+Q-XHGEL;*9Q_%%9(!.\9X(,DD+=
M<H.M?F'_ ,%G_P#@L)X^_P""Q?[47]GZ.=<M_ACI^HBR\%>$8 S/<NQ\I+J:
M),^;>3%N!\WEAQ&F?F9_TX_X)'_\&@_A?1O!FD^./VI_MFM>(;Z,7$?@.QO6
MM['3%(RJWEQ"PDFF'!*1.B*006E&< 'P[XO_ .#O3]LCQ+.SV6K_  ]\/*6R
M$T_PQ'(J^W^D/*?US6O\-O\ @\6_:X\%W$9UBW^%OC"%6'F+J/A^2!V7N UK
M/$ <=#@X]#7]&/P\_P""9'[.?PHT*+3?#_P)^$>FVL,?E_+X4LGED'^W(T9>
M0GN78DUY_P#'O_@AA^R1^T;X<O-/USX"_#O37O!S?>'M)CT*^C?LXFLQ&Q(/
M.&)!QR".* ./_P""%_\ P6+E_P""Q/P*\5>)+WP+'X%U;P9J4.EWD,.IF^M[
MUI(O,$L9,:-&.HV-NQ_>-8?_  <'_P#!6CQM_P $BOV=/ _C#P+X=\*^(M2\
M4>(SH\\6O)</##$+:6;<HADC;=N11R2,9X[CTK_@E-_P2'\$_P#!(WPWX^T+
MP'XB\2:[H?C;6(M5CAUKRGGT[RXO+$7F1J@D'4Y*@XP.3DGX+_X/;/\ DQWX
M0_\ 8\O_ .F^XH ^FO\ @WG_ ."OGCS_ (*]?!WXB>(O'GAOPCX<N_!^LV^F
MVL>@QW"1S)) 9"S^=+(=P(P,$#%?H=7X?_\ !D-_R:Y\<O\ L:K'_P!)#7[@
M4 %>$_\ !3;]JG6/V(?V"OB?\5_#^GZ;JVM>!]'.H6=IJ(<VL\GF(@$FQE8K
M\V<*P/'6O=J^.?\ @X'_ .4,W[07_8LG_P!*(: /C#_@@]_P<=_%K_@JG^W!
M<?##QMX*^'6@:/#X:O-:%UHD-XET989($5<S7$B[2)6S\N>!S7[*U_*]_P &
M<7_*7.]_[$+5/_2BSK^J&@#\&_\ @JG_ ,'5OQJ_83_X*!?$OX2^%_A_\+M4
MT+P3?Q6=I=ZI!?O=SAK:&4ES'<HF=TC 84< =>I^N/\ @W[_ ."^@_X*YV'B
M_P +^.-)\.^$OBEX7(U"'3]),JVNJZ6VU/.B65W??%*=L@W$8EB(ZL%_ 7_@
MXL/_ !NJ^/W_ &&[?_TAMJ\P^&7COXI?\$=/V^M#\16L;:7XV^'U[!?I$Q9;
M;6+&>)9 IZ%K>ZM91SP=DN>&' !_;K17EO[%W[7/A']NO]F'P?\ %7P3=?:-
M \76*W21LP,UC,/EFMI<<"6*57C;'&4)&003ZE0!X#_P5)_:UUK]A3]@'XF_
M%KP[INEZOKG@G34O+.TU(2&UF=KB*+$@C97*@2$X# \=:_.__@@E_P '&'Q8
M_P""KG[:^I_#/QOX+^'?A_1['PK=Z\ESH<-XERTT-Q:Q*A,UQ(NPB=B?ESD#
MGKGZZ_X.)_\ E"O\?O\ L!0_^EUM7X?_ /!F9_REE\0?]DYU/_TMTZ@#^I2B
MBB@ HHHH \9_;]_;A\&_\$Z_V4_%7Q7\;SXTSP_;XM;)'"W&L7CY$%G#GK)(
M_&<$*H9S\JL1^:__  0[_P""\O[3W_!7;]JJX\/S?#7X6Z#\-/"]N;[Q3KEI
M:Z@9[1'#"WMH6>Y*&XE<<;EP$CE;'RA3^>O_  =1_P#!0/6OVX_^"C$/P2\'
M75WJGA+X57:Z#:Z=9DNNJ^(92$N7"CEY$9EM5!R5:*7;_K#G]^_^"0W_  3I
MT+_@F)^PYX2^'.GVMO\ \)$]NFI^*[^/#-J>K2HIN'W=T0@11^D<2=\D@'CW
M_!P?_P %:/&__!(K]G3P/XP\"^'?"OB+4?%'B,Z//%KR3O##$+:6;<HADC;=
MN0#EB,9X[C/_ .#>?_@KYX\_X*]?!WXB>(_'GASPCX<N_!^LV^FVL>@QW"1S
M)) 9"S^=+(=P(P,$#':OF7_@]L_Y,=^$/_8]/_Z07%8__!D-_P FN?''_L:K
M'_TD:@#]P**** /"?^"FO[5.L_L0_L%?$_XK^']/TS5M:\$:.=0L[340YM9Y
M/,1 ) C*Q7Y\X5@>.HK\W_\ @@]_P<=_%K_@JG^W!<?#'QMX*^'?A_1H?#5Y
MK0NM$AO$NC+#);HJYFN)%VD2MGY<\#FOM#_@X'_Y0S?M!?\ 8LG_ -*(:_"3
M_@SA_P"4N=[_ -B%JG_H^SH _JAHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _B[_ ."N'BS5;#_@L5\>UAU/4(5A^)FJ; EPZA,7SXQ@\8K^T2OXJ_\
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MK_VPOAK^P]\(;SQU\5/%VE^#_#-HPB%Q=EFDN92"1##$@:2:4@$A(U9L*3C
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MUJP&-QECW9\M< ']3U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M<%\;OVF_ _[.7]E_\)EK?]C?VQYOV/\ T.XN/.\K9O\ ]4C[<>8GWL9SQG!Q
MCB,12H4W5K248K=MI)=-WIN;4,/5KS5*C%RD]DDVWUV6NQWM%>"_\/-O@?\
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M - U3_P"7^1[U17@O_#S;X'_ /0[?^4>_P#_ (Q1_P /-O@?_P!#M_Y1[_\
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M )1K_P#^,4?ZP97_ -!-/_P./^8?V!F?_0-4_P# )?Y'O5%>"_\ #S;X'_\
M0[?^4>__ /C%'_#S;X'_ /0[?^4>_P#_ (Q1_K!E?_033_\  X_YA_8&9_\
M0-4_\ E_D>]45X+_ ,/-O@?_ -#M_P"4>_\ _C%'_#S;X'_]#M_Y1K__ .,4
M?ZP97_T$T_\ P./^8?V!F?\ T#5/_ )?Y'O5%>"_\/-O@?\ ]#M_Y1[_ /\
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M / X_P"8?V!F?_0-4_\  )?Y'O5%>"_\/-O@?_T.W_E'O_\ XQ1_P\V^!_\
MT.W_ )1K_P#^,4?ZP97_ -!-/_P./^8?V!F?_0-4_P# )?Y'O5%>"_\ #S;X
M'_\ 0[?^4>__ /C%'_#S;X'_ /0[?^4>_P#_ (Q1_K!E?_033_\  X_YA_8&
M9_\ 0-4_\ E_D>]45X+_ ,/-O@?_ -#M_P"4>_\ _C%'_#S;X'_]#M_Y1K__
M .,4?ZP97_T$T_\ P./^8?V!F?\ T#5/_ )?Y'O5%>"_\/-O@?\ ]#M_Y1[_
M /\ C%'_  \V^!__ $.W_E'O_P#XQ1_K!E?_ $$T_P#P./\ F']@9G_T#5/_
M  "7^1[U17@O_#S;X'_]#M_Y1[__ .,4?\/-O@?_ -#M_P"4:_\ _C%'^L&5
M_P#033_\#C_F']@9G_T#5/\ P"7^1[U17@O_  \V^!__ $.W_E'O_P#XQ1_P
M\V^!_P#T.W_E'O\ _P",4?ZP97_T$T__  ./^8?V!F?_ $#5/_ )?Y'O5%>"
M_P##S;X'_P#0[?\ E'O_ /XQ1_P\V^!__0[?^4:__P#C%'^L&5_]!-/_ ,#C
M_F']@9G_ - U3_P"7^1[U17@O_#S;X'_ /0[?^4>_P#_ (Q1_P /-O@?_P!#
MM_Y1[_\ ^,4?ZP97_P!!-/\ \#C_ )A_8&9_] U3_P  E_D>]45X+_P\V^!_
M_0[?^4>__P#C%'_#S;X'_P#0[?\ E&O_ /XQ1_K!E?\ T$T__ X_YA_8&9_]
M U3_ , E_D>]45X+_P /-O@?_P!#M_Y1[_\ ^,4?\/-O@?\ ]#M_Y1[_ /\
MC%'^L&5_]!-/_P #C_F']@9G_P! U3_P"7^1[U17@O\ P\V^!_\ T.W_ )1[
M_P#^,4?\/-O@?_T.W_E&O_\ XQ1_K!E?_033_P# X_YA_8&9_P#0-4_\ E_D
M>]45X+_P\V^!_P#T.W_E'O\ _P",4?\ #S;X'_\ 0[?^4>__ /C%'^L&5_\
M033_ / X_P"8?V!F?_0-4_\  )?Y'O5%>"_\/-O@?_T.W_E'O_\ XQ1_P\V^
M!_\ T.W_ )1K_P#^,4?ZP97_ -!-/_P./^8?V!F?_0-4_P# )?Y'O5%>"_\
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M"_\ #S;X'_\ 0[?^4>__ /C%'_#S;X'_ /0[?^4>_P#_ (Q1_K!E?_033_\
M X_YA_8&9_\ 0-4_\ E_D>]45X+_ ,/-O@?_ -#M_P"4>_\ _C%'_#S;X'_]
M#M_Y1K__ .,4?ZP97_T$T_\ P./^8?V!F?\ T#5/_ )?Y'O5%>"_\/-O@?\
M]#M_Y1[_ /\ C%'_  \V^!__ $.W_E'O_P#XQ1_K!E?_ $$T_P#P./\ F']@
M9G_T#5/_  "7^1[U17@O_#S;X'_]#M_Y1[__ .,4?\/-O@?_ -#M_P"4:_\
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MY1[_ /\ C%'^L&5_]!-/_P #C_F']@9G_P! U3_P"7^1[U17@O\ P\V^!_\
MT.W_ )1[_P#^,4?\/-O@?_T.W_E&O_\ XQ1_K!E?_033_P# X_YA_8&9_P#0
M-4_\ E_D>]45X+_P\V^!_P#T.W_E'O\ _P",4?\ #S;X'_\ 0[?^4>__ /C%
M'^L&5_\ 033_ / X_P"8?V!F?_0-4_\  )?Y'O5%>"_\/-O@?_T.W_E'O_\
MXQ1_P\V^!_\ T.W_ )1K_P#^,4?ZP97_ -!-/_P./^8?V!F?_0-4_P# )?Y'
MO5%>"_\ #S;X'_\ 0[?^4>__ /C%'_#S;X'_ /0[?^4>_P#_ (Q1_K!E?_03
M3_\  X_YA_8&9_\ 0-4_\ E_D>]45X+_ ,/-O@?_ -#M_P"4>_\ _C%'_#S;
MX'_]#M_Y1K__ .,4?ZP97_T$T_\ P./^8?V!F?\ T#5/_ )?Y'O5%>"_\/-O
M@?\ ]#M_Y1[_ /\ C%'_  \V^!__ $.W_E'O_P#XQ1_K!E?_ $$T_P#P./\
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M_ X_YA_8&9_] U3_ , E_D>]45X+_P /-O@?_P!#M_Y1[_\ ^,4?\/-O@?\
M]#M_Y1[_ /\ C%'^L&5_]!-/_P #C_F']@9G_P! U3_P"7^1[U17@O\ P\V^
M!_\ T.W_ )1[_P#^,4?\/-O@?_T.W_E&O_\ XQ1_K!E?_033_P# X_YA_8&9
M_P#0-4_\ E_D>]45X+_P\V^!_P#T.W_E'O\ _P",4?\ #S;X'_\ 0[?^4>__
M /C%'^L&5_\ 033_ / X_P"8?V!F?_0-4_\  )?Y'O5%>"_\/-O@?_T.W_E'
MO_\ XQ1_P\V^!_\ T.W_ )1K_P#^,4?ZP97_ -!-/_P./^8?V!F?_0-4_P#
M)?Y'O5%9_A7Q/8^-?#&FZSIDWVK3=6M8KVTFV,GFQ2('1MK ,,JP." 1GD"M
M"O5C)27-'5,\N47%\LMPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 &**3./6B@!:.E%% !0:*
M* "CI110!^.__!7K_D^KQ)_UYV'_ *31U\WZ'<I9ZU9S2-MCCF1V.,X 8$G]
M*^D/^"O?'[=7B3_KSL?_ $ECKYDK]^R37+:"_N1_)'Y_CO\ >9_XG^9^UO\
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M%/F #H'1D? X!9@.E>P>(O$-CX1T&]U34[J&QTW38'N;JXF;;'!&BEF9CV
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M'J=A_P $S_\ D^CX>?\ 7[-_Z335]\?\%IO^3-%_[#UI_P"@RU\#_P#!,_\
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MG[,__!.7X;_!'X76&FZKX5\/^)M>EMU;5-0U2RCO&EF91YBQ^8I"1@Y"JH'
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M\<:OXETFUCN=8N-&GTZQ:09CMY97C(E8?Q!0K$+W.T'C->8R?ZQOK7??LO\
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M,D&\$GB) ,T ?O%7+_&WXKZ;\!O@SXN\<:TWEZ/X-T:\UR^;.W$%M \TG/\
MNH:TO GCS1/BAX-TSQ%X;U;3=>T'6K=+NPU'3[A+BUO(7&5DCD0E64CH0:^2
M_P#@X.\6MX)_X(Q_M!7B,RF;PV+#(ZD7-S#;D?B)2* /Y3?A3X2\;?\ !6S_
M (*2:3I>J:B9O&7QM\8!M1ORI9+3[3,7GE"]HX8M[!!T2,*.@K^T_P"!/P/\
M,?LU?!OPWX!\%Z7;Z+X6\)V$6FZ;9PC BB08R3_$['+,QY9F9CDDFOY8O^#2
M7P3:^+/^"SOA.\N(HY'\-^'M8U*W+C_5R&V-MN'OMN&'XFOZRJ "CI110 5^
M1/\ P>,_MD:A\!O^"?'AOX::+?&RU'XQZVUM?;3AY=*LE6:X0$<C=/)9J>Q0
MNIR&-?KM7\V__![GXM:\_; ^"^A;FV:;X.N;\+V!N+UXR?Q^S#\A0!G?\&</
M_!/#3/CK^TIXM^.WBC3[>^TOX4K%I_AZ&>/>AUBX!8W(!XW6\"\9Z/<HPP4!
M']+/2ORS_P"#/KP3;>%O^"/UOJ$,,<<WB3QEJVH7#K]Z1D\FV!/T6W4?05^I
ME !0:** "OQ7_P"#VS_DQWX0_P#8]/\ ^F^XK]J*_%?_ (/;./V'?A#_ -CT
M_P#Z;[B@#'_X,AO^37/CC_V-5C_Z2&OW -?Q;_\ !.;_ (+3_'#_ ():>#_$
MFA?"B^\-VVG>*[R*_ODU325O6,L:%%*L2"HVGD>U?1W_ !%[?MC_ /06^'G_
M (3"?_%T ?U=5\<_\' __*&;]H+_ +%D_P#I1#7X%_\ $7M^V1_T%OAY_P"$
MPG_Q=<#^U)_P<Q?M0?M@_L^^*?AGXRU+P3-X7\86?V'44M- 2WG:/<K?*X8[
M3E1SB@#UC_@SB_Y2YWO_ &(6J?\ H^SK^J U_*]_P9Q?\I<[S_L0M5_]*+.O
MZH: /XV?^#BW_E-5\?O^PW;_ /I!;5^MG_!P3_P2)_X:^_X)B_#'XZ^!]+\[
MXC_"GP-IIU:&"/,NN:&MI')(,#[TEL2\R^J-,/F.P#\D_P#@XM_Y35?'[_L-
MV_\ Z06U?UQ_LGQ+/^RC\-4=59'\):6K*PR&'V.+@T ?S<?\&H__  5R_P"&
M.?VFF^"'C;5/)^&WQ8O473IKB3;#H>N,!'$^3PL=R D+_P"VL#950Y/]11K^
M2#_@Y&_X)(R?\$S/VS'\1>$=/>V^$OQ.FEU3P\8$Q%HMT"&N-.R/NB-F#Q?]
M,G506,;FOW%_X-L_^"MJ_P#!2S]C.+0?%>I+<?%SX7Q0Z7X@,K_OM8ML%;;4
MO5C(JE)#_P ]8V8[1(@H ]&_X.)_^4*_Q^_[ 4'_ *76U?A__P &9G'_  5D
M\0?]DYU/_P!+=.K]P/\ @XG_ .4*_P ?_P#L!0_^EMM7X@?\&9G_ "ED\0?]
MDYU/_P!+=.H _J3H-%% !7DO[>/[14?[(_[%OQ4^)C21QS>"?"]_JMJ' VRW
M4<#FWCYXR\WEJ,]V%>M5^9O_  =M?$BZ\!?\$9O%5A:W#6X\7>(M(T>;:<&6
M,7'VHKGW^RC/J 1T)H _&_\ X-7_ -F'_AL;_@K_ &'BSQ3'-K5M\-[&[\<7
MD]TQD^TZCYJ16SNQY,@N+@3@]2T&>QK^L(U^%?\ P9!_":SL?@C\=O'1AW:A
MJFN:=H2RL/N16T$DY5?3+72D^NU?2OW4H _%?_@]L_Y,=^$/_8]/_P"F^XK'
M_P"#(;C]ESXX_P#8U6/_ *2-6Q_P>V?\F._"'_L>G_\ 3?<5^+__  3F_P""
MT_QP_P""6G@_Q)H?PHOO#=MIWBN\BO[Y-4TE;QC+&A12I)!4;3R.1Q0!_:10
M:_E%_P"(O;]L?_H+?#S_ ,)A/_BZ/^(O;]L?_H+?#S_PF$_^+H _?3_@X'_Y
M0S?M!?\ 8LG_ -*(:_"3_@SAX_X*YWG_ &(6J?\ H^SKRC]J3_@YC_:A_;"_
M9^\4_#/QEJ7@F;POXPL_L.HI:: EO.T6Y6^5PQVG*CG%>L?\&</_ "ESO?\
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MOBG:Z)^T%;K\3?"/G^3J8GTJ'2_$6F(>K0M&L4<A7EC',F7Z>8G6OZ7/A?\
M"KPS\$O >F^%_!^@:/X7\-Z/$(++3-+M$M;6U0=DC0!1ZGC)/)YKYK_X*U_\
M$BOAM_P57^ &J:+XAT?3++X@6-A*OA7Q6(MMYHUS@M&KNOS26S/P\394AB5
M<*P /Y/?^"D'Q5T#XZ?\%._B[XT\*ZC%JWAKQ5X[OM6TN]B!"W5M/=-)&X!
M(RK#@@$'@@$5_;MTK^"C6O ^I?#'XOW?AK6;?[+K'A[6'TR^@SN\F>&8QR+G
MOAE89]J_O7H *#110 5^:O\ P=._L":_^V__ ,$TY]0\'V-QJGBOX4ZHOBFW
MT^WC\R;4+01217<4:]2RQR"8 <M]GV@%F K]*J_-_P#X+9_\'%/@/_@E1'_P
MAGANQL?B)\9+N(2?V(+OR[/0(V7*37[IE@S9#+ N'=>2T:LC, ?DC_P:[_\
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MN-.R/NB-F#Q?],G506,;F@#^M^OBO_@XG_Y0L?'[_L!0_P#I;;5YS_P;:?\
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MK7Q1M_#?]N>"M;ATB*\TBS>T^WQO;K+YDR%V3S-Q(S&$7&/E'4_D?_P><_\
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M_P"#AW_@H3_P4*_:>TWX=_"RX\%SZUXCNGECMD\,P?8]%M=V7FFF8,R6\*L
M7<LQ^4#<[*&_I'^#?A[Q-X4^%>@Z;XR\10^+/%5K91IJVL0V*6,5_<X_>2)
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M@_3=#\"KXR\:>/X;N;3)+ZZ\C2].2W,2N\P3][*Q,RXC4H",DN, '\.O$_\
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M -L=VT*BY3CCY)Q(O']VO8.E?F)_P:*_$FZ\=_\ !&W0=.N)VF3P?XHU?1X
M3_JHVE2\V_\ ?5VQ_&OT[H *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
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M "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110
M=Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "C
MI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*
M** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI11
M0 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z***
M"CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110!^T_P"RQ_R;#\./
M^Q7TS_TDBKO37!?LK_\ )L/PX_[%?3/_ $DBKO:_JS+_ /=:?^&/Y(_EC,/]
MZJ?XG^;"CI1178<@4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M5WG8%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH 3-%'YT4 +1110 4444 %%%% 'X[_\ !7O_ )/I\2_]>=C_
M .DL=?-VA6Z7>MV<4B[HY9T1AZ@L 17TC_P5Z'_&=/B3_KSL/_2:.OFW1+I+
M/6K.:0[8XIT=CC. &!-?ON2_\BVC;^2/Y(_/\=_O4_\ $_S/V[_X8$^"_P#T
M3;PK_P" 8I?^&!/@O_T3;PK_ . 8KC3_ ,%:/@)_T.DW_@EO_P#XS1_P]H^
MG_0Z3?\ @EO_ /XS7Y%]6SO^6K]TS[#VF![P_ ]R^''PP\/?"'PTNC^&-'L=
M#TM)&F%M:1"./>WWFQZGU]J^#?\ @O?_ *OX4_75_P#VRKZQ^"'[=_PM_:,\
M:-X>\'^(Y-4U9;=[HPMIUU;CRT*ACNDC5>"PXSGFOD[_ (+W_P"K^%/UU?\
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MS5\@2<2-]:]4_8L_:+/[+/[1.A^+9(7N=.A9K7484&7>VE&URO(RR\.!D9*
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M%8>/V^_'GTT__P!-UM7DW[.__)P'@7_L8+#_ -*8Z]9_X*P#_C/OQY]-/_\
M3=;5Y-^SN?\ C(#P+_V,-A_Z4QU[.7?\BFG_ ->U_P"DHX\1_O<O\3_,_?*O
MPA_;!_Y.T^*'_8VZK_Z62U^[U?A#^V"/^,M/BA_V-NJ_^EDM?"^'_P#O%7_"
MOS/=XA_AP]3L/^"9Q_XSH^'G_7[-_P"DTU?M=7XH_P#!,[_D^?X>_P#7[-_Z
M335^UU8\??[]3_P+\V7P_P#P)>OZ(_.W_@O?][X4_P#<7_\ ;&OSMK]%O^"]
MMJS6WPKG _=QOJJ$^Y%F1_Z"?RK\ZL5]IP?_ ,BFE_V]_P"E,\7./]\G\OR1
M^Z/[$'_)GOPS_P"Q;L?_ $2M=1\=O^2(>,O^P'>_^D[UX;_P3>_:D\&^,?V3
M/"NFS^(='T_6/#-DNF7UG=W<<,L7E95'PQ&49 K!AQU'4&O:[[Q'H_QR^$6O
M?\(SJFGZY9ZE9W>GQW-G.LT+R;&C90ZD@X8XXK\GQV'J4L=-U(M)3?3S_7H?
M6T*D9T(\KW7Z'X&U]T?\$)F_XO9XV'_4#CX_[;K7PPZM&[*PVLIP01T-?17_
M  3!_:7TG]F3]IB._P#$,PM=!UZPDTF\NB"RV>YTDCE('. \:J?0.3VK]DX@
MP\Z^75:=)7;6B[VLSXS+JD88F$I;7/V8K\??^"PK _MQZY@_=T^Q!]OW"U^H
M?BW]JCX;^"/!\VO:AXW\,+ID,9E$D6HQ3M,/2-4):1CV"@DU^,/[6WQT_P"&
MDOVB?%'C)86MK?5[H"UB;[R6\2+%%N]&,:*6QQN)KX/@7!5EC)UY1:BHM7:Z
MMK3\#WL^K0=%4T]6[_F<K\,?^2D^'O\ L)VW_HU:_H'K^?CX9<?$KP__ -A.
MV_\ 1JU_0/71XA?'0])?H9\._#/Y?J4?$_B;3_!?AV^U?5KN"PTW38'N;JYF
M;;'!&HRS$^@ K\7OV^/VS-0_;!^+LEY&TUKX4T<O;Z+9/P50GYIG'_/23 )_
MN@*O.,GVO_@K3^WE_P +4\13?#/PG>;O#>CSXUBZA?Y=3ND/^J!'6*)A]&<9
MZ*I/P_G->EP?P_\ 5X+&XA>_+X5V7?U?X+U9RYSF'M)>PI_"M_-_Y(ZCX,_"
M#7/CS\2])\*>';7[5JFK3"- <A(5ZM(Y_A1%RQ/H.YP#^W/[+_[.&A_LL?"#
M3O">AIYGV<>;>W;+MDU"Y8#?,WUP !D[5"CM7S)_P30\%_"?]E7X:_VSKGQ#
M^';>.O$D*M>D^(;-CIL/#+:J?,ZYPSD=6 '(0&OI[_AK'X5_]%+^'_\ X4-I
M_P#'*\'BS-,1C:OU>A&7LXOL_>??T73[ST,HPM.A#VDVN9^>R_K<] K^?7XD
M_P#)1->_["-Q_P"C6K]\/!/Q%\/_ !+TR2]\.:[HWB"SAE,$D^FWL=W$D@ 8
MH6C8@-AE.#S@CUK\(OCWH$OA3XY>,M+F3RYM/UR]MF7T*3NO]*[/#].-:O"6
MCM'3YLQX@UA!KS_0]W_X([-C]M_1^G.FWW_HDU^P%?A?^Q5\=+;]F_\ :=\*
M^+KY6;3=/N'AO@JEF6":-H9' ')**^\ =2@%?LM;?M/?#F[\(KKT?CGPI_9+
M1>=]H.IPJH7&>06R&_V2-P/&,\5R\=8.L\;"K&+<7%*Z75-Z?BC7(:T%0<&]
M4_\ (_/O_@NPX_X7GX+7/S?V$Q(_[>)*^&:]Z_X*-_M/V/[5G[25UK6C;FT#
M2;2/2=,E="C7,2,[M*5/(W22.0" =H7(!R*\%SFOT#(,-4P^7TJ516:6J[7U
M_4^>S"I&IB9SCM<_?SX'_P#)%O!__8$LO_1"5^1W_!6'_D_OQY]-/_\ 3=:U
M^N'P/_Y(KX/_ .P)9?\ HA*_(_\ X*PC_C/OQY]-/_\ 3=;5^?\ !/\ R-:O
M^&7_ *5$^ASS_=8>J_)GD?[/T*7/QY\$QR*&CDU^P5E/0@W$8(K]]:_ W]G?
M_DX#P+_V,-A_Z4QU^^5='B#_ !J/H_S1'#OP3]4?G[_P7G4?\(M\-6P,B[U
M9Q_L6]?F[7Z1_P#!>;_D4_AK_P!?>H?^@05^;N*^HX._Y%-/_M[_ -*9Y.<_
M[W+Y?DC]N?\ @G7 MO\ L2_#E8U"J=*#8'J9')/XDDT[_@H>BR?L3_$<,-P_
MLACSZAU(H_X)X'_C"?X<?]@E?_0VIW_!0S_DRCXD?]@=_P#T):_+_P#F<?\
M<7_V\^J_Y@_^W?T/Q"K](_\ @@U_R)_Q(_Z_+#_T">OS<Z&OTC_X(-<>#_B1
M_P!?EC_Z!/7ZAQC_ ,BFI_V[_P"E(^6R7_>X_/\ )GK'_!3']OF?]DCPQ8Z'
MX;2VG\9^(H7EADFPRZ7 #M\\I_$S-N" _+E&)R!M;\H_B-\5O$OQ=UUM4\4:
M]JFO7S9Q+>W+3% >R@G"K[+@#TKWG_@KOK,^J_MV>*()@?+TVUL+:'/=#:Q2
MG'_ I&KRS]DC4O#6D_M,>"+KQA]G_P"$;AU:%[TW S"H!^5I!TV!]I;/&T'/
M%9\.Y?1P66QQ,(7G*/,WU=U>R_*P\RQ$ZV)=)NT4[>7:Y>^''[$OQ9^+6FPW
MN@^ O$%U8W*AX;F6W^RPS*>C(\I567W!(K%^/7[-OC']F;Q#8Z3XTTM-)U#4
M;07L,*W<5P?++LF28V8 [D/&:_=K4/%6EZ1X;DUBZU&QMM(AA^TO>R3JMNL6
M,[RY.W;CG.<8K\:_^"E7[2NF_M0?M.7FK:&YFT'1;2/2-/GP1]K2-G=I0#@@
M-)(^,\E0I..@Y>'^(\9F6*<'34::3N];WZ*][?@;9AEM'#4DU)N3_K8\1\'G
M_BK=+_Z_(O\ T,5_0E7\]O@__D;=+_Z_(?\ T,5_0E7D^(7Q4/\ M[_VT[.'
M=JGR_4_G=E_UC?4U]?\ _!$FTAN?VP=0>4+YEOX:NGAR>0WGVRG'_ 6:OD"3
MB1OK7JG[%G[19_99_:)T/Q;)"]SIT+-:ZC"@R[VTHVN5Y&67AP,C)0#H:^XS
MC#SKX&K1I_$XNW^7S/!P52-.O"<MDS]SJ^3O^"SMU;V_[%LRS+F2;6[-(#Z/
M\['_ ,=5_P Z]U\%_M0_#OX@^%(]:TOQKX9FT^2+SF=]0BB:%>I\Q'(:,CN'
M (K\X_\ @K=^VUHW[0WB32/!_@_4%U+PWX=E>YN[R+_47]V1L7RS_$D:EP''
M#&1L9 !/Y-PSEN(J9E3]UI0=W=-6MW]=CZ[,\53CAI:KWE9?,^-*_4O_ ((7
MV\B_LT>*I6SY+^)Y$4>A%K;$_P UK\M.AK]F?^"6'PEG^$O[&'AI+R'R+[Q"
MTNMS(1SB<CRB?<PK$?;.*^ZXXK1CEW(]Y25OEJ>#D,&\3S=DSZ*HHHK\>/L@
MHHHH **** "BBB@ HHHH **I>(_$>G^#_#U_JVK7UGI>E:7;R7E[>W<RPV]I
M#&I>261V(5$506+,0  23BET'7['Q5HEGJ>EWMIJ6FZA"EQ:W=K,LT%S$X#*
MZ.I*LK @@@D$&@#A_P!IK]DKX:_ME_#6?PA\4O!6@^-O#\^2+;4K8.UNY&/,
MAD&)(9,<"2-E<=C7\]?_  6P_P"#4S4OV3?!7B#XL_L_7VI>*O >CQ->ZMX5
MOLSZOHL Y>:WD4?Z3 @R65@)41<YEPS+_2Q4-]=0V-E--<R1PV\*%Y9)6"HB
M 9)8G@ #.2>U '\IO_!M!_P69U[]@S]J?1?A7XMU6^OO@[\2M1BTM[6:<M%X
M:U&>0)#?0JQQ'&SL%G P"K!SDQ@'^@K_ (+G?#2Z^+/_  2%_:#T>QMVNKI?
M!]WJ21*,L_V3;=G [G$!P!R3@5_'_P#&2/3?&O[9?BI/A[#';Z-JWC2['AF&
MW&5B@DOG^R*F.P1HP,>@K^Z#Q%X=L_%OAR^TG4K>.\T_4[:2TNH7'RS12*4=
M3[%21^- '\B/_!L)\<+/X'_\%H/A2VH2+#8^+/MWAII&;&V6ZM9%MQ[EKA84
MQ_M_A7]?E?Q(?\%#?V0O%G_!*K_@H/XH\"BXU+3[[P3K2:GX7UC!CENK/S/.
ML;V-L8+;0F2N0LL;KU4U_5'_ ,$6/^"OO@__ (*Q_LQZ?K%O>:?IOQ.T&VC@
M\8>'$DVRV5P/E^TQ(>6M9B-R,,A=Q0G<IR ?9E%%% !7\Z7_  >^_#2ZL?CW
M\"/&'V=OL.J:!J6C>>!P)+:XCFVGTXNLC/7YO0U_1;7YW_\ !S9_P3VOOV]O
M^"9VM3>'+*XOO&WPMN?^$MT>VMXR\U_'%&Z7=LH&2Q:W=W55!+20QJ.M 'B/
M_!F+\<;/QS_P38\7>"?,7^U/ ?C.X>2(-EA:WD$,L+D=MTB7*_\ ;/ZX_7ZO
MXX_^"!O_  5:;_@E'^VW;^(-:%Q<?#?QI FA^+;>(,[06YD#17J(/O26[Y;&
M"6C>91\S C^O_P"&?Q-\/?&;P!I'BKPGK6F^(O#>O6J7FG:E83K/;7D+#*NC
MKP1_(@@\@T ;M%%% !7XK_\ ![9_R8[\(?\ L>G_ /3?<5^U%?BO_P 'MG_)
MCOPA_P"QY?\ ]-]Q0!YG_P &:_[-WP[^.'[-?QGNO&O@'P7XPNK'Q-916TVM
MZ);:A);H;4DJC3(Q4$\D# S7[+_\._?@+_T1'X1?^$=IW_QFOR<_X,AO^37/
MCE_V-5C_ .DAK]P* /(?^'?OP%_Z(E\(O_".T[_XS7R7_P %V_V*_@WX!_X)
M%?';6="^$OPST76--\.^=:7UAX7L;>YM7%Q#AXY$B#*P]00:_1*OCG_@X'_Y
M0S?M!?\ 8LG_ -*(: /PE_X,X?\ E+G>_P#8A:K_ .C[.OZH*_E>_P"#.+_E
M+G>_]B%JG_I19U_5#0!_&S_P<6_\IJ_C]_V&[?\ ](+:OZY?V2_^35?AG_V*
MFE_^D<5?R-?\'%A_XW5?'[_L-V__ *0VU?UR?LE_\FJ_#/\ [%32_P#TCBH
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MP)#_ &.U0H947^&:1]K$$B-DVLWP9I/_  5>_P""FO[?322>"=>^,WB"QF)
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MSD_\A[K_ -C!J5?E1_P>UG_C./X0_P#8BO\ ^G"XK]5?^#7+_E!1\#/^X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?M1^RO_ ,FP_#C_ +%?3/\
MTDBKO*X+]EC_ )-A^''_ &*^F?\ I)%7>U_5F7_[K3_PQ_)'\L9A_O53_$_S
M84445V'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF@D$D;CU#*2#^%1A\=A\1_ J1EZ-/\BL1@\10TKP<?5-?F6****ZCG"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHJ'4=0M](L)KJZFAMK6W0R2RRL$2)0,EF)X  [F
MA)MV0-I*[)2=HR>@Y)-?-WQ__P""E7A/X4:BVF^'[?\ X2S4HGVS/!.([2''
M4>9@[S_NC'^UQBO!OVT?V_+[XJW5YX9\(7$UCX74F*>Z3*3:IZ^ZQ'^[P6'W
MN"5'R]FOU+AW@.,HK$9FM]H;?^!/?Y+YOH?D/$WB)*,WALJ:TWGO_P" IZ?-
MWOT74^ZO"W_!731[NYVZSX/OK&'_ )Z6MZMPQ_X"R)C_ +Z-=]XX_P""D/P]
MT7X.ZEXDTG4!J&IVZB.VTJ9&AN)9VSL!!_A&"2RD\*>^,_FO5'68S=SK$/N0
MC\V/7_#';\Z^3\7H95PWD_UK#)QK3?+!7NK[N33N[17GNTMF<O#?&&<8JLZ5
M62E%+5N*37:UK+?NBG\7?B/X@^-WCF]\1>)+Z74-2OGRS-PL2_PQHO144< #
MC\<FN.NM-P.E=A+I7'2LR_T_ /%?QE]>E4FYS=V]V]V>U4IMOFEN<7?V&,UD
MM-<:1>)<6LTUO/"P=)(W*NC#H01R#76ZG:;0:Y[4[;&:]G"UWN>?4IV/K+]@
MO_@I_P"/O &KR>'_ !)J$WC#24020Q:A*6N847AA'-C=QP<-N& < =:_2SX(
M?M%^%_C]HYN-!OLW4*AKBQFPES;Y]5SR,\;ER/>OP5\+ZV_A3QCI^H)_R[3J
M6 Q\RGAA^*DC\:^K/!WC75/ 'B*VU;0[ZXT^_M6#PSPMAA_0@C@@Y!!(.17M
M+C;'91B(.K^\HRW3W36_*_2VCT]+W/J,CS:K&'LZCYDN^]C]>**\/_9!_;#L
M?VA-(&FZEY%AXLLTS+ IQ'>J.LD8/ZKVZC(SCW"OV3*\TPV88:.*PLN:,OP\
MFNC75'V5.K&I'GAL%%%%>@:!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 8HI,X]:* %HZ444 %!HHH *.E%% 'X[_P#!7K_D^KQ)_P!>=A_Z31U\
MR]J_?'QA^SQ\/_B%KLFJ:_X&\'ZYJ<RJLEWJ&BVUU.X484%W0L0 ,#)X K+_
M .&0?A+_ -$O^'?_ (3=G_\ &Z_1\OXWH8?"TZ$J3;C%*]UT5CYO$9'4J595
M%):ML_"&C'%?N_\ \,A?";_HE_P[_P#";L__ (W1_P ,@_";_HE_P[_\)NS_
M /C==?\ Q$##_P#/J7WHQ_U>J?SH_-G_ ((K?\GDR?\ 8OW?_H<->M?\%[_]
M7\*?KJ__ +95]Q>"?@'X%^&FLMJ/ASP5X2\/Z@T9A-UINCV]K,4."5WQH&VD
M@<9QP*N>/?A%X3^*JVH\4>%_#OB06.\VW]JZ;#>?9]^W?L\Q3MW;5SC&=H]!
M7SM;B6G/-X9ER.T5:W79K]3THY9)8-X;FU;W^:?Z'\_U?N7^PGQ^QO\ #3_L
M7K3_ -%BM3_AD+X3?]$O^'?_ (3=G_\ &Z[G0M!L?"^CVNG:;9VNG:?91K#;
MVUK$L,,"*,*B(H 50.  ,"CB3B:GF5&%.$''E=]6NU@RW+)86;E*5[HX;]KS
M_DT[XH?]BEJO_I'+7X0]J_H:U?2;77]*NK"^M;>^L;V)X+BWN(Q)%/&X*LCJ
M00RL"001@@D5P7_#(/PE_P"B7_#O_P )NS_^-U/#?$E/+*<X3@Y<S3T#,LME
MBI1E%VL?$?\ P08_Y&CXE?\ 7KI__H=Q7Z&^-O!>E_$7PCJ6@ZU9QWVDZM;O
M:W5O)]V6-A@C/4'T(Y!P1R*S_ 7P<\(_"N2Z?POX5\-^&WO@JW#:7ID-F;@+
MG:'\M1NQN;&>F3ZUTE>1G69K&8Z6+IIQO:W=627Z'9@L+[&@J,M=_P 6?C/^
MVQ_P3J\7?LI^([N^L[2[U[P/)(SVNJP1F0VB9X2Y"C]VPX&[A&Z@@Y4?.O:O
MZ('194964,K#!!&017DOCO\ 8+^#OQ(O6N=5^'OAUKAN7DM(39,Y[EC 4W'W
M.37U^6\>.%-0QL')KK&VOJG;\_D>/B<@O+FH2LNS_P S\.*V? 7P[UWXH^);
M?1_#ND:AK6J7)_=VUG TLA'J0.BCNQP!W(K]CM._X)?_  'TN?S(_A]9LV<_
MOM0O)E_)YB/TKUSX?_"KPS\*=,:S\,^']%\/VK8WQZ?9QVXD(Z%MH&X^YR:[
M,3X@4%'_ &>G)O\ O62_!LQI</U+_O)*WE_2/G;_ ()N?\$]8_V3-"G\0>)/
MLMYXZU>+RG,1WQ:5 <$PHW1G) WN.. J\ EOJDT45^<X['5L76=>N[R?]67D
M?24*$*,%3IK1'\[LG^L;ZUT_PJ^#?B#XU:EJ=CX:L)-4U#2]/DU-[6(%IIHH
MV0.(UQ\SC?G:.2 <9. ?VW/[(?PG8Y/PO^'9)ZG_ (1NSY_\AUK^"?@'X%^&
MFLMJ'AOP5X2\/Z@T9A-UIND6]K,4)!*[XT!VD@$C.#@5^A5O$"GR/V5)\W2[
M5OF?.PX?E?WI*Q^!<L36\S1R*T<B':RL,%3Z$4G:OW0^*W[%'PI^-NJR:AXE
M\#Z+?:A,2TMW&C6MQ,3W>2$HSGW8DUC>"?\ @G3\$_A_J,=UI_P]T5IH3E#?
M/-?A3Z[9W<9]\<5T1\0,)R7E3ES=M+???]#-\/UN;22M\_R_X)^=7_!/#_@G
MGK'[3GC6Q\0>(+&XT_X?Z;*LT\TR,G]L%3GR(>FY21AW' &0#NZ?KY;6T=C;
M1PPQQPPPJ$C1%"JB@8  '  ]*+6VCLK:.&&..&&%0B(BA511P  .@'I4E?!Y
MYGE;,JWM*FD5LNW^;?5GO8' PPT.6.K>[/QF_P""L'_)_GCSZ:?_ .FZUKR;
M]G?_ )+_ .!?^Q@L/_2F.OV_\6_LY_#WQ]K\^K:[X#\&ZUJEUM\Z\O\ 1+:Y
MN)=JA5W.Z%CA0 ,G@ #M533?V4_A=HVHV]Y9_#;P#:7=K(LT$\/A^TCDA=3E
M65A&"K @$$<@BOJL-QK1I8..%=-WC%1O==%:YY57))RK.JI+5W_&YWU?A#^V
M#_R=I\4/^QMU7_TLEK]WJX/6?V6_AEXCU>ZU#4/ASX#OKZ^E:>YN;C0+26:X
MD8EF=W:,EF)))))))KY_AO/(995G4G%RYE;3U/1S+ RQ45&+M9GY&_\ !,__
M )/H^'G_ %^S?^DTU?M<:XGPQ^S7\.?!.NV^J:+X!\$Z1J=F2T%Y9:':V]Q
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M[3L[JZ=OP.W!Y9.A2J0YM9;/MN?SX=Z7M7[N_P##(7PF'_-+_AW_ .$W9_\
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MA/X5^*D-M'XH\,^'_$D=FS-;KJFG0WBP%L!B@D5MI.!G'7 KF_\ AD'X3?\
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M^)'P_P#!/Q T_39C<VEKXET.UU:&UE*E3)&DZ.JL5)&X '!Q0!_-%_P9F?\
M*67Q!_V3G4__ $MTZOZD^E>6_!?]AWX*_LX>+)=>^'?P?^%O@/7)K9K*34?#
MGA2PTN[D@9E9HC+!$CE"R(2I."44XX%>I4 ?RP_\'&W_  05\6?L3?'7Q)\7
MOAKX?O-8^"?BR\DU*X%A"TS>#;F4EY89U492U+EC%+]U01&Q#!3(W_@G/_P=
MK?'#]B_X::7X)\=>'=+^,_AG0X5MM.FU'4)-/UJVA486(W@259448 ,D3. ,
M;R, ?U.SP)=021R(LD<BE71AN5@>H([BODWXR_\ !"3]D'X]Z[/J?B/X!> _
MMUUS-+I5O)HQE8]686;Q L>['D]S0!^27Q@_X/@O%VL>')8? 7[/_A[P_JK+
MB.\UWQ/-JT*''7R(;>V)P?\ IKS5[_@W$_:I_:3_ ."EW_!6V^^,OQ3OO%7B
MCPEH'A34M*2_6S-MX>T6:9[<I:P(@6!)&"9(&9&"!G+8S7ZH?#7_ (-__P!C
M7X4:I'>:7^S[X%N9HONC5TGUB/CU2\DE4_B*^M?#/A?3/!6@6NDZ-IMCI.EV
M,8BMK.R@6WM[=!T5$0!54>@&* +]?S,_\'(7_!O5XK_9\^,7B3X[?!GP[>>(
M/AAXHN9-4U[2=-A::Z\)WDC,\\@A4$FR=B7#+D0EF5@J!"?Z9J* /Y0_^"9_
M_!U+\=/V!?ASIG@7Q-I.E_&#P/HL:V^FV^KWDEIJNFP+PL$5ZJOF)1PJRQR%
M0%52JJ%KZ7^-'_![]XQU[PE+;?#_ . ?A_PSK4D9"7^N>)I=8@A8CJ((K>V+
M8Z@F3![BOV%^/G_!%O\ 95_:<\0S:MXR^!7@&^U:Z9GN+ZRLCI=S=.3DO+):
MM$TC'^\Y)]ZP?AA_P0+_ &.?A!?V]SH_[/W@.::U<21MJT4VL88'()%W)*#^
M.: /G+_@UA_;!^,'[<O[.OQ>^(/Q@\1Z]XEU+5/&BC39KR,PV5O +.(-%9Q
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MG2;70-*MK&QM;>RL;*)8+>W@C$<5O&H"JB*H 55    P ,58H _FK_X/;/\
MD^/X0_\ 8BM_Z<+BOU4_X-<CC_@A1\#?^X__ .I!J=?6WQM_8R^#_P"TSK5G
MJ7Q(^%'PU^(&I:= ;:TN_$OABRU::UB+%C'&\\;LJ[B3M! R2:ZKX7_"CPO\
M$/ MCX7\%^&O#_A#PSI>\66D:)I\6GV-IOD:1_+@B543=([N=H&6=B>230!\
M'_\ !PQ_P153_@K+^SUI^I>$6LK'XQ?#]99/#\US)Y,&KV\F#-I\S]%W%0T;
MMPD@P2JR.P_G)_9#_;G_ &D/^"%G[3.M6NCV^I^#M<CD6V\2>#_$MA)]AU14
M)V^= 2IXY*3Q,K;6.URKD-_:-7F?[2'[&/PE_; T./3_ (H_#GP;X[MX$*0-
MK.E17,UH#U\F5E\R(GUC930!^'^@_P#!\AJ4'A-8]4_9ML;K7%CPUQ:^-V@M
M)'_O")K%W4?[/F,3_>%<S^P#_P ' 7[2'_!5#_@L3\$O#MY<+X/^',.LSW%[
MX9\*13);SP"TG&^^F):29 Q7ARL6[:=@8 U^K&G_ /!N1^Q/INN?VA'\ O#;
M7']V74=0F@_[\O<&/_QVOIO]GW]E7X:_LH>%9-#^&?@/PGX$TN9M\T&B:9%9
MBX;^](44&1N?O.2: //O^"G?[ 'AO_@IG^QEXL^$_B*;["^K1K=:/J83<VD:
MC%EK>Y [J&)5U&"T;R+D;LC^2?Q=X"_:._X(1?MN6]Q-'K'PZ^(7AF9SI^IP
MH9=.URVX#-$[+Y5W:R+C<I!'\+*KJ0O]K%<?\:OV?_ O[2/@U_#WQ"\&^%_&
MVANV\V&NZ9#?VZO@C>$E5@K $X88([&@#\#O@Y_P? ^+-$\(0V_C[X Z%XCU
MR.,"2_T3Q1)I-O.P'7R);:X*Y//$AQZ5XY^V3_P>)?M"?M#>'[G0?AAX9\.?
M!NSU &(WMG*VL:TH88*QW$J)$A.3\RP!P<%64C-?M+JW_!M]^Q+K6J?;)O@'
MX?2;).VWU74K>+_OW'<JGX8KV3]F_P#X);?LZ_LB:M#J7PY^#/P_\,:O:_ZG
M5(=*CFU*+_=NI0TP_!Z /!/^#:WP!\0OA_\ \$H_":_%#3?%&F^+]:UG5=9N
M5\1+*NI7*7-V\J3R^;^\S(&WY?E@V>^:^9?^#U[_ )1P?#/_ +*3;_\ IKU&
MOV0KC?C7^SM\/_VE?#-OHOQ&\"^#?'^CV=R+V"Q\2:+;:K;03A602K'.CJL@
M5W4,!G#L,X)H _&W_@R#_P"3:/CI_P!C/I__ *2O7[B=*X?X'_LR_#;]F72K
MZQ^&_P /? _P^L=4E6>\M_#6A6NDQ7<BC:KR+;H@=@. 6!('%=Q0 5_*;_P=
MM?M40_M*?\%79/!^B77]HZ?\*=$MO#/EP9D5M1D=[FY"XZN#-%"P'\4&.H-?
MT7?\%1?V^_#O_!-7]BKQE\4M>N+7[;IMJ]KX?L)3SJ^JR(PM;90.2"XW.1RL
M:2-T4U_.7_P;3_L(Z]_P4H_X*CM\5?'$-WKGA?X<Z@WC+Q%J5VFY-5UF25I;
M6%FZ,[W!:X88(*0.#C>,@'](G_!,K]FC_ACS_@GW\'_AK+;_ &6^\*^%K*#4
MH\8Q?O&);LX][B28_C7NG2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %?!O_!;;_FF7_<5_]LZ^\J^#?^"VW_-,_P#N
M*_\ MG7R/'?_ "(Z_P#V[_Z7$^LX&_Y'=#_M[_TB1\&]Z***_G4_H8*.E%%
M!WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *
M.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WH
MHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%
M% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH
M *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !
MWHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.
ME%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHH
MHH *.E%% !WHHHH *.E%% !WHHHH *.E%% !WHHHH *.E%% '[3_ ++'_)L/
MPX_[%?3/_22*N]-<%^RO_P FP_#C_L5],_\ 22*N]K^K,O\ ]UI_X8_DC^6,
MP_WJI_B?YL*.E%%=AR!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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M\3[#XS_##0_%&FMFTUJU6X"YR8GZ/&3ZHX93VRIK\COVS/\ D[_Q]_V'Y_\
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MTWRQC\4NRO;;JWT7^1]R^-?^"AOP=\!Z@UK>>-;&XN%."+"":\0?\#B1D_\
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M[6?_ $7+_P O/6?_ (S7Z)44?ZU8O^6'_@"'_9-'O+[V?G;_ ,.\_P!K//\
MR7+_ ,O/6?\ XS1_P[R_:R_Z+E_Y>>L__&:_1*BC_6K%_P L/_ $+^R:/>7W
ML_.W_AWE^UE_T7+_ ,O/6?\ XS1_P[S_ &L_^BY?^7GK/_QFOT2HH_UJQ?\
M+#_P!#_LFCWE][/SM_X=Y_M9Y_Y+E_Y>>L__ !FC_AWE^UE_T7+_ ,O/6?\
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M,U^B5%'^M6+_ )8?^ (?]DT>\OO9^=O_  [S_:SS_P ER_\ +SUG_P",T?\
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M1P<E4(_92B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _&O_@O-_P $4_VN/^"N_P"T[IUQHOBSX2Z#\(O!\0M_#>E7^MWZ7&^15-S>
MW$<=DZ><[#: KL%CC0 Y9RWZ-_\ !-G_ ()^^#?^"9W[)/AOX5^#8UFCTU/M
M.K:FT82?7-1D \^[DZ\L0 JDG9&D: D**]YHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^#?\ @MM_S3+_ +BO_MG7WE7P;_P6W_YIE_W%?_;*
MOD>._P#D1U_^W?\ TN)]9P-_R/*'_;W_ *1(^#:***_G4_H8**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /VH_97_ .38?AQ_V*^F?^DD5=Y7!?LL?\FP_#C_ +%?
M3/\ TDBKO:_JS+_]UI_X8_DC^6,P_P!ZJ?XG^;"BBBNPY HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW>^][ZW^9\[_ /!3+X :G\>/V=F_L.WDO-8\.W2ZC%;1C=)<QA2LJ(.[;2&
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M'X7_ /83?_T1)7WU_P ''_\ R;?X _[&5O\ TFDKX%_X)+_\I$?A?_V$W_\
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M_P"#UW]G*YU"..]^&?QJM;=CAI8[/39F3WV_;%R/Q_.OL?\ 8(_X+U_LS?\
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M1?0/:17VI:K<:@^G0.07BMQ*Q$8; !;ERN5W8)! /KR@T44 %'2BB@ H-%%
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MJ7\0_@G\.OBEXNT#P)I.NVOA+3-$T*^.FK<70BA@N%FD@"R3;KLS#;(S #
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %?!O_!;;_FF7_<5_P#;.OO*O@W_ (+;?\TS
M_P"XK_[9U\CQW_R(Z_\ V[_Z7$^LX&_Y'=#_ +>_](D?!O>BBBOYU/Z&"CI1
M10 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z***
M "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110
M=Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "C
MI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*
M** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI11
M0 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z***
M"CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110 =
MZ*** "CI110 =Z*** "CI110 =Z*** "CI110 =Z*** "CI110!^T_[+'_)L
M/PX_[%?3/_22*N]-<%^RO_R;#\./^Q7TS_TDBKO:_JS+_P#=:?\ AC^2/Y8S
M#_>JG^)_FPHZ445V'(%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M'57STU]8M6OYI_)'Y4?&;]N#XF?'OPW)HWB3Q$\^DS,K26EO;Q6\<I4AAO\
M+4%@& .&) (![5TO_!.3X5^(/%G[4'A75+'2;Z;2](O/M%Y>B%OL]NJJ3AGQ
MM!/  SDDBOTJT']DWX9>&YO,L_ ?A6.3^^^G12,/H6!(_"N\L;"'3+5+>VAA
MMX(QA(XD"*H]@.!2P?AWBY8V&,S'%.;@T^K;L[I7D]%\@QG'^%C@YX/+\,H*
M2:Z)*ZLW9+5_,\._X*7PO/\ L3>-@JLQ5;1B .@%Y 2:_*[X5?$[5_@SX^T_
MQ-H<D4.JZ6S/;O+$)44LC(<J>#PQK]PKZQAU.SFMKF&*XMYT*212H'213P05
M/!!]#7,CX"^!@/\ D3?"O_@I@_\ B:]?BG@VOFF.IXZA6]FX126CO=2;3337
M?\#R^&>,*.68*>"KT?:*;;>JM9I)IIKR_$_-/_AZ[\9/^@MI/_@KA_PK[$_X
M)J_M.>*_VF/ 'B.\\626UQ<Z7?I#!-#;K"K(T>2I"\<$9S_M5[1_PH7P-_T)
MOA7_ ,%,'_Q-;7AKPAI/@RS>VT?2]/TFWD?S'BL[=($9L ;B% &< #/M71DG
M#N;X3%QKXO&NK!)WB[ZW6F[>VYSYUG^58K"NCA<&J<W:TE;2SUV2WV/RK_X*
ME'/[:_BG_KC9?^D<-?HU^QM_R:E\/?\ L VO_HL5U7B7X1^%/&>I?;-8\,^'
M]6O-H7S[S3H9Y,#H-S*3@5N6-C#I=E#;VT,5O;VZ".**- B1J!@* .  . !7
M1D?#%3 9GB<PE44E5;:5MKRYM?R,,ZXDACLMP^!C!Q=))-WWM&Q^:_\ P5R_
M9W_X0'XNVOC;3[=ETOQ:,795/DAO$ #<@8'F)AAGDLLA[5\C6O%S'_O"OW;U
MWP_8>*-->SU.QL]1LY,%X+F%9HVQR,JP(XK#L_@CX,TZ[CN+?PCX9@GA<21R
M1Z7 KQL.000N01ZBOF,\\,_KF-GBL/54(S=[.-[-[VU6[U^9])DOB/\ 4\'#
M#5Z3G*"LG>UTMNG1:?(M?"RTET_X8^'+>>-X9H=+M8Y$889&$2@@CU!XK\/]
M<'_$_O/^OA__ $(U^[U<G<? ?P/=WSW4O@WPK)<R-YCROI,!=F[DG9G/O7O<
M7<(U,XIT(4ZBC[.^ZO>_+V]#P^$^*X91.M.I3<O:6V=K6O\ YE[X7?\ ),_#
MO_8+MO\ T4M?G!_P4,_8+UKX2^.]4\7>&--DOO!NIR-=RK;1Y.CN>71U'2+.
M2K 8 (4XP"WZ>(H10J@!5& !T%!7<,$<'K[UZN?\,X?-L''#5G:4?ADMT[6V
MZI]5^IYF0\1XC*\6\315U+XHO9J]_DUT9^,?P+_; ^(7[-\$UKX8UR2UL;AM
MTEE<1+<6^[^\$<':W3)7!.!G-;WQ*_;6^+G[2\4/AZ[UB\N(+YQ"--TJV$/V
MLMQL98QNDSP-K$CVK]1=>_9C^'/B>]:XU#P+X1NKASN:632H#(Q]SMR?QK4\
M$_!?PA\-IC)X?\+^']$F(P9++3XH)".^650?UKX>CX?YM&G]4>.:H]ES;=N6
M]OE>Q]I5X\RJ53ZTL$G5[OEW[WM?YVN?(/\ P4:L_'WP_P#@A\(]4T6;7=/F
M\,VGE:I<V,KAK2?R(%4R,I[E9%W'C)(SSSX[X4_X*[_%?PWI$=K=IX;UJ2,8
M^T7EDRRM]?+=%/UQDU^HDL2SQ-'(JNC@JRL,A@>H(K@]7_98^&NO7C7%YX!\
M'S3MRTATF ,Q]R%Y_&O<S7A/,I8N6+RW%NGS**<7>WNI1OIILNW?4\7*^*,N
MCA(X7,<*JG*VU)6OJV[:Z[OO\C\EOBM\6/&W[87Q7AOM0CFUC7+Q5L[.SL;<
M[8T!)6.-%R>I8]R<DDU^F7_!/K]F.Z_9C^!26.K+&OB'6Y_M^H*A#?9R5"I#
MN'!V*,G'&YVP2,$^I^"?A)X5^&N[_A'O#>A:&7&UFL;"*W9Q[E5!/XUT5:<,
M\%O+\5+,,95]K6E?7HK[O75M]]--+&?$?&"Q^&C@,)2]G2C;3J[;+31)=M=>
MH4=***^\/APH-%% !1THHH *#110 4=*** "@T44 %'2BB@ KRC]NWQ%-X2_
M8I^+6IVY99K'PAJDT9'4,+60BO5Z\;_X*'V[W7[!GQDCC4M(W@S50 .I/V22
MNC!I/$03[K\SGQ;:H3:[/\C^9GP[9Y(-=YX=L,E>*Y'PW'PM>@>&HQ\M?T)3
M/P'$2/I;X ^,CXB\&QV,\FZ\TI!&-S?,\/1#]%X7C@?+ZBNZKY]^'NJS>'M5
MM[RW;;)&>1V8=P?8U]0_ 3P3)\>?B#X?T72V+-K-VD+D#+6Z?>D9A_L(&8^P
MKT(XB-.FYU'913=_)?Y'S-;"RG64:2NY.R7F_P#,^T?^"8'[-0\/>')/B#JT
M/^FZHK0:5&Z\PP D/+SW<@@?[()Y#"OKSI5/P]H-KX6T&RTVQB6&ST^!+>",
M=$1 % _(5<K^=\XS2IF&+GB:G5Z+LNB_KKJ?TMD>4T\MP4,)3Z+5]Y/=_?\
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M?YFOT4K^C/"F3>32O_S\E^43Z+*OX/S_ ,@HZ445^F'I'YS_ /!Q_P#\FX>
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MI4W9M.W_ ($SS<PKPHYNZM172:O]R/Z()/V8/AI,C*_P[\"LK#!4Z#:D$?\
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M^V'X'\!^ ]6L_$EA\(=/O+;4=3L9$FM9=0O'@:6"*121)Y26\*L0<!RZ]5-
M'[A?\$$_VU==_;W_ ."6OPU\=^*[AKWQ=#%<:'K=VWWKVYLYG@%PW^W+$L4C
M]/G=L#&*[+_@H1_P27^"?_!4&3PBWQA\/ZIKC>!Q>#2?LFK7%AY'VKR/.W>4
MR[\_9HL9SC:<=37"_P#!OW^R'K7[$_\ P2<^%7@_Q/:&P\47EK<:_JMLRE9+
M66^N)+E(9 >1)'"\,;@]'1A7V=0!^;7_ !";?L4?]"#XF_\ "LU#_P".4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^*?\
MP>'?\%.+CX(? C0_V<_"=_);>(/B9 -5\3RPR;9+?1DD*QV^1R/M,\; ^L=N
MZD$25^UE?R-_$@W'_!='_@XSFTMKBXU'POXS\=G2X6B<_N_#>G;@S1XX0M96
MLDG'&^0GDDD@'Z^_\&GO_!*ZW_9#_8ZC^-'BG3(T^(OQDM4NK-I4_?:5H1P]
MM$O]TW&!</@\J;<$ H:_6>J^DZ3:Z!I5K8V-O#9V5E$D%O!"@2.&-0%5%4<!
M0   .@%6* "OS[_X.=OC'XO^ W_!(CQIXD\#>*O$G@OQ%:ZQI$4.J:%J<^G7
ML*/>QJZK-"RN RD@@'D'!KN-3_X.$_V,='U*XM+CX^>$H[BUE:&5?LUXVUE.
M",B$@X(Z@U\&_P#!QW_P6(_9H_:^_P""5WBSP+\-?BUH/BWQ9J6K:5-;:;:6
M]TLDB17<<DC9>)5 55)Y(_.@#Z9_X-5?CIXV_:&_X)6Q>(/'WC#Q1XXUY?%V
MIVHU+7]4GU*\\I! 5C\Z9F<JI9L#.!DXK]):_"+_ (-E/^"N'[./[%W_  3/
M7P7\4?BKH/@_Q0/%>HWW]GW<%R\GD2+ $?,<;+@[6[YXK]"O^(B7]BO_ *+_
M .$__ 6]_P#C% 'VG7A?_!37]I+4/V/_ /@GU\8OB7HTUO;Z[X1\*WM[I,L\
M8ECCOO+*6I9#PP$S1Y4\'IWKW3K7YB?\'<OQS7X2_P#!';7M"6;R[CXD>)-+
M\/1A3\Q5)3?OCVVV6T_[^.] 'Q%_P2M_X.GOBAJ=U\6_&'[26OZ#JG@3P/X2
M^U:7IVEZ-#8W^K:W-=P1VEI"Z=3)&+DMN!"JA<X"-7QW^TG_ ,'/G[9OQ^\9
M:AXD\/\ C6;X;^$H[K%II7AW2;<VEA_=22YEB>65R,$[WVDY*HHPHXW_ ((
M_P#!)&3_ (*R?M>S:/X@DU"Q^%O@B"/5_%ES:DHUR"Q6WL4?^"2<B3YNJQQ3
M$?,!7]<'@3X"^"?AC\([3P#X?\)^'])\$V-G]@AT.WL8UL1!C!C,6-K C.[<
M"6)).230!Y7_ ,$J_B+XX^+'_!-WX+^,/B9K3:]XT\5>$[/7-3U&2VAM6N/M
M,?GQL4B1(UQ%)&#A1G&3R2:_,G_@KW_P=RZ/^SQXXUCX<_LXZ7H?CC7--+6M
M]XSOY6FT>TG&0Z6D*$?:BO\ SU+B+<.%E7FO3_\ @ZQ_X*+W'[!/["?A_P"$
M/P]>UT#Q!\7(I]&7["H@_L;0K:.-+A840 1^8)(H%P !&9MN"H(^-O\ @U0_
MX(;^%_VB]!F_:0^,&A6'B3PU:WDEAX,T&_B\ZTO;B!]LU_/&?DD2-P8HT;<I
M=969?D0D ^?Q_P %6O\ @JI\7?"\?Q&TFX^-=UX4AC-U%J>C?#6+^QA#C)?=
M'8^5)&!R6<L .IKZF_X(N_\ !V+X^\<_'_PY\+?VECHNL:?XMOUTVQ\:6UG'
MIUSIMU*=L27<,*K \+2%4WHD9CW[FW*#M_?3QGXVT+X5^#;[7/$&K:3X=\/Z
M- 9[R_U"Y2UL[*)>K/(Y"(H]20*_C+_X*+>-_#O[:_\ P6$\=ZI\";'_ (E/
MQ \;PVWA=;. V_\ :%W*\4/VB-,*5^T76^89 ;]\,@'- ']$G_!R+_P4I^-?
M_!/'X/\ PS_X47IMQ<^)O%^LW?VZZ&@'5HH+.V@7=&R[65&>2XB()P2(FQQF
MOYG_ -O_ /;L^+'_  48_:"C\8?%RZCU#QEIMA'X>2*#3EL?LT4,LK"'R5 P
MPDFER,9W,:_N"FN$L+-IKB5$CA0O)(QVJH R6/8#O7\>O["=K)_P4P_X.%?"
M6L3QO=VWCSXK7'C"XB=<AK.&ZEU-XB.RB" ICL.* /3O@?\ \%[_ -O+]G?X
M,^$_ /A?26L_#?@O2+71-,A?X?B1X[:WB6*,,QCRS;4&6/).2>37]$OQ3_:F
M\8?LT_\ !('4OB]XXDL5^(WAKX7C7M2"VWDV[:W_ &<'\L19PJF[8)M]_P *
M^G:_,+_@[F^/7_"H/^"/FM:#'-Y=U\2O$FF>'E"G#F-)&OY".^W%EM/L^.]
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M\X^ 8/\ P5 _X.&-&U!A_:&F_$7XNR:W)&?F#:5%>O=M&/9;.$J#Z**_L3H
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MZI/&UY:_$+XL3>*[F%AG=8Q7<NHRQX[*+>%E]@/:O[&* /R5_P"#GC_@L_\
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MHDR:<+AXX_$6K.D3-:I@_)&(UA:=UPY7R4!^;<@!U?QH_P""^O\ P40_;O\
M[:\8?!_POXX\'_#.P+,8_!'@R35K:QCC.29]1:VD<NH^^5:-."=BBO5?^"'?
M_!T?\8/%/[6?A/X5_M#:W8^-?#'C[4(=%L/$#Z=!8ZAH=Y*?+MP_V>-(YH9)
M2B.77>N_?OPI5OZ'O!W@S1_AWX6T_0_#^EZ;H>BZ5"MM96%A;);6MI$HPJ1Q
MH J*!T   K^,3_@L>^E?"_\ X+#_ !UF\!LNCV^A^/;RXLVL_P!W]BO$F#RF
M/'"[+D28 Z8&,8Q0!^\'_!<;_@YPT?\ 8 \:WGPE^#.FZ3X\^+5N3!JUY=%Y
M-+\,3'A861"&N;KGF,,JQG 8LVZ,?E'\:/\ @M+_ ,%-O@U_9OCKQQXB^*G@
M71]2D\K3[K5_A[;:7H]TQ!8)&LUBL,IV@D9W-@$YZFOU:_X-S/\ @A-I?[,_
MPXTO]H#XT:7_ ,)'\<O'*?VU9+K ^TOX6@GQ*CXDR?M\N[?)*WSQ[_+&TB0O
M]<?\%X]%\.Z[_P $>OVA(_$UO!<:?#X/NKFW$JA@E['M>S89Z,+D0D'KF@#P
M/_@W'_X+DZI_P5?^&WB7PI\1+72['XK^ (8+BYGL(S#!X@L9#L%V(ND<B2 +
M*JG9F2-E"ABB_II7\Q/_  96:5J4_P#P4S^(%Y;^8NFVWPVO([L_P%WU+33&
MI_VCL<CIPK?0_N)_P6P_X*)0_P#!,C_@GMXR^(EO-"OBV\4:%X2AD4,)M6N5
M<1-M/#+"BRSLIX98&'4B@#PG_@M+_P '(/P]_P""5^LR^ O#NDK\1OC T"3R
MZ2EUY&GZ"D@S&U[,H+>8RD.L"#<5(+-&&0M^/L7_  7?_P""E'[?VOWEQ\*_
M^$PFT^%RLEA\._ (O+:R)P<--Y$\RX!'WY>_O7-_\$ ?^"4&H?\ !9_]LSQ)
MXX^*VH:IK'P_\(WB:OXONKFYD^V>*+^Y=W2T\[.[]X5=YI%;<$  *M(K+_59
M\*/A'X7^!/P^TSPGX+\/Z/X6\-:-"(+'3-+M$M;6V3T5$  R<DGJ223DDF@#
M^57XB_\ !8G_ (*<?L7PVMY\0/$OQ<\%V=Q.(8)?&/@.WA@NI,,WEJ]W988E
M58X5LX4D=*_8[_@V3_X*?_'+_@J%\'?B=XA^+\GAJ\L?">IV.DZ->Z9I?V&>
MYF:*66Z$VUS&VU6M=H1%QN;.<C'R=_P>^_'K[/X8^ _PPMYL_:KK4O%%_#G[
MOEI%;6K8]_-NQG_9]Z^RO^#4#X"_\*5_X(U>#=2DA\B\^(FL:GXGG4CYB&G^
MQQ,?]Z"SA8>S"@#O_P#@Y$^/?_#/O_!&;XT7D4WDWWB;3H?"UJN<&;[?<1V\
MRC_MV>=OHIK^>?\ X(0_\%#O _\ P2FUOXP?&K7[#_A)/&J>'(?"O@[PZD@C
M;4+F[G\^:>1^?+@A6RC#N 6_?JJ@ER1^H'_![=\?/^$>_9@^#/PSAFVR>*O$
MMWXAN$4\F.PMA"H;_9+7^0#U,?\ LU\7?\&O'_!$O1O^"@GQ.U;XN?%71GU+
MX4^ ;I+73],F!6W\2ZL-LACD_OV\"%6D3@.TL:DLHD4@&-\4/^"TW_!3;]I/
MPU>?$[0;?XE^'/ANS-=P7/A+X?LN@V42Y)Q>-;2.\:@'+2SN!W(Z5])_\$)?
M^#I#XF_$7]ISPO\ !_\ :+U+3/%&D^-[Q-)T?Q9]DAL+[3;Z3"V\5P(52*6&
M1]L>[8KJT@9F89Q_0?9:?;Z;80VMM##;VMO&(HH8D"QQHHP%51P    !T K^
M.S_@XC_9]T/]DG_@LE\6-%\%VJZ'H\]Y9>(;*WM%\E+&6\M(+J41!0 BBX>4
MJ%P%!4#I0!_8S17._"'QDWQ%^$WA?Q!(NQ]>TBTU%E_NF:%),?\ CU=%G% '
M@/\ P4Y_;]\-?\$S_P!C/Q;\5O$?DW$NE0_9=%TUGVMK.IR@BVM5[X9@6<C)
M6-)'P=M?S>_\$,/V!_$__!<#_@IUKWQ2^+#3^(/!WAW5/^$K\;7ERG[K6KR6
M0O;Z:!T"2,I+(.%@A9!MRE:7_!PG_P %%O$'_!8;_@HSH?P=^$_VCQ%X+\'Z
MM_PC/A:TLFW)XDU>:18I[P?PLI<"*-B2HBC+@@2M7]#?_!)S_@G5X?\ ^"7W
M[$_A;X7Z1]GNM6A3^T/$FJ1)C^U]5E5?/F]=@VK'&#R(XHP><D@'Y>?\%\/^
M"Y7[4G[$7[>VN^ _@SI_]G> _".@V,MY=W/A+[=!)<20FYEE6=T*B-8Y(D.#
MM4Q-T.:_"OPA\=_B%XH_;!A^+6EPR>(/B5_PE7_";[DT[[8)]16[^VM*T !#
M)YWS%2,8R.E?UX?\%Y?CW_PS?_P2#^/7B))OL]U>>&9= MF!PXEU%TL%*_[2
M_:=W'3;GM7XP?\&47P$_X3']MSXI?$6:'S+?P/X2CTJ)B.(KG4+E65@?7RK*
MX7Z.: .I_P""=/\ P78_;Z_:@_;L^$_@'Q#;6\/AOQ-XFL[76I)O @ME33Q(
M'NCYFQ=A\A9,'(P<5^[G[9/[9_PY_8'^ VK?$?XG>(+?0?#FE+M7/SW.H3D$
MI;6T6<RS/@X4=@68JJLP]4K^3G_@XN_;X\5?\%0/^"HLGPK\)-)J/A7X?:X?
M!/A/2[5]R:GJ;SK;W%SZ,\MP!$AZ>7''CEF) /7/VI_^#M?]IW]K/XJP^&_V
M<_"\?P_LKJ5H=-M+'2(_$GB+5#S@L)(I(@2!D)%"2N2-[X!KROQ?_P %H_\
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M^"PGA?\ X*_?LXWGB.QTU?#/CCPK/'8^*/#_ -H\X6DCJ6BN(6X9K>;:^TL
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M<\-00ZM<L<M/J%MFTNW/NUQ!*<>]?1U?D[_P9L>.IO%G_!)?5M-FF>1?"_Q
MU/3X48Y\J-[6QNL =@7N'/U)K]8J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@
MW_@MM_S3+_N*_P#MG7WE7P;_ ,%M_P#FF7_<5_\ ;*OD>._^1'7_ .W?_2XG
MUG W_(\H?]O?^D2/@VBBBOYU/Z&"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]J/
MV5_^38?AQ_V*^F?^DD5=Y7!?LL?\FP_#C_L5],_])(J[VOZLR_\ W6G_ (8_
MDC^6,P_WJI_B?YL****[#D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *XW]H2ZDL?@CXHDA=HY%T^0!EZC(P?T-=E7$_M'_P#)"O%'
M_7@]>5GK:RW$-?\ /N?_ *2SNRS7&4D_YH_FCP;_ ()RWDTGB/Q)&TDC1M;1
M.5+$C(8@']3^=?5]?)?_  3B_P"1H\2?]>L?_H=?6E?%>$G_ "3%#UG_ .ER
M/HN//^1W5](_^DH****_2CX\**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHJOJNJ6^B:7<WMU(L-K9Q---(W"HB@LQ/L ": /E'_@IY\3O)L]!
M\(P2+^^)U*[7N ,I$/\ T8<>RGTKB_\ @FQ\.F\1_&"\U^6/=;>'[5MC'^&:
M7**/^^/,_*O'_CK\3IOC#\5]9\02!U2^G/D1MUBB4!47ZA0,^IS7W-^PO\*O
M^%9_ :PFFC*W_B _VE/D<JK "-?IL ;GH7-:/2('LE%%%9@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5S/QF\&K\1/A!XJT!D\Q=:TBZL=O\ >\R%TQ^M=-15
M1DXR4ET)E%2BXOJ?RDZ?:RZ3J5Q:S+LFMI6BD4_PLI((_,5W/AN?&VN__P""
MHO[/\W[,?[?GQ T/[/Y&EZIJ#:YI3!-L;VMU^^4)ZB-V>(G^]$U>5^'K_;MK
M^@\'B(UJ4:T=I)/[T?@688>5*K*E+>+:^X]6\.7. M?1?['?Q;U;X(>.(_%>
MC^2US8L(MDJAHY58$.A'7E>,C!&3@U\L:#J@4+\U>^_ ]XY_ [3+_K7NG5CZ
M@*N/YFO15.%:+I5%>+T:?5'SU>I.@U6INTHM--=&?L;^S;^U7X:_:4\-K/IL
MZV>L0IF\TN9QY\![E?[Z>C#U&<'BO3J_&'P]XDU#PEJ\&H:7>76GWULX>*>W
MD,<D;#N".17UY^S]_P %4+C3+2#3?B!8R7PC^4:K9H%EQQS)%P&/7E=O;Y2<
MFOR_/N JU*3K9=[T?Y>J].Z_'UW/U#AWQ%H5HJCF?N3_ )OLOU[/\/38^XJ*
MX_X8?'WP=\9+99/#?B#3=2D(W-;K+MN$]<Q-AP/?&/>NPK\]K4:E*7)5BXOL
MU9GZ51Q%*M!5*,E*+ZIW7WH*\/\ VT/VEX?@[X0?1=,GSXEU>(K'L/S641X,
MI]&/1??)[8.M^TQ^U;I/P%TF2U@:'4/$LR9@LMV5AST>7'(7N!P6[8'(^ _%
MWBW4?'7B*ZU;5KJ2\U"]<R2ROU8GVZ #H . !@<5^.^(W'U/ 4I99@)7K2TD
MU]A==?YGT[;Z.QGB*_*N6.YFLQ9B3R2<D^M%%%?S2>:5=<MEN+(2 8DAX)_O
M*3_0_P _:L6NF2-9\QL0JR J2>@SQS7,LIC8JPVLO&".E>EA9WA;L>?BHVE?
MN?4'_!+3PXU[\6]<U+_EG8::8CQ_%)(N/T1J^[*^;O\ @F9\-9/"?P5O-<N(
M]DWB2[+Q9ZF"+**?;+^9^&#7TC7]6^'N!EA<BHJ6\[R_\">GX6/H,OI\M"-^
MNH4445]J=AQ/QM^!O@/XZ:)9V?CWP_HGB#3[&<SVT>IQJR12%2NY<]\9%<;X
M _8O^!7PS\8V&O>'? W@C2=;TV3S+2[M88UF@?!&5.>#@D?C7F/_  5HT?3_
M !)X9^#NEZP(FT;5/B3I5IJ$<LOE12V[[Q(KMD84J3GD5'\4_P!BO]E;0?AU
MKEY/IW@_1EM[&:3[9;ZXT$MN0A(9&$V=P/('.3V->M1@U1C>I)*5]$KK>W\R
MW]#RJTTZTK4XMQMJW9]^SV/KAW6)&9F"JHR23P*(9DN(EDC99(V&593D,/8U
M\E_LWZKXDU;_ ((\077BJ347UIO!NI9EO=PN)(0+@6[L3SDP"(@GD@@UD:Q\
M5M8^#7_!$/1_$6@W<ECK5KX#TV&TNE^_;O,D,/F+Z,HD)![$ UE_9\N9P3UY
M^3R]37^T%RJ;6G)S^?H?7M]XKTO2[CR;G4M/MY<XV2W"(V?H37GGQ+_8T^$?
MQY\4R>(O%'@3POXDU:XC2)KZZMEEDD1!A1N[@#@5Y_\ #C_@F'\%?^$"T9M9
M\#Z?X@U:2RBDO-1U2::[NKN9D!>1I'<G)8D\<#/%<U^S?X+T_P#9<_X*)^*O
MACX7DOK7P9X@\&6_BBVTB2ZDG@TZZ6[>"0P^8Q**R\E0<9QZ"G3IP7-+#U)<
MT5?:UU=7U3?J*=2;Y5B(1Y9.V][.VFC2/=/A%\!?AG^S;-J,7@WP_P"&_"<F
MI;/MBV2I"T^W.S<,]MQQ]:;\6/V:_AC^TI?V=UXO\*^&_%USID;16\EW"L[P
M(QR5![ GG%?,'PN_9A\!_M)?\%!?VD/^$X\.VGB+^Q[_ $9;+[3))BV#Z>A<
M*%88S@$_2K'[1'[//A#]C#X[_ GQ!\,=+?PMJ'B'QQ;>'=2MK2\G,&I65RK+
M*LD3.5;8/G!QD$9K?V/[U)59>T<4[V[QO:_-?;38P]L_9-NG'V:;5K]I6O;E
MMOKN?3?P=_9@^&O[.VKW<W@KPCX=\+WVK1B*=K&W6*2X1#D ]R 3FI_C/^S+
M\/OVAFT]_''A'0_%#:2)!:-J%N)3;!]N_:3TSM7/^Z*\,_:;UF'1/^"G?[/T
MUU>16=K_ &/K_F--.(H\^3'C)) Z]*^@/&'Q*\.R^$M45?$&B%FLY0,7\7)V
M'_:KEJ1K1<*RDVY*]];K5K?Y'53E2DITG%)1=K:6>B>WS.=^#_['WPG^"OB4
M>(/!/@?PSH.J-"]N+W3[=4<QL1N7<.Q('Y5>U[]FSX;W5[-?:EX7T%I[J4R2
MSSQC=*[')))/))S7E/\ P1_G>Y_X)[> WD=I&;[<2S,6)_TV?O7G/[?'@:3]
MNO\ :ITOX(V-[=6VG^$/"]]XGU>:WE,?E7\\9@TY&(_N,?-(.05<>]9XK*J6
M,Q4J.-M-0OK)<UDNMGWVWZF/MH1PL*L*:O*UHZ;OY?IT/KOP%\)/#/PP-PWA
M[0].TEKS;YS6T05I0N=N3UP,G\ZV[O5[73Y MQ=6\+,,@22!21^)KQO_ ()Z
M?&JZ^.G[)GA74M4\Q?$.DQ-HFM1R?ZQ+VT8P2[O<E W_  *O&?VC?@YX:^/?
M_!6#P?X=\7:3#KFB?\*\N[LV<[N(_-6[ 5\*1R Q'XU.%RVG2G+#)*$8<VD4
MK:=EHM3:6*4:,*E)?%:RVW^3/J#XH?#'P/\ M">'%T'Q9I>@^*=-69;E;.\"
M3H)%! <#/4 D9'8FO/U_X)T? '0)X[P?"_P59R6[J\<WV14*,#D$'/!R*\7_
M &\?V$_A3\!_V3?&?C?P;H*^"_%/A.S&I:7JNFW]Q;S07".NQ<^9AMQ.W!!S
MN'?%6/\ @I-<S_$[_@G[\/9-<\Z.?Q)K'AS^TEB8POF=H_-4$?=^^P]J]'#T
MI/D5"K)1E*W:STULG9[]SEKU8KG=:G%RBK][K7JTFMCZ2^,'[,'PY_:-GT^Z
M\:>$=!\52:?&RV<M] )C"CX+!3Z' /X5P]W_ ,$WOV>]/C#W'PL\"P*3@-)9
MJH)_$US/_!,+Q)J/A?X>>*?A#X@NY+SQ#\'-9ET;SI3\]YI[DRV<_P!&C) ]
M-N*\&_X*Y7=Q^T1XU\4>%[2\N(] ^"O@VZ\4:MY$A42ZG<)Y=G"Q!SE4)EP>
MWUHP]"O]9^JQJN,5U3=K/9I7ZW5O46(KT?J_UETTY/H[7NMU>W2S^X^HT_X)
MI? %U#+\)_!+*PR"+!2#79?#3]FKX8_ N^C;PMX+\(^&[R7.R2SL(8;A^QPV
M-Q_ UI?L]'=\!?!)))/]A67)[_N$KX(_:W\.>(OVG_CE\8OBAX;O+M5_9QMK
M*T\-112$0W6H6TJWM\6"D;ML0:,@Y!#CK@5GAXUL14E2J56HKJVVM[+2_5O[
MC3$3I8>$:E.FG)]$DNEWTZ)?>?I/17-_!WXH:;\:_A5X=\7:2X?3?$>GPZA!
MSDJ)$#;3[J25/N#725Y<HN+<7NCTXR4DI1V84445)04444 %%%% !1110 44
M44 %%%% !1110 8HI,X]:* %HZ444 %!HHH *.E%% '\HO[!EC'^U#_P=>PW
MFI ZC'=?%[Q'K\7F'=M^Q/?WL!'M']GCV^FP5_5T:_E*_P""#9_X07_@YMT;
M3=2_>72^)?&&G-*_59EL=3&[ZDH5_P"!5_5K0!\\_P#!7+_E%7^TI_V2_P 2
M?^FNYK^/;]@E_P!H%/C3=?\ #-O_  LO_A/O[)F^T_\ "#BY.H_V?YD7F[_L
M_P _D^9Y&<_+NV=\5_83_P %<O\ E%5^TI_V2_Q)_P"FNXK^?G_@S!_Y2N^*
M?^R::E_Z<-,H ^?OV@?!7_!2CQYX4N++XB:5^V-K'A^ZB:&YM=0M]>N+"1#P
MRR1@&(@C@[AR*X[_ ()+?M@_!W_@GS^U):>*OC3\#M0^)E]HM^GV5IM3%NWA
MB5& :==/DB\NYN(R"56:1 K!2-K*&K^SZOR7_P"#LK_@G-X#^,__  3V\2_&
MZWT.QT_XE?#"2TNDU:UB2&?5;*:Z@M9K>Y8#,JHLHD3<2R&,A2 [!@#](OV4
M/VL? /[;GP*T3XD?#77[?Q'X3UY&-O<QHT<D4BG;)#+&P#1RHP(9& (Z\@@G
MT;I7\\/_  9&?M$:M#\5_C1\)Y[^YET*ZTBV\66=DQS#;7$4RVL\B#LTBS6X
M;U$*>E?T/4 %?RQ?\':7[<UU^UI_P4EM_A3X?N)M0\-_!N :+%;V^9!=:S<;
M'O&4#EF7]Q;[<9#6[X^]7])W[:G[2FG_ +'?[)/Q&^*.I>6UOX%\/W>KI%(<
M"ZFCB8PP_6279&/=Q7\M7_!N?^S9??\ !1'_ (+2>'_$?C!I==@\+75W\2/$
M=Q.-QO+F*4/"SGH2]_/ S _>4.,=< ']*'_!(K]AFS_X)U_\$^/AS\,4MXHM
M:T_3EO\ Q%*F";C5K@"6[8L/O!9&,:G_ )YQ(.U?2G2BB@#S?Q7^V-\(O GB
M*\T?7/BI\.-%U;3Y/*NK*^\2V5O<6S_W7C>0,IYZ$ UG_P##>7P-_P"BS_"?
M_P *[3__ ([7Y2_\%"/^#1K6?VW?VT_B+\6;7XZZ9X=M_'>K-JB:;+X3>Y>R
MW*H*&07:A\%3SM&?05XU_P 0./B#_HX[1O\ PBI/_DV@#]Z_AC\>_ OQL:\7
MP9XT\)^+FTX(;H:+J]O?_9=^=F_RG;;NVMC.,[3Z&O)?^"N7_**O]I3_ +)?
MXD_]-=S7S7_P0B_X(0ZE_P $:?$GQ*U"^^)=E\0%\?VVGVZ);Z&VF_8OLK7#
M$DM/+OW>?CMC;WSQ]*?\%<>/^"5?[2G_ &2_Q)_Z:[B@#^/?]@GXW?'?X"?&
MF\UK]GFX\86_CF?29;2X;PWI1U*\-BTL+2 Q"*3$?F)#EMO!"C/.#]AC_@I;
M_P %3/\ H)?M"_\ A!M_\A5W_P#P9A?\I7?%/_9--2_].&F5_490!_)I_P /
M+?\ @J9_T$OVAO\ P@V_^0J\1_;W_:^_;6^/GP6L]%_:&O/BO/X&@U:*\MU\
M1^&FTRS^W+%,L>)/L\89_+>;"ECD9..,C^SFOR5_X/-N/^"3OAW_ +*1IG_I
M#J5 ' ?\&2?_ "9#\8/^QYC_ /2""OVI-?BM_P &2?\ R9!\8/\ L>4_]((*
M_:F@#^=__@K3K7_!32/]OKXM6OPE3]H3_A5W]L'_ (1\^'+64V?V4Q1D>0\2
M[L;MW0YSFORK_:[TO]HBV^)&BZE^U-I?Q\OT@G6+/C6;4+:\E@W!I(K6XOHY
M$C+*#@JCJ#@[6 Q7]NE8OQ$^&_A_XO>"M2\->*M#TGQ)X>UB$V]]INI6J75K
M=QGJKQN"K#ZB@#\H_P#@V?\ VX_V+=5\%3?"[X*>&[[X6_$K5#]HU#3?%-TE
MWK'BHQ1EC)%? !;A8UWGR56+8/,980I9C^NQK^.S_@LK^RI)_P $</\ @KOJ
MEA\)]4OO#]CHMS8^,O!L\<Q>XT=)?WJ1;FR6$,Z2QKO+%HT7=N);/]:_[+GQ
M<D_: _9E^'7CR:W6SF\;>&-,U^2!<XA:ZM(IR@SSQYF/PH [75-,M]:TVXL[
MN&.XM;N)H9HI%W+*C AE([@@D8K^4K_@VMFD^ O_  <*Z#X/AEDMX)YO$WAJ
M9"Q_>)!9W<JHWK\]HAY[@5_5Y7\H/_!(-O\ A8'_  =+Z3>:7^YM[KXB>+=1
MCV=%A%OJDQ'T*#'XT ?U?4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH \U_;+^)MQ\%?V0/BMXRM6VW7A+P=J^M0MG&U[:RFF4Y^J"OYR?^#,
M'X2P>,O^"F7B_P 47*JP\&^!;I[;(Y6XN;JVA#?]^O/'_ A[U_0-_P %4-)F
MU[_@F+^T996[,MQ=?#'Q)%'CNQTNY 'X]/QK\,O^#(O688/VOOC1I[!?M%UX
M.MKA#_$%CO45L>V95_2@#^D>@T44 ?BUXB_X,I/@WX@\07U^?C%\3(OMUQ)<
M%!:6+;-[%L9\OG&:^2/^"SW_  ;&?#G_ ()E?L%^(/BYX;^)7C7Q)JFBZA86
MB6.IVMLEO*MQ<+"Q)C4," V1]*_I<K\U_P#@[,X_X(J>.O\ L-Z+_P"E\5 '
MY:?\$/O^#:_X>_\ !5']B/\ X6GXG^(OC+PSJ3:_>:0++2[:V> ) L1#YD4M
MN/F'/;@5]AK_ ,&1WP:##=\9?B:1W_T.Q_\ B*]@_P"#/3_E#^G_ &.VK?\
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M30^9!X+\*P:+"S#B.XU"Y$@8?[0CL95^DA]10!_2=7Q#_P '&WQY_P"&??\
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M/^"ZWQ&M?![0WTOBGQI9^!]#,3;XKE[<0:5&Z$?>622(N"."'R.*_;;_ (.
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M)O'_ ,5M6M39W?B2ZM1;0V,#$%[>S@W-Y2L57<[,SOMZJI*5F?\ !T[\?/\
MA1G_  1E^(EK#-]GO_'M[I_A:T;.-WG7"S3K[[K:WN!^-?7W[&/[8W@K]O;]
MGW2OBA\.YM2O/!^N7-Y;Z?=7UD]G)=BVN9+9Y%C?Y@ADB?;N ..H!R!^//\
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M0 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=***
M#O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4
M=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1
M110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=**
M* #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110
M 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #
MO1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=*** #O1110 4=
M*** #O1110 4=*** /VG_98_Y-A^''_8KZ9_Z215WIK@OV5_^38?AQ_V*^F?
M^DD5=[7]69?_ +K3_P ,?R1_+&8?[U4_Q/\ -A1THHKL.0*#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !7$_M'_\D*\4_P#7A)7;
M5Q/[1_'P*\4_]>#UY.??\BS$?]>Y_P#I+.[*_P#?*7^*/YH\!_X)Q_\ (T^(
M_P#KUC_]#KZT-?)?_!.+_D:?$G_7K'_Z'7UI7Q?A'_R3%#UG_P"ER/H^/?\
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M5?VF_P!BSXN?#?0KC3[/6_'W@W5_#NGSW[NEK#<7=G+!&TK(KL(PT@+%58@
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M1\,]%\+^ ])NX6M_$FHWUM<->7,R-*Z+!:3J4,<$ R6!RIXQ@GZY_P"",'[
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M!$7GAA<NLGVAC\F,2+@GFOT"HH *_(7_ (.'_P#@@[\>/^"NG[3'@GQ)\/\
MQ7\+]&\(>$?#/]F+:>(]2O[>Z-[)=323R*L%G,GEM']F4$L#F-N,8)_7JB@#
MPG_@F1^R+/\ L&_L#?"SX1WEQIUUJG@O1([;4Y[!G:UFOI&:>Z>)G5&:,SRR
ME2RJQ!!*@G Y?_@KQ_P33T?_ (*M?L6:O\+-1U=O#NI+>0:SH6K>29UT[4(
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M@!ST]?GJW_X-B_V_K;2W\-1Z);Q>'Y.'A7QY:C3V'O$)LG_OBOZN:* /Y_\
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MP8_97^&'_1./ ?\ X3]I_P#&Z/\ AE?X8?\ 1./ ?_A/VG_QNN\HH_L_"_\
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MA_T3CP'_ .$_:?\ QNC_ (97^&'_ $3CP'_X3]I_\;KO**/[/PO_ #[C_P"
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M'@/_ ,)^T_\ C==Y11_9^%_Y]Q_\!7^0?VABO^?DOO?^9P7_  RO\,/^B<>
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M_"?M/_C==Y11_9^%_P"?<?\ P%?Y!_:&*_Y^2^]_YG!?\,K_  P_Z)QX#_\
M"?M/_C='_#*_PO\ ^B<> _\ PG[3_P"-UWM%']GX7_GW'_P%?Y!_:&*_Y^2^
M]_YG!C]E?X8?]$X\!_\ A/VG_P ;H_X97^&'_1./ ?\ X3]I_P#&Z[RBC^S\
M+_S[C_X"O\@_M#%?\_)?>_\ ,X+_ (97^&'_ $3CP'_X3]I_\;H_X97^%_\
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M_P#A/VG_ ,;KO:*/[/PO_/N/_@*_R#^T,5_S\E][_P S@Q^RO\,/^B<> _\
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M-11168!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\57AT_P[X5TZ;4]0G$9D9(HD+,%0<NYQA5&2S$ 9)%=110!_*[\/OA!\5_\
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M6&N+D_[*^G^T< >N<5\^_'?_ (*20Q0S:?X#MVDD92IU2[CP$/K%&>OJ"_\
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** $S11^=% "T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 &**3./6B@!:^>_^"EOP[_:*^)W[.L.F_LP
M^//"?PY^)"ZQ!-+JOB*W2>S:P"2B:(*]I=C>SF(@^4.%/S#H?H2B@#\@?^&-
M_P#@LE_T=C^S_P#^"BV_^9ZC_AC?_@LE_P!'8?L__P#@HMO_ )GJ_7ZB@#\@
M?^&-_P#@LE_T=A^S_P#^"BV_^9ZC_AC?_@LD/^;L/V?_ /P46W_S/5^OU% '
MY _\,;_\%DO^CL?V?_\ P46W_P SU'_#&_\ P62_Z.P_9_\ _!1;?_,]7Z_4
M4 ?D#_PQO_P62_Z.P_9__P#!1;?_ #/4?\,;_P#!9(?\W8?L_P#_ (*+;_YG
MJ_7ZB@#\@?\ AC?_ (+)?]'8_L__ /@HMO\ YGJ/^&-_^"R7_1V'[/\ _P""
MBV_^9ZOU^HH _('_ (8W_P""R7_1V'[/_P#X*+;_ .9ZC_AC?_@LD/\ F[#]
MG_\ \%%M_P#,]7Z_44 ?D#_PQO\ \%DO^CL?V?\ _P %%M_\SU'_  QO_P %
MDO\ H[#]G_\ \%%M_P#,]7Z_44 ?D#_PQO\ \%DO^CL/V?\ _P %%M_\SU'_
M  QO_P %DA_S=A^S_P#^"BV_^9ZOU^HH _('_AC?_@LE_P!'8_L__P#@HMO_
M )GJ/^&-_P#@LE_T=A^S_P#^"BV_^9ZOU^HH _('_AC?_@LE_P!'8?L__P#@
MHMO_ )GJ/^&-_P#@LD/^;L/V?_\ P46W_P SU?K]10!^0/\ PQO_ ,%DO^CL
M?V?_ /P46W_S/4?\,;_\%DO^CL/V?_\ P46W_P SU?K]10!^0/\ PQO_ ,%D
MO^CL/V?_ /P46W_S/4?\,;_\%DA_S=A^S_\ ^"BV_P#F>K]?J* /R!_X8W_X
M+)?]'8_L_P#_ (*+;_YGJ/\ AC?_ (+)?]'8?L__ /@HMO\ YGJ_7ZB@#\@?
M^&-_^"R7_1V'[/\ _P""BV_^9ZC_ (8W_P""R0_YNP_9_P#_  46W_S/5^OU
M% 'Y _\ #&__  62_P"CL?V?_P#P46W_ ,SU'_#&_P#P62_Z.P_9_P#_  46
MW_S/5^OU% 'Y _\ #&__  62_P"CL/V?_P#P46W_ ,SU'_#&_P#P62'_ #=A
M^S__ ."BV_\ F>K]?J* /R!_X8W_ ."R7_1V/[/_ /X*+;_YGJ/^&-_^"R7_
M $=A^S__ ."BV_\ F>K]?J* /R!_X8W_ ."R7_1V'[/_ /X*+;_YGJ/^&-_^
M"R0_YNP_9_\ _!1;?_,]7Z_44 ?D#_PQO_P62_Z.Q_9__P#!1;?_ #/4?\,;
M_P#!9+_H[#]G_P#\%%M_\SU?K]10!^0/_#&__!9+_H[#]G__ ,%%M_\ ,]1_
MPQO_ ,%DA_S=A^S_ /\ @HMO_F>K]?J* /R!_P"&-_\ @LE_T=C^S_\ ^"BV
M_P#F>H_X8W_X+)?]'8?L_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)?]'8?L__
M /@HMO\ YGJ/^&-_^"R0_P";L/V?_P#P46W_ ,SU?K]10!^0/_#&_P#P62_Z
M.Q_9_P#_  46W_S/4?\ #&__  62_P"CL/V?_P#P46W_ ,SU?K]10!^0/_#&
M_P#P62_Z.P_9_P#_  46W_S/4?\ #&__  62'_-V'[/_ /X*+;_YGJ_7ZB@#
M\@?^&-_^"R7_ $=C^S__ ."BV_\ F>H_X8W_ ."R7_1V'[/_ /X*+;_YGJ_7
MZB@#\@?^&-_^"R7_ $=A^S__ ."BV_\ F>H_X8W_ ."R0_YNP_9__P#!1;?_
M #/5^OU% 'Y _P##&_\ P62_Z.Q_9_\ _!1;?_,]1_PQO_P62_Z.P_9__P#!
M1;?_ #/5^OU% 'Y _P##&_\ P62_Z.P_9_\ _!1;?_,]1_PQO_P62'_-V'[/
M_P#X*+;_ .9ZOU^HH _('_AC?_@LE_T=C^S_ /\ @HMO_F>H_P"&-_\ @LE_
MT=A^S_\ ^"BV_P#F>K]?J* /R!_X8W_X+)?]'8?L_P#_ (*+;_YGJ/\ AC?_
M (+)#_F[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.Q_9__ /!1;?\
MS/4?\,;_ /!9+_H[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.P_9__
M /!1;?\ S/4?\,;_ /!9(?\ -V'[/_\ X*+;_P"9ZOU^HH _('_AC?\ X+)?
M]'8_L_\ _@HMO_F>H_X8W_X+)?\ 1V'[/_\ X*+;_P"9ZOU^HH _('_AC?\
MX+)?]'8?L_\ _@HMO_F>H_X8W_X+)#_F[#]G_P#\%%M_\SU?K]10!^0/_#&_
M_!9+_H[']G__ ,%%M_\ ,]1_PQO_ ,%DO^CL/V?_ /P46W_S/5^OU% 'Y _\
M,;_\%DO^CL/V?_\ P46W_P SU'_#&_\ P62'_-V'[/\ _P""BV_^9ZOU^HH
M_('_ (8W_P""R7_1V/[/_P#X*+;_ .9ZC_AC?_@LE_T=A^S_ /\ @HMO_F>K
M]?J* /R!_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>H_X8W_X+)#_ )NP_9__ /!1
M;?\ S/5^OU% 'Y _\,;_ /!9+_H[']G_ /\ !1;?_,]1_P ,;_\ !9+_ *.P
M_9__ /!1;?\ S/5^OU% 'Y _\,;_ /!9+_H[#]G_ /\ !1;?_,]1_P ,;_\
M!9(?\W8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\ 1V/[/_\ X*+;_P"9ZC_A
MC?\ X+)?]'8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\ 1V'[/_\ X*+;_P"9
MZC_AC?\ X+)#_F[#]G__ ,%%M_\ ,]7Z_44 ?D#_ ,,;_P#!9+_H[']G_P#\
M%%M_\SU'_#&__!9+_H[#]G__ ,%%M_\ ,]7Z_44 ?D#_ ,,;_P#!9+_H[#]G
M_P#\%%M_\SU'_#&__!9(?\W8?L__ /@HMO\ YGJ_7ZB@#\@?^&-_^"R7_1V/
M[/\ _P""BV_^9ZC_ (8W_P""R7_1V'[/_P#X*+;_ .9ZOU^HH _('_AC?_@L
ME_T=A^S_ /\ @HMO_F>H_P"&-_\ @LD/^;L/V?\ _P %%M_\SU?K]10!^0/_
M  QO_P %DO\ H[']G_\ \%%M_P#,]1_PQO\ \%DO^CL/V?\ _P %%M_\SU?K
M]10!^0/_  QO_P %DO\ H[#]G_\ \%%M_P#,]1_PQO\ \%DA_P W8?L__P#@
MHMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=C^S_P#^"BV_^9ZC_AC?_@LE_P!'8?L_
M_P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=A^S_P#^"BV_^9ZC_AC?_@LD/^;L
M/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL?V?_\ P46W_P SU'_#&_\ P62_
MZ.P_9_\ _!1;?_,]7Z_44 ?D#_PQO_P62_Z.P_9__P#!1;?_ #/4?\,;_P#!
M9(?\W8?L_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)?]'8_L__ /@HMO\ YGJ/
M^&-_^"R7_1V'[/\ _P""BV_^9ZOU^HH _('_ (8W_P""R7_1V'[/_P#X*+;_
M .9ZC_AC?_@LD/\ F[#]G_\ \%%M_P#,]7Z_44 ?D#_PQO\ \%DO^CL?V?\
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M?_,]1_PQO_P62'_-V'[/_P#X*+;_ .9ZOU^HH _('_AC?_@LE_T=C^S_ /\
M@HMO_F>H_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>K]?J* /R!_X8W_X+)?]'8?L
M_P#_ (*+;_YGJ/\ AC?_ (+)#_F[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\
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M /\ !1;?_,]1_P ,;_\ !9(?\W8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\
M1V/[/_\ X*+;_P"9ZC_AC?\ X+)?]'8?L_\ _@HMO_F>K]?J* /R!_X8W_X+
M)?\ 1V'[/_\ X*+;_P"9ZC_AC?\ X+)#_F[#]G__ ,%%M_\ ,]7Z_44 ?D#_
M ,,;_P#!9+_H[']G_P#\%%M_\SU'_#&__!9+_H[#]G__ ,%%M_\ ,]7Z_44
M?D#_ ,,;_P#!9+_H[#]G_P#\%%M_\SU'_#&__!9(?\W8?L__ /@HMO\ YGJ_
M7ZB@#\@?^&-_^"R7_1V/[/\ _P""BV_^9ZC_ (8W_P""R7_1V'[/_P#X*+;_
M .9ZOU^HH _('_AC?_@LE_T=A^S_ /\ @HMO_F>H_P"&-_\ @LD/^;L/V?\
M_P %%M_\SU?K]10!^0/_  QO_P %DO\ H[']G_\ \%%M_P#,]1_PQO\ \%DO
M^CL/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\ H[#]G_\ \%%M_P#,]1_P
MQO\ \%DA_P W8?L__P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=C^S_P#^"BV_
M^9ZC_AC?_@LE_P!'8?L__P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=A^S_P#^
M"BV_^9ZC_AC?_@LD/^;L/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL?V?_\
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M  62_P"CL/V?_P#P46W_ ,SU'_#&_P#P62'_ #=A^S__ ."BV_\ F>K]?J*
M/R!_X8W_ ."R7_1V/[/_ /X*+;_YGJ/^&-_^"R7_ $=A^S__ ."BV_\ F>K]
M?J* /R!_X8W_ ."R7_1V'[/_ /X*+;_YGJ/^&-_^"R0_YNP_9_\ _!1;?_,]
M7Z_44 ?D#_PQO_P62_Z.Q_9__P#!1;?_ #/4?\,;_P#!9+_H[#]G_P#\%%M_
M\SU?K]10!^0/_#&__!9+_H[#]G__ ,%%M_\ ,]1_PQO_ ,%DA_S=A^S_ /\
M@HMO_F>K]?J* /R!_P"&-_\ @LE_T=C^S_\ ^"BV_P#F>H_X8W_X+)?]'8?L
M_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)?]'8?L__ /@HMO\ YGJ/^&-_^"R0
M_P";L/V?_P#P46W_ ,SU?K]10!^0/_#&_P#P62_Z.Q_9_P#_  46W_S/4?\
M#&__  62_P"CL/V?_P#P46W_ ,SU?K]10!^0/_#&_P#P62_Z.P_9_P#_  46
MW_S/4?\ #&__  62'_-V'[/_ /X*+;_YGJ_7ZB@#\@?^&-_^"R7_ $=C^S__
M ."BV_\ F>H_X8W_ ."R7_1V'[/_ /X*+;_YGJ_7ZB@#\@?^&-_^"R7_ $=A
M^S__ ."BV_\ F>H_X8W_ ."R0_YNP_9__P#!1;?_ #/5^OU% 'Y _P##&_\
MP62_Z.Q_9_\ _!1;?_,]1_PQO_P62_Z.P_9__P#!1;?_ #/5^OU% 'Y _P##
M&_\ P62_Z.P_9_\ _!1;?_,]1_PQO_P62'_-V'[/_P#X*+;_ .9ZOU^HH _(
M'_AC?_@LE_T=C^S_ /\ @HMO_F>H_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>K]?
MJ* /R!_X8W_X+)?]'8?L_P#_ (*+;_YGJ/\ AC?_ (+)#_F[#]G_ /\ !1;?
M_,]7Z_44 ?D#_P ,;_\ !9+_ *.Q_9__ /!1;?\ S/4?\,;_ /!9+_H[#]G_
M /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.P_9__ /!1;?\ S/4?\,;_ /!9
M(?\ -V'[/_\ X*+;_P"9ZOU^HH _('_AC?\ X+)?]'8_L_\ _@HMO_F>H_X8
MW_X+)?\ 1V'[/_\ X*+;_P"9ZOU^HH _('_AC?\ X+)?]'8?L_\ _@HMO_F>
MH_X8W_X+)#_F[#]G_P#\%%M_\SU?K]10!^0/_#&__!9+_H[']G__ ,%%M_\
M,]1_PQO_ ,%DO^CL/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL/V?_\ P46W
M_P SU'_#&_\ P62'_-V'[/\ _P""BV_^9ZOU^HH _('_ (8W_P""R7_1V/[/
M_P#X*+;_ .9ZC_AC?_@LE_T=A^S_ /\ @HMO_F>K]?J* /R!_P"&-_\ @LE_
MT=A^S_\ ^"BV_P#F>H_X8W_X+)#_ )NP_9__ /!1;?\ S/5^OU% 'Y _\,;_
M /!9+_H[']G_ /\ !1;?_,]1_P ,;_\ !9+_ *.P_9__ /!1;?\ S/5^OU%
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M_P"&-_\ @LD/^;L/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\ H[']G_\
M\%%M_P#,]1_PQO\ \%DO^CL/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\
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M (+)#_F[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.Q_9__ /!1;?\
MS/4?\,;_ /!9+_H[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.P_9__
M /!1;?\ S/4?\,;_ /!9(?\ -V'[/_\ X*+;_P"9ZOU^HH _('_AC?\ X+)?
M]'8_L_\ _@HMO_F>H_X8W_X+)?\ 1V'[/_\ X*+;_P"9ZOU^HH _('_AC?\
MX+)?]'8?L_\ _@HMO_F>H_X8W_X+)#_F[#]G_P#\%%M_\SU?K]10!^0/_#&_
M_!9+_H[']G__ ,%%M_\ ,]1_PQO_ ,%DO^CL/V?_ /P46W_S/5^OU% 'Y _\
M,;_\%DO^CL/V?_\ P46W_P SU'_#&_\ P62'_-V'[/\ _P""BV_^9ZOU^HH
M_('_ (8W_P""R7_1V/[/_P#X*+;_ .9ZC_AC?_@LE_T=A^S_ /\ @HMO_F>K
M]?J* /R!_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>H_X8W_X+)#_ )NP_9__ /!1
M;?\ S/5^OU% 'Y _\,;_ /!9+_H[']G_ /\ !1;?_,]1_P ,;_\ !9+_ *.P
M_9__ /!1;?\ S/5^OU% 'Y _\,;_ /!9+_H[#]G_ /\ !1;?_,]1_P ,;_\
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M .9ZC_AC?_@LD/\ F[#]G_\ \%%M_P#,]7Z_44 ?D#_PQO\ \%DO^CL?V?\
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M?_,]1_PQO_P62'_-V'[/_P#X*+;_ .9ZOU^HH _('_AC?_@LE_T=C^S_ /\
M@HMO_F>H_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>K]?J* /R!_X8W_X+)?]'8?L
M_P#_ (*+;_YGJ/\ AC?_ (+)#_F[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\
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M /\ !1;?_,]1_P ,;_\ !9(?\W8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\
M1V/[/_\ X*+;_P"9ZC_AC?\ X+)?]'8?L_\ _@HMO_F>K]?J* /R!_X8W_X+
M)?\ 1V'[/_\ X*+;_P"9ZC_AC?\ X+)#_F[#]G__ ,%%M_\ ,]7Z_44 ?D#_
M ,,;_P#!9+_H[']G_P#\%%M_\SU'_#&__!9+_H[#]G__ ,%%M_\ ,]7Z_44
M?D#_ ,,;_P#!9+_H[#]G_P#\%%M_\SU'_#&__!9(?\W8?L__ /@HMO\ YGJ_
M7ZB@#\@?^&-_^"R7_1V/[/\ _P""BV_^9ZC_ (8W_P""R7_1V'[/_P#X*+;_
M .9ZOU^HH _('_AC?_@LE_T=A^S_ /\ @HMO_F>H_P"&-_\ @LD/^;L/V?\
M_P %%M_\SU?K]10!^0/_  QO_P %DO\ H[']G_\ \%%M_P#,]1_PQO\ \%DO
M^CL/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\ H[#]G_\ \%%M_P#,]1_P
MQO\ \%DA_P W8?L__P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=C^S_P#^"BV_
M^9ZC_AC?_@LE_P!'8?L__P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=A^S_P#^
M"BV_^9ZC_AC?_@LD/^;L/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL?V?_\
MP46W_P SU'_#&_\ P62_Z.P_9_\ _!1;?_,]7Z_44 ?D#_PQO_P62_Z.P_9_
M_P#!1;?_ #/4?\,;_P#!9(?\W8?L_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)
M?]'8_L__ /@HMO\ YGJ/^&-_^"R7_1V'[/\ _P""BV_^9ZOU^HH _('_ (8W
M_P""R7_1V'[/_P#X*+;_ .9ZC_AC?_@LD/\ F[#]G_\ \%%M_P#,]7Z_44 ?
MD#_PQO\ \%DO^CL?V?\ _P %%M_\SU'_  QO_P %DO\ H[#]G_\ \%%M_P#,
M]7Z_44 ?D#_PQO\ \%DO^CL/V?\ _P %%M_\SU'_  QO_P %DA_S=A^S_P#^
M"BV_^9ZOU^HH _('_AC?_@LE_P!'8_L__P#@HMO_ )GJ/^&-_P#@LE_T=A^S
M_P#^"BV_^9ZOU^HH _('_AC?_@LE_P!'8?L__P#@HMO_ )GJ/^&-_P#@LD/^
M;L/V?_\ P46W_P SU?K]10!^0/\ PQO_ ,%DO^CL?V?_ /P46W_S/4?\,;_\
M%DO^CL/V?_\ P46W_P SU?K]10!^0/\ PQO_ ,%DO^CL/V?_ /P46W_S/4?\
M,;_\%DA_S=A^S_\ ^"BV_P#F>K]?J* /R!_X8W_X+)?]'8_L_P#_ (*+;_YG
MJ/\ AC?_ (+)?]'8?L__ /@HMO\ YGJ_7ZB@#\@?^&-_^"R7_1V'[/\ _P""
MBV_^9ZC_ (8W_P""R0_YNP_9_P#_  46W_S/5^OU% 'Y _\ #&__  62_P"C
ML?V?_P#P46W_ ,SU'_#&_P#P62_Z.P_9_P#_  46W_S/5^OU% 'Y _\ #&__
M  62_P"CL/V?_P#P46W_ ,SU'_#&_P#P62'_ #=A^S__ ."BV_\ F>K]?J*
M/R!_X8W_ ."R7_1V/[/_ /X*+;_YGJ/^&-_^"R7_ $=A^S__ ."BV_\ F>K]
M?J* /R!_X8W_ ."R7_1V'[/_ /X*+;_YGJ/^&-_^"R0_YNP_9_\ _!1;?_,]
M7Z_44 ?D#_PQO_P62_Z.Q_9__P#!1;?_ #/4?\,;_P#!9+_H[#]G_P#\%%M_
M\SU?K]10!^0/_#&__!9+_H[#]G__ ,%%M_\ ,]1_PQO_ ,%DA_S=A^S_ /\
M@HMO_F>K]?J* /R!_P"&-_\ @LE_T=C^S_\ ^"BV_P#F>H_X8W_X+)?]'8?L
M_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)?]'8?L__ /@HMO\ YGJ/^&-_^"R0
M_P";L/V?_P#P46W_ ,SU?K]10!^0/_#&_P#P62_Z.Q_9_P#_  46W_S/4?\
M#&__  62_P"CL/V?_P#P46W_ ,SU?K]10!^0/_#&_P#P62_Z.P_9_P#_  46
MW_S/4?\ #&__  62'_-V'[/_ /X*+;_YGJ_7ZB@#\@?^&-_^"R7_ $=C^S__
M ."BV_\ F>H_X8W_ ."R7_1V'[/_ /X*+;_YGJ_7ZB@#\@?^&-_^"R7_ $=A
M^S__ ."BV_\ F>H_X8W_ ."R0_YNP_9__P#!1;?_ #/5^OU% 'Y _P##&_\
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MH_X8W_X+)#_F[#]G_P#\%%M_\SU?K]10!^0/_#&__!9+_H[']G__ ,%%M_\
M,]1_PQO_ ,%DO^CL/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL/V?_\ P46W
M_P SU'_#&_\ P62'_-V'[/\ _P""BV_^9ZOU^HH _('_ (8W_P""R7_1V/[/
M_P#X*+;_ .9ZC_AC?_@LE_T=A^S_ /\ @HMO_F>K]?J* /R!_P"&-_\ @LE_
MT=A^S_\ ^"BV_P#F>H_X8W_X+)#_ )NP_9__ /!1;?\ S/5^OU% 'Y _\,;_
M /!9+_H[']G_ /\ !1;?_,]1_P ,;_\ !9+_ *.P_9__ /!1;?\ S/5^OU%
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M_P"&-_\ @LD/^;L/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\ H[']G_\
M\%%M_P#,]1_PQO\ \%DO^CL/V?\ _P %%M_\SU?K]10!^0/_  QO_P %DO\
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M (+)#_F[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.Q_9__ /!1;?\
MS/4?\,;_ /!9+_H[#]G_ /\ !1;?_,]7Z_44 ?D#_P ,;_\ !9+_ *.P_9__
M /!1;?\ S/4?\,;_ /!9(?\ -V'[/_\ X*+;_P"9ZOU^HH _('_AC?\ X+)?
M]'8_L_\ _@HMO_F>H_X8W_X+)?\ 1V'[/_\ X*+;_P"9ZOU^HH _('_AC?\
MX+)?]'8?L_\ _@HMO_F>H_X8W_X+)#_F[#]G_P#\%%M_\SU?K]10!^0/_#&_
M_!9+_H[']G__ ,%%M_\ ,]1_PQO_ ,%DO^CL/V?_ /P46W_S/5^OU% 'Y _\
M,;_\%DO^CL/V?_\ P46W_P SU'_#&_\ P62'_-V'[/\ _P""BV_^9ZOU^HH
M_('_ (8W_P""R7_1V/[/_P#X*+;_ .9ZC_AC?_@LE_T=A^S_ /\ @HMO_F>K
M]?J* /R!_P"&-_\ @LE_T=A^S_\ ^"BV_P#F>H_X8W_X+)#_ )NP_9__ /!1
M;?\ S/5^OU% 'Y _\,;_ /!9+_H[']G_ /\ !1;?_,]1_P ,;_\ !9+_ *.P
M_9__ /!1;?\ S/5^OU% 'Y _\,;_ /!9+_H[#]G_ /\ !1;?_,]1_P ,;_\
M!9(?\W8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\ 1V/[/_\ X*+;_P"9ZC_A
MC?\ X+)?]'8?L_\ _@HMO_F>K]?J* /R!_X8W_X+)?\ 1V'[/_\ X*+;_P"9
MZC_AC?\ X+)#_F[#]G__ ,%%M_\ ,]7Z_44 ?D#_ ,,;_P#!9+_H[']G_P#\
M%%M_\SU'_#&__!9+_H[#]G__ ,%%M_\ ,]7Z_44 ?D#_ ,,;_P#!9+_H[#]G
M_P#\%%M_\SU'_#&__!9(?\W8?L__ /@HMO\ YGJ_7ZB@#\@?^&-_^"R7_1V/
M[/\ _P""BV_^9ZC_ (8W_P""R7_1V'[/_P#X*+;_ .9ZOU^HH _('_AC?_@L
ME_T=A^S_ /\ @HMO_F>H_P"&-_\ @LD/^;L/V?\ _P %%M_\SU?K]10!^0/_
M  QO_P %DO\ H[']G_\ \%%M_P#,]1_PQO\ \%DO^CL/V?\ _P %%M_\SU?K
M]10!^0/_  QO_P %DO\ H[#]G_\ \%%M_P#,]1_PQO\ \%DA_P W8?L__P#@
MHMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=C^S_P#^"BV_^9ZC_AC?_@LE_P!'8?L_
M_P#@HMO_ )GJ_7ZB@#\@?^&-_P#@LE_T=A^S_P#^"BV_^9ZC_AC?_@LD/^;L
M/V?_ /P46W_S/5^OU% 'Y _\,;_\%DO^CL?V?_\ P46W_P SU'_#&_\ P62_
MZ.P_9_\ _!1;?_,]7Z_44 ?D#_PQO_P62_Z.P_9__P#!1;?_ #/4?\,;_P#!
M9(?\W8?L_P#_ (*+;_YGJ_7ZB@#\@?\ AC?_ (+)?]'8_L__ /@HMO\ YGJ/
M^&-_^"R7_1V'[/\ _P""BV_^9ZOU^HH _('_ (8W_P""R7_1V'[/_P#X*+;_
M .9ZC_AC?_@LD/\ F[#]G_\ \%%M_P#,]7Z_44 ?D#_PQO\ \%DO^CL?V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ,44F<>M% "T=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** $S11^=% "T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4453\0:_9^%=$NM2U"XCM
M;&QB::>5_NQHHR3_ /6')H X[]HOXZ6/P!^'-QK%QLFOI<PV%L3S<3$<?\!7
MJ3Z#'4C/QO\ LR?!35/VKOC#=:YX@DGGTJWG^UZG<.>;ER25A4^^.<<*H/0X
M!H?$WQIK_P"VS\?;>STR*06\DAMM.MW;]W:0@DM*^,@$@;F(STP,X K[M^$'
MPJTWX,> ;'0-+3$-JNZ24CYKB4_>D;W)_( #H*T^% =':VT=E;1PPQI##"H2
M-$7:J*!@  = !QBI***S **** "BBB@ HHHH **9.[)'N5=Y';-)!<)<QAD8
M'^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 &**3./6B@!:.E%% !0:** "CI110 TNH/) _&CS
M%/\ $OYU^//_  5[X_;J\2?]>=C_ .DL=?.7AABGB73V4X9;F(@CM\PK[[!\
M#_6,+#$^WMS).W+M=7M?F/GZV>>SJRI\FSMO_P  _H5HZ445\"?0!0:** "C
MI110 4&BB@ HZ444 %!HHH *YWXJ?%?P]\$O ]YXD\4:I;Z1H]B 99Y<GDG"
MJJJ"S,3P%4$FNBKX5_X+K:7J]S\'?!-U;K,VBVNK3"^*@E4E:("$MV' F )[
MMCO7I9/@8XS&4\--V4GJ_P ?O>R.;&5W1HRJQ5VCJK;_ (+:?!^?71:-8^-8
M;9F"_;7T^'R1SUP)C)C_ (#GVKZH\ ^/]%^*7@ZPU_P_J-OJVCZI'YMM=0'*
M2KD@]<$$$$$$ @@@@$&OY\Z_5S_@B-I^K6?[*.K27RR)IMUXAGDT[S ?G00P
MK(R_['F*PX_B5Z^OXGX7PF!PGUC#MIII6;O>_P"IX^5YI6KU?9U$MNA]D4=*
M**_/CZ$*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110!\Y?M??\%)/
M#/['7Q(L?#.M:!KVJW5]IL>II+9&+RU1Y98PIWL#NS$3Z8(KRK_A^KX!_P"A
M-\8?G;__ !RO#/\ @N7_ ,G7^'?^Q2M__2R]KXP[5^J9+PKE^)P-.O5B^:2N
M]6?*8[-L13KRIP>B?8_H<TK44U?3+>ZC5ECNHEE4-]X!@",^_->._M/_ +?7
MPZ_9,OH=/\2WU[=ZU<1B9=,TV 3W*QG.';<RH@..-S GL",FO5O!/_(F:3_U
MY0_^@+7XM_\ !1?3-6TS]M;XA?VRLRW$^IM-;M(I&^V908"N>H$>P9''!KY'
MAK)J.88N5*LVHQ5[+=ZV/7S/&3P]%3@M6['Z4?L^_P#!5#X5_M"^,;7P_:7&
ML>']8OW$5I!K%LD2W<A.!&CQNZ;CV#%23P,GBOI#I7\]/AVQO]4\0V%OI<=Q
M-J=Q<1QVB0 ^:\Q8! F.=Q8C&.]?T'Z8MPFG6ZW3(UT(E$S)]TO@;L>V<UT<
M69%A\NG3>';M*^CUM:WX.YGE./J8F,E46UM?4GH-%%?(GL!1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !7PZW_!=3P"I_Y$WQ?^=O_P#'*^XJ_G=?AV^M
M?:<(9+A<P]K]93?+RVLVM^:_Y'BYQCJN'Y/9/>_X6/V-_9._X*;>%?VM_BE)
MX4TCP_X@TN\6QDOO.O#"8BJ,@(^5R<G>.W:OI4U^2O\ P14_Y/(F_P"Q>N__
M $9#7ZU5YO%&74,%C?88=6C9/>^]SHRO$SKT.>IO=A1THHKYT](*#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
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M444 )FBC\Z* %HHHH **** "BBB@#\=_^"O?_)]/B7_KSL?_ $ECKYQ\-?\
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MP7*/_&5_AW_L4[?_ -++ROC#%?H'#7_(LH_X3Y[,O]ZGZG]!_@G_ )$W2/\
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M_P"1:_ 2BC_4S!?S3^]?_(B_M6MV7X_YG[]_\/L?V8_^BF?^6[JO_P BT?\
M#[#]F/\ Z*9_Y;NK?_(M?@)11_J9@OYI_>O_ )$?]JU>R_'_ #/W[_X?8_LQ
MY_Y*9_Y;NJ__ "+1_P /L?V8_P#HIG_ENZK_ /(M?@)11_J9@OYI_>O_ )$7
M]JUNR_'_ #/W[_X?8_LQ_P#13/\ RW=5_P#D6C_A]A^S'_T4S_RW=6_^1:_
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MJU>R_'_,_?O_ (?8_LQY_P"2F?\ ENZK_P#(M'_#[']F/_HIG_ENZK_\BU^
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M_P#D6C_A]A^S'_T4S_RW=6_^1:_ 2BC_ %,P7\T_O7_R(_[5J]E^/^9^_?\
MP^Q_9CS_ ,E,_P#+=U7_ .1:/^'V/[,?_13/_+=U7_Y%K\!**/\ 4S!?S3^]
M?_(B_M6MV7X_YG[]_P##[']F/_HIG_ENZK_\BT?\/L/V8_\ HIG_ );NK?\
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M5?\ Y%K\!**/]3,%_-/[U_\ (B_M6MV7X_YG[]_\/L?V8_\ HIG_ );NJ_\
MR+1_P^P_9C_Z*9_Y;NK?_(M?@)11_J9@OYI_>O\ Y$?]JU>R_'_,_?O_ (?8
M_LQY_P"2F?\ ENZK_P#(M'_#[']F/_HIG_ENZK_\BU^ E%'^IF"_FG]Z_P#D
M1?VK6[+\?\S]^_\ A]C^S'_T4S_RW=5_^1:/^'V'[,?_ $4S_P MW5O_ )%K
M\!**/]3,%_-/[U_\B/\ M6KV7X_YG[]_\/L?V8\_\E,_\MW5?_D6C_A]C^S'
M_P!%,_\ +=U7_P"1:_ 2BC_4S!?S3^]?_(B_M6MV7X_YG[]_\/L?V8_^BF?^
M6[JO_P BT?\ #[#]F/\ Z*9_Y;NK?_(M?@)11_J9@OYI_>O_ )$?]JU>R_'_
M #/W[_X?8_LQY_Y*9_Y;NJ__ "+1_P /L?V8_P#HIG_ENZK_ /(M?@)11_J9
M@OYI_>O_ )$7]JUNR_'_ #/W[_X?8_LQ_P#13/\ RW=5_P#D6C_A]A^S'_T4
MS_RW=6_^1:_ 2BC_ %,P7\T_O7_R(_[5J]E^/^9^_?\ P^Q_9CS_ ,E,_P#+
M=U7_ .1:/^'V/[,?_13/_+=U7_Y%K\!**/\ 4S!?S3^]?_(B_M6MV7X_YG[]
M_P##[']F/_HIG_ENZK_\BT?\/L/V8_\ HIG_ );NK?\ R+7X"44?ZF8+^:?W
MK_Y$?]JU>R_'_,_?O_A]C^S'G_DIG_ENZK_\BT?\/L?V8_\ HIG_ );NJ_\
MR+7X"44?ZF8+^:?WK_Y$7]JUNR_'_,_?O_A]C^S'_P!%,_\ +=U7_P"1:/\
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M_P#(M'_#[']F/_HIG_ENZK_\BU^ E%'^IF"_FG]Z_P#D1?VK6[+\?\S]^_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[92VF _]#/Y5^7=>'P-AHPR]U5O*3_#1?K]YWY[4<L1R=$OS/O\ _P""2W[
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "ORM_
MX.9/^:)_]QW_ -QU?JE7Y6_\',G_ #1/_N._^XZO>X8_Y&=/_M[_ -)9QYA_
MN\OE^:/RMHHH[U^N'S(4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@
MHHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 4
M44=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH **
M*.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%
M'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBC
MO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111W
MH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T
M %%%% !111WH **** "BBCO0 4444 ?TG_L*_P#)D7P;_P"Q'T3_ -((*]5-
M>5?L*_\ )D7P<_[$?1/_ $@@KU6OPW%?QY^K_,^OI_ O0*.E%%<Y84&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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MLGY_W6P#^.<?F:A^ 7B?^U?#TUB[?O+%_D]T/^!_]"%5T [Z@T45(!1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** $S11^=% "T444 %%%% !1110!^.__
M  5[_P"3Z?$O_7G8_P#I+'7S?X?E6#7K&21E5$N(V9B<!0&%?2'_  5Z'_&=
M/B3_ *\[#_TFCKYCSFOW[(U?+:"_N1_)'Y_CO]YGZO\ ,_=G_ALWX1_]%/\
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MO^9^S/\ P3P_:NT;]I7X Z+$E];?\)3X?LH[/6+#=B:-HQY:S!3R4D"AMPR
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MPQ7Z/PU_R+*/^$^;S+_>I^I_0?X)_P"1-TC_ *\H?_0%K4K+\$G_ (HS2/\
MKRA_] 6M2OPFI\3/NX['Y5_\%R_^3K_#O_8IV_\ Z67E?%]?:'_!<H_\97^'
M?^Q3M_\ TLO*^,,5^[<-?\BRC_A/A,R_WJ?J?T'^"?\ D3=(_P"O*'_T!:_'
MG_@K#_R?WX\^FG_^FZVK]AO!)_XHS2/^O*'_ - 6OQZ_X*PG_C/OQY]-/_\
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M G$JPOFV@!'\#),>AWCD5\4S?\%G/V[OC)--JEG\8OC%J";C)(^BQM;VZ?\
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M,".5=@>M ']RU%5])U.'6]+M;RW;S+>\B6>)O[RL 0?R(K\X?^#DK_@LC/\
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M <K^VK^W+\,O^"?/P/OOB!\5/$MMX>T&U/E0)CS+O4YR"5M[:$?-+*V#\HX
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M)\;:DFJWNGR:A->06\J1^6!"969U3&3M+'D\8& /S3_X/;/^3'?A#_V/+_\
MION* /8O^#7C_@I=\8O^"EGP)^*6N?&'Q):^)-2\,Z]:V.GR0:7:V AB>W+L
MI6"- V6&<L":_4:OP_\ ^#(;_DUSXY?]C58_^DAK]P* "BBO$/\ @HO^W1X8
M_P""<'['WC#XN>*HVO+3PW;JMEIT<@CFU:]E81V]LA.<%Y&&Y@#L0.^"%(H
MP?\ @I!_P50^#_\ P2S^%$7B?XH:Y)'=:D631]!TY%N-7UJ1?O""$LHVKD;I
M'98URH+990?P(_;(_P"#QK]HCXR:SJ%G\)M)\+_"/PXS%;2?[(NL:ULZ9DFN
M ;<$]<) "N<;FP#7Q-=WOQT_X+M_\%$HT:27Q5\2/B-?E($DD=-/T.T7<VT?
M>\BSMX\GC)P"?G=OF_I0_P""8?\ P;;?L_?\$_/!VFWVO>&])^*WQ,\E&O\
MQ#XBLDNK>WFX)%E:R!H[=5/1R&F(SE\': #^>:[_ ."SG[=7Q-MGU2'XR_&*
MZM8?WCSZ6'M[=!ZG[/&J8^O%;'PI_P"#E3]M;X/:G;M'\:-4URWMG_>6>OZ5
M9:BDX'5'>2'SA[E75O>O["K:UCLK:.&&..&&%0B(BA511P  . !Z5YA^TO\
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M9O\ P<^?\%(?BY_P36_97^'GB7X/^(+3P[K7B'Q4=,O;B?3+:_\ ,MQ:32[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^D_]
MA3_DR+X-_P#8CZ+_ .D$%>JUY5^PK_R9%\'/^Q'T3_T@@KU6OPW%?QY^K_,^
MOI_ O0****YRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBN;^+/Q+L_A'X%O-<O8Y)H[4 )#'PTSDX"@]O4GL >O2N?%8JEAJ,\1
M7ERP@FV^R2NW]QK0HSK5(TJ2O*322[M['25X;^V5^RI#\<O#3:MI,,<?BG38
MSY7\(OXQSY3?[7]TGOP>#E>4'_!2.V/_ #*,W_@Q'_QNO7O@+^T+I/Q[TBZF
ML89K*\L2HN+64AB@;.UE8=5.".@((Z="?F<GX\R+,\2L)@<0I5'>RM*-[:NW
M-%)Z:V6MCV<PX7S3!477Q-)QBMW=.U^]FSY+_9&_:YG^ %W=>&_%"7C:$ID9
M$*DS:?,,DJJGHK'(*\88YXYSS42>(OVY?VA\G="EPV3U:/2[-3^'0'VW,>Q-
M?17[7G[$A^+^JKXA\+_9+36I#MO8)#LCO!VD!Z!QWSPPYR"/F[G]F/\ 9\L/
MV9_AQ*+R:UDU:X4W&J7PXC4*,[58@'RT&3DXR<GC@#[*4XI<S/!5WHCOO G@
MC3?AOX2L=$TFW6WL-/B$<:_Q'U9CW8G))[DFM>OF[7O^"C&EV.KSPV/AN[OK
M6-RL<\ET(3(!WV[#C\3FNN^ 7[7]C\<?%DNCG2)])NA"9HF:<3++MQE?N@@X
MR>A& >1QGXC!^(7#V+Q4<%A\2I5).R7+*S?9-QY=>FNO0^BQ'">;4*#Q-:BU
M%*[=XZ+TO?\ #0]CHHHK[,^="BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"GX@TP:UH=W:G'^D1,BY[''!_ X->$_!3Q$?#WQ+BMY&*QW6;9@W4DGY?UQ
M7T%7RWX^-QX8^,MU]EC=IH;[S;=%Y9OFRH'6JB!]245YO\??VL/!/[->BQW7
MBC5/)NKB/S+?3H%\R]N1_LQY&!P1N<JN1C-?)_C'_@M:YN)(_#_@9%C!(2;4
M+\L6'J8T48_[[-?.9IQ5E673]GBJR4NRNW\TD[?.Q[^6<+YGF$/:8:DW'N[)
M?)MJ_P KGWQ17Y[^'_\ @M;K$%R/[5\#Z9=19Y^R7KV[#_OH/G]*^C_V8O\
M@H9X&_::U>/1[7[9H7B24$Q:=? '[3M4LWE2+PV "2#M;@D @$UAEO&>3XZH
MJ-"LN9[)IQOY*Z2;\KW-\PX/S;!4W6KTGRK=IIV];-M+SL>\T445]0?,A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8HI,X]:* %HZ44
M4 %!HHH *.E%>,?MR_\ "W_^%3:?_P *5_Y&G^UXOM7_ !Y?\>7DS;_^/O\
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M9]=\%^&/[%U6YM6L9)_[1N[C="SH[+MFE=1EHT.0,\=>37JQK\[?^,_/\_\
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M\>KT:Y^'?PH_X)L?!+7O%.CZ'8Z4;.T*FXED,U[JDV#Y< D<ECO?'RKA1R<
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M4_\ !-OX,_""^BO-/\&6>H7T+!DN=5D>^96'0A9"8U(]0H->Y(BQH%50JJ,
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MWTBGKB>Z4J1Z6:$=:_([_@X]_P"4V7Q\_P"PO9_^FVTH _K;_9$_Y-/^%_\
MV*6E?^D<5?BW_P 'K/[&/B+Q5X?^%OQTT>PFOM!\+P3^&/$<L:[O[-6:99;.
M5L<B-Y&GC+'@.T0ZN*_:3]D3_DT_X7_]BEI7_I'%72?%3X5^'?CA\.-;\'^+
MM'L?$'AGQ)9R6&I:=>1^9#=P.,,C#^1&"" 000#0!_-C_P &O?\ P79\&_L
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M(XT4=%55  ]!7\J/_!HIH%OK/_!9;P_<3^7YFD^%]8N[?<.?,,(A.WWV2O\
MAFOZP: "@T44 %<K\<N/@IXP_P"P)>_^B'KJJY7XY?\ )%/&'_8$O?\ T0]
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M_@B_\=I=>:'R-0T:'3K2-SS+=S7<"6X4=25D*OQT"$] :_ W_@TE\)7WB/\
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M$_?^%5?LU^+/V@M=L?+UKXESMHGAYY$^:+2;63]](IZXGNE*D>EFA'6OR/\
M^#CWC_@ME\?/^PO9_P#IMM* /ZVOV1/^33_A?_V*6E?^D<5:OQ\^._A/]F+X
M->)/B!XYUBVT#PGX4LGO]2OY\[88U[!1DN[,0JHH+.S*J@D@'*_9$_Y-/^&'
M_8I:5_Z1Q5^'O_!ZO^W#J4&O?#3]GG2;Q[?39+/_ (33Q"D<A'VMFDEM[*)\
M?PIY5S(5.02\38!530!\S_\ !2K_ (.G_C]^V?\ $NZ\-? ^^UCX3^ IKHV>
MEP:,O_%2:R&;9&\UPFYXI&.-L5L5VEMI>0@-7C\G[$__  4JGT'_ (3-_#7[
M5#'KYS:EJG]I^O\ J#+]I_\ '*_4?_@T,_X)2>&?!?[.<?[3?BW2K/5O&/C2
MXN+7PF;NV63^P;"WF>"2XBW#Y9YY4D&\<B)%"G$CY_;>@#^5#_@F?_P=$?M
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M7EGHEI;ZWXBT/3VO-?\ $EVMM&+N6)MA-I;)*7S,NUV*[_,13M/QG_P<R?\
M*<3X[_\ 7YI7_IFL*_?S_@V7_P"">F@_L4?\$S?!OB;['9R>./C%I]OXMUK4
MA$!,UM<QB6RM Q&X1Q6[H=N<>;),?XJ /Y\OVG/AC_P4$_8QB_X3GXF7W[2?
MA.")TC?Q)/XDU&:&!W/R*]Y%.ZHS'@!G!)XZU^B7_!OA_P '-WBSQ!\5M/\
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M HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0
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MR=U,++EJU)*,7H[=9.SNMDUY-H_)^#,EIYCF"A75Z<4W)=^B6GF_N3.WL_\
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MNZ':G2[J&Y6-XQ,SI.K \88D@C&>#TSP>WF/[%^I7%A^T1H:V[,JW(FBF4'
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MB2CBU4S+$QG3L[I;WZ?8CU\SPL[S+AZMA7#+L/*%2ZLWM;K]M]/(^=/VPO\
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ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%CQ#JUK!JWAW39=-\:W,SA5M+ZPC'VF>0]%$D02YQV6<>E?S%_M(?$GQ?\
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M:MIFFW&M7(L]/BN[I(7OYRI811!B#(^U6.U<G )QQ63\<O\ DBGC#_L"7O\
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MYTG2/A^VF7+A?W:SW6HV<D*L>FXK:3D#_9;T-?L1_P %_?\ @G+-_P %+/\
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M5>?"7X@"&R\46\$9EFT]XRWV?4(D'+-$9'#H.7C=L!F5,?UM?";XN>&/CO\
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M \7: [[/[1LQ)Y=Y:,?NG.W?&_*ATB<9 &0#^U>OQ7_X/;/^3'?A#_V/3_\
MI!<5^OWP/^-/AO\ :-^#_AKQYX/U*'6/"_BW3H=4TV[CZ30RJ&7(ZJPSAE/*
ML"I ((K\@?\ @]L_Y,=^$/\ V/+_ /ION* /S1_X(;?\&_MK_P %C_A;X[\2
MW'Q5G^'O_"&ZK!IBVT?AP:I]K\R$R;RQN8=N,8Q@^N>U??7AG_@QV\)VEZK:
MS^T1XBO[<,"R67A&&T<KW 9KJ4 ^^T_2MS_@R''_ !BY\<?^QJL?_20U^X%
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M^2_Y&W]FO_KT\1_^AZ97V5_P:"_\H<]-_P"QNU?_ -"BH ^H_P#@K5_P5/\
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M /!R9$L/_!;GX]*JJH_M.P; '<Z79DG\2<U_8Q7\='_!RA_RF[^/7_81T_\
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M**_7#YD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /Z3_ -A3_DR+X-_]B/HO_I!!
M7JM>5?L*_P#)D7P<_P"Q'T3_ -((*]5K\-Q7\>?J_P SZ^G\"] HHHKG+"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4]C)LFH+*JF5?6(U4[V:M[O-MHF]I:IGV+_P4+D9/@E8J"0K:Q$#[_NIN/\
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MEJWLEKJS\D65XQU)4E2ES1O=6>EM[]CRK_@HY_R+/AG_ *[S_P HZ^<OA?\
M%K7/A%K$]]H5PMO<7$)@=FB63Y"RL1A@1U45]&_\%'?^19\,_P#7>?\ E'7$
M_P#!/C3[?4?B=JT=Q##.G]ER$+(@89\V'L:_G+BS U\9Q^\+AJKI3DX)35[Q
M_=+56:?ENC]>R'%4L/PK[>M352,>:\7L_??=/\CS'XG_ !U\4?%U88M>U)[J
M&V;='"L:Q1JW3)50 3VR><5])_L7?LWV_A"TA\87MY9ZA>WD)%FENXDCM5;A
MB6_YZ=5('W>0<D\<'^WI\&K'P;KFF^(-*M(K.VU3=!<Q0ILC69>0V!P-P)Z8
MY0GJ35O_ ()\?%.33_$M]X4NIO\ 1]00W-FA/W95&7 _WDR3_N"CAO"_V=QL
ML)Q W6JW2A.4F_>:3A+6[=U9)-^[)KL/.*WUSAOV^5)4X6O**26E[26FUMWW
M7J9O_!1.9V^+FDHWW%TI2OOF67-=?_P3=C0:)XL8#]XTUL&X[ 2X_F:J?\%&
M/!,SRZ#XBCC+0*CV$[CHASO0'ZY?_OFN%_8J^-MC\)_'-Y9ZM,+;2]<C5&F(
MRL4J$["WHN&<?5@3P#754Q5/*_$=U\:^6#D]7LE.G9.[Z7:3>RU['/"C/&\'
MJEAE>26RW]V=VO6RO;T/MZOF/_@I$J?V5X4;_EIYMR /;$6:^AG\>:'%IOVQ
MM9TI;/&[SS=Q^7CUW9Q7Q=^V/\<K7XP^/+>#2Y/.TC18VBAEVE?/D8@NX!YQ
MPH&1_#GO7Z-XM9Q@Z7#U3#.:<ZKBHI--NTHR;MV26^U[+J?(\!Y?B*F;0K*+
MY87;=M-4TEZMO;U-[_@G>9O^%O:IM_U/]E2;_KYL6*\[_P""UNB20>// ^I$
M-Y=U83VRG'&8Y Q_]&K7O?\ P3Q^'LVF>'=7\1W$15=19;:T8C[R(29"/8MM
M&?5#Z5QW[97AQ_VOOA!XTTG35CN/%'PWUF6[LX$&9+JT *NB ?>/7@ Y,:#J
MPKPN&\BQ%3@+V5GS2O42ZV4KK[TKKO='O8K.*-'C!59/W5:#?FXV_!O7T/,O
M^"*OBF&S^(?C;168"XU#3X+M ?XA#(RG'_?X5]:?MH_LS3?M7?""+PS;ZM'H
M\UOJ,5^D\D)E5BB2(5(!!Y$A.?:OR?\ @7\8]5_9_P#BKI/BK2=OVS2IMS0N
M2$N(R"KQM[,I(]1G(Y%?J=\$O^"@_P ,/C/H<$W_  D5CX>U)E'GV&K3+:O$
M_<*[X20=<%3DCJ >*]'@7-LNQ652R;'22W5F[<T9.^CTU3;TWV9?&V58_#9H
MLXP46]G=*_+**MJM=&DM=NA\5_M'_P#!+O5/V=O@WK'C"X\6Z?J4.D>3NMH[
M)XVE\R9(N&+$#&_/X5YK^P22/VO? G_833^M?<'_  4I_:"\#ZQ^REXDT&Q\
M6:#J.L:FUJMO:6=XES(Y6YBD;(C+;0%5CEL#C'7 KX?_ &"AC]KWP)_V$T_K
M7S.?9;E^!S_#4<NMRWIMVES>]SOK=VTMI_F?1Y'F./QN18FMF%^:TTKQY=.1
M=$EUOJ?HE_P4T_Y,D\:?2S_]+(*_*GX=S>(;?QE8OX5;5EU]6;[(=,W_ &H'
M:<[-GS?=SG';-?JM_P %-/\ DR7QI]+/_P!+(*_/3_@GSJ]KH?[8'@N[OKJW
MLK6&XF,DT\HCC0?9Y1RS$ >GXUZWB%0]MQ#AJ+ER\T8*_:\Y*_RW/,X!K>QR
M#$UN7FY93=N]H1=OF:']N_M(_P#/Q\8?^^K^OTO_ &1YO$5Q^S;X1D\6?V@?
M$+6.;PWV[[23O;;YF[G=LVYSSZ\UT'_"Z?!I_P"9M\,_^#2#_P"*K7\/^*=+
M\66C7&E:C8:E!&WEM):3K,BM@'!*DC."./>OO>&^&XY;7E56*E5YE:S>VJ=]
MWV/A>(>(GF-"-/ZM&ERN]TO*UMD?E1_P5*_Y/6\5?]<;+_TDAKUK]K+]GT^.
M/^"??PN\<6$"MJ'A31+6&]*K\\EG(J@'/4[)""!V$CFO)?\ @J4/^,UO%/\
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MZX[I<:-M?;)]C\WY[2>,AOW7$;'<&4,0Z@']>E!KD?@+\=/"W[37P:\-^/\
MP3JUOKGA7Q981ZCIM[#TEB<=".JNIRK(<,K*RD @BNNH *.E%% !0:*_*_\
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M0W[3WP\_9,^'TOBKXE^-/#O@CP_$WE_;=7O4MTE?J(XPQW2.>R("Q]*^>/\
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M^S^+[Y;SXG?"^>+0_$$S-F;5(3'FTU!Q_>E5)$<_Q2V\K<!@!^B- !1THHH
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M_A/X/:2\M])5KG4]3EC\N;6M0EP9[MUR=NX@!4R=B(B9.W)]X-%% !1THHH
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MA.PMFSZY2('->G:?IMOI%G';6MO#:V\(PD42!$0>@ X% 'SS\?/BW>?L*_\
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M_M;_ ++W@NU\.:CJGA+XGV6GQB""7QIILUSJ$*+V-S;S02RM_M3&1O>N?_;
M_P"#C/\ :[_X*7>'I/AS#>6/AS2?$RFRN/#_ ( TB>&?658%3"SM)-=.K D-
M&D@5P2&4CBOZHOB)^QU\(OB]K,NH^+/A7\./%&H3-ODNM7\-65],Y]2\D;,3
M]36S\+_V?O 7P125?!?@CPCX06=0DHT71K?3_,4= ?)1<CZT ?A9_P &\_\
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M %!HHH *.E%% !0:** "CI110 4&BB@ K\K?^#F3_FB?_<=_]QU?JE7Y6_\
M!S)_S1/_ +CO_N.KWN&/^1G3_P"WO_26<>8?[O+Y?FC\K:**.]?KA\R%%%%
M!111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@
MHHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 4
M44=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH **
M*.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%
M'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBC
MO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111W
MH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T
M %%%% '])_["O_)D7P;_ .Q'T3_T@@KU4UY5^PK_ ,F1?!S_ +$?1/\ T@@K
MU6OPW%?QY^K_ #/KZ?P+T"CI117.6%!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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M^,FOP/FO]M3]@^X_:'^$OA/2- U:&SU+P3;FVLUO ?*O(S'&A#LH)5OW2D$
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M444 %!HHH *.E%% "9HH_.B@!:*** "BBB@ HHHH _E__P"#NK]I?6_VFO\
M@J;X?^"^BS27UC\-M-L],M=/B.1+J^I".>1O0LT3V4?L8SZFOZ*_V'OV4]#_
M &'_ -DGP!\*/#J1_P!F^"='AL&E5=OVRXQON+AA_>EG:24^\AK^9?\ 9BTY
M?VR_^#L%9=:8ZC!/\9=8U:(-\P,.ES75U;(?552SB7'=5K^KV@#YY_X*Y?\
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M^%+)IV_A$PO/W6??:9OR-?IQ_P '3'_*##XT_P#770?_ $^Z?7G_ /P:N_\
M!+;7OV /V,=7\8^/--FT?X@?&&>WU&?3KB/;<:3IL"N+.&53RDK>=+*R\%1+
M&K ,C >@?\'3'_*##XT_]=-!_P#3[I] 'Y\_\&-G_(S_ +2W_7KX;_\ 0]4K
M^@ROY\O^#&S_ )&?]I;_ *]?#?\ Z'JE?T&T %?@G_P>4?\ !-+0XO WAW]I
MSPOIMO8ZY'J$/AWQF8$V_P!HQ2(19W;@<;XVC\AF/S,LL(Z1BOWLKX:_X.3M
M"M-?_P"")/QXBO!'Y<&FV%S&7&=LD>IV;ICT)90/QH ^*O\ @RH_:UOO'O[-
M7Q2^#>J7GG1_#W5+;6]%CD.6CM;_ ,T3Q)_L)/ 9/]ZZ/7/'[=5_-'_P9,:K
M-#^WM\6+%5;[/<> #.[=@Z:C:*H_$2/^1K^ER@ HHHH *^<OVJ?^"3?P#_;>
M^/7AWXC?%?P':^./$'A73?[+TV+4+N<V$<(F>;Y[97$4QW.W$JLN#TX&/HVB
M@#X4_P"#@?PAI/@#_@A9\<-%T'2].T31]-T&T@M+"PMDMK:UC&H6N$CC0!44
M>@ %?F#_ ,&/?_)</V@/^P%I'_I1<U^I_P#P<:_\H4?C[_V!K7_TX6M?EA_P
M8]_\EP_: _[ 6D?^E%S0!_131110 4444 ?!/_!=_P#X+96O_!'CX1^&9M-\
M)3>+O'/CBYDCTBWNDEATF"& QFXDGG4<OM=52)#N);<<*OS>X?\ !-#_ (*7
M?#G_ (*D_LX6/Q ^'][Y<T>VWUW0KB13?>'KS;EH)@.JGDI(!MD7D8(95Z[]
MM;]BKX>_\% ?V>M:^&?Q+T6/6/#^L+NCD7"76F7"@^7=6TF"8YHR3AL$$%E8
M,K,I_F$^*GPJ_:)_X-7/^"B=EKFAWDFJ>%]49AIVHF-UT;QUI8<%[6Y0$B.=
M 5W)G?$^UT)4JS ']:=?DS_P5"_X.J_A[^PA^U[H/PQ\'Z!%\3+?0]1\GX@Z
MA9W6U=)3E6M;,@[)KN-CN<,1&I3RB0[,T/R;_P %</\ @[=L_C/^RMHO@_\
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MS:@ HHHH **** /SC_X.NO\ E"/\2_\ L)Z)_P"G2VKXC_X,9_\ D'_M/?\
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MD@^L\+O]6-?UB YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E;_ ,',G_-$
M_P#N._\ N.K]4J_*W_@YE_YHG_W'?_<=7O<,?\C.E_V]_P"DLX\P_P!WE\OS
M1^5M%%%?KA\R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '])_P"PI_R9%\&_^Q'T
M7_T@@KU6O*OV%?\ DR+X.?\ 8CZ)_P"D$%>JU^&XK^//U?YGU]/X%Z!1117.
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/[1_\
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M3_\ AA7X(_\ 1&_A7_X2=A_\:H_X85^"./\ DC?PK_\ "3L/_C5?9_Z[4?\
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M']DS_F1_-A17]*'_  PK\$?^B-_"O_PD[#_XU2?\,*_!'_HC?PK_ /"3L/\
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M9,_YD?S845_2A_PPK\$?^B-_"O\ \).P_P#C5)_PPK\$?^B-_"O_ ,).P_\
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M).P_^-4?\,*_!''_ "1OX5_^$G8?_&J/]=J/_/M_>@_LF?\ ,C^;"BOZ4/\
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M_KM1_P"?;^]!_9,_YD?S845_2A_PPK\$?^B-_"O_ ,).P_\ C5)_PPK\$?\
MHC?PK_\ "3L/_C5'^NM#_GV_O0?V3/\ F1_-A17])_\ PPK\$?\ HC?PK_\
M"3L/_C5'_#"OP1Q_R1OX5_\ A)V'_P :H_UVH_\ /M_>@_LF?\R/YL**_I0_
MX85^"/\ T1OX5_\ A)V'_P :I/\ AA7X(_\ 1&_A7_X2=A_\:H_UUH?\^W]Z
M#^R9_P R/YL**_I/_P"&%?@C_P!$;^%?_A)V'_QJC_AA7X(X_P"2-_"O_P )
M.P_^-4?Z[4?^?;^]!_9,_P"9'\V%%?TH?\,*_!'_ *(W\*__  D[#_XU2?\
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M-\0-;U_1-1B\7Z);/-;3ZC//;S*KWJ21DHZ, RJRGJ 1BN+/_!O?_P %)O\
MH0?%O_AR]'_^6-?UH44 ?R7_ /$/=_P4F_Z$'Q=_X<O1_P#Y8U^AGQ*_X)W?
MMG)_P;B>$/V<]'^'NH:Q\4_$7B>Z/C"VN/%NEF6QTA;Z>[B'VF2[$4AE=;4;
M8Y&(3>K 9(K]Q** /QC_ .#6S_@B-\4_^">7Q(^)GQ'^./@^'PGXJU*PM_#_
M (<M?[4LM1<6COY]W*6M9I47<\=LH!(;Y'XP1G]G*** "N%_:;^ 6B_M4_L[
M^-OAOXB3?HOCC1;K1;L[=S1+/$R>8O\ MH2'4]F4'M7=44 ?S/\ _!)G_@B!
M^W/_ ,$Y_P#@I7\.?B.?A"LGAG1-:_L[7;N#Q=HC176D7&;>ZE$7VSS&"PN9
ME0INW1I\H88K^F"BB@ HHHH **** "OY]O\ @X]_X(@?M0?MZ?\ !2B]^('P
MG^&/_"6>$9_#FG6"W_\ PD>DV/[^(2"1/+N;J*3C(YVX.>":_H)HH XW]G?P
MI?\ @/\ 9_\  NAZI#]FU31?#UA8WD.]7\J:*VC1UW*2IPRD9!(..#6#^VK^
MU3H'[$/[*7CSXK^)F7^R? ^D2Z@T)?8UY,!M@ME/9YIFCB7_ &I!7J%?SF_\
M'3O_  5)U/\ ;-_:"T;]C_X.I<>(;/1M<@@\0#3AYLNO:\6\N#3HMOWE@9\.
M.\YP0#""0#Q__@UP_9I\1?MW_P#!835OCAXBC^U:=\/9KWQ=K5TR$QW.KZAY
MZ6\8]&,DD]P#G_EUYZC/]25?'?\ P0^_X)=6?_!*3]A[2O!-S);WWCC7YO[<
M\77T6&CEOY$1?(B;J88$58U/\1#OA3(0/L2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *XG]H__DA7BG_KP>NVKB?VC_\ DA7BC_KP>O)S
M[_D68C_KW/\ ])9W97_OE+_%'\T> _\ !.+_ )&KQ)_UZ1_^AU]:5\E_\$XO
M^1H\2?\ 7K'_ .AU]:5\7X1_\DQ0]9_^ER/H^/?^1W5](_\ I*"BBBOTH^."
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS7]I?]I#2_V>?!S7$K1W6M
M7BE=/LL\R-_?<9R(P>I[G@>HH?M+_M9:'^S[I+6X:/4O$DR9M[!&_P!7GI)*
M1]U1P<=6[<9(^ O&7C/7OC1XY>_U&6XU35]2E"1HBEB23A8XU'0=@HJXQON!
M#XE\1ZQ\6/'$]]>-<:EK&L7 X4;GD=CA44#\  .@P!7WM^QW^S!#\ O"#7FH
M)')XFU:,&[<'=]F3.1"I]N"Q'!8=P :P/V-OV.8?A!91>(O$4,<_B>X3,,1^
M9--0CH/^FO8L.G0=R?H6G*71 %%%%9@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %<3^T?_ ,D*\4_]>$E=M6+\
M1?" \>^!=6T4S?9_[2M7@$N-WEDC@X[X..,UY^;4)UL#6HTU>4H22]6FD=6!
MJ1IXFG4GLI)OT31\R_\ !./_ )&GQ'_UZQ_^AU]:&O&/V4_V9=0^ UUJ]UJF
MH65Y-J"I%&EKN*HH).26 .3QP!Q@\G/'L]?*^&^5XK+^'Z.%QD'":<FT]U>3
M:V\CW.,,=0Q>:U*^'ES1?+9^D4G^(4=***^Z/F0H-%-EE6")G=E1%&YF8X
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M'=,R";; -Y,/ITC^K<@_PFKY4M6!XOX/\$^)OCOXW^S:?!>ZUJUXYDFE=BQ
M)Y>1VX YZD]_>ONC]E_]CG1_@%:QZA>M#JWB:12'N]O[JUSU6$'D<<%CR?\
M9!(KT;X:?"K0?A%X>73/#^G0V-N,%V49DG;^\[GEC]>G08'%=%4RE< H-%%2
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH 3-%'YT4 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% ''>(?@CH^KWC7EBUYH.H-S]ITR8VY8]?F4?*>>O&3ZUS&IZ3\6? Z
M-)INI:'XOMX_NPW<'V:X(] 00I/N6[=#7K%%.X'A>J_M>ZYX$+?\)5\-O$6F
MPQYWW-NXGA..N&VA>G;=3=*_X*(_#N^3-RVMZ:V =MS99/\ Y#9J]VK(UCP!
MH/B$_P#$PT32;[O_ *19QR_^A ^IIZ >7']O_P"%X'_(;NC[?V?-S_X[67K/
M_!1SX=Z9N\@:YJ&.GD6BKG_OMUKT*Y_9D^'UVN&\'Z"O)/[NU6/_ -!Q5<?L
MH_#H'_D4M*_[Y;_&C0#Q7Q#_ ,%1M,@W+I7A2]N>/E>YNUBQ]556_G7FOB?_
M (*!_$CQO.;?1X[+25F;:BV=IYDA![;G+<^XQ7V%8?LZ> M-D5XO!_AW<H(!
M>QCD//\ O UT^D^'=/T%-MC8V=FO3$$"QC] *.9=@/SWMOV?_B_\==06ZO\
M3]>NO..?M&JS&-54D\CS2./IVZ5ZQ\-_^"8+>='-XL\0+Y?5K734.X^WFN./
M?"'Z]Z^O:*.=@<;\+?@%X2^#=KLT#1[:UF(PURX\VX?ZR-DX]A@>U=E114@%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !BBDSCUHH 6CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
M1EOP_P#_  9C_P"65 'Z_45^0/\ P\E_X*K9_P"3+?A__P"#,?\ RRH_X>2_
M\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\ HRWX?_\ @S'_ ,LJ/^'D
MO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/_)EOP_\ _!F/_EE1_P /
M)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_
M  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_R
MRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_
M\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_
M  9C_P"65'_#R7_@JO\ ]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_
M /\ !F/_ )94?\/)?^"J_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?
MA_\ ^#,?_+*C_AY+_P %5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HR
MWX?_ /@S'_RRH_X>2_\ !5?_ *,M^'__ (,Q_P#+*@#]?J*_('_AY+_P56S_
M ,F6_#__ ,&8_P#EE1_P\E_X*K_]&6?#_P#\&8_^65 'Z_45^0/_  \E_P""
MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
M!5?_ *,M^'__ (,Q_P#+*@#]?J*_('_AY+_P56S_ ,F6_#__ ,&8_P#EE1_P
M\E_X*K_]&6?#_P#\&8_^65 'Z_45^0/_  \E_P""JW_1EOP__P#!F/\ Y94?
M\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\ @JMG_DRWX?\ _@S'_P L
MJ/\ AY+_ ,%5_P#HRSX?_P#@S'_RRH _7ZBOR!_X>2_\%5O^C+?A_P#^#,?_
M "RH_P"'DO\ P57_ .C+?A__ .#,?_+*@#]?J*_('_AY+_P56S_R9;\/_P#P
M9C_Y94?\/)?^"J__ $99\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__
M /!F/_EE1_P\E_X*K_\ 1EOP_P#_  9C_P"65 'Z_45^0/\ P\E_X*K9_P"3
M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
MAY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\ ]&6?#_\ \&8_^65 'Z_4
M5^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J_P#T9;\/_P#P9C_Y94 ?
MK]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %5_\ HRSX?_\ @S'_ ,LJ
M /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\ !5?_ *,M^'__ (,Q_P#+
M*@#]?J*_('_AY+_P56S_ ,F6_#__ ,&8_P#EE1_P\E_X*K_]&6?#_P#\&8_^
M65 'Z_45^0/_  \E_P""JW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/
M_EE0!^OU%?D#_P /)?\ @JMG_DRWX?\ _@S'_P LJ/\ AY+_ ,%5_P#HRSX?
M_P#@S'_RRH _7ZBOR!_X>2_\%5O^C+?A_P#^#,?_ "RH_P"'DO\ P57_ .C+
M?A__ .#,?_+*@#]?J*_('_AY+_P56S_R9;\/_P#P9C_Y94?\/)?^"J__ $99
M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45^0/_#R7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^
M#,?_ "RH _7ZBOR!_P"'DO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\
M_@S'_P LJ /U^HK\@?\ AY+_ ,%5L_\ )EOP_P#_  9C_P"65'_#R7_@JO\
M]&6?#_\ \&8_^65 'Z_45^0/_#R7_@JM_P!&6_#_ /\ !F/_ )94?\/)?^"J
M_P#T9;\/_P#P9C_Y94 ?K]17Y _\/)?^"JV?^3+?A_\ ^#,?_+*C_AY+_P %
M5_\ HRSX?_\ @S'_ ,LJ /U^HK\@?^'DO_!5;_HRWX?_ /@S'_RRH_X>2_\
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M+?A__P"#,?\ RRH_X>2_\%5_^C+/A_\ ^#,?_+*@#]?J*_('_AY+_P %5O\
MHRWX?_\ @S'_ ,LJ/^'DO_!5?_HRWX?_ /@S'_RRH _7ZBOR!_X>2_\ !5;/
M_)EOP_\ _!F/_EE1_P /)?\ @JO_ -&6?#__ ,&8_P#EE0!^OU%?D#_P\E_X
M*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\ P9C_ .65 'Z_45^0/_#R
M7_@JMG_DRWX?_P#@S'_RRH_X>2_\%5_^C+/A_P#^#,?_ "RH _7ZBOR!_P"'
MDO\ P56_Z,M^'_\ X,Q_\LJ/^'DO_!5?_HRWX?\ _@S'_P LJ /U^HK\@?\
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M\/\ _P &8_\ EE0!^OU%?D#_ ,/)?^"JW_1EOP__ /!F/_EE1_P\E_X*K_\
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MJW_1EOP__P#!F/\ Y94?\/)?^"J__1EOP_\ _!F/_EE0!^OU%?D#_P /)?\
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M_P#EE0!^OU%?D#_P\E_X*K?]&6_#_P#\&8_^65'_  \E_P""J_\ T9;\/_\
MP9C_ .65 'Z_45Q_[/?B3Q5XS^ 7@?6/'>BV_AOQQJWA^PO/$.D0-NBTO49+
M>-[JV0[GRL<Q= =S<+]X]:["@ Q129QZT4 +1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH 3-%'YT4 +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4453U_7K/P
MOHMUJ6H3QVMG9Q&::5SA44#)/_UNIH N45X3^S_^V]9?'?XHW/AV+0[BPC\N
M2:TN3-YAE5/[Z[1LRO/4\\<]:]VHV **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKX-_X.!_^"N\?_!)[]D!+SP^+
M:Z^*7C^2;2O"=O* R6;*@,^H2(>&2 /'A<$-)+$"-I; !W'_  4I_P""W'P#
M_P""6MB;7X@^))M2\930"XM/"6AQK=ZO.C?==U+*D$9QP\SH& .W<1BOR;^+
MW_![]XJNM:N$\ _ ?P_8Z:O$,NOZ]-=SR?[3)#'$J_[H=L?WC7S!_P $5O\
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M!_@/39YLLNI^'=,CT/48G[-Y]H(V?'7;)N4]U(XKVG]D7]E_P[^Q;^S9X/\
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M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %?%/[?O[2S^,M>/@709_,TZRD U"2(Y^US@\1#'54
M/7U;M\H)]C_;;_:97X*>"O[)TJ=?^$EUJ,K$5;YK*'H9L>IY"].<G^'!\>_8
M!_9F_P"$OUA?'6O0^986<I.FQ2+Q<S@\RG/54/3U;O\ *0;BK:L#V3]B?]F=
M?@EX)_M35( /$VM1AIPP^:SBZB$>YX+=.<#^')]PZ445#=P"@T44 %'2BB@
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MP:BND3^*+VWN!;66C01747V98C%EWMYR%W[6\P$D%F \[_X,@=<N;?\ :/\
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M_8(UO_T=9U^CO_!L+^S7I'[//_!';X:7EC9^3JWQ$%QXKUB<CYKJ:>5DA/\
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M\Q_V)/VQ?VP/^"A'[-G@7]D']GR\\2:?_9K7VI>+_$Z:I+;SS1W%Y(ZFZO\
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M2E-TZJ:DMT]&:0G&:YHNZ"BBBLR@HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[_@\^^%]YX5_X*;^$?$S1$:;XJ\!V@BFQPT]M=W<<J?54: _\#%?U U\'_\
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M*/"\-N6BC\6^'HSJ'AW7+97R%N/E:(H2 WDW2*P(W!1@-7T]\/\ _@]:^/\
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M !7=Q9Q%A,=0A0PUVT[W:M;1JW?K^!SY3EM:A4=2IVM8O4=***^#/?"@T44
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
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M\1"GP%_Y\_B!_P""F'_X_1_8>/\ ^?4ON#ZW1_F1]TT=*^%_^(A7X"_\^?Q
M_P#!3#_\?I/^(A7X"_\ /GX__P#!3#_\?H_L/'_\^I?<'URC_,C[IH-?"_\
MQ$*_ 7_GS^('_@IA_P#C])_Q$*? 7_GS^('_ (*8?_C]']AX_P#Y]2^X/K='
M^9'W31TKX7_XB%?@+_SY_$#_ ,%,/_Q^D_XB%?@+_P ^?C__ ,%,/_Q^C^P\
M?_SZE]P?7*/\R/NF@U\+_P#$0K\!?^?/X@?^"F'_ ./TG_$0I\!?^?/X@?\
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M^Z:#7PO_ ,1"OP%_Y\_B!_X*8?\ X_2?\1"GP%_Y\_B!_P""F'_X_1_8>/\
M^?4ON#ZW1_F1]TT=*^%_^(A7X"_\^?Q _P#!3#_\?I/^(A7X"_\ /GX__P#!
M3#_\?H_L/'_\^I?<'URC_,C[IH-?"_\ Q$*_ 7_GS^('_@IA_P#C])_Q$*?
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M_1_8>/\ ^?4ON#ZW1_F1]TT=*^%_^(A7X"_\^?Q _P#!3#_\?I/^(A7X"_\
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M /GU+[@^MT?YD?=-'2OA?_B(5^ O_/G\0/\ P4P__'Z3_B(5^ O_ #Y^/_\
MP4P__'Z/[#Q__/J7W!]<H_S(^Z:#7PO_ ,1"OP%_Y\_B!_X*8?\ X_2?\1"G
MP%_Y\_B!_P""F'_X_1_8>/\ ^?4ON#ZW1_F1]TT=*^%_^(A7X"_\^?Q _P#!
M3#_\?I/^(A7X"_\ /GX__P#!3#_\?H_L/'_\^I?<'URC_,C[IH-?"_\ Q$*_
M 7_GS^('_@IA_P#C])_Q$*? 7_GS^('_ (*8?_C]']AX_P#Y]2^X/K='^9'W
M31TKX7_XB%?@+_SY_$#_ ,%,/_Q^D_XB%?@+_P ^?C__ ,%,/_Q^C^P\?_SZ
ME]P?7*/\R/NF@U\+_P#$0K\!?^?/X@?^"F'_ ./TG_$0I\!?^?/X@?\ @IA_
M^/T?V'C_ /GU+[@^MT?YD?=-'2OA?_B(5^ O_/G\0/\ P4P__'Z3_B(5^ O_
M #Y^/_\ P4P__'Z/[#Q__/J7W!]<H_S(^Z:#7PO_ ,1"OP%_Y\_B!_X*8?\
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MV6YD;!U&->Q/>4#/^\!GJ"37+I<#Z0H-%%2 4=*** "@T5Y3^UK^T3#^S_\
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M_P"9^>?@C]I_XC?#?48[K1/''BC3Y(SD*FHRM&WLT;$HP]F!%?I!_P $WO\
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M[)O[*_B#]KKXK1^&=#DALXX8C=7]].I:*R@#*I<@<LQ+ *HQDGJ "1]^6_\
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MYL-4F,TRQYY,,[9=6 Z DK_L]".^_;S_ ."4"_LX_#Z?QGX+U;4-8T'32O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Y6_P#!S)_S1/\ [CO_ +CJ
M_5*ORM_X.9?^:)_]QW_W'5[W#'_(SI?]O?\ I+./,/\ =Y?+\T?E;1117ZX?
M,A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!_2?\ L*?\F1?!O_L1]%_]((*]5KRK
M]A7_ ),B^#G_ &(^B?\ I!!7JM?AN*_CS]7^9]?3^!>@4445SEA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX%WCZ?\ &WP;<1_ZR'7+*13[K.A'\J_6G_ATK\!?^A+N/_!U??\ QZG>&O\
M@F+\ M'\5QS:?X77^U=%FANC&-<O)'MFSNC+IYQP"5R-PP<'K7!_KMEJI.E3
MIR2M:R44E_Y,=']AXGGYY25_5_Y$W_!5O_DP3Q]]-/\ _3C:U^,F.*_9O_@J
MW_R8)X^^FG_^G&UK\8^U:\ _\B^?^-_^DQ(X@_WA?X5^;/U _P""%/AN&U^
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M_I-)7ZH_M"?M!>&_V9?AE>>*O%%S)!86["***)-\UY,P)2&->[-@]2  "20
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M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BOY-_^"VW_!7#]J+0?^"K?Q6TBQ^*WQ&^'NE_#_Q-<:1H
M.BZ)K-SI=G#9P/M@F:&-E69IX]LS/*&W";'W-J@ _K(H->#_ /!+_P"-_C#]
MI+_@GE\'?'GC^V^S^,/%7A:SU#5/W @^T2O&,3^6  OFKMEP  /,X &!7O%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %?E;_P ',G_-$_\ N._^XZOU2K\K?^#F3_FB?_<=_P#<
M=7O<,?\ (SI_]O?^DLX\P_W>7R_-'Y6T44=Z_7#YD**** "BBCO0 4444 %%
M%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BB
MCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111
MWH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[
MT %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z
M "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.]
M!1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@
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MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
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MRE*I0E3CNT?A'7ZQ?\$2?^3/]0_[&6Z_]$6U4_\ AQM\)?\ H8OB)_X'V?\
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ML#.!N. ,UX.>9YE4L#/"8"%G*VJCRK1IZ[/IV/0P&!Q:KJMB'M?=W>UCS/\
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M4PA[*?#H+?G]IQ^E?93XGR/%P7UK[I0;M]R?YGC1RO'T7^Z_!V_R/ECXE?\
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MTF>/P*-,US1;J027&B7\>H7;/"7  D0JZ.D@ W(ZY"L&10#^@#_@V2_Y0;_
MG_KVU?\ ]/=_7WE7P;_P;)?\H-_@3_U[:O\ ^GO4*^\J "N _:0_98^'?[7_
M ,/H_"GQ.\(:+XV\.0WB:@FGZI#YL*W"*ZI)C(^8+(X!_P!HUW]% 'R3_P .
M'_V._P#HWCX:_P#@N_\ LJ_);_@[8_X)W?!#]B[]FGX3ZM\*OAGX5\"ZEK/B
M:YM+ZXTJV\I[F);4N$8Y.0&Y^M?T/U^(_P#P>Z_\FD?!/_L;KK_TB:@#Q_\
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M:GIMTG'F12+D!AU5U.593RK*RG!!%=;)(L2,S,JJHR2> !0 ZBOP[_X*R_\
M!WWI/P1\;:KX!_9KT;0_&VI:;(;:\\9ZJSRZ1'*#AULX$*M<@=!,SK&2/E65
M2&/YNV__  7%_P""BO[5-U>:EX7\<_$K5[6.0[T\(^$H?L]ICG9FVM21@?WF
M)]2: /ZYJ*_DK^%/_!SM^W!^ROX_-GXN\7+XJ%C(HN]!\9^'(8W&.2&:*.&Y
M0D?[?OBOWL_X(R_\%V/AS_P5Z\&WEC96;>"_BCX?M_M&L>%;FY\\F#<J_:[6
M7:OG0;F56^57C9@&&&1W /NBBBOYW?\ @M?_ ,'&G[3_ .Q-_P %//BE\+OA
M_P"(/"^G^$?"<]A%I\-SX?@NIE$NG6MP^Z1P2V9)7/L,#M0!_1%17X1_\%=/
M^#JKQ)^SIX;\,_#7X*KH>H?$IO#VGWGC#Q5=VHN+;1;Z:VBE>UM;<_NWF7=E
MV<-''NV;68-L^>/^"(7_  7E_:P_:D_X*K?"OP'X_P#BU=^)/"/C+4;F#5=-
MFT/3(8YD6RN)5"&*W1HL/&A_=LO3'0D$ _ICHKX3_P""T_\ P78\!?\ !'_P
M=I=C<Z6WC;XG>)X6N-(\,P78MUC@#%3=W4NUC%#N#*H"EI&1@N KNGX3^//^
M#E/]O3]L7QUJ%O\ #_7KS0[>8[TT'P-X2ANVM4Z#$CPSW7XF3!.< <  ']8E
M%?R(:/\ \'"O[?7[,'BBW3Q%\1_%2M"_SZ9XM\,VK+<@=5;SK=9A_P !=3[U
M_3;_ ,$K/VJ?$/[;O_!/;X6?%;Q9:Z38^(_&FD&\OX=+BDBLTD$TD?[M7=V4
M$(#@L>2>: /H*BBB@ K\Z/\ @ZB^/6M? G_@CAXY70;NXL+OQIJ-AX8GN(&9
M9$MIY2]P@(Z"2*%XFSP5E8=Z_1>ODO\ X+A_L/:E_P %"?\ @F5\2OASX?3S
M/%3VL6L:!%D#[3?6<BW$< +8 ,P1H020 902< T ?AK_ ,&C'_!,[X>_MK?M
M!?$3X@_$K1=/\5:3\)X-/CTS1-0A6XL;J^O#<$3S1-D2")+5MJ."I:4'!*5_
M2WXZ^$'A/XH?#VZ\(^)/#.@Z]X5OH?L]QH^H6$5Q8S1_W&A=2A'H,<5_)M_P
M;X?\%7T_X(^?MI:]9?$*QU.U^'_CE(]"\70BV;[7H=S;ROY%VT.-[&!I)T>(
M#=MFD(#.JJ?W;_;K_P"#G']EW]D'X7G4O#7C;2_C!XMO[-;G2M!\*W0N%E+K
ME/M-T T5JHR-RN3,O.(F((H _G4_X+:?LC:+_P $X/\ @JQ\1/ OP]N;S3]!
MT&]LM9T#;<-]HTI;FVAO$B63[P\F21E1B2VU$)8MDU_8#^RYX_U#XK_LS?#K
MQ3K$9CU;Q+X8TW5;U"FS9//:Q2R#;VPS'CM7\EG[+O[-?QB_X.+O^"I6K>(]
M8M;YK7Q5K46I>-=?M;<K8^&=,7:BPH[94.MO$L$$;$NY12<A78?V!>']!M?"
MV@6.EV,*V]CIMO':V\0Z1QHH55_  "@#Q_XV_P#!2/\ 9_\ V:_'\_A7X@?&
M;X:^#?$UK%'/-I>K^(+:TNX4D7<C-&[AE#*01D<@@]#7KGA7Q3IOCGPOINMZ
M-?6NJ:/K%K%?6-[:RB6"[@E0/'+&XX9&5@P(X((-?RR_\'A]K96__!7W=:JJ
MW$_@C27O"!]Z7S+E03_VS6,?@*_HD_X))6MY9?\ !++]G"*_W?:E^&?AT,#U
M4?V;;[0?<+@'W% 'T-1110 5_&S_ ,'%O_*:OX_?]ANW_P#2"VK^R:OXV?\
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MCDAG01W>F728$MK<)D[)8R1D D$%64LC*Q]>H **** /Y6?^#Q7_ )2\Q?\
M8C:5_P"C;NOAS]A?]I[Q-_P3=_;>^''Q2M[6[M[[PG>V>JW%GG:^H:9=0JTL
M77&)[.=@">@D4]J^X_\ @\4_Y2\Q?]B-I7_HVZK%_P""Q_\ P3_.@?\ !,K]
MCO\ :1T&QQ:^(?A_I'A/Q4T:<+=16N^QN&]WA66$L< "VA'5J /ZJ/AYX^TG
MXJ^ =#\4>'[Z'4M!\2:?!JFFW<1S'=6T\:RQ2+[,C*1]:V*_(O\ X- OV_\
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M"A'@C_@IO^RGH?Q4\#M-;VM^S6>IZ7<.K76B7\>/.M9=O!*[E96XWQNCX&[
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MGOV)?^"GGQ2^%WP_\0>%]/\ "/A.>PBT^"Y\/P74RB73K6X?=(X)8F25S[#
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M&XK^//U?YGU]/X%Z!1117.6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP/PO\/\ [9\(O$7B2:+,=K-!96[$<&1B6?'N%50?9Q7:_L(?\E[M?^O:;_T
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M]$?KU17EOQE_:ETCX,_LXP_$*^MY)([ZTMY;*R#A7N9IT#1Q9[8!)8X)"HQ
M.,'\V_B#^W/\8_V@?%(MK/7M:LVNY"+72_#_ )EOUYV*(SYDG_ BQKZ+B#C3
M!96XTY)SG))J,>SV;;VOTW?D?/Y#P?C,S4JD6H0B[.4NZWM;>W79>9^NU%?D
M.OQP_: _9ROX;K4M6\?Z/YA^2/6TGDAD_P"V=P"I^H%?IQ^RU\5;WXV_L_\
MA?Q1J,,,-_JUJ6N%A&(RZ.T;,!V!*9QVSCG%5P[Q=0S6M/#*G*G4BKM2[:+]
M5ND3Q!PG6RNE'$.I&I"3LG'O9O\ 3HV>@4445]<?*A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7X=?\ !9#]H74_C+^V)K6CR7$G]B>#G_LVRML_*CKQ*^.Y9P>?3BOW%K\-
M_P#@L=\ -2^#7[9>N:G);R_V-XP/]J6-R5^61FYE7ZK(2.>HYKXSCGVO]GKD
M^'F7-Z:V^5[?.Q^]?1Y^I_ZPU/;V]I[-\E^]US6\^6_G:_2Y\HUO?"_XAZM\
M*/B#I'B'1+J2RU32;E)X)4.""#^H/I6#WK6\!>#M1^(/C32]$TFUDO=2U2Y2
MWMX(QEI&8@ "OR2ES\Z=/>ZM;>_3YG]F8A4G2DJ]N2SO?:UM;WZ6W/Z,O@)\
M2U^,7P8\,^*%7;_;>GQ7+#'1B/F_\>!KKJXO]G7X9_\ "G/@9X5\+LQ>31=.
MBMY"1_'C+?DQ-=I7]%4>;V<>?>ROZG^8^9>P6,JK#?P^:7+_ (;NWX6"BBBM
M#A"BBB@ HHHH **** "BBB@ HHHH **** "BBOB__@L)^W=XR_8V\->#K7P1
M)9VFI>))KEI[N>V6X,,<0CPJJV5^8N<D@_=&*Y,=C:>$H2Q%;X8]ON/<X;X?
MQ6=YC3RO!6]I4O:[LM$Y-MV?1/HS[0HKR7]AKX[:C^TI^RSX2\9:O###JFKV
MS&Y6+A&=79-P';. <#@$UZU6U&M&K3C5AM))KT>IY^8X&K@<74P=?XZ<G%VU
M5XMIV?J@HHHK4XPHHHH **** "BBB@ HHHH **** "BBB@ Q129QZT4 +1TH
MHH *#110 5XQ^W+\9?B'\#OA-I^K?#7PK_PF&NW&KQVD]G_9ESJ'E6S0SNTO
MEV[*XPZ1KN)V_/CJ17L]%;X:M&E5C4G%22Z/9F=2+E%Q3MYGYV_\/#/VL_\
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MHE_MWNR!5S)Y:C)Y) ZD4 ?MM_P=4?\ *#OXM?\ 7YH7_IYLJ_G2_P""&/\
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M8_V _P!MG]J#]D?0?$L'[/>L>,-'L-<N('UHZ)H$6I+-)$KB+S&>"4J0KO@
MC[Q.* /[1?AG\,?#OP8\!Z7X6\(Z'I7AOPWHD MK#3--M4MK6TC'14C0!5'4
M\#DDGJ:_+S_@Z?\ ^"4?@S]IC]B3Q5\;M$T/3-+^*GPQMDU:YU:&+RYM;TN+
MY;BVN"O$ACC/FQNP++Y.P$*[5^0/_#YS_@I7_P!#G\7/_"(M_P#Y"K!^*/\
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MWN-8\#:M+ILMQ "(KM%PT4Z \A9(V20 \@. ><U_==7\BG_!U186UC_P6_\
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M HHHH ***.] !1110 444=Z "BBB@ HHH[T %%%% !111WH **** "BBCO0
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MSMO^"5O[0G_"W/V?T\/WLQDUGP65LVW-EI+5LF!O^ @-'@=!&OK@? _[9O\
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MN1"692%C"FO(O^"9W_!U7\<OV!_AOIG@7Q1H^E_&+P1HD2V^FP:K>R6>K:=
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M_@3_ ->VK_\ I[U"OO*@ HHHH *_$?\ X/=?^32?@G_V-]U_Z1&OVXK\1_\
M@]U_Y-(^"?\ V-UU_P"D34 6?^#(_P#Y,Q^,G_8ZP_\ I#%7[7U^*'_!D?\
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M !.\5>"UFUVR\2^(8/#_ (92U_>'4H;:.*PMFA ZB<Q"11U/G>M?1G_!2_\
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M?M,2E-4L'M[EH]!MQ&K9TH;@"_FAN;APNV18\!4#^8 ?>'_!L#\*/A/\./\
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M^Q&TK_T;=U_0%_P1(_Y1%_LY_P#8A:7_ .B%K^?W_@\4_P"4O,7_ &(VE?\
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M-1]ZOZH*_C5_X*W_ /!)/XG?\$<_VH7*IK4G@:74OMO@GQI9[T615?S(4>9
M/)O8MHW+\IRF],J0:^V/V/\ _@]'^*7PA^'%EH/Q8^&.C?%;4-/A6"/7;/63
MH5]=!1P]P@@GBDD/0LBQ ]2"<D@'])UW>0Z?:2W%Q)'#! ADDDD8*D:@9+$G
M@ #G)K^*O_@M5^UII?[<'_!4;XQ?$C09UN_#^K:RMCI-PGW+JSLH(K*&=?\
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M + EO_Z7VM?BO_P95?\ *4WQ]_V2K4?_ $[Z/7[3_P#!Q=_RA4^/W_8$M_\
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M%B#='4  _H._X,[?^40C?]CQJO\ Z+M:]$_X.J/^4'?Q:_Z_-"_]/-E7G?\
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M?AO_ ,')?[2W_!.?]J?XG>%9-4MOB-X+L?&.KHF@^+Q+/+IX^VRY2WN0PGB
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M@Y_V(^B?^D$%>JU^&XK^//U?YGU]/X%Z!1117.6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*_+<K_WRE_BC^:/ZWXF_Y%&*_P"O<_\ TEG[^ZPGF:3=+TW0N,GZ'TK\.O\
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M_P##HOX"Y_Y$N/\ \"'_ ,:/^'1?P%_Z$N/_ ,"'_P :^EJ*Z_[)P7_/F/\
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M1(]=L\N/;=7Z:?\ !TQQ_P $,/C3_P!==!_]/NGT ?SR_P#!&?\ X(G>)/\
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MG_!2S]L>U_8 _83^)GQ=N((KJ;P?I#2V%O*<)=7TKK;VD3=]K7$L0;'.TG%
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M)^)O!NNZ;\0KC[/8ZO"R*T)T^R_>6[\QRPE]^'B9D8[L$\U^IG2BB@ H-%%
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M* *NMZ'9>)M'NM.U*SM=0T^^B:"YM;F)98;B-AAD=&!#*02"",$&OD#XD?\
M!OE^QE\5?$4VJ:M^S_X+@NIY/-<:4]UI$);VBM)8HP/8+@U]DT4 >'_LN?\
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M ]@N!Z5]J44 ?/W[-?\ P2H_9Q_9 UJ/5/AS\&? 7AO6(&#PZHFF+<ZC ?\
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M"/PG\=/ UYX7\;^&/#OC'PSJ!C-UI.N:;#J%C<E'61"\,RLC;756&0<,H(Y
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M 2;0#^CGX$?#5?@S\$/!O@]9%F7PGH5EHRR 8$@M[=(=P^NS-0?&S]G?X?\
M[2GAJVT7XC>!?!OC_1K.Y%[;V'B31;;5;6"<*R"58YT=5D"NZ[@,X=AG!-=E
M10!P_P $/V9/AM^S+I5]8_#?X>^!_A[8ZI*L]Y;^&M"M=)BNY%&U7D6W1 [
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M **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "BBB@ HHH[T
M%%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1110 444=Z "
MBBB@ HHH[T %%%% !111WH **** "BBCO0 4444 %%%'>@ HHHH ***.] !1
M110!_2?^PK_R9%\&_P#L1]$_]((*]5->5?L*_P#)D7P<_P"Q'T3_ -((*]5K
M\-Q7\>?J_P SZ^G\"] HZ445SEA0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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M.'BHQ7+HMM8IL*.E%%??'RX4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH ^>?^"C_P 1T\+?!>'0XY-MYXBN54J#C]S$0[G_ +Z\
ML>^3Z5\W_L*> ?\ A.OVBM(:1%:WT8-J4N>WEXV?^1"GX9J3]NCXM?\ "T/C
MK>PV\@DTW0!_9]L5/RN5.9&]\N6&1U 6O>/^":/PQ;0?AWJ?B:XAVRZY/Y-J
MQ'6&/J0?0OD'WCK3:('TU0:**S *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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M!'#DY //'O7Y8VT7FW$:]G8+^9K^BS]D'P9%\/?V7_ >CPJJK8Z+;*2!]XE
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MW@'9?\%</^#K;X=?#+]E;1;?]FW7K7Q5\1_B)I8NH;YX04\$0/E6:YB;(^W
MA@D#9"D>8^4\M9?D#_@WX_X-^-<_;]\<0_M'?M'0ZI?> ;Z];5M,TS5I'DO/
M'ETSEVN[EG^<V9?)))S<'/\ RSR7_+SX#6=O^RG^T)\+O&7QA^%6K>)/ =U-
M;^(1H6JPS:?#XJTS>RB2%V $L19201F-RFULJ6%?VD?L:?M5?#G]L_\ 9S\-
M^/OA5JUEJG@W5+98[5($$3:<R !K26$?ZF6+A3&>G&,J5) /3-.TZWTC3X+2
MTMX;6UM8UBAAB01QPHHPJJHX"@   < "IJ** "BBB@#^7O\ X/2O^4JG@O\
M[)?IW_ITU:OWV_X(]?\ **+]FW_LFGA__P!-\%?@3_P>E?\ *57P7_V2_3O_
M $Z:M7[Z_P#!'K_E%%^S;_V33P__ .F^"@#Z/HHHH \M_;9_:@TG]BO]DGXA
M_%;6O+:Q\#:'<:FL+MM^USJN(+<'^]+,8XQ[R"OY;?\ @W@_9IU;_@I%_P %
MI-!\4>+/,UJW\,:A=?$KQ/=3+N%U<QSB6+=V)DOIH"5/51)P<&OTD_X/2OVW
MO^$&_9^^'WP#TF\V:AXZO3XEUZ-&^8:?:-LMHW'=9;DLX_VK+\_S1_X(=_\
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M_P %3+KQ;#\(]5US4)O!*6CZHNHZ3+8^6MR9A$5+\-GR),XZ8'K7U!7\^/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_*W_ (.9/^:)_P#<=_\ <=7ZI5^5O_!S+_S1/_N._P#N.KWN&/\ D9TO
M^WO_ $EG'F'^[R^7YH_*VBBBOUP^9"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^
MD_\ 84_Y,B^#?_8CZ+_Z005ZK7E7["O_ "9%\'/^Q'T3_P!((*]5K\-Q7\>?
MJ_S/KZ?P+T"BBBN<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]Z%3FMY2BDOQBR*VD\FYC<_PN&_(U_1;^R+XPC\??LP^ ]8C^[?:+;2?0^6
M1^E?SGXK]5O^"%/[:EAJG@^;X1:]>1V^J6$CW.AM(V/MD;99X@2?O*<D#CY?
M4US\#8^%'%RH3=N=:>JZ?.[/2\?N':^89%#&X>/,\/)RDE_))6D_DTF_*[Z'
MZ04445^N'\4A7$_M(^.+?X:_ /QAKMRRQPZ;I-Q*S$]/D(_K7;5^>?\ P7/_
M &U+/P;\-?\ A4NAWHDUW7PDNL>2_-G:=1&V#UDQ@J1]TYKS<VQT,'A)UYO9
M:>;Z+[SZS@?A^OG6=X? T8W3DG+R@G>3?R_&RZGY*KP*1N!2]Z#TK^?^A_I
M?T"_\$UO^3$_AC_V!E_]#>OB;_@XD_Y&?X>_]>LW_H1K[9_X)K_\F)_#'_L#
MK_Z&]?$W_!Q)_P C-\/?^O6;_P!"-?L.>?\ )/\ _;L/_;3^+?#S_DY=3_KY
MB/\ V\_-.O</^"<''[:/@7_K_7^8KP_O7N'_  3@_P"3T/ O_7^O\Q7Y;E?^
M^4O\4?S1_6_$W_(HQ7_7N?\ Z2S^@:OEO]NC_@E=X+_;-U(Z]YTGAWQ<L0C.
MH0)NCN@.%\U/XL#C(YKZDHK]ZQ6#HXFFZ5>*E%]&?YR9+GN/RC%+&Y=5=.HN
MJ[=FGHT^S5C\E=:_X-[?&UG>,MCXST.[A[.T;QM^6*I_\0_/Q$_Z&CP__P!]
M/_A7Z[45\_\ ZFY5_(__  )_YGZ9'QWXN2M[6#_[<C_D?D5_Q#\_$3/_ "-'
MA_\ [Z?_  J)_P#@W^^)(8X\1^'V'KYC<_I7Z]44O]3,J_D?_@3_ ,RUX\\6
M_P#/V'_@$3\A/^(?_P")7_0Q>'_^_K?X4G_$/_\ $K_H8O#_ /W];_"OU\HH
M_P!3,J_D?_@3'_Q'KBW_ )^0_P# $?(O_!,+_@G#JG[#DOB'4=:\00ZI?Z[$
MD"V]L#Y,"JVXDYZMG&,=!GUKT?\ ;3_8#\$_ML^';>/Q!#)8ZUIZE;+5K91]
MHA4\[#_>0GG!Z<XQDU[G17M4\KPL,-]34+T^SU\^I\%C.-,XQ&;O/95G'$:>
M]&T;65K66EK:-=>MS\F_$W_!O7XPL]1/]E^--%O+<DD-+$\3K[$8-9)_X( ?
M$K_H8_#_ /W];_"OUZHKQI<&Y4W?D?WO_,^ZI^._%T8\KJP?FX1_2Q^0O_#@
M#XE9_P"1B\/_ /?UO\*/^' /Q*_Z&/P__P!_6_PK]>J*7^IF5?R/_P "9?\
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M^PMWN+J^N)-.G2.&*) 6DD=B%55!+$@ $FOPZ_X-*/V&_C7^SA_P4P\2Z_\
M$3X/_%'P%H4WP]U"RCU'Q'X5OM*M9)VO].98EEGB13(51V"@Y(1CC - ']'5
M!HHH *_/G_@Z8_Y08?&G_KKH/_I]T^OT&KX:_P"#D/X1^+/CI_P1J^+GA?P1
MX9\0>,/$VI2:*;32=$T^;4+Z[$>M6,DGEPQ*SOMC1W.T'"JQ/ )H _-?_@QL
M_P"1G_:6_P"O7PW_ .AZI7]!IK^-?]F3]GW_ (*!_L8SZU)\*?A9^U1X!D\1
M+"NIG1O!&L6YO1#O,0DQ;_-M\V3'IO->IRZW_P %8OB2TEJT7[:D/F#:V;+7
M-+4C_?VQC]: /Z>/VQ/V[_A+^P1\-;CQ5\5O&^B>$]/CB>2VM[B<-?:FRC)C
MM;<9EG?V13C.3@9(_E2_X*S?\%*?B#_P7J_;K\/Z?X1\.:NVA6]S_8/P^\)Q
MJ)+P^>ZAYI=I*_:)V1&<@[(TC1=Q"%V],^!7_!L+^VM^VEXW@UKXA:;_ ,(3
M:ZBX-WKOCC71=7Q3J3Y$;RW+/UPL@0$GE@,D?NM_P2*_X(&_"#_@DUI3:OI8
M?QU\4+R(Q7GC#5+58YH488:&SA!86L1&=V&:1\D,[+M50#OO^",O_!.*R_X)
M=?L%>%?AJ?LMQXHG+:UXKO;<[H[S59U3SMK8&Z.-4C@0X&4@4D DU]5&BB@
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MM5N;>1XW#HVUAU5@"".:ZK3M.M](T^"UM((;6UM8UAAAB01QQ(HPJJHX"@
M < "@#YK_P""G'_!*GX9?\%1/V9G^'OB[3X=*O-*C+^%]=LK=1=>&;C:%5HA
MP&A(55>$D*ZJ/NLJ.O\ .7^S=^T%^T3_ ,&NW_!1#4/!GBC2;K5O#.K3QC5]
M!CD<Z9XQL"Q6*_L'(P)@,['QN5@T4B_>4?UG5Q/Q1_9O\ _&WQ9X1U[Q?X/\
M/>)-9\!WYU3P]>ZA9)/-H]R5VF6%F&5;H?3<B-]Y%( -[X?>,$^(?@+0_$$>
MGZKI,>N6$&H+8ZG;&UOK,2QK((IXCS'*N[:Z'E6!':M@T44 %'2BB@#^7O\
MX/2O^4JG@O\ [)?IW_ITU:OWU_X(]_\ **']FW_LFGA__P!-\%?BW_P=Q?L/
M?&K]I'_@I3X1U[X=?"'XH>/M#M_AS86,NH>'/"M]JMK%<+J.INT+2P1.JR!9
M(V*DY =3C!%?)7P^\4_\%2OA/X$T?POX;\/_ +8VB^'_  _91:=INGVOA+6H
MX+*WB0)'$B_9^%55  [ 4 ?UT4$[?I7\E_\ PNK_ (*S?\^?[:7_ (2NM?\
MR/7UG^PM^T5^W]X4_8._:TNOB7X-_:<\6>,]2\.:7H7@6QUOPKJKW<5S>RW-
MO=7-K&T(=C!"PE9E!"E(]V-PH _/K_@K'^T1K7_!7;_@LGXDD\).=6A\2>);
M;P-X*B5MT<EK',MG;,G7"S2%ISZ&=J_HZ\!_\&W7[&_A+P-HNE7WP5\.ZY?:
M;806EQJ5U<W8GU"2.-5:>0+,!N<@L<#&6-?D'_P; ?\ !'WXJ:7_ ,%,-/\
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ K\]_P#@N_\ L?\
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M$MU7_P #[/\ ^/5_0A11_KIC/Y(_<_\ ,/[*I=V?SW_\.?\ ]I#_ *);JO\
MX'6?_P >H_X<_P#[2'_1+=5_\#K/_P"/5_0A11_KIC/Y(_<_\P_LJEW?X?Y'
M\]__  Y__:1_Z);JO_@?9_\ QZC_ (<__M(?]$MU7_P/L_\ X]7]"%%'^NF,
M_DC]S_S#^RJ7=G\]_P#PY_\ VD/^B6ZK_P"!UG_\>H_X<_\ [2'_ $2W5?\
MP.L__CU?T(44?ZZ8S^2/W/\ S#^RJ7=_A_D?SW_\.?\ ]I'_ *);JO\ X'V?
M_P >H_X<_P#[2'_1+=5_\#[/_P"/5_0A11_KIC/Y(_<_\P_LJEW9_/?_ ,.?
M_P!I#_HENJ_^!UG_ /'J/^'/_P"TA_T2W5?_  .L_P#X]7]"%%'^NF,_DC]S
M_P P_LJEW?X?Y'\]_P#PY_\ VD?^B6ZK_P"!]G_\>H_X<_\ [2'_ $2W5?\
MP/L__CU?T(44?ZZ8S^2/W/\ S#^RJ7=G\]__  Y__:0_Z);JO_@=9_\ QZC_
M (<__M(?]$MU7_P.L_\ X]7]"%%'^NF,_DC]S_S#^RJ7=_A_D?SW_P##G_\
M:1_Z);JO_@?9_P#QZC_AS_\ M(?]$MU7_P #[/\ ^/5_0A11_KIC/Y(_<_\
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M^RJ7=_A_D?SW_P##G_\ :1_Z);JO_@?9_P#QZC_AS_\ M(?]$MU7_P #[/\
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M<_\ [2'_ $2W5?\ P.L__CU?T(44?ZZ8S^2/W/\ S#^RJ7=_A_D?SW_\.?\
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MQ6<4<B$J2"592,@D<=:]"-%%?)5*CG-S?5W/3BK*P4=***@84&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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MQ[_R.ZOI'_TE!1THHK]*/C@H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THKYO_;1_;'A^&MA<>%_#-RLGB&X4QW=S&V1IRD$$ @_ZW_T'ZXPT
MK@<C^W_^U0LXG\!^'[K.UMNKW$;<$C_EW!]C]['^[_>%>'_LN_L_W?[0/Q&A
ML=LD>CV96;4KE1_JH_[H/3>V,#\3@A37,_#/X;:U\:/'%OH^DPO=7UXY>21L
M[85S\TDC=E&>3^ R2!7Z1? SX*Z7\"? 5OHNFKO<?O+JY90)+J4]6/MV [#'
M7DFW[JL@.IT?2+7P_I-K8V4$=M9V<2PP11KA8D48"@>@ JSTHHK, H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
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M];\2_P#(HQ7_ %[G_P"DL_H&HZ445_09_F<%!HHH *.E%% !0:** "CI110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_L]>#UL;%5N=2N0'OKYE'F7#^@]$'.%_'DDFO0J**S **** "BBB@ HHHH
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M /QNOV=HH_U)RSM+_P "#_B/W%7>G_X!_P#;'XQG_@@E\;O^?KP9_P"#)_\
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M-^(O%CB'.:U.IB*BC"$E)0BK0O%IJ^K<M5U;7:Q^,7_#A+XW?\_7@S_P9/\
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
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M  3QAU!]1GH?<<UYKK/[*EC:M)-X6U[7O"ETW(%M=O)!GW0G<?\ OK'/0T]
M/5J#7A>K>'?CKX,W-INN^'?%=O&/DBN+=8)F],\*/;[^?Z8[_M"?&KPRN-6^
M%L>H-@#.G%R,_P# 6D]*?*!]&4=*^7;O]NSQU9(3-\)]4M^HS*TRXQ]8A6'K
M'[>GQ(N,_P!G^ [>VW<#S[:XF(/X,M'*P/KZF3SI;0M)(ZQQH,LS'"J/4FOB
M+4OVDOC]XPD\NPT;5K-95) L]"+<>S,C']<U@7?[.WQP^,%R&UBWUR:-VR3J
M-^$6/IR$=^![ 4^7N!]5_$G]LSX?_#6"43:Y#JMY'TM=-Q<.QYXW [!T[L*^
M;?B[_P %(?$WBL26OABTA\.V;94S,1-=./9B J9]AD?WJV/!?_!,#6+UXY/$
M'B.QLUSEHK.)IW^A9MH!]QG\:]N^&W[#?P]^',T<_P#9;:U>1\^=J3^<N?\
MKG@)],J2/6G[J ^)_ /P4\=?M#ZTUU966HZIYTG[_4;MSY2GN6D<\D>@)/M7
MU=\"_P#@GCX>\ 20W_BB6/Q)J:$,L.TK9Q'_ '3S)_P+ (ZK7T-;6L=E;K##
M''#%&,(B*%51Z "I*ER; 9!!':PI'&BQQQJ%1%7:J@<  =A3^E%%2 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 F:*/SHH 6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MQ129QZT4 +1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\ R#1_Q%M>*O\
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M#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\
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MXP_\1;7BK_HROXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\
MQ%L^*A_S97\8/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5
M_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^
M;*_C!_X'3?\ R#1_Q%M>*O\ HROXP?\ @=-_\@U^SU% 'XP_\1;7BK_HROXP
M?^!TW_R#1_Q%M>*?^C*_C!_X'3?_ "#7[/44 ?C#_P 1;/BH?\V5_&#_ ,#I
MO_D&C_B+:\5?]&5_&#_P.F_^0:_9ZB@#\8?^(MKQ5_T97\8/_ Z;_P"0:/\
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M0!^,/_$6SXJ'_-E?Q@_\#IO_ )!H_P"(MKQ5_P!&5_&#_P #IO\ Y!K]GJ*
M/QA_XBVO%7_1E?Q@_P# Z;_Y!H_XBVO%/_1E?Q@_\#IO_D&OV>HH _&'_B+9
M\5#_ )LK^,'_ ('3?_(-'_$6UXJ_Z,K^,'_@=-_\@U^SU% 'XP_\1;7BK_HR
MOXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\ Q%L^*A_S97\8
M/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #
MIO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\
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M%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\ R#1_Q%M>*O\
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M#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\
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MXP_\1;7BK_HROXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\
MQ%L^*A_S97\8/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5
M_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^
M;*_C!_X'3?\ R#1_Q%M>*O\ HROXP?\ @=-_\@U^SU% 'XP_\1;7BK_HROXP
M?^!TW_R#1_Q%M>*?^C*_C!_X'3?_ "#7[/44 ?C#_P 1;/BH?\V5_&#_ ,#I
MO_D&C_B+:\5?]&5_&#_P.F_^0:_9ZB@#\8?^(MKQ5_T97\8/_ Z;_P"0:/\
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M0!^,/_$6SXJ'_-E?Q@_\#IO_ )!H_P"(MKQ5_P!&5_&#_P #IO\ Y!K]GJ*
M/QA_XBVO%7_1E?Q@_P# Z;_Y!H_XBVO%/_1E?Q@_\#IO_D&OV>HH _&'_B+9
M\5#_ )LK^,'_ ('3?_(-'_$6UXJ_Z,K^,'_@=-_\@U^SU% 'XP_\1;7BK_HR
MOXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\ Q%L^*A_S97\8
M/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #
MIO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\
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M%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\ R#1_Q%M>*O\
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M#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\
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MXP_\1;7BK_HROXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\
MQ%L^*A_S97\8/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5
M_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^
M;*_C!_X'3?\ R#1_Q%M>*O\ HROXP?\ @=-_\@U^SU% 'XP_\1;7BK_HROXP
M?^!TW_R#1_Q%M>*?^C*_C!_X'3?_ "#7[/44 ?C#_P 1;/BH?\V5_&#_ ,#I
MO_D&C_B+:\5?]&5_&#_P.F_^0:_9ZB@#\8?^(MKQ5_T97\8/_ Z;_P"0:/\
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M0!^,/_$6SXJ'_-E?Q@_\#IO_ )!H_P"(MKQ5_P!&5_&#_P #IO\ Y!K]GJ*
M/QA_XBVO%7_1E?Q@_P# Z;_Y!H_XBVO%/_1E?Q@_\#IO_D&OV>HH _&'_B+9
M\5#_ )LK^,'_ ('3?_(-'_$6UXJ_Z,K^,'_@=-_\@U^SU% 'XP_\1;7BK_HR
MOXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\ Q%L^*A_S97\8
M/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #
MIO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\
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M%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\ R#1_Q%M>*O\
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M#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\
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MXP_\1;7BK_HROXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\
MQ%L^*A_S97\8/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5
M_P!&5_&#_P #IO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^
M;*_C!_X'3?\ R#1_Q%M>*O\ HROXP?\ @=-_\@U^SU% 'XP_\1;7BK_HROXP
M?^!TW_R#1_Q%M>*?^C*_C!_X'3?_ "#7[/44 ?C#_P 1;/BH?\V5_&#_ ,#I
MO_D&C_B+:\5?]&5_&#_P.F_^0:_9ZB@#\8?^(MKQ5_T97\8/_ Z;_P"0:/\
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M0!^,/_$6SXJ'_-E?Q@_\#IO_ )!H_P"(MKQ5_P!&5_&#_P #IO\ Y!K]GJ*
M/QA_XBVO%7_1E?Q@_P# Z;_Y!H_XBVO%/_1E?Q@_\#IO_D&OV>HH _&'_B+9
M\5#_ )LK^,'_ ('3?_(-'_$6UXJ_Z,K^,'_@=-_\@U^SU% 'XP_\1;7BK_HR
MOXP?^!TW_P @T?\ $6UXI_Z,K^,'_@=-_P#(-?L]10!^,/\ Q%L^*A_S97\8
M/_ Z;_Y!H_XBVO%7_1E?Q@_\#IO_ )!K]GJ* /QA_P"(MKQ5_P!&5_&#_P #
MIO\ Y!H_XBVO%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\
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M%/\ T97\8/\ P.F_^0:_9ZB@#\8?^(MGQ4/^;*_C!_X'3?\ R#1_Q%M>*O\
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@!,T4?G10 M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 456U?5K70=*N;Z\FCM[2SB:::5SA8T49)/T KX^T?]M7QE\4?VG=-T
M_P ,D?\ ".W%^EO%8&!"9H ?GD=L%E.W<Q(.% [X.6HM@?95%%%( HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#^<#]K#_ (/!_P!H[X+?M3?$OP=X=\%_ ^Z\/^$_%>J:-IDU
M]H^IR74UK;W<L,+2LFH(K2%$4L55023A0.*X#_B-3_:H_P"A#^ /_@CU;_Y9
MUS__  ;0PI\7O^#@^Z\12*MPL<7B?6R6&X?OEECS_P"3'ZU_4M_9-K_SZV__
M '[% 'XC?\$-_P#@Y6^._P#P4P_X*#Z#\)_'7A3X3Z7X<U32]0OIKG0=+U""
M]1H(&D0!IKV5 I8 '*'(Z$=:_<&H8;&&V?='#%&V,95 *S_'7C33?AOX)UCQ
M%K%PMGI&@6,^HWL[?=@@AC:21S]%4G\* /@O_@MS_P ' ?@?_@D=IEGX9T_2
MH_'?Q<URU^UV>A"Y\FUTNW)*K<WL@RRJQ#;(U&Y]AY1<,?R)@_X.5/\ @HE\
M9='OO&_A'PC#_P (;:O(\T^A?#N:^TFT53EE:Y<2D!0,$M+D<YKQG_@G1\&]
M2_X. ?\ @N==:S\1O/NM#\0:E=^-?%4"R']UI5L46&Q4]1%EK2T!!#+&V0<@
M5_6KX2\(Z7X!\+Z?H>AZ;8Z/HVDVZ6EE8V4"P6]I"BA4CCC4!455  4   4
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MKR0Z+XFTD>+-*@<_)#?6SQ03[!_>E@EC+>UHO3'/]&E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 &**3./6B@!:.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
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MHHJ "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
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M_P#!0/X2?\%%/A3_ ,)A\)/%]CXFTV%UBOK<*T%]I4I!(BN;=P)(F.#@D;7
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M445X9W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4OA;!\.?A.=#L_'DOA6.YD@U W9MUU VHD)%T$\S8,Y"@9[8XH _H,HHHH
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M74[VQ^"'PCT31]/5REOJ_C&ZDO;J=.SFTMVC2%L=C-*/KTH _HBHK^3S5O\
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MU/\ ^3*/^(V+]HC_ *)?\%__  %U/_Y,H _IFHK^9D_\'L/[1'_1+_@O_P"
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V658(FDD941
M69F. H'4DT 8/Q1^).F_"/P-?Z_JTFVUL4W;%QOF<\+&H[LQX_4\ FO@KP=X
M>\0?MP?M"2W%XTD<-P_G7DJ\QZ?;+P$7/MA5'4DY/<UK_M;?'F^_:9^*5KX<
M\.K-=Z/9W/V?3X8A\U].3M,N.^>BYZ+SP217UQ^S+\ ;+]G[X=0Z?&L<FK7F
MV?4KD#F67'W0?[B9('KR< L:T^% =MX6\,6/@KP[9Z3I=O':6&GQ"&")>BJ/
MYD]23R223S6A1168!1110 4444 %%%% !3719$*L-RL,$'N*=10!1>=M(/S[
MFM\@*0,E.V,?Y_QN1R+(@96#*>A'>AE#J589!X(/>L*2X_X0Z\ 8,UC<-U _
MU9X'Y?Y^@!OT4V*59XE=&W*PR".].H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***^?_P#@JM\+/%7QN_X)P?&KPCX&L+K5/%_B#PE?
M6>D6EM,L,UQ<-&=J([,H#'H,D4 ?0%1WEY#IUI+<7$L<%O ADDDD8*D:@9+$
MG@ #G)Z5_*?\'/\ @L=_P4?_ ."<^DQ^$/$&F>/]1T_1SMCL?B%X.NKV6!1P
M%%S(B7#1X VYE*@ ;<"H_CA_P4=_X*-_\%B-!D^'^G>&?'<GAO66\N]TKP7X
M4GTRRN8W^79=76"P@.2"LLPC.?F!P, 'FO[27CRQ_P""E'_!Q5<:I\/3%J>E
M>._BEIMEI-S;QXBNK:":WMOM>"/N-' TQ)'W221UK^KG]LCX$K^U!^R3\3OA
MONCC?QWX5U+08Y)/NPR7-K)$DG_ 696_"OS._P"#=O\ X-RKW_@G9XD7XR_&
M:33;SXM36CVVC:-9RK<6WA..52DSM,N5ENG0F/,9*(C. SE\K^O5 '\J/_!J
M+^U)#^QU_P %:IO OC"1M#A^)FF7/@Z6.[/E"UU:.9);9),]':2&6W5>[W"B
MOZKJ_G]_X.*_^#<OQ]XI^/\ J_[1'[.6BW>O3>(;D:GXF\,:8VW5+74<[GO[
M%!@RB1L.\:$RK*6=0P<B/YM\ _\ !Q5_P41^$?@6/X=7?A^\UCQ#:0?9(-2U
MWP'<S>(8@HVJ6&%261>/FEA=F(RY8DD@'TM_P>R_M@Z;?6WPD^!.FWL=QJ%G
M<S>,]<@1PWV3]VUK9!@.C,LEXV#@A=AZ,#7Z1?\ !NQ^RU>?LE_\$A?A'H>J
MV\EKKGB*QE\4ZA%(FQXWOY6N(D93RK+;M C \AD/3H/R/_X)2?\ !OI\=/\
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M$1$R=L<: EB"Q^BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P )3\%->\#W4VZY\*WHN[12?^76YR2 /]F99"?^NHK[@Z5^,?\ P2X^-?\
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M0?\ !3;_ (*=^._%5G-)K$WC+Q0=%\+VZM\HL5F%KI\*#H,QB,G& SN[=6-
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M,NO[6\0?$3XK>'UF(F#:[X6@2W(/0A+BT\L*?0#%?M]_P;-_\%8?BK_P5.^
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M'>7Q>^)/Q>U70_V;[RQ^'_P_TNXDMK379M+@O=7U]1\OGE;E'CMXVQE$$?F
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M"C@ LQX'2K_Q9^+/AGX$?#;6O&'C+6].\-^%_#MJU[J6I7THB@M(EZLQ/X
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MMU '[B4=**YWXL_%GPS\"/AMK7C#QEK>G>&_"_AVU:]U+4KZ4106D2]68G\
M ,EB0 "2!0!T5!K^='_@HM_P>7^-?$7BZ_T#]FOPUI?ASP[:R/#'XI\16GVS
M4=1 .!+!:L1%;H>H$HE8C!(0Y6OCVW_X++?\%'/B3HP\6V'C[XOZAHRYD_M'
M3/"L2Z=CU)AM!"1]>* /Z\*.E?S@_P#!$'_@XZ_:E^-'[?GP[^#GQ.U_0O'6
M@>-]6.F75QJ>APV>I::!%(^8I+40KN#( ?-23@D<<$?L!_P7:_;&\;_L$?\
M!,/X@?%+X=W5A9>+O#\^EQ64]Y:+=0H+C4;:WDS&W#'RY7 ST)S0!]?4&OP#
M_P""2'_!T/\ $#Q+X9^-_C7]I?Q#H^I>%?AYX;MKW2+#2='@L[S4]1FN?*BM
M8B@&YI.G/RJ SG"J2/BW]IW_ (.O_P!KSXX_$"]OO"?B_3/A7X=>7=9Z+HFD
M6ESY"#[OF7-S#)+(^/O$%$)SA%&  #^LZCI7Q+_P;T_M;_$']M[_ ():>"?B
M%\3]>/B;QAJ-_J=K=:B;."T:=(+V6*+*0(D>0BJ,A03C)R<FOE?_ (+8_P#!
MTYH'["WCG5OA7\$M+T?Q[\2M)9K;6=7OI&?1O#EP#AK?9&5:YN$P0RAU2-L!
MB[!XU /V"H-?R&S_ /!>#_@H-^TIJE]JWA_XB_$"^M[5C/+#X6\,P+:V*CL1
M;VQ^4#_GH2?4GK7I7[(/_!VK^U/^S;X[M[?XGW6F_%SPW#-Y=]IVKZ?#IFIQ
M)GYA%<V\:%9!_P!-HY1U&!P0 ?U44=*\A_89_;>\ _\ !0W]FW0?BC\-]2DO
MO#^M!HY(9T$=WIERF!+:W"9.R6,D9 )!!5E+(RL=S]J_]HC3/V2/V:/'GQ.U
MFQOM2TKP%H=UKEU:66W[1<I!&9"B;R%W'&,D@<T >A4&OY;?VK_^#O\ _:>^
M/'B>:S^%=EX:^$NBS2F.RALM.CUK5I%8X59)KI&C9O3RX$.3WX->-^*_^"PO
M_!1GX=:>OB37?B!\9M%TUN5O-1\.+;V+?]_+81&@#^O:CI7\[_\ P2*_X.[?
M&]U\8-#\!_M0-HNL>'->N4LHO&UG9QZ?=:1*Y"K)>11!8'M\XW/&D;1@ECO
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MW+8'</COB@#^LZ@U_(?)_P %Y/\ @H1^R[KENWB7XC>/]+;S YL_%GA:V*W
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M_AN74);S3+[3X$+W,D)F+S13(@,F#(8V5&4*I(-?O)7PS_P</?MS^$_V+O\
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MF_\ B*^ J3M1_P 1FS?_ )\T_NE_\F+_ (AKEW_/R?WQ_P#D3[^_X:X^'/\
MT-%K_P!^)O\ XBC_ (:Y^'(_YF>U_P"_$W_Q%? 6<TE'_$9LW_Y\T_NE_P#)
MC_XAKEW_ #\G]\?_ )$^_O\ AKCX<_\ 0T6O_?B;_P"(H/[7/PYQ_P C1:_]
M^)O_ (BO@*D[4?\ $9LW_P"?-/[I?_)B_P"(:Y=_S\G]\?\ Y$^_O^&N/AS_
M -#1:_\ ?B;_ .(H_P"&N?AR/^9GM?\ OQ-_\17P%G-)1_Q&;-_^?-/[I?\
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MI?\ R8_^(:Y=_P _)_?'_P"1/O[_ (:X^'/_ $-%K_WXF_\ B*#^US\.<?\
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !4=S<QV5O)--)'##"I=W=@JHHY))/  ]34E<[\6/ K?$OX;ZUH
M*W36;:I:M LZ_P#+-CTSZKD#([C(H TO#?BS2_&-@;K2=1L=3M5<QF6UG69
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M%_PBFDQ^.-<M_P#B97\>-,AD7FVA8<R^S..!Z+GKNX^H#38XUAC5$5551A5
MP%'8 4ZI;N 4=***0!0:** "CI110 4&BB@ HZ444 %0ZA8QZE:20R#*R#'T
MJ:B@#D_#^KR>&]7.EWA/EDXA<_I^'^?6NLZ5SOQ$T$ZGI'VB+_CXM/G!'5@/
M\.OYT?#SQ5_;^G&&3Y;JU ##U'0?Y^E/S Z*@T44@"CI110 4&BB@ HZ444
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MLO\ _!3'X)^+M9S9V/ASQKIXU,R_NS:V[7"PW#-GH4C=S@X^[B@#^WBBBB@
MHHHH *_B9^(7_*877/\ LL=Q_P"GMJ_MFK^)CXA?\IA-<_[+'<?^GMJ /[9Z
M*** /C;_ (.#O%K>"O\ @C%^T%>(S*TWAL6&1UQ<W,-N1^(E(^E?S_?\&DG@
MFU\6?\%GO"=[<11R/X;\/:QJ4!?_ )9R&V-MN'OMN&'XFOZ&_P#@N=\-;KXM
M?\$AOV@]'LK=KJZ7P?=:DD0&6?[)MNS@=SB X Y)P*_FR_X-A/CC9_ __@L_
M\*6U"18;'Q9]N\,M(S8VRW5K(MN/?=<+"F/]OUXH _K\HHHH **** "BBB@
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M  3_ /\ @]#\2^';BQT']H[P/:^(K'<L3^*?"L:VM]&.ADFLF/E2GG),3PX
MX1C7[R?LT?M0> ?VQ/@_I?C[X:>*-+\7>%-84^1?63DA7&-T4B, \4JY :.1
M5=3U H U/B5X*T;4_"&NSW.DZ7<326,Y>26U1V?]V>I(R:_CG_X(,6<.H_\
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M@\5RZ<I<\A+6..V0?0)"H'L!0!^JG_!KU_P0)\&^(O@QH_[27QJ\.V?B>_\
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M^3J_C=_V*=E_Z64 ?T6V'@S1]*NUN+72=-MKB/.R2*U1'7(P<$#/0D5\!?\
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MEQJ+1-E6D$H,46X?(T,C@9,;+_0+/;QW4#Q2HLD<BE71AN5@>"".X/I7Q?\
M\&[7AVU\,?\ !%GX VUG'Y<4FA37;#UDFO;F:0_B\C'\:^TZ /Y2_P#@ZP_X
M)H>%?V"/VV_#_B;X?Z/8^'? _P 7-.GU&'2K-?+M]/U&VD5+Q(H^B1,)K>0*
MN%5I750JA17[#_\ !IG\>=0^-G_!'3PUI^I7$MU-\/=?U+PO')(=S>2C1W<2
MY]$CNU0>BH!VKY-_X/BM)@F^%W[.M\R?Z5;ZKKMO&WHDD-BS#\3&GY5[#_P9
M5L3_ ,$LO'WM\5=1 ]O^)1H] 'E?_!Z%^WWJG@#X<> ?V>?#]]/9CQK&WB?Q
M0(GVFYL893'9VY]8WN(YI&''S6L?7D5Y+_P:8_\ !%[PG^T%HFK?M&?%KPS:
M^(M'TW43IG@G2M3A$UC<SP_\?-_)$P*S"-RL46[*ATF)!9$*_-/_  =T^++C
MQ%_P67\0V<TDCQZ#X8T>P@#=$1H#<$+[;IV/U)K^@;_@@CX'@^'O_!'']GFP
MMVC:.X\)0:F2G(WW;O=/^.Z9L^^: /KJ*)8(E2-51$&U548"@= !7XR_\'37
M_!%'P3\5?V9?%'[1GP^T#3/#OQ'\$C^U?%#6<?DQ^)M/SMFDE1?D-S%D2>;@
M,Z+(K%CY>W]G*\1_X*7V-MJ?_!./X_6]Y''):S?#CQ"LJR?=*_V9<9SZ?7M0
M!_+]_P &KO\ RG(^#_\ U[:[_P"F2^K^N^OY$/\ @U=_Y3D_!_\ Z]M=_P#3
M)?5_7?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5\N_\%)N/^$+_P"W[_VWKZBKY=_X*3_\
MR7_V_?\ MO7P?B;_ ,DUB?\ MS_TY ^LX'_Y'=#_ +>_](D?+@H[44E?R6?T
M(+1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "
MCM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1110 "CM124 +1
M110 "CM124 +1110 "CM124 +1110 "CM124 ?9G_!.__DBNJ?\ 8;E_]$6]
M>]5X+_P3O_Y(KJG_ &&Y?_1%O7O5?V'P)_R3^%_P+\V?SAQ9_P C>O\ X@HH
MHKZT^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#R/\ :T_9AM?V@_!_F6JQV_B734)L;@_*)1U,
M+G^Z><$_=)ST+ _+_P"RG^TCJ/[-'CVX\->)%N(]!FN3#>0R []-F!VF15],
MC# <D#(R0 ?OROGG]MO]DM?BYI,GB;0+?_BIK&,":)./[1B7MC_GHHZ'J0-O
M.%Q<7T8'T!8WT.IV4-Q;RQSV]P@EBD1MRR*PR&!'4$'.:FKXI_8<_:T;P/J,
M?@OQ3<&/2YI"MC=3MC[#(3_JWS_ Q/!_A/L21]K5+5@"L[Q9XJL/ _AN]U;5
M+A+73]/B,TTK?P@>GJ3T ')) %:-?#?[>'[2,GQ/\6+X-\/S//I.FS;;AH,G
M[?<CC Q]Y4/ [$Y/(VFG%78'&^)M;\1?MQ?M"1PVJR)#<2>7:Q/S'IMJIR6;
MZ#+$]6)P.H%??'PS^'.F?"CP38Z#I,7EV=C&%W'[\S?Q.Q[LQY/Y=,"O._V.
MOV;8O@-X!6>^B4^)-719+UCAOLR]5@4^W&['5NY %>Q42ET0!1114@%%%% !
M1110 4444 %%%% !1110 4444 (PW#!Y!['O7EVM/)\./':R1[EM9&WX!X93
MV_I^9KU*N,^-FA_;_#"W:+F2R;/3DJV <?CC\,TT!U]I<QWMM'-$P>.50ZL.
MX/2I*X?X'^*6UGP_):2-NDLFX)[J>?QP<\^XKN*0!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?-
M7_!5?_@H_H/_  3"_94O/'VIV2ZUK5]<KI/AW1_,\O\ M2_='=59L';&B(\C
MD#(5#CDB@#Z5HK^6;XA_\''7[8/CKQO)J]G\4+?PK:M)OCTC2- T]K&-=Q(0
MFXAEF;C@GS 2!V-?J/\ \$'_ /@OKJW[?'CF7X3?%JSTFQ^(RV;WFC:KIT9A
MM_$,<2[IHVA)/E3HH+_*2K*&QM*X(5RL_5*BBB@D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** #%%)G'K10 M'2BB@ H-%% !1THHH _'?_@KU_R?5XD_Z\[#_P!)
MHZ^<?#7_ ",6G_\ 7S'_ .A"OH[_ (*]\?MU>)/^O.Q_])8Z^<?#7_(QZ?\
M]?,?_H0K]\R7_D64?\$?R1^?XW_>I_XG^9_0M7Y__P#!>;_D4/AM_P!?E_\
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M^%'PJUWXV?$'2_#/ARQDO]6U:810QJ/E4?Q.Y_A11DLQX !-?N-^S1\"M/\
MV;?@AX?\&Z>5D72;<"XG Q]JN&.Z64]_F<L0#T&!VKNXZS"%/!K")^]-IV\E
MK?[_ ->QAD.'E*M[7HOS9W=!HHK\E/K@HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ K^-G_ (.+?^4U7Q^_[#=O_P"D%M7]DU?QL_\
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MA/63)#'++"6421L/FM[A<LA;:P(X=&VKM^[OVD/^#U_XF_$+X>7NE?#/X/\
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M&7/?R_+7.<*!Q6#^U3_P>F?&CXG^&KG3?A7\-_"?PLDND,?]J7MZWB&_MO\
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MOVE/^"O?B:'0=1@U73_AUHUGX.:> [HQ<0--/<Q@]S'<7,L;?[2,.U?T#?\
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M/$&CI/H/B+PWKD,ML+RV9U\ZUF7Y7C=7C1E.,H\:DJP!4@']LM?G?_P=4?\
M*#OXM?\ 7YH7_IYLJ^:/^";G_!U5XN_X*2?\%%/A+\';#X/^'? >@^+)=036
MKR?7)M7NY!!IEU<I]G(BMTA_>P+G>LN5) P?FKZ7_P"#JCC_ ((=_%K_ *_-
M"_\ 3S94 ?F7_P &17_)VWQL_P"Q1M/_ $L%?J'_ ,'/7[/VH?M _P#!&GXG
MQZ5#)=:AX->S\5)$B;BT5I.IN3[!+9YWS_L>F37Y>?\ !D5_R=K\;/\ L4;3
M_P!+17]'6N:)9^)M$O--U&U@O=/U"![:ZMYT#QW$3J5=&4\%64D$'@@T ?RP
M_P#!HS^VYHW[+?\ P4CO/!OB6^ATW1?C)I T&UGF<1Q)JD4HELU9CQ^\'GPJ
M.\D\8[U_51TK^2?_ (+H?\$#_'G_  2^^,>J>-? NEZMKWP-U*\:\TG6+,23
MS>%\G<+6](^:/RV.V.=CMD4+EA)N4>L?L)?\'AWQN_9H^'^G^&/B=X2TCXU6
M.E1+!;:G<ZF^DZVR* JB>Y6.9)B !\[1>8W)9V)S0!_4!0:_F^_:6_X/9/B9
MXY\)W&G_  L^#_AGX?ZA<(4&JZQK#Z_-!G^.*(0V\88=O,$B^JGI7ZH_\&WG
MQG^(W[0W_!+#PSXS^*6N>(O$7BSQ!K>K7<NH:TSF>XA:\<QE-P 6$+PBH BK
M@*  !0!]U37T-N^V2:)&ZX9@#4JL&7<""IY!'>OX]O\ @KCX@U?_ (*7?\%\
M_B!X?\.2?:KSQ)X[MO &BD?-$HMGBTQ7'_3,O$TI/3#,:_KH^$7PQTOX)_"C
MPQX,T.)H=$\(Z3::+I\;')2WMH4AB!^B(HH Z*@T44 %'2BB@#^4C_@[[Y_X
M+%ZE_P!BAI'_ *#+7] __!"S_E#[^SO_ -B59?\ H)K^?G_@[[_Y3%ZE_P!B
MCI'_ *#+7] W_!"S_E#]^SO_ -B59?\ H)H ^L*Y7XY<?!3QA_V!+W_T0]=5
M7*_'+_DBGC#_ + E[_Z(>@#^.O\ X(%_\ID?V>_^QKB_]%R5_9\:_C!_X(%_
M\ID/V>_^QKB_]%R5_9]0 5_*/_P= ?\ !(G_ (=]?M:_\+&\%Z7]F^$WQ9NI
M;NTC@3;#H.JG,EQ9<<(C\S0C@;3(BC$))_JXKQC_ (*!?L0^$_\ @HC^R7XN
M^$_C")5T_P 26I%I?+&'FTB]3YK>[BS_ !QR '&1N7<A^5B" ?RU?\%$/^"K
MLW_!1G_@EK\!/"WB[4&NOBI\'];O=)U::9\RZU8/:PBTOLGEG*Q-%*>3OC#D
MCS0*_6C_ (,GO^4=?Q/_ .RC3?\ ILL*_G8_:I_9F\6?L;_M#^+?ACXXL#IW
MBCP;J#V%Y&,F.7&"DT9(&Z*2,I(C8^9'4]Z_HG_X,GO^4=?Q0_[*--_Z;-/H
M _6OXY?\D4\8?]@2]_\ 1#U_'5_P0+X_X+(?L]_]C7%_Z+DK^Q7XX_\ )%/&
M'_8$O?\ T0]?PV?LJ_M*>(_V._VB/"/Q.\(KI[>)/!>H)J6GK?PF:V:101B1
M REE()! 8'W% ']WE5->UVQ\+:'>:GJ5Y:Z?ING0/=75U<RB*&VB12SR.S8"
MJJ@DDG  )-?RV7'_  >0_M<30.JZ?\(868$!U\.W&Y/<9NB/S!KYD_;&_P""
MWG[57_!2'1H?!OC/X@:K>:#J$HA'ASP[8QZ=;:BSD 1RQVZA[D$XPDK.,X(&
M>: .,_X*Z_M0:3^VM_P4O^,/Q)\.2M>:!XF\0.ND3^48S=VD"):V\NTC(WQP
MHV" ?FY&<U_8I^P9\*]0^!7[#?P9\$ZM$UOJG@_P-HFB7L;')CGMK""&13]&
M0BOPG_X-ZO\ @V@\::U\7_#?QP_:'\.W/A7PSX9N8]4\/>$-3B\O4=8NXV#1
M37D##,-O&P#"*0!Y&4;E$?\ K/Z,* /X\_\ @XO_ .">U]^P%_P4Q\916]E/
M'X)^)%S+XM\-7)C(A,=S(7N+93TS!<,Z;<DB,PL<;Q7[I?\ !MO_ ,%I]!_X
M*#?LQZ)\-/%^L6UK\;/A]IT>GW5K<S8F\364"*D>H1;O]8^P 3*"2'!<@+(N
M/J7_ (*H?\$O_ ?_  5;_9DNOA]XS,FF:A:2F^\/Z_;1+)=Z#>A2!(H.-\;#
MY9(B0'7NK*CK_*1^V]_P3)_:*_X(Y_&RWU#Q'I?B#P]'I=_N\/>._#TTJV%T
MZD^7)!=QX:&4CGRW*2CGY<<D _M,HZ5_+'^R]_P>$_M0? _PY;Z1XQT_P/\
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M&6& 0* /[2/V%?\ DR+X-_\ 8CZ)_P"D$%?SC?\ !YS_ ,I8/#/_ &3;3?\
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M]**3M0 M%&<TE "]*#THI.U "T49S24 +TH/2BD[4 +11G-)0 O2@]**3M0
MM%&<TE "]*#THI.U 'V9_P $[_\ DBNJ?]AN7_T1;U[UTKP7_@G><_!75/\
ML-R_^B+>O>J_L/@3_DG\+_@7YL_G#BO_ )&]?_$%!HHKZT^>"CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BDS0!\
ME?MV_LB_:3=>.O#%LWG+^]U6SA7[V.MP@'YO_P!]?WC5_P#81_:X_P"$EMK?
MP3XFNO\ B80KLTR[E;_CY0=(6)_C'\)_B''4#=]3,HD4JP#*PP0>AKX<_;7_
M &4I/A)K;>,O#$;PZ'/,))XH>/[,F)X*XZ1D],<*>./ESI%W5F![)^W5^TU_
MPJ;PC_PCNCW&WQ#K415W1L-8P'(+Y[,W('<<GCC/G7_!/C]F7^TKJ/Q]KMOF
M&%R-(BD'^L<9#3D>BGA?]H$]@3YA^SW\)-:_:Y^,DM[KEU=7=E"RW&KWLC?.
MR]%C4]F;& .@"D]L5^AFEZ9;Z)IMO9VD,=O:VL:PPQ(-JQHHP% ] !2>BL!8
MHZ4 YHJ "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %5]4L5U/3
MKBWD^Y/&R'VR,9JQ10!X/\+M>;PE\3([>9E6.9S;2 'CG[OZX_*O>#7SA\<K
M=O#?Q3N9%+1K+(LZL/4@$D?B37T%X=U8:]H%E?*-OVN!)<8Z;@#BJEW NT=*
MKZCJUKH]LTUY<V]K"O62:01J/Q)K)TOXI>&-;N_L]EXBT&\G_P"><&H12/\
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M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
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M;<?SKTCX5_\ !":SM;V&X\:>.IKR%>9++1[/R=WMY\A;C_MF#[BJI_X+W_\
M5*?_ "Y__N2C_A_?_P!4H_\ +G_^Y*[ZTN*ZD>512]'#_,YX1RF+O>_KS?Y'
MW%\%/@+X2_9X\'QZ'X0T6UT>Q7#2&,;IKEQQOED.6D;W8G X&!Q785^=O_#^
M_P#ZI1_Y<_\ ]R4?\/\ #_JE'_ES_P#W)7S53A3.:DG.I3;;W;E%O_TH]2.;
M8**Y8RLO1_Y'Z)5XG^UC^P1X"_:ZM5N-;M9=-\0PH(X-9L,)=*HZ(X(*R)[,
M,CG:5R:^63_P7O\ ^J4_^7/_ /<E'_#^_P#ZI1_Y<_\ ]R5IAN&<\P]15:$'
M&2ZJ4?\ Y(FIF>!J1Y)RNO1_Y',>,/\ @A/XSM+Z8>'_ !MX8U"VS^[;4(9[
M.0CW"+*/R-6_ 7_!"3Q-=:@A\4>.="L;5>7&EVTMU(WL#((@/K@_2MS_ (?W
M_P#5*/\ RY__ +DH_P"'^'_5*/\ RY__ +DKZ+GXLY>7E7K^[O\ G;\#S>7*
M;WO_ .E?Y'U]^S%^QOX%_9+T*2U\*Z:WVZ[0+>:G=MYMY>8[,^ %7/.Q JYY
MQGFO5*_.T_\ !>__ *I3_P"7/_\ <E=%\(/^"V/_  M;XM>%_"__  K/[!_P
MDFKVFE?:?^$B\W[-Y\R1>9L^RKNV[L[<C.,9'6OF<5PWG51RKUX-O=MRB_\
MVX]2CF6"BE3IRMY6?^1]X4445\N>H%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>-_$?_ ()U?L^_&/QMJ'B;Q=\"?@WXJ\2:LXDO=5UCP7IM]?7C!0@:
M2:6%G<A5506)X4#H*]DHH KZ5I5KH6F6UC8VUO9V=G$L%O!!&(XH(U 5410
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M!\0QZQ\-_@[X#\*ZU$GEQZI;:6DFH1+W"W$FZ50>^&&>^:]YHHH *\Z_:/\
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M8?Q%^&?AOXO^$+SP_P"+?#^B>*-!U!0MUINKV,5]9W(!R \4JLC<\\@UN44
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M[+_AW]M']F_Q;\+?%ESK%IX<\:67V#4)=*N1;7@BWJY".RL!G: <J002,<T
M?S7?\&DG[+]W^U-_P5:U'XH:\DFH6?PMTRZ\07%S*-RS:K>EK>W#?[1$EU,#
MV: &OZF*^8?^"8__  21^$__  2:\%>*=$^%W_"27">,+Z*^U*[UR\CNKJ0Q
M1E(HPT<48$:;I" 03F1SGG ^GJ "BBB@ HHHH \I^,'["'P/_:&\8MXB\?\
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M\#_V)$N/^%4_"[P?X)N;I=D][86"_;IUX^1[E]TS+_LER,Y..34WQ2_X)[_
M/XX^.K[Q1XV^!_P@\8>)M2\O[9J^M^#=.U"^N_+C6-/,GFA:1]L:(@R3A54#
M@ 5[!10!5T31++PSHUGINFV=KI^G:?"EM:VMM$L,-M$BA4C1% 5550 %
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MIXG\#_!'X0^#?$NGK(MKJVA^#M.TZ^MA(AC<)-#"KJ&1F4X(RK$'@FO7J**
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M* %HHHH !1VHI* %HHHH !1VHI* /LS_ ()W_P#)%=4_[#<O_HBWKWJO!?\
M@G?_ ,D5U3_L-R_^B+>O>J_L/@3_ ))_"_X%^;/YPXL_Y&]?_$%%%%?6GSP4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8;A)O*'J0K$@>^.*^1POC!FN(H2Q5'+'.G'XI1E)I65W=J#2LG?7H>]6\/\
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MV?QS^V'\:;>UDN[OQ!XGU^9EC\^8*J@ NV,X5(T4$X&  O XQ7L?C#_@D?\
M%CPIHGVRS/A_79MN6MK"]99E_P"_J1J?P)->+1X^S/&.5;+\$YTHNS=VW^"M
M>W1)V/8K<"Y;A%&CC\8H59*]K)+\7M?J[7/U(!S17S__ ,$UM+\6:#^S1#IW
MC"VU:SO]/U*XM[>'48V2:.!0F -W.T.9 /I@< 5] 5^D9;C'B\+3Q+BX\R3L
M]U?H?G>8X3ZKBJF'4E+E;5UL[=0HHHKN.,**** "BBB@ KX__P""[G[07C3]
MEW_@F5X\\:?#WQ#=^%O%6ES6"VFI6T44LD DO(D?"RHZ'*L1RIZU]@5\&_\
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MM+&%'.'GE[J,?E#5"C'N>L>(OV]OCMXMU1K[4_C9\7;R[8[O,?QAJ"D?0+*
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MUN?"[_DJOA'_ +#^G?\ I7%0%D?VM6$C2V,+,<LT:DGU.*^#_P#@KE_P7F\
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M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
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M>_\ @G[\:O'7A.\73?$_@_P3JVL:5=M DXM[J"TDDB<QR!D?#*#M8$'&""*
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M-'_A/V7_ ,FT ?K11TK\E_\ B,Q_9-_Z /QH_P#"?LO_ )-H_P"(S']DS_H
M_&C_ ,)^R_\ DV@#]:*#7Q3_ ,$S/^"\OP5_X*N_%?7_  ;\,]-\?6>K>'-)
M.M73:]IEO:PM!YT<.$:.XD);=*O! &,\]J^UJ "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH R?'G_(CZU_
MUXS_ /HMJ_.7P[_R.MK_ -?0_P#0J_1[QE!]J\(:M%G;YEG,N3VRAK\W_#;;
MO&EJ?6Z'_H5?SOXX_P"]8#_M_P#.!^M>&G\#%?\ ;OY2/I#_ (*+> BT>A^)
MHH_N[M/N''XO'_[4Y^GM4/\ P3K^(0AGUKPQ,W^MQJ%N.P(PD@^I&P_\!->Z
M_M!> A\2?@_KFEA=T[6YG@QU\V/YU ^I&WZ,:^%/@Q\07^%'Q/TG6_WGEV4X
M%PJ?>>(_+(H'3)4D<]ZGC"7^KO&N'SA:4ZUG+M_)/[E:7JRN'U_:_#=7+WK.
MG>W_ *5'\;Q]#UC_ (*"?$3^W?B)8^'X7W0:+"))0/\ GM* 3GUPFSZ9/K7>
M?LK?#T>%?V7?$.K31[;O7K2YDR1@B*.-U08^N\^X(KYGN);[XS_%9F&#?^(M
M0^49.U6D?@?[HS^ K[Z\2:%!X7^#6H:;:KMM]/T:6WC&/X4A*C^53P3&6>9W
MF/$55>[&,E"_3F34?_ 8*S_Q#XE:RS+<)E$-VTY?)IO[Y.Z]#\__ (9?\E+T
M'_L(0_\ HP5^E'2OS6^&7/Q+T'_L(0_^C!7Z(_$#Q=#X!\$ZKK4P5H]-MGGV
MDX\Q@/E7/N<#\:Z_ ^M"C@<;6JNT8N+;[)*39CXF4Y5,3AJ<%=M-+U;1\:_M
MP_$3_A-/C/-8PR;[/0HQ:* ?E\S),A^NX[3Z[!78:C\!C!^PU#<_9V_M2.8:
MX>/F*-A.O]WRMK_AFOG>]U9M9\037U\TDS74[3S-_$Y9LD_CFOI6Y_;^T>Z\
M.R:4WA&;[#);&T,8OACRRNW;_J_[O%?$9'G&49ACLRQV=U?9NO&48)QE*W,]
M'[J=N11BE<^CS++\?A,-@\+EM/F5)IRLTK\O35KXFVV>6?LA?$(?#WXX:7)(
MVVUU/.GS?20C:<^@<*3["OM;XN>(IO"7PO\ $&I6[;+BSL)I(6_NOL.T_@<&
MOS>$_D7@DBW+L?<O.,=Q7W9>>+V^+O[(=]JD;>;<WFB2^?@<F:-")!CW93CV
M(KZCPESZHLLQV61?OQC*I#OM9V]'ROU;/%X^RN'UW#8UKW9-0E]]U]ZO]Q\+
M6\3:IJ2K_'/)SD^IK]*_!/A.U\">$=/T>RC$=MI\"PH/4@<L?<G))[DFOS6T
MNZ;3=4AF[PR GVP:_331M5AU[1[6^MI%DM[R%)XG4Y#*P!!_(UMX#PHNIC)N
MW/:"7?E?->WE=*_HC/Q0E44</'[/O??[MOPO;YEB:%+F)HY$62-A@JPR#7FG
M[8O_ ";?XF_ZYP_^E$=>FUYE^V)_R;?XF_ZYP?\ I1'7[3Q=_P B/&O_ *<U
M/_2)'YSD/_(SPW_7R'_I2/CW]F[Q18>#/C9H.I:G<+:V-K*S2RLI8("C#H 3
MU(Z5]._&O]K[P2?AMK%GINI?VM?:C:26L4,<,B@;U*[F+*!@9SCJ?UKY+^%/
M@"3XH^/]-T&.Y6S?4'9!,R;PF%+=._2NL^/G[+VL? :&UNKBX@U'3;IC&MS"
MI7RWZA64]"1DC!.<'TK^8>&<_P _RWA_$O+Z$98=R:E-J[BW&*>G,M+6U<6K
MO4_:LZRG*L9FU%8NJU527+%:)I-O>W>^B:9RWPD\!7?Q*^(6EZ19QN[74ZB1
ME&?*CS\[GV R:^KO^"@'B>;1O@[;6,+!5U6]5)A_?C0%L?\ ?6P_A7$_\$__
M (GZ7;ZE<>&9M/LK74[I&F@OE7$MV%Y,3$\G !88XPI[\UT__!1+3GF^&>C7
M2JVR#4/+)';=&Q&?^^37U7#N6TL)P)CL=A:G-.LDI6NN5)V<?6TFV]FFNFK\
M+-L;4K\48;#5X<L:;O'K>^O-]Z22[H\3_8O\'6_B_P".^F_:HUF@T]'O"C#@
MLJ_(?P8J?PK[P-?#O[">M1Z5\>[6&0[3J%M-"I/J%+X_\=K[BK[/P3ITED4Y
MP^)U)<W?2,;+[OS9\[XD2J/-(QELH*WWN_XGAO[?7A&'6_@U'J3*OVC1[M'6
M3'S!'RC+GW8H?^ U\]?L;Z[)H?[0F@A798[MI+>0#HP:-@ ?QP?J!7T=^WCX
MEBT;X%26;M^\U:[B@50>2%S(3CT!11^(KYO_ &.M$?6_VA= VJS):O)<.0.%
MVQL1G\<#\:^-XZC!<>X-X?XFZ/-;^;GZ_P#;O+\CZ+AAR?"V(]M\-JEO3E_^
M2O\ ,]&_X+(W<EO^RUI,:#Y;CQ);I(?0"WN6_F!7RQ_P2EL+>]_;(T9Y]OF6
MUC>2P9'5_)9?_06;\J^S/^"GO@YOB/\ LL>(+2S#3ZAX9>UUQX5'S+#NDC+_
M $">:Q]D-?G+^RG\8E^ O[07AGQ1+N^R:?=A;O;R?(D!CEP!U.QF('KBOI.,
MJBPO%.'Q5?X/W;OY*6OW6N:\(TWBN&*^&H_'[ZMYN.GWWL?K9^U!XXU3X;?L
M]^+M>T5Q'JFEZ;+/;2&,2>6X'WMI!!QG/((XY!%?FA_P\Y^-F/\ D;%_\%=K
M_P#&Z_5_2]3L?%F@V]Y:RV]_INI0++%(A#Q7$3KD$=BI!_6N7^*'@?18/AGX
MB=-'TM&72[DJRVD8((B;VK[WB7(\=CYQQ&#Q<J48QVC>SZWTDNA\-P[G>"P,
M)4,7A(U92EN[772VL6?FQX1_X*?_ !C3Q7IANO$EO>6OVJ/SK=].MU6=-PW*
M2J C(R,@@\\5^EOQ_P#^2#^-O^P#??\ I/)7XG^'?^1BL?\ KYC_ /0A7[8?
M'_\ Y(/XV_[ %]_Z3R5\EX>YEB\7A,8L54E/E2MS-NUU.]K^B/JN/<OPN%Q6
M#^K4XPNW?E25[.-KV]3\4= U*/1_$UG=RAFCMKA)6"C+$!LG%?I.?^"R7PP!
M_P"0/XT_\ [?_P"/U^;&@Z:FL>);2TD9ECNKA8F*]0"V#BOT<_X<R?#S_H8O
M%W_?V#_XU7RO!$L\4:W]CJ+^'FYK>=K7^9]1QI')7*E_:SDOBY>6_E>]OD>_
M?LV_M*>'_P!J3P'/X@\.QZA!:VUX]C+%>Q+'*DBJC]%9A@JZG.:^)_\ @M)_
MR6#PG_V!_P#VO+7VI^S)^S/H?[*_@&X\/Z#<:A>6]U>O?2RWCJTC.R(G\*@8
M C7MUS7Q7_P6D_Y*_P"$_P#L#_\ M:6OT'C7ZU_JS_MMO:WAS6VOS(^"X-^K
M+B3_ &._L_?Y;[VY6>0^+/@:=<_88\*?$&QM3YNCZI=:3J;KR3"\F^&0]@%=
MG0GKF1!]/4_^"0?[0G_"$_%"_P# E_+MT_Q2OGV9=L+%=QJ>!V_>)D>I*(!U
MKVO_ ()Q_#K3_BW_ ,$_;[PWJL8DL-9O+ZVDXR4SMVN/]I6PP/8J*_/OQ+H.
MN?LZ?&>>RF9K/7/">I@K(O\ #+$X9'7U!P&![@@U\%7HU,FJ8#.Z"]V<(\WJ
MHI27_;T=O.[/N:%6GG%/'9-7?O1G+E]&VXO_ +=EOY61[G_P5S/_ !EQ+_V"
M;7^35]Q?\$\/^3,O O\ UZS?^E,U?GM_P4%^*EK\;OBCX;\66?EK'KGAFSN'
MC1MPAE#2I+'G_8D5UY_NU^A/_!/'_DS/P-_U[3?^E,M?4<'U85>*,95IN\91
MDT^Z<HM'S7%E.=/AK!TZBM*+2:[-1DF?F=^VS_R=G\0?^PY<_P#H9K],O^">
MKB/]C#P(S':JV4I)/;]_+7YF_MLG_C+/X@_]ANY_]#-?IA_P3XB$_P"Q9X&0
M_=>QE4X_Z[RUQ\ _\E!B_2?_ *6CKXZ_Y$.$]8?^D,_*'XN^.)OB5\4O$/B"
M9F,FM:C/>')SM#N6 'L <?A7ZR?L#_"6S^$7[*WA.VMXT%SK%G'J]Y*% :66
MX42#=Z[4*)]$K\B?%_AZX\)>*]3TNZ4QW6FW4EM*IZJZ,5;]0:_8S]C+QY:?
M$;]EOP/J%G(KK%I,%C-CJLL"B&0'T^9"1[$&N;PPY9YI7G6_B<KWWUDN;\;'
M1XE<T,LH0H_P^9;;:1]W\+GIQ&X8/(KQK]NSX/WGQ9_91\2:'H=ONOK>%+NT
MMHD_UIA<.8U4?Q%0P4#JQ KV6BOVG'8.&+P\\-4VG%Q?HU8_'L#C)X7$0Q%/
M>#4EZIW/P_\ @W\6M9^ /Q1TOQ1HIB35-'E9E2="T<@92CHXR#M9693@@\\$
M'!K]%_@'_P %8O 7Q/,-CXFCF\&:I)A=]P_G6+D\<2@ IZ_.H '\1KI_VEO^
M"</@+]HB\N-4CCE\,^(IR7>_L$&R=SWEA.%8]22I5B>I-?GC^UC^Q[XD_9*\
M3VMKK$EMJ&F:GO-AJ%OPEQLQN!4\HPW+D'CG@GK7XD\/Q!PGS3I6G0O=]8ZZ
M)M?%%O176E[*[T/V58C(N*>6%6\*]K+I+36R>TDM7KK:[LM3]C+6ZBOK:.:&
M2.:&90\<B,&5U/(((X(([U)TKX:_X(W_ !UU/7].\0>!-0N)KJUTF%=1TS>=
MWV:,OLEC!_NEG1@.@)<]Z^Y:_7\ASBGFF!AC::MS;KLT[-?Y>1^39YE,\LQL
M\'-WY=GW35T_\_,*#117L'DA1THHH *#110 5\'?\'*O_*'SXE_]?&F?^E\%
M?>-?!O\ P<J\?\$?/B7_ -?&F?\ I?!0-;G\NM?K9_P:"?\ )Z?Q0_[$I?\
MTN@K\DZ_6S_@T$_Y/3^*'_8EK_Z704&LMCDO^#MO_E*#X9_[)IIG_IRU:OS
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MG$^#7/QK\"_]C/I/_I=!7]'?_!TWQ_P2@U#_ +&C2O\ T*2@;W1_-#7Z]?\
M!H'\/='UO]J;XK>)+JR@GUC0O#EM:6%PZ!FM4GG/G;">5+>6@..H !K\A:_9
M3_@SN_Y+7\;/^P+IW_H^2@J6Q^[VNZ'9^)]$O--U&U@OM/U"![:YMYD#QSQ.
MI5T93P59200>H-?Q4_$[P_;^$?BEXKT>S799Z/KNH:=;*?X8H;J6)!_WR@K^
MV"OXJ_CI_P EZ^('_8UZQ_Z7ST$0+7[.7@G3_B9^T?\ #GPSK$/VG1_$GBW1
M]*OX2<>?;7%_!%,GMNC=ES[U_:+964.FV4-M;PQ6]O;H(HHHT"I&H& JJ.
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MPP\2V_Q0\>7MM)'I5OI43MI]I,00LMS.P5-BGG8A9FQC !W ,^5W/Y]_VX_
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M^$-]I\C0WD'CK0A$ZG:1NU&W1N?=68?C7Z(_M)?\&T&@_L>_#Z;Q1\3OVI/
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M?]97PO\ :=5E^T"\\4^,_$5W*UI9-*V=\\Y#/-._)6-=SM@G 4,P_;;X"_\
M!E?\ _"'AN,?$3XB?$KQKKA \V73'MM&L0<<[83'-)U[F8_2OTP_8#_8@\&_
M\$[?V5?"WPI\#VRIIOA^W!N[QXPMQK%X^#/>3$=9)'Y]%4*@PJ*![-0!^-/Q
M[_X,K_@'XP\/3?\ "N_B)\2/!.M8/E/J;VVLV.<<!HA'#+U[B;\*_$O]O?\
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M5M;8X_LC4;6UBBN;1TZJ4<?+D#<C(XRK*3],4 ?SX_M:?\&7NM?#W4K/Q%\
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MQ!F7:^UMLB,R-M8!LJP4 /\ @QK_ .1<_:8_Z^?#7_H.JU^^%?@?_P &-?\
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M-=K\.9->\!ZUXW;XBOJ2VZV%_%:"S^Q"U+%BZMNW?:EQ@<;3[5Z/_P $FO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R[
M_P %)N/^$+_[?O\ VWKZBKY=_P""D_\ S)?_ &_?^V]?!^)O_)-8G_MS_P!.
M0/K.!_\ D=T/^WO_ $B1\N"CM125_)9_0@M%%%  *.U%)0 M%%%  *.U%)0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*]NG6SM=O4^$?VN?@99?!+QK8QZ4MQ_9>HVWF1F9MQ5U.&7.!_LG_@5>H?\
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M^:/@'Q=<?#[QOINL6_\ KM-N4FVEBH<*<E3CL>A]J^^OB;X.L_C[\&KBSMY
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MUK:CY?,G>$K=6P=MSYMW; =0RG!:N@\N+/Q-H'S.JC+,[!% Y9F)P !W))
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MJB1MQ_K$\,^)=/\ &?AO3]8TB^M=2TG5K:.\LKRVE$L-W!(H>.1'7AE92&#
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M<3?\!K^F?_@L5Q_P2@_:1_[)MKW_ *034 ?SG?\ !HO_ ,IF/#O_ &+&L?\
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M?^"W/_!(3Q/_ ,$=_P!H.'PS!K6I^(OAIXX@-]X>UF6/R?M8B;Y[6Y53L-Q
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "OEW_@I-_S)?_;]_P"V]?45?+G_  4F_P"9+_[?O_;>O@_$W_DF
ML3_VY_Z<@?6<#_\ ([H?]O?^D2/EWI0>E%)VK^2S^A!:*,YI* %Z4'I12=J
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
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M>MB2.UN)8SL9U'#VUTH!3S%'8!T<*%'[C_!#_@\K_9A\>^&HIO&6@_$CP%K
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M8X_\C[^TA_V#_#__ *,U&OV$_P""Q7_*)_\ :1_[)KKW_I!-0!_.?_P:+_\
M*9CP[_V+&L?^B!7]85?R>_\ !HO_ ,IF?#O_ &+.L?\ H@5_6%0!\R_\%GO^
M42W[1_\ V3O6O_2.2OYW_P#@T*_Y3(:1_P!BGJ__ *+CK^B#_@L]_P HEOVC
MO^R>:U_Z1R5_.]_P:%?\IC]'_P"Q3U?_ -%QT ?U=U\N_P#!;'_E$;^T9_V(
M.J_^D[5]15\N_P#!;'C_ ()'?M&?]B!JO_I.U '\]_\ P9^_\IAK/_L3M6_]
MHU^P_P#P=G?"V\^(W_!&3QA?6</VC_A#]=TG6Y@.66+[0+5F ]OM.3Z*">U?
MCQ_P9^_\IAK3_L3M6_\ :-?U"?'SX(^'_P!I7X)>+/A_XKM/MWAOQGI5QH^H
MP]&:&:,HQ4_PNN[<K=58 CD4 ?SI?\&5/[06F^!/VV?B=\.[ZXBMKKX@^&(;
MW3@[8-S/I\S,85'=O)N9I/\ =A:OZ6Z_BQ_:J_9A^,__  0H_P""A-K;FZOM
M%\3^"=3&K^$O$T$!2UURU5OW=Q%NRKHZ'9+$2P!,D;Y&<_NA^PG_ ,'A?P ^
M+_P^T^W^.$6K?"7QI;PJE_/!IESJNBWD@ !D@:W62>,,<GRY(SLR!YC_ 'J
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M6]_PJOQ1_P!"WKW_ (+Y?_B:/^%5^)_^A<U[_P %\O\ \31]0Q7_ #[E_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLWCS5(/D7=;:2K#JW*R3?AR@]R_' -:KW5<#Z:^$7PYMOA-\-](\/VN&CTV
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M0?\ CE>S?LU?\&:?[-OPHUNVU+Q]XF\??%*2W.387%S'I.F3_P"^EN//_*X
M]0:_7BB@#F_A)\'O"OP$^'FF>$O!/AW1_"OAG1HO)LM,TNT2UM;9>IVH@ R2
M22>K$DDDDFO#?^"H?_!++X>_\%:/@EH?@/XCZQXQT71] UQ-?MI_#=W;6URT
MZ03P!7:>"93'MG<D!0<A><9!^EJ* /E;_@EC_P $AOAK_P $BO OBSP_\-]:
M\<:U9^,+^'4+V3Q+>6MS+')%&8U$9M[> !<$Y!#'/?M7U2:** "CI110 5\)
M_MX?\&Y/[+G_  4 \;:IXL\1^$]4\)^-=:D::_U[PK?_ &"XO96Y,LL3K);O
M(3RSM$78GEC7W910!^%WC;_@Q\\"7^HLWASX_>+=*M,_+'J7AJWU"0#W>.>
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M4K70O'NAWF@:A/I\B1W<,%S"T+M$SJZ"0*Y*ED89 R".*[:B@#\]_P#@G/\
M\&V'P+_X)C?M,V?Q5\!^*OBQK'B*QL+G3X[?7]3L+BS,<ZA7)6&RA?< ./GQ
MZ@U^A'2BB@#A?VFO@!HO[5G[/'C;X:>(KC4K/0?'FBW6A:A/ITB1W<,-Q$T;
MM$SHZ!P&)!9&&<9!'%?&?_!./_@VW^!O_!,']I6W^*?@'Q5\5M8\0V^G7.F)
M;^(-3L+BS\N<*'8K!90ON 7@[\<G(-?H-10 5P?[4/[/.B?M9_LZ^-?AEXDN
M=4L] \=Z/<:+?SZ=(D=W##.A1FB9T=%< Y!9&&>H/2N\HH _/W_@F[_P;?\
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q129QZT4 +1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH 3-%'YT4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
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M_P#BJ3_B+Q_8V_Z#7Q _\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\
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M_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\
MBJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5
M'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U
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M8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_Q%Y?L;_]!KX@?^$Q+_\
M%4?\1>/[&W_0:^('_A,2_P#Q5 'Z?T&OS _XB\?V-_\ H-?$#_PF)?\ XJD_
MXB\?V-O^@U\0/_"8E_\ BJ /U HZ5^8'_$7E^QO_ -!KX@?^$Q+_ /%4?\1>
M/[&W_0:^('_A,2__ !5 'Z?T&OS _P"(O']C?_H-?$#_ ,)B7_XJD_XB\?V-
MO^@U\0/_  F)?_BJ /U HZ5^8'_$7E^QO_T&OB!_X3$O_P 51_Q%X_L;?]!K
MX@?^$Q+_ /%4 ?I_0:_,#_B+Q_8W_P"@U\0/_"8E_P#BJ3_B+Q_8V_Z#7Q _
M\)B7_P"*H _4"CI7Y@?\1>7[&_\ T&OB!_X3$O\ \51_Q%X_L;?]!KX@?^$Q
M+_\ %4 ?I_0:_,#_ (B\?V-_^@U\0/\ PF)?_BJ3_B+Q_8V_Z#7Q _\ "8E_
M^*H _4"CI7Y@?\1>7[&__0:^('_A,2__ !5'_$7C^QM_T&OB!_X3$O\ \50!
M^G]!K\P/^(O']C?_ *#7Q _\)B7_ .*I/^(O']C;_H-?$#_PF)?_ (J@#]0*
M.E?F!_Q%Y?L;_P#0:^('_A,2_P#Q5'_$7C^QM_T&OB!_X3$O_P 50!^G]!K\
MP/\ B+Q_8W_Z#7Q _P#"8E_^*I/^(O']C;_H-?$#_P )B7_XJ@#]0*.E?F!_
MQ%Y?L;_]!KX@?^$Q+_\ %4?\1>/[&W_0:^('_A,2_P#Q5 'Z?T&OS _XB\?V
M-_\ H-?$#_PF)?\ XJD_XB\?V-O^@U\0/_"8E_\ BJ /U HZ5^8'_$7E^QO_
M -!KX@?^$Q+_ /%4?\1>/[&W_0:^('_A,2__ !5 'Z?T&OS _P"(O']C?_H-
M?$#_ ,)B7_XJD_XB\?V-O^@U\0/_  F)?_BJ /U HZ5R_P $/B_HW[0?P7\(
M>/O#CW$GA[QQHEGK^EO/%Y4KVMW D\)=#RK%)%RO8Y%=10 F:*/SHH 6N?\
MB5\)O"OQF\.?V/XP\,^'_%FD>:L_V'6=.AOK;S%R%?RY59=PR<'&1D^M=!10
M!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\ C->P
M44 >/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44
M>/\ _#O;X!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C
M_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\
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M^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\ #O;X!_\
M1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\
M@_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__
M .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\
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MM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\
MO^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\
M _\ HA_P?_\ "-T[_P",U[!10!X__P .]O@'_P!$/^#_ /X1NG?_ !FC_AWM
M\ O^B'_"#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z
M(?\ !_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\ X1NG?_&:/^'>WP"_Z(?\
M(/\ PC=._P#C->P44 >/_P##O;X!_P#1#_@__P"$;IW_ ,9H_P"'>WP#_P"B
M'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\ _A&Z=_\ &:/^'>WP"_Z(
M?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[? /_HA_P '
M_P#PC=._^,U[!10!X_\ \.]O@'_T0_X/_P#A&Z=_\9H_X=[? +_HA_P@_P#"
M-T[_ .,U[!10!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__
M  C=._\ C->P44 >/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\
M(W3O_C->P44 >/\ _#O;X!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-
MT[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\
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M/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\
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M_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\ @_\
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M_P"'>WP#_P"B'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\ _A&Z=_\
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M_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\ _\
MHA_P?_\ "-T[_P",U[!10!X__P .]O@'_P!$/^#_ /X1NG?_ !FC_AWM\ O^
MB'_"#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z(?\
M!_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\ X1NG?_&:/^'>WP"_Z(?\(/\
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M_P##O;X!_P#1#_@__P"$;IW_ ,9H_P"'>WP#_P"B'_!__P (W3O_ (S7L%%
M'C__  [V^ ?_ $0_X/\ _A&Z=_\ &:/^'>WP"_Z(?\(/_"-T[_XS7L%% 'C_
M /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[? /_HA_P '_P#PC=._^,U[!10!X_\
M\.]O@'_T0_X/_P#A&Z=_\9H_X=[? +_HA_P@_P#"-T[_ .,U[!10!X__ ,.]
MO@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\
M#O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;
MX!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^
M?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\
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M'>WP"_Z(?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[?
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M#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z(?\ !_\
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M[!10!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\
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M_P#X1NG?_&:/^'>WP#_Z(?\ !_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\
MX1NG?_&:/^'>WP"_Z(?\(/\ PC=._P#C->P44 >/_P##O;X!_P#1#_@__P"$
M;IW_ ,9H_P"'>WP#_P"B'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\
M_A&Z=_\ &:/^'>WP"_Z(?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&
MZ=_\9H_X=[? /_HA_P '_P#PC=._^,U[!10!X_\ \.]O@'_T0_X/_P#A&Z=_
M\9H_X=[? +_HA_P@_P#"-T[_ .,U[!10!X__ ,.]O@'_ -$/^#__ (1NG?\
MQFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\ #O;X!_\ 1#_@_P#^$;IW
M_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\ @_\ ^$;IW_QF
MC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_A
MWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\
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M3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\ _\ HA_P?_\
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M44 >/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44
M>/\ _#O;X!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C
M_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\
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M^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\ #O;X!_\
M1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\
M@_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__
M .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\
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MM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\
MO^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\
M _\ HA_P?_\ "-T[_P",U[!10!X__P .]O@'_P!$/^#_ /X1NG?_ !FC_AWM
M\ O^B'_"#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z
M(?\ !_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\ X1NG?_&:/^'>WP"_Z(?\
M(/\ PC=._P#C->P44 >/_P##O;X!_P#1#_@__P"$;IW_ ,9H_P"'>WP#_P"B
M'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\ _A&Z=_\ &:/^'>WP"_Z(
M?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[? /_HA_P '
M_P#PC=._^,U[!10!X_\ \.]O@'_T0_X/_P#A&Z=_\9H_X=[? +_HA_P@_P#"
M-T[_ .,U[!10!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__
M  C=._\ C->P44 >/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\
M(W3O_C->P44 >/\ _#O;X!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-
MT[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\
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M/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\
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M_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\ @_\
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M_P"'>WP#_P"B'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\ _A&Z=_\
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M_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\ _\
MHA_P?_\ "-T[_P",U[!10!X__P .]O@'_P!$/^#_ /X1NG?_ !FC_AWM\ O^
MB'_"#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z(?\
M!_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\ X1NG?_&:/^'>WP"_Z(?\(/\
MPC=._P#C->P44 >/_P##O;X!_P#1#_@__P"$;IW_ ,9H_P"'>WP#_P"B'_!_
M_P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\ _A&Z=_\ &:/^'>WP"_Z(?\(/
M_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[? /_HA_P '_P#P
MC=._^,U[!10!X_\ \.]O@'_T0_X/_P#A&Z=_\9H_X=[? +_HA_P@_P#"-T[_
M .,U[!10!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=
M._\ C->P44 >/_\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O
M_C->P44 >/\ _#O;X!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_X
MS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L
M%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\ AWM\ _\ HA_P?_\ "-T[_P",
MU[!10!X__P .]O@'_P!$/^#_ /X1NG?_ !FC_AWM\ O^B'_"#_PC=._^,U[!
M10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z(?\ !_\ \(W3O_C->P44
M >/_ /#O;X!_]$/^#_\ X1NG?_&:/^'>WP"_Z(?\(/\ PC=._P#C->P44 >/
M_P##O;X!_P#1#_@__P"$;IW_ ,9H_P"'>WP#_P"B'_!__P (W3O_ (S7L%%
M'C__  [V^ ?_ $0_X/\ _A&Z=_\ &:/^'>WP"_Z(?\(/_"-T[_XS7L%% 'C_
M /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[? /_HA_P '_P#PC=._^,U[!10!X_\
M\.]O@'_T0_X/_P#A&Z=_\9H_X=[? +_HA_P@_P#"-T[_ .,U[!10!X__ ,.]
MO@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\
M#O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;
MX!_]$/\ @_\ ^$;IW_QFC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^
M?_1#_@__ .$;IW_QFC_AWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\
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M'>WP"_Z(?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&Z=_\9H_X=[?
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M#_PC=._^,U[!10!X_P#\.]O@'_T0_P"#_P#X1NG?_&:/^'>WP#_Z(?\ !_\
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M[!10!X__ ,.]O@'_ -$/^#__ (1NG?\ QFC_ (=[? /_ *(?\'__  C=._\
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M_P#X1NG?_&:/^'>WP#_Z(?\ !_\ \(W3O_C->P44 >/_ /#O;X!_]$/^#_\
MX1NG?_&:/^'>WP"_Z(?\(/\ PC=._P#C->P44 >/_P##O;X!_P#1#_@__P"$
M;IW_ ,9H_P"'>WP#_P"B'_!__P (W3O_ (S7L%% 'C__  [V^ ?_ $0_X/\
M_A&Z=_\ &:/^'>WP"_Z(?\(/_"-T[_XS7L%% 'C_ /P[V^ ?_1#_ (/_ /A&
MZ=_\9H_X=[? /_HA_P '_P#PC=._^,U[!10!X_\ \.]O@'_T0_X/_P#A&Z=_
M\9H_X=[? +_HA_P@_P#"-T[_ .,U[!10!X__ ,.]O@'_ -$/^#__ (1NG?\
MQFC_ (=[? /_ *(?\'__  C=._\ C->P44 >/_\ #O;X!_\ 1#_@_P#^$;IW
M_P 9H_X=[? +_HA_P@_\(W3O_C->P44 >/\ _#O;X!_]$/\ @_\ ^$;IW_QF
MC_AWM\ _^B'_  ?_ /"-T[_XS7L%% 'C_P#P[V^ ?_1#_@__ .$;IW_QFC_A
MWM\ O^B'_"#_ ,(W3O\ XS7L%% 'C_\ P[V^ ?\ T0_X/_\ A&Z=_P#&:/\
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MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M!0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ44
M4 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 )FBC\Z* %HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M Q129QZT4 +1THHH *#110 4=*** /QW_P""O7_)]7B3_KSL/_2:.O$_@5X
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
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M73?,_P"$C^*NM7CW\5IY@74;7R]5T\LB;MES:'S(!DHL:\AGKB_^K9OV-_\
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MNF^9_P )'\5=:O'OXK3S NHVOEZKIY9$W;+FT/F0#)18UY#/7%_]6S?L;_\
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M_N;_ (K_ /E2LO\ B<Z5_P!O=I^^A_Z9)_&U'_5LW[&__<W_ !7_ /*E9?\
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M&O(9ZXO_ *MF_8W_ .YO^*__ )4K+_B<Z5_V]VG[Z'_IDG\;4?\ 5LW[&_\
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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MS<'3)BW*MGI&3G/]T\]S7V^I#+D=#SGUHDK +1THHJ0"OD'_ (*$?M-F61_
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
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M<**U]IQ;R-3TIC_#<6SXDCYR Q!1L':S#FO<* "BBB@ HHHH **** "BBB@
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M(;596!(,CK=NRKP>0I/M0!^DU%%% !1110 4444 %%?S(?&7_@X[_:\\&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\5__*E9?\3G2O\ M[M/WT/_ $R3^-J/^K9OV-_^YO\ BM_Y4K+_ (G.E?\
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MZ9)_&U'_ %;-^QO_ -S?\5__ "I67_$YTK_M[M/WT/\ TR3^-J/^K9OV-_\
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M +F_XK?^5*R_XG.E?]O=I^^A_P"F2?QM1_U;-^QO_P!S?\5O_*E9?\3G2O\
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M)ZDDFN'_ &7?V?K3]G[X<Q6.V.36+X+-J5P/XY,<(#_<3.!ZG)XSBO2J)2N
M4445(!1110 4444 %%%% !1110 4444 %%%% !1110!YS\?='9+:UU*/CRSY
M+D?FO]>?85O?"/Q*OB/P=#N;=-9_N),]>!Q^G'X5?\?Z.-<\'WT'5O*,BC'4
MKSC\<8_&O*OV>O%!T[Q=-ILC;4O$. ?^>B\C],C\:KH![=1114@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=J2?D,Z%5FMN=HW2((]Q"AV)&?K;_@@U_P '.'C3]G7XAZ'\*OV@O$5]XO\
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M)_Q*\ W5CX+M_&/PW\0&#;::I:ZS/J<<<HZ/+!=,XD4]U1XR>S+UK^>?X_\
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MO!7Q,T_P#9Z/X>\)OK=L^A:9/:SM.+RVA 9I)Y 5VS/P #G'/:@#]CJ.E%%
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MEG>*//;?GM0!_/9_P>&?\%!#^T!^VGHOP1T&]\[PW\'K?S-36)LI<:U=(KR
MXX;R8/*0=U>2=?6OC3_@@C_RF-_9Z_[&V#_T!ZZK_@CG^R]KW_!4O_@J0WB#
MQ?)/K-CHL]]\2O&U]*N[[7Y,AN-C]C]HNWBC*\'9)(1]VN5_X((_\ICOV>O^
MQM@_] >@#^T"CI17SK_P4-_X*H?!7_@E]X$LM:^+/B9M-N=8$G]D:-8V[7>J
M:P8]N_R81@;5W+EY&2,%@"P) (!]%4&OP(^-'_!\%;0ZS-!\._@#/<Z>KGRK
MWQ'XD$$TJ]MUO!"ZH>_$S?UK&^%?_!\'K$>OPQ^-_@!ILVER-B:?0_$KQW$*
MY^\L<T#+(0/X2Z9]10!_0A1TKP7_ ()Z?\%)OA3_ ,%.O@E_PG'PKUN2^M;:
M06^J:7>QBWU/1)R,B*YA#-M) )5E9D< [6;!Q[U0!_%7^TC_ ,IM_'O_ &7#
M4/\ T_25_:H:_BK_ &D?^4VWCW_LN&H?^GZ2O[5* /S[_P""HO\ P;B_!'_@
MJ;\<+/XC^)-6\9>#?&"VL5CJ-WX?GMUCU>&+B,S)-%(/-1/D5UQ\H4,&VKCZ
MP_8M_8W\"_L"_LW^'?A9\.K"XL?"_AN-Q$;F7SKJ[ED<R2SS28&^1W9F)  &
M0%"J H^+?^"NO_!Q_P"$_P#@DI^TWIOPRUKX8^(O&5]J/AZW\0?;;+5(;6*-
M)I[B$1[71B2#;DD\#YA7V9^PK^U;9_MQ_LC^!/BUI^CW7A^R\=:<-1AT^XG6
M:6U&]DVLZ@!C\N<@=Z /6J#17Y>_\%*?^#J[X#_L)^-]2\%^$M/U'XR>.-)D
M>WOX-'NDM-)TZ=#M:&6]97W2 \$0QRA2"&*L"M 'ZA4=*_G8C_X/A?&PUSS'
M_9]\+-IO_/ >*)Q/_P!_?LY7_P AU]^_L)_\'/WP._;;^%7C*\_LW5O!?Q$\
M%^'+_P 1OX0U.YC>36XK.UDN9EL+H828A(FRKK'( "VPJK, #]*J#7Y6?\$T
M/^#I3P?_ ,%*/VS?"?P;TGX2^)O"]]XJCO9(]2N]8@N(;?[-9S71RBQ@G<(2
MHP>"P-?JG0 4=*_*#_@HM_P=7>"_^">/[9?C3X.:E\(O%'B:_P#!<EK%-J5M
MK$%O#<F>TAN1M1D8@ 3!>3R5->W_ +?O_!PI\#?^">7P@\):MXH;4M<\<>-=
M%M=;T_P9HKQ3:C;PW$*RH]T[,J01?,%#-\SX)1' ; !]X4&OYW=?_P"#X;QA
M/KF_2_V?/#=KINX_N;OQ3//.P[?O%MT4?]\&OO#_ ()._P#!SS\'_P#@I5\0
M['X?Z[HM[\)_B5JGR:;IVH7R7FG:S)C_ %5M=A8_WQYQ')&A;@*7;B@#],J.
ME%>0_MI_MU_"S_@GM\'9/'7Q9\56OA?0?.^RVVZ-Y[G4;@JSK!!#&"\DA"L<
M 8 !+%5!( /7J#7X1?M!?\'O'A?1]:N+7X6_ W6M>L5;$6I>)=<CTUG [_9H
M(Y^#VS,#CJ.P\\\%?\'PGBRVUR,^(_V?O#MYIK/B1=-\3S6TZKZ@R02*2/3
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MM 'ZAT&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
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MQDFN_*_]YB].K][963U?>V]NK5C'$?PWO\MSY7_ZMF_8W_[F_P"*W_E2LO\
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M5_V]VG[Z'_IDG\;4?]6S?L;_ /<W_%?_ ,J5E_Q.=*_[>[3]]%_TR3^-J?\
M^U[W_IRI_P"V0#_AM/\ TF/ZL/\ JV;]C?\ [F_XK_\ E2LO^)SI7_;W:?OH
M?^F2?QM1T_XQF_8W_P"YO^*__E2LO^)SI7_;W:?OH?\ IDG\;4?]6S?L;_\
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M5_V]VG[Z'_IDG\;4O_VO>_\ 3E3_ -L@'_#:?^DQ_5A_U;-^QO\ ]S?\5O\
MRI67_$YTK_M[M/WT/_3)/XVH_P"K9OV-_P#N;_BO_P"5*R_XG.E?]O=I^^A_
MZ9)_&U'_ %;/^QO_ -S?\5__ "I67_$YTK_M[M/WT/\ TR3^-J/^K9OV-_\
MN;_BO_Y4K+_B<Z5_V]VG[Z+_ *9)_&U/_P#:][_TY4_]L@'_  VG_I,?U8?]
M6S?L;_\ <W_%?_RI67_$YTK_ +>[3]]#_P!,D_C:CI_QC-^QO_W-_P 5_P#R
MI67_ !.=*_[>[3]]#_TR3^-J/^K9OV-_^YO^*_\ Y4K+_B<Z5_V]VG[Z'_ID
MG\;4?]6S?L;_ /<W_%?_ ,J5E_Q.=*_[>[3]]#_TR3^-J7_[7O?^G*G_ +9
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M2?QM1_U;-^QO_P!S?\5__*E9?\3G2O\ M[M/WT/_ $R3^-J/^K9OV-_^YO\
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M'_IDG\;4?]6S?L;_ /<W_%?_ ,J5E_Q.=*_[>[3]]#_TR3^-J/\ JV?]C?\
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M_P""CO['W@_XN>%8GL[/Q);LMYI\L@DFTJ]B8QW%LY&,[)%;:V!O0H^ & H
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M]_P5)\&_\$D_V:K7XC>,=&UKQ$FK:Q%H6FZ9I31+/<W4D,TP+-(P"1*D#[G
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MN[BXEE^6XNE(,-HD'V<MN>.,F8^82-N/GOX(_P#!E;\=O'/AM-0\>?$[X?\
M@C4+D>9]@MHKC69XB1TE=1%&&SUV/(.^3TH _HB^$G[4OPQ^/_\ R(?Q&\">
M-LKY@_L'7[34OE'4_N9&X]Z[PU_'/_P4M_X(Z_'K_@AU\0_"WBR]UV.;2;Z\
M*^'O&WA2\GMFMKQ%W^4Q^26VGV[F7DAU5BK-M<+^_P!_P;1?\%4?$7_!33]B
M.^C\>2_;?B)\,;Z/1=8U/Y0=:ADC+VUVZC&V5E5T?C#-"7_C*J ?HU1TK/\
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MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *KZGJEOHNGS7=Y<0VMK;J7EFE
M<(D:CJ23P!5BO(?VX)GA^ %\JLRK)<1*X!^\,DX/X@'\*\K/,R>7Y=7QRCS.
MG"4K=^5-V.[+<(L5BZ6&;MSR2OVN['4C]HKP.3_R,NF_]]G_  KI=/U32_&^
MA-):W%CJNFW:-$S1NLT,JD893C(/H17YGV.F3:BDS0IO^SQF5\=0HZFO=OV
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M*&)K1@WK:4DG;OJSX#"Y9C,3%SPU*4TM+QBWK\D>\4=*\'_X>8_!/_H<U_\
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M_P"5O4?_ )(I?^'4/P!_Z$'_ ,K>H_\ R11_QC__ $^_\D#_ (4?[G_DP?\
M#U_X _\ 0_?^4/4?_D>C_AZ]\ ?^A^_\HFI?_(]'_#J'X _]"#_Y6]1_^2*/
M^'4'P!_Z$'_RMZC_ /)%'_&/_P#3[_R0/^%'^Y_Y,'_#U_X _P#0_?\ E$U'
M_P"1Z/\ AZ_\ ?\ H?O_ "B:C_\ (])_PZA^ /\ T(/_ )6]1_\ DBE_X=0_
M '_H0?\ RMZC_P#)%'_&/_\ 3[_R0/\ A1_N?^3!_P /7_@#_P!#]_Y0]1_^
M1Z/^'KWP!_Z'[_RB:E_\CT?\.H?@#_T(/_E;U'_Y(H_X=0? '_H0?_*WJ/\
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M_?\ E$U'_P"1Z/\ AZ_\ ?\ H?O_ "B:C_\ (])_PZA^ /\ T(/_ )6]1_\
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M_H?O_*)J7_R/1_PZA^ /_0@_^5O4?_DBC_AU!\ ?^A!_\K>H_P#R11_QC_\
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M )'H_P"'K_P!_P"A^_\ *)J/_P CTG_#J'X _P#0@_\ E;U'_P"2*7_AU#\
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MRO;\0HHHKC-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXX5\>>&-.U\PQG*P-<VT<S1CO\K.5Y]*_'[_ (.^_P#@K-K'P4\(Z/\ LT^
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MBQ.L4>L>(=+\C6HXEV)'J5M(UM=[5_A1IHG=1_<=>O6OY<_^"UG_  6JN_\
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MTE=,\:KJ>M:IJ4NV+2[$65S&THC'SS/N=56->2S#)5=S+>_X-?;J2\_X(7?
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MHS74EL_B06RK T\TR$.MI%Y?D1QQ%"3"1E40*_QI_P ',G_*<3X\?]?FE?\
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MB\L?!_Q1U*'P;XGTR<%!'/+(8K2=E/W)(+IU!8C(C>9>-W'VB?\ @^*\4?\
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M +F_XK?^5*R_XG.E?]O=I^^A_P"F2?QM1_U;-^QO_P!S?\5O_*E9?\3G2O\
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M^WNT_?0_],D_C:C_ *MF_8W_ .YO^*W_ )4K+_B<Z5_V]VG[Z'_IDG\;4?\
M5LW[&_\ W-_Q6_\ *E9?\3G2O^WNT_?0_P#3)/XVI_\ [7O?^G*G_MD!?\-I
M_P"DQ_5A_P!6S?L;_P#<W_%;_P J5E_Q.=*_[>[3]]#_ -,D_C:C_JV;]C?_
M +F_XK_^5*R_XG.E?]O=I^^A_P"F2?QM1_U;-^QO_P!S?\5__*E9?\3G2O\
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M^QO_ -S?\5O_ "I67_$YTK_M[M/WT/\ TR3^-J?_ .U[W_IRI_[9 7_#:?\
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M\-^#]<FL;G7/M%I=?VW=RV]O>/-]HM0$GV1W44&XJK+]G\L@B,$^_P!> ?\
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MLY7U""X?\BPKL?AC_P 'F7[*WC*^2WUSP]\7?!^[&ZXO-&M;JW7\;>YDD_\
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MYUTO5=1T+2[9S_JWFMHKZ68#U95NX,^@<>M?G+^WW^V[\9_^#CO_ (*">']
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MJW[QYQ%"VF7-J"W^R9;F)?JP%?UQ5^5/_!K]_P $8-5_X)T_ W5?B;\2-/\
ML/Q8^)MI%$-/D4B;PWI(*RI:R#^&>60))*O\/EPH<,CBOU6H YWX4_"3PO\
M OP%I_A7P9X?T?POX;TE"EGINEVB6MM;@DLVU$ &2Q+$]222<DDUT5%?$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]X=\56@G16(\ZRF'RRVTRC[LL4@9&'3*Y!(()]0-?Q=_\$Q/^"P'QI_X(_\
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MXC4;+*TM],GT>QD?GYI9[J-71!ZI"[<CY>I !\1?\'O%OH2_M3_ ^6W^S_\
M"3/X5O5O\8\W[&+L?9=W?;YAN\>^[WK] O\ @T3M[Z'_ ((TZ UWYGV>;Q1K
M#66X\>5YR@X]O,$OXYK^>OQKXF^.O_!?3_@HY)=6]C-XD^('CZ[$5I90;ET_
MP[I\9^5 3D0VENARS'DDLQW2.=W]>O["'[(^B_L'_L@> /A'X?F:ZT_P1I26
M373((VOKAF:6XN"H^Z99WEDQSC?C)H ];HZ444 >0_\ !07_ ),*^-W_ &(.
MN_\ INGK^?G_ (,G/^4A7Q2_[)W+_P"G*QK^AK]LWP7JGQ(_8^^*_AW0[.34
M-:U[P=J^G:?:H55KFXFLIHXHP6( +.RC)('/6OQI_P"#57_@E/\ M!?L'_MF
M_$+Q1\7/AKJG@G0=6\%OI=I=W=Y:2K/<F^M)1&%BE=ON1.<D8^7KDC(!^\%'
M2BB@ H-%% !7RO\ \%PO^40W[17_ &(NH_\ HHU]45\K?\%PN/\ @D-^T5_V
M(NH_^BC0!_/5_P &B'_*9/0_^Q5UC_T4E?U?&OY0?^#1#_E,GH?_ &*NL?\
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M &/&G_\ HRO[4: /XJ_VD?\ E-OX]_[+AJ'_ *?I*_M4-?Q5_M(_\IMO'O\
MV7#4/_3])7]JE '\N/\ P>=?\I8/#/\ V3;3/_2_4J_<C_@WZX_X(S_L^_\
M8L#_ -'S5^&W_!YU_P I8/#/_9-M,_\ 2_4J_<G_ (-^O^4,_P"S[_V+"_\
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MC_"GP?;7OBB>SN&47NJI96\DTNH7Y5C'###"K[(@S#>_+.[1J@!YA_P:N_\
M*<CX/_\ 7MKO_IDOJ_KO-?R'_P#!J[_RG(^#_P#U[:[_ .F2^K^O"@#^/'_@
MYD_Y3B?'C_K\TK_TS6%?UD?L?<?LE?"W_L4=)_\ 2.*OY-_^#F3_ )3B?'C_
M *_-*_\ 3-85_61^Q]_R:3\+?^Q1TG_TCAH ]&K^:O\ X/:_^3X_A#_V(K?^
MG"XK^E2OYJO^#VO_ )/C^$/_ &(K?^G"XH _5;_@UR_Y04? S_N/_P#J0:G7
MX%?\'-O[9VO_ +6'_!5_X@:/>WCMX:^%-TWA'0[%9"8;;R.+J3'3S)+CS"S8
MSM2-22$%?OK_ ,&N7_*"CX&_]Q__ -2#4Z_G<_X.'_V7M=_9=_X*[?&.'5K.
M:&Q\<:Y/XRTBZ9<1WUMJ$C7!9#WV3--$?]J)O:@#]T_^"9'_  :T_L\_LY_!
M+PWJGQ8\(V_Q3^)E]90W>KRZU+))I>GW#J&>WM[0%8VC0D+NF5V8J6^0-L'Z
M$_##]C_X2_ \1_\ "%_"_P"'?A'R?N'1O#=G8%,>GE1K7YC_ /!.S_@[B_9]
M^(?[/FAV?QWUK5/AQ\1-'LHK759FT6\U'3]8F1,-<V[6L<SKOQN*2JI5F(!<
M#<? _P#@L9_P=?\ AKXS?!C5OA+^R_8^(M4U3QQ:OI-]XMNK22RDM89OW;16
M$!_?-/(I*B1@FS<-JLQ!0 _(+]H+XC6?QB_X*M>-_%VGE6L/%7Q9O]8MBIW*
M8KC6))5P>XVN*_MWZ5_"1X/^'FM?"+]K/2_"?B/3YM*\0^&/%T6DZI92D&2S
MNK>\$4T38)&5=&4X)&17]V] '\>/_!S)_P IQ/CQ_P!?FE?^F:PK^LC]C_\
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M\&<L?@SP5K7C;]F;Q%J^K2Z;#)>2>!]=99KFY5?F*65VH7<X .V*926Z>;G
M/Q+_ ,&W/_!3CQI^PY_P4%\#^"4U:ZN/AM\5M<M?#>MZ+<W#"S@GNY4@@OHU
M/RQS1R-'N<#YH]ZG^%E_:#]J[_@[@_91^#?PRU.[^'?B#6?BOXN$#KIVEV&A
MWNGVS3[3Y9GGNXH0L.[&YHQ(P&<*37X,_P#!$3]DOQ9_P4!_X*N_#F/3K"2>
MQT3Q-;^,_%%Y'#BWL+*UNDN92V.$\UPL*#^]*O& < ']EU!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "OE7_@IE_P +N\??\(3\,_@W_P 27_A8'V[^U_%?^GVW_"-_8_LU
MS!_IEKG[-Y^V:+YT;S-VP8R37U57RK_P4R_X7=X^_P"$)^&?P;_XDO\ PL#[
M=_:_BS_3[;_A&_L?V:Y@_P!,M<_9O/VS1?.C>9G8,9)KORO_ 'F+TZOWME9/
M5][;VZM6,<1_#>_RW/E?_JV;]C?_ +F_XK?^5*R_XG.E?]O=I^^A_P"F2?QM
M1_U;-^QO_P!S?\5__*E9?\3G2O\ M[M/WT/_ $R3^-J/^K9_V-_^YO\ BO\
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MW_%?_P J5E_Q.=*_[>[3]]#_ -,D_C:CI_QC-^QO_P!S?\5__*E9?\3G2O\
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MK+_B<Z5_V]VG[Z+_ *9)_&U/_P#:][_TY4_]L@'_  VG_I,?U8?]6S?L;_\
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M1_U;/^QO_P!S?\5__*E9?\3G2O\ M[M/WT/_ $R3^-J/^K9OV-_^YO\ BO\
M^5*R_P")SI7_ &]VG[Z+_IDG\;4__P!KWO\ TY4_]L@'_#:?^DQ_5A_U;-^Q
MO_W-_P 5_P#RI67_ !.=*_[>[3]]#_TR3^-J.G_&,W[&_P#W-_Q7_P#*E9?\
M3G2O^WNT_?0_],D_C:C_ *MF_8W_ .YO^*__ )4K+_B<Z5_V]VG[Z'_IDG\;
M4?\ 5LW[&_\ W-_Q7_\ *E9?\3G2O^WNT_?0_P#3)/XVI?\ [7O?^G*G_MD
M_P"&T_\ 28_JP_ZMF_8W_P"YO^*W_E2LO^)SI7_;W:?OH?\ IDG\;4?]6S?L
M;_\ <W_%?_RI67_$YTK_ +>[3]]#_P!,D_C:C_JV?]C?_N;_ (K_ /E2LO\
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M89K]1^E%<K\<?BC9_ [X*>,/&NH;?L'@_1+W6[G)P/*MH'F?)_W4- '\C?\
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M-WP-TJ2'R;S7-$/B:Y8C#2'49I+V,M[B&:)?H@K^=C_@X"\=7_[8_P#P7?\
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M8["%D_HB\,^&=-\%^'K+2-'T^QTG2=-@2VL[*S@6"WM8D 5(XXU 554  *
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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M_P""C6B20>/= U';^YN+!K<'U9)&8_I(M6?^"<_C*VL-=\0:',ZK<:A''<P
MG&[R]P8>YPX./137NW[0WP6A^.7P^DTWS([>_MV\^RG8<)(!]T]]K#@XZ<'!
MQBOAOQ%X'\4?!KQ0JWEKJ&D:A;/NAF3*Y(_B1UX8>X)%;\94,9PWQ:N(H4W*
MC)WNMM8\LHM]'NU?NK7LS/AZKA\XR%Y1*:C4BK>>CYHM+JNCMV\T?I!7R/\
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M]T/Q,*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
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M_@UH?[.7_!:+XS:/X2M[?2--DO[#7(;>S'EK:7%Y86UY-M"_<S/+(X Q@,,
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M*_MS_P#!,KQ%JFDV:W'C;X1>9XNT9E7,DT$49^W6P/7#VX9PHY:2WB%?(/\
MP9=_M^S>-/A;XZ_9RURY>6Y\&[O%GAG<<[;">58[R >BQW,D4@'4F[D[ 4 ?
MNE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\$ZO <WA_P"$/@?2_"T-YM-_>@M<:CJ;+T,]S(6EDQDD*6V*6.U5!Q7MU%%
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MHZ+/#\)_ MGI>K7T0BOM>O9&OM8OEXRK7$F65"0"8X]D>0#LSS7TA10!Y?\
MMA?L<?#W]O+X$ZI\-_BAH;>(/">K21SRVR7<UI)'+$VZ.5)(F5U96Y'.#T((
M)!_)OXL?\&2/PC\0:M=S>"_C-X_\,VLSEH;?5--M=6%N#_#N4VY8#MGG'4D\
MU^VE% 'XH?"'_@R7^#OAO5K.X\;?&#X@>*X('#S6VFV%KI$=R!_"2WGLJGH=
MI!QT(/-?JG^QS^P?\(_V OAO)X5^$?@C2?!NDW#K+=FV#RW6H2*,![BXD+2S
M,!G!=CC) P#BO7** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OE7_@IE_PN[Q]_PA/PS^#?_$E_X6!]N_M?Q7_I]M_PC?V/
M[-<P?Z9:Y^S>?MFB^=&\S=L&,DU]55\J_P#!3+_A=WC[_A"?AG\&_P#B2_\
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M *3']6'_ %;-^QO_ -S?\5O_ "I67_$YTK_M[M/WT/\ TR3^-J/^K9OV-_\
MN;_BO_Y4K+_B<Z5_V]VG[Z'_ *9)_&U'_5LW[&__ '-_Q7_\J5E_Q.=*_P"W
MNT_?0_\ 3)/XVH_ZMF_8W_[F_P"*W_E2LO\ B<Z5_P!O=I^^A_Z9)_&U+_\
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M +F_XK_^5*R_XG.E?]O=I^^A_P"F2?QM1_U;-^QO_P!S?\5O_*E9?\3G2O\
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M/XVH_P"K9OV-_P#N;_BM_P"5*R_XG.E?]O=I^^A_Z9)_&U+_ /:][_TY4_\
M;(#_ .&T_P#28_JP_P"K9OV-_P#N;_BO_P"5*R_XG.E?]O=I^^A_Z9)_&U'_
M %;-^QO_ -S?\5O_ "I67_$YTK_M[M/WT/\ TR3^-J/^K9OV-_\ N;_BM_Y4
MK+_B<Z5_V]VG[Z'_ *9)_&U'_5LW[&__ '-_Q6_\J5E_Q.=*_P"WNT_?0_\
M3)/XVI__ +7O?^G*G_MD!?\ #:?^DQ_5A_U;-^QO_P!S?\5O_*E9?\3G2O\
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M_P!,D_C:C_JV;]C?_N;_ (K?^5*R_P")SI7_ &]VG[Z'_IDG\;4O_P!KWO\
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MRJ(RW_++'RU_3]J&G6^K64MM=00W5O.I22*5 \<BGJ&4\$>QKA_!G[*GPO\
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M\M3R5'G(V!["I?AO\!_ _P &[<0^#_!GA/PK$J[0FCZ1;V*@>F(D44 ?$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX9(GU*XL6DTGQ%X<AW "<M ^)X5.W?(A1DSN,>Q6=0#]OO\ @B3_ ,$KM/\
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M''L&5E_X#7]6?[&WCRS^*?[(GPL\3:?)'-8^(/".DZC;NGW626SBD7'X-TH
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MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110!\\_\%+_ /@F=\.O^"JW[/MO\.OB
M5-XAL]+T_58]:L+O1;Q;:ZL[M(9H5D!='1ALGD!5T8'.>" 1^,_Q>_X,@O%-
MKK=U)X!^/'A^^TYF)MH?$&@S6LT:]E>2&216(_O!%S_=%?T/44 ?S5^&_P#@
MR3^.-UJ*KK'Q>^%-C:[ANDLX]0NY O<A&AB!/MN&?45][?\ !/+_ (-(/@/^
MR#XOT_Q7\1-8U#XV>)M+F2XM(=3LDL-#MY%Y#&R5Y#,0>TTKQGC]WD9K]7J*
M &QHL2*JJ%50  !@ 4XT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
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MSI7_ &]VG[Z+_IDG\;5]=_\ M>]_Z<J?^V0/-_X;3_TF/ZL/^K9OV-_^YO\
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M?0_],D_C:C_JV?\ 8W_[F_XK_P#E2LO^)SI7_;W:?OH?^F2?QM1_U;-^QO\
M]S?\5_\ RI67_$YTK_M[M/WT7_3)/XVI_P#[7O?^G*G_ +9 /^&T_P#28_JP
M_P"K9OV-_P#N;_BO_P"5*R_XG.E?]O=I^^A_Z9)_&U'3_C&;]C?_ +F_XK_^
M5*R_XG.E?]O=I^^A_P"F2?QM1_U;-^QO_P!S?\5__*E9?\3G2O\ M[M/WT/_
M $R3^-J/^K9OV-_^YO\ BO\ ^5*R_P")SI7_ &]VG[Z'_IDG\;4O_P!KWO\
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M *MF_8W_ .YO^*__ )4K+_B<Z5_V]VG[Z'_IDG\;4?\ 5L_[&_\ W-_Q7_\
M*E9?\3G2O^WNT_?0_P#3)/XVH_ZMF_8W_P"YO^*__E2LO^)SI7_;W:?OHO\
MIDG\;4__ -KWO_3E3_VR ?\ #:?^DQ_5A_U;-^QO_P!S?\5__*E9?\3G2O\
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MOHO^F2?QM3__ &O>_P#3E3_VR ?\-I_Z3']6'_5LW[&__<W_ !7_ /*E9?\
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M9)_&U'_5LW[&_P#W-_Q7_P#*E9?\3G2O^WNT_?1?],D_C:G_ /M>]_Z<J?\
MMD _X;3_ -)C^K/M/_@G)X5^%OPU^".J>#?A'J7_  D'AOP?KDUC<ZY]HM+K
M^V[N6WM[QYOM%J D^R.ZB@W%59?L_ED$1@GW_I7@'_!.3PM\+?AK\$=4\&_"
M/4O^$@\-^#]<FL;G7/M%I=?VW=RV]O>/-]HM0$GV1W44&XJK+]G\L@B,$^_U
M\=CW?$3>KUW>[\WZ[VZ'J4?@7Z!0:**XS0*.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH 3-%'YT4 +1110
M 4444 %%%% '\HO_  3%NH_V>O\ @ZNM=/N&6SCL/BGXJ\/8<[03.NI6<:_B
MTB >I(K^KJOY3?\ @XY^'NK?\$_?^"][_$_0;5[5=:O-&^)&BL 5C:ZA9!-A
MO4W=I*Y[CS1ZC/\ 4A\)/BEHOQP^%GAOQGX;O(]0\/\ BS3+;5]-N4/RSV\\
M2RQM^*L..U 'Y\_\'4_[$NH?M??\$K]9U?0;7[5XA^$>H)XQBB1-TL]E%%+%
M>QK[+#*9B._V8#J:_)G_ (-.O^"K6B_L3_M.ZW\)_'VJQZ3X$^+LD L;^YD"
M6VDZS'E(C(QP$CN$;RF<\!T@SA=S#^HJXMH[RWDAFC26*52CHZ[E=3P01W!]
M*_FA_P""\_\ P;%^,OV??B'KGQ6_9X\.7WB[X:ZQ/)?7_A;2K8S:CX3=LLXA
MA7+3V><E=@+Q#Y64JN^@#^F(<T5_)E_P3P_X.C_VCOV!O"=CX+UQ=*^+'@W1
MU2UM;#Q*98]2TR)/E$$-XAWA0!@+,DNP !0H&*^Q=;_X/DKV;1573?V:K6WU
M)A\TESX[::%3[*M@C'_OH8]Z /Z"**_E-_:2_P"#G#]L3_@H%XOL_"/PX\WX
M>V^I2K%#I'P^L9YM8OSD?\O/SW&[_KAY0QP0>M?U94 ?Q]_\'/O_ "G/^.G_
M %UT3_TQ:=7]>OA7_D6--_Z]8O\ T 5_(5_P<^?\IS_CI_UUT3_TQ:=7U5:?
M\'L'QNT_28;:'X0_"O=!$L2.\M^WW1@$@3#^8H _I:KY+_X*^?\ !6KP'_P2
M@_9JU#Q+KEY8ZEXZU2WDB\)^&//'VK6+K[JNR@[EMHV(:23H -HR[*I_!'XV
M_P#!X3^UM\6M*;3?#5M\-_AX\X,:W6AZ%)=7I+<#!O)IX\^F(P<UY_\ LE?\
M$3?VP?\ @LW\8H_''CI?%FE:'K$R_P!I>//'KS>8\ /_ "ZPS$37( W!%C A
M!&TO&.@!A?\ !#3]B3Q5_P %;?\ @JWINN>*&O-8T/1-:_X3SQ[J\Z;TNB+C
MS_)=L;3)=W'R;<@[#,P!$9K^O^O /^";_P#P3>^&_P#P2]_9SL_AW\.K*;R3
M)]KU;5[S:U_KMV0 T\[* .  JHH"HH  ZD^_T %?$O\ P<:_\H4?C[_V!K7_
M -.%K7VU7Q+_ ,'&O_*%'X^_]@:U_P#3A:T ?EC_ ,&/?_)</V@/^P'I'_I1
M<U_117\ZW_!CW_R7#]H#_L!:1_Z47-?T4T >#_\ !2S]O'P]_P $V/V,O&7Q
M;\10_;ET"W$6F::)-CZMJ$IV6UL#@E0TA!9@#M17;!VXK^9S]A']CCXT?\'-
MG_!0KQ)XN^(GBR]M]!TUHKSQ7KXCW1Z/:,[_ &?3=/B.41F"R"-#\J*DDC;V
MR)/TK_X/;_B#-I?[&_P;\+JS"'6O&4^IR ?=8VME)&,_^!AK\R_^"1G_  <3
M>*?^"1G[.>L?#WPS\+O"?BJ/7-?FU^YU+4+^>"X9W@@@$6$&-BK "/=V]: /
MZCOV-OV)?AG^P+\%;'P#\*_"]CX:T&SP\QC&^ZU&; #7%S,?GFE;'+,>  H"
MJ H]6K^</_B-Y^*'_1#? /\ X.+O_"C_ (C>?BA_T0WP#_X.+O\ PH _H\HK
MY;_X(X?M_P"K_P#!3?\ 8/\ #OQ>USP_IOA?4=:O[^T?3[&=YH8Q;W+PJ0S_
M #9(4$^YK\>_^"C_ /P7L_:,_P""4G_!:;XT:+IMPWBSX:WE_87-KX6\4),]
MFD)TZU#26$N0]N"XD_U9:(ON+1LV: /Z**\I_;K\2:!X0_8E^+^J>*E@D\-6
M/@O6)=3BF("36XLIO,C.>#N7*X[EL=Z_'S1/^#X7P?+X5634OV??$D.N!.;>
MV\40RVK-_P!=6MU<#_MF?ZU\"_\ !4K_ (.$_CA_P66MK7X4>&?"/_"'^!]:
MO8/*\): TVJZKK]PK9BCGF5%:<!\,L4<2+N520Y52 "#_@T[T;4-4_X+8_#V
M:S69K?3=(UNYOB@^583IT\0+?[/FR1#MR5K^MJORA_X-C/\ @B%KG_!-WX;Z
MW\4/BC9QV/Q8^(%DEC%I>X2/X:TL.LI@D925,\TB1/(H)V"*)<AMXK]7J "B
MBB@#B_VAOVAO!O[*7P:U_P"('Q UZQ\->$O#-L;J_O[IOE1>BJJCYGD=B%1%
M!9V954$D"OY=/V^OV_?CE_P<O?MQZ'\*_A;H>IVO@6WO6/AKPT9-D-O$ORR:
MOJDBY4,$;))RL*MY<>YW9I?Z@/VH/V8?!'[9'P+\0?#CXB:';>(?"?B6W\B[
MM9>&4@@I+&XYCEC8*Z.N"K*"*\3_ ."5O_!(#X4_\$E/A=J6A^ 8+S5M=UZ<
MS:QXEU58VU+4E#$Q0ED4*D4:G 1  3N8Y9B: /F#P-_P:B_L_P"C_P#!.BX^
M#^KVZWWQ&U$#4;CXCQVH&J6VJ!"%,()XLER5^S%MKKEF/FXD7\>?V=?VC/VA
MO^#6O_@H/JGA'Q=IEQJ/A/4I4;6M$65O[*\7:?N*QZA8R,,+*%W;),!E(:*1
M>&4?UH5\W_\ !3G_ ()<_#/_ (*K? "3P1\0;.2VO;%VN="\062*-1T&X( +
MQ,PPR. !)$WRN .C*C* >A_L@_M?> ?VZO@%H?Q*^&NN0Z[X8UV/*./EGLI@
M!YEM/'G,<T9.&0^Q!*E6/IM>2_L1_L3?#[_@GU^SKHOPQ^&NCKI7A_1P9))'
M(>ZU.Y8*);NYDP/,FDVC+8  554*BJH]:H **** /YV?^#U3]B74-%^+OPW_
M &@=-M=^BZYIX\':V\:?\>]Y TUQ:NY]987E0'M]D [BOI;_ (-(O^"K6B_'
MG]EFU_9U\5:K';_$+X:1RG0([F0*VMZ,6+JL1/WI+8LR,@&1%Y3#.'*_J9^U
M=^RWX-_;3_9[\4?#'Q_I:ZMX7\66;6EU'P)(6X:.>)B#LFB<*Z-CAD!YZ5_)
M[_P4I_X(P_M ?\$6?CDOB[1V\0ZEX+T6^2]\._$;P]')"MFP;,7V@QDM9W"G
M PQVL?N,XS@ _L&HK^97]D?_ (/._CA\'O"MIH_Q2\ ^%?BY]BC$2ZI%>-H&
MJ7./XIGCCE@8]LI F>^3DGU+Q_\ \'Q/B*]@9?"W[.^BZ;+MXEU7Q?+?+G_<
MCM8>/^!?E0!_0Q5?4_\ D&W'_7)OY&OYYO\ @BQ_P63_ &K?^"I'_!9KX=MX
MPUS5E^%]@FKRZMH7AG3)+3P[IZG2;SR/M17<SCS_ "=AN97_ 'FS;@XK^AG4
M_P#D&W'_ %R;^1H _C[_ .#97_E./\"?^OK5O_3+?U_897\-'_!/S]L[6O\
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MF^:+YT?]U)L&WYBWUI179_:F)ZROKS:I.[[OO;I?1=#/ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
M@FG??"3]F./X9_ _Q=:_#O\ M#/]M>*YM/9O$^H;+L7-OB\LY+;[F^:+YT?]
MU)L&WYBQJ?\ P33OOA+^S&GPS^!_BZU^'?\ :&?[:\5S:>S>)]0V78N;?%Y9
MO;?<W31?.C_NI-@V_,6^M**/[4Q/65]>;5)W?=][=+Z+H'U>GVZ6^1\EZG_P
M33OOA+^S''\,_@?XNM?AW_:&?[:\5SZ>S>)]0V78N;?%Y9R6WW-\T7SH_P"Z
MDV#;\Q8U/_@FG??"7]F./X9_ _Q=:_#O^T,_VUXKFT]F\3ZALNQ<P8O+.2V^
MYOFB^='_ '4FP;?F+?6E%']J8GK*^O-JD[ON^]NE]%T#ZO3[=+?+R/DO4_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%)G'K10 M'2BB@
MH-%% !1THHH _+[_ (.J?^":5Y^W)^P3'XV\)Z3)J7Q ^#4TNL6L-NFZXO\
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M7!( KSG_ (=/?LLC_FVG]G__ ,-YI'_R/7T!10!\_P#_  Z>_99_Z-I_9_\
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 F:*/SHH 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?XU^';KQ7\)O$.G6
M,?G7EU8R)#&#S(V,A1[G&*ZBBN?&8:.(H3P\]IIQ=M[-6-L/6=*K&K'>+3^Y
MW/FK]@CX8:_X+U7Q!>:QI-]I<,T4<,?VJ)HFD;<2< C) QUZ<BOI6BBO(X9X
M?I9+ET,NHR<E&^KW=VWT]3NSK-9YEC)8RHE%RMHMM$E^@4445[YY8444V6(3
M1,C;@'!4E25/X$<B@!U%</J'A7QAX:PV@ZY;ZI;K_P NFLQ[G '83)AB3VWY
M]S7/ZE^TM?>!1_Q5G@KQ!I449PUW;!+JV'N7! ';C)/UIV ]8HKSG1?VL_AW
MKIVQ^*=/MW[K=;K?:?<N /UQ76:-\1_#WB-=VGZ]HU\, YM[V.3C\&-(#:HJ
MJVLV:C)NK88ZDRK_ (UEZQ\4O#/A[=]O\1:%8[1DB>_BCQ^;4 ;U%>9^(/VP
M_AKX;4^?XLTZ9NRVP>XW?0HI'ZUY?XT_X*<^&],\R/0]"U35)%RJR7#I;QGW
M&-Y(]L _2JY6!].5R?Q-^./A7X/VGF>(-9M+*4KN2WW;[B7TVQCYN>F<8]2*
M^)/'_P"W9\1?B:[V5A<1Z/;W!V+%ID169L]!YA)?/^Z16=X&_8X^)7Q=U$7%
MQIEUI\5P=[WVKN8LYQ\Q!S(V?4*:?+W [CX\?\%%]8\813:=X/@ET&QD!1KR
M0@WD@_V<<1_AD]PPKR'X6_ OQA^T%K[G2K.XO/,D)N=0N6(AC8G)+R'J><X&
M6/8&OK'X0?\ !.3POX.,5UXEN9?$5\A#>2,PVJGKC .Y_J2 ?[M?0FDZ1:Z#
MI\5I8VMO9VL*[8X8(Q'&@] HX%/F2V \@_9T_8J\._ \0ZC=A-;\1*-WVJ5/
MW5LW_3)#T(_O'YN.-N2*]HHHK.]P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%)G'K10 M'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %(P# AL%3P0>]+10!R'C'X!^#/'JM_:OAO2KAW^]*L(AE/_ TPWZU
MYYK?_!//X=:L?W,.M:>O]VVOB0/^^PU>Y44[L#YGNO\ @F)X6(_T?Q#KT9]9
M!&_\@M5S_P $Q-#(PWBC5BN>1Y"_XU]044^9@?-FG_\ !,;P;#(K76L^(IU
M.Y4>*,$_]\&NM\._L$?#3P](KMH]SJ#H<@W5V[<_12H/Y5[-11S,#%\+?#GP
M_P"!XE71]%TO3=HQFWMDC8_5@,G\36UTHHJ0"@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@!,T4?G10 M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !BBDSC
MUHH 6N'^/_[2WP__ &5/ \?B;XD^,/#_ ('\/37:6*:CK-XEK;&=U9DCWL0-
MQ".0.^TUW%>9_M7?L=?#7]N+X7+X*^*WA2S\8>%X[V+45L+F>:%1<1JZI)NB
M=&R [CKCYC0!Y7_P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
MP;:G_P#)- 'H'_#ZW]D?_HXWX/\ _A2VW_Q5'_#ZW]D?_HXWX/\ _A2VW_Q5
M<!_Q#>_L2_\ 1 _#_P#X-M2_^2:/^(;W]B7_ *('X?\ _!MJ?_R30!W_ /P^
MM_9'_P"CC?@__P"%+;?_ !5'_#ZS]D<_\W&_!_\ \*6V_P#BJX#_ (AO?V)1
M_P T#\/_ /@UU+_Y)I/^(;W]B7'_ "0/P_\ ^#;4_P#Y)H ] _X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A];^R/_ -'&_!__ ,*6V_\ BJX#_B&]_8E_Z('X?_\
M!MJ7_P DT?\ $-[^Q+_T0/P__P"#;4__ ))H [__ (?6_LC_ /1QOP?_ /"E
MMO\ XJC_ (?6?LCG_FXWX/\ _A2VW_Q5<!_Q#>_L2C_F@?A__P &NI?_ "32
M?\0WO[$N/^2!^'__  ;:G_\ )- 'H'_#ZW]D?_HXWX/_ /A2VW_Q5'_#ZW]D
M?_HXWX/_ /A2VW_Q5<!_Q#>_L2_]$#\/_P#@VU+_ .2:/^(;W]B7_H@?A_\
M\&VI_P#R30!W_P#P^M_9'_Z.-^#_ /X4MM_\51_P^L_9'/\ S<;\'_\ PI;;
M_P"*K@/^(;W]B4?\T#\/_P#@UU+_ .2:3_B&]_8EQ_R0/P__ .#;4_\ Y)H
M] _X?6_LC_\ 1QOP?_\ "EMO_BJ/^'UO[(__ $<;\'__  I;;_XJN _XAO?V
M)?\ H@?A_P#\&VI?_)-'_$-[^Q+_ -$#\/\ _@VU/_Y)H [_ /X?6_LC_P#1
MQOP?_P#"EMO_ (JC_A]9^R.?^;C?@_\ ^%+;?_%5P'_$-[^Q*/\ F@?A_P#\
M&NI?_)-)_P 0WO[$N/\ D@?A_P#\&VI__)- 'H'_  ^M_9'_ .CC?@__ .%+
M;?\ Q5'_  ^M_9'_ .CC?@__ .%+;?\ Q5<!_P 0WO[$O_1 _#__ (-M2_\
MDFC_ (AO?V)?^B!^'_\ P;:G_P#)- '?_P##ZW]D?_HXWX/_ /A2VW_Q5'_#
MZS]D<_\ -QOP?_\ "EMO_BJX#_B&]_8E'_- _#__ (-=2_\ DFD_XAO?V)<?
M\D#\/_\ @VU/_P"2: /0/^'UO[(__1QOP?\ _"EMO_BJ/^'UO[(__1QOP?\
M_"EMO_BJX#_B&]_8E_Z('X?_ /!MJ7_R31_Q#>_L2_\ 1 _#_P#X-M3_ /DF
M@#O_ /A];^R/_P!'&_!__P *6V_^*H_X?6?LCG_FXWX/_P#A2VW_ ,57 ?\
M$-[^Q*/^:!^'_P#P:ZE_\DTG_$-[^Q+C_D@?A_\ \&VI_P#R30!Z!_P^M_9'
M_P"CC?@__P"%+;?_ !5'_#ZW]D?_ *.-^#__ (4MM_\ %5P'_$-[^Q+_ -$#
M\/\ _@VU+_Y)H_XAO?V)?^B!^'__  ;:G_\ )- '?_\ #ZW]D?\ Z.-^#_\
MX4MM_P#%4?\ #ZS]D<_\W&_!_P#\*6V_^*K@/^(;W]B4?\T#\/\ _@UU+_Y)
MI/\ B&]_8EQ_R0/P_P#^#;4__DF@#T#_ (?6_LC_ /1QOP?_ /"EMO\ XJC_
M (?6_LC_ /1QOP?_ /"EMO\ XJN _P"(;W]B7_H@?A__ ,&VI?\ R31_Q#>_
ML2_]$#\/_P#@VU/_ .2: .__ .'UO[(__1QOP?\ _"EMO_BJ/^'UG[(Y_P";
MC?@__P"%+;?_ !5<!_Q#>_L2C_F@?A__ ,&NI?\ R32?\0WO[$N/^2!^'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ,44F<>M% "T=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** $S11^=% "T45\W_\ !7'XB:]\
M)_\ @GM\0/$'AG6-1T'7-/\ [.^S7]A.T%Q!OU*UC?:ZD$91F4XZAB.];8:B
MZU:%%;R:7WNQ-27+%R?0^D**_F__ .'B'QW_ .BO_$3_ ,'MQ_\ %4?\/$/C
MO_T5_P"(G_@]N/\ XJOKO]2L1_S\C^)Y?]K0_E9_2!17\W__  \0^.__ $5[
MXB?^#VX_^*H_X>(?'?\ Z*]\1/\ P>W'_P 51_J7B/\ GY'\0_M:'\K/Z0**
M_F__ .'B'QW_ .BO_$3_ ,'MQ_\ %4?\/$/CO_T5_P"(G_@]N/\ XJC_ %*Q
M'_/R/XA_:T/Y6?T@45_-_P#\/$/CO_T5[XB?^#VX_P#BJ/\ AXA\=_\ HKWQ
M$_\ ![<?_%4?ZEXC_GY'\0_M:'\K/Z0**_F__P"'B'QW_P"BO_$3_P 'MQ_\
M51_P\0^._P#T5_XB?^#VX_\ BJ/]2L1_S\C^(?VM#^5G](%%?S?_ /#Q#X[_
M /17OB)_X/;C_P"*H_X>(?'?_HKWQ$_\'MQ_\51_J7B/^?D?Q#^UH?RL_I H
MK^;_ /X>(?'?_HK_ ,1/_![<?_%4?\/$/CO_ -%?^(G_ (/;C_XJC_4K$?\
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M_P /$/CO_P!%?^(G_@]N/_BJ/]2L1_S\C^(?VM#^5G](%%?S?_\ #Q#X[_\
M17OB)_X/;C_XJC_AXA\=_P#HKWQ$_P#![<?_ !5'^I>(_P"?D?Q#^UH?RL_I
M HK^;_\ X>(?'?\ Z*_\1/\ P>W'_P 51_P\0^.__17_ (B?^#VX_P#BJ/\
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M %*Q'_/R/XA_:T/Y6?T@45_-_P#\/$/CO_T5[XB?^#VX_P#BJ/\ AXA\=_\
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M$3_P>W'_ ,51_J7B/^?D?Q#^UH?RL_I HK^;_P#X>(?'?_HK_P 1/_![<?\
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M*H_XBA@_^?,OO0?\0RQG_/Z/W,_9VBOQB_X;!^*I_P":B>,O_!K-_P#%4?\
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M?\_H_<S]G:*_&/\ X;!^*O\ T43QE_X-IO\ XJD_X;"^*O\ T43QE_X-9O\
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MJ9GBEA:<E%V;N_(^KJ*_.K_AH+QS_P!#=XA_\#Y/\:3_ (:!\<_]#=XB_P#
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MI/\ AH'QS_T-WB+_ ,#Y/\:/^(T8#_H'G]\0_P"(9XO_ )_1^YGZ+45^=/\
MPT#XY_Z&[Q%_X'2?XT?\- ^.<?\ (W>(O_ Z3_&C_B-& _Z!Y_?$/^(9XO\
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M_P"!TG^-'_$:,!_T#S^^(?\ $,\7_P _H_<S]%J*_.K_ (:"\<_]#=XA_P#
M^3_&OL_]DWQ!?>*?V?\ 0+_4KRXOKZX^T>9/.YDDDQ<RJ,D\\  ?05]-PIX@
MX;/<7+"4:4HN,7*[:M9-*VGJ>%Q!P?7RK#K$5:BDG)1TOU3?7T/1J***_0#Y
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!LZ^\J^#?^"VW_ #3+_N*?^V=?(\=_\B.O_P!N_P#I<3ZS@;_D=T/^WO\
MTB1\&T=***_G4_H8.]%%% !1THHH .]%%% !1THHH .]%%% !1THHH .]%%%
M !1THHH .]%%% !1THHH .]%%% !1THHH .]%%% !1THHH .]%%% !1THHH
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@!,T4?G10 M?*W_!;'_E&/\ $S_N%_\ IULZ^J:^5?\ @MC_ ,HQ_B9_W"__
M $ZV=>AE/^^T?\<?S1CB/X4O1_D?@+1117[4?)A1110 4444 %%%% !1110
M445]9?\ !.7_ ()87G_!0CPEXFU:V\:6OA6/P[>0VACDTQKPW!D0OG(D3;C&
M.^<]JY\5BJ6'INK6=HKK_P ,:4Z<JDN6"U/DVBOO3]L3_@A3X@_95_9[U[Q]
M:^.K7Q8GAT1S75A%H[6LGD-(J/(&\Y_N;@Q&/NACGBO@NHP>.H8J'M,/+F2T
MZ_J%6C.F^6:LPHHKZ?\ ^"<G_!,?6_\ @H5+XGFM?$,/A72?#(A1[V:P:[%S
M/+N(B50Z=%0LQR<97CYJO$XJEAZ;JUG:*ZBITY3ERP6I\P45]^?M;_\ !"C4
M/V4_V=?$_P 0)OB59ZW'X;ACF:Q30VMVN-\T<6 YG;;C?G[IZ5\!U&#Q]#%0
M=3#RYDG;JM?F.K1G3=IJS"BM?P'X!UKXH^+['0/#NE7VM:UJ<HBM;*SA,LTS
M>@4>@R2>@ ). ,U]^_ 3_@W3^(7CC2;>^\>>+=&\#B==YL+6W.J7D7^S)M=(
ME/\ NNX_E48S,L-A5>O-1_/[EJ51H5*GP(_.NBOUNG_X-J_#3:?MC^*NN)=?
M\]&T:)H_^^/-!_\ 'J^??VRO^"%'BW]EGX4ZUXVTSQOH/BGP_P"'K?[5>K-9
MR:?>!-P'R1@RHV,CK(OTKBH<19?5FJ<*FKT5TU^EC6>!K17,X_D?"=%:/@_P
MZWB_Q=I>DQR+"^J7D5HLC#<(S(X0$CVSFOTQ_P"(:35/^BOZ?_X3;_\ R377
MC<TPN$:6(ERWVT;V]$94</4J_P -7/R]HK]/+W_@VGUR.+_1_BUI,LGI)H$D
M8_,3M_*O)_C)_P &_OQP^'.GS7F@2^%_'$$>2(-.O&M[PJ._ESJB?@LC$]A7
M/3X@R^;Y8U5\[K\TC26!KI7<3X;HK2\8^#-7^'OB6\T77M+U#1M6T^0Q7-G>
MP-!/ P[,C $?B*S:]:+35T<NP44450!1110 4444 %%%% !17=?LS_!*7]I#
MX^>%? L.H1Z3+XHOTL5O'A,RV^[/S% 1NQCID?6OT(_XAH]4_P"BOZ?_ .$V
M_P#\DUYV,S;"822AB)\K:OLW^29O2PM2JKP5S\O:*_3C4O\ @VH\0Q1_Z'\6
M-&G;TFT.2(?F)F_E7B?QV_X(3?'?X-Z7-J&FZ?HOCJQ@4NXT"Z9[I%'_ $PE
M2-V;_9CWFL*.?9?5ERPJKYW7YV+E@ZT5=Q/C.BIM2TVXT;4)[2\MYK6ZM9#%
M-#-&8Y(G!P593R"#P0>14->QZ'*%%%?HI\!?^#>SQ#\8_@OX8\6:A\1+/PY=
M>)-.AU(Z;)H;SO:)*H=%9_/7+;"I(VC!)':N+&9AA\)%2Q$N5/;=_D;4:,ZC
MM!7/SKHKV3]NS]C?5OV&/C[<^!]4U"/6(_L<%_9:C';FW6]AD!!8(6;;MD61
M/O'E,]\5XW731K0JP56F[Q:NC.47%\LMPHKZ*_X)T?\ !/NZ_P""@WCSQ#H=
MKXHM_"W_  C]@E\TTM@;SSMT@3:%#ICUSD_2OK@_\&T>J?\ 17]/_P#";?\
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M.N -RC/.3GTJG^V1^P+JG[(WAS1M6DUR'Q!I^J7+VDDD=F;?[+(%WH#EVSN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6PMKZ!R#W&^8Q =B(Y!ZUW<4595ZM/+Z?7WGZ*__  7]QAE\5",J\O1'8?\
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M_$W_ ,#+'_Y%KXF_X*Y_\$[?"'[ &L^!8/"6K^)-5C\4PWLES_:\L,C1&!H
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M?"/Q/DTOQ%H?BK4(-*%_%8QV=W833.(XY/W06-H][+O!7(&2#QM;[;_X*_?
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M5LENA6- B (@ &%4?6N)HHK[Z$(PBH05DMD>,Y-N["BBCO5""BBB@ HHH[T
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MSQSQ9K*^(O%.IZA&C1QWUW+<*C?>4.Y;!^F:I6UM)=W$<,2-)+,P1$499V/
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MNZ[9/I)7Y9?M0_"=O@A\?_%7AD1F.WTZ_<V@/>W?]Y#_ .0W7\<U\+Q!PS#
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
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MN0_\84?&'_L2-:_]()J_FNKXO@G^#4]5^1ZV;?''T"BBBOMCR0HHHH ****
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MG[67_!0"^\.Z%YFHV/A&5/"FDV\)W?:;H28G*CIN:X9H\CJL25^A'[;?[/\
M9_LL_P#!#OQ%X"L_+;_A'=#L(;F1!\MQ<M?V\EQ*/]^9I&]@:^#/^"%G[.,_
M[1W[<J^+M81[W3?A^AUZ[FE^837\C%;8,?[WF;Y@?6W-?IU_P65_Y1H?%/\
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MV335K+71OK?[@%':BO(/V]OVC(_V4OV1O''C82+'J&FZ>T.F _QWLQ$5OQW
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M:M_V&]/_ /1IKY$_X-J#_P 9'?$3_L6X_P#TJCKZ[_X+]_\ *.G5O^PWI_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*F-I(L-'<1GK'+&P*2(< [6!&0#P0"/T/^#_ /P<E:E8Z5%;^._AO;:A=1H
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M!E8'U! -?IOJ/_!R#%XE\(W&D:U\$8-2@U"S:SOE_P"$KV1W2NA20;/L9PK
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M4=Z "BBB@ K[]_X-RO\ D]WQ5_V(]W_Z7Z?7P%7W[_P;E?\ )[OBK_L1KO\
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M[;:I'EY?PMEN"K_6<-3M+7JW:^^C9]F?&7_@KG_PMOX4>(O"_P#PK_\ L_\
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MEEKR#]G?_@E7X \;_#SP7XLU35/$ET-6TJTU*[T_SXD@EDDB61D#*@<1Y8C
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MW;\!>E?/7[;/_!,GX7_MTVRW7B?3I],\3V\7DVVOZ8PAO(U'(23(*3(/1U)
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M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1T
MHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %
M'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%
M% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@
MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH 3-%'YT4 +7RM_P6Q_Y1C_ !,_[A?_ *=;.OJFOE7_
M (+8_P#*,?XF?]PO_P!.MG7H93_OM'_''\T8XC^%+T?Y'X"T445^U'R84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA+U+_P ']]_\=H_X<9_LV_\ 0EZC_P"#^^_^.T?ZY8'^67W+_,/[+K=U^/\
MD?@K17[U?\.,_P!FW_H2]1_\']]_\=H_X<9_LV?]"7J7_@_OO_CM'^N6!_EE
M]R_S#^RZO=?C_D?@K17[U?\ #C/]FS_H2]2_\']]_P#':/\ AQG^S;_T)>H_
M^#^^_P#CM'^N6!_EE]R_S#^RZW=?C_D?@K17[U?\.,_V;?\ H2]1_P#!_??_
M !VC_AQG^S9_T)>I?^#^^_\ CM'^N6!_EE]R_P P_LNKW7X_Y'X*T5^]7_#C
M/]FS_H2]2_\ !_??_':/^'&?[-O_ $)>H_\ @_OO_CM'^N6!_EE]R_S#^RZW
M=?C_ )'X*T5^]7_#C/\ 9M_Z$O4?_!_??_':/^'&?[-G_0EZE_X/[[_X[1_K
ME@?Y9?<O\P_LNKW7X_Y'X*T5^]7_  XS_9L_Z$O4O_!_??\ QVC_ (<9_LV_
M]"7J/_@_OO\ X[1_KE@?Y9?<O\P_LNMW7X_Y'X*T5^]7_#C/]FW_ *$O4?\
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MK7X+?]"U>?\ @VNO_CE'_$-,U_GA]\O_ )$/^(D97_+/[E_\D?E#1TK]7O\
MAUK\%O\ H6KS_P &UU_\<H_X=:_!;/\ R+-Y_P"#:Z_^.4?\0TS7^>'WR_\
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MC*_Y9_<O_DCX4HK[K_X8B^')_P"8-<?^!\__ ,51_P ,0_#G_H#7'_@?/_\
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M(OAR?^8-<?\ @?/_ /%4?\,0_#G_ * UQ_X'S_\ Q5'_ !!W._YZ7_@4O_D
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MB^'/_0&N/_ ^?_XJC_AB+X<X_P"0-<?^!\__ ,51_P 0=SO^>E_X%+_Y /\
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M^6?W+_Y(^%.E!Z5]U_\ #$7PY_Z UQ_X'S__ !5'_#$7PYQ_R!KC_P #Y_\
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M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** $S11^=% "T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &*
M*3./6B@!:.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI
M110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *
M.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
M HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:*
M* "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!
MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ4
M44 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "C
MI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M*.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB
M@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:
M** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %
M!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
M 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%
M% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ
M444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "
MCI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH
M *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&B
MB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0
M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M"CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HH
MH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&
MBB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !
M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI1
M10 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.
ME%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@
MHZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
M "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!H
MHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4
M&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%%
M"9HH_.B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY=?GM;B^EOF2XDAAA*K),S2>6$@0!69L'<<\FO;Z "CI110 4&L7XB^.M/\
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MT;PO-=7L^LRP2"2.*62>"!882RJ6(#LR@KA"VY0#^@B@T44 %'2BB@ H-%%
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M9Z:V>O\ HD&R#\DK^L[_ ((=? @_LW_\$DO@'X7DA^SW'_")VVL749&&CGU
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M?\([J$VG'5]#TK39M-U!HG*-);R2W\;O$2#M8HNX<C@@GZY_X)<_\%6_!?\
MP5F^&GB+QA\/_!OQ(\-^&_#U^FF"^\4V%I:QZE<%"\B6_P!GN9]WE*8]Y;:
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M;5OB%_P4/_X+8? L?$/QIXP\>3:'KS>*)[O7M7N-1> :=#)>H=TKL5!EAB0
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M0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@#\W?\
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M_!>__@X^^.O["_\ P4>\1?"GX1ZAX3M= \):7IZ7PO\ 1TO97O9X!=.=Y88
MCGA7;V*GOFO4O^#:K_@LM^TA_P %3OVH/'FE_$[4/"]SX)\&^&1>.--T1+27
M[?-<Q);@N"?E\M+HX[E1Z5^"O_!3GX]_\-0?\%#OC3X]2;[19^(_&&I3V+YS
M_H:W#QVPS[0)&/PK]Y/^#*+X!_\ "'_L2_%/XBS0^7<>./%L>E1,1S+;:?;!
ME8'T\V]G7ZH: /VDH-%% !1THHH *#110 4=*** "OS=_P"#E?\ X*P^.O\
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M:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444
M%!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI11
M0 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E
M%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110 4&BB@ H
MZ444 %!HHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:**
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MX-_#[XW?$#P]I6I:I8^&=$TVQORL-G]HN$AC1%QTW2=*XS_@DM^SE;_M9_\
M!2WX)_#^^L8=2TG7/%EF^J6DL8DCN;"!_M-VC*<@JUO#*#GC!YK^P'P5_P $
MQ/V;?AMXOTSQ!X=^ /P7T+7M%N8[W3]1T_P7IUM=6,\;!DEBD2$,CJP!#*00
M1D&@#@/^"L/_  5L^'/_  2%_9[M_$7BYKC7_%&L*]MX9\-P3A;S79XU7<S.
M0?*A3<IDF(.W< %9F53_ #3?MG?\'(G[6?[8OBB\F3XF:Q\-?#LLI:TT/P3.
M^CQVJ=E:YC(NI21C/F2E2<X50<5P/_!;;]O;4_\ @HE_P4:^(7C6:^DN/#6F
M7\F@^%K?S2\-KI=J[1Q,@Z#SB'G8#^.=NV*^P?\ @VK\=?L:_L@:/XA^-W[1
M'CWPQ:_$>QU V7A31+[3;G49=%MXD1VOXXHH9/\ 2))&*(V-R"%BIS)P ? >
ME?\ !13]ICX2^+/MEO\ &WXUZ'K#!97,GBO4HY)58!E+JTOSJ00?F!!K]W/^
M#:/_ (.%/&W[=7Q,N/@7\;KBTU?QI'IKWWAKQ'!:K;S:ND"[I[>[5,(9EC_>
M+(B*&6.3=EL%OSA_X.4_^"ROP]_X*O\ Q;\!6/PST&^A\,_#>&^1?$&I6PM[
MO6Y+HP$JL7+QP1^1\N\AF:5R57 W._X-)_V?O$GQ5_X+!^%?%VEVMP=!^&6E
M:GJFM780^5$MS8W%C!$6Q@.\EQD+U98I".%. "3_ (+M?\%F/C=XZ_X*%?'[
MP#X2^*GBS2/A7;ZC=>#6\/V5[LL)X((!8WB%0/F6:1)V8YY$A[8K\PZ_H"_X
M/&O@[\&OV</@'\,=/\%_"WX;^$_'/Q$\67NLW^MZ1X<L[/4[V"U@(G62>.,2
M,LDU]"[9/S,@)SBOR!_X)0?LZ0?M9_\ !2;X)_#^]LXM1TO7O%MD=4M9(Q(E
MQ80R"XNT93P0;>*4'/&.M '7?LK?\%/_ -K"SOO ?PD^'?QL\?Z'875Y9^'-
M!TNSORD%L9I5ABC10.!N<<>]>S?\%%?^"L'[7_[,/[>GQC^'\/[0'Q+M;+PG
MXQU/3[&-=2*J+1;F3[.0,< PF,@>AK^G#P;_ ,$P?V;/AWXMTO7_  _^S_\
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M76O$S>&=.M])%]=$3:SXQU,1'Y8U) ,TS([G)"1J&)(52:_,7_@SN_X)8?\
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M!D%Y&PB @DY*@_S4?MT_\'2W[4O[7VL7%OX:\3?\*9\*[V^SZ;X0D:WO2O\
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MKKVEV7B.VTFW&(-)>X#K+#$/X8_,B=U4<() H 50* /Z1_\ @B]_P5P\-_\
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M$8_BQ\2?CU_P3$^$/CCXN:W_ ,)%X\\7:0^KWM_]B@L_/AFN)7M3Y<")&/\
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MY9_^"CO[</B/_@HI^V3XV^*WB.>Z_P"*@OG72K*63<-(TU&(M;1!T CCQG&
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MD<[510,DD]@!7\)G[7?QOF_:8_:K^)7Q$F9V?QQXGU+70&ZHMS<R2JN.P57
M [  4 ?O%_P:1?M@_M!?MO\ Q_\ BYKGQ0^*GC3QQX5\&^'[2QAL=5O#-;I>
MWMP724#'WUCLYESV$I]17TK_ ,'7'[=7CC]B#]@OP?<?#3Q=JW@SQEXJ\9P6
M:WVFS^3<"RBM+J6<!O0R"W!_WJXS_@S1^ G_  KG_@F5XC\:W$.R[^(OC&ZF
MAEQ_K+.SBBMHQ[XG%W^?UKY!_P"#W7X\KK?[0WP1^&<,W'AOP_>^)+F-3P6O
MKA;>/=[J+"3'<"0^M 'PW^SA_P %V/VG/^&A_ ?_  FO[1WQ(M_!O_"1Z?\
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M ;<);?QGJ,;@^N5F!S[U]W?\$4_^"P'[87QD_P""B/P;^%__  O#QAXB\/\
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M/[*UM=8]V/I7RM_P;V_\%&?VIOVVO^"KOPW\'^*_C=\0O$'@ZU6^UC7;&ZU
MR07%M;VDK(CKCE6G,"G_ 'J\#_X.C_CW_P +T_X+.?$N&&;S]/\  UO8>%K0
MYSM\BV22=?;%U-<#\*^O/^#(SX!_VY^T5\:_B=-#\OAKP]9^&[:1AP7OK@SR
M;?=5L$![@2#UH _H'^/GQ9L_@)\"O&GCK4=O]G^"]"OM=N=QP/+M;=YVR?\
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M7$BDA!^T/@']B[X,^$?C>OQ<\*_#WP5I/CC4-,DL#XAT>PBMI;ZUG:.1M[1
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M&S]L;XFS:#\.?B!XN\!?"OP^JV&FQZ-?RZ=J'B$1KL:^O9XBLKM,07\DMY:
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M7ZAX=_9UC7X8^";:5X8M?N;6*ZU[6$Y'F;95:*U1AR%56D'!\P'Y1^:OB_\
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M>M?S_P#BSQ)=>,O%.I:Q>F-KS5KN6\G*+M4R2.7; [#)/%?UK?\ !JY\!?\
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MFOP_?SVVB:791^*/%:12;5O[F5F%G;2 <E8D1IBI^4M/$W6,$?FA_P $8/\
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M#?/]GS]@'X,6.DZAX)\+_$SQQ<1!M9\4>)-'@OIKJ8@;UMXYE=;: 'A43D@
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MMB?![]ISXC>$6_:$^)4+>%_%&IZ08UU'8L9M[N6+ 4   ;,8  %?KM_P96?
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M-\.>)[B$?VK:7YYAM[F1<">*7!0.RF179,L5)V_T)5_%W_P0C_9^\1_M%_\
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MO^#KSX]_\+K_ ."ROC338YO/L_AWI&F>%[=@<J-L'VN91_NSWDRGW4U\W_\
M!-#_ (*.:S_P3"\?>-/'W@W2++4/B)K'AR7PYX?O;]!+::#Y\T4D][Y?_+69
M4A"1HWR?O69MP78_G/[:OQTD_:<_;!^*7Q$:1I%\;>*M2UJ+=_#%/=221J/0
M*C*H'8 5^IO_  :M?\$1/"O[:>HZS\=OB]H<.O\ @/PKJ']E^'="O$#V6NWZ
MJ'FFN(S_ *R"$/& A^221F#9$;*P!^<WQ$_X*O?M-?%3QO)XBUKX_?%R;56F
M-PCVWBF\LX;5_P#IC##(D4(]HU4#TK]=/^#9G_@X1^(_Q7_:,TO]GWXZ^*)O
M&%MXIBF7PIXCU1C)JD-\@\P6=Q.3F:.1%DV/)F02!4W,KJ$T/^#Q;]@#X1_!
M;]F[X8_%'P3X*\+^"?%$GBC_ (1F\70M.BT^/4[66SN+A6ECB559HFM@%<C=
MB4@D@*!^/?\ P2<UF^T'_@J+^SG<Z=N^V#XE^'HD5?XP^I6Z,GT96(/L: /[
M/OVF?VEO!?['WP-\1?$;XA:Y;^'_  CX7MOM-]>2@L>2%2-$'S/([LJ(B@EF
M8 =:_F=_X*1_\'9WQZ_:A\7:AI7P<O9O@O\ #]7>&V-DL<NOZC'G"R3W3!O(
M8@ A+?:4)(,DF U>J?\ !YI^WOJ?CW]I[PK^SYI-])#X;\ V$6O:Y!'(0MYJ
META,*R+T/DVI1D)[W<GL:^"_^")?P[_9\\8?MK6.K_M->+M%\-?#'P?9/K#V
M.HI+)'XCO%=%@LF6-68QY9I7&,,L.P\.2 #S'5/^"@'[24UQ:^(KSXV?'!I9
M9&%MJ<WC#5"SNOWMDIFY(R,X/&:_0S_@BU_P<]_&3X(_M ^%? GQR\67WQ(^
M&'B748]/N=4UDFZUK0&F.Q+A+DGS)HE<J9$EWG8&*$$8;W#_ (.!?^#A/]G;
M]HO]A/5_V>_@;IY\81ZY)96YU9='?3=(\/6]I<0S+]ECFC21I#Y7E+MC1%1F
M(8\*?Q-_9C^ 7B/]J?\ :%\&_#KPC9S7WB+QCJT&F64<2%]C.X#2MCHD:[I'
M8\*B,QP : /[JO'_ (^T7X5^!]8\3>)-4L]%\/\ A^SEU#4;^[D$<%G;Q(7D
MD=CP%5023[5_.#_P55_X.\?B3\6?&NI^%?V:9%^'_@BSF:!/%-S9I/K>N*.#
M)&DRLEI$W)4;3-@*Q>,DH/HK_@\]_;SU+X;_  C^'W[/?A^_FM?^$X#>(_$Q
MCEVR3V-O)Y=K;L!]Z.2X661LX^:T3W%?A[_P3E^%OPO^,'[9?@G1_C5XPM?
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M&G@OX6?#'X:W%MI<RZGJV@>&K/2Y_L28FE222&-6,>8E<J3C,:G&0* /$?\
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MEW&E_#G1=-\-:'XN\+V/B:;2-.B$-GI]U+-<P2K#$H"QHWV99-B@*#*< #
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M;ZZD1%"HIEE9G*JH"@$X   XK^V3P?\ L\?!?_@F'^ROX@OO!/@/PSX/\*^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8HI,X]:* %
MHZ444 %!HHH ^%_^#DGX]_\ #/\ _P $9?C/=Q3>5?>*-/@\+6JYP9OM]Q';
MS+_X#-.WT4U_'6!FOZ/O^#V_X]?\(]^S!\&?AG#-MD\5>);OQ#<(IY,=A;"%
M0W^R6O\ (!ZF/_9K\.?^"7_P$_X:?_X*)_!7P&\/VBS\1>,=-BOTQG-FDZRW
M)Q[0)*?PH _LB_X)[_ 7_AEW]A;X0_#UH?(N?"/A'3-.O%QC-TELGVAB/5IC
M(Q]S7L1HK+\;^,+'X>^"]8\0:I+]GTW0[*;4+N4_\LX8D:1V_!5)H _C_P#^
M#DKX]_\ #0'_  6:^,UW%-YUCX7OX/"UJN<B+[!;QV\R_P#@2MP?JQK[X_X,
MA_V>XM2^)?QQ^*EU:KYFCZ=I_A?3KAER<W,DEQ<A3VP+:US[.*_$/XQ?$R_^
M-/Q<\5>,M4.[4_%FL7>LW9SG,UQ,\S\]_F<U_4M_P:(_ 7_A47_!(#2O$$D/
MEW7Q+\3:GX@+,,.8HW6PC'^[_H3,!_MD]Z .V_X.DOCU_P *,_X(Q_$J&&;R
M-0\=7.G^%K0YQN\^Y22=??-K!<#\:_D>\+^&[SQEXET[1].A:XU#5KF.SM8E
MZRRR,$11]6(%?T%?\'OGQZ^Q?#GX$_"^WFW?VEJ6H^*;V$'[GV>*.VMF(]_M
M-T!_N&OR@_X(,_ 7_AH__@K[\!?#KP^?:V?B>+7[E2,H8M.1[]@W;:WV;;SU
MW8[T ?OM_P ')7PID^ __!NWJ7@?08]VC>#8?"^A2E!M5+2UNK2",X]/,2$8
M]Z_E9T331K.LV=FUS:V8NYDA-Q<L5A@W,!O<@$A1G)(!X!X-?W%?\%#_ -D"
MQ_;X_8F^)'PAO[I=/7QMI#VEM=L"R6=VC+-:S,!RRI<11.5')"D<9K^*_P#:
MG_93\??L6?&S6?A[\2O#E]X9\4:)*4FM[A/DN$R0LT+_ '987 RLB$JP[T ?
MJKX'_P"#*/X^:TUO)K7Q9^#=C9S .9M-FU'4#M(R"H:VA#9_WA7UY^RE_P &
M9_P3^"-];^(/C5\2=>^)$6GD33:=;0KX>TAP/X9F$DD[*/5)8B?IQ7Y _LV_
M\'#_ .V!^RG\*]/\%^$_B]>R>&]'MQ;:=;:OI-CJTEA$O"I'-<PO+L50%5"Y
M15  4  5L?LY?M0?M%_\%G_^"@GPA\ _$WXB>.?B%HFK^+M-DU32_,*:7:V2
M74;W-P;.W5+=-D(<[_+&.!D<4 ?UY_#GX<:!\(? NE>&/"NBZ;X=\.Z';+::
M?INGVZV]K9Q*,*B(H"J!["MKI110 5\A_P#!63_@C#\)_P#@KC\.K.R\9QW7
MA_QEH,;IH7BS3$0WVGALDPR*WRSVY;YC$Q!!R49"Q)/^"]/QWD_9R_X) _'K
MQ%;W#VMY<>&GT.VEC;;(DFHR1V"E".0P^T[@1R-N>U?S-_LL?\'%'[7G[)&@
MV^CZ%\6M2\0:%:H(XM/\46T6M+$H&%59IU:=%4<!5E"@=N!0!S__  5I_P""
M,/Q4_P""0_Q$TNQ\:2:9X@\)^)GF&@^)=++?9K_RMI>*2-OG@G570E&RI#'8
M[A6(^@/^#4?]M_Q9^SM_P5!\*_#FWU2Z;P'\7/M.EZOI3R,UN+I+66:VND3.
MT3+)"L9?',<K@]L?+G_!17_@KG\<?^"I.J:#)\6O$EG?:?X9\UM+TK3;".QL
M;1Y=HDDV*-SNP11ND9B ,# )S^B?_!I7_P $E/'_ (E_:UTG]I+Q?X?U#P[X
M"\%6=T?#DNHVS0OXBOKFW>W$D". 6MXHII6,P^4R>6J[B'V ':?\'Q'B/4)O
MB=^SSI#><NEV^EZW>1\_NWF>6S1^/55C3Z!_<U\)?\&RFDZ+K'_!;OX(1ZXT
M"V\5QJD]L)B%1[I-)O&@&3_%Y@4KZL%'>OV0_P"#P#_@GWXD_:J_8U\'_$WP
M?IU]K6K_  8O;N74-/L[<S32:7>K"+B<*H+-Y#VT#$ 86-I7. IK^9#P5XUU
MCX;^+],\0>']4O\ 1=<T6ZCO;#4+&=H+FSGC8,DD;J0RLK $$'((H _M[_X*
M(_MP^%O^"=O[(?C+XJ>*KJT2/0+*3^R[&:41OK.H,C?9K./NS2. #C.U [GY
M5)'\0WCOQKJ7Q*\;ZSXBUBX:\UCQ!?3ZE?3MUGGFD:21S]68G\:^G/'OQ,_:
MH_X*[^#O%'BOQMXN\5_$#PI\%=#FUK4]0U6;RM*T.(+@ +&HC^U3L B@*9),
M98[$9E^3>U ']7W_  :+? 7_ (5!_P $?='\020^7=?$OQ+J?B%BPPYCCD6P
MC'^[BR+ ?[>>]?E=_P 'DOQ\_P"%E?\ !431?!=O-NM?AOX/L[2:+.?+N[MY
M+N0^V8)+7_OD5^_?_!''X?Q_#'_@E+^SOI,<8C(^'VC7LJ@?=EN;2.YD_P#'
MY6K^2G_@L+\?/^&F_P#@J)\=O&:3_:;34/&%]:6,N<^99VK_ &2V;\8((Z /
MM?\ X,WO@'_PLS_@J5JOC*>'=:_#7PA>WL,N,[+NZ>.SC7VS#+='_@)K^G'X
MN?V@/A1XG_LE#)JG]DW7V-!P7F\E_+'XMBOQI_X,E/@'_P (U^RG\8OB7-#M
ME\7>)K;0+=V'+1:?;>:2O^R7OV!QU,?M7[<4 ?P!U^F7[ /_  :W_&;_ (*%
M?LR>%?BUX7^(OP@T_P *^+$E>WANKZ_DO[5HII()(YHTM"BNKQMP)&XQSS7E
M/_!<S_@DIXP_X)@?M>>(HVT>]E^%?BK4I[[P?KD<1:UDMY&,@LY).BW$ .QE
M;!8(' VL*\U_8=_X*Z?M#_\ !.33;[3OA%\2-2\-Z)J<_P!INM(GM;?4=/EE
MP 9%@N8Y$C=@%#/&%9@J@D@# !^P'[.W_!D/HUAJL-U\6/CCJ&IV:D&33?"N
MBK9NWJ!=7#R<'I_J,^]?L)^PS^Q%\(?V#/@K#X/^#?AO2]!\/-*9+FXMY3<W
M.J7"DHTMQ<,6>:0$%?F;"8VJ% "C^2G]HK_@N?\ M??MHV9\/^)OC)XPN+#5
M&%M_9'AZ*+1X[P-\HA9+*.)I@V<;7+9)[\5_5A_P2,_9\F_99_X)E? _P-=V
MDEAJ6D>$;*;4K:1"CP7MQ']IND8'D$3S2@YYR* /P._X/._CHWC[_@I-X0\$
MPREK/P#X,@,D>?\ 5W=Y/+-(?QA6U_*N>_X,Y_@?'\2_^"K]YXHN(U,?PZ\&
MZAJENY'W;FX>&Q4#ZQ7-QS[>]1_\'@?[.WB'X:?\%5)O'=Y8W \-_$C0+"XT
MV^P3"\UI"MK/!GH'3RXW*_W9E/>OSK_9A_:Y^)?[%_Q%D\6_"OQIKG@?Q%-:
M/82WNF3;&GMW9':*12"KH6C1MK C<BGJ : /[MJ_GZ_X/@/@;LU/X"?$JWA_
MUL6J>&;Z7'3:8;FV7/OONS^'UK[K_P"#77QC\2OB_P#\$Q%^(WQ2\:^+/'6O
M?$+Q9J>IVE]KNHRWDD%I"8[)8HO,)$<0EM9V"( H+GBN;_X.ZO@=_P +8_X(
M\:UKL</F3_#CQ-I7B %1E@CR-I[_ (8OLG_=SVH _ ?_ ((T_P#!26;_ ()>
M_$KXO^.K%@VO:Q\--0T#P_"R[E;59[RQ-M(1T(BV/*0<96-AU(KP+]FK]G[Q
ME^W'^T_X8^'_ (9CFUCQE\0-76UCEG9GS)(Q>:YF?D[$7S)9'.2%1CS7FU?T
M??\ !GU_P2L_X53\)-2_::\9:;L\0>.(9-+\&Q3Q_-9:4'Q/> 'HUQ(FQ3P?
M*B)!*S4 ?K1^Q#^R%X6_8-_96\%_"?P=#MT7P?IZVOGL@634+@Y>>ZDQ_P M
M)I6>1NP+X'  KU;I110 5_++_P 'D?B._P!8_P""M.EV=UYRVND^ =,@LE8_
M*4:XO)691[N[ G_9]J_J:K\!_P#@]!_X)]^)/%6L> ?VC/#NG7VJZ1H^D_\
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M2OXJ?&W@C6OAIXNU+P_XBTK4=#US1[A[2_T^_MVM[JSF0X:.2-P&5@>"",T
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M^!W_  HW_@M#\78X8?)L/%DMEXFM3C'F?:[2)IV_\"1<#\*Y7X?_ /!3J_\
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M,L]'\7_%KQY>?!OX%^ -4U^XT.XU65M-AM((4M(87CSATB$X>-&R$\@%<;>
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MH#_P2]U[2/"-G=:IXP\ ZG!XQTC3K:(R3:JUO%-#-;HHRS.UO<3,BJ"7D1%
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M#\;_ /@Y5^-DGQP_X+0?&:X\PO9^&KVU\-VB9SY2V=K%%*!]9Q.WU8U]X_\
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MCTNROI9_#NI3P,D>M:8[$V]Q&V-K_(0K[20LBNA.5- ']-/_  :R:3HNF?\
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MKZ<\9?M@?M4_\%*?AW=^#_$OQ$\>?$#P?\/M'F\0:E!?7A^P:=:6D98W5VP
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MX$_"^WFW?VEJ6H^*;V$'[GV>*.VMF(]_M-T!_N&OR@_X(,_ 7_AH_P#X*^_
M7PZ\/GVMGXGBU^Y4C*&+3D>_8-VVM]FV\]=V.] '].__  4T\$?\,P_\$(?B
MQX1\/B0V_@WX2W'ANV,/RE;>+3Q:%AZ 19/T!K^,ZO[P_P!IWX'V?[3?[-OQ
M ^'&H7#6=CX^\.:AX=GN%0.UNEW;20&0#N5\S</<5_#Q^TS^S9XQ_9"^.?B3
MX=>/-'N]#\3^%[V2SNH)XF19=K$+-$6 WPR+ATD'RNC*P)!H _LR_P""0.E:
M+HG_  2L_9V@\/O!)I?_  KO1)0\1!5YGLHGG)]&,S2%AV;([5_-S_P='?\
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ME U^FE '\,7_  4&_M#_ (;V^-W]K1M'JG_"?Z]]L0GE)O[1G\P?@V:^G_\
M@EU_P;N?%C_@J]\"+SXB> _'7PKT;1=/U>71+JTUB_O5U&WGCCCD):*&UD0*
MR2H5)DR>>!BO7O\ @Z2_X)*>,/V5OVTO%?QNT/1[W4OA3\5-1.L3:E;Q&1-$
MU6<YN;>Y(^X)9M\L;-A6$I0$LAS\(_L4_P#!1SXV?\$[?%>H:Q\'?B!JW@VX
MU9%CU"WCBAN[*_"YVF6VG22%V7+!7*;E#-M(R<@'[$? C_@R!NVU.WN/B=\>
M+=;-<&>Q\+Z"6ED]0MS<2 +]3 WTK]<O^"<7_!+KX%_\$S? NH:)\(?#\,-_
M=.MOK>NWER+W6-2D0 A+B? V@9#>4BI&"VX("Q)_EO\ CW_P<3_ME?M':#+I
M.M?&[Q!I6FW"^6\/ARUM=#=P>H,UI%',0>A!?&.,5_1%_P &S'P"U+]G?_@C
M_P"![CQ+;WVG^(O&U]J7B[6!J"M'<;I[ETBDDWX;+6T-NY+<_-^- 'UI^U_^
MQ]\/OV[/@+K7PW^)F@P^(/"^M*"T9/ESV<RY\NX@D'S1S(22KCU((*LRG^9_
M_@LO_P &PGCW_@FWX(UKXG>!-?3XC?"/2W5[UYXQ;ZWH$3N$5KB-?W<T89D4
MRQ8.6RT2*"P\%L?^"[O[27P5_:E^)'C;X9?%GQ/HND>-/%6I:^-&NV34=+"W
M-U)-A;2Y62*/Y6"Y158  9&!6I^VC_P<7?M1_MV_ ;4/AKXT\5Z'9^$]:")J
MMOHVC0V4FJ(CJZI+(,L$W*I*H5#8P<C(H ^9?V.?VN?&G[#/[1GACXG> =4N
M-+U_PU>)/M25DAU" ,#+:SA2-\,J@HZGJ#V(!']CW_!2?]IJ'X/_ /!*WXN?
M$[3Y6@:/P#>WNER'Y66XN;4I:D_]M9HJ_E$_X)(_\$GOB)_P5)_:6T'P_H.A
MZG#X#M;^)_%7B9[=UT_2;-65I5$N-K7#IE8X@=S,P)P@9U_J@_X+5?LXZU^T
MM_P2<^-7@'PCI[W>M7OAOSM,L+88>Y>TEBNE@C4=6<0;%7N6 [T ?Q75_:Y_
MP17^!\?[.W_!)_X ^%XXUCD3P;9:I<H/X;F^3[=./?$MP_/>OXIIH7MIFCD5
MHY(V*LK##*1U!%?I/_P1,_;I_:5_:4_;V_9Q^!J_&CXC+\/](\0V<G]BVVKR
MP0G3-.0W<EH[1D.]O]GM6C\MV*!> ,<4 ?N!_P '3_QLD^#?_!%_XCV]O(8;
MSQK>Z;X;A<'G;+=)+,/^!003+]&K^2#0M&N/$>MV>GVJB2ZOYTMX5)QN=V"J
M/S(K^L#_ (.S/V=_$?[0'_!(G5KCPW8W6I3?#_Q'8^*[ZWMUW2&SBBN+>9]O
M4K&MSYC8Z+&S=%-?R;*Q0AE.T@Y!':@#^[#PSX*C_97_ &0=/\.Z''YT/PX\
M'QZ=I\<:_P"L6RLA'$ /?RE&*_A/>1II&=F9F8Y+-R2>YK^B/_@T9_:8^.G[
M;/Q<^+OB#XI?%+QUXZ\*^"?#MAH5GIVM:I+<V?VB[G>3S=C':\JQV;*9&RX6
M8@G#<_B__P %0O\ @G_XH_X)L?ME>,/AKX@L-0CTVQOI9O#NI7$#)'K>ELY-
MO<QMC:^4(5]I(2174\J: /Z9?^#5C0])T?\ X(B_"N73;B&XN-0O-:N=1V$9
MCN?[5NDVL.S")(NO48/0BOS$_P"#R;_@HAI?QJ^/G@WX!^%]2AO[#X8F75O$
MSP2!XO[6G4)%;$CC?;P;RV.ANRIPR,!^8G[,7_!2'X__ +)/@+5O!?PJ^*/C
M/P?H/B6?S+G3=)NBJR3L ADBX+12L JEXBK':H).!CSWX^_"7Q=\$/BKJ7A[
MQY:WFG^,(5AO-4M;R0O>6TMQ$EP%N,\K-ME4NK?,CEE;#JP !]&_\$#_ ("?
M\-'_ /!8#X#>'Y(?.M;'Q+'XAN01E/+TU'OR&[;6-L%P>NX#O7[0_P#![%XC
MO[']@3X5Z7#YJZ?J'CY9[EE.%+Q:?=B-6]<^8Y _V?:OCO\ X,K?V=I?''[<
M_P 2/B5/:F33O /A,:;#*5XBO=0N%V$'U\BUNA_P.OUB_P"#E;]@?7O^"@'_
M  2]U[2?"-G=:GXP\!:G!XQTC3K:(R3ZJUO%-#-;HH!9G:WN)F15!+R(B@<T
M ?RZ_P#!,/2=%UW_ (*1_ &S\1-#'H5U\1- COC.0L1A.HP!@Y/ 4C@D] 2:
M_M;^.WQR\*_LT?![Q%X]\;:Q::#X5\*V3W^HWMPX5(HU'09^\[-A50<LS*H!
M) K^#B6*YT74F1UGM+RTEPRD&.2&13W'56!'U!%?76@_'K]KS_@L>=+^$=YX
M^\;_ !%T7PS9OJUQ;ZC>,--TJUMHR7OKZ15^<1KD"2;?(2VU-SN%8 \2_;B_
M:DU+]MC]KSXB?%;5H6M;KQUKEQJ:6Q?=]C@9L009[B.%8XP>X2OWI_X,D/@+
M_P (]^R]\9OB9-#MD\5>);3P] [#GR["V,S%?]DM?X..IC_V:_G!K^NG_@U7
M^'\?@?\ X(D_"ZZ5%CG\37NLZK/Q]YO[3N8%)^L<$= 'PI_P? ?'1@/@+\,[
M>4[?^)GXGOXL]3^YMK9O_2L?C7YP?\&XWP0B^/'_  6=^!^GW,:O9Z#JLWB6
M4M_ VGVTUW"?^_\ %"/QSVK[Z_X/;?V=O$*?&3X._%>&QN+CPO/H<WA6YNT!
M:*SNXKB2YC1_[ID2>0KZ^2_I7XI? [X[>,?V:/BEI/C;P#XDU7PGXLT-W>QU
M33IS#<6Y=&C< C^%HW=64Y#*Q!!!(H _O0K^/#_@Y4^-DGQP_P""T'QFN/,,
MEGX;O+7PW:(3D0K9VL44H'UG$S?5J_9#_@TA^.GQD_:[^%'QL^*GQ:^(OC+Q
MX-0UZP\/Z4FL:C)-:V#VMO)/<>1#GRHMXO8-VQ5SL6OQ0_X.!_V=_$?[.G_!
M7;XV6_B"QNK6'Q=XCNO%6DW$J_N[ZSOI6N$>-NC*K.\9QT:)E/(- 'Z'_P#!
MD#\#XM1^*WQX^),R*)M'TG3?#5HW\16ZFEN)Q[8-G;_7/M7O?_![5=WJ?L*?
M".WC7_B72>/#).?25=/NA'_XZTM?S_\ [+7[:/QC_9%U#5H?A'\0/&'@>X\6
M+%:W\>A7SVYU':6$08+U=3(X5A\R[VP1DU_5Y_P5&_X)::Y^W[_P1_L_@S<Z
MQ)JWQ,\*:1I>H:1J^J71E>_UNQMA$SSS,26:X5KB-I&)P;C><X((!_*U_P $
MSKK1;'_@HW\ Y_$EQ#9^'X/B)H$FH3S,%BB@&HVY=G)X5  =Q/1<FO[@]:UJ
MS\-Z-=ZAJ-W;6&GV$+W%S=7$JQ0V\2*6=W=B JJH)))P "37\&/Q:^$7BCX#
M?$;5O"/C/0=4\,^)M!N&M;_3=1MV@N+61>S*>QZ@C@@@@D$&O9?B7_P5K_:5
M^,/P"C^%_B;XT>.]8\"I;K:/I<]^<74"@!8IY0!+/& !\DKLO XX% '7_P#!
M<W]MW3O^"@?_  4[^)GQ T&9+KPHMW'HF@3H#MNK&SC$"3C/.)F1Y@" 0)0"
M!BOTP_X,BOV:[V;QQ\:OC#<1R1:=:V%KX.L)"ORW,LL@N[D ^L:PVF1_TV%?
MD[_P3M_X)@_%S_@IM\8['PK\-_#=]-I[7*Q:KXCN+>1='T&/JTEQ.!M#!<E8
MP3(YX52:_KX_8J_9*\"_\$H_V%-)\!Z),?\ A'? &E3ZCJVJRQ".;4YPK3W=
MY* 3AG8,0N3L0(@.%% '\M__  <K?'W_ (:!_P""S7QBN(9O.T_PG=V_A6T7
M.?)^Q6\<,Z_^!0N#_P "K[L_X,B?V>X]6^+/QP^*=U:J7T/2[#PQI\[)GFZE
MDN+@*>Q M;?/M(/>OQ+^,WQ.O_C;\8/%?C35#NU/Q=K-YK5V2<YFN9WF?GO\
MSFOZC?\ @T&^ W_"IO\ @D19>))8?+N?B7XIU+7-[##-#"R:>@_W<V<C#_?)
M[T =[_P=)?'O_A1?_!&/XE0PS>1J'CJYL/"UH<XW>?<I).OOFU@N!^-?R/>%
M_#=YXR\2Z=H^G0M<:AJUU'9VL2]999&"(H^K$"OZ"O\ @]\^/7V+X<? KX7P
M3;O[2U+4?%-[$#]S[/%';6[$>_VFZ _W37Y0?\$&?@+_ ,-'_P#!7SX"^'7A
M\^UM/$\6OW2D90Q:<CW[!O\ 9;[-MYZ[L=Z /WZ_X.0?!C?LT_\ !N[JG@'0
M?,&EZ#;>&/"[-%\H6TMKFU1<_P"R3!&N/]K%?RI:;%#-J%NEQ(8K=Y%$K@9*
M+GDCZ"O[9O\ @KG^QI=?\% /^"<?Q6^$^FRK#K7B32EFTEG("M?VL\5Y;(Q/
MW5>:!$9NRNQK^*CQSX&UKX9>,-2\/>(M)U'0M>T:X>TO]/O[=K>ZLYD.&CDC
M8!E8'@@C- ']XVFZCX;^''PNM[N&]TO2_".@Z6LL=V]PD=G:6,,0(D,A.T1+
M$N=Q. HSG%?QK_\ !;[]O.W_ ."C?_!2;X@?$32I&D\*Q3IH?AHG(WZ;: Q1
M2@'D><WF3[3T,Y':JWPL_:Z_:V_;F\$>%OV7_"_CSXB>-M U4Q:7IGA*WNR8
MYH4Y6*63AC:Q*H8B9S%&L8)VA 1\W?$CP-=?"[XB:]X9OIK6XOO#NHW&F7$M
MLY>&22"5HF9"P!*$J2"0"1C@=* /VD_X,D/@+_PD/[3_ ,9OB9-#NC\*^&[3
MP];NPX$E_<F9BON%L,$CH)/>NN_X/?\ XV27'C+X"_#F&3;#9V6J>)+N//\
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M)\->#_$FM>%_$&L>*KOQ'%?Z1?26=Y -/MA"I62-E=<MJ&>#R4]J_+KX._\
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M'/\ Y)8_"OZK-#T6S\-:+9Z;I]K;V.GZ? EM;6T$8CBMXD4*B(HX554  #@
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M45X/_P %0?CW_P ,O_\ !.KXU^/(YOL]YX>\':C+8R9VXO'@:*V&?>=XA^-
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MCU-?"99(-5L[6-9#TBBTZTCCQ[%%4CZU^B'_  8Y:5HK^(_VCKZ1X#XBBMM
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M_P#Q?\,^%;&?5/$5G:6FNV=G#S)<BQO(;J9%4<NY@BFVH.6;:!DD5_&X1MH
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M ' %?Q6$8K[P\3_\'+7[9WB;X0KX+_X6\^EZ8+)=/:YTK0M.L-0,(78 MQ%
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M\1>(/AWITND>(]*LXS-=W&E>8T\=Q#&.7\B1Y]ZJ"Q6?<!B-J /P^_X)<_\
M!+7QM_P5E^-FL> O /B;P+X=US1=);6I!XEO;BW6ZMUECB?R?(@F9W5I4)!"
MC!SFOTP^%?\ P9"_$?4KZ/\ X3CXY>"=%MMP\S^P]&NM4<KW \YK8 ^YSCT/
M2OQE^!WQW\:?LQ_%32_&G@'Q)J_A'Q9H4IDL]2TZ<PSP$@JRGLRLI*LC JRD
MJP()%?9GBW_@YY_;>\8>$O[(F^-$EG&R;);JP\.:5:7<H_ZZQVP9#[IM- ']
M 7_!,W_@W>_9Q_X)F^/+/Q%I<-]X]^*%K$T]KKGB6:*6?3UX5Y+2U15CAY('
MF%7D7<0) &(/WKKVA6/BG0[S2]3L[74--U*![6ZM;F)98;F)U*O&Z,"&5E)!
M4@@@D&OPJ_X,Y?!OCOXW?$WX[?'[XC:KXJ\3ZMJ5GI_AG3M>UZYGO)]05I9K
MB[59YB2ZHT5J, D G'&*^;_^#E/_ (*=_%;X$?\ !;;6/^%4_$3Q1X)O/AWX
M9TG0)?[)OWBM[EGC;4&$T.3%,,WJ@B16&4 Q\O ![M_P5>_X,\S>7>N>//V7
M=4BC\PR7DGP_U>;:H/+&/3[MN!Z+%<<#_GMC"U^!JMJ?@;Q.&5K[1]9T>ZR&
M4M;W-E<1/V/#)(CK[$$=B*_12?\ X.Q/VT[GX?SZ(_CKPU]KGA,/]LKX7LX]
M03(QO7:@A#>_E<5\,_ [X!?$3]LCXR6OA?P+X=\0>.O&7B"Y+_9[.%[F:1W?
MYYIGZ(@+9>60A5!)9@,F@#^O3_@@-^V3XB_;J_X)4_#'QQXQNVU#Q=#%<Z)J
M]Z^=]]-9W$D"SN3]Z22)(G<]W=SQTK^4W_@JO\<V_:4_X*3?''QMYIFMM:\9
MZD+)R<YM(IV@MOR@CC'X5_7E_P $GOV)9/\ @G9_P3X^&OPBNKJUOM6\,:>\
MFK7-N/W4U_<SR75SL) +(LLSHK$ E$7@=!_'1^WA^SMXA_9/_;'^)/P_\3V-
MQ8:MX;\07=OMF!_TB$RLT,ZG^))(F216[JX- '] ?_!E'\#X_"?["WQ0\?O&
MJWGC3QDNE@]WM["TC:,Y_P"NE[<#'L?6OT _X+3>([_PI_P27_:*O--\T77_
M  @.JP!HCM9$EMWBD8'MA'8Y]J_D1_9M_P""D?QZ_9#^'>K>$/A?\5O&G@?P
M[KUR;N[L-(OF@1YV5$:9"/FCD*QHI>,JQ"*">!7]B/AW]E:^^)/_  3%L_@K
MXXUK5K[5O$'PS3P=K^L7T[7E]-<3:8+6XN9'D):27>SOECDMWH _A^K^W#_@
MD)I6BZ)_P2M_9VM] D@DTS_A7>B2!XB"KRO8Q/.3Z,9FD+#LVX=J_C-_:=_9
MI\8_L@?';Q)\.?'FCW>A^)O"][):7,$\3(LP5B%FB+ ;X9% =''#JP(X->G?
M O\ X*%?M-:?\&[?X _#OXD?$/\ X13Q+,=.L_"NCSN\ERUP^&MH-@,RK*SD
M&*-@KEVRIW'(!].?\'1__!172/V\O^"C$FE>$=2M]6\"_"6Q_P"$<TZ]M91+
M;ZC=ES)>W$;#@J9-L(9<AA;!@2&%:_\ P:+? 4?%_P#X+ Z/K\T/F6OPU\-:
MGXA)8?()'1;",>F[-Z6'NF>U?GU^TK^SMXF_9.^-VO?#OQE!:VOBGPS)%!J=
MM;S"9;2=H4E:$N.&>/?L8KE=RMAF&&/[8?\ !CI\/X[OQG^T5XJD0>;8V6A:
M5 _?;-)?2R#_ ,@1?I0!]#?\'H_Q[_X03_@GIX#\ V\WEWGQ \8)<3)G_6V=
MC;R22#'M/-:'\*_GJ_8*^ '_  U5^VS\)_AP\336WC3Q9INDW87/R6TMRBSO
MQV6+>QQV6OUO_P"#V2S\=^(/VBOA+)_PB_B%OAQX9\-3&+7A92-IHU*[NF$U
MOYP&Q9!%:VIVL02&& <5^-O[-O[1OC#]D?XX^'?B-X U5-$\8>%;AKG3+UK2
M&Z6!V1HV)CF1XVRCL/F4XSD8(! !_=IJVK:7X#\+7-]?7%CH^BZ+:M/<3S.L
M%M8V\2%F=F.%2-$4DDX  ]*_C%_X+=_MVVG_  46_P""E7Q$^(VCR22>%/M$
M>C>'"^1OT^T00QR@'!43,LD^T\J9R.U7/VS/^"[O[4W[>GPYD\'_ !"^*%Y-
MX2N2#=:1I-A;:3;WV.TYMXT>9.AV2,R94';D9JQ_P27_ ."*OQ9_X*L_%C3[
M?0M)U#P_\-K>Y UWQI=VI%A8Q+]]("V!<7!'"Q(3@LI<HN6 !^H__!DS^R%?
M:3HOQ=^.6IV$L%KJPM_!^@W#KM^T*C?:;XKZJ'%FH8<;D<=5('YO_P#!RI\:
MY/C?_P %H/C-<>89+/PW>VOANT0G(B6SM8HI0/K.)F^K5_69^RC^R_X0_8N_
M9W\*?"_P'8-I_A7P?9"RLHY&WRRG)>2:1L#=+)(SR.V!EG8X'2OY%/\ @X'_
M &=_$?[.G_!7;XV6_B"QNK6'Q=XCNO%6DW$J_N[ZSOI6N$>-NC*K.\9QT:)E
M/(- 'Z'_ /!D#\#XM1^*WQX^)4R*)M'TG3?#5HV/F*W4TMS./;!L[?ZY]J^C
M?^#T_P"-DG@W_@GY\// ]O)Y<GC;QFMU. ?];;65K*S+_P!_I[=O^ "OY[?V
M6OVT?C'^R+J&K0_"/X@>,/ ]QXL6*UOX]"OGMSJ.TL(@P7JZF1PK#YEWM@C)
MK]QO^#M_]D;QRG_!-_\ 9O\ $EQ-J_BEOA G]A^*]5FF:ZN'ENK.SB^VW#DE
MFWSV9#2,3EYUR<L* /Q _P""?WP/C_:6_;G^#_P_N%5K/QAXQTK2[L-T%O+=
MQK,<>T9<X[XK^YW&!7\"O@[QCJWP\\7:7K^@ZE?:/KFAW<5_I]_9S-#<65Q$
MX>.6-UP5=&4,&!R" :_<G]A3]N?XSZ__ ,&\7[9WQO\ BG\3/&7C"]UIH_ G
MA]]6U*2;[ TL,5I));+G$;,VJKN9 "3;@DY3( /UE_X*R?\ !&#X3_\ !7+X
M=6=EXSCNO#_C+08V30O%>F(IOM/5LDPR*WRSVY;YC$Q!!R49"Q)_E[_X*T?\
M$8?BI_P2'^(FEV/C232_$'A3Q,\PT'Q+I9;[-?\ E;2\4D;?/!.JNC%&RI#?
M([A6(Z#]EC_@XH_:]_9(T&WT?0OBUJ7B#0;5 D.G^*+:+6DB4#"JDLZM.BJ.
M JRA0.W KSO_ (**?\%<_CA_P5(U309?BUXDL[[3_#/FMI>EZ;81V-E:/+M$
MDFU1N=V"*-TC,0!@8!.0#ZD_X-1_VWO%O[.__!4'PK\.+?5+IO ?Q<^TZ7J^
ME/(S6XNDM9)K:[1,X$PDB6,OCF.5P>V/JS_@]\^/?VOQY\"?A?;S;?[/L-1\
M4WT.?O\ GR1VULQ'M]GNQ_P(UP?_  :6?\$E/'WB7]K72?VDO%_A_4/#O@+P
M39W1\.2ZC:M"_B*^N;=[<20(P!>WBBFE8S#Y3)Y:KN(<I\P_\'2WQ\_X7G_P
M6;^(]O#-Y^G^!+73_"UH<YV^3;K+.OMBYGN!^% ')?\ !N-^SU%^T?\ \%D?
M@SIMW:K=:9X=U&;Q1=AUW+&+""2YA)'I]H2!?JPK^OGXO?$FQ^#/PG\4>,-4
M;;I?A32;O6+LYVXAMX7F?GM\J&OYX?\ @R1^ O\ PD?[4_QE^)4T.Z/PGX9M
M?#\#L/E$M_<F9BO^T$L""1T$G^U7ZN?\'(/QZ_X9]_X(S?&J]BF\J^\3:;#X
M6M5S@S?;[B.VF7_P'>=OHIH _C\\<^,;[XB^-M8\0:I+Y^IZ[?3:C=R'_EI-
M-(TCM^+,37]9?_!JA\!?^%(_\$9O M]+#]GOOB#J>I>*+E2,$^9.;:%CZ[K>
MU@8>S"OY([:VDO;F.&&-Y9I6"(B+N9V)P !W)K^[#]CGX'1_LR_LE?#/X=QH
MB#P/X6TW0WV_QO;VL<3L3W+,K,3W))H _BI_X*"_VA_PWM\;O[6C:/5/^$_U
MW[8A/*S?VC/Y@_!LU]0?\$NO^#=SXL?\%7O@1>?$3P'XZ^%>BZ+I^KS:+=6F
ML7]ZNHV\\<<<A+10VLB!625"I,F3SP,5Z[_P=)?\$E/&'[*W[:7BSXW:'H][
MJ?PI^*FHG5Y]2MXS(FB:K-S<V]R1]SS9M\L;-A6$I0$LAS\)?L4_\%'/C9_P
M3M\5:AK'P<^(&K>#;C5D6/4+>..&[LK\+G:9;:=)(79<L%<IN4,VTC)R ?L1
M\"/^#(*[;4[>X^)WQXMULUQY]CX7T$M))ZA;FXD 7ZF!OI7ZY?\ !.+_ ()=
M? O_ ()G>!=0T3X0^'X8=0NF6WUO7;RY%]K&I2( 0EQ-@;0 0WE(J1@MN" L
M2?Y;_CW_ ,'$_P"V5^T=H,FDZU\;O$&E:;.NQX/#EI:Z&[@]09K2*.8@]""^
M,<8K^B3_ (-DOV>]4^ /_!(7P))X@M-0LO$WCN_U'Q7JJ7T;I<O)<7+I$\F_
MYBSVT-NV6Y.[OUH _GC_ .#D+7[SQ'_P6Q^/4U\)ED@U6SM8UD/2*+3K2./'
ML452/K7Z(?\ !CEI6BOXC_:.OI'@/B**VT""W5B!(MHS:@TI4=2ID2'=Z%4]
M17B'_!X!_P $_/$OPA_;P;X[V.GWM]X'^*UE:1WE_%;L8-*U2TMX[4V\C ;4
M\V&&&1"Q!<^< #L)K\QOV7?VO/B9^Q5\2?\ A,/A7XSUKP3XB:W:TDN].E \
M^%B"8I$8%)$)53M=2,JIQD @ _I>_P"#LO\ X**Z3^R[_P $^-0^$NF:E;-X
M^^,P73A9QS#S[+1U?==W+J.0DFP6Z[L!O-DQGRVQ_*]96<NH7<5O!&TTT[B.
M-%&6=B<  =R37O/[3G@GXZ?'+X66O[2WQ<OO$&MZ?X[UHZ'INNZ_.[76N211
M.[FV5A@VT(01Y7;&K,$0':X3-_X)K_#^/XK?\%$?@3X:F026VN?$'0K*=3T\
MI]0@63_QPM0!_:1^RG\'K3]EG]DOX=^ V>WMK3X?^%=/T:64L%C7[+:QQ/(S
M=.2A8L?4FM;X=?M$?#_XOZO=Z?X2\=>#O%%]IX)NK;2-9MKZ:V (!WI$[%<$
M@<@=17Y)_P#!Z9\6_'_@7]C'X8^'_#MSJ=CX)\7>(;J#Q1-:LT<=R\4"/:6L
MS+UC?-Q)L)PS6ZG!VC'\_?["'C'QYX$_;*^&.H_#&XU2W\>)XEL8M'^P;C--
M.\Z((MJ_?1]Q1D.5968$$$B@#^Z*@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
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M_ ?7X-4\-_ +X<PZE:LLD%Q?Z;_:<ENZG*NANC)L8'D,N"/6OJ55"*%48"C
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MX;^,7@G4/#/B[P_HGBKPWJR".^TK6+&*^L;Q0P8+)#*K(X#*I 8'E0>U;E%
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M?L>:SX@;4IOV>/AJMPS[RD&F^1;Y_P"N*$18]MN*^B_@Y\#O!?[._@6W\,>
M?"?ASP7X<M7:2+3-#TZ*PM$=OO/Y<2JNYL9+8R3U)KJ:* .'^/O[-/P]_:H\
M#MX:^)/@KPQXZT$OYJV6MZ=%>Q128($D8<'RY "0'7##/!KYQ\/?\&_/[&?A
MC6FU"V_9]\#23L<E;M;B\A_"*61HQ^"U]C44 8/PU^%OAGX->#[7P]X0\.Z'
MX5T&Q&VVTW2+"*QM+<?[$4:JB_@*WNM%% 'R9\1O^"%'[(?Q7\?3^)M;^ 7@
M&76+J8W$\EK;264,\A.6=X8'2)B22260Y)).3S7N/A/]DKX6^!?@?-\,](^'
M/@FQ^'=U"T%QX:CT6W_LJZ1L;Q+;E/+DW8!8N"6(R<FO0J* /G__ (=/?LL_
M]&T_L_\ _AO-(_\ D>O=/#GAW3_!_A^QTG2;&STO2=+MX[.RLK2!8+>TAC4)
M'%'&H"HBJ JJH    &*N44 9_BKPII?CKPW?:-K>FZ?K&CZI"UM>6-];I<6U
MW$PPT<D;@JZD'!5@017R7KW_  ;^_L9^(_$S:M<?L^>!8[II#(4M4GM;;)_Z
M812+%CVV8'I7V)10!YQ^SQ^Q]\*OV2M&FT_X8_#KP;X#M;KFX&AZ1#9O=$=#
M*Z*&D(]7)K"N_P#@H?\  6Q^'E]XLE^,_P +U\.:89%NK_\ X2:S,4#QDJZ-
M^\SO# KLQNSP!GBNG_:G\9Z]\.OV9/B)K_A72M2UWQ1HOAK4;[1]-T^W:XNM
M0O8[61X(8HU!9W>0(H4 DDBOXCM2_8P^,UEXBDTV\^$_Q.AU;>0]K-X8OEN-
MV>04,6[.?;- 'U=_P<*?\%>F_P""K/[7ZR>&;BZ3X2_#]9=-\*0RHT37Y<K]
MHU!XVPRM.R(%5@"L448(5BXKZD_X-&_^"2TO[0'QZ?\ :0\:Z;N\%_#>[,'A
M:&XC^75=: !^T*#]Z.U5@P/_ #V:/!S$XKRK_@EG_P &L?QT_;(\9:7KOQ8T
M75/@[\,8;A'OCK,#6NOZG$""T5M9NN^(L./-G5%7=N59,%:_J#^ _P "/"/[
M,?P?\/\ @'P)H=GX;\)>%[1;+3=/M5(C@C&222<EG9BS,[$L[,S,2220#KJ*
M** "BBB@"OJVDVNOZ7<6-]:V][97D;0W%O/&)(IT889&5@0RD$@@\$5\E_$3
M_@@A^QS\4=>EU+5/V?? $-U,^]_[,MY=+B+>OEVKQIS[+S7UY10!X1^S1_P3
M"_9[_8[UM=5^&GP>\!^$]:C5E35;;2TDU&-6X95N9-TRJ>X#@&O=Z** /PY_
MX/<_CY_87[.?P5^&,,WS^)O$-YXDN8U/(2QMQ!'N]F:_<CU,9]*_&O\ X(J_
M +_AIK_@JY\!O"+P_:;6;Q;:ZG>1$9$EK8DWTZGV,5NX/L:_I@_X*S?\&_O@
M'_@KM\:/#?C+QI\0/'7AN3POH@T6TT_1Q:FVQY\LSS'S8G;>WF*IP<8B3CKG
ME_\ @F7_ ,&SOPE_X)B?M3V7Q8\-^-?'7BG7--TZZL+2VU@6GV> W"A'E'E1
M*VX1[U'.,.: /TBHHHH **** /FWXY_\$?/V7_VE/&]YXE\:_ WX>ZUX@U*4
MSWFH_P!F+;75[(>KS/"4:1C_ 'G))]:[#X$_\$^/@9^S'X<UC2? /PC^'WA6
MQ\16C:?JZ6.AVZMJULP(:"Y<J6GC()!20LIR>.37L5% 'S__ ,.GOV6?^C:?
MV?\ _P -YI'_ ,CU[-\._AOX=^$/@K3_  WX3T'1?"_AW28S%8Z5I%C%965D
MA8L5BAC541=Q)PH R2>];5% 'FOQN_8S^#_[3.LV>I?$CX4_#7X@:AIL)MK2
MZ\2^&++5IK6(L6,<;SQNRKN).T$#)S6?\(_V"/@7\ /&D7B3P'\%_A/X)\16
M\;PQ:IH'A#3]-O8T<8=5FAB5PK#@@'!'6O6J* "N"^./[*_PP_:>M]-A^)7P
MW\!_$.'1VD?3T\3>'[35EL6DVB0Q"XC?RRVQ,E<9VKG.!7>T4 >!V_\ P2F_
M9=L[B.:']FWX!Q31,'1T^'VDJR,.001;\$>M>^8HHH *JZYH=CXGT:ZT[4K.
MUU#3[Z)H+FUN8EFAN(V&&1T8$,I!(((P15JB@#Y \??\$"?V-_B5KTVI:E^S
M[X!ANIG\QQIL,NEPEO:*VDCC ]@N*[_]G[_@E7^S?^RQJ\.I> ?@G\.?#VK6
MK;H=331HI]0@/^Q<RAY5_!ATKZ HH AU#3[?5K&:UNH(;JUN$:*:&5 \<J$8
M*LIX((X(/6OE_P"*_P#P1%_9)^->IR7FO?L^_#0W<S;I9M.TI=+>5CU9C:F/
M<3W)Y-?4U% 'R+\.O^""O['?PMU>&^TO]GOX>S7$)RG]J6CZM&#Z[+IY%/XB
MOK+2-'M/#^E6]C86MO8V-G$L-O;V\8CB@C485$50 J@   #  JQ10 5\S?M!
M?\$:_P!ES]J7QU=>*/'7P1\#:UXBU"7S[S4H[1K*YO9#U>9X&C,K'U?)-?3-
M% 'B?[-?_!-[X"?L>ZJNH?#+X0^ ?!NK*C1#4[#2(AJ.QAAE^TL#-M(."-^#
MFO8M<T*Q\3Z+=Z;J5G:ZAI]_"UO<VMS$LT-Q&PVLCHP*LK D$$$$&K5% 'R7
MJO\ P0B_8\UGQ VI3?L\?#5;AGWE(--\BWS_ -<4(BQ[;<5V7Q]^+GP;_P""
M.O[%&N>,_P#A$]/\&_#/P8\#S:3X1T>WM\R75U#; Q6ZF)&=I)4+$D$@,>2*
M^@J_/#_@YE_8\^,_[<W_  3NM? GP7\/Q>)=4/B:UU36;'^T(;2:XL;>&<[(
MO.9$=O/:%MNX$^7P">* /3],^-7[&?\ P6L^#FGQ76I_"OXMZ/&3<0Z;JYB3
M5='D8 ,?(EV75JYX!8!=P'!(KYM_:0\8_P#!.O\ X(7^$;[QUX7\%_">;XI6
M,,Q\.:/IDRZQKD]Z%RBJ[O,]G'NP&F8H%7<!N)"-_-W\1_\ @G5\?_@_>S0>
M*/@E\6-":%RA>\\)WT<3$''RN8MK#T*D@]B:O?"G_@F'^T9\;]9AL?"WP-^*
MNK33=)%\,W<=N@]7F=%C0>[,!0!YQ\>?C3KO[1_QM\7?$#Q/<+<^(O&NL76M
MZC(@*QF>XE:5P@).U 6(5<\* .U?U3_\&K/[#NH?L=_\$M])UCQ!IYL/$WQ<
MOV\77$<BXFALI(TCL8V]C"GG =1]I(/.0/B3_@C?_P &CFM>'_B!HOQ(_:F&
MEQ6>DRQWUAX!L[A+PW4RD,O]I2KF+RE(&8(F<29PSA0R/_0##$L$2QQJJ(@"
MJJC 4#H * '5\Q_M#?\ !&;]EO\ :J^(=SXL\>?!/P7K7B6^E\^\U*."2RN+
MZ3^_.UN\?G,>[2;B0,$XKZ<HH \U^ G[''PI_9<^'EYX3^'GP[\'^#_#NI!A
M?6.FZ7%#'J&Y2I\_C,V5)7,A8X..G%<3_P .GOV6?^C:?V?_ /PWFD?_ "/7
MT!10!A_#;X8>&O@SX(L/#/@_P]H?A/PWI2LEEI.CV$5C8V:LQ=A'#$JH@+,S
M$*!DL3U)H^(_PT\._&'P1J7AGQ9H.D>)O#NL0F"^TS5+1+NTO(SSMDBD!5AD
M X(Z@&MRB@#X\@_X-_\ ]C2W\1-JB_L^> S<L^\HT<S6^?: R>4![!<>U?3O
MPC^"O@[X >"X?#?@7PIX;\&>'[=B\6F:'IL.GVB,< L(HE5=QP,G&3BNFHH
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M^V/\/_A/X?AFDNO%VJQP74R#BQLE_>75RWHL4"R/[[0!DD _W%>&_#ECX/\
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M^QCXMUM]0NOV??!,,\CF0K9?:;&#)](H94C ]@N!Z5[9^S+^P-\%?V-(YO\
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M:?JZ6.AVZMJULP(:"Y<J6GB()!20LO)XY-8/_#I[]EG_ *-I^ '_ (;S2/\
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M&0#@CJ :^6(/^#?_ /8TM_$3:HO[/G@,W3/YA1HYFM\^T!D\H#V"X]J^PZ*
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M>V*^@J* /(OV6_V"/@Q^Q/9WD/PI^&GA'P*VH*$N[C3+!4NKM1T62<YE=1U
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MJ[#.&\N567<,G!QD=J^6+S_@WC_8MO\ 5S?2?L_^#UF)SMCGO(X?^_:S!/\
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M_%6DQS>=9_#?0M,\,PD'*[O)-[*![B6]D4^Z>U=A_P &G'_!.?P#^WA^T_\
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M ?V9?AW^RMX)7PY\-O!/ACP-H>[S&L]%TZ*SCE?^^^P N_\ M,23ZUP&K?\
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
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M>)]7N=2NK^[D \SRVG=VBMUP%CB!PJC)R[.S>STUY%B1F9E55&22< "OSO\
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MYR(Y'*X((!X/E?P&_P"#R#]ESXJ>+;/2/$VB?$SX=K>3"+^T]3TVWNM.M@>
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M=6)-?TZ?$CQY8?"SX=Z_XGU63RM+\-Z=<:I>/G[D,$32N?P537\H_P#P;<>
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MWC;PWX?^*DWBI-2\56,FH6*Z1I?VQ?*CD\LESO7:=W0<]#0!]=T5\B_M _\
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M/US6O"_CBX#-:>'?%5I'8WNHA4+N;=HY)89BJAB463S,*S;=H)K[@H ****
M/QB_X/5_CW_PA?["_P ,OAY#-Y5UXZ\7/J4J@\S6NGVS;UQZ>==VS?517K?_
M  :(_ 7_ (5'_P $@=+\0RP^7=?$OQ-J?B LP^<Q1NMA&/7;_H3,!_MD]Z_,
MO_@]!^/G_"??\%%?!/@.WF\RS^'W@Z.69,_ZJ\OIY)9!CW@CM#^-?I$O_!:/
M]G'_ ((5_L:_!_X)>+M0USQ-\1O!W@[2[36/#7A6SCNKK3KMK5))FN7DDBAA
M+3,[>69#* X.S!!(!^JE%?EU^Q__ ,';7[+_ .U'\2M+\)ZU#XR^%NI:Q/\
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M%K^L*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\HW-M?011,1TW;+N8 ]<$_A^P7_!<_\ X*HVO_!*#]B74/%]@MA??$#Q)/\
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M!?[<_:,^-GQ,FA^3PUX>L_#EM(PX+WUP9Y-ONJV" GL)!ZU^V/\ P5@^/O\
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M/XF6NI17F@QW,DUO:7-B;7,T)D9G59%NU!3.U3'D8W8K]Q/^#>/XBZM\4O\
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M!_\ "P_^"E'BKQQ<0[[/X=^#KAH9,?ZJ\O9H[>/Z9@%W^7UK]./^#O?X]_\
M"I/^"0]]X;AF\NZ^)GBC3="**<.88F>_D/\ NYLT4_\ 70#O7D/_  90? +_
M (1#]BKXJ_$::'R[CQQXLBTF%B.9;;3[8,K _P!WS;V=?JAH _::@T44 ?B7
M_P 'NFH6L?['_P %[5_+^W3>,;F6+/WO+2R<28]LO'G\*]S_ .#0K1KK2O\
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M\\4_\%1/$WQNU?3[#QA*GQ$E\3?V=J#-]DU"&&^\V*U?:0PA\J-(\ \( .:
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M ."-?QTOK^15;7-"'AZTCX+3S7TT=LH4=\+(SGT5&/:@#\\_^#([]I36-?\
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MN&.I^.;T2,;F1KER72!9,J\HR\CEU5D*,PQ_^#OWXQ:K\6?^"N4/@M9FFL_
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M16)4VGI;VSKD$J3_ %3QQK%&JJJJJC  & !0 ZCI110!_,=_P>C?'K_A//\
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MT44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M*#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB
M@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*
M** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1
MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
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M8L^+WA>Q\[[;XD\$ZSI5OY0/F>9/8S1+MQWRPQCO7Y&?\$A/^#9;XW_L9_\
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MGZ5HMIKFJZC#?6\,$"^:)$BL98QFX>X8;7.58$X.0/D'_B"J_:F_Z'[X ?\
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M5(!P1''"I 96K^DO_@WY^"L?P'_X(W_ /25B\N35/#2>(I3CYG;4I9+\$_\
M ;A0/8 =J_-K_@IK_P &CWCCXT_$OP):_L^ZQ\+?"_PZ\#^#+3P['!XFU.^A
MU2]O$NKNXN+N8P64R2-*]SN+[AS\H54517[<?LX?"Y_@?^SSX#\%R-;O)X/\
M.Z?HC-;DF)C;6T<)*$@';\G&0#CL* /Y3/\ @I=J=U_P3C_X.2O$WCK4]-OO
ML?AWXHV7Q"6%5VMJ5G/<PZC((B>"'#RQYS@,&'!!Q_6%\'_C!X7^/_PRT7QE
MX+US3O$GA?Q%:K>:?J-C,)H+F-NX([@Y!4\JP((!!%?#W_!<W_@@IX5_X*]>
M%-/\0:;K$?@[XO>%K%K+1]8EC,EC?V^]I!:7B*"_EAV<K(F6C,CG:X.VOQ]\
M!?\ !M?_ ,%%/@3J5UX=\$^(X_#NAWCLL]UH'Q%DT_3K@'@LT:-'*P; ZQ9Q
MU% ']'>N_ME_"WPW^TCH/P?NO'&@_P#"SO$L<T]CX:AF\_4#'# \[R2I&&\A
M/*C=@TVP-C"EC@5\*_\ !V_\%K[XN?\ !';7-0T^SN+R3P'XETSQ'*L*EFCA
M!EM))"!SM5;LL3V )/ )'!?\$%?^#<3Q9_P39_:'N_C5\6/'FB>)O'%UI%UI
MMMI.DQ37$%D]P\;/<O>3;'EEV*Z%1$ /,8[VXK]7/B%X T?XK^ M:\+^(M/M
M]6T#Q'83Z9J5E.N8KRVFC:.6-A_=9&8'ZT ?B'_P9:_MN^%1\"_'_P  =4U6
MUL/&%OXBD\5:+;7,ZQOJUK/:P131P*3EVA:UWN!SMG!'"L1^W7Q#^(_A[X1>
M"]0\2>*M<TCPWX?TF(SWNI:I>1VEI:(/XI)9"%4>Y-?SK_MQ_P#!GE\8/A5\
M9IO$7[,_BG2_$'A8S_:=.L=5U8Z9KVBODD()]HBE5>-LH>-^0"G!=L7P?_P:
MX?MR?M<ZOI-G\;OBI::/X=LF&7\0>+;KQ-=6*8Q^XMU9XRV.QFC&._:@#^BG
M]GW]H/P;^U1\(M)\>?#_ %R#Q)X1UXS?V?J4,4D4=V(9Y()"HD56VB2)P&QA
M@,@E2"?Y*/V"/B=HO_!*'_@O?8S?$*S^Q^&? ?C;5_#&MK<1!UM+6;[38BY8
M$',<7FQSY7)*QY7.1G^KS]C']F/2_P!B_P#92^'_ ,*=&NI-0T_P'HEMI"WD
MD0A>^>-!YD[("0IDD+N5!."^,GK7Y\_\%S_^#:30_P#@IYXWD^*/PXU_3/ ?
MQ;EMT@U(:A$[:3XE$:A(FG:,-)#,B +YJI)N5%4ID!@ ?J!X,\0:/XM\*Z?J
MWAZ^TW4M$U.!+JQO-/F2:UNH7 9)(W0E61@00RD@@UYO\9OV\O@]^S[\7?"7
MP_\ %OQ T#2_'7CK4K;2M$\/K*USJ=Y/<.$BS!$&DCC9B!YL@6,=V%?SJ^ ?
M^#<?_@H]\&))/#?@_P 33>&] F+(\FB_$E['3G4G))B1U<@GG'E9]1FOLK_@
MCM_P:O\ CS]E#]KOPM\<OC=\2- U;7_"5])J5GH6B"?4!>7#1.B2W-Y.L9#(
MSA]J1ODJ/G'((!^R/QV^*ME\"?@AXR\<:EM_L_P;H=[KEUN.!Y5M \SY/^ZA
MK^7O_@T_^%EY^TE_P6KM_&VKDWMQX+T36/%UW-(.)+F<"R#'_:WWY<>Z9[5^
MWG_!S!\>_P#A0?\ P1C^+TT,WDZAXMM[7PM:#./-^V7,<<Z_^ OV@_A7\ZG_
M  2]_P""*O[1'_!0SX4:]\4O@CJF@Z7_ ,(?K0T7=/K<^E:A+<>2DS&"18]F
M%26/=ND4_., T ?V(>)/$NF^#/#]YJVL:A8Z3I>FPM<7=Y>3K!;VL2C+222,
M0JJ!DDD@ 5_,7_P<R_\ !92S_P""F_QH\,_ WX*S7GB;P#X3U4.;O3E:8>,=
M:D'DQ?9HU!:2*(.\<9 _>O,Y *^6QDU3_@V[_P""C/[35W!HOQ$\7>=HZ,(U
MF\6?$>;5+.%5.01'&UP^!C( 3/L*_5+_ ((Z?\&U'PP_X)@>)+#X@>(M4D^)
M?Q=MX&2'5+BV$.FZ$SC#FR@.6$F"4\^1BQ4G:L>Y@0#V?_@A1_P3C;_@F-_P
M3N\*^!=35?\ A,M<D;Q)XK92"$U*Y2,- ".HABCAAR"0QB9A][%?SX?\'%GB
M5OVC_P#@X'\8>&]3O!8Z39:EH/A.&:5MJV=N;6U\UR3P%$L\SYZ '\:_K4K\
M1?\ @OO_ ,&Q_C[]N[]K'4OC=\%=<\,_VMXJMK9/$.@:W<O9E[BW@6W2XMI@
MKH0\442M&X3#(S;FWD* ?M7;#3?"-AIVG1M:Z?;@)96,!<(&VH=L: GDA%/
MYPI]*_+W_@\.\!77C#_@D"=0M_-\KPKXWTG5+G8#CRV2YM!N]M]TGXXKY_\
M^".W_!NA^TA\ _V\/A]\8/V@/&V@:MH7PT%S)IFC?\)!=ZQ=M,]K+!#LWIY4
M4<;2+)P^<QJ-M?LW^TC^SYX9_:N^ OB[X;^,K,WWACQIIDVE:A$I"R+'(N/,
MC8@A9$;#HV#M=%/:@#\C_P#@RH_:&\.:Y^Q1\2/A=]NM8_%WAWQA+XA:Q+JL
MT]A=6EI"DRKG<X66VD5B!A=T0)&\9^XO^"R__!7CP3_P2B_9FU36+[4-.U#X
ME:U:20^$?#7FJUS?7+!E2XDC!W+:Q-\TCG .W8#O917XK?&?_@TG_:P_9D^-
MESJWP)\8:-XCTJ&X(TC6+'Q WA_6[>%L?ZY6V*K#H3%*P8#.!G:/J?\ X)=?
M\&K_ (S\'?'"/XQ?M2^,--\;>+M(8W>B: +Z?589+U1F"YU"ZE ,BQ/\P@4,
MK$*6<J#&P!^2O_!%/P3J/[8__!;7X+MXBN9M:U36/&Y\6ZK<W'S/?36GFZI,
M\G8[VMV+=CN-?UG?\%!_CY_PRU^PO\7OB(LWD7/A#PCJ6HV;9QFZ2V?[.H/J
MTWEJ/<U^4'_!#W_@V;^-G_!-S_@H5X?^+OQ$\5?"C6M#T+3=0MT@T#4]0N+W
M[1<6[0*P6>RA3:%=\G?GGH:_1?\ X+2_L:?$+_@H'_P3P\9?"'X9ZMX7T/Q!
MXPGL8YKK7KF>WM%M8;N*XE7?!#,X9O)5<;"""P)&: /PO_X,P_@)_P +"_X*
M/^,O'=Q#YEI\/?!\PADQGRKR]GCACY]X$NQ_DU_3U7YP_P#!NC_P1D\9?\$@
M?A3\2[7XAZQX-UKQ7X\U:TE$WANYN;BV2RM87$*L\\$+;_,GN"0%( *G<22!
M^CU '\WG_![9\>?^$D_:L^#?PUBFW1^$O#%UK\Z*>!+J%SY(#?[02P!&>@D]
MZ_:7_@BW\!/^&:/^"4WP&\(O#]GNK?PC::E>18P8KJ]!OIU/N);AP?<5^;7_
M  5W_P"#:?X^?\%+O^"GOB'XM6WC3X4Z?\.]5DTNSM;.]U/4$U6UL+>V@BG7
MRTLGB\QI%G=0)<'>,E><?M[I^GP:3806MK%'!;6L:Q0QHN%C11A5 ]  !0!_
M*M_P=Q_";5/A#_P6-OO&"V]S:V_CGP_I.LV-YM/ERRVT0LF"MTW(;5"1U 92
M?O#/]*?["_[9O@[]OK]E[PG\4/!.I6=[IOB*QBENK:*=9)=(NRBF>SG /R2Q
M.2I!ZX!&58$^0_\ !83_ () >!?^"O?P$L_#?B2^NO#GBKPS)-=>&/$5M&)9
M-,FD51(DD9QYMO)LCWH"I)C0AE(Y_"_1?^#8G_@H!^R]XWO+7X:>(M.L[:ZD
M\N35_"GCV32(KA,'#.K&";&"1@H2.<9') /Z/?C/^V7\+?V>OB%X0\(^,O'&
M@Z'XK\?:E;Z3X?T62;S-0U2XGD$4?EP1AI/++D*92HC7/S,HKX4_X.XO@W>?
M%7_@CIKFI6=K+=-X#\3:7XAE$8W-%%NDLW?'7"B\R?09)X!-?.__  1^_P"#
M7[XI?L[?MH>%_C[\?OB1HFLZ_P"%;V34K;1;"6XU:?4+@PR1QRW-[-LVM&[B
M0!5DW%%^9>:_:;XB_#S1/BWX!UKPMXETRUUKP]XBL9M-U*PN4W0WEO*ACDC<
M>C*Q'XT ?AG_ ,&8G[:/@&+X0^./@3KUYH^G^.U\0OXFT!;QHXYM8MIK:&*6
M"W+<N\+6QD9!SMGR 0K%?W@OKZ'2[*:YN9HK>VMT:2665PB1(HR68G@  9)/
M %?SE_MQ_P#!FW\4O /Q4NO$'[.'C+0]>\,M=?:K#2M;OWTW6M'.[<L:3A3%
M,$XQ(6B?I\I(+'B+#_@VQ_X**_M$:)#X;\>?$"&Q\-PL$6U\3_$6[U*SC0'J
ML,/V@8[@8'X4 ?T,_LY?MR_"7]KSQ;XRT7X8^.M%\<7?P_FM[?79=)9KBSM)
M)Q*8T6Y"^3,3Y,F?*=]N,-@D9]8KXM_X(A_\$@+'_@CU^SCKGA,^+/\ A-O$
M7BW55U?5M32P^Q0HRPI$EO$F]V,:8<AF;+&0G"]!]I4 %?GW_P '0?Q[_P"%
M$?\ !&/XH+#-Y.H>-I+'PM:'.-_VFY1IU_&UBN*_02OCW_@M3_P2<M_^"OW[
M+VF> 9/'.H>!;SP_K*Z]I]S'9K>6D]RD$L*K<1%D8KMFD *.I4L3ANE 'YP_
M\&07P0BLOAE\=_B1*L;S:EJFG>&K5N-T*V\4ES,/7#FY@_[]_6OV<_:?_:N^
M'?[&/PCU#QS\3O%FD^$?#6FJ2US?3!6N'P2(84^_-*V#MCC#,W85_-[J?_!J
MA^W)^RYXTGOOA?XF\,W\K92/4_"OC";1KIX\Y ?SE@93T.T,P![GK6WX$_X-
M1/VSOVL/B%9WGQL^(&BZ'8K(/M6I:[XEG\2:FD;'YO)C0NKMP.'FC!_O4 ?/
M/[1'Q0^(7_!S!_P6/L;;POIFI:?I6N3PZ/HUO(OGKX4\/P/F2[N-ORKC?+._
M.#),(U+93/\ 63\$OA!H?[/OP;\*> _#-NUKX=\&Z1:Z)IL+-N9+>WB6*,,?
MXFVH,GN<GO7S[_P2T_X(_P#PC_X),?#.^T?X>V=YJ7B#7A&VN>)=59)-1U4H
M/E3*J%BA4EBL2  9R2S?,?JJ@#\.?^#WCX*_VS^SC\#_ (B)#SX=\1WWAZ60
M#J+ZV6= ?8'3WQZ;CZU^9_[8_P#P4Y\6_P#!0?\ 8L_9/_93\ 6NJ:BWA/2+
M'2]3LH%82ZYK:R/96-LH/WDBMQ&5/W2]PV?]6IK]E/\ @\0^,'@7PI_P2VA\
M'^(+U?\ A,O%OB2RN/"UB@#2.]JX:ZG89RL202.A89^>>(?Q$CY/_P"#/7_@
MD]_;FM7O[5'C;3<VFG-/I'@&&>/B6?F.[U$ ]D!:WC/(W&<X!130!^NO_!(;
M_@G#H?\ P2Y_8@\+_#/3Q;76OE?[4\4:G$O_ "%-5E5?.<' )C0*L4>0#Y<2
M9Y))^G:** "N/_:%^+EG^S_\ _''CS4-OV'P5H%_KUQN.%,=K;R3MG\$-=A7
MS[_P54_9I\<?MC_\$^?BA\+?ASJ>@:/XN\<:6FE6MWK4\T%C'"\\7VD2/#'+
M(-UN)E&U&RS ' R0 ?S?_P#!JE\([S]I#_@M?H?BK5-^H2>"M*U?QA?R2#(D
MF>/[(KM_M>=?(X]UK^L*ORJ_X-S/^"#?Q"_X)%^.?BCXF^)^N> =>UCQ=8V&
MF:.WAF\N[E;:".2:2Y$IN+: C>WV;:%#?ZMLXXK]5: "OEW_ (+7?'O_ (9G
M_P""4'QZ\6+-]FNH?"5UI=G+G!BN;X"Q@8>XEN4(]Q7U%7Q;_P %Y_\ @G_\
M3/\ @IE^P@WPH^%^M>$-"U/4O$-C?:I-XCNKFVM9K& 2R&-6@@F8R>>+9@"@
M7"-R" " ?CQ_P97?"W2[K]L'XN?$75+RPM5\(^%;?1;;[3.D>)=0N?,WKN(R
M1'82+D=!(?6OZ+_$/QT\$^$;3[1JWC'PKI<'_/2[U:"%?S9P*_FK_P"(*K]J
M;_H?OV?_ /P>:O\ _*RK6E?\&4O[34T^+[XC? FWB_O0:IJLS?DVGI_.@#];
M_P!O'_@Y?_9;_8H\-WRZ;XVL?BSXPAREMH/@ZY2^5Y/^FUXN;>% <!OG9QSB
M-B"*_GP\>^./VC?^#E[_ (**6D=OIXO]6NP+:QLK<.FB>"-)#DEY'P=L:[BS
MR-F25R%4$E(Q^F7[,/\ P9'^'](U>WOOC%\:-2URU3#2:3X4TI;$,1S@W=PT
MA*GH0(%..C ]/V)_8\_89^%'[ WPN7P?\)?!>D^#]&9EDN?LRM)=:A*!@2W$
M[EI9GQQN=C@<# XH S_V)?V1? W_  35_8[\-_#?PW);V/AOP3IS2W^J76V%
MKV;!DNKZX;. SMO<DG"+A1A5 '\N'_!4[]L#QE_P7U_X*S:?H/P]ANM2T2ZU
M)/!_P]TY]R1K:^8=U[*,?)YK;[B1R,I$JJV1$#7](7_!:?\ 97^-_P"VY^Q#
MK'PJ^!_B#P5X5U+QE<)9^(=0\17UU:J=)VL9K>$V]O,VZ5A&C;@ 8C(O.[CY
M'_X-\O\ @W(U[_@EK\9?%'Q-^+FL>"?%'CB2S&E^&/\ A'I[FZMM)@DS]JF9
MKB"%A/( L8VK\L?F#<?,( !]?_LJ?\$6_P!G3]FC]G3P?X$N/A%\,?&-YX;T
MV.UO-=UOPG87NH:O<?>FN)9)8V<EY&=@I8A%(4850*]!_P"'9W[-_P#T;[\$
M?_"%TO\ ^,5[=10!^!/_  >*?L&?#GX'_LM_"'QU\/?AWX)\"K9^*;G0M1;P
M[H5KI?VS[5:&:+S?(1-^W[%)MW9V[VQC<<_8'_!H[\9O^%I?\$;/#NCM-YLO
MP^\2:MX?;)RRAIA?J#]%O@![ #M7N7_!=+_@G'XA_P""I/[ .J?"_P (ZAX=
MTOQ8NLV&L:5<Z[--#8QR0R%9-[PQ2NN8))@-L9RQ . 21X9_P0A_X(R_%S_@
MFQ^RM\:OAC\3/%W@FZM?B1*)=(NO"5[=W3::\EI);7$K_:+>#:V/LY7;G.PY
M(P,@'V%\&?\ @IO^S[^T/\;[[X;^!_B]X&\3^.+ RA])L-222:8Q9,ODG[LV
MP!BWE%L!23P":]UK^>;_ (),_P#!KM^T-^R7_P %//!?C[QQJ7@_3_ _PVU9
M]435--U,W$VNA$=8XX8=H=!(67?YNS:F_P"\< _T,T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_8-_9W\/_#'X<Z0FD^&_#\.T%L-<7\YP9;JX< >9-(WS,V .@ 50JCU$T44
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MHHH *.E%% !0:** "CI110 4&BB@ HZ444 %!HHH *.E%% !0:** "CI110
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M* "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ KXI^-?\
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MTHHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M%'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#11
M0 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-
M%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "
M@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH
M *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2B
MB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=
M*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !
M1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44
M %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#1
M10 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H
M-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M"@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THH
MH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2
MBB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4
M=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M!1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T4
M4 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#
M110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
MH-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=***
M "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1TH
MHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'
M2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110
M4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%%
M !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T
M44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *
M#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=*** "@T44 %'2BB@
M H-%% !1THHH *#110 4=*** "@T44 %'2BB@ H-%% !1THHH *#110 4=**
M* "@T44 %'2BB@!,T4?G10 M%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.
M] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%
M'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.]
M !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'
M2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH
M**!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T
M=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH *
M*.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=
MZ "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10
M.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0
M 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11W
MH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0
M44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH
M[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B
M@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>
M@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BC
MO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@
M HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I
M1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %
M% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.
M] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%
M'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.]
M !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'
M2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH
M**!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T
M=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH *
M*.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=
MZ "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10
M.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0
M 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11W
MH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0
M44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH
M[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B
M@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>
M@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BC
MO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@
M HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I
M1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %
M% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.
M] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%
M'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.]
M !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH **.]'>@ HH'
M2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH
M**!TH[T %%'>CO0 44#I1WH **.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T
M=Z "B@=*.] !11WH[T %% Z4=Z "BCO1WH **!TH[T %%'>CO0 44#I1WH *
M*.]'>@ HH'2CO0 44=Z.] !10.E'>@ HH[T=Z "B@=*.] !11WH[T %% Z4=
;Z "BCO1WH **!TH[T %%'>CO0 8HH%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mgnx-20211231_g2.jpg
<TEXT>
begin 644 mgnx-20211231_g2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
M                                                    /Y*M%BCW
MH     (+)/.E      *O$]'3@     A4[LZ\                    &)N@
MV4<<47[#73=2_27;<*]F    #)3!R*A\77U&%XU[]-EW5_Y0    !BMF8V0W
M0E2=]5DY^L&!2OHP    9:?3\8*WW5730F2_7A6TS]^  ?/V7=.M*\DADCD^
M&6A;@_<]J>L(]+B%@BGI3$E,D<K.3P?D2.5_)X(@.R.*.A-'0  #!2&[VT'G
M/U'R6VPHE]%>7MTM_K0   *P&.7&UZWPYWL_.+I^HOH]ZRICW@    !@1M<"
MCO5=$^/\OW;OER\?HFT^Q    @,^6.[*TDJW*_ARJYU]>%%VC(( /R,PR0C\
M#FB2BE)H\5S/(.D.G(P)!)K)U*P$!G='%GEG:F?1I&0X>\.[(7.F/V+_ ( .
M8/G^BVW\C796D4ZCV5_,-N:)<F714&X8/H-W=SG?3]   /2GSA4I/M&^&>AH
M.FV@['T.YA@W$^WK8QMM#I]'+Y?T  /6GS>[+#]5G8^KL?VF"%I0;K;VJV.H
M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
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M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
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MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
M00,&TX(@T;ML]C:VU_-/#;D/A*-<B._1V5?%D4]1K:K\Y\*88 HLEZL(ZF(U
M9+:OFDBNHM++':ZD#4SS*P).T2B!2-5"'5PM&42.:P>_29M*^&M>%?R'7M=V
M<DBB2PK<:75LI: &U[6;4J/V]S5^NZ M#=M4@[Z@1<-/XJ7.(4E4K(6L=9.G
M.+V]5XLK:M+%BCA3EA*9<Q$$[18"\)A\*_M@WIB:-O1F&Z-5NU,:N5U KF+\
MLV\'KUL]K9S,U*J902Y:GH8Y6LK: OL&(X>5UM YSF)U?7T&-U(8Q'98@9Z(
MJ%A7<1*Z^A4Y!%JGKB%*M/D>8I.@;*$IYH6XQ@..&ETH;(7&G&7^281." )T
M=GJ20R/+@@">8XMY1YR]"F._TCN9\^HK&0/G\ARV-5LM5@@D>DI\SB4:_=J]
M:WH908"'AG<__P!+,E30AA?.W..*3E,DFC<F*62N+-SKU9+,HW$.JNF4;;9/
MINE$:>%_1*)E&(6G0S*-N4GZ%ZY*UH(Y(V:6LG5SG <,DKBTFTZ2N+,BWJRN
M8QN#MW4>9E&X\\:2RB-+W;HE<RC$';B9E&SY;T&& )+BDMC\X9.Q>)Y!X\L7
MRR,MD?0KDCFBZADKC94C4776J:1,+\T2=HTZ6# F-<A7H'--^Z(U][?)=%(P
M(B91!4T_RQ5FBS"SB^PL+V#M]4_QG)S\GS"P5,VM&Q;#/W#SH=71::6LPW B
MLFY[#CRZ]I5+&>X$LX1-3G-[,G=FJMPDV3U$V3:X(O:]IVM/(@N6O>9->E@2
MLB#PJO $57+93-K7<[CE,XG\\V]R-;:$6@IB:QENY%'N1DB6F!S6W*TG+C/K
M>LE'!K#DE=P6"3V13*U.H[<JH(TRNWNQ31SQ_<YO9D[LU5N$FR>HFR;7!%[7
M33RX;,7&[AI1(('?**P&^KI1.K"D]L"O2>H*T3V)<<<F=M63-HJYR*4'364R
M9^1Q:/1A2&!KIK-[247&^S>Q)I2+ZMM"+T_(29VJW0-.X:3,M:KI[<M:K54^
MMZ?3*L[#DE:U=$I[(I7<?86#D@.YN!.21AVYS"U))'!3JQ[%8%,5M:<Q6:D;
MEY4F:G&;6?.K/6NK_P#SO $]H)(F1:<M_:<(2SA$U-D3C,OW4UVF;ZMW GN6
M<$;AW)G/LBC&".3NP8C7,#5[F"22DY/821J&^QV0[=%#]33I2/BM+I4D_89V
M+;<)/7SO72MRM\%#V/&T$DV]FE,[Q4D_EK2^U-.FFP5FVP\=3RVNE<DL@[;U
M-"4C?3S@BE5QUVYV?'I]MF@$@C,:K1[;+0142J!"%=,6%(8#(:AL@NR"=LZ+
M-1-M26!(9>.A)ZU.EC5^VP_:WMRB2B*59U%9'F4AFW10JHUSH,1M8/M33IIL
M%9ML/'4\MKI7)+(,I6QHRYO.V\LN#26H[)G<-EU4S NQO_SPO'6DJJQ;('!=
M1$Q ])*0<TVKA@SS8\)F&V:M7F)Q*J) SS]#2"@#*II&PWVL9=4L]4V8T[;R
M<UJEIBQ)&Y*Z2G;7-I)6+? MK^V2)*(U5O82NIY\?:I.WQ85 I=75EN$?L&N
MU\-<(;23UE_A]0VS"TS_ %!/6VQ$=7/!5FQRGG!DB+KM_?OVU VJ9M33(*?L
ML%I$[?G9)&3-LU9"A;51DE(5,M6+XY<3#6:UHN3ME;DW-X^MA]8Q+@B",/8F
MDDG@[)<Y-S6#K"?&4#B 8# =B:44>#\NQ6N3<V](BBABZ?OK)]P"((P] #2C
M,\'*C<RO=#-%+(?=<@M@VOE<+O@MT VW\^_1\N:1G31([HQ7M#%2[%;YM5+#
M(?/W[[VI:+)MDW<"QWZC7PR/2AXD%?T/:L]<FP6Y&3DL214G7)>UM,W,FOZU
MUC9F\'FT4M6-<'N]0[2 C<6\8:I7<#ZGG1[PB5WI$ECXI1LUKM4(K6VI -YA
M#K9-LI-PK#>R-P985*W&7P2E+.LMZE9FY"3',;,[(7]H[2?FYE&Y.QE309=[
M]:H:U+A%YY=5Z+<(]^4DEQR'$X"\(C[TAJMU-B2&UT4-A%G/WWIG4V=<*:_*
MOG,8C862\)#EU9+FDDMEUOODBCE;P6ZG]BIEMO*4H)'VST7F.;L+0'<<N1/4
M>EM;V$PU-/)RIK^HW%M48CUM5=9\9ATT*O:,5;.F[;^_5Q9$?-E4?M6PS7&/
MV-&+_NB!K55\E%%D%06O;$;4!D/O%XJQF;"65G[6QB\L&Y:S5]NNV)-#9966
M8W6\]G\SA]+.S2F>HW:%>W(BB$^7W;$*WF37 EE5V9'V2P6&V+1A4WC]C,5X
M7]"'$ZZ$B5.A2P^%V"Q3E)$+S;*LA\>+B44[28EYCVZ:SE-P2)._Q66UI((Y
M5\\GD@@U.NC7A9'+5K6VV6'SHR\(C64V:Z<<*SLR,XG$?M6R6:11^QHW?1E+
MRU\;:SJ]6WN\SKR>2N?S=E4R2%AK2SIO1*^/VS;\G[9[B<=D:K2R)QYPD78?
MLZ-?NG@9%$X[+"M.T3CSZZ]@;#HT?*> ?XG'90/3C$X\[/G';@7"X8,VLLVD
ME;-[/=T%>HJAW'5:X)(Y>T1DDG+W$UP:X.NXDMHN*6R--$8Y%-P,J7EV/8EP
M,%H7X]ND'>^"ODZVHNT1"<2V%QR-W5"I,T-.XZK7G3)N AKW(3=Q5<%KYIN&
M!$+:=WI,S,K5N-E"IBNG^<HZWSR?2PRHBC2SRNTG;1,WIGK:3W/(U+%N"@;Z
M_/.X.N&.1/FXZO6)4]7?#F?-E;A6QBK'^>8:5&XI*$,O:9=>ZQ@M6+SZT)+2
M^W*9R2>5I.K)CE?89[N@KU%6C<=6+W(IG>]?P:1[8) [R6OIM=9\;N"OY1;-
MJU+3TPL)RL3;7)7=TB7;;I$2Q?3-GRF6QHAA:'D<6M8DMHVKP!S22>:1=J:C
MH5,';%=;C+N^]_Q;!X'8B*S+[G"%SL+<Z[IIC57!;ATJE;3,ND<TB581=N<U
M3G)4N&?9C7SRA?9_&6MO20NS%8:WNFQ3G?-=PN 6,0]7!.QS*Q+[E;/(MNK(
MC,;F7M:MQ+H['0KWR9/=/M)Z>Y6UY1N#-.#!M%VO\+2@VR3Z5UM/H=0#W.G^
MOYRP648_D.V:DJ/:0_%)H=?$ME4??F%H>1Q:<,B[-9 ?AU)?&U1N<6RN9XQV
M.HLQ7))U2^W_ &Y/$+;,[: Y7/7 V'7+%933&:=;&24]62UVTRN6\+8$ 8;*
MCK'2S<ADG5F==M,Z=. ,+ :6#;7'R&UN;T;2W]JM(&J1UY F6M8K_P"-O__:
M  @! @ !!0+_ &RNC@4UH#YO(C3XI)</R?LU*@E(0X3UZ/4Q&4C?,=HG(&I/
M)CS866],_P!O%V8 ",$CC:(LI\90(0_A3^VY=F@TLPDQM<%#6M;'%.ZHNRG,
MB\Z?JNVH[QNT0J?**RC '%J""U)*Y&8@4]E'&ON!U)U@ )_PA>Y@1Y2/03C-
M3R.^('4/D/V9;C/U[&92+[0DTP,ISXX)TY*0A8M*1@)?0"'^?8$)LG:,0]T.
MHZZ>"9IY;<.";.,ASV#(V?<%&,8QA>M+0)CSS%)Q10CA"09^F<?3\&=RQ@6Z
M:5_F ""$099'Q,:[4$D7F2NN[.:=G0KURAR6$DFJ#8XQE,3><: @M4I&J.TE
M (M-UT0L9*TL([N=,3IYXC4D:_IV"5,:K/1I"D2<0L!"\.67%2$.19)*P2#1
M^<"._!5J0*PDPL10RS!E#1J@*R7=K3O"!<B4-RL@\U,='GHI\;^J(00AED@R
M]KM02.^ 7IT7>:,TSH/KGL"C,E# + PYQ@6#R<DC2J349Z144M3B"$87=N$W
M*>LQ-?D2-2-TZ$A'AXTL/[N/P=V0>.#2%8)&< 83 S2._=4FHZ]FL3@2<4H)
MZD\D7<#J(1[+TMQC&,/"_NXTW(LK#L8P''8I3_"%HXK!P!!R 3&Y^04:<4);
M@F.),3F]2.M?C#T\.6&Y-G.191D=_.CSL$@SG.<_A#LA\ >FA?X0M3B._;U.
MH)(O+F=,F?0,3>88,XQM;E#JM;&Y.U(G!;A&2+.19()&H-3)P)2>S1G][&E9
M'B!U''3Q0:D+7YDKI;&\;BI++ 26H/+3$KEAB]203DX>,8#@0L ":;DT? =\
M/>X@PL)H%J02,[34N\R6K2D+DSVT'LCAC.<9B,AP](=*U1"),^.Y[VX8Q]=0
M^/?9D1QP$Y2E0-4=^>FQ#Y0KM,9SC)!V#@:5D=S)9@RAMC@!Q3:?VOR1^BRQ
MFC:V\#<FT_NGG#@AR,1)6"0:5'^(+@)N[J6MK <<6;$W8UX9E2HI(64^DB'C
M/UQ'6PI6,YO1'EK$^4BK@ER0*PD8!%C*-&28D5 5DR=A ^MXP#*&Q+CV]VU8
MZ\_!FH)'?,FZ=%WFC=,Z#Z]N2;DH818&'.,"P>5DD;6X#;E)9@#0*DY:LC45
M3EC,U(73RQ6DA'AATL/[N.!GZ;QV'5;&C\!Q5^;/TWE&X11LO &O2\[QUO!N
MZ'Q@:8Q#PJU(^?(?6ZLCFFHM[>=QC BTVHLJS<8QC';I#_#%I;C'@Z8^5=$3
M_3U(.;I<8$?I0=@D&<YSG@7M-YQH3)SE9^$Q+$UZ:$7F3R2<%E,BSR"Q:=Y=
M)PJAD)-&C0E(PZD?/D/K=61S346]O&%@-!E@#WR""TY? E+1@"<H&=T,?*NB
M)X_^.I!S?&<ASA?GZ&&"-%P<<8 ,IYIHSC"RQ'&-A)2/H4E>*!0[^:8N(D?/
MD/K=61S346]O<.Q\JZ(IZ?4@YOPSNL\P=IE1]P&DAWB TL)[HN(D?/D/K=61
MS346]O<.R<JZ(IZ?4@YOPKJL\L1IO295GMCHE<PZ*).*(#G L#!@P(P9+%P\
MCY\A];JQLY^]:BWM[AV?EG1%/3ZD'-^$,&$H"M0)4?C&<YDSEA@:*V4_0[36
MB+$RX+,0J=+">^'AY'SY#ZW5C<[U%O;W#L_+.B*>GT_9^KMPCVKS]=,Z3ZZ=
MG(YW7PE3Y:1!#D8BP8*+DB,)B4@WQ2]*2O",X:1\^0^MU8W.]1;V]P[/RSHB
MGI]/G->$>$)HC4R$]2866$H#XDRA=V?Q?NS2$(G+4H.[B%,=X(^^#.%9N#3.
M&?LY$^(?6ZL;G>HM[>X=GY9T13T^GSFO#OD6;7W+)$6QD-QG(<D2HX!:]P/<
M3N)?>=H?6ZL;G>HR'NL'#L_+!_X!J*>GT^<U_%7WG:'UNK&YWJ.<AX=GY89^
MGJ*>GT^<U_%7WG:#&<KM6-SO4<Y#P[/RPS]/44]/I\YK^*RR'+C5T8ACAY_4
MRC)[T%#"WU6H2IRT:;AV-[3DIW-_2 3Z8W4#>8<_-A1:D\:I1_Q4O__:  @!
M P !!0+_ &RI$PUBDN/M8"WEJRW&=F44,XQ-&T!93VSA;^U-,"248[K1C;7#
MS>.S$+ 0J'E2,QL<A*L_A3:JPB6@$$P*I,4L(5I3$:CLH\U^ 7J4+"^YVBDG
MS! P"+&4:,DQ*H J)[)X7=[.F1.(1OX0G29/T<AR .HXY]W.GQL\^1V+$U^=
M.TY+P-Z8TT9QA! SQ#;Q8QV!AN"] 4?7.GA#X@=-RS*0[&<9QV#DM\H3^>DJ
M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
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M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
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M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
M:B2 9#O$3T\I*&X-Z(OLU37BOP7).XBWF#1;=;J=20<3CTDZ[EK8.6BMV=V=
MW;/K$.6YYA; #411$)-->$F3<G]7UN\"]V;-KX)TTG%%:Z5'C:%\6/HP*E%7
MWA([UM>8)RX[A-?BGI7F:9M7YE"M_@Z$W4)1K&^!TTB&Y8NI:,0FF3%7=S2%
MU->EY=I=P';_ +C/V-WW"K<8J9EH.-1XX5-=23QFSX%7":M1:&)9BT#0(NBL
MIN,^NX:EQW4D1\D&"_W&QVDQ2O4:970Q6AJJTJR1!9'XLT=HEFVX1&JDQM7V
M*GC.A=N4SH95CVSI<#Z53@HV-/.:@1SA0!C9@Y-"%C(M- *2B=%#:!55LE-1
M)N-VYCS0JI?X'_##MFW']8,6=*J5A3[%N.C\7KEZIYQU$Z@:JOCQC&/9KW$E
MY7AN)% <K,1A8U7XU62W*P=(?QQYF;93+AD%350,T0E_PKKE]*.;JQV\SO,'
MLUR2@"C;^/2)DQZ+)GU,;(_7HD:JER(32ZI'ZH .Q/$B+NK!#)TA2>Z%E1&_
M.8HT_P!S4&/I$8@4+,?XJ(R]D!EQGK;FQT=_=<M%S"Q>N"8CY'VV9[9U,-BO
MT/'*<.JZ\;<DYQI.1Z80N=/ILHFW35==>(=K>]Q$MK*F[=VF!8VC.,M0H- L
MR*W B7#++5LGK'8T05ZH%L.01?O0$1'C"K&-?H\&"]OY>(U$5RG1$^.63ZO6
M>5&Y\2+1):*H^CV\D7]\O%-B+4Y;5:Q)AR+0XWI'+"7/GRK"3*<863,(")V4
MJ<W3Y(G/Y*&O@Y$UCKE%E-7E*/O4OQQF8_4!)]+#?B?%*I/3J^^AEYUUV:<9
M=*R'/'[#+LPJ:O&Y.1,X]'@PZS%X%M!MI%1543-FHMG9.0D1UYV2\J:ZH/BB
M]U)$?)!@O]QL=I,4KU&F5T,5H:JM*LD061^+-':)9MN$1JI,;5]BIXG)Q//'
M<4KY_;ZL[?6T=JAC6$PJ^GC^EA/U<QZ:W\-)QC03VBI"B*H&AJ)-Q C97L<K
M.T$KM?4G\#3;!G61N.VF7H"6Z=65))U=D;5! ?%PUY\=N9GQ<Y$#MKA5IC5?
M6MUO3?F6-O 9K[3(!E>O,8TB9&:7W*-'YC_>>SCMC1R$S-S >W$^\OD9RO"!
MPEJ%*))+M$TBNS)3V1W(V,Q5-UM588:3R*6\UXPNTI,O:Q29AEE/MHQ/8XUD
M3<F=)9CL17E8?M:YEM8( [IN1S<KGLV\\S3+,RMLCS',ZR%4OY=(KX40:F%6
M6,*WA0JBBBF,6)7+8P&S?:%U%>3[0JJEQE%MEF;Q['+KW"I>!55G7XX,&IQN
MCL$7XB[%J/BBN3+.>9D1/*^ULW;01!Y<85=1;I$8P'M\YAF/UYU>Y&K)]IJ*
M_DCK_P 0\Y/0V4 H^Q%)=55[V<=M!Q;.OA=W@#>41W[J1CK%A\7;RYYQZUEI
M E6#HQK "<5&U-QY--->0Z+V]9D92]:MX9E.3YE:*]5=-[)[Z[1P:R6Z\5I(
M6O.F$TW*J2%DJFON]>,/HY>3I-^ =R#[F7TGX)T/Q3;^JF2F(SC'Q=Y*^.TL
MD$+<4E#Z2<OH_0M+VS=Z-=3U\RSG.HFY0BP6#DOJ(_;/IMKH/M7EQ/R&SR6=
MA7;IF:Y$J:6N-U?4)'5/+T6G8C<^0WK[V6^IHCJJ+0;4VB>7]JLYNIH4P%*L
M,=F)Y9,!GSO_ ,&#A5UJV#2*I,DR!H@[FUW[4XF0[-AMIV8Q\.R*L:/611W3
M6CL:="4U(T;ZS8R(IKJBCY"U5'$XL>S6:GH<>29XO8GJ,:8P^I.L!&,U7^$L
MP]XPFNH/;VE\_E3AFYI-[&6XXOK*F1&(FI,@&#]0L)MT-#%]'!ZD=?LO)RTW
MJO")8D#688^C4')(FB-D^6A!&N&6N6C-@C:[TT3IOB8Z;=FOZ<VULY3,*NKH
MK\V=,D%L9C18S9.OO.%[ ;;%5XD9;:LO-=O,4?*'C]7(30)>PD<;!YOS-%(F
MJ(OS?'0-C.JIH7R2;9_8[-<UC5,)5YS)YBO314U0O3L?7=+V"GTJFLSNYG?G
MRS*&79L(I^T2IJ22/6.8YOVC$E6;7/3ET(B"'EW."ECB7:NXD8M@=&JLVN51
MC>CO6.Y3;20LF/TIB,R^F218K1@KH(INEIR;6]P'NW?6%W"#K?#)A2H;-ETD
M4E8%'[2SKY"FOU&932LD7UC3QXF#<1P@9=C4ANOR*( *R+I.(YZ6Q;CGYXR2
ME8< VU_=O-%X#M_3E3YKP1X<&,_+ER'/W;$:,V3S[QZ:KL;:!57BUEMY!/Q#
MMM F.0X%=!-YLYB#YF_4ML.LC8SR942>)UQ6F%-$;%>?"Y%VQS>\]96CZEVF
M-2$;!MO5Y]M&&G%@V&Y=5],\PJ&O@N_36RJLAB1EGE&^#Y?3-^7H2'!W1K6O
M1Q7'6&7S;ZT8^9,OMJFJJWJMA@-^2N0R<]3C]FHJ+,Z#),O22&]>0I)VJ#@I
MJC<D"'GX_)N9\EA$][#=1=I;DYJUNY*G4TY+["T7@J:]?_\ ;;%VPC6PN^5^
MU@CHS'NMBHFKI%[J5I]5Y-RZ(X*?,/RY;[4:+%9=D29+[@M,1X[ *X\^\Z:H
M#;338JI$O)$3@GF"?;P/&3<C4L4]P>LU5.M8/-KII)M2;1=%1%:C((_6U541
M$1$1-$1.2(B>"(GL1.'9CW/;Y6F]=">>+ZC8_P#C7Z$3@N[N7L:VUNVXN+1I
M :>AK74V.7*@XFK;LYKR1OZ,7S<T=32?@/:2W6DQBGW-W670W'6'YS@&33YL
M64=5>9KU=39&&/L<D[2/?TOJI;8IW8R!V\C^^1F3)L(;$TQ\_3)Q;2<T2.+R
MV/MFT>OF5$UXMJ7*66XN;XF^,:X &QCC81R-QD)Z1101CR6I+!M26P38![23
M:CB /Z$^VLGQB5U7"E6,^4:$H1H4)@Y,I\T;$S466&U)=$5>7%?D$&6)T]K!
MB64&:^#T('H,]IMZ&^K<UN.^RC[3HJB&(ES\."<\Q"(*?NQ5PB1$U\@!J1DO
ML1/'AR@8P+NTMS'&,[,KEP62DR!'F$@QY<^-ZOKPXCFO)PQ053A5:<!Q$(@5
M0(31#!="!5%5T(5\4X<17&T5H$<=13%%;;7=H;G/R NQ>:_1P)@0F!BA 8JA
M"0DFHD))R453B?DMS9,Q*.K:ZTZP%'93;((Z+/)N&W(?>-7C04$!(E)=-.&9
M+*J3,AIM]I2 VR5MT$,%5MP0<!5$O D14]O%5'KO7?[WK,ANX[\AAEF,S28Y
M;#2OV\MU9/N(-A-+^%+Q=!%)4%.,B@8J_,GMXR5<,VS*(4>LDE9C).-\.>>(
M7Y8;(A+OZ: H[5%5$A5?T:"HLYR1K+*)DB!11$CRWW)\F+'67)%%C,/ PVQ'
M3<3CJ@VGTZKPC"NMH\0[Q94QZI GB:-Z[E%/IX"WF4N3W<=7B;>;Q>D?NI$)
MEN,_)=GS@:)L8E>R#&A.F2(BJG!R:V@S&IJ_1!.CWF24!5%'/;<?". 5UF<A
MV-->(S\ 5>2+QJO#.CS2^H3=']X'OQ0.HJL\_>H@<^7LX%77&VD(Q;%7#$$)
MPOJ@.Y4U,O8G%5BLB<@7]W#GSZVO2/*=)Z'6[/62''VF#BQ6V^HB)UC#J+R#
M547B+-L4DN^OMZBB@Q8;8O2YEE=SV:^&PRV;C(+H;V\U4DVM 2^S3@[:)2YA
MD0_'+ZBB0<9Q]VXGV+N-2%B7$^&TR\+/PF+) @Z[KC2$H\N7$/*L=67\.EN2
M&>E.82/,C2(KBM/1Y+0./M=05374#,514T7]+/J^O;)Z8]C5B;+((JN/+&;]
M43+0CJ1NNML*(C]HETXIJZ$X'K<><G5]K%Y(XP^_83)[#VWDJM3(\E"0_!3W
MIXBOR1NY.*QG'L!R62,/*:./Y6(ION*X]';;_=LB2ZOP3Y(VZA,\@5$*LS3"
M7PDY'5PDN<5L8:]-VU@K_$/4Q.#HZ$C>*DPBZ$S+';Y-SG!,6"]+):7;$N8Q
MCTW'=-0;L!:T':CZ@J.#_HW45-$11UXK^[^(-*5>_)&/EM4WY6'VI9@DL74%
M%$(]KMUWJB]&:@'S4D3BJR:BDI*JK>*,J,YX$/-0>CO#SZ<F*^!-NA]EP53]
M./V0P>1K"CR0<S:T9\['5BF!G!-P%T6'3KH3Z:^\E[6N1!H4&CJFNE#@,HT&
MNG4>/ZSTE\D1$.1)=53-?Z2\29\Y]N-#AL.29,AU=K;+#(J;CA+] BG#F<9#
M%<'MSA\KHU-;(3W5K-;('V83C2[FG!-4!^?XHH]-CF*ZC$[$]NRZ]Y>&VQE,
MN.:H$&";?6*I-YO7HM^E]]-+[$=-G/<8I!QRJ3?T4ZUA.4$%ZSLG1'U4Y[QT
MWJ.@#JO3:$1U73@W'#%MML2-QPR00 !3<1F1:((BB<UX[VY14CNQZ;8[8LH1
MZ;4ER9<6,MAQL-$U5UAHG%^TG437ZWZ>;TM<AE86N)Y#7PFP^L]*E54IEB/]
M4O+(<- 7EKH7"5#6UNQI9\T)["\GB29(<E1Y1"J_5(35KV<V5_Q\1.[&'LJY
M2SG_ $V6TP*H1WFICH%*;<VHJ-1[!Q$-L]%1B6(KS14'BOR'%'F7[=F(=OB-
MBNQITG5'2;C\]55?3^I<9Z3@JON)38JJZ"2%(J[-MR/=5+CD2='D"K;^YAQ6
M35QLD0@?:<'8ZGBAI^WY*SN)BY;)=<^/Q&+S2/-C.^ZDLRA3ZT:<R73<]HEH
M8^9-R56543N^#9L;U:-1Z\*4"[)<"6(JNR3$?11+V+]9-15%_33L]B,G<_(5
MHLQFL.+M:#D\U1=0.>B"B.S-/L[6O:X'#4..GD;3S']IUQ?KNG_E&O\ R>'!
M.&2  "IF1+H(B*:D1*O@B)Q\1LV7$[?XH\!S=R$ 6TK]Y'J@+3F<Q10Y&G-N
M,FWRD8+Q%[-8!Y\IR)IB':K T#X-3R0T;K6U;T"+(L(O-Q5T2/"U+EU!(8]1
M&VNRSTD6L]!T*=.(4WGSYC':3R-#[ 3^DI*O'=')*E.I0-T3U<<IK_5W9TJU
MI?3N#M]V?J_@TIP2\5'G[?T<L :X[%[6G].(,O/^D,[J T=@8,(;NV''<,M4
M$M%TY>WC&(MOC]@79]KM[(O<3JV\>OS@97G<V>$63*F5:1NJ=X_41P1AJ: ;
M-XEY-R:XM59$U(B60-3I/PV43IR*F'.LI<ROJW5>57D.'"> 5 M%;7R:>7C^
M\SGE7%MHL^XRNFPV#,CQ903F,8QE85/96E8R@@^4<ZZ:X76;T35%/=Y%T[H9
M;V\Q>]K,:Q3M%\&Q;U===L.W>2Y0G1#)8D*S;29UY+4,&C46@ZK0(XHIN1>.
MT-3<5UN%'DT^B7N_9Q&;FRGV7P:I6748[/;@B_.&G2QE&PVPR J+; (GF!%X
MS&[Q:%88MA>8]Y*S&+02AWD[X'@&.QISG2L8-;*2XCU,FVL3"2TPZVH^9A"3
M>B<.7<5_XO29?W3PL;):+#<AQW%\4@5<:9%LK7'\;E%86RL/PR)A^6/566X:
M"//AS'NW^.UWH[]F#04U%(@S6V&AS*:C'J/0]$W&I$63:++<20@B.T]_/DN9
MY[E6.8Y4U5&L7"ZR534UW93R2A7\/6UQ%AMU3EC-9R>?,+JOHT3CZ!JJ=)-R
M]T;%6+");7V<V-RW%ETEQ6ML8JV#%?C+:29M?&AF[T&G/=@>\4\0']+!867T
M"SJV1A$L&'7:NQGPKBX?N'HL"K?=B-/,LC4L=641.JVRV)ZD7F1%QEE:B[+O
MU,[J?',RMI5=<MR,(I:J[EF>ZU>!N#'IF:E&!CQV7.FX9[13<@\9P59'E2["
M=3'2Q8\*.]*E.%>O-4[G1:8$W5-N/-,]4^KMUX[:X3F]#=WV#8OVG)VFH*F#
M:3HV2]P8FVK*!(^%@2%(CU;"N@ZZ2-LD[N4D0RU[%8;=U]J%?,'.^Y6=?^L8
M_7^)$<"FKYLQ5]0'K(A)'D ;O5<8,D7QX[JUUKCMRYEU99X_A?:F"S$NF:K%
M<5CC%AU-A66+/3@11G..*1(3A./O$B:*ANKQ=8+F%G&JJFEQ3$<(P)BRP?*L
MO<*K*BB1YMOA0U,R-51[MRQ;VG)?;?<:Y#RZ1)P%3?U,RR?I.W^(0L<G6T"Q
MG+=W-!'9DEE$VS;9* DZ%!JVXY./$V+COD1")>(:L8G09'68)BTF^%NUA6$P
MK&URJ4N,5E,@M1'([SH2Q26+.[IZM";ZB*!KCW9K':]<?N9M6R[FF>T>/WEQ
M6UY2&4BRK"N9A5ZS+;)[.+$'SDC3;"[?,G)6\;K<2:FMT00>M$.SBOPK.44E
MPWGYMA'DLQWVY4M\R-44!T14040=$_38[I8A$<=P')Y7I<HHXR;8\"1)<ZKT
M8&^3<=B26K\$^0LOH3/E;(1.!=U$IN;6V<9N5#DM^#C3B>U%\S;C9:B8KH0&
MBHO-.+"BN8P3*RTC'%EL']H"YB8%XMO,N(AMFGF Q0DYIQ)[19G*,\.R"7ZG
M$;R0NV-$D2W5;CN*:Z-L1;$_=24^JQ*%#Y 1FL?O;A47_=LR4+6;5C7DC^IF
M."VY,<$!5 BW1*B.%HO3F[7.9.<H-W5/=:%/91UI? P7P<8>'5=C[#B*!I["
M3B573V DPIK#D:4PY]1UET5 Q7VIR7DJ<T7PX?[<Y)+,L"RV6,BALY*Z,5T^
M0J,QY)G]1IM]4&-,\! Q!WRAJJ_HA549]7.<G$HE%':3K/5[!ET7[DF$U52;
M5>G&'3WDA? A TX*39)ULGN]LNYDN%U765)5<;@(]J2ET5/5TM5ZCRJNJH@_
M) [/88[I&&2+V66H(1QHH1#0I*/JVNA1:KEN'5.K+VM\E3G58IB##?QZ1$*L
MQ6N5!=?ZR_Z]D=D(BG6(9#RN+Y?XB4:"B;=VV5E.4;Y6=Y5NEVLB42NR:^/)
M/U7P\G3U)9C[R]667M=T'GT]Q<0>R';W63?7SH,9'*9-4"%#,.LY7NO!N5EH
M8NK\TOL,)LY[B1*[%J=-_03U%E/($!ZUMG@!)E@\G/3J*""V.J]-D1#5=NOS
M#?>7"HRKC]K+Z695#.J,1Y4UQ.L^HBB].#<.^;<J:,3=/8X(I!NJIY'X4]D7
M6B^V"^#C+P\]C[#B*)C["3B573V DPIK#D:2PXFH.LNBHF*_XE\?%%X>PC(Y
M3I=N,ND^HJ;*07N:J:XK;+<\S_=MB/ECS_JZ)TW^0IH0=X\1CIJ!,MYC#CCY
M31=K#%[L%>;3P[69>WV['?\ G#1F9'7R.CS'[39IR-H_\H%X-MP4-MP2 P)-
M1(230A5/:BIPM%<2"_ &62 ZSSBJK=/.7:S'M>:[41CRM2_:3&USFK8CPA"J
M$)(A"0KJ)"O-%14Y*BI^BX[%-IW++L7H6-PBT)0=VHC]N^VNNL2L1Q%T7]XZ
MH!X*JI(MK1QV3=V[CDN=)D&3LA3D.*^YU7#U,WWG2WNDO-3_ ,'R5?;S%@ZL
MZSD"$^1YO3PHP^\D/2W 15")"917'O:NB FI+M6!3TH,OVQ,.P\?B/(B2+N\
M5L%GWMF+:H11V#-'7]-$YMLBHZAI-SO+R>F9EE!.S'G9O.5!CS#ZY]1%1.G.
MG$NYQ-$Z8;6]!\Z+Q![682#DW*\G<:AR_3%YX427_P"C*Y]6.Y)8U-XRT1B*
MBFNB$A)#QZ#TY%@YI,O[5 T.TM3!$=<35-PPXZ>[CA]EM.?G(R7YF=V]6^RN
MNRC#H3=M.3&[B[QS9#MV82JP]/KGF&9J&Q*8)0+7:CGE^WQ"Q['H0P*J +B,
M,(XZ\6YYTY#[SS\@W7Y$B0^Z1F9DI$2_/3,HR-Y]BJA.16GCC1W)3V^9):B,
MH#+2;EU==37Z$XAY=(E9%<MG8L9365=ADUY*QF-9FB28MK#Q^1*]"RZ&_> J
M&T->0I\Y9X]=Q0FU5O$=A38Y_::<3D8%XM/LFB&V:>9MP4).:)Q*[4YA)-W#
M;R2LO$;Y_P L=OU3NR.\I?48:E%[J6'U6)2;_J$IEP]6'TV+J%OET%B2?ZM-
MV\V'21%+T4Y!V.I[.1Z:@G&3X+W;JY5IEF.1WL9;IY0&IY3$>!V&$:QE;3".
M[7B.V1(+FXSL<#J.JNM15YI5S*3%\]C#;4ISM09BDZZL=B<.\R)AE_8 O"YM
M<%LFGE\BHI</UI[&K*-NE4TPD_U>:(_NS).?I9:>1U.?+0M-PCQ)[;Y>9LYM
MAH%&;]6O\1;5$0_3ZDJK[R?4EHT[_3:V.>9>HJ?+:Y5?/=*!5QU<Z8J/J)LD
MO+%KX@DJ(Y+F/*@ G@FNJZ"BJEAWES<-7),@QQ>N+58T1AA2:8<BMG_Z)6![
MMA5YF]O>7SZ$O#-12[G\LR%?25,:.*NR(X.FC"S4:#4U=5PNG'33SO>&NTN+
M"N[F8H11,PJF+)F^K4&98>HC1BD)7-3#(&9 A+D=&6SJ)-/J+FI-[5*7WRS]
MGW/J=F%U![CBQPAN&,=]@'$1/0TY:HPNFKLO>\NA)J?'3KU&1EEXAQ,?A(G5
M)HET!VT>9Y[F8>]-@Z+U7E$=--ZI(RO*4*3W!RT5E6STGWDBIB27/5)5JZ>I
M+,>=][,+VNZ!S1O<7S$ZHM8C,ZMLHKT.=#?'<S(C2 5MUHTY+H0KXIS3V<2,
M0N'7GNWN4/E+QZW?YC%W$+8./.:"VC\12%B:GEY;'M$'1%U3FB\T5/!4XD4\
MO:U)'615SMNI09XBJ-.?23#FNUT?M OTZ*F3=O>[D.3-ML3A/5E5"-I9!9+5
MN@D1N@DNF)L(C+3R;7S]VY +715#WE7=6]#+HL5S994ZCZ_4)A(H2%%MR.;J
MK(V,-F'-Q$)YA1<3<BBO&J<T7P7AR(YHA_7CN^UE]/JG_FKX+^Q>"[596\HY
M%C[1IC[[Y>>SIHPZE7J1+[V54M)JVJ?O(FG_ #1$7RVF2WTE(E5413E2WO$E
M0=!;99#5.K)DND+;0>)N$B>WBPS_ " 2;BH[Z>@K%-7&8$*,9>DC-:HB$,75
M2,D1.K)(BY>'R:,^>PE+TH;2)N+<O)7=GM1O7DGM+1.(UEW(Q0SI\\IXI'<Q
M0]5:U9_ZXY#!QPF@28R\\B3XA*)JH@8D2 B'+[JY>P3=!7R%BXE2.+OCMMQ'
M26,T.J(CS$ U4WCT1'YA+]D5#Y#F>[>MYN^/2P27]])04WR'13S>DA(2$?TJ
MHAJBDB\2>XF:-N/YWE@%($9J:R:6LEEUE Q5/<V=GR-_VM-[6M!7J(OS7>7\
MH8W]T87^C)O<EM8E/4Q$3K3)9J@[BUV,LM@AO29+NGD:;$G#7P1>'O\ ASVC
MSS.X+)FVMHS%D089DV7F4"AUMXH H:J/5Z;BKHBBBKPS29_C&4]LK*02(RN2
MP'AK]") %7I!,19D85)>9G&1D4YD:<-28SS4B/(;!YB0PX#S+S3@H3;K3K:D
M#C9BNJ*BZ*G#U;<9$DNWCJ0OU-)'=M9;#@?69DFSI!B/IK]1UX#_ &<#&?L[
MBCWKM"1<4SPQE)51$0G:YRRZ*+K]8T$$]JIQ&LZJ;$LJZ8TCT2=!D-2HDEHO
M!QB0R1M.!JGL7]#(_P"88[]]PN,:_+]-]W1_G7Z=WI1[R!U9N-6AI_J5CL_<
M.F**?P^Q0$;?1->6T]%(!XG=L\VZL3.,0)Z$@35_B+*!!+H$)&JJC\ZN5-#5
M%7JL[7$W><ODC=TL4B,GDF,G%G6T(HK4IJV@UC@/LS78;H&Q,?K$:]X!BJ/1
M4VKKL$5WL^FKLGA>8!)=SF.94PSS9-=#>*FM0^UH6Z.>O[YO09_;S+A<AY=B
M9NPNE+7^(EQ(9] FR+54>DP%3:I(J]1K::;O,7R5W=S"2*+DF-.LRK-&15?5
MPHX[/5/-!IZ@&H^K4D%Y.1%77D'.NRBKT:-U/36M?O0W:JV8$?5PG/:HHI(;
M1<M[)B6B:Z?(I$J"(HI$1+H(BG-555Y(B)PWC5.^Z/;'"Y'4E3&2VA<2=Q-/
M3Q).2E.V$S"UU4&$-[DID'#$2(RW'BQ66X\=AH4!IEAD$;::;!.0@V Z(G$Z
M]M'-L:$WJC:*G5DOEY6(D=%^L_(<Y)]'BO)%7B=WY[@BVVVAO%B,26NR'%9B
MH8.76C^@-0JQL%;BDOBYU'EYH!JU4UY2&.TV#OJ;\T$-GXL\7E<?!51"27;=
M-6XR+S8B(3NB&2@L:#"8:BPX;#46)&8!&V8\=AL6F66@'D#;38HB)]'%CDEV
M]TH->SOVCIUY3Y>6/"B@JIU),IU4$4\/:N@HJ\2.^_<&/_#-R=F#5#NIQ@6&
MX8LS6@<1$]!3'J,==-79>]Y="%%/YJ9CECL8EIK+I+/9N<J[5L"1B0GVBCN:
M['@^VV2^W:J6':C-Q*)D^,N'$@=<M2F0XP;_ $HN+R?6/&VN,$G[V(J*G(-5
MX;RNCC@614((ZXQT&G_BT".76Z1QW0<:E2(:HI !"75#<VJ%J*<2*J<,6OR2
MN!IJ4VT";L>R1A@TK[:$TOO/A%@.[R^UDG6=VX-W%G@N3LE$O*&0Y$Z9JJ]0
M&DW(C9JB=5M65%QDO!Q@D5.7R0,MQU]R%?T+[,UB1'TZO\,?4!Q$T47"9TYB
M2*AMZBNJ<N(>01NDQ:,;8.0U@*NM?;-MBKJ )*IK"EHO58+GJ"[57>)(GR#@
MF.2R_!F+RB*RFL'JS<6[*DT_*$D\CL6'J3$;Q$SWNIJ*CHW'8!&V60%ML$\!
M$4T1.'I<D]C+(;B7VK] BGM,RY(GT\%W9RR-_N2IDJWB<%]/=3+"(2_Q^TTT
M.#3G]5?!R7JO^B)%9P;&Y)CVYQ&5ZFVM&%U:M)K:N1W9[;G-LA(5./ 3GJBN
M/\Q708M=7L!%A0F&XT:.VF@-,M#M$4]JK]*KS5>:\3;FU?2/ KV5??<7Q]@@
MTV/+J//.*@ /B1JB<.]W\TBJF+4TI6,0IGTW1Y<J$\JLKH2:/P:EWS.EIM?F
MKI]4##YSO+^4,;^Z,+_0&VRRQ]*+Y&W @1P]39V;S:(IM08B**GL0DW&2@T&
MJ;B35.*_(NX-1DLCM=2[@H\8@HQJZ]R3U=JBS8\5UV2ZA$\+;VNP!9W**$I0
MK+!I4!^B;%(C,: R,-*PVA%5KGZY :*N>8$D]TH#Y50AU%459%'E%3%MJ^0)
M)L?#WT<U31)$*2.C\*4'V7&R$DXR'^[)B,]Z8_9W\-C%\@<,@F4N-VL,[.Q5
MMQL%].*P7P==<;_U8@D*VFXA48P0JN):WZ-BL_)[.*U(M)<I>;SD<GNM\-C$
M:^5IE4\NFY3+4E__ +4&DDPIHN-0Z^?!&RLYBA]=:R*TT[/ F2--7PV"R1)J
M8ZIQ,J<?N[ECL]D@NO+'R.,ZKF,W"MFK#K*1G+!YR.3C(L$[R4FG15[56>IQ
M&L:V7&GP)C(2(DR&\W(C26'$U!UA]HB;<;)/:B_+D?\ ,,=^^X7&-?E^F^[H
M_P ]%[PX"CD3,\3V2[0(8>]M*R$/*8C:)I(EUS"*+@*B]>)J"Z[!%8UY$Z;%
M@SMB7E8A:E7V0@BF(H2J91)">=@_M NB^821.(V?XY&>=[<Y9)2'DM-'3W,,
MG7%>>C--ZBTVXUYY%>OEVZ.,:HVJ[J?O_P!L9#;UI5PXMG8O0$U&XH0;U:M.
MF*(3DBNCDK<D#YG$U$M.EM6)=PM&W5]Q8P]VXX-@V(J_'+VJ'F0FR^TV2+^S
M@@,4("11(21%$A5-%$D7DJ*G 6+:/'VQS5T(]G'!#<&L)#4A,!'_ -*IB=(V
M4YJ[$,PYFFY(\R(\U)B2V&I,:0P8N,R([X"ZR\TX.HN-.MDBBJ<E1>(W9S!S
M)_*<G1IF]=C&FZNJI8JJ5N\?W$FR9\[Q+IT8?-?WJ$,2EA[7'D]_93-NASK!
MQ$ZSZ^U&QTV-I]EL43QU7A2)4$112(B71!1.:JJKR1$3ANDBF^WVSPYY)-O.
M94FQL"W*W[EQ.7J[51)J-[6HR&[XZBM7_=X[6MM-OR@BP,D=@>YAU56RV"A0
MH;*:1X<:$'5G;4\K*"SS4G&^(&-U ZA&'JS)A"@OV5BZ@^JGR--?.Z2:"FJ]
M-L1!.0IPX\\X#3+0$XZZX0@VVV J1N.&2H(  IJJKR1.$JXSDJ-VEPB1UITI
MO>REL]J3:&'A_'6^T@CZ\XT-#/D9*!1*Z!'9AP8,9F'#B1P1MB-%C-BRPPRV
M/E!IIH$1$]B)\Y'[@X:VXQGF) ,G^#3^)N:R(2O]%M!35VSKBU<C^*N!N:T)
M5;VA,]VU<0NG&NH0_P"BDJ*[)+0KYO234!2#Z%0@U51U^2)W2Q-DG,<LY'I,
MKHVEV1R"6:%(95$Y,LS#3JL']5B6*)]0D!:GO+V[))=Q65H3R*(*>HN*!G<Z
MZTXT.O\ O>A<0_)]=11QI=Q(V*!('07P]W*:3_1O(GBG_P!VYXC_ /1\D;)(
M@O/8I=$,+)*QGFAQ2-24F054#U<$B5Z,OE^VWJ@DO$*UK)34VNLHK$V#+8+<
MS)BR6Q=8>;7^BXV2+P';[%WR7+LIC].8[&/1ZFI9.K)$ACS:GVOF;:Y[FVD-
MSRKTU48Z:$^>CDIU/]([IX)[>FWX#_R^WY(N+0#=9Q>H,)N2VK7U&H@'M<Z3
MBH3:RY:HK,5.?F4G-% 5TJ>P/:UD&;6PA1JJS" 6T:6B-@1:J4<155N181//
M),EU"+JI:J[N&/3P]KDA='[.=MT.=.(4ZCJ^U&@^JV/V03Z=575>2)S55\$3
MAG#:-]V/V^QF0$S(;AGZDE -6S=:/0FR?DZ&S!'GRWO+J/)(%+41&H-96168
M4&(PFC;$=@$!L$\5)=$YDNI$O->?SG>7\H8W]T87^AFAY(/K*?!=:NLJ7EWQ
M?]W/A$;%QDMP''>F=>2X/@9DB*BCJ/!P9$6,]"<;Z)PW66W(QL^'2)@A5I6_
MV::<+AT!UQG%\]JW768!FJL1Y 1ILV 2;N9%'FUTB,TOCTW]"U\>+#MEV8F-
MU5?2]1K(\Q Q%5-MU(\I8L\1>*+"COETP5A%DR'!4@5&TUX/.L9[ER;S-FF5
M<>D2O61;69HST3C-6LZ?9I/4V 0$&1TP(?*NB<3\3S,&86<4;+CSCO3&$W=0
MX[G1E/+$T (EG <T]0T*(*HN\!1$,0R;,KMTYD-+!R+20W%4HT:K9<<2NB V
MOD1IB)M(D31''G",N9+JL=Z#&V*FB;&@;-OZ%;,$0FU3]G&8=L)DER37P(A9
M'3"YJOHT";&AV(M>.QN:ME'<V:Z(XA*B:D2_+D?\PQW[[A<8U^7Z;[NC_/:+
MPSW%QB*Z]VXRZ5Z7(J>,FC-=)>-7G8@-^5IOGOD5Y>5!5'&%VA]>%;U4IN;7
M6,9J7#E,KJ#S#P[A+GH0E["%="$N2Z+Q8X_=1DE5EI'*/):7D2(NA-O,GHO2
MD1W11QL_$#%%XD=E<Y?5_%+R4KN&W#Z?PK;M@\0,#H>HM0;AQ5;>#F+$Y%^R
M9N<!>UC#J]L,V?4'8[2*3=1)W$Z[!$1UT<K%-78FO-R*IMIJ0D7#,J,Z#\>0
MT#[#S1(;;K+HH;;C9)R(#%=47B]KK!M#;^'RI+#FFIQID5AQZ+*:\-#:='_R
MAU%>2KQ!:FND\E+=VU/#(R4C&"WZ::RTI+SVL%/( 3[((B>"<9MW&M_XF^M;
MR0TCKBJYZ09>EA*&.I?50_4 VG]%MI!31-4^2O[382)2\ER5QJ-8] E3T<.0
MF[TKC@:]!'X^KL@E_=Q$U7D?*MQ'&%:G9W?"8Q7$:$WYEP^ -6.32V-"7TL(
MMK41HMVY4;;\R"Z2/Y#D6^3G.4IZRXDRB5^5!9D'ZKX<3YJ1E*<>+JRSU\[W
M+S(V)+Q"[&]O5]1;73K;64SF25&8414ZSM>\^WN5J.Q&3K3B3P:1&O,I&'%=
MBM*&K<4>K.G$"#(M;-Y!]98R=-?.\0Z".J]-H1!.0I\\SW=PZ(I8K=RO3Y93
MQT46(<R8>KVHCR8A6KGO&BTV,34T^J8 L*XJWTD0+!@7X[B>.B\B;<'_ $;S
M)HHF*\Q-%3B766,<)4&<PY&DL.?5<:<31>?B))XB2<Q+FG/ASMWE$IQS ,IE
M]>AM7U]U6S'R%IF41?4:;<+:Q-'D@'M>Y!KN#-L>BJF$Y5*()L-@=&:>V<W/
M/PT'ZC;$K0WXGL%4<;\HB.K;[)HXTZ N-F/@0DFJ+P_#?'5M\%'_ #2\0<'_
M "FSYIQ8ULMTG6:#)YL.MW+KT84N'!LBC"G] 9TIX_\ \3C/\FM35^P/(;!I
MI37<D=A)4F,PRVJ_8B08S;#?T-CI\D#$\=8=G7]Z^U"CQHW-[^)+I@"+JB-F
M]K]9=$ -273QX9A1?2V.>9!NZ9:;OBV0JR"2)AHJ"[\!QYMU$ =!W>5%VF\1
M<3,URLG9F9903LV4],\\J(S-<]0XCBKS2;--=[W]'D'+0M>(/:C!P.9D^2&W
M$L%8+18<.2.[TI.)^X5^/JY(->345%5?K:I#QRNV/RUTEW=GLVN6EJX H_(7
M[0QV]-C(?8;%/;N5?G.\OY0QO[HPO]#*(0HK<3,ZE+&.*^43>D0(ME)>]B$O
MQ"LE(G^<OR8/=44QV-D(A81HWHB_WD&CL;T;L86]SNXG93HBJ)KN^KSXCQ)(
M!^(;?999$^B[E]60KT("'JNYJL9/9R7:3BF:?6^3N'G7;]UUF)07+SK]G7FB
MH(V/4J9LH-$49$2RD==2\1)HU7ZNJ\-&BBJR'Y#QZ*BZ$A]%$+3V[&4^3N3F
M!#Y6&(5%#<_IMV,UZ=( ?;[INHCZ_P"<GRY'_,,=^^X7&-?E^F^[H_S]GC=]
M%&956\4XDM@N1;2Y@\R>BJS)CNHCC1IS!P4).:<3.SV9RB<Q>VD^KPV\>10C
M(4US2,8D7E8BV)HK3X<Q8G"OV3)Q>*VTD(V%K7Y%$:J9'U7_ .-8DK-BMEX[
M'&HR.DGTL(OLXF6%JVCEDY18!/?-YO5UJQDW.-#+='J;C:>7U+@*NN[:2I[5
MXP_\O5G]F#BY_E-C_8WN)'YON?[%4<7WYA7[M@_)W2?<9:-Z-3R5CNF D;"N
MV-.VX3)*FK9&VNU53Q%=.)D:^T>8QNAKWL;CR/,T3[-!7V3?2 N2K&FV<J0/
MT.-Z^SY!B5:I(S#($.)00P'K.1]VC3EJXPB%N&.1HC(JB]9_1-%%#T>R'(A6
M1GV5#ZJZDR"ZTBNC/GZD:E'B4E5\G5ZLL]?>/\EU1L5^86M&Q@%8BBJ4 9<=
M9HH@[U58J.==$0.?AX?ISZ2XB-3ZNTBNPIT1Y-6WX[P[3'EH0$GB)"J$!(BH
MJ*G#^"WS[LC!,E>69C5R_P FV4<-&FW7'$06@>97:Q.'R[5V/(B 2;N)4J4@
M>L@3ZYRK-=.IZB1*:C2&@7QT.$;A*GMV:^SA9=T"2)KW;3'9KY2!0S.4$6K?
M9FENUTDF2"[KR5#7V<5O_1N?VA[Y,K_-Y?<U7QG/YDG?VZ?\ED;K3;AQL5G/
MQR,!(F'E9I(_5:54]VYT'S#5.>TE3V\8O5W6CE=68Y$>K(SHZ,NNM1[>T M"
M\CI+8IJJ_:Z2#[/D*0&QZ[L-\:EAKYMS^GGENAXK&A[D5?Z1*(^W7B1GF8 ;
M^>Y8VLEWU:;I--73"22L9S<FK=G/+1R3[0Y-<MIZ_IE=Y5;Q::L%YJ/ZF5O7
M?(?71IAEED'9$ATM%7: DJ *DOE%52/,AOLRHDMAJ3%DQW!>8D1WP%UE]AUM
M2!UEULD(21=%1?T>\OY0QO[HPOY-5X.346=?:QVWBC.2*V;&G,MR&Q C8-V,
MXZ O +@JHJNJ(J<=H,Y'06W7CHY[WALC0+*/(VFJ\O>Q;R1I_FKQ,M+!X8\*
M!'=E27B\ ::%2+3^D:^ IXD7).++N[D<<DIZ>7Z3$X+W,$EQ^<<P1=1(*AH]
MZDGE*:YN'F!)\C6,43AEEN8(L"$$9=94.N>+TTF8V@+U0DR2/H1E3GO4B%=6
M^$HIC#,F7:-&[D2DB.-RGY373=B:ZJAQ8S"])/87,O$EXF8S)(RI;(TE4DIS
MP)IY=K&X]$3J@H]!WP\XH7U53B=)UT5F*\8?YZ-KT_\ [>G#-D8:.9-?6ULB
MJGF]/&)JE9'P3R;JLR3_ #]?;Q-BU]I73I-:]Z>QCPYL:2_ ?0C!6)K3+AN1
M7M[9)M-$745^CY,C_F&._?<+C&OR_3?=T?\ 4%JW29A7U<3DO'+=P55(<LQ%
M'8TE0$G5K; 007D'711$T15!$X'',Q[5W&8%7CZ2%?5J3S26RTFV.3]I6UUS
M"L#Z8^*HT^H_O//N7BIR#NI4.X=@5&\C\7%GP>B3;$A,"<C%!D*-@UZO8@R)
M+XM+TO*P*:JHYPB(B(B8PB(G)$1,PQ_1$3V(G&'_ )>K/[,'%S_*;'^QO<2/
MS?<_V*HXOOS"OW;!^3NS_)GOO2FXI>YO;9X6,\QH :.'N896XAL&X;"L.2%&
M*LV,CS@$V]Y)#![-4VH)_!['LAD+F5)[I CQ[QF,\[YAZS5:M++EDVIIR$7S
M0T\#X<[O]Y&@&]11/&\:<1LAJ]O.+,>8!UYN$$ "TC1U4G1<577='4Y_,2/S
M_EG]AN?F)./SU"+8,DLRBM^GO=J[(141/1-"<AR1]V^WKY@77ZX@J#CF2]N+
M3+X5?_"UUS3!.EM/1FDVQT^*5\"R:<:Z:)TQ?:9D;>1IJG*KDYY2R<%[?5DI
M)1UTII^%8V&WZS;$25T[!V7(:+I^J<;99:;-5;0BU$L[BQFFV(T;&ECQV&A0
M&F6&7(S;338#R!ML!1$3V)Q6_P#1N?VA[Y,K_-Y?<U7QE\S3:DJ_ENH'CLWR
M93NFO+73J?)<_E";_P!WN*?,<*D)%SS% 08($X#"6L)N0LMF($EY48CRXDDS
M-E3]T?4(3T145/@][V@R)W(@]R"QX=O'8ENIJ/5;B)4S"<#EK[ETP<^RHIPQ
MW3[PP4A>@Z3N-8F^&TFWFU4XC\R$1N' BUQKO;8=]^Z_YW-$'1SYA::<\<&S
M@FY+H+4-Q>@GDWL7KL(2#)A211!=#QTYBJ$B<+VH[M-/M8Z+H_#;(E.2W2!)
M,NC.@2--9V,RSU4D'S1SW:(A(XWPU)C.M2(\AIM]A]AP767F710VG6G04@<:
M< D421=%3]#O+^4,;^Z,+^3N$_&=-EW\-S6>H"J)(W)V1GD14YIO9>)/\?&(
M1Z>K@U3<K'*&PFA!BLQ?66,BEKTDSYJM )2I\CICU'G-SAZ)JJ\?%4#WF-9#
M56"N(G,8T[K4KK:K[&W)%BRJ_M%.,([;8N\JE<0:FTRF:.IM12*&S,?:DJ!(
MBM50;G71U\[_ $P3SIIQ68]3L]"NJ8H18P<MQ(.I./.DB)OD27B)QPOM.$J\
M65];OI&K:J*[+E.KIKL;3DVVBJ.]]\U0&Q\3,D3V\5?<'.*Z0S6Y*_-B8M)D
M=1*ZN6,ZE="],9IT9#-:9=)U4T0'W5>71?D="*VGQRIZDZG/3SN&@IZBOW<M
M!G-@B)]#@@OLX<C2%4;$)+$"4!>5PMBD\CRBO--Z1]I?Y6O&&4"AL=K<;J69
M0Z;?XXH;3M@6U>8[YKCBZ>S7BB^"0(=3^).V]Y+OAKXS4,+>:MW+EG/GA'%L
M)4]V0VA&\:*Z:IYE7Y,C_F&._?<+C&OR_3?=T?\ 4\Y_ZL_]L,?XP_\ +U9_
M9@XN?Y38_P!C>XD?F^Y_L51Q??F%?NV#\G=G^3/?>E-\WE=U3Y9#&IML@MK&
ML:<RFZAG'KYDUZ1#BE&:B.-,^ECN"WH*JGEY<'@4:Q9#-!N;*L*R6RE@S\0A
M-2G);OQ,6EF;7 8/S[-Q:\^,9R#(<IAO4M9.-^Q8:R:YGF_'6+(;5A(C\1ME
M[K*X@^941-=?FNX7\@=__78XK?\ HW/[0]\F5_F\ON:KXR/^<O\ ]=SY+G\H
M3?\ N]\U/"N,&K X4H8+CFG3;F$P:13/4338+VBKR7C_ -?V'_O1CO\ Y[C_
M -?V'_O1CO\ Y[BEB=V[AJ?+49#]3$>MJ>SL(\<MH/O[:\G)$6&^;:)YU$'3
M#EJH+HZN6FZ%#+>C2,*KYN[XA$KC%\IKVA^=FKG.&V<5M?H,T38X*K\M]W"Q
M3NM;X+-R&)6Q)T>NICD.=.O@0("!ZUB_JR*.ZE<V>P@70_;X: ?_ /TMER[#
M$M%HY1(NU==%%S,'&U1?VBJ?LX=G1[-3QNC<C3LUQH1;AR<PIVK"L-8C=Z(F
M]3>G5HC)&F_?H6FJ;40JB;6-HU6S*N!*KVD$01N%(BM.Q6T =1% 8(4T3DG&
M31;A4<?R*-\$IX0J/6D6;Q(^R^*+K[FMZ/J#+_(0?K$/'XFM8^S(\I8:>07!
MT=K:,MKT.%HOF;>F+H^\G+_1BJ;F_DI>R&*2"&OB2QG9E9,^=J.L70Y".[30
M'&:9@_J$OO)Q@WR($XCX9C\-B%.Q.$#F%DNW5J1$90#@OR"T)6[EH=CQDO-Y
M1=+51X<IK?J-Y+C"C7V+4A%"2\PTJLQY3H'H?7%6U:>UY]0-5^M\E1F9Q''<
M7MKB$>0QHHIN9DA(;>G"WJJ"BVT4#(=>760]?%.(-O626YE=9Q(\Z#*975N1
M%E-"\PZ"_0;9IQVKJL-G_A_/$@9!.?R@Q9FQ:[$FPZ<J'+HI &U<?$'NH+**
M3/3<37?]H%M\=[T9#@];Z.-'2BKJQR3&!YG?U9(O1[ZIW+(W(JH0$2+]K31$
M=J<@_O!Y%<U;YM&_ GX])D1G28<%YI2:=S$@4FW 14Y<E3B!7-$9M5\*+";-
MS3J&W%8!@"/:B#O(0YZ?J><_]6?^V&/\8?\ EZL_LP<7/\IL?[&]Q(_-]S_8
MJCB^_,*_=L'Y.[/\F>^]*;YR1G$C&W6\47+,@MTN?7U2LK G0[$(KJ,C.66I
MNG)!-G3WHJ\T31?F^X)&2"BT:AJO]-V7%:;'_"3AHG%;K_S1K_RONJG_ "I\
MF5_F\ON:KXR/^<O_ -=SY+G\H3?^[WSB6T>N=L;BUD'64HDTY\,CS>B3OJ;1
M\=$%EEL5(6D5''U31-$WF ]XN\!OVOQ%QNRI:JR1%*YY"L2SL8^T6F:1IM!]
M)%01!T$1=J,;1=T3]+.JFJCN3+"7CTWTL1D5-^2ZPB2?3L-CYG'WD9V@*<R)
M41.,>E09#P-T-)5TES\0AS*LJZSJ:2N6RC/?$&(XF$1'$W/-J;"\]#71>'[R
M0)N=L>WKG0K([HJD>U=1U29W-GR([F0QUWT5-4AMMM'HJHOR2K%HVUOK'?7X
M]&/:6Z:8>>:;:KJ4:M;7J%[%+8"_7XP0\B=<]1G5-..:KQ$4@7+QNR*(Q+<<
M)2=F.64%@G=?,A.?2G.7/E'TXT*,_+D'_08C-$\Z?/1/*V"\.]RQ%7!GY!8G
M<1Q)?XEJT>];.CDJ^(NJ^O3)>0O *\0[2O>&1"GQVI49X? VG10AU_HFG@2>
M(KR7BPHK(-\2QCJR:IIO:/5#8D-;D5$>C/")A_E#Q;]C,N>VS*U^5,Q%]Q2V
M265W3)M;'4UU5E]@O71DT^JKVO@(\1[*B:G2:W!<'N,?R*Q=KIT.#&O3NIC'
MPMF1,88&6_YMR$UN;,!50(D1=/U7.?\ JS_VPQ_C#_R]6?V8.+G^4V/]C>XN
M'&R4#;R+(S Q70A,:JL421?8J*G%N>GF+*I@JOM40J:513_$IK_R_)W9_DSW
MWI3?J^>_R^O^^ZOBL_V8?ZQ?)E?YO+[FJ^,C_G+_ /7<^2Y_*$W_ +O?..UE
MW60+>N?5LGH%G$8G0W29<%UI7(TD'&C5MT$(=4Y*G""*((BB"(BF@B*<D1$3
MDB(GS%9V>P]2D97G!,L60QR]Y#II+O1"(9I^X*W-%ZBKR"(#BEH)BO%9C4':
M9QPZ]E,0=JV%J^(K-FE]K0S%!;1>8,@ ^SA^5*>;CQHS+DB0^\:-M,,,@KCK
MSIEH(-MMBJJJ^"<2LNF Y^!\.=2+0Q'D5&Y3C1]6+U&E+;UI3J>JD>/D1MHM
M4TX[:YTP.AXYDK).&GB2LR8=M%;7VJG^[GN7MW+QF]I'>'^/H_A,0Q7]Y^(W
M6*C<S[=R1IY&BIS1$U]G$>%(#4)K!NN_3_$F3C9I]! &W1?I3B7VYNGO(;CL
MK'WW"T#J$G5>A-[EY!+#WS:>QQ#3ZQ?)7=P\8-R)D^&.M3O41T3K.0(;OJD>
M1-I(XY5O)U41?*K2N(NO).*O*(G3:EF/H[J !;OAUS&04F1N?FZ1[D=:5>:L
MN#KSU_5LY_ZL_P#;#'^,/_+U9_9@XN?Y38_V-[B[_G^2_=-9Q:_FR=]T47R=
MV?Y,]]Z4WZOGO\OK_ONKXK/]F'^L7R97^;R^YJOC(_YR_P#UW/DR%P/JQ\,G
M..:\O*C^-1>7T^]=3_%^J7N13!(XM#3V5Q(;!=#<9K8;TQQL%T7WC@LZ)^U>
M,A[WY88S+R^L)T6F14U""PGN)K\="W=,!;TA,)XML-&G-#^1GMO42Q:FW LO
M9)($]/151D*QX!DVNX"GJF]U/_VZ(FBB[Q7T$#F$-KW[^FTYDQSSRI;G-5W/
MNJNB:KM'04Y(G%R0CN=K'8-HTFFO[B4#4@OV;8<AQ>.RT!I_?*R0H82EWZG)
M/#H)TEANYKJBV[S9%]!(G#+ ?59:;:'_ #6Q0$_^9.(]_#>6)94S\=]B2VNU
MQ-)#?2VE_P XS(5"#_']/$.W'8$]O^#MXP_Z"Q9$>JHC[&)(JCK?CH)Z>*+P
MHDB$)(HD))JA(O)45%Y*BIPUB<<B7#.Y6P8\7FH0IKAR4K.FG/WD*=K'\><9
M\2+5433]5SG_ *L_]L,?XP_\O5G]F#BY_E-C_8WN+O\ G^2_=-9Q:_FR=]T4
M7R=V?Y,]]Z4WZOGO\OK_ +[J^*S_ &8?ZQ?)E?YO+[FJ^,C_ )R__7<^3,?R
M)8??6'_JF2XT1BU\?H;:G1XDU1@[""_%;D:;2YL..H?@OAQ.[3YU(:QK(,<M
MY[,!NV<])'?;D2#D2(227E2,$EN>XX0:DB/@\/3W<^)5A)MZZ;9= EJZ6),9
MD3;"20;HX])@G#9B*I(IO$B (_2JBBY?WNRSU+N475M675:T?4!6\>>GC#E2
MU84ET8F^M F 5/=1(P*'E/C&[431PI-1#20J+KI,8:2--#7Z0EM&G^+C*$GJ
M@PUQ^X&02^QI8#Z$J?Y?]'VZ\=L:ZQ @J(2W<BE<(DV.%)O7SE@ ZKII.B(B
M_3N_9\D.O813D6,]IIMH?K.[? 43VJKQAQ6OZR)/;[+X,1B5)03=&'81V@&:
M)JG-7Z^81/M)IJ<-]0'<8DJ):,7=4Y7*WU?6I/C)'%M$U)7'%<06MGVMVBC[
M>,2=H <D8UV]=9N)]MTR]*KM=+6<VXV2Z#I-L66&6?M&@$XFHCR_5<H$2T1Z
M9CC;B<O,"9!7/(/_ .8T*_XN,,$$T1<6H3]J^9RKBN&O/Z3)>+G^4V/]C>XN
M_P"?Y+]TUG%K^;)WW11?)W9_DSWWI3?J^>_R^O\ ONKXK/\ 9A_K%\F5_F\O
MN:KXR/\ G+_]=SY,Q_(EA]]8?^JA*R:F7XJVV+3=W6/% M49#78RZ^"$U+:#
M7RH\#B!]G3AFQ.!;9)(C.(['#)9[4N(VZA;A(H,&'6PY2#X;7@<#]FO/B?16
M49N15V<"16S(BIM!R')9*.ZTFW39[LN2IS'V<38^$5X]P<(DR'),5@41R=$W
M_8=KVY#$]B=L'0BCH]'<TW*@DNU(]1?4@=N\/Z[1V;LL29D/@V:%M6$[(*RL
M'@TU;;V,1MZ(IEJB+QC6/X3TJV[P&.3>..2G.FE@P]L=L8D^4V'EEV$MOU O
M;=HR=?J"X2HM3?\ ;G)%LFRZ0N,5LXF)9)RW1WX<.9#FBNB^=AP@54Y<56=]
MR:MRAI*)]J?48]/ F;&?.CF+\/U%<XG5APH\@4-[U" Z\H(&S8JJDBBR:JB7
M%5*T5V)+!51#'78\RX"@_&DMZ^5QLA<'V+PL@)^:1V5<WI 9MZM8@C_S2'(H
MGYW37]KRE^W@:3$JEBKA;^J^HJ;TJ;(VH*R9TQXG)$I]43[1:"G(40=$_5LC
M_F&._?<+C#/RGCOW1#XN?Y38_P!C>XN_Y_DOW36<6OYLG?=%%\G>&9KMZ$-R
M'T]-=VMQ%'J;M4TT]%X:?:_9^KY[_+Z_[[J^*S_9A_K%PXJ<E1LU3_ZJ\9"[
MM3J'GEBV1>U0;Q[&2 ?\ JZ7_+QD?\Y?_KN?)F/Y$L/OK#_UF4Y-RJBQ>;!M
M;2IET^47M+46K#U7.?A$X<218(?1D='>"_0O/GP=ZQDE ]1MJB.7+5Q7N50*
MNW1#L D+$%5WI]OV\6%E^/\ #9_H(<B6D&MRFAF6$Q8[1.)%A16[!3?E2%':
M ^TEXI+^.Q(BL7E16W#,:6(A+CM6<-F:VQ* ",!D- ]M-$540D\?UG(_YACO
MWW"XPS\IX[]T0^+G^4V/]C>XN_Y_DOW36<6OYLG?=%%\G>C_  E]]._J^>_R
M^O\ ONKXK/\ 9A_K%P[_ -&?]5>+_P#/]I_V=Q7C(_YR_P#UW/DS'\B6'WUA
M_P"LNV=U@^+65C(7=(G2J2 Y+DEHB;Y,CH]60>B::FJKIQ&N6ZIF-0A'W3<*
MCBZWCEE<L=9NONY,,9(L=>%$EO-]-&^F>_5?;N;D,]NL.1UHMS9%05SJ"7L+
M8ZP8;A]G+DO/A$1$1$31$3DB(G@B)[$3]9R/^88[]]PN,,_*>._=$/B[,E01
M&HLB(E\$%(;RJJ_L1.+E2$D0[W)B!5140Q^&5X;A_I#O!4_PIQ:_FR=]T47R
M=Z/\)??3OZOGO\OK_ONKXK/]F'^L7#O_ $9_U5XO_P _VG_9W%>,C_G+_P#7
M<^3,?R)8??6'_JQNN$@-M@3ADO@( FXB7]B(G%KWR#N3E%99_$[6XJ\?F)3R
M\8*G')7*N'5N5S]7ZM#D)Y6SZ^FBCH/MXO+;(;Z3C$"APG!HMM$NK^NKL,8R
M#,8?XC%N*Q.8C.?&H\8.DKAR279J.SBFQ##*6MS.=<43>11IBYC3T%9/@/SG
M8#+&/SI+4UB_LC..X72;4 VC]?ZVG=2\*D?>@]L;B)0DHSFA*\LY"P67&6?X
M<AA(Q,L&V^:NJ7CHGAQWMRF!ZHV\"[?XIC<:M2U0*JLO<I:<MG;CHO?PLZ;4
M2G6VRV@CSJ(C?+V5$#+X^8XZYC';VW[G9>^[G+>2P<M*?'ATQV%I7/L2'V93
ML]M5A0@DM=-W15%24B/M<.08[8]N<98C9#W*L'UR1FP^)XI38])F0G[6+6!'
M=AH#GF>BOB>F\?$D)$H*!C&/30,I@W%C43XV2U5Q:0H=4WUA?RV@KFS+%PL0
M\K&^0ZI.J@:?6V_JV3XB!@U*LX(E7NN<FPLX$AFQK>H::DVR<R( .*G-&R7Q
M\.%P#N(#^,WN+FM6)3F'>FXRRJ]%A]60<Z#L=I403_=.M;2$EUX>Q#!"D9)D
M&2"M.U\.C23!D)W\.Z+'NP<ES7VS4&Q:U05+<J^7:M%BMEL<L59DS;L$5'&D
MGVKIR),1%34#"(VX+&J<CZ>[V\9#@F8,3&L8LIYV6/7J,./,N157HLSMK0D3
MX/Q!;"0C>XV'FMNU==>'94.W;NYFQ?2UU>+W4?=T\@NO&RC,1K7ZQ%S1/ 27
MEQE/<G*([D2US^8$B#%> FG JA>D3"F=(UZC3-C*E^Z$O]"R))Y33]7R;$S<
M!E;RHE0V'W$U;CS5'J0)+B()*K<>:VV:Z<]$Y<^)>'9A$D4UK32'8Y#):/;M
MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
M(2J7%;46H=*ZLY<G(+F/X^DFV#<=EN(JIRZL6OAL@Y[.JA:<N+VMLXLC\+WT
MZ19X_:"V1LN0G7C=;;WIR<DP!?Z,D/KZBAHFTAU5T9B2"TU!ED35PUTY#S%$
M;_\ *TXR/NA?1'()9)&&KH&7@)MUZJ*2W-FS4 T0O1ONQ8X,%]M&B+P457]5
MNJ9N64!RVJ;&L;G VCQPCGPWHHRP94VT=*.KN]!W#KIX\4&.9=W"N\KPS&7(
MSM;A[=34X_4/%$(G(X7!UXN3KA@'2W;77=5+Q7C-9M@;&0O9GE+N1OC85T?H
MPF1CA%K*QIEPI(.C61T(1=\JEO7DG%2]:Y1##$**ZJKJHQF%B%7%LJXJMMG2
MNAY4W*]5&K9<EKJ.B$='%0MB&B(.F0-R.X%DF*WW<8^Y+N+,T<!MDK:5-CR9
MT:PLEDG*L8AM1T;:#1IMI=#4'#37B[PRIAW=^YW8[CU6693?%7-1<?H,5@3X
MSY5$F<LL^M)@A7#T@TW/[O >2+W%FV-W*$\\QRCQN.+<1O\ ]GXU*ZLU#9)7
MM9R2[,0>(5Z7@HZ\]4N+',,\M<JGW7;F9V[<>6IKZEJOB2WP<]=4Q8KCK,0F
MFV1]V74WN*9D:[]J)"L<K@7L!BNBUT*+7X;58PJ)$1MMN992HLJ=*LYW0:V;
MM[8<U514M%3]7 \KQ:HN7VQ0&YDB/T[!MM%U1H+&,K,X6=5^IU-O[.#D8KB=
M142W!4"G-,D_8=,M=S0SYAR)@,EKS!#05^CY%K,EI:V\@JNY(]E$:E"V?AU6
M%<%3CO(G@8*))]/#5E6X'2!,8)#8=EC)LQ9<'F+K;-G(F, \"\Q-!W"O-%_6
M6@RS&JJ\5@5"._+CIZR.V6JDVQ.95J8PVI+KM$T37GQZ[&,/IZN?HHC/1DY4
M]L2^N+,V<Y)E,"?M0"37Y'*K(JBNNZYQ4(H=G$9F,;QUV.B#P'TWF]?*8Z$/
ML7ANQA8#1^J:/J-%*&58LMN(NX3&+8R945# N8KL\OLX1$1$1$T1$Y(B)X(B
M>Q$_5[G*KCU"UM)".;*"(#;DIT140!B,#KK#12'W3$ 0C =R\U1.?%#>Q:"^
MM4R"12,L5L%B(MC#"[ 71D6#;DP([+4%LO?J+A[5\-4Y\,QRG0QD2''6H[!2
M64>?=C_OVV6E/>ZXS]I$YC[>,[I B>CBX/9U50Y;/RV^C93YT'U<IIME6P2-
MZ!Q1;YN&KBKX#[78JSH:26 ;<?CK)91]EMXA!HW6M_4;!TS1!54YJO"Q79T-
MN4+/J2C.260?&.BH*OJR1HXC*$NF[33B/&D38D>1++;%8>D,M/22_HQVC-#>
M+G]E%_\ !)RG@P+:P&_R/'JRQ;IJZ793&:MJ;\7FR.A":=>%L0J]%7DBJ2#K
MYM%[/K68[E,3%L=N<DR^Z6TQJSJBB/XK3"F/B$5YD44I$Z80-)R5=/*B\=F+
MRQQRT8S7+>Z]GW R2T?B677Q^FI9ME<#3/..-B%3$M#=;=T)&R>?+VZ)I3Y#
ME^,W-GBN=Y=W!RZKII%=.89H,W"P(**QRR(;.XX;];"%NO\ 4[6(Y&K@Z>8E
M[51IV%9,N;/]QK').Z>97-%8PPWU$N=:ICKTV2 L.PY#$9G5M/(T0 B>\/;Q
M74.28G>+W0S;O.4?(\BMZN=&9JZ()QB=366+G3:EP?@+7ECL[FA:0E+1$9US
M6LS^7;P+ZY[@DQ!8:[;W-A>Q,6I9S;M _CO<(S<I\9H3B![UQMD7' U(C-"_
M\%V,CAP+"3;0O6?"W[>^O;MNF2>BC,2HC6UC,C5ZR +:I *'MY:Z*OZ@[(D.
MML,,-F\\\\8MM,M-BIN.NN&J VVV":JJ\D3A]_&\@H\@9C."U)>I+:!:M1W3
M'>+;[D!]\6G"'FB%HNG$2AL,EH(%Y/Z/H::9<5T6UF^I<5F/Z2N?D!+D==T5
M$-@+N)-$_2IOQ%9)7?B"YBT%1_"SI7J[:;N]-%_@HTGH(YL7WCNQH?:2?HT>
M&S;)&<DR2/.E4M;Z6<XLQBM8>DS3]4U&.#'Z+$<UT=<!2V^77Y)U54Y%1VEI
M5D8V=;76T";/KB;=5AP9T.-(<D1"!]-B]01T+EX_+!EY1<1J>/96#57"=D"\
M2/SGQ,VV$Z#3JCJ#2JI+H Z<UXO,-A62/9)C<>#*NJWTLYM8;%DPS)A'ZIV,
M$&1UF) +HTX:CN\VGRS;.>[T(-=$DSIC^QQSHQ8C)R)#NQH3=/IM-JN@HI+[
M$X@9%CTSXA36C9NP9G0E1>NVV\Y'->A-9CRF]KS))H8"O+])5541$3557DB(
MGBJK[$3B2F-Y+09!Z/I^L^"7%=:^EZN_I>I]!(?Z'4Z9;=VFNB\0ZRZR6@J+
M&QV?#Z^TN*Z!-G]1WH-^CBRI#3\KJ/\ D38*ZER\?TF;;*+)*NOD6$6K9D+%
MG3-\Z9U/3,=.!&E/#U.D7F4=B:<U3]'&Z"XLDAV^72)D7'HGI9S_ ,0?@#'.
M6'7C1GHT7I#+;YO&VA;N6OR2Z"#D5',O8 F4ZEBVT"1;0A:)L'"EUS,@YD<6
MS=%%W@FBDGT_*S;99<1J6ND3F:UF5*%X@.:^V^\TPB,-.GN)F,X6NFB"*JO$
MK!FK)#RJ%3C?2JKTLY%:J3?CQAE>L*,E>?OI3:;!=5SS?5T^5QYPMK;0$XX7
M/R@ J1%RY\D3B-D>+V'Q2FF'(;CS/2S8>\XC[D:0/I["/$E!L>:5/,":^*<O
MFEKK_,\4H[!&P>6#<9%45LQ&G=>FZL:;,9>Z;FG)=-%X<RN;>U;6-M-MNG>)
M+:>K>F])"&T02F"<:=1V4X+8[574UT\>(=E7R&ID"PBQYT*6P2&Q*B2V@?C2
M&33D;3S)H0K[47]&/B#ES #)I4$K*/2J\GKG80]7<^#7M%$8-=/':*KX<7&+
MNY$*6F/QK"3=$$"R=KZ[X5%=F6#$BR:B'"]5%CL&I AJNX5#]XFWB#?4,YJR
MJ+)I7H4UE'!;?;%PVB5!=!MT5%UM15"1%14^1ZKN\WQ"GLXW3]176F2TU?.8
MZS0/L]:)+FM/M=5AP3'44U$D7P7AN;6S8EA#>UZ4N#)9EQG=%T7IOL&XT>BI
M[%X_#/XBHOQ)LZGX?^+0/C?3]/ZO?\*]1Z_9Z7WFNS]WYO#B,.2Y/CV/%,1T
MH@WEU6U)2A8V(\L9)\EA7T95T=VW7;N37QXDWT;*L;D44+3UETQ>5CM3$U(0
M3U-BW**&QJ9HGF-.:\?_ .EX!_[Y8[__ "/#;S+@.LN@+C3K9";;C9BA XV8
MJHF!BNJ*G)4^9SC\H9+]S3>.WTV2]Z?&.\F&SF9+SI=.)'RC&;2R;9(BT5.4
M5L!3G]>>NO).,$[PS.KLS+O_ (_38T#F]$:Q7&K&MB0S;%?+_$.>5S3_ $S!
M+[5XSO$>VUQ08E4=N_20YUI;57Q>7;W4I)0C&5MW<U$@]>$\&X!4Q1K=YM^P
M:>]BP:AO-8/=F'V[R"*;2K5V8_#;"<IQEZB^B]:;3;1$AEL(#)-!(>*OMUW&
ML,;O8^58S*OZZ100#A!3R8GK"<AB3J-/R(Z>@<'WJ.$6YLD)/./&;]RL)N,9
MQ_$\5EW#=-CT^G2?.OX='#"PDO3;!TE6(_(BN)L0-@]3R+M1.HO9ZLP-BJI\
MJ[J#9%-GV;+DR#C[5%)?K[1Z'&-4221RX4@FNIO]VUM5%4T).TD3/;2EN[1C
MOCCXP;:EANUXSZA6 ..]802]U%LAE$\!"UJWTQ!==57C+L"[<6]'B=;@D.(M
MK>6E4ES+LK68"$$1F,\O1CQ!/>&[;N3I*6J[D'C)+U^-4,9UA&=1L0NR:CD]
M53V^NJ')8:,O<N/](VUT5410WIIN01PG%>X<S%[*J[B0[5R/#H89LEC<VMA.
MRUC,RG4!^: .HVV1NDYO$E(=%'1<FEQ^ZG:^%)I9\E:CM]#KSM[2?6M3!",Q
M>3G"5^ONW8*HXXR&P=RZ"2)S3^[/DBL)&7(.WU[=K&0MZ1UM<.M9ZL(7VD:Z
M^W7]G&396_M7X)4R93#9KH+\Y1Z-=%5?9ZJP=;;_ /*X[)9J5RQ+/N76V-/G
MH#/8?>8G9#9?$*M^>T#I.Q"3XA"5W=X+"/7:J\7':_ YN-5D=G$(>0?%+J"Y
M)<JPZL=J5(9!O>DV0])F--B!BH"*J6G+CN*%W+IX]OA66/8SEKT>$O3OJV#)
MKQ!8.PP;A3?B<@=ZH" 337)$W*G'::TR6P[?Y7C-I<X+55=//PYB=*K4GU#L
MF'+Z]AU6QG18,0F^L"(YN/5%X[RQ.W-E04LYREQ ["VOHSDT8\=K&:'T[$**
M#;P$_*DDFXS A!L2Y;M$XLLDLZN!(SZMS->WC;2 3=7*N3C+-9L7F67!1 ;B
M-NH38&(FZUR4!/EVZINXMWCN64?<:P^!:U-2E5*H;IUV#'9!DVT'UD,9-@VF
M\T53#?J@*@[N\%IBDG&(.!8B.18XM+9PG%L+V''KI@64E)P[GHM@,'WS7F!K
M>8 J%H9+_=UD;X7X!R6198YDBO1??P9TF]LD@S/7;]6FNFZ3NU$7RQ3^GCN;
M5-'"_ N$%"H8BA&_BY.2%M^(DLW=YPA/0Y($WIRW-_HV7\OF?V=SCM-EVXPH
M>Y[>1X->*NJM-746_?2G?-=%!LGS*(V'@J #RZZ:\3.[1D1U@]Z</[=8<6I=
M(J.FAW<JQDL[OK,6$P&'Q5.2.&XG[$R[ NW%O1XG6X)#B+:WEI5)<R[*UF A
M!$9C/+T8\03WANV[DZ2EJNY!XR2]?C5#&=81G4;$+LFHY/54]OKJAR6&C+W+
MC_2-M=%5$4-Z:;D$<)Q7N',Q>RJNXD.U<CPZ&&;)8W-K83LM8S,IU ?F@#J-
MMD;I.;Q)2'11T7N%:=O+C',9QS!;2=3UD2RJ1LIF3S*T#=?]7*?W)7-2  5%
M0%-J.H*ZJBGQVN7%X-3!SWN5D,O%U=G-O.TU2_52HL*QLF6E)3,#6QC.@!=7
MIB9#HXHIK$B9]=4>1/!W*Q9:FWJ*\ZIZ1#.)8JZ%E7\XK+[,C5 Z2JA!X\^+
M'M1VYLJ?&$QFA8N\CR.UK/C#Y/3 @/18$&$X21]BLVC*JJIJNI<TVHA]X?B:
M4_\ Q"[37U)3/6<6(IU%DQ;Y,U4-S$A&HBCA-,2?Z/+8J@*ZIQVM<S23BLS&
MNZLE8;5%30W D8Z<AN&Y#UL7D!Z4^VE@TKA;G&RVN"@IY"XR5R+W6[9X[\'9
M>ET6%I *YR"X9C11DC$NG7MZUEC8DBBR("(KN'FGU^/[H6528[<65=OY+,E,
M,[N@W*6-C+<GH;U(T8)\"4$555!5$55XN\DG_P"IT=5.M)";MJN!"CN/]$%T
M+WKZAL'DNI*G':;O=,N(SMIFN79(G<*.DYAUZ-791+<2&\[$%TGQ:&"#\OS>
M#FSV\?\ ##!)>.0&)6$,7BV-W"<D+5.)8NA)GMBVI+,=)ML609(>GJYN7ZO'
M=ZHO9U*UD';_ "6?CN43X\%?3WM+#ZT>2Q"; F@BV!63:*CR (*R.FQ%5>.V
M=U>6';_*,1EL8%%JL>M<.8LY$)F;2B=:Z\[8]6.<Z%!!6U>%$/<2JGCQDD7M
M]-I:NXD]L(;<NTO&');%=5I/IW'9$6(VA))G%-;8;%#1007")4Y<=R9V70JZ
M?G/;G)DQ$BB@3%;:6$J8]!C27VVNF@C%?AR"<1OIHXVT.FQ2X[>7>?W.-Y%C
M6<VM?46M774Z5TS&I-HV+S7H937GL$B-D2JI[M_24.6Y'..YU?@$G&*W&.VC
MTBEE5UW#<<?R6>TDZ-.CE,!">B*;U=(Z9MJR )T]V[4BX[+6[1POP+;9CD%!
MF'J(NYZ)ZR[E%$FM2]Z*R+489#FFG-6-/M<=PL=BG#7!<&KZ^M,QC:RI&43.
MBX\GK-WU(BL2VC;]BMC]/S-KZCMW_P 3@7 (:)C?I*V9M-?3:66RT;=CAZ;Z
MN]$WCU.7'>%E(\*3;U&3G,M,(R&J=EPL8.79U,*'6RX=F ^L(%KS/=RVOM^&
MX%4NT>/1;JH[8XQD6 U-G(S(\3^-54>T6 @LX[!KD=9A0(D86VM?^9;?!=4$
M>?9:DQJQQ#(;;N"UDD.5:BTX..V$EB+4!37,5UEV2\S!86S]4XVTI];9L%=%
MX[@8/W3DU5Z>+89,SR!=TD)*])%=7169DJ$L<0!-29?7:I A ;))N-"%>*C.
MIV;8;-2;=BS:]IX5(XW8UE 4IYA9;%\3Y27;(&6D/87N]#15U^HF88-VYN,?
MQ:KP")!6QM;:J^+R;>VFMH8PNDX6V- 1S>"F ]0>DI:EO$4Q2@E5N',93,[+
M.6,J^9I_5O0<F)V[BO#7V3^RR6@:F,>5DM")HBUYDO'?6XK+[#SKJ;),WEY?
M67.-_% R&965SLRS%@'E5@($]H% 674(4W<^.QN&X/%QFCRGN/7R'W9@U#4>
MCQZNA&XKSU;2Q>G#1US:X:!HH>Z5-NIHHR(F>VE+=VC%D^,&VI8;M>,^H5B*
M<=ZP@E[J+9#*)X"%K5OIB"ZZJO'=^#E%'6WL-C%L;D,1[.*W*;9D?!,.9Z[2
M.(O3=Z3A)N3GHO'<'!Z-\XF"/86&7OUCDE^1&H)<5*QQQ]"=-]P&T9ENZZZ$
MK;C:*J[!UC?WE0G-)D1]WI$TJ7U\=9GX$) K68I1NJD@D#TQ0_!/=.:\=A[:
M112LSI)#5Q-^!5M2S?2KV%(^%.M,Q:B2HLV!/ :$@%RTX[L9)68S H^V]A!A
MXS)[?V#< '5MF':R7ZJQQJ.;S%6##]?(5L51 1QXD;U4#V]U<9DXC0/X_58O
M0RJVF=K8QU\&0_68FX\]&C*'3:<=<EN*JHG-37Z>&H[#8,L,-@RRRV* VTTV
M* VVV Z"  ":(B>"?,W](VZ+#EQ2VE4#YBI@R=A!?B"Z8CHI"VKNJIQA_;I;
MR"SD&'S"EPK[TTCTI>HE3G)D?I(:/@TZS,%=>:]1D?9QV5IZ>RBPHO:G(:.Z
ME=:,9%<?#78LF<372419E6,MDW%5?+N<XRK-.U.64-,.<ML+D-3DE8_,CLV#
M"'MM*YR,CG4?ZCKC@@Z.U#=/7<*H(XUB$'(VW;6#W'K^XF17DZ*XOQ><S$F1
M)+,=AMTW&$Z+S:!N,M5!27F?+$^Y8649N'CN-V5(]6$RXLF2[-^(H#[;R%T@
M;#U_-%37R\9=A>!YU0UG;S,9D]]^-:5$F1>TD>U8&)81*MQ@DCNH<($:W$;?
ME'4=AZEQVU_X=Y$&/9/VO!\*BRLHOJHMJ,UU)4_XDVTA=$I$XG7?*VX&C[@*
M*HJ*.(IF&;55I>T/<FMS>2]&J#AUT>K@Q(T9*"K::4#/:XP3J.N"*D3Q:IRU
M6_[@]J\HHJ>1ET./&R*GR6ND2X"R8S8 %E"<B;G.OJVA["'1'#<751+8EI@C
M&3-/Y)D64,99D&2SH;G1F6"&BNMM167%<;9$/JZDNIJ1<MVB=MLX9LHT:+@_
MQ[U<%QEPWYWQ:(,=GT[@DC;?3)/-N]G'</&*O)L0#%\ZM;6\.VL,>E3,U9D3
M=CK-24WU(Q$KNNT(N.^=S13-L (U1.RV0K<PS9[6X4>+3HZ1GD<M7UQMZB27
M$+=M8:ZCW4T/5=$TXK,7BV[%35KD%;89%U&WW';&J@J9E7L=$P02-XA<\WVV
MQYIQ+K\0I*?$<BZT-^NO&&9*^G)B4V;[;H@_O)M^-O'ES$U0O9PYW(M[N#/?
MF=N:W$)\:/&?;<=MX[U/(FV8&9;$B/O5IJ(Z;DW_ +..[>(3+Z.J]Q\HMLAA
M38\1W2L26_%EPFI33CB*^K<B(G4VJFH^"\8EB659=C\F9B&9XW=5TF#6R CI
MC^.5$BK:KS79&=?L7ED;U<(=/9QFG<C <[J*&=D\2F@#66504V*<6#30:U]9
MCQ"^C4AF37@]'(&B\5$N6NLKM],R W<BFY"N9O90$8E$,HZ7I@<&.;W7.$$'
M5A?>":J9.H@J6WC#\G[L9=1W3& F<K'ZO'*U^($RU+TY#;6S\E&OX@'8C3FQ
ML-NYM-NQ-R%G=;AW<"!18%W!ES)]M7O5'J[F$=@+PS(5:X2=!MI]MY6>MO$Q
M9T\JD&Y9N(Y-9,2'<6K@D0;.,R8BY>+>'(K&X[+I[T26[.]*:KKHVX1:<N*4
M['>MUE#DC+KEUXB-]V5=['8JODY[Q7TJVV$<UY]3=^C*C(6SU$=YC=IKMZK9
M!NTY:Z;N(/:N5>05NZFY=O*N^;BR/21IIV<I]?<[QD*)ULYUE>?(RW:+IQVX
M[?55M#ANX9E-+E%E8.Q72;M)45NU*UZ0-J+@%*F6I*UO5=K8H*\7_<'M7E%%
M3R,NAQXV14^2UTB7 63&;  LH3D3<YU]6T/80Z(X;BZJ);$M,$8R9I_),BRA
MC+,@R6=#<Z,RP0T5UMJ*RXKC;(A]74EU-2+ENT3MMG#-E&C1<'^/>K@N,N&_
M.^+1!CL^G<$D;;Z9)YMWLXS=KMGFM#48OG\V5/L8%W5R9$^ADST<"6Y1O1M6
MG#VODC?4V;0$$74AW\8#1X=D:T^5=N;1^\I<BF1$=:F6<Z0U-LEEQP(^@V_-
MBL$WR>0&V$;(3157A:;-,ZI9UT664=\R4&G<BT]9 J&)3+D"*(*U(D/3#D]1
M7'!3GR\--'NZ/;+(Z:FOK:G;I<AK<C@R)=59,L#&;8DH</5]MX&H+":;?%E/
M-HI"O</&Y63QYV;]S+BNO,AR5Z$;5?ZJ!?1KD(L>&T742*WM>05Y>9[ZHBB"
MG9V8S;18X]LK*--F@Y'=(K0&&*MK9%VEHP1+7_:U^M^SCN:-)D>)-X[W2DV4
MNVFW&/R;#+:D;09GJ:RHD));AI$+UA-B;BJK0:$ (8ZKV(W7L$O^$7Q?XCI%
M?_WO\22OV^B\_N.D4+GO\=W$K$*:YC4?Q.= 6SER&7G^I5Q7O5.QFA8-LNJ[
M)::\5VJ"$*^/%E2XYCM3CUV]%9"LOA;D.OQ),=YET7'O?:NC(%I6W?:HFOMX
MH,YN\@@V;]7VR@X+.!F-(!^=80Y &MKU'2VH$AIO4D\>HJ^SCO933;UA0[KY
M#=W4-^-%<W4XV3\F3&;D@XX*2B8>>'?M4=R#R5->53@&39ACSYX[=XR_12(5
M9(%B/0XY!?@MPY"[([\B:ZVX/F5-$V>*ZZ\6'<[!<UJL?LWL>AT3,"QJCGQ9
MC+9!ZJ/8EJ?3C&33;H$ &:.-)RTY\9EB>3Y#\3RG.KC\26^3QXNB1[MEY)4(
MF(YDVLF.U)5U7=>D3J2'$39Y=,('NAFE%<8WV_F1I]774=9)CS+R9 1L(4B^
MD2MC8F(,#OZ:$A"IIR4M_&:7&!9Y!QS&^Y$CU>4Q)-5ZZUAR7CD',?I2,2C^
MI=.;(('%)K9UN:$H"7&2X=E5M'F)30[.UCVD6.XV'Q9RY*?1-,MNN;T.3/=:
MC%SY]54\.*ZPL=Y7.9RI&763SQ$Y(=2TV)7*ZZY[PU<K6FG5U\''2_:J_,2>
MYN$97C]-*DX]'H%CW%3)L=&0Z:OKH!BW[PF0T7Q3CN722<K2VS/NC+B6%]D<
MFN2'7I(AV2V++3%;&=<)MD#?>YH7/J<A%$0>*?%,=R+"W,<:PNJQ:WJ\IQT[
M /B$&.]$D9!5OM@ZYZA^,;8@T[J#2M;DYDO']U[M_CV2O1;:LGYRW R8X3;O
M2M),FAMBE+6N.N-E"]9((>@1E[CRJJ\9OEW=+(8.3W^9X[)Q!QJFBG"KX&/S
M&&X\MN/U@#1]]AD '1I.FB$JDXKA:0,5K<UPES$*V>3L:PEXEZO*QKG)Q2WH
M2#(WU^KB.&B$9N*WN\JZ(B)?9]VLS.HQX\PC1F,DK+RK*?'%Z.#3?Q"!H#XN
MOJK?40#0-KA'YE ]HXAW!L,C9M3Q[MO&PJR5V&3$ZYM6G9SLF[5 <./&":Y-
M4U;Y[5Y:KQWBQMVYAOO=S+/,YL*2$9X6ZQO)JQV!'&4!%N>.,3FX]O)4\..U
MA8UE<*ISWM;&./!MW83CU3:-/N(Z['DLKU'FF@+7:NQQ"!PQ(?,BC*3/,DAY
M+>S;)R=UJVO2NKJR(42%&:J8+7(WF&7(IN]0Q$R)Y=4Y:KEO<C LZHL=<RF!
M5USK%A2?$WFHT"KJ(1C_ !#;\;<<FJ1Q%0?!=..X)?C5R[[E=QH#-5<9G;0E
MCL,5)O1DL*V%!B.N.LL2H#2LK[S:J WH "&W@L>#'JL+_P##GPL<HZ3_ *SX
MRE?Z=+Q1]1S<6<G64/#[/AQV2E6N3ULUWM.-I&DDW$EHMG =?;^$L1=Y>Y6#
M!9!E=W+0$5.,B[B4UM$CX_EU6#-_CJQWNJY;MHVHV49P"1A#5]GJ*I(JZR'O
MZ2+QG'<YRTBO0LLI*JKCU8,NC*B.0(='%-UY]2Z1@:U"JFB?;_9\_$;GSX4(
MY\D(4$)<IB,<V8[^[B1!>,%DR7/8 :DOZ<BK&YJBLXC2ORZY+"(LZ*PFW5Z1
M$1[KLM)O3S$*)S3A"%4(21"$A742%>:*BIR5%3YI6WVFWFUTU;= 7 71=4U$
MT5.2_-M.V4^%7-/R&HC#DZ4Q$!Z6]KT8K1OFV+DAW:NT$\Q:<OTUIRN*L;86
M5DE5E81$L1CH'45]82N^I1E&_-NVZ:<^!<;,7 -$(# D("%?!1)-45%^:5IY
MMMYLM-S;H"X!:*A)J!(HKH2:\:)\S&6QGPH'K)34&'ZV4Q%]5-?W=&'&ZYAU
MY3VU=K8ZD6G)/E;,VVS-I55HR 2)M230E;)4U!23Z/T'JGXQ5?%8["R7ZSXA
M$^(,1A$3*0]#ZOJ&V$ D7<H[=%X$P(3 Q0@,50A(2342$DY**I\IBVXV9-%M
M=$#$E;+QVFB+J!:?3^J8!CCWO:O \5L<L.,6FSXQ.ZS#+ZIR4RC*D$P\5$A7
M]O&85W?6]S7'*QYR*/;:QIYLJ#00JX5<V2T..S)TD<VO>B!-A(ZW7TY:=OL$
MI*.T[G6&0XDT=':QKN/ZV_E5S$>.Q)ER7(S\8VK%ALY<F<KVQH$(]I)QG\+.
M\;?P?(NV\)RUOZOUK5N#M4VR3ZR(+[+;*.O)Y1V)N%SJMD!EOT'#;[)NWA8]
M@.?6\>EH<@_$4:=/BOS^K\+D6]4D*/T(MB+!.:BY[MD5+S<MU_AG;CMZ[G,G
M#V8[V4S7;^'01H[LA-XUL!94=Y),PDW"FJIYVS1 )!W<9185&%7<G/4[.QKY
MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
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M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
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MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
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M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
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MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
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MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
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MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
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M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
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MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
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M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
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&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mgnx-20211231_g3.jpg
<TEXT>
begin 644 mgnx-20211231_g3.jpg
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M 0$              0(#!00&!P@)$   !@(! @0% @0% P(' 0 ! @,$!08
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MFX)BDT0*T;8EFG6DGCG\= 0<F"EFWYJ4;D%E@TI.V8
M !+&/#)@!RJ/0ZF%)*V     4PM$R"                         4Z]+5
MY&"A9L4C:/0K6+)<6#-<N#-]                         !;>?#AW::_%
M^QX-H\KC?)  "J8LF2.!S,LZS89,U_,]$@                      6SGP
MZ\[S48IV? @F     !<?&S[!:3;9>UFPB                     (3!6XU
M>O.]U$O:H       R!P.9M-UW>5_#E                    E;5U7['H\6
M;+@  !#Z10B/A"?)?!( "J8LFVG6=]?O#Y8                  $K:NI/9
MM!CKG\, (2MJXYYG%QYS>/9?)PVSFQTB[Q34<=[DP9L@\3/E_@<F]N/D^2 $
MU2VW'6.P9#X7+                  ^&J/9-#BG9\  4N],*[/7XBV/"I]Z
M^4V\)2Q+S,I,R9(3:1M-/LR#Q,VTVEYV9>!G2 GZ6W*ZIV.[.-R
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MS,I,R9(3:1M-/LI\J7::9-J3::39=&*>MW3-K6:2-@-)MMA='MP
M     !@G<:O7#?Z86UGPZF]BT7G+Y4(+((GS/*7E-O"4L2\S*3,F2$VD;33[
M*?*EVFF3:DVFDV43)7;'3<OHSUGG"NX,N\_3^T?0     #$AEL  &"3(Q>
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MDM3/2HX\EO9*VUEBF3:DVFDV43)6C7OM1I^5T[ZKS,MZO8;5=<WH
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M62>QY)O':9I;3C[C^8L'^W^94NTTR;4FT_$].NI[','"R[1==WF8]5L0
M   !3,?+TDZQ]#ZYZ?TW!?#['XX.=TT[A\Q8\X'8N;/1/JG'5-CY1>.)B3$F
M):.)I_TE^?M!]=^:IR]9O)6V^+FD\=KEY.&M<C'/9:YKZ]QY_ \SRE?GQO\
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MI:;O6<R5K&NY?2KXS]X]]3L,B^S>;95[/H_3A<NU>-GH$K+F-KL=LQUL
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MF?C)LOP-ML3N_,.QWJWP,   *!,:QWK0BS[18$Q-%YQ-TQ-<AL%2V0XD
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M!$11,1'$_4_4Q)C3%$Q)BB8TQ1,4(DW?AV6=.!VJ]LNN[!>G_!&PN[\N
M  UTO7&LQ5R>*F6Z6\65:,N5G;G'<        #FQTGZ[YH='^O\ &W+ZCA_G
M]$^(B3$11,43&?4_5HDQIBA$FHTSY;X?9LD\3>YAV?0>O7IGPEEK9='
M &BV7'+IN*%5AZRDRW965,9FK.V6.X        'G$\L>B?://GIWU5;^358G
MYW1[.SZ 1$28HF(CB?J8UKIP[7(?%WV0>/O:[?B= .X_+?1/NWRG5<G$
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M34ZW      MR8UDO6@2LR8L.8W\PY-%,V.?AFJMMNL=Y@     $!SY,U&SX
M                 (36J]<;3%E6BZ8;V8LE.1;4KSB8P
M           "4,8VBFHR_6TX
M
M         #B 9U.I0  .(QVO)H &&C*14S5HY%'4PW.  !S/,UFOAU(.1QT?
M,I PD9B)L            %HGYH3%ITU,:%;-9CO4<&S"YT5-YC!1HX;9''<[
MVG10_)X?J',0'"\S,9B-7CK&<F33(_0 4XYDFIA^A(Y.&X!R6.\9H 7>3)DH
MR.= 3,          -!SB0=O#BV?I[/S!F5RXS?4YL%BFXA7#')WJ/R\'ZC2P
MC\WI^G8X:&W1S:,3'0DQD3!J@;&%TF3S04HAU@+'.<9U1.3ATX+",=G=DF@
M        #GN9Q-ESC,=F3@<9"-XCE.=%#4$L0[6G"$ZM')T[Z&3SA"40Z,'+
MLZ4&L9?!NT<4C;,I1T2.+QN04DU3.S)P].T9QY.H!SS-PS7H[<@
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M!S; Y4%B%YDF4@V7,@%<.')U/+,,0';(UU(S8<X=&9BP24-HS#A(E*.Q8
M               !JD;6@         'D:N&U           (3X1GD>I">)[G
MB>I$>)]/4@(P>9Z                      '.XYS'Z$3\>1^L4X4&;#K0?
MFQ-E3K\<8"=.SY^>0_5:8(/S_GZ=S!99!LB:[@ES-1:1FT M<Y;FV1JB;MF/
MS%1L>;+@           '. Y1G2LYI&_9NT<X#I(<Q#LB<,C)AZ'8DXA'?<XC
MF/3] !QX+I*28#,I$D7L=.3 AH4=ISBP==3 IC(T<.LYQP-U#>,RF
M    #G 8[.8AL^=0#E:7$;X')(V -]CF >!^C8X#G;,Y('.L_3^<QRZ#>TYB
MDZ;5G-H_0R:E&MIU .0QL,3AJ08G.MAQK.C1L";%            LTJ)8I$9
M9,*F-39PUF,PF4#$IYF7C$YE@&)S+!H$;/F4RP@9",9&4P 0&IYFPPX;'F*#
MQ-73HL>@
M
M
M
M
M
M                               /_]H " $!  $% O\ TK:;;7:5%?\
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M_EE_B\L/2/0]]Q\DE@Y;>7./2/;_ &Z'D1\F_)ZVF%'DOE#&XZ1K7WU?DI@
MQ3E$ATA\H(\8(\X@@=PHBD1!/R7'E)1'T+@/ _KY(1 ,$1'"$,J=FT*U3^)S
MX \ ^3=H?<(" @*9^/(F,!<$><33.J=FS(U+\4/@#Y229]"*<?&$0##*<]&S
M15R9LU3;%\L/E7L<)>A3"7 4 ?A"<H8*H]"E,<6T5A2E('QP^ /EG4<FOBS9
M9 < 1#/=-GO9[I,]TN>Z7/=SW#9R(]$T%5A1B!Q)!) /,CY<0 <5C6RF*1*P
M8=FY)@@(> J"Q\)&NC82'Q./:IX  'E0\8^;X <%%$<]A#/24/-AXA^?C_\
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M*.>8 _3G.<YSGP/&:#]N\:G9.O" <B <  <B0GH+Y*IUX8*+]8\@?$S\FG&
MQDM4O9DZY"U<T3.(!P3%4P4!,/23I;8,9V+C;ZT;14]<)N>5]U4!:W&5*R^@
M^ ?!%2SA@X W.<YSG.<YSUM@ $MX/UPI?2&()>GR;==1JNRV9+HXAL>"< 6T
MTY7!L%63"\/X:4=:Y>>EPHG@?0/%M!=$\[U+@^ ?!6WWW3'I]<YSG.<$X%+*
M//OW_4 YPI?3T11\NTK4N_9.&3QH;*Z__&S ? V4V.E9?@#X(5]]@_P,#/2
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MQ+V_MEM/_(0Q(?73_,FG&)<;53/<LL#U8:E?B('Z;Q4<+$."E3IGO.3H;ZJ
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M:(2Y!\[M$BV";I:R:@MNI;5+="3<;K M4+F;4XS46%?M]WN#S[L>6V"M9Q1
M0CHNW:_?)ID[-NFA=)3)SI;W9SLFQK-=\X]CDG,J;:T7$+]8+[_/M8[T_P"L
M.\O^V#/["3?U@L7\^[C2VF-1WR3#O-L]M\Y&;L]UE"WSNH[O<(]'XT1QD\\6
M6"[%V5IOQ(L>DKP_<+C%MSMU>9=M=QA",)B3$B..<67&9;)4?G-IEK7;XL:!
M_J"#_:*?X-1_U_KW_0;EB?%L[)R[I8+A$U-#A-(1.S.08F19C#(BM7'_ &=<
M'C *$IF*"B55,6S26MW;98;[I])$-N5<;=FB72#QW7XSR2PC.@S*CMN<(P=4
M5)00A5<RH-ETIIV; O5\N\HV8OLNS'RT8V(STSC/W"1&BQD% C+3A$X>:FS&
MC.\RW,N.QH$5JR39 @KC5NE6^YO76SN24]%N8[/>%"\W,V@JM2&L:Y7/42V&
MX+& Y]FEVV[/RHDG+ZUAIR' D,36\_F&VNT:9D%:BERN^EN9.#=X=_M4 YS*
M1#>>9YNV\7AJX:ML.OC4<V4LN]$W8U[:]:70-//7<+%RKL]IX&$>L;E\;G1)
M!B!+'DHMS'*A(E<I)OHBO770TCV^%ON2:CLRPVWQ]IE8WKG9;LS':>::>><;
M8=E<,<OK3;3)7,*XM.D]77R/IZ\::!^$"SFGFXEPM_,NO1'X\AMMQE'66GD:
M< U$U4,R51=FDM)Z 1^XVFVL\C[62(\T'VV6V]?+P0O@T\W:[?%::1%<$5(P
M7*BYPK?F6DRMLS----C55R@W>8 @E2526@ITXT-_M-_;#4'@D1)+:.QY3+L>
M0T5:.,O@K;K:THM# E3%UM^H($R=I>Z-N1''6 1"NMDYCC6N]VTC(&'9L%>R
MXTIT12<;546A(DQ=;--HHH2QSL]_YL"6B<-8X6LS4T)>BH]-:;<:H'3STQ+/
M=X]_T@Y+F15C&IRK6D=^0RSQ>+P$;N*4S9#5478F_&K] ]ZMO"UH_,8RW"3;
MRFA;KE!XK!"ZC<=Z0Y;;G'= VGVQ4.RA>:>82D%?++<W,JJW#LUG<N$E]4]
M5"&,5HE_A7&Q\>-:.1V^$PY:+4XRT@B'#:.\6HP'('8&@KN39B%^L%]_GVL=
MZ?\ 6'>7_;!G]A"LVI;7&N]K-YJ04.4A*TKS"JK3G8(%S JX_P"@%C_(D?\
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MD,>SX^VA<2<O+JH+\YIDB/\ %PI$M$%%)5ZD1*KAUXM[ID?DJN[X$^Y=[O\
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MOR"OP"X!%_>I[F.Y'%?:$&,T+76\T()G9(>DNE*;:X5MX";,5H0&E%3_ 'O
M++"4'>XZOFM@GG%UE3J3I7#4=M$06A0=B4JOI%T[27WG)AOIF9EQWHSP];3[
M9-.)\(EB=;I"4?@2Y$1U-WK([I-%OZ%4<,RT38OJ7/*E2;7X4K\7O066D\9G
MZ+8])%@&&D[([UZ3+I,O&N(UJ@CVWBJZ\2+PXS"?G9#M/1;'HZ5V8B6F"&5B
M*WES41">=7:Z^YUN.FM5^Y$V:9@,5$DZT5*+@FG$V;VSWH8=%%HFU.GPL H_
M96#1^62IV5;;5"X7C5U:#XJ^!R3<(P9T'\^/9<JN447<H&= 1$51):;$ZL*4
M=IX0Z$=>SJ5/2*@B*$72B;$Z,<.,X3(;>RWV:53*JB8T< E3I%47",7-55DN
MR+V]6UH*#F)5SY-FU24EJ6]$3"*BU14JBIN5%W*GO-N\L@O*7YE'#7T0N$00
M9D!U)Q&>&?C)2P['+]T&B+\TMX%^*6#:<3*;9*))XT_ OO)&F1^N:^8V/SB7
M"--;][CB^<X76OX$Z,,6^WL'(E230&VP^4B7<("FU5Z,(R.5ZYRD!RY3*;3<
M1-C#2[QC,5[*=*[?NG"D"JBBYDHJBNY4^%%1>GR[T1<*;<E@&! B==?,PR4&
MO9:1ERHUZW*HG7A45_,%=X"J9ORMV$"+F%K9G:3E4%Q1Z2<6&4E5_'WJN$;=
M40>W;$41+S:=DE/AJ1K1$S&F[;4D3#4:O8;#B*FW:X=4VIN[(IL\ON)$!TE(
M[>0<)5JOV=[-E"JJOYHP5.BB4]YS+8*"DUNDNV.%1,DYE"R"I+YH2 56RZD*
MO1AQA\":>9<-IULTH;;C9*)@2=!"28YIA/7-CZP4WNMIU?3#Y4]XH2U:C]+I
M)YWB;3TE^3"-,!E'I^<2_.)>E<,6VV1SDRY!4 !W"GI..GYK;3:;2)=B8%TL
MLF\OMTES.@,U%*/'3T6A5-^]?NR6ULJ-,(!OY5\]TD0P$MFYL=N]=J^+PB8+
ME(5JB_[MZ8XY><0-H5$HF81HM$S%L]Q<_P#-6OY[WH[K"S-9EHGMN(V.WLBB
M)<6T%/FI1[X"Z_ 4F&B([O<9W(YXPZC\73A1)%$A6BB245%\?W7(PV3B^+<G
MC(MR)A')BH\YOX2?FA^LOI_>PB)L1-B(FQ$3Q)T8X5O8R16U3F9[U1C,(JJB
M=K>9KE78-5V8Y>W@KDAQ$YJ>ZB<Q(5/)^;;KZ*?=[IGK5)CB;?FIL#X,E/N%
MW*FYF(E?K&_L^'+[T(#$3 Q43 D0A(22A"0KL453$J_Z895Z!VGYEL#:[#3:
M3KL9-[D8=ZIYPIY,*BU14V*B[%1>I4QZT<KOHO!L-/+T&GEPI-IS+?SF_/1/
MI-[]F**BHO4J47XE^X4%%)>H4JOR8JC/"#Y[W83X$WKA"E.*^7S![#7_ (Q)
MC(T M@GH@E$_W\-Q8,9Z5(=(0;98!7#(C5!%*)UDN&IVJSX;?8,+4P?K#J*K
M24[^Y47+V4JN]%IAJ'!CM18S(B#;+(H(B@H@IXR*B;57:OO ;HV)+'F( O%T
M-R6QR4WU1'&@3X:^[7%[*FQ5MR(OC3GJ_?\ >SDZV*%FNQ;5)L/L,D]NV0R
MU EKYP=6[!-W6WO-M(JY);8J[$=1*+F!X*AN)*]2^#U[#;GC4>U^4E"QZLGF
M/(J.#\"%3'JI3:_7$D7Y*IC9P#_E4'[^/,93^7#':=8;^%2_:ICUTM?Y)O\
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MHE$2J)A N5WMD UW!,G1HQKLKL%YP"W81Z,\U(:+S76' =;+R&"D*X[NE_\
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M4+]]T+JR1:XC$9Q]'VVO;[I1;=*%MLR8BSX-W[#A!1'6*J255,O=W_6&H_\
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MBNW"1$?>>AR8GKTE<I&8X7,YJ@T2K2F-,QK?>H5G6PR+F^Z4QA]Y'TGMP@%
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M91K=)@?I)9+FV"Q3;FRVH@JP!NNFY'YV2(+P^"ZB&B[D7!:KAMJRQ?6])S^
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MQ414\#,W43[KTV:I);+)!0'+G<.'3BN !D#;,9FO:=<40KLVDJ)@G87=Y#Y
M3_=;O+-TFT-=I/-V[A-&0>(D%>O%PNX:>FV);7+:M\A7GFI4"3,-GF'6K?*%
M&G75BM$VKF=L*<4?=Z:+3!0PO%\NTH5*='YIKV;;H=9:"SG;]8LJ;'[5=B(O
M7B'K:[0V[QJN3IF\:AC6R#'**%Q<$9\NQP&&A5XT*;%;8&J5J1UQJ7].[$Q
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M4MDF!<;GL;M]MBW6VJG+R''W<Y<0B1&VZ42M<0](ZNBQPU'"GL62U::MI,)
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MG6F[QP; ID*4PVXJMD<<7A)"%P'"5$2B(N+;)_2N%?M:S)DJ5JB]7R=<R9X
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M&-F*7V$7-E5>GP0)&L+R%I;NCKS,&L>5)<D'& #?RM1&7W$!I'1J2I1,R=>
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M9'=!.E86-)]VUG7B7CO U)#C\N)_G8<&1&1AEP4VHDB]3(JBJ[/5%U;+%IJ
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M\#<7932IMW4IA;8$2.W;ECG$Y)IH&HJ13!6R8%EM! &E J43'_V_T[_P4O\
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MD**+1A"C- LE9GI^18"A<ALWT.RH&TD9?UF6XJ@TUXN9#E#?I3[IP%E*1OT
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M)J"+46ZKCH9XK.[7SPP'I??ZGBW?6=K9IX=\WS1P[_."QN&-1N12.S""E M
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MA*.TV77[DKP>[A1VY.]0?9I4(@ZK&H[T.P-7!"UZW"M_ 8EYZ^\]>YC_ "X
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M -\WS1P[_.;^&P[.*FM+FM4Y%-N&O3RHY->J/?9"+0'6[JH<P9*B@BRYK^-
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M7$20QL4XQ>8Y89FI;DHP&;%O3@[YOFCAN6U  K95+TL:AEFE%T+.C!?GYM&
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M*#DJD]9HS2CEH<'D&+MW+Q60KM6/+RF#3<T9MS*K3J+YL%:*PJ<D.Z3N ;S
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MPQA"H6#5E>2R<"HH-WK977W"U6W9Q2CAA#G YN4-+J&'OX=D3PN95GFWN1
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M*UI7KY442B=@0EH -IRS6)F4?-"95JV\#@)V2Q4A=9P"+%?*[D!C6GHJ$8"
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M9&C+J4E N>.'Q8&QO.%Y2:?!W4#^0.\29BW](,''[A8,38.U^(G4PA00++4
MY,]@$6,!9=7HOX]@948LP'3'B"X*6'K'TVN_=0#[) K;-5F?N7A1^*\E<@H-
MZJ,X)*)77>%XL_/B6MM>UC!6VP:CE>J9AP#W<Q9ZI$HK=H>%$*TH7N\*[>6=
M=OQ_^:F%/#IBR:375NFVK<Z\%L8:!(&?W^"BA ))Q7;/(P$4+7AL-!X(L+/
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M^Z&L/H&F:\%_N#BJ.-O]VM_]N'__V@ ( 0,# 3\A_P#6QJX([)$N?I.AZ/\
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MW52O_MP__]H # ,!  (1 Q$  !
M           20       0                     0222"22 200
M            " 000"0"""                      2020"0"  2 "0
M               "  "022"" 0"2"                   0      0  "
M                   "00    0  2                     20     0
M"2                    " 000  "  20                    2  00
M    0                         "_JJ@
M"B4  0&<                       10     !6
M !*        +                     @  #7O\H  )@
M   "P !%W ]I2@ 9                   < #)83$/268 &@
M         ?/"8AZ!CD /@                3 :&YX3$/0.(T <
M        !@#:W/"8AZ!Q88#                 (!#6YX3$/0.+*@
M           8 4:W/"8AZ!Q9# =          "    "@,#6YX3$/0.+($@,
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M_K%H:D:"N+(#C         !E@("( *<!=2B-@OZ!Q9#4         !:@ /\
M%MH5*^OKF56T#BR"!         &; \P$!M/C#M !W#5,<63&X        MJ8
M3F].0.H5,N!P'8?CBQ          #VDOO:SC-=';ASP)D45<3P0
M $@O>D_<YZ/XF>\U<0#APT          "J> 3D/A]\ C.PV)IB"&@
M    0Y((A_P*$G>K9ARZQTDP           ,MED:="8C]/Q]1*%$!C
M      %-D(3AMLJFM6J8Q7T HA           &N!'3II8=)E%3!4=7-Q>(
M         $A7%*%N -U%I7CYCC_HA           $J#,NH\?SR6;.+R8TC)"
M8           +;4LBUD <' QB3 ![-X7           DF*F4Y!T!#%C/>@
M?K&@          $E"W):1,:HNTB)V  FEXX           'O4;]QWG #AHX(
M8  [+3@          !(DO27X+6(C5%PO   )[JX          %0U[W+.G'5Q
MAUUP  $K]$@          N)$$,Z2_!:9$8    %_*J          IBS^(J7
M;^RSYN   &/X??         'B4O0,EEG16XI;8   =;"#$         #5I<V
M;=%RXB?EH   !O,-#         'P94R-Z5TL(WI@    J9E;<         *[
M,;=K&S;A&UT    !($X:0        %8>;."&S/>*#N0    BZ02H
M 'ZJ:^'K,P"]!8     W$/H&         L$BJWYTP7X<X      #M->@
M     #6\,S>P]]?@      #S=L%         "+\6H566:CX        G)&X
M         /Z,$,GXV        'AA83           9?2](&          !-/
M"             $1Q    @       !9X\        @@@  $  @@D$@
M $OS            DD$D$@ @D        Q[NX         $ $@D@$DD$@
M    $KY$         D@D$$D$ $D$        5[NM            @
M       &K<_M    $@    @      $ $       _]C'D    D$   D D$  D
M $D @     !JL '0     @   D $ D$ DD@       J]#I       @D@ $$D
MD$@ DD$@     %H(4]      $$                   %>(<
M                 @*
M
M     @   @  @$$   D@$ @             D @  $$$$DD@  D@  $D @
M        @D D@D  DD D@ @D @$D           $ $$$ D@   @@$D @D$@
M                                             $D@  $
M              @ D  D @@DDD$ $ @@@@@          D@@   $ @D @D@$
M @$$DD@          @DD@@$@DD  @@D$  @$$@                   $
M        $              $@@@  @                      @DD$@ @
M$$$D @ D@D$             D@@ $   D$ @$@ D $@            $$D@
M   D@DD $$   $            $$@D$@@    $@   D @
M
M
M
M
M
M
M          __V@ ( 0$# 3\0_P#%4.\-;4& "JP<*C2O@&M.$*4#X$+6E' !
MJAF:KSC_ /@X<(@I!(?(;X,MZG@LH[,R"-RV9M'C_,)#K'U*Q(S)K-5YHP-
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M"BP 9_U5S;=BO 3G)D3*[H()%B.J>2)FA4!/]42H2R*;M591:' \R$R( ,
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M2W4-2E_RU6<RIT@GJ@M;;<;J6UW,YF(_@E( !\Q$I*X1%$?ZQ^P,SC"&U50
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M1(M"$1;=.I? @4<.FN1 4+!;C.NU!YP1V!%N*:>%8>*U6-1L7P%Q+3VN2&J
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ML_EA*2Y:#<$4;8#2ES4I)4$&I5E6C:P/;[2IULKY<M\Y31@1_P#<^X H446
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M< E![U+"H(!  @B(EB)A$^U4C#0FX8"PB8+\R()1J!II$QLE/,A S_9S?'G
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MY(ZV: *4'V5P.LZT <)JW&C5A4"EK0*>M1 [)9 5*, :#R1AYO:!=_6#-_6
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MN^[PK4,#%44M%8A]G*[*"Y3&K5S*4H6"M66A%FCB()BE4E=+;&[#L0PSCP(
M  "@,!_ X"-O'X;$(HU9'IG C**@51=H9AR[D$ ".RB%,_SUI(\LA%<4FQ0"
M%AVNG^Q6U98JJKQ5M4;E="CX@5WM=;+F'S%2R.7M:!#F%E*J@S?V!N"5*+$D
MGI@%G:_F)R,E63I(M$GH<DAK$- K!YF!&=$$O0ED7ZX6+. 2,->"J5#F GX3
M(46<1"K:\C7$@MP: N)1&P,#:K,@2"<X'8X@[S&XUH.\4T4TM<B(!8*"IY@)
MY^4"HZ/**)D%7<0?;1>DBJU&4 S4(^ +E$;GR5]!<M,AX*^ 20T;&)&Q(M&7
M;+NXT!S$A%K7:9@!@0TMI@\NN[,:=UZJR&-1HO)"D@2E([D1?X<!TM'$V4Q[
M$8HQ8BQ4311R(-02( J0*"A7*OL5E9A'Z@U'F)2 B(,4V'%D$!3-Z*RZ @F@
M3K0(7O3%@\W\3%SY'Q,'F//.?691K\:-0*&@;P_:.BKC*A@9.G&MB;U7/[]#
MI1^CDT/\MQ"QS8UD9#,CSY#H:$HH]+[;7HED9-8]QV9!AY'JZ\E(Z?:6 \HU
MME<!#0L7'.(T=%2T6GX'P6318(=SO#CW&Z),QSRUTBB1FI8>H+$G*&[\YR*E
M (9"+IT 4<F5HLJX]-?J<1Q)+;+!P6+DM.R=0TT$$-PY>H186M(*NB]B@?63
MY3%_:8>U8+Q+M9) M$P[NQ&21,BZ1I+S3#R-OZ9^)B&^'O,--<_/O'&=960:
M;3#E2"*35A$^N%EYR(&0/LM&L#0S E)M52S:%FR28?!P <%8Z)7:D"*C%#8:
M*,5<E@M%8';Y1(*N"PV'HW/+73N,]),6IT#W@!,6_500T_U9EINL@BE8P0#K
M2 5"+8PX"A8$>\:*#5(Q +!$<- *C((TG!=0W8B,RKAIEH2U2@; _?&JA%!?
M4 BKP.M7 0C0?B7R(,D;4VEX35U7-S8U5@@7/P2#*K1\NB6?9P]JQ-$,T,D9
M0&3DSQ=QCPG=\>1,!T3UF+JN\Z>"/92J%J&$G-5Y0*V-$D!K>+'M4"-$_P Y
M3H^1%$^P[6>:AQ&W0X*SLAC*6(-XTRV1,Q)%O!#4,F[? W)"B(#,P1]86-G?
MEF"(HP)BOTLP<(#6#5HW1X$%GI BPL@%?9$RT&BBK:V'J,GG\"X7LYV8"JBP
M:HV6.!'C$[BWRGP(LY)K]^ESVB/+'L"Y^CG7!TLUM*3(@!P(I& Z-]U(RO(Z
MJ0\D^@!L*+M7C)8*G@X,L&HSSSO(/BY/M\C)'G4<6T,"<^@3S8@PL<L P%&C
M--Z]BI17WW6LW;X&Y(41 9G[$6@(U6*%V6)-8\>,QUX-D^9C/3+Y,N]5^.\'
M,LV\5H.=!IY2ZK>WC>42E&598I@J!^V@GNQT+7D]J HU"Y4@F,.1N6E4:B)H
M5I8BCL02Z6RV&<6Z#J_?BM2_?"IT N]HJ\K%CL:\=V)73?G0U+'+%^]I[P1M
M%E=?+2D$'HY'2#&< "/0)!L3#<-*,15[(D)@X/X@ @H%7!KNEQ,2GSLUJ@&T
MF965_ EG :I,(2"SHB^N6BF(Y6<B@D(?;@Q$HQ>&C_E)\3600!$$@/D0#7S7
M'@L4*$\:>8TV]G& !"E*F;O0>J(8^6V+J %S'2V)X8;&,0\K4[FE<P_RF/(P
MHU!#:[ H%<W6@M$UCIX_$5!X+_R/7FKOX)8_0>=_B 2ACK#-+]Y2[6_C)*1D
MO;J2Y%7.A@4U6J(0"R TU'EX*V3X$6'\#1(@C^SK,%$N?@VTXF^;Z/M,)$OA
M.2( 00WKB6?T<)@^B(O <")_A4,0(>S:@B+I8ACF7Z*MG?Z4)JTH[2H!<!X4
M:CGOWTQ6I'?Y59>BQHT1'2Z\64$=44J%EDB[K$2:1BG@WI."BPQEL8,!T,S.
M<5QS"6PH'6]\($L X;)]35]2#]1 !/B943T9H=@'K\=>)#4&7#M7$3#=!C8^
M31(/F:*WV7M!$;B4&X#KEZTD&PB]$"R3G64N9#^T'$ K%<M1#JM9N7/A6FK,
M,&D>HG%!9FQ#!XB9:QY4LF< 9F"YI5?K D .,8 L<;1I> )[:\/\K".5'32O
M[GE'2O<^8L>//]3%?K_OL2[NP],QF]*AM@*.^D).UOS@#M/G^EEP(]R[EB^C
M1J+)'"TM:%;_ (*<8-O-J<8C0*L")]A ^F2/K3TBTP)]J[U(A$CZA5)F1[&.
M)I5E6'J*H_4KN(4/TU?Q:X@<G4!LD1/JR@1WR6<-2\B.7?<\VD75G;5-B4Y3
M:KAO]A';N1HH+3 -<P87AJRT^#8+%]E(  34-I9;#/*<.B",1DB-/(7N\(ST
MEX>GAC11 @0FH"9#@>&8FYK @/-8" F_9'4#O0&^(C)VN-]DI'FT&6A,6YEW
M?T;R<9+E;06X$X(8BC+, D(BO>%-AHO!;'C+S6*I9)!*!+C4I@:A#: D4SA.
MI'.E&%,R]O '0"STA#+!BY:R10,TAJ'%RB!F/YK>+I+U<(P"J[QK+UOV:6X5
M_+2XJV\GJ:)76:W3_L]Z'F3#S9]+<17U6OQ->(\\&5=G6? LHJJQ#K9!3M=H
M8\2:^I*E):(I]#8JKURTK^&MY*RRI7&"98-,/TVLHYUV*A9)%(0_CB,'>*TL
M0+ :_ 0,H#,\2D>[170Z:K(44HA2:%GEQO"5"<0ATUB1<"1S(M-BTYR '6L*
MV;Q$E%F),S38A228WU!FB8M7VE58>FE9SUO N3(#6+H*O!J%+8"#"1$(/,'G
MI+K"[$;22<1ZB/E#("@.A?L=V$]YP%7*OOY7IM$8T6+5J/W29VRCV-M@S5!J
M_P ) EFI6_FKHFF6;\+ER%V@F.- 1J9)).(]1'REE!<0*)_662#ZLQ9I& IV
MU@00J0$0ZLVEIM"VLNJMP)\"V41GE464[$MF*55JHA"HA#3[GA..Y2A2(N\0
MXWA.D!-X-4H'UIE]%I=_DO" CM+S1AUE0G.J](\'?\7\S!S9^?W+&2@ 4J@!
M:JNDKZ$KK8%K*!)E0*HBE0@=\O%HJ':%$!E2@ &56!NZGW(QK"QEK3+[7H$"
M((LJREW_ )7H?2N@"< 0-.(5LX3A)2#8D 2+3S 9>NS:)</]-:^SU!AR(EB8
MS"=?<B%U(#(C5(7!W(OVF+S^Y^I3HR#33208=2M<$3R_7)0RK<2X WVH_IU(
M$N[2X8DF>M^    "O[B_4E]DM*EWR#F,'Y#&]"PL$,B,7=H=0@\@JH&P08SO
MBH %J=9/5"O_ .J$#H<D2^Y7B&,4_P!, _KCNXV\3"']JR9)PM3=>1V(.:#6
MIEE6_0TN'5\2:]2JH88;HPCKWS@3"$* QH1G]QW_ ':T[RXLJNPFYX#*X;VA
M@*'[\'Z]*YU0*KM,3&*JP ^ S*?\+/8Q;-NIN&925W8>&RW^WI*BQ(#Y*HYG
MM^S5!S%A@<*@794 TM5 W2+!?40 +[IX03[L,V3)TH5-@I>!@+:]0C;:DUFF
MEAK,?T$P8,VQPP]VQ!RH$KT>> 6VUTV^"TTB ?A.<ZD$!2QGR@:B93#-<J)
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MP_"*$9MHM06L%0J!#IR"(*<&@&B-%5)D+>"N#_<@98+<&9YG.I%.0!](H%
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MB3L@-9#FP2P48QT6F-HN ^/7S8ZB>SX$?@(<S11N5E-Q4U:--!A;H<TS1#H
M1:D!CY=A12=NFY@T4DTK= (AM6N_";CH9>HCC[DP#;&!7C7.>HMWK6",1N.7
MG+"XD5,2,9R%::\$4%X+.=^_$SUT$BYJS%'<Z6M;IIKC9;:P@(0S\PZH;[W'
M@T$/L&UX?R_I3RA94+]RSN&1I@6FIXYIR(&=YB+-GFX1S/;RBZC<OA/C<?I;
ML9(I+#=70,DD2%+MG0\[J4AG17 49\C28A8OM*R3B65P"P/-DMD$BN@@":4&
MU]Z;WB:B34D.QE2Z4YO<DG\%/Q)_#-4@)>,:GH0A2H95X=,%#('^YM="@)A
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M!5ZY$'OEHEID/4>J:(X5MM=L&*DP)$JK1]/2_P"N.[>8[05S%0.NRTZDTCA
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MR#[TZKE*GE.\HZ11*X(/26)?.5<8IE<+YQ#&42*&$5@1LI!U--(-%#P 4^J
M&S*35EAPG%%N.9^_W] +E+E9'<ZUE$@/,B)>@!65:9C@PF!.1.Q945W#F2O$
M#2!H**-M*0JYGYN'X?*5>970 _;YK-' UEC&C]PH+<!&?K?"=I?6YW=F289F
M(,>65P:=83@IJ<J<*SLOI'/7H@@8!OA1BK&BIJ*O?V+F=KP9'QGD#)#2JBG-
ME>6]:GF,W#B\K<]@M>A&O#),##TI*>L,S#K'EC]18U&%U /E*3P@."\);5[\
M8<OAS?+?VSY06'"<V&KMFY\_6J\JX)N3 S JD-.!-!W^XL=74]Y4ZH$%K1F
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MX5$\@:.D-%W5?CXX41Y(DR2^<IM$368E2DI.*&\>6(G#O$.DI)8I^^58T >
M]$R#!XDUR=TR@NB :L:%!J/<@R>BG>#?$>(\;UTWD8YHE4X"\Z;7=S;W^FMM
MHQ.&B$(>\T.WV]$- NXQYK0=8/*"!T2DG?C2*E3)*&6--)WE1.<Z)DUXH,42
MN"#K+;04:9E_7_@4J=$>G$0TGX/M^<W<[KV5@%1JS'26FLPQBDXH,>2)*9?.
M4=(B3$J(2DX=IAUC;2(G!8)ATE\=5/,3V'U"C9K L-)JX$('+:OM]3U[(1"C
MT?F9)C>)=)0E\Y5ROH0C%2TF'66VG?A4Z)DUF&9E#,$)B6S@(]P7NOUVLZ1U
M.!#29M.D2FG[8A#NUV-^7Y2RF*3A4N4,7M,FLPQBGZ.B,5+YRAB),2HB4D[Q
M7AM-+,G= >[,19 [!1_ Z\"$-L2GVROF&] ^?:"N[\,Q&+&D[RIDF'6,TDLE
M2JG?C1&*F28=98TG>5$-Y8)SE@&L]*)]@\_X#7B-.&J)O!L^U\-Y3CW7\,H9
M22^<H8Q2<-)?.(8HTEIK,,8SQUUCR1C)+YRCI&9=\>LQM&K\ )WKTZ]7\!J=
M^(A'6^">D%/3[3QWE-?-^&)*32=Y7*9-9B(EMIWX9F&/+*$LWE7*32=^-#&*
MCH.T[Q!M+KM</6QVC^#0[PUX'!(G ;?:)BX"OOI\Z]HB_H]\2N%1C),,I-)?
M.4,8I.%2^<H8LTF3688QDXJ]((E%JL6ZNU(CN8!/P?PZ$-7@<4X)M#3]G6>J
M_)_,2,?(C,]R8^@DI-)WE<IDF(B/)._#),.L2Z2DE\Y0RIR"->_^2XN$'9J*
MS\J-IL#^'2AP. B62MI5XX:J^S0U9QTL?8)C>5'RKS,3O*Y3O*Y2JX5&,DPR
MG:7SF&(E)PJ7SE#'EG<^G[EG7,J+0%LP&>2AC5Q2/XFE-' A-<U3#',J,Q5;
M?LS OM0$?9A:UW"2/XEY9G4^?B=Y4MF&4DQ]!)T3O*'29)9$N/),[\$?I<XY
MUF&GFO86O*#W:&4E!0M75;INF7;8  /XE9P-9WC@PTH(9B#K+>K[2L56WD"!
MYF3=>1FHT/\ WVACG9*'3$R3$S+YRN4[RATE5PJ(E),;RN4OG,,L%V-WM-HN
MQRCQPH/RNP&5<!:M2A:,/.?4-K=;6M'\8HV0Z)<2UNL7L@Q<T<#65-F_V="U
M,[M91V"M="VT8 L!*1&D1R(X29HS</)_3.\[1.<KE._#,PRGRF)T<:G1,[PZ
MC/+^Y=.W\=H@Q= >ZN@-5<!+A\@!KTRA>Z+=@_EP<";FLU(%%0TX$T'VBO8;
M+7&T[;.77G1'KDVO+OT@F)AE)VF.TSWE#*28FDOG*-HWO*&4R\ $$\\W_P C
M>\L()QGK<N@6^=&9AN&,7]]N08.K:_S'&N4>?!PV3:&D(30?:()3D8SU6R6\
MZ#+SG.R\(;T8EE?*Z?YY3'+OZ>L$%ZDKE'K.T3G*Y3O-8NITZS&MN0S,<*\]
M7]16U6.4S *OD>_*(PFH;/DOKE]D*MM  '0,?8,3F(GI$X.D-(:PFS[9(1[5
M#/TM%=<FJBBZ\:!Z 8+Y4Z)DB_Z#TFE ])H5\J@FQY2G1]2"T3M/WM_4W\'0
MF89[L[SF3A##NJ&CJYVS&P=S+V+PZUT'-G.%R9[A?F.-OLA1LUB!9$X.D-(0
MFH^W0F*D01.2.$B:@NKH]=Y] ?5NWY(V[&;'R';69#KPK[Z>=7M&T8U B=Q"
MIN$I)9UF],RJKW1*6^355UBX\S_A7^WG#$P=Z?E8^NOD2F /=]=L?+Y6=(B@
M  = P?:VLQK$FB$(>\T.WW?OP _F=6>KOK%6D-[0 /P?=WY:Q.(A/P?W)C)"
M-[\1"!N]O[JY>T=>!";3I!:O[IUX'#)B66UFG]P:\1PU1+[P66:_W!J<1#K$
MSP3<@K)I_;Z'>&O X)$X#TB5C^VT(:O XI'@:?[;2AP. #'!."S7]MH31P."
MV;006:2H1WFO]N[.O @T&O 4TG6?[FZT@B-45<NO_P!M_P#_V@ ( 0,# 3\0
M_P#6P!9G5#\S'+/2W\#-"7V_:I_R4":@\G[FMKN_0S7D]R_1S_;$6(\M7T,P
ML^:_0_<O!A;8/;YBJO)^OV8%KTTE('T#ZF/:4"]'1ZZ>M006K'^PQ=.P97L>
M"7'E>KSV\O6(6*OY7\_4R>GZS*;Y-Y[>?K!O)I_6*!;I+"C=VG;GWT[Q"JNJ
M_8I'>FW=MVTF98W-SN>#E_5(5 ,K$&WW.[IT]>G\%2I7\)M0??H\R5G &?D<
MSW-^;_3IT K7I,\T8.?5Z\C;U^JD+J-?]F""],'JY]H-@/5]\>T;;#MC\1"T
M/>&X8&86?+%FLH.H?]@?I_3^YI=T.'W^HPZBQ)B@%DY]3I^/Z;3+$N,WJY]N
M7KV^BIP>[V()1U'+Z:'O&;',6YRAI-XPC;@>!\RI!OE<_P"DHQ[3IY/TL128
M\<N9!6,X')_3L_[_ $N3L&7(Y=W?IW^E-KW78_;[=XH57G&'2<H:3>,(VX'@
M?,/'K#3SG^IAV_4MU?T"]RL#F?LU/U<#I96/1_H]KDP<W8]?;,?*TMXJ"U02
MXQZ%W_0_/MP=8PZ3E#2;QA&W \#YAX]8:><-98O],T*#4Y?1KOC+\_D>?]'2
M/S.[]&.Z_0B7Q<O-^OSK#@ZQATG*&DWC"-N!X'S#QZPT\X:S;RE^\D\[0Y<7
MBIA/*:&IZ.YY./Z'2,L[NQYM$<K;*O5XUKLM7QY[^G/@<'6,.DY0TF\81MP/
M ^8>/6&GG#6;>4WFV;<YD%K:..9G@H?A]?Z'=8K=C!ZK[<5';'-_1JQ$EIMX
M'!UC#I.4-)O&$;<#P/F'CUAIYPUFWE-X2]N-._\ OYXILF3LX?:YKDT_H,?V
M1Y:_EQN.4'?=^/+B<'6,.DY0TF\81MP/ ^8>/6&GG#6;>4WA$C9K#'?OWXVG
MHL[X>]7Y_?@V@+BZ@%]6^%5:#'=P?OZ#@ZQATG*&DWC"-N!X'S#QZPT\X:S;
MRF\."IK1/<X]$%]'W:B#Z[*;>^:&L=76?22X\KM66G X]DA:J*!:<+KU3@YJ
MV/4KYXXAZK\'S]!P=8PZ3E#2;QA&W \#YAX]8:><-9MY3>' HG9FN33A3M&W
MHG[^Z8A]+:!;8HV<(K6&A=@Z88( H%O,3P(.F(QJO+<&@T&Y@,.: R@J7L(M
M+*5@,NAF.H$ PDVV6 QJG'I&AZ&?=?H)1JD47$8=)RAI-XPC;@>!\P\>L-/.
M&LV\IO#BNW2O3'"H<P]K^/N1R&7D[ *^D8<^KQRJIH%!:HPX:Y0WY(:> &2J
M2F)T>JBEX00VMJ(&44556U5RJY5RL= 1)^)@ $$1!&X-CJR9PQC'.31 <>MO
MYN.]HKT'0=+VL5AQK-RD\P1Q#UCHOX27K\U<4ZEV^YWE:F 5HVJ01K5J62$#
MU NG'1R'9'65B;049NCJ7%#6 8:3>,(VX'@?,/'K#3SAK-O*;PXG=>2X- Y_
M;@ "IH#58#6X 7G324NK6BE8>%@;!4YM76E!T(2@#JJYO=5P-CJ88PMD4:/3
M9!T<Y:\:< @!HP1YE%3N#J<5MOANQ%:K41[EX&6T$[=0T.0?.KO#@SY1]6 Y
M"6K>BD(B5YT@6\]4F05%<\-\Z0#Q2BQ$8K4&VW<+ERV1<HLJ3>,(VX'@?,/'
MK#3SAK-O*;PXO<<#;\OP)]K><64@PNAF6 TBWD I)R+1@BA"A '%TT4*1U-"
MQ@,SI;B1TA<J@'18TN7P[)AG8.WT^?#T1^.*(TZSK$QI1H/=UZ(5%G8 TQS=
M7TT#@</6DX*/83[O1Q>R4E;:M"O4*1I=8I%'6,(VX'@?,/'K#3SAK-O*;PXO
M<<.2B>Z'[^TQ63$ISDPQ:'"P965 $,D]5L7+%2N=<D].3S2Q:6FM*&C-L5#5
MZ@M 4VZ3Y[.ITCE9A6F0'GWN\7]&$:_N$QI&X/**B)Z0$ 2K)C%FRTU<(C3K
MPL?9GHQ:<SF];'R@  H!0: "HH "JT%P]5VDAK@MRJM/(2HK.+HWR'G!>Q,L
M!8+@Y.N55/*'^#.<(T>;Y:N<WINS;BLA5!V@R8O;50:#&4G,%IH<WX-7U1KB
MY:*'EN\KN+:"A59@KB_)SAN'0)$I*R-(\VT"@/.7Z'F/E<3);09P4SRIU*>\
M:BU!0IR"]<Y<F$UTAIYPUFWE-X<1IO-?'# G0>Z_'V>#PXV]I?"!@%"DH+VT
M#U"  4  $\]=4TU=1^?DQ=+6EM8TB#H)<N DO:'*"CF]2]Z)0V&T?J0A$MXO
MECO2^VOFWFH>JN :@4R(X_AT/KSY+)HHEN *T96)8=46][B4YJ;1Y!S@!0'"
M!1'4CL6<"4+0W:! B$#C= 9/:C\Q@U1<%WOE7OO%3)&X86O#DV;SB*H!L J6
M!0L-:^FM<+,(3:Q@$[C8^<K%"*ZP:]5*( ES/'EZ^D0:=>%;-OU(MPC66M(9
M0QF-IY>X(*>XG5FN77AD$,47!)RF!Z)V041UUU=KIDTK/E "M!56Z4 KG#."
MW-U#3SAK-O*;PXJ-O5^N>%D=6_ ]@^R:,+LAIE*:C5:7 L%$6Q"9O6C%1+&Y
MUYS>C&^O*\!K16A+X765&$<CAM +,19%$\?KDKQ+5@E7'B#)TI;4VRX&G1,&
MD%81;R'//T<%8G>XTTZZ 9 "(,L8,G8B7(0$!:NQ%-!JC#-%,7I>T?X[J2#&
M$*-52!9",\U504RC 4+Q5X9 Y*_)\P7O"+79>FE>IB&[55J2XB3!NHVEZU9X
MVA<ABI9YHJH"$$6,#Q%Y[Q%;OHR[0J%"G)%T%8,&(=DS6TT0KK5;S0P=0 ;V
MQK8&,!^+/>"'&PK2P&I0="6A*-!K3I?G T($--;>;2BVA3!(P%"P<TC63HL'
M$,7VC0\[RUH%W<-/.&LV\IO#@8SJM>\ "C0FDG [K4TF@'8*^SS:?2R%5:L;
M%Y )$>< Q2 ;** .!M65AL%5(4^?S<&AP=8"9A X;VA)<@$)!>A6@,N7+81Y
M2JL5:RJHM2X S!B7FT:!/2QY0SH@A0&E'N_U+<P'PFSXJ$<A4"(5W TU*VKJ
M9\*T-O)@0^Y3@/,8SC1HK25 ",J@\MV@B6:1B8(-_KA"(,5%XL8>EILW4'$M
MQ7]Z;H;:!L$G)@,+P@MK*&8:8A=JQ!:\ +6@1ES,LEBQR+Y)^$GL"M7YE03G
M%OUEZ([OW'YAM WLB=60*OYAIYPUFWE-X<%RM![O"P+'?FP?+Y?:,1M"86@E
M,13C$Y"'09$.H%4ACQ!G1,I56U7*JY5<JZ\;3 H]@=A)W=)9(5 K'%#4WE,M
M8.5_P \Q)Y>N@E"PG,=9F5J>8U>I0/4[3R,)R-W%-W-:L+Z8E/S?="OD\RMI
M8N1PHM; I&UC= @M/6&")'S_ $URXP<DL]!H$YO%3FA)!&"G1](2;&W;SHH,
MT*965%FT5 &A3HM41R,Q"/9[D "G<6S'@?,/'K#3SAK-O*;PX*U=3WX5:KUA
MV\BCO?V=AFA<E:!HIS7NW4G<-AX%0,  !H0KR2W*^W_6M]!'H0*Y"5U=Y\Y9
MOGBPTJ4CN24"BR6.DB:+E0,H$U$@ 5$KOH79Z?DU>\'O LL2M+DJ[0YX7GEV
M(-04;!O TCJ'=D"PA4KX!S&)S,&\JLG% M8:(\9@$CJ+R=$2%JLMOV#5CN@(
M3><J!/-@0YH18Q8Z[.#5#11-D<3%5L,JWIN/.LK!!;+:-+N>-"VPEH,P^8>/
M6&GG#6;>4WA/^[3_ )PHQTEZNQ\O0Z_9H%R47FLDJ^U8YBMA&Q0<L%5N:ZL#
M(IWB8DU"U4%R3]J''"SLK( 6(66&H!@(-0@L54FE(,XYS*]@'FV_@AY67H[)
MU(YW1@!&T'*>: J+_5@4A".8LZL&7#V32-?E@Y LKB'/K"5"@MK8,J\@W7!
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M."LNP2Z:"PCST+:ML@V+*HH6AH<@&BJ%#+F$D0!I,(5M#<QG(8V&"'+4%7-
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M=_0"7YQ=':L$<"*-VFK5Z$/F'CUAIYQJS',_'.4H\]W@M1YUWZ]'3??&'[;
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ML-31-*YJ.KF70:[C,/+("PHN'-5:5(_BJGC8]. 6LI<N&=/VEL!8*M@AUW4
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MT?VSI-^#P1/HT?VSIP8\*%;Q*:=>%G;^X2GC<]."#AG0/[JDKO #!_\ ;?\
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mgnx-20211231_g4.jpg
<TEXT>
begin 644 mgnx-20211231_g4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-  !+(P  TL   1_;  & L/_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@#)P'T P$1
M  (1 0,1 ?_$ 4\  0 !!0$! 0$            (! 4&!PD# @H! 0$  @,!
M 0$!             0(#! 4&!P@)$   !@(! @0#!@0& 0,%     0(#! 4&
M!P@0$2! $A-0(10P,3(S%38B-3<X8",T%A<8)("0H'!!)B=($0 !!  #! 0(
M!@L*" L%"0$" 0,$!1$2!@ A,1-!(A0'$"!187$R(Q6!D:%"4F(P0%!R@I(S
M0R2U%K'!HK)3<[-U=K;PT<)CDW2T)6#A@Z,T1%1D-887P].4E=9P@/'RU"8V
MQH?'$@ ! 00$"0@'!@0%!0     ! @ 1(0,0,1($(#! 05%A<2(R4/"!D:'!
MT1.Q0E)B<B,%@I*RPC,DX?'2%)"PXG,THD-3LW03 0 " 0($!04! 0$!  ,!
M  $ $2$Q01!187'P@9&AL2! 4,'1X3#Q8'"0H(#_V@ , P$  A$#$0   >_@
M                                            .9!K<O!UG!#,B"=,
MC; -0$534!UH                        !I<_.J?H:-\$2#CX=M#8AS$/
M<FL<X",!^EX                         _-"?I>!R%-Z'08AV<$R@.SQ&
M$C ?I>                         /S0GZ7@14.(YV)*@Y,'68R@YUD8#]
M+P                        !&<DP 1H(UD_R/)J$G(:[,7),
M
M                   %ERXL"W=7#MK6QW/BM&7'27KZ1-QQVOF'+E>MGSC3
MVLTU=GTB0                      !:LF/3O5YVI.GH89M:R0    N..^T
M>=O;CY71S_2V_P"@                    %GRX] =KDZ:ZW-IK0/X:\V<>
MJ-W%@^QCL.7'X36MB;]CME^"V?:V;9.GFN]+ 9GJ;,A>'U]F\_=
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MQ6IB?<]HK['N>D/17TAZ0^C[/J8^ZAM?G[TA>/U;_@RSD\?Z?Z2
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M>AX>F>MS@.+_ +CGX%LZ]RK&RN9N;^\UU(Y>PX50K7JUT1E?%Z,EOA?T^/\
M]B^=6WT_$JZQ4E5%:DJ(>Z/:(]CH%XWTT#/8>9G5Y'T>![FK6TMK_>U='];E
MS6\KZ.%OJ?.#^R2&5ZV>6'GNX)Y>,]5<\=P         (E>FX&K^CHBAU\T$
MM^^(Y\5QI.T.1O1\P;.V?F_L-:_4/#X1]!\C>=+//;^>?ZYNGDN]B_7T(Q_O
M#\K6;W'EZM%1$5)[P]XI[)]B]X;VW+BOV')[PLF7']GU,7;#DMF3&/[8!D6#
M++GSG>$W?(>FRC7S@         1#]/Y[6W0T\>YG0^[5YF>_X&A>CKR"\UUM
MF?/O53 _"7ZANNMGJZS%']9_!,9]7P9@?B?]*V#9U[!M8-4_=_E>G/U]^>JJ
M*U)40]D>\1['K#U1Z1'H?43]H^T?1]0']DD!D>#++CSG>$U/)>DS'5V0
M     (C>F\_IFT>UZ73<UH >CT8P>AU,YT]K/_@WTV:'XR_0M[U\]TP9:RE\
M']YY3(_$^EQ_:U[!M8-??4_"Z-_</Y?J%:E/O#WBOJ>Z/6)]%?;7RW7RG?N?
M6T;]I;:8L/4YUCZ7/']L &9ZNQ*CS_;$U_(^ER[6V          (K^CX4>J7
MRCK\P1L[FK"WV6C:,%Z[POI9[_SP_561Z6S>]?/<\.6LQWM^7'C6YK8_M:^"
M?2?%Z+_=?Y8J"IA[(]XCV/6'JB[>%]3M#\6_IK)/+]WW]AYW07[[_(O\S8LH
MXW4OO,Z&O_5^<^+U &T.?NR+XO6$Z/'>HON'*         !'3N<>,&;'DO5Y
MPB-ZO1BIZ34M.ODQ[7R[V_,7V*6?Y8^UY!JY[WK9KEARU5+XSN:N([^I@OTG
MQ>COW7^6*@J(>\4]4^Z/6L^V')M;\"_K7)/(>DO>MFOFOGT/^\?R9BOTWPO]
M*S!FS7SO=U_ZOS@ W[Q^IM[F[_I$S]\5ZOTB0         --=3G<F?:<6A[.
MAO3E9M2=?!%?T>I:<%\?ULU#K3+O\H_:M^?G'[%D&KGO6OGN6')45O@'4Y^M
MOH_C-&_O/\I5,/9'M$>YZP]499^?OKNQ_P I_?KS@S7W5S7O7SQS_H'^0,=]
M[Y#[QW\]C%E_ [5CZ?/MF[J@2Y\WW<BPYLLU=B;/DO2@         #FK[/B\
MC_HGF[IEI=,U,ZQL0V*VK!?']?+;M6VPZ:DC_P @?H/=/P7ZK?\ 5SWK6S7'
M%E]*SI'ZGX*/7[[_ ";40]XKZGN>L*GG;>VOY^_KR_\ !ZU\U\U\UL]QS8\'
M^S?,\[^.?2O?G;N$_5OGVB?VQ^8,EU=K"/2\$93KYI9>=[HW)R>C*'SW<
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MYQ.1[&&];&.YYJ2H\[T>Q?R3U^:ZV:/!(<QPTX2&(=F*D[C7I!XZ$EZ
M         !36KIKI:$.-+<SZLY7$W8IRRF,3&'Y*1U^D>3@3Z'!34FFK/PG(
M=C#?MC%=LU+_ "[^_#O=[3YFT.$!W?.3Y'<Z*D92>9OHUD<UB0I/$
M        '-#-BS")SB)KH6J6.2P^8I.MS,G[?)UALUP'-.28,O+SV7.R'8PW
MG8QW'+7I9\_]#TZ^<^E X0'=\_.(8\3A-Y')HZSDD"&Q[G3D
M   '.7-COL-C1- 6&6)3%$B>96(N%+U]+ZMW<'YM/M7B;[GQ73-3;&EG[]_#
M?=WG%<#E47TWH20-'D1B@.MA%XA>=*39                .?N7'F:;A"RF
M+S&%VB9^*^YJV  Y%?1O-0+]UP9#<G<[ _*_5[BY.X
M    !$_)2FA:98W+#YC8U4W<>0                           6U$9KUL
M<K!+$IBQHZ'X<F0)                           &A;UUS,64Q:8PNT;T
MI:8>.X                           P:8C]:MHEC<L.F/%$E:7DO2P
M                       %*1FO7&IC'Y8E,8?,;CK;.ZI3TN
M                !I2U=56BQF+3&%6BZ1.T:S?H2UI?Z
M           +:B+-ZV66-RPV8QB8V!$YI6;_  E;2]>
M         8=,1GO7'Y8C,8;,4YG43FT3D4)0X[7Y(
M      %J(>9*8A:,*F)&4M&*]<MB<YB<EA*G':\I
M      HR.-ZZ^M&\Z3NBMH/9<>MYC.XMLFLRDI;^@
M      _A#?)2V%_-[5ML:LZZF(H9*;-K:15)OR0
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MH/BR93$@                          "'62E068QB8PR8D[2\DZ6
M                      &'S$=[5M4L=EA\Q>H= <63T
M            / C3>N+S%AEBDQALQ+K'>0U+
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MQ.[JSOBE@                            +&B/%ZY1$[SK:H
M
M
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MSO.>QT;.E9L(      UH<$S:)TH)?         @T3E            (-$Y0
M     ##CW,J
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M>#6#<!N!/\9MH"$A)"%#DSY6&8Q&Q''^FM/[P!RVRJ3!PG%*9.@N0G(+-YV
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MTMPNC<I20E:5DO\ !]A$/_Q^_4S! @72RF_2-..N.G\*(S()E*[>,B[G%>)
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M"4)3\#4VA8)AE/5<<C"D*0$?B^P67\?V$9CWE(0E!?"C(C"HZ>_C,^Q*+O\
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M3[-H8B\+D9@%$?"H$GJ?@7>2,\Y/4"\]E%B\(2M&A0!':PE7>[R4WR<8$)$
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M&E;2FUF_84DPH4IZ!7T;L-QT1$U*.Y(U%%>)O _G-BOFV_\  -?_ /RO3O\
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M@*HFP=X<W3O.U@W,KYX6_O:];PEU4>-$@.]@:LPJUY$>&V.')REEQ)%55_\
MLR_29;#*_1-P<_P-^NOQ;>R[1)7_ #360?C>5M</@V7D5XIY">?4OC &Q_=V
MZHQ&OO6C7X^8Z>VZ8@^B-%_RF2V_Z>Y_HV/_ '6VZ>7PL12_C,KMO=9<X>O'
M;3^CR<=O;1(KGWG-:7Y3=3';](A2&OYHVWT3\;D+LB#-;;+Z,A"8_A.(+?R[
M(0$)"O A5"1?0J;ONCS)<AM@>C.76+#Z )B9KZ$791KXQ.K_ "TCV;?I1H?:
M&GI4-EYDQP 7\W']@&'D7EX$2??*OV3-&D/,+T\IP@Q^^1%P+X=D&6VW,#Z7
MY![\8$Y:_B[(*/=F=7\U)P;Q7ZKF*M%\>/F^YO-EO@R/1CO,U\C8)B9KZ-B:
MK6^S-\.>Y@;Y)Y1'>VU_"7977G#=<+UC<)3)?A+%?$5)-O$SIQ:8/M3J+Y%;
MBHZ8KZ<-E2)$GRUZ"46H[2^3 B<-W^!M^C5$=K^?DN/^3^3;C[=5FL:^\COK
M\/M)1[]ORD3_ .%'_'MO*&?F*-N_@F*[)S8E>XGU0D-DOP]H,?DV1)-62>4V
M)*%\39LA_&V3F.2(BK_VAA53'[Z.KZ8;8Q)<>1_-.@:I]\*+F'X?$067N8PG
M_5WO:-8>0=^9O\%4V%MU>QR5_-NDG*-?\V]N%<?(N"_<G%=R)Q78X]9E?>WH
MLE=[ +_FT_/+Y_5].RO273>=+B9KC\"= BGD3=X<UG/98-4Q".B\V4Y]Y';S
M.X+Y<$'S[$W1UXLAP258>T=5/*,9HD;;+TF?HV7WC9RI(DN/)5SEQL?-&:R1
MQ_%^Q(0JHDF]%1<%1?*BILB)*62VGYN7[=/1S%5'D3T%L@3V3AGPY@XO,>E<
M$YH?$7IV1V.ZV\VO VC0Q]&*<%\(M.JLN)PY3A>T;3_,N+BJ8?17=Z-N;$=0
M_IMKU76E\C@<4]/!>C[C%(E.BTT/2O%5Z! >)FOD38F6LT>%_)(O7>\[Y)Q^
M]3=Z?"LRTEMQ6=^3-O=>)/F,,CBX\>_H3=T['&H@*JB+N[464K%T?,O6;B(O
MU<3^ML3KSANNN+F-QTB-PR7B1F2J1*OV?FQ'W&#^H6XL.@P]1Q/,J*FPM6C?
M++AVII%4%\[C7$/2./HV%UDP=;-,1,"0A)/,J;O +\9TFG0X$/\ %).!"OD7
M=L,>1ECSN@?S3_G:QX%]7[B+(D%YFFA_*/']$$\W2O!-N;(+ $QY+ JO+9'R
M"G22])<5\+E?6<NQN4Q$TQQAP"_[T0+BX\B_FA7'Z2CTG.M)3LN0?SG%ZK8]
M#;+8X-LM)]$41/M//&<ZBKBXP?69<^^'H7SI@NR"GL92)UXYKO\ .K1;N8/R
M^!%1<%3>BIQ1?*FP0;(_:[@8E%P<Z$;?5?SGD+YW3OX_<$I,A?JM-IZ[SF&X
M!\GG7H38I,DM_!MM/4:#H $\G[OA>I-,/[NLU.MVEWK\TV*XTZ.A7D_ ^EMB
MN]5WJJ\57S_:HF!*!BN(D*JA"J<%14WHNP1+$D%[U6Y*[@=\@N] .>?@O[O@
M;K; ^ON"+))?6^BRZJ_.^BO3P^X#DF061IH<57I7R"*=)DNY-BD.]4$ZK#./
M59;QX><EZ5Z?#(TW0OX1QS,VE@T6]\N#D&,:<&!X.$GK^JG5QS?; 0; _9[A
M8D%^;Z$;=7Z'D+HZ=W#P) EG^EM#[)PO^L-CT+Y76T^--_E^W^0P7Z#&)>7A
MP><X$^OFZ!\WI\):<J7LMG+:_3Y#:]:#$=3<T!)ZDN2'P@WOXD*I]M!73#\@
MQ'2^1@U_B?%Y/ #K1*#C9(8&/$2%<45-D<W)):P"2VG0?08I_)N<4^+H^W?=
MS!>WDCB^J<6XZ[LOF)[^+Z?"_8GE.4?Z/71R_/S#%<F*)OY32)G/ZJ8<539^
M9+=)^3*=-]]T_6<=<)2,E^%?MSD/E^EL#O5?SS?!'/OD^=\?@;D#BK:]20W_
M "C*KUOPAXCY]@>:)#;= 3 DX$))BB_%]MORWO49!25.DEX""?6,EP39Z4^N
M+CQJ2^1/HBGU0'<GF\+BL.*576YXE<F/4<P+](F)YY3@[OJ"/VZW(97!QLL4
M\BIP(2^J0[EV:DM>JX.].D"3<8%YQ+P'5/%O#%V)C]'BZS^"O63X?MMJL;+J
MLX/2<.ETD]D"_> N/X2>3PNL,'EL+G/ C8+@3;*C^FR$Z?9LEE14WH;@K]O]
MC<7V,I4R>0)' ?\ 2)N].'@9DLK@XRX+@^D5X+]4DW+YMF)37J/MH:?57YP+
M]8"W+YT^V7Y3GJ,-DXOGRIN%/.2[DV>D.KBX\X3A^DUQW>9/#*9;/-$ID]V,
M(G!76BQFG]\LI5#T GV#M57075E&0R:[17U<Z8QS11%)OFQV'&\XH28ICCOV
M1VTH[>M;7#!R?6S(8*J[DP*0RV.]=DBUL&9825$C2-!C/2WU /7)&6 <<RCT
MKANV4W-*ZC; ?6,Z.S$4]*E&1$V(#$@,542 D42%4XH2+O14\+MBQ6V#U?'5
M4?GM0Y#D-E1RJ2.R@;5AM10TXKT_:"*BX*BXHJ<45."ILS(_.8<MY/(\'K?C
M<?0O@D5IKZOZ3'Q^BJH+P)Z"P7X5^V6((KODGS7?YIG#*B_?NKC^#X;2U+#]
M!A/O-H7 GT!4CM_\H^HC\.QNN$IN.$3CADN)&9KF(B7I4E7[!J2SK7NS3H4^
MR>C/\MI[EN(U6IFY;[;K)[E^<*IM(TYJ8XUU EULMTU=@1&2;Y2MHH.A%89C
MNQG1<450PXJF_H6WK8?_ $6"YJ*+'3'%099=4&VU+%<Q-"F55\J;7\.-<-K"
MK[VUB1HCM;5DVD:+/?99:)P882206@1,>9F7R[2]7C!8@ZFT^C_;RCIE%\83
M34B4!JO7<CG"/F-9LQ-FB@BKUL=HW[4'*;IT1PW^RBI$9@"FTTYD]LC+I)E7
M)UM_1Q35[]?7-U=9 .15UD-M!%0AL1JQ\2=0/9HZX[))5R\/.N)+]H.0R7J2
M1S!_/-)C_";Q^)/!%E]#3B<SSM%U'4_T:KLBIO14Q1?*B_;$I<<087LK?H8W
M'\;V9?#'KQ7KVEBT)IY8T,5DG\4A&OL-]+M8/O*N8L;(Y<#%$[2URJ[%O%=W
M'9]C0VBH-'*DAE.P?)DS'>N&+33.>3D5<1SNY17YJ["^\9.O/0+1UUPUQ-QQ
MQ$,S)5WJ1DN*[:L_M+>_K25MK"WGB3+5FU/2"+J8(\AP4KHSB"N'4D3GLGG0
M=H;VI-2W<"Z/M';(D1AXX[664^,?ED-!-%<\40)?:EO7HX),9H)3\ZG P[%*
ME"HOO!R6U-7!*-#5%1Y23\F.Y-M:?UC._P!@I/M%E\/69<!Q/P"1</0NP.AO
M!P!<%?*)HA#\B^"*2KB;"+%<]+.X,?.K.5?M>3)7\PPZ[Z5 %5$^%=E(EQ4E
M557RJN]5\-1 QQ&)6')PZ$<FR3 OAR0A^PW>C'8<UR=9O2W&I3?([(VD@8B#
MS,SPO;NSKP%? W<S8\B2P$25'5J+R^;F?%$%?:FV&"8>7:3:+H*5+L9,AZ6\
M4TV39?DR'5>><=;<F26.NX2K^25/-LS"[.S54L4A.-5Q5S)F 5!HI#V5OFJR
M"X"@B "GS<=_AOM*NQ9;DRVE2'V9#?)[,V+T>O91'<SB.XHL1> KQ^TFD5<2
MCD;"_@KF#XFS3P38:KQ$)()]ZO*=7X<P?%]KNBFY9+K+'R\TOC%I?$MDXC'"
M!''\&!'<-."<'7"\; 455Z$3>NV*Q9&'''DN8>G'+M@NY4XI]EJYE[=WT%;*
M.#C67EOB3G):=>$4C4DD@$>:GK;/:DTG<K<5L;%9#3R#VAML53F$CC8,]=@3
M0C VP7+O\VUU:W<RQB,U!*;APC901C-QBDON&V<*6ZX0""^KO\VPPZ;5\]N<
MZN1GW@T@MFX6X $7ZVKYA$O0CF*[=AGH)(8\R+*:QY$IGAG#'>) NXA7>*^;
M!5V5J$'+BM*G;+![%(L4>/6+\XZJ< 3?Z$W[4LBMF2YJV/.YCK[D<V#1MJ.8
M.QD88!1!SFX[S/=AO\:9'\J-O#\"J!_QA\$3Z+V>.7GY@+D_YU!^UZ]CZ1ON
MK^ C8#_'7Q-0EOW63S>__,X-?%U-WF\3L\%A7"W*9KU6F1^DZYP!/E7HV$[Z
M7VV8J(21&\V7\%AM>:8X_.<407R;<NGI6([703F1K'TLQA1/X:[;XM=E\G+D
MXX>GM7[VR-VU.TZ/28<M_#[UI\4PP^_V.3021;=1,2B&I945>A1/VS&/EZP>
M38V)#9-.MK@0$F]/\:+T+P7['I5NI%@EAQ<SW/>1E$1Z)#0,N*+F_)KM=55I
M/BOV]Z$L&84<U7+VV*,#J9D!PP8;13,U$1QZODQU_P#ZA8?J:3X-)V<G$YZ.
MP&^828NO<Z%(;>PZ5*2<<'%\N&Q&>GKP  5(C*IGB(B*8D1$K&""B;2ZN-.?
M8@3R Y<9LL =4$4>/K"ABN!HBHAHB9L<$VT)_J"?J^N\8!_EF7F_B'F_^R\$
M9_\ D7V7?]&X)?O?:\9OZ$,2^$WG?W@3Q-1?UO-_IB\*1F.HT&!RI"IB##6/
M'ZSA_-'I]&*[>X=-B".M]65.ZIJ+O ^MA@]+7YQ< X(GT2<=,G'#52,S)2,R
M7BI$N]57Q&EK!=*4*XCR4Q7#IS_-Y?ES;MF'G66HMLV*(29T5LDQZ[:N!GZO
MSAXX+N\^R)*9($7U33 FR]!CBF/FX_8M&]FD/QU..YFY#KC6;"' PS9"''#'
M93,B,RWD1*I$J^557>NVM8,84.1,9DQ6!4D%">D5;[30J18"**9IO78?>A0Z
MN$"YI#Y26WW49'>:M SG!2P^F0HFU1IK3[HNUU%RR5]HD<9.1':[/&!L\,CW
M9F<V)[T)3\VSC+MSF;= VW!]W529@,5$DQ&"A)BB^#0G^H)^KZ[QH2_YW+^.
M!!_E>&*[_*1F'/QVA+]_[6<3Z## ^CJY_P#*\/7+?]%-Y?%T;6-K>W*LE.DG
M*2 VXVT8HYO7%L!D2GL>.(H/';*W E2?F\S_ '@N*?2P?E-8? ..P,1'Y->^
MX2 V/,EBI&2Y13-,&2RJDO1FQVD1:!IR5+=-5D2DRI)0#QSO@"+F,VFT0 $=
MZ>MMSVFACQE5?TJ81-B:X]96Q03==]*)ACT[=6SA*70BMOB./WR(2I\6RN2H
MN>.G&5&7G,)]^J(AM)]^(^!J.R.=U]P&FQ\IFN4?E788[2(3RHBR9&'6><Z=
M_%&Q^:G0GGQ\!-.@+C9I@0DF*+L36]6RZ[)+Q4%Z%^L*[OL+02YLN4#.YD)$
MAYX&DP1/9"X9(&X4X>3P$,*?-AB:YC&+*?CB:IN121HQ0EPVR2[&=*#Z$B7(
M>'\5QPD\1IJ3+E2&V$RL-OONN@R."#@T!D0MIE%.'D\:!_K3/\=/#6KQ_0V!
M_$;0/DP^UI/\W'_H \'(C]8^"DG1YD]'EVSO>T-=^_>*+_E;3',,$EQ8$A/P
M8P1?W8W@22X.+5:TLG?PYZ^SCHOG%54T\X;2.SR2]VDKJFPO79['&3E-& 8]
M1UTU%<R=)=*;O"J+O1=RHN]%1>*+LY:U#65H<3F0@3<VG$GXX]#:?.!/5XIN
MX$^:8I"BN.C_ #KBBR/\ R^+Q =^<RZF_P"HYU23\;#[6@?ZRU\A8K\GAKO]
M73^,7VL\OTFHZ_\ -(/^3MD#\HYN3#BB=*^G;?\ E"]9?\E/,G@I;##<]$?A
M$OD[*\CX(OI[66R./8BB[Q!/67SKY-I#=>\L<)0Y9"(('S$03%,5<$U3!'%X
M888[2A^<4 \OP2(^9/\ #R>+/FQ, ;G UC'0<$9< C4^5AP:<S8Y>A?-P\,C
M_DOZ=O[%@**J^1$Q7;'L[OXJX_%QVQR<H/I.XC\0X9EVP>G@)>3V8?QG%7;]
M'FMN>;!%_A :_N;*IMYA3Y[?7'X?G)\*>/#\Q.'^(RX7[J>&N3_NK:_C=;]_
M[6;+^4A-+PZ4=>'X5P38B7U6>'X.Y/X6_P ,'G+[5JS;<83#'.G9WT=%?(WO
M15\Z)X8LM5]F)Y'_ .8=ZCBX=.1%S>E-A(511)$5%3>BHO!47I14\7%.'[GA
MD>@?Z0?L.";A3UB\GH\Z[8-CAY5^<OI7P&T)DV2[Q(24>MT(>'$%Z=B DP(2
M423R**X*GQ[8IN7RILB$7/#Z+B];X'/6_=V5Z'@V^GKM>JBKY"3@*KY4W+LH
MDBB0K@J+Q1?%<<Z&8Q_C&0"G\''PU[?T(445W8;T9#'=Y57[6KW_ "MOMK_R
M:MFG](NSI])$G^/_ "O#4L_-%J4[YE5PVA^1&_$&GG'U$3]#?)?5WHB1C7Z.
M_J+T</)XV9/47Y/-X)'H'^./V!$3>JK@GI7803CQ)?*72OB2$3@7+/X3;!2_
MA>$76UP)/B5.D23I1=DGL)@8I[8>G!/6Q\[?RCXLF0OYUT6T^]9''=Z2=^3P
M""<3(13TDN";""<!%!3T"F"?:W:G"$&X;Z.NN&J"#;)-N"9&2X((HN&_9UBK
MAI+3,OZ5(,FFE5-V+;(IS#!?*J@OFV3G5L(PZ1:-]HO@,B>1/Q=@94B@RSW(
MQ)5,IEY&7T]F?F1<I+Y-JD_I,RA\W4-E?\OQ$^]+8(,P_:I@,=XOSJ=#9K_*
M>1?G>GCXBHN]%XIMCQ;+U5\GU5\^TG^;_?3[ KR\!W!]]TK\">++)-Z(YRT\
MGLA%M</A';!-_HVWB2>E%3P*P7Y.0F&"\,Z(N'XR;MG6N@2ZOWA=8?D7Q(K"
MI@2-H3G\XY[0T7T$6'@KV_\ O(.+Z&/;E\C?VO3Z9C.$V-NX].L<N[F18)-)
M&CEY6W)1YU\[*>) BS#YWN_M",O%BKJMR.1[-POG\OD;EX[_ !&_/G_B%LBI
MN5."[#%DE^DBG4-?SXI_[44^/Q5 TQ$MR_X>7:0B[P)M<A^7>FY?K)XX@/$E
MP380'@*?'Y5^%?$-&5$75%4 CQRB2\"7#>N7;-)-R4?%<?9MJOEP%<Z_C;96
M6FVD\C8"/QX)O\"J(#'>Z'&AP3'ZX)@)I\NV4TP<8<%?3@J$*HOT239AU.#C
M6'IRKC^X?ACM*F+8ESG?)RVNLJ+YC7 ?A\+\A4W1H^">9Q\LH_\ -B7VOIBP
MP+E2*V9#1?F<R)*%Y4X;B49J=._X/L#/WR_**IX$(542%45%1<%14X*B]"IL
MC+RH,H$_TPI\\?K>5/%=C/IBVZ."X;B'R$*]!#LK+J8@N*L/8=5X/+YC3YR=
M'C*^7WH>CYQ>#U<J>4MW_'MUEQ]&Y-MR8>,V[+:4S,5 <N;@"X[T0A'Y^T99
M0J@D/L?7Q!%$%7'EKY,/+LIP9*']0U1?@S)@H_"FR@Z"@2="_NHO!4V.8:=>
M4N >9D%7^D/Y$3PJ^J=:8\1I_--^R#^$)+\/VO(8A-<RXJG/>E4*(F=]QH"&
M1"%>/Z7&)4%."NH&.RB2*BHN"HNY45.**G0J>%?O?WT\1C^='Y5\(N 2B8*A
M"2<45.&V!8#(;3V@IP).','ZJK\2^*4>0/G;<3UVCZ#!?\,=BC/IO3>!IZC@
M+P,/,OR>(/+CFC:JF+QIRV\O2J$>&?X,=A1US<*(F1OS?67C\6WLVQ3S\2_&
M7?\ 84CI*C9FO99>>WFYBE@:*F;%,%W>E-HK2< :54]!913^CV0VR4"3I%</
M\$V6/);Q=;'/G!/FHJ(IHN"\OBF/1LVC*96P% $/H(*8('P)X&F&TQ<><!H$
M\I&2"GRKLQ&;]1AH&A\Z *#BOG7[8EZRTI%7MJ9I%Y41PQ[8GK.V4)L?^MIZ
MSS:?E4ZR=?'/X/P5_>\1A?(\U_'3Q'FS3$#@/B2>5.:POR*FV5=[:^H?F\B_
M63Q59=ZIIO9>PQ)H_P!\2Z4Z=CC#$<,VRP4T3!E?(2/'E#*2;(4V2C:?R;"9
MR_TA8"*_ 6V+48"/^4>]J?I13Q0/@P^Q*JK@B)BJJN"(B<55?)LY#JG$>?)%
M$Y8+BTQCN7DDGY5WSIU4\^V*\5Z=A$B(X_ FU55R)CZS?T53Y=D4=Z%@J8=.
M/#;.\/Z3*1"=14]1OYC/Q+UO/Z-L/S+OR?\ Y%^3P%,-/9PAQ'SONXB'XH8K
MZ</MJ5J'3T;!N9GFS*YD=Q$JXRGX8)^<%Q<QMIQ0L4WXHNP^="_<Q\1M?(8K
M_"3Q#_U)_P#CL[*!IBB_(OE3S[9"X?-+RI_C^S]8TQ\B;U^)-G'=P-MB1FXY
MT"*8JN";.D[(>2*1KRHJ&HM"">IF;' 3/#BJ]/B1["2F+3.8&!7\XXT9"AK]
M5I$W?6]'@+RAUT^#UODV;Z2]3SJJ;D^%4V98)/;'[:1_/.(F(_\ )BB#\'VT
MXV"(LAGVT;RYQ3K-X_YT=WIPV?O:)CVG6<LJUL?6Z7)45M/SG2XVG'BF_%%:
M_"_B%XGHVP7PI]:*^B^CJ%^ZG@P7X%\B^5-LI?\ X^#/\"?8>L:)YNGXN.WL
MQ5?.6Y/BX[;S7#R#U4^3CX!JV2XY7):IY.+3/P^LOP>+5M$F!*PKZX[E_2G#
MDICYT%WP*GE3#8Y#B?HT%P7=_ WU3V0?@Y<R^CS_ &BEAJ"YJ:* KP1TFW-C
M$K(BON(9-L))FO,,\XQ;)4''%<%VC3H,F/-A38[,N',B/-R(LN+(;%Z/)C2&
M2-I^.^T:$!BJB0KBG@BT]OJ?3M5;SD96%565U6P;&8DEXHT98L&3):DR$D2
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MU1J>*.H"G7D=N>%9 FXR("0PG";33SL,D?=D8<TB=5,V1$VK[ENCT<%U6O\
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M/,F*]&P@*((BB"(HF""*)@B(G0B)]V#=<7*#8J1+Y$38WRW(O5;'Z#:>J/\
MC\_B( (I$2H(HG%57<B;/,;N8;".NE](T,4_%'/@GW9["TO5# I"ITG\UOT#
MQ7S^CQ%V[:ZGE1A/D(_@X)MA]-AP?E _\G[L$YNYI]1D?K_25/HAQV4B7$B5
M2)5XJJ[U5?.J^(+?S>)KY!3C\.P@*8"*((HG0B;1O/S1^-ES#Y?NNJJN"(F*
MJO!$3BJ[$Y^:#$&1^I])?K'Q\3#;ZY[R_>'X/!#7_O#8_C+E_?\ NNXB;E?(
M6/@+$C^,!5/A\7,O1^[LG@CG]%YHN.' T7CT?=>-Y.<7QY-WB'E%20!4SP3U
M03!%(O(F*^(B^3ALB^5,?C^ZSK;:8NA@\TGE,,>KZ2!53947<J<4\_@"/';-
MYYTLC;;:*1DJ]"(FUL#J"[:3(+BFH[T;Y0\]J(VN_'VK:9EZ2]">(VTG%PP!
M/29(/[_W85WKQI!>LZSA@:^5QM>J2^=,%V]M:NDW]%N*+9X??D\ZG\'9>Q1\
M'23 Y+J\R0:>17%]45\@Y1\W@/(/Z%+(GXA(G5%%7$X_D16"7#[W#9/!VTT]
MDQN;Q^>\J8;O,VB_'A]W#B36D=:+?Y#;-/5<;--X&/\ ANV7L,QEUKYHR<[3
MJ)]'%L' -?/U=D6?);44_-QLZY_,KK@!E3\'86F@1ML$P$!W(B?_ '*Y6CV=
M&_M$Y!A0)$N;^T:57*D3V$EC%[-[BL\<D5QLLV=,<_#I5F-J71MEIV(\Z+96
M$&U:OVXPEE1'Y+"UU1(Y(*N)\M'304W"2[MHT^#(9EPIL=F5$E1S%UB3&D-B
MZP^RX*J+C3K9(J*G%/&4B5!$44B(EP$13>JJJ[D1$V9H3MXRZ/.1J"R<B#35
MK;[=+%9EE6L+*2,,I"Y[D8"+-FW[_&6_U=:MT]4DEB&DDV)<HG)4C/R6&8L"
M/*EON$+9%@ +@ J2[D5=JZ]IY"RZJVB,SJ^4K$F+VB)('.R]R)C,>2VC@+BB
M& KAX)>HM36+-950T3.\YB3CSQX\J+%8!">E2WE3JM@BDO'@BKLXUI70R.P0
M<7ES;ZT5J3(;W[UKH##C<0L?^\N[5>C[#1$F%8VI.@Q.J+$)\0.1&=DOO3(L
MMB&[%BLM,$1$+KR_5\OCQ-+:(LH\1EBB@2+)MVK@6#IVD^1+<  65'?-$2!R
M%1$XJ>UC?UD+W]K"LIJH7!;B<YLK!YV##L[0H4-1SL0^<[(R-IE3+OP;S*E_
M8:_BHC<6QBL4EDM6E4<\29>*P;Y+8,L/,PR1K*X()UC)%5<N[;2$+1\]B%9W
M!VTJ<;T&).RP8(PFF!R3&G0#GR)18**8^R7;2-[JN2$N\NJM+64^W&8A@;$]
M]Z5798\8&V00:QQE-R=;CT^&PNKB6W!JZN(_.GRW<RA'BQFU<=<40$W#5!3<
M(HIDNY$5=VQWND;);:J"8] *4L"RK_TN.VRZZV+-I#A2#0 D#UD%0QW8XHOV
MU[41EP9O>&^YD7!QN52Z5-QT <1<45J144B9T^BJ[:0C4,.FA:EY%H=ZU4QX
MT9WW>O8$J5LPBB \U3%[DYDSY$7YN7:EU(AHS?1J-ENE)YH7<$M]1&Q2N\F3
MS&W09IY8.X+U5 -R88)M&T[IN,]?Z]FS)\N79UFG&Y\JOJ &.S$AUU-"@%'>
MD\T3==?<:> 1<$>/J0]:][)6EAJVQL+%B!26,1JHMG92RY4>NK'V!A1NQ-#&
M@%)<,VR,&BX*64-K74ND G,T-23QOMZ?HJE:Z+RA[0<=I^SC2IUK)9845)H7
M'CP5%R)FWS='ZR2,YJ*'!*SK[>*RW#&VALN,M2V9<1K)';L(Y/B8JR( XUFZ
M@J&)Q-.Z9;B2]86<=99N2DYT:CKR4VVI3L="3GS93@+R6R7*B"I&BIE$GM2:
MYAVEIHS5U795L.7/JZNMY,NTK)8UD^$] AQY$$><0N-HZWR7V17EIP)-<:G(
M=T"JKJ)@E3URM99SY.1?\TE.UC]^FQ=WVG+>)%TW^W,73BQO=-9)=;@UTAF)
M?.I*?CG(,U[+)=];=P3!,-JZPTS+9B7MK?QJ^.X]&C3$&&$29+FN<B4#C1(G
M);#'#%.9LNN>\"TCN*[-O)B3UB1*Z-%HJC"*Z9C$:9:5MB1!DF1JBK\6QZ<[
MFH,J#!SNC!&'51;&_LH[6YR?/<G-2XE7%X%@*!RD7KNKL_5=Y42>YIZ'1V5H
M^5G2UHG*?:$&X4"HN:=IIAV>Y+?$E R>P9$NJBY52-IS6M2%#*IY #7Z1AMJ
MA1)%NS$..4HB>?>ESI48VLI$J(B'U!!"7&#0Z]K7J30U#IE8T%A^EJ8@N' "
M#6U-<U)C-]JS-1R5SCO%E<5\NT7N^IS-Z#I^=#T_7P@<7E3M3V9L-S'S%-RO
M-2'QB#CCDY18>NNT2NA55?/N.0'O?4$N&P]86,M13GJ+SH&Y&@(?Y)@5R /'
M$U(E75-=IFFK]0%#>@.6D&"Q$D.QI#C+KR/=G%MMYTR8'VA(KJ#U4+*JHK^@
M.Z7 7HDY*A^YB0F;:SM;?/R'H%+&>:E1Q8:>7E9^6;KCB*H**(BE;:8[P*]P
M=2V$")-TO<V4"L!^ A3FDDDZW"9]VVT4X@O"./M&7\,V*=48&M]=3@DS);=U
M:NNM0XL)&:F!)E,LIR8H,LKBQ!5W'BJ'M<US<1K5.I+CD0M&44:ICBW%DO.2
M)$N=(6!'COS6JV"QAE)T$ZV<NJ)8-PN\>2[(::?BG=:;GUE,RGNZ5E<YM=(J
MXS2M.C'-5:('2;4DP-"WIM9:KMTYPQ<D>! %Q&GK2TD9DAU[)*A95<RJ1E@7
M+9 SP7+M9ZDT<U)?J*8U?E5E105CU-%:0>8L%3G,.S[&03.]01YR3@N8<N[;
M3=Q*B)%*_P!0Z;DSH(FKS3473]? .S98)41>0<:H=R8[T1>MBN..E&M)3&(-
MO>V-@XZ\]#BSD]VU<9D7FN3+:=;%79-BTJ%ACU%\^U;WA]Y%FUSRJ[*^LI8Q
M(T, KAF2O=S;$:,VP#CS\$&L@HF9QUS*F.*;2HO==&DUT.+GE1Z>HK:J:XQ"
M;/*U(NK.VC/-*ZYC@J9FF2)<J J[:;AZBK?=^J:>O8T;80\A1P?O!O;+F2EA
MJ&:"\\,MEMUO>B.-*HX"J"D!U&0GS(T2%I[3-4I\GMLF'"%D''LJJ;<"''9S
MO*/U0Q13%=K#O!JDE3]+4SKCU@TSI^K33S<>.G-E1A16!LY+$9I<73;>-YH=
MY&FU;3Q#CT^BWH\B=-INQ0)<B/&KZ15='WF<<99I*N\O611R@YPW;6&@[*H#
M3>C7K!Y:\LBK-U3$J9F#4]]\W2PKRD@#C8 VVF*)BIX;M"T=;4R:SNVL+.%;
M2[!VDJ7&WZ.S>"SF2NW/-G,QG0BRM'Q',.'#9=#Z$BQK'52(PEG82&CEQZEV
M4(G'KXL(,O;K5QMP27%5;:S(.4R54"FU7K&>4>MN9'*8@V<'2KS#CJM+)2%.
MKZUAN=6N&PWFP167!P4542Q3:/WPE6AVN7!1F/3JX0LNZ@]Z.T3C N?E%@MV
M$=QWZ:Q@^EM8ZAT9(>?JZV4K#S=7"TE!@QY"-!*6'';N1[99. TX)*&:0:(:
M8^LFT^9WH0&Z^RBV[U=!%RK.HLY+,1L$E2K"'B$<4*4:@VK;32+D5<%3!=AT
MNV#[-''U4[6V>ETJ8W9JW3$6<3,J=+F%$6:C[<%.<DA71%UW*@]0A#[3U/J)
M5%/<=#;6@9L,"=@P7Y#+?6Q12==!!1.E5VM1T?;0*B;2Q6Y<NQLK"T@;ISCC
M M-2:R#/D*^_E-5Q04447?LU:=XVIF;IIIX7W*:E&6C5@XA9U2?;S48EK'-?
M7%MD'#1?R@[:-TE#%N*U979R@CL"C;05^G*_LXQ0:#  C@];,JB(F[EIAM77
MO9@&YUB;UK/DJGM5@MR9$>HC(?\ V<8@<Y$^F^6VB:927L<2AFV8!F7*LFPL
M%BND0\%46JP,%\Z[:6=7)'KJO1<;45H\F H3LBM]^6\HEW8YWWG%3'HP389S
M0D#59I^\GRD9]DRC<CL]>#1#A@K?/GBHA]7'YNTRKNO:0W^\DJ&0R?6!RHTW
M.]VK%1. I*@5>7[X\=O<YJV,F^O*J'!CI@A(W7.>\I#P G!I@(H@O0G-%.G:
M?JB4/4M++4.H7#7JKV"G9&LR8JF" +E0\2??KL_J.;@X]55FH-2/F7 I]FX-
M9PW]=5N7#3[W';2^DHSPN+INKE6%B(+^2G7QQE9CO)_+-P*]MU/J2$\NU50Q
MT*/*DTNE*FP^:;+MH_&LKMM/,^]SFE^J:].VK=5\H"LYNH4T]SU'%QJ!65M?
M8\IHEWMA(D6^)HGKJT&/JIX&YJ8/Q'=?S[ALEP("J]*F_-@<S>HJ#D2H:!4X
M+FP\(':$(G_ZN70O+(RI^FE?6 ,HOS4<[8HH/UL/!K"^B_\ 2:32^H+>/_/U
MM3+F-<=WY1E-KB^GHDA_3U"])A<WKF-C:2FX:S,Q8]<(:OCY<7<=M*4$<Q=E
M4E')DS4!<RLN7,IM6([B)ZKO(@"YAQRNBO3M/J@]E(@:'J=)]7<9S+5F%137
M1PR^U(I;KRJGG7;5VN9+(F]%6-INI<(4+D$Z"3[<P5<<CJM+%%%3!<A$G MG
MM/LX$R]J'3&CA45X("0(=@1D&].3+>?Q7YJ#MH/3HDHPD8M[IX47JORB<C08
MQ$/EBM"[E_GEVTQ8NJU'@AI(-:7,K!!4RLX'OZ8\\6Y7'&([J-)C\QL1X(FU
MGJ%QM!;HZ*TGAE]5N=;R&:]IM-W!8<F1^+M5:=C9G?<6GX$5&!ZQ+9W$EZ:>
M1,>+L1R*F''%-M(:,@%EC'.TYIV40*J"["HJ=]\6U3B7-FU[)[_H['>M@"S]
M37=@[*?R^U[-5N+6PXBEABK;+C3KB>=Y=DFP<CU8NO+*]9?#>R]#TSVB?%E=
M.+4XZQM4\O,3;3U&I%V*HTNU,9;QW=LMK":DMY$^NQ7L#^!M*CIR6(5#H!YA
M.#:3;276$VGD_2+>XE?";NVMM3F'_AM17TC!*GS[B6<V1DW>LV%,&/F<\^S.
MFH2\QVL@Z=TO&$=X+.LS]Y="X*?,NQ O.&'1M JXJ98U;"BP(XX896(; 1VD
MP3<F#;:;)JO3-(WJ?6!VUEJANNE1^W,E+<<>DG)-CG1,_879".-X$.4P%>C#
M:N#7S<+3=%">YK RSKHL*%SQ!'WF*>L?EV<R<C"X#VE4PWAS Q+9ONBA2WH<
M.%#82MM7&P=>;MH\PK);*0R/+!SML]QQ7@'+U72053<NW9SRLUUD[S>26-EI
M/4S<900S97V3K$D 5$)4[/, 53'JJF.GM91(YQ&[J&;CD0RS]EF19+\"PCBY
M@/-:9GQ'! \!SBB+@F.'VIJ"CTG53;BWNW:R D>"B*\$/WA'ESG5Q(4Y11HI
M-K_.;:JDZIIY-);W=W%:&+,0$?.MJH.:*_@!FB-E*LY IT]5?-X*;]F=)6]O
M24VGFV EQ6VR8*QF393\W(I. NY@(XKYQVT[IYK#ET='55(X;\?=\%B+F5?G
M$:M8JO2NU3J#2B,O:DH&)$-RM>>;C^]ZQX^T U'D/$,=J9#D9E!'% #%TL21
M4'&%W92:;4XZ=BMQZ\6)4*OJHQ0H>0(T6;?.!&67 BBVF42?-"04]; =I?O"
M1'GZJOBCNW,N,BK%BLQD/LM7!<<$7'&&"=,C<P'FF7# 1VGZ][OZJSMH]G>G
MJFKL*-H9LVJMY+_;IC$R J.N(@3S,A50-AQHD1=^8$J-5:RKY]W;/&["@Z?A
M-0$<I:UML'7)4J+ 5F! *>\0Y13.^>1>;ERBBTN@Y2%%<+104ME@G69FV560
M6IHF/K)-E.KQVF!HW3MDW8R&GJE;:+%KK&AGP77P-M[ME@AUK+9&P#H\[ENM
M\"0=Z;:82VBV>J5OW::=KK5(D+U=&GV5R^EN /'RW5C5=7R\>KORJH(@J(#=
M:2;D-PIDD8\JKE.(O(8L8#P2(J/H"$21G\BM.*B*H@:JB*J;6=+I33M]'8L'
MT*2$:JK;^H=D@B--SX\IQJ;#9<5I$12S#B.&=.JF%D]WL/RGM36FI)=FR$N9
M#E.1JEVKIX\:.C=>90:\$DQ7B[.UE0%/%40B79R=I/35M)L(AS(4*[K:Z-=5
M<^#+Q9YRJX$B.T$EI4+!Y <:7C@J;4#G>/S$UFZEF[<(Z->VX/-N;!RN$FZI
M!@M*-43"901,O NMCX)7>#W<L]N?LG F7%&U(;B6#%FTC:%:5+CSK3;Z2<G,
M<;SBZ+V*AGS8 W1,MZU!M!1H7IE125[^"=3%S44^%&E$7URDXKQQVCZ+U_+E
M/7UKIZ\I]12WK!;67C>'9-N&=ASG%E/MQ9J;^8N],$7::WHNBL^VR6W:OWM7
MQ*^SH+.";B&R\4BQ X$<,[8N#S^4ZTNXL.LBZ;F:O@3K]J=>4-OJW48J+U>
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M]GF%\]S,73MJ&)J.=9#I'3WNRPF4\"6L0;2ZG]NCUI22%%+E18<:3O'!P<^
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M?=D2.PQ'B$X"X*:HX]@JHAY55-K*@NXH3:JVB.PIT8U(>8RZF_*8*)M.@N!
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M;E5-JR>L>);5LH:^\JSF0T<#$@"973VF)C*.1Y ":$"J(N OD7;_ ,O_ /\
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MFB+O3;NGL@ARYC-8=G,?&(R;IY(UE1OJ"8)E0S%M<,53;_\ @.O_ /X&N_\
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M'J>\ZR%/R?>]J9=R\=E"GIZJI DP(:ROB0!),RE@J16FD5,RX^G_ (8__]H
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MU&!=A,:DP>0K[A%@KJ-$%VCR ."IB-QP879T&=$1RJ)BZHIJX$MM6O\ QL
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M<X8(((($$(0AQ(1$PRE(6@R(Q )H+% ,= N$V#AK3W!?((&=3[G7^P#OHW(
MXW.+E0X8LN<+SV,RK<NE=UFG]9(&G]3MGA@N.@2RU$6*#;.+5.8.=GEE+< D
M9;*-):D;"-O&KPK4YF8<JQYFNF8$5H,OW%JJ8K:Z6XI"R7U^$D.1W8!!2@$$
M$"!!"$(<"' X:H3%T$5.6NYO","E4.?ITVM+K$3!@-@+$=Q/N*;H?0LJ=Q"[
M\<3_ .T-'_BK4 :,ZV.=J"T.>4P\.PPE>1.'F3Q$WR^S/>;3=88>Z@^EM=-C
M:]08J^D$9YK.:9> ?<+G0X)"\9AU1'!!!! @A"$.!"''U^JVQ=FGI&TZE2CS
MX&Z$@MPW-52=7[>A.JAT\@_#SCV%&U58ZJ\3>EC9I&=;7&B>6G_PK@"9V)4.
M5@[-P<+/JP'/N<\M4(!)"!@UX-113$6ZB#>UR=O<@,,'<+^I+NNT*'6""! @
MA"$.!#@?1WK!] ?8'RX.8YR_:AU'V\9U2KO2R[#/1^BH&S5)L0I@M[JQKZJD
M,(6 J=@RRL23*=-<E*J*D%%(4B8I'(G$C##!#!!!! EE,4G\8U-;(ZN9;GKV
M#FNH%[WT3)M)WYF$ V"A,/C 5( (PA>D#,;9[*6K*3UJP7 %1JBI=]#57WU<
MI/2-\OYEV#F9JGTTK<#N5V\_8X-F4FUH4?;BL;H?.+3R;]OZ.]=-O5V_&^@6
M?-M3(U?.E,Z 7$(^ZPVU*Z@0JG1I"DJ*N?+6E5G6CKY+0?2NR^L#IO%DZD?6
M+2TFK[G&LKK(2J&8M0M:3F;&R%ADQ###!!!# @@A.?7Z?+5K*TC:M1JOA6K$
M=+;<-C5C%>TKF)J7TR9'1(F>'=PAB[5P$U_44;4%6 BZ*HA/IR]7F]%>#*M9
MWER&OM]4Z.=+TJM;GG]8_6":(Z%,"A0EPL= %""HL&YZ&IIYA4(\^,C:U>U7
MZ G4"FE"N^^5UA.CQ@CEC/FIM2PQ5*4MR?A%VKHX0A@@@@@01-&)JFO5395Z
M7%EAU.)U.\?P?S>B"Q0#>/&O%*@PM^KEQ25'2UK?FB-?AJOF:?1L]&+$3:'U
MP<YU;UUM?GAQS5>8$;R5F&_MF4+P_4J'O\^)OD<Y^CJT2GKFB0KQ6P-^H3D[
M8!Y'0\Z'1*:WC 1JQ*H5^A)Z9,CD((-M,C9P4U!E*E3?0V5RE-7RPY$LZVGS
M<N>L&:$"Z<!O@A;6'0U'8FSYDSY6+/&CU"=\P.@45GHCD=1R0F(VY$EH!6MS
MUW@A@A@0((0LAJ]2P)I,# A#.' !4?G 7,^8RM]5D..VY>%VV(HF ;?\4&:"
MEX[%C?#]P%K+:X!MO;B]RP3+&N"?,,OJXZ2@J 2JK#FAEX6E@06WZ!"@XFL;
M4+BC 4;+@  ,&QRZ<# 81  % <(FL-0+=)!NHP!S1!+;0EAC]Y-'9$WS?YS=
M*P^P#U ],,$$$$""$(0X$(?64 7F\@3R'W*14JPO0,KK<&T?9A#>UT0 BP'E
M;^ MX.3W*7H W9BD!: #D5NKRU[0Z@&,=UW6J2L9EV*M+5TP76VQKET32S-#
M@6>-8>E>0NM[*V"QH(W^.4WS?/>3F""!!!"$($:]%)V"U@E*'3Q/M.:564:U
MSJNP=9T#BFEY=(Z2HN\%'TNE@75$M0<Z /4/KJU88Z4#Z7'*UWZ&@\C[;C/%
MB4M6+L#Y5!K2\Y;7SGBP/%&PK;=!S.!OP;I:<8MFP:#51')B=4. P@80PSK<
M"R610UMWAM-\W\#(@@@@00A-G'QW3D-Y'R^8ZNN_$TH 'J04'FOP//6+B>W5
M1'4$0$0R)2=DR1Q(=; /.#WITFH.J4AL= QUCHX\A] U$^FQ3(#R.O/BXXIY
M :;LR'K]MAG#?%E)TO,#:M"7L/RXKJN.7J33=P>_$WS0$/3HIL<P?)PTLRRN
M*"!'(X3F3>7<Y^;IRF[A[$,"""$(*=,!JI0>;*V*%#>\1TFE-#@8A$I_]*2P
MX6,SHY=V!>+F-2QU82FF]8?T?37[-[YAO0@[\'LKUCWF8W3?& : &A]L5=F\
MH[66IH"84#NX$E'Y8ENW6+TY%NJ)%(.7&U(N+-T4,J-KNX$#J7O@W3=-!S/O
M@:]H3J<#0PNY.]T0T\S0SP+(AV"I-$E-6A\)P]R$;"]6>BGHP000((0E>]7K
M(]R]7IP]":$THZ8,PWZ-%WEF(@%.@+7L$#LWF)ZIPP[4\X37C5ZE)U)G:&7=
M*GK]&&AUN*\T6]APPO8!<[@>EWV]M*!9+2LV(I-J\?T,Q:-Z$<-A::UHHN#@
MW3?-#T??_4ND*!!I$;$3(C.AOOBWE\SRYYS2EM9EO!/02A^3D'26Z.*L#L!N
M>L,"!! A HLWF:KT#+#^P"]UJG7)PM#@:#!2"H(0M=;U6)EU=#4&[-2^:'E,
M8_K(?)*ZL!$<CA'(CLG)E"@J8W=P=7'7-K_%QS0U!'DS?4+=F>]/'O2$VC4?
M<G'F$:G($\_MVPMVZ.:_EG 8,KXGYQTX-$W3#MW@M;X3?0/+K I1F$&'>0"9
M#8U[QC!IS1S-'@H449V.I6,FISLBSGFT*X&H5#57,11""$)I#6[?0=W'DS2E
M2W[#]',\IJN^7_H?:!47A[QEX'J\"M8T$IEH(ZG,6EY6(@!/88E8:+U+S"OD
M>9-F)3J<A:N99,&&9F3@FYD>J..)9NT='3M7,^W43HLS_FJ[)H(1Z#CU!2%*
M#)MQ.H=3X._%&L==M]C]P\)522TM:)@V5WQ*7, FYU)I9FC+^'8T&P##KGAN
M:## M\Z5D<\C)JL,$"$4L5A"=&:&UTQY #04T3OT(<6)O/D,N\9>!ZO"Z\ZD
MZDU6;,1R@5O&$@W15ANW3OAC0HTQ=L:K<T8E/1N:G(*P#G?D P)S:O*17,X=
M-% ,X:[ E4[D6C;U?N+I"=[2C]EZ#K'4\875Y_(N#?-T75%7:9AX1 &AV!]1
M&B:),A&KSO9AKSUFGF6UGBYH%LXPV33"K;<D$V>0LG.^$%H]+Q-[*.,\DQ>A
M2I .]G,!VPP\#U('.=>=:=2=2$G4"9 A@ 0"QGA;@%&F9IM8'6Q4M2JKE5<J
MLPN>6%LBN0K1C=S"25$Y4%HYV,-PZ@*IL'1+!SUFDL%W;O3*K[IZN&?G--!%
MY-73^Z$Y;9"E(" ]"X(%HWHO?3VX^^/*5EN5)?EPC#!"_>L +I-A$N35L?J&
MY-+,TY@!E@HSK&&$\ )UYUIU)U)U)<>$O43SC(%X,.='AS8G,)PZK6D6!;-4
M33XSD5->04'+.KU(* WWIH>=_..V0S#*?<:'FS&1D]_,#N#/[K.B2;D4\E]=
M,SI'7@:S66&8&0-YP.LVGU+VXVZ.U\P^C<)KR']0P1B&G8S]#-\>=_<V("_8
MT=ALDT\S-K=\@U?-XIUYUYUIU9U)U)[A:WV-J!DZK^PM'I-'G^(=0[WPYV71
MI<9W5TCG9H31XLR8]@&FFAH#.2J> ,:(NR4Q++54O<UJ+?:1^Q+S49U C"%F
M## K$ ; "+,B(CP0^+DV%(K?MP3@I?+CPPKV #66L%K6QS(@XY]DOJJU?&2M
MNAPTO*R!LMW6#G*V\R*01SY.XQ&Q-X9H4-:&(Z>F6D[A&T[6L!EI'!W3?#AE
MJ7J_J(-$SHWPP02_?P@&]3*Y/\B;P1V747O^HDZ\Z\ZLZDZD.@;-3O6A%17[
M'QH'JE%H$M&P%^'*R#+E;7=R\:A'5%.!NNFT"[1.J7<P4:!= 8#!-/C%6!4"
MPH^-%F^.PH89QX$H"@!@X9(6>BZ8O)U6@%R[(7=O:'&BQ]F-RU H "JM &55
MT"*NZ5UAP1/6Z6L4M/Q!E&5XH*JJ$U%^VNOC0YRY$TE5JGMX^K6(%VD6";V5
MFMHD<+]2' 7;BHF$A-4K%(S_ %L-1)V#EIK>"C2"<R*HKGJZMNUR-D=1-/ =
M9I9D[_\ 'PRIG#"O."Y6S"\$LBHT#T)+0V3=P[HY(09P*E%,TU",G6[Y EW6
M>4/_ $DFDSJ1W!EZ3H7KE]"8S9ZOT/>X" #8 >AB6W,&Z#%VN(-UB]9M;L]%
MB#H?1DJVU=K,4/5&(T.-B5\,<R:GN[:I6PQ%-_ZZ&B;$'1,NP^+3336@;RM=
MFNYWO?-6AJK*-Y>84OD?V<W+K0-0G>TRZ%+15Q'CYM2$ND4O ].*:ZJCMU*M
M, !M[!3#@+75&6O:-5]3"O:.$5,7OP8I)-46L>C.MW2(2U*PG5D##=7OO%A6
M\MH5"7.?8X0N:P@@;J#PH^1<AN.C@WPZSR4O0'ZX^P7#8[(\G%-.M2=TWS=#
M6Q57@E1 G_JJ&&,6@\49>&MR:KVXUH32FR#&;LM>L.O)#CLK&.F*.R@:4T<<
M0(5N_$ZLZD'C'\X@ ZQ,C#P-"FC$:@K4?LM>4EAF3(UV2MT@S>!=??$)S(N9
M83&$P YA?ED(TT7E0D*@  )@*^L@>UZ9HU3#]?W%13KR-4@5H"+O_&9B-W0E
M*KHYI9NJ-X/"6SYEQ;&VQ$+&64$C5Z?K7AIZ'"V&61=X?PM@QF:)NF^;Y25Z
M%>CQ]4"K4!4Y,DKWISZY, 7=&_!NAW,R0,!8MI;6D$"%6Y8YX1]HTIH<#?1&
M_B;N'8S.JM>F*C87@V.-@(J0!;LASJ+SN 5R,TA[)H$TYI<-4X@6Q&YM#D;$
MZLZLZL15'+2 .OW-%-_OUHT:JERVF_,V>#?-TJ5R7Y^C^CM/+I2[0<SGCE-1
M3HB\TY8EEM)'O"5YB# T!590:1.D5RQ(3R$W80-B-G4Y79^F)FQMOQ#XPV,C
M-":$TH2UUS%Q)"K*ALFMW81=]PJ 1G9B^>K@?-*DUZOCY: ZQF@E#:_J(ST.
MLT)H<6$1]G=U\C7@]3@DX[CO,PH911 >M[80-==+H@5]^Q6=T";>5O.;P[X7
M2!)\!C@ &L:_:\-&G"AR*1E 43\!$) ZD<CPV0%  +4X #*K'G4T.>5CS:?:
M8#RC@#6SCTY";9U]>?#3Z[/5O=@/S2X5E.Y<]S%+IIAW( C$3@E  %J7 !#E
MQPBJY^!WOJL)"[ !;[4;/!ZLT!#8;Z =5-0[)^CH,'2:?&*9K^ 'EJ]"7)$4
MYK*SJ2QL['-!D6@%LV:#QK.7"/,$LE6VU"I8XEL*#?\  $-RD$8K VP)J,0=
M<X>FA @FB"6)!#:3UZJZ"046:,E=ZH:W]B%O;9#7/38ZP"",#1-)5Y+&6A40
M$=6]\B'\5 P+2!5EVJ%WI*[K<Q$>DU@B]A4OHYAIV5.[GH;]M6@ !0  .0&"
M5W&0'P$P]AF7 M49JT8#7W#I2=3@]7@H&HYY;GZ=YH8FAPS!PY;M +0^!2QW
MEG6)-N.K-B]=ZS+K&HP=>7V+XV7C-:T.5)I4&MO^#4B*OVF18LA+G4(]F0#O
MKZQP8.^.#AG'@2D+ .29\Z0+78!*\O).LR[I 43D)KDV;U+XM<'?@30BP0TB
MU-2:N93>9_96FV7+Z.6.#U>"BB\1?E-*:/$&$V[#"U+5Y@1(5L!JU]*UJO(5
MH."A8X Z54PK0T>!4<W1X-E*  4$<@K%:!2E74-N%8L7=:@LTM!'%N,&Z)<E
M%"RT%X:N9R!R'0U 8,LPB*KK*V-7OE#,'LJ]^Y:-1Z:_?E[ZN[T5A'-*%SFJ
MS;X0'!:4>G>&#AU7-?,T&B]U4/HUM^ G2288SMA1L2Q'4342=2=2%M=CQUFE
M-+AFS_\ N]MH*N5 ,N)H%(!EI4@!Y(6E_2JN&KS)O &MLU(0)2T,*B:E(5M5
MH0;R.'9[(K0;,4,%6*3"GFC&R\83DET4U?*NE!$=(^8O35^M934>MLJ:%B:=
MJ$2D"\%^LZD=!OP&#NB5C>CLVF FI^&[*"4W-3,ULP&M2SL=DX[O3A>V:GM=
MYB>OM(.S(HAEHM1TUN,8,*.R>#M[Y:FE-'BVHAX58MNSHR.Y3ZE02?QDA+'%
M'5R5A4HG>?GL0TWTXV^*I'*78(FH5+)$GN!6G!)%PSQGC_&PE*U3;E:/S9;V
M1%JK0@A)CJ+BAFHN[=I"]E+G@:"S5X/K8EW1D1<XW^!E$4+D50/>1!N:)AV#
MJ]W0E P H.036FK-7,NC62J8TL5A#5EF8,1KB!9E!:92X*%M #LEB;?VF)SZ
MH7PP4]EX)]M,#KHZ33FEP#>Z<7_FEO83[3)SARQBY)*BJ_0?WR"UWL0+*=)1
MFRY.W\E@)B*T>:1U+K.0H(EUK8XN57)S)%D>  #4)GO;,+FUB&>0555J"R46
M==M4V&D<*45 [PK6ZS$H%EA:5591BML!;L"&*B?W9U5Y (*K12/P#U[99=FN
MJN?HE=&(YN'LG/6^%K37S-7,V]*?)Z\UT,-[:?JWJ2;684[46*C/" A?)E%5
M<O.+58F%+NFE!V,O;_A"BIEB$K^02Z%89#DIU"UW'*4$IOWFIF:V8SHU-K$'
M!4?>*7YE0^?=F_\ *3.A+2.+L;";H@&P37E=S4S,I\G>_0M1/##VC1H -VK8
MT,!^9U<E%?*7R::\'6E=YFKF8N!FUX5\W=N[\SHW8UV#R>HVQ22D9J9FMF*=
MA;6BM]69Z'I*"PIU1NI^8W5^&]&@;XPW6)AS!9@=)ZS;OP]?,ULP[DLFZJ)4
M\Z+M#KUL="?)%=*WT_,<Q_3!B9CD7/?R<#6\8FOF:F971MW;L<=[0=.\>#M%
M9ZD<K5GO #( #T2S\MH59UT<PZ*$1<LV4K1W591<U,S6S#&+5GM_L5"8  .0
M;1:31,A7FKRS'-K^68]%'2_Y.'7<ULR@*  5*T &56.C-":$<ULQD=/T_EN<
M1'-!Y8"S135GN! 37S-0O,#JNB'T5 *$S?5;VD'KW!!^ >".((I,NHBNWY8*
M;ET!R&[8!:=(>Q9@&*343!:O6Z"(5&XTT*<_*PZ1>7\LT UC(=.2DOA?!)XU
M[358<SD)P1:2U=?+T11VT/5Z?EE MP&5= CL+FG+3?4-@UR6DT17PK=WA*Y0
M"]5')9IEP&K WP&J673C=F0+QM"JX)SK7Y($W*@&W7TSD.L%H:*:L:I@NP8'
M55_*Z4#[%"WDQG*KFA%@\HY8!9Q0SR<4ASRC=I794/?/6ZY8*Y1?C,4/<XK4
M9J,=W<O\L(=.X6/SP\)B(M.%1P];,MY +%WT#+1KS_+X*NG '?<\N":$RJ:3
M4E-S5S!UN%M4^_Y=,7V\T.DU+2G7@M*4O4/3D2N57*KS-7,T7:BM&CG'W4I?
MY==54]8;D<!T9FE$=>G7K!U!EE1*[E5YFMF-B]"ZQJ\*TLZC2_F; ES)&B'P
M1JI-EU7OJ+UR34FK-7,47F\J[.=G-$"RF_0NAS=C89JV/S*W:? KR 5Z!IF5
MRJY7>9JYB80H!:U(YKCQA>GYE95QK.B]N^8<F4WSFO-::V9C^#[# XE;YNF@
M ;RA(=0!0?F" J/L[>[R-V7KHM[MYV<WS)FI*;S*;S,YPXEP!S5C V 3JY6"
MQ[#N_F:[-$'6\*4WXNKO,YJ7.@7#5S[MU+Z3P9C\P(P5<JFT=P.7D;QMK K7
M4'5$IFIF:V8:%+4=]EN6T.K!-:< %!Z3H&YX#0?EP3/*4!:' ! XI>6*#I;+
MEY&TUI3?C,HO,:IO"M30?P8OZL>)U&]![?R]5-()K5Y%9P6M-?,U<RBRVL/9
MZ< \':;-=.,]Y&OY=!LZ[EERZU<IOWFIF:V8F--,B$1@1+=T(JC2CTB4,*'N
M&S7M"-T(7K0O/Y:UIMS+8=-NK%=A"((@PB.1&47F5_$T*M;+CT(!H+I5*738
M':K"1T9H30\I;.UWR!&F# :'Y>]>6M/WG%ENL+1$]=F,_P"L4@=0YP!B9-'.
M7"QTJV:'Q@D;M[\(\$M;+D&,@V*2]7YP_5PY;GNR\)J*-I%BMZAR:EV_"\B.
MU/-Z.8O.I*;FL!=,RF^5<KJN7_\ Q7M+0R"%,CVPU @RJ*IMHIF3 Q*:D.D
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M>SE B'X4Z[C8:FE(!M*ZN5YVJIZRWL(+'<$-+BYI'11K#HNQ J^N415K6Y^
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M#(E;8+"<'X;_ 'S,J0 6QS40WX%6CB"<DX,A4N:&TLB0;A4EK!CT''J?!B+
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MF1SDQ9 ,H$%BG>TE/= JKDW?$ 03<;_*O@*U1B%8]0=791:7+R5*C T\[OT
M10&#(V^Z:V#:?6 %Z&F;.3D":[@=&?B/"S+F-EES2&4X0O3"<&D422HHB &I
M-!N\W2A;AJFGI% D2&D3HQL) <'_  2K]@Z"Y1275SE&[W;B>96W-)6NV@MK
M8<,_A5-FOJLVQ<+%"K-,&+(X!T0L3>U!ZD9.+7HNAWJ=-2+JE92_-'[$S.H5
MW8F$C$*V\&8H5"%6RT1!?.Q\#:)&N$L:E6/.:08O<+GPKV+E+2MPA@M&<WP1
M>;<K+] NZO;H#?TN]3(@DF;HV8 $9<;]'#KBBNX=T4?PD[DM;]*+,J<MXJE0
MSAEO<SX@>QR:NN43"<C[2BA#61U@L<6I>$W@KT>MFS)N:]$0[;I;I*L"5_'G
M-106@@C_ !]^0SWYJ+*/%6K60:4F@,7735P\PL WG_C23HEG:Z)0;6QP;9\H
M\9^*[><:V+D[!$=ZDT@M)25_!E@?> 5!!%' E+&R++=VH9IKK7'MR%0O(V'K
M.O9R L:32IKZ;#*\H+ +4T6@A#LD#8H%JI97"%91$T!; 90': F;6=C0::UM
MS*HYBRD?20 ZLXDA"P[86**J:KL,9^[Y9ZN!&5!F%!=:.+6W[J@NN^=TYR.*
M5WB9^!P<FW0@8J:1HT<I%"UND:%VPPW\I'.O:OF,S=F=9Z0IPP+$BG ;2C),
MK:J]XS), 7M^DZ;/8=4#(_ HH:TC1Z\=UZBA#.Z,(*.N7P,S-)P:N"(=N-J@
M2%ACZJ:>*FI+L$RN<U,5OOCGV(X_[+?U@5"QS7 K,,?$7(M%&JJ4_/*8EA\,
MN$(H@DL4E0=[$!0<*75583UH195QQ_V6_K J%CFOI,?]DGZ0*A09J%&\?DH
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M5BD.[A@92I&2MLLLTDDQY9+6,]S:[M18XA:C4Y**V+.(H6@)=>H>*U,-Q6C
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M#['Q7#3)/6%W_P!E^;GOWQ]!](7GA?!<N<F&""!"'/I]#?\ 0_R7N+\6C:D
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M ,R'_]H # ,!  (1 Q$  !
M        2 "0""                         2002220
M           0" 202                         " 2  20
M              0 0" 2
M                                                #SK"/MD
M                  !V<     #0                     3$ .0];C "
M                   #"@9G8+*4_0 3@                 "(#([1/KJ8
M8C@(                  $!6*)#/PD :" <@               "<1R1J;_
M /80P%FL 8               R %,26.9AN$0&4[@               ' I7
M&Q;?/@" D0>O#@               D-4VQ00MUB ROBY%P            !@
MDO>VP=:L$=%B#US@%             ( EN&"8C'*L0N5\3<X,
M P 96B6RZEDC@D0>N=O88             ;HP27\AX=*$0GB;CL%8
M    ("JPVSIST:T@"'TWKM,#           ' IB.VY#<JITB)\3<=P88
M        #ZPR&/!$', #[6 =K""           H PQM"1X=Q"E5FE*3N @0
M         # %VF7)TLTY@&:=8YM0& @          @!*-2_K8.,$JG\+8UP
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M  !! .<#=F%>6\P![/G+!P0        ) ! ) VK9\TAQ @=[:73_ $!@
M          -^6_)==@6D7>7Q0Y(              !?]&_RO6225[E@:VX
M             ;P%[D5C.Z.=KK:W                 =AM_P YO@[^P<-
M@$$                 !1?M[H#<]] $$ D$@                _\ VD0Z
M4ZL ( ( )                !&>(2R%!H@ )!)!)                .+^
M:  -%0                      !6TN                           !
M_P"1\                            U\H
M   #/[.                           !#R2<
M      4_Q-P                          -]:7?
M         \0*2\                          ;VF8%@
M           !(47S0                         ";63=<
M              +"R7P                          "Z&OA@
M                 +AFP\                          "U^]O@
M                    2O\ FL                           #/!=
M                         Q?<                            OZR@
M                            \,@                           %K
M]/                           %?V/P
M ' !\                           -_L_8
M   ">0 3                           ,% PT
M       T@V%                             #_@
M
M
M           $       @$$    D$@ @            @DD@@  @@D@@DD$$@
M@@D$          @ $D$DD @ $D @$DDD$  $         $@@D$D D @$D@ D
M@$ @ D$@                                         @    @
M                  @$ @@@$  $@$D@$$@ $  @$$D D    $$ D D@   D
M@@D@D$D @ $ D$ @@    @@@D@     DD $@DD $ @@@@ DD     $D$$ DD
M D @$@ $ @ @ $@$D@ @                                  $
M   D                      D$D@$D $$@$D$@@$ @$   $@   D@  $@
MDD @   D@$@@@ @@    $$ D$D@  @$@DD $   D D@$D$D@ D@ @$ $DD
M    $ @
M                                 '__V@ ( 0$# 3\0_P#FF\ZK"1#$
MIXV"EBP0WL/F;CG!:)<+Y2!\1\BUNY&4C2X(^S,G$*31B,X7U=E;IEXEE>8"
M(7#R[:7,"<$/7MX'GK3F.*_'SZ.VC_)ZT?1"]:NXPX!:"-F>Z5JVQD=/ ?T
M[C#;.J '@UQ! H0P&J$2:FB9&YG&L"%3J#NT+P!( %%(G=;LPT6U;4D/*J2]
M9$@UAV$%"@?S1B,"][2+7[\M J2]@%PQU8U08 '8HE5@9K69\)>T"JHA$80;
M1+HR-?1/D88!<VLL>H.9.2*=*'%4WM""C2$! _,6OWX.1-X3LQNJ;O.4">I
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MXTIC"K&4%U$R.:R'3- )AFB<OG_)>Q>Y('H2(IEV@7X?'2>+XZ3,'+YE'P3
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MB@*S#EZ>TKK$JK$4LOSI7KLF$*C9' *1-WE+E,U:K<$J!AD2"H+5/&6!$AD
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MZHI2P1#&TUO:,8M4P%E6[T,QLR.F6T.E-GS2-1X33 [,$O4AHF\*^P@@P+:
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MW-]7)<H-+7E_[-1*"M8<@MM6@,NDHZ0'5N0T4!<A&LRQ3A016(L+E</YBGO
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M'#D6CV_+4 ( L8+G!E2H*U#+M5RPN)&405 !K=WV*N*5H=P64E-_Y[%EZK,
M>&+= <H!Z3(V&E.8\N7B]Y>9F:,=2&*C>H@O5T.N714      % &  P ?E4"
M %  %JK@ E23KU7(TX5@7,$HP]]5WSZXCPZ_K/S*/055L@M N56H4"@!40 "
MU5P 2Y;=B.@6!76-F82%6(]'=$$'DIPO?)I- E0 3'2V1V.WNN T%1G1U_+
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M5MZ1K@N' E:OO$P 1*P@7EUE=FM%9"$!IT%DG+;*I@#J5)*ABJ^ 50(?*!,
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M%PS&I0D:<)L@50"5G$ &"CP!!.@@"CP3GXPUDXL3WRX"3:A.;.B^4*FH)7D
M4LY >C*MD-*RJU&O\*#,7 .\8:1NX"='YLN@W-A-7"<&R7@QA?M8+YH !#2D
MX3$CAE"2B]93V6,2Q%<8=$-**UNS15@T6! #-4XKIIHAU1P6@HEVE?! SPLB
MTG FW&3*U[48"O*)%X 91VDA?S=;>#@1+BK6N8\OF4L]HM!\.&N 3AIIP1/K
M-T+Q!@'06"H@I='($@T1,P&&-<;M5"XR2 @U6EBF=!0-W7B+;GD5@AA!W58
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MPO=(0!F*)A)HND:9RHRA?ELQS4\)VV6UE2YG]4<#8+)@,*!4J253%5]0(HS
M6VEL6!<P@6%@N%W%%JDO9 4&H<%/6HJ$R(SEW$04V)"03,S>MYB!?DA(^A2%
MB21ML^F<$D?1T<#-&*#)IB MNFL!9!!R:7!"D7V8Y(3-"^VED)^8.ZE H0H'
MAHR;7*\G1C#D)M&-6:LU#D&KG7269'8\B#-HAGT22#Y00TEVFES2!FZP[#7
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MQUE\HX=ES3P',6K@7M0!]#% B"(HQR(-"@LWS-*VU=3BCHE$>0'%D6;PMZA
M;  B=G!>6K1>(@&V0'0AEO@YASF[";41A.=:L5\,X)@,N0S_ )[S3]$2VKA
MX1;P3\ 0J!)(!JM ;U$ O$&8P1$&]A%4^4((%TT\[$ZGL&T$(.YL\DU'F()R
ME=U[N_A[KQPK1GFY>R'E]O0<"S8%'R0MV5(""-C+^!>SPR33Q]?!A,W+L6D.
MIHB(Y$08?!*92Q7.4"".(UJ)1&^C"3DB9J.IF&X(DI;$@PG,%@@M*T(1>#+@
MAQEDF@&HLEH"_K5BJ(# MH&@  !%LJ<M#TTA H<0]"6\ B(6(;52LH5&'?7
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MU(T^FWGI,O#*^?&Z#D<%HBMOA54WG2=9E[%6)?*P2 ]5!/<)BKF@5C7 +!*
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6G :.%3TAP&_YQ!*9<TAS_P#\R'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mgnx-20211231_g5.jpg
<TEXT>
begin 644 mgnx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
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M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
M'B7A_2[*^@D\(_#.6ZDMW,::WXH=CED3_EE$W<]5&.%%>[QJ$C5!DA1CDY-9
M&IL?#7AMGT+2!.EOMQ9VJA3LW ,4'0D+D@=\5Y)X/UV\\(-ICZE-JESJ6JR3
MK)IEPQ\R6,396[<,<1!8\Y'&<"@#W2BJ>F:M8:S9B[TJ\AO+=B0)8'#+D=1D
M5<H **** *6J:BFFVGFL-S$X5?4UPUS=2WD[33L69O?I["M7Q/=^?J0@4_+"
MN#_O&L6F 4R6"*=-D\:2+UPZ@BH;S4+73XP]W,L:GIGJ?PJ6&:*YA66!Q)&W
M1E/!H$+%!% NV&-(U]%7 IS,%&3@ =23TI:P/%EE?7FGQBQ!=48F2-3RW% S
M=1TD7<C!AZ@YIU<GX+MKRW>Y^T1O'$0N%<$<^U=//.ENFZ0\>@ZT 2UDZKX<
ML]6N5GG,B.%VY0CD?E4YU6//$;$5)%J,,C!3N4GU% !INFV^EV@M[4-MW%B6
M.22:N4TL%4DG '>JG]IP;R/FQV;% %RBHXYHYES&P85)0 4448H$*I*.&4D,
MIR".U=EHVNI?J(9_DN /P?Z5Y/XA\3RZ7>"UM8E=PH9F<'C/:M+P]J\NJ6'V
MED$4J.5.P_K0,]>HKG-'\1APL&H'#=%E['ZUT8.1D4@"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 0C(XKSK6/ ^I0Z#=W%O!9ZYKM_&UMJ%S,/
ML[W$!# *A&0A4%>G!V\UZ-10!\Z6_BG4/"'A!--\(:4IUN1[?3-1U #;;)<_
M<41J<!Y,'YB!CY<G->O>"]?L9$E\.3:W-J.M:63'=F[C\J60Y/SA<#*^A&:T
M-?\ #FF:I+I]]?JX&DW)O8TC^ZSA2,LO\77/UKC_ (?Z;=>*O%E[\1-;MV@$
MZ&UT:VD7:\-L"<NP[,_\OK0!Z;6!K'B)+<-!9'?+T+]E_P 36GJT_P!GTFXD
M'!"$#ZGBN [9H <[M)(SR,69CDD]Z;UKG]-\5V^N^&[O5-(20K \D>V5<$LO
M]*PO#&J7<GB "2=Y5GSY@8Y'3K3 T/%ND7UY>1W%HC31JF"JG[ISZ5J>&+&Y
MT_2/)O%*-O+!2<X!Q_\ 7K9^M'''- !12,X5<L< =34+7MNH/[U2<4"*SZGM
M=AY><''6J5Q<-<2;CP.P]*BSNY]Z3\:0Q:.M<_KWC'3_  _?06ES'<7$]PA=
M$MH]YP.O J"X\;VT6GV=S'I]]))?3F&"V,6R1F'7@GI0!U1FD:+RV=BH[4RN
M?TWQ6NJ:Y/IMOIMT/L^%GF8+MB<C.T\YSVKH,\_I0 JLR-E&*GVJ_!J948G!
M/^T!6:SA5+$\*,GVJ#3[^VU2QCO+"436\N=CJ.#@X_F* .B2_MW;&_!/]X8J
MR"&&17.=1UK1TISND7.> 0*8"ZGH5CJTBO=(V]1@,K8.*GT_3K?3+7[/:@A-
MV[YCDDUA>(?'NE>'M133Y8[J]OF3>;>SA,CHOJWI6SH^KVVMZ1#J-EY@@F!*
MB5"K*02""#T.0: +QYKK?#.I?:+8VLK9DB'RY[K7G.O^);?P_<:7#<PRR'4K
MH6L93'RL>YSVJ[X*\4PZQXANHK6.6%M.OC9RE\8<]R,=J /5Z***0!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %   XX%%9NN:@VG6&^,9D<[5
M/8'UH SO%&HQ^3]BC.7)!?'8>E<L?NFG.[2,7D8LQ/+$]::"&]_I3 \"LVF/
MPWTZ&WN9K<S^)FB9X7*MAN#S6M'X1LQXI\6Z7'=WR66GV:W%O$MRPVR%,[B>
M_3]:]67P[HZV\=NFF6HACF^T(@B&%D_O@>OO4XTJQ%S<W M(?.ND"3R;.95Q
MC#'O0!Y' ]UX@_X5W:WVH7:K>6]P+AHIF5I0HZ$@]P,5G3:2\/A7Q;<KJ>H[
M]"U Q6 -TV(E#CMGG(->MQ1Z!#X@M-)M[*$7MA;--;A(N+>-CM.#_#GT[U>.
MAZ6UO=0-86YBO',ERGEC$K>K#N: /-+GQ"+'Q],^JW_D0W&A02 2R85GQDD#
MIFN5MI+B_P##?@^%[VY076H2QR21RD,5+8Z_2O7=;T;2-0O83<Z?;3M:H$C+
MQ@[ .@%54T3342W5+"W5;9S)" @_=L>X]#2 \SO+B]T+3/&-GI=U<"*UGA$1
M:4LT2O\ >P3R*V/#-C>QZXDUI<VL-I/9'=!%?F<R-VDP>G7DUW']E6.ZY;[)
M#NNL>>=@_>X&/F]:AT_0-)TN9I=-TZVM9&&"\484D>E 'EWB!;FT\?:0/MRZ
M7,(W!N90"$]^>.:T]=L(-1U/PHUQJ1U)YKEX9;J"7:K@<\;3@'G&17H%_HNF
M:K(CZE86]TT8(0RQABH_&B+0]+@6W6"PMXQ;N7A"Q@>6QZD>AH \K>U.CVWC
M.ZTI[A+BSG$4;B9B51N&)YY..YZ5IZ-!J%I<1ZAIMQ;1Q-ITA>&/4&G:=PF5
M?:1U!ZUZ,NFV4?V@I:P@W1S.0G^MXQ\WK5>Q\/:1ILYGT_3;6VE((+QQA3CZ
MT <-X2M-%U/PY!-<ZI--JMW!+YZ"\;<YYR"N>,8%8=G<1V/PQTXV-[)"UU>Q
MQ:@T<YS#'O?MGY,C\Z]272-&T=I]1@T^VMW6-GEF2(!MH&3T]J9IVE:%<Z69
M+#3[7[)J"K(X$0 E'4$C\: .)#1:=XIU2R\.WDD^G_V+)+.HG,BQ28."#G@]
M/SKH_AK8M8>'+75?M5Q/=WUNOF--*6 &>  >F*W+/0]+T^WEAL;"W@CF&)%C
MC #CT/K5FVMH;.V2VM8EAAC7"1H,!1Z 4 <CX9UJSTCXL>)_[?GAM9[P1O;S
M3L%!0#H"?P_*F>*M8&M^.-(M+&:"ZT>>TEDC1KQK>&>0.5)W#J1CBN@UZUT5
M;5M1UW3X+N*T7<3)")"%[_A6S#IWAW6],M;>33+.:U10UO&T(**#S\M,#SF[
MMK^STSP?!J=[#>/'XAQ$\5QYP5,C"ESU(Y%==\+Y!#XA\62'HFNNW%7=<_L7
M0K6SM(-)M7:W?SK:+RP%A;^^/0YK2\.3Z==6\]QIUK';2S2[[I47!:0]6..N
M?6@#V"">.XA66%@R,,@BI*X;2-7ETV8*Q+V['YD]/<5W"L'4,.A&12 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?%*YTE3_ '90?YUM53U6
MS^W:;+ /O$97ZCD4 >5>)DF?P_<"VSN&"<=<9YKEO"-Q>_VPD43LUN03*I)*
M@>OUZ5W[#!(/'."#3(X8XL^5&B9.3M4#-,!^****!'F5YJ-YINN_$34+)2U[
M:VEMY'&=J^6>1].3^%9_A+Q/=Q3RW<VJF33EL ]P+B]$[B08S(!C*CG&*[O5
MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
M]C@<BD,Y'Q=KT]WKHAL-2FA2:P22V>.Y$"!V;[S9QN&*[.VUG3["%K&YOQ)-
M8VBS7#NQ8[,??+=ZI:KX*MM3O9KA+J2W%Q"L$D2QHR[!V7<#MZ]JT)O#5A+H
MW]F>64A,*0,ZXWO&N,*6ZD<4 4/&>IR1^ ;K4-+N6C+1QO%-&<'!9>1^!KE;
MNWU.+4]5LE\0:D8[?3%O5/F?,9,'OV7V%>E&T@:U%LT,9@50HB*@J .@Q0;2
MW,C.T$99UV,Q499?0^WM0!Y?K7B&XGT6"1+Z\BOXM*CN69;H0QY/<+U=B>HJ
M]%JDNH^)%CU?6Y].BAT^WFA6.41B5V +$_WN>,5WKZ3I\K(TMC;.8UV)NB4[
M5]!QTI9-+L9GC::RMY&B&(R\0)0>WI0!YI>ZQJ5M!XFU!-6NC/9W<EO;6^<H
MB$C+8]L\>F*D35)K.\NXM'URYU.W;1GN)'DEWF&4#@@_P_2NRUG1//?S+2WB
M._/FJH WD]SZTMGX9MH="N[#RH[<WB,DC0J!@$8H X.SU:XD:!+?6Y]3%[HU
MQ)>Q.^Y8F$9Q@?P\\?\ ZZN: ]UHCZ S:E>36U[I4TLL+'*Q[$##8.Q ./PK
MO=,T*PTNR2W@MHLK$(GD\M0T@ Q\Q YJV+.V'EXMX@8E*QX0?(#U ]!0!Y98
M^(;N+45DLK^Z:"XTJXGQ=7(G8,JDJQ4?<.1TJ.QU;51HM_JUAJ5Q,8-.7]S+
M>"5C,2 \@49P "37I-UX<TRXL+BU2TBMA/&R-);HJ,-PP<$"L_1_!=KI>H)>
M2W#W4D=O]FC#QHBA/0A0-Q]S0!A:";J>WU(7=^MSILVF%C&]Z+AU;!RW'W01
MV]:[7X:6\A\ Z/<7/,K6PQG^[SC],56N_#MA-I5W96L$=B+N,QR26T:HV#UZ
M"NGT2.&WTF"TMUVI;1K$H]@,#]* *^M>'8-9ECDDE:)T7;E0#D5/HVBPZ-!)
M'"[2&1MS,V!6C0.U,"UIMO\ :M2@BQD%^?H.37H(X%<7X9Q_;*Y&3L;'M7:4
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>X\,V5Q</,
MS3(7.2$( S^51_\ ")V/_/6X_P"^E_PHHH /^$3L?^>MQ_WTO^%'_")V/_/6
MX_[Z7_"BB@ _X1.Q_P">MQ_WTO\ A44_@S3KB/8\UT!G/#+_ /$T44 5_P#A
M7^E?\_%Y_P!]K_\ $T?\*_TK_GXO/^^U_P#B:** #_A7^E?\_%Y_WVO_ ,31
M_P *_P!*_P"?B\_[[7_XFBB@ _X5_I7_ #\7G_?:_P#Q-'_"O]*_Y^+S_OM?
M_B:** #_ (5_I7_/Q>?]]K_\31_PK_2O^?B\_P"^U_\ B:** #_A7^E?\_%Y
M_P!]K_\ $T?\*_TK_GXO/^^U_P#B:** #_A7^E?\_%Y_WVO_ ,31_P *_P!*
M_P"?B\_[[7_XFBB@ _X5_I7_ #\7G_?:_P#Q-2V_@?3;=RT=Q=G(P077_P")
MHHH L?\ ")V/_/6X_P"^E_PH_P"$3L?^>MQ_WTO^%%% %BR\/VMA=+<0R3%E
@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mgnx-20211231_g6.jpg
<TEXT>
begin 644 mgnx-20211231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"&?!FG:K\2-&U74K#PMH<%A#=7TM[&);F1(54-*P107(SA5'0"O&_VC?\
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MDDB>\N)'C@;<L43*Z!\;_@E \T__  :(?M&QEF<1VGC8*N<[5^PV['^9/XT
M?7__  3L_P""RW@C]OC_ ()T_$'XC_'GXC^*O GB>\TSQ=J5_J'A;X?ZU=IX
M.T,74MO;3VUY;61AN9;2&6!R4=I,QO(ZJ$?97_X(^_M.?L6_\$_O^"4NJ?%S
MQ]_P4UU_XV?#W3/B=>V^I_%*_P# NO>1HMS/%:;=/\AXI[B" %XY/-?]T9[U
ME#;G"GSS_@A?>6:_\&N7B2Q:ZC$[^"/B,Z0EQN95:^W$#J0-ZY/;</45SO\
MP:I? ;P!^U'_ ,$)/BO^SG\4M/\ M/A[QK\2_$6CZK& "RQ3Z1I:>8F?NR(2
M'1NJLJD<B@#])_"?_!37]BKQU^R+>_MX^$?BMJ%_\)=.-Q]J\8V_@G63$$@D
M,<\RP_9//>&-U=7F6,QJR."P*-C=^+W[='[,WP+\(>#?%OQ,\;W]A)\1+N*T
M\"^'!X9U"37-<N)%5EA@TM8#>EP&4N&A'E!@9-@-?C+_ ,&_M[^T'IOB_P")
MG_!O_P#'#PO=W.G?#/XMKXB\2ZL8_P#18M!L[GS;FQ4L<&*\U"#3"D>");;4
M+YL_* >I_P""K7Q:\?\ PV_X.K?V;]2\7?%"R\&:%'X!BT_P;XA\0:3]NTZQ
MGU"/5[-I3 TT*,[W,J1,YD4H/*8DA%% '[#_ +,_[6O[/_[7WA+4_&/P!\>K
MK$.A:Y<:+XCT^YL)[*_T74X&VS65Y:7*1SVLZ'JDB*2,$9!!/ _MN?L5ZK^V
M;X^^%FFZS\5/%WASP3X3UN_U7QA8>#?&-[HMQKH-L(K:RDFLI8Y?),CF1MK
MXBP""V1YU_P3]_X)QZ3^Q/\ MG?'+XUWG[6$GC+Q9\:S:>(?&'A*'P_'I]O8
M2BXN1%>)$D\K(LC/<HN\_-LDP6V-C[*H _GE^-NG>)?"O_!U)X8_8'T#XT_%
M&W^$5[=Z6EUX+'Q<\0-#(LOA[[5(#*UZ9N9OG_UG7CIQ7[!_LH_L2P?L0_M!
M_%_XDZ+\9?%EY\,O%_ASP_=:5HOCKQ]?ZQ'X:OK)M5_M$P2ZA-*\-M)%-92'
M<Y^9),D*B*OY$_M'$?\ $;)X.Y_Y?]%_]145^F7_  <;7/Q1M/\ @BI\>I?A
M$;L:F?#=FMZ;+/F#2VU*T74>G\'V(W._MY>^@#N/"/\ P6;_ ."='C75- 32
M/CM<PZ'XM\1R^'_"/CK5/".J6?AO7-5C9D>SM-7GMDLYI-R.HQ+M<JP1G*D#
MPS_@NO\ \%N/#W_!-BQ\)?L_?#>TU&;XE_$'5[2*'4_[%FEL]"TK[3$MW=!C
M&5N;GRWVQV\>]E,BR. /+67\V_V\5\/6O_!G)^S;':B'Y_'ED;8KCBY-QKC2
MX_VL^;G\:Z#_ (.#Y_B9=?#;_@EMJ'QJ6Z'B]]#1O%K7V1,-3,/A0W7F9Y#^
M;YF<]\T ?MA>_P#!0[]D72_@WHWQWUGXFWNGZ#XDU\:'X:M]3\(ZK:ZIK&IL
MY1;.TTN6U6^NIV8';'% S, 64$#-4/V:?^"EO['O[5_QF\5_LW_"OXB:A;?$
M7P2GF^)? ?BSPOJ&AZO:0$IB?[-?P1/)$1)$=Z!@!+&6QO7/QI_P<?\ Q'_8
M-\'W7[/>K_M ^%_$?BSXJZ=\2&E^"GASPYXS&BVK:@)K$32:I=E'%O9I+]BW
M.J^<"0(RJF5E^5_V1YOB9'_P>1>,H_B[XV\/:YXG?P&$\07WA*QDM=.\\>%M
M/+6\,<DLK[82!%EW+L8BS!"2B@'H'_!,CXE?%73O^#IG]I#]G5OB_P",;WP)
MH/@[5YM%\(ZMXLO;S3[%S<Z.X,4$\KHFTS2A<#Y5<J,#BOV5\=>!O#/Q(\+7
M?@OQA92W&G7R;+B*"]EMW(!R"LL++(A! (96!'8U^*/_  39_P"5P#]J;_L1
MM5_]':%7[BT ?ST?\&N_A_Q'^W?\:OVA? _[67QR^+'C"P\'V^EKX;6X^,7B
M&UDL#+<WT;NDEK?1-N*Q1\DD@J",5Z[_ ,$:OVWOVNOAU_P79^-'_!*GQ!^T
M+XO^+OPHT&\U\:'J/C?6I-7U'P^+&9/*)O92TK*-_P!DD1FVF0HRA#D-\6_\
M&_G[)/QC_;!TS]LOP'^S?^T?XS^&'Q$MM(TV;P;X@\)^+;S2XY+O[9J#"WNQ
M;R*)(9=GE%R"T7F%TY!#?6/_  :1?M,_!OX3_$;XE_\ !.OX]_!72_!7[0]E
MK-[-<^(]0M-FK^)XH)7:ZT^ZFD)=KBUDWR!%.UXBSA<Q.[ 'ZX?M _\ !0G]
ME3]FCQ^/A+\1_'6HW?BU?#EQXANO"OA/POJ&N:C9:/ <3:C<6^GP3/;VRGCS
M) H<_*FYOEKRC]O;_@M#^RK^QM^P!!^WGX.UL_$/1_%%@?\ A7,?AF&6:WUF
M[;Y$6:=5VV<22$+*TNUD*M&%:7$9_-G]A'QU\8M>_P"#FC]L#X/>(?CEI'@G
MQAXO6_LO#\WBKPM_:K:GIEK/ ;:RMT:Y@VDZ?Y,R@%MT<!.,+FM+_@J!^P!X
M(_X)H?\ !MM\6?V2_A[^T7??$FQT3XQZ5=3WM]91P/HTT]SIKO8;(W=0 2)^
MN=UT<B@#[L_8:_X++?L]^*_^":OAK]K#]J7XHZW:7V@^#M$NOBKK[_#'7([.
MROKY&&]&CL3'+ 94=?-@,D29C#./,3=Z5XW_ ."S7_!-GX<?LR^#OVRO&7[1
MK6?PO\?7]S8^%/&8\&:S+:7EU!+/%) WEV;-!)OMKC:DJH7$,C(&521\9?&.
M:"\_X,_+;3[69))XOV9O#\LL"."Z)FVPQ'4#Y'Y_V&]#7Y]_MBZEIJ?\&;_[
M+6G27\ N)OC7?M# 90'D"7_BK>57.2%W+G'3<,]: /WV_:7_ ."G7[#_ .Q[
M\(O"7Q[_ &COC/+X;\&>.8X&\+^)'\*:K=6MX9K?[1"A>VM9/)D>$-(L<NQV
M5'('R-C'\*?\%>?^">'CS]INR_8[\!_M%6NN?$34/#;ZY:^'M&T2_NG:V6S^
MVF/?' 4%Q]F!E^S9\[ P4#$*?S'_ .#F3'_$.A^S1_V,O@C'_A*ZE7Z:?\$\
MOV-?V7/AM^S?\#_BAX8^ GA&'QCH?PCTJRLO&8\/V_\ :PCN+**6Y)N]GFDS
M2R2R2$MEFED)^^V0#AA_P<)?\$A9_!WBOQKIO[7$5Y#X*DB3Q%IT'@W61?V[
M.91Q:/9K,ZJ8)!(ZH4APOFLF]<_2/[,/[47P&_;+^"6B_M$_LU?$2T\4^#]?
MC=M-U:UBDCRR.8Y(WCE59(I$=65D=58$<BOP(_X(@:3I-W\+?^"L&HW6F6\E
MQ%X'U2"*XDA4ND4D'B@R1AB,A6,<98="47/W17VY_P &<<\LO_!(J[CDD+"+
MXMZTL8)^Z/L]B<#\23^- 'ZM4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_:3\&>!;:R\9_$BWTR'QEK49)DU!-/B>&UW G"[(Y"O&-P"YSM%>??MY?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXN9HX%5IIAXBN(A(Y RS>6B)N/.U%7H *O?\%O;SXCWG_!#_ /X)QV<T]R?
M<WAG2%\5,Q/D?;5T:P6Q$G;(@_M';GL&H _=#X$_\%(OV1_VA?BQ'\!/!WCK
M5=(\<W.@1Z[IW@[QOX1U+P_J6HZ5)NV7UK!J-O"US"=KY,6XKL;>%P:Y?X@_
M\%E?^";'PF_:'U?]E'XH?M+0^'?B#H2RMJ/AO6O"VK6T@"0^>/+DDM!%/YD>
M##Y3OYY=!%YA= ?SF_X+N7?CNT_X.)OV$_\ A3B3?\)&M]I@F%F#O.GMKC+<
MA\<^3]F^U[^P0R>]9/BC3=-U+_@]OT--1L(+@0^#?.B$\0?9(OA"8JXR.&!Y
M!'(H _53]AW_ (*8_L6?\%&],\2:C^R+\8E\22>$+]+/Q)IUUH]WI]Y8.Y?R
MVDM[N**0(_ER;7VX)1ER&5E''^*_^"T__!./PA>>-7NOCE?:AHWPVU&+3_B!
MXO\ #W@G5]3T/P]>2R>7';W.H6EK);JY?Y.'8*V Q4D _FE_P0*T*3Q%_P %
MO_\ @HGX(L]6N--CU+Q3XGM5N;)MKVQ;Q+>QK(GHR!R5]#7)?L*?L6_M4?"#
M_@D_^UQ_P2]^&/P)NOBSK_C'XCW.E>#_ (C>"=0LF\-:DYCL[6X,E[<3Q^0U
MH;5VD5@2LC&)2SJP !^W/[+G[77[//[:/P[E^+'[-'Q!/B7P]#?FS;4QI-W9
MJTWDQ381;J*)G4QS1L'4%#NX)(('QW_P<!?LO_%3]H#X8_#;PY^S%\3_ !AX
M,^)7B3QMJFG:1J?A'Q9>Z<^H&U\'>(]6@L)5@E5&66ZTRU3<REE#$@C)S]$?
M\$I/V2/B!^PE_P $\?A;^R=\5?&L/B#Q%X.T!X-6U*VD=X1++<S7!@B9P&:*
M$3"!&(7*0J=J]!:_;"('[0W[*@)Z_'O4<?\ AO\ QA0!\(?\&D__  4@\:_M
M:_LB^*?V7_CUX]U37/B!\)]<+I?^(;^2XO[[1[UWDB:228F25X;A;B)B2=B&
MW7C@5\)_\'#/[5G[5&M_MI_#;XP_#K]I?X@>%_ _Q%U>_P!(\(Z%X6\87NFV
MLVAZ9J,.GB]*6\J!WN[K^T+A)NK6\UJ!]T$]C^T'^RI^U+_P3I_X.8#X(_8A
MADTK3/VJ](U*+2[JW4K%I=IJD<G]JW"[1C=IUW"VI)&!@)% AX:H_P#@[5^'
MWA#X1_M1_L?_  J\ :1'IV@^&?"O]EZ+81?=MK2WOK.*&,>RHBC\* /W8^)'
MQD_9I_8;^&VAVGQ#\8KX>TJ]U6'1_#&FM]KU/4=7OYF/EVEI;QB:[OKESDB.
M-9)#R<<$UR_[-/\ P4M_8]_:P^,WBO\ 9P^%7Q$U"V^(O@E/-\2^ _%GA?4-
M#U>T@)3$_P!FOX(GDB(DB.] P EC+8WKGXX_X.1O'O[#'@6\_9XU?]HKP=XF
M\3_%:S^(IN/@AX=T#QA_8=K+?>?9":;4[LHX@LEE%EN=%\[/$953*R_*?[(L
MWQ,C_P"#R+QI'\7?&WA[7/$[^! FOWWA*QDM=.\\>%M/+6\,<DLK[82!%EW+
ML82S!"2B@'ZT_M-?\%1OV*?V2/%6M>!OB_\ $^_?6?"_A]->\7:9X7\*:EK<
MOA[2F=4%[J L+>8641+J09BI93N4,.:;\6/^"K'[ 7P2_9J\+?MB?$+]H6VB
M^%_C218_#OC;2]!U'4;&XD.[$;O9V\IMWRDB[)@C;XW3&Y& _*'_ ((A>-O!
M'Q6_X*Y?\% _V*OVWK6*]\0?&75]2M+K1]:N&B?4K"TOM2M[FQ@;<KX^R7L+
M1B,@B&#>F!'D>B_\'%O[-G[,_P"Q[_P;ZQ?LR_LEV%M9^#O!_P 5=/M(K&'6
M7OY+:[>YNI[E)I9'=_-\V5RRL<KN  4   'Z#^#_ /@L)_P3C^(7[1?@;]E#
MP+^TSINK>._B-X<MM<\*Z+9:9>-YUG<6(U"W,TAA$=K+):'SEAF9)-I7*@N@
M9?BM_P %=OV"/@[XW\9>!/%'Q<U*^G^&[0+\2M2\,^"]6U?3O")F8I&NI7EE
M;2P6C%E8%7<,FQBX4*Q'GG_!+;]C?]GWPK_P33_9R^,G@3X!>#IOB3H_P#TN
M^\,>+[SP_;/J5K?ZEI$<]P4NF3S$$LL[AOF^ZY'0FORR_P""%DM])_P0I_X*
M*:I\4'N)/$LVA>*?^$C.K9^UM=?\(W=']]O^;S#.TO7G?GO0!^M'_!5__@K!
M\-?^"?'_  3CO?VW_AU?:/XRE\0K:6/PO^RWPFT_6;^\C>2WE\V)OWD"PQRW
M#;&!=(2H92P8?.G_  14_8UUK]O+]D71?^"AG_!3KXC^*OBOXZ^*,]WJ6BZ-
MKGB.[@T7PUI:W$D,$5GIUO)';1-((S,7"9 D0+M(=G_-%_V5?VH?VH_^#1[P
MGXHT70]4U6#X5_&O4_$VE::D;222^&%6ZMKF6% ,LL-W=7,I(R%CCF/1>/V4
M_P"#=OXQ>%OCG_P1=^#4O@+7X$O/#WAB7PUJ@B"R/I]_9RR0D2)V8J(I@I^\
MDJ'HU &EIW_!/_XS_ '_ (*#?"CXI_ CX]_$"_\ @A#'K<7BCX6^(O&%WJEC
MH.HR:;,MI>VK7<DDRP,3)$8&=DB>1#&JAR%]@_:"_P""C/[)'[,_CZZ^%/Q(
M^(&H77BC3?#$WB36_#OA/PKJ.N7FD:+$1YNI7D6GP3-:VZY'SR[=W\ :OSI_
M9Q_X*\_\%'_BU_P7E\2?\$H/$WC_ .'L7A'PQK.K++XDL_ ,JZA=VMI:FXC3
M#7IC21LHK/M(X8A>0!XE_P $VO$GQ?\ B)_P<#?MR_L^>)_CSI7@KQ=XZU?6
M+73?^$G\*C5)=4T>TOI8H+6V#W,&W;I\MM(JC=NBBW;0L9- 'Z^?&3_@IM^P
MU\!/V;?#W[87Q+^/5M#\,/%/D_V)XVTG1;_5+";S0?+#O902^3N(*CS OSJ4
M^\"M>;P_\%ZO^"3UU\2/ GPNLOVMM/FO_B0EL?"=ZN@ZB-/N'N!&8HI+QK<0
M6\I\V,-'*ZO$SJ)!&2 ?SM_X*N_L,^"?^"<7_!M9X[_9&^'_ .T/>?$?3O#7
MQ@T]AJ-[:1P-IDTU[;2RV(2-W4;)'>0X.0T[ @$&OF__ (+5:?I^A?\ !%O_
M ()L2Z+8P6C)X8BG0VT03$DFGZ;+(_R@?,TA+L>I8DG).: /TK_X+AWWP$\3
M?MA?LT^'/B1_P5$\9?L_:UX=\8+J&F^&=*\':U/;>,?-N;152&ZM46W$Z,@A
M)D:58UO#N102)/N7]HG]LS]GG]EK5_#?A/XM>,KD>(_&=S-;^#_"&@:)=ZMK
M.MR0QF2;[-8V44L\B1H-SR!/+C&"S+D5^1G_  =D8'[=?["9_P"IYU#_ -.>
M@T[]H;]HF?X&?\'D'@C4OVCM8&F^%-0\ 6WA[P'J.JR[+>UCOM+G2-D+<*)-
M3:Y@W#^*4Y/!H _3_P"$_P#P55_X)_\ QK_98\1_MI> ?VE-&E^'/@XR)XNU
MR_M[BTDT:5-N8+FVGC6XCE)= D?E[I"ZB,/N&=+X$?\ !17]EW]HGXH6'P4\
M!:UXHLO%FJ>%9?$NFZ#XM^'^L:'/=:/');Q_;H_[0M81)$S7,(5E)R2PP"CA
M?E?]L_\ X(V_\$[X/V(_CO\ LB_!#Q5IGPIU?XS^*]"U?6M0FUBXO5@UVYU5
M%T=);=Y':"TN+X/;HJA5S))LYC 7Y9_X(J_M3_M[_LM_\%'_  __ ,$C/^"K
M'PWCUCQ%X6\#ZJ_PE^)-W/YUUI^CB)998UO 0+S39X]/ 5Y/WD4ELD;\KLB
M/W KY2_X+;:&DG_!+OXU^/=-UG5]*UWPG\.M4U;PYK6@ZY=:?=6%W#"9$D26
MVD1OO(N0201D$$$BO2?V1_\ @H-^QC^WC#XCG_9$_:#T/QR/"5^EGXA723*K
M6<C[_+8K*B%XG\N39,@:-]C;6.TXX/\ X+7$#_@D?^T;D_\ -(-<_P#21Z /
MBC_@TN\<^(/'O_!./QS^U)\>_B#XW\:>);#XF:KI[ZOK6M:IKEW%IT&FZ=,M
MO;VV^9F.^65@D49D=GQ\WR@?3[_\'$__  1VF^%^K_%[1?VP[;5-(T.Y2#48
M]-\(ZQ)=QL^,/]F-H)3$"5#3;?*1G16=6= ?F?\ X,P/^447BG_LN.K_ /IK
MTFO@;_@B'I.E/_P1,_X*.:JVF6YNF\(2Q-<F%?,*+INH.J[L9VAB6 Z DF@#
M^BGX4_M5?L[?&S]G2P_:V^&OQ=T:_P#AOJ.BRZO!XODN?L]G'9Q;_.EE:8(8
M/*,<@D$@5HVC<.%*D#R/X6?\%B?^">_Q@^,?A/X%>%/C7>6NO?$#3VOOAZWB
M'P?JNE6?BJW5WC,FGW5Y;10W0+1L%V.?,X,>\$$_BKINM?%6Q_X,L2GP\GO!
M:/\ $B:V\4/:DYCTIO$#%@2.0C7!MU;L0Y!X)K]+/^"?GP/_ ."<7_!0;]@[
M]CC]MCXEZ)H]YKOP-\)Z%IGA;5CXADLDT77;1+.T:SF1)421A?6T)BBE!)8Q
M[01*0X!^C5%>+>"_^"BO[$/Q#^/GCG]E_P '_M)^&[SQW\-=/FOO'&@?:'C;
M2;>$J)Y'E=1$PA+JLNQV\HD"3:>*N?LA?MZ?L@_M[^%-7\:_LA?';2/'&G:#
MJ?V#6)=-2:)[2?&5#Q3HD@5@"4?;L<*VUFP< 'E__!8'_@JA\-O^"3_[*=]\
M</%'AJ^U[Q'J2R67@G0+6QF:"\U J-AN9U&RW@4LK.S,&8 K&&8@5\=_ME_M
MWC]K;_@VLU[X[^%?BKXQM_BEX2^%?@O5_$_B73M*U?PW-;Z]<FR6YEMKCRK>
M.YC=GNE)MFDA*N.S(3UO_!WTK-_P1SU,JI(7XBZ$6QV&^45@?MN7EI)_P:#:
M191W4;31_LN_#MY(5<%E5H]("L1U )1@#W*GT- $/_!(;_@N#^P_\ /^"9W[
M/O@+]MC]L2X'CWQ):WUMJ&JZ]%J.I^3<-JMWY2ZAJ"QRQVS^4T+;9Y%98F1R
M%C(:OTJ_:-_:D^ 7[)7PQ;XP_M"_$NR\.: ;R&SM;F6.2>6^NICB&VM8(%>:
MZG?!VPPH[M@D*0#C^<O]OK2-)T[_ (-"_P!D>?3],MX'G^,TTLSPPJID=O\
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M0+\'?C!X&^//PZTWXK?#:;5)=#UB 3Z;<:OX=OM+EGB8 K((+V&&8(P(96*
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MVFLQ1Q6=U/\ 96D8PK,Y>)BZ!@"P^(_^"*6K?$G3?^#:3]N&7X7S70U.*[U
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MC8$Q\NVOH;_@MWXA\>6?_!J?^SKI?@&^F^QW/A/X9IXSBM9.FE-H)>(R@?\
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MQM#:I<@;F("1X6XD# ']$=M<1W=M'=1*X65 ZB6)D8 C/*L 5/L0".]/HHH
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MX_J']IK]ECX*_MA?"V_^"G[0&B:OJOA;5K=H-5T?3/%NIZ3'?0L5+13-I]Q
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MS'))))-6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JOJNJZ7H.EW.N:YJ4%G965N\]Y=W4RQQ01(I9Y'9B
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>
M_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5
MNUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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MT)-6LQ,DPM-3 GB\Q#E'VN"-RGD'&0:O0> -!M8$MK5[J..-0L<<=RP50.@
M'05MT5O97N>RJ=-3<TE=]>NAEV?A+3;&Z2[AN+HM&V5#W+$?B*U***984444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\
MZ&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P
M[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_Q=L='A.&?2O#<!NIR/[K32!4C;Z+(*_3JBL\3EN$Q=95:JNTK>1P9]X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[E&#@ ]?HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
M0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7<Z?J%O'K]GXDMI/#[:5HE[;#]_),TTUY;K9NI9O.F:( X<>E^ ?^"COCO\
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+7DO[2G
M_!1+]EK]EY9],\:^/$U/7801_P (WX?VW5X&_NR8(2 _]=&4XZ U^??[1_\
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MJK_EY/WI7\M+1_[=2\[A1117HGW84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%9WB[Q5H?@7PIJ7C7Q/=/!IND6
M$MYJ$\<#RF.&)"[L$C!9L*I.%!)QP*3:2NR9SA3@YS=DM6WLEW-&L;QY\0_
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MJ/#O!O#?"U/ER[#J,NLWK-^LGK\E9>04445UGU 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\
MFC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^
MB4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
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MQGXD^(W_  3O^ OQ!\93R2ZOKGP8\+ZAJDLQ)>2XFTFVDD8YYR68GGUKVF@
MKRC]N?\ Y-'\>_\ 8!?_ -#6ND^,VB?'+6],LHO@=XWT70[M)V-]+K6F-<K+
M'MX50"-ISSFOGS]JWP;^VG8?LZ^+KSX@?&?P?J&BQZ2QU&RL?#CQ331[ERJ.
M6^4YQS0!],_"[_DF?AW_ + 5I_Z)2MVN(^%=CXY'PP\.!]<LBW]@V>2+4]?(
M3WK?^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **X[XR_M _!?]GS
MP\?$_P 9/B-IF@VI4F%;R?,UQCJ(HES)*?9%)KX+_:6_X+J7MQ]H\-?LK^ O
MLZ\H/$WB:,,_INBM5.!ZAI&/O&*XL5F&$P:_>2U[=?N/D^(^-^&>%8/Z_72G
MTA'WIO\ [=6U^\K+S/T+\??$;P#\+/#<WB_XD^,M-T+2X!^]OM4O$AC![*"Q
M&6/91DGL#7Q!^TM_P7+^'7A;[1X<_9C\&OXDO5RJ^(-;1[>Q0_WDAXEF'^]Y
M7XU\?>#?@?\ MX?\%&?%R^+KF+7/$<;2%6\2>(;DP:;: GYEC9@$ !ZQP*2/
M[M?;7[-/_!$;X)?#S[/XB_:"\02^-=53#G2[?=;:;$WH0#YD^#W8HI'!2O)^
MNYIF.F%AR1_F?]?DGZGYD^+O$3CI\G#N%^JX=_\ +ZINUW5TU_X!&;7\R-?_
M ()+?MM?%O\ :IT_QCX?^-4TM_J>FWR7NGZM#I@AMQ;R (;4&-0BF-E#*"=[
M"4G)VDU]DUG^%_"?A?P/H5OX7\&>'+'2=-M$V6NGZ;:)!#$OHJ( H_ 5H5[>
M%I5:-!0J2YFNI^N\.9=F.4Y-2PF.Q#KU8IWFTTW=MZW;;M>UV[M+4****Z#W
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\
MDT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I
M6[6%\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_\ @GE_^,T?\-D_\%7_ /HHWQ/_ /!/+_\ &:^-_P!=L)_SXJ?<O\S^C_\
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M%_ 7.N*<@P^:T<PP].-9749RDI+5K6T6NG<_=:BOPI_X;)_X*O\ _11OB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJW7\X=?1_P#P20_Y2$?#_P#[BW_IIO*_:VBHH</>PKQJ>UORM/X>SOW.3)?
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M3SV(]P5/TKZ)^&/_  2I_8'^%7ES:1^SOI.J7"8+7/B:234BY'<I<,T8_P"
MH!7T-17DX;(<GPG\.A'U:N_O=V??9SXJ^(N?76,S.JT]U&7LXOUC3Y4_FBAX
M;\*^%_!VF)HGA'PW8:591_<M--LT@B7Z(@ 'Y5?HHKUDE%61\#.<ZLW.;NWN
MWJPHHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MILT$B1"-BHC5@HP#C*@@ _'[_@R((_X90^-RYY_X6'8<?]N%?7WQX_X(U_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M(UY"+;_@H]^W/*"R?$#QC97+9!<R0:4"?KY=JGZ?I7D5,^P[ERT(.;\E_3_
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M8U2Q')/V?+%R7/ROE=^5PTE;=V[IH]9_XB!O^K2?_+]_^X*](_9(_P""PO\
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MY/X\?$>Y^#WP3\6_%>STV.\F\-^'+S4H;260JL[PPM($+#D E0,CUK\]H/\
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M8J_5-75XMJZO<****^T/YI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?C#PWD^8U,!&E5JUH2<6HQ5N9.SU<DWY-)W/VIO+VSTZV>]U"[B@AC&9)II
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M^NM9\*QZ4%8$;%C5;NX,@(W9+;,8& <G'Z8_\$T_^";'ASPKXB^'7[;WA/\
M:)&N6$^CR7T6B?\ "+" AKFRFMWA:87;A7B>5@WR'+1$<9R/R.D,9D8Q*57)
MVAFR0/<X&?RK].?^" O[6?\ R&OV/?%^I_\ /36?!_FO]/M=LN?^ S*H_P"F
MQKR.&<?1K9RHXE?%;EWLI+;KU\[ZV/N/%[Z*/A?PWX?X+&<.9=R3RN;J*7/-
MU)1G-3E*<N;]XX349+GNHP4DDEH?IU7B/QW_ ."BW[(7[,WQ'/PI^-WQ1DT3
M618Q7?D_V%>W*>5)NVG?;PN ?E/'7I7MU?%7[='_  1YMOVT?CE=?&__ (:%
ME\.3W&G6UHNG-X7%XB+"FW._[3&>22>G&:_2,UJ9G2PO-@8*<[K1[6Z]5^9^
M*\"8+@G'YVZ7%.)G0PO(WS4TW+GNN5:4ZFEKW]WIN>G6/_!4C_@G?XHC$/\
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MVOQ_S/S^7A?P$WK@(_?)?^W'P!<?\$"OA:V/LG[0NOI_>\S1X&S^3#%5)_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,F*_=ZBODEP73J-O$8F<[[]/SYC]^A](>.53E/(LAPF&;ZJ-W\_9JE<_-_\
MX)/_ /!-O]KG]D[]HV3XN?%O1=%TW2+OPW=:;>6L.MI<7!,CQ2)A8@R$;X5S
M\WYU^D%%%?3Y9EN'RK#>PHMN-[ZN[U^X_'.-N-,WX]SMYIF48*IRJ/N)QC:-
M[:-R=]=[F9XU\):1X_\ !NK^!/$*.UAK>F7%A?+&P#&&:-HW )!P=K'L:^8?
M"'_!%#_@GQX8VOJ/POU37'3H^K^);OD^I6!XU/T(Q7UC16N(P&"Q<U*O3C)K
M:Z3_ #.#*.*N)>'\/4HY9C*M"-1IR5.<H7:T5W%I]3R#PC^P!^Q+X&VMX?\
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MR^K_ /! /]M?3B38>+?A]?@?=%MKEVI/_?RU4 _C7[)T5XT^#,CEM&2])/\
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MFQ@X(\?\!_\ !'/_ ()]>!-DS?!-M:N$Z7&O:U=7&?K&)%B/_?%?3]%.MEV
MQ-;VM6E&4K6NTGI\Q9;QAQ5DV7/ 8#'5:-%R<G&$Y03DTDV^5J]TEY:'%> O
MV;?V>?A;L;X;_ SPCH3QXVS:5X=MH),CN75 Q/N3FNUHHKIA3ITH\L$DO+0\
M7%8S%XVK[3$5)3EWDW)_>[L****LY@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR,YQ^DTO"G%Y;35?B7&T<!!Z\LI>TK-?W:4&V_O378Y7C%)VI1<OR^\^Q?\
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M/[((S9:M<_$O1K7[W^D:5KWG8_ZZA;\_AC/UJ6T_X.3?^"A?[.%U'I?[</\
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MWQ"5ZM**NU?;V=M9N.TEN]X]C&EF5*=5Q>BZ/_,_;K_A,?#'_0:@_P"^J/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
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M'M MM:F\26VAV<>HW,2Q7%^EL@FE1?NJS@;F [ G JY10 4444 %>4?MS_\
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M8[HSQ+] @'M1]<\&LT_BX7%8.3_Y]SA5@O7VEI->FH<N.ALU+UT_(^Q_AO\
M&_X+_&2R_M+X0?%[POXKMMN[[1X;U^VODQZ[H'88KJ*_'KXD_P#!I7X*M;W^
MV_V=?VU_$.AW-NQ>SB\2^'8[IPW./](M9;<H?]H1GZ5R_P#PZT_X.-/V5OWO
M[.W[<C>+K&WYL],A^(5PX '0?9=6C%NA/H&(]31_J1P)F7_(LX@IIO[->G.E
M;UGK%^J0?6,1'XZ;^3N?M;17XI?\/&?^#EW]E,^7\>?V,W\<6MOQ=WTOP^-X
MH4=6\_0Y5A3_ 'B"OM6_X _X.R;?0=3_ .$:_:8_89UC1KR @7DWA_Q$&E4]
M_P#1+J"(KWX,I_K45/!OC*I!U,O]CBXKK0K0DOQ<6_D@6.H+XKQ]4?L=17P'
M\)O^#EK_ ()8?$KRHO$OQ#\4>")I< 1>*_"<[ ,>Q>Q^TH/J6 ]Z^G/A-_P4
M#_8<^.GE1_";]K;X>ZU<38V6%MXKM5N^>F;=W64?BHKX[,N#N*\GN\;@:M-+
MJZ<N7_P*UOQ-X5Z,_ADG\SV"BD5E=0Z,"I&00>"*6OFS4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\HATH_L'PDS/_=,VK89O95Z//\ )RI.R]0]IC8?%!/T?^9^S-%?BD/V,?\
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MIM<QZ[^W_P#M/R^!O#%VXD?P]J6H+,44G*M'I.GLEJ& _P">KI(.,Y.:^O\
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M7@C]":*^EROC+BS)&OJ..JTTNBG+E^<6^5_-&4Z%&I\44S^1W]O']@[X[?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%"?V<OV_?@KI_Q>^#GBZVBN)56+6O#-]=QK?Z1=X&Z":/.2,GY9 -KJ01W
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\
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M%)1%M^Y_Q);ZR_\ 15V^.K?Y/'['_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^->A'QK\2;<M3&*:[2I47_P"X[D_4,+TC^+_S/QP_X<&?\%H_"//PW_X*
ME"$K_J_^+B>([+Z?ZJ-\<A?\BC_AUK_P<K>"SC0O^"BYU;;P#_PM[5Y\]O\
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M8>PQ*VJ_@C^3C]O']O'X[?\ !0GX[7OQN^-VL_WH- T"UD;['HMGNRMO I_
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__
M ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2
MMVL+X7?\DS\._P#8"M/_ $2E;M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]
M>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"
MM/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWC#POJ<=[IFK6,-YIUY"<I/!*@>.1?9E8$?6KU !7E'[<_\ R:/X]_[ +_\
MH:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/
MP[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\
MH;O'?_A7SU[U10!X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/7O5%
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M5\#_ /H;O'?_ (5\]>]44 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
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M,H^93]X<]*^N:X[]H+X9WWQE^"_B+X7Z9J<5E<:WIS6T5U.A9(R2#D@<D<4
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M4 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\
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M89HV+7"F(IL4CH<G/->@T >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
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MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\ ]#=X[_\
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M4 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\
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MY,-N?N^9).UN"7^54WMARH1@#ZQO?$WAO3=4MM#U'Q!8V][>L19V<]VB2SD
MDA$)RW )X!Z&KU?C=^QK_P $2OV1/V!/^"\/PT\-?L\^)O'/B#4/!_P4U[QS
MXKU;QWK-O>R&:\N$T:P5/(MH51BLFHOR"3Y8Y&WG]D: "BBB@ HHHH ****
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MT>+7X+R,V<ULMPEPS87RBNX-D]!CF@"S17Y\?$W_ (*K?M\?$C]DWP#\5O\
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MYT^7Q+XCTA[F.ZNKMY9;N\>VBFC+!IIY66'S1M4JF_Y<UY!_P31_X(S>+_\
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M^T5^TQX$FT^Z\)_LJZ1H]]>/#'';OXKUB\2ZUR&!%8[?)_LNR4D< 3!03@T
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MG_@FE_PUW<:_X6\9Z-K5C!XAA\%+8ZEI)U.'R;AH3]KEC9 K2LJLNX/(3O(
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M_LQ^)_"UY!X_^$'[6Z:#+X1DA)OX]1FD5!;K"/F9V?49E4*#N*/C.#7Z-?\
M!RM\/+;0O^"!NE_![Q?KEG)XQT!_"*:9I/VE6N]2O+=X+6X%O$"7F*I+*[;
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M@MIKVVA!8CS9))V3Y3\OYY?%;X?^-OVA/^#73X"_L_:#X;NY?B#X$_:UNO!
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M\$H/#WQ!TJ.-W\._%[2-06\A ),,UC?6QPP[,TL)S_L+Z5[5XW_97_X*(_\
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M%OYUO!$TGF3+'YG"A )5Y(P[?7%M96=GYAM+2*+S9#)+Y<87>YZL<=2?6I*
M/S7_ .#7CX5_M-?LT?\ !/#_ (9E_:J_9Z\7^!->T3QAJ=]IB>(M-$45Q87'
MDRJ48,</YKS@HP#?+GH:_2BBB@ HHHH **** "HKVRL]2M)+#4;2*>"9"LL,
MT8='4]00>"*EHH ;##%;Q+!!$J(BA41%P% Z  =!3J** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&_P!/
ML-4M'L-3LH;F"3&^&>,.C8.1D'@\@'\*ECC2)!%$@55 "JHP /2EHH ****
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MX6^*?@C9?M':1XQM&\%:AX6C\1V^ON^V#^S'MA<BY)[)Y)WGT% '5T5\C_\
M!/C_ (+/?LL_\%-_B!XF^'_[+7@;XA7,G@OR1XNU#7] M]/M]):8SK"DHDN?
M-9G:WF4+'&Y!0[@HYKJOB!_P4_\ V>_#_P"TO=?L:_"'PYXL^+/Q3TJS^U^(
MO!WPTTZWN&T&#Y0'O[R\N+:RLR2R@)+<*^67Y?F7(!]'45\^^$?^"CWP<UG]
MHOPW^R%X[^''Q \#?%#Q5;W=UI/A#Q;X9">;9VUO)/-=)?VLL^GW$:[!&1!<
MRNKR(&4 EAYYX-_X+C?L3Z]^WD__  3:\=P>,/ ?Q86\^QQ:/XVT6&VMY[IH
M5GA@CN89Y8G::)U>(AMLNY0K%G56 /L6BO*_&_[55AX'_:4\,?LPW'P5\<7^
MJ^+M/N[_ $C7=-M+)]+^R6C6RW<TLSW:O$(6N[<,K1AW,@$2R5X'X&_X+H?L
MF>./V[5_X)MCX;?$O1OBY_:4ME/X=\0:#9V:1-' ;EY//>\\N6/R%,RM$S^:
MF#&'W+D ^T**\4;]MOP_+^UOJ/[&6D_ CXB:AXGTGP_;:[J.J6>G6)TFWTVX
MEFA@N'NFO%5#));SJL+ 3MY3L(]H+5VGP+_:&^&/[1&A:GJWP[U:4W>@:Q-H
M_BC0]0@,%_H>I18\VSNH3S'( RL",I(CI)&SQNCL =O1110 4444 %%%% !1
M7DOQW_;F_99_9F\7V_@/XW?%'^Q-6N]-2_M[3^Q+ZYWV[R21J^ZW@=1EHI!@
MG/RYQ@C/%?\ #V__ ()[_P#1P/\ Y:FK?_(M<T\9A*<G&52*:[M'@XGBKAC!
M5Y4,1CJ,)QT<958)I]FG)-?,^CZ*XKX$?M$_!S]IGPA<>//@CXP_MO2;34GL
M+B[_ +/N+;9<)''(R;;B-&.%EC.0,?-C.0<=K6\)PJ14HNZ?8]?#8K#8VA&O
MAYJ<):J46FFNZ:NG\@HHKX\_:W_X+@?L7?L)?M.Z!^RQ^UG8^,_!>J>*'A;1
M/$NHZ'$^B7%M+,81=&ZBG?RX5<$/O57C'S.J@@FC<^PZ*\K_ &B_VK-%_9Q7
MPI<:E\)/&?BJW\8^(+30](NO!UK9W$:WUT2+>.7SKJ(QH^#^^(\I?XG7(SZC
M;RO-;I-);O"SH&:*0J60D?=.TD9'3@D>YH ?1110 45\Y?M3_P#!3_\ 9Y_8
MX_::^%7[*WQM\.^+;;7?C/KL.C^ -3L-+@N-/O;M[FWMF1W6?S(?+DN[?>7C
M Q("N[!Q]&T %%%% !117RQI_P#P5R_9Y^)/QP\0_L_?LH_#?X@_'#7/!UQ]
MG\9WWPOT:TETG0[C+#R)]1O[JTM&E^5OW<4LC?(PQE6  /J>BO'/V=?VYO@G
M^TU\5?&?P-\#:?XJTSQ?\/+'3KCQKX>\5^%;K3)]+-\UR+>,^>H6<LMK(XDA
M:2)D9"LC;N/8Z "BBB@ HHHH **** "BO ?VQ/\ @I)^SC^PY\6_@[\%OC='
MXC;6?CAXM/A[P8=$T0W4,=T)+:(O<N&'EQ[[N!?E#N=Y(7:K%?9=4^(7@G1/
M&VD?#?5?$]I!KVO6MW=:/I+R_O[N"V\K[1*B]2D9GA#-T!E0=6% &S113+J6
M2WMI)XK5YV1"RPQ%0TA ^Z-Q R>G) ]2* 'T5\B_!O\ X+-?LX_'3]MS7_\
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MJ.[FDMK66XAM)+AXXV9((BH>0@9"KN(7)Z#) YY(ZU\D_!+_ (+,_LX?'_\
M;9\0_P#!/?P#\)_B5_PL_P (>>_BS2;[1[&*#28(988I;B2X^VF.2-6N(>8C
M(S"0;%:@#ZZHHHH **^<OBW_ ,%/_P!GKX'_ +=/@;_@GO\ $CP[XMLO'/Q(
MM_M'@V\CTN"73;^$+*6?SDG+1[6AE0K(BME<@%65C]&T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'/;7OPTL((=0TF*WN[6*WM5@E06@$%[.I>874A8A]W 0:7A?_@A]\</V:?\
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M.M_#?C72_A];V%MI)M+R"X-S-:K,6U&XE$ 21I94C9"RB-=\K2 'A'_!!O\
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MRQU.>1XZ-"FHVDI*]Y7>OP2Z66Y^1G[:/[77B/\ ;0^*5A\4O$_A"RT6XL-
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M)_;Y_9UT7]OG6?#WA;X > =6\1^!S9>!= :_AEMH6N(;;[1]B7,)P4<NKRE
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M4\*6NJ37OA-)? ;:1<:+Y[;Y[</_ &A<K+ TA:4)M4J\LAW,& 7Z[H ****
M"O$?^"@O[5?B#]C7]G2Y^-GAGPI9ZU=0:M:V@L;Z=XXRLK$%LISD8KVZN:^*
M_P 'OAE\<O"+^ OBWX,L]>T>2=)GT^_4F,R(<JV 1R#7/BX5ZF&G&A+EFT[/
ML^C/7X?Q.58/.\/7S.DZN'C.+J06\H)ZQ6JW7FO4_,/_ (B)/C-_T;IX8_\
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M /!(O_@IWX4UZQ\4>'/@'+9ZAIMW'=6-W!XQT</!-&P='4_:^"& (^E?M/\
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M ,&I?AKPMI_PX\+I\!D\:W-Q\2_%.C:S+?\ BJ'3XO$KR^9!IDT%O;(JW2Q
ML+R1B@W%44OL^GOVR/V]9/V4_P#@DK^Q3\0?^"3/Q_UNP^'NK>,;+PKY/BSP
MIH]_=W*6_FK,UTEY:3FWO([F"8%K=U0%F,>5V-7T=X&_X("_M(>$O^":,?\
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M\3/VFQJUQX-\57/B'P#\1]-\%&QETV\EGN9OW]HU[,+A?],N8V"RQY1T( 9
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MX?QZW;75T9#+)=6[-<Q!)&E:652ZGRWFEY>.0Q  \H_X*\_MD_\ !67]E_\
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MMP_]H7*RPF4O*J[4*O+)\S!@J@'UO1110 4444 %%%% !1110 4444 %%%%
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896641752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,324,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2022 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902047944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898925960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,469<span></span>
</td>
<td class="nump">$ 181,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">120,147<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,386<span></span>
</td>
<td class="nump">23,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">21,170<span></span>
</td>
<td class="nump">16,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">279,560<span></span>
</td>
<td class="nump">312,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">37,676<span></span>
</td>
<td class="nump">42,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">18,009<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">335,245<span></span>
</td>
<td class="nump">378,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,500<span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">33,755<span></span>
</td>
<td class="nump">34,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">20,646<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">74,578<span></span>
</td>
<td class="nump">50,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">20,791<span></span>
</td>
<td class="nump">25,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">95,627<span></span>
</td>
<td class="nump">82,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,307,428 and 56,244,771 shares outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,213,002<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">239,618<span></span>
</td>
<td class="nump">295,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 335,245<span></span>
</td>
<td class="nump">$ 378,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903279000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,307,428<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898960472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">214,577<span></span>
</td>
<td class="nump">193,201<span></span>
</td>
<td class="nump">195,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">63,014<span></span>
</td>
<td class="nump">42,742<span></span>
</td>
<td class="nump">46,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">280,242<span></span>
</td>
<td class="nump">235,943<span></span>
</td>
<td class="nump">241,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(202,795)<span></span>
</td>
<td class="num">(131,060)<span></span>
</td>
<td class="num">(177,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">25,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(202,115)<span></span>
</td>
<td class="num">(129,739)<span></span>
</td>
<td class="num">(151,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (202,169)<span></span>
</td>
<td class="num">$ (129,762)<span></span>
</td>
<td class="num">$ (151,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (3.37)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
<td class="num">$ (3.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (3.37)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
<td class="num">$ (3.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">59,944,717<span></span>
</td>
<td class="nump">52,442,389<span></span>
</td>
<td class="nump">48,082,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">59,944,717<span></span>
</td>
<td class="nump">52,442,389<span></span>
</td>
<td class="nump">48,082,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 63,294<span></span>
</td>
<td class="nump">$ 97,764<span></span>
</td>
<td class="nump">$ 62,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">7,119<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 12,349<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897690008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 732,727<span></span>
</td>
<td class="num">$ (490,271)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">118,657<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">118,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(151,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">170,456<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">170,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,580,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">117,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,213,002<span></span>
</td>
<td class="num">$ (973,936)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896490152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (202,115)<span></span>
</td>
<td class="num">$ (129,739)<span></span>
</td>
<td class="num">$ (151,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">11,258<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
<td class="nump">12,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">23,126<span></span>
</td>
<td class="nump">20,676<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="num">(10,337)<span></span>
</td>
<td class="nump">16,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,188)<span></span>
</td>
<td class="num">(5,697)<span></span>
</td>
<td class="num">(4,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="num">(1,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(607)<span></span>
</td>
<td class="nump">6,994<span></span>
</td>
<td class="num">(6,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(3,780)<span></span>
</td>
<td class="num">(1,324)<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="num">(8,472)<span></span>
</td>
<td class="num">(20,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="num">(143,830)<span></span>
</td>
<td class="num">(111,898)<span></span>
</td>
<td class="num">(134,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(231,208)<span></span>
</td>
<td class="num">(223,745)<span></span>
</td>
<td class="num">(264,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">200,800<span></span>
</td>
<td class="nump">221,866<span></span>
</td>
<td class="nump">189,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(6,201)<span></span>
</td>
<td class="num">(5,906)<span></span>
</td>
<td class="num">(4,289)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities, Total</a></td>
<td class="num">(36,609)<span></span>
</td>
<td class="num">(7,785)<span></span>
</td>
<td class="num">(79,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">170,456<span></span>
</td>
<td class="nump">118,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by (Used in) Financing Activities, Total</a></td>
<td class="nump">122,777<span></span>
</td>
<td class="nump">174,342<span></span>
</td>
<td class="nump">119,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(57,662)<span></span>
</td>
<td class="nump">54,659<span></span>
</td>
<td class="num">(93,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
<td class="nump">220,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets modified in exchange for operating lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures Incurred but Not yet Paid</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897576952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of Operations<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include six immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report was filed. In the longer term, the Company plans to meet its operating requirements by generating revenue from current and future strategic collaborations or other arrangements, as well as MARGENZA product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903075864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2021 or 2020, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported as cash and cash equivalents and $91.4&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2021, and 2020, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 10, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product revenue, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the year ended December 31, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,494</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (ASU)  2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses, (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13),which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative effect adjustment was required. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Issued But Not Yet Adopted </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs.  ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903101912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2021 and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2021 and 2020 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $2.0 million, $0.8 million and $3.4 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903116328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2021 is net of a reserve of $2.0 million for unsaleable inventory which is reflected in cost of product sales for the year ended December 31, 2021.  </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,035)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,035)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903199112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and Software<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,485&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2021, 2020 and 2019 was $11.3 million, $12.0 million and $12.3 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896610376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases&#160;&#160;&#160;&#160;<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Nzk_1f9bb43e-2188-4db1-a2dd-eef9b62cc89b">five</span> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> fourteen years.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2020, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $6.7 million and $5.9 million, respectively. As of December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2020,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $16.6 million and $19.3 million, respectively, and are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_14efbc58-6be4-43f5-936e-e2b8c4ab192a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_b4c5924c-e837-4d82-8676-20ffc42a5e51">other non current assets</span></span> on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903117448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2021 or 2020. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0&#160;million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0&#160;million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on December 23, 2019. During the year ended December 31, 2020, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5&#160;million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an ATM Offering. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December&#160;31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the year ended December&#160;31, 2021, the Company did not sell any shares of common stock related to Amendment No. 1 to the Sales Agreement.  </span></div><div style="margin-bottom:21pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 10, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897560072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2021, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees purchased 34,922 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.7&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2021, under the 2003 Plan, there were options to purchase an aggregate of 187,543 shares of common stock outstanding at a weighted average exercise price of $2.96 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2021, under the 2013 Plan, there were options to purchase an aggregate of 8,186,378 shares of common stock outstanding at a weighted average exercise price of $21.90 per share. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Options</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -87.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 76%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64% - 1.55%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,010,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019 the Company issued 332,767, 504,445 and 219,045 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $5.8 million, $5.3 million and $0.7 million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2021, 2020 and 2019 was $15.20, $10.68 and $13.98 per share, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was approximately $3.3 million, $4.3 million and $2.9 million, respectively.&#160;The total fair value of stock options which vested during 2021, 2020 and 2019 was $20.2 million, $16.7 million and $17.7 million, respectively.&#160;As of December&#160;31, 2021, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $31.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.5 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded RSUs under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of December&#160;31, 2021. The Company also grants RSUs to employees from time to time as a component of their compensation. Compensation expense related to RSUs is recognized on a straight-line basis. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there was $0.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 2.3 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897574984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,524)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $837.0 million. Of these NOLs, $238.0 million will expire in various years beginning in 2025 through 2037. $599.0 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $81.0 million which will expire in various years beginning in 2022 through 2041.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2021, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2022 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $824.0 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, of the total gross unrecognized tax benefits, approximately $7.2 million and $6.1 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">The Company's U.S. Federal and state income tax returns from 2002 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903197992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA.  Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $70.0 million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $15.0 million, $40.0 million and $0.1 million under the Incyte Agreement during the years ended December&#160;31, 2021, 2020 and 2019, respectively.  All of the revenue recognized during the years ended December&#160;31, 2021 and 2020 was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being  recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2020 and 2019, the Company recognized revenue of $1.5 million, $8.6 million and $22.1 million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.   During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, the Company recognized revenue of $7.8 million and $1.4&#160;million, respectively, for services performed under this agreement. </span></div><div style="text-indent:42pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of  $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the year ended December 31, 2020. Subsequent to December&#160;31, 2021, the Company earned $5.0 million upon Zai Lab&#8217;s achievement of a regulatory milestone.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the year ended </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020, the Company recognized revenue of $8.6&#160;million related to the 2018 Zai Lab Agreement.  No revenue was recognized under the 2018 Zai Lab Agreement during the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service.  During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $2.8&#160;million and $2.7&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized revenue of  $20.3 million under the 2021 Zai Lab Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, there was $16.1 million in deferred revenue under the agreements, all of which is current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  During the year ended December&#160;31, 2021, the Company recognized revenue of $1.5&#160;million for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">I-Mab License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $11.5 million and $2.2 million, respectively, related to the I-Mab License Agreement. At December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current. At December&#160;31, 2020, $11.4 million in revenue was deferred under the I-Mab License Agreement, $4.5 million of which was current and $6.9 million of which was non-current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">I-Mab Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the year ended December&#160;31, 2021, the Company recognized revenue of $1.3 million for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in other income on the 2019 consolidated statement of operations and comprehensive loss.  In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $12.0&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2021 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.8 million, $7.1 million and $2.2 million under the NIAID contract during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897508216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies&#160;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal, and on January 18, 2022, the Lead Plaintiff filed its opening brief.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903095896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.6 million for the year ended December&#160;31, 2021 and $1.4 million for each of the years ended December&#160;31, 2020 and December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897529768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventIn January 2022, the Company entered into an agreement with Incyte under which Incyte reserved capacity at one of the Company&#8217;s GMP manufacturing facilities where the Company will manufacture certain bulk drug substance for Incyte.  This agreement is unrelated to the Incyte agreements described in Note 10, Collaboration and Other Agreements. Under the terms of the agreement, Incyte will pay the Company an upfront fee of $10.0&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902236664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other </span></div>contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2021 or 2020, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2021, and 2020, the Company determined that there were no impaired assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 10, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product revenue, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the year ended December 31, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA </span></div>approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs, Including Clinical Trial Accruals/Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span>. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (ASU)  2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses, (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13),which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative effect adjustment was required. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Issued But Not Yet Adopted </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs.  ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896475256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported as cash and cash equivalents and $91.4&#160;million reported as marketable securities on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table>* Amount is less than 10% for the period indicated.<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</a></td>
<td class="text">The following table presents the number of <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,494</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903110632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale</a></td>
<td class="text"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2021 and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898929944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">The following table sets forth the Company's inventory, net of reserves (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfInventoryReservesTableTextBlock', window );">Schedule of Inventory Reserves</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,035)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,035)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfInventoryReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserves</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfInventoryReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100903223768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,485&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896613320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock', window );">Schedule Of Supplemental Balance Sheet Information, Operating Leases</a></td>
<td class="text">The table below presents supplemental balance sheet information related to operating leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Balance Sheet Information, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898294104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -87.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 76%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64% - 1.55%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,010,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897677944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,524)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902273352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset', window );">Impaired assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893395464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">120,147<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">120,147<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,348<span></span>
</td>
<td class="nump">143,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">17,202<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">81,132<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">7,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">37,280<span></span>
</td>
<td class="nump">33,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">98,334<span></span>
</td>
<td class="nump">109,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">17,202<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">81,132<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">45,014<span></span>
</td>
<td class="nump">33,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">7,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 37,280<span></span>
</td>
<td class="nump">$ 33,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897781992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Imab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Imab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | ASD Healthcare and Oncology Supply [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ImabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ImabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897605096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100899455912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">8,395,421<span></span>
</td>
<td class="nump">7,467,603<span></span>
</td>
<td class="nump">7,159,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893446392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 120,208<span></span>
</td>
<td class="nump">$ 91,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">120,147<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">81,184<span></span>
</td>
<td class="nump">60,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">81,132<span></span>
</td>
<td class="nump">60,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">7,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,285<span></span>
</td>
<td class="nump">30,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 31,281<span></span>
</td>
<td class="nump">$ 30,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100899455784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898292264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">$ 3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898137528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Expenses</a></td>
<td class="num">$ (2,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember', window );">SEC Schedule, 12-09, Reserve, Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897657688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 110,485<span></span>
</td>
<td class="nump">$ 103,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(72,809)<span></span>
</td>
<td class="num">(61,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">37,676<span></span>
</td>
<td class="nump">42,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">11,300<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">2,890<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">9,453<span></span>
</td>
<td class="nump">8,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">45,693<span></span>
</td>
<td class="nump">41,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 51,056<span></span>
</td>
<td class="nump">$ 48,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896201400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non current assets<span></span>
</td>
<td class="text">Other non current assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100979180696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100899363752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,613<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(814)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="nump">$ 5,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100898272584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 6,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">6,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">5,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">4,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">32,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(6,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 25,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893075752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="nump">$ 118,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember', window );">Zai Lab | 2021 Zai Lab Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.60<span></span>
</td>
<td class="nump">$ 26.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,200<span></span>
</td>
<td class="nump">$ 170,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Common Stock, Maximum Amount Available For Issuance, Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893468056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="nump">$ 118,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897772888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">8,373,921<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 23,126<span></span>
</td>
<td class="nump">$ 20,676<span></span>
</td>
<td class="nump">$ 19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">187,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">13,856,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">8,186,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,337<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
<td class="nump">10,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,789<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="nump">$ 9,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100892994360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.20%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.64%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.55%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100892767880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,941,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(332,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(493,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">8,373,921<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">5,546,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,010,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">20.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">17.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">21.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">21.47<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">22.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 7,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">4,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 7,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">332,767<span></span>
</td>
<td class="nump">504,445<span></span>
</td>
<td class="nump">219,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">20,200<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">8,186,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 21.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">209,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(184,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(20,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">209,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">26.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">15.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">16.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 25.97<span></span>
</td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897783800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">824,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">837,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Tax Year 2025 To 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">599,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">81,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100892992440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">$ 175,802<span></span>
</td>
<td class="nump">$ 136,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">49,965<span></span>
</td>
<td class="nump">37,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">60,514<span></span>
</td>
<td class="nump">50,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">24,858<span></span>
</td>
<td class="nump">23,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">7,008<span></span>
</td>
<td class="nump">8,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">16,727<span></span>
</td>
<td class="nump">14,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">336,119<span></span>
</td>
<td class="nump">272,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(327,595)<span></span>
</td>
<td class="num">(263,403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">8,524<span></span>
</td>
<td class="nump">9,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(1,688)<span></span>
</td>
<td class="num">(2,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">(4,576)<span></span>
</td>
<td class="num">(5,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(8,524)<span></span>
</td>
<td class="num">(9,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902237768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (42,445)<span></span>
</td>
<td class="num">$ (27,245)<span></span>
</td>
<td class="num">$ (31,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(12,806)<span></span>
</td>
<td class="num">(8,100)<span></span>
</td>
<td class="num">(9,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(10,243)<span></span>
</td>
<td class="num">(14,691)<span></span>
</td>
<td class="num">(5,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">64,192<span></span>
</td>
<td class="nump">48,510<span></span>
</td>
<td class="nump">42,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902280216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 6,126<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
<td class="nump">$ 4,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 7,197<span></span>
</td>
<td class="nump">$ 6,126<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100892850024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100892033448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Feb. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember', window );">Zai Lab Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EntitledMilestonePaymentsUnderAgreement', window );">Entitled milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Lab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Lab Collaboration And License Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesTaxWithholding', window );">Revenues, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Lab Collaboration And License Agreement | Zai Lab | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Collaboration And License Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, Net Of Tax Withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT', window );">Estimated Reimbursement for Research and Development t</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EntitledMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entitled Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EntitledMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Reimbursement for Research and Development t</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EstimatedReimbursementForResearchAndDevelopmentT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Payment, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt-in Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893309976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement | Revenue From Performance Of The Research And Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893414248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember', window );">I-Mab Biopharma Collaboration And License Agreement | I-Mab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OneTimeMillstoneCredit', window );">One Time Millstone Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember', window );">I-Mab Biopharma Collaboration And License Agreement | I-Mab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember', window );">I-Mab Biopharma Collaboration And License Agreement Clinical Supply | I-Mab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OneTimeMillstoneCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Millstone Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OneTimeMillstoneCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893511944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100897661976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details) - Boehringer Collaboration and License Agreement - Boehringer Ingelheim International GmbH<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementTerm', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentMilestonesAmount', window );">Development milestones</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100893304504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember', window );">Boehringer Ingelheim International GmbH | Boehringer Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">RevenuesFromGrantsMember | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100899315896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100896662760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Incyte Corporation (Incyte) - Incyte MGA012 Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Revenues From License Agreements | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140100902336312">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
<td class="nump">958,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>mgnx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20211231.xsd" xlink:type="simple"/>
    <context id="i9142c213b886498f9196dea58b4b4251_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37eeac76fe9a4ee09f98fe9eb786de75_I20220222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="i0de3c7dacb78433f9459d81078d7fa6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0476cd5394264601b79261912eab342d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58fec438d9ae4646875042505289ee11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5089e1becc4a40a38b3b484eab37d9b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42358bb227514ae49d829ac1733ef857_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00c530cb42694976a0a5d52af3aafa8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f3974741d1c498b99f8a988e3a436a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibcc526fcd5c54d52a90d55d37856964c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8e2b21a437348b598121ecfdc9b9df4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99d45dc278504512b2a1022987fc80b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if4c75130354f448cb0610b16a488d692_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7daedbbfe1d34ee1bdc1e20516be6dae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ida7e57f295ae49d897b71843458bab53_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie4ecb39d5f42493faf2bf88fe9d7478d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibef0bb29d42b4d0eaa2df5672eae4ae7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09cc8fc3b9ea4814b48196d223df5899_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i602de41a128f4eaa954138a4f48a76d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfd003024ad64612a490d329efe545b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd3f288834b84b7bb3fb22cda39b1f12_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab6a99969335484aafa2c3d650cc7be2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b98867374514f4084ff535c13783e98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9cccb6db34994ec2825d89e1e8e9e5d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0eddd478eb64a50be4d0792a14a3d43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cae1bdacdfc4c09bfd62025b0041738_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4291d4100d2946dc9a44dc34ce540d33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia88b7c32e47a4e3fb38db1475b81d73d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ceff59a3256484e8c5aec6dccf28729_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibaf4328b36c34fe98d0cd1ccb2e9a7fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iffbb346889914074ba3ec066de2f190b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73cc242d37df4e43ad348da2cdcc8786_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ce9c21295c045d299c67921090a0e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i984196a6f9894e27b6e2c7d801d41348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f72f227590e4d73b71a3cd5eb786ac8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a42b204c7ac4b96b2efdd29380bcefb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c0993f3d52a4ea094ec1edb6598a865_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf781227292741cca6941ae8752cdc90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7aaf64ab813e4d7abb51d05d48d5cd9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia72da0fc0ac74829bfab2bfa1b6a4295_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7e20ca944414c688558e0c138dab25f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e0b50f677364cfda16e92a9660b911d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c082935f9bb4e5786832ef1a7cec74f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia780b693775f41f2b9d2b93f91aeb2c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07cde9d1e0dc435e983217063f27a631_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a2c0b6722614803b9f9e8801058dcf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7342585a6dde49dc9e30b562abc13e18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i363eb5f7afb94ce287279a79e80834b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94d8cefe777d48e3a76bd2b84fe5dcb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1304d0f8356e4abbae5d98d9f4fa3f56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i093a88a4bbf74bd3b948328faaf3d256_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie94a07f241b54f1691ed49732b3c0ae1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icef087b39eeb4d259811e54d29f775db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1534796b1ba49499aaf26bbdce2e184_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icca4ce8fba5d48eb8625c2cc87e156f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb1fc07cd6f74785bf5181914a299bfa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacf461f8bd8944e2a1b163c0f85cfed0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19a458f53b4d483d806f635005a4289f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1743997f4174cf3b7ce02d8d189ecbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90e0af088a8b485681a6a2cfd9025765_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a9984b5de6d4f54918b58b5fe6cf688_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dec97d172754754841a40dd976b4e22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9442a64247474df8b1461add74aaacda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90ff6ac23bd34894869aca014c7b476d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53501799fb3d4cbf8748227063b31e3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5feac2025e8d48bf8cd74e582995d13e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia51bb3e3b4fc40308c8090fc4154ddae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic810e0c6d6cc456284b6df45e6ab5613_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf78a63b685442e7a6b074034658ca90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bb8128eb5c64ebb87cdd3c2321b0d5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c5477c51959420fb6ada04c4079057a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idaebcf345af04995bc12d851fe3ad345_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib886448527284148a9cd4abc404044c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b5be726a5b24402b410d091823c143f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fa3401fe2864c42a216e6ff8b3f73c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81cc50a482614599917ddedb148b766e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6da65abefa7a47aaa53a42be5b560258_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i509383488634405f80d7cbfb16dfbcfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14aaa6274a1f4698a0529bccda6863f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7512c174d93d4b40bd56c7de25b4cc65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i482c81605c314f92b439395729ec9358_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b5c8da8f19745d6898a617604443be6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6c95d46b9e34932876caa0130763aca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib144434d1fac45d38bcdaf750b51e786_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bf993cac6f64ab8ae585d3a0284bff8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib18071c232bf4c1f8935ca41ff645bb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e329af75a644cc48324b311a1c967cf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20a0b84a19744f28ab6571e422cc21ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60e9b541c7d14da4b142d7261904ce4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i268a3aae59a84907bef761d5aed331fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia48a351150ac4a5eb9e5e9dda3c114b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4e6d9783b92432ea33daf8eb921627f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib28a044d1dfe4d36a71c069813f7c53c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcef9e6df6fc49d8aacf159f30ee4514_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f7c22c8312a430ca1abd6f404d03919_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb8206a542994cf6ae5a0d5d787ddd83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i045caf1d0b3b47e9a583b3518ce82462_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9141e7bbac044ed0b92ea1beb2676495_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa8238c19ee74d50b77649fc0430ae5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68ecd57bb740432882d856e06fb03953_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfd4ac0aa4f84f12b9173dabcc85a1e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bf50eeea4f84d868f237bb8d23137a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f03cac289bf4ae48981b949d7420242_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a11109968df48d4832bc46bd0626e2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02618b2ea51d4cd3af3550dd4354387c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdf7adc47c73485eb154e973b4a0c805_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2e033b068624ccd94d4101edb79e5d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82158f1c3e8248488d95c8b5bd40b59b_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba492058a73347a0a5489e85e2e14c17_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4c67b59b55c4ed49bb7327fa669d24b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b85187757a14127bf72d33a7726047d_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia35cfb96164647f3ab6265a6387a0ad6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b9ef449adad42c281b17649822997df_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i5cd4d20af737483f900bfdde13332313_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1a04d0404924490b3850604be6a89bd_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia806a05d835e448d9a55bdd709901742_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4cc03fb113394648b6bdf6152f7f62a0_I20170518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i6c715158e6064e159bcab21034af9af4_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9275d7191a54f6c8cef0a06cd60f348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf57af4d358745b3b61d2a28c3928667_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17b8363a661845b8b88668665eb30137_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida585248332d440d8b323582780c5460_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib40eceed5a1a4f0bbac51e606900df93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffd525d4970a470494f9448eb7781e63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4f4b23a571a4c828aa3564e2cf02b6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6003a2136a8f46d480f8bb29b428b7cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72620f596efb4d87830df652d48d868b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6a79b00742544d54ace1cbe572cc95e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15761487f3c647019105907db9a09b9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccd7737654fe4891a7d522515d8d2f96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i137fc423fc124b71bb9d9d0ea218086f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f48a736a74a46c48d9e72e00bec62fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95796e3e505f42ce851397ea0c19f8d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f6da34d58144c65bd270cebe6dfb2e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d5f2f6af1b44ea983621a977a1a87a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6308c33e7e5b4be5b26db9579c7deaa2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93b4bb09dae64bad959730c0f8dc14d8_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ic2378ab796454164a230b9cc2d7faa0f_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="if421d26f11f845ee931133022aca115d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9cd8e55dd2e43a6b2c8992d16bc68e1_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="ifa1a228424a64a95a007cd7763fe9af6_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iea4888039d1b4ab7aa399c1ee0fb212c_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i51aa661b71304203b27532bef5a74fda_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i3d11f08a9b004f7386c9c4c263eb7355_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibe770ef261ed4f4a9306a45bca01f142_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia95774cf1200470694fcafd3bf7ec9ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if911c7bcddb24ab59739871990c63da1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5513c4a35d44bd7aa7138877117d5e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9ccfbfd141f41db8e5179255ee74463_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id01efa0761354d62a3103622dabffb96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36ba3c13ff3547468eb072c96419c534_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iacf0564421e9468ba07b3edabd65d7c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i2d501e4822e04d958b40b530762460c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i792d3a81b74946ddad05c545e411fb39_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i3a760482c5564290aeaf43f8d43b77eb_D20220101-20220224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-24</endDate>
        </period>
    </context>
    <context id="i5612ac4f2da44022b008ed9b0154cf3c_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i90aa1101cc4c45c0970ae75b5e31eda7_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i5d46c300f18a459cb051be0f2ec1b59e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id56a1c317b0c4eb380a90f7cf2d2edd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2e893ab41645da9ad74d3d817f1e4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cc661c7a12847b8a62549a312da1610_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie768d1a8776c43debb1629980a72e2b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i190bb429937844f9815169af38df6990_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44996a78ebbc4831af9aa001839a44eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib57a28be4be44c419ffec77b716c5c4f_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20708ad0030840aea94ffda954ec8390_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2a115baa21f04453b29af91ceecedbd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ba60bca18874586a933ffcf1f9ec4d5_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i379c6fe0225946f5bfd1ba393f064bbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i862de472d0f64045b43008af95f4bb59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32bbffe268d44dd5869451d63139c197_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd0b205b720243ee89a12573c7a8fe9d_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="if2a1dcf4a9df4c959ddbb1934d1a6bf6_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i8662ec0dbc144632a584c73f4938b548_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="iefbbd3ca3757470f9bc0909619e0664d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i8e0a8985fef04a7bafcbb4cc03c35452_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i576f9279609e4017a60567b1d894e7c6_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i3acefd7dc96d408ab172307350cf602c_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8d998ab8e404b8194f6c63d78bb64bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d006afd97914c30b1c39b119a8f1fff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i197aeb0afffc4bdaa28739f0f1fc2ca8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b6a818854f941c79c5bc2d50e4f7fc4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieafca778c80146dc9c099099f62a8ac1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7cda7295203d408e87a17554ea99f6dc_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="productcandidate">
        <measure>mgnx:productCandidate</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8xLTEtMS0xLTE3ODUz_33f7fa5c-18c0-49e3-ac70-2bdfcc57948f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8yLTEtMS0xLTE3ODUz_23927c59-f961-41b1-b4c9-dff2279a3121">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV8zLTEtMS0xLTE3ODUz_85b0df74-93dd-479d-9542-d5213cc096d5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl80L2ZyYWc6OTA0NGU2ZWZmOWZiNGIyNzlmODdkMDZiNDA1NTI4ZDkvdGFibGU6OWIwZTA1NmJlODlhNGIyNmExMDVkNTBmZTc0OTk0ZTEvdGFibGVyYW5nZTo5YjBlMDU2YmU4OWE0YjI2YTEwNWQ1MGZlNzQ5OTRlMV80LTEtMS0xLTE3ODUz_30a5cf89-d430-4362-a1e6-b926c697119c">0001125345</dei:EntityCentralIndexKey>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9a11109968df48d4832bc46bd0626e2d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Nzk_1f9bb43e-2188-4db1-a2dd-eef9b62cc89b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_14efbc58-6be4-43f5-936e-e2b8c4ab192a">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_b4c5924c-e837-4d82-8676-20ffc42a5e51">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF84Ng_eca75ccf-e02e-4e35-a204-b21ad6e9da17">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6ODI4Y2IxZDcwMTM1NGRjZGI3ZGFjNzgxMWIyMjg1ZmIvdGFibGVyYW5nZTo4MjhjYjFkNzAxMzU0ZGNkYjdkYWM3ODExYjIyODVmYl8wLTAtMS0xLTE3ODUz_f1b9b2b3-2a47-4364-a4c5-d0ab3331b95c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjY2_e89c506a-dc7c-4210-a4fc-5c45270efaff">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjY2_c769ce5d-fd10-4478-b99d-c044e6dab483">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6YjJmMzhiZGQ1MGRkNGUyOTgzYmYwZTE2MzZkODhlZjYvdGFibGVyYW5nZTpiMmYzOGJkZDUwZGQ0ZTI5ODNiZjBlMTYzNmQ4OGVmNl8wLTAtMS0xLTE3ODUz_59062949-9d37-4fc3-bd9b-f8fee06856e9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yMTI_c012990d-f713-415f-b60d-dffeebbf2ce7">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yMTY_0d0b0fa7-c4c1-4d4e-8b0e-a96042e32b49">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6MWIyZmUyNWM1ZGExNGIyZThhMjU4MzYwMDVmZjA4ZDAvdGFibGVyYW5nZToxYjJmZTI1YzVkYTE0YjJlOGEyNTgzNjAwNWZmMDhkMF8wLTAtMS0xLTE3ODUz_ca7f536f-f4c3-4868-af07-ca6cbcbf9d0c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6MWIyZmUyNWM1ZGExNGIyZThhMjU4MzYwMDVmZjA4ZDAvdGFibGVyYW5nZToxYjJmZTI1YzVkYTE0YjJlOGEyNTgzNjAwNWZmMDhkMF8wLTItMS0xLTE3ODUz_5c62a569-5b4f-49c2-8f83-c88b25612397">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTA_9fd5c299-3375-45bd-b937-158bd1470c24">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTQ_056c871d-db0e-433f-b8ce-bac8d11c7521">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNTg_9c0b4c32-145e-4e89-9687-28b29d99ea03">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNjE_bc5de91f-2025-4355-a50a-df4a49a84ea5">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjE_fd3efedc-0779-4acc-8b3f-13e8f53a4481">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjY_ef239f09-1091-4761-ae36-0c074e143cb0">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTAtMS0xLTE3ODUz_2ae965dc-a0f0-4e73-ab43-0e4eda72e20a">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTEtMS0xLTE3ODUz_adce99bd-e271-4230-af35-6f179e3fddec">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6N2I1ZDA0ZWMyNzYwNDk1NTlhN2Y1ZjlmM2YyMmFjZjMvdGFibGVyYW5nZTo3YjVkMDRlYzI3NjA0OTU1OWE3ZjVmOWYzZjIyYWNmM18xLTItMS0xLTE3ODUz_dfe5a981-4fe5-4cc9-80db-910c30ef3064">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF82MTQ_173a87d5-1c73-436f-b446-5a27338409e4">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF83NjU_d9baa839-c747-4596-88a2-2f79ad6ff558">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMTE3_df29e8d0-28fd-4c08-aa3e-7a6b7063c598">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xNDE1_23a02177-d3e1-4cca-8ac8-26448674179d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM18wLTAtMS0xLTE3ODUz_9dcf8cbf-120c-4909-92ba-083b600b735d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM18yLTQtMS0xLTE3ODUz_73f77f3a-228c-444b-8e43-89e3265a6a45">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGFibGU6OTQ3ODNmZWQ4ZTI3NDRmMGI1NmRjZTVjYWFlZDczMjMvdGFibGVyYW5nZTo5NDc4M2ZlZDhlMjc0NGYwYjU2ZGNlNWNhYWVkNzMyM180LTEtMS0xLTE3ODUz_79831253-4915-44dd-b54e-47751a82a13a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zNDUz_c440217b-a9fd-4fb9-aadd-7d23e5441871">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8yNDk2_c704b491-7ff4-4a98-bc50-f4d2ad49607c">false</dei:EntityShellCompany>
    <dei:DocumentFiscalYearFocus
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF80Mzk4MDQ2NTE0NTgw_23927c59-f961-41b1-b4c9-dff2279a3121">2021</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8xMDk5NTExNjMxMjMz_1d62b58a-6c1a-418a-bd7b-03e34049fbbd"
      unitRef="usd">1600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i37eeac76fe9a4ee09f98fe9eb786de75_I20220222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zMjQz_dff2e13b-b2ba-427c-9ffc-e450d658e9da"
      unitRef="shares">61324258</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xL2ZyYWc6OTc4MTUyMDhjNDJmNGYyZGJiYzQwZWI2MWJhMDMwNjQvdGV4dHJlZ2lvbjo5NzgxNTIwOGM0MmY0ZjJkYmJjNDBlYjYxYmEwMzA2NF8zNDU0_726adae1-7617-4a75-8c2d-07d9834d5c94">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2022 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMTgvZnJhZzpjMTk3YmM3MWViMWY0ODU0YjUxZTkzYWRkMjIxNjZiMC90YWJsZTpkNTNiNzk2NGY5NWI0Nzg1OWQ3MmM5N2Y1NWMwMTdmNC90YWJsZXJhbmdlOmQ1M2I3OTY0Zjk1YjQ3ODU5ZDcyYzk3ZjU1YzAxN2Y0XzItMC0xLTEtMzMzMjcvdGV4dHJlZ2lvbjo3MzZlZmE0YWVhN2E0OGU0YWY4ZDk3YTMzZGM5NGU4MF8xMDk5NTExNjI4MjMx_050d34af-2f46-40c0-9eaf-793f83cd731f">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjEvZnJhZzphODNiNjEzMDNjNWM0ODQ5YWI2NTVlMjRhNzM2Y2RhOC90YWJsZTo0ZWZjNGJmYTk2OGQ0OTI4YTFiMTlmNjNjNDYzZTk2YS90YWJsZXJhbmdlOjRlZmM0YmZhOTY4ZDQ5MjhhMWIxOWY2M2M0NjNlOTZhXzAtMC0xLTEtMzMzMjEvdGV4dHJlZ2lvbjo5YzlmNGYxYjJiYzQ0ZWYxOTYzOGYzMzViNDllOGM1Yl8xMDk5NTExNjI3ODE4_702c1ee0-06a3-4dcf-8898-81ae13e78362">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjEvZnJhZzphODNiNjEzMDNjNWM0ODQ5YWI2NTVlMjRhNzM2Y2RhOC90YWJsZTo0ZWZjNGJmYTk2OGQ0OTI4YTFiMTlmNjNjNDYzZTk2YS90YWJsZXJhbmdlOjRlZmM0YmZhOTY4ZDQ5MjhhMWIxOWY2M2M0NjNlOTZhXzQtMC0xLTEtMzMzMTUvdGV4dHJlZ2lvbjplMTYzOTY3Y2M5ZTk0MmIwYThkYWQzZTMwM2M3OWEyMl8xMDk5NTExNjI3ODEy_913523bd-4a1f-4cc9-bf67-c325e1a9f992">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzQtMS0xLTEtMTc4NTM_01350a3f-7b75-465c-825a-2a268a5876d2"
      unitRef="usd">123469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzQtMy0xLTEtMTc4NTM_eeaabd77-282a-4754-b9b4-d72558d0929b"
      unitRef="usd">181131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzUtMS0xLTEtMTc4NTM_09448c34-8b52-409e-a740-1722bd19daa5"
      unitRef="usd">120147000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzUtMy0xLTEtMTc4NTM_941fc583-1ef8-4c70-838f-d5f6f8f43f50"
      unitRef="usd">91400000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzYtMS0xLTEtMTc4NTM_7beb98fa-53b5-4876-86c8-a9346c9834dc"
      unitRef="usd">10386000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzYtMy0xLTEtMTc4NTM_5dc5eed6-2051-4afc-b22e-d4f70e5e6d91"
      unitRef="usd">23081000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzctMS0xLTEtMTc4NTM_868d30d7-1895-4c23-aab9-08197f5655e6"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzctMy0xLTEtMTc4NTM_d208c4b9-7d87-4781-90db-732450e6a438"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzgtMS0xLTEtMTc4NTM_d0820dec-0c34-46e1-ab91-b6836127e0c1"
      unitRef="usd">21170000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzgtMy0xLTEtMTc4NTM_2dc3322d-350c-44ac-a91a-9580bfa179fe"
      unitRef="usd">16982000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzktMS0xLTEtMTc4NTM_a5b64134-a0f3-4a21-a578-25274f734b6b"
      unitRef="usd">279560000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzktMy0xLTEtMTc4NTM_3d3c2d52-5f75-4061-b815-fb68d6016fc0"
      unitRef="usd">312594000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEwLTEtMS0xLTE3ODUz_a15d650a-d0f8-4c25-ac82-eeba193a5ae2"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEwLTMtMS0xLTE3ODUz_7d8827d1-434c-4368-8f61-616d13267831"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEyLTEtMS0xLTE3ODUz_86ccdebc-1c84-4ef2-8647-42a16d5ed0e0"
      unitRef="usd">18009000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEyLTMtMS0xLTE3ODUz_29e60a61-1851-4cf7-82a3-81c724d881e3"
      unitRef="usd">23924000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEzLTEtMS0xLTE3ODUz_e20753b9-a0bb-4581-87f6-15c9508980b4"
      unitRef="usd">335245000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzEzLTMtMS0xLTE3ODUz_54943b25-dc0e-460b-893f-8539754aabc6"
      unitRef="usd">378743000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE3LTEtMS0xLTE3ODUz_dcda4cc8-5b71-4166-a0aa-8b9b83be5d74"
      unitRef="usd">15500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE3LTMtMS0xLTE3ODUz_2906e6a0-42c3-4f09-8856-25cbd9fb6636"
      unitRef="usd">8031000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE4LTEtMS0xLTE3ODUz_3a17001b-45fe-4bd6-b12e-8344c85308ed"
      unitRef="usd">33755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE4LTMtMS0xLTE3ODUz_eeb0a193-ec4e-4aa9-b6f2-d76f0f701888"
      unitRef="usd">34198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE5LTEtMS0xLTE3ODUz_2c2bc77f-4780-4352-9c5b-d83c032e7478"
      unitRef="usd">20646000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzE5LTMtMS0xLTE3ODUz_6cc2b06e-dac0-4e2c-ad25-fe33f3546ac5"
      unitRef="usd">4456000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIwLTEtMS0xLTE3ODUz_8bed324c-1eb8-48f0-a574-d06fe1b64991"
      unitRef="usd">4677000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIwLTMtMS0xLTE3ODUz_5100ec3f-8470-4a77-a0d5-0e6a4b2dec53"
      unitRef="usd">3988000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIxLTEtMS0xLTE3ODUz_48b8cd95-d233-460e-b4c1-73cd8e729c18"
      unitRef="usd">74578000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIxLTMtMS0xLTE3ODUz_c8f174b6-a035-42a8-8098-0a8a675a394f"
      unitRef="usd">50673000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIyLTEtMS0xLTE3ODUz_a2df4e84-138e-45b4-961b-2b9e7ee1fc64"
      unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIyLTMtMS0xLTE3ODUz_426c5ceb-0e7c-484c-ad67-beb4f09d1094"
      unitRef="usd">6926000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIzLTEtMS0xLTE3ODUz_b83bf5b4-af91-4b0b-979e-4c1d622388a4"
      unitRef="usd">20791000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzIzLTMtMS0xLTE3ODUz_c80a771b-809a-4dcb-8750-c6742a80aa2c"
      unitRef="usd">25260000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI0LTEtMS0xLTE3ODUz_16a7caf0-9802-4687-a366-2f5eafed8fe1"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI0LTMtMS0xLTE3ODUz_c435c413-09d3-4b05-9e27-b322c890b7af"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI1LTEtMS0xLTE3ODUz_e7d445ac-315b-4abb-a734-ae8f946f0ad5"
      unitRef="usd">95627000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI1LTMtMS0xLTE3ODUz_8070a188-8d0c-4f2b-b2f1-d6ddfeef550e"
      unitRef="usd">82859000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzg5Ng_27c1174c-1fdf-4b64-b64d-b798a67eb3ad"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzg5Ng_d95a9d02-a52b-40f1-a750-e2ae6b9a17e3"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwMA_6deac4a7-2bcd-45cc-85b9-9cf22b56c1c9"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwMA_804d36d4-7bd2-4acb-a1b0-87a3d4c2d142"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwOA_adb17c3e-d503-4165-9aae-cc1a158e9acc"
      unitRef="shares">61307428</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTAtMS0xLTE3ODUzL3RleHRyZWdpb246ZWM1NDg3Yjc0ZWM5NDU3ZDg3ZjY1NzQzZmFiYTkzOWZfMTA5OTUxMTYyNzkwNA_abb26143-bb7c-4e59-b7cb-17014135c4c6"
      unitRef="shares">56244771</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTEtMS0xLTE3ODUz_e5532352-3b50-4ea8-b099-227aa0445617"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI4LTMtMS0xLTE3ODUz_37c25852-0c60-4497-855c-9886bfed702c"
      unitRef="usd">562000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI5LTEtMS0xLTE3ODUz_b3a18cfa-4254-4459-bf01-04e97c4da704"
      unitRef="usd">1213002000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzI5LTMtMS0xLTE3ODUz_067c9240-20fc-4e3a-8906-121c80ae8207"
      unitRef="usd">1067150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMwLTEtMS0xLTE3ODUz_63eabe6c-1397-4f29-b203-50541348bf7c"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMwLTMtMS0xLTE3ODUz_4cbe3831-ce14-4010-a8c7-f3fdceff560f"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMxLTEtMS0xLTE3ODUz_a135740d-e195-49ef-ac65-6e8854429c51"
      unitRef="usd">-973936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMxLTMtMS0xLTE3ODUz_15f82155-115b-4d13-9286-e68478e1765a"
      unitRef="usd">-771821000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMyLTEtMS0xLTE3ODUz_671d1448-b09c-4e58-97ff-9d43ea84426f"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMyLTMtMS0xLTE3ODUz_e3d513d5-a7fd-460a-a915-cd5b386edf47"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMzLTEtMS0xLTE3ODUz_efbacef4-556c-4a18-80e3-7e1fdf09bb76"
      unitRef="usd">335245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjQvZnJhZzoyMDdkNjg3MDM2NzA0ZTA5YTQ5YjI2ZDViZDYzY2YwYy90YWJsZTplZWQ5Yzk1Mjg2YzM0NGQ3YTNmNjM3YjE0M2E4MzY1Ni90YWJsZXJhbmdlOmVlZDljOTUyODZjMzQ0ZDdhM2Y2MzdiMTQzYTgzNjU2XzMzLTMtMS0xLTE3ODUz_fb2fdbca-7a70-4363-b743-0fed6c31ff37"
      unitRef="usd">378743000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i0476cd5394264601b79261912eab342d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtMS0xLTEtMTc4NTM_a7ea8d1d-bf59-46e7-8c06-552ae8078152"
      unitRef="usd">63294000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58fec438d9ae4646875042505289ee11_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtMy0xLTEtMTc4NTM_68665cc8-9aac-4042-8bac-a85a01ca4cfc"
      unitRef="usd">97764000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5089e1becc4a40a38b3b484eab37d9b2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzMtNS0xLTEtMTc4NTM_efdf3b7d-3ff9-484f-8838-69fa71927ea6"
      unitRef="usd">62024000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42358bb227514ae49d829ac1733ef857_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtMS0xLTEtMTc4NTM_0ef5a1f0-f5c4-447a-ac42-e48f816b4899"
      unitRef="usd">12349000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00c530cb42694976a0a5d52af3aafa8c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtMy0xLTEtMTc4NTM_94ea00ae-178f-4504-98a9-85a73503b6e8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f3974741d1c498b99f8a988e3a436a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzQtNS0xLTEtMTc4NTM_4551de0e-97d9-4830-91a0-ee09d689ae6f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcc526fcd5c54d52a90d55d37856964c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtMS0xLTEtMTc4NTM_600c3a6a-bdf9-4f40-a374-c725bee830f0"
      unitRef="usd">1804000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8e2b21a437348b598121ecfdc9b9df4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtMy0xLTEtMTc4NTM_cab6690f-c307-463a-bb40-85749b35f75a"
      unitRef="usd">7119000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99d45dc278504512b2a1022987fc80b5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzUtNS0xLTEtMTc4NTM_3b40fb02-e0b6-47dd-a79f-c8d410c71089"
      unitRef="usd">2164000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtMS0xLTEtMTc4NTM_4266b89a-416e-4991-ab73-2caf37052c29"
      unitRef="usd">77447000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtMy0xLTEtMTc4NTM_ae8193a6-591b-47bf-9ba7-ccb827879113"
      unitRef="usd">104883000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzYtNS0xLTEtMTc4NTM_81e26e57-53e9-43b9-9429-61f90de33a7f"
      unitRef="usd">64188000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtMS0xLTEtMTc4NTM_04f11c25-2f4f-4210-947f-a7bfc51dbec5"
      unitRef="usd">2651000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtMy0xLTEtMTc4NTM_44382697-f212-4e0a-bdf1-1b5665050a41"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzgtNS0xLTEtMTc4NTM_99af1193-f107-4871-9a6f-0a08c10af2ca"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktMS0xLTEtMTc4NTM_70cc04a2-7c56-471a-b47a-bbd92d94eb1e"
      unitRef="usd">214577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktMy0xLTEtMTc4NTM_97060c60-64b2-4113-a7c0-9c54d76d2bad"
      unitRef="usd">193201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzktNS0xLTEtMTc4NTM_2debd325-deba-49f8-8af4-c27f6831527d"
      unitRef="usd">195309000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTEtMS0xLTE3ODUz_5e099ed6-e472-40b8-a4f0-a745087bb652"
      unitRef="usd">63014000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTMtMS0xLTE3ODUz_ba986c35-3ad7-4c84-87eb-b5a658856e44"
      unitRef="usd">42742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEwLTUtMS0xLTE3ODUz_63b48e1f-dba5-458a-8f31-fb7fae5c5a13"
      unitRef="usd">46064000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTEtMS0xLTE3ODUz_36d68cd8-4147-479a-bb80-7c09910d197f"
      unitRef="usd">280242000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTMtMS0xLTE3ODUz_ec4fb255-3e8c-48a4-b122-d866ec5ea37e"
      unitRef="usd">235943000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzExLTUtMS0xLTE3ODUz_d98e6bd6-4639-4b0e-9165-2afeaefe2fe9"
      unitRef="usd">241373000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTEtMS0xLTE3ODUz_bc8ddf30-362e-4161-9908-eaa6c436a6f5"
      unitRef="usd">-202795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTMtMS0xLTE3ODUz_10146399-c84b-494b-b48b-29045da38dce"
      unitRef="usd">-131060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEyLTUtMS0xLTE3ODUz_dee251f7-dd9d-412c-b37d-888bb5deca1b"
      unitRef="usd">-177185000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTEtMS0xLTE3ODUz_24b7d3c8-bfe1-4731-9c8b-4aab63cea56f"
      unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTMtMS0xLTE3ODUz_39ae9db4-4bad-4132-83c0-dac8aed4e959"
      unitRef="usd">1321000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzEzLTUtMS0xLTE3ODUz_b5069d9d-bdff-40dd-a029-9b4c6a2666d6"
      unitRef="usd">25374000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTEtMS0xLTE3ODUz_91892d8f-518c-4903-bb30-38c27907d3fa"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTMtMS0xLTE3ODUz_48255d1d-ba67-493e-aff7-7b6352e1f554"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE0LTUtMS0xLTE3ODUz_51c41a09-ccf3-44d3-b500-cf877b223a3a"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTEtMS0xLTE3ODUz_2b623693-9c24-41ae-905f-c487a6530239"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTMtMS0xLTE3ODUz_924ec158-73f2-4003-b908-846d59f07e7d"
      unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE2LTUtMS0xLTE3ODUz_1ac4fdd3-7243-4919-b9be-2692d7e9e35f"
      unitRef="usd">19000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTEtMS0xLTE3ODUz_963923cf-870d-4943-a8d4-699cef141736"
      unitRef="usd">-202169000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTMtMS0xLTE3ODUz_ce141035-66e1-40bd-8fdf-35079152ff9b"
      unitRef="usd">-129762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE3LTUtMS0xLTE3ODUz_9294810c-e95a-4f53-9917-aca70589b791"
      unitRef="usd">-151792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTEtMS0xLTE3ODUz_a4345912-47b7-4d8a-bcd5-4b4f488f401f"
      unitRef="usdPerShare">-3.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTEtMS0xLTE3ODUz_cded2eb3-eb5b-4620-85e9-97a285c89128"
      unitRef="usdPerShare">-3.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTMtMS0xLTE3ODUz_1df9657c-52af-442e-9a2f-ed33fe45c579"
      unitRef="usdPerShare">-2.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTMtMS0xLTE3ODUz_602240a4-9e3c-470b-9231-e568e3f550ff"
      unitRef="usdPerShare">-2.47</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTUtMS0xLTE3ODUz_ead972ab-1fae-45b2-b518-026f88a464f8"
      unitRef="usdPerShare">-3.16</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzE5LTUtMS0xLTE3ODUz_f9a952de-1a05-4cf9-a08e-0ecf32e63461"
      unitRef="usdPerShare">-3.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTEtMS0xLTE3ODUz_619f1f0f-db6d-4ec1-b0d7-29e934f6d183"
      unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTEtMS0xLTE3ODUz_f5ee067f-018d-417b-a80a-e3644c309b4b"
      unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTMtMS0xLTE3ODUz_07d3385a-8a7d-424a-80ed-5184f918fa83"
      unitRef="shares">52442389</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTMtMS0xLTE3ODUz_94438ccb-9b59-4d90-adec-b07781faa13d"
      unitRef="shares">52442389</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTUtMS0xLTE3ODUz_4d6674c8-9f5b-455c-b42d-73acd53ac6ce"
      unitRef="shares">48082728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMjcvZnJhZzo2OTY5NzBkZjU5OTQ0OTcyOTUxZTIzOTBhOGQyNzg5MS90YWJsZTpkZDVkNGRhMzgxMGQ0ZGM1YjRhOTVjZjIyMjE0MDQ5Zi90YWJsZXJhbmdlOmRkNWQ0ZGEzODEwZDRkYzViNGE5NWNmMjIyMTQwNDlmXzIwLTUtMS0xLTE3ODUz_841d6806-8ae5-4918-bca2-9e9a2470b373"
      unitRef="shares">48082728</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMS0xLTEtMTc4NTM_7d46e8c3-c9b1-4601-a463-0d9707636e6b"
      unitRef="shares">42353301</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMy0xLTEtMTc4NTM_0a9a6e22-2f1c-4460-ab77-6b2668a7c1b4"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4c75130354f448cb0610b16a488d692_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtOS0xLTEtMTc4NTM_78eeed2b-ea72-4bae-8745-cc685a9b4e5b"
      unitRef="usd">732727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7daedbbfe1d34ee1bdc1e20516be6dae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTEtMS0xLTE3ODUz_bc12169d-ed0f-48ac-a68f-808af55026bc"
      unitRef="usd">-490271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida7e57f295ae49d897b71843458bab53_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTMtMS0xLTE3ODUz_24ccb330-24db-4d18-8b7e-cd9e510ae0cb"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzMtMTUtMS0xLTE3ODUz_894f5fc6-0591-4749-ae7a-bcda1c798386"
      unitRef="usd">242877000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzUtOS0xLTEtMTc4NTM_3edb3c31-b8a4-45f3-848f-5ad7d15ae2f0"
      unitRef="usd">19571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzUtMTUtMS0xLTE3ODUz_73ab81a4-6e4f-484c-88d7-ae9d1e5d3fd6"
      unitRef="usd">19571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMS0xLTEtMTc4NTM_50aa40db-df02-4fd4-a4f7-0e2af0322533"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMy0xLTEtMTc4NTM_a7447f97-1ad2-450c-a673-e00eca51631f"
      unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtOS0xLTEtMTc4NTM_03cb0472-e8e6-4ac1-b132-f31fd3bdabea"
      unitRef="usd">118594000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzYtMTUtMS0xLTE3ODUz_e1689ac1-12f8-4356-8381-18c543744dd0"
      unitRef="usd">118657000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMS0xLTEtMTc4NTM_bdc90b06-e313-4189-b96b-64e88f8adcb5"
      unitRef="shares">280462</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="if6cb67ce67eb4536ae5bd18bea367861_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMy0xLTEtMTc4NTM_49360609-37fe-4015-90d7-2a9a57226c3e"
      unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i6994673a79cd4f0ab035e4c0b2cd9eda_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctOS0xLTEtMTc4NTM_55dda248-ac50-42cc-a630-96057ddc5d9b"
      unitRef="usd">1312000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzctMTUtMS0xLTE3ODUz_0b8f5325-e0c3-49d5-b411-d338d0f94435"
      unitRef="usd">1315000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie4ecb39d5f42493faf2bf88fe9d7478d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzktMTMtMS0xLTE3ODUz_a780698b-8763-4d56-912d-5a474f0700da"
      unitRef="usd">19000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzktMTUtMS0xLTE3ODUz_421d2e18-2b4d-433d-8079-edd8a45c8080"
      unitRef="usd">19000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ibef0bb29d42b4d0eaa2df5672eae4ae7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEwLTExLTEtMS0xNzg1Mw_95a282f1-840f-4a71-87d0-39c42c14b6e2"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEwLTE1LTEtMS0xNzg1Mw_4258fd88-7b5c-43a7-af85-67a4876b7eef"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i09cc8fc3b9ea4814b48196d223df5899_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTEtMS0xLTE3ODUz_d7d9b198-c03f-4f7c-9ce0-ab6b51f7fefc"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i09cc8fc3b9ea4814b48196d223df5899_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTMtMS0xLTE3ODUz_fe1ecfce-6a8f-4c68-badd-cb6ad548d081"
      unitRef="usd">490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i602de41a128f4eaa954138a4f48a76d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTktMS0xLTE3ODUz_9edb0a06-40ce-439f-9a4f-45f732dfcfec"
      unitRef="usd">872204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfd003024ad64612a490d329efe545b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTExLTEtMS0xNzg1Mw_78e5464c-41e8-463a-913e-e72ae77e2983"
      unitRef="usd">-642082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd3f288834b84b7bb3fb22cda39b1f12_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTEzLTEtMS0xNzg1Mw_5e82caff-f056-4be0-872f-69b40ced44ba"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzExLTE1LTEtMS0xNzg1Mw_c0605e2a-8375-43b1-942b-5968e7e843c5"
      unitRef="usd">230628000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEzLTktMS0xLTE3ODUz_dd5bcbab-ac73-4886-b022-f3e63e9d629e"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzEzLTE1LTEtMS0xNzg1Mw_3a0c16a0-ce0e-41df-b637-8c638b0bf65a"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTEtMS0xLTE3ODUz_356febd4-9fc6-4793-9adf-b71d3c9f3d8b"
      unitRef="shares">6612815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTMtMS0xLTE3ODUz_4e713d73-996a-4d3a-baa0-205d5a4a313b"
      unitRef="usd">66000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTktMS0xLTE3ODUz_e93626d0-a080-4207-8829-f6b2be5437e9"
      unitRef="usd">170390000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE0LTE1LTEtMS0xNzg1Mw_3478f76e-140c-416d-bb9d-4f1ae550e387"
      unitRef="usd">170456000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTEtMS0xLTE3ODUz_57c9716b-d698-458c-b47a-f35187fbdc6c"
      unitRef="shares">673193</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ifc7691e92c5243769f5f66eb8abd480d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTMtMS0xLTE3ODUz_b1d8f025-0575-47b3-840a-e655a729217f"
      unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i2b98867374514f4084ff535c13783e98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTktMS0xLTE3ODUz_fa737823-d4ad-4497-8d7c-2288c9db130b"
      unitRef="usd">3880000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE1LTE1LTEtMS0xNzg1Mw_9b2e526c-7577-40a9-9b45-9495abfbd0af"
      unitRef="usd">3886000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9cccb6db34994ec2825d89e1e8e9e5d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE3LTEzLTEtMS0xNzg1Mw_80809913-9823-428a-99c2-e88d96c04c49"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE3LTE1LTEtMS0xNzg1Mw_aa0ae4ab-d99b-494f-a55b-f737fd350b16"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ia0eddd478eb64a50be4d0792a14a3d43_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE4LTExLTEtMS0xNzg1Mw_7b1e061f-fc1f-4083-8ed8-7093539e0ecd"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE4LTE1LTEtMS0xNzg1Mw_e1402629-dcbb-4df1-bca0-648e7d4fb53f"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7cae1bdacdfc4c09bfd62025b0041738_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTEtMS0xLTE3ODUz_df6f570c-9333-4e47-9de5-77f31b3fc7b0"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7cae1bdacdfc4c09bfd62025b0041738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTMtMS0xLTE3ODUz_c0095d65-7abb-4154-9e15-3257353f0796"
      unitRef="usd">562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4291d4100d2946dc9a44dc34ce540d33_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTktMS0xLTE3ODUz_6ccc39cd-fa03-49ce-bef8-7c17953f4eb6"
      unitRef="usd">1067150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia88b7c32e47a4e3fb38db1475b81d73d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTExLTEtMS0xNzg1Mw_84b1fc03-c60e-4364-b2c8-ca4fce321d0e"
      unitRef="usd">-771821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ceff59a3256484e8c5aec6dccf28729_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTEzLTEtMS0xNzg1Mw_c8dbc470-b90e-497f-972c-cc948a98f6dd"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzE5LTE1LTEtMS0xNzg1Mw_ae550fd8-88a3-4cef-b5d3-a2524f75a67c"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIwLTktMS0xLTE3ODUz_74795a32-689f-4cb3-91f5-368b60331b9e"
      unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIwLTE1LTEtMS0xNzg1Mw_77169898-44f1-4211-9a1e-e8c07a472afd"
      unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTEtMS0xLTE3ODUz_a9851b68-8b6f-44ca-88fd-996c7788a87f"
      unitRef="shares">4580653</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTMtMS0xLTE3ODUz_fd9a6175-4243-4833-90ec-10dbadb2dd20"
      unitRef="usd">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTktMS0xLTE3ODUz_91b88f8a-dc45-48c7-926e-2e0c0f60bdb8"
      unitRef="usd">117772000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIxLTE1LTEtMS0xNzg1Mw_22345af1-570f-45d6-8c1e-9c03eabd326e"
      unitRef="usd">117818000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTEtMS0xLTE3ODUz_e4d14534-18b1-441b-b63f-c2770584b469"
      unitRef="shares">482004</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ic2e0b8e0921a4f79a10aea4c733a2b86_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTMtMS0xLTE3ODUz_323d285d-374e-4dc2-a212-be4116602783"
      unitRef="usd">5000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i67688742d2984cc89030eda5b3f7ad02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTktMS0xLTE3ODUz_48ff79ee-a8f0-4a75-a36f-1480a974cdc5"
      unitRef="usd">4954000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzIyLTE1LTEtMS0xNzg1Mw_cf50c1ea-4440-4b46-b7fc-4a214e0634a2"
      unitRef="usd">4959000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibaf4328b36c34fe98d0cd1ccb2e9a7fe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI0LTEzLTEtMS0xNzg1Mw_74712f4a-1973-4731-874c-3917e63d3629"
      unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI0LTE1LTEtMS0xNzg1Mw_938b9b2f-ea05-4908-8593-d48489e7827a"
      unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="iffbb346889914074ba3ec066de2f190b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI1LTExLTEtMS0xNzg1Mw_d56e009f-185f-4353-bd18-851bd8e57763"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI1LTE1LTEtMS0xNzg1Mw_ac34e87d-8582-425b-9bf6-2795ca277d32"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i73cc242d37df4e43ad348da2cdcc8786_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTEtMS0xLTE3ODUz_f8749328-27b9-44c8-b096-1b9a48cd1ad0"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i73cc242d37df4e43ad348da2cdcc8786_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTMtMS0xLTE3ODUz_ba87562e-6a11-44d1-bd1f-9be7a5fefbdc"
      unitRef="usd">613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ce9c21295c045d299c67921090a0e2c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTktMS0xLTE3ODUz_46f42e4f-7381-4930-8544-c7b657d0c4f5"
      unitRef="usd">1213002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i984196a6f9894e27b6e2c7d801d41348_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTExLTEtMS0xNzg1Mw_6b26cdd9-fd4f-4b24-91f6-e422f38e1b15"
      unitRef="usd">-973936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f72f227590e4d73b71a3cd5eb786ac8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTEzLTEtMS0xNzg1Mw_acb6fb45-2d2b-4135-812c-cab5627a443c"
      unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzAvZnJhZzplZDM5MDM0MWIzMDU0NTIzYmJhZGNiOGUyNTJmZTQ1Ny90YWJsZTozYmM1NDNiY2Y3MWE0Y2VkOTRiMjhlNDU0ODJmYWRhNi90YWJsZXJhbmdlOjNiYzU0M2JjZjcxYTRjZWQ5NGIyOGU0NTQ4MmZhZGE2XzI2LTE1LTEtMS0xNzg1Mw_25e44965-f2a1-4010-a8b9-465a64c6fe83"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtMS0xLTEtMTc4NTM_d250e5d5-e155-4207-9c67-043c0234eed4"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtMy0xLTEtMTc4NTM_a3ca9767-1bca-46c2-92f7-220cc975d7ef"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMtNS0xLTEtMTc4NTM_889ad9ab-162b-43c2-a46f-9989167742aa"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtMS0xLTEtMTc4NTM_b97721af-8840-49bc-9bdd-7ff3ae62d93a"
      unitRef="usd">11258000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtMy0xLTEtMTc4NTM_10fbef98-2a06-4d33-9e4c-8a2845972bdf"
      unitRef="usd">11957000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzUtNS0xLTEtMTc4NTM_59b63134-8940-4c50-87cc-199cae789229"
      unitRef="usd">12306000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtMS0xLTEtMTc4NTM_cf85e5e3-128c-43c0-a759-110331ae377c"
      unitRef="usd">-1607000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtMy0xLTEtMTc4NTM_8ae78dfa-e615-4150-bfc2-f771eae51a5b"
      unitRef="usd">260000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzYtNS0xLTEtMTc4NTM_24a98108-ee31-4add-92cd-6e33ccd1e44d"
      unitRef="usd">1461000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctMS0xLTEtMTc4NTM_2832d6d3-ddde-419f-b6d0-75e67847a579"
      unitRef="usd">23126000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctMy0xLTEtMTc4NTM_45018e45-2e7d-4dfd-95ff-4593780763c4"
      unitRef="usd">20676000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzctNS0xLTEtMTc4NTM_8e7e33b1-9560-48c4-94d2-b936fbb72893"
      unitRef="usd">19571000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtMS0xLTEtMTg3NzM_0b63e654-c96e-403c-aaa5-4ffaf0ce8a8c"
      unitRef="usd">-2035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtMy0xLTEtMTg4MDU_eaf86794-6097-42b9-965d-269ef0c8ffa1"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzgtNS0xLTEtMTkwMzA_b68af16e-62ee-4556-a9d3-25600844cfcb"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktMS0xLTEtMTc4NTM_538cffd7-ac89-43f0-a343-4db7178251da"
      unitRef="usd">-12696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktMy0xLTEtMTc4NTM_6ac88e84-f9e7-4c26-bfa4-f78e05c50461"
      unitRef="usd">10337000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzktNS0xLTEtMTc4NTM_c1cf3554-ce79-4270-a9fa-f1e99bf98006"
      unitRef="usd">-16839000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTEtMS0xLTE4Nzg3_d40ab6b9-e5e3-41b1-8fc5-74586d02ea1f"
      unitRef="usd">6424000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTMtMS0xLTE4ODA1_9aec686c-6f41-42cf-81b6-8087d2959a6c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzExLTUtMS0xLTE5MDQw_d1b7ba3e-1b77-4e0d-b89b-da4f71ae59bb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTEtMS0xLTE3ODUz_745d5d29-61cd-48d3-a438-cda1d9a6917b"
      unitRef="usd">4188000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTMtMS0xLTE3ODUz_08d36e77-7c91-4b1e-a19e-eac3f9411d09"
      unitRef="usd">5697000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEwLTUtMS0xLTE3ODUz_205db515-2b50-4af7-8151-920dbe5c16ee"
      unitRef="usd">4878000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTEtMS0xLTE3ODUz_23b7f07b-f021-4f12-a55e-fd90ec6ac0ca"
      unitRef="usd">-5915000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTMtMS0xLTE3ODUz_d64b3a25-db50-44c4-b640-eead7b439523"
      unitRef="usd">-581000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEyLTUtMS0xLTE3ODUz_eba49369-0501-4cf5-8f85-d1f630e327d6"
      unitRef="usd">1578000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTEtMS0xLTE3ODUz_35574ffa-2d96-492e-a2e5-0a5ce1b12dc1"
      unitRef="usd">7125000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTMtMS0xLTE3ODUz_656ae482-d54f-4506-8425-dd8adbb36a18"
      unitRef="usd">3723000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzEzLTUtMS0xLTE3ODUz_32c234fd-af53-4404-9b81-549763bf21ff"
      unitRef="usd">787000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTEtMS0xLTE3ODUz_81665951-7203-48d7-8768-5df36b076403"
      unitRef="usd">-607000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTMtMS0xLTE3ODUz_28b3ffdc-472f-4a9b-8e38-18efe4eb8ed3"
      unitRef="usd">6994000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE0LTUtMS0xLTE3ODUz_9ddc7c2b-963e-4b21-af4c-c26561d6367b"
      unitRef="usd">-6057000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTEtMS0xLTE3ODUz_d8e57d7b-8822-4556-aa1f-a547e3e57001"
      unitRef="usd">-3780000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTMtMS0xLTE3ODUz_599ccd8c-3cb0-4117-b2ed-785237fecffe"
      unitRef="usd">-1324000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE1LTUtMS0xLTE3ODUz_87b86730-0b71-4604-ae0f-37b2ba7149f9"
      unitRef="usd">2881000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTEtMS0xLTE3ODUz_2fcd2f49-a7d3-419b-93b6-f75d59475890"
      unitRef="usd">9264000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTMtMS0xLTE3ODUz_920faf62-260b-4e66-85ce-9d85882a0c23"
      unitRef="usd">-8472000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE2LTUtMS0xLTE3ODUz_d344535b-72d6-4baa-8a44-615af6cee5dc"
      unitRef="usd">-20869000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTEtMS0xLTE3ODUz_cc0e46e2-fb30-4300-947d-4bdf9dbc12e4"
      unitRef="usd">258000</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTMtMS0xLTE3ODUz_c09d0789-2735-4f29-880b-d7973ac83085"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE3LTUtMS0xLTE3ODUz_227c2a3c-247e-4234-b8d5-fbf1fed45dc1"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTEtMS0xLTE3ODUz_10d2ea00-c6f5-421f-9c65-90536ea9e8ba"
      unitRef="usd">-143830000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTMtMS0xLTE3ODUz_571e7ec1-f251-4434-928e-24c0a7c02f98"
      unitRef="usd">-111898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzE4LTUtMS0xLTE3ODUz_75f32682-6633-4fd6-a25b-d78b5c854e26"
      unitRef="usd">-134270000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTEtMS0xLTE3ODUz_eca0ce3a-6884-46bf-9f9c-11093492f20e"
      unitRef="usd">231208000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTMtMS0xLTE3ODUz_37b995be-f194-41e8-a6c5-2c5f1f434ca9"
      unitRef="usd">223745000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIxLTUtMS0xLTE3ODUz_e5ce845e-bc6e-474e-a5eb-97344e2f6c8c"
      unitRef="usd">264399000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTEtMS0xLTE3ODUz_7091391a-f508-40fc-a64f-35d72441f56a"
      unitRef="usd">200800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTMtMS0xLTE3ODUz_a2b6126b-4779-4823-a950-4f1f55dc25fc"
      unitRef="usd">221866000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIyLTUtMS0xLTE3ODUz_003521e8-560a-4657-9fcc-670ce695d168"
      unitRef="usd">189330000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTEtMS0xLTE3ODUz_17b2e6ed-512f-4721-936b-de9c16fb94d3"
      unitRef="usd">6201000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTMtMS0xLTE3ODUz_d8e8a99d-0910-4de9-96df-4994d891f508"
      unitRef="usd">5906000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzIzLTUtMS0xLTE3ODUz_89a7c94f-a3f1-486e-ae53-a38e772150f2"
      unitRef="usd">4289000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTEtMS0xLTE3ODUz_f7b9148d-f465-4322-8792-873f59b4ac1c"
      unitRef="usd">-36609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTMtMS0xLTE3ODUz_5936e500-a091-4a14-b637-45ee410a8e4e"
      unitRef="usd">-7785000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI0LTUtMS0xLTE3ODUz_de586f1f-b883-4b75-aed9-5fde0875cc90"
      unitRef="usd">-79358000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTEtMS0xLTE3ODUz_2149050f-894b-4ccf-b1b4-efbbb23103f3"
      unitRef="usd">117818000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTMtMS0xLTE3ODUz_3827ca22-4464-4d1e-8f9a-9a3c0fd2cbc0"
      unitRef="usd">170456000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI3LTUtMS0xLTE3ODUz_4e1649f2-45c9-4099-a0a5-0a9ba6bf41d4"
      unitRef="usd">118657000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTEtMS0xLTE3ODUz_f8aa4136-2996-4fc6-972c-d2b2c93841db"
      unitRef="usd">4959000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTMtMS0xLTE3ODUz_54fd1d41-5871-47be-8594-6d64f44e5fc3"
      unitRef="usd">3886000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzI4LTUtMS0xLTE3ODUz_8aed6713-9614-48eb-a2ef-f5c1ac759b9c"
      unitRef="usd">1315000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTEtMS0xLTE3ODUz_dc9ccef4-2a5c-424e-834a-cf2345518187"
      unitRef="usd">122777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTMtMS0xLTE3ODUz_67dbfa8f-1387-4732-94ff-13ceb4adcc34"
      unitRef="usd">174342000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMwLTUtMS0xLTE3ODUz_166f5e11-db94-40ed-85e5-383ff3a4fa08"
      unitRef="usd">119972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTEtMS0xLTE3ODUz_0a02d1da-ba04-4d07-878f-3eab0744f631"
      unitRef="usd">-57662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTMtMS0xLTE3ODUz_bec85aac-02f8-43d4-b4fc-d66376465647"
      unitRef="usd">54659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMxLTUtMS0xLTE3ODUz_ff2ba7af-d601-42ad-967b-fd2888e97ca8"
      unitRef="usd">-93656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTEtMS0xLTE3ODUz_54ff6f03-11fa-4c43-81a0-a563ce349a86"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTMtMS0xLTE3ODUz_392d3e3b-6660-4e56-9e28-899f285d5774"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMyLTUtMS0xLTE3ODUz_313466af-a4aa-4971-a690-a6548561b3fe"
      unitRef="usd">220128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTEtMS0xLTE3ODUz_cf5acd55-8cd2-49cd-86f0-bd82798639b8"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTMtMS0xLTE3ODUz_e6fba544-f19a-49e4-9126-c4a086d2e59e"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzMzLTUtMS0xLTE3ODUz_b2785f05-bc39-43f6-afe6-1d6e7b85fead"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTEtMS0xLTE3ODUz_6c2aa29d-cfc0-4ebe-94b0-72a572f7700c"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTMtMS0xLTE3ODUz_cb8d4320-cb5f-4715-afce-85d5ab5a186f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM2LTUtMS0xLTE3ODUz_488eb22a-feb0-488a-8f54-24e07fad7470"
      unitRef="usd">6408000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTEtMS0xLTE3ODUz_7c4ff7cf-5a10-4f26-82bf-df263832c731"
      unitRef="usd">508000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTMtMS0xLTE3ODUz_268e7362-8f85-43c0-a13b-8dd61cfb3f0f"
      unitRef="usd">66000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzMvZnJhZzo1YjhkNzM0MTZkYmM0NTE2OTk0NzE0NThjMzY5ZjZkNy90YWJsZTo3YWZhNzBiNmUwNzM0MTQ5ODkwNThjMWRiNDBiZWY5Zi90YWJsZXJhbmdlOjdhZmE3MGI2ZTA3MzQxNDk4OTA1OGMxZGI0MGJlZjlmXzM3LTUtMS0xLTE3ODUz_188050af-e774-4488-b3de-72f0750b838c"
      unitRef="usd">66000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xMzkvZnJhZzpkOTg1ZDM0NDFiZjg0MWYzYTVlOTIzNDFmNDJjNDA4ZC90ZXh0cmVnaW9uOmQ5ODVkMzQ0MWJmODQxZjNhNWU5MjM0MWY0MmM0MDhkXzgxNQ_6faf6516-644b-41ad-8dc2-e5c7cada9c7b">Organization and Nature of Operations&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include six immuno-oncology programs, some of which were created primarily using the Company&#x2019;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report was filed. In the longer term, the Company plans to meet its operating requirements by generating revenue from current and future strategic collaborations or other arrangements, as well as MARGENZA product sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk3_19e55e44-1329-4388-8426-665b5718ca21">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2021 or 2020, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported as cash and cash equivalents and $91.4&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2021, and 2020, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 10, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product revenue, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the year ended December 31, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159,494&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update (ASU)  2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses, (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13),which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative effect adjustment was required. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Issued But Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs.  ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDkx_7dc88dc7-fd73-4233-a13f-f22639fbe3a8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTI5ODk_feefbde5-82b8-42db-9b7b-1f32490fd858"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTMwMDM_feefbde5-82b8-42db-9b7b-1f32490fd858"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk4_8904166a-80fc-4513-be25-c8035a75791d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other &lt;/span&gt;&lt;/div&gt;contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg1_30703a1b-2c93-48b4-ac73-c665f68a2359">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg4_0fbfe9bf-7ca2-4b9a-bd64-ea574588f0b3">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2021 or 2020, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzU2MDU_5baae835-bf56-4b8b-a0cf-d4ebce20edb0"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzU2MDU_955afa8e-5dd3-426d-a024-3065a7811ca4"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDg2_b415b283-e3b1-4842-95d3-7c208c8ced5e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAx_f8347aa9-658e-49d9-83c8-79bf318eb118">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported as cash and cash equivalents and $91.4&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a42b204c7ac4b96b2efdd29380bcefb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtMS0xLTEtMTc4NTM_d5def750-1c47-4461-a695-56201d9058fd"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c0993f3d52a4ea094ec1edb6598a865_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtMy0xLTEtMTc4NTM_31cca62c-b100-4434-af71-cecd9bf69c1f"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idf781227292741cca6941ae8752cdc90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzQtNS0xLTEtMTc4NTM_1706bebf-2d8b-4009-b602-396113df66cc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7aaf64ab813e4d7abb51d05d48d5cd9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtMS0xLTEtMTc4NTM_06424caa-7242-4354-8346-383d0671730e"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia72da0fc0ac74829bfab2bfa1b6a4295_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtMy0xLTEtMTc4NTM_9c7431c0-c5a2-4b50-b1fb-13f5fc426595"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7e20ca944414c688558e0c138dab25f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzUtNS0xLTEtMTc4NTM_8969ec64-636f-47cb-b262-102851f49c8a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e0b50f677364cfda16e92a9660b911d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtMS0xLTEtMTc4NTM_dd1fb4d2-5eb0-4356-a36f-b6d62ec9a942"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c082935f9bb4e5786832ef1a7cec74f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtMy0xLTEtMTc4NTM_73f77fd2-f8bd-4f71-8729-6babef7b7784"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia780b693775f41f2b9d2b93f91aeb2c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzYtNS0xLTEtMTc4NTM_f6447b1e-98d0-4d73-88c7-4386b651570d"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07cde9d1e0dc435e983217063f27a631_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctMS0xLTEtMTc4NTM_80c472f7-4175-4dca-9824-2900b7ccaa2a"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a2c0b6722614803b9f9e8801058dcf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctMy0xLTEtMTc4NTM_231a5c85-f0c2-4a16-b6a3-1e3b587b7f56"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7342585a6dde49dc9e30b562abc13e18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzctNS0xLTEtMTc4NTM_236ab365-d604-4e87-b244-c15f0e75c15c"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i363eb5f7afb94ce287279a79e80834b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktMS0xLTEtMTc4NTM_5cc3e3c0-b0f5-4aef-92bc-b0fef3feb09e"
      unitRef="usd">143348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94d8cefe777d48e3a76bd2b84fe5dcb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktMy0xLTEtMTc4NTM_74a41264-999b-4624-92b0-b98aa1f414f3"
      unitRef="usd">98334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1304d0f8356e4abbae5d98d9f4fa3f56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo2ZGJlMjY3YzVjODg0Y2ViOTFjY2MyOTE5YmVhMDcxYi90YWJsZXJhbmdlOjZkYmUyNjdjNWM4ODRjZWI5MWNjYzI5MTliZWEwNzFiXzktNS0xLTEtMTc4NTM_dfd9b66d-794b-4c6b-a684-002cb1b89e25"
      unitRef="usd">45014000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i093a88a4bbf74bd3b948328faaf3d256_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtMS0xLTEtMTc4NTM_31765cdb-a6ae-47e0-a2f7-9d6ab857360d"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie94a07f241b54f1691ed49732b3c0ae1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtMy0xLTEtMTc4NTM_19ae4b0d-a5e7-42f6-b683-d8573ce3f652"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icef087b39eeb4d259811e54d29f775db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzQtNS0xLTEtMTc4NTM_597740af-778d-4c46-8720-a1eb4c1f81d8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1534796b1ba49499aaf26bbdce2e184_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtMS0xLTEtMTc4NTM_f686ad06-70b1-4b66-ad0c-f79242593773"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icca4ce8fba5d48eb8625c2cc87e156f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtMy0xLTEtMTc4NTM_b6686c07-564c-4bde-90aa-4fe89b03b04f"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb1fc07cd6f74785bf5181914a299bfa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzYtNS0xLTEtMTc4NTM_f1a6cfad-7fd6-4ba8-87b6-b56df2e275c0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacf461f8bd8944e2a1b163c0f85cfed0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctMS0xLTEtMTc4NTM_669ecb0c-5a74-4f4a-8931-1b49d0c6a453"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19a458f53b4d483d806f635005a4289f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctMy0xLTEtMTc4NTM_25c39f31-4130-433b-af8c-bc70a1840a7d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1743997f4174cf3b7ce02d8d189ecbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzctNS0xLTEtMTc4NTM_cbcf0943-bb9c-4053-98ab-30a6c3fb9b64"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90e0af088a8b485681a6a2cfd9025765_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktMS0xLTEtMTc4NTM_302de439-a43a-4db7-bc5e-721867ebc43e"
      unitRef="usd">143403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a9984b5de6d4f54918b58b5fe6cf688_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktMy0xLTEtMTc4NTM_662b6605-6d9b-419d-940f-059f7510cc38"
      unitRef="usd">109627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3dec97d172754754841a40dd976b4e22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo5YmM3MWM0ZmI1ZmY0MzhiYmJmZGYwMjIwZDIxNjM4Zi90YWJsZXJhbmdlOjliYzcxYzRmYjVmZjQzOGJiYmZkZjAyMjBkMjE2MzhmXzktNS0xLTEtMTc4NTM_0212633c-12da-41fc-9d5f-d0f2bd4ff4a7"
      unitRef="usd">33776000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzE2NDkyNjc0NzY3ODA_27d4a1fa-6ef8-4947-b547-f62bbf823fb7"
      unitRef="usd">23200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTgyNjU_db5ad63c-99da-4baa-b23f-2787d4a38fef"
      unitRef="usd">120100000</us-gaap:Investments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzE2NDkyNjc0NzY3ODg_03714334-d314-4c6a-80bb-7ac92ec1a9cf"
      unitRef="usd">52000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzEwOTk1MTE3NTgyODE_fb1a658e-3b2f-4fe7-ae37-de743a2d2e82"
      unitRef="usd">91400000</us-gaap:Investments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDc3_ad65e104-42ae-41f0-bee2-e61effde3f6d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDky_25fb8c60-260c-43b8-8a0d-021d2a924ee2">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;* Amount is less than 10% for the period indicated.&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9442a64247474df8b1461add74aaacda_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItMS0xLTEtMTc4NTM_93d7078d-f834-46b5-9b73-f1c8251f2381"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i90ff6ac23bd34894869aca014c7b476d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItMy0xLTEtMTc4NTM_ffd2463d-dd5c-42bf-9968-019e6195a2c6"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53501799fb3d4cbf8748227063b31e3f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzItNS0xLTEtMTc4NTM_81b84e70-437d-4346-aef6-49f168857cbb"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5feac2025e8d48bf8cd74e582995d13e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzMtMy0xLTEtMTc4NTM_d7e0efb0-e220-41a2-a13c-84ad7f787629"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia51bb3e3b4fc40308c8090fc4154ddae_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzMtNS0xLTEtMTc4NTM_96d1ccdb-e60d-4d41-b877-869c611af01f"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic810e0c6d6cc456284b6df45e6ab5613_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtMS0xLTEtMTc4NTM_a081d56e-f36a-429c-8675-b472ccdbbd5e"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf78a63b685442e7a6b074034658ca90_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtMy0xLTEtMTc4NTM_41f7770a-5a04-4268-9901-f34c1a81eae5"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bb8128eb5c64ebb87cdd3c2321b0d5d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzQtNS0xLTEtMTc4NTM_d40b2e93-bbd1-450d-9c00-7e22cc6135aa"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c5477c51959420fb6ada04c4079057a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzUtMS0xLTEtMTc4NTM_4604e8d9-f596-454e-9824-c1fab5aae4ce"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idaebcf345af04995bc12d851fe3ad345_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzUtNS0xLTEtMTc4NTM_d74f2fcf-c314-4d2d-a091-f8753749b985"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib886448527284148a9cd4abc404044c2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZTkzZjkzOTI0ZmY0MGI1OWY5ZmI0YzA5MDlhOTJhYy90YWJsZXJhbmdlOmRlOTNmOTM5MjRmZjQwYjU5ZjlmYjRjMDkwOWE5MmFjXzYtMS0xLTEtMjQxNjQ_88b4585d-3558-49f8-92a1-ab5bbbd61d20"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3b5be726a5b24402b410d091823c143f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzItMy0xLTEtMTc4NTM_15c93e36-47f2-4243-92d0-010b5a3fe55b"
      unitRef="number">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fa3401fe2864c42a216e6ff8b3f73c5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzMtMS0xLTEtMTc4NTM_247499fe-2a70-4a39-aa56-418e9d777ac8"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i81cc50a482614599917ddedb148b766e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzQtMS0xLTEtMTc4NTM_6bfe80fc-ed1b-4eb0-a225-284a797cacfe"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6da65abefa7a47aaa53a42be5b560258_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzQtMy0xLTEtMTc4NTM_aa0a12e6-aedd-416b-badf-0f146e087402"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i509383488634405f80d7cbfb16dfbcfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzUtMS0xLTEtMzEwNjE_32e59ccb-1d90-4695-bc7e-c5607ac922e6"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14aaa6274a1f4698a0529bccda6863f1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzUtMy0xLTEtMzEwNjE_67d44c02-02f1-41c6-a8fd-001e54b629b1"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7512c174d93d4b40bd56c7de25b4cc65_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzYtMS0xLTEtMzEwNjE_814c1e29-e1a9-4d85-a238-2373b80a6946"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i482c81605c314f92b439395729ec9358_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTo3YjZhMWNmZjEzZTU0MTlhYjk3YjA2YWE3MjdiM2M1ZS90YWJsZXJhbmdlOjdiNmExY2ZmMTNlNTQxOWFiOTdiMDZhYTcyN2IzYzVlXzYtMy0xLTEtMzEwNjE_0fb01839-9f99-4ab6-8a8a-60c24fb29ae1"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA0_dba3e348-15e4-4a25-a1f6-90a3c962213c">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDkz_bd3ec05c-218e-4c3c-a454-c76c47011738">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk2_03a4f917-82fb-4bcb-bb87-42bd46964e6f">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9b5c8da8f19745d6898a617604443be6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzAtMS0xLTEtMTc4NTM_12580f66-3316-49f9-a704-5c5f12424632">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie6c95d46b9e34932876caa0130763aca_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzEtMS0xLTEtMTc4NTM_ad81f4d8-d9e8-4b36-b2c4-df9b41f9d242">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib144434d1fac45d38bcdaf750b51e786_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzItMS0xLTEtMTc4NTM_0adbbb8c-8e51-414c-8bd6-f85b045c3d66">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3bf993cac6f64ab8ae585d3a0284bff8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpjNmQzYzhkYjMxYTQ0MmI1ODNkYmE3Y2JiZTExNDNhZC90YWJsZXJhbmdlOmM2ZDNjOGRiMzFhNDQyYjU4M2RiYTdjYmJlMTE0M2FkXzMtMS0xLTEtMTc4NTM_056765ab-1a3c-445c-ba52-5833e587dc9e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDc4_07084372-4be2-4e60-a94a-5142dd4a90f8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2021, and 2020, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_307a51de-784e-40a7-b4dd-e19ae278eba1"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_d15dd22b-3f8e-4bad-80d9-718405defef9"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzExNzA1_f9716d51-e60d-4dd6-ac6c-373d358e3c20"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAw_666ed3c1-b9f2-4444-afa6-fe85fb78ca14">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 10, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product revenue, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the year ended December 31, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA5_cf44da2c-ccbc-432c-ab5b-8ead43991027">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA &lt;/span&gt;&lt;/div&gt;approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTAz_7d610699-4107-48cb-b3aa-a539062cf195">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzIyNTM5OTg4NTAwMzA2_4885b5eb-7bf7-4269-8013-87bd4384c6a1">Leases&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MTA0_5b20ae02-8bbc-49b5-a52e-9442391d11e8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDk0_4ea77a91-f7e9-4fe2-9f31-b66099391b19">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDgy_97791a1b-5587-49ca-a4a9-49c753f51b00">The following table presents the number of &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159,494&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItMS0xLTEtMTc4NTM_e198e66d-c761-4e40-8217-66275d085e3e"
      unitRef="shares">8395421</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib18071c232bf4c1f8935ca41ff645bb8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItMy0xLTEtMTc4NTM_a3ca2c8a-4cb3-4320-9b00-9065d26e766a"
      unitRef="shares">7467603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e329af75a644cc48324b311a1c967cf_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90YWJsZTpkZWJjMDlhYjdiOTg0ODg0OTY1NTYyMThlOTliZjU3Yi90YWJsZXJhbmdlOmRlYmMwOWFiN2I5ODQ4ODQ5NjU1NjIxOGU5OWJmNTdiXzItNS0xLTEtMTc4NTM_51872199-8c0c-41a9-8dfa-8eb7710993a9"
      unitRef="shares">7159494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDIvZnJhZzpjNmQxOWM1MGJhMzg0MTViOGEwZDU3NDhhZDc2NmNmOC90ZXh0cmVnaW9uOmM2ZDE5YzUwYmEzODQxNWI4YTBkNTc0OGFkNzY2Y2Y4XzM1MDgz_4ac6d4f6-8dfe-4005-aa3c-47174ab4937a">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update (ASU)  2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses, (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13),which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative effect adjustment was required. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Issued But Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs.  ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzE0NDI_dc89f9d6-afa3-41f8-9f84-27285611c710">Marketable Securities&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at December&#160;31, 2021 and 2020 had contractual maturities of less than one year.  All of the Company&#x2019;s available-for-sale marketable debt securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2020 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded interest income of $2.0 million, $0.8 million and $3.4 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzE0NDM_646b43a7-e402-4ffe-a73e-48e2e1254a74">&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItMS0xLTEtMTc4NTM_a9791b4a-b8f3-4e63-84c9-e847109fe296"
      unitRef="usd">81184000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItMy0xLTEtMTc4NTM_3a8e1768-60b9-4ff8-bd8d-d3f6ea421673"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItNS0xLTEtMTc4NTM_34363f5f-bde5-4d84-98f2-6fc7956bf1d4"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69eca97b2af144f5bb1574bcd4bb0cd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzItNy0xLTEtMTc4NTM_d9dd09bf-c3e8-46ef-acd8-ce53d0361322"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtMS0xLTEtMTc4NTM_83298619-0689-4c50-af7d-3ad227601bd7"
      unitRef="usd">7739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtMy0xLTEtMTc4NTM_ad1565bf-044f-407d-b7c5-eb4e4b15c6d2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtNS0xLTEtMTc4NTM_522ec135-a7c4-46f5-b784-3a0f324075b1"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20a0b84a19744f28ab6571e422cc21ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzMtNy0xLTEtMTc4NTM_f75e6e65-ced7-444f-9b0a-8eb8d5af64da"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtMS0xLTEtMTc4NTM_210891c1-eb74-4aaa-b0b2-f13f1ee1da05"
      unitRef="usd">31285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtMy0xLTEtMTc4NTM_df92033b-0b5b-467a-856e-5776df669d89"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtNS0xLTEtMTc4NTM_7054dea2-c0a8-4087-b359-4c92acb791e0"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibae666d2a990461cb86c3d8e0fc6cad4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzQtNy0xLTEtMTc4NTM_ff641242-a29b-4893-a0d6-03597e605a19"
      unitRef="usd">31281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtMS0xLTEtMTc4NTM_37004661-bed1-4caa-b907-56f409876f35"
      unitRef="usd">120208000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtMy0xLTEtMTc4NTM_6f57b8c8-1671-46de-a14b-25888121dda9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtNS0xLTEtMTc4NTM_246ec051-f724-4159-bdcd-3a69bfe0b724"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZToyZDkxYmQ2MDY1ZTk0MDNiOGQwOGQ0YWI5NWQwMGJhZC90YWJsZXJhbmdlOjJkOTFiZDYwNjVlOTQwM2I4ZDA4ZDRhYjk1ZDAwYmFkXzUtNy0xLTEtMTc4NTM_bc0649d0-3755-4930-9c9b-50a30c38ba44"
      unitRef="usd">120147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItMS0xLTEtMTc4NTM_ad8fbe98-ad7d-4baa-bd35-4e4caf0331ed"
      unitRef="usd">60630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItMy0xLTEtMTc4NTM_814660c8-9666-4f39-bb08-502ad5871528"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItNS0xLTEtMTc4NTM_4b9ab093-6ad2-4d7f-97ab-9619416e0d09"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1b8cbb9365442bc8d08e2a0512c33ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzItNy0xLTEtMTc4NTM_e367b6d0-8d98-4797-abdb-9eb3fb5987b7"
      unitRef="usd">60624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtMS0xLTEtMTc4NTM_594c6571-2b13-4970-b90d-df9196c2bc5a"
      unitRef="usd">30777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtMy0xLTEtMTc4NTM_2849894a-7e51-4a9e-acc0-d4ad2dfb4f4c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtNS0xLTEtMTc4NTM_22074d10-fd37-4907-8856-7914629ebe9c"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbf0531df5184ec1a31784b1fa6a7a3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzQtNy0xLTEtMTc4NTM_d550c9b7-a27d-4e2f-8846-c8ec9372f9f0"
      unitRef="usd">30776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtMS0xLTEtMTc4NTM_e03825a0-c9a2-48fe-b9e0-a24ea3fe8191"
      unitRef="usd">91407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtMy0xLTEtMTc4NTM_1f9bd564-ec63-4f80-9a89-155865af5c34"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtNS0xLTEtMTc4NTM_23979b21-b267-4466-8e2c-2d165935fe24"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90YWJsZTo5NTU3NGM1Y2ZkYWQ0ZjA1ODc0YmZmMGI5NTRiZjI4Mi90YWJsZXJhbmdlOjk1NTc0YzVjZmRhZDRmMDU4NzRiZmYwYjk1NGJmMjgyXzUtNy0xLTEtMTc4NTM_58e35f40-17ce-42ea-b1f0-61926c0b033f"
      unitRef="usd">91400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2Mjk3Nzc_e8baa312-9602-49f0-810e-dc9173d0449e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyNjg_f18a3bed-9c6c-479f-96e3-79eab24582c2"
      unitRef="usd">2000000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyNzY_8b258676-d2d7-4b6e-a74e-63ac6cf85a2d"
      unitRef="usd">800000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDUvZnJhZzo4ZjAzNWM4ZjIyZTI0MTM5OTQzMTUyZmU1YWVjYTZkMS90ZXh0cmVnaW9uOjhmMDM1YzhmMjJlMjQxMzk5NDMxNTJmZTVhZWNhNmQxXzEwOTk1MTE2MjkyODQ_da97363a-fbe1-4f8d-a489-e209b3ec7cc3"
      unitRef="usd">3400000</us-gaap:InterestIncomeOther>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjgzOTQ_f489f2a0-9f75-4a63-b888-cc5369023142">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2021 is net of a reserve of $2.0 million for unsaleable inventory which is reflected in cost of product sales for the year ended December 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxODY_b5086174-19fc-4cd4-9408-2a59b39c2b04">The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzMtMS0xLTEtMjAzMDM_a3d0330b-303f-4a64-b2cc-f090e6623149"
      unitRef="usd">3929000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzQtMS0xLTEtMjAzMDM_b2533a99-50d5-471f-9bb4-047c1b5c3d14"
      unitRef="usd">459000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTo1YzhjODg1NTdhN2Y0YzE5YmRlMzc1NDFlNjlmZGNmYi90YWJsZXJhbmdlOjVjOGM4ODU1N2E3ZjRjMTliZGUzNzU0MWU2OWZkY2ZiXzUtMS0xLTEtMjAzMDM_cf182360-122b-467b-8060-53674c2c405c"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxOTA_49632b8d-31f0-484d-b9cf-a4c669f78e08"
      unitRef="usd">2000000</us-gaap:InventoryValuationReserves>
    <mgnx:ScheduleOfInventoryReservesTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90ZXh0cmVnaW9uOmY0MjhjOTExYjk4MjQ2MzA4YjQ1Y2Q0YjJhZjc5YjhiXzEwOTk1MTE2MjkxODc_4f49834d-f66c-4585-b125-0988742b3054">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfInventoryReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i60e9b541c7d14da4b142d7261904ce4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItMS0xLTEtMzI1OTc_61f09d4a-14b4-48bf-9e2b-a7401a726c97"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItMy0xLTEtMjkyNDY_456c4798-dbec-4dbd-84be-d748517f3e4c"
      unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i268a3aae59a84907bef761d5aed331fb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItNS0xLTEtMzI1OTk_ed4ed42d-4dfe-430c-abb4-6b507e25afd0"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia48a351150ac4a5eb9e5e9dda3c114b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84MjMvZnJhZzpmNDI4YzkxMWI5ODI0NjMwOGI0NWNkNGIyYWY3OWI4Yi90YWJsZTpjMjZiYjNkODlkZDg0MTIwODhiNTI2MWUxNjgyZjY4ZS90YWJsZXJhbmdlOmMyNmJiM2Q4OWRkODQxMjA4OGI1MjYxZTE2ODJmNjhlXzItNy0xLTEtMzI1ODY_3de90328-7732-4093-823f-6b167e5bfc6e"
      unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzI2Ng_5740fb24-550e-46f8-bc5b-b59d51f1d80b">Property, Equipment and Software&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2021, 2020 and 2019 was $11.3 million, $12.0 million and $12.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzI2NQ_5069ebaa-f578-4708-89eb-31364cdb3901">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id4e6d9783b92432ea33daf8eb921627f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzItMS0xLTEtMTc4NTM_b607d2b2-c47c-4917-a506-28735e704496"
      unitRef="usd">2890000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib28a044d1dfe4d36a71c069813f7c53c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzItMy0xLTEtMTc4NTM_8a1aabf6-29ed-407d-b6ba-fdadfc1484e5"
      unitRef="usd">2663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idcef9e6df6fc49d8aacf159f30ee4514_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzMtMS0xLTEtMTc4NTM_17424128-0cb5-4fab-8422-09b3ef80e852"
      unitRef="usd">9453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1f7c22c8312a430ca1abd6f404d03919_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzMtMy0xLTEtMTc4NTM_74e64142-9aae-4b8f-9d49-b5814a9e337f"
      unitRef="usd">8242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb8206a542994cf6ae5a0d5d787ddd83_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzQtMS0xLTEtMTc4NTM_d73809ff-36d2-422e-bf28-86b7ff61f882"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i045caf1d0b3b47e9a583b3518ce82462_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzQtMy0xLTEtMTc4NTM_565f2bed-430a-42e4-9097-05f6136a425d"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9141e7bbac044ed0b92ea1beb2676495_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzUtMS0xLTEtMTc4NTM_2b12de51-69e1-4e6c-9562-400d54a65155"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa8238c19ee74d50b77649fc0430ae5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzUtMy0xLTEtMTc4NTM_2ee85ba7-5e94-4bd1-8ee5-84664f2901c8"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68ecd57bb740432882d856e06fb03953_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzYtMS0xLTEtMTc4NTM_7ff46ec9-88d9-44bc-ba6d-540619ea2ccb"
      unitRef="usd">45693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icfd4ac0aa4f84f12b9173dabcc85a1e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzYtMy0xLTEtMTc4NTM_e3922bf2-6219-446a-806f-5b22bdceb6fb"
      unitRef="usd">41202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1bf50eeea4f84d868f237bb8d23137a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzctMS0xLTEtMTc4NTM_bb2219ef-357d-4651-b1c5-4efc8d88e4f6"
      unitRef="usd">51056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f03cac289bf4ae48981b949d7420242_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzctMy0xLTEtMTc4NTM_7ef7cf21-4b66-47aa-9ca5-0f5cc2ddbe39"
      unitRef="usd">48884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzgtMS0xLTEtMTc4NTM_50089e08-9d39-44f3-a915-3db712a8b1dc"
      unitRef="usd">630000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzgtMy0xLTEtMTc4NTM_b822b94d-8c75-4d25-a007-6fa2c322bb78"
      unitRef="usd">2022000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzktMS0xLTEtMTc4NTM_c4b71da8-dbf8-4d06-b39c-39ad3e958b72"
      unitRef="usd">110485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzktMy0xLTEtMTc4NTM_7de3633c-affe-4755-be3b-34a5ba51d4cd"
      unitRef="usd">103776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzEwLTEtMS0xLTE3ODUz_c9312072-5eaf-42dc-b23f-7e39663b8895"
      unitRef="usd">72809000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzEwLTMtMS0xLTE3ODUz_06c2c3de-6ff7-445b-8acc-f48fb8468fdc"
      unitRef="usd">61551000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzExLTEtMS0xLTE3ODUz_251dd911-7652-4b5d-a12a-91772f13f50b"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90YWJsZTpmODg0NjFjMjI3YzI0MjZhYmEyMzU3MDgyNjZkMjE4NS90YWJsZXJhbmdlOmY4ODQ2MWMyMjdjMjQyNmFiYTIzNTcwODI2NmQyMTg1XzExLTMtMS0xLTE3ODUz_770e9a6a-8011-46e4-a82b-e6d05920e273"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNDY_c7b50fe0-674a-49fb-ba8d-b3d4507cda61"
      unitRef="usd">11300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNTQ_f9d109bb-e9f7-4485-9f02-75ea1591e78c"
      unitRef="usd">12000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNDgvZnJhZzplODA3NWM4OWI2YTI0Mzk0YWEwMmIzYzgxNzJiZjRjNS90ZXh0cmVnaW9uOmU4MDc1Yzg5YjZhMjQzOTRhYTAyYjNjODE3MmJmNGM1XzEwOTk1MTE2MjgwNjI_ae7e6ff8-78bd-4871-a547-a00925fdc226"
      unitRef="usd">12300000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3Mjk_ada498cb-5252-43c1-b75d-c0ef23d2aaf4">Leases&#160;&#160;&#160;&#160;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Nzk_1f9bb43e-2188-4db1-a2dd-eef9b62cc89b"&gt;five&lt;/span&gt; to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; fourteen years.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2020, t&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company made cash payments for operating leases of $6.7 million and $5.9 million, respectively. As of December&#160;31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2020,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s ROU assets were valued at $16.6 million and $19.3 million, respectively, and are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_14efbc58-6be4-43f5-936e-e2b8c4ab192a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njc_b4c5924c-e837-4d82-8676-20ffc42a5e51"&gt;other non current assets&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2020 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i02618b2ea51d4cd3af3550dd4354387c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0ODM_0b3a8cdb-65b4-475e-8501-010cc64bf16d">P14Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2Xzc2OTY1ODEzOTc4Njg_2cdc2ade-999e-4cbc-a863-d5bd8d5584df">The table below presents supplemental balance sheet information related to operating leases:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzItMS0xLTEtMTc4NTM_855b13ce-4cc0-4c67-bb09-fb61b8417c70">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzItMy0xLTEtMTc4NTM_804f8da7-4ed1-4287-9438-12fd09861123">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzMtMS0xLTEtMTc4NTM_57126d55-f75e-437a-b7d9-8eac26bc588e"
      unitRef="number">0.097</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZToyYzk5MTY4ZTM5ZGU0OTBmYmEwZjY2OGIwZWM2M2JkMy90YWJsZXJhbmdlOjJjOTkxNjhlMzlkZTQ5MGZiYTBmNjY4YjBlYzYzYmQzXzMtMy0xLTEtMTc4NTM_8ac24f93-475b-45a1-aa14-1e47cd11dbae"
      unitRef="number">0.097</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MTE_7b780f49-660e-445f-8522-2dae8606d881"
      unitRef="usd">6700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MTU_e2ebb90c-2a69-4695-9737-c2f8f27e4b65"
      unitRef="usd">5900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0Mjc_020ca73b-aba2-4895-816f-eebaa407285e"
      unitRef="usd">16600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE2NDkyNjc0NDM0MzE_227b4bf4-8663-4921-8381-16bd8d25b5d5"
      unitRef="usd">19300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3MzI_955cb2cb-c515-4f9c-9dcf-9e730bdfd3c8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2020 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzItMS0xLTEtMTc4NTM_51acc162-ec28-4d80-a6f2-3790e3a407ed"
      unitRef="usd">5613000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzItMy0xLTEtMTc4NTM_eb1cffcb-172a-41bb-9962-b5d4689276ab"
      unitRef="usd">5410000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzMtMS0xLTEtMTc4NTM_2445a8e8-7059-45b9-a4ef-5c63e95f98c3"
      unitRef="usd">960000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzMtMy0xLTEtMTc4NTM_0d70a3d4-9cb4-4771-badd-db35341144af"
      unitRef="usd">1083000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzQtMS0xLTEtMTc4NTM_3b37607b-5ea6-4488-b0a9-1151a9c7040d"
      unitRef="usd">814000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzQtMy0xLTEtMTc4NTM_155509af-0533-47a2-93c5-7738a59e4397"
      unitRef="usd">770000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzUtMS0xLTEtMTc4NTM_a6700f04-18c5-4eca-a095-aab6fa021c87"
      unitRef="usd">5759000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo1ZDE3Zjg1YzhlMzE0MjY2YWRmMTM5NGM3YjQ5YWIzMi90YWJsZXJhbmdlOjVkMTdmODVjOGUzMTQyNjZhZGYxMzk0YzdiNDlhYjMyXzUtMy0xLTEtMTc4NTM_72b587f3-3fd6-4b8c-93c8-50fc1b8f37c4"
      unitRef="usd">5723000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90ZXh0cmVnaW9uOjc2YmU4OTIwN2E4NjQyYjFiMTUzMGRlNmUxN2Y2YjY2XzE3MzM_0ef09791-518a-4d33-be64-8e8dce9399e8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzAtMS0xLTEtMTc4NTM_88566d3d-7916-4495-8d3b-937b53703d87"
      unitRef="usd">6940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzEtMS0xLTEtMTc4NTM_3d944c66-8ce6-428d-a0f3-a6b85faf2f07"
      unitRef="usd">6796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzItMS0xLTEtMTc4NTM_5a5569f9-d57b-4fbe-8731-26bcc0d19627"
      unitRef="usd">5856000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzMtMS0xLTEtMTc4NTM_ef21941b-1bdd-4f3c-84bb-5ac862be6721"
      unitRef="usd">5084000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzQtMS0xLTEtMTc4NTM_53693cd2-f644-4e1f-ba25-7ca6348ac6fe"
      unitRef="usd">4210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzUtMS0xLTEtMTc4NTM_a4f77860-72ba-4fca-9a0f-99a5e29c9255"
      unitRef="usd">3554000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzYtMS0xLTEtMTc4NTM_0097a1be-2e95-41c2-9717-d5fc706cb7a5"
      unitRef="usd">32440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzctMS0xLTEtMTc4NTM_04d787b1-4370-4310-a1b2-2454b51b1acc"
      unitRef="usd">6972000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTEvZnJhZzo3NmJlODkyMDdhODY0MmIxYjE1MzBkZTZlMTdmNmI2Ni90YWJsZTo3Mzk0ZGEyNzA2NTA0NWMzYTcwYmY5Y2EyYzAwODAwMy90YWJsZXJhbmdlOjczOTRkYTI3MDY1MDQ1YzNhNzBiZjljYTJjMDA4MDAzXzgtMS0xLTEtMTc4NTM_69fd7244-995b-40ef-a36b-90c1a911ceed"
      unitRef="usd">25468000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzIyMTY_6343a291-83cd-47cd-ab69-6d1e680ef334">Stockholders' Equity&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2021 or 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0&#160;million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0&#160;million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on December 23, 2019. During the year ended December 31, 2020, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5&#160;million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an ATM Offering. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December&#160;31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the year ended December&#160;31, 2021, the Company did not sell any shares of common stock related to Amendment No. 1 to the Sales Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:21pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 10, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5Mzg_1ef05942-6491-4db7-903a-1cb27934764a"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTE_893e3f0c-e26e-4917-9f01-802ae84b6123"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NjM_688ecd06-b808-4d68-a74a-08352ab98cf7"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NjM_9d71d7d7-7bb0-4898-a241-10f2fe3ee793"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_21df1928-a818-4ea8-9f57-703bfd0a1eab"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_43c48df2-ecf4-4c46-9a6e-75259181501c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id2e033b068624ccd94d4101edb79e5d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_7e7ce95d-5753-4b4b-a19e-bdd93c4d0692"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifdf7adc47c73485eb154e973b4a0c805_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzE2NDkyNjc0NDQ5NTU_d31c4272-42af-4fef-b94c-19e4057b81d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i82158f1c3e8248488d95c8b5bd40b59b_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1NTY_0f8654a0-3c33-4a03-bcc6-06692293af97"
      unitRef="usd">50000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="iba492058a73347a0a5489e85e2e14c17_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1Nzc_3637a0c6-e04c-45de-8a3c-a7dd8a65f246"
      unitRef="usd">175000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1OTM_d8a120e6-6698-4071-b2d6-c58e23089575"
      unitRef="shares">6612815</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id4c67b59b55c4ed49bb7327fa669d24b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MDI_cf7bc1ef-8d2d-4005-a78f-22579b3c9b4d"
      unitRef="usdPerShare">26.46</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i45c48ddfd33c4eab934d7de5c64036cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MTk_9e99dadc-71be-4817-97ad-2cd9cdd402b1"
      unitRef="usd">170500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i2b85187757a14127bf72d33a7726047d_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1MjA_2fe1ec5e-6e03-4593-ab48-3a5270e4526a"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1MzY_455c5fd3-90f6-41b9-92cb-3b0cae6254c3"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia35cfb96164647f3ab6265a6387a0ad6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1NDA_5a996506-699a-46e5-b72f-ec226f0012b9"
      unitRef="usdPerShare">27.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7de5ac75d28b42498f5070452d22dcaa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk1Mjg_bce930f4-a7c2-4879-8759-4348673a6345"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i2b85187757a14127bf72d33a7726047d_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2Mjc_1c0faacf-33fd-451e-9f7a-57093762f6b8"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i1b9ef449adad42c281b17649822997df_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2MzU_74b24564-887f-41dd-b8ad-61e7c894d441"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA3ODQ_7f36304f-5c84-4ecd-8f77-6bf7410a942d"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1a04d0404924490b3850604be6a89bd_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA4MDA_737fd7b9-63f0-41ed-8dcd-758769250686"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2Mzk2NDM_9827dc00-7e91-47dc-b1b1-dc9ad41acfa1"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA4OTA_fbd685b8-f239-4152-a142-196baf642d26"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTQvZnJhZzpkZDhiNzk5NTk4YTc0MDRhOTg3YTc1NTUyNDAxY2YyZC90ZXh0cmVnaW9uOmRkOGI3OTk1OThhNzQwNGE5ODdhNzU1NTI0MDFjZjJkXzEwOTk1MTE2MzA5MjU_099f9206-7d31-4edc-84f4-50f65fc2f62e"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzU_eb08dc01-904a-4b54-9389-82b14bcf447c">Stock-based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the year ended December&#160;31, 2021, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;employees purchased 34,922 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2021, under the 2003 Plan, there were options to purchase an aggregate of 187,543 shares of common stock outstanding at a weighted average exercise price of $2.96 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2021, under the 2013 Plan, there were options to purchase an aggregate of 8,186,378 shares of common stock outstanding at a weighted average exercise price of $21.90 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -87.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64% - 1.55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,546,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,010,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, 2020 and 2019 the Company issued 332,767, 504,445 and 219,045 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $5.8 million, $5.3 million and $0.7 million during 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during 2021, 2020 and 2019 was $15.20, $10.68 and $13.98 per share, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was approximately $3.3 million, $4.3 million and $2.9 million, respectively.&#160;The total fair value of stock options which vested during 2021, 2020 and 2019 was $20.2 million, $16.7 million and $17.7 million, respectively.&#160;As of December&#160;31, 2021, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $31.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company awarded RSUs under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of December&#160;31, 2021. The Company also grants RSUs to employees from time to time as a component of their compensation. Compensation expense related to RSUs is recognized on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, there was $0.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4cc03fb113394648b6bdf6152f7f62a0_I20170518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NTk_33c256e8-f72c-4deb-a609-5a187b03f7c5"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NjM_653b6537-9045-4875-b651-2e511773ac3e"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i6c715158e6064e159bcab21034af9af4_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzc2OTY1ODE0MDI2NTY_1662d3e6-4d83-4ce8-abbe-0289b3e9552b">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i12b49d3f97c7471cbce1494b3eb8030e_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4Njc_3b2180f7-ee3d-4620-babc-c3b192911450"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NzE_09171b69-8711-4d3b-a521-4c9c7ee00a8f"
      unitRef="shares">34922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03ef750628f2420fb9391bdf140401e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg4NzU_8c29d42f-8c9e-4021-b82c-e47a9007ac43"
      unitRef="usd">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id9275d7191a54f6c8cef0a06cd60f348_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MjM_fa301d1d-3b07-4a84-8ffd-e353a4071640"
      unitRef="shares">187543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id9275d7191a54f6c8cef0a06cd60f348_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MTg_e721778c-6805-4a2c-8e08-446c7a7ed5c6"
      unitRef="usdPerShare">2.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idf57af4d358745b3b61d2a28c3928667_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Mjc_33323c50-611a-4773-b6b6-e874bf603c9c"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idf57af4d358745b3b61d2a28c3928667_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MzE_33323c50-611a-4773-b6b6-e874bf603c9c"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5MzU_75878768-897a-4e83-820f-74ca2f5153d7"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
      contextRef="iea07f27493114824bf0e08ea6c7b7031_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Mzk_ece7c1c4-ba46-4298-93a9-171f7212fbf0"
      unitRef="shares">13856781</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NDM_f1400b9a-fa30-416e-bbb1-b3845a815e43"
      unitRef="shares">8186378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4916c9fc24724f659aef3d6dfd8c54c9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NDc_4d0edcc9-73e4-46d1-9408-6a3d985a6779"
      unitRef="usdPerShare">21.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzM_289d948d-d7da-4044-88d1-17e054b7087c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17b8363a661845b8b88668665eb30137_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtMS0xLTEtMTc4NTM_238d8ca1-188d-4d52-9cc6-15b09e215bfe"
      unitRef="usd">11337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida585248332d440d8b323582780c5460_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtMy0xLTEtMTc4NTM_e6e43eda-7c27-4253-8010-717a1f63e145"
      unitRef="usd">10833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib40eceed5a1a4f0bbac51e606900df93_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzMtNS0xLTEtMTc4NTM_24e5558a-1103-4db0-92f3-90bd39e36a21"
      unitRef="usd">10023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iffd525d4970a470494f9448eb7781e63_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtMS0xLTEtMTc4NTM_f9137d06-38ba-4aed-80e1-9572d8f489e7"
      unitRef="usd">11789000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4f4b23a571a4c828aa3564e2cf02b6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtMy0xLTEtMTc4NTM_fabb2154-bcc0-4562-a1e1-ebaf7003c025"
      unitRef="usd">9843000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6003a2136a8f46d480f8bb29b428b7cb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzQtNS0xLTEtMTc4NTM_9e1793d7-ec50-4428-816b-5d3d577fdb5d"
      unitRef="usd">9548000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtMS0xLTEtMTc4NTM_6d379a7f-90ee-4280-8c9e-9ec2795a3cd3"
      unitRef="usd">23126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtMy0xLTEtMTc4NTM_9cf5be6e-284b-4aed-b2ff-687c632ef469"
      unitRef="usd">20676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTo4NjhhYjc1OTE0OGU0OGY5YjllN2YxYWEwMzBhOTNmZi90YWJsZXJhbmdlOjg2OGFiNzU5MTQ4ZTQ4ZjliOWU3ZjFhYTAzMGE5M2ZmXzUtNS0xLTEtMTc4NTM_d0309b02-3f12-4ba8-a547-730438fd8cc9"
      unitRef="usd">19571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxODA_ebcfb7f8-2d21-4fe2-b264-4fed70aec59f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -87.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64% - 1.55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItMS0xLTEtMTc4NTM_60faa58d-e189-4312-b024-f5d618f121bb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItMy0xLTEtMTc4NTM_dcce8933-e0dd-4c55-9367-aa90c640d9bf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzItNS0xLTEtMTc4NTM_354fdde5-b092-4b71-8d35-da2cb9256917"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpjOWIxZjU1Mjc1MDQ0ODgwYWY4M2Q3Y2Q2YTI5Mzc1N180_464b4bff-603d-4b13-b733-0867091249af"
      unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpjOWIxZjU1Mjc1MDQ0ODgwYWY4M2Q3Y2Q2YTI5Mzc1N184_0dc2b975-a4a4-418f-8798-f3cdcacbc4de"
      unitRef="number">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i72620f596efb4d87830df652d48d868b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjozNGYwZWMxNGY2MWQ0ZmQ0YWQ5MjBmY2NjM2Y5MzYyOF80_29e43f37-0f30-4039-82a7-07a8c85e1ca3"
      unitRef="number">0.673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjozNGYwZWMxNGY2MWQ0ZmQ0YWQ5MjBmY2NjM2Y5MzYyOF85_7a108162-2f24-49c9-8205-f3a135758f5d"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo2NTE3MjAwYTExYTM0NzhhODFhMjNmODM1ZGY2OWQ3Nl8xNjQ5MjY3NDQxNjc2_dc9183b1-9507-4323-977e-35d8d4ef71ff"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzMtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo2NTE3MjAwYTExYTM0NzhhODFhMjNmODM1ZGY2OWQ3Nl8xNjQ5MjY3NDQxNjgw_8e4aacb7-97fe-4984-95f1-06d6db9ebfbe"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i67f28d28c3c741018e3db7acf78939b7_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpiZjI5ZTE1NjFmNWE0NmQ1YmRmMzFiZTZlMWFkMjUwNV80_5ddf14b6-52b9-4250-8b47-01f95240c38b"
      unitRef="number">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpiZjI5ZTE1NjFmNWE0NmQ1YmRmMzFiZTZlMWFkMjUwNV85_a5577e96-d3aa-4115-91d2-e80e391b01ea"
      unitRef="number">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i72620f596efb4d87830df652d48d868b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpkYzhlMjM0OTY0ZDU0MDFhYWYwNGRlNDg0NTg5ZjJhMl80_a837d028-3ed6-4237-a007-1f1eb67d79a7"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if6406387dc3e4a2cb724f4402234d455_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtMy0xLTEtMTc4NTMvdGV4dHJlZ2lvbjpkYzhlMjM0OTY0ZDU0MDFhYWYwNGRlNDg0NTg5ZjJhMl85_fbcd1c89-d607-458f-8a7a-09336f16b91f"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0ca396abee9c4ee8a8d80bb6766d915b_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo3NmY3OWIyNTc2M2M0MjljOGUwYjc3YzJkMzZmNTg3Zl8xNjQ5MjY3NDQxNjc2_1195e9e0-41e2-4eb8-91d0-71f88a0eb3a7"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia6a5aadfa1764139b89e42de07d870d0_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzQtNS0xLTEtMTc4NTMvdGV4dHJlZ2lvbjo3NmY3OWIyNTc2M2M0MjljOGUwYjc3YzJkMzZmNTg3Zl8xNjQ5MjY3NDQxNjgw_0517a1b3-f719-4aba-906c-4fc7aa0caae5"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtMS0xLTEtMTc4NTM_fd15ff85-7bd4-4ff4-b963-f1e09f2491c3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtMy0xLTEtMTc4NTM_50b6a16b-dbce-48c9-a587-fdee359ecf68">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZToyMTllZjMzMTM0OWQ0MDJkOWRjNzRiMWRkZmFkZTE4Ni90YWJsZXJhbmdlOjIxOWVmMzMxMzQ5ZDQwMmQ5ZGM3NGIxZGRmYWRlMTg2XzUtNS0xLTEtMTc4NTM_24fbaf77-e3a3-4e71-affd-523e1d6bf59f">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i24f3632158e1497a9d3662eb59cb125f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxNDc_349c3937-1225-4705-ab95-7655eba87fbe">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzQ_7a042386-24a1-4d0a-9c78-1a79b6ff02cd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,546,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,010,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtMS0xLTEtMTc4NTM_2bd78c51-8f01-40ca-a124-a688de9e133b"
      unitRef="shares">7258353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtMy0xLTEtMTc4NTM_b8767258-62ad-4ba9-a7ef-942e03ba092b"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzEtNS0xLTEtMTc4NTM_f1476ec3-f126-4e7a-83c1-ff7c3d520d48">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzItMS0xLTEtMTc4NTM_0f84c6f9-2060-4fe3-952a-c3cda567178a"
      unitRef="shares">1941671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzItMy0xLTEtMTc4NTM_e1666157-3a0b-4f03-bf7e-6d38ace02ce7"
      unitRef="usdPerShare">20.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzMtMS0xLTEtMTc4NTM_674622c4-2014-4460-b1a9-4b31938f533f"
      unitRef="shares">332767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzMtMy0xLTEtMTc4NTM_4248f2bc-9493-4b67-b093-6ac01d093440"
      unitRef="usdPerShare">17.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzQtMS0xLTEtMTc4NTM_05bede74-dc71-40ae-9997-3810ac2c1680"
      unitRef="shares">493336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzQtMy0xLTEtMTc4NTM_786a68d3-9b27-4c5e-9cdc-3913a620b875"
      unitRef="usdPerShare">21.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtMS0xLTEtMTc4NTM_ca3ee6dd-3606-415d-b6c7-09f7332c0a26"
      unitRef="shares">8373921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtMy0xLTEtMTc4NTM_d7004c28-4ce3-435d-9705-f1ed6a20071b"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtNS0xLTEtMTc4NTM_c49d7041-d4c0-4954-86eb-689b7b98c4cb">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzUtNy0xLTEtMTc4NTM_efc16498-29ca-4c47-b516-4360c274cdef"
      unitRef="usd">7841000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtMS0xLTEtMTc4NTM_7ef57826-71ba-48ea-9446-c46600ed6de3"
      unitRef="shares">5546382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtMy0xLTEtMTc4NTM_5fe0fdf3-067c-4611-aa85-36757efe8e96"
      unitRef="usdPerShare">22.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtNS0xLTEtMTc4NTM_8e64e686-df0c-4469-833d-3d1e1e18bb9c">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzgtNy0xLTEtMTc4NTM_989d2953-0df1-4edc-b45a-bd79f10c2113"
      unitRef="usd">4764000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktMS0xLTEtMTc4NTM_4f247898-e64d-40a2-b7ac-12c7abe93567"
      unitRef="shares">8010695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktMy0xLTEtMTc4NTM_56cd8837-40e5-4362-bb0c-199d08af0914"
      unitRef="usdPerShare">21.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktNS0xLTEtMTc4NTM_f56a6294-570c-4ec1-a81a-4ec8904dce5e">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphYTVlNTU0NGM3MTI0ZDI0YTVkZjU2MzVkMDk0NDc2Mi90YWJsZXJhbmdlOmFhNWU1NTQ0YzcxMjRkMjRhNWRmNTYzNWQwOTQ0NzYyXzktNy0xLTEtMTc4NTM_c3cd2db2-66b8-4613-bc2d-c68f30ab5b08"
      unitRef="usd">7468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTA_75a31af2-e5c7-4616-afe8-bb41a0a191a3"
      unitRef="shares">332767</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTQ_767ef965-302a-4ea6-8584-308c70beaec6"
      unitRef="shares">504445</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNTg_958a0af5-59c1-4498-8a1e-85c0581f6d96"
      unitRef="shares">219045</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNjI_5535829b-7b04-4660-8796-0ed5dbc24b77"
      unitRef="usd">5800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNjY_beb39add-6521-4973-b862-2423cacccb80"
      unitRef="usd">5300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwNzA_b1cc898e-9df7-4980-9791-22c300e8cdcb"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwODU_8e68f03a-7dfd-4b02-b1ad-438efa90873e"
      unitRef="usdPerShare">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwODk_1ecaee5a-9dc7-41ca-af1f-c1ed00c14a08"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwOTM_dd95968c-6a1a-4f34-a5e1-477443f12a44"
      unitRef="usdPerShare">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkwOTc_c259f627-d4f5-4317-b132-aef1adbc7bb3"
      unitRef="usd">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMDE_56b64bc0-7e50-4636-9c97-4b21af9fec13"
      unitRef="usd">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMTM_cf3aa70a-dd1e-4900-8679-b64cd0dd38a2"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjE_1839352c-0a49-4e5b-b1b0-52fa6e294230"
      unitRef="usd">20200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjU_40d6101e-565a-48a2-b28c-2c81a14cee5d"
      unitRef="usd">16700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDkxMjk_d673a347-c95d-4f7f-838a-84f55f02ed76"
      unitRef="usd">17700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5Njk_6751b80d-6a32-48c9-9e23-49487c8d4951"
      unitRef="usd">31100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NzM_0344c758-aeee-4fdb-ab8d-2770b674a3bc">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzcxNzk_0aa42e60-56e6-4d5b-a298-471a6eb78062">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6a79b00742544d54ace1cbe572cc95e9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzEtMS0xLTEtMTc4NTM_15431485-5b75-4f07-8196-9e136cf1662d"
      unitRef="shares">209250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6a79b00742544d54ace1cbe572cc95e9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzEtMy0xLTEtMTc4NTM_79d83da0-38c7-4f64-9150-a98fe4d295c8"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzItMS0xLTEtMTc4NTM_5cc66006-de36-449d-914a-112dbbfabc2b"
      unitRef="shares">16500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzItMy0xLTEtMTc4NTM_c5c247f7-815d-4397-aeba-99c0cae34f62"
      unitRef="usdPerShare">26.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzMtMS0xLTEtMTc4NTM_8a9c0566-c4de-4158-a7b4-fedf3e02a121"
      unitRef="shares">184100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzMtMy0xLTEtMTc4NTM_7c723a92-1a26-4e24-978a-cb906b1c6ac0"
      unitRef="usdPerShare">15.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzQtMS0xLTEtMTc4NTM_83112e03-585d-4e2a-9936-5919db904bcd"
      unitRef="shares">20150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzQtMy0xLTEtMTc4NTM_f0a166a2-b209-419f-9c42-e9e4ad9ec2d7"
      unitRef="usdPerShare">16.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzUtMS0xLTEtMTc4NTM_895d3a0d-4b8b-45d9-ae63-c12575cf2344"
      unitRef="shares">21500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90YWJsZTphODQyZmM1NjY1ZTU0MzJlODUwOTI1NjE0MWQ4ODQyYS90YWJsZXJhbmdlOmE4NDJmYzU2NjVlNTQzMmU4NTA5MjU2MTQxZDg4NDJhXzUtMy0xLTEtMTc4NTM_020e2b92-f390-4733-865a-16c93fb5f6a4"
      unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="icdf5ab669a614d2f9a5f35f91d56b6a2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NTI_25ba2fe9-bd88-44bb-ad65-222d9533cab3"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i15761487f3c647019105907db9a09b9f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNTcvZnJhZzo0NTc4YzcxOGE4NTA0NWZhOTVmNzE1NWE2NWY5YjA3ZC90ZXh0cmVnaW9uOjQ1NzhjNzE4YTg1MDQ1ZmE5NWY3MTU1YTY1ZjliMDdkXzE2NDkyNjc0NDg5NTU_915fc564-4bc7-4f6c-9949-c9ae21cf4636">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzg_682a9291-9868-4767-86e9-50655e21cff7">Income Taxes &lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021, 2020 and 2019 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $837.0 million. Of these NOLs, $238.0 million will expire in various years beginning in 2025 through 2037. $599.0 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $81.0 million which will expire in various years beginning in 2022 through 2041.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2021, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2022 &#x2013; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $824.0 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, of the total gross unrecognized tax benefits, approximately $7.2 million and $6.1 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021, 2020 and 2019, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%"&gt;The Company's U.S. Federal and state income tax returns from 2002 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%"&gt;forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_78f01a23-31b3-4fec-a222-f4cf82ec3e42"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_bb9b772d-dfb1-4a64-a69b-4dd385e57a6a"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzY2_ce983365-6269-4770-b367-fa56e6909220"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzk_47cac2c2-c287-4fa5-bee4-18e43426dd28">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzMtMS0xLTEtMTc4NTM_dfc28c9e-a4f7-481d-b4e6-3f58ec8e0646"
      unitRef="usd">175802000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzMtMy0xLTEtMTc4NTM_d581c89d-22a4-4a7d-8645-2f5aa51bf7a3"
      unitRef="usd">136086000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzQtMS0xLTEtMTc4NTM_b55e7319-1537-416d-94e4-ccb5616bd361"
      unitRef="usd">49965000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzQtMy0xLTEtMTc4NTM_aef4c2cd-bb42-4aec-aa5d-f6eec21473f7"
      unitRef="usd">37465000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzUtMS0xLTEtMTc4NTM_396d7cd9-49bb-4b31-8ffc-51906dc818aa"
      unitRef="usd">60514000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzUtMy0xLTEtMTc4NTM_372e8552-b465-47c1-84db-4d3a22d17cc0"
      unitRef="usd">50271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzYtMS0xLTEtMTc4NTM_447e675a-d697-4d25-8f1a-ea697ab21b23"
      unitRef="usd">24858000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzYtMy0xLTEtMTc4NTM_2f9d26ad-bd96-42fd-85a5-a433189c01d4"
      unitRef="usd">23409000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzctMS0xLTEtMTc4NTM_0c8d008e-8fc4-45ce-911c-d3dab85efc06"
      unitRef="usd">7008000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzctMy0xLTEtMTc4NTM_3e2fa569-9aa1-4973-aa01-5ef478bcec32"
      unitRef="usd">8048000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzgtMS0xLTEtMTc4NTM_59f1b008-4093-4681-8760-8b8f9a473423"
      unitRef="usd">1245000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzgtMy0xLTEtMTc4NTM_61a30283-d8f2-4daa-9a8f-35e328ddc415"
      unitRef="usd">3132000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEwLTEtMS0xLTE3ODUz_68827eb9-46e2-43a0-a7f3-747c58d8c431"
      unitRef="usd">16727000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEwLTMtMS0xLTE3ODUz_e03c31f6-ef8c-42d2-a83d-ba47cf928469"
      unitRef="usd">14285000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzExLTEtMS0xLTE3ODUz_12cf00b4-81f1-42bd-87b2-661e2736751f"
      unitRef="usd">336119000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzExLTMtMS0xLTE3ODUz_d4c29bf1-f5e7-4135-a417-e668b998a1dc"
      unitRef="usd">272696000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEyLTEtMS0xLTE3ODUz_3d4244c0-6d45-4483-9e2c-4a83c4237cd7"
      unitRef="usd">327595000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEyLTMtMS0xLTE3ODUz_7cca9073-1a15-4ac1-a688-2dc142b0625a"
      unitRef="usd">263403000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEzLTEtMS0xLTE3ODUz_41c9d123-ae9d-4254-82d3-e3c715eb3411"
      unitRef="usd">8524000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzEzLTMtMS0xLTE3ODUz_cd50a11b-2fd7-46db-821f-55985f8b098d"
      unitRef="usd">9293000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE2LTEtMS0xLTE3ODUz_2006dfe4-8e6a-4a5c-972c-778987a85874"
      unitRef="usd">1688000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE2LTMtMS0xLTE3ODUz_440f6b8e-19ac-41ee-8bcc-b7ee1111a595"
      unitRef="usd">2123000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE3LTEtMS0xLTE3ODUz_befbc240-f413-4e84-ab7e-c5deed72a17f"
      unitRef="usd">4576000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE3LTMtMS0xLTE3ODUz_f2b1765f-7b30-4c70-80f0-41508f616f31"
      unitRef="usd">5316000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE4LTEtMS0xLTE3ODUz_93d5dfb1-b96e-432a-8153-2b37b09c75a5"
      unitRef="usd">2260000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE4LTMtMS0xLTE3ODUz_03e90169-3753-42b3-b7dc-dca0686cf316"
      unitRef="usd">1854000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE5LTEtMS0xLTE3ODUz_ff496856-c456-4a44-a2f3-9602ef3791e9"
      unitRef="usd">8524000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzE5LTMtMS0xLTE3ODUz_21f6a913-2d58-457d-9bb2-dff93ddd2211"
      unitRef="usd">9293000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzIwLTEtMS0xLTE3ODUz_567da834-f9ac-4e2d-ae5d-5bd7789f6dca"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo4YWJiZGExNWIyYjM0YzE3YWVhZTI3Njk2OGM2N2FkYS90YWJsZXJhbmdlOjhhYmJkYTE1YjJiMzRjMTdhZWFlMjc2OTY4YzY3YWRhXzIwLTMtMS0xLTE3ODUz_0798f0e6-9a58-4241-b73d-65ba0d9269de"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="iccd7737654fe4891a7d522515d8d2f96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzExNjA_d8bfb76a-1ebf-49c7-8579-944ba48018ff"
      unitRef="usd">837000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i137fc423fc124b71bb9d9d0ea218086f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMDA_070e2efa-dc09-46f0-ba58-07728a458e22"
      unitRef="usd">238000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i9f48a736a74a46c48d9e72e00bec62fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMTY_263aa141-f61b-416d-a56e-a8743d5f1bdc"
      unitRef="usd">599000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i95796e3e505f42ce851397ea0c19f8d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxMjQ_6c56e493-aab5-4fdb-99b0-a800b643547d"
      unitRef="usd">81000000</us-gaap:TaxCreditCarryforwardAmount>
    <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="i7f6da34d58144c65bd270cebe6dfb2e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNDA_3bec84f0-9b65-4e5e-a988-8fd5b72516f9"
      unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i0d5f2f6af1b44ea983621a977a1a87a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNTY_c76b7af9-e6e7-4d16-b3a6-20cdfbc3381c"
      unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i6308c33e7e5b4be5b26db9579c7deaa2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNjQ_85cf41f0-2cea-40ad-85dd-7db182062048"
      unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxNzI_1b742876-f80c-440d-bd6e-5d966708152b"
      unitRef="usd">824000000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzODE_6d5e1bc5-0a9b-4e9c-b4f6-a619256251dd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtMS0xLTEtMTc4NTM_971328fb-df82-4fae-b31a-61a6a5852e6d"
      unitRef="usd">-42445000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtMy0xLTEtMTc4NTM_cf74fde4-58e6-42dd-bacb-2cee26e4ec71"
      unitRef="usd">-27245000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzMtNS0xLTEtMTc4NTM_1e6792e3-39df-4edc-8ab4-dcc091beabf9"
      unitRef="usd">-31880000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtMS0xLTEtMTc4NTM_6593085a-0ad2-4a8c-9b62-a0b2de0e3d3d"
      unitRef="usd">-12806000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtMy0xLTEtMTc4NTM_7df02c46-43e0-4122-a47b-843bee517f40"
      unitRef="usd">-8100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzQtNS0xLTEtMTc4NTM_1933bcfa-5d31-4fae-959d-34f0a710eb6c"
      unitRef="usd">-9524000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtMS0xLTEtMTc4NTM_22c84817-f96e-4e70-9339-a5e894db27e5"
      unitRef="usd">473000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtMy0xLTEtMTc4NTM_83f47495-5fa2-4e48-b5f4-ded907c3e88f"
      unitRef="usd">344000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzUtNS0xLTEtMTc4NTM_cbc70a33-aff3-4ba4-b162-b64f8b1f9192"
      unitRef="usd">2004000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtMS0xLTEtMTc4NTM_9b0aff6e-1fee-42c8-820c-cef74ede2854"
      unitRef="usd">10243000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtMy0xLTEtMTc4NTM_f0071340-0cb3-49ca-9496-4087c421770b"
      unitRef="usd">14691000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzgtNS0xLTEtMTc4NTM_13aa20a6-d762-479c-ab6b-ec07afacc37e"
      unitRef="usd">5830000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktMS0xLTEtMTc4NTM_577691cd-68e8-405e-8338-db6ce15ef47f"
      unitRef="usd">1449000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktMy0xLTEtMTc4NTM_bb55d437-bae3-488e-b35e-309f6d2ba212"
      unitRef="usd">528000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzktNS0xLTEtMTc4NTM_8d289cdd-9ce0-40e4-930b-24ee77f13440"
      unitRef="usd">301000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTEtMS0xLTE3ODUz_7e7b5273-5b83-4110-8d5f-e4f20d06a28d"
      unitRef="usd">1199000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTMtMS0xLTE3ODUz_14278c0c-4fe3-4bc3-8a82-b938bc4ef343"
      unitRef="usd">1156000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEwLTUtMS0xLTE3ODUz_3ee57187-3a12-417a-a60a-9f047e131bfd"
      unitRef="usd">1206000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTEtMS0xLTE3ODUz_7a8fc76c-8c35-4bf7-a5c2-cee8ae65d728"
      unitRef="usd">1079000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTMtMS0xLTE3ODUz_e46a730f-4c23-407d-822d-17727f660a03"
      unitRef="usd">554000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzExLTUtMS0xLTE3ODUz_aaedfe65-9a86-4502-8cba-2367252090e4"
      unitRef="usd">1889000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTEtMS0xLTE3ODUz_9186c49c-087a-4180-b9c2-8fd9619c8d1f"
      unitRef="usd">64192000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTMtMS0xLTE3ODUz_fc2d7db9-84ae-4ba2-858c-a58a2e7c4142"
      unitRef="usd">48510000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEyLTUtMS0xLTE3ODUz_9e667034-ff86-46df-a78c-9928e992206d"
      unitRef="usd">42436000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTEtMS0xLTE3ODUz_35a4fbed-2521-4460-b5e7-241e7a3f529d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTMtMS0xLTE3ODUz_aa524ed8-8d62-4997-bccd-652f3323c2b0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTo5MTNjNWYzNTFhMjY0YWI0OGNjODc1ODYxZTY5YzQ5YS90YWJsZXJhbmdlOjkxM2M1ZjM1MWEyNjRhYjQ4Y2M4NzU4NjFlNjljNDlhXzEzLTUtMS0xLTE3ODUz_dab83a2f-e86d-470d-b769-be2b5b1260cf"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzMzNzc_e5f3bf9d-b033-41dd-896b-62dd5a0f6f9f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItMS0xLTEtMTc4NTM_99710d00-0f95-4334-86a0-a56a4f0cbce9"
      unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItMy0xLTEtMTc4NTM_13713dc7-7d71-43ba-9ab9-e333e8c3359b"
      unitRef="usd">4950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iba28ae17d5454e65aeadecbd8ea2feb2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzItNS0xLTEtMTc4NTM_384f0bb8-ba7c-40ed-8e71-b5acc81a1908"
      unitRef="usd">4318000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtMS0xLTEtMTc4NTM_f44e7499-54af-40ae-816c-eaaa07d0d8d1"
      unitRef="usd">965000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtMy0xLTEtMTc4NTM_bcecd84a-9b8c-4c2f-a154-115bdaa39dc6"
      unitRef="usd">839000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzMtNS0xLTEtMTc4NTM_70747f10-e64a-4535-a51e-f1859706a9dc"
      unitRef="usd">637000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtMS0xLTEtMTc4NTM_1c283908-8283-4ffa-b614-fb38e6023cac"
      unitRef="usd">106000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtMy0xLTEtMTc4NTM_19fbc7af-d738-412d-bb75-d94378da70a8"
      unitRef="usd">337000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzQtNS0xLTEtMTc4NTM_e2ee7206-d152-4d5e-ae8f-c0c8585ffa54"
      unitRef="usd">-5000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtMS0xLTEtMTc4NTM_31028463-2d26-476a-a21b-bd659a1485be"
      unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtMy0xLTEtMTc4NTM_deec74be-252a-4b0b-abd4-2239ebc89e6f"
      unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iab6a99969335484aafa2c3d650cc7be2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90YWJsZTowYjBiYTk3MGI0ZDk0ODc1YTExNjkwZjIwYTJiMWYzOC90YWJsZXJhbmdlOjBiMGJhOTcwYjRkOTQ4NzVhMTE2OTBmMjBhMmIxZjM4XzUtNS0xLTEtMTc4NTM_8ea3b2d6-a8e2-4687-9f75-d4ca483708d0"
      unitRef="usd">4950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxODA_4c8d9c9d-42a8-43bd-9ff4-0c7f2d927d46"
      unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0de3c7dacb78433f9459d81078d7fa6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzE2NDkyNjc0NDUxODg_bcb44ac0-4e22-4905-8ebb-6931ed62a9ae"
      unitRef="usd">6100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_71329f13-3974-491a-9e19-356b867c8d22"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_758c83be-1125-4626-96d0-2d636acde066"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjAvZnJhZzo1Y2ExMDcxYzNlOTE0ZjExOTI1ZDA1ZDEwNzlmMzg2NS90ZXh0cmVnaW9uOjVjYTEwNzFjM2U5MTRmMTE5MjVkMDVkMTA3OWYzODY1XzEwOTk1MTE2MzEzNjc_ab851fa4-0430-4e65-9968-312dede23421"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzIxOTkwMjMyNjU0MTA2_f9b34cb1-719b-4c0f-8448-214c07e270ec">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#x2019;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA.  Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $70.0 million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2018 through December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$70.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $15.0 million, $40.0 million and $0.1 million under the Incyte Agreement during the years ended December&#160;31, 2021, 2020 and 2019, respectively.  All of the revenue recognized during the years ended December&#160;31, 2021 and 2020 was related to development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being  recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2020 and 2019, the Company recognized revenue of $1.5 million, $8.6 million and $22.1 million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.   During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, the Company recognized revenue of $7.8 million and $1.4&#160;million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of  $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the year ended December 31, 2020. Subsequent to December&#160;31, 2021, the Company earned $5.0 million upon Zai Lab&#x2019;s achievement of a regulatory milestone.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the year ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020, the Company recognized revenue of $8.6&#160;million related to the 2018 Zai Lab Agreement.  No revenue was recognized under the 2018 Zai Lab Agreement during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service.  During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $2.8&#160;million and $2.7&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized revenue of  $20.3 million under the 2021 Zai Lab Agreement.  As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021, there was $16.1 million in deferred revenue under the agreements, all of which is current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years.  During the year ended December&#160;31, 2021, the Company recognized revenue of $1.5&#160;million for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;I-Mab License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2021 and 2020, the Company recognized revenue of $11.5 million and $2.2 million, respectively, related to the I-Mab License Agreement. At December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current. At December&#160;31, 2020, $11.4 million in revenue was deferred under the I-Mab License Agreement, $4.5 million of which was current and $6.9 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;I-Mab Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#x2019;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the year ended December&#160;31, 2021, the Company recognized revenue of $1.3 million for research and development activities performed under the I-Mab Clinical Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2021, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in other income on the 2019 consolidated statement of operations and comprehensive loss.  In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim International GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, BII agreed to a payment of $12.0&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2021 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.8 million, $7.1 million and $2.2 million under the NIAID contract during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i93b4bb09dae64bad959730c0f8dc14d8_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ3MjQ_a40e9416-b6e2-44ce-9830-68bd928735db"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ic2378ab796454164a230b9cc2d7faa0f_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0MTk_4e33ccca-112d-4cca-9b61-8393d94870c9"
      unitRef="usd">420000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ic2378ab796454164a230b9cc2d7faa0f_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0MzQ_cf9ad1d1-3deb-4d70-bfb9-d519e701c9f7"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if421d26f11f845ee931133022aca115d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODMzOTI_11ebe134-b67f-4ee3-95bc-cfca9db59879"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="if9cd8e55dd2e43a6b2c8992d16bc68e1_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0Mzg_a324b88f-3cef-4d1d-8b59-70f8c9aadee1"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ifa1a228424a64a95a007cd7763fe9af6_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NDI_b86d433d-d174-4d18-b8be-4e926a314505"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iea4888039d1b4ab7aa399c1ee0fb212c_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NDc_813761e2-ba6e-4aca-9fae-036b37206465"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if421d26f11f845ee931133022aca115d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NTU_11ebe134-b67f-4ee3-95bc-cfca9db59879"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i51aa661b71304203b27532bef5a74fda_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0NjM_fe7039cf-bc95-47be-bd94-a1d5b5de3018"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i3d11f08a9b004f7386c9c4c263eb7355_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0Njc_23666a6d-9bfd-47b8-958d-ea4fe703b2c7"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="ibe770ef261ed4f4a9306a45bca01f142_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MDg_715fd441-f1d9-484d-8a4d-caefc5220cdb"
      unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia95774cf1200470694fcafd3bf7ec9ba_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MTY_8f80b1f8-861e-4237-9dcb-d75d723f867b"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if911c7bcddb24ab59739871990c63da1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MjQ_8b61c953-7b74-45b5-9ba3-31d0def37255"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5513c4a35d44bd7aa7138877117d5e8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1MzM_111da07e-8c16-4691-89eb-77d687fbee27"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9ccfbfd141f41db8e5179255ee74463_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NDE_bad67b04-6600-48fd-8a33-3fc17d3a7821"
      unitRef="usd">8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id01efa0761354d62a3103622dabffb96_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NDk_a8f3e7d4-8c52-4f39-89b0-75df060d1dae"
      unitRef="usd">22100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36ba3c13ff3547468eb072c96419c534_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1NTc_ff5793c3-717c-4078-b9a5-cc1aeb1cb14c"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacf0564421e9468ba07b3edabd65d7c6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjI5OTY_ee207fdd-ba7c-497a-8723-565081bc3cc8"
      unitRef="usd">1400000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0ODI_01a4ceae-0481-4944-a8bb-5c5d33c21897"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0ODY_e984bdbe-ef9b-47c5-833a-fe8a826c12a2"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTA_72037843-49db-4ded-9d2e-15526ba8d86d"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i2d501e4822e04d958b40b530762460c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTQ_b1b860c0-1577-4e09-a271-35642db62182"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:Revenues
      contextRef="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU0OTg_86fabc8a-ad6b-4ffc-b5e3-86d0f38332be"
      unitRef="usd">4000000</us-gaap:Revenues>
    <mgnx:EntitledMilestonePaymentsUnderAgreement
      contextRef="i792d3a81b74946ddad05c545e411fb39_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MDI_44412d62-ff47-4210-9463-9ec7aaa05e94"
      unitRef="usd">3600000</mgnx:EntitledMilestonePaymentsUnderAgreement>
    <mgnx:RevenuesTaxWithholding
      contextRef="ie11c9d3cde8f4c6ba28c50015d78d8ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MDY_59ae3bbd-82df-47ce-aa18-46c563c8c124"
      unitRef="usd">400000</mgnx:RevenuesTaxWithholding>
    <us-gaap:Revenues
      contextRef="i3a760482c5564290aeaf43f8d43b77eb_D20220101-20220224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwMTQ_fe1fddb7-da38-479b-93a0-adc5b76513ad"
      unitRef="usd">5000000</us-gaap:Revenues>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i5612ac4f2da44022b008ed9b0154cf3c_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTA_3dacb753-8f06-4612-be77-f1f9d702ff77"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i90aa1101cc4c45c0970ae75b5e31eda7_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTQ_bc9ae60e-0d19-448a-9cb6-42c3e66c5ecd"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ic26a9a2e8b254e8b922f753d0ec6af67_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MTk_e984bdbe-ef9b-47c5-833a-fe8a826c12a2"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i5d46c300f18a459cb051be0f2ec1b59e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE1ODg_92c6740b-842a-4f5f-b63e-98c8991aa331"
      unitRef="usd">8600000</mgnx:RevenuesNetOfTaxWithholding>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id56a1c317b0c4eb380a90f7cf2d2edd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwMzE_2af11429-f23b-4788-99dc-9ba95cce8fea"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i2f2e893ab41645da9ad74d3d817f1e4d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2MjQ_fbbb47d4-08e3-49d3-bac1-e3cc956c8c8b"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cc661c7a12847b8a62549a312da1610_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2MzI_cabaee94-9c1b-4285-a6e3-e4183242bd1e"
      unitRef="usd">2700000</us-gaap:Revenues>
    <mgnx:OptInFee
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NjkwOTQ_5ca262bf-7d49-4b6b-9ca5-ed9c47383bfd"
      unitRef="usd">85000000</mgnx:OptInFee>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2Njk4NTU_e6abc386-b4c2-4fa3-aace-a3f43167cfce"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAwODQ_7f36304f-5c84-4ecd-8f77-6bf7410a942d"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAxNzM_fbd685b8-f239-4152-a142-196baf642d26"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAxOTc_099f9206-7d31-4edc-84f4-50f65fc2f62e"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzAzODY_1e76d5b1-01af-4528-8055-d23cb3cdc6a0"
      unitRef="usd">800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzA0MzU_b92e3f41-bdef-4317-bb0c-f108012bfdc8"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIxODk_e8b21c40-fdaa-457f-a8df-996fae323527"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i5cd4d20af737483f900bfdde13332313_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIyMTI_5e3b50e4-4a6a-4717-b769-05db8f85eb15"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="idba5d6303390421a90b03a830e1a4bf4_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIyMzc_067cefe0-0815-4111-8a6a-e006f36594ef"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:EstimatedReimbursementForResearchAndDevelopmentT
      contextRef="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzIzMjI_574aa662-17fc-44fb-a939-d905d81549ec"
      unitRef="usd">5000000</mgnx:EstimatedReimbursementForResearchAndDevelopmentT>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ia806a05d835e448d9a55bdd709901742_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzMxOTc_cdd8ef0e-5075-4356-8dae-6832f329fa4d"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="ie768d1a8776c43debb1629980a72e2b4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ1MTM_829ed820-609d-482a-85ec-f2005b6285f4"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i87d7763dd39e49138fd636ebf2cc8eb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzQ1ODg_28f81be7-4569-4a49-9d30-0b23f1d69567"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiability>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MjM_db05c760-2729-4adb-839e-2d89479aa25c"
      unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="i44996a78ebbc4831af9aa001839a44eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1Mjc_abb6452b-bd28-4155-af26-74ce8444bfc3"
      unitRef="usd">312000000</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MzE_6b2f41d0-7ede-404f-a535-6269c2909d1e"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i44996a78ebbc4831af9aa001839a44eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1MzU_e4071385-f3db-4f15-a9ee-13214972255e"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="ib57a28be4be44c419ffec77b716c5c4f_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1NDA_fed29520-bcb8-4a48-94d5-35140a1c1427"
      unitRef="usd">20000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i190bb429937844f9815169af38df6990_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU1NDQ_4c75a71c-f3c1-4989-a75e-77761b9c0180"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i20708ad0030840aea94ffda954ec8390_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODI1NzI_9dff37be-9331-4117-bb7a-c0456c662267"
      unitRef="usd">1500000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MTQ_c74d602d-8918-4c96-8b8e-41351ec693a9"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MzE_bc1a6195-e94f-4df8-9a04-ba2180230038"
      unitRef="usd">135000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNjY_d159da2a-12cd-48b7-bc01-e3a862c601b1"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i5ba60bca18874586a933ffcf1f9ec4d5_D20190701-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU3MzU_3f5b9f2a-9522-4cf7-b3bf-454721ae2636"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4MzI_c74d602d-8918-4c96-8b8e-41351ec693a9"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4MzY_a60dedf8-4950-485f-a7c5-a6b47bce8f05"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNzU_d159da2a-12cd-48b7-bc01-e3a862c601b1"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:OneTimeMillstoneCredit
      contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwNzk_f2361ca0-107d-44cb-ba62-19c005fbb60d"
      unitRef="usd">4500000</mgnx:OneTimeMillstoneCredit>
    <us-gaap:Revenues
      contextRef="id4d5586e8d5c4e8dbe91b1f443f6af2c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NDg_b101d465-6634-4e29-93b2-c6ca9916b3aa"
      unitRef="usd">11500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i379c6fe0225946f5bfd1ba393f064bbb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NTI_4faeea74-9841-4dd8-a40a-7d3684729f5e"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2a115baa21f04453b29af91ceecedbd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU4NjA_dedb6e82-2337-4bcc-b737-70726dc5bdc4"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i862de472d0f64045b43008af95f4bb59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NDA_5231bd8b-34aa-4130-ae0c-b09eb23c5441"
      unitRef="usd">11400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i862de472d0f64045b43008af95f4bb59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NDg_e1eb41ab-55fe-40e2-8912-5c6dee1bc190"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i862de472d0f64045b43008af95f4bb59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2ODE2NTY_b01d6a23-6d23-4ac9-b538-0d15c6d9314d"
      unitRef="usd">6900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Revenues
      contextRef="i32bbffe268d44dd5869451d63139c197_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMwOTg_ef374f1e-900c-495d-a991-cc790f38897b"
      unitRef="usd">1300000</us-gaap:Revenues>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="icd0b205b720243ee89a12573c7a8fe9d_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTE_8853c31e-6d6d-4db7-89c9-4c4513207310"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTU_fba72d29-6ccd-47e5-9695-57785c3d805d"
      unitRef="usd">65000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i2697ae4b1f0744f8a86c9d74a82f981e_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MTk_7a04cf27-6079-4d9f-8625-52f016c8b458"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="if2a1dcf4a9df4c959ddbb1934d1a6bf6_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MzE_6133c540-8bbe-4954-a9ee-6f3ce831eb5b"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5MzU_6aa2d383-ecdb-4934-9e45-f69b57cede6d"
      unitRef="usd">170000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5Mzk_3ea84f41-7f00-4b77-a12d-310552286b26"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i8662ec0dbc144632a584c73f4938b548_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5NDM_d6d897f0-3a8f-42da-a8cf-de8c29009a3f"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iefbbd3ca3757470f9bc0909619e0664d_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5Njk_76735466-b9f6-4ffa-897b-4ab2ba6d1f9e"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="iefbbd3ca3757470f9bc0909619e0664d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5NzM_6098c151-9ceb-47ab-a51c-7ebb2fb04ad8"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="i8e0a8985fef04a7bafcbb4cc03c35452_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzU5ODE_7bd7d953-58c7-4b84-b1f5-c4ebf7280af9"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:CollaborationAndLicenseAgreementTerm
      contextRef="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzM5NTc0_72235157-e789-43f5-8ba0-cde3a47476dd">P5Y</mgnx:CollaborationAndLicenseAgreementTerm>
    <mgnx:NumberOfProductCandidates
      contextRef="i576f9279609e4017a60567b1d894e7c6_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzYzMzQ_249ce37d-5268-47b8-995b-a1333ad76381"
      unitRef="productcandidate">2</mgnx:NumberOfProductCandidates>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMDY_daf10685-a6b7-4724-8116-c1e30cca0b3b"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentMilestonesAmount
      contextRef="i3acefd7dc96d408ab172307350cf602c_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMTM_fa8d136b-934a-417a-946b-ad3e19de1861"
      unitRef="usd">12000000</mgnx:DevelopmentMilestonesAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic8d998ab8e404b8194f6c63d78bb64bf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMjE_a6e30dfb-69ab-409e-ae55-f3127880262f"
      unitRef="usd">12000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:NumberOfProductCandidates
      contextRef="i576f9279609e4017a60567b1d894e7c6_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMjk_01036d1e-cc7d-4ac6-b8b4-0a2e488c066b"
      unitRef="productcandidate">2</mgnx:NumberOfProductCandidates>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i7d006afd97914c30b1c39b119a8f1fff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE3MjMxMzQ_2972ad65-0667-40b8-8c7d-c5abeeaa1d10"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="i197aeb0afffc4bdaa28739f0f1fc2ca8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzcyODk_ac958b02-5b1b-463c-a9af-3157cf81602f"
      unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b6a818854f941c79c5bc2d50e4f7fc4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzcyOTQ_5f597c95-85fe-4809-a937-be31733e2a75"
      unitRef="usd">7100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieafca778c80146dc9c099099f62a8ac1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjMvZnJhZzpkMDFhZWViZDE4YmI0MGJlYWNkZGRjOWU5ZWIwZjBiNi90ZXh0cmVnaW9uOmQwMWFlZWJkMThiYjQwYmVhY2RkZGM5ZTllYjBmMGI2XzEwOTk1MTE2NzczMDI_9e68338e-18f0-4095-8c50-31c1ef8a26f4"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjYvZnJhZzpkNDNmYjZiNDI1YTQ0ZjRkYjhjZjBjNmRjZTlhNjEzNi90ZXh0cmVnaW9uOmQ0M2ZiNmI0MjVhNDRmNGRiOGNmMGM2ZGNlOWE2MTM2XzExNzg_53dd986d-eb9b-495b-81ee-8f15c26358e1">Commitments and Contingencies&#160;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial.   On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal, and on January 18, 2022, the Lead Plaintiff filed its opening brief.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzY1Mg_75c5eb69-f5c4-43e2-a81e-d1a13091e097">Employee Benefit Plan&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.6 million for the year ended December&#160;31, 2021 and $1.4 million for each of the years ended December&#160;31, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMTk_caf5ca27-5279-4eb4-b6b0-2ab25c65dcf4">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMjM_cbe78a41-8ec3-44f9-8193-3068214cb675"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMjc_258d7ec6-e98d-4d18-a7f8-90086f787537"
      unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzE2NDkyNjc0NDIzMzE_84b3351c-3d2c-47f1-bbac-e5b19cb097e7"
      unitRef="usd">1600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6a5f80913d024364844ab14c28e1a5a9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzEwOTk1MTE2Mjg1NzY_59a4ffd0-0f0b-4b48-9d96-22a276402662"
      unitRef="usd">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i24f9240511824a88a1df9c3df403d65d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl8xNjkvZnJhZzoxZTEwY2U0NjllMzk0MGQ5OWJlMGVmOWI1MDllYjU3OS90ZXh0cmVnaW9uOjFlMTBjZTQ2OWUzOTQwZDk5YmUwZWY5YjUwOWViNTc5XzEwOTk1MTE2Mjg1NzY_74bc328a-6121-464d-8925-f8a4c384a455"
      unitRef="usd">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i9142c213b886498f9196dea58b4b4251_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84NDIvZnJhZzozNWIxMzA5OGRjZGQ0M2NjOThhYmM2NThkNmY0Y2Y1ZC90ZXh0cmVnaW9uOjM1YjEzMDk4ZGNkZDQzY2M5OGFiYzY1OGQ2ZjRjZjVkXzEwOTk1MTE2Mjg4Mjc_f3d949c4-a0fa-486f-bd5d-78d0eeff4551">Subsequent EventIn January 2022, the Company entered into an agreement with Incyte under which Incyte reserved capacity at one of the Company&#x2019;s GMP manufacturing facilities where the Company will manufacture certain bulk drug substance for Incyte.  This agreement is unrelated to the Incyte agreements described in Note 10, Collaboration and Other Agreements. Under the terms of the agreement, Incyte will pay the Company an upfront fee of $10.0&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i7cda7295203d408e87a17554ea99f6dc_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQyZWYxZjY5NDUxYjRhYTFiNzE5ODRiMmUzMTg5ZDEyL3NlYzo0MmVmMWY2OTQ1MWI0YWExYjcxOTg0YjJlMzE4OWQxMl84NDIvZnJhZzozNWIxMzA5OGRjZGQ0M2NjOThhYmM2NThkNmY0Y2Y1ZC90ZXh0cmVnaW9uOjM1YjEzMDk4ZGNkZDQzY2M5OGFiYzY1OGQ2ZjRjZjVkXzEwOTk1MTE2Mjg4MTM_7794929b-9ac4-43c7-8179-bd5957bfb3e3"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ:? /W8=BA;?I5B9O6OBAC)3ZM'=C*+SEN<8B42$UD%P^'D2@4@2AP0\_MF
MMG;?=!WWK[?H-\7@83 S;D2@DA\RLO%YZZ1%(C'G>6+OU>HWL1E0W^&%*C'%
M7[):M^WU6B3,C57IIC,P2&6V_N7/FT#L=3CQ#G1@FP[L30=ZZ O^IH-?#'3-
MK!C6%;?\XDRK%=&N-:"YBR(V16\8C<S<-$ZMAK<2^MF+0#T)328P8Z1-ODVO
MR(?W'\E[(C-R*9,$ FW.NA:^XUIWPPWFY1J3'<"DC(Q59F-#KK-(1*\!ND!P
MQY)M65XR%/%*A!WBTR/"/$8K" 5X]QLQZQ#&BNX,H>/O@N87>#X:M+^&,V,U
MY.'?"&1O!]DK('N'1JC"'%:')0\O2U$5<KP[]=J?$1;]'8M^,Q;#+,MY0N[%
M4FE;10?'L3H7")W!CLZ@&9V)T%)%+IT(9'EE?&J0-@GTR[MW_TVA5]R.=]R.
M4<0@U]I1NY$FA$C]%%RC_'"T=INRMH_Q.MGQ.FF82)J#V!9:>7@:<:PY3PPV
MCZ<[3J<HSG5FI7V!4"6"W.7I3.@J+CB&Y]&V/Z 46[_4*U7/:\+H7BRD6\,0
MKCN>5LY;#=!X&-Q_O;V^&P73(S*Z"SH8O3U1IDWHC;)0:9@Z[F;QB$PMY!91
MF@0JSZQ^@=^HFC..?G6-D60E2=:$Y -_)J,(,D[.95@P1>:X!M(;M&G_E ZH
MCS$L99KZ31@.HT@+8XZV%^0+M"-?L^K8X9"GQUZ/C$4DW:(/8-1@!%<:=B(8
MX=($*"[C;PD'[@XF_$&MLDJR.-R]"A^?P,91<J4W4%S4WY+;I>-$JR>9A=7A
MQ#''5QBUTB<H+N]OJ4V4L3 _?\KEX36"(S+OI.]AW$J?H#5&43"#+?9A*CB
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M?^9"J;?6.9AJ=^8/:XH-%(Q0[P613@OB(?6$;[(XLQZOJ2EV9U'@1,Y0MVU
MR-N0CIR.:"^,]!1A5)8M:R5LZ;2<R"=&Z;/@(B\,1P[:M-=&>DJ[=5#_=GW,
MJ?1#XVK">@RWX6S'\,7!_55S>?B9R8>L5"CG&S#$YP'DEMS=Q^U>M*C:*ZU[
MH;4HVL>4,Z#= .#[1@C]\M+<DG6WHJO_ 5!+ P04    " "T@%A4="%<!G,"
M   0!@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)5576_:,!3]*U?1
M'EJI(]]051") E4K;2TJW?8P[<$D%V+5L3/;0+=?/]M)(_K!VO) ;.>><\^Y
MMF^&.R'O58FHX:%B7(V\4NOZS/=57F)%5$_4R,V;E9 5T68JU[ZJ)9+"@2KF
M1T'0]RM"N9<-W=I<9D.QT8QRG$M0FZHB\L\Y,K$;>:'WN'!+UZ6V"WXVK,D:
M%ZB_U7-I9G['4M *N:*"@\35R!N'9Y/4QKN [Q1W:F\,ULE2B'L[N2I&7F %
M(<-<6P9B'EN<(&.6R,CXW7)Z74H+W!\_LE\X[\;+DBB<"/:#%KH<>:<>%+@B
M&Z9OQ>X26S].8"Z8<O^P:V+3@0?Y1FE1M6"CH**\>9*'M@Y[@# Y (A:0/1>
M0-P"8F>T4>9L38DFV5"*'4@;;=CLP-7&H8T;RNTN+K0T;ZG!Z6QR<[VX^7(U
M'=_-IG ^_C*^GLQ@<3F;W2W@:$XD<EVBICEAQ_ 9/H$/JC2K:NAKD]UR^'F;
MZ;S)%!W(-,6\!W%X E$0A:_ )^^'!T_AOO'<&8\ZXY'CBP_P+331:(ZC!K&"
M"\H)SREA,!>*NO/U<[Q46II3]NL_R>(N6>R2)8>J+*K*<)K=S.]/H"82MH1M
M$(XHAT(P1J2"&F53V^/7:MOPGSI^>S.W6= +3!FW^Q5\(^B)]*23GGQ >K/Y
M0#:Z%)+^Q<)9:%9?U=V0]_<DA5$:N-\S\>^)?.(@[1RD'W=@&IK2A!>4K]^R
MD+X0U@_C8)!$I\\<O Q,^U&2# ;/M\#?NZ^V5WXE<DVY H8K PUZ \,DF_[3
M3+2HW15>"FT:@AN6IF6CM 'F_4H(_3BQ7:'["&3_ %!+ P04    " "T@%A4
M\9K M6X%  #*%0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+58VV[;
M.!#]%<+H0PJTL4C= \= 8KEH@"8.XJ3[S%BT+502O2)M=_?K=W2)9%,4&R#8
M%UN7,Z,Y,]2<$2='7OP26\8D^IVEN;@>;:7<78W'8K5E&167?,=RN+/F148E
MG!:;L=@5C,:549:.B65YXXPF^6@ZJ:X]%M,)W\LTR=EC@<0^RVCQSRU+^?%Z
MA$=O%YZ2S5:6%\;3R8YNV)+)E]UC 6?CUDN<9"P7"<]1P=;7HQM\%9&@-*@0
M/Q-V%"?'J*3RROFO\N0NOAY9940L92M9NJ#P=V SEJ:E)XCC[\;IJ'UF:7AZ
M_.;]6T4>R+Q2P68\_2N)Y?9Z%(Q0S-9TG\HG?OS.&D)NZ6_%4U']HF.#M49H
MM1>29XTQ1) E>?U/?S>).#' WH !:0R(:N ,&-B-@?U> Z<Q<*K,U%2J/$14
MTNFDX$=4E&CP5AY4R:RL@7Z2EW5?R@+N)F GI[/%PW+QXRZZ>9Y':/D,?_?S
MA^<E6GQ#B\?YT\WS'0#0S4.$9HO[QZ?Y]_G#\N[G'/U8+)?H*WI91NCBTV?T
M"24Y>M[RO:!Y+"9C":&5#QBOFC!NZS#(0!B8H'N>RZU \SQF\;F#,7!JB9$W
M8K?$Z#%BJTMDXR^(6 1K IJ]W]S2F$?O-L>A@8W=ELFN_-D#_I[8@>5[)JX,
MOIS6EU/Y<O[@2U>EVM*O+,N6<9CZON/XD_'A-'5]%+:<(+#/85$?YCDX"%K4
M6?1N&[UKS,2,"RD0K#+$?D/S$^:<>*U7SYB3TBOB:[0K>+Q?221HJD]0[<8[
MX40\%ROYZ8,L)34FQ!D!OR7@_Z&H@M%BM:TR$T.%4[Z#]BQU'/P^!^RXOEKE
M/@R'-JQGA8H.YMI6J.<3M'P"(Y\E*$&2;[Z@#<M90=.*%XVA R9"%K04"QVU
MH!>,9UO849CU40[Q':(0TZ \RW/TO,*65VCD]<PED%GU%K&.3-BO4V 1-<Z9
M!F:[H:.^C1J8@VW?UO/!5B<@EI'1#RX$6A<\0S",E)7AN5X K%X 7Z&Y^J&K
M\-$!L8TM3WV)M$#?QX$[P.E$%+&1TT)N60&2MN*9=IDUYF?K++!4'GT0MHGZ
M^FA0Q+7]@66&24>!&"D\P,R80FFTX1-M*3#NE4(#Q"3T[5!EH0.Z.,!X@$<G
M?-BL?'4IH! PUF[+>?/ FL*8^C[NQ!";U? EAW$Y3?YE,=K F(PNRJ1]1C"2
M)OF!"5DV47T2G3YE5^TT.A!1WTP-" ^T3]S))';_H&BG&1M<"6Y/HZN5X(4J
M$0VP7 F>VC6U0!?[(1E@U$DT-FOT+17)"N7-ND:[>EED4"FQI05#%U"]O8BK
M&]65SUK&]4."T_CL2UL5/QV,7*J34*3WAKT!KIV:8[.<1TFZE[ D/\S6?Q];
M#4S'5NMMD&VG]=@L]G5EC]4W&I"F!]"1#4/Y/GL%=C"6G3(7"#Y?A03QA/F@
M2D-]6<^_+^)N&,)$BWLIT"")XQ [Z/4ZS6 06 'QR<!HB[OA )NG@[>R_R^I
MZ \ 0ZG0( =2T4>:4T&ZL8*8QXKF*Z6>+. K-Z6OO)[[$-T4C&GZ\OF3.K$G
M^,/?5J3376+67=/756-Z]D5DDU 5#0TL]'U/@44Z;]"[!R8'TBDNL=^?^0V'
M%9B7R7YGVCOA)<['T][)'3'+G3'M;E]? ZN7]3[*QUA=\1H4J.50SCMM(V9M
M>ZR_.TVIZ+2#^!]/;->;B;DW&Q,;]#<"B.VHLX,&IH[R1D@=^?ADDRMCQ:;:
M+!30&O:YK+>%VJOMAN1-M0VG7+_%5U&]K=BYJ7<Y[VFQ27*!4K8&E]:E#\4N
MZHW#^D3R7;65]LJEY%EUN&4T9D4)@/MKSN7;2?F =OMV^A]02P,$%     @
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M7!5OE<5%^8D>#[8>':#5OA!94CE+!4F4'K[#[U4BCAQ(EP-4#G"N ZT<J.8
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MKP/#(&O17A%4$N$$:,DK8!DPQ%CK.V5]!#KSR *$"),?&>\I0,FW6[(3 )F
M#*1AU.U <\#7R*3PQ8+94F5M.)70S#*K2$VQ!X<4!$@1*'*GZZ:A79KN%JTB
M,78(V753'^EWTL>@-!"2I-\U+'(=(1.YSH*1=&QL ):;H13V^/SW?WMZ=OKD
M.2R'-(Q8BK Q,",\!^8BJ?: G$6&$PB+D'_#;<#I0+' RM^A09&<S?"F:A'8
MDB/>$K"FV@S8;Q]O.\KR%IBFKT'@5411:]!+HA\;M(]HQ[VEAY.K@-Z";-^@
M(PM2"V\FWI.Y \.C60V-IXE'V1Z#F9RM&$T)HCW_C&@#B?4-<0:BZ6,,-,H=
MAAF]@#&5AF1&AJRCT=Z*VD_L#FQ'H#$A5$=M6P/"GNWV4)$ZP50#?<SC$ U#
M0AK<WVP-V"I@[:U95BF_RF^,"69P1^B K6T)JH=^1-N&S(:%.D46,)$;$!9(
M,.Y:ZZ^13AD8*TQ_G7*(4BJ1=871!4*2,\ID7R.C*&(/XEVP^5$_D@4AQDTJ
MRJ F,_R6'D!)4#3]LEOUE?-P8M*\A9TBHV(%U"D0E;@6ORQTO R#596?07UN
M&M@BLO<J#8^4B(=MTPWDG3> >%%TOZ( #9D))")1P?=UCR*+C"H>TRT+[![T
M@L#H@5G9?B?QHM;'"@R%IK61D17:>H#;HG0N["[;\UZ174-0<> $6" E^^Z&
MC'<TS#!,%*W;1C:04E_D2P+KU\T6*%W!@CU!$Z_C9W,Q^\1 7_4=&M/3,RR2
M/S?![MYF5B0+*PR [#6@<;L$$#3*@;/!WY,TR6)W8D-2(%RT3 GH:HB&8B)S
MQ/,&%= O).W@J3<.JV\#P1B0P#=V1G@&4C:?,TC2:=633M%-<!&VE)X@?A-U
MK?X+TQ+JX;UGGAE2?."0Q,#>QU-MQ?M*1N[.Q4UNC#B/@$2XB/N/UT+[?FGR
MK+?!?78#HN$(A6A2H^H:\)B#$;F]122UZ@"C.O97 M-A"W8W##3KL2*E^*T-
M8D+72! 9ZK)7#?Q)#MY<7K\ZG+[CJBF\8#^XO+XZ3)XB)084]#Z$ R%^[1Q*
M2X_@$X<@@/F3!$5"^RI%>Q^VI@3AB!0=+-(I8\+,M$>JF"ABVTJ]7/'#8:<S
MC$$&_JZ5R,L,4GF+%&P/24MF,J+WMSY3*0C>7QD(Q;+>]4C[3>1"I: ]O7Y0
MI>I45V@7AJ#/+)L-T<&JU6,(S-#:K9GGIAB61#\:E$0L7EN#/-69=8/F[;,$
M#;.SQ\_%?CJE[Z>GSWGK>:YR:+VR<=#76?$KR%^X]EO?X!^Q:CF, 9SF@UBE
MAN5%3 Q-W[D@1 S=V=\ '6^-B'F J'8KG &V@$W(*1"(1HG_MK2F)1F#(1$:
M,X?!-!@:#[8*3/B9[1QC IX9CW(?:G <H*EH)#3_*HEY.D"SRC9!Z!9#&$J=
MK/&)*EM!%$+ \;?"5.@)HM>=66^2M2Y\LR\-V.P@L6X4BS@=$F73MLV2'#G:
M#X]!]4O!5LJ&>WO^H+V5A;E-Z^M@=):CW0B :-:?G;RV1H<#IZ.I<!DV"*_C
M:+9?_BIRWT>KF/4HL@6#9V(0(M9PRT PZ$+,8KU(W0)8TK/S"6@FGXKX1YV=
MS-FQ8H P(50<=""?R=HF+VE9$FQ8 VBUZMO]G$7GU?H,,<DZ$8HYU2.VGFHH
MLO;P?K<_G!<(5E?1OF8:\D8SFL45Q1*VB<G@JD<>FDY-@4L(=IW)\\XHZ^0>
M900;N2]N2W/C1;;C@7!W!H(93&F,,2 'R$-5:4*/;J0S"/_PS"W^4S><G%AA
M2$D]<,()+*_7J*HLVR9B>&#&X\UPNZ8UW_26T-R9%9D/JIF !6,;EF0/G\VH
M=!QY;)%^:CH 0N6FRN!+ NH9IOR&H::ODM,G*3P:?B!N.'N.L:/D4TM3[D/'
M\^EI>GI^IG_T;A]'.K(NCN23*39YDCXYOW"W\[>K.( 43'(.T#P]<;?+5U[?
MW4@^R YQ-1?GZ?G%4_CTW=/T'*;Z*KGX-CTYO?@;\'GR]^#SXKOTY.0B_' ?
M/A^?I(_/SO6/WGT':L[3)T\>>]3PUP>A9JFHN3@YQT\GW\&<3^"3#(*X>\A
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M@ZS]SB?%QCY>%#"FHX<K(YDK$7$ZWB P$VB7P+D(S.W3,RR:P48?84GYY*E
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M:0/&OK@L46;D6 #W*VO#?L,&NLG][!]02P,$%     @ M(!85%^(HZ:! P
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M #3S'KT4R]?)CW98="9F+>JMEVQ#7^W0V5'7CM[CJ7 WBN$)/AXICUQO16=
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MUHZVFZ@/J;"H&SCE/<DS& ]2^LV?*Y;<%*J3EARU"//!%'[N_]_Z:O&)\2"
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MGO;XL?)33BRSP8=])LGS)!;?W'XZ? 1*!Z19UFF;7.9H:IFB+[^<OA<;_W,
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M%(79\.5:290^+<#SI3%%?4,;-#]F>_U_4$L#!!0    ( +2 6%0[*(T43@D
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M.6W4 OWM_)Z6W@U4'$M/X+IW#&5/0O=OIW1C66&9;*_8/?2K2.;J%G[E.P
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MG>)TKO40%\9Z9IS\P#J <T=$;Y\S-@EZ'5:I??GK1]),E:U^_2)@0%:*_X
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MN7(+_Z5:^J5:NK-:2IBYDNG?HF#:G[;%&"%4"%2DJ7'N3K2\57=]^D8+-O3
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MM9Y^@J'O#?23;F1N[/]EE*B[ZKZ-.RWFBNUZWY$.YP_N=:2#RV-%Q4%TB-C
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MW*'C1=QLK0P^NP#&1"K7!;#ASE?A,[BSBH_%P8/_BW=5LZY3EPSSW0/@=,)
M ?_8="/W(-&@P'IXHFY9J]2=TF709[YIV3633:-0A\/>8'P0@SR7%-=P_BE7
MF6D*QW<-YIAAK^-L=M"Z-P/XZ*@0\P%;<J$M9&X".P9^WDB7(_-UJ'[=^N2T
M?O;D5&GXD<*_JKR!GWHI97TE:O'L"2S_0KZ0>8Y""D'VTX/)07 5S=_3@\O)
MMY?3@U-XTS_^[,D:(IA7HJ+FBES.X=6S\:,'!ZQ+[1]UN<8A\3R NES1KTLI
M '5\ .[/R[*V?^ $V*%!X#W[/U!+ P04    " "T@%A4!QYXGGX$  #+"0
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M-FKG0.>%HH+UA@LP_ 3F?P%02P,$%     @ M(!85$6RJMV *P  I)8  !D
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MU^ VO D?X6A^7/]=^'YTIS'ID>L-!B]$3T6HX9$!8]"-N(O-11XVP)R>37,
M,UF<1#]J"A9!RQ>]B!&A89<,693>=V5-VQ)7S :6UJJ\/9S21+X*FLA7ISU,
M'8B6=HC^W1M@N?60O:_]QSD5Y)\?S8@MJVW0V>X[M YJDM)R"%,?<&F'9B<G
MC]WCV*JSB$^9!A+])7^J\J(JQ%392(4ZAHT',OYJ(CE1D);<5/,>J8C1=ZX2
M[01^1W%WD?W'MFZ"7X(<&9VOHV%$>&R&ZNX&C!U]*AT\\A,/!UHPO82ZW]B3
M]G COB@\&(PS#1.7+6K#2$U1UT8A<S#FMOIJ XC@5-AMDVJ5QN.QQ[#D0>9+
M/'MXHN*D'@Y[]NZ2D^RIKKH\\=.)]\6 10QOG7&UZ9&"%6<H&L5O[9L"P8SL
M#KBAP+153XV.G: ?+0E6S;/B*GO17A$PKM\7?7!!J$E61O@#Y!?0 L>SWDC=
M'0 '';:Z?+5)3C& RQ<QG/[B)-&^46?Z;(S\B>\"UKK$/P9,LZG=/4$6#5EZ
MB+CA/>X:%'=@VH&/LQWHU?@+%N,:E/<[V/%=W^W8>5-(,+C  :JQ)#E4U>RX
M$ZV>?30I?I?%OA[H!W2!MB/RW)&T;W2P@DX+%K[X;^ $6R))G@%0D**9?3=N
M4 &O^VJ%)TP&!<7:)P-V_:9HQ;7CSUF>"I@N,*2-HW7"8$AWP8W7/;"O )^P
M7\+ZGSKQ2_W0CYOLND+QXA47SW[ZX?H<>4.P?-G:3>(Q;!!59-3R?H%/HK.T
MLB$8=I+J5DAPOKU^__./O_ZOZXPL;>]066;EDV.AA*<R_,1 @BD GO@[LFA_
M),Y86XZCS!\J;V1LA5N@6"3UGB-ZQY@%_Y5.O(WDKRG*CTP_;.=K9%I!0UK^
M\3#(CA#881V@;MV.H'S\/HK\!K ;?#X)_K4#A(@8J&<>8/L$G H8Q,>'RJE^
M44L$'\\7=U,\A&@=<!K,,%K5[4K@DFN<!,TR9#9=Y4,8 :UE_&).I2==MYA*
M0[&,E;OC@HR+'ZP0@ =Y5M"?T(=(8&6<J33Z3+PB:(+J.6.7Q&2J$)U7+ZV&
M/ U:!V@(4CP*; )QSFXX(DP 8"Y_(>X9EYRN5E(/V/M("0F*TXRH)?G0HBD9
MV5%ESK;B^5T!.XIZ)@KDKLHE.*7^RJI[:#,F;CY84(V[!K,R -!CBV<EME@\
M%Z;QVA[$]!#4CN5)\1,#F @:]EKW.XFP,,M2)SIJ+K=H/M#R:'5H4&R[D0,A
ML.L2.$XNOE[QV9EP@AZP<@#F]--80QIJ."D 33[9Y4DA]J['$8=#3D'6?0@$
MWH)J]0#+G96+?V[(^+M+?O?R^R0:B+ !6V9/6MA0]P(*IL@\ 9_8CV!;!(Z@
MK- H<.-NE$0&=($A5Q:[, E+\%'M '6K*)$2URY'F/S8$*)B4$1#-,262%UA
M^5ENBW[#]&C.#TQ81"E-QJ$H :FK+*1P 5%V1:%U\MROXKE?G59>(CICO*UK
M-ZM?:MSK-<%P]MC_U(BI=Y"XA'"W8P:!? XC2*N&!I!C7? (HA2B)"I2C="Y
M]?(+D$$1R]XU:N-&?#R3Y\2+!W_9!!S NN/I2;O"&  B!%JK<;\8( %A'CS[
M?.3MAFDXS<Q!?PLE<M$TPX+;EQDI\N8#629K R:40^^/8,8R)UTTXF%P)9(!
M3REYH)+$?*:9V0G3Z7U 6-%*P:H3BUT$&%E_=R#ETD#&6IW.0[1>>"SU=G*2
M&PCQNS@W<U^VXQ@I_+C#I233QBE3%6- ]7LB,HW_4'8$0[F^X:W:=5QCG#.>
MI>K1E(A#$BJ%(6V(006?HGPX"4>:*ME?%$+'*TV7Q]C'RTHXFXT;3I6.V17U
MB2^9XH7,:F!P[YH&E6U6$ ^@Z\*YDG?Y**C$POA8TS/N*\5M6.(#_M-V N)
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M9-(E*9;PV#$,0H?*%R53Z\V+24&)V1R"91$1HD<B0? IR(,?:]Y)@>613:X
M!3G0U-1;(\Y#WF.9O@IHD)Z^VR64/WOL!TEHDV8\A5\FK$=/]VV( KZ3*"!
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MM@\_F48>J0@(/33C+1#19CIBCR2G" =!Y4*^'@?C&1)LTM2,JD;60[VF]0Z
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M7>%;6=9N4[=\Q2YQY' "*,\#_R>.5>^"IA128[')@1WOF'FGR%.0_RO%NDM
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MCOK3,&SH@X#&.]!ZK;4[3#S!](E9_0=02P,$%     @ M(!85']!D^J@ P
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M?A:-W#N)0OC,%'<M<:8SS4*(_' RHM[<M/=<4# (5Y,H&<#5>!P.X&_JCA^
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M5%:!OF^E-$\'ZZ#[=;+\'U!+ P04    " "T@%A4)([T<!,%  !R#   &0
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M7-"/ M2L0-_G2MG'!0<8?F9,_P502P,$%     @ M(!85#LTRF"-!0  H T
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M$,?_%0OMPZ[4;>(?$%A1I"[5WE7::GNEW7LXW8,)!JPF,6L[L)7VCS\G9.-
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MYY<4FZE:7#5!O?27?J:16H@?%O17 .,<:'VN-6XG3J#YSPS^ U!+ P04
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MBJDS<5 .&UQ3=<]W'Z'M9VSX,DZE_46[)G?L.2BKI>)E"]8*2L*:)WYIYW
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M P48M 5@>[MR=K&#RB4O]LL-D60TY&R#>&X/?/E#L>D*/&R3*,WK8RHY?(T
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MRP;S78T9]6"&"/PFBG*CP+LBY>FI@IE>@.,JH,,JW"&OQ@5?3@&&;P *$'0
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MP61E1.QV;]M2V5^YPMRQ,1*5JXQ5J)B/^E+"V 42=D@]WYZCOA0P=DT!8Z6
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MWAP)0=8"\WPKA'Z]J \=[2%S]1]02P,$%     @ M(!85";OFVG? P  9PP
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M!J,'2916O_RQWH@M .KI![ :P/8%.#7 >0[P=@#<&N ^![@[ ,,:,-P7X-4
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MT:\D3]J4?[-BH*SU@1VH'&C+E-0QKOM&:%1<Q"*3(@ (%<&22(@4:QZ7@<E
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MPL21U3%:=:-%5I[BW NM15)>+H&'( L!?#\7V)WJF\) <Y@Y^0=02P,$%
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M#H=1-!S[=X<"'UO1(!J->@_-KH[-!A$=C1JK!^S[#?M^)_O]5IES:2!.R;7
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M;^VR'UGHKO5KZS9]KL)-V\I-?[ATS^EQN>W8\+2MM_17%]QV1:H%68%R#;C
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MJ>![)/1MD*87)OH&#?&*4DV4>R7@:00X-8< Q_21"UJD+0W0;RID EUM!6-
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MAXB\?O7F2%R+\UF\TRS1V2ST\C3+33_+I]BT+(-"R:2,S0+EY@DST*-8T)Z
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MD!29JEE4$]2E+Y]SC52,_7!%_16,,Z#]A=:XGS@'3<>>_ %02P,$%     @
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MTB:8]:40>AO8#;K_4?H;4$L#!!0    ( +2 6%1&Y='P^ $  '0$   9
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MCA^?16>:_C.?C?_MN7H'4$L! A0#%     @ M(!85 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "T
M@%A4_"<YX.X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "T@%A4F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +2 6%3(O&;\
M+@8  /L8   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "T@%A4T4IX,1X"  !M!0  &
M@(%Q#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ M(!8
M5*OI[4)Q!0  (14  !@              ("!Q1   'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( +2 6%1T(5P&<P(  ! &   8
M      " @6P6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" "T@%A4\9K M6X%  #*%0  &               @($5&0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ M(!85%VIS6NK!0  3QH  !@
M             ("!N1X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( +2 6%1RG^T);0<  *(>   8              " @9HD  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "T@%A4!= 3#\D'  #Y
M$0  &               @($]+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ M(!85%465LX-*   )84  !@              ("!/#0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( +2 6%3F(.'T
MPP0  ,4+   9              " @7]<  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ M(!85%^(HZ:! P  [0<  !D
M ("!>6$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "T
M@%A4M*K]1BH#   W!P  &0              @($Q90  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +2 6%0P9_.$800   D*   9
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M970Q-RYX;6Q02P$"% ,4    " "T@%A4!QYXGGX$  #+"0  &0
M    @(%KIP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M +2 6%3?Y\@%)0,  !('   9              " @2"L  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ M(!85"3*ZKC) @  $ 8  !D
M             ("!?*\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " "T@%A41;*JW8 K  "DE@  &0              @(%\L@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +2 6%1H\-L)* 8
M /H/   9              " @3/>  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ M(!85/-/GO4. P  \P8  !D              ("!
MDN0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "T@%A4
M)2"ZB,\"  !S!@  &0              @('7YP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( +2 6%1W[/K3!0,  &X&   9
M      " @=WJ  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ M(!85']!D^J@ P  J0@  !D              ("!&>X  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "T@%A4)([T<!,%  !R#
M&0              @('P\0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( +2 6%0[-,I@C04  * -   9              " @3KW  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ M(!85,:JDAQ^
M @  MP8  !D              ("!_OP  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " "T@%A48>^UN#@%  "F&P  &0
M@(&S_P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +2
M6%3**2%GF00  #X6   9              " @2(% 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ M(!85,_^R1&I @  [P@  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( +2 6%0%@_#.P@(  ) '   9
M  " @?@8 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MM(!85&U<_YL2!   1Q$  !D              ("!\1L! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " "T@%A45J^<F@L#  "2"0  &0
M            @($Z( $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( +2 6%06[TA'* (  '0%   9              " @7PC 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ M(!85$MV'SF& @
MS@8  !D              ("!VR4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " "T@%A4"SZ*MY@"  !T!P  &0              @(&8
M* $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( +2 6%3X
M,(!<Z 0  &,4   9              " @6<K 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ M(!85$./*$B] P  Y P  !D
M     ("!AC ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +2 6%3QV-[*#00  ' .   9              "
M@>M( 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ M(!8
M5";OFVG? P  9PP  !D              ("!+TT! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " "T@%A4B7.=(QH#  "U"   &0
M        @(%%40$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( +2 6%1X6Z$TE00  -@4   9              " @994 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ M(!85)>XHGT"!@  LAP
M !D              ("!8ED! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " "T@%A4(9S @L8#  "5#0  &0              @(&;7P$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( +2 6%0*.WXA
M'00  'X/   9              " @9AC 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ M(!85&/)5: S!   @!   !D
M ("![&<! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "T
M@%A4\"!R__X"  "_"   &0              @(%6; $ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( +2 6%3=8.BE3@,  -,*   9
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M;',O+G)E;'-02P$"% ,4    " "T@%A4 2G'DPD%  !X*   #P
M    @ $4?P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ M(!85/5)DLP!
M @  7B0  !H              ( !2H0! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ M(!85-9,P)+@ 0  XR,  !,
M ( !@X8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $4 10#:$@  E(@!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails</Role>
      <ShortName>Inventory, Net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Leases - Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesCostsDetails</Role>
      <ShortName>Leases - Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Collaboration and Other Agreements - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails</Role>
      <ShortName>Collaboration and Other Agreements - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails</Role>
      <ShortName>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mgnx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - mgnx-20211231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - mgnx-20211231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mgnx-20211231.htm">mgnx-20211231.htm</File>
    <File>mgnx-20211231.xsd</File>
    <File>mgnx-20211231_cal.xml</File>
    <File>mgnx-20211231_def.xml</File>
    <File>mgnx-20211231_lab.xml</File>
    <File>mgnx-20211231_pre.xml</File>
    <File>mgnxexhibit23-1202110xk.htm</File>
    <File>mgnxexhibit31-1202110xk.htm</File>
    <File>mgnxexhibit31-2202110xk.htm</File>
    <File>mgnxexhibit32-1202110xk.htm</File>
    <File>mgnxexhibit32-2202110xk.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mgnx-20211231_g1.jpg</File>
    <File>mgnx-20211231_g2.jpg</File>
    <File>mgnx-20211231_g3.jpg</File>
    <File>mgnx-20211231_g4.jpg</File>
    <File>mgnx-20211231_g5.jpg</File>
    <File>mgnx-20211231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="642">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 220,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 522,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 7
   },
   "keyCustom": 49,
   "keyStandard": 359,
   "memberCustom": 47,
   "memberStandard": 31,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Inventory",
     "role": "http://macrogenics.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Property, Equipment and Software",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "shortName": "Property, Equipment and Software",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Leases",
     "role": "http://macrogenics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stock-based Compensation",
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Income Taxes",
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - Employee Benefit Plan",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://macrogenics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Subsequent Events",
     "role": "http://macrogenics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Inventory, Net (Tables)",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Property, Equipment and Software (Tables)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "shortName": "Property, Equipment and Software (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Leases (Tables)",
     "role": "http://macrogenics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Income Taxes (Tables)",
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9442a64247474df8b1461add74aaacda_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9442a64247474df8b1461add74aaacda_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9b5c8da8f19745d6898a617604443be6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9b5c8da8f19745d6898a617604443be6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i59d5e663668240cdb7d13d2e26f36f9b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Inventory, Net - Schedule of Inventory (Details)",
     "role": "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails",
     "shortName": "Inventory, Net - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Inventory, Net (Details)",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Property, Equipment and Software (Details)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "shortName": "Property, Equipment and Software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Leases - Narrative (Details)",
     "role": "http://macrogenics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Leases - Costs (Details)",
     "role": "http://macrogenics.com/role/LeasesCostsDetails",
     "shortName": "Leases - Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "ia806a05d835e448d9a55bdd709901742_I20210615",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i6c715158e6064e159bcab21034af9af4_D20170501-20170531",
      "decimals": null,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i0de3c7dacb78433f9459d81078d7fa6c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CurrentIncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CurrentIncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i00a6c80f6d9a4e90a13892c6d1d2cc1b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i0de3c7dacb78433f9459d81078d7fa6c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "iba28ae17d5454e65aeadecbd8ea2feb2_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "if421d26f11f845ee931133022aca115d_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "idda30ff7043944c08d210fdf9d95c99e_D20181101-20181130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i190bb429937844f9815169af38df6990_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "iabedb65de0b8461ba14f9c8f45d006e4_D20190701-20190731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Collaboration and Other Agreements - Provention (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
     "shortName": "Collaboration and Other Agreements - Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "iefbbd3ca3757470f9bc0909619e0664d_I20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
     "shortName": "Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i8dce4423b4cd4bc68d810ef872202702_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i7d006afd97914c30b1c39b119a8f1fff_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:TotalPotentialValueUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i8f52fbf26ebf40598a45c0dded3e0b4d_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i93b4bb09dae64bad959730c0f8dc14d8_D20180101-20180331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Subsequent Events (Details)",
     "role": "http://macrogenics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i7cda7295203d408e87a17554ea99f6dc_D20220101-20220131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Nature of Operations",
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "shortName": "Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "i9142c213b886498f9196dea58b4b4251_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20211231.htm",
      "contextRef": "ia1a04d0404924490b3850604be6a89bd_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - mgnx-20211231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - mgnx-20211231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 84,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Collaboration And License Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ASDHealthcareAndOncologySupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASD Healthcare and Oncology Supply",
        "label": "ASD Healthcare and Oncology Supply [Member]",
        "terseLabel": "ASD Healthcare and Oncology Supply [Member]"
       }
      }
     },
     "localname": "ASDHealthcareAndOncologySupplyMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://macrogenics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH Collaboration And License Agreement",
        "label": "Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]",
        "terseLabel": "Boehringer Collaboration and License Agreement"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH",
        "label": "Boehringer Ingelheim International GmbH [Member]",
        "terseLabel": "Boehringer Ingelheim International GmbH"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement, Term",
        "label": "Collaboration And License Agreement, Term",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTerm",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration and license agreements.",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Transaction Price",
        "label": "Collaborative Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Common Stock, Maximum Amount Available For Issuance, Increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage vested of employee's contributions to defined contribution plan",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "terseLabel": "Percentage of employee vested contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Amounts recognized",
        "verboseLabel": "Development milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones, Amount",
        "label": "Development Milestones, Amount",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "terseLabel": "U.S. Federal and State"
       }
      }
     },
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "terseLabel": "Deferred income tax adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum employee contribution percent"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan.",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "terseLabel": "Eligible age to participate in plan"
       }
      }
     },
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_EntitledMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entitled Milestone Payments Under Agreement",
        "label": "Entitled Milestone Payments Under Agreement",
        "terseLabel": "Entitled milestone payments"
       }
      }
     },
     "localname": "EntitledMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EquityIncentivePlan2003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2003",
        "label": "Equity Incentive Plan 2003 [Member]",
        "terseLabel": "Equity Incentive Plan 2003"
       }
      }
     },
     "localname": "EquityIncentivePlan2003Member",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EstimatedReimbursementForResearchAndDevelopmentT": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Reimbursement for Research and Development t",
        "label": "Estimated Reimbursement for Research and Development t",
        "terseLabel": "Estimated Reimbursement for Research and Development t"
       }
      }
     },
     "localname": "EstimatedReimbursementForResearchAndDevelopmentT",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply",
        "label": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ImabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imab",
        "label": "Imab [Member]",
        "terseLabel": "Imab"
       }
      }
     },
     "localname": "ImabMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in deferred rent.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Clinical Supply Agreement",
        "label": "Incyte Clinical Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteClinicalSupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCommercialSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Commercial Supply Agreement",
        "label": "Incyte Commercial Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteCommercialSupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Corporation [Member]",
        "label": "Incyte Corporation [Member]",
        "terseLabel": "Incyte Corporation (Incyte)"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration And License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Laboratory and Office Equipment [Member]",
        "terseLabel": "Laboratory and office equipment"
       }
      }
     },
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Les Laboratoires Servier And Institut De Recherches Servier (Servier)",
        "label": "Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]",
        "terseLabel": "Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]"
       }
      }
     },
     "localname": "LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC",
        "label": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]",
        "terseLabel": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]"
       }
      }
     },
     "localname": "McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial fee received from collaboration or license agreement.",
        "label": "Non-refundable upfront payment",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable Payment, Tax Withholding",
        "label": "Non-refundable Payment, Tax Withholding",
        "terseLabel": "Tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates to develop"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OneTimeMillstoneCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Millstone Credit",
        "label": "One Time Millstone Credit",
        "terseLabel": "One Time Millstone Credit"
       }
      }
     },
     "localname": "OneTimeMillstoneCredit",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsAnnualLimitationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss which are limited for use, utilized on a annual basis.",
        "label": "Operating Loss Carryforwards Annual Limitation Amount",
        "terseLabel": "Net operating losses limited for use utilized on an annual basis"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualLimitationAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforward, which are limited for use over the range of years.",
        "label": "Operating Loss Carryforwards Limitations On Use Amount",
        "terseLabel": "Net operating loss for limited use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUseAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsNotSubjectToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to limitation.",
        "label": "Operating Loss Carryforwards Not Subject To Limitation",
        "terseLabel": "Remaining portion of net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToLimitation",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptInFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt-in Fee",
        "label": "Opt-in Fee",
        "terseLabel": "Opt-in Fee"
       }
      }
     },
     "localname": "OptInFee",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.",
        "label": "Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan",
        "terseLabel": "Percentage of common stock share outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Commercial Milestone Payments Under Agreement",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which purchase price exceeds fair value for common stock purchased by collaborator.",
        "label": "Premium received on stock purchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Royalties, Percent",
        "label": "Proceeds from Royalties, Percent",
        "terseLabel": "Potential proceeds from royalties percent"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated useful life.",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Table Text Block]",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ProventionBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention Bio",
        "label": "Provention Bio [Member]",
        "terseLabel": "Provention Bio, Inc. (Provention)"
       }
      }
     },
     "localname": "ProventionBioMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "terseLabel": "Provention License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "terseLabel": "Provention PRV031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "terseLabel": "Provention PRV3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "terseLabel": "Revenue from collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Government Agreements",
        "label": "Revenue From Government Agreements [Member]",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance Of The Research And Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "RevenuesFromGrantsMember"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Net Of Tax Withholding",
        "label": "Revenues, Net Of Tax Withholding",
        "terseLabel": "Revenues, Net Of Tax Withholding"
       }
      }
     },
     "localname": "RevenuesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Tax Withholding",
        "label": "Revenues, Tax Withholding",
        "terseLabel": "Revenues, tax withholding"
       }
      }
     },
     "localname": "RevenuesTaxWithholding",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ScheduleOfInventoryReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory Reserves",
        "label": "Schedule of Inventory Reserves [Table Text Block]",
        "terseLabel": "Schedule of Inventory Reserves"
       }
      }
     },
     "localname": "ScheduleOfInventoryReservesTableTextBlock",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Supplemental Balance Sheet Information, Operating Leases",
        "label": "Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]",
        "terseLabel": "Schedule Of Supplemental Balance Sheet Information, Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares authorized after increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase",
        "terseLabel": "Increased number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2013 [Member]",
        "label": "Stock Incentive Plan 2013 [Member]",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TaxYear2025To2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2025 To 2037",
        "label": "Tax Year 2025 To 2037 [Member]",
        "terseLabel": "Tax Year 2025 To 2037"
       }
      }
     },
     "localname": "TaxYear2025To2037Member",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to total potential value under agreement.",
        "label": "Total potential value of agreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated Preferred Stock [Member]",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "terseLabel": "Increases/(decreases) for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Collaboration And License Agreement",
        "label": "Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Collaboration And License Agreement"
       }
      }
     },
     "localname": "ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Limited",
        "label": "Zai Lab Limited [Member]",
        "terseLabel": "Zai Lab Limited (Zai Lab)"
       }
      }
     },
     "localname": "ZaiLabLimitedMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement",
        "label": "Zai Labs Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Agreement"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs",
        "label": "Zai Labs [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabsMember",
     "nsuri": "http://macrogenics.com/20211231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r100",
      "r101",
      "r244",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r279",
      "r282",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r243",
      "r254",
      "r303",
      "r305",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r475",
      "r508",
      "r511",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r243",
      "r254",
      "r303",
      "r305",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r475",
      "r508",
      "r511",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r279",
      "r282",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r279",
      "r281",
      "r479",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r279",
      "r281",
      "r479",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r243",
      "r254",
      "r284",
      "r303",
      "r305",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r475",
      "r508",
      "r511",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r243",
      "r254",
      "r284",
      "r303",
      "r305",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r475",
      "r508",
      "r511",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r100",
      "r101",
      "r244",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r117",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r117",
      "r121",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r117",
      "r121",
      "r230",
      "r304",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r19",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r220"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r51",
      "r54",
      "r60",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r389",
      "r512",
      "r513",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r341",
      "r342",
      "r343",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r307",
      "r309",
      "r347",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r309",
      "r337",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r176",
      "r195",
      "r197",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance recorded"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock options"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r156",
      "r159",
      "r165",
      "r193",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r387",
      "r390",
      "r411",
      "r438",
      "r440",
      "r481",
      "r496"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r45",
      "r95",
      "r193",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r387",
      "r390",
      "r411",
      "r438",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r182",
      "r203"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r180",
      "r183",
      "r203",
      "r484"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r310",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital Expenditures Incurred but Not yet Paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r29",
      "r83"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r412"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r93",
      "r95",
      "r124",
      "r125",
      "r126",
      "r128",
      "r130",
      "r135",
      "r136",
      "r137",
      "r193",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r252",
      "r253",
      "r257",
      "r261",
      "r411",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration and Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r231",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,307,428 and 56,244,771 shares outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r66",
      "r488",
      "r504"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r408",
      "r409",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r408",
      "r409",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r408",
      "r409",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r140",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Percentage of significant accounts receivable"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r143",
      "r145",
      "r146",
      "r147",
      "r408",
      "r410",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r408",
      "r409",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r277",
      "r278",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r277",
      "r278",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r277",
      "r278",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r285",
      "r299",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r479"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Product Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r373",
      "r379",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Provision for federal or state income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r144",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r184",
      "r203",
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r364",
      "r482",
      "r495"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal U.S. net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r369",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r369",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenditures"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of employee contribution to salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r154"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal Government"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r134",
      "r194",
      "r268",
      "r275",
      "r341",
      "r342",
      "r343",
      "r375",
      "r376",
      "r394",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r512",
      "r513",
      "r514",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurement Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r396",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r299",
      "r397",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r245",
      "r285",
      "r287",
      "r292",
      "r299",
      "r397",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r285",
      "r287",
      "r292",
      "r299",
      "r397",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r299",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r402",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r208",
      "r209",
      "r246",
      "r266",
      "r393",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.",
        "label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset",
        "terseLabel": "Impaired assets"
       }
      }
     },
     "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r63",
      "r67",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r128",
      "r129",
      "r395",
      "r485",
      "r486",
      "r489",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r63",
      "r67",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r128",
      "r129",
      "r130",
      "r395",
      "r489",
      "r501",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r223",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r356",
      "r363",
      "r368",
      "r377",
      "r381",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r119",
      "r120",
      "r155",
      "r354",
      "r378",
      "r382",
      "r506"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense/(benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "United States federal tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80",
      "r476"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r43",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r44",
      "r90",
      "r133",
      "r210",
      "r211",
      "r213",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserveMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value.",
        "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]",
        "terseLabel": "SEC Schedule, 12-09, Reserve, Inventory"
       }
      }
     },
     "localname": "InventoryValuationReserveMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r43",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory Valuation Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r480",
      "r492",
      "r519",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r434",
      "r436"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r95",
      "r160",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r388",
      "r390",
      "r391",
      "r411",
      "r438",
      "r439"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r95",
      "r193",
      "r411",
      "r440",
      "r483",
      "r498"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r95",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r388",
      "r390",
      "r391",
      "r411",
      "r438",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Financing Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r57",
      "r62",
      "r65",
      "r82",
      "r95",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r127",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r395",
      "r411",
      "r487",
      "r502"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating and investing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r428",
      "r436"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r423",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, ROU Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r433",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r75",
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r310",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r77",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r219"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r440",
      "r493",
      "r499"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r221",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r350",
      "r478",
      "r527"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs, Including Clinical Trial Accruals/Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r275",
      "r344",
      "r440",
      "r497",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r194",
      "r341",
      "r342",
      "r343",
      "r375",
      "r376",
      "r394",
      "r512",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r64",
      "r95",
      "r152",
      "r153",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r411",
      "r490"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets modified in exchange for operating lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r145",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r309",
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r309",
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r310",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r315",
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r93",
      "r135",
      "r136",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r261",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r362",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r143",
      "r145",
      "r146",
      "r147",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Percentage of Customer Concentration"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted in period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r317",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased by employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r308",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options granted, maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r332",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair market value to purchase shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r93",
      "r95",
      "r124",
      "r125",
      "r126",
      "r128",
      "r130",
      "r135",
      "r136",
      "r137",
      "r193",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r252",
      "r253",
      "r257",
      "r261",
      "r268",
      "r411",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r60",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r134",
      "r194",
      "r268",
      "r275",
      "r341",
      "r342",
      "r343",
      "r375",
      "r376",
      "r394",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r512",
      "r513",
      "r514",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r134",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r268",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r268",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r268",
      "r275",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r268",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r95",
      "r178",
      "r193",
      "r411",
      "r440"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r430",
      "r436"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r419",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r419",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r419",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r419",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r441",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "US Federal tax credits carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]",
        "terseLabel": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r246",
      "r266",
      "r393",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r285",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises",
        "verboseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r99",
      "r285",
      "r299",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r353",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r138",
      "r139",
      "r141",
      "r142",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r102",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Year",
        "terseLabel": "Balance at Beginning of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "negatedTerseLabel": "Additions Charged to Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r429",
      "r436"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeasesCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Motor vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r528": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r529": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r530": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r531": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r532": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r533": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r534": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r535": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r544": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r545": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001125345-22-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-22-000013-xbrl.zip
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M:]8:,R29-30X)(0/)&*-[.(1^H$MP)E055+G",A:*GUD@5'C*5/>$ <:DI+
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MLM2(RR9XJ!\'NGYM.;\-)2SGY+[)LR*4VZ$XAKE>'?B-00E$' W7PA;8$*&
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MU&>./7.>FD@Y1]XSRAE5TC5KZLUI@Z8^^BB-=TPZ29GBP6+.@I9@@!KD%&J
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MFZ];._]>;UU2^\Y5OM57.^ER"CN^,C_5FG]6<;O;U/LK_(]>G:F9:E5@';;
M9FW%K 0ZM<[ Y&V!413\0^@P[RIK:[VVP:XL_^=IX[S=AV<>I-O:WIRUT]C:
M8=!(/O#32L]I9^TS[^ZLGW8/.Z>=PUWR*2CM.!*F[9UT;0;3#&LZNC9WC!.)
M0C0Q3I5WOQH5!1#O=86872#*70FXI)V30KO ?3MZ(!MC4K6MUK[M$&-!>&.9
MHBLOUH*KO2_)3W&5)S]I)8K\E&X[4S:SN=4T]7NI[2ZUW7NWV0L87Y:<U(NN
M\4)?_<Z7@VSO#3SGS=;G[IOW9_",+[O]W9.]G772^;+W>7/MH =COZ;Q'L&X
M=[]LOOGS\][:^Q.X'^WM;,#[=+.]PY>]SL[NEV[_+[;YYD._>YO&RS421#/=
MUIZ"QAL=;5NO;3NJ& (2BHN@QQHO6VB-=V=KM;N]4:FV#ZWUS@/[;J */CSG
M#JUZ&Z(5B[Q_V5'[<S^'>>OJW,PA=1Z>%K</\U7>[V=EVO!JO<Y _@-G2(K8
MP\S<[?"8HEQ:KS;8THO6[]E(@?/3ZOE99V?CDT.8:(U (Y>8MAGFL6T%?/01
MY(5-53""3#O:N$T%S-]7)<95WG?;9MQ-7@3"X;EX"$9$[K;--76D;87]K$QL
M;I@V\1\=VG8_(8\LBD:V'7.XS3P+;651:!LM$".!$LM .^FLOMK:?+/>W7BU
M_:2UT7WU]+NHFP$;K7I\G@WA:>X.C/6W]5/CAA4B6GEL%>=(^'T>7F8![4(F
MGFI-[]TP)$^YX/?>*Y-/@;],V=RL071]SON9][WP\-":MLU9<]R-@;N(C*J"
MA:I0JN+L5>[#3?.S3"V.BOPX]=-0=UUM@*8ME;W^^[/NQP[>>[-^VGT#GW<.
M#CJ'[UGGR^Y)9^U#?^]PE>VMK5[?<CE-QBL8G7CWRX?/NSOKU;B 'Y]UP8#M
M'JZ>=#_N]6$LGSNO;S% G9&14Q';D8'MR910;1,1<'PCG'4V:H]<<O'US(DI
MPO0MT)GB^YK6_U,O]1B7[8XYW1B'3+IJZ398/W_H];AQS2'D!#%<Z#:W++:9
M=J2MHJ)MIY0EJ?8[U4G!%VW,-1:8?G-%-DWXW%U)JW#]6R4ADGZ6%_MFD'VI
ML/?[96?"DD$UE+0;3[>>;C]MK?>/>OE9*%I7^<O8T?'[G;U[W[%PYT5WGSJG
M7O6^"&4Y_O46!H ;R:5_WJ[M[JQ^TM%S1[1N4RIYFW'KVU93"3Q568^91(ZP
ME1=:(M;J!)]62>M5!8O66I$=W]""GDPS^. *W5[!GYO%3G[23%WW5ZCVUR?$
MA5,2^[9//@A&:6Q;Y4+;&J<\QDYR@E=>;.7N\W'6Z\V02I58VBQ2%J!LX!;4
M;OD56NY_T@Y9,#A(&S.> F.5;FNA9)N EJ.]UL$@NO*B8XJSGAGXFP$$#T3)
M=SF0JK>7'=7VY^,BT^'Z)^NX#QK'-%/ *"GG;<.1:?O(#--&,9C7E1<$*8X6
MP>DWIGK2*(\*6+K9$7#^<!K<: AL'[X&_0,& (AL?<F. '8^-,T?.+?#_&U!
M-ZV2R%XM@GE\'.1+!SA(]#3$X%T;2:G;S#C75A8D-Z9!14X-8PJ$-D4W@L1F
MN?M[JPFY8+A\FX-:^^X@'SS*S53 YNZG$$E*KZ';&&G<9E+@M@E4M)%#D@7,
MJ+,(I!O';8[E]_=2YXZC7NQ?_J-L#4,O'"5RMP;7;.<YMY2_<L81A')1%24=
M;\Z%(OC6T:@H1_"^K6'>VJ[.RP]:F/QF?T\B/06MK+KA\SEZMV])[)GNX\FG
MA)"?V<>C<">[_QTW+)[B*6P/,OJ4B'O9R!N3)'D,G^.C8:O,>YEO):S\<WPI
MA4]<NS)W7KIO^N1VLF&O\K8&XPY:KF?*\@Z>R,<P,85)HVUMG_5MWONM_/U>
MIJ6HG["84]8=!U944 JG[B!EJ6@!MSXYR.";"Y;^(_L9X\D9,[K;9^[></C-
MO8'Y$BK3W@0<R^(S3&S%(QJI2M;[?EVR@??65M'>Q\Y9]\ON27?M,^[N] ZZ
M9!?O'?;Z';)[UNF_/MP[[%S?]Z.[AQ\^=]:V8+P;M'NXBC9WWN/-C^MT[_!#
M?_/C[I>]PPUHV^UW,(SQ^CX\,4$+#G:201&U69"T;2RC;1182#EQ D&FCO>$
M1;(]S-WG)ZTC4[2.36\46O\;/44XA>&VRH-O;=/7:3:^RY4>9@7-(5N:XB(9
M"XE:1BQ7R!U6R/K5%6*\"UI;WPY$@K5&*&J;2'E;1"QUH-'[X%9>=-YT__L3
M42J_"/R%EM4/(#G6QQI '6=[?;LDZ0<-WBEYZ'5S+:+$Q\"-5K!DX(\V<TZW
M%?*VK3%R%(5(D6!)(2N]^;OUII=;TP/;N0?6<ROEU C#[X>8-.-(S1QH8C_N
MNMB_XKIH=?-!^&7'S6S/K6X,TH[Z,+3L6<L=!/>YU4^I6[+Z+2\BK5M9V3*M
MD]#KM3\/\A,89S EO+Z'"^4H%$]:IFSY$+/JJT%K:P36*4-\,E^7IAFF[NG\
M3\S4-S4_PES^)TWE]G@F-ZJ);"13_6G/+^GL_/4)2VJ4]+R-'2C:+,6_6L9$
MFQLB*54L%>I8>;$;RNN\[^9QM6]L#Y#J?U-E>%HR_L\'.N]U^QB )=UVDF]\
M8'7>U]S=149SF.8@'\(W?X^R)%9 FL1T,K"H3G"7MXL9VLJ+\:G:,?.<*&2W
ML\[9S $LQQ]:?C\_('WWU<?FX9CJM 7'A[PW&@Q-49V]+,K')3! XW[_R6MK
MC**Z[63*3,6U:"ME2)M$J8T7,7*N0(G.OR4OYD!2S#^C:SA#/CD(*:7R=:[\
M&_Z]=0#J:F+%OF5ZO7-^?)E1VS!N 'U^@S=?4FPOL^ET.64\:/E1JI!2-3TJ
M@@O5W@0FK2J[4=GZ#?H#"[M5CMQ!JSR 4<!XQR?XAP=F>'WL)Z:\*4ZJF\?O
M\'L5$/4;J5_1@ID.E^UA,B"A>=42[DF#&'=3Y5BNQE"-T93#ED8M;\[*I98^
M/!OGJZI3KB2/X= ,1X^,YYYV=M;I)Q^)#LJC-E'1MYE#JFT,#6UIA)5(4,>U
M:HZ6/G=*^ORH3O.[VA=3'"4^#2RZGPV'P-,K7U^1#Y*_N7?6"L>A.&M55;6,
MJ^)>U\S0U/E%KDFKBSXNFQ67'3%;87_4JX_L;+=WIBV:ZO&<BYQ0_KX4*.E0
M]3DI$R7'\N61"93NVCK^1*B!69*R[6G R15NVLHXU2:",24DPU+[I4!9"I39
M"91K136.\CK#UO,B)"YZ'+Y:9F.\<XDN;C&V!+-]>/.6[Q7@J'\>%!=G2?=#
MVQ;!?&Z;"*SDN>F=@*Z^\FP6)4&N!C->2T?4)!E<[6[TX&U"RS@',K@P29 F
ML96V-@:W?ML"GM2^<0&^+_LFE8H:FV1)JKJ\#W-P]B29C] ;&%UIXO9;^T5^
M,CR87+Y26&,[A&J4U:9*!:+J*,S*UT:YTEJY\>7*D];*5P>S\J0R%5>^,IB5
MUOD^#B:V3;[IC'S@@%C^5&#V,P&QA#PE^OXSGM*GB*C[CX=E\)KWWRW, 6-R
M"LE],+Y;3/#])GVMD;%XT1@7^?6*5["B]_/B[)9@C*I1M=;=N%&CXS*@?[JY
MUNWO??R+[>ULT.[:5K_S9@-W^UN'>SL?#G<_ON[MK;DOG9MQ&? N\#RR!]</
M>IU#A^!Y)[N'[\G>FVZO^[%[L/OQP^?NE\Y9!]^2>4=[%Y6SL0W2P[691KJM
MB35MI*@5"%E).2BC;V_GO=-/Q#-3D)^7>+CS6Z'T3BL+,P&K%P2O9?.8ZHM'
M97:5RF-.?4T?IA5M[PT!\]5T@813]S;U]!&@]E'QINU:O:_YTKF.7W\<:_(+
M1O*IZUS5E+X<E?#DLES<-/L/I&N=O=WYZZJN)6F4,E+3)D2!KL68;:O :%OI
M0(G@1AC&[Y9F?RF?FKR0UV]W/"S9U8^QJ\DTOJEF\=7$>[-D6[_$MM"-(R]2
M*YHJDX-UB#FP+>_;EK/09E)R;!0QF)K[J [R4$SD>P7GTE$9=JM+]Y\_X#.>
M68#B1OR&I_5)*[MK#&?:GJTV94&#3L&<P[PU*FO7+,Q"7>[NHOK&G+S\I 9(
M7E1OW#M+4W"2P03 R[<&\) \>82/L[*R"P9FX#+32YZ-E.$Y-2Z'9N!-X<M6
M2HV6^:\=BJ"_F=OC5%O3"83^M1VHA\3IW4;ZX[$"X["UL4,_'=-.;GPS'(:4
MR2X1!>B3#4OH:&#VJ_BN?Y0M4Y:@S:8/$VJ%&$.U#ST89]E*]V1I>WH 4$AR
MJLA[K1QDZ26$7.PBC #YQ3D.&&*7$GMLF\(:Z+:]>=H+9U4\W&^8M]X_W7[Z
MZFE+$I&R@/R>7OGB_<;G;FP/A.0E',:LZ-?A!D?P;),: 72K0R>^&K$9^6PX
M'M>W03?UK> IBOH-%XO5]*9YL7I!Z=<]LW^U<F+,3H-O#XM1,\]]_WP*H6Z5
M/YVQ%%)@VT:G&+5H==N _&M+3VC@C&$E\:4=^SN58YF3/>G&[**6!Z'7F\C9
MUF^W' O[ZG;B+0%"R\,-#^/R2$1;8-/A%Q)OKGU.I5<13*;&;1DC:S.C5=LZ
MCMJ1>6(\TP))]UW5OPF10<NC#TV+-=T!'FKV]X$+)S;=K\Z(C_.0Y-=M&5 #
M79VSI/Q.SI(G+6 (U=&'*L8EIB,#T']YL\^D?_XY&H1ZOBB::F+G22W4B_+1
MK^&;1Q:.CSI?/K/.VE^DN[..NCO[)Y\(U40ZKMM1"]QFV.*V94ZG.G2$2&TH
M3KFX;RO^_*2B9B\=^K!CAW<Z^G$K=/IYF?3L=%J_=U:;E2$9Q2 A\H&?%('_
M>V12H/"3*AS8'('Q>)J!, EPR_\>(^-U%?\*N!D-LAH7H]*O7 4*0D8XA:+P
MVK"@D<%4:>*$QYXXA^VGC0M\^.#@$;WR7RMM=5.TO:M,BM>]W%PMF?M\,.JW
M?3YLCV]?::7QPZWZ<<'I6J'QSI=/V MBN3)MX; !.,%?UH-2C6B@8.?I:*U?
M>8&?B@F:)@1]T;)9KY<H:TUR+"13%%#D>GF93+DC0-SWN=+DKF_DP*B;@$F8
MZL1?"9H#;;(WJBIPPF,J3E:><[*DC@*#*].##O)1KW;GV)" 5R:+J8I:/_<+
M50^H@M?'-QWEE0D-/581\_E)0KG/BC2N9)(.ZK^?I%XNOG9FXBVJOQN/[<(V
M3XV.<H!H=AM[K2(&;PPE*R?V^?B &C2J[?'Q3$ZL]\KE<[7'K^G83<E8D01>
MG33U$HV_#ZK1L/)H)1RF^JS!%L"HSFK4$/*D!>R$5#SKJTRJ?M0U/D5E",9)
M$4/B4P'I"%(MZ&"E L$F><6GTC]RF4]M=%_?<M2L&F^536R[>M3FQ9COQKG0
MX^)<7SJ'?Z6,.I$$T"C:-L5K,1"$;1VC:P?&D1=<!>W-R@N!GU#"GA"N;C"M
M!IQ*F;M<.K>G 5[;?/6^L][=V4Z%1S>WWFUNK>ZLK[5>[K:VUE^O;ZUW7ZTW
MG/D\@&Y;7I1=#/[E&?0=BC!P80<>]+('S.&1+7)X!_1)$F&\"6" "RS! )>\
MK1SQ;22]5I1Y[C1;:07@@T<)+LG]^>)=<E2/H^8[QA7YFS#(7/FD!1/\]!_E
M>6#]<3K^EI^>M:I",)5(GIR&KH2"&0Q&H('T0Z@<TDGH)!Y]D/= X(*.6P20
M_1<D2^*XF! M^=/SUCM0B5L;&QNUF +AO5IW69\JOGN%WODYCY+ZKE#(2(@X
M"LTXMLP8;"76BED2*%;:8_))KLSY&99Y89ZW%&Z><W:_VNV^7WT+O!T8_4YK
ML]MZO;G5:6'4_L_WBI=/,CN2ARA@?L>WV5E]^7:]M?FZ]6H3K"$08DTKVHS1
M4T&_?OEGSW4H^13+NW5[:VR2^.6HG9^#?HS3 0LPGWKDH'V/:R,_KVROU J&
M8^9F+*V#(BDF__-])HTIB,M56,0;?SPSMR4H7J"HLPV0\2T\Q2"S;^U:W1,0
M;GNS68'R!\?R Z 4*R\F4;B/!9:K2US./R[URHNMK/S<>FW<,"\>#39?+K$Y
M]]@D9.7%^T$1P+@[!E-T>VAB;"7'8G(L/!*@DB5.YQ^G'!3.(C]*TQP>"S#I
M$ICS#TRU\N)MV#>]%L#3A2HGUF/!)UOB<^[Q2?'*BP[<TMHV,0S/6FM9F;;7
M1\6/<=%?=\K,YK#OE6VPI<NIP2XGRB8NIX?Q.0WSHUGR5G[_O+5^HR5CO2<\
M2F"L=711VOV[4JUW7.AM_>]1-CQ[ M=ZU4;?]L4V8*N3SM\4=37ZNI!'Z]VH
M< >FK*-3ZGLO98M^)#J%6.H4<P]]AE9>; 5X_G&J\/DH8"F7L)Q_6-+$D2\=
M84RZ[JBLHCL3FUT=F-Y9F57L]?7Y <57^<!7(0Y5&X#UJ#>LFFP>A7HPCX7U
MRN5FPOR#7 +O_2L=JLZ&50A/A5KXHC?Y?,G :QF;C\YCH-,6Q"-!LEH">?Z!
M#-SZ@@MO3T+I:HUX>W1TU*L^F^*LRF#_2)"KE\B=?^2*E1>OJC/(*?U!A5=@
MNF:_"&,$5X<H5NN4!"9] <K%ZD6&@G3#!?(O^/5C@?A2S6@ QG4J5U^=":HY
M<K6[X7_4;=QDF"[#%^8?IHJLO-BL,DML#.H#3U5*I<<!T%<+!E!,Y@>@WQ[+
M#P!4 D(O1'QR$YNB.E3X.B_@6>DL?)&5/G/UT9/JY.:[(ARG4R4;@_*H/@&Z
MW*M;[M7-?"P_@'IUOE?W: +$T8)QXT54%S1.S#B=JL^+\DEK_32X4>4TVXPQ
M<Y/MN%>3HWFM-RF973+4'HMMAI?G'!J 8K;RX@*Z*0E7&)2/2?/%RXC=!J!4
MKKP81R^<M39/!L!=#[*CM+'V"F;>9(/6RS (P':3$ZR^7G'?BQV\\8;<5V,G
M'@O:EV' \X]VZ&CEQ038%6:3U0: +Z^@>"?E?:[3B)1/QI[C6AT!8\^'HY0=
M^A%I&\L XB8@.YWU+;*!RXZ 4U]L:[1>AS#>K0O%,:C/2R?%TDDQ\['\"+#%
MQ$OQX;$PW"E$%2\9[KWC4B?[[B"SV3@:XI8PB=:V.PA^U'LTVW%X&1C< .AB
MLO+B=5[TJZ0^K>U1OV^*L\5'Z"UJP1*@\PE0OO)B&Z;6#+\7RG"CVM&=$@\V
M,>,:1O.><NUJ6BQ]=>',- G8Z\VMCZM;:^VWFYO_V>B^:6WOK.ZL=RYG [OK
MR]R<F@?D8N-$N5DY*1($YEYOY*'OF!<GIO#M7IY_'I=Y&EX*<\OJW,O]8 ;C
M7(>3 C]$KIY7]SD_Q%15]H%OL:9T;#J.6^/U6UI?KO4QOHT]33OG7QO2>-B7
MOZIVU/LFY5CL56F:\U8^*EI'/9-<,+D]K&L:P=_[N>G!KW2*:QCVL_15'"4^
MT:JVXR\^5MOSHW1.JT@)EJO DX$+3UK.'&5#4-/":?+D9!6/>3(IA@0C'83@
M:Y4NKX)6LHN@E7J<0("48QH(,<R+) @N-WF:?*.35.OEE9<T1T?!%*E(64K1
M#R)DU$L?ZQ3/:5(/@JE.IK=6+F>B6:G&LC*50Q,KK0H;UY-75LF4)QK"-VGI
M3$I\/0R#E'([2XLCBUF=+C.]4<J2G:8B%,"$8(7LG]49KPV\8SFJR JT7GG2
M6K&AEP'%TI\I;C[Y,8;5IX2!]#N1RPW37ZF:U<!7WY7#*@U]U:[(#\<- $CI
MUTG6ZZ7?=5[PZIO)'^[\CZKS--1!JK60,)8^%2&/3UK'ILC,).0C?5?/9)G!
MNC9% A! IZS=A( R>&=_3I>R3BE:H?3LZUD?YY;/K/9ZWV K3\:+&+Y]4K&8
M=(2A!_-25[!Z4JW>< H#&YA)<O1+ZR6O 0A=#@L@9?*RPHJMT\N/CE)SN!T8
M3)&,J)KP8SJD^4]DR4=5\;-1_ZCZ_FGK(]Q?0ZBF55VV"$1CF0^J5(_0>U9Q
MRO'8KG5:W1QA)!;>!'HX&Z> 37U5I1%&P#PJSW'UK,2K$A. !_1@5F_T6?N-
MT[?CCL_O2(7W4G;Z(KF4GR:F.:HJL-6KLP(FP"A&X D)VH# 'CP]%GDJF);#
M>@*&[XK,CDNF]8]ZX_56+:ROD^QI*^58CWFOEY_4E=[&[U,Q\33::,9;[J:?
M)S&1YK%L_79.Z?'SR_HP[?!@S+FN,JO?GXS?P52%Z";<^!('KIY5)] W5U^^
M2K'_C3?OCX_CCA=>77SJZB1\_?V?WW$-BJ01UA9 .ZG[SXFZMBK;6,UL6?[?
M_U&$B.E4K;K3$*[.#69/>9J+Q$!+6'O5/F*BKQ\5YPL_7002&7=>I/#5YH>-
MM3;6K?VZ#@2\A0_]S+7&2W]2M>3)A%-4*\K!6"KV 4MHOS!]^ I>9I1@"[I(
MXD27*QK6D+H0XZ8*TZO8\N5'?#W_^A(6OPR+<QVN6MJ CUY^5"__E+RL2)2:
M,$^@J1\!0EPJC9 J@"PI,^T%"S(;Z!#.EP0P_7QR]"51+57W.U]SP\2.Z_64
M[@6]:VQ*U*QYTM<EQ2#5$QS<Z" I996NF)*T5]NMDVJVJ>Q0+3:K&P$#YKQU
M;?#4C8NP#XHS")NS5#2UTI<GS?K&AR5LI@R;"])/5!QC@0[ ^)/59JO-]72E
MGW2+].$2P:K24<<)!Q-%[.:Z/\=8SR3=*56+A;;)J*KO3@5EZYN6+&+:S'MB
M8"67PR0FOK*;RW##TKZPK(OP]R@K+IT4K4WJBHR^-DFAU;G%O:3BE*EX:7T6
M)DMZ]P45)C0;'A3Y:+\N*S7YKJX[6-;%JNK+^2"DC_V\J&R8<0AN<F>,8\<
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M,6;-!KCQZJ^;<V0Y]HY/3_;]H,B">C#^[0CGV5Z3*2'-DP>9K!OV6$<5)()
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M)?.< ]J2!8*JF*:6\*W%([6:-[PU1A\M%BVSEG!1(_&XJG940B$YU,^XT+!
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M1=B7XKVSO==OC_<=6<M__L?#AW?N/<[NW?E1ZD+\8.=<ZC1G;*6JY3B,M>
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M.&:XLFT +0<;,'S!QR[8\AO,U1]D;S<RF/!EG6N[>[+\0MEB_I)E-T.M2XB
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MY+D<49I02QBB9/W!?W)<FD+>IL]L@GQJ1YXLPQ>+2+U3[);(!+-<?!<H8$)
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MF-8L4.S[TX4IA$ @VBBP!YEKVB K8+UKMFF17_4JV;%8%V3HAPJ[6%^.V6^
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M>&]>IAJPR\W4<4UV^.(1W1:B7D%[6857C*;V#QFMW0'9,U"CD8)$[/A+A+C
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MEGX9NZI?2N6<Q#B0TX0@#=[$P49%L>F;1A H6C3F ;_HVEFUZTB=NIR^"4X
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M')I!SF??"@FG6@=Z0;O(A%+&H1EA)O]09(^>YE0LM\7RKS^98OG=#%!ISLU
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MRH0=T;M7=65"'Z/;9&''@5LE%P<$D#8Z6(MVZX)14=[@4\[E3I-H0FNJ&?Y
MK"G=#M[H >:WXL;3:G"]!85F9K&@/+:?8G+#P.DK:W_T+]'Y<\W:+Y*E:2F+
M?@XV:=V5FZB$U[<;%S% *+J^W#@#K(>S(F_73DOKF#ET#8M-) P-!G2X@G_=
MC15#WKN8VI5:4S-.#S=WV,/81A=AL930#<SA+=2L$$NA"L5=!5%C/_J%61+?
MFX,68OCADY?_>/[T[.'7_CG]U&Y\U'1:-,=;-+/LJCD<(\(:6'>.'!&1QX >
MZC*U*BB!I(Q^H8OU&CKLHA78"T#]-/M'17).>6%-^AYX8?NXDIQ.\6FZCHF
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M1F5N@$:^9\A(U4AE%E=0P_TB2-)HBJ]2!#HX:4&N=>,-,%A6.(P0]F>7"J[
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MD4"ZC7_:LDX3_[,D86OP?H/R=YSBE^PFO!^)HI( SAGAQ,PEDBXZ,<PEIA#
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MGCCG;G8 .Z.<J!W/XJ;*N'BZ!=E%FX_ ]/.@.+6RO@\R,A= 25DG(N,\9;V
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M#TZ)B><(OP2[<SM&,W0;%)W-3J0SVN]%U7$>[P;<U8=/EN')"<0YF38K0YQ
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MRC0((@/U6)&A'AL.]"!>N@?;X6G5=R-WB?*TQ]8UBOP1/MN#) :JZ?D',3S
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MK\%P(F, ]^8Y;GC^3WYWOFV)MU:P.1OK^S!;-Y8'L2)*KA=/L:3T[+@A8U1
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M1&CYL4SDI' 4\TWEG8[35-W)5 'N69A"B-*CIM(Y9Z0+P9B3RB,XQXMRJPJ
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M?X<_?PYI3[!.@%':MA6FN:^42;ANK\$#"[\VWR9V7\;T$*K=4(H.NRUD52F
M<XX)5*&?MA*\'+)6IN^(QR?IU_LW6>XL2\UDX*(I6#(B+[!A<75@B<_ZZ///
M:<+]?WPE;'T7^S!IU\1L*2N/&7[\0/I5F6QER"+$?:U?/?YRQBVMT?K=VV%J
M%W;F<@_#U<2Q/)]]QS%SX#= K]0,J-*8&G:.R9+"BHUWR[D]@58>6:9#PWT^
MNVAVYM^)RKGW**N0G2VQP,/_&+@M-#&/;6=&(1GA.1"<.#8=C-,UE*D2,(_@
M><"UH)R#+:5 O[5Q9&*]41F$9[X#,?*6W"QT(JGC76B8L,=9B'X+;@OQ,]?@
M@_NKH=]%%R]2IWQ4,+8[XS&>KAF,8/:]+CJY^$HQT84L(_-6;.O,'C$[(N8G
M5>Q);2<JM#7:' QR%%712WV4:8$/IW]XBF [AWFKQEMQB#1>4:3Q,;[@K_!&
M--D*>[C<(C9]@I7N1$O-<*^%7B BMZ/E$/]03<H\N<#8YR,3%0S@ODF*U-,H
M49M/)W_3*"MTV!5QYDICF31ZOQ?>D[ TB#=C40\(%0,*ZGS/@__20)/0M*'X
MHA?8J9R$!5I@]&]@%G@<X^4P@A'IO622,&S7'EL_3)6)X>8^AG17E&8&0!0H
MS6".PKZ+3=:C00TY$KAX0?T'TACZO%GL!G#/B%L1BP;_4U:S'\OY[$?Q!9^?
MO?#__+9JJ4L#!^9O?BIZ[SSY3R%+@%=2/BO&OZ<+$)8[C@ __!(2?_C&80=8
MV8:]D3$:?<E-8.OT0,1="6=%J_2(F:R +4<D3QI5/Z25^D9C$*HP^2U_[;2X
M,K24R-IBOYY@8J&@ J8VK;>L6CA/_;].8.5CBM1'4F6X;B/QG:KW!SZZ.]BX
M#?DL0C)R(5[I/;R/X%>RYD;]GYE>@T(=ZG68+,)3R?W.YEH:B)02 B,XPY4+
M8:BPJ9SFZ>[G"7L ;M>0MD<9BO+0W*^>[0?LJ#J._4MP4]N^AL4%E+&P'41=
MY@GT"*.6,4!?1JAW@<U'='N$[C1O_E^F&K!J%R.ULFFI1!MJ64 2W17MAI&J
M!E#YA B_H"'PJ]=U@S%9\!;$+F@1116KN)T6_YTN?M)CF_1-B&]8-4G171RK
M,EUUO"P+D@Z9_!D%0/UFP1K(9/= B7<++)A4EL0_PF;(,-EH#RM^ 8RK<*RW
MJ]REB30Z:7L[+;H[6W1"JK3DX!]2QFSSN-Q)M:1<]3'&(9(U@5*T=]&Q&[/#
M_B[^%\5!D3YIOAES-;6.&B>9&Q%_>B!>Z1SE;A/N&R--$LNQD8Q7TOS.$41<
MR,3+"KR+.$L'XNF^XE0Q5-=.:_@.-+G-N@'O';+SU"6?82X8M8#$8E3S74;
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MQ*F$>".IZX^G1;OD!\,"!Y*4E@3=V'GR!W" ''=AQ[Q?A'W*9DT!5.MF/EI
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M:>+\\1H-7ZC+$ ,(KE!I>(BR#-<D5/QZ\@U?(M=PK2>\CC;#M]!=^,-M:C]
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M,SJG2"\=0]ZG>472E4MIBC1S(15/=K+B4!!C>E<8 $@+]V&R\MW;80%V&AJ
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MR4J+A7#L]Q^[%4MS(E9[$UH6NDR*U+;;1\RH+&1=)6$C[0YR;8I3LKH+F)M
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MRDQ'_AFE2D=Q .+$4Q"P^C)UL,C9MZ(Y]0H0\R-FA*;7UAGD1\>]8G2B+&3
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M'HV;GM*(=WY297!KA;U3'P&N9T@]<D$NOF'I0SP5ANP^:%U#K,0X);:%O,1
M(T-I$\2+CS,F290R>8RK5D)9]?+K)]WZ3+$.$ BP5=YN&WR4$ A$01YU%*$U
MX<8OI:!C8PW9ORF_/K&3(9,3?'B^J:'0"&U7#E -'. 2\=^D'%.<@^PC-8I-
MK_R*<7[?XT\K[V)F] -#R')H*":&D2>2%(X3'*892Y/#^AA(6%$37PFR\R#_
M#05D,&0.+XM^/S15P-#X\&P%Q1+D%+ET4%NKHU[F(-HE,Q#$NB@##$:3H75
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M7_Z#?T*\^$NZ.'[ZK?/N\$=\?1\^R-LG[\N&Y^EHM7+@BZ)U-ZW/=)'#X8L
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MS%\R)_W:'E*.%AM'RD]IYH&F0%86H&>K-0$1T*XN5X1PT#84&0EB7B=E,V+
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MI+WQQ<5 *6Q</)#YSU43>T1<E"(:Q<NR4K'J>(4RVY2.D!7+PU(N<Q)/J>;
MM^$ &WUW*2V0O"*4%K#LB?8#NA9+45J<N!I5/$98??OC5G!T,L(2CKV&6UG4
M_06XGI?*)__/H_SYH9L>3+_[X?F+@]'S+#L8?7_PP\OGHT/W[.#E#Y.#P_][
M>/CH88W$Z:>3=\G!W_?_]_\Z^.[IC]W_)C^_/SLY__#VOT]>)>>?CEZ_3HX_
MO'MW\O[3^0W6Q1TQ9>_+PNW__L?N2WG<8 6]>(@KZ'!X 7T\^_#QY.S3Z<GP
MBKDCZ^,7:+< =L#,6\*&18O 9?H-NT:].W+X[$7JGR&I_[5&'60?7C$;G^7)
M)G9&[P!*NS&!=N!$FY=P?/J7&Z,')/2+I)<(,EAE5>09D=W.73:!^R!0=K3.
M%T)5>.;-\X7WL_PM] (&'0*WJ,W-Y8$8J1?Q] 229Y1TPA)H+ II<-7^8407
M!(G'_4?DV%J48^8)]"?[>+Q>08V"\)P9#RKF$-QO*]0U\V]Q^/3P^R!]Q -?
ML( K#A _#YZR2TA:57MXS^&7L(/#RHQX747PX'7-0RA%NW^:Y^+)XG=8AV6A
M81O_EIE] VN#JYCPGGQDAK:2U[#2L?63XRY3T=HJL3#O?T,4QMX-J!.0I\Y%
MY'<*)7M@E0-&2D E;5Q6$7!GY!8(>,<78I2\/ 3Z7.0S$?'@K"PG 9:9$F!'
M6-&A!@!8'NQ#(A):'[8RO]XXJZI-6Z,N>@ ;FP8V;.+*59VW)DSMQM)8^^D3
MGG>K*K;$'<5\U)AH8MIN8%ZOO[WQ?OD0C?>S0>/]]N3-T5NPX,<G)Z].W[^Y
M\R;\=#"N#S$]QR8H?,"A* JI8P@C\?C"S>  4!UM,.)^HXW],H2$&DB 9OF2
M&A@,ZJY.#*DGF"RHK1/9"Q+DYRI!'Y("H$:P@/+KFLA$8#-O5$&;\'%XG8N\
M7-A>=[;+:1!!2DT<S.</92E4P]82;RY94-J;+M1."!% M-\G)<0. (>\=*B*
M1'N3@F<:)S,R*+]W+5T5DV7I:37 H>_I--A/?I+G(-9U/ )HVHN,.L4C$LB,
M5?R8AB=%'44D[/#W6Q<*K[+0!XJ]Y/ECI2(^:0V97>]S$O5'/4^FB_*RQW)M
M-4>WOGE\K/OHO\X=%A1<<G"0(HN["(BA=U)BF$F4Q:DPL$(5J%Q@;];$3"/F
M#D,U @_#O$"&5F+,_M:&_-G!0S3DSX>]\'>G[T^2\Z/7)Y_^)WEU>G[\]L/Y
MSV=WWR5_3PB!A7='_18=/O__E$" PV$@P UVPG/="?<"/8"BUITIN/T4PP"R
M^^CL4W)Z^L5FZ?O?;Y:^/VR;)?C-MS1++_:3(;OT[NCLGR>?DM<?SI*SDS>G
MYY_.CMY_^NLY)ID^O$]._M^?3S_]3TJ?/3MY>_0)TU ?CO_YTX>WKT[.DG='
MGSZ=G)TG1^]?):?GYS_[7WW\^>SXIZ/SD_/DPVN^0')^<OSSV>G6'$1GD+_1
MB+TCT/-I."WO7Z+M0YL?'36<:\8-@-_P/JLGV;^2-XMRY-V%<T0?)OSJE#9
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MVQXH^1P</COXO[/O]G]=S1[YUVV&_A0[Z\]>/EW]]F-\3_ A02@+1H3OBX]
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M0VA;[2>)Y$*S9)6O'#PQ2H=VN>!'#N[IB.Z?3%U;Q1&Y-TH&-ELA%J/[01K
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M.X/#VX\.W'J/ CL_8Q $U0WO(^S_PXEDLA^_M"Y+12'Z]<=4\7MP$5@-WJA
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M&GPH2>Q'9FV]CPNQC^L6^%<+-\.  NJ<2%'+C*@S@HD0Q[P_6<7AMG)](3W
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M@KH^JY5V]DA P/]:^@4\W/^G)ZJLL#798;Z'FH8@V=,R#Z!K+/;63W?A9B6
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M'1'SKXUYQNYHDHPPV(B:1I$1 =K;J)0$/A!6C%BE57FM< B%F<+/WL.H 9U
MS$,[%.D7A:X[;R7A[.  S-I^E-P;:#>A]V/!G@1&\I0:YO4I34+,J(EA98XK
M,ZOP"8MY.^;<*0^P]QA=<Q?L%(J5O"7<:0:/EJU8CMT\M;DBR/)E%R!XM::]
M=.?W/5B.X@F^B]P>277,_#1E&0 7UT+75?X]GBW##%70WU&9Y(X]-O>,DI33
M!"L'SDJ<!1J)E!C.ETI]B)DM5L[(%^M0$6'G"RWP_XCM#2E*#8+#T$2B]_0Z
MI;LHUR3.,3VX1V3.'EH9W;)IAWP'*;^9;,H@7ZQPZ!42KL5PI32IK3"GO=LR
MEG#7V6V6$YX+1L#SI,A\6NR*SGML5X)(.';>9^%VOBRGFNGL5]Z?-J/)PE6<
MFQR93285K<?%/2QM&#RS2;IRCDK&\8^JEXK>^TZ%[Y_GWOM-JB&]@K&FI999
MI<A0V1FU$&T6QB:R)L9Y6RXV7&NV%SISK-&$)9^Q0<O<OY8O@]B_,1UH?L;$
MM+Y3V6YA9Q<L,J]BP\2>"@><Y5>YSE3>/[^[7)7WV4CNK+6!J ;&G_HLZ9.Y
M3C,5*>MZ#Q]3+&3V*1-7S' 1TZIYA_[,<UAZK>AHP@_*/6WW @CW5T<@W2O>
M<M6-,_A%.V/<>(EDEIU,[W"W/+VCWC(FRW5DTQU9K=J&[5AD.:5@.YK\/-.Q
MFBO!#:9<4ROKG-E@$J2JHGR..U6RG.TQZUV-GLFJ/<CB,CR\4YI2/Y/@R(<>
MX93R3%/%HE>4.ADWF]GO'*&3#X(NJSULHRV1G%[^W;27)"V/RE[$?^;%STO7
MRUOUWYN#.'.+F>S)F=M=@;7,*U5U/%36*+'F[")SN[0<JLKK<ZINLSQOI@!_
MX<.N,.WIB\Z#-//=VFP@02N[1M!6L'>C@([(V<&(J'A]D ._"G,ZJ,BPN<#F
MG=3I+Z8:L3TL%!;WPO1%*+^=/*OID\AJVBQK.A@+EVX64\O:/LVD!N5=5\HZ
M[6R25C4O1C"R2E)%:9*J,.ZY,X6[)7B>".S"H[Q.[0H+B8*I<O"2[<2Q3^PN
MUX%F"7Z29M&:A9DS#-&7RUCA!JU(LN"ERWEF2FO:R53<$G?61.G]^VU+G=GA
M3[E#!-^5Q2M+R2AQU1/UKSR3ONBS/J=@)FWE:RX'"S[0A&?)YXMDX406>*PZ
M'.;Y_8J6945[XW(Z8*OD\"OWWN%E2.PB6#Z#QZT'UIR%B;DK4?)(Q2QC6"\I
M02 JY=U$:2GMAODD$@:</'<(CY][DJ+A==R_YB K9QU5G5Z/01S@[H(E\R'W
M/ VD*%R:]LU4: W$=DYM<W(AQ,7D15K]?ID.2TZ3/$%JO-CUDU8"]AFWCME0
ML/X\7#X8W@KHL^=%OX9R_)EEL_B3P42(79!M_I4\&?'\E4S8\@L333RJ31E(
M,F0S2Z+<)HRXRZQXY0N1(6=9\NMF1<?[N;4NF1N$):6(<0)%MBZ'8E9H+!+F
M6.Y:IOK(HMDMU[\ %Z\BGDK#VI?G <92F$1H(EP.<,RG =C-0R0Y;!A>#4V6
MAG(S^W5!+$?H(_B-!'>(.4:YPR&S?$76,6?ZL#^6.#37+5'U*O/=I+'P"??S
MV!_?W"T+=;(LLD+-RW]5\BPGG,>Q!+*2I=WC+HABCM^T*@C4F+VIX$D(BWQ&
M>:FI:<G568)V76GIOD( UF3I-YW*X^;I,&5<SL,&&7OG[*O\'2$0I!_,G2_:
M%# YF><D5WQZ(H\?5HP9"< %7?$O9[(J&A&^L(C3EG.;BT?HKU$L<K4JTH47
MZ#+/^PVK7)P) 972ZTNM0?G)2G.8SF>.6LI3O*-&PE&<NA5$5JN.#DIGVB3K
MY$60<%VO,(L9.T2(GS%)"!LMEE'S>JK*0_0=Q%@< &82\3Y=;+XPTX+R1@B2
ML,.SSL(B&\D7/U>;6E7:5L_@>@NUF]RI2H* .6 KR6084^%.6FX9D#'.%BD4
MSWWU%<^@*NM.TX&N":S&M96\$!?9JE;AO<5+L4D%FIS<*4(S'0Y(+@NB%>N4
M$E(K1)QF"?<5US-P">Q<B2D'/!Y>+-3'=XHX8C+5+HCUTKB5:)]R]:<2=^)N
MB5)^;%$W(U(AT\+57^%,Q3#YS  0A:Z('$Q\<JDIYPZ$BOC<I^W+=FL^(W]5
MG%N4.<ULD]] :9/%394:@+4DOMML@ AOPTC9H$3"QD,$=]Q4F^/&6;FTJ-*!
MFX4^1.%]?@LS2D2%:BIWD'<KJ"S58N-G<2)510FI/%J@L!_+BTI2IG,I\6;8
MH#XN\._MNI!91>5002X\'MXYH-K"IY9UH=D$V+,L*[)+Q[5,@%RJQ)"9A\PC
MEXW'&4Y88PG$KS+?8?B(R=H14\,P I1$WH39R7.[*&)<*?L2+4TEQ>AD0/N
M\,E,'_K<%<N[: TO^PNUTH(]ELRW-(N+B9 T)JP6:Y=*L#,'Q-U92ZV2'C$9
ML6G>/-/%NYU*:5M0,8&;G+>'TCE+GJ%YM?XEKZW(OBW2SHM6\_( ?;X\><'+
M>Q/Y5X!]\+/_$\<79;!@ET>1!Q0K%?L#,3&L3# *,K; V@?ZR21SG90*4$K
M*+[.%R$\[2TK4,D;P+#,G3!$WREAW6W'G.GZO,V.>%$[;P*1.Z33&=:5,ZZT
M)(FSG/)LJ##GI'?E6F,4@OV&Y:=,7XA08)+JI2Z8%%Z (*O*Y,ET,SRWJ"G@
M.T\FM-0XLU@RR[@N=X)<XE!L2'4))%PESX1AI;5KV55)"K\:NO(P#R#ZQ8@<
MCSX6J6;3[2,!:64>2.Y-U6UE=@=AOB$<&88*?4 O6>0FS#U6K(RQ<(*U&"16
M0O)\.*-P+'9H !@5<6^L;BCO\@D&]XJH&K6R4<U%H[JW>0#YXE-)S0#R;1Y
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MFW<\V R8*=&OI6__@)D-L1".=W*'>&V)T>_]Q=6"3C*D961B*"4TC^8@;+H
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M,PGXS@0XS$F(C(3@RX;9[3 #$V %?\5+K6R/\RG .T"S@6"T@O'B9^)Z"C:
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M*=[-&1DRYUP!+<O4)$I_BL7Q:!F_*^U]%(-^=ROVS7]?1*.!\<+. \J"FYP
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M<+>B_Q2=H@'@SGASIJ7;-BWU(::EYK9MW7Z0$7CW9Z9NK-VTU,VV83W,#M[
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M. #C +31B@,@MS=:PIV :WJ3,;,D^M$@*EE3Z-88LP<S, J7"O,UQ1ZPH%(
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M#B\Z-WLZP,*:E4EQF*LSHSA!&#6.DF<.O"RJ^6_&3#R4:<VV["!:$!K4,60
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MANOI9FBSGCHM57VT)=]0;WVIUW4#PPQ\#62M8I@J4#)1%4US'3OT'<4SFXA
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MFY&BGA^;?)>"K$*F0J;'''DKVO*!+>'%\!MV.@E&!8K8@S]K@D".$X+RY-.
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MUYXCPP-%SC"9G%-4&P;>@FD+M>PNE&S&?8CDP>@X#EJP[Z@JU>R,XDE)43Q
MBJ*BPWZ_EZE0%Y>_^I)1*A:$6A]"'<WY#D<,[O,!.\FB%!QY(\%WP,PC:ZU
M/"6;L(_::@_F1ANSY?-X)0OQ9.1Z[:[#-<4Y=;[$@+[&0;](\DTE>>8X'/&]
MG;<?HDU:*L.1Q$8A3IU!!NQ$1*6)(,D:!)K,)A,767ZZLKQVSZ'(\EW+\H7?
M\.EL[^OV!R>U3004LJ01M+(0$ED3&*+@1F# 9I^\:Z(L/Z=DP\MCVSN"RUT^
MUS4<QE%="=7M6-?IWN*,U_?;LC0/IFYQ8.FZD:&R967+UG#&ZQNH1TS#H6?;
M3VHL!]''SN=<8%E"%O<?L@!;:!#M,.[$^N=N;TJ8OV9T*=&+]=E)GY8RGX)I
MGU)0R'IM$&<)(\LX0SPX190&Z@9;58M+<^MD27%Y&EQ[M?;X19'M>Y?MA41H
M'HVGH^8HF:@0D%(BERS\J73$P@O,)0'9QFW&E@ND2TEE8\6Z$1ULBGC?MW@O
MID8]\8F)G'B("E0W5:"Z3;(HD6B,2T9C+$&\95NO:+CU-"(<C?<S<E5Q;]0?
MG#^S LI[[DOZ/6B:DJ$32W'W&C'I8J8U_.3[7X_8A\"Q==(95!W,XL01I),7
M2'&A)9B6T9*TL27;G/)F]-HJ95=-3X3>0)Q+ N46DCQK-LP/=K;)!V.CEUIZ
M)!,G8%[XA#1Q$FFL5:!&&"O]VC(H1:";*]!KSX86@;X?@9YU=!)[.W^>?0C$
M*6=91/!3(1YQ0$X;AX+E21$;A7'K2XDVM):R\0[#'X-X:CNA%>OZ@#H1VJ\J
M+/UX,  IF61(GUFZHF$.Q81,I<!R_<!U-N=3L(.=MU\_@.\0!)@<2!(?$->!
M(<N91CZ *@(SQ! %P,7;1"^WH2MAS"<ATO?@5!21ODN1WKLLTAB$6$8P0Y0W
MX%PX$I$E)J)H/4N&$Q*PV=@2;6E*9N*)BO0]N!5%I.]2I-]>%FF*17"""$2=
MP(C;I) F@B!#<7!1>")CS%I:JX9HZ6>5B)@=TEJ'&_$LPA[W6?5446<V07*[
MHDR!JS7"U?F24T&94PDKAQ(0#_%$*+)"1)2"P=%+Z[&WV0(Q*\:HE>#FDY'R
MNYL]=ETI+X)\0T%><"6"Y(Y9*E"H[ [N.7*28Q2C#<IQ9@1E(,BZ2<?#BQ@_
M0F^B*.F[E^T%GR(ZRPV3!F$!A.,^":23!E$G23(<&54AESBUQ:U\BI*KN.4A
MBE-[7DY0/'!&8DJ,/VI:%&!:(S!]7?(>F! J-WA -!B)N*$161H%PE;X2!RA
MP9.-+=4FM#1]>,)R?8^')HI<WXE<+S@34D@;N:8H")X[QF&)-,^^1= V.,>D
M)7ICB[45946NGZY<WX,WL237171O*+H+O@(#"XOQ%)!-@B'.,4?&:8($-THR
MERA)"52R;M(LB&>5@LC-V,?QFZ5-<QT?GEEBXI[KFVYRJ"L3[?<+PA2DNAE2
MX27G01,IA1$$*8I9KF=22"NID0B)28>5!"VSL;5J:DTY(=%8 6Z<U[ DML5Q
M6*=,+S@.5#N64O"(*PJ.@S4.Z<@T(CJFR*/3,629;ANS?.ZIY"&:+=KWG(>X
ME6XN0KY.(5]P,4P(7GGJD)$L(NXH 6>#>^2I%)($R60N1)9MO&)H;DE'W+68
M_IZEXM8NQ..-;SRL"W%RU/NR J,JHA2$NAN$(DNN1=!1J*# ^-"43MI>6I*0
M%5Q%!N^!65G%+W49HO=$17O]%4U%M!]$M!<\#&&,]T%[Q+S#B!.BD*,Q(*4%
M92I%GU+,M1#L5IT5BF@W-VZPMJQ$$>@'$>@%;T(KIZ5B&&&G".(2<V0C3H@I
M1YU5A)N4A\ZU]>U+%TO*XL>$<R>F.!C$T!K$S[$W_K$*I\<;^&A6A=-+N%]>
MR=^=T?'+\1"V)0ZF:'5>L&J-6$673TLD'VCB!ED5<ELGXY!A3J*D1!"&*Z$-
MWM@R;2I+>/.Q2?G#.A=%WALA[PO.AJ$XV20IHA([Q*.42 L?D0E::$TM]OE0
MA6YS19L1Z2RB_I@S&474[U'4%]R0P#@73#BD:)"(.VN1MIPC200@ #@.(OAJ
M7*Z6RVUD2U;C_@]N/]\,QT/X(U?$2J:>X5] D8)!-\,@MN1>>(\CEY&BY!A&
MG&&,P*D(@$:@<X+SA,8\LELLG_(J1==/1F375A9U+9$M72;7),H+GH/')F"E
M#:**Y2&XU""MP8<(RBAFO698BR8.WBOB_,BR%46<[T2<%[LZ4>6I91Y1KB+B
ME''D=!"@J!-),7!1'71LGCBO*4W1:-=@/XY:>:)L:SR,86&*)NS_YUN?HW#]
M08@#-.J?OLAT&/:[G=":/M<C1*]F'+( LKT$JOTQZ'_NA!A^/7\+Y-OM7726
MF-&N1#[6B&U\R>L@.-!HP=?P,H&I0DE"QDN!#!9,1FNB=GGV'6=ML%IN'_JX
MMC3=4PST6NNY38#T.</'W25*"GP\%'PL%F0I$E7T!"50!XAS,(T,D!<L)8^M
M\I@FHP$^"&EKLX;V-$V#CSM%B*<.#W>77"GP\%#PL. Y*9$8E9HB*1E#/ 6)
M+!4Y$**=\%KP2'/O*L;;5-VE=;%.=VJZBBG?LTKRUQTZ*==8SS6>E@^L5H)N
MQKI6ZO;/AJTTZ)^ %_PY#J_K M]N+YJG@5:'6]:JU,N6E2U;WK(U9>0;@C17
M3&8:#_RQS7U+^JEU8@>?XB@W[FD-HQ\/GF,V_D%',OUAST]B;S0\[&_[_QUW
M!G'[L^UT,T%>]P=OP')],R/+3G2C8NNNS];=_;(428O>8A^915)KCKAT"1GP
M9Q AV#!N:*(X;FP!4=L4-V3Z0\GW-3#D562\03*^$.YBRADC7$2)&)!Q$C6R
MT@M$O4@D<<:]S<>5*&LKOMSTM,CXDY#QM3=&+#+^H#*^V&]=^*BYB,AY&1%7
M/"(KHD-&,<XC3=+K7 LL>9N9VQ0#ET3_#8?"]F'#PB3$,00>KYLG@B!,9&.]
M/LGC/>#PH"[)A$JO@4@9N;9[8:\FT/E!NAK6"J2M$=*6YSRI;)$:8E$26"..
MDP>SA2?$1%"4<Y*$M/EX VYKO!R&+V<7GXR\K]\]*?+>!'E?<%,L=9)0Z<!Z
M409Q31FR)@^& B=%B."I2-F$H:2MI2SR_G3E??VN2I'W)LC[@LN",1,T!R.$
MQ!9Q*10RR7LD%?91&A&(S%4XVK39BB*^AY/W9Y<R.1WD\N31>;L5P=$_/:EF
MT((3,^RGT9D=/+?I4<W*GOPQ(<X?7=L; ;"]FI*HH-<:T6MYCA11CD89 Q(D
MMXU6E"##P'@)T7@BDS.\;AL-&JH9X9824GU\:9,BW/<DW(N3:774UIB @+K@
M@(!,(\!M$',#8JT-R1&):L0T7G9$BG _">&^^WQ)$>Y[$N[%[HW&*F]X0I8E
M@KB6$=DH&/RIHP(]+G"B&UN\375)E#S<B<@;E8/>[, "?6Y'FN[]1.3NE'CE
MS,*=@-KR9*JD'%!9!Y2X%(@S2I%6)O_#DC".6T_\QA:3;8G7T OJVL+TB&*J
MSQD@[OW,8P&(.P>(I2;T3$:!,;) 9\0MX<A)IA 7,7*"K8X\YKG72M^F!*S@
MPY/$AWL_]%CPX<[Q8;&99!1:)I(0&(D,<:<$>$7!()%"Q%H)[W.?:&7:;$4O
MM^8!1#GV^ BO\;0<W>L=>TR=GNWY<NRQG.$K6U:./=Y=[7%G.!P#T,2<T/?]
MDY-^7D_??VJW>G&47^RG!/<!'/+]X>BYG8AL2O7Q[H1*!^EE1:,WF43%\EVC
MY;O<PI@2;K# "6G#'>+>@PU,'$<Q.>> >I@EEKL!J;8FI8WQ$Y;L.ZTS+I)]
M#Y*]>/!14^5M'J?*)4<\D(@ KRTREGF< O7.@T]+%&YS<>N*XB+9S97L.ZTH
M+I)]#Y*]$*WBD8#QE?*@9&\0Q\8@BZU V!IGI4N<!)YUMF[+%1/=2W/C>SSS
MF*6AU3^M1#1^B0/?&4X.0;YZ\\<?K=-II7$Y[W@_$U&FY,G4J:#JH*+-\-6$
M-B&7(@%E9B7@!<K6"&7+O8R3MI83)A$U1B*>O$1&48\"==0;I@'*7"Y',F(Y
M<5\./3T9(5_O#)4BY \LY(O9=YX"F"0$"9TG1BL'GH@P',D@>>(\BN39QA9K
M \(7(7^Z0K[>R2I%R!]8R!<+BVT,4A&&C"0<<1T=LC0FE(0GUBMAG/'@E+09
M62ZQ:>QQQM 9GG;M>5YL_#8N/.9//H=\T*S$^G12;--RYW/IY]O664]VY*F5
M23UD9NB*XJC74YJ5XJB[0/:]LR4?+7@#[)TXHE9XQ"D'\XUQBWRBC M!--$*
MD)W2ME+K"C<UIH9RC5'F9PP.:T\N%7!X*'!8\.VD"BY9G1!A6H%OQR@R/.4_
M?73<!N]9CD4KWF:<%G HX' /^:D"#@\%#@L^(9$RB4@("B[WWL4Q("VB0$RS
ME)CER>)JU)1I&_5HP.$Y9+$J;^G8]HYB/HU:^4TY9U7]DMO@? :YZ/U@G5PY
M47*'1U(S[N7_7UT0Z:\X' TZ?A1#?F.[%RZ_,/?)/^#)^V%Y9+'OCC,U7GVI
M6>(O.XJO4HJ^G-5?)WPNCR? %M- @D7.XES!@Q72"DPM%JW#BO,D@2^VA&I+
MN8R>S3N54HZM/6J7JT#+8X:6!;?-1:^%M1YAFC3B+'#D>/(H2,F4Y%)(K@!:
M>%NN+?%>\*7Y^-*,8[$%:1XSTBSX@"E19Y5- "W "9S:@(Q4#J5 M=;1*&_!
M!S0,D.8V[<3N^6CMD\Z5O;S*WVO94<O%HTZOEW-FN3EJ)6SEN-15&(E#9%X%
MZYW2G+%DN#!!$ZQT4,E*_V'W'FRO G!K!+CE20V"IR039HB09!'WG"%-+$96
M2.8CX\;J/#!9DS9AR]U0RSF+)R/LUDEKC)&&,0'NEK7)4I]-(>R]<I%F8;].
M^+H(>X.$??%0E:&!1>:0E!(C'H5$)E*-M#&):A&$4CG=166;KRVB782]@<+N
M+-4V$A4$%SQ*8:,%(7-!1TM3=+6PZR+LCTK8%UP71AB7$EP7"V".N%$$66E
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MMX:=+_53]5&_EWGEZ#Q__&A@3X".P_Y)M=BSXXX_;IU%8/?<ERLO[G0 ;LD
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M"8"\AI.9B5JW2&JWNI.#T)4A.@G@#R?QI=/8&T[BC[,@5IC5J%4!Y(J9CZK
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MU8?;7SXDS;BRUB I=$3<!(,T\QHIXX#(.CI";M:WH2F*^_6BZEP=IUFM'BL
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M_M])YRF9NTA]=X$K&J/D8V:(;:[H!9 G"N0+;&S]9']><53Y&L[XY"C;I-\
M.QU58R.ZL3X;>KU3HT^TK'@M6_-D5#63+#J1E$W.<!^I5E09J\  QYIQ=WWC
MNY*\<DCB3G7SIR4?6GC/(O,8.9S A[8Q(4.=SW_&Q%)TV ",$,[:C.LU!?K6
M(4 -/UU1X+/ Y[7@T_"@?4Q1*16XCLPJZ0)UFJ<H@G>FP&>SX',Q^<DM)U1R
M9(QQB$O*,WP"FAIM+4F<\-S=S.@V6UN:I*!G0<^"GI/*,(9YP$DS(2.WSED
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M4<1M5G"<(@9Z$+ 4E82G1',=@;JZAI[J'YF'4B%2$J1:1#*F&KY)I%*A#,*
M"*PBU7O,GI*'NFJIHE@$FIGN>(H@&H%NRB3&* $34()B&D:<OW@=W&3R_0P>
MLS_A5G_Z;,Q\!M]\T+,ON9[91,L=G^$*E#QXK^4QT.AQXR,O_1<_D5_M;JB!
M94231$:$18P&.!,Q5X#J8/ F#$?)/<>(>R/W/M#DXY)62V-,=:H8RB(6 YI0
MC5@:4"1)!D8(YYI*?5LCM_<B]8[KI\,CQ;60H$A&/,.4L4A($J@T(ID.N8(?
M]UK,4^+.DA:3T"S(9(:D+2!6@4(<,[ $TB0*$\H$2XTED/9^M=<[:,B%B?J=
M'7,0@H.7]@>]5^T*'+#U+32-@B1(*:$I9U)1+D O@3]4!KU7[>EPH#'?[^3O
MK[LG?W].4T&C-%(HC"+3R25+$0LX0:!\"#!P8J("##BPW+6I]P@\@NK1;]>*
M9EN=\J:[MM]ZT#+V:XL:5Q=FW5AHU2G,(C)6 >!J0#--,Q6:'LXIDXD@6<HY
M 6[]G\'6V-2=#?)B,-)%49>8@177J"6K2\DV5^UJMX:T_>O&=ON7I,%F8EN;
M+74^]S4_3I@T+O0'A.M+N"BFH\7\ZDN6R/:I2O8':, Z>]3X^WA6U]D<:21F
MFI\BGL%Z?^&C<WY1O/A7FV*!.#O;>.T.+%?HOOY_Q>Q?W5.S?Z^D.IR%A,0!
MIT*"9.:!<302#8);QJ'46=BE.I%1' =!I!*<41%KGB4,UH99PE(29>(JZKZ9
M6I]-/?+]EGJN:*=@NCD9[C3E^ZTR3W>FCUYNF>#D6\HMDV"3T?LO821D,XR_
MK=KP^D=&T?W7AA*\&8>/4\3(GFD-8U^XV!<N/F;AXL_@JO"YR&M2<#?.E1KI
MM; @^NJ/1_+^A"(2.@EB'HF 4AP(2K#"C*1!* EUU1]]/DBG;W=X<')X//RT
M.SX\>7MYN/\1KAD='YR<PL^W GAN.#Q1^3 8DL,/W;[=*M\=P[J"P_%P?W>T
MNV^>_2[?VX?/;Q_".\J+W6#G\N#RG]&JVBH221;J,$8TR0)$ QHB%BB,X'Q$
MQ,-,1Q%H]NE-M54_0RS;)U/VT>BKRA9X2#')=)#&5-* !R36<9:E(LR24$:]
MU_?I^'ZX%'4VA>6,91H%W)1^<3-)BD<  R353"5)PF5J^G?W >=[=V/^X!JH
MC8WUH;$K$OV(E!'F- UB0B/&&$F4TDH0FHHDCG4/DD\'DLL)Y['(=(HSB;0B
M E$M,.)!$*$@I3QAB>0R,T/VED<<]*&Q!^2A6/$XXD)G/.$TX2"V0DX#H2,1
MQ3B(TOLU,'[LM+='Y*V.X<$YYB30IMA<*5 [8H$$5QG"&:&QQFD"IN.#U78]
M0^MC*/\_713 ''^->#'F@__%QV>_FIR4T?0HEZYS:?69#V?:])"=7PS>F%:S
MV[EIGRML+]G!GW^^Z4V8*TP8S,(TI&D:AY3B*$NQ2J3(!(E5)F2F>NG\= C2
M2)R]?'N^>_+V<QCHB$DI$%$,3)B814C(1",)8L!.P0!TN44"6V_"W"L/$=.@
M+ X2,QT*SB3E. J8D!*$-K!51GKIO):\=='FK3A1E$H<(!QD!*2S!#F=9@K!
MP>F(BAB.E/25US6/;'W8'OQ?#1+W6!J!:X3QWL0\_.AB\&%Q=C:ZZ"WBU7B1
M1"20)*&*A8H*BH6*8IDH'42"2AGW;L,GQ(6#)9F;$BJ)#AC2A#-$51J!11RF
M* B34*28QXS>I\SM+>);\1!- YF2&$<FE3]C@: A"UF4!$Q+%O86\9KR5D?F
MXDQ@DH8,L8P!;W$1HY2G',58!C03 >/Z;C+WVX;3/EUV[/\,?O.SQ);25KD=
M=;*<&K=BT$D[2?5AQW&8$763^71V\9>=I?/SSMS8N=C='T:P%KJ[OW4^O-S"
MGY7@H09C&I%(4R#G $0%R6+$, \EBP/8>7FGT6./1J3VCK>?1%81P4UCQ_S"
MUR6C]=.QGK1&30D]RO47.V[I:#$R\W,NW.S0+V8<46&FYPB7I0KJK9E'92;F
M9(OY C1>#:PU'0.+"3W163YWPW+,W=VL'9/O6HW?D69*D67D^10N@.?!5E]J
MU9Y\!81AS^!2FPF$DT4&2+>8F>Q;.2W@R2_/CS5\?@9H .)[8H=UN2=H-;!I
M[J ''!W#O_E,(9.5>S$H)_UT;CB='?%)?NF&,+TR:).7A[HY&/PUR\WMICY1
MUUQ@QEME^:R8UQM4O;"=$/1N.E5VG[9GBZ/!EAKG$^.$\VW1WVUOO3)37:H,
M2".6VV]O]G=2F+%>HY%_X7PB%S,S ;:<^ 5+,I?4[Z+-/E<3CWA1SS(R2U%P
MN*/IF1U;Y&\/NR_YHM ENN83V%#S>S,YKC"C9Z<RM\^R,Y8L #?NLOI4W8LL
M)GZ&&&P[%].%RVQ>15KPCS1H;]9H/C,"'<Y-MBKL!\N:A7)KX%>K;F.&E)G-
MKM91P-E]6(A"_V=A%@N[!?O>H.AK]U]H((F:!LM#KS;W%E15T9 [O[O,)EY/
MQ*B0SJ"!A(V:&@(UQ\'/S4PVN"LHE!N#\^GL%):+_,%NV)/-# <<:S/';*K,
MAXYS0Y= L_8']>@]_H7G(XLSYN -?&P.FI/^[-QC-^:OW&$[4\T1V&AZ#N=I
MYAO"GAL8T,7<CCY6=@*8@QI[=WN?]JV5AG< 5K79^]K?(NL^JEQ[/6!Y7";R
M5WQ9[8:GZAN)Q9+(AAENQQVRP 9N^*\,\PA>Y$5[M6=Z9G1Q\P@[)+HH2J9T
MG";-E#(N\E$^]Q,?2T!5#=I4[OF:PQNYH:_F6U<?Y$X.T/Q\EINQ:VIZ/ADX
M='('.S75.K!I9J,7$W-6OC"B/A<'4GGS(+J'T!YP9;YS&VP1"=XUG]D7RTO,
MS0TCY%ENIC)^6, '[?+LZF!-Q?%T,;)( F\M 3(W+%F9_9@ICV3^@>4!M^?"
M^5\6<UALN:-36)L3#]\Q6V]M5)8'5HO_FIGMFE_\!=K\?&NBS,QO*S!^=C79
MCJ:[_"Q4J"58ZR@@J494AA)Q&E$DDUC2!!.2A.E2T1_!09A1)56@* ]#'G+&
MN-"),KWOV-(4W_(,-@;5[EMF_C#-YN? #U>-CGL^,W.O*#>[:9\:.Z-;.U/X
MG;%H89E?&:%B,&)S\/',3EJ=YS,/"4XR;;1@Q( PB %3@%5*QE*G:0QI78P7
M[FME:L.,>F4G&,^,& 'P=5JHAZSQM!H\:>Y2E8S9<;R PZ#?+486L(_,M%:X
MB9D+:\6SG0CJ-&%Y#&?HY%(#QP;OM8%6=S,[/E=/K/7MM$VS@%H)K;7/%96B
M@P?"D_'1Y.O58/*VE"<?"YTM1G_FF=XW,L7]]7-C3/ 9AYS"7B<H#3*!J) "
MF;YR9GR&HC&+J8ZS+L9HTV)<<Z;#-* )2SBA5"2IYED<1FG(NABSW21@2Y)=
M"C9*XL)0X:*P99-6K,ZXX6)D.'HP!A,.1+[15.QOZQ++6EU8V/,=C'*P3:\<
M>7DS;EV%&#>^]6,77A*,-[%S ]^U\I*R3?P E9<TW4PB>A_%C/<5[0/+Z(E<
M\V\<2<]JZ?% H;VU"W)>B_(BDJGB:4980B,5IRSE,4EB3"D-A8Z_1VNL\;T5
M?(#7D+^ ]7*A^>R9HKSO_6*NN3RX/#X].!E^/=C_&YZ]0_:V=T\![<.#X(_\
M</\M/&/W^/!-M_>+D0R[)WN_PSM<OCO>W?[[XN#D(QT&[_.#?75R,(9U[K_%
MP^#=Z;\OMY827$D0I3B+8Q2&Q$Y\88@GF*)(1AD)J)FZ%+QX'78Q=V"VO/B6
MDMVUY^Y:/;Z1IW\4UM6Q9!'H! (D(&5AD((5PCDF(4[BD,O5;21[UGU4UGV[
MW Q=I03,G!0IIE/0[\(8B4!2I#(F*,F8 O:]%]9]_A+[W6(VR8UWO!?4+W)!
MC$2FBF1<@J .4R$5SY((BXCH).T%]1IP^_* 4<R5 /--HE1')A^/PE="Q2A+
M(X%I)$,5F[P;_!-)ZK*MM D!38RO)<NEOI-2_J.P="@RQD+)99S%E(N4:]//
M+^38S#/)LK1GZ:=GZ>4*7!S%B:EC0H2'$E%@8B1X%* H#4,XP$1)IE^\CGH!
M;KK(\T(?3T?*1(-FTR_6!5O\+-+\P_%T-G<QS9'9B(&)4=J 6^D7R_0UR5]7
M-$M\X,2H*FJW-]NV[G ^VLO^G$Z._LR_:+5E'>5]-&BX+>EGG."4ADD 2KR&
MOW2,$6>4HPB.02G*&<[2.R5*K4V8L:8"0[SF])$]_H$[_Y)HGR)X]+_^'Q+C
M7Y]?T*L9_W<Q?Y^KL!SN-UD+([/G([OG/CB53VP4::9LJ*?*ZC&PFA<F+F0N
MW?KP9A#&>&/PP$=T)3VM?ODZ<F?U%*OWU='-IR2GEW['7FV6>P<' BN;E7T@
MEP_"YKU]R?6Y"? !FC<2'<Z/]42;B(@V:12%#^%-CEQN@LQG<C$NYN8 BRH5
MUCW&1B/Y;'9A(B@N+<5%(=U3!V-^,9A,Y^[AGF!,?LW[)>IQN33M19NXXAA$
MT,(DH0D@0!O?X;/<U)SZ:U8\W48N[?7S:9DO""(Y+US#3)>8(WEQ/,A&T_/"
MIQ:Z>"4L] @V8V8#0?#(^EXF8&J_, +^;'.PD]7/=EDE)DE%*\<>Q6)LEM)Z
M;/W(=NK7W"1&=E*!,C@;?UO_1G K/1NY5VVN8PONT#C+,L-13H\F+O.FO8?V
MA=Q6P7=UWLNU^V@?U7J_.EJVO-+V\ASUN66U(M4VX&SR?US<NY5,M7)%L\:S
M-ES"M@L=P\T+/1J9+$@7U;,ZZT!/3/I-F7/G$#@D&R;YCKA,H^4TO.H85$7@
ML,YS\]>5-1*+0G4GY6 >2^/I5HQ3S3 G8<H"&2MBL@*(^+RSJK9H9_?=:KVF
M5&#VI[_I;;^%>]EO%T,;S-PS:]P'?OW 1_J-W[1_S";M9?:Z&TLH\$^G"H&)
M=;E%/H<XX1%1&B4IU8ABGB!!E4*:,*Z#)-6"DVN*8U8<O-*A3!27 NX8AAFC
M$5,IP4FJD@QHPA[\4D%,?_"/??"*1$H%@4!A9C*B!%<HQ8JAA*041TIG.F-W
M.G@N8LX8BUD81C2EG&<\,%ZR"$N9@)YM#GYY!$U_\(]]\!E+2*PB4HYX5C'B
M,I8H3$(51BEPKYD^,9DNU3O=_ ,OA2N-Z_L2-Q_67GYO-+V%?N_4!+/\WC@>
M[F^=?X[C6*M0$B28Z4\)_T/ RC'*=!IE .J2DZ7Y"$R'41@ W"=@1T<J$\#S
MC N:B@ $?RB6C.GUL)8]#92ZHB&"-;*0NUE7_5"(JX9"$-P!FN<T%>+&*0\=
M7@MT@$&SED)10JDI8<UPR+.,*YFD,<-7SSRYB4<[Z<^QS"*"PP #JM*0IRR,
M(IR!*)<1RZ(;ITA<4U!#\6:T%OZ<RD@TE20."ZR1:5T*^],SD#LQCM?-*5/"
MEDU2?N.+6PKG67JS*.  ].PI<:P86.<,[-PKZUBQ?C'I%S:8"E.B5KBJG.G(
M%X.,\Z(L5+*9WF80K32%/\9[-BD-8#_@(QO90DB7"#XI<N4SK!O&O"E7F5]4
M-9-5*:&M? $SWCIW?)V;F22R].1-./_:%J[(HR$J[-6@>IH[V?"(+ZB:E ]O
M.#2,J=^H@BGD]$R7;C]+88TU5T5&[>S<S"R^F.NSXI?!R_Q569)S46Z#I8*7
MQ2M'![S:\%_AT]V/^T=8A^14 (B[!/5!5:3C[F8OA6OK;3"_A5]-"F\/G(%H
MTN9C7UZ9LLFI]XNM^%!9.GGK1QOOQ$NX;<6CU1E8FGIIO5&OFAM7P*V*S%:F
M7?&8=C57@_MY#0 -]Y!WPZQX%W/0>5&]<E48.M.%(3AS5*M7L+SX*SX'=R_?
M1VT.GIO;W*U"F0(P^SJ_.-\=?,JD\XY&+I/ ;)/-)+!%Q?QHICMQQF?RMFVA
M8K4A0]! $P#H>F(3\>NWJ^LNKT4$)XA\W:/S([N[ 969)WM0<]7&&V61\$:K
M-MELKIR. 05,<T+#0P:*E\J'?<E@/E,#/TK),8KA^K(-1*$[6'=Q9L*UHXNR
M*!,NO2C]KYW:X>G$EBO:>4R>IRI<^V4 2BX"3(?W-9YQ>/$S$&QPG_)M,ZV+
M7^%-\[%8S(JJ/M#7.CL'Z*\-^7)F^4=_-2]=7=ZHH=YHU3*W=F@ I*'A/I/J
M;8I?G59N/C>;7O"1'30%]S<>]*K0WB]5E5O;*1LU9\='Q=21AJ.,9E&W*P=J
MUJ9Z*=2D&@OK5I)6_#.=W:G$>4UXQ;BH;>UK@YY*R6YJJZPL\&C<B1-49:@6
M>J^2)66UL-GVDCAY14ZP]Z;P:F1TB(6KA;<A+GL*IY/I.3J>GF]<7<=O!,&7
M?&ZKDJUD<,I _6-SQ;\,N:\Z4:",'5,U9GA[/KU)LCKU1RGW"/B\V822/SR%
M=IH8^*A$T9%C7_@LMR4U;87)1QVFB[D-\&0M&3S0N07FQ3SW]?A6V):Q(A_Q
M,'Q=&&X]U0 &_HFNR,B@TIF>*-OP8>*C.M(7T[6#:J6)6J)'N88V(YG%FV(F
MT!=>SK3I.U%J -5K7_VNQ<+JAD9RSUO--1P>#PJP98&VI(ES&O*;%=QKI_I+
M/ET4HXMF4*E21G(@1!/@LX7/FX-/S5"6[4EP]8)<V;30]7N9CAQ -]QS1?GY
M8E!VWG#1&",\S$X" -BS@\\TJ<!V+$I^K75L^X;2/LWQF*6K*]_8OYLEU3$_
M]2=?Z$;->X<QZX7:():AA?RX;,@QYD9C-ESHNE=,YX:+X5$KG[EOGU0?J(N2
M(1]Z5ZO+YIT"9\._SU!;>O%Z;R)U)ZJXK'4"S<*O@9!L5X>-J@F"K:#M:J)7
MZ=F6%([Y%].(Q)AFC<+^_96Z+CS5Q8.-K&\]QIY$H4%E,%K_%7JL;:]0<;=A
M=\5'1L":>*4]0/N4%<T6QB#12^0UE+<8GS5>P9_VX&2ACDJUHXVF5SXK;P"P
MK^\M.YX439';,0&ON^?&2O9K+KHIC(SY5N: B$8&@#.-S4V!4$^UI>^ZVTTY
M1W:Y^8LU\&J. ?6&SU2)U_!3>Q]?%EW!=Q4XKK9X25F\XG'6,LO;SX35^SR#
M1EJ!=5#4[-[N^6#U&6\O543;?=CFX,,5.UZ89#Q+AI[P?#>=W#[*TVE9%&OP
M>7&F7#VX\?W5,@[.1)\MVX9J"D\PE]4*1):;8FW7.61\!@MR1&=4LNNXUB)O
M]V&@W=OH/4BBIL0VG_5J[57\6\D;H6L#L;0DS"Z9R/]MM4(2K \$;E4M7:R?
MQNC251.H9=]+J[\(@+\)6/I.35Z.E/?KY+8T1'C#Z&]88B1P&O\85GQ<-"?0
M'AN8<NWR (!!7[(-M6S1]0A8W:*HN:FMVC<*FA%1+D^GN[S2W6'@QQ*<(ZN)
MG5CG,F^:3RKJUS%'__BOU%W_AK5_C!76?M<UE;UW=+#^Z4R%8O,ZQV\0F3^/
MV2WN"+#%B/N6*6/-I17FS(;!EJ?T C>\GPWE]4EW=,++CFU.5JRR F%/&REA
MI5/!HJ[5FKSOQ71&6DPLSMO&9JMN];+QB9V_7I5FZ3'P4U/S;N@4]06Y.4'C
MCKX8"Q.7ONH1U>_A ?[^E>BRZ[W-DS8'@U9,H;5N\ZI-A'$6X]DTGU@K H27
M]\@V'/JV:UT.@@WN4U$KW,=*1X\DI:'GMWBSO83&>W464#6N .PT(M0; &VO
M4Z6"K=RVAZ'!X%8T"'O]E%RYX_-,:P2Y]:Z9<V@F!Y;YC.Z4JXXYSIGK0SHV
MI'*ER[^R/2IQ6'N$VO;EBD"=?>!5OD/C]%NVB<JW/B^1]7:D:17>);]]]5L3
M![!NA*E12>V'EUIR^@=9B]I9LD;\EKC(R^VZ>K?LYM^PUU>9Y*6GP#I >)F\
MWG$<NSUO^ZRZ%H%;B>1GSF;)==4CV+^?KLP,WU*PE=S<Z&UI-!A0&(I*$?(F
MIC=\SD9<^LWRSJ^KWJTI6JI% -BUCZ#>8)OW[66F38X]6\Q,;IE5E^J6F:""
MGC7Z^HV]6>;OLM%Z;"OSMWR.Y17C^[+>ZHG/7ZX5]E5W\HX==ZA Y&HZ*XT"
MZ[JQ%0/>T[-B39Y*[=7.PU7:YJ/:<^JZ/);TLW07ET#L-[(1J0 J$);KK=5V
M'=DY9R%<VS3,'<G;S[5E<'7?*ZB^9=0W-_VF"YOA,R\RC* R_#NW/JBF^(*=
MVS!^NNIS[I6LZ0U6B%&)RZY)F4\E]WMV-#/O98C*TU'A?%D.K<R'*GODIK[9
M?6;/JLP>\HPS>V[,U.EDW*0D)7%,XBP+8\J"B&&5$AYC3E0JDD!>V8#OIDR=
MSG.20"4X) IG841C13E5F,HHCL,HEB2-GJS8[?8A5H.Y593#%W?X3!+'DE=X
MB3VC3[11'?D,=&RN3A;%?/E&#5BQL3_?37"%+\(YCE8L8J.4AC,M+OP2"@<R
M3E,O;U8' FH]U[50+1;BQ/O':C^1N&C&")R'_<+7*]7J,<B,6=UF^NIP%GR_
M(DKMV[SR\K9. EF+@E>M=FV^KZSD6QUM:N92-%6XF;+!/>\I]#MR:Y_!(WNK
M[IR556I4V^WM-;' 84NO^E#% I_2%-BOU97"9QNL=&+7(>BF#_M*@KHR\NDM
M!L]9=2U6E2A@E+9C/LIJY<!4C<UL$V=;;>8<]-7]#(.L@4&R.D6H:WRT%EY;
M,;5J(K@M"W/I;BW-8QG=*@.F^2:=[:S< !($HW'JE16)+C\,OAO9)OXV+E,:
M+LT;&#^%36:#)TC79=HZ/ZS/W>=Z5$&)QCJ,1]-TJ+9O[ISX-YZ=6>=ZG]^-
M&F=E6#E!<=4:+:K?.;%KO:&O3#H=[)WY1K=/[.(PU-U(+C'JC\LY;2<)=4R7
M6JMH6AK^H_;@*L'GO8#E+(>YZ7QN*.:\[1JP 487IRP-6;AX*=?4LE$&,%O9
M)V7-;,DZ2RM? 7XSTQNVL$*GLU#WFNV?==UZQJ]\4RQW9;9(8Z/;(;22@Z[B
ML$;/_FH_2PRL..FZH'$U%:#EEVK=HX$(Y996.-<,OM:EW"V/;Y5$5A-"'8EI
M(41WRZNPX^K@#-P@'VV4&PJ"=)2#?K?1>(Z-]OO'JXH,VJ>OQRWH7'GL%[ZM
MM)7:=@U7(M.-I_M#@-6P2O'[RZ?X/2U<;<U]-*(,#</.KTZ/JZ9?--6MY8S%
MVX!:=57AW3O.G^8<4RXK"I8AM+4)Y+$94N1R>5;FESGR\\NK9.\RQ]<MJ:],
M&;.4?KO\+&>&^0RB<VN?5'E8&UV'8[U-?OY%<?-Z-P?#I<VM76+F6:W!%JWH
M1Z74MEV3&Y43=L4\G6*CNO'M#L2BR, 5,%0W*4/C-HC>1N2:%E:YA N9.["4
M&P,)=&K2>YNYLAL-7_!&(V_;#2ZR^V)3=H33:N'#V@E NUH'N2:[6,+]9HT#
MR1M)9GG1R#&SBY]I-_K&)\Z9C:@\B_GDRW3TQ9U@,^6N[07]'CH"M/<0;1O>
M^92G>L+1\OB6MI+9=E1TTGW\SE1SG4:C)E\V3/\J/7!^G0>CF8A2DJ%M,0+W
M74';IFN&.WY[O:/N5EJ%3=WRPQ.,' 9A)X_1XLPE:Y72U^T8SS*SV#)MUV$%
MGYGCJ&H[O!/&O&KUR!]$J+PO4\.?5I:\6UF15)KL-N\*.?VHSF6OIT)Y/Y%)
M#[6)FJ4NA%PLPBMD0(O'N<L6,VIK'2QO!-.\:N+D@J-\K<!^FQB>R^=ZW ZS
MUXMQUM.-L;^R60KW7=I,0EUE$Y<6F,_.=^( 5FJSY%9:SNV @UM7,?7A@E&%
MZ6Z9SC"VR9.U!EC]J!%TF#FXLWF3#8MOWQG%[7<TUW>U1?/J_HDU3)7#1UQ8
M:U*WG:I=>(WS7U?NNGW#+;"7+B[][+&Z\,%E@#7IO(HQE=COH*WY&2\M!B<V
M]N/'LEAQ6F7NMWQ3OA0&[CBU[ %;=>P^7 JR_(R[&_M\A&8%0'V)_NHZ_I@>
M/4W1X^;]6=_R.3>>T:6 8:,P!5['9CO <;LWJQY6>FJ;K]I(V+VFS"C%Z;J5
MMK9KP[8:[_24L.KJ66&[7IG\?A#1Y?:9O#B;X23;-6W-LS G[".W<#"+W+6!
M,P;>Q*I(]= S;[YS%^\N$_"D_][Z6<&&'4V-.[ U^FZ)UFWR5^4 Y$I9KV$K
M?])$#9QGT9D1?&ZJUFK]]"5YY9(&FXI5-RIJVL$X3<::UFZPY^!ET$+C^J'2
M#(V#*YTO19<*'K!<&7&M[]-(R&XQ<5%6I;3\I0 3TR.;O.5K">L;C<PS?=!Y
M9C]<_^[,MOP8:)/J8A;8=J%VW!GE)"BSLKKXS&<"%[73N@52I?.\MAM\^;*A
M$RMEG7!%E>.A)65?ZLVCS8W5Z/ZJW@)?-'C-@MVV-)9;;Y\9#EA,)RZ!QJW;
M9%#;W ]X:&'2MT?62AGE;I[6%=NWZ0AF\+Y9JE?4CESOS_=3&:L-65([6KS4
MVHZJ>6+K5J9*"E;)55MM:5U:$[:<HJO*N;I)Q69K3#ZZ5PQN'.U:&E)-)W<E
M4IYC3K;5)RN'OH6?15%X)T6'65MY6?+&&E\X$*T'NU.X+<$;@S=MMH$+;(NG
MP59=C?',A[E>5Q+]EZ][:&97]_DBWY(O$CSC?)$;\S\Z>1R9C@5+14:%PI2Q
MD <B%E@%,<ET1./PJGR1;\K_6"M>6E%P;[U UA$_RL=V#.-D80=-VT:;#0W"
MRA!3=91;T\K$&V>Y6%AWF->2/T[L#3[,R]KXZD.Z&D==%BJV=;VV+]79OV7U
MCW]T*9YJ*^&*%@!M:6XL1#-T=UYF6M=WM$XI;P?6=Z\+_8S+:W(TNM+F12[-
MSK2=G545[(.%F[]994(V!*NKGD-E)*6X)L+I%$%_<S\=N)X[WA#5UE]9N<G,
M$C8'=@.N.*K:"6?K<DU@:&7Z0EE2!J]XK.$VQ])*9:>0SPH[;+X%OF5@S"H!
MOLK%ZC[2A<"U$>\^9K>ZL'?#>UR,9"RC3D53")I H2U[!ML-=).S,M?V&/X:
M5:.I75IA63-W['HN>X=&71S5#@Y6!80==[0+.98$5[V>;Y]@K4KC+6GWC^VT
MCQW4G6,MN98K=XLMAY6Z3K'YN Q%W:DBZ,FPYAMR?2HB^*<D@C=-(GCB//]6
M,45GV':#OKTCK6YFT0ZLE@&G6Y37;UK.JVVA*VK>E]N&5!RR4:USIL%<F[@?
M6#;U\W3-<(FB,H1KMCHR;N[)V#GDA5GG9GTJ[>?GS6+-=B%<I[&!S_A=T;W=
MX[.;U%YND34ORK!*HPBPQ.J%MZF,N;^P81]?P5QJPP;FP-JW+2@F/@^^;$=N
M\1)NIVQ#+ 7L;L;(\SG?*/VP6O+"5O664" 6%R6LE,DZ9];&G_@RZQM[0Y1-
MCFZ.ZYF\L'87 [<WR]=V" WLS]%%B6+ ['6H\_8=&O)N\J%#Q"IJT<G8O+1Q
MLS+9K:K,;;=Q<.T16FF*FX.W32:8V\3_E?MF =#<RGO!F]NB7$K<%0C;;M!]
MH\&S]C!9Y05MM]C5IS\.WFG#J$^> ]GLTE.66-1JE.7X&F[J: G !>Q";M0/
M/[J\T\*L*%7$!EA=XV!HI,VVXV6MK++5NHJCZ^6"F:*I?3:S-TM-LNHSU-*0
M?<9R,T !&%*XJBH3CZQWYWA:[5GE]B@]+3X 8Y7%.F%YPP-7Q7I<&>^B89'*
M]J\T/=LFI>H%:-H^^%2&,G14KD^ AJF_5$FFM>?*':!MF^\QU<+[LG+=2"&R
M+U"]3E60[M,9JR#]<JIB5_DT.^ 3-YU2[2MV6S; ADL1K[R@12/;H&[4<0NR
M:?KY*Z>R:2O1F$#_[#&EU-;?.QWAB?'C38?.*N%\9GMB=QJ#F)%Y98^<*\R:
MM@I4YL6=@=&TX"[39MD(]#GF=;S47%IUT[1.VJJEVTU]HIK]X1S_NL0.)^&K
M6P,Z+-%QE>%ODH8K'6N4EQD/UOJX9\!KOI+7N$;-E^MHE#X#J3HEH2?RV,""
MFRD"HANT /C7V6GYQ/60MZCDZAE'C0P>,[W'OYKU/+@L+J.P.>VN+*WS+]?"
M-%-5,=&C#6.9RW:=1+M\V^RRT0?+%["%DSDLNXU@_[NCHW??VY^?R[NH1977
M<.I8@--3EQ^VX=52T[JM:B!3#\AQZ:55Y:8-M[L]]!KQ\]=E_BI-D3<=4Z32
M;9X:BAKKLOG$6G=MI2M\((W,8:N'5[S;].IT4@^:9HT)4^?S*A!O73%-B?<?
M^)#+P5WY=#XO._JXX3< .&5U=E']RAF :EG[4&!"2</T@)'PH:+=M:@KF:V*
M9!D8["6C4M0W<T]HL6)9W:!R@]O:%EGH^;D1Q^<^8=AJ1DN]F4K_EMDQFX[5
M;D#EP>+Z?7'\[=U-+NC8..%V+[#*A<C'#13E\Q:4KH30C<;!YI,N/G?0=[-!
M_*WN8W6^04.+\H]W=;<&ZZTV=)MW-^*E.IBJBJ[N@U(]+2\*DVPF8=&Y=Y@Y
M=/9K\QH1F'+ 8W!NIW68UM^^4M4 <:M@^XH6ICY(R4>M32A*1=.VPO&K:&7?
MUOVG[5KM$DW4O.IB9J3$=2+";./J8D8]:1QR]X'6GC4MHLP,SUOPX$2UR,M5
MG5>\8461''$X2J 86& G]:N;QG1A)Y?!^QJ)[_;E!U ]?Z_=3.]+-]/:6*]Y
M*V.T6>SP+QN<%38KM 'HS@EB#87!4)N1=KER%69\#$SG?E3U$&XXL3HM:=M.
MK5:KP6F5)_%.*]O>P9K_]I$FU;CJ-%PT_.I=!_4RKMTOI#4VL0*#6FFMTU"\
M9['D>(LD)J6L;2-:G#:,4G:_LWYZX+[9O!V4<2W<0)*<F7TW\KKB*#XI;]QB
MJ-(,M _::.M[Y2.]'"J=C_ZY&YW4_4:S/G>=758)&6.N="OVX!==U(;H4D&+
M X6RJGELBZUN +5N5G47W]81,&[G[;JUOZ?*T'&GZK+\*R?2-;W@R@!2ZYBN
M]9IO-)WDC=Q]3]26B;TOR"F.2RNOFQZZE<\6OH^+[112W[*DO9*'?+_LFU[J
MIG2'AYT&]69:S/<R,TSLIY^1O'.QNS^,8"UT=W_K?'BY%7V6&:6*!Q))*22B
M(7S%1210JKFB(6,$!TDW.2&*9(0E41'7F(8T2,-4 I4KA:F.% [N-%^Y$QA<
MAP%2)++N'Z?ZE4XI2T#/(=YY@U/+O57;#^1DKK/PRK[W=3*$E^)5+-AZF<L8
M\*J^4NWP\4;3^U*7 X!M58)BJ]]^^5P?@JM]+DZ'@.5LU39H-T!=A<[?;6^M
MZ,K3FKG5YUBMR+$*GW&.U8TY4QT8"VD,8"642&5*,ZJ%!% +<)K$F<9!O#;
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M;K*3-P#J +5R1@&'?3ER4^,,BU65JCX\7:ZCF<_A \.M WW*4$[9BZA9]]H
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MTSD?W=4WT^XR$,*[JNG"-/VP21\_9_+8?6[-#X/G&/-8ICB+%>-4,\Q)F+)
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MM>^6W1/JLR#4OEMVWRV[[Y;==\ON>X?=RK^KB4BE$"R,(TH#(5.%4QUP')%
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M,'<U;^EO!9\WS0V C/T'9WEQ:LBTF,K<F&.#\WQ^#)>#\@#K:I"R03$I0?3
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M&U5]/M%(2C=9%-Q_-))LQH1]X^#[ZWX'ZFZ_V&>UV.!VU/6] >2 /-,(<H7
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M<F;4RII2T_S]^57SIX\,;,6S6X("CZJ?O^@.':\A+KO(>5EB.'Y)HE2[:4^
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MA*BIT7-"4B>WVJUV]H>%YA]#E1Z1Q5C#UGUAJT:JQ2'5[A1286R4)2XB&HU
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M&5L:'_5S]LQ[T5.9M[;-PW7;O <5"Y)6&8>Q D+'@4QPZR/Q+@I%O3<BFC+
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M9V>=;7_=O=S>V"7_N6Q>;EWN[TE-K:&&(*-E/MHN%1!@,+0"2R%*:$JJXET
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M1'3DC%,9 M53I8I>JO10#QR_5FKY7&_CJB!7;[I"61@L_(CL%[:4@.*7]K4
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M5.X)2L(4C5H(BAQP#L25!^7F(>?D,4MI(,KG$E8"-ZB:;A1:!TZ>I:!$]_0
M[AJZ_?U'LY"WX40]+PLI3S36*+4XE-J=HB"<JRB5L"A(HP";J  *0BR*%GZW
MCA)'V<H:Y0TM]!(Y3G5XY'53D%JS%Z_9$_R#)A.HM &Y8"3B- 6DA17(PO(2
M;3PF(=<>8 V.S1)I]EL*B6Q?;]=$VXO%2-IQ'0EY*@YRO'_RX[8H;EZ)D0,
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MYS0 $EQ%VI(EV9AD%(D+@.X^^_([@B@:*<@LZXF2EI&BH(%)7LB<1O#3>'%
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M3G1VHK.K%+^OHG-E$'(PW#)?$*,"(Z)0DNB(,4'AC%!<9LIGUU0I?@=$YPU
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M"+ N8MP/$S.^7.J#1TMQF-R3LH]M[6881M.R[D]OTF07HS6M\557>!*2YCR
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MJD!$+G8E5V-L9YS8$ WM:J3/K 2A43*+O#(W8=8I%N";)Y@ZKZ)/*QWR]42
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M2:^?'G+L&G*>#7+&0=P5H8ZS6M2I8]@KC#F9^.Q$K\2<Z#3L8.DACA("62Y
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MO0H:+$H.RHD 42H-R'.(@O%L..]"AKNQK4,/\7W2H[%BVA$FD0M0I8SYS?(
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MHUAD49PDEG)-5BF*,KQ/ ;(KSH5H@\9.^^)V.LX=UH<P)[W)7I'AJ$D?<HO
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M'KWN=-;G/8$.,9>Q-:N^85&;*Z^YJ;V \/);_ZZJX$WY?8&GA^H(%V4H/H-
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M2[MKIH5/OZ\_(KT)?_W3_P-02P,$%     @ M(!85 @>U[3_9P  5L0$ !4
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M#*WEP;EDC6DS1[26[-Z3\:1,WR#T=C'8+J;59^?3X?C]!<R+Z?8W_'/QH]G
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M9DS?J=2GT1K,2+^__5I,].W'R7@V(64]'\]Q^G$ZG*U?Z*\BW',$;[)A-!*
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MF0F82$41&0B21SEE4T%,11QH%OD*ZE@'*GV8_"X6[:CZ)O6IUJ6E?[@*[^H
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M<;8\6:T\DQYHZVRM9,$3$!5]D#8%'WFGD,5.]OOFU8=;,/=2_J0/S?7HUBR
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M0 ]5QYAULGPP'->OXH5KX&QS83\$F-&*]Y-5'*88>?(:.%U(;B5LL@T,!]/
MH4JJ2!U "Q?!&(\00O% TFN-Q63CXDOA2J\&SOQ4Z?'^3/<S#[T@7!+:^@35
M^ P&"T'2V8.BY%7TVF#NNM8[;KV;+K^ON2'9PFGSW. ^&*(\ARL<P9;HF:DF
M6DBB&*"BL H5"5>5K!Y%[T6#MX7+YFAZLEQADB+42A!8) 6FA@(8)%.I*2:)
M+'Q)DYJ_GFPOHVV#O.T@&'@EM=J%8HH9+[6741<$&[K@;.._.7L9"<IHM $?
M"_.25"L:2 6491BLK,X-;%4Z.XR3>AF-0+'';:-[&7W7SJ4&8:R)'J(/[6+
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M0_^X:Q_!/]M^^;6=4$'GK(Z0E4<P0EI(SDF0$9VQ4HN:YA&GW6#0.0(9!M?
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M X#V=I?0H+"?8\2@ E  M  3P [P (* "" )R &*@"H8(TX >H Q8 Z<!^P
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MEA1H F%+  "HF@$ %T0@8.X1"+B'H+ 3(-P)_(GIB9L@6%^$GP5HL\0G$QX
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M- G %W2L!'P\??8 YNT8ZXE?A>H:PUFA)=+X #@QLAFY$R/;'3"RC5G7?#M
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M-C=HV<1///S\SA6:-Y7[/J-/E2GP1F3EP<Z9__&GX1P'JZ"EPE&8 *P9$=V
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M]5O-=!8 ;R^05TNPP%J@EGSK5YPIB@=;Y)<G)M]FGL@QN1EY7A C(AHF@!"
M>\E?4\*_GZUKS-+A^_!$O#9PSI_9\1O#%79QL=?>D3.08^)&#E/!C1(\/:9:
M.AH9D<<'P[V'Q:@$/E+&PQY"GO5B^9@P)V)'HZPR7R^TEV$AR*IM$RVEU>RZ
M@T<=Q_I>V!;3(XQF1*;)8)X1WGCZ$:1K]<VWE='!*+V=71T['ZPF1>4)3*FI
M,-2TXT5%P;QGJYT)3 Y^Y):Z$E(U%5>"*T7,]?LS1TBT3R8]1Q* 1?VL*J.R
MJ;=!NXY" Z)#PT^E7%+F<WQR*(\Y\^]M8Q? *7,9WJZS8XZ62E[7YNH4D.C*
MT^%HR35I&L9_CO3:8TE,=COG=2,H?*??:S!/(]%0XT9>6LS;@)PP'6)?T!<Q
M=P=! Y82I5!.'5'Y;E_Y\Z/;H M.>.ZIAG%.IN>=O:B\:5;SM>["92'J?#Z'
MJ/NO$>:(N5K$LZ)VQ(0!GAJ!*H$F0^E;N.9YCKP8,IA<"WF9!^;P!6\WG2M)
ME.Z+Z;6Y%V:1IYG01[*N0^=R=>30R>7>CAH#6.=6U;KG#2FR=?MRIN6-D;?S
MCGYXI>/!'](=HP).'FE<MC_<GVD\K;>(9GO=:ZQSK/58W*1D/=UMWHBJ]VH!
M%UVS#26.L+8(JKG71X_*"/2G6Z;CNL:NA+0FGW;RB"SJ6>? J 0>/@G<E(GD
MB55%Z]TY?X,Q.8!$9/9]38_CR YWM(/TWJ[9KOH29R,8LFR,A&'$I:L2Q+)*
M\!AH5DMLX+"6Z0-/ZUAQ\#ZDR.6\@WVJ+E-=A?/[V*ME7N+N5N0,J+0:8STN
M'42][U(?8P&:[3YXWH55"-*J*/V^*-(O;>&S6ON>H," V8L]M0;_D%SY(G9-
MTE(I*L7X(J_E+HS\95QCY_"3F0.(3^PL%!F*1V",8OMY-Z[B^:/5_$FF(Y[V
MF&I:CF[L7(L)I&AY8NFQOFB;;35A!%.Y?8.F@[)3?G&_9L1_DKA:U@55M):%
M44 O+K@N=]?0>UNWT@P^&G%[GFQXG^=HCA9KZM(;\LP['/OG+NY'=4I"*WS'
MX,-/[X[MQ:7B='&)\+GQ+*[8:<2+\/A8&4\$1XO:/$:>>\HDF+,H^*&I<EZ'
M^E)"4F@ XYG32,VQ#'B['GPN"<8"=8)DPAE:!58TZN <6J8H'9GDP;5M;47;
MKTQT)2]N.D\[[7&^H7W:_8Q$Y6'@L-BYB7+OFODFK9SZ_NL>*A@##(A VN\[
MRJ ,$JMV(&DP#N4-FN]*3YL&ZA@T,:9SY)<K\Q6U0(\09AG3YL]\7=;#A%;R
M-M<1N ]+)@!\\C;6&49)4UV\1^I;UC,Y'B>=&$@G ,P9^*3GD3TL)OF%2-<K
M4I!$=IORV''X\_PNZ+C!HL/>U5@Q#T6/YJ6"E.)0?]4QBVLI-('^DON7,Y[I
M&P@E6=/V]6DUUD>QY.1\36M6&@?3[OF?J0S2 D>Z^6.O0\#XO"9<3 "^O?J.
M8<(S7@1SZ[%H$,Q7@Y7Y?1_OQ7ZTDAK^-%,6 =AE_@3F58>=&%!:*CD"T,<=
M*P<?\V4C .:J*BATS3ZO/,I@6Z,4J[1O1TR2-<_43R$:-N)@F_K1('"[= &*
M8[Z%-1S;_8PTP1OV)\#7Z,"47<+:ZG^](;E_6T,R%%H(06N4X2T'*N#CSQ_!
MOS'!"G<.3H)7.P_OLU?QQW JU^!(5I=GT6(26#9Y&] WR['P,2V2TH@*4V3&
MQ[3YE983>^$-64$Y#\-5/T4Z65PC+[P1/$0;XSW</IRA)2JAS6KXT2;HA8[3
M@[%5JG5S<#J5H8=V8;C"EE 4[^K"1N*.-XS,(SSJRZB%QU:WV."%KL$7,ES"
M1K0G1%U4]J$.W-%6&F^;S5;8).M?@MD?E_,)/O=Q0\![DN'6)M8'>=?["JD9
M\S<;\B>A#%D[]VKU13B,$U]7U'<H^+N@&N(=Q\! P(A+"Y5'2]2LARYD)317
M-[DO:&[0RQ6V%GN2Z;(O+ SRW>I0$/5EH]"ZKP>"X;@ ?&=!%I;]PN[S3WCV
M%7M<?I*_RCOO5S>'CZY/+D@FMC I4+#'!;$)1'R -237[C;N^5[9I[LUTYLX
M 'NN<YSXNGM+Z!R"PINW'3TP+Y,XZ//XM0(#ZWST[%'5F*8M1J5&GO95,%RW
M*R#FKL%YH'./HHY$E(Q41I,AUQ]M#G5I#"LJ# <8PI]/5?/&/+STW&/QC9#Z
MI1/+F4Y)-R\.;^M=47?L[0SAQ6VF$3/#)21&GP (:)E--B*GF1C;&A;Q$Y'=
M63@LQ_X2\=>X0'UHHVW!?UT\31?2TBH@@E@5[\1&&(OG#2U%.R5^H98&YQZ&
M#VV7-@UR*EJ4I&^7WIE_^BZ'=>QKLG20\1K:*_7 '4\#0B3R C2(^RFT4#%+
M19VXHZ/])P8=;,ZC!"LW*/.=>ZG>S3S](-IM=CJP0I5:KM[L.\X""</R5,Q?
MB>&%H@U;-;SW"N*%CH9L,';[T_MFGM@2O_&,"O$N>SSD:9?;\2C%I7*Y6)3^
MW?M/L!R@G[BOCX!^4H@U1E/,F>IV0VBP,'^4]9!I2O5192/EQ;)50?OT(F'=
MMP*= ,TXK?JWI^M7X6+N<29V,^HLI3FJTF\ZO:4$3@KVUOLF=UM6-Y5KIEIX
M!]99%\5A.2JC#5!^A0_0<)-AE=?!MDTF)G1TW+P+7S?=+Y7S!SZ1?=]U%>!1
M.8!CI,# \A@JJ*.TPCE9U@5ECG"?U\X8I.+,31JIMVW_XA_':9N?V1/3ACS/
M/P#C,$Y];6<KPKD+E0&CT@[QT7:A(TEC+5UYM \J<:1GFJMA0*[J4V/U:(YN
ME@]>90E1YX_E&5G(8HH(6\#,P[H_J'7E(XLO#T;K/A(X_MY T_JKNJA#[P,&
MWO2=2^K\@1^/94P1@Q$/)'7;Q@[5.V>3AG!#I$;UQD6'SN-T.W4D/[EM^H=@
MWNR^99E+(G=UX#%T#16S,W059?8FZXR2B<CMLH^]FR-K"@\6>!:DR/R*XJW@
M1(V1D4J(F^6#L;4][,G:Q?=@1>>'S,)35T/12]$&Q*<TINCV101:4B(=X3Y+
M>F$277L>*3<<X-5Z1'(W2CO!G]6PUER$4B$.0D*Y[%Q5?X&R2>HK=U3^4LZ0
MM4UMCHYV"2*LE8UH"EY+#]7-B.7%L&+Q<M'(^[.G/EG(S<'U\CQ-#*G*,VBV
M.9:+ZA%87HI%>9((Q2U;-!1UI+_7IB'[#O19Z#TMSWR;XWAN/TZ#E+N[=IQ@
M9O=[D>F?$+2TC!5(W;6$\DJJ%"]L4'^_#Z#,2HM7"T)WLRI7U)@\K[A$TND&
M>BHJV&0,7)7N:XNC?G.D=G50Z>_\A[)@$[-K()@2ET#:X+NTF0B *=(&E3*)
MJ$6,L^'/F,_5X*Y'0?"%<S7W%B!Q@I7?BH?WS^%IP;*,BH38D [$Z'O.,M87
M)<<*H5R_%C]HKZ%[)W>*SV/ ]?X"B^"8I1'$70*ZSF2,0B3.(L/WVHK8O$9'
M6Z613%TUM+V!1WKV GJ]GTQ-D4:&3TD;U85JBKAM4[82EZ,V(Y8DB*_WO(@L
M@Z_$EL+RZFVURIBL$]S%*ARZI7,LG^.>8TEPQ2ULF'/1<D/1OLB]K@+_U!;Y
M"DJ,"BXW)Z&\4T2*)'L8^69.\?X#FZ5^K  #Z&&//L7*1),,(SS\J58";"-6
MVTW8(O+75I]Y-[N==K-C#QAJL^.#DW?QLTZ)D+5#YSYF91YT(WKZTR#TEU\W
MYW;N-?,[2L0-%(9P[AV;UO,5384F/C1:8,AJ$;Z(&\B:[)^"=(2U:N*R6Z4\
M\LOY\Z(0":$7U/-.WI02N_LT&,V+6N*Y]#PO?J*FP W!;[[0$V\3K5:J=AUK
M4+:R(I0" L7U6V_>G%KC@B9Y[^KBA<91<P2@X/,\!,L\#4?U'6#U%3/XKMC9
M+\LZS_0N<G#LAB= YY*A7#HRH-.?B@[$0-'2IDJ.S>C(8/ZHY93'3)X/5Y#-
MI;(O6'DZ5;&R7CSC%<RT%<=PI/6@?97D>N.G33$GSH0N)-XH2P!JK?$KE!N1
M/(MA!M4S([<NOF,PF]Z<=2S-4-?.ZCA@,"V?$%"S?-DHUU3UQ>,=R1AYZD$G
MGF8%-.E9- J,T\))<A?:6R&- UKLKAY%W;S;59YE2E*=U,^J9+_P9WT6D71*
M<JU^>JO83&LK[/3#F>O[XJFX:;0_&':]/!4\SR+26C6\E&!J2KJEZ, C2=!=
M:R-WY]D-=M@C$Q07F'<^/1XL\Z>)#AZI\C_OQKT#9^S5,HOA6;A#BSMU-XIW
MBP T!.0WJH'F>H-P$4%&Q</L0< 'G4N#\B/F"E[50WD\\IK'XK[<N93<K<&?
M$5S&Y=^<LV1MR(T$;G'8(BM'-AVBV+]W/(Q\\..Z9Q4WF/</IO TJX?:;?S4
MSJ9]!M+X"<L^6&>^D!&E7S>4!FIWU3HOC$IDS["/V^F.1[DU^^('BPE2T[7H
MW),UG_N3(4BWZES.6W3H5XN/2U6VZ#\P9LUWI4H2@ D[L7MI,<;R@P_1*40+
M?#OG&:R6T*K^?73LJ1*]/2+9Y;Z$3CKJ3&)LL9DV0R0!F#IN L9C^!?8\VPT
M5"_&D[B$",RQLM%!Q!^M2AK&NA9/KCK2YKC&,;%_"U(9O>O0^MV8VDXHN*WK
MR=/>1+>:'(Q-L5FEM$$!X[>D@NEQL+2N1^5GA6@+&O$JCX12RTZ,/4T1/2\:
MHP2;>AQ?/(%VT:T="L%$5&[C=,@;&N+$)F^<3N5@,;C$#E ]J&F#3^3B&;11
M9=>WLY(1S/F+5(D+]8AD4Q3M1$.:>C9+5[B@]882#[#^4:$ ?[5B2:G%2N.C
M=.'KF@,!9>?1Y2TN,'@<B_VLHXPF]AP84/!.E^KOG 2 "<_WEO*.2VE[T*JW
M=O^-'/-@V4N)D=%O'4B$UD^?5<B3V.I8[9D<V4M8#^&I][7T9>P+;VX<NO]=
MOR[.C=N3]4B8S#. $V %:F:*II;Q#+ZH\/44C OV%/I>&?8"<B;-?='!JEZR
MTB_$\U'.L.*3\?<OG)Z=_$)2Y(4%PUE<)7%]6&@66BQ\G:D4JSW:8O$8W;QH
MB]P6%,[<[!M9'SR^U-34R'(KR&QN]'T0X['.F=<M"([D@ Q>__,-V/=>^C:O
M=%P?#.A%)3G]UDEJO8Z+A\[EP7GA<Z5XD;RI^:)$QT6#%W<N#:O@3IF_\-0(
M9KFKU<6Z1D+>R]IR6VB]_4-L<;0H.#=5[FQ?_XJ:[17FP+C$5,?/;RARXP*U
MAJ3\>\2PWIFM3LDEZY;VN[.;TLI?=J$,'C4S!( ;E+Z@E;GY62Z>A0!D.HH^
M;Y[ U#Z)B.)[^>Y*0H%(5IG(#$(;+!1+($C_LMX:M$1OTH:61:A+&1K3IBKU
M];/WC*"\Q&Z0.U^U[S2-L\"[)Q'#H8%WK4."M53L@GKL]U?V;ZZ\]8I6 .L&
M)JQJJP+J1W+IFW56K^8$3I_5D=,YTJPZ=RI3<3=Q=Z!S0[.\$5F&Z"LH&IUC
M$8XR%] ALRQR=P;<%8\<SUQ\]_FKBQ"_._<'_^O=YTIJ+"8Q;-R-SS$;Q1YA
ML=P#LMN?=69D-!D.W4YE\D;7[VY7#U><1093K0\MFF<BD&=GN;"J&E^+_<$R
M=_Y5^V/;;\B+&I/]P5]$<Z?[KJ[_R6GZMU=@Z8C&?BSOU (XD9AV>]")*$US
M=./\:\[^GN:*[Q:VTQY#;^6>N%H\OW.YO9WJ!D5TGKE]AO3'T'MU0\/?GQ1:
M&\R][L^HKYBEF?RFY'7P<%(@?3W4OTQ[.,.3_..Q0='3:S:7 %E*0XX\[Y4:
MM'0_ELV "(!M8@<TH)V?O;MY_=/\5+*83BYP;\A6.7X6R;Q06!C(8R/Z@\&G
M5VB17GOUJSU&VDKD>'FG6Y!FF1NQCSKR( YQ&;Q9,U"T4%@^YM2W,*B CIK'
M"X<(O4>L:/-.&Y,&N6 P"F2]>Z15WS!_?5'+).[#;:0H]AMX8:?87GG,E=C/
M<*98KKJ<]L?>D]<*K>\I\O+1A7BGW?O_V'OW>*C"MV]T.@J5(BFGJ9 BJ9!R
MFDI"DLJ9F.1,2,(XS2I".880E2GG$N,0<AQGE9#C.,0,0W*><1@KLV9YU_1[
MGO?W>][G^>S/_N/9>[^?O?=_/LMRN^_[.GV_][JOZ\H!S=.CXW1I 5F 39H(
M?3[VB9JZ3>:TSW/G=8=D-[&LK(_<Q;(XVQO/A'.I,KFHW76F(6]L)Z_*1"OG
M023JJYNAJ[8%[I\0"P;QNMGQG7K=GZH>+"RT;:O)/%V@*SEV4U"[$.5O.L4W
M[XN\HX?OP)3$U/BEXTQA?KY(B^:48SVX((E8W=TJQ*%)FVJ@E$<G'.-/TD#6
M.FD GG"H8*S1?"KH?'4JI2T$^F*]K[[-^'FWH\,;*.Z3&2)\9Z1EOY8_KK_P
M1EC+1_51K,<$R>57VY+9-YXL? WF^_O^_BZ,;SY 7;82+ U*P'=69OH</)BB
M9A=[5I5P8A#!2K'D?DI1*R3ZGJ6 [[?H*X@,*G#!\D*:/@WG\@,M]_F4E9#2
MK3*JMZASI7;%XU#D);*6;^\7>K%)A.L4;"?3K=(9:UHX@Q6%G#T]%$WWKPFO
MKL3IB6S7W?/S_,[,^Q>Y#L64?NT:*G 21Y,8#A6.6=,^RJE)6;G7DOK+D@H_
M]?S\-B%SY$CP]^\ZFRY()E@7=QW<]UMI/86%!NIS$%*%5_M]MK*S2=_K$JB9
M,S*6]&U!XOTL3_B;=@^1$\YQD/RI^SA[0ZRI,X'NT/G(IM"^&ARD\49^#"S6
M?#>L>4#CM]U=_*M0OU6%>R?$7M?.EFA=OP9M2R<Y8IP0@E_5,GK@QX)\[7[(
M[ =D[K73GJQ'?MC2G?DBEJK;K?N\:+[FIE??HU^DHQLHI]C!DE9LL4<S BNV
M0E?H'3EC& 'GS\X?B3?LXTK*=$9T=27NB:HH'*^O/Z?4%=YRDP@=QZ[/74NG
M533^<"+VR@^8PKN>(L[W*TL:ISQ>]H9AV>B_C1 EEU41:5#1?335TD9TJ?'O
MT8P=7;6/W-23(>Y2\(7#9N2=B.4D:CJ!KBG_%"B,;<6$4?@4HTTP$6E'08)@
MX[2/OWC*"2^NT"[SJZ?=3[$B[;89WQU I;*$F+:(VU0+-!V/Y1F>0>^OE7&&
M!7JEC;TR?@O[,E_5[?AJ?M**=H'V;D=,18=HS&>#TXT-/)E9&</P 9?7KXK
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M8F?4HD$#(]<GW=#-<7U5W6I77]XSC>J]GN>O''HT?)OZ_,(Y*EE@B.1&LL.
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M>0%'N@#,K4J;5?X<IF[9NF2)L[W^;#@EJOMC M7[7%F$5UJK(,>U;B=!EI]
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M:>)@&U6D<^L(=L!@6T'16YVAQ$C5RW4G"@L%KBC4V9V9B'O^5@";A*'K;*#
M8^H$2$">65L.O@'& @A"EMJ95M-N-MOH)0D*6QO#[3SKK[^<4L=-->(5(&X&
M86Z*5D78"2XW#"T^";SH_#U)I?1U4HG;UTV]IT2>T\)NY^V^>*3BZKK+N9UJ
MME+;%MJ"KDG=TI\!3 "ZC@$HEX3L\S9GAE#,IQ'E,3B+FJ(FX.;X8-'K@]32
M2&18ROVS+:^N_K'^,S(LRM[" O!D'U*AQUPX33[2-%6L]9E<('I7-3&[\8%<
M9L5RP;MRE(YQ,/6[R,+K^=8:O"KG"!"S9*2A#@S(:R,\F>R]+H=X@ST(41"N
M/0N0TUYMH'(L9?[<,]G_^O2W*-,J''Q61>+HF->X,T!=(O&T"<A#QX ]@8WH
M)87&#=2755".4TX5&8KZE$+7!! 3JS>M%0"'F_RG8KU)._3'U"W$SAZ[=^](
MA64H+K#]N]7CK>*G9*=IVKL>A^0F)I2NX0DIG7[Z Q U0]1T<0JZ6(H@(3C2
M,0I#UW7;0#5W TTB6+X-U.\R'/+_MB91("M[=ND3V*,^O"@.W"&[.ORW-B?E
M7VIS@KPPCP=+W RN(Y1+Q]3R.U>.D)]^#)202FW._5E7J'=?NJB\4C5.=XOS
M:R+7FPK:.2*)DZ3P1WT#A6!9I@2:+5^:]]TA)^0%K<04"DY+*&)Q(1)YAV%\
M\(@E,*61F/-;"0JQC8!K >HGS%+$OSXUY4,FN]V:],Y[#?-Q$52FP#?FZ1BX
MWA?@=#MV9V=5&].)S+M%)'"9(;C"1L-[@O9;G9M-WM&MY^BLUJ50SW-2UR]+
MQY2']_2.VKYQ#-V#]&]5>4XBX6?,&\M)2IQ BWK+H>N ;;5BYJ.W-;-=D_V3
MJMX/9[CIA959XO++@0#QH/K6:]35+>**]Q?*SG?7$*4!?7?7=J?;S6 B(N\7
M2L2FX[;TV+J!1359#U49_3Q<U# %>YGO&TOB<?=VB8-6W8]G7%=%8&Z$8&Z3
MH"M#^Y:9?K&MUKMB%O4K2@ASPJ/1N(L578N;95^VH;;&)=[Y>H1Z:D8PY,@&
M2FR5A6C!=B](I[('<#6(U-AC^<RDU8P>9=$XO*!A^=75;Y\,./V\/$KA=TM-
M8)O,NYVJ;Z0<:JY-][J;./XDT!_FS 5D!P8B'L^3$G@AID-BG/C$]_F,3[D,
MH3;@X&3,Z,S.#907GVBK^GR8"F+69VID68BG":YR[IHAT?4(0YN/;S<.W);W
M'3,:TZ^-_A !J\O>#LYX*(J]HN_6$.6)+:$4&D#"(U32,!_S/!C 4+T!%HU'
M[U]K2;WJ8F@V/'U*3S#OM$VI^>O]HMY':GSA0T,@@(2TDA8T*,FIQ#R;;=ZR
M_XSG@SZ_,T$ORC&;MHG)KG$RLG92Z;ORGRQ)MW0*+<:<M>]XYG[EPI?.15GZ
MT<K"ST-FD2SI (%CGQ?P#$2"*:2E0X'(J(5AX1NH],6\%0I'9_>U_<U_B0BT
MHD>@][:.G5>[Q3RII%VDG.?&=!TX2>KCEABI^CJ\UJ+L^/H.; =PAC& ,4A8
MTT2B4I=OWWHYRPT>2!-B!V,<8O= 1HPWV>5!8YV[2C]8:69>%"7'N)^\6Z;_
M3#+N?>/WS,D6E'1"_1^UYG;;X1R&E67_MU9C3(@A8PT^U-J'^3TV!]"? ?#U
M#/C0ESXNZ*=2.+S7 *%W?2N.D-88)Y7K1SXC@Y-J@JQ#^N8&:J\O_!U8D8$X
MAW$G"9PWR?,EUIT+V D#.84I#!B"-D0OW^_'@%K(C*5-%Y2# Q$"N<,W1#$:
MW<'29EJ].(MW;T_S2'JL[/:UQ?.U':V?=!H81_1^,!8.]8A&MK]G _5'A71#
M38%8/T[:-;V>E1OG5BKKM)"^O)V\8^: G<\YB1H_</UEA=0J(>D97DLS>8[P
MG02)&2)DQKF/-&?VMW4PPB^W!W&N78LPIM@) 9WL\].)=<BD^]!+26\LX>9H
MA$IKU?A2Z(X4*-.CE<347\2L3&6;_C" M0C,&63ER>'SR9!@[@:J!<&J3O(L
MZ74R'*>';<6?(\YIPCQ]"!@AL=^2Y@BSV'5M.4!L-9D/X+$FO9U=>&3*9-$7
M8\/7T>P0A&VO6) 9VZ(XSV9A73AT W6'!;#WER;O=3.86M^-L.8'",!-!B85
M"/LQLV&1&ZCL )ENY)&--N2.KL,P>?LQ*R/J#LCDVRA+*9V1Z-5&K0U4CWJB
M,U!?2%IZ&8M"E$/>#'D4N/H;\T<(&":\0R\M_P)N6BQ$NHY;\2_KUT9VE/0>
M"G"F_33]'MV;MS-XQQ=)NSVNR\HP#R>/;1.$^,5@ S#! %2@4^J8^),,3-@]
MN?D%1= ]C)")<]@D_&?_Q <%M323QLG<&Q^^Z4W)8K/]6_*WAV1:8:TPR6[V
MO)V<)O#[]MN"*%<P%1QD>)B!?QCAS>+*C&V]R:E3D4IZT19,![5/)3K=9]51
M<H^X4"BNS=6BA&VBEX??TPO2[@U]_&D2OO*,$P"0Q<<&HCG" TGH1NP^W!6#
M<'&57@G?KC@E@5RS68=S0[JVIJ=;?GS;:QY\ZD[]=;3//C@L\!;HF XY@JY$
MG'93TFD7/)IQEJ"1DCOT1<.<FL*CPK(W6SK/E0HK K8>SX2P7( K$*8A4_PY
MJ9_6",OT>#R)*^O?=#+# 7WI;3#?5GX58;CGN -XSN:#5G<7IOYMEK34>P;7
MO ++.) ?F2 .L,'L !^T7JVN#NY7[JE6&/M]5*LW\.*#SWX+CLE.QMM>J_7<
MJW,VDA'[DL@(G^M$MCGT-WP2?)\]C=E7NT_^":20>]O/T+7R>O%:>U8&O^!$
MF9-@UL66\9@#J*L9HG*!G$\.%_$_A'.:$7 BLQBAINJ)Z_E-VK4RNTM _XFH
M]M[X?MF*831%X?:9I)G++BK'B!WKJX5^^L(OC&9=C[L&K)U)O/(FCMWJ+%Q3
M0,JRH)C]U/2U#^ W\% [*7X^X\Y!*[/[1L$[)'*5H!I$M=JQQ=:O6/) O8%2
MM*9F24RK%O@JJWZ\*7C?\#[E6[HGE"\$5/]0;!T%KK)_(;HB"<*SXUB(/X!Z
M/2M 0M]3*'2LI[SHJZS3H@L!G)/%)F+I?G)//*$ 4.HAU^)1.IPA@+;[_#26
MO9/\ZH5UFE+/*M87.IVE;^.UW /O6/450TQ-@BK9HRMZJI5F=3YE)/A#[+D'
MNE33^35H'R^\^PV(8<GA4ED-&ZB=*WZUIQ!5C7M;455::ZF^>Z1UJUP_V368
M#UK2#_^40OS5O*<J](;Y2^JFG^2?E&(L))+'NH7O'Q*K+?*@#F,W_?8U.X7%
MM4Q^:CQ#&+>\'^M5?N!PU$6SO<&N/UMM[B^GYCWUEW*UIM"OV1R7<B)H6P#U
MXVA1PZ:[EK%A&!Z[;H7V3\Z 6(="3X?R-G_?)82"<5I5)G-*#G4B&*+^)N H
MR""'G5AXJ,KBS<AQ]9?J;3NQ;OS#^)[[;;\XE4*[!)>%@UME98]![T!7Q$NY
MXI" T^9Q(/ !?2%AA-95K7[V'>'.4CO7+R.V[$H>S"V-F 2.3H'XL5<86:1P
MR'E<7DB?EE3DVI-;OZOZE%+N9YZ[E[<&4YS<AM_4SJRT:HC;K'(9K*&%$MO?
M+U-&_R9 5I-LYZ6;,27AP?!9LX%6]#,UZ3SM,?;U\7-UKODJDW9.4,M,8-Z3
M&R'E0YG$>G3HS\!K]$7VDWG2B@MY!6%\7.<MM3V1>7B"41U5J;LTKSS$C&"&
M?-H(7Y]"KG^>@%8;*"F%1A)S'[*6KCSK,MV;;;R.7:7K<+8WPLW\B'& !S!<
M3B5 >_/&:JMH8H[Z(^/$9Q:OAUZK:+Q6R,5ELX]$'(T;*9:(.->_S5ED4FM(
MT/RIR?H,*2D6/$^@Q60QO&">05K^T?&E<9HN72R;\,[YN6I@4AM3I^#H4,WY
MSVFW#&Z='D!I +(-'[7<==U<20HN\9.F&FU@  <+E4XUY0HT8[;8%M&CFW['
MMV7CHG[.[#\ML*PC2+W\YM'$T;N=^@TDY]I=@7?HBZT(T]809Y0_*3VVZK$3
MS&Z0T].OTI(Y&J:U,S,/]:WQG$S=F><74<&R8&R+[#HBPY";L*05;A;FUM_]
MQLM3K@G/Q_#)R1C.*]*X?*]L[970L/>P*/#)M;OCS)#B>YD7B:5%^SZ<G>L,
M Z@+B.M>TP,=69=!+MKV2,==[\%H1XV4@AT)+FT!#D>6I@#F1+"Q05:NNJXT
M8U;4= 4AVEQATUU?6=R!2M4>JX4XYCDC6GHM 6<P*TQ>+K'.-KC9R2NR4GDF
M+_,?W9A6=_X?UZ#^WZGR/> (%$JC"PGU6-:>%0Q;N1[;<O3T?TR_X_V;?M?!
M$*KG,WEX8P;/!=2/8)<22 @<'53K(:V0;A*_&_#B#(T8K4\_K@0)Z?<J15O>
M2KSSJ;BX/" R\KU(NK;PYN^MA:@$[!"VJ7/0=2RVA;!'.P_7-M;Y"#+_T+QY
M6&JAY*T%]J?D5?.D4TLMW_<HG.9]O;EI32D'82U4(+A6X+) 0RT?G11F?.6'
M8KX,[R&NG(4^UU=\:3)&MOJ7YD_2$D6J"*](=#<^B-^TF5((-,8*!EX!WV25
MA=.(Z.9=B6FQQTT^=ZW\'B M%CTO;C]L<GKBA5E&QX%B8B^);A$[!%QG)P#4
M%&!_H*:?US[EH99GF'#%IX/,FN;5%3>/ Q<AK2W5F7QCH9VVUBDL"_P(!MD>
M&]*6K\3 &XRRR+$ 0"ZS[%/JG;7UQ]BQ\K+;;;(^?XP>_WS<#BA@Z19H\(3C
M4\Z53*&Y_H[NQ4: %Y*50)P8)EWOD'-67%A_=:7L4LH(CH?;+'GREJYOX*E/
MLK:>XJ/IW>O,GG31S'<B$A/8T$;XI$<X,">-T+<,$U)Y K9)N6%!XRCH"S<D
M4=:57%E^!05'1@F=*T?##:<V4 BHX8=W(^HB5RL$LL:!J%5+[.X!L-PJR-&X
MRJFZK?TNK--_+G\L^LJTJ!;/D;?4K0Y25YCHO: TO)O!3JO6I*WV>&.YH.MT
M.%PQ6[%OJJ3TS5WK^TN-^]J/Q-HM\ZGOXL %+AM\OT5Y,Q$\)E>.! K%UK'%
M)^NW>9[+3CK4U@;+OG>PF9VH*49Y14<!3R.@TOS[Y]557AA?);MC@W\+?.@I
MUF BD8T?J)>?0P2= Y3%9'B.ZQ18C@&/S;VC@3O'V9G=5_'M-I\?U'J:.D@0
M3AY$R33KP._2PQ'6RH47GX]6C-V)LVP\NW5>*Z:C5>]3F%K:=OYS&5I,8^.Y
M;7@/9/DY&*XY:!OB1YL^,V2T80*-*(BU;C^.?=GJ+E$:S?4A3U.6ST\XDW-O
MDN0BYTA5A@3B>QK6=Y$'%C2.NQ;]]G\2H?-\NJM9<CD]KB= \G3YW7B5#93@
M?5J6FHG"@'2Z#S9/9G_425SGO!=G2CB#.O2>@D_8)^A=V8R.9)O3STK9MC?=
M5$;7G ^]/&0V="G\0W54]*S80W1A."3VCHJ-(? _7.0)Q-)-(=FC?=F6 1Y[
M+%RP;MT9<3%"\S*_8]U3:-^_1YSAO7>[$/;SC) =]CLIE)!$49V%KU@/F6(^
M\PGCY*^ KZCS>A<9VU_9Y/^VZ"L9LAX8O51B.=) VQD3M</^T(H2E(ILA0N&
MBA [^KS\<(@%W2>9^;Y:H.!2Y53H@K34J[E;)5NV*#/4SIR(B[]N;BSZF"3(
MY@7J-VV@G.5LF>F(E(P"3Y'5-'V9\[[:P;1&<O+6R>S]AM5[2M*RVBL;S&-/
M-*6M,C"0N#:]LIM%)=1["/\)\/A4X\ZZ?&;3&JWB\=%--??=KJLK*^?C*HQU
M?S17\CD^9)L:6B1Y5OQ!G-Y6)(X'6PPCL]0#7)V!L6-A5$@!#-IGD?/TDOV5
MS+D)RP$/46+JK2MWSR^-/]_\T3A\]? ^#7'P/)UUSSD39]M0>[!0VN6$CX^*
M5>;QA+H&[7U.F4SCFP,\$ 41[74\GSG(!7,_\QPWH[6OQ50;!P4H9CZP+=\[
MU!+"3G2RLUF4,"+0O7WGM3Y"VY&9/!C"65ZL9(FU-LOYJ_/=B-/E%SM_)-ZO
M2V>ZIOO <)\8&<QMO8K[Z%%H<'D>OG?8J6$J"B9CZ+Z44+5-C.VS6N!%^JB'
MJ+./P(%7V'ZE_3WYBSZO!;;RBNC<6.63.+P:4\DWH GO[J0KMV*?"?N&:LB#
MLK!@@DN/7&GY4SDE^;+IFU]:>9F)#[7+8]7\4N*N/!@6.H%)LY =^J?T-3C2
M1POC9#G29VM?)*\,[_*XU)^?UL]L61),'5T0.F#W\%[8+3Y-[-<<:'\&S(W0
MO-T][,]*1"YGP"6Y7F5"M@!G/?[ //K%Q[JZ=LA@9Z2D74*2L?8ACV;@$J(H
M%X A/3-V+HF:B.9=[=QCQ:ZRZJ)^IJ].UI]W#GVQN/7$Q-+MX8]2+Y>^ZRYB
M!8#Z"8#73;Z6)W _@YA<QM(CRW_2/(3&J[[DOR/RNS]'_-6K_NK;'S)_WQWA
M*JG$Y[TOO9PE\A(H1GADW!AI-Z@ZUMHX6,LS&ZL>G98R1JXQV-M<E,(OZW5,
M$W7NRTBYQB!QF(9M(M3%;:"$&NM)3+%B)$ ^(<X7)WD_R;ITD^E"1D U*N/H
M&N8XX(8%50P;244Y\X8T('0-R^6=[T^K]W_60[D1V;37,JN+)__SX<<1[#G;
MHR1QQ/.4 '1#.0S,\YYUPPFSYQ.%VQIW9I=(0S\LYBK[:K7:ST*VJBU6424=
MM:."-PK8[M4I"% K,$M)G3$4YAD2'!%3)0\>04/\'IJ([A0&7F?TAQ3@&HWI
M3_![N^=7=V07E<1,%NR,?_FM\,&I[0IQUAUHWK#&6V9)^>E5?0OVQZ\:O #Q
M49Q&'XSM9,2SK<NEG4(L0:H<6:KN!FJ/6R!"[=,':4ATLP08WL"PF<$OZ$!-
M5&S=1>Q5H%X:0R58A$/[B,PN^F)C[J_*'DCCZ3KQZ>H! :\!YQ^T[[)I6[ZT
MB^KH'%+[H'-HKY4TM!^ N8F(SZL_L8%R:9<8&XT>C]9L[O?/"7,K7?8+<$KJ
MOM+]<^22[5#4Q2USU*G8VBOGOK(Y=\N5-?C,AZ#38 ]M+39H%7YO,P;:2;"-
M;EQ>_L)Q%042TG!%OG-4R[$Q*_\@$\*IJ*!9!28?E5AOP -WD'@_8;>!TIJ%
M],6P0(Q[6=G9_9YS,5)BN@L=K2<ZFDI.GVB*U\??0:9U$4.=!<(I)1Y-;_3J
M23QJ1_#'9X35VMT"\MO>\\J)21F&F?%DU'S9NN?VO4M7C%\_P"-K"5Z&>_T[
MYQ#UV%H.)HX;[!H)"F^RR#SE)!STY5R 3W7*H:3+$G%'ZGK.Q*V9&S&)$V75
M:CGR88=5^DI-H<#V#T:>7>@:0C$9$A<8VT#MARZ4=L,G ^42&OS%YAHP\^V\
MM]PNF&V^+VSI&&WUW-LANLWV7'2L(.OX&(G?B2(0*&B;Y^SK(SP5#EVT%QO)
M^GZBQ!([?.UQ7.]2 >*#U7<H01B:(%L.J,\%/L40&3DP=W,NSM*BBF5'V EI
MGXW-41#]DL3?+/A=IVG)YZM4 S%=YMB8RW)@6:(,?BBB_*&,L8B/X^0B)(J
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M69@)$K+GWS'DFTWW^)6+B] C!H?/3_..6%W1XV.6#1=/(=">Y$MR!:+X\9U
M,;&))'XI3Q+FI1?D%#1%1ZD.6^B=(6I\?(17 K,0RNL\ZVD)68'SV<5$@F_&
MM/(QS^5M$0%9]P(<C*%0/.<XXCJ$]J8M@M+HUFCQEO-':VOIN\O*&-IKOYZ;
M??\2POZ%PBLMIQ!K8CZ5]:PHY]#1K6+P.\\\;+NWMV*YD/(MQ>(VB?U^5C'F
M+],XA>=G]#4Y5(C3NOGO9VGB[V%X%X(^@K5_DTK("-K+@/P9V0F"4TT>:(L@
MHJ;EYTT:8CV2G2\86]8</E_3L1-]^F:/V_=7)(+\8P("8\?<H7MTX,E:-4!_
MX9ID<66%U3;5$6<7$+W*+OPM+)@3NB(KIV!0'M/?>#U8U=+IALW=Z'TRQY@\
M*$AV:GGNVKL=W;%#E!^C4>X+. #:IP#S7*238>X,NDV@#8,?I@6M1+ME.C%E
MBEV$>V<VV84>R!UZ&[S0=&1SQ7E[$RB1C"CF4N=>TK-,-WGJE4CQ""F1(Y4,
MQ?R'C*BIDV5CFN)\(X<>_JDD?^.4Q<9P0 2G+6XFCMB8K!P J=)K#ZAA,BT/
MJQZQW>DUHJ-M<#HGKI>PT'P %H;6<I(G5JP$53[,S_Z62;2:BYTUA+D-$?U.
MYWQ^WF;TPYL7RS<\"AJV6HANGC6B=V3(M)VY9"8_)#=Y8RL]S/[6L'%BBN:1
ML$O=B P=2-27*ES0/A)3O^]38E%9Y+AT6/YDKYK$AZW&J:I9MRAVOK,3!H^B
MN.NDT%O?$G\A6R#$TIG90!43H7T!8^B(AZ](Q:W*3^<5@_1UV2/-H1-Y'@^B
M5- C7[Y7_/X=W:<%W%F==#@ O+\KH2*O3_XC8IBLYHT)8[$U@H["KI:Y]N65
MI7'IJ<>-,IIF[G^K6]HAL54\D6V+S(R$7@KWX-PMY?W'W5+@/(5N3@DM(W A
MQ @MIJAZ 'IE %XM4#I V[+YM&_9HA-Z9'O@IM_;@"O_:*$P3 UG<WH:KHQY
M6R?Y&1)XN0OR,?4I-[OUQ4=8>KB\,>Q<JRW F!J7G5['0(?63U1ZDD_NS4SJ
MZ/9+=PS>=SM^^6IA+@_O:9[:OC\B#%F8[[@K]NDM[3'TXZ)1G,FHC]$K$\;!
M\MK:2(SL7 R7SH&8JPLO^ PM ;H?5ZN<G@X=7>\1;N*;O&<Z=7(TJV#&9V;X
MUEA^TJBL&V6TE7#?L^?<N2];\;N,[/WL93X96WQ;&_ZZ.XMS&/@4J%=$M"<3
MSX&5:?C.F^!L_7O?[)^#!LQ='E>J#_W\O?98\+O]H\TZWPKMXG VO;+;M?XX
M(FZ3'?N0%$N@7U==?+IWL"G0F!ZS)':]>])PK=->K6AXY")AP8;V<JJFL-60
MT\F$VA'[3,C"=]Z9X=C ZWFLN%]-8G\A\P][6-<Y8)\,N+J9$19T@#PG#PD.
MZ\<:<[H=P3_V?M$PIN\G(E##7]5<## 6G#+*6KW](%J]H':J9T71(%68T/J6
M^%L:WH6XRF#,;])N>.\TYI-OTZZCE!L,WPA;!=RE[B54V[M!]\,>1LI0.4$D
MKNY;DU%(R@&^^MB0#11?)EC"<&V !8,-CGH(N#!3KSVP517VBS\TL!B,V"VH
MT* "<(C<M,KN!/>D5)-GCKM"7_.NV81)[FT)&9!Y#)H6$>YF\;B\P/?#!/HU
MIY:%J4VL._ @QR'8R >7CZJ#B43-=[]]H@Z'7E@^67KPBY3<_#A:,;Z,NXZ*
M^MYL;!Y.6VPF@6JIC$!31?Q64,)]2/2>B6QT@)5]987U_?9]IU\\7?ES.1ZH
MP7)*776@RZX36=K(3[JEB]MYIV.?X/G3G?S=WGI-!KW/T/60ENWY?J;\A<'#
M\MA1DHK+ R@M(?.#B:D']F+OAT4[X#*V1 @2<Z0G,./I'45CA AQD5X-_EG?
M(;>FLPB4<U')CO4\_.R12:*MKHV#)$KX[,71BRT P2,<R[<:&XG>HXCA!?'?
MK/2L&6*0L,,;YSU_%MR/QME&<U4X;&%\O'>7=!&@#A!#^H']&&H^S%=5$Z7/
M%[R2K]W$??"@2>)AEIK=!JI*JN&S1JYLY3E_,Q6O//V'-34[?GDY*ZRMP=RN
M"'#HHP.0@ 33H2=0Y-U%UX!QRR_=4TU#X),3ZWV_-&RK1)Z<CC<YMBZSW*90
M$O@*<3_^2'Q+@-196Z";-: CG=*8A-< 'V=\UG<97_>)U>UZ_=9FTU+'GU\'
M11*ORCANB]QNS#['.-3+%^[--T=  +H+.]6@*"BW,*1C*)!T*E?:8<X1]=H1
M15X>'O< %1V9SQF$IZN[;$W =_3D&WU*KBGR\B=S2+UIEBF9=Q<EBDJ^.MS5
M5?^JM&R&MC'Y^($FA4QI U6G(OT],=V?,H?(C.NAB[@R2,H" 5IKL)K".QQ@
MEN(&C!VB=Q+XG=WG!.W2N">??Y+ J)YX_&+SI?*K[#B019=N $J5ZPWVX/A:
M+-QJ2\<\! =JWOR4"WEAL_15Q*OL\CV5<Y/FQN&'3*F<^Z[J@!/?^C$"%T!7
MN+6!FE!A_V+':NP'PZF^<QET2KWUB=X3WA[\.,U&"WQD+L5"5_+YJ+Z;^_,4
MP4QCGY&2\_9;XQ_(+!\;NTM3DR7GDT[EM'^*G>!C#K"3O0T&2IA%C,6&$9LT
M5]+VF>Y!;=6"1C]W3ZF:%E7N.[C,+86>V!_:D+#E!NI8"6D#533%Z?P<H +]
M1*95HK;)C;H(R@059'GLB3$0!*7U^TZ: 6VZ_*YY%X#%2+/6,6PF0'=VA-([
M;_SS;U=*9#H*L,*Q^5'O\ZZW_N9J,7@"[V!<KQ@CB>*Z1YN3Q^Z5JRP0?(,.
M65H=U71G?/5AU=ZP??(US%U JO*1]D3GO >RZ0#.HXZTUT,1BQCY+LN65/4G
M+1+$68M(9P9V7G)_\(BMXU*GL=]!LYBBB#4#4"6'^;P/Y@+J%3)^/%2=/N&.
ME\+%4!K76A1*)PKW&'BJ;.G=[G3W2JM1W NZ/G!F-<PPJ2??8*B_[][SF5[G
M073W(L1?!>^VHLO/+S*P!J GS8,7TV@@ZJH_\7M);@,U_+#FKGOZMN?I:@K*
M=(GMIA*;U@0UU^497F.8\%K5P-/D:I'Q]I-D"SKEV;W,GE5>V="?"4W48/6+
M8IH[!0_MN8@B,Y3&L/M<-+8SKKS*GQ9*F!XJB_46G$_\N:O,TGS\/N-+>(GL
ML4/K$9RFG/:=$<6!WNR46C%PU%!$CX;>Z5Q)>]G2)^?E*MJZI;!MI2"0LF6G
M6L:MI&?PS@^&#[H(7Q#,*<V\4LL.Q=RC/$7S+-I]_AS;4/E*V\;KS*.UI#/'
M4OMM8Y35^*^8[=ZR7RR/J<>\C(BW(%!YG+(W4!YT0-";4IME]*VIJ_1ZDOB1
MB,O/,IWRJ^?3+IS8I%HVX9BM;?$'"^^>I8N5AY&HF:-"_7)C2\--:5M*TJ9)
M4Q\9UM:-53 [4P+>@MT$-VR@E@( +F .UP6LU/(PV=%JUL)*,GE5V%_VO@?-
MT4.">%U\'YKNW1KV]][VD&$K8?=)C9VNJ<VMC[UGVWGT?D-:^X[[]"\K7KD0
MMMGH[$]J0M0JL7\(5@6H^9BE!.1/>.%OVTL11E!,#DD8.V[Z.L/8^LO0Q]<F
MX1P\\Q*)),G3G.1@S%"L)O@L&[RZ7%_HK"%43F<45Y L6Q/3*ZM>?Q.[B=IZ
M.W0XEBJMQE@R^-OM\+AA]+ECFG8/RGW_WN5U.O3?=*3>#=0/V<)GDW,XU]BR
M-U#36I. GO??Q\#2BQH,W.2FO(&Z*B\[=49^C9B@G$\GO SF'*&;#KY^_'_5
M;5!\/U"?@LCJ[Y4BV2L(ORCW9O5UD[8!U/9-L1%H<=*<4,8&ZO=L)7N&&-X!
MC$XN07&#>F.8%YW@.:&ZH5$BLM<QX(_^5(WW#T_*KR .I-E9XIE"MCG-G0L3
MBDBB'ED4-9PB3')?C+)0REH,A@RHE/"BT2O>%'Z7,CE;L9HRKT-E ML4OIN&
MFC6BOF<Q"_0!LQ73JYTR5R)R=@QF)BX8%)E6R4Y;V-<^R[8T'VHI'!IL*FP4
MCI'0VF3$]Q9EVH2A>R;/B]BPU(%Z:?A(HU)#\P<<PX:>G;QWUE.J+>04)&?[
M^=YZKMCLM,=0([,#=&3M@4Y5,'R;*/N=\0>[WYF<RNQVK^P5!=ID<4)G] _3
M)B]X]E(W:R^QD,4E(HI4ZDJA&QL,;1?3E7-71(>G"2Z[59].__(G<>\7BK=G
ML-%/O=(S^Q*UC"]8[EP,,W[\QN6#6\#[T0W4.V/)^**59$@8"2;'Y1DY[ 2]
M#11;Q=F8?4@81OP;]0>G)>?)__ +8T?"HD$73VP#($>A>ZU!V2*M!"8/PH]7
M@H79B!L,08*O*Q%TC@6/:H2\I5CY#2'T\E6%FMQ#L5J?TAM2)8$^-[<\U7Y?
M[@(%(F\32).G1E4W4(4FL1NH;-"5Q/FD!2 #W*30;R#/PWW7K*]',KRNNI[K
M>^6RZ^H/]>82\9^MS-RZA>Y<ID:V--_\@X'2ZEM &.GQ:WN7\!5/AE!=JD<S
M)GQH+4SI*;XK$Q=K\+E[,7T#E59H(*)U!)9I,F68,AK'SF;116B8R$"^CR='
M#.O7VT<C_9;FOY<MJUV_L"+%+=['+C==6OO[(;P=H+]#-N/]T$*%F\?$-"#P
M*<^ O_%38+!;=C_5D=5BZ?-\ T6^$Q!!&UOOSY,Q^$#Z:66?U>F"+.4"QH$(
MZB,[@GZ*W5<P#[5A-OT^/6URO:UA%%OQY\7ZQ_W+QULOGEL59.]Z2.SH!)58
M3.<-5"@W E&*?Y2VO0*DC< W'T; I*"VY:?*O*XVA(67^?T7-U!6L>^)N1P\
M#91&D^8PK-V0#OA*,DYN*ORA'Z:X_]K>L^].[QDZ+%:?IK,,=]"&/I?(Q-2>
M;E&?(\E__^!_&7X(4*F+0Q$L)B?1J@",U**O$?*F8>XT]&:GLV5U7\B&S8?-
MF<=8W]?BK[V-6C".'4)(-C4&2[]JP(L8#8*5'89Y-SDZ!C'DFTRZ?H+$V\?R
M3R04AYV-P]QTX_YCM"7\4,7!>WQ3G%+2&RC0"CV_"5'6"/!J)24E5SMGQA0O
M51EO6#,4H&>^\"[NV0R^^WD\8E>"PZ^-'K[;*7E6#XN9?> L.WHM9UQ^KS.\
M]X>'DI7%>J=>]\J ]:^%I07[,%ZSY_O]Q 9"C6]P2SY'"3+R%R%179;(-'Q2
MY01!6)'YV63 ,?9R[T3)R/14?E%4+#/$;2H_4)N338D?$)X*K9:G4ZAI"=Y2
M:<GC1LE-E8O)ATUJ= C?2D,?S1X SG\YORU>H4^6[AY%D@YUL>[/\Y^W,?K0
M4XSYS+<9MZP%OJ/.*S=IB/1]^A_LO7D\E._[-SQM9$^R+U-1*H4LJ<BT(4DJ
M98TA9$M2B3+F*H1L$T*(24C6R9YULDZA9 \Q,V3?9BSC8F8N]S5]OM_?[_O[
MWM_G?E[W\[I_K_O^/<_S!Z^7T\QUG<MQ'L?[.,_C>!]S/F=Z=UOGRIZMI]X]
M4C!R]T:GWCY+DP^:2WB6* #QA%.1X,&)V?8/ON@;Y26%]*@$D2%?:_11(911
MU98]DH6?!K^<MA1)D[#3>J?*:N<0)0%N'FY+%F F[?;Z5,%#;>OC+.O,\_.&
M1;'?C-S?!C()M4,?5;?L.76S;S[N\:<PT_I;)VZM6*M;E!Z8!O8"M(MD*5=\
M80A+-(0ZG$D_.P/MF$%N\@V>'D3',+10_3$& HV"41\DBXHP&8C'A*DNABTL
M &\PW.P2C/]C*O!\ R&\#(C/#&!3U_.;4O+$A:O-OBIX:61\E8K@3M*<P;_Q
MZB6^P8,GME U\?6>H-)$XU@7=?$(1K_LY'R;U_@OJ_/.GN"N>K/U0@(GN A%
M'-NG>P)VK)W]-Q!9QH=J9DE"_/JRMX866FI0^9<.?FV^F;7\&'T2^P-/,\/W
M]S&N@YG^%#R\6TI0_&"N<=3!NR7,<+]$A>=.D8X1L3*7B&IJY;;!M>&$L01(
M\-X?WI +&PB"@/0&PCB^ASKV^OB(6^4##R6T272^X?'<]$]P)]YL(#QPSXEE
M?7-[:&0ST'R4#RDQ5:D2G%E<\ZDDV*67QVKJUYXEX?N/WM!32]<Y)Z<*[#06
MWQ\^<6[L#C!]1#Q< \DU*;:0GU;3X[ES6 N8JSD=9$Q2GN#>_K9P5@!0]6WR
M/\KD\/R=(+K@P(//@_$9+-2/TAJ_>JQH]&Q:MZ;QZ<'))\)Q;9TDZ9;!Z_$/
MY$F;BV.882G]**.PUBFVE8:3DK[R*H!:4HTT^/: P1Q58<GBF>H8[9ZQ8MIX
M,EV<5&LM*I[T*$XT,WGTD]:U)I531&];3AXB#1YAD.Y6^-UZN@?J*,:B.E<I
M9&FT?&EPXHBT1;3WM=#O,YX::A<B6G(N]_ULW%)R3!"E"^T"ZI+E#G=[O(LE
M(65TM-._/74L_[',4[I/]ZV11MD&(C&"K33=WH^$!&S <TQES&U:2"./KCSF
M8I^.(27%ML_JHW!-2N2;V,&6HK<QJ'U#Z?M..^WD#]!W;\XW.1(A%92<X ^T
M-!=ZJV2O/SMLY"5BL#>WF9*KQ!_,_6$O\14*/,[-D.@DVI'! ^30AVC^_J8L
M7U2SF)=OUOGB%X](#J(-7V(^UP1D-JI[7%V]TJRT7DOXC =UTO7"A"+)6TI%
MKT[8N#Q)*9:Y;Z8=*@E86J7+YQX8>2SV#;4DZS3_:PD-:O!!U]"C)LS]"1N(
M]8>=N>NG-3E78'5O88QC\Q_:,_^D_._"BJS=_;M!TOF;0<K8T3?1=Y&][5\8
MJJ7IVJPMT)Q)!]9 T^3%<QCH*.6]_,_(>V''<.X;0'9FK1J,S(J=842I3Y3V
M"ONK'7;$QO[A']6S@^Q.H.^Z*R>5B@?=AF+)FL"VW:T7-6OY)SAQF?ZGT?@_
M-+8[HA90BNO29J#)=^&_:FI'7?FOFNSS7^[QR'XD2V0+=#6+"8M7OQJ-#"7E
MY_Y:-P\&ZE118U) ,8D=BX*-Z%3.0,UWHE8^R_!)<:TV3](!UF1>\Q&LZ5^A
M,)$H3BC,I7_B#=A M&BPA& 71JT!UH]6I3Y.Q(4K*WNSZMLGN +U1%=)._XJ
MHK,,*Q(N6*!:E+T]F4A-%?:^P@('2 C&(:_\.!&:12$P''P_=)8HB7+$@4JK
M<Z),7HQR<AW "^W!\_G>'H&,KQFA9F75F%IJ"BX+M>/#!I(6+ST$2AQV.[[I
M97\D4O*()4)S2["NNDPK;R*$(FGQ+B<OOZW,SR0P]J?8C]W,NW]>8<C#4Z1L
MIR47C_SX=[5-<OSW*XDWUYMZ"-AR5F3-N]]CN@__U#7P;>10+R![?5C2=!C0
M^X![-A!V543V<1OS<1Q+#IZ0?544'_;3%10;N0TCS]0%ZNX3W=#]:,IX"$5H
M$^;*2?$@C)9T0Y8%4'\B8\@_1<X\+B11,_=+OX_#TM'F>ZH(T7%BF3GLK8YR
MLW;QW?RQHA)>J[*!"*I<;;AGY)%ER$YPLF>X_+;[?FR@8<>=.%L+$9(HA5I4
M64*_6YU42O:;63P6=W[4H6DF&T32\8VHXJQF)#\X4^]#,J8K!JU(>)_2'96.
M<WH1B&AE7? J?45KN: C-?:!X)W1D_B"[0/4'491<LE"1,H'Y#:/4@\N1I\1
MO3G1 \E22)6(02_G*]]!M$OHM-[YMKI/4F+WL;YM^B%S5-@2A($B,,B2=/'4
M5? U:*.+9NP=)C=*79]SR-&3^+ZCI?IBNB+?H<IL181CWZ(FO!0CBJ&Z(F M
MJ5%7K'?%4W!FP#'5XWWZ>YN:_)[B]8S0<P?7I9CME F6[#;8BU3L&"VLI:."
M,5XRQX6_CLCR:B5>?Z1F_=H2*K"LF1G/=2QU[6:\MK2F 8\[I+[F7F#?XZP+
M5RFV!>#6<?;,1[O6:M"II2^-1!->> ?%MZF>D$XO#T8>!?I?%D77;;U=.PM&
MT]7KT$43]7SM.WP3KG?HB%,(O/V$1)TFC_S#NT^+RNMMD45<C^0R',CAV6V^
ME#PJ!&JK,#[0E?$*Q\S(?*Q3"F$WG+N6>3)BU-D49>5]-W'>\@.U\NP<V+<+
MWT"4+83NZ:X]A#G=QW(XDGW$8UMWKFA*VJE+9AW/@]4>!%S=)-^W.8LI+VIK
M..*<E0_-/YO;6[O+']X"VUIAB%0R!-1=W4"X\OG\Z)UNH (!.H,F_ .7J_97
M*9M_KTGTT\G<=0C_*31]05SQ-_(Y4F2%$( 786F/"@D.:4;54&TNDLVZ"KAU
MC1MW'HXNTXYL4=..4L+/&;BM'[IN?SDI4_2=ZGV/7U #BI((T*XN; /J8(_K
M]C>MYE3)RM+ROB,C44([76QOW]50&B%JW!':OW]/Q'T'P?1BKAOH01+$8T,S
M@7A1&?TDNG;]NR6SSE'5G^Y)F#GG',L]"K.6"0NDF$:#W0^WQH@K:K+BL.W$
MDBP<X(0*9=0J@P]&:MSKH+VETF9+E]\T.Y[[&J4WIA!!<9)1>\,?B/;W58($
M&]DYU4II!LX8(C_+R$MJJ]9 0LCOJ)&SJ-#PQU2<8C^"04C)C^G-,L4+'#EU
MIZ/:?7^^_$HLPP4V4/"/$[X_B\2HW0=O(*!1[F2WQMIY1C18?-6HU<A')GA1
M/NI !BDC9S2M^;3F<M9L*],'%&>4@]_HY^IUM]2$W"P&38\\CTK+LVHKZA^R
M^75XEE;?^K)>F#?XW@7EMK>81,_Q$$8%O$#K4!>YS.3YW6H4P7<)$B8+D,__
M&)K"2I;:J$DWWI7<%VV8V/&*DG[A2E3.8T*?"J@1R/#IKI7 ?AX^0&_.\CQ"
M8!W&[=2IO.<%U;9T'MW<HEN<'+>N+_2D0?99+J]RV7Z?^!<J,U\^&&NYI'<2
M*9/O83=H:P ]A&DU_)*;N'[+?''>??TR/.(R2-$*-(!XLM^!_AFPNJ,[1^2E
MA>U^?/2,0.,BZH=:HVY!*>MG7^[+ICP8D4PZ6X^@2H3^J1YKNR=+%OA;FGI)
M.YMWI#KD,YIV#S_WC$;Z# /7951X<ZL>;25(ZC8GIW)[6;A*M">_NXQAS6QK
M6?<-Z=?QQ[\J+*%/87M@L>=N]!P,'"GV'1T)"252#]#/63;9>6+K/)R8H:MW
M3)2'CX^./GA0KJ@3:SFV9F,E$6+F86U#Z/LM\N'-'9P&H8< :@HQ)G^@G(4&
M2$UH?I8IX)GY$V-;5A)N5)E23V)GNW6NJ8KIJ+Q)V)D3\_AAI+X1+RLS33;=
MV^E67M;NP "!)S_?G"08=L:W?5<KKF"7L=Q!):KG@ K5K(("2+N4I>ZA$5X<
ML>JZVC7_H&A$/;#G@I.3G:0-_-OLVG8NXO'#1$K'0G_\(.F:6\P,64SYX?O8
M;\:R*^$WRB\_&%L+O[/_ />6B:'IQB7T*WPQDB6#8UZ'VE)WEOY(I]^-&\W?
MWWQ4-,_V2!=$UCB@BF">U7E0BQAMBR[\86=N1(==B#AV+G08O#UA7-A3+4FQ
M?U@E-]-0N<<HP[3/_=?7$V>!ZD_VW3L>$U(RXT8_E$N9%F$!FL#0A5.6; 1K
M-YA,<V?<!ONH^/X0ZE@P[MUT+U:NHB\X).-0Z++[<=NM.V\^J/J6,L'/-_9[
M8)Z4Y@;[.!N(-;V%.1A1WN(JA@'F_;[%+.8IB$R60#D1<)6$)I6MX.C5C^"S
M@C.GRM+RR=9U.;^&,^9CC,;]"T[<2$S5V!<Z1+*M8 B%$VEHDX&N46+]P@Y?
ME2:T&*I41WTDF:>DYEH[)!PI19XSZTPSE%_:6V)^,UO^T.<(FMNPP8WK$:,*
MC+NK5?Y/^ :5W#!^Z']!TC&R@2CUQU-4P.,FC,^@/<5&O,$*V;10Z%(K^S'P
M4M=<^_,22VS[W\2M?]#M4$3A8:\8PZ\$ \W/W8W-AY*M?#80P;<?CJ=7S&P@
M:-ZKK$PGXJQ)YP9B62F,U:$YA2X%YI[1I1D4L&#X.)@V(C^"VZ7YQHQK=5:L
M%_TIW.O\XMQHE*Z6EO;]!U\UQTN'GF<>NNYPV3KC4LI0^]0#2$ 91B669. G
M/1N8##^Y!+L%UM"E4:H).PK>"QGJ?:,;B-DX6&T_8[_;0-@#SV-\5:CH1A-0
MCZ5^A)64; G8327T?XJ^:K/Z:_ +*\^U>9;_'M?E!\0[GN A JE]<+5NX/(S
MNB<)3XMW/2E+[3X,@Z/"AS-">^\'JS'S[5XDC]U2;8QZ<KOZ]9BWF=:,0*XM
MVW--RD_O:PMFY2_"!F2YXK\3-JR)VU8P9:$AHBC1SD36#;L?-!HA@.=7\F]]
MGDI(0/:7)0Q[5T0K]!>-']R!H:?]0MP]^F:G4'9$^J%NI\O:Q<<O?I^%LHB4
M8O)B&,!)!40#DZ*L@+X^LA1 J2:7ALP)T=+1-(,(727@CB^Z2<S3/KM?B'^2
M 1NK9Z C+ "&XKHYGYE]7T[E)BC5F0AP2T6ZK8M><[L\"<,HV[37_TGD6>@L
MSJ4+DG;]VSE8M&!K=O'PS-).XF4BI;-][:)M&H?<(Q/V6<2\&UYO(*I,?N0
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M  9--+3*FM$J284I ".@C$<KBP+^,!#;!JN.5T1.P;./W:AU T_T[D>$M_7
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M[Z:&0=&^9]/=/ZNUM;]WDU*XY7]1XL7:K8H2]/#C\!\E;E]^?K^>$C[^VW?
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M=)4BX!@\;C,<J/B]%/:<*.SB:F.*7ZYV)JUFK#$IX;E*1NL^*%$^5KR==<T
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M>=!B&2=JQ=U6EO3JD)B^T[28W=:O?6,O^6/R<?*A!T_HBYH- M&9XI4HV"T
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M#<.$.[B!!>I"/:C\+82U/ZE;3&3HT+R[]7T?X[U1LX5*'[D#3G_GUF1'8B3
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MFC6Q7XOZK23&#2FGL^5^8?8MC:JR'HD(YV=WBG;ZAVBR0CML5=:)^AL($9;
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ME N!P_YUC9U2K>3UP9!NKD>/F[5;DW(.&F3:CD\]_?ZC [\/-1QS'HVAHW<
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M-IS\;^Q]9U13W;INL"%84!#I1 5$J4I'D-@ $2%*%1"BTD&(H @HL!2D2(N
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MWOW(3G/SD_O-?8]B<3]SOART/+US]77FW.=$O2I+6ZK(2/A#E!,A>DB(MO(
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M:#WOKST7X9T/?![5Y<E"I&2]>.;_"D"=^M4KNUWP_Q&;YU_S9=\M\8#]%O]
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M=$]C+H+Z$,\^T/WNN]G>RAU^(T8%35^*A-.SET)Z1[W@AVW,7.JBRS%+@X2
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M[P[KY7K0LU&4G4^2U<ZU/!9.I,0?$IT(R3LT]\1WY^XPM=YI:8:H\KJS+=2
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M9)G,JS_YD*GHQVF;^-495JBCX3<8.7#.C["2:8NXDT#%_8)VO+"6JF=GF[W
MQRX1?IT8_V_[@XJ-= X:Z=CV@ZLLZ%+"^4 #J2<Q@V(T;0JS:,U,Z$O=G4HJ
M::)GFDH)S=5YW.E^3ZRX;G,D^2..&_E(K<QFPFEP%5-:?JJ^JC'&/<SCC5K
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MHSM()C<K*QP:@GNP4/.1C["AMMU$-,6Q1>R:VW-:V?GAU4!%+:$?GH55#_9
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M70I,Z57BK\Y \R $^_)3-B8,I#X(?9/:%$^WV@,A.AZQ8L4$2YQ&1T'(M]'
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M* &5L;R;RI:DV@-Y+V/')YA<1;F>]=VKD.CF$T[HPY/&JU_7%',3-:M2M_=
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M@WK%1Y[+N<4<HKD]"FS.K\'<"R!E)ACM)]WNK$YSC5_>H2BW/,^]"=2^ Q0
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MK<"SL9PK("\+[D$741[ RB%A1=E@U\FRGLMG!C.$=JYF'T!3%&;,%ESUH.]
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MG7=VDS2U;#'2N(F@==;PN^9.C](R4\6MZU^?%;Z%54D"/KZ#-<C>OLO&I%B
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M+)6-_HS?^YF7O'P<Z=##:1>!;PLEU,>^>U_FL<:O2][:'81?%GHK"+E<YT$
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M=:M#_URWPO&(:C95INBE+\?!OKP&F94*/DKF]_??D#F3"BG&,XC@20S]7>&
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M6/7.HX^+'PUT:\"L8+-7X^ @'4L2P7HMF1H'QHX5L:'R;NL=/%BR#H-#]G,
M>JS)LFF.+'$8 6KI\<PA<UF'L;>Y &OJ:Q5V$]Q.M$:K5 >([R/"L2<9_/6X
M0G8N#LH_"S&[77Q#A-=PV4ZR8Y_']IZ<>V9\V^/SIQKYH W3JC$,XJPS _B>
M%#:@C0A!['CHGM;I#A>VL?V!H)COU5ELY^P39>+K@ T Y25ZM\$E"D'476X/
M\Q#!\WU.<6:&?45.S]>XJT71U69/->=,G(X;A,JG$<=9HSS!5C9RZ*^.$OH6
M9KCJ_7-^Q<NVB[LW(@17!W?:HD0MVW;G5Y2NRHIEO9MMG]U4ZZ#8B=U S4Y!
M6G=KT\5,NVXMJJO/35BXVYIU!T[X'+AD^G&_X!_U\A$HPS>FRL!%BDA/"07%
M1=RB3^Y'BQ(*1FU-ZC*BA 4;=T1Z)UC;?4S!G;WL(W%+&E';_HR_'+%6!"]Y
MK'44+^O74._UEY?,3&E/V[L?@5%MM2A9AWHQ^9 37CW887L$Y553P:/]XEPU
MH"JC'*A2TX"Z_A\"^DEVMT@91/XBG4NN6<"O10CL3Z6XIZ[#RK _+X'1&/ D
MGA72@]L.5&G\[E@*F,C_"D;3+) [AU:=[[ZP\;\RV/)V6;!^6/NNMXU@ZE[R
M(CQ&=8VO\5.'Y-PD5A/9LM PFSD3)U)33?=\*;&W%<>$<Q6@SZT,E8;]Y'F"
M91F37X;,=V1&<?0^3I7L"EZP\[\D5/1C^<H]LU,FR%M>W,/8:U_P5T$;FKL-
MT&,WA;IT?'F'4#!G9A6"S&#G!LX]""*Y 3/H-><*XK0J38,31P_@59'A:VK9
M#>WB>>:YS8MW"G%B8' NB>([RQT%^FT;BGF2($"U#*B7V_]-IK/A7$' :ZL-
ML!\#)KN/Q2;>56Y70!U DY4XH@V\[154$JBD-.M+K9 8L<A#R_D%5>\PJNO/
M_W!/@RCK^\HB%?M*[U6'B:2@[8:4B#7A!KDO7RIRA^NUJ2WM]? @!,,515=D
M2EXH*6=:YS%6J!POE8)^AVG-$;1Q:IW'J-\#Q$S)]34DM80CE?EA8/6!7\UH
MW3(9J3EBPJBNPK_/'S3$?3CFP(92!W\J]R56C[^G FS.PFHPD,$DJB&S/BIV
M'>9N-^20;*EA'OOS9,U"MD%GB+(-ZE8N0R]!.'NUC*G!VUG#_<BYVYD;0]C!
MD979O6LJ26S0++C8LKM@8R#K"=W!_L2X-RU3QAB!!(]TL'72N#+8+:"%.T.(
M@@G&"CD&!G[L\],PRO^9,Z]Q+CDRBW[#[+*Y8(C];-;V[YL4F.@V(D>VQ.TY
M4'6I,,&JQI)R2F=PC5"$5@<4X?$XZ-FK$.4 C1@)_S)2C1#WH\W3>>I,O:</
M6]%67Q?D@]M2:?TG7D=Y?GHG1IK[]%AD+_%[.Z@?S+L< @6'7T\R@2DGKN?O
MQL^.R #-3QR!@1&&RSJ,#KP%)UA&3)&J[$@J/!(KDHW,'K#Y<9H__V4T;CI4
M;.>?]AVND0Q?F9E#@H=+.&)*WP'&5?23HZ!^_95I:<NYN >80DNWFJVCY[ZJ
M%L74K]Z.)H>9U)_>+'[C,R(6<D-)["6&#.U0(FT>0C=":+GYNQ:E_.Z[2D=;
M-^'_.OE1:LL%JR?[@[:+LQ79.X&JX=(/8<[N[W@_Y00\/!P'I)@:(58'2F]V
M/>Q]H%G?\BCAF=GW!M&DZ8:Q^![,YYL5V*Y#XN+?;F/;V:Y0]WPA%#K/%KD&
M?/:S;D>")&K993L+ZL^93PJ.8&H=SP?#NN&*1]CAO*?7=$;"BBPB9?_J':]G
MM9F$!@2$)YVX$7M!RL9VR[5=$-V@6#;L?;P1Q'8 @]]D2<2J,A-2:.X!IX+6
M.HS.!'XH<'9KQ^RWD6_;NU7>W4/?8D/2JA)/: :R*2\&GE[!/@$FTY1"'^KO
MT!A5"IZ%7RWI]GBW\)NYI:+<Z7W^5Z':J(Z/HOH;FZ8COQZX:?6T[4/F;)[%
M1%'%Q7//BFBXOZ WR4,(?.8= :IL.7!?;.I#0Z'.(O@N!:<'.2I&+#\(*[SG
MK*IX"X*\- -S+C2ZV^;2N'$L)!U98,[2*)*X9L#-;%X4#/KK7OW][?7W=P Z
M!(8K,>+F3X#R"261;^"V1@XJTE<.EK-/<+=AG&)5-TSN ,P=#,GS!H<IENY7
MNY;FZ0%<W>J ;'>X?B/[;EY]2RRF?\#WBU"9N^.)JBD[FU',GL07*OAJP'#X
M$.1/)B17$2F_N(N].NAG\.W>.ZY8?7NQL# =P#4?^Y9DHKZ@+V.0<$?AQ:.X
MJP ?86% JS&HOPY[DI0(<10Y?QU6ZPR]E,GP" A%\95B/!BU^A_L2 8,/3C9
MZS#%=9@F\!#WG:]7B#5BZ+,N@1@*4<)-XGI)A,$!:@["N!OCH?#"[-YX<8G9
M=2M7<?N2NVTV9Q3>/.,]0E!FVV$#?OH\08+[1]M:^;@ZW/8N;XL$^$+OV:3I
MGW VK4> HCH%_._42IX0X$@(0:70.DS$GOM>&QX.9T#E2/764GC8 0;C"^\7
MKUO+WU=/:[72.6ZG%BNES.?-W;8+][6:&,>3KA%<K74M#;.7;E[V],PWO,@'
MC<!C;7S4$%^+A]+W-#30>]2 >W@I<Z8[+?2UPHB@@9KO[ZFUA]^N,BW7=MG(
ME%VOJ^?<T'_^^L#M3<(F!R$NB?N55=?8MY?$,,:#>L0Z>,E86PI3C';+S6$7
M>#)7L03F?Q+_[#O"9T1^Q6<B_8)I:^?1"_:(]/:0$2&# VP=SJ&N<@VJO9(Y
M@Q#,.>;B6%Q8<FE'T4L5(:UC",8AYUL6NUMJ7U@:,7UI*\$()V)P:6:D@7VV
M*VXW Q/BL3E1[\HMU0"S1,'P\'2%N*+=VEM>Q5MM?J[*7[$2U R]396A%O2_
MD.GKB4^PF]?"@G@[CH3J%HF,3<L=@C$51P^OWCK^H^0RJBSQ@ ^VA&WB=*40
M-4AJ39&C:P>@./N@TE-@XW5>YTGK'(8>)29#WD_VO2[O$/-46;S<04'_PN)3
MN,;81<A0U/(*<3.'T TX"-I0W3?O?TD3<;;<MQ 75R;(%8',T<Z C]KK,([X
M3+5/,L3:]UP>5<0@*HH[YA"L4$"0PR!V($&=S&H2XSGTU/8&6OXEOBS)L&7W
MV768KW=>23O/M&'49AP^UZ/1%X*(@'];AS'LT4) M2/DXC'@C&N);QRU*S *
M:"]GVCDS%@K0/R;.\:!>H)15JOX]IRC.[%ST&=$_+<&?4HQ\Y<$$5[\2?P>5
MM\%)>8G$R6C5.3Z<$K&U_[^"]Q^]=SBS\#]5X&W_WU3@_SQ99<OO_ZGI:M*7
M=E#!X0D\%.J_1'3!<J%G>"\2-B5Y=B==Y[W7,8Y%'$AF3J!_(3F[Q6J/@03>
M=@P;,5BS/]:1<2C.Q6SVIZW"$<0F*7@(5!CM @0-26D5.]JC$91Y/%3]W(8&
M^#A6YH/J+4M;VHY4ZLP^'\E9@#DJ"QP_I;K&7Y54CE7C%D#C^HN1^C[[M380
M+G&A=6I?@AZ3P/%K6$4M^MM+R59^JK#1J93O0=R$JA"I$H8OKR$:JF,M*$3Z
M-C(S@"T$--(YLNNPO%'C=5@GJ,K^BZ@77GG\D=8YF:/I&;@ H*J>4#+/%X92
MRIQ-HQ#W8%5[<[35W*\S;[FBO-HSJQX1[]V=<U*1<'*"&[@\V.I7[Z\#-GX&
MJB"O*G;(%DB4K+-0E:O+X:B^GT-$#NA-V1VW^U!\4*YSAVW;.NRWW2?E,JVU
M-SU%[O8"Y[]65I:6Y!<41C4;+/Z0?[;GTHN6UL>?!!12M^#D@:H _I8'^,Z9
MD9U%\T%PV')&[X?>T;@+3$3D["_N"QG'A49WQ_WKL.N=.YH619X?.""4,$B(
M)10"G#TRH[YT[TUGF/*TQ"B.S8W.[4#!W+*D_2F[!U(>%S^KF&:==F]P[Z^Z
M[9FI>#*7_G#2485L?5J5'1<<?H7;@:ZY<PP]^ 8^C>)VV'&@3E+G 6E73Q(@
M'OX!%#H4L2$WJ3ILX*'[Q)]_N'#]'+F:1C.4.ZYN$UW]D5ZY;0Q_*OC-#0I^
MS'D?:JD,"A3.0-.1NQ!^^W8!2\9#@+85^7G=$1VHUJZ47^,?,' #=W0:+8&@
MQ,E)%O6HOR^/JRIM2Z."<A=L]D?W^L6=JE;\?FGRD\ 9]-N3K4\?Y<9ZNVNL
M96<Y**UI/@=2<$[0T[SG0(2_C&3++6MP#^43NQJ!'KV?Y-8[@K]>9PRE[ (O
M<73(7? \/$<LF14.A;U7UUS7D#5<(3MRN1+51JY)UN@J27=-+LC)2_NC3-/
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MNFZ$O'FZ^6A[Z/6&5^1AH5ZEKJ=M9;@>P>))YTWL_.J.'Z?>H);5()I&\(7
M0TB49-Y&1@4]LP]K2>3+"5G0=C47GPGT^32N!Q\.%146X'TEM_#/\"&!\DN(
M(@1'(H 5 (;()93(B?7V#-2#^(<>W.=;:N4PQ/Y+Z5 IYW.@LY+'+4*X5FBP
MM+DO#0*91M8+_>2J4@-R1S6]T'[0T:E<:CGA3LRQ.=HW+V&OVLN9%V0JT+DC
M*>NPC1]KXHN!4P3&PPEZ^CIL!Y1CM@B@85,E#D"8X<X^X/;CZ%*][LP!M5&\
M=^VNV+Z<@5X2&J ,&"(HSZ"OKL/F($K-'#(A)2!D_<A7P?C10,?:1T.#2:$%
M-*&I957V1Y%6+T_M:(47<)\["ESWM3>0DT&0.B8(A1K$G-Z?/RXM<%.)$=Q#
M-B$=LCSAX$$0X9^P3&".LH]#21&Y&U [1!)BUN$F@:H)TG^TJI!.D"CAA"].
M89P]^CS!'51@RTSCN)^I:2A:U._9KMEH;\>[/X1A'S?[YS<*GPW:9K,W^+EJ
M@>I':3_Q$W>)J_DJJFT-.GS@D.<A<".-LA,U)-BTI)SL'17LF8]'NY9B"^,]
M"IJ?'-Y\X_.97W)O4<,$(<A(V@B1TBWW2Z(JU; (QAQ#*#?>R3=;&S=2+D&)
M76ZHP-']NNJ&!;FQAK#IDST+4\-B#'@-]\"<@H6MIVQEBC-&SL=T]\XG5U7>
M1<4]WFI&K$7W(W@B>Y@AO I_# -/189IMQ[>EU&T$JE^J*(T!:C\:5MN(0,4
MC/\0^#AEI[TH?$\%.3VE0,HE_487/,7)S[1#29LC8T7%@$J^=!TJ\5DST[9V
M^ A3)/3RU,%B2Y4=AO6_[:XWWZ6='5%]+G'YNP!<DZBS=H*YLT_#8$.NT<&Y
M& ]#ZEXY2OWW9QPH! 190IWOMPYS'1D8X EZ0!QJ>)!<KN]!X;K16/:VYSN7
M9/P<$[;=57<>M]D<I[Q#>E]VD-DF PIO!IS@G4UQY)7?68=U>#@XW!1D?JK\
M,J^*DUR5ON)94@J(5),^SX-ZHWA0GO1]'<;>:@\Y>?4T*6[?K3\?C/ NSC.,
M>%6^P-K]4J)7..()'-WQJF.0T\F7J$'\+OF7[G<Z)?<*3W@5/.5,(PQHT4RC
MU1T7#S'P(9>;NN[3#F/N26J*L,K+7"6GY%$HJ"YZ"33> Z'X<N,4A!2F59?Y
M9S7B#@>UT^8;/'8D'?/*<EFS7')#MEW>GGLIG+65JK4L3M"RN9!"NDP:FV(K
ML0-Q/_70^<39*TPD33U5;> J(RP44R1K<*'LG9Z[T+9-.Z>=E+?-'2>.6M3B
M#E8R?<,Q11Z7YVA0!NA15R@K*TUI;O;2CK+_[?./&3\T68\CT4 =3V.:\K:;
M,KO,.SO--21K=D]OD-]<&.$VY7WP\0F%]T>.C1PG_M8EB!@'G+#(J4/?)PX#
MH!:1%=NSS%>^M@.O9-F_7B+L1#K19*653KA[>8W7/7R[#KM?:#V[Y[[4X+(C
M.EB<?0ER,W>.X=<R\!NSIL[DA#49V;'4JHC>;#)OT'7N]*GM&W\%/*[I+2L(
MSWP:SR%I&VN$<S4A*UCDJ!>!15#0>@[V.7K++69,!ML^>;R:_J+)9>Z)W&M1
M<<,6TT>\BY62GDRM&A)+# I#'=GHWG:.1&9] F\3=(5+V$>5WQ*..Q*J]1[=
M=S:0+-W8(SE]W6G3X#.>>:4DT'C^7SN!)(R FXH3:Y*V-%/6(KJ5P)$-85^;
M'I$@4=X6CPAQNN!A.+$IG^GGJK\M @,WHRZWU) ; V[#)F3VKL.DQ+F'4 M7
M^.LLRQ,@8A/:P&PR3WGOW7LC2JSO<M/059S@6YSXQ&WM[KP=E9&<R,_<KE&F
MZ9]=#A?^3#_"<%^!JE3X0B!A-U0Z&P'<XS;DZ1+.OF,-'%'2J"_7[QHPU=9&
M4@$H[:+X@?_2KP96C<+^0[\Z <$SN;2,G_2^ HK4 J NA@69;N@5_KIA%YYL
M=RZOG8J/?(X7=MAZUR0Q:F#V=H//XCKLP:DM7:@E5_8]7LM)##V%K0AY'Q7W
M<4R-%%7H_SDMR7BP.'$_II@ 7VIZ^ SY"<7$OYO1P\GT>NC("$5\GO^L9)'L
M3_/(/Z-RU,E;/DUX@T WBG6*O^V8F^N!N(?_%4<=J67[A-%Q\IUQ[,O*H$3_
MT[,UOGME'Z>>T)WX%']J6XY7O[JX?'C84N\(.5;;R;L)@ =3UF$1""J4JZLW
M<..\H4H\#&)O^7587S(0R)I'S/),$!7CG*_+Q%D,:Q\W\>'(+R++E"%0S=5H
M<L'"WQN[>FJ[%]V;B[G]#7KN3M\$)"B+%1'AB*[!P8BMR,@&"S1XFGQ:SA!>
MQFU@,3%YJ^CYU<?#$^R1^, ST& 2N850J@0H;PB[#.R=O5GHW6Z](XP8T#N^
MN)'%_M+Q/H+7?6FU8!TVL.G:^+7,R(=35V:<%X'?5L<7A@I6R5"/S_#Z$8Q!
MOD"YG%]0TSS=08I1.\*(],-FWXOJOZZE:A96VGPB]4:@XJ8BX#R:<1Z^:I+(
MEXV\W5P#K+D5$T=]2/D(\) ()QW)\E^'Y3M125P=6Y2)O^65M MO?*[C-G?X
MQCE3R1RY[1#UR#'@W#AW!/>D6_RJ42<)1:(P$*MF*X\ADTJV@<)<^U4B-"3!
MKM ;5<IQH:KZ;L45!V9ELG..'YQJ__)Z_/#K!V74;J*SLX59AD/TKH7Q^)>,
M>G%KX<_5%4=D73J^U[\O-HLP6<P;'<D#.+O:62^XWPK= ]VK*S?'&3,J:$>>
MNU<J)+/5Z\=DMCC(?F_6%&T#T[U'<^^KTD=" <:=B5HU2ZBR>=H\:AK\T(#R
MHU07[_6)OEP5GU.PBJ*CZ-%L6S\-EB WB7.&J5K_HM6#.B+\/<UCEK;#TU=U
MU_.!TZ]A9=^LI Z8*L1?-.,8@5/\$U"Q5N0BBU>\?1P-AD9H8:_/-2?RG6\]
M]U@^F"$#T6RYKS5/NI1R_ N97SE60YM?\,K68;'W=L5,3)9P=F-XV^2I *B(
MK-^!;I!&UZ+%_&IL>@M/:*N&J]]-*\A?&/8[M+C9S7XE],EI[OC1UJK6 ( C
M/MRG3J(D(@HW_DB+QPID?Q7H\;A] ]BX@=A&!/>+<"24_DPZ/><-]T^$X?:#
MP>;?&'=BJ3*M#I;ZR Z/G(,QWJ6%SPXM;GP=(><%J[RSK7$_Q7')D2<XM Y3
MKN"^)<V>[@668LXM>N[*V6=GY>MO#]COD+^'?L@S</^C38U#C.T<^9<RM= G
MWOGLM;9_MF]&_+.9]348%%WF2D7O:'\%4.;@_<W6X"FV#*A'38A3M06J^WJ4
M/"Y8W=7Z-<4[F[.-Y9]9HK!F@MI\C#B!R,!U 55COOF-S#"*59E9_=Y"C^MG
MD51KUYQ@>.U!GA588&^CH[/OR/497S#.AET_7TU=ATGJ_3L"#S02:3)47[@8
MEK^+TH*_BY);3DZLM>U:Y86^/$G8P&N#,TPC5=&@*KQNOM^+)IZ3L]PSGD]@
M!+FV65\MM"H,/:$C)2#?.I@;>W@,YEQ/"PDD\ 03(9_48  <L4TL]W)F8KBT
MK&GMR5 V4GCRH'V!.RKY@<"G&CDC\T-'/YV6\C%V(=UI!P_C0W!ZO &$9.6&
M:;AS1[D_@WQQ:_W6N#%RX7B0E,$DY+QJ!UU]?J0F[[M_34D2NL$':/#.N1 8
M5]O[QCP\'$;,P=?4/0D3U:6%3\.;OVR9G6BXIO@KW?>0KF#-?DU28FNK@Y D
MHR^PMVMLD)P^ADB$]Z-8L<PPNA>35 O?Q?'/MOP,)M<F'J)-^U#E97<KD]\9
M2X></5/]Z8E#'A0? T!]5^8H3S" 851S_2G..XIWN+CR6WCN6)+^^:%\46[O
M-4'"+?=JGC)'@RE0A0Q/(C_EH-X/NS@H,)8'$TY&AW3>3>J]?=Q)GI0EOS]H
MF\(N]VDDN%\CXB8CD2,A1/'NIN]SU25ZWA9*U4,Z>FW$?W2%R?U&]:$*[R_\
MGJ6ON#PPI77SBE09CJP*R(8<(.02Z:]AI3-7:J,M:*;5CIZCECXS5\^FKL,N
M.Q>'FF\/%0&7#(PE?GS?_'C7AN_$X4<<&Y $^6& '4<:+*+A!:;A!<&Z:51[
MAWG34@0CE=Y2O&B@T<#RA6O*::$/)'!=SR$%<]?H:RE6)W =BR3.F1GV:9'5
M+)( P-""H.CW22Z$#T$7<(VIQ[BAB!OMFSF'F;T%[V;Z)YZV_D;?[1Q+LO4-
MLOV6&6%T#O*S@TUB6TYO.+U/D%/[_ZA7D#MK)=PL*G<NM@M'&#_K=.%D.K\$
M:,9N\LC$HD!1VLLPR:3ZN.RIRXW<2?J=HGA)AMX+."C.7XZPE0<TW?QSC,SE
M&?[1KU8=0)4+@E)(8JSXX?;5&T+U9C4)'39Q^1Z4H>A7</=XS>NP"S]7 PQ;
M>;UT;EX[Y -;N>NP?US$^N^+3'=DG/03$(RTDL)]N&?>78K($>3)<6XC:,0>
M8&8!PQ4FKVQ'UXQ$D7YC_F[8D=U&'9K&DB[/+&D9\TMW8N:):G[QON&/( RP
M$ ;_MR!,X!;V7[@^@B!PNV\IG'<(>X:1^>0WN3;S@KWS18LK?@?[QO<,^@N-
M'T)Z5%<&_E^5B3D0$ 2W"7"ND@H:N %^P>NPO[K<J=0P*V9GAIKZV%K*F\$O
MW]@VC(#1B2> "WJG^6<_@7H'<69QW)[4JXE)$ME;TS8CHV:=(UZI.H)('2@Z
M,*QW6+#B&%#4JLAR(Q1H#TMC)%P_*JST)O9[EG7GYE1#]]C-:+FIE;MW]4$]
M[\9QNZ-0;=:L-&O.]@#9K(W@ZGO.&1#(-G?,^O75MEGOUMWE@+L<%EDT."PZ
MC)8IG&%S!DY&S-Z$,@B*-<9-,E!E(JH6[W5P+%T4W7UO=+FN"/JT>J@CQMY?
MWGKE%^5HTW/+T0>K-R:D(X?Q29R]?V&G&Y@US#@:/M)0&WNQM]QR-,?1FEQN
MDVU7F!0_ERE_JOL%_F7HT(K/J,M%V,6-CV$;OZ7&LQ&0X5L 58I4T)5FQ#;W
MVV1Q3=L2-^51CG'VD/LU.__^./XB[+Z$SP$% ]Q2^@.G6XB]JM,,OW#K]YDB
M926QS<J%L^U\E1D$SYS00&(+NHRLJ2Q40KX6G$X:VY4*E>M?QF/781FNZ*/\
M<@&^<)YG"/SW]L2G_]J>N/K9E!,M"::OR8KRI$!1*+H\ 4TQS&:>H"]#OZ;D
M6;Y-*ZU9?R!\R/=(Q_62_E3-4U(W50*32%]P\9S7T TJK[^7AHH"#<I3\H;S
MF(\.W_7D]!HS[>L)X*+ZJ9FUED^T[0@/\;&U+^EY' #Z_@V$ZQ":5<3/=MAK
MS L?/2?..!/M)I.NNO7%#%>W69>46,GFQ\[?O>]@>FIF_(VG0PC;SD]ZAHJG
MHR!>+QGV'="&B[OYB$F=&6X5'\PR7Z.W^M,#C?=F=44Y%L6VJK7WBX!:^%&?
MCZ[,$MI\C6]I:9QQM[8^L-OH;LOYHW9G3MJ:39_<^O!KU.Z3X8F(AZCI"8Z$
M,QY41/U+BQ=GPM<]QFWXVHUP(T8.*UMA\B=Y>THZWQ\?#>RA-9$RDLDSB?_Y
M1Z0E>^P'1PQ]RSTF=V<2L('SA+R<_(^CI"K_XR@ISNM_'S%5N0WX9_.4IP!#
M?F9-ZZ0,00*Z,PU=J/Z1BG@"D:NAM.M*YYE,L/ER9:^.B_QQO>VWBV<VDCYA
MOOD,_"P\]RB+^-TP_K]W$]I"E:(MBM;J?9MIL5W&F\3?.LZ%"HS@XSBEX6NX
M#OC><DG61T3!,GKG]1GT';4%_V+R05F*C_X]AME,O=<3?.\\>,3RZ:-$SNZ&
MT:4'#[(IT1<N+9M)-4R_(T$WH+3C5\V<:S782KZ(-:^N;%8R3Q#R?.6OW+>(
M6:,>TE+\3$U+? '4%[J9#'A#%E\F4NOL*"VL@<C> MFJ[AQI#_,9E[_Q7!OQ
M.XO#WV!K'0U5QO=FAB%2&5):X'1$:T3 WXTP/"4Y:<119Z[_%&G-.Y_X>V4?
M:CD$>ME=4%R4YND"Y%2HES-M57A(=WP8]*=C/(T.<5NO61*XWYGNG\:KAS.N
M )O N#K42%^E)%G^*V,\TZ]!M#^CT^.9^7:*2<%GQ5_<'N&A[+4*\I(J?"_X
M@&W1K4:M[%RV=56[=^/YO1B:U)[LM&7KRZ8_R8SY*-2D'D<,S=NI"?:P-[A(
M8YYZ7RT""8P99.U]UY/E\[*LE&T-<W0,[,Y9V8UF^0=CQ*]:W>F[/=-HE4&Z
MD7E)36K9EP[Q_=8(]X0D7@81UUYYM NC_>V]/XU!BKCMHJYV1B'\;?G%9F6I
MZM6FIS ]LX8D3BPW@W0;$4'(:X^1J2&(E8L10;VKS?X66;;QH;,:6RBOO?;\
M0%3(:++)2QUL :"J!EY HO?D3/%D2WKGRS>,>IAW"@6*U3)S2 .'')_(5E07
M&!U0>_S)1N&6B9@!J@=>2)K]1H$/"%%UTRB$"#FI+NPE:NMIIYRYN(F@\[L4
M0\^$/;-JK TW$DZ];WF_JS7ON'^ P7G,*F2FO"+MAZ-JMP#Q@S'Q\_PYO_9?
MMA<AK_;B]<NI@6A?G_X$PH<?B4FGV#MR C-;RB@^>S?Y7;[$K =']MT@/T9U
M=65EBA^?;7/^\(0_LYSW?[+$X&_!5SA?\'6$UYCX3\'7SG(MWG;(7Y2[N*F(
MV=<@!DJ6UCUSWJL5&)I%3PKSU_D.TPGC.\?<%PA_KTQV!>&\)J<_LJ[<:\0F
M #00X%W*I #LPPGP-;>>[#(HB#X*^RAN* $<UY96)E8>#_IS-B;BO0:H'3#:
M@M@%4%*'Y1D&,81^N CVTM%M(@<[F1)^K[AW)(TF@RJAJBOX!^ \'EQ+VLI3
ML:UM2;0N2=U#2MQW(+JNY],Z['OY0,TZ; ,Q%:#TB@R8-+,\N*2Y<J$<N\!D
M8[#Q5I*!IA;=;/FXS?N"H1G20T;63.7#%2(4U]0)L\:>;+\_BR!<J2DJ0W-8
M*^J72F4&QZPL*:#Y[(.;EX8RGDQ$/,)V?IQ4'7,'"NZ<P[CB2A&UT_B*"PT+
M5XSWIA<%7FH2YV* *B@PC8DB-D+9%3:R=D4'4-#ABD%IB40I@^<39R%7W#P.
M7J(@]F$OGX1'&NB\U\G-N(75R1[DIB(-K1M>[\BN'U'=%'_KQ#*M_/S"R^E+
MSSXDD]^13#R,WR\;B/%$H%#Z(H,AR:NZWL"+*22VM(.*[1&%(Y"-FO$V32?5
MF,HE.X\.29O_?LEYO@[[4+OYZ9K\31)%AV7*V5<'(;48?TW9EBU075MMV_[4
M$+K<TU)RC30N8V>&$LN2'M:7ZJK6XBAYL=;VH.Z)BZ<;CA-;]F:X**"B7\ON
M'',ZKA(@:G\B4"KP@O9XD@^0?.A]!3N=_9(X9L03M(=>S0**5G?F^Y/K(C,X
M)YB9^'+%'#>R7K]Z&95^*-!:/^O0R](CU>(^H3?+W(\\WMUT;N[R7EX"4*4,
M4":1895ZH%6ZGQXKO$?=0'[40VXS5! \3;5P5=<>"KP*RV]QM'91VH]E)S8[
M)@B7%6L,KP ,%+'O7K,YVYWW$[[]^C[GNSC%HA<8-BL7S1A(6IW5K[OAIIT6
ML*J/,,&HVZ0S\;QM_/PQA[4 (]EG_'QIB :1[</\WS5%*RW_.B5V/2)G^12.
M=L3@4O(#/=.-/W;]<!*TV_$LTTMS'68L#J9#'?<0,L%W!LHCPLO\T%C@,<;*
MRW4_VNP4,*I7\J)SQ"(BM%?W'/6V_X\CFS]_^EBCOG &G<.!_]D95?\(>/KP
MJWJE9K[]&><]7JI^2+M;N;NV;H[4%#GQ6PPIBY0*+[K^'&>NE,DY?J;ZI#RC
M@;=S'^15C5B/=1B1#O&-I8_WL@9':JB!7L5$\&JA\CV#5<34X$@@66$,@ X-
MP!8U,(.YZ?O)/#)6GJ9?=D(; MS\5G=62$QUOZ2AW8\7Z@K1#2UOWSBGB<\#
M# \"G<K(9&WB?L)ZTQ"1#BI0?R.->\N5'P[H$V:;(70^.4I/6+@[X+$GQO"L
MUXNWGE$3,';\5.L8)T)_(>?DTM%(NQ6$'XE2B%AXAL$36$K#Z[!)'4XP:HFO
MKGH2"EM+N,9U6*$&1VR>-A&$E66BV(YU<LJ,H3;"!QL1X1DH,;NF?!>LO%T<
M(3W1\TKD$<\SP/J$K%17AN(E':+5O1#K%YB_//0O$LRZ]Y<6)9C=\[AM\RYV
MI[3>E?@;@6>D6H$[\"^F=.?WO$%$ON030R57,=LO3-W$/24_SU(K:[#I3CW?
MEHZUY):/[M_T\QE/TYV^#@/E41P)8AV!<8ZX;]B5+*$%%E QX1-B,](;F^23
MAK%;V$[I>D)'K2XV_;(1/ZUHAK(ON"N<MZ<KK$ZVO#'#$/5QC;_1;0=0);+<
M#BH_E$;4SH=X3LU#$.6C=*&R,U?1]B9-7^<6<W-\N/'7B-??%[>A4%7>O][R
ME$& MRV3C?)+KF^FLH''(Z('*ERQQ)/S%W2+]R\UEC[_+ /TC^ ?\:(--T.A
MR/_/LBS\L&S06ONH9"A6S^"Q?[&ATO/)$HD6$Q\]0K&N?)G)'(DN[5L_#VHH
MS:8P-&I\I4,FZI%"X+-KJ&._0+<KG^T&]9PNP6YO7BM3B?F-PH<T.+J8_LK2
M\\A]79BV==XK AHA"$VKY 0XN\F4#SF!M.04/6LP8S189D92U]]/N\QEX59^
MJ GLBW#+'$791^7H6;>&V9'_7=IV598-E0=5S@9\^W.%KM@%RIS[N=3<+LB1
M9ZBG?)Y.N&Y1.9.]HOO 5FULZO(5O\7J=^K6B&.A$TJ>7$?N>^_WC)'9^5'Z
M.>3R(R!,1RBQ_9VM6<,J:JMFBI,-9$-[/G,-(D-RTCA(U+(1Y+YCO(%'&#ID
M8)O[& G1BK_5:.TANDR_*ZC"12T5HXWT_&2,_0O;3SL:@ICG!(9T.$0?(H;[
MF'^^S"X2Y0U<CHX-8/#6M).=^[PM-2<E\WMSA+:Z'+IXIOZT2I/1 2F!+(3M
MZQN\ HOX>T6F.B<>%*SQ?P.9 :HDT_C:Q%B=CB*BH/W427@=()!=E^DP<L\B
MT+JU1,OFPJ20\FY99N5>>>W@O;&O $- @D1Y3BA<J?)PHS78@I),%2./PR&Y
M#RMV!E[N^'&\J?UNOLEWUH%OQ.'YODV\G0'<),"%)&+3,+KCSB(5_DQA@W/7
M\J_;2<V E_BLF>/A22=1/;8AZ1S_/"TW;N)8/OLT]VVER*J?@$"=S[EUV$I5
MG"_U&>/^KY8[X@&'SQ1-0GT5G;&WV9;02IJ%0O]F(>XGA)NLS_ PF7KG&Z55
MUYH[]W%T6[)Q20EZ?N_81E_X<IN2TE2K%XF!0H*'E@"&!;Y?HX:T$Z J Y(.
M(WZ7N^Q)E6REOENV$9G?(M(C](XMD'_829PXH?#D)W"&( =01A%]2A3K1,^#
M' NTM-NNB3L$:J"AQU_F$$2^?%JR#JO,$.?PE^C?@GCCO2Y$-U<Q_8L\"<6P
MD'%&:F+FY$\77=U$R5OCM&LWD_S/=L9?_#3K?,)X< ],3^_*] W/:Z4]F,L&
M7Y;688B?;9>>7;^'S48/2,Z.T 8 .*Y=;B/Y[FI!;[E^YLAW+\(+6Y<A_[6C
M1)H/Z1Z"$@(P/$N"*K=@M__$"7,>E7<7)J.%ZGN3!"+/:CK8YKP:5[5X-6H=
M;T#Z)O,I?W;;9[$[XV_FA2X7'6]*(FE,[[D=5P#%QJHF$L,,$4600MSM8 93
M$X.*\'*3..7.'#5O96T7PZZ S&';M+#Q)^:QZ7Z7#\I>?6QTN*&Y;*&=1> ^
MP:GCZN7$&+@\IFE54E@0E=E7SFLH[I:56+CI_CLBZOE63>-@3[G-3\P;]SLF
M\;*6B. 1I=F"SV"@]W$< JMJZ_-;@;<_2 A?+WE3F6--@BQK2@-4-JT6&0BN
M(P@LM8<X'"MBODS=8N_B+BGATZ56J/;PKL'S%Z4JS82"QCBI&\<GE,1C4%&U
MW_YZ2IW++0Z4"+D:A5-H;USCE9,HSP@%B[B6$88%)EA.*NE0Z)K'QE-NRWNQ
M4Z?813/I 6D$Y^(6U"*_AFW@1LZ3,",#P'= F-[IU.7M3O7*&31MZ-/^!00\
M9).>ONI^%U?E>V:8E(N/'I'DZ+'5.=N82M'E9Q0>84(-Q-Y;9MFMNDG>/FIB
M%J,S>8UR,&NZ[O3,%4(O27';/&F2=/%=B?.B#5^(CN,?-HKDB$?62CMEOT\8
MV;ET"E$C=! >/Z@Z; %^+HD)&S[)F<^M886 K1]Q'00YK.LHU]YG&J?=.Z]3
M]G+'MUL!$:F7GP&E9<7X&R=1\/Z*01T-YW/:; 7'P_:#RMJ7;%_\?SJU_=^G
M)2BG%\EFP=YV&,/^^X*J2_.\'4=&>8*O_R5(C+N%FB)SI*$W/&S1C9@UZ28M
MO6O[Z@5?<5T31]),E[ZAV^8Y<O+K,*4:*/W7WH0R_(H55Q2U6 'U23A4C#*P
MQ_C:\L!4X!"VTIRW5"'58TM%',S2OH2^ZQD"V, 9&&=.6@,%SPV>)RU-^*(;
M26Z\$!(E!LZP(_1A6-90#'/#JH' Z/PS^"\Y=<90RN#UZ">,X1QOED_ S&O4
MRO/KY1XO8T6:&J2JJC:+2!IDG'QY.<ACY)\(FLP3.;X.BTUD0;A,Q.P")J][
MX Y(<\]#7)3$UR7:"E#2I.>KOE7N\JL%2Q';JSX?^C32I]<+OZ.WX_8M^!0$
MEKYQ2H-MNHM143P;LK75=B.AO:TV,ZOY;OK-I_D=3#S=PE7A+TY=AV%:M5@(
M[M=Y QE:Y*3VR';.C>(P\X!OOQ=HA=UISNY*/@9;O!1^_EYR_?D"IL-5Q-J"
M5F\Y#T$T360KF([$7V7,/]->+6PUZ?SK=.KVB^E1,5<IC)K-^W:=V4@*_^+S
M)NH9-Q;JCRM 55=2XO=UV+8IW 9NFC;7L:Y4-S7;PY$VLR-_.N'+8_'+<Q+R
M] W Q*<O<9OBX[\14UOS^^.5Z)/S/;BLX?BSB:H&0CS!35"\_<7!<>,KY:<U
ML0A&VT>F^W>M\^T?W*05;@6>VQNQ>NM;(7K8/_)GH5M'L5:\TJW5^=F\/SO)
M>=U X4K,YZ5&P[T0L(DLA;T4&G*NZR5FG'&"^RYD;'1%OJN/,J_WB8KE"G/X
MYSM"91I)8BD<HST2D[HESX8TEEKD\]#_^9JF_>?;CN3,-!U'&IPC4<:Z"#IF
M6/IG<?Q!?V_QTKG;G=XB=%<D.Z\_0A;_9>NW]"3'J_ZRIP+Z>,8!QS%>W8A;
M^#ZM&M*7D=DRRGQ(I>20>B)57_0>&;DWQO(O:H3_G)TP-2,^Y4?C)A\!&(JZ
MPI%]#26CK5V&6AQ71OMWDM"TQ,H:IN8U^@ISST_#)5YO['E7C]CZR0,:95(U
M=IIO-(_FLGF"$,X*W&B@803=''9PDQ]67$$FK0KO!@>LGQII;\,Q\XM.' BG
M6.@*+H8O%C70=+,_#;F79M0MTUM6$A-?%"X.(@^\L/E]RR;EU4++M1?FOU^X
M8XEJ69\"[U1R)6TK/UNIJ#ZH#2+E0J1W$!&I5@X1R>9D4,3?O>4^:"VT=0)Q
MJN!4V3ILE*D#')3-7H:8; OT#DL_(9PA;&UDA-$6W#JQ!E^[I1>->^D7!TM"
MDZZ\3G^Q9<OP$$'SCD&IOIF/X3HLL>!$=5L1?"B[<,Y82F'9,(]?%@"4!,0>
MA#L=H*[#:M=A(972%<P4<MC#OD(UYW-=W3I+]U>''XH9R_F>*WO_VN:B!/HE
M):@.V(N#"K(J'=YQ',3;F]0,#W),0/]</_D:R;661UL*9E2*2ZX,E6M=V&-[
M3&QSW^:P@/UVCS<<(F6U;P.JG  GM,RDTJ4"<)51+W-?J^!B;WK7Q#J,I+=%
M81W6X+XHP-N)A<PE!2O$GQFZW;Z-8P"Z,P4LF)E0S2@UX)[HFE&G7?REO\$Q
M<#NF\.ZN LS7* ]KM>[GQQQP-I&U=0T[J9D!IT2]Y>'/)DJ J@_HXO$4)HJE
MWX,3G)9\#HUAJ%Z!@RNK56E>O3#[VW7,L3-CY66O%:T;!!7#V-65?$&L*NCM
MU)80H HP6XU55>OY$#F*%&GS%A&:\:JWO^N\?_O!.$S+C=<PE- ;\6A&_=',
M51MN(E06S,O@&A RA8APM(AWQ$.$F(MF8I#3169+E&ZY9AK-;,C<^DJW7.U&
MQ-N17UZ\G1\AO.JJD?!!2]2-5",E/WWV%5$L)_?K#+ZJ\OL084.[_,"GY>W^
M_?[XQHQ7-U0[B<MO3I+L]9!=!8+>8G;Y"*@.<8&#!YWIINSC8.;%+F]T,$Z;
M[#%[6T4'L6,J?T97[W#_V1=#UT+D"6]4=T9]>J ,;H#LRIS[D>1"?R1S"DYI
MB-;V4[Q/!&CZDC_I!QWF'"9-;$S9&R(F-QB@EIHS@2I;DA/]0C-=E/<3L<W:
MP%G,[T.;)$1$]C6^2T1]L)6_K8<_#[-%N^]#*5CU#@R=UFGQ294M(5@E4-9A
MW@Y[CFV:FTL?_G2B^%BNE07:1*[I5/MW %3%<'9O9/.VZU.13Y_/#*L7,4V?
M80',1SNW6!O;O;,/>XO=+^95T\->PD_ESWY\(ZP\/T%BF+:OGD-_%V'+/21Q
ME:^SD*#Z!$><#<%UT!?L1<;=5'%&S$<J29B#>+8F)!-]@2J]<I5]Y;3-[V<&
M[_6Q(1O.OG!62) 5:(, SG(^LE(.W,(.X.QG$B,UVN*I!"&_W)K+/1H&$4IL
MM7(O58-4.[>V7Q<OB%K(?4]5)6?0,T)P [0"KD=><HEN,KS/"L+D8A(G%55'
M8N];QG/5DT@?D&"$%@O"[G?MZ["$&,A;?UAQ:G%=/*TNG#RN<V07QRA],)!H
M1BZW_.BFJ_6J'W%R>^[[%[K]WS7'KNT[NMEY\R8':Z._<DZT=D=>5^N)5C77
M2:M!+3M#L78(:)*H%%J'E>4 4XL7B6-:1<#I$?X9BVHCLR3V0<A6CQE*8?7!
M"*8>3W1DK]]#M^"+7>LPZKZ>7 Y>WZK\*_Y/@BP][(B)C]&[00D2L/8_YZVL
MN'F 9(R+2E([[.:?R9'#K,/DD;.+ZS"'2OZ1DTO3G+,Z:U"H%-"&;F"*$X;^
M_<O@#.,>YJG<,4/UR.J$M5*W:&Y<X$W6G93/449<E;V1]Q9NLU_7#WO&$II/
M3C>E*=]TE,H^!>A:FOJ[  YPQEE 8@ D\[:?8,@M=(\?QZIN>?(?D0W+_S'D
M+'27(SAE'+E_'5:S#HL8$<+J!(SJ$W=.%;A<[XV_D3:?'M:V^#9)>;'4:DBA
MJ>EQ/B=SLX3J L#9)<03FDCC53GLB*.*U(WUO =]/;-TQB-S^M.^&4J[7KCS
MS&R/9( /,/SO>,@*J(8S;-!]J/HUT>Z[E8;88Z%#)CYNTMV/H/BS,DYY3PCM
M7^TOS-M[_DKVMB'[ 8L/KTL]7]YM'VL?+>&(H4?#9BL8NF2:1BTF+&DB"*L%
M?&YX.V"8G^WN?6J@1IMJ7"!ZU/ZYF>]+H><P!?*DTG]/@DRA&5X3G#WS%#3=
MF:T(FE(G:M#A)]'1!I8?P+8!NS)+]<,914$]1_X7;>\=U]3WI8W&+RJ"%$7I
M)2I-I2E5*8F-)B(""E*CT@2$B(BTD"@H2!<04! B@B("1KK42!=0D=Z$)( @
M)9!0PH$DA_?$W\S<F7?>>_^X<R]_ !]*LL_>>ZWU/'NOM1YTC@HC/ES$9[5-
MNU!DW@1FVTGZ?WD*(GS<IN6&ZZRDZ5J9NJE1"+P.1;.';QKJ<&XNEG%K$B"*
M2$Y'*/1A.#+(LH#@!V]^J1 ??.)]3\5DZY7S8.8^H0-_XB.W80^'ED19!Q?
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M*19"GC2O"3A=/F[4]ZW;"8330-U7JPNG9E-OJ>^1?7]HB,Y;9!FA>BWJ4,(
MIP1XYWMHS._1B'U!QF8T0:JP2U%0IGG?@$]1G5O^(^U<OD.PPF">1CR:Q3!:
MW2.5%Y^F-S-R9]YBK(?T@6VI^4&NVFX*3K-4 [0UIG"+8W1NJWZ$T)\-E# H
MTZUD=FM0(,JN;TK_J:]*-+^2VAE:%-_NBVV7>U;3FU# $6.J'3V]U=)3%_>%
M!/>T,J$XSSKW91I5//78%5?E;/],EU6M*/5/$&%.EE+%$AF"F$5![OFP=ZQ
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MH O,V*FA-QG!\FDBAAR7]]6(D^>CM1GM%.PHSZ?L(N]!F.EXOZPB.$ $-#9
M*],I E.ABK1UO[>0TY00 EE'FSBE$=D+N*WS*C@$G.:S0272B(P][$J6[>1R
MK(P"Y%ZMFVOPCY;*0[V)BPN0#U>?6UY4N,YP,)2-:]^9[W>%J*J1O(-]$=H:
MD;A&+,X5GX#\%-6FMANPG6QG$*+UKY&IUA=[%]LCM5X@^ORUBI+:,J?+KSJ6
M[4B_P7UO5]!(FDQ1R0>_6&_S.XO>ETW/M:^ZH'I%61(&]!E.^RD+M%"0C#&*
M*AC5</3%GL9I>^<CW0?@14U_PO;9KH:BWI%H7MLP:JX'4QLD#3GO'/RXJR&6
MGMRJ&>3J,1I=\.6[?/:R$S/_B;'3:OZ=(4*F9<#=WLH%5"VXZUO!Q5X$1T+B
M*])C)NK?T]"J;(:R#Q)3_I6&!B)\(+KTT'92&F=/HCDAAQ-P8\T@3_.4!=_<
M%:WN&(Q.5:L,/%K4WR+X]L=+Q_7*/^G3U2PRKAGL($SGT92D$DJSX2E%][=A
M1PJ->JNW=M"X0/Y5X"7S)JY17U^6WDQ!%.8'I5P??-=_A$A[.Z82WQ3K7?W:
MIC)KK.O9ISBA9#%ZMGC9HU5X @1ELO!PA(1WKV?&;",N1C=LVD/2H5DT@?!#
M/:$DU6\I+X9]%UJ 7;A&"/9X0(3/@W&,AF\D1-NW59.IH6=KB?X%XYZ)?F]_
MQ<9V>)B7GITQ><SS3XJ<U^NXI7:M+9?7N,:;2#>\D%TY8QL&!P^VQ:@;#CWU
MH4IMP[ZXN:%[JS_,G*K1<A,5< OTD1G7.G]U<C".]12:/#=.934>WB"&'6/@
MA.M,*4@AE@%-)CUO8A3%?V_0'.&#ZWZ:=\5XYT.3^=+%%]57(CK$;IEP;U@P
MDH#4/)8$.YOE-_G]WFV?-1S_'YV:^*E.K(7J4>FO&S].P*:38=-#WU 22#)Y
M>4217!6UM"P'5+P%LN='_&7PE"[/"J78=^"\NMISP=JOA<NH6"BBV\&!4^@6
MZ!LK)$]5<_>N/X'9_P#V?<I#/W\Y\F@A]ZEK_P%_6D\G"!]VZ+#:#.!S^I03
MY P_D/#QPV7]PJ6^=;6,$_$I2.V%!0O@<-3B%JD\BB7L0IZ(Z=%,TT54-LC6
MG=JT43&PI^W>AKGE19X"2W>@Y(>6 ED2/,S]CG;YB<C;TL[<"9+O,YMDI 6(
M"[88?^<?&L/J9R4^+2E*%_[QEP"[!(\%VX64\?K5)0X+CAV8:H&7;L,6W](E
M)^6;C;@C,'IAA1<(O9YOGF0<!0D*+3*+2D#) ]763.7KT\G!"L0\04"/F]%;
M!F@P!3VA\+GXD2LH<7)@S4??A*35\-)#V?_KK%3\:M'^AW?%,1-8*Z5-(M49
M>]XX+?8]V,<27>LJ5KG#.>X):OF_O^W^__SZ_/^?%\06X1KQV["5Y&XIW(@&
M<1O6]S$%]9Q=N.X"\G%:/3]/!:; #LB%@EGW,S@09=SCCQ,R&MZSCM,CTH(2
M67C!9CAS?Q3'EV\=^9=^,$2 *9QSP5LG.+*,'S;C4MAS(1KOJIJPACW0N&S'
MI&[^3Q^5:YQ(?H&2N<E^B2/GH+CK_.[/R>#? .^^H;ZV/Z4J^.UJ#KN@_A7[
MADCHCB/R%6&U,(?HMA$!!J21!I6>I37OTMT6J?Y[F[9AP$(&*.O-W $9OB$X
M*H*K2E_D@B)TN^6OX(S^!TJY0+CZ6#;_Y0&;TQLAP2_LGLL\N/22D#')JW+/
MQAG_@7TY1BV'%1.TVF@?U8R66G"6'LC1WGKW"(?("MZ_#4OS/R]K? 3DR[,Q
M)?PD J?1C".?V2E$<NXH*;J(G(11H4=\HQL^KL5>K?-H99U>:O*?H??XNDB]
M&II]&PJ$=!:?ZG>RC$O-2IQS /GEH<5PG"<Q$%ZH+3,7QW:6#$17C@) ,&1%
M J1MF'G-DZ HEB1'"!+'SL+=1 ^K6=%0K19/4;08( TMZCSO!Y&6&_.!8\5Y
M51474L(JZJ*[C*9V5?'7Q>U_I0:<AH.\W4PDE@0O(45@CM'2VTFT-.]1B[B<
M@8]4XJ=U);C"R!W"$;6&F0DYI'Y)_+^.K!I\3X401_59'X<F?I"">[Y5*V-5
MH85L>/_[7TOYW]7D..('R/\L?I!/*D6QI%28<)8F.[5!'/!W!#[?"2 ( M9F
M?0%[72A.7JBR7^<]#MY36"MS]?E8I)Y7T'96=C=1&DFF(,<D*=W4#NB982A)
M:#Y%6?(RHBB^X3F2#W/70)I'_*QJ]G\ZJFBP/=8\$*G2Z>?I77AIKD!NRA6C
MA:J!/)V[#BN6T]3W/_03:+D5V$^XQE(\S6HY'$>S"%.<TD2*Z=_&' &5,HW"
ME$"YC:VHT<?_ .;;,)E/767H+#AI+.N7![=,F\]EZZ;.$[8A/O-Q!7IFUFLD
M4, ?6KO3F L0ZDF(WX;E*X6PK#A='NH@#NX"[H73WE8H1"(KC3^,V'<<_F(Z
MW:>:>G+IU^L-#*<40!3ZBVM,#>P(G&:.%L<@ 33]*)#2.EJQ]%*E.)$E.UJ,
M?_&)=%XYZMOGRH23CXWT/RF*B>O;4I#-Q*<2[4UH^.V&H[2E'.UT0M"#+6FS
MRW6/)\T<GCJ:2L6.'>\4U/=S#':60'/K6E]6(07X]![/2S?HIH9.=C]T 8II
M92T3HADS9J?J3-\Z>5KXB75]*6OJ$74V5JJ53>HE)I-&U< ]1*89^ ,EJH91
M#*;AVK/E5SY*2*K8-M?(_RC,GX].*35Y]TC:Z/>.2L30%:R;=2OV%Q2X(0:-
M#T>6>S13-2R ZD('UC'@"9^9\,;8D6=_1A^_AKF'4\[O26U@=,0\_\%U2C)Q
M0$8.,M!F;!?B8*_$UL+41E/US0NJ-MVH\)4[H89[]5(61;5^4[QN?;*Z.^T+
M6M!N#U[4&)R=\6!)0EM^)S>]O0D9/VK;;I$@H<B2]:$,!&/4*(5E()Y1JKVW
MZ[G4A9*">TDE$XZ%^QZ)XI94L-(@B42[;QR)E<>XT-3"$?M^>658-+_ 6+X=
M#VINL[4I.^\7G-\<>C"EV=N7^]6G\MN!94>3#97#3_"H,#98%UXRA;=A/;>W
M85W&$$&>/OXJ@,_-\WC%D?4_*3T"0N$]\.]HUD%)T&)L"L=.W-H 7WD02I$^
MW8"VSE35XCJ?[D:S@PW02F86WE[B\DS:$Q!KWLECJMQU0('GR^V]*?T?[A.B
MMF%WU&3FD,(X;W2,\]&?O@WC.=">V*HLS'<,MH"/JN37IUW'NSSLJA:_+/:/
M1OB.26(>8<08%#!B/V]0#U(RK^QGH8-I&[85Y3&G[V L\DW1D==X6SUBOSV,
M6_OVZ.GL[5F9&>U*A;ACG7'H=Q\F\!IB1BJU^!]*V":XE.AUL!NYNT$)=YO[
M)#L3W*^T#=.[2XYOL/%'_=1A27(S]V)NL&-Q[GAI,[JU13WM.S%>R\%[7+(Y
MG1!;N./@Y11'4SBKU+/J0JTD?^Q=$W'QK6H( !&0I:.>2!]D.7<32E%\5-_,
MRWT;1@S=V "I$.-F6N$:OT-<:W:131F1HRU':PG&V$_]<[BO[K3'H<1 %_EO
ME"-7%6O$Q7#WA])CVFZ57&$<3P,MMHR2XFXMWTMD2>O0U4QIMBPAAQ8)@[6?
M'W.F^$/-^LJ'7X KIK+5#E7'#=Y48;(C#@7((F.1-/0RM2(?;(9L/Y%W08+]
M2Q?W1-\-K?9XO; @;T3ZE:V:I*'&@:8WCH8[W/6/H[5:.(=CT"-\:.!TT'J/
M\8QH<3Z:("W8'"+1P1U5=]I3P]3G[85I$?=;W)EZE,#.:_X59ZY=.8@ACM;?
M$4!U/+E_G%U(FG$YGI[:PVX.RF_:0B?J*Q7<KFE-_5B0NV"3/.(\ZG@H6?*S
M_+EDH_D@-]=;>PS.$F;:05[4-FSW#Y8[.Q.KX)51U007G,!<!OS>.YLJ9.U.
MNS3:EG1 J&-7"_=L^NW-"R5H_BKE?<^4^I#D9T2:_^_9Q1&R$YR";R_D1[7*
MB/:Z)'2;T@T?'O"R=ZMY6,#?8@R_'0^#F13/'(^[Y7QR:X V!.[U8RJRKO7D
M-/1A]8)V=YY.1SB7A+$3U9EB2X_O(%5#W>OL[[;=.(ZX/H[,P$W[+'V'?T,\
M@NROGIU79SZ)7,RT>$@4XV>PXU*"C+9VQ6W#*I>%W@@^.!0Z-"0#YS04QRH%
M<3$0P$NZ_]3N A>R)LWVB=HZ%=E<^2,C,C=,J[ZV,_KNGXFK^[-R]>R-YWES
M9HC^=1!0W_6"G8KAOBG_?:.].S)P?WN_Y^BWD.=1?]) %_@7VUD/B-F" CZ
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MC\(7C]<6KF9Q2LB)Y>% +%..M1-H9>=\5DN%X,V#'%+#LI(OB5&6& )F- A
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M3\X?K@/2)Y7XY5VZOQVN2J&NF!A$V+?D@S6)]J#;PCH:%/C*+B\"=;$CV=*
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MH@KS)K!!\<V?A<+_GH9W].%?)B?0=UQ;*LNVW"A!PX]Z8@7:/@=A:WZGBBZ
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MTRZFT%I*JDZ>Y/<3FMU#7[IW0OJL9"8<Y('"%+<<4,@0HKW#TV8G(U\68,X
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ML<4TP+WBGIC*EXD;;\]B!6->=&X6V;?I06G/X*ELEZ?9BQ?KHTU-:"A_U,
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M,\CI6?$5U!UQ*(\X0,(M'?RY&*\X%()C%]JFV)&ZG&DV\$0N8I4HB%@]!7@
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M)?SQ/EOC_X!0= N,G?@*T"M KP"] O0*T"M KP"] O0*T"M KP"] O0*T"M
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M.LD"<KXT;/_:5(4"@UD E&/* M0660#V.9HAAF,!UO"2>H_. LJ/TY,,KK*
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MLS.XJ2:F%L>$)A(RNH*:FF%N-7K_1F&?PM,I3+WS_.9\\P?-1U?//YI_$E\
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M<36H@2?$PN-$AM H;0>55*OT9K6'L"VXM5TBL9E<NC'6;Z2WQEWXD'GE0(/
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MXN^NDIF?2+W& UW##5 Q2Z8?,+2M8YCEO=-!*$?B0!0\V\N8Z[B!'+PPUF3
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M'JD%-<+TN!BH-I6\#]<""7Z.\LQY\FD6$-,Q)OH6!:J;TG:#2H]J/%[X\IX
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MEG(DH=-]A!T5H%]QL!H\*5@*AS-M%C+'4HX<+5/-V9)R2%2Q_Q2\&<&2O (
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M,IN28\O,9S*/?I8I'6LI?I0;9G]L]NHV8+N9U/I^4"./+ZQ4W5OMY]CJG/S
M(XCQWDW+<\_K]I*ZY+^.IYM&NC\RP[ D+/TQAG5+B]R*B=U/OH.HCX"7F6Z*
M3>Z;K ZS[=ZYMJ^N(I#G4G5<8=K13LOL;W9M%Y6U91H/L&HAQ0,<%Z]&%9=N
M#B9*]GU<^HTA'&/E80HAP#&9<2Y4K)/LFK$:A4"31:!Y(ZP =V%?T*(:5:&3
MK!/I3$)BOL&+%,>[OC76-QLE:^_Q1XQL?L3G<?_(Z6XUDZ:9GYO/-*\>@@6O
M_7DHJ8XL*II+;CCTL)M.$ )].Z,'SBZ@);R=;QH9#P0URW7]?I1DD;-Q""W^
M55(EJ4SR,P^"3"/6\ZF"&X209P%6V9.BLK1Q ;"(D7NIOK]AGVK/B/++VJX'
M#559/EDQH;M>E O+!/!?O13(^50$2&-9EICD^IX9A/KR!8.:Q9JV3[J(;GZ,
M)%>$ YD-]G$COBD "3[OWB=?[7TF'XX?,421$&;7?)%*9P(Q>)8U1MH95,0)
M^HZ;@=E/O2NFRB?MCNTVX+C<DCV<;/UKV"73:U1(WO_JDVO'$^&#1#M$UM\!
M/CCIJ1?&,<0#+'*+D<P.C<(^;8(G#[=.]>6NMI [)V?QI9C:04CN%0,+[HR!
M)#H^36#:=<3&C%MGU5N6]INXRO1EE\X9VOQQN2[UW3)F_H/PBX(V?(.[R_<4
M+ZU%&L+AU*V:\,.YK5<G2;P@EC77&EA><$BU,<9_4/_"!1G/ +VN(7BG0LIK
M%&"&7:?$O]=0(_K-BFJU!$50GT%)KM*:7OK#KU2]3V<X=.7&HQ39=/BSS@CU
M-D#/Q;+L\3%8UFG\<,LGID[KJ^)8YEE2>_&D=('64DRPA+Z%7H0%(U+SV:XI
M"_E?)UG&D/PHLJX704>VSI(8.Z@#SP/JMS:BP236A[$ [U]5H085*<Z?^IOJ
MXIE[PZP"K+P=CMC3VVNO.NR%.,A<Z5&]3&T8RY!$3#L>W=Y&'<*+FJB:5+IL
M6I&=[SB=*7!TT2E_%IBE5*, W.=_'8&CN?YU%,9__SJ*14EBW5]E(/^/0PG'
M[RG>LP^D?*U<%7'6^."ML2'$+N2D]4B85+Q^SC&4ZY__+>![F/@]+4RZB+](
M(N_I!J_"?8\*^"8M)BW5?5#_\]#_AQ[B60BB!_W'.IAJ=03$+OS'^,;EK6?@
M;U:0*)0*5:>LH4*>P>HKY8BP.=YZ\]\VXNS_!S==Q581.GTQ8=BM988N*=J^
M*Y624<],OMBDX'Y1[$F1^W:\PHB $3TM.9+C14_/6?EZ>(C;&E!Z);:DKZ$&
MIG"2*VRV<H?S\FPEQ]QE9/)C5\V\]9*?V5CNU\HP,6?'&0%4I>)KU ?4\T1_
M_N>DIGQ]]G);3\+^1LHSGY&,I8ARZBCID[Z)FN<^RR3KD9)]6(TF.RL9%#>\
MKXYR!Q"JHD7F;ZSX:/"2S?<0GK??,RB&>:T<FKZ"XC?7+"I2#UP?F?E_VZ)C
M_P_<)&YP<J777.C_[>#2_ZL7OJUS-HGA"\BO;TJ3=GEEW>)H5[!3'"IR%0)M
M2M\EK>I29O.I\=210_ IP@2-HRT; Y,?%:!G;45V1-E).H:A)FTL)39 EO!'
M[%:#V5!8L'."L+F*Y)I^B^V_AK*ZR/.K:;4MU0->,>36/;]S;D-8(6IK/^1
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M7?7N0.P/I_OA/=WFF)X>2.84VZ>GA58[UT;>?-[FFRV3QB>7:XX3Z_8.$M#
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M:XHJFZGBD%9);91G'FRK>2Y4P,XE@C03=&%7^,BE%)[E,B^>3H ^@O_/Z7F
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M,(F]XU.K$6E[>:_;QWM>@3AOWKN6!O.%^QO2Q-4\+[@H^9W9-J&^&HOHJT=
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M<&QVA0&, B]ANXIY1VHR,9)B9[_73[[_RI+%4^BDST4GKM=']7?@Y]^Q^57
M^>]'2;/K'8?8SSL,88/)_ZQ1TE^J5W+3[ ,$!H8#&7NX%5/GLMTYE0/YGLJ!
M((D,)(*'C&0F.60R CB0BX9;/T ,F# !W<[,-4M8(>64"R8S4[!GMW=:(0H4
M8]F_>D=!P-,O(&4@ =L9WW_YTLX>8T'(7ET;<\/_NNP_?QG/K_E_:"?GG0*
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M/5%2V]B@]+,,@62&,0I*HMNW2*I2_T0I<" IPO8]N90UG&XWB?]!'0@AN8T
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MKHBGCYJYQY]^^\I"SZ\FN?_9 2-2N$X+]AB<ZA_%%#"Q!N2$*9G^(5-O],F
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MDK@;B)%/^78ZNCF.E_MV1:K4_"UNY<Z<!,0'(A1+VECFFOAU*5,(O9OFFEE
MV6G;&\@(:1>M258S/01Y2(J(?Z7OO=9-!P%VN#KF.[$RY5WP![0Y8#DU8=FL
M';%130E+LAR0N7ZR:.-PE]@W4Z1&U;2(=,SFH6VQ8AV"F\L5FVM9M<"7_.;B
M)*0O6>&(-EW.TMXG5.0(9--C&L^49/=ZJH\QU8&])8@SF#D.I)DMM7HTFC!:
M7AEMB<M==,T#:5PKZ)_M#4YC&RYR(#[=<8ZI+;C#6GGYGI/BI>D7>I1\4_K,
M>T4_OL3,R<[[.X>OJ+<;-MR$M/5B^0BD?N)PY51%@?<#?^J&,^WJH)^,33&0
MN.+P)LJ*UDS+P=&O6620XA6781%$+CUAACZ@!ML/0!M=Q:CN$4@VWKI' V3Q
M_=.B(P+OE1>LY<*V2UC^GQL0,189US#MV/T<B!\B/"VJ"1_C*@$"LIR&ZMR?
MSLZ_P=-?/J_*1!K)^,Z-=8@7EO>+\T"F>:1C5C.'H]B\1[>+HAMT:J]\]$;L
MQL"@NQ<P,N7QG3:9C(#+_9B>O0;K+I7! A^FOGP+LPXPA)EM;TKIS=.;0?Q@
M"KSC0&Y&%G,@N5?L5RRW"V]HH)_^=^UPA^@P,DB6/-GZU(R"MPN#X(CVEA>:
M^ZA>5^F8/W=",$'[^#ZU(A.C71[ABC.X$0)[SPZ&-+N=*'8?^I0(Q0B ( D^
MK<KW??5W6A13]D@7<>0-&?5R\\I$K=6+A+;O[T2[+^V!,([]5:A_Y=\5ZN,7
MTNIL624$4C2Q%$9AT0+1#V@!4YE,V0PERSUE#2"IYMU?>(.-.QAT?H7B=Q,7
M(<T<"Q9?N;@;HH;]A\J><CJ/Q31[!WHW-7.)0$4V$:%,OESP]P&FC17A;9:?
MA-6=62D'S/GF+BQ+W[-6:68,W3 \..%D&N(KHVXJ_O-[GDQ<OUIU0O@>O0,/
M;Q(28(!.$YM76IYYB(_>755'_9%!8\H +U:]ZD3N7YGUO.>W>]I*OC+Q^UZ/
MHLNFG6IU</R)%=R8,!T&V#.P3!D$%]J5&H=_5GM*8LGQF=WG"6='<^[F&^&=
MXH,KIDJ^Y1,7AT3M;V^+=3"SL0UEA)5T#B2, UGG0 JPO[.W""4JR33BTK::
M)B\KD7"+&'\$VHR+@H-0>$J"]B[2]9K&A"E;(-1]=:E+1LUP_EO&'[/T4]\6
M5X^VWCMI*/V[&^1^0O<YD$=P;B9B.M3A26^M6/:D=VI4T/@Y7Z[O3 ZD.C(,
MGIH)* 4S!5/I80!H?=R%0#1)]3%,N.XX"FDEJ5A.58G(1F%;4K<",\>.KOBX
M\0FJ??!+I-R6#>M0)@JQ3-!'J1H<R#Z#0RA$D[9C71Z9+Q/J>3C-K3H_1]?9
MU<MZWW$Q9ROIQ&Z9)Y:EIV1*!<SE-9GEV(9/L+^_CKCQKZ\CF/_R.N*;U7O+
MH_'$S&56_G0W8FL#:<$N_O7/Q;C_7D#TKW+:^"6$4P^EUCC'U7,CX0']+PZ0
M:/I*K,#.^9FDD72\]PP,-%P0H+ 2.! W;%P:3S,RBL"+G8+14I_,/ECK,@1R
MKM4PU&N1AV G0BJC/\<WS9U[-G-O1Q;TL^),)@""J24>&%,PA,U+F%Z&C#KF
MM<4L^8)0@'FB&=WQP;%0S^Q=Y>M(IWLAR@WZA8M>"ER $RL:Z_8&2Q]AX6MY
MJ+'GXN\$(D6]3WE^-KLE\YL:[C@WE?KQZ!/9A"AG$V]&.&!*Q9\#1*F%31@^
M:E>:YZ0$->,5,N=W2F<OWYUC#CD(](GXD SO9@.0]34<(WA8C\32<X8,-%#"
M4V_B(VB*S=8ALG^*TMZL+3BN6&N16I!*74C>H.ZM]WU>*;:-)5?6XB !!&'"
M3!*0PVX0QF[)+@)3VR+7VT4E<:P,[-]J?A()I7'VEI5#&C7IBN^9BT[M:;S/
M$[5S=A:IG9X1T,''L7=@&[YFEH"#\966U$0\H,='C6) 6R:%:H1'73@0INR9
M@:$1=TC8I/,03NRN]?[<D$L\HT),)K9A+)-J@COHG:&?3L\'D#G.BX>U#]N,
M >S6'\JK#NFH9G^O&_8IL1U7XR_S_&'F!B1[N+$?_?YL4FKR[5M1T<GZ9^&Z
M<V'P%TC@6#=3O&4:"<AN- $&H@"AR9<F/655UFOUSLDT2#G0&OI*-,.X,N%%
M;H)Z*?P%Z<;+Y,!=!2SU02QI'3F2/]84IY5)79X.''Q_Z459NE6?5"PVQT+U
MY9/NN\]":^Q[L>7!3#$KQE',X.3QZJ%R:)0 2MN5\*(K,&1*;*,W90IWV;=U
M\;IYAU+)[NTF':)4(E.TA7'LU\/$[D#0>3E$(_PK:VF"?&+0/TG\14A<CL=D
M&!Q>MRTMV8N0V.Z:F%F^T=B]@WFZ%S&E&JYI?<3SP/BU7Y5JKMYIS7)T"9I5
MD)!%<V=B3].1VY:*I07'"'E-"'UV*YQJ@06='2]]'Y&W3A@5W'0FQ^1FDD-@
M",7Q/+(V_\]4[FOI8,.IT"JA-5G(OQ:7'/I[<0E^49IN,$VWV&Z>=#,^Z:_M
MVD>8/@35L'M$E=X*3./19@".FLD64#V">D4.M;21E!_T8??VG!,_F'EB\H].
MZL'FV)6L'^.O$\VW.ALE!?N8/%-6JN=Z?5OR4W,<C6]Y0(*P<B+/93R_1-]Z
M<DG-7%X\R1#6/L\4;V/L1R71SX&6]HYI.(2_SW@TI1KK^&Q2^6>@<E1'M7>X
M3&U4T$F9F*EQH1]G]2Z@_!%H;(,NG+2"W\<\P\J\#]_+_BFYB_:QF(SD'S&^
M7G>4^GET@M]3VJI0B6JM(7DUEWN?S9MKG^OE@G#CT%%M^DT@E.&"5JFC(IJ[
M]_S*T*#^>/L]Y4QR58+-)\-$K2ERPKV@#C%%_$W%50(XJ!YM2R'D4#_=&A$#
M>530A)-_:1_30I)'\O'X.:676SH&:SLV)[9+/+=;0&".8ANNU&ID0C@0#V14
MG11U,I5V(.X(\-UNL5GRZ#4GY/"4F;G9L4#R!?72 NE[*A1B2@)::@"\&C_F
MC^8B0S]S($@4K U&Q2T@W).^1U&T4MGG:\2X[BW'?;JK=@HQ#%_:3O[W9;T!
M[21=6 #!5*;R%^.BY:.STIO/O%A^[]5K0GQPV--\Y05I9\DNN_IV^;1I/?^_
M)6I@!0QTO#@0 4U\Q.*#:?T0Y_3FU%$P&CN.8S!OE>;(YK6YM0=5?CM4M!A&
MZ.SE$=Q!S_LG9K)TIDZ/E4\@/<K\C*#$T=I<@20:; K.E''5H*F?W4K) 4.R
M0:D'/4GP5'W4M\J:>-EF_V/,]^J5\C*)AOH;= ,0;_P'(\NY7[2\!W7%FBK_
M>.TKU+R2(9>:/?IW<SDF-R<;+V38(?/ZGM6=GSRKMMM)'1Q(QPKZ* =2(D18
MF_)'?"!0O5.963DD)*L-#)%2_8NC'(@O 9"!+5' J1&EU>'(UL\(4/C4J<$R
MOD/YP\X@E%IXB$WP<_/4\BVKBG::=S]]W5K?W[60H<+NK.-FQ;*Y[V#Y#8[<
M05#C4/)-9_WS?Q-]JFH9\$Q_Y>^$KU4/9'W[K*31/_QKN" 0B($-./F/X*1$
M+O;>)H:XRBO0:Y8Z,2]1Q7L7V (9[E<M*]WX]!_'CQ]S/I$O\ORP6;8,91]T
M%<'8B6TX5P<"U+T$;RN4@Z?V$?>W^YHL:;CP6J-]SQO>[XD>_8SG%R_XDG8Z
M-:&6M18$\MK">H*O-2 [7X\ %%P>GV(Z ]Y9P(>57OB)L:NLV8P"G]JIRW]V
MFU?L#/CTY<+Z%4/8:^)^ FE]>639COHZ ,!/X5HEH,XCKXK6VC4H%OW:V=:R
M_?N(=M'>I+]BO80I>1E0@#7&79E"-G;O<T5K B$?WU8.XI$J*;[>+I6GN[ZL
M<"#!2+YG/.<]/+@\[SY)(%P(M ;48^G&A &#'O[YEDZ1TLQ2(Q"S'Z6DEF\G
M!1?^0@POL_D764F$FPB!$2"B$00%OH%X0<_EN;%% [GJ)/NJ2O\-5YU9@_-^
M7\^U"7S2_\6U&L7F!W%[N"@*5R^I5<)ZQU:YD^HH_MRQBKH_-O1P9_0NVF>#
M=QJ^W[UG=95.U!]>/7(!(NW.6MM.>F#:LGOA*^E820YDY&X_?(TEB_6*K%.D
MR3/%FA@20,TT"'Z:X\Z1ML91?5>&W&C*/]Z"1GNQ+-OEK&7$W=4'EJACHB]2
MA@_(^U:1Z_JS=A)B",^P*^D((>S(W1H.I&]UB%Z $%J$49'0I6 \T[\:2 BF
MAKK3WORI9LNF7P(A>Z'3I:T(9['(]&_"?TO-T@H:BU?@HEC\M05B/XW8M*HK
MWJZK0K+@FE@W0IEPHR4"1]R!1I)T?Z=-=K>.<K,C]++<VB0&:I^KWQHVLT*7
M_V.Z%>(?TZUZ_Y9N5?9GI-3C;]\<.L5HJL:W( &0(S(%]P^N.!V:(D:#*RAP
MQ7'TS[&?W^U/U$?@U";)PE)JT^@KNR^K\6,6 2@;>@>0?T!MY<,=8LH">>^
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MG,8T:7\_3"XDY$T[!]ZU/3,41>\1;Q_$+)QRU?LN/#3>W2!@P3^&.E2"_K%
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MF&_#+:UU]4?58^?V]G96\<M\YS)^'5 ^=[.[=_EFN>:(2^C-KLMFVH3AGK>
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M/$(?MO$(/H6O6E,1X2+SNL&WC9SD+>5S63$*:=J-PXAK+T/5U=6?/0>$SL/
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M1EBZ/_/N$>E"/D0/5<U.G*Q3DFNNN+H_ V-[-BM0@O6W$]9*S6Z]3ID^FRU
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M.PYAJM1D:6&\>TA^8)\C 8:H@86:Z(2D 0RQ:O=:^>V)IO?1T@4;XRZ;E<H
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M2/$P?>N'$6O?L$K:0J?[;'#J'NA@@(I. DE,+)^*V0Q)!9(8+?#=Y=2SQ;9
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M:<L1/VB/GZ;H2XF-@^LX9?F%A]UQN,.-FV%)5@@?#TQJUKL]%0&DG!TZ266
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M@5%A]W>N-*LE UL)L$G'J,D7?9CBP!ZK)Q2'R3'5:EM;\<;Y.G\01IJ6!7G
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M;+ /G-^1#ZX#Z& >7[O]24+80^(B^I0?G722+UBT[/LW'V9]F+*?%^VM^TJ
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M+08GN*E)33I[@6(UZ+PDHWS<]'JW")G-5U2;;_I\B2/G'TM<E[^@G(O89V'
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M'$@$W5#;I];B8%0MT'S9B40,VZW(@*YM/=AV03JZDWZ1!7F8QQ3;WEV'Q=G
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M(7"T[X5 N[;$CO>1BE50RS#A3FB?:/&=]VFGI!M_'I]D&_<5#MKWR9JZSDA
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MM6.B34*4PL=TZT /\8R0JFR7Z4W"&7^)#,5;N3DG/-E+WL1[UW?&_!%C*Z%
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M.^IF/6!)QK7!#@3UZ9X;*/&MMJ";N88'!DEO-H?&*T6MB@AL\]XU5G94[7K
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MU#MD5$+C<>(GG@Z'K?C&"_4G*T;>9IR\_-VA7ZL"K1H[6?8,6Z!@-#*%:CG
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MZ;"J$R'1]I7E:;X_:J>:2 BK<G16SHM.0W/L4P,4[0'=!'C5YWHS0 ;MY_]
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M6-!1%[%K39J4BXG8UF'F\P+WL*D_O=;L[?1D(X4W%V>B5#QEC=.'%!ZJ*6L
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MMZ<9K?62?4MNQ$$('QI#3%3F;UH/6WV.",T2#TD>%5Q 1K]  O*Q")-C/'H
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MX  [ZG(!B(-FB)8YK*PXS&=P 64T0^)US\KRB;ED+K"-8/NI]V_5X *_;+C
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MGOY_EX1SM:R6U;):_NN7&IP<^S*(;4D\=0EO.<8%1'X9]A[:YAIA=2IJP/&
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M1_.\&(0QKW*U1S77NE6F%#2_D+3$X23:Y".-Z$>%O=K(":,RD!@X?Y(1FFC
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MS\&5)%(4>OWB$B+&_'O+U;'3Z$X40S(=B8J1-,,G>B<[Z$=Q*GU*QWWLU$7
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MNIX@-.OE'B ;>3>B;RU 6OD9LTL@_>\(OI2-&?9N=^^Q#^;V 'NV@H 9F[Z
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MA.%/0%<'"WP*[*>4[ZV9W&Z&6P,^"?\2*9&-%FFQ@RWVZN./,920_PT"Z\U
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M(?G4>EUEI;VS7G#/TT'IS?TM56%5L69*[R[:GQ&+_W63TQ6 W]?834C*C+&
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M_,104K'%DU@NG,HXCT-3FEHA,2!W>&3.JR7U@J+$B;B:3X+1CW=1\C,N<UX
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M Q/385<6\P*CE4AS.=BO]^+:A!GA7*G7=K>J=/O$. =@M\T[DS4]XPFM7QK
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MDY_:LZ@IEFU3FQ>CMK [T*(Q.8I4#F<::![V,996N"2='!DNEC\R4R=*?_'
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M+E+8#/6; \M/8 !?A[=![0 ,0470&'T6IQJS,4$E1BTFU])FKSW)\VD9JQ1
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M*]4X,SUX)9@X$T_"PW$Q#0\>46K#;["[22O?X<2T@$"W)8-ZFC8@#]5?B&T
M*A7,X)3![&&UQ&QEAMJ*3/"S?*R5KV2'K\^VFR]]'J1\N=;6D93A,;2+0L@B
MB9 HFVV%SJOOK"4]JG%D2-(R8M2.U(5YO0]7WY[A=M1 FSATX:#,\_T<']BF
M[> 33LK>!PJQ5$,!Y@/&0&SYF!O-L_E0S!OJ$%'.L3-FI8!G87''R8O90=]>
M7UI_<-LLDKC$@_L,DAHV,,VHG7.Z,K6O'7QTCQ#]F!G]8OWS ;YW!:*(4BDE
MRE^_6LA&[8")(Q,V/!EXHD4N0JJ#D7"*SK=H'/!J/EMRX+=;:71K/S/ :^V>
M_@\3^7'SW0X*53]T=%]J;'58XN'9D+/?E?M7C)W$MD MMA_04$^B8UXH0?R?
M84,XPO",8JO[5;KR,WC?R2C1QPI3" MV(8J]#>F*E2T!0LT^J9:G3<Y9$F?)
MT Y?QK0-)Q^@I );V,YO.Q7[\]$Q;CU'WBOHO?J8WFJIZF1F,)14>BTL]0;/
M3&<"6A3.PI2HE1432 F?>T ,6YTZ8E?;6Z$R^\".F:)NYV%8@]ANM1>Q[;'*
M^C+LMO&;^E60%@.50%Q!#A&;=+&Q^GH^\DVH^'!3+^9W\_.(QXHQ?8_BQY V
MBGM+Q;^<>E( -$P1Z.?'G)O1$OHG6<?!D/,?*^A<1.Q-*@.9(!_'?)\7IM/I
MM>WIY*NC][61O._WI3SMQ9O !^8*[^-]0R&&6$,2BID*]E%'U(7)8%PFP!L*
MV$9:N[E[)U_T%FYLNIGZY6NK;/W+',>CW^;<$.R-RLWF[/"#FALJWNB@S2-1
MX=C>X]>_Y=GTZ*OLG1V<3KU:OCME@"BRBF?OX8-VG>2\,=2$R,"NNEWAYP96
MU*5OR.CT)3\+"GA[X];0G-.-/1;K\5;G=_X6C#;TMFR03]X!X64?JE$=)BXE
MGZB_=$G\$D\D@G@ 3&'QA$N#%2P3T);6^AE>H?%',(52E!N2'YHL/CQ@D]3L
M*[ZW?8^M+J]'HW6MV6W$\2WSW18EK3\6WK[5:'Z.,/"AYT$[X>R.[VY!(R#C
M34("'FIH$X9(:X:*,S9TVM8VJ* \X?'\U:U/A.&<YL^QI$=ZYWO?Q<X00#TX
M6Q=^"[6AZ9@B]:V@*Q2ATX*55#_85=<GL)!./O-09.FKS*< U=THYA&%R=TJ
MRV*0$!S^HXZ GM!.7H9Z,UK,4-G+;F.I"1U;Y?-Z:*9*LB8IQ.Y0*NV*X<IN
M,\9GL]"4UXE2.4%7D'M@@+\/VZ0@6.P50/NN1[-O$5@\TI?P/>15J!]O3T[[
MS+AUX:,M/4+830%T-(E"1R<3>/6#"F8),FH+ABJA1RSM)$>^W)3M"5HTT+G2
M+FSR9EN+F67R:<')+;\*#I)>CXF9E=%_I?@4S#+3^[5%CZG55E346.W39N3L
M+'R4PWL)@4#4\XB MO ^X> 9#K$E7[-%RCFOPX5S9[-1C(.$HI8"\*=CR^3K
M3R)=_$*C\:3#V2<K\PQY+,JFXHX5(W!#X=O!>2IFV)]"CM4'*!'7R*YT0H)J
MFDV/.N6+(\W_DJQ&]>-+*9'N[NZRNTW#U>&)U.")+'"'X+\::#?T]M .JF'N
MJ]EJYJ>)$X'.;_Q75FI/W>S72=M=R.:I$U^?CS2_!TY#@B\X1"W4WO"38 7]
MU,4:KW=L30-2?+GX6,?Q/:.B,7^T^'ZW*EB%( *J[R+MIGO0E%4N8MV,BVA"
MLPYKP_F>3^\-GJ_H*P0X:6_)WO>WF(4#^(;Q>]Z2$9M83MKM-&.XXV?@R*&5
M_C[/U*'\ 'FS@IO'*'I?C(>/YH@&V:ZO,J*A79F<\KI#X/#$Q1Y(R1%4Q]S-
M=/:5/T7G1):7VW;Q8 3++!";OSLRN(.F^P^PA971H'+(8E<^:-7"<R&-ZA_E
M.\E0BIN(\8ASQQ^6"G[;]-N@.4KQVL<[^RZ(R.;(;XS3,0M4V-2II,;"<($<
M4+XQ$Q,M&[W0\=+9ZU;;%;?6[N(=+DDISW]O>_Y\^F"D_A+$'[:IXE4.L(7+
M*"2\OEOAD2(:42S4'-.GY=S@+_VQ^E.ZB"=P1.OBY5*E';GF5U36*V H>$-R
M[^-LML<EWHN-9VONJ]8J:/XL@)5T^NY]%O#L/4L4Z<G;=3HF#-#/SBWH#,#/
M537(\'7A),!3UIM0<SQ)Q_AGH$]@>4E/^?S%BO(/#[?O/?'22&2/4?TEQ$ZV
M,3P#V5#8D1R.!(4G<G>-G;(:")+F?<TC2?M4E7RK>#ZF0N&>G[\3@@-3WR@<
MKFN>Y0K! <'PX-V4CH )C,"@M_UGQ(CTB,G+J1,3D\\M:H#@VNA\W#6@X25I
MKU]-"$Q??'\&SL<-7Z<#\5H1,@C,1N'PQ9H1+B+"I93ML_+[_R?JD")T?[;H
M".25P6D!F#_J_A"C 4HE>1DFN+]5N(C*H#_Z\%+D8.;.7((RA.=/2$+F@>C%
M)8Z<>4/MS,MX* B=&[7Y;2G?O<TY=,^;(J1G_BG2&/+RGY+0XYN5$_][V/_Z
M,%0Y%_&AC9V%;,*S1%8Z.0KQGWLNBRT0N8B#3?0)J"5"DXNPE'O/)!5I<!%K
M3@ 5/XF?2FSBS!6 A%^-\">XQ,K^_<7PYDS[]O_'I_Z+9O>_"FO^[T'_RX.(
MV8 O:>@P3LU+(S3+N$J 9B7>GBW>\^*<EI1@2(K1.N:"H>NMCQO[X[T&D?'
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M+=N/U]JO$O0-.M>..]L4Z_7Y7,1Q\V62^D;K1N8&[ 4[TKR$.A>C"_5SPSL
M(1?]D_HQRXM_34!;OV-E+3=5IRYR$M WREBJ4)<N*N'ZP]^!,X[%0>(V[N/#
MYRN^_M'H:+J?DAH9J+4FT2H31->ZT0,^=R%U_ IU4$XI<!5.;R=\ZOL3PA8-
MGALG,]6>>5QNUZ[R>(PR7X<18>(M%_$BC C[L#<J%M@=?EBF(A\<:-+T^F,Z
MK5F7N\]ZYZKAM9-"$M)-D::X -B?G4F^Q9+,&,;!% J<!,X)O GU;_I0^WUL
M$CNG_OO+8)TCI)!D%3D1HZ&M@5#ZXR?1$2"BJ8R;/[/K]VR1,^E]VX!'Z-N
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M*E3B8@:]']@1?H%N%SWAC^Q,5:M0N;+H-^GV+<8X[D":%+^\>\#@P/( G+G
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M,L ^!KZ)5#;0J+X7G&\93G3"Q(0KONY\.Q=R.S!FA\WGW>BX1^([3UXSDE"
MMWDSLGJ45/0 E!(TBEJ6?(**VJ>5/DP(U/36T 0F6CX2%V^3'@#):'%%3B[@
M@Q(/W;@Q&>\O%5JYA@W\*VIF( 1_DJ_2_%D\]/L?0HMM:$HNJD(5*$4OF#-.
MT8I,A9HA?OIJ?Z[G-M+<[R/,FY5)I*&[PUJ&W['MYNR]GYDZ#)B^^D,[HU^!
M=UJ&QW/#ZQ1(GQC8I-6XRQ6]_8]HSJ\%=2TUJYN+$U7.%HB+$V<+H%VR=%,N
MHAD%RI';6$+:)_,_5OV4ZWU^6F/<.G^JMK>9M2/W=L1]8@,:/.[#3* /U*-
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MS!,F CS]YX)S1^;]$E;[*3"%J8KWU$PAJ1(-QEVF6D.>%0NH9C@Q%#?>Q,%
M@,GM"PF&FY0DNN VZ74^;PA[%%,>O'[>OD-/^JS7,Z^?97_"Q;/'?K"F[>1Y
MO[[4EP>Y%$($Z>I-M&9R$&A7QQS0Y_1409-996UKYJ=1_]]$'0=]EIV$YJ%[
M7;[\/%[7DB.KAQY6,RI'D(DM4@L( 8R:[QLPZ\HWNG[>Y#,SY[>VAD&>9_9@
M'N=9K.CZ,$ -@!%(ZSBB#GD@AOR>2HAD2M#U@R\GK7 J%W['%VZ>O@,<2V5^
M5IS&>V7-R-.E^JD=-M_%$-ST$R J9TJKK8Z0OGV3^T_QAW:UB7O)R^@MS1X"
MQ3MIV9DJMX5.,-P*HY@V9? X=*=[^><?W(,%*+LD6(2>A%D26($V5J0S$-.(
MA+*_*SZF5@IEMJ+CKG&-@?V^YDK-@7<@P1,]= '#K??[K;@A*Z&8G$M2YZC"
MB1AG,I(+3/;V7O;WO+!"1^9V_+RJ.S93HQ]UD;?*1,_^5_=L-E"<9T. ,R6"
M@\B:4<K^"*X%;95H?QW!<<\B=RMS6Z)]TE]Q&A;F&P=JBEEW(#43P0#:WA&W
M*F<G_6:MEP?>U%1(U?M"_.1I$[O'$?F:EQ^^W_[=U^H?V*?Q?F?XQ8Y3VA-?
MIB.V$T6Q HCV3$[EF>8KERAFL=6>;%]&?@[>H@0]72;.FAFU[7003:-K,V1^
MN3U[*'$G10N_<KJI:.L9(XK)BQVU:D%UKD8QV:@="E$F"?:&T3.+AY'SKWYB
MAC9V;'R[8%B.8%<FW!]L=,_OD:J@6)._Y&($V#,'S)NK8K,DDL5%KXK.BP](
MN#:'6*\([\'88YE#T\)5\0G(MBT$'"L\_IG#OE_%)'1%GV51MZ\V!=%YF0.R
MT!H :K)OR=6-6.VTL(#^UYJB'&[=M %6O]9S ()X6W!_OD86XR5D%>"PW9(4
M+RA,Z=$?4;J^Y'G)7T2NJ<9[5?:[HG9MW1TW5K(*J!YC"3;/3H^MS@HGM*@@
MDS9YS;JQ\M4M[X?I-VOU-X.CWHVD<,HCFIY*G#Q+SV,Q./NX<S_R<6O.! Y@
M^1' T)RP7M'W!<2!^ZLQ0%5+I'L!QI "CV ><W\4UD-<>4 W>F/O\=7>M*KH
M1:RV=NG*?8=6UFB9W!QX#_)?QQS!*5>V[H/>--7?FD2@ XB9X@##G$L^GU91
M;M+(M?M]9K*7[>O:B89C@=RM2IRL<7].POY-<0YZV:.'"HF1 3C=FN*52QX0
M6'B$C,5<*.V:0[D_*G\5E!Y4,2>9TB']07N.3^1(%PPX#0&3JS"]X,LVLU/Y
MUA[,<&QT\R+Z$V3C#L1!@BM2&/E43XHN"5J33!^9!%5YFG1,\;__OBHFI-!_
M))TC>>OH6^/Y@\6SCQU++B+V6\G;[\%.O?T/K>274K=,9K<L04@2W2W,V(/E
M^UKK4!%,SF&:'MV96I,[XRV,X00U9_!'/;[(M@P')!WZ73M:^TS@F+M<NE#0
M<4L+(7F6BPN*H^KE"J.7!Y67'WB6+R^7S=@HD_9/NQOD*+PIABF$PV ^L"Z8
MS=N&J7C7&5.Q==,A9<_5*L9EX9KZFKIG1H*=UPL<),UXRO(CX >/*@P+L- ?
M[I^R09+^#L)1C ?&T3>^^Y?:1X/.L\ZG*TCCM7T':Y5TQX6<1TQ<[[Q*N>;)
MG7W[\88F7?1E#UTP]3]T>7<$)VGJ]/.,0G_T!<T9PP[(_^B7!C?&$OH+\+'^
M.@YVXK;&::H&&1QDFQ(9'QAIYCV3!]N!.P2XPH5,\!@=$$FI;;6;&^EWD<LC
M3W/9N <]O/BY[)OHG5B)W'N7+5X=C?-MS8'?_$=WO!F <E-EK'*_^?X6!]A,
M&;YC'S\@'&RW.VAV64NX7>9$'M#J=52.KCA^<G^$&9/W%*/$F?&20"H["R(=
MZCW/=<P4Q@>0H^/FS[[U.-MPVYZ-/2\]^JH%8@8G>16_V#NZ!@4.^UEFN]TJ
MG1]@<B4@NO"L'4%O0.<9O9P6U:\:BG\1,ZUJ)4J5AXQ_M/?6LGA9^!SXDN/J
MU+.!@M9=SVC9?PEP2($1AY&DFERNJZ8%YGFD9Q^KB&WQE+&,%7"P/[,(\ZOG
MI'UK\OP6!<-Z_O?!9(6DB_+V+-=3>YC=I0B&K ?C&3A.TZ3K, K5Q4T59PS#
M,<)45I/!/WJC:,C*1\>M:FNRW,W.'O4/L"9^;@QGA_C4$' 0>=\[>@]6>3HU
MK(BN"8:1@)@1[5=]OB&>Y'*N4:.X/Q?/Q21[?F-][\CRX)7O1<DNMKB3K+,X
M4 O!O-%/NP3\^ !LO!&CR^X7LP5#Z%H_!?R(>@OLU[B]P0"4;<C&0KKBQ<%^
M779223/>< ^JB$I5L]4GG3[%'VN<1D[/5?\96CX &\$I*0*HQ,5G=4*8QD=7
MI$@UGVBT.U?P3TLG< LJ_R.$SEJ>\(NPV#>T!7X^DLFW/S.6"\0SA9BU-!.,
M!(4Q_]0?=80E8#:,_WIL8=.@5VO'XMF_\OS:CK$4<*<G;%]]F-B-7,#&P?;G
M=:4C*7["/7!0#@A_0&?W=2Z@WP"]"U.4U,,\0HXU?K_QZD6YUZCOU=V9\T?U
M;]-S0]B75Z4@0U ;^E=C9),@#EN9GE'H\05WHKMD5K.E)K9Y)O&+$)3X/84(
MCD@W%"B#6JZE68")8:X]"-:F0V_1FE[?;R\*C1B:-C8&GE=1JBD7[^VA?3':
M?B?>"D&+U^JR/67[9N)BQQ9 2>A\_OI30UK_GR+1W1X_]:?3EWEAV'/[$V+V
M8*0WR&I#NI :DUN' G1.G:D;U<"S!K/:9E@T?]_@9J^F3$=+H^V?V+I8RGJ=
MV%*<T/D4)&AU;(: )9#>[,$^7$/6NB[K4'7(LAEG;4UG/8_:ZRB^O'1VW/'4
M46(OZ:&E:Z+<L8<7-7[C>+%"P<ZD@2?*34@2I.'=] 2_/C!0WIB4:E<4O\I.
M._+7VWB0:RH'/J-"KDW"G@?:A "OT#"["TASBG 7'#9IQ+,E5E I'OK#_J&1
M1/SS6J'*TSX+XS:>_G<NOV=8U$%>0Z;;3;%&3R'&YCM*9AZ+'$4AX^70;)B'
M[>/+[1<Y/Q)=9?DTI:II.-HU+)1/./9@#YJEO_3,%'7@.(+7)+4J*CV=31-G
MT!>F0S_]G4"=;QD1;1VXY,A)PH.:^*TS%/8X8>OW#!Q=7(/X28ZSV"2H>-Q+
M(FGBMJFL/3 V5DL,1V8!Q*#+C$(DJ1S!VJ*(_4$0\CY-('.!0=ZN+D6W^]P\
MJ\:R9RUJ*AUTKL5K'>G:RD@Q8F,Z=U1>W4$X 6TIJ+50G ARV3!I#V9"PB]D
M=2-8FGBIW.1KV:Q4]@BZ_+M@*9LW472=8G>A;;M;/?QER<>K_<\*&O[E(NY3
M%F? P?8>R\'L!B"6?-_S_OI-T)M21,9WK%RY&6[O,!F,[A"RNS9JSL8CD[PR
M8^#"PT(T$A7-86..(3\410->\#&@F\"EZR210-Z#B;OCG76367X1C9Y3)@RS
M=7L+KL[=IC:<??4LC@E!C0=A3'R60#^"V/I6&7/3T[X=JTAIWH.-TU5FFM55
MQQ:_Y>YX>;K(H$M/=72.R?@92J]=8HXJIH+]%/$V9)5KQ'W*:!)=ADP0 ['D
MVA9<^>\*U'@&+)Q\PHHE^KK(0[4V*$TP,0<@DT[0_<A(V/@/S%50,@<<[!2B
M'O2T-J2*+_A.'CY;OT(DDA0U;YI'S&M=U)(Z0C,#VJR0:#AX7F7F_DN*&GGZ
MB1-E]4FUXI/Z>LJ?6*4DE@2)(P%OI[5$(^04?HQ+A$8X29FFT5[*T\63:?P?
M\8 [(APK3KMX_H>&Y,5+>S"L?@^4-Q-'!Z<ANKE,H,QOW:+<!4/)^,=T%9*#
M>,16P^DLP<S/'>#<29;D/1CQH<WN5W:J)LT*^V5VZRJCN@E-@=CWDGRKU$G<
M)4B3*'ZB.=L/_*QZK!H8K7!5%!+7D/[)^>VHN#^G16Y^>87*WIW!E!UM8:$+
MC>KJOW706/E36APL<ZV^N:G.N;XPQ?5)8Z]]RF<C^5>CU?]L0]E/C7GB/XT
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M\;KE5'"/.54X=I\,4!%/-6(3^IE%;R$RT-34_/=FBNV])XT5?SX;:4QA1*#
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MA*E4!65I1CCZOE_1HD]NQO51Y3J>;SHJ:4%HZ=F'SPTI'TI+N!EEU@AJZ19
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MQB>C=:W) OTN&ED/=R/8( $I:BOTA2K<U!O$]&8/S_N<ERG6]7F "J"I/+7
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MAOL.CB+&!"6'#2"78IF@7;E%B_&T!ODFL/@<)EZ_JG;9+. %KS(35'=L=_5
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M&=RV1? !8WKF=$;#.NS+8J3U<[=065/*<XX.TQF#NW4M0>U?YF%X'""/7)&
M4;48OU*KGQ;'\(>7&OIU&UHM/"QN3()^K"U%CBHU:J&'J8J__16UO)5FXXE3
M!.$K>7'ALM'&1J<D#UW\(5,2BF3OS'9N[N_Z8&#;_DZCVJ&[@@F2"'DW3<[U
MO*L*S!Z)5(,JFB[OW#)'B.SDD*?M@&_D\>:G#]-J([Z3==IZ)(.2)QR<3,3O
M/SO_\X*8K$!!Z39%A/X9<QP&KH2\\*.;M4D?'ZJ@&RXM5PM75_<[&)W02>PL
MDY$)$[BGN (!3C6R.*4L&;7W)<7><04<]0 O8@2SGPGZDHZT R8&5%KNCTY)
M\$A>FLTE*%8-;W@.URV'1M@F-,_N*,L?.2T8'IWY,"GXHNY4U[>]"HD'U%AI
M7):<W\^B=V;'T#^AH\W3AP!V<KX1^?$ $U0)*;L?9- U%V3@/3]ZK@[F(E'^
M:Q,]@ 9.Y=/>J<09I")W;0\@?!@LOLFOAHS!5K2_#-%%VU7.)A>8GW PE'/O
M>LX;:_#@6/R%>5@_F4,]KT7+G3"9W\5O1;DUEY+1MTQ#?9@E'?W<?JREZQ":
MWV-#KLXAL=;>;\-D<([!XR,-^9-9S>!G)8O+H:]((L06J)2!P+R!4D2/N;YZ
MG0]DN5?^K?/QZ)3)Y]EW-IXG_K9.13:C#7C .RFK$)*;+Q/4.E()9V]X"FT6
MX%A@@/N4+F>GY+4<KWIQSBLFZ6F2J6S2DU#8IK14$_G Z?Z@[^X]PGV7%:>6
M'(]+IRV&"".C?WC>C.[TN'H$4VH^-CQN:U92"TZ%D.Z@=_1]A) C$BITV8AB
MQ"ATW_AE0)Z41A3*A<[O,D&1#RM6+A22JL\V?-20'R(ZN##>)N.BF2#2G0\L
MXEM"1.U.L[:)W-<C$]*\@"*,>I&U9VC7:Q+LXUZ=_$#(N.VA*+ EPB5>8;')
M"]+Z4^ \A3W_(1GI,:O]22S$^DT.0T[3!VNY ;F"SD2ZXL__- .\A%1(-8KT
M,4@B8:^+#V0,G&5/P.0\'@G(S^74%Y .,9*GCX >MT06S+'"9EP-#+#0!!CY
M&X&D\W]#1QJH#6/=H'%/$27<'6[%<+>;]$V5]:J;T5U'@L].O'AZQ Y;*1"]
M'!)(-07R'09.;FRNN-S2'.Z-%8Z_4/I-*O[@_@!MH8V:"0+Q_&FX.!J7HZM"
MJEC9UD7+N<P_"KK:/.=_K@(C_J5NKY, "[:7;P1"G T.(3M.DK#T,"7(YE5K
MHC#KHLR!.7H(A/$"1MDF<-*2?'B8H-\G6"YX*0]Q?"D3"-M@8,!,D*$Z)?L4
ML@[_76[G H#C12;$;"7,J5+,V@P4DANA9;,?BII^5HO[O) F"DL9E61;,T'2
MK0BU!:OSGK4EWVOY^AVNEGW6[SH$*4%TP>N:^N$X"F10#2Z4/GV+%#/>E%,0
M4-[$!$W_1K<%2Q2H31J+]46;[H]>-+G'?_D)@.I>.9N)$Y"A;F+G_>&PKF6R
M U;D/+6R>A$Q!S_26(44T!/*G==Y&A2@HY\;\(@7R:UPP^);F\6W$L\YS%':
MY3*@FC1^B:R<<<+4K<1.KM/K[C@7^/P1^HQ7I\F]7&LC:+7SC'E_3 YIU&[<
M;LS^#^*<D[J0[6FLT.3:][42AEL/R[BW59Z)H]H31D>Q7U;^U _KZ?K5QEKU
MQ?4[M!TM_AQ>YW7\F6366S%9;EHWH$)&M^#*$UJTZB\2QC^5#:X,?4B12_#S
M;;NB=#3J:4'#YK%G%_?O@W@7L8+7W>*W#*%W141M)#TU=<RI6L-T<+/I6%9O
M<?@!68/EO.^MB-#6"9&H]GLY[QX,:7L6>00[C:L-]^:[?2I"3Y'R16\T.F<[
MOC5*3_9Q7 D=L/ ?J1U!9$.H^LA&J)[ZM.V*'T[*HX20L?/6A$)]XOK%5>]!
M)"[*+6&:O>"8&]C98_>%>.4+3:MR(U^8KW@7;Y\6?,98S,J*M>/N%VP4 G!4
M***+9<JO/JUR)/K0IDY>R4Q-?5EMW%6Q$V<Z-0NHQ=R2SZXL=(?NI>8 X,-G
M>!T^_AN!NB!;D]"LV4$Q"9C\>BI<,U4_);&7QCLB<I#LZJS7^&?GZ_;0\N;U
M!<=\+^GT3UB)K$S;IM\'[PK[I& ?CRW9V]:=1!>.&*,(+DN+"A^Q=R#G_C&?
M*G22&2:2>B/16XH)6^*A%6GG?1-2CI;1V3[ /O)5NN%-:)(7J3>P*VQ4_R[\
MN$3XR7!2[9!?)?=HO/W"OBX_1JMI_&$!N$!)$)IV!.7$Z/U&EHZ4T5#^&+U[
M0&6]Z+@"7F#MK!_DRE*SP7$X9HDXTHH] O^X:YR^T6)7TI.OEC TY6%G:$$<
MFJ"!R"(T16S4F-,GG%+]DR!KSGYY"1L2EQ:GEF3F/2RB@U3$99RE0'^#Q=-W
M4>%S0U/GAI*IUY<VZ0+5"N]CGX(-^2_NWNS'O*<MAV@>OHA2&M5\].AQ^B3P
M@-1N![1/!^L+7"Q/HMZJ]^8DM>44U2&YXW-1<\_OA,@1](W:G63+^]4R;%7\
MI0PM(PZZ@%7+IDG2N20.TP;TH,4HA.+0SP2Y)K"9P,2;_8D\@]:#:TT;,EOK
MO[8$T1>T>F]W3/^I06DUS;RAY\L^L+)W5/G^?1DKE68?ZL--F@F9PBIZJ^60
M(7U!V.; /H- "I+^O!Y,RF=E1+>1XH<A]D63"IJJN(:3$2>TQ[DU#)\A8];
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M$:2;8I:AUAI"C.996>T2D:JKK^%J$8I]Z)#0OH%FP=>["8 *=+F;94X1\@D
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MVWTH69?&VKRA77&61U1]="TO2(&(V,1)9RQA'D)ZI!?#!!WGDR>ZM;$=8D"
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M9;F<[X,9YFHCR(9UP"U68>;M*7Q1'R7:J[JP,MWT4_HZS:(; CQ=:[/8Y?&
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M%!'7W!D537NLWAFMEMJ*Y?!1ZXFAFU),*F@NG\//Y> \"1G O=$!-98=>?6
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M0^[F/Q<_O?2WGEZ>3'F*4VMZ8AP??5S@&1_G'T1SQQ$,1R$S(\ZM<NX+$WY
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MRFLU$S$[_Z!56=\_K7$;'NHMD:YK^#&LN;F#-;Y#PL80KG\?4!1]T '=2[2
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M?OOW!9V=Y]7:^\V,HC!M=,?[%O/S_ /P#!!!1'KY%$Z)PK;S3,%L0MH8O*E
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MY?'RG3NVSKF)E"6G+!$JL!%^,EAA94!Z,@=1"PJ7/]+4W(K*:3]_N''-4T8
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MWA@\KX\3[8#57Z)1G!?6%1<\?'=.<ZNG^U]>R-*5Z$IT);K2_^:+4W&ZRU2
MJ VO=RX [9Z3#:CTB<XB:ER-A?5>R#C.N_ :?AZT%!*$P ^17_&,H4+@[[WS
M:G%2I7RFD<C4+YP-V@N\JSRCHN6J*E1@#XF<FM:4VDU8M SW>12=2SQ_BI$$
M_<)QE@I4AN?FPRO5*O)=:O&ZWY/QSJ ]4 YRWIM+/(T#0[>&&/JZA?AL\"HL
M@<'@<-$A-BY#]S\Z5PU*U[)9H23%V-I*">S5@B)L]RZ([2Y,?J/Y9G K:O7=
M>+)R7K[&A]%#YFTOAMDT.BR2R*OL#WTZMZ@ ZQWG(V\O]$8.78(9+W 8J:[O
M<OEW?%7V/T7II%/66F;PX9]>_,71 B=(C)*0NA'PQ2\M5$#+#O4<*D<%A(60
M5  B0P7F+M7$THJ9:@["%^0A."8]G)*@"5$@.%&!)LU<*H!IAV\?0(V>A6P=
MUJ/%&2X"@]/4[R,)R!GXI6]ZZK!]L& N/6L?HBZLQYJ?_+2&9\@_K5&_6,SC
MY)?/QU6[7M^XKQ%,$4FH?RWZ55"L*]WLC6'OU+H6YX6XAY;92W%SI8@"DMI7
M95F)DSF%3MN!J!&+M$\3PI3MXV@!L#.8<(JC<65 UJC"3*X-Q3;'.M60/6]P
M[N ;WT-7*P)NR*2WN <P5TO4B?@F:=R^?=M62V0JWI56.^\RUIMI[-4+BD=/
M^FPCP1:/CZ;G:5 \+F\?^$JRR28@*6J5K])>>WXD'YD^.8F9/EF2OS714\H?
M<QROE*8=4>!NX];5QOG46_5%K'J0"?$XK2@P)?E@Y<U*>JIL @(G=9GL-8];
MHE->FZ$V)U)J'%LV140.G&'>>(L;VFO]7 #;R[7<E0].*H"IVZQMWTM\TY+<
MZ;7Q.?(3%A1;@HP88>N!JKV$7'X]?Z&$Q=/5\^"6_>7M$(X] @?4&/<<A(C#
MZ^[XM TSX V_WBZJJGR?4F5TY]'RM--W5+\T^]ELSR<*>!2B]I9#1),F\ZA$
M0EF^1]R2K0QSNJB12_P'/#<WB8B(L*9UB"]#+:A [3R<\&:;#3V6*22*Y5CR
M&H>'4WCZ/ I\VL(_?NB3\[S;O#!R_D-"6WE,IUB3QD3ME(38'GL,9D*!XR"[
MT;7,!/=!\\\=PPM$(75ERG-4![^9W^@G<N#'OJ5UXK/QBJK2$&=T;XO(F[=4
MX.(-'2-<<L@Z\C&,KZK+9_A\IW&WSY[5'Y+NF8?4Q6>%CVX?V*^B!L2JPU7+
M,6LN)O&6EAV238WMUEHG;%>$A;(36D6_819X2-SY5C5?X3:@79UV 3Z.LJX7
M[O$=3<RR94=ZW[WV9&?PA5 _)FVFQR\UY H7SJ-<S?*55B@:SZ#C1KGZ[D?4
M_6CM@'!7 148BQO=O;S15$4%'EIO3!J/2$*,/YP)DD%["C7ESR'8"!ZZ6%BH
M:\[\^?.5[FEVO&$C?0/'N&X>G7N3%:R:2&!6/>&?0 ECH]69##E48")_HX?"
M)/G6VA59! IWEW8OE)8ZLKIU/>&3_;V];6/V\?[Y$W<0/(\:-&I$#RQ(9"?4
M).M:62R=+A:\5J#)[/W-&[WQ<CV'.P;'V%*I6[^RQR7C.$9JLJC;.]"OLC(=
M_8#+5_ [%A"(ORB02GI,?D<[^QR* CFGZG* 8_8"SP@/UN6#A=OY;@,N#--7
MN<;(>TOWE[XTC=V*JR $2*D];G_5"_:5"%"IYO'ULRMF]G=8<1GY1/;^1CGI
M[W&EFB@W^_B<DE+,(#1O)3-F;3ZD=J;L],HQ=)E6P72LDSV?9DRH!(>M@AP)
M&S1)P+RB=,!+6V+0#D@>BP5KOM["P^U7CZQHIU[J,VG-,)J<8Q)@M#RSY+I0
M) 1J-:@^@DF^_1;YY4=+@NYC@\1<%FD(@?%'*3>!<Q(<HWH4IQGMXW9#TLZ\
M)$JO*G7^*,_JP?U^ISE?SS_W%E0RJ:91):;L64!K*<M%'[D5;L3H+XQH!R[C
M=/Q$'G\O?A8=<O?N1?"C>W8*0MYG>AHOY ]'^4XOH=PZ7L_&Y1D9W!P>A!,8
M%X>Y3&I'L3<[">(;M!;JX*@__WCT5[C+]P^A!ABSP_9E3^Y^K<T5M])E7=JO
MOQ] /H.^,DN<D-FHCA5T[5W7_JARQU@\0TA@ T3B_+$,L2K"DLO3X0&N=NR>
M,Y;7BE SC<PO,Z&:V)4(]ST7W*LS%PX5U6J[?I^V#3KS5@>VC]#3,C#;Z.:B
MH]UXI#FG /))RS5J,;GBR6S&6RV&@?=Z Z+&Q@X.BGN$U%"5X>'YR2,HU%-O
M4N=>W.'*R[HT5ZVKJ\,4*9] 6 .$(*5CFYR>4?0:XE]<USXN=6ZQM:J_X!L5
MX*XJ2-*O]N5\MWJ&:0AL!=T[62 QX1%ZKO. DU_<PI$;1>[EYXM;NJ_8(&MC
MU1B?J#'&0833[7FCRYR-^J1OEZVOPKM5HMEM=#GY6S3*-:JYM_QH76,)#E8P
M3@4&TAJPWUU2'T5+CEOXV8=,3QI[E(ZP/LEF'=N%="$L0:_ACH)7S[A"X3WK
M:))18(K'7EV>L+ 31MHIUD-H[ U6#=\\(^\/TAY@VE .&MWJ6_J!RNA3:C.3
MLB/B3K_IEN[UBH,\@9>#25S2C4B0SPQV)#3?VKF&J7O"0D:P9"G<S =07CM3
MYW.;SU!Y5XC&A&L<;2)R+P.[@\+A^(,>9,X3!\92VQA/&]U_7J!>8P%Q"++J
M1:M5K;*_S]D_?#[Q1R CB4>:<@/=@,:?&J0"\P[34 C$"5YW#T%R@(?#EPQH
M'7)WVV=" _<V(QO\TWL$03>C'3V2NP!7HS!1@3CYJU0 )09?WUL(PC\@/X$)
MP7IP%D@^?]]1O<IBJZ3-HD_X33UI48\4/E83D?2"Q%91OL+).E&*6(<PI>HE
M%?AZ&"V,'LNC*/25P <_MAS&WV_.<_7@[<&KLWV+RYS5+1,%!%CC=2<A3[$4
M"PO^F*=BAM[37,.]Q)RNPMG>&=YG>B]R%-9.=I>W479MRV)E*4SS6"0^ '?6
M%0;"?BXK98>F#2Y&2$V5;T8KBL=\D1=CBY6U[H<\I +%LXT>!SIP:W4'RZK?
MOE=%WWI;$'B*E:WQ5HB\R8\FU\8M*ZB@J;*ZHUZKBM5Z>;[]M/\;GQ?DYXKZ
MS!*X10HS<C+&59/\D>3IX?C6):D,%P.VOSG\Z?&'GN6(6D9!+7",_V:]=,R%
M\D<4"8*=P;<J]0(I9.Y"7[F\YK*7ZG&M..0T(_*ID!(F+VSL?N*[HL8W:"[#
M@K9AZ\'GI;*?ZO.SQXM+5V;G8&O&M'GH4)6B:UY0K.X!IZ(1H2=RZY=TB;.^
MKJLL^"9:L)\01O%('-MT3M++@''TOC"GY9)\K6@=+R%_UR2#%-YH!ZWOU6'W
M6F:O&Q.D=N5?</%/?5ZP?@V_0>O[1QPM'@OSF3]U_SC2LGZ9_^WKM]EGWWT2
M?LFU0+(B/T9[H+EAGV&*/<L_Y%B&#>HX/Q>Y'#%<+2D:;+2821KB7+V:)<H2
M/,QAJR*,WZ2=2*Y_Z"1CI+2R(G;-N.HKB<]E1KK<7'9PQ'7/7<MR#@'-)P=N
MQ;7Y#%3)*0@?*;KVT-S3A30L.?-Q"Z8TF*DXS:@]H$*$6W%\D_28 (639#VG
M%LQG$+GM-W9;CK1P<J[?YG[Y:L&WLBEUR&Q(S<=#=#B);\_CT4L*J-E4Y]2
M#"V^['B-T^TM)R(6M#;D!D@LY$RH#5&!4"/H6&_>VY=VSOV(Z]WI @\N(7VG
MM=)OZ[-QWP[<U<RS:)C)&TEW;?MR7A?G2[IA#KWTO'K.>9$* .2ES"HBWI)
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M5_9&C$\DX>NN$308[.P1O9V[[("+[U''DOQXCEC*DA.TR_1*AF2.GFM7P67
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M(P&20_VGV5N:V'_=X2E)&LF1@4\N-1(,,"S H*>;LC5=*R5+& $W;QJ"6BS
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M+,QCJ.:28HF&"$J%D<,0@%+'#:'#&8O]:5!H]T0GPY8"UCL+35R[?#9&_]:
M6/8]W\:#.?G'I>(].'(!\'&7L9_,C6"+CD5G^<&6DO(7MB](Y3EL',L'2:?
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M_;L(_P#Q;!N!<AT=1J 8./=C1Z=?X%&0?V=M66\([J9;\^"+U68'%J#TV]Q
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M"C990\.ZQ&06,(X!VQA2<=8TY,X82J0)P;@%,V.-8D@<\'V$8;+KLP! IY?
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M<P["%!)"%XO:1"%;NL/-@D*+?1EP^[?B?NYO7RT_-X6Z=)S^(3*==^*VZ=8
MY60!KSD0.N$3Q0*D37^R "J!M#6T3]#Q( '2D?/QQJN^O7ET2K##XI!Q6J7)
M0;/0K:ST@T216E7]V7%&JT/.R[0Y2-"L_1P]:R>0:8#W0-3Q7]\]\D\P,N78
M+&$!1C=!"@;:R0(&L*MS((1B",R3(\%\M5KT@&&]Q\!T!.XDLRCKUH!\.&(E
MNZ'!1X&6OQ7Z;"Z=LA>?"%_IW9<G!TM<H&P'6P)80'P%,HABY*9!J(W\5W+:
MQR1AD.073S94;.@,#=2L2=*_GU68V-2PI^Y:[%2"I $+>(9^7^P1/4N+MJBI
MO'W\0T,H:NC:\1U>Z_4$2*:W!AVII55)U0G%23$S\^;P9J5E<%=%0,ORN%GG
M1*3-N>>7Q-G>/FE362;\ Y2B_I$7G_SZX7 M\8RXXY&*O"Q$UV^WOR'!'9;@
M=KCWK9.?_&@;=!A5U<;E%51KW,E T7R92F,:W^S!8G>.Y<F(@%1'^Z:WQSFV
M[_8-L-KH(&F _Y;$C>\I^4!!R3C'HQ8.W<XKYS/",PPONTE72%G/M84AV8_X
M'"->#OJ-10E".O0;EEWE^4^>,#-].5Y/-N1G_!!O"N ,/<5^:OIMCV$P9N05
MAAUW:$R,U]20@NE?6FT.^;.8KM[P#KZ=_]G-,??TC2!@Q!_EXC!%^/>4/W!J
MUZ.["^.O;AA=[J'E]2PZ/+I0=\WY]>@DB(3!Y7*$>O0NE(X8#CBU&910&P*9
M)7R1RWIV6OVNCA,%@;N>[ JYZD&\O4H,^_?>F<J+!Z4?S8K+CTL]5&!\#%Z-
ML'VE[9#@]J#W+3A"N,@":C_A 1;P:\OCK7]Y?!"69&BUPX*0C %EZIDMDY!J
M?SS,5Q]4F5Q^>7_\24PC\;H>\=D6%]H*ASCP[U"4>Z1MC"1!<VCNL96[!:-=
MD'HS\UO-\\2T/5H;4""%!>A V2.Y^K5E3,+@JI^5@+.G\U2YU4/)U,>[:S.N
MG2/RL8#@:PPV],I_HG!D^.3Z7P-2&^/\M[7VX;*%SCW^U7@C=#FK=\+_HVR\
MCD^<-//.:UIBE7/_DRI2P:&$=.<1/QXZGX3E>,PB?M#UR=27G=Q/E".UU21?
MS5L*UX%!5FBH8E0C@J=NX%)D4=J0=4MQ693/A-O=(3,/F_V1=:;5X'_X!/-W
M%^/CEM4+,A<S(M(FA[H\Z8N/4R/]HPZF:GA,_EH#=R.H(UC).V_^QM#1=5S^
MX.'3>WN2XAQ%H\X^"-5I["ZPBJ9PP%SME R::\_[[D)+-F)1ML<07VK6%:>,
MIYOO3ET\@[>Y]GN-^ KS[X[S>Z2JE8NQN7'\8Z_SP[6USAN<-VMK;K=OT=6_
M.(PE]0D-@'2HY,9$_&$J]CFI2*5Y,D*F%.XJ#_"ZR$DX]D0V7/99U;30A2H2
MQ8#@3^+5M/X(!5RB8/O6_"1'%7*FX=[*Q!_Q?,;%Y?574?<X_VK#?_'IODFH
M&W6_@!M77%217?3-O"<?-/LPV4)9)N$OXE^8_EQ$AN(':%N+'@5U@[#!.X=A
M1&/5M\")!6RA4^/B7[B:X[*A)84"[T:FBRT]S,7V?,]ZU>2.>7'>L$=-JQA2
MI',SY)@IY=C#%:,H[KS8K!^/:(XGNIS^G'O1E&!9<'G^A_&TR/C\;4Q]&R2]
M5$T,4^\:"*:IL("@)06S\M8/ECQ>$]8_<1FF$?B0++DJ\-^ZX'7']7/F8NJK
M&U,#</?PL ^_[*JXMZ2DR>)W7[0_.!).WL&0^=3HZHUZ47XQ_^V&>D+:]D=^
M=5S\F"OCO2JKY !-@53&:<I07M2[V6)UK?C[W_87%3Z_)&C=QS>=>4;OM&9O
M%>:_XKGL"6\G.2&8&IFN:)[DU_-YYF]62_R;U9XC!L!(R-0Z(6'=3R$Q#A&6
M95F PP#XB 5\YX URR>0.._&KS"M6$#IBL^34'I-I>?Q9CCS$-J>B[QQJ"4Q
M+V3U,Q3U\,VDZYK)ULD#WM-G_\]/*OC'%@33?VU! .]W,Y#*J^O+P>J'E1BP
MSPE)B+KRG]AGER#U>:3->![<;<B6.GXA?YF!H3K4TCS4.[5?Z:J\L3#K=5VH
M]/L<_JRKJ+S%6V6SE 7L),+(URG]R'6E5:9FLWY] &=#L;I(*8(\AZ1[#O#8
M=T8S.[>]4O*6MYNN0#B;8"V-)P#FWGIM<E1WI6BCLV"*-,@[\!#>%TW9)5I4
MR'/HZW9FNTPKN]K]Y/FM7!V L 5G+A9PQQ"2M0I(A?S'+-5J0$$Q>'<%7BR\
MH3AQC^Z.MS\SQ,PUWGUJZ>N+O6+'OCF3=Y(6"BTAPZ8?',&$:QWTRAI?J)2@
MF,0^R<%^;1@7/Y%XY.F:1Y6Q54[+N\<.!<0Z-*0Y"'/S(,)U?D0G8&N1\4[Z
M@\SQV1MU5H?,R%-15TI>AMG=]C%P0W3>8G/[)_9E0YHFI#=&A!1(C+W7ZS4-
MIENV7O=GJ!;",#YV9=!M459U)2-"##*^8UP2DA+>SOT&YI/K="S$0L?6&WG$
MY+P>+>0H%M(M[ Z<C:X6]#%..B@;N2WK$\#WU'2^A"'R'K$/PH,"3>DJ7@4T
M_]Y'N J'L9N+'[R\)PR3Y _W8,FZ&7DR9=?3?&Z]EW!8UH#Y$(O&]>-P+.!S
M!0%^XWB$?7.0&8V9Z(2%MPZR2P=GQ8TAA#)PY, -6@>IIL'P7H9;^\+ARE\X
MQ>WP/JIX?M[20G>23<)/D\:#:M$9X?DC&A?5OQ('#/L%8 /,*,@,-3>%H^LM
M9>H- _$2T"AEW(("AA7Z(OK0MB[AL=E#<_<)_'TUEU.U4J@);<[]N\\!OSA6
MK)$0V7K9J0=.C X,.F"WP\<M>040QX2Z6^?,P%(GRJ-G>I=U!)4N/18^Y)AF
MEGKP[ FQ(/GE4CL6D+[$#1'UJ;U!"^X1J.N=:Q'HFX%.QY9RG/:,#?PY+&(:
M>?&0I>Z$D+0HC(RND5P"Q:XW"L\UGU02 3Z(_TI=]]]7U.QUV;Z .,L><_UW
M\8X)AY_MT5K'O]F<?D+A6, @0N0F,Q4<B2'S*[@A_WC%WOJU^$BAWQW< ?ES
M'>J8C$,G'RZ(M0\ZKRTR?J*Y0<WC'6KQ:F3\1B[B&]^M1YM:@EMGI:EH*+)#
M23V80+*PC+&9<EAS_F$"$0-^_KT[/6U<Z^)3+523S4 +YK(=.P4+HVYM'3XZ
M1D0QY*'YU#Y#OW>0%1?CQ-AI:TMR?_:Q9OFWN9$7G:4,1:RK/$+<7;&:2 U$
MD&))V E7F93U5F/"A2]<H'"$NC_H<0/W[!O67778D H5.5C*$U/<<<SH\\M=
MVJ-A-K<+P0[/>NS??B+_)S]Y_(]^ZEW96M'A@'1)&^=+,;3H+G>D*^<V1I7O
M'LS#UMQH309UQ1-T>>Y8:9-JE&2J>8IO).Y'=R@&XDS3H?E:#_6?P9GVFPU1
MF34EJIX]:ERNCIX"NW*BOS_/SA3WY]I9J&Y*O47?6F9DC+%;@J1)=?IAJ']9
MV_F?UAZ6[GGL:'=?^F[*2?%R:\^'<"AI)(I >4RJB8*.?LRP&8D2,&^DE(Q-
MS&7NC/;VDNY<FUZBB?D+%B8S7@ X=%QST2L '_=K"_=&6,!#3*0'I@"]T#O.
M D(&$A-ZM'90UN!OLJ>KXBPLRM]KY5P[PAYCQE<T;%J/@)<+4N@C@L_\SK2G
MI8&WD@RVR5THR>M?DA]UKGT4K-7%QLB%:TEL:VV0+)HA2*S6XJ7NS/3SS6*8
M4*TMO8*O_YQ_?=#3]QO]&4R.*_BZ2'@(]^'$1A851\D!JR34C(]?7OR'&8]H
M,WN:R?<]8OI>+Z5=#T:&9KUCFY';0,A/P"5-C',.8B*;<HPK)G'*7DNX1V%Q
MG<_SE8E "?D^$7I RA']&]=-Y:C-L&Y&.&:!"PG"#Y)E69/XT^ /@7^M_Z#V
M(@&*0%G<=WP;2%-!NO=A@KA 3P>Y2/G3BQ?R\/6$PFE_6-;+J?%R5U$;^YQ<
MYBWS.3VI 8.#V4?V< Z)$UOP\^Q+V$_"&(I/[Z+\H6\Y6#[\SD:IH]S3!MUB
M]FN-@PT(R-Z$"%2U<] )ROQMJF=HD;X!JA8OEI]XO6OI#_:1J@?U@+>T]8R@
MY$Z]&24'*!%J__002S%J@XZJA1'+A=)^ZV7B'*!@7_</?8A@\LJXUB4Q9L).
M_V#\V_?NBS\.,\Z1&,H-Q<&3,,\HE4</TG/V<R7R&H6_]#I90ST<^W$H3J,E
M<<>$Y+V/;#O'KH?<Y"^<(/0M06KC,&\)%I(Q?"&//X&[4Y;?HW5<OOSSK+EE
MG+\CIB:_*5V"T8+?G$T]%IC(&?I'V%MCAGTMK"8%'59C)=SI]FE?H;I-CDET
MC'J.W6Z\/RF2!4"G8FGY9<P\TD@>N'=-L43/^P.$N:[%UQ[K,;.8N\JHWA_%
M3"P55IHN?97RBKC@3PHB\RKAS!'"%CH[?</8C&% E<04O0@Z*S!GC4=PC_WT
M.]0\">;LI//,DBF&BI",:2TAN(>6N?/K@)M/XXO#RS5Z[EE#LLTNM]>T;LEQ
MQ[8E;N/K7A/Y;P<0"2V3&,(<L!$O_1+8%_:)!<RD8F^:-I$IMQ4W+BHN"B&Z
M52$5<7T$ )[!4NQ QD?#"RP@W]2,!;3K6V H;HV,/5+POANT3"3-Y(_D*BX@
MR0^6M](['<I)JWTW+Z-DZ/"LIE&M5?G",[@4X-G]4XTABF8!1V-_L8 %XQ[,
MZO7>U7JZ.[X!OP?I[5-\T_!QR'!<5\T.EBTXH>,6(NJH-(FW4QAK8Q2&GLW3
M4.5^F[W[+ 9#&NDF0W*)##74 @*DW,$-21D#6D=P4@61G.DI5UKS9E+YJUUC
MF_6XY+8'Q^C$U"5$YV^6.4"9E(P0+7FPF@LSDI&M_)(9T ARN1?P#N4_L##P
M^!'<4MI@/C#77VW2</Y[SO&F$\Q@_'=2$>8YR3&JOZ0&(UB.\J:1>:&::D7'
M9OZI08R<?/D[ER_U!\N=E%R^_XYN!4 M$L77DY%"KF8!=/X)%M"Q,;^Z#O,:
MCL.<SRA$F+36QM08ZIT29D@B/$JFA +"==Z8U4H?)I)X Q!Y/<F)YF8!\RS@
M-@OHK!C:VN@@R4'?!X717B+F\;;34J?4/]],[ZUF/C2PN%D2Z*GI<YORZH\,
M>^9R\OX'C;J,QE.<#LLZ,.\WI/A/.S+ELN& 0)TY)NK]5^= DD!,C_R]S0'A
ME/'SI<4KN+"BB,?WPP1TOWSPGQ"T^6W=QP)Z/#(^6CCX.-8G3Y8+)WBZ*I^L
MUKRG.Q7Q;%=X1M!UKNV2G"K0U@H&A-P$7" JJ@P9CG$L?#P&M[I63JV/,IGD
MF'OX#+KZV(42>Q:0(J 4./WHN5#$68P'S,>PHR0N<E&FKU ]GS%T4J&"6O6Z
M\P[RAOIE%F'>O94B>K7LU3>"KB.YY)(;4PZ*AMCH%O@.-$5G*<H\D!CD'B7"
MD*->)9RRM*X=B"^H=_;0N526GXPK9;-B5[K/'G>WFD@VA*0-&1(@99W6TEM(
M '"/.E?)@=C=1-K@P,/VWVA(QSWS)W!V68(6<^+4S?ADKGTKGDKO :8/L9X,
MG9%#1BCD0!=E:$#Z'\EZCFIU0QZ6.C<C55E 5!CO::/G5S%?>]7V+J-,2F@J
M]$MO>U?N(D2H! JU( P:COR):1HV2/2W^78>/VM/G-)NK-R/;;G&88DP%S-\
MS:9G&,./BJ8][\G=,^7,%4\A!+5$_['PS4P5L/J9QNS?N]/_N [E=Q/*"-N.
MNLQ N$[ N54>/S&8<SS]]KG)C:22,'??;Q&IR:/CSYW6^_?@]Q&[_N,(*[P<
M OB+A&5K$B>XX ,RU7Z;+E[Z^\.W^-I_?GAM)X8APLL"#I=2&^&&;#136H7^
MU&%K=>BN(!80:P$A"<[:. J.4<&/7&/#_EQB2+;3S88>$H1@?AQ_?F6TVR+:
MX$V#>E&6VI^IKRDZ184*F IQER'^Q<>&KMAV(? PAN)1$O*QAS12F*)4_/*X
M ?ILN^/!-G=5>S7)P8_.C<ILF[<08]AN&:/6L)^C'BWI+G8SMHZP9TW$S4_6
M,VJJN",GK6],=4YS\+T"Y13&)NRK"OVBPS@)4D.D#PT612):&6Y+H%5BXV4"
M.Q:+^1!4*<",5VJW53HL7/YW8-.IZ[U^R\OY6M+A?FG5#G6U==WKY[*[WXRC
M-@3=L9LKB2S@K#(; _E5?08<(;$ R7(T_2'C3 _^.,X'"LS$G>Q4,2R"(G_Z
M%KA*='_07FC?.(N;#&&[:2W]S.H;M1/F?HTHM^K'L!3DC^E?/P=%CT8%E=V&
M;XIB_=-\!8NLLA3=C9=;8LM&7C&ZK_CU0<= !9*ML_] XJ(4_:P7>G0XZIC)
M)C%*\]S=T?G3-ML;!7L]^:LBJYX4F9\U_*S"K(%_D+XL/0?O(>J#7 /N*N?]
M6/L1<JXQX>\_FRF:DZC L:1P:#]OYV5ZFH=F@88H )_#'\ Y,4M((Z_10FX;
MFK?&EJ)(/(QS;E/+W>X1)AN.19;A[*H_+-]].ZN[B]-]8MMIX@ 6.IS(D' >
M-43CJTB[-8VH\PO%6(%*@?Y:Z80!ETCV\?<:KQ9;TT[7&$PYZL7QANR[?#PP
M!E..N!B;'Q5,<G*&#B_5*W+.FZBN/%3'!S_)LU-[(!3CJ&%4^"+CV;A,_.\?
MDUH=/#I2Q O8!O("G8)%J#*L"<F-_@GZ];%H/->CL9:FJ(HK3)ES>R9"_?GK
M)]>9ITB<*%(Y8&[]K:/-$9>/XZ[VBHT> _<L:,ID7*U7Q@#Z"HD?9T\4>UQP
MQP6=5 [TKEMFU.T)29U$J^/TH52Z,UBMA#]H_\7K6ST:7;EW7CA\N;\X,QM;
M[YCY2 H_].=.Z;7+?]"G)NX_EMND,,/!^]B=< VIP#102Q@2-@QJ/$>IB+'8
M"-NMY\Y%T9PO#:%W7M[PT,I]]A20M$':%,%\Z88>M(:Y*JC6U9L_7SOX^7$$
M$U7\N+T/\LH'93CPM#H><^Q&O7JV+W-'JN>-VMUGM4R0X;PE+KZ)$AA")ZLV
MEY[B#_-PXH][2;8K3GPK?'$GN*[,VU6DC/\(CWC^=VI:Z-<+4PU-P+'L32'Z
M==R3OUXF]("$9FAWE1?G4Q2#B6O]1C^W?Q@8FNQ?N_?LK'C,6>+$$LP; J5Z
M4VIA'DL*SJ*E?0"**)+80SM>?Y%JD/%;Z,;\BQCAQBQN. QI",(@^ U&0>A@
M[R*;.W>!9MEVDV!GRX)ABQIR4#]J]"RZ:7I!@X)&<I _(B&K+S,$1LB['WKV
MEA'KG?>J](:X*U8\D;ZZY/GI-M\@(RVY\1'=E%8[TL9AC^4K/Y .@1<Z%]V2
M!2X4AM;4-/5O=QFPJ'LF%2'H9FP,H,YAFZ(8HD??6<QC*+><4;\-$7 S#%P+
M^^972SA><T##CW:9!00Y;%;_??#<%D^-\D\YC@C20TMPB,]<=OQ_V_O9B&7L
M5H1O2-&1'-K7*PR'Q9 *QK$US@O>]&L.A'S;Q=,CI- 4L?R.(GG/JLW0.0^3
MLB1=6JSN^SBN[4Z1IE,8]V?KQ"X> G3&@980,WPI;+2MJF_BSOG23G?M 3]7
M&C4)@..U9!@&O_ \#/5>3<NQW.N=%RCDH)P'744:](1!WO1R72N]?9L[.)[]
M^)NF=GZ:^Q=-%4AK.YQ.S1Z36.P)NR/%'$O6N18]NL52C;[2:@6&*X.VL'?'
M"68!9J02L[N0\#QAO5=T>2[\?D!UBO +Y635A??#][^2]Z\('>=S.G3?X%VX
M>"Q=8FM_,5A=C%"%[;/40\0&Q7!A$_7&AAW^9FZY"@WG5/\_\MX#JHGO;1<-
M@B+-B(!TH@+21:1*"U9$1&QT(2I($0&I@@8&04"0(B#P Q1$0+H1J=)"1T2D
M]Q((TJ0EE#"09'*'W_?_RO]\WSEWW77+.6==U\H*:]PSV;/WNY_W>?;,^[[I
MTW8)5[5V_J)O]5W^^3=/+:AY/_5//-7\'SQ5*2%J7TRWV8P^30PF_2>U2&%0
M6P[,/_Q; OJ&B'B:V,@_'T7 >KSA#6'=.5T$6'Y4#+.<R[CQ0PFT#OAP<3K)
M GB!)EU#OTCG55%\G3)7EO5'5WK(Q6US\VO/?)W%B>CQS".V+#(3PT,+#LU=
MH+8MQ8!DDA7U<91VBQS2VFAKA-:+GA LKK?_EG8B4^?*[9@+O8&Z07OO4]*<
M,D IZ"">/&KME[&NRB4DJMFKKMWQ5'6<S9776]).EN9UT%C/F:0.<4F2$K9?
MP99>JLM=4X*D^+,VC7;25WO>''>^7"%(V7!X36[Q8R!H1]$01PM9'>+@^+QH
M*3H7[SR%#]WE6JSNQ2K>5QYO=W]R[F)EU5\OYG_F_RPHX[ZCA?CVH(WR'.(R
M@5>&SA+ABUM]K2>1T/S^E N*J-XB;/ZAI'?U</:OD,R\(_G7LO;%&Y\<$5/^
M(7\CN&P[%T&$^[.)'VU=FL8M.Y/6ID^E^DN6$GB\1[Q%;TFGIOZ#8U3!'&-5
MQPA?C$/ ]RR/OA^EU3*I"T91SSN;%H]W3)^IXR&-Q.ETN'FK/'!N[T^O/E'?
M??D@))RL[WXWAB9&(,I\QKN@@ZL,Y?S4=-D25Y"DQ)1=N\?/B?MI+0&A0,,'
M"%71@Y^*UC1I%L,D%_A6F%57CI[=8&X[.+'V58*FI(?*]?K/&X*8UBZ:".R_
M90I .@-QOQJ@'RO'+:?@H])!C1+HM@F9"C7Y,!"[YUST4,9 PQ"&9$P ;^'Y
M=05IOMW+6#R29DFBOX\N[?ETA,M^<%!U?"(L_;'X,6\%-V4QHX#/0$,!+)]O
M(,'':^!)U_AI_P?4%;$SH.()7ZL;AT;BG ^'E"YV44_RG;9;M^SI>D;!@#)A
MR_RL-%X 8A,MP*I&3\IHZTN%KJ@"G#] L<M%+OO:79G07@8;>ITC4L^@I_#(
MPS8\U@@,\T#L"1\6H&-IUNJ-Z?_E_M^KO?T_(SW4D(X[4&K6!B"AGR@FVGTR
M3XL9^B%I+6CS]?L'] ;AR">MOVXR_5D)S*^U2-;[/>2$>84F^57LO0#+-U0/
ML$*_JK@HG69MO3FO:J[&XCO%DMUDCG97;J8LPOQY+"GS!NOO]&4_4GP+AF0=
M \J_C_!-[4J&)'W3W+C!?//D\L71.X_MTU2 :9,7II,GGBE?E'6#A]JHO >8
M*B&(R#\NFBKY^@7?M^+R(62?/LO-15/'5_D:[/D?$)I,F,\$DGT8C6<;XC-;
M'B)VC7)8%Z]OX<(]R\.GYV-U'4M3+=#^)](JTQ:OQB[:O_3&?=]3J-LQH$)2
M6Q>5 QZIQ?+>0'01[I\W[2SQ*%TMT)CR %0E&K\2.SNH4(ID V^UKVW)[6R4
M"PQ]N1FW^O-\OK3\\H]\MF,B_S@[[!]G8\+PI&?XE::\<SBL"CW-*[6MHL^N
MA(%XV=<L(_+2ORC%P&7Y(Q9@]S,[PW>6I<8HT,0(@>V"@5$67@8Y$#H [M:1
MU1I5DB[5'#2>DOD<E99T(!)/ON5\/-7.3;71U3?+-JK8BF_4RLGO()<-6FIY
M+R9%-OT<_!.=-%7J':6E>;7L?,!IEX'(/4.'D4P$UP^ *LH0F\%T^G[HESO4
M%Z#06[CE)@#V$HE#C?:K(W90PY>*Y*DXHD+3;)K?K7,U'B<NL;N+SU,F ]$)
M2/ D0!/EINI!S7C>Y4UD9$IK+=EY^O?3$WUF7X?^ZB!R2<B,KEM-7+D8)<O]
MTXSSQ]C58$')MBU^4AAQ*"Q FZ8 L^\H;?%\*^< 0;+12\VT9'^FGT]/7WW1
M$_;DB=_MH(/' L_Q@<*PR,@(J$\3))W,A(7-2])JNG/6GS1I/,#AF^RR,JC2
M_YGEUEW+"=UN9?4DWH6?(_)YA[O:NWHQ)'OC%76 ; :Q+<V@PIXE](U7-!)X
M8G,.,!!)SSG GXL"#$3%VQHWJE-T/]-&#FVO9H.XVS+L 6S2Q!F([LT?5$6(
M:S^L7.<_P8YU EZA"S?-6@$2-HD6A2_!T/W & ;B0I_<,AY4X8%N+/Y[JQNL
MDZ@*Q15A]'((511K!&8Z9U_X?!=D;4JJ^FV)+?E+O,;WN(/Y2&/QC2N(-T@^
M6B7M&@RHPP&3, B8(,.?6BJ^T#Y'9D=I)+UNPG!X+:4J.?"(8'LM@SW:ATM[
MORQUV^/S":/Z4V(AU-M89G)8$\!3M@X^;=TU:HW*396Y:+:/[4WFCNN%_8]Y
M@L[-%Q?"'-J3<@5THQ[%GBPF&3<R$ <7("1I-@*AL)S1G'3J &?)#T^)WK3U
M*S_;OGU SJ*(_,OP:.P_!NI/I\8(.MN@Z%D*+O)$Y^0UE[*ECNK7OMVN#MZA
M3Q/X]"3B/B#85FQ@ <$2#AMJIJYRP \\_R;Z$,V5;%],UI_6S?9(K(KZ]75N
MPZ([=EBF.O3WG%.0_UR$J?^/@T:1'D!>=4%EH4)6RE["DA<.L<.R'T0-I%Y@
MONO31/I(9O7I!_9VI<7.I$]/S+UVSP![6X>:*PXOFBD9NSGXZVY6G9N-XTXQ
M3[L5]L9^^2 O$]UO,>5]7<6GL4F+\0O>#GY'_G[E?^XR4T)"V/XKQX(TC@T1
M<3316>ISVD-Z!.T2Z2AA6K_9C<?W$(I[S/GK(^>LNSMH%T<K8VY^C7G'Q&M
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M-B?A7JM8:S7K"@^MV'3<['.;LBA:.^X>JG^[ 96K(<["CJ#YP_,,:]*&;IZ
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M$JNT]^P RUQ7DOS1>>VP6JSTBH198I]E52PAW'-93R>7F2K__TA5@?^V%LR
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M_RCI\.BB[HG:]"9^CQ]C)D;TFD32D6=,E+# .-]Z'<TABA*FA4 ["I/<H<]
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M[]/&W;#(&I><RL2^9AN%;T;G_[2T70Z2O+)"O.=QH=#F'D3W'[C$RT2#^]L
MK^&#;@IU$MC]Y/4+>./:/F^=?4YZ#(2)_*TF[4>$-?GU6 ;B[FA=X%Z\&N X
MIB@<T$@X# EVN",I72^PIMX7PWQ0R^HD_>)B H_5N%UTZENQ$2H2XJ#"DSB;
M#K%;P-]$LGZ(BA:ZW'>C<5TQO$8Z,,1IK6B@R6K?$S3 W'F8)>00N9A:1FL"
M&B304UDVTK#-7(+&+=VB9_K63JEDX,^30X.69CN?W^M5?"]@VMKQ*DW5:R)2
M^[G5K#T+,_7&QQH"Y2:]J$X,&@-8-F->83AI!K9$-TYG[M!H7^$C5@8OJ@1G
MT"JWCVO8/1'P/RC5N[>OVM&#=<KTC3<;4*%KF?:I<M /F03?+"^O,K#O^_WP
M4-X9F9-JLA<0]4<.ZD@SWXJ8"M""!M"<P,-.M'$5F$1&-J"01=Y^8G*"6/VB
M,2?W24V$M:UR59BLP!%^C>\%Z2QH1P !]8EQIS:C#F%=IM%BCC[;1K:G,J=7
M++FN#FJ%W/$)R0I)OOC"[K+L=3UOC09>II&_T8)< I.ZH_ B? 3]6^*M NI)
MW(P#=$A^'N+XIV"\8?X&W(Z$&,R"O^CL/4."3-!3BYAA-@;B@2(H\SF'V'EH
MH+ &18[%M#RS;6:7+(-(J@?OQ!!Y8G59V2NNL%Z%\B$N!J+]& GWK[N/Z+]W
M'S?^B]U'5&)RHN_T!4K'_6CC9)?:H)A:"25VQ&8,*&Y&XWU^;:]^_522&#=8
M3!2U'.2R:JIZ7.46]=G^C>PHQORR;I]VV,?P$VR>RR4Q5Z$',/ CPW5/P_.\
M#-O@ ]>Y[L&9E?2CVB9'7T\OV-]JNM(;^_*&<N["E]&<]Z>4XB1=LX84J9)
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MM 'C=)]J"&".*?9^J6FV[$U*&YQ4#9T<:ZC2OGFYEMOTQV$$!6&V#C-SUC/
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MIKI %4]*%UB+'9J4UF4BM?035/I\PUHNK[IA4Z^LG@%0K76F,(2)I(-CA+T
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MS3=0XWU+O/K>P+>_29?F^I@7KZJD^=W1+'WK\^H7&[#I-KK7NEPC5*0W)S#
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M.#UIQP#S1FN:Y7&N;"?5 EGH-J2W,Y;+MV&-3:3JDL(A/14XGBUSPLOST93
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M:2WF"QHS\3)->(#8C0[?MDC6)PAHB9_JF@][(WCJ)O=;9Y?W2-A+S<HD_$B
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MXJME1'[/8R-7OP8HIKLWBMZZJZ>\VI/O.U]YI(V0"$<LM!MN/!,ZS$0^NF%
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M51MH\:+>QYX%G;W0K]V)*%:]_)^GJCCM%L_/O$PP8<^N"Q';'5U.H'$(4F#
M$0FCR#!CFCBI=P0_YK?B>UU$\GNX_)C6:!Z0==^'_O=CX!WT5IL%$=FI<*B*
M=DP!.HK]7J]<5X%"+A$X@5)Y?5K7N'S\1\$H^R;-HMA83>M+/T>W8G@,]NL_
MRW_V6#H_]@#S9Q[$XC\S=O\I(V_OL8!8+<A44119O4HC8=>[$K^<%(WX#1V5
M,GYJS\MV9F]O2#1WU;16RL'*P='/7&?_N<07EY9=__.](4>W_^;>$- Y69QY
MUN:12Q0@[RO^N<_LZ*/1+3\8.LS08S?QH,3:LBYI;>9TVJ\NK$2V6'#$URNL
M '#RW.3/X)D_0<>9NTPS*_[+S:%8H&W\ZP8#<7M"'^J$79X&/?%E[G(FJ>W,
MB83#"Q?#)^A'I=?QH(P$C5N]A4"ZY37&8@&ZSQY.UA_)?.%F+S2Z7^M^^NF/
MT<WB$XFURN8NOZ['=?TY?KM0ZQ5L>3'&L:@RS(HV_(S2]+R5"O<"+QZ:$EDG
M62/154MR\'FRP?=3WY#)/N6M&D;OCT5>>LLA%F?,N[46!A WO,:K6J!C\9TW
M2-/-"5SV'6^ <ORF^H]B<?247U5]M"P#41LMLQLV6H^^,ULD,F<T(GM_2TZ+
MS.8[87>Y[,JYC/RNIDB1-HN7W?#-5^FX^1'V#2PKJ#::6]1,<DIW1),4)-!%
M"$ .X >(>80J%1H?BVWRS%2*[RR!RS4XD?-GH'%3K8'50K;0'%WNXQ=%S7.>
MV2ZCGD9G# %C#,D@X7&&&#T-37Q'. @)@RWC4WTP;R U9+S+MVE5^ZE[H$7B
MVY-1Z0F]CILOKA$3>Q\9/Z7Q9X(LV@F&_>7O5+2'[C 0%NYWW%))G9M7F72)
M,D:/T3@4J&4(*RRNS,8AH30PUAEB^5?%W+F]34=5UR"B2DS%@PM+&^V8O)<W
M6'[!6!0F2/L]R0"-QV"&[RDDAI49G+ %GY/&55?D'UJ^-I^S'1)W?/ YM<GU
MPPL^RW65PM(G:3^*_FE<S(!]:%@E-( FZ4P+@#%72'8]"Y6C?![T.N(:K^L#
M/6=*N2!K-]/9WOT]/%*2?]ND(W_R,,'4@YNL2W$#?<EM*K33L&OCGF-O8J97
M?1A?Y&=^ M4(/$:G 7$HDC=JI0%6Z <8T QB*ZT80K7'5I:Y,!!''SYZIJ#P
MT2LER>#YZ73+&75"8,M5PYJC_IXLO[U Z3X:M\3>L?DMFB'H0T3SNIV9!EO;
M,@Y4DHWJA.N>RSU<JEE;(U)EC5B^B4:/G^CM.L=W8F4",P:T(L.T6$&)7#UG
M8M\A$-.B[.NQ<6+@89XB^&OBK>/=6RS\%_JNC\)4@A>VTSII,^A0"8G%6Q02
M,Q,!EBB_"6<!XHXXFI0:VNL1K]4]>Q8'BKS&]/OQ,.T$,! 'PZ50)%U-A3"5
MP#H+44W(I6"+.YOG!LN\,4U$&HY0+TI\ACJM3;2F:VOQ*7L%:]KJ@)MH. P+
MGMY@3J"R6ZQM\3"ES27L7T!QT?@+ @/:!/QR2CZX?_=UW8V+&[Y[34%N_HI0
MHEK&D=*SINIA[CM6L CV1LA6XG@)1!R&R\^+'RLUX-?W#'7PU[NUPC7%KHP_
M9J1:3]D3=<_/G[3L-$@Y<.@&YHM#.-T._HK=^.4BV,!O0]\9B-+ML!6L:MYB
M!A>(<\SM.!&&$7 MLUWD^$A14=ZX)%L$#7?H;!<#E"880L8R$.X$4"H@*@OT
M99]/B%+$<4N55L,D]+'B\QF<E?F!Z[(K8J-&A8?9!:[Q-I]\&2^S^Q%\3A7&
MG@(;"K_D@64SF-8$'C=NY1WY"H#="G/]SW!]8AGWEE(9B4 ))?$U\Z1@^8@)
MA\!+SC>2XOATJH9H[<),ZR8/M,J9P+V)Z+ 7:B[-D"0![7(L<[DK)]\S$'?P
M4;]A;64+/+7#NYI=8ZMHD?8EZ93E!-L+E6]VE[R?*.O1F?8V!2$-@/C;4>8?
M+KOV0G?7_B6,;C\K10!6Z-(C+^E)$)\,&^>,L!C'(^!#NWW,GL=^N%<_*0U[
M[ #R$NRQSP[UH2E'2O'+UM$((L'13XIZ!JMB?N :J?'5(4W"P*GBS0%M!""$
M)OGL[EGC& W;)0J=_NZ,HQX<M]@:H:I(&8]--)V,'-10S0T[M #%"?O#-KIN
M :_$7DLH#NA4:#.J?#M.ZT2@;ZM::AGI2KOUV]H.7)'E9:>HUA6?DP&EM4?.
MLZ2)\L3]O/_P[$S,ZJU^>CJL32L*XWV4A[#0B#O%&@?(^S25?UJ/+39*#WK*
M*UUPN,'+;'"@[93I^Y"%6S\9"&XEP))/>6#*IIMM(*N_)UM8^(K,)V*8>OB"
M/28?:D7MKYCF8G>C$M=:ZGKO!/%MP-3= &9)'FPV!&L$Y!Z*H/'0BP'B7]RX
M[Y7O6J>7!.;Q+<9(HR*@H-.5PLZB4\7"U9G;FB#OWHV0J=N./6PFNO\6[SJ>
MQC$C"(E0J>KR0]6!<\9=G=?U>@%7-:?7'A\7^JW&)II=7=V/1Q\_&:LK="V3
MZ98N@JF)^8E9__^<3K+XGFE0-1ERP=$[@6UA3/ZMO<P;EG- +S<#4;T&S15,
MS23L\,- L8JPF>KS&[6ZOA/J0BOZ&*T^NA3U->+_2S.*_O?\&":Z!-1"6+^'
M.0CS/MT!]&;8D2VS_T?58 O:O-\L_Y>W&OX_X$5X-#U7"^6&X6Y$N@GH) L]
MF+Y.KG=9Y5 >W1^;@5;;/-)'QCSWP/+/%*Q8;Y:.+Y 4UY?Y[^:??WSAUZ;0
MZ+NW=R3O?E;Z_"/7[4'LR_3![MR $(][?L2SO"YW7;^_QU_H5JPKWZ09P^[*
MT7@LO /%KB5GO20P$M?P+J7>-/+4HBI_C*@D0DIS@G#\8./'5/'TTW'#YZJE
M+_V]A%>AXQ@(5SOUN9GANU4EU4.KY>O'.]9^RW08,1]L^A.O<Z'K%V4S?V?U
M0,_Z6Y&;F<DW_22_&=D.CE1E8:Z-_ZPLTRUJ^['L+RHTY7#@2**>E?^D7P@5
MQPW.403(V54Q?@<&-D$%18)F;V'.NI)3+"[-^^Y1G]'X&GP.V@EX.H@5!,V<
MLR<+W?.^KO@&E51))E8S:_7P"/F\<.^7+/84)JU)=</!G;A3DY6N;ZC$,SDM
MEQ0B5Q LZ$2S2?CJ/= R*]>3'GSZC:N-':;XB]DWP T3)9#;;ORT2L \0<@,
MPS^78O*+,Y)9M5DC8&W!WH J$?HU5 %T()MJVMB45)6511_F/C4OYB2;A=B7
MO#35^/YC;9D\RQ?R6(/L8EE:1>Z7>^GSV*(*/Z?M$($SS61Y!?:T/KF<S&[U
MJ87I6\[.CQXN8W%4 Z@7PZ$EC;4?KK#1U!(LTJS4=NE8%Y\0R#O>RJ&K*N;P
M2=-]@H%PPCS=P J!)L[94[+NGPQ%?TX%>=1<C7M\,"3EIL@8"^]?1=.>"RB%
M+QO68^U2^K?<?#&O<]+.UU4DN9?6!;MH -QWR8$"0=CAFR?=K10G4U*V0AMK
M([!OJ->@+A%),J:]R,"<]!OGY9>[>,]6Z&<GO]XU^N\KG".ETR3IW9[HY=EX
MWF9GT'+&I[Y;Q[:[/6NHS*9\TW4IU^&-6-]95;L #+M[A=.[\8JAOZ,.,&:_
MAXYJ/ TZDGXOZ9+%.%OG)Q53GYVV\L]DJL9F/5;9YS,J._)G6@1]>VVEP73.
MG(3]3EGQ_JVG.!;?-9S1:/80@9NYP%S2<2#DO+;/W6JD=+OCS=)8?=\(<9=N
M0JA6G/B"NW6WG4M\OH9)?&9\AE:,R4M(+*V6;D:8?K2XI<543T]L/&5I%R0W
M,Y'JT-\IK88".>Z'.C5<H030HVEZ[\%MPU&-J]]W[ZO9+CQX(1:C6*;V-F]'
M[T:-T-L_E:I=N[71.X55S5\36*(C9=*S?EJ[ZIM4#-429,V"=W8S.E3:9/LX
M=6[*'?IT^HW>5)]NG3M)PX;2"Y['T^[T*UJ6"[H49Y>DFZ<(.,8^;O;6F64A
M96Q]"^V8+B-$:W$&3I@.*RU=D%WY7>+^<-^,F)-3DO+?+-(^H3_#?BN;CKR;
M*=5\"@49\B=>YJZDO"NN>9@@/91*#5H-W 3?\+&5S.OICM4M.8?8;3=4K5_
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MX^7)0\@-\GO>A5\YP"-L<[@H&QW(GV'P+E*5#-@H#:'^<NM)) >0RF1?R^0
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MO> _/2ELK:6VOJ&:(OLT^=EIRCC%*_47.XJ=7?7K*H_URB=CM2Q%K4X"(@
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M!+P1@X@0@UL9Y,T@;7CE0K#EW8.1' #2Q,)O,A$Y,PZPQH8#9*I!*V?9:G"
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M#SJ\951&^^6Z"S=XN+AL2G$[0[,R;,2QO9Z%[+1R$&;AD-Y.O"RBW ==4]M
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M#G"+;(N7]?BZE"1V)>%9W5:F[Q[])M\.R[EY+PZP?2T]_P5/#^X"V/,DF"]
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M2"8BR,,!'M2Y<8 %97<.L"Q@_99U"*RB#!8E3UFG-U+14F&LDI\AD_+5PWQ
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M9CK)MC6CI]6NW\\TK6LZUG@%UZGTL?W#T'GQO0.?FL%'=#*C"R>&&\LA'.(
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MWHMF$)$XHG#G4RC"5#4?ZK4  4:;,#==)@$34HAN@<S<W4)D7"3@PN"?P4'
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M];2!E@T6?4Q9G41[=9?-?:78V%W9OMK@@?E&^T4YQ00.2E!JB:KWP@P0?+"
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MV:;FURP.'=2TJXM;I:"N%GUE J.CQ<(9/,8OQBWS=O,67$R6E?4K/?*6J^D
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M@JJ-XX#9YUYN]'.H'DIERDWG%)N]492!/,5QX4FT-L&QJY_6$XG!UV1P"$"
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M&E_X/V;K]CJH5Q$=]0'<C-9)L$<O&]6!HLBRTI"X1 T0>KPM*MPL/L($7E7
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MT#L?+;4#VU:W29*S-PFU/LS):]Z1^?5_>#-< \BDL )$XR,XN(B-DFHR7DR
MO6)[J'[&PXKE2C)![F1.1OS8DP-]J:<\\!,7YZ!2G"4/SGX#0I]IHN:DR&&@
M!P*]T$,4Q%W@"!%\ X)+0W1A9?29I]S<D.\!T?C+"2_1A/W#KQ<Q1#_<:I9]
MX)S!]/JA*<F579, LY^G1-.O%25B-;;VT9WO]F%X,/CG.*)/9"N"(NVUFDW
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M>((71=Z_I8<B 6W#1#8($"'/U8Y,R\($'B8OI?FXDVS57JG<=C UDGSX3?#
MN]E9\@?NP3$5\TX(4=MH'-<"2H QCB(U',$X']!\\^=3=7^;A@$YY_+>/M-R
M;71-$N_9,_XA*==N6VQFIFR'_@]?RO27,Q5J,<0GW*U(RIG$U68!$& =H$@1
MINJST9'GME-KAD_7)<UV*?SXDMV1J3AVP#V!O4-M"PN"T4-4D!TMF6(@.U"T
MAZ2\9DRTG0@1\9QF\LG5>UD%^)DZK5PAS4.KS?%6*X5<Y'AY*4(M_^7,;#<
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M*,*\A<I]D1BX+%DQZ'%BH_LCDGYBXW3O2H;Z%S_E-A'_4_A93Y,)\RP*DCQ
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MMB.(^E)WE5 $;=P3*4[/&1E=S/!(8EM=];"WL(_0==(&I,G[Z^IF$F2"I0R
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M^D:\TDI\H8*"@E+,^6B)V61RL!66R$T[.D-8B_ ].25&4HJNTRQ+YKBN*OV
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MQ<G%[ITG"S?( D[?:K,K:,@\FX64H^,_'CS+'OAB<>K4CIJMX34XXA$/0G]
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MWUVKDYQ=R9BE?B($YZSKM +>PL\")^8+R<\N"B>YQD*DR,616I<A;G8*3K1
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M,'=1.;N'F\9VI>9X"H^/S%4QQL9;C"SEU*\AOD'4^=JYVZ !*1!4N*.$]E7
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M#MC"&/D42_K^D7 ;;XOS@JV-G;*TCVZ$]3DMZK!0: &NL#Q+?Q:^#RL_[X!
MXUS$%)[\RG>??'[GF>38Q.%+'9XJ7CO/['*V4=;8 _5XT[!=TW"1.S)IP(G!
M49[A]IBILXUK/WUFA"7\[:-]SEWI#7J=[!:@/[3BHT\EA6E$YS^,'2,=Q5%R
M</10<JIR#U8;7<%\-KSV$FE)ST\(5(NO#)2_4%U.&@H]5:9_3"*KS>+;SY\3
MAY3UA798":P=,<<=)2O!*5/=XYW,#M)@W1GZI"GRV^3N\O2>,4"[B0<)BN_0
MR5I=+HQW%HT.R1:3R_QN_IT/STG'41:TQSJ92" V@*O/T".T$D3/TC1^[VW9
MO\=U(E#@SPGW9KF+&90]HO'G%7MZ!-8SS;'AW $8_8[T-W(TC'Y)6Y =V5M8
MRS =;GGV-K:I06KB4X"T= \[9\\$ARIZ?^6F]Y/=L).WR?4Z0";#ABM^D$/B
M06[;_/9L41(9-#E#)0F/Z8_>9HM03ZAF/S-B;]CNZX]OE-76-X[2 7GC$^AO
MJYF@3(E]3T)VCU:W#ZV@JUNS2?OJX*CCKDO0EMQ[$E;SAL$YQ]LRVP\;[==Z
ME?PTZ PW#W<#,?ZX$4>W1XPBFF'[341TR2/< XG92.,84D!?68&Q#_'9D0-6
MR6;)1=>]KTONV'Y\D4:BNT(!H[NG.: (*,%H *I%LUQ3(*NPPF7!J'ZU8K9!
MX8N &.KSR=*[P<\./C4J#(QJ'3$)V,':98X[6 'B"@VGO")7YI=$EJ!Q-.T6
MD84'CCHVTG%U.CO'1M47S>O+-T^W;S79O3=%]I&\8("Q$[.8DX<)0Z$89Q=L
M@1KJ%Y^5Y<K?"+N$BP.TB^PFC3QTS\=8;IZE^OQQPP-\6^_>U"4P93G5=7R@
M0Q'CY-W33H*+K1_1KH.7[DZU\CVC./G\WO\;%F$>_TE;@\[X<J%2/,C3.E#K
MW-+/XD$*@A:HW2,(9C[#@+TWC#D)A#"L)X?^3;*:PJHB2EOS[S>\?NM^MO28
M>TCBXM\;0K,J5\8:IL!U:(7/:)_ C:04X6;'/VP+)S \:83_B@;9Z<=V_..O
MN+M]?\-! %>(MFNUE0NNMG=9+O^""HOS?EC^;>>8Q. [<"1 ^-22&HT0=0^^
M#XW=4K0YPSB,W_W^[>^6NXJ#E8R/Y58-/Y,+(Y&W2(= ']JC/<Z#<.6,F7L&
M&J +89-A268B[H+'6M*>:^DBL\,UOW=KSEBK/4Z5X.?[0ABVAFBL.''%MX/0
M6%SS26[C?IS0/>-EM5:<O);<KVD+(&/<HOKH1F"[G=Z8S'&T5SACPQ9;:?S1
MS_G1-?N,"Q0G!AF<WEA.B=XR< S/!N?L:EJCF4_-3=Q'5[3(-\?O+46MGR_=
MC#<WS0Z?SL;DQP1AER 8RQ)T$.OLI[Y_94N%,63G*F2GVLW6ED/^-[0:FJR\
M$1_DN#_ D9"Y.$H*O.(O)VD.7( BPM\K7/&+G)PUQ B>60,XT7.:&UUMZ-"F
M0'F;O?QC*!_6-7:.M*BQ;G_'L=+E@X39$J[8]H'O3W6YW3BF1C$W-3O*K.5-
MW0:3P'FCVSVJQO1CD%N6?-I8#GWL76_<D3F.V:[8WCM/++S4\[Z[M\MT'+B+
MZ,(M(4"VC<+VDY5,[/3P35^UQ3"JO3Y/6WW%4E\J$4NL/@:7J Q;]5;<5W(3
MO/. [L>WE?&&] 0/SD3C31RE ";^4;JE=KD%FCRFE3M1^J> 2JPN1[$V;Q_B
M:"RA !4GMN+H%!*?+ >+XD$"=O>&IHDCAX6\I5,^+A;T_ZM,=(MSUC[TZ!@4
M]2+(KT\_6;(=+0.!]>["@7Z!CLEAIY K$)QP((T'.=>OL05U%*V1.;!BNK )
M+FCL-&DZD)/+@RQTM^"VE)Z?AOG@&E^15A)L#;AMVZ,ZFT2R,7D 7GD&>$_Y
M;=/<H-9[CR2!QEV/&D?,U6:]<7?Q.!]1F&XE7(L_*TCH@@.Z^W!M+W7)+'DB
MCB-\=$N>*T)D>:+'F=N_C]YDGP8%][_YIL[621C>)ND'LM.\-OY$R+MQUXYG
MXS-JG5G?NL_>/:TTPSJ%;<,)D;PTQ,Z.4\.:\;N!W9K.+3GDD8B+^BBTDS&F
MS5R4>N=^O(K6I1.Y:S_8_N!(O$ T5,(4291B,HQ[&/V -D1\'9"+BL? =Q?<
MR#8RT3^6:?H].>/[R6;_6233!723*\-<D11PX8X"3ERA-,($1@\(*YHC[3$[
M(<@W:7Y7!^>-1MR)3UOR<(8>^UEX/%I6T$'VY9T/Y,>U:6P%(18..Y2O6YO6
M1-J#N1ERBC,_IR1*_RD?N-<$<C#ZK4;^R7\M6V!X\U6=,)/&# ([^(9T&S6"
MI[66/6=\D$^#^94<TN/&T4K%="-=#*%7^!FM\B7Y;5Y9:%;=GWIEKK >V#,_
MME<L,Z\FC_F 89>PQ-T_+V?V_$'Q^+R'4@QMZU?X;=J#=VH^':O*7TZ^AF1M
MFCG\.+<'.N>0M +JA,>T; *CDZD-G)M"[;$1W=I(-I$J0$8\33]_*-4F+T_&
M)RM+0%CDZQX!2 A" =?8B:,[P)) C8P;Z6_$G@3LWOD;!=67H7\I2OYQY9AJ
M7Q[72YEN.0J'+,>;15 D)J/@YK.$1@2@ML%6]"U#&S/W L\9,&9\0W^=YY2-
M*99L07=*T$6JZXZN.R%]LL_.6$@*CM_,N%5:'1'U\><'K#9  ,>W!S2 T_#;
MKB^OM"@)U W7:5.-'1QM$#L!RU\5G_A8&W;[^H,:9375%9O*0D[#!@?!V!G[
MDT2_1UZ*91FB5R91DN@^,LTG$71<OZ$M6UZ0'P7Q(B&B_B:HU(<5Z@<D4[[#
M^V$@%W.%)2AIP!'28O%K]E6ZL2T*B>WR?3\7)EX:^@;1GF8TY%XG^34KZPM9
MOH 2] VRD704_TCO79W!*T2 SL<4<3Q*]6=2U'YO\V,A&;N#3<UQNHBJ=K:2
M$Z.95OP(=0PK"*":MW_N,"IS'.)!+A-M/5V?6^[(Z]H]9+(^<BBR..U$[1/H
MW-LD[CDB =#88.^+")3G2GXE*++]JGN_K>(JI9M%=N-C?]VI>J/@B;_HU(,#
M10!@S)JR;-)^-.:1R3HC#TN<Y*O-.E@_J+DV<CNTZZA.>Q[L27FSH<?'U.AQ
M!2OH9>A<;5('72VU$I?(%>QE7Z!RS@X[]6#.>(L7O26[-@ HS;?F&4<N;SA:
M. KT#(/427<GC,NW@<K1DKT72A-HU4X(<]3WT**SM]P<KTRZ: ZHJPT$ED[_
M#%S!__Y!\7U]:NDT#&&/Z":S)9%<\1>,JO<%&"\&;ND,+? P#]+$%>H)].U9
M6Y*WJ*XD#1)ERTPJJQX>09P8/0=[%F=N>>>T _(/(77[K''84B,K!!B_BHIU
ME$N+,=&Y]:NS"#!H1HQ+!Y^]H!Y45ACO-+GO3N^CJROWA2'<MWZ$:0TJC*U
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M"/P^??_5-8C3ZG:9R8=H)>A^7*-G9>E9GQ0O>OM#8N0E2'OV?:LE<7)DM2;
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M#D+,>\D+E#7-H^_=+!KGXB&V$0AP0SI%(3;]\UVTLL'\'P2G0WI:'TZ0Q)6
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M=?F?J$05<1JH?AX/^I!29..:7QO^FPP)R;)1S3C_7+A\ )B65I]BHXHYZOQ
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MC7JRHPEH1S3H-N1/0JMY-UD<&7L6&R6"F6II((,<;%1_)HRFT._!>+PV<@S
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MB.D<POSZ 6L /P>0VV?Y= -U<\!2K%<HF6$NA;3/8_4>@E*&4#*Q>9$IKH#
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M"#SO59 <G<S\[M'H/M =-L:]GEY1?J?*R9HFM&W](=H?J/N$X=+="VWN;;\
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MIYXO9B]NSO0+J?;+DF]Q>_<^WC%>SI#SF'G$ <>*NZ=YHCY\1@_N$(+&X Z
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MR;^Z"9LKQYE9F^I5G>8'[4]'&G<9(4;!Z1!G-]Z1MC0Z4GL<KQEF\:DT_K0
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M9AR?@N/T40=7X"%P @."S+8^[TI4C*=HN89B]M85*&^="()_*3I4@.0!(SF
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MU#K7UOC9Z88O.UE1@?J$I!\Q%*#]NMS?%%1K':KL%L2R(=5X'(NN1+U8XP^
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M0Z*]B3\Q"_O1#J\=?6[$W>S4M:F)*6^\EJ&8WDDFD5P&/NY!5(=R(GSWWI'
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M'3N&8Z7=2,(X])O)WIIO_G:.\5<6K-6_7)4WDL+$GM>)OXF]B2TJHH5GX7M
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MOG2(1D/4<[M'UUV'\$+X5D<T),7\V5;6IU!\$[O?_LV1*'&7=7NS@-$.Q9C
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MAM<6#'&!'B=F,CVQ5G65V_[>_>$,GROI73DJVT3Z*M[:/W))MC)<=T7^T3[
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MC#FW,4,/290G2]Y1FN:8/"AOV*$22AE/]E$(OFJ9A#/I/&;TBY\3^A"KAMR
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MAU=.8#X4HG)W:"\0?Q+AM<X, E62+1(!"V+3(!.'3Q[H#U !;O6PATQ04T(
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M[WM]O>YGN7]?POFL!B:Q5E\:(&_8 D'-FA>['1>T=I5%$96UU7,+]_[(/MW
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MRQ&"C.4]?!15EV?'N>1_7*3*HWH'<(NP&\$\.? 1%@UQ>S&1<RA>G)J*NYB
MKKO.2B%]*<ZN/^N:D+W(K/NTH.")QVT2.Z\'MLWE_L]D[?]04S<^]'#1&*'Z
M3VMZ^-L(@,H02+1YA5K\ =O.+(/T'J?!1LB+PI4+H\Y&S)VM@PEY8"V=Z8N-
M@VJ6".OQ.EMM39@_ZO-LQ,8:$GJALOD] 3*&BP3R&Y)()4QF0TI;Q.XR/ &.
M@B?DGY8 S)$P"6S$]BZ1[1T8^+8TQ_MZ\K0QB R'X/H>E3^.L"O$E"&)4&Q7
M82=Y0ND/V+-5>>$\:GM]=)U_E#!=,\53=WIQU#[FB67'$7?1C***+\:I1V4
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MM1;,V/;#8'3\0C^BJ=\'.3N/_LX7!AOVV?_JKH;DDS#1FV4CGA%+M9;]F%*
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MF'(IG^5,+3$U3<3Y.,F'%[DV$ANU/KORYT=F$[WM"3H:;/>N&960N9K3/UC
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M#U?:=(@%I>3#(G;WD[^$K"*^61QH@4*.1Z_K=%T4<^^L&8]7MF%L 4UTTFO
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M3\TT0'O(Q'9@D ?T,TVFQQ/$X?1DZGE"7&FH@MD,GKNCMNY'<HQQZ?,MR]S
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MI!X719!5@AO"(WVQUK2>CBD=FB7Y>DG)0K/'4(U;W3$=2<<G1U23X_,SCDK
MA5$3&9U?R+PNEW[T3O?NLQLO;L;SGV)RDWIV8'5RS$.-=$]6$Q9>.,^6!-VG
MB0?!F(43@KERU"D\WXOBT:L7QX]C,JY\YL<KW9P+Q,"?<OQ&4?U6.OM^;K8!
M53P8(3JZOF' 7_VMLN[%/$R2)?+HU+=+19\:.%[<A?\6I=R-UXWB..O D*=_
MHWECN.@HL(Q@\"W-HYEO>&4XJ_AYZ?M[AJPU= <AW@<G [2(0MZ1EYV1FU$2
M$=M)WMMD3G,D7SAVG&@W_OOVQZ['?_:)IC:O!PF<-P5NC]56^3.\<"VVVC$)
MB&VY=@),HSU*38OJI1W@,92K<^V=.@?S"21(;EU^;QH7FX>+H3N_&6"HKHKI
M'C3_N0,+KBE??,;,WOV]8<P:.+3+,)&)_3A(*-0;RH]Q2B- _Q)69];WK-==
M]&2.X_UZ.[]C5?UY?G_AC/H98MU_K0A.-0-/V2X=WNWJ ['G.RS;:61<S:19
M:X/2Q\+YS:RL;*RQ+"G+-U2@U2"';>U^^!G?Y;V3K\J2"FSINQU#PYFBK(?8
MO8A8-C_(<XE:RB/2&11^E-/4T$(R@I%0\*U*=7%-E>LLC$^^#Q)0"9%J0XPA
M4XU1CU3 DHZ.61O21JN"A AU.">JB>2>> I[;H\^;WA_ESSG4;6'Y=\*R0_1
M$M!S2^AQ?OIKVE"V?^O>'SAQ!S(JRS4?XW\QQ6[(.4+$\?EO=X#^-EGOY<G7
MB 71&?=6)!_3G2I8-HT6G'N ?J*K5>X(8?3W7IH] =YA_"&V!GL.]S,.[?]E
M2[.&*(<<ZV4.^\ D]#]Y,(."Y"5/.>I3&6U_?/<M!C@F>/#UE)QI+$J53E/.
M^>A$R]YNP2*AH;=9E5;J"0PK8T^LVI$__]9:-6\4S=UO=&RS[9\5H*8L/Z'R
MS]@NM3,,,>DM2&&%E5*<]-R?*=.[/+W7%:\&>RZ_K4_ TKJDSJGT')X>/];2
ML@>&^"=- =KV@554QQ;V:8\!39KF$[?B9V8-,9@C3HA;S<07*:#N(MNR91K/
M.#'FS\Y:L&:)X[X05^^@]T%AP/ ':OTQ-SL H*R5 Y02-I0**WW?0Z$!EW\!
M>1G2;MY_."S6B"I+6M:@H5JW_>,VO8[88?C-AJ0<$\+OU]W.$DFX,FKS]"JO
MA1]2^K+THW11Y76>\TVAYKJ6;[O$XJU_Q/R^B9%,IFS;[E:7]"/%^F)5H;AL
M#W+YNB.SCF8?)?F<OY--_^.)F%E597HO:\/8$#^E+"+ $['1P,V4<?]6]@D0
M>/<3#/V\ Q-2G]\0#B[16%U>9QF,Z9NTQ>L]X3]0]HN[WMK3V>ITM  #BKS[
M7C##AO0T@19Q78V"!=LCDZ;43?10D[)8FGCOKW>&H4?^_I!NM)*(?WB?D Y0
MP+(3!YJ%<-_KON'G;;;+&_U%'\@\_5F%:.O 9X0CF,=LVG;_'M(4L4RSM> :
M9\N*G-\%4!+1C(B%7!@80$&._FW='!Q-$>F8DJ-=>$+/R1%V4QT=Q]M-S9S+
MN]79ZXUTT0]39HKLMEAWH>*7][[U(E>[MQ-XQ\ $P\$0_O<8N:M#T_QV$WT(
M)I;<Q<]9M7^BU,*O.];XR=Y4;B9$+N#!8.5L&YIJ#QP:[95)D8B<3I+X IL\
M+,)U[Q+#[U7*4/9NS;C'>O#(Z17FX4YZV(<ZCS&=E ,7B])>)FWZ;9J!_UY4
MK63#MA=.9N[/D+:^<K'&VH#S43\'.I%(#28Q#QNVH 2 N^BCN!]X1/7!,ZW$
MP\PCJ!JL^4C EBJ88_9]-"]#Z)>6ZAWC/Y0S;[^6VFV% ^[R;0 EGZXYAF?R
MI\QN?/H5T.6MU9IRJ+1$;E*>]2+@Y79$. 0;6) VRB'8$*@'Z854"P'*]R8+
M[,;%+2@ 1=H"O\^AX#NPQ7%GB-3*;@#.Z_^76K?:]A"IEGZH:2CGUZVPZ@B%
M);_)X"D4LPN@0_.HW:#NGL;HTH"B9!UJ_1>BE )LB4,PJXZX_@2IQ*UC88SN
M<E^7K+;0AW$F#UF:<_Z WKE[^P(/!(%@)Y?U96&*1RTNP-[5''T&^[]U& ?=
MG<E/9!N5%^V690+6]3^%#V.4_W>W@%M4.68ZB*8J]^*_BT%41OK!#FR&^^3;
MYNHMRO_\B^C___K_F8OKZP[,VVPTAD2/I (OO"K&P2S32SY^B&Y9\6M*0$-8
M"RKXY;H" LKUE?AEZ4)VK\3Y>BKIB>#,^7W>Z0=_J7$139^+O]='7TM4$7NJ
MIG8!OM*]]9<^SDHCS?Q)EWM2S0. 1:6NG![I*<O"6;6HOV^38XNX_,\Z.:$-
MX/V"6OT+]\TG''O$Z)O[9>.O^/9(??AZT]#\XG<O+[" +L8J$_V\G8CCH9FV
MI)AD7ZK5NE&KUWH<M4!&?6ZC E&,(X9CPXIVG%5-]C,E""[0;]-F6.D(R6QP
MYHRI/+!?(C=O'19H#+-)PFI!7&] #6M&NPUJM:[I;E_/T1R/B91;WI1.Y(WX
M??GSTG4S:<\"@?MPT1E?_S9TG=#R 3'-$JG+ 7)9WOQK$CE>!;(Y<VIM&[?O
M:3]"8[%GP*#WV)-4T^3(O/;?HS\[A (8:UHT'8FESO2MX,\$'58R\>[/9B[,
M7O?F)V9/-(+ME>VFF[]]LMFK-^'7:?/O@L"2U57G0WN/6EC^'[5&XU294 F#
M5ZRX.)?IXOET[U<:?O2]XPO"8VZ,;^/N?KI:WY>4C1QGJM1Y?$SKJAI,*WL8
M ,Y2>]7A:,\@\>7JH"LMLQF72_@HZT7RL2!R)G,$BY+-2VHP.4')70ACW@OJ
MJR^?>?I?>I;]G[IL>]%4:P \R8Z$,M,75H:R;D31J%)-&=JI/'UZ$OEM=0=6
MHSPI/FS_X7Y'7(KT4S4!OG-2#_4RWA(S_>. W>IYD;,$T:Z24:9Y';6LQ+CY
MO+11OSJ](BGTR*&<.+<7]12\RA&X*[H0ROL7(3JO7%[&P&+^H*/(@J7K.<BX
MGKN;V9HE!0:WZFB\ 4KS[SR,]:SF7A.[KU;&= S4'W<J95E"MBWS_ZDN-__?
MV>T&3=PM6/HK%6/+_DS';\O*;^W "'-<E!5FFC+W#NRG!(0?KN1'N,>A6]\L
M*O>O8D)G\#T;*!$(8KTA[T%-7\*-3"D,W(KM&@SA25GVU>6(7E4Z<V*8;JB,
M9%41%*FDE!#4 0\)R4&%]ZM+3-.[F5ISAMM?!V;DHSO?(+C7YNQ""3_,0"7;
M%N0RG@/C.+.W5.?]#S]18Z*;V'/9GK;.T3LVZ-+AK7=CS>]B*Q)$LVX4*3I4
MXBH6P1-A8=%"E_E/EM6YI&Q7U%#_?B81^9LE/7+%!FU#V(T1!Z..B<$SOG!&
MQ 1&1..V,?PMM6B^IL/O0, TI6=PW?&DCV+6P-E^J;]DF.WO+.9A@%+ 5$"-
MW?_;+G1H*U-B?Z5WM(P;;OBLQUOX7&X0XM)CHMWB-&9-?%E5Y4NGASS1=@?&
M20[[]TL8YW"]9'%+&92CD)<A'")G2)-G=Y3=V(%=_5T^SC[P6I41A-6%A#H/
MK&=[S0!>*UO:J"<HNH87?MM6\3Z9>FT'MJ7G'XO?8"FSTTW00#RD):M=4+,#
M&S##Y[/IQ#;B&7KQPIC.N.?Q%X)&=RV3$]5*\VY&;A!:B&/NE/R5)1IML"WW
M<'-2%N/$<G15;OIX71_O0\C[CMU8"M2.1'\26"4RC];1]Z#'&K\<QD2V!EQ&
MIJB?Q=9SJ22%.-XS$;WO^OFF\<G.Q#0^+C= 95KLC[#8C6AWC^M=S;T^+"VS
MH>V7LWM/KZ?'MB/G\6EL;EKR&^I:^[;+I[P)C?*"=Y.&89XJ?WO2-'D+R*G]
MU >VRX@E=T8@:$MOH)I69];=;_"/I\0!GAZ51H(>$X@7,WO^&!G_4OG.P?$!
M0V@G\(.NEE1TG-+Z*Y>.1=.A4AF5B;&)-M=,(?'+IWY9^^I8U@\HWVZHKL\>
M^2.($/OPT5CZUH3*+V0^+B7WCGK05>,Z3\6\&C(Q&#L"5\D5-#,I+V3'>E/(
MH-(F,VT%!IFPS5_(A,NP)GGL24"XVO2\KR];!FSLLAY[Z[CYXB'=O8OE_02,
MIOFW(P5#!!IIAG$UA$-.AIM(\Z:TV1ZZ<UNT1*O VJC6/E++[/$G118:HG.$
MT'SBC1\=[E:+%L&S0O>#AAF0*^]Y,TOGI")8;:CUV1!TXGOB78#R#+EZTX5C
M!U8?RW[I5U*20OR%1M (K!,&3B@V=0?V90>FOMOY>^\S4#R(NDA_IW<J6;S!
M+%DQ;>;<46Q)$+?,#3D2I];FVODD;,H8,1CE31X-,F25-1^< MTMY7TQL<O:
MSO2)FNBO>^1G&UYFN/W+6Y<\#-;1")30)T1W M(9X]^>[33FE^\3^/&/_//5
M"YER<W,!+>*K?/LE@^\EA_#:'#GKB9JZZ# Y,$K(3&$?R UXE''Z^UO0C=!7
MM!F[6PJ?V_Z='7C&%/2G\5@FF-0/]#O.-7P:C*K-Y/CB^.UOU!TQ>;%3YAR2
MCQK7^0[,?GPDDS1B],O\ZT)@*4(R<D*$'=H;TKP?W)S%QV2B[U)7$INL7X]M
MJ,QOE])_X$%N%61^P%\Q?C-^>U*K6>HG!Z\%%LG?%&?P4W?5ZG71L&V=2\%*
MK7<?FEX,XLC"ZD38.$0GAG3M2UY<L='TI4<*9?%WL[U/V*@):D['R27+TPP[
MD-6A;<IQFDG^Y9B_[6/M)9R\0MF?VGX<>L!,; >N;IB!LLI,//DAK@Z*E'X-
MA!,%7*5Z(OD/-OQFCZFG+:0_J!O\O:8CG1M^-;7@NDYUS9K[TGA#1_[S:.MC
M,NN<61J?V</H56_R$=22S6ZG@30')A8\PXA@.H(\>4JOIG=@Q]!*61*<]E.=
MXNNJ'#_,KY6ZHN^<EO^[ZB=6]L+BU54UX_9\]PB<%^3DY,1O;V*R$P>KEG 4
M4A= M2&,]9B!6E2$.=4YZ9?_#$'$,>?B'C^>,7LM_JNS'T(.BOP]IF#T?1 M
M!":PH=A,([H,2(R<#S(>=+@8&>"9WW:B$RO$"Q^"&?K8?I<X1;M;-)MRR-EK
M[/N;L.*%4,(?LY#0,R;JO0O?VM+1%FE44R^[.%*'L8/2O*+?".F'YU:NBY9N
MU'R]Q?65DC.+&YOL W"JC5DTLE(CM^A^DOAFDA+>]F;K7DE)0]CV43,5@.0
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M)_&1V#,%<]M8*;+90-GMJMHXH.?LNPMQQ,</Y?E0'3?N%42;31'/K-I4,E9
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M,)'MV2,)0D_6QT>9\I0D)1/O_;=,ZE_D>BP_RK3K/SA>+G&A_KO!F0O(D0V
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MP>=-6W01Z][_B\0BOW<RD9 >9 ET2,4?3E3LP-XM>_\#0/4S;/-):/8_2:7
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M;5(,W3\IGV\]81;*?Z^HGW;M^/IF)=NGL]MDX8M/76ON9 \%-) J)6[M+JJ
M[J18:TV]#@K5(\3K8',58U)UH*_-A; )!ZV6?4E+=OFRB=P]UZJ>7']L]SKA
M\K$G/,[94\ +%9J($I4;I;Z;?6[O^"_T>9V4>;6@)J<WYH'ICLH?QW4+SW]'
M(ML_]PP(29U)X[@1*N W<ZORW4'%1;O"*1B#8W67<J",=NMO>?D8D<+*_3-I
M?X ..9874NBOLJUT;2]@7;^Q^UC$F*WY+QO/=5='G=M3](B@Q\ 32%Y.K;S#
MT?6]7K)$0F,"/.!%UIO14Y)]#LK"RLO.VT&V<4]1;R*/NUX)/%032OOP[ Q
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MXW=8O@DNG3=B\Y75+?MU/L]"5-3"1UY4+I;3QTOJ4/->^SVYD@5[<E\"P .
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MONQD+@R TOREQ0^J&))F THU88U6$CV2:Z>>?SW9H:ZN+E??=CTE]*3D5)(
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M=#3V'1K B6(<W@:S+]N2V;?"F,"QFB0FL!Q/WRWY^^(L9K#KV^,HP\&I*2:
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M*1@FERS9J4U2 >@E2GBWZTA3])L3"PKZ[A7D^3^IJ)>[Z;?8(L[7T$+#;WY
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M*IPR E5#]F"8:<B3=SH9.M53H=^F^0Q>HIRGCRP.&=2L.5;5OY:^&YV;,')
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M_2O.GR1!OCB4?OVI0X2171!QH @]W=[.9$$H)T!73NR77+N]#B.ANWAN4R.
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MC#"" !0ZJ-Z7/F#H:B,U&69'BHE]// S8W+B<HVUSH]].OJ_]*6?G&08TR\
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M*ABG/R;K-_0&_OG8EBWS9<<,T7U\YH'5R8?Z;'H:RF&8<IA),9# " ?[%":
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M[HC/&<<^\U^5'2+I[BL>%5+*ET;9*DH$(*"?@ W^8\_X!%N:;T?L\A8CL((
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ML>A5GV:$499&RJ4JSX*SWX(2V3B>7#^(>=*/(WQL6$E[58YP?1:R-5XVK?W
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MI=*X-$MOH*AK4&VF?')"WOB)R077-)K/=BN+2ZTN=E9.<\[>/5!B!SH*SW!
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MY/4E)@:.>FO#/XG00+%)6&!AC 0>P#4#0A"F@BG2%P5+0ON+*WIUG/I=1^^
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MD@:$<"9T0Y*.1G61<,N#V44G7AOGXH<\AQ,GCUV[UO\Y:IMH<H0",5K0=%W
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MF05O\;QG]?+7\OGFPM^_[C:=ZG_ D7G1P?Y3TV</%Y6,OK%H[)0M+V5I$/=
M=S\]1D>Z6E,I/7?R[%PA[99:$X_787'YG_6 7]=W37[F=H&A^*++><:#+&43
MI9+[%E9OU^@M;OC&15.G=:@P(]<^WE?W'*RU9P-S+GG5,=((M.41)(J^KDP8
MXMU-+3GEH3IIM?Z5X'!.4YQHZ,JR/_*T12OQ/8$I-'66SJ+>T:.@'F#$[%S
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M@Z,#/^XVM@_S-2[L!+94;%F60X5P=3KVZN##%I)<Q.2E"_/RPJ^$RNRT;#$
M$$?W=0B:7Q9<_4WFC]*3<I%\S?/'VP/ZFA' 6/P*:J.SE$BYBTC2DMNCI\VO
MD<T+.FL*1SX/2^HMOBGN?"19E%%62JC]BON97/=.6S;7*'WRK)-&=,$3@@?J
M7%P;<W'/4XD+@F8GUT3(O_QW%&[!LPZ2^:9K6O[T"PC3>_5G"O#+HD\<5#J-
M7$C4I"+OV@)QY(2:$A1_Y;;$V?,%I1&=!U3+W5U43R!%UE@4@I6V=%9Q*;S6
ML/5"KAA+N(,4U$9M0I_=X!<VD%F,;=QI\?.I:&Q&;-4K[_-MC%3,'JE]EEW"
M3&+6T-JK!/ACI%"D*!O(+Y4@-X<MG;.W4?+LO"&$W;/WH'B%W[[BNL \T65>
M:),PQ1 2E)MQ(3=*[<2\.+0RQ+!  5<PD5%?"@(>-< +C1L3("EY=:3!XU"7
MY+:.UTE?VMQ^@A\*UIP1_O*1-3!*,]PKQ\K+;)*O5_EZ?5_ U73$A1R"'FE2
M^Y#B7@\O,($I0",3#H"DCV@QY* LO7*0N*:WL9A8?<A^A:K'!A*2HH3,);.W
MIR 6N[LF"G/>](U;7>A8'/[BYN0@T*R6&VC9HF=O-PW(4?"52"P;$/JI>P3C
M0C6,S"T*ZRH0N6EGH%V[[7 $DK[YBC#$C>:M^(APB8J7LCZ'CFR;^S3KT!UC
MM2^1@:*@6X5)N&K?0%D?W-EP.T6WU'&_^*);W5]3K7H:#O1/MTK)==2ZT\GE
M':N+7J800WC:C,H@"WT['+M4K1D:=GGX\H/6CI'G6--O5T06H[/)R1TKM@([
ML\D*YV*^.V%FO)?[AC&-SKI-SV6@CIZE)>96-\@0]8 -+([ :X.T/?@6?@EZ
M5=O@;+!ZM+^I:Z&FXN.N);[D1S51,RM[\4UP&[V+R(S!;4=.?86-;F""/@M6
MGF6>@H19(=J>,F?5[M@:NMB_$M^QO?]8#%)0&9U E43TC4'5R\^%!U*QF0W.
M_MH\R&M$<O-G1"0;$"Q 1>,$"IIWN)SU38PO\5HZ2V*^OU>5R@8^1 B=]]JT
M;PG.!'Y%,]NHWL<I@9$%;IY9S#S58+O"J#6MI[HAP:.-,?3Z<Y?<\:4@Z7[@
MVJ)V2,YGOB96WFDAX%!OE91A/^-TS+0A8>4 XEB R\*WOAWO1#!3Y]";/MCL
M^!)0_XTTSK+;MM,XNVO>80#,2YCN&D3W> ^.$,)*E:_&4S/-2TIN\=6E*!VX
M_J0XUG]+Q&%@BP)!K4?LJBKH84\XU ?Q?LGYJ14H/F'9'&!UF@V,%S,=>.+M
M\HR:TH6:.G+[C/V7 @U[S6M-J^H.)D>^?E'&W^K\M1/#GTH/N]3F:7+<J,U-
M75'B6[S&G3Z9N(OOUQE%?_XZO'W+AB:7^3P(\247;#G2"E)<Y=B 6!J$J/_C
MO_$&VHBDG M(9B)R]([VT/JE!!(;^,R2QS<0Z$HXYG.Y^\C5KK[O6?:"/ZD9
M>XV>1?&O2I:/[[\Q3-T3[?!&I[A\,:AYS2E3\<UW2T0JFA3FPR#>##8@MQ$>
MAR%L"#UNM*)XB*M>WWCS<0+)X([L?FF7S_1@ KR@M@]$VK.!,#9 4W0BP@$?
MN$F4-<5Z1AC^H8N 6]R"#'!BO^="X"XVL!Z;S7PT2IFM1Y[P7GOM#GHMO/@\
M3R"]6%%?NEN@')Z\L>URF[J-K$E3T157R<]NEQ&!@Z:W/NQ:3MJY.25\.:QQ
MJ<"\8R$IP/]D\?N2:/N"LA!2XJ$)J0/[*EAZ4@3DU_E]W>(G7%K];Y;D9N'T
M(ZJ/E6EL9)9BQ^++:^'84,#8?:18S!SQ'-1($O6.>BN#ED_F:RS.?_]N::ZF
MFGAK 1_+1*?@-OODG6_S5@4=;!I<X]JG;Q-:RY#01C:0?2B:X8@Y],PREW5S
MYV$V\/H9'-/V^+X[B0=KKB]>IKF[8IYTD;%AE29M-7K+^#F'?@+EDG*XJH\;
MS9NR%$I*:-#=T['4](D-6/,5NRDLS$L*L $NH66'WG(F3#?G[*H<'2A^\:>6
MZS3^->^X[4D#< XQ@>:R2*I<N*#])@GM5 C1"#(QST=O6GY2ZD3?9?"R@;7A
M= N>:D)WO7Z[]A/CV1V7FM]<>H]^BCU0N[4Y(T'TG41D41;>G(4/W%E-#:-=
MH]:'C8;8NS1*^2K>O33S,?KT.US5B>-F4.V*\P3R@W+U3M/+&B$+$RA&\\T8
MT%Q]0K6BZ$#I;7G'X;-O^6_YJ"_K:HEH/&T6"#C?AY9+6?SH=W EWVFA@,"]
M3,1_(I!"DK7B3.@]0PB^_+>%*W51"8,;!U\5/3.U(]Z8H?,[T_U-"QE"S.]L
MH%E$!"D=L1();1@*H*'Z[IS&0H'Y)=T$^24V,%W D-O6=D&E&"X6BM ,>)P\
MUW.8_)(YLS0>^ 9SE7X$7A)C==<G50?*Y;FP1$=]'!)_G&I9?KUWA_[:+!ZG
MZR) 5%3G:$B*)=W:H* MOT_+!HGZ$'7<S=5M:XS\UEM"%VX!DL&Y9N@0AM''
M?:XE<OX>)9,!8_L(Z@6;F%/P=9AOR/!E WS2:Y SKL7W#N[\ ;NM8=U/>G^)
M6PMK:@;1:TQ[0<%-OR=M+)@51+_5NL>K)?_9)<?@J(ITN!:M07S?F$P$\S(+
MCAS'&3=:)KTRTZ?D4L_F!*[+^?G1D89V-Y_U;(_K$I%)5OE6SWT8GT]ZFUMV
MVJJN]WOTXL_>@@1B%GG,)],@,HWVHMP&I8OO)=+WW,0=>L+@96K'#'G1/B1>
M^6@W[/_L!9+O[<&9"&88*QE:/X7,]ZZ=$:[2E+G19?6JPOC0C_17TL_V@#2S
MVP%-P/!==(DM#\436TU<[Z2YY9E(Y)F6&X/O"H[=-I=_*'5O-D1HVAU2D?R:
M+(2Q&%TP4BMG$#X.#:ZHC#ZQC2^:=+:(@WH(!;H)#!FF0+NVOM?WYC??^ JQ
MU^J3&E*W?#>TB5QZ2C.+><4];JM)K8NCM%6NQ)?EVE9G3&B>YKOCZ;ZWJBZ2
M^64<&(X%OD@1! FNV-ZN\RQ\N<J/J2)=S]Q(N^(^@W?VY%:BSDEQ7VQ04\ M
MU1"K95N1S^E/KQ[)8!Z>'1N9G^K!8"W4ZO?K:!F2_<%GH[;RU$-95+':I=["
M='?W+!?1QK9+* 5,ZR5CZ>UG>&ZC@(!U1D-$;F<DG[9=YKAFJ13Q?*O]H24S
M[I*O#P-&FC.U)7LDIJ;YZ3(\TU>)0KJ[L.&2N_(5!XF\S6Q@^\<1=#RT[+M%
MYZRDF,X/O,U;A3$X;>(A%(*,9D5I@"L'NB:[,4TO3GN\4RN\?Y/YHB-VP9K5
MSQ^;%?+8<=\\ X6:UW&!-L 91RZ=GW57&4E[$?A)E!D%^]9!\,MX-1NX;-W,
MBB5<FIJWU60#CQ)8Q81# 8>.0S/SX$NSU@B%(93CO_2],([2_WXEH3DB4S!^
M:0@;F5O*3QDB%5>G:6 #B2P\^=/5LFB,!NV@F_N6FSG5O"!20)]1XZ:J9>&V
MI_P5_@E(>HVFE)0&L($-J&KD/9 JRP9"[M)F9\ =8$8?6*5!0^9=JH2>N>#R
M?!GVD6,&\ZKO[&2Z B]"\\(9Z,CKUQ8#9LJ*>^L.8P?+(.MD8:H&+88Z6U=V
MIH'FSDK$H,G\.QI?+^,HCY@7.MUL(07T :4TEY')8M]K)GU*BOS/@"_ZT;Z;
M%S FK+12?VKV^?>LYZ ]3MCG7NV'B7('I@PHY)E=3XCH^L:;V;OLEYM\4>"6
M<=+QT:,J9G:VQW7<P<4;;. ]@=4(M\ML8"[].AL0>*$ #<P@ _A9*J@A9^1D
M#\$.9"1!"FQ@Y%0#)*=IP2KK#5Q17KF&J^M8/)AF8M5BY=_P3%&9#2C#?5%A
MQ?QR.K$!Q9(-?#NCNR>P94"'WO'&$FI"YJ$BF7KD'H]F56@[,J*X8XA8ZS2Z
MKMT54V:!VA_^4;8Q97Z7B/Q[_.YD;#@AWQL;J.[LA<S#3K>1V<!6GP\V&M_8
MP'TL.;? 9XEJY7O74PRM?*&M0>IFSQU'S.?UI_:[?';(589RDE9/H_M$(!.@
M\V\)Y#OI8%]_QFP*W#X8,5T-6=8:TVYLX Y8"S*S+H(U8Z?80%$)BGB<#9R.
MH_<^:'F=XYBC,_*MD UDQ,%9Z+*2DV>@%3BAL.C@]&]U9=H-HM5=])UFE:[E
M$YBE.*B/:]Z8$(];.<6ZV(LY_6<B^BI1\C^(VOZ:""$ .LY*,IW;IT$'1$]&
M+;2+>JW8[1D;V(BHM7&FSI+SY]=,'BJWS<Z(/]'_8?3[\L/-CRV['C9?0O\W
M5L>N%+IU$Z%1-A#!!I;/?F #X4U/V(";%ZX\#'HF1RW8]IN3N;(!U"\?N]0Z
MR<QG ZT6DTUM9+<9B2%BM-^+A.DAAAJ=4".IF&0RCQR4IF>_'2ACFI=?MC'H
M:NCPF/N<5'C)"J'"%1LI.B<R3D]B&/HL#9EGV3$.0XVZ2E2>R.MMF&;Z26C?
ME 46%,(_%38KF%NTT?ZPAY1P*.Q;T+74NM)0/]@9)WO8P%\9'O'+\&!'7F =
M&UC28%JP@:]/$IAG// ,_WS6 GKA"S(Z,UK4N3.B;>#2%R=PV1?)*N0>30 5
MD0M/5O+RZ<_^1*3\BTC['T09?TVDNP?Z%619W;\'V1</XE\&6<GU?P391\)_
M9W;$X@WB?^6 T@:)!:GY2PDJ?5 RB@VX!GU*[UAV8@.O\!TO,FJ(O5KU!-%%
M+>6>>IH3%7R@;7TH:12L,J1:7"SSI^=@*HJC\0EO)D8>:=SXF*][C5MVA_JP
M:LO?@RSG;/VO(+.!@ZSAMR##2_XIR"J57'\+LD6X^'?D07]I=N0OL\/+"7M6
M-!OXZ4;'LX$G"LKTYQ-HVI(38YPP$0N*F8FJ=>0(991^BFV%ISH',F[P-"I!
MOP6^ZI^8T+^8?/_!A/I+IM\#_]P_PBSVCX'_AS#S:OASX/^79O_/XA[QI[B_
M7L327@W[.\;9<VULP B=K87Z>UJ=]$+_GE8+77]+JWE^<%I=_D-:=?\]K:;]
M/<2LTK&_0JP$#K&$OX=8CJW.GT(L^%+O;R$V%0E;W>&OK0[^LCH;,&]</1'T
M!Y&*9@/[S-'4(ZV$F9]M2RU@FPQT*%7-*=M* ?4_V'OW<"C7_7_\*45$<JX<
MIB**'$)1#I-:0BJ=4,143CE.""/,4X000E&**25%3,YGXRP)Y30.,3,4.<\X
MC(>9>>8WK;WW6JV]UUYK?=;>W^OS^5W7^N.IZ^J:F>=^WO?[]7J_WL_]NN_\
MO7>D<Q[U,Z??[15,MOD9^$Z_&-4WX"<=^VY4J;\ZJI^ G_$SS'9\#_SO8#;]
MS\#_C<#_6]PC?X'[%O3*-]BO'DVR_)(!QQ,L?'%_XU77KBG"/WC5K?\?O.JX
M.#M<^#VO#O_$JT9_AUBA*>)'B/EQ(*;R=XA95?P28FM*?X(848(3]?9?C3JG
M4_P6]F?_IHBF_:V(_G"ETZ+ (G5NU-24#;1PNL;I-PC-\I^!W_Z+47T#OLK#
M[T:E^ZNC^@GX)WX&F>GWP#?[OKK^$_!_*^[_'OC@+X"?2%KX!ONUK2KXG\3+
MC[Q*?-6'_4F\%/R=5ULG20VNW_-JP[^*E\2_B9=9#LA^J5V^ QGO+[4+[L]H
M%\-_TBZ)26P@Z4?QHN_L]S/V<;\8U8_8M]'X-Y+JNV']A/V4GU"V^Q?83_V^
MO/X2^[\9^'^+_;]GX4_@5R:,_PC]]<DVJ'\HF+]1*_Y,WD_4FN_\=VI]1/R%
MIO)MB?H7!=.]^V\*9HB#M%\HF.^0]DGXEPH&^2<53-0O%<S/,CFP8_8G D#^
M8EC?"*#,Z=>%U??#^HD ='Z"VOE?$,!W4'/[)P+XS=#_.P)X^D\$8 UV_@A_
M"<TRPC\TS-_(U3;#X2=R=?P'N6KA?Z&JII/$_T7#_*-1J/C6*'RG85Q_O5'X
MIF' /ZEA)'ZI8:Q0L.V/(N:O[N6O[N6O[N6O[N6O[N6O[N7_7??27H6TBY6&
MG!H0 H7*B-JJ?3U5LN/P^F[[CAVT?1FO!B;B73IUU4CBU@_4XI^[8NZ.N=Q7
MR[OK.X.V&K==Q0;6?*86UY+""&M\S+B9LET$RE8J*62Q^;6'3WN!E0WH/MB"
M1F/F@]*ZUN#L_4X9E&3FL7 M6V_7Z+,!E&QTI/GG9P&HG-B>0=7*,IG[DG-*
MH=R12O<^_)_:OO/7A_Y_^B&N]P07?!\=V2]"J3O7I-6WZ*X7W7HK8R:ID=\=
M;KFJT;514'LK\R%C#_9#&7[J%8UOLJY*+FQ"3]PT1(R5M4O98:=.X!>9WL^"
M%7K&8BNK;-<R7+#-'YF.'W"H#V1CYJF,ID1#Q)QPM-$GY,('P;( 5F=O]A&;
M33+3+R8L5AIQ:P=??_QD]2FM132WZ'.<\=N+ <&*WBA!N %1>(O 5^A#=8I\
M'B\M[GS'MZ.UIE->^5W1]2,GO%F=[=XH]"O^4FG!_8MI1ZN5I7>F/5]=9< &
M@F]A.QW/(ZH/B-4%OI:T3-98NEUS;A5=M[B$*Y]K"E'$,RTK48T$-'V]E# )
M%F>D;P5JW=5Y7TVW[>-1CEG'7>7#"@.=>+&JF'=FFS"1NU0T@_8%T2+FZDZ5
M3K9AYU[5["<_WF#@=L'2@N<-MH:4K\!49 /K52/W9KE7;>W9+O.#EVJKG8=_
MHXX.U>RJFG8+WXIL^NK(Q)EOLW#PWRUME"(C^D5:KR31R<L?I/2'7NN X2,V
M#NH8BU&>&,-/\;LL>$ITMP!OJ:H1Q/I^]7+$PFWL>6Y_.C*6LGRYJ,SRWOC*
M(Z8V=%-.7=S:(B@ZH>9,#!C'TIOL#D>.'+_!F?6[_X=6;OXK'UJE88A($04*
MOK.K87780(TM&_B\$FCZD[,*234S6]9#AW'(?),9:VU6T3_O*;M@QA3A=%&-
MKH$<'?^F%ORJC"JA@)\-$2N+'.6'6V_)8K&!V$7]IF_.::803*1JA6*W6M65
MN<OX=JCV&<GS>M'VL $'^PV$\Z%8YY"0N+M&9BZL<=8+K.!A&H.,B*R057S!
M<C6+U_$%RZ5KF=12-N!K?ABR) \NWNEWF.I9$JK0$I_YV"QY1UU->VOL20Q>
MXV8N/+"&.C?TB"F312OM3J4L*V5&.6-=5XS&QZ85&/8FV6"-_#5P8W83TTS7
MSTDBW.$J2>.85A.FWJ=NMX@@>@^(:(%&G)^;FSLZ:IMSR>&.3A02HI)3"52_
M.GC]0\+P><KTD?F3Q3I5\Q=> Z]D(B]?%F3M=5G 0_)C-6:0+5C(!D+=Y,/;
M.J_YQQ1BU[V[G?W69PWHDSYWEZ%WO81?>G?&>JMG_7-)+6F,^.7\!"&K<V5O
M8N-1^AE?!Y=J0EDX CDQ=2LUZTCNH#/,W26SL*IGPM39X=%DA/0-^FJ"9-:2
M*[V%#20<@5+8P.4<3KE]GF=)V:=43[;JR#I:>7YVE\U*H7>YWHNGBE=CFL\Q
MEN!U>]F ;$9][,I<+AOXF&#90:):I&R=P+T![\B=*GV=GEO"!9.VG5G9LW?>
MC+G1%38RBT#\PYY5685DJIO=X13A0$N*!6^Y;<=8?L2CM*-O XO9P(VJ'J;2
M*!2R\:6G8%'BQWN2"T<5TI,Z?=1G#+M-L$YDAR &YXM2-+=]J?N@Z*<:X',7
M\7V6-#QCHXGB?N:,<-7ZG@57O,"D97+08D5B<8](966],+^NNJR8@VPN_SKD
MT5DV8-_>OYU!MX)FTZ#:-JVRL.9^R4ES=X)KT5WW./V2Y21=;G.]K(4[\]RT
M!WSW=LWNR'AT?.]2[_)K 0<CH2WQ?7J@[)+CJ3+YE2U,7380M@;ZR 9^&&A
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M]48P"ZKKQKULWZL1M53GK'JW(;'G]X1*7]WOV"@JTG =G!+A$!ZC!W1#"YF
M?IK]R.""TEM^_3=00Q<(9]9LWJ0:K-ZTC6NU@=PNE@>D0[6L0P!,$31EEG=\
M7_^1A^CF<XVV?K-R,5@G[\$'"0-/5E<1=(>O;W;#9H6:M#JC\Q'66--1#,2?
M\V('PRKG(Q.U^&F>@V4\?2=U=LJ3C,CM7;X>>WMQ[9G,B5F9/I5SWE^>3,3M
M^EJY\C@UM=M0;%E%0<12R+SG]:Q"N7Y9BG9GY"VQ>*0<2,[@T$H]&R@(CW:@
M@F$S\N'5*P(U%I?N'VAX)\S_&CF6_/C6&9CV^4;5>L:^0*E":)+F??R#CT"
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MP@P-:;>3%9BBQ?280LB&NG04BG,>-BU?'VTHUU/PR-45I;*6?QDS8^_>JRM
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MV$#(9>;^ $HLM&VL&D(_O).T<8(8MPLQ,?SH7%7\'BB+FZ,-+(>Z5BU+,I3
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M$?KQUQ. W=S85K\G@E9//J*2"-33..A .1DYI3 29%J#%>Y<1-Q)U>ZP#PB
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MVM&FGQA"?/!>O6DY/C&B5-J C>!/^E7$VE;_FL -1E#Y#<B3S^+TSDWR198
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MU$/PDN4,.4W'VT%5T"\[Q_ &5J# F7^@+E[K<[.'RI5#7VL^MLD-1UQ>T!W
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MXIWD'T0O @A?^'FB_IC).K8CAA0C.3.P6N<#EF2-+WXX9UI'$LBYIK.81R*
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M _T8#9AC'TWL*]LY_:N>L\<S_O!4IX^SP/IF6;KS[]8P/>04"I*,94A"M\%
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MTL?0:1:E(YU<25=4ISWM#HR4X%6DC4:A(/A77D3O3BQK)W/K7BI C%J3C.]
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M,Z\\BQJ68PG*@#JT#\._\%(A.@4A\D,S?)(+>V^LF6UWH>SU+*3'WS,_=^A
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MWF>-F>A:A=4]1W?=?'S;7VV <?('-++P:**^#;Y2&I82CRHC0L)R='N@.\$
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ML+>YSF$C:4C 6M??RI$#,V3??RB@K,TZP4?O.Z,M0*V\1-T?M-G_W,$9J:
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M9:)%D=Y7Y!&*?-(]CEFU*Z7%N[UXF9IMD/O+B)MR4'7E) X\&^1H5JGRR\>
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MU!K2;U^><BX;L&2K\3:),2G!=KX>*I\K5UN<VFE.R/(.#+R3OT=IGU-!D9P
M=;UT!MJ&YRD^XR[OJ:>]O-X&EH&L!Z6$>%:5;._">3B#@ON5Y/B"X[N@T]?@
MY.VF[>2C?K.H);9!:OKC =0/D>GF22Q7E("<&AS D\X'T9^IXG9^@2>*:Q/.
M.WVKZ'"IEZAK'QU).C_N=_:AY;L5)-P8CH1ARS=/U@E0QV=8-'CM73)LTR)
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M*5,)TB<;F49F>NY/]P*?KPPFN[8::-5-O3\"[,W]6C[Y;LV(VB8AKBU7&VX
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MUMLAV-TKT-E/6%^[D1PE\5;@[NO7Y8*7":&MI2U*^Z+,7#\!OS;\B_KN56%
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M(N"CJ53A$<ANKF N=/4%K<C27?##6G($/.<O'?Z)8M5@.(5%.(=RL>M8RO*
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MFCTRGC#X<I1B8U8^T;D5_!31(HGMPD<!X!X1O#$;N.%:R3KKUNLRBV2U5[:
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M(/T=I$83[6DM74VMO>3KY4(=9^Q!NS4GOLIU/:QXJW0+:!\K?BW_WNQ9Z;B
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M&/0GVN[S8P,;YPJ#35%0/=9I8%!7!.J>YL$O1M(P5W+?7?"3&1LX-3PN#VG
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MXOD\R!]R/,@(@4423Q]]?4U7^$)"H22K$.S*I*-?D$=Y-"[U03Y>%(MC+ZY
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MH6Q _^;0$2-=T !]+?#K8QXN<8E+_P_08KE'[W4<'RPB18%=K[ 38>!UXHP
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M3$F>5M^A?A0S-U6Q[' +<;@4OE<2\O!.D$M$3B1][LKYR+>""<,2%Q/=ELZ
MH/?*_Z&ECE;%2*P8$@_PL2%+"M UU>G-1>A7#"/K+Y8-H?,8,F)>"AO2-Z&4
M=C;$V!"5 7P;9$/V84XCF\>=;UGC7,5ZBSWMC1^^-IJUXOY])W#9 *:ONCT.
MHL8(&NB W(26<:%VM7=3^)9;09&;22\4'T*E!!9Z'O#M3+G,*]'.;+70<6_8
MD$,ZXE,9XFU! JU4/YD][1G0>$_IN+FY>V855I?I=@CE2F8A['');7%9UZ54
MRPN++\]%*C^)%^B.<Z\/OZ>7(,(<C?B"O8A]Y#F'GK PST3.X@E/&Y\QU$,7
MS11:)M=!6?F9=QY=&X"OU *GD9?PPS"R(>H-E)R(,!_4\0HX[*JCRC=\+BV,
MU^?\R?=0ZJDQ/J:O#6U46'5GDJY!TVNG*C*C%%94_1EIE0UJIEY64)^)2?PO
M$(?7ZUT/*^V!IY(E;,4,'#;3,9R"OP@F&VP(+'['7?RI\L=4IDUJ^[VUO,%Q
MH&LVT#4[=_^'IVM/[B%Q)T--\T_>?Y"\ Z)88X8KLQR87MQM#!A"KK(A!E7(
M1%"_V@AX((6#"N_;7#8V4[\UZ*-K3)ULL#?I>$\:S=PSM >>SH94FS&RW%O,
MZ'R@S.<&T5\H',?*[ED*'4U.&F?1QK9C]S37J[E$8!N()5O&[?T$LC%J:+#]
M;I\4+6O*1:56S\7PPPCNQ#/\0ZS=D9?O?A0Z?K1TJ[M.51KU8AT4^HSLJHCA
M,*RJP>L\5'ED^<;PU.A- V'+#'>9N'T&W-)B"7OL)KK(A"N5-!CYJG[?P"%?
MI'A/3LPKZ 7^*^K0@B;9,3R)JT5)#(XPH0RBIWAO7E7\6#S>X:<MD'FQ3$,"
M^T'\U=[*WV5QH6OI&CK'DYV=9P;G%1T7_9X$Q6>;!=\W3!]L<_#)-].72'%=
M0YO(U[GAG@Y@B/F 2)7"W5('RF/?,S<M)W@5\9V7Y]3;?@%'35]R->%HY_AB
MZB\4G$,J]U6R(<><5BX%2,8\7YG:E/RR-HIW,D>M'J1 0X"RU!9<3/;1.'LR
M)E1F0"5-QC^!:&][3?C=9.BPM"5QJTT>!+=A+HSG(/:2<&<(#P.4!=J8A'9$
MHG6D8F7B@--9?4:Z4^Z2A[^$B-/DHMP%%\-B!YEU4Q6<&.5I>>,IRLW\+P8Q
M8GYXSS$Y]8E;*[9<\^EYKJXRXRTO6F*D*\Y?TQ=V=/@!>9EH0SBB!UV$\N@X
M!$TR7W97,N&F+U+59J\E=C[Z^&KL;<'D:V)VU1**; H$0\G?8,Y!QXVFUE4(
MAX*+QQ\C/K48)C5F=CIHK @6_26_%QDJ?OXBI7)&7KLD:[-V;2&05NPCIGC8
MNFB"/P:?7IV"#-(U^\.&A&KMSZ*+('^F>"SLL80>>+8:\.6YU,7[KLJ=Q[84
MI 3AA9&.RP[DWZ/4=&:R:IVXNNMT*I6GT.GH&5R:W!X56X  E>WI#N!C'.>8
M B$W:+1[O0D';;NJ5UM3/WZ^%4!7;<2[_[[*U[^_%,TZX$$)9AT'EBKRY]>[
M9ITECJ95IGDB'8Y@FY%OU+AABVGH";V&T&PMA+:[QVV3OZX8\G'43X;2@L;[
M!PXMZEOC(%L0!UFD-/X7HT#'O+<ACDJE@8YW$$;]0#F==4C/,J/ A%GT -*\
M?3%AU&I8>OT(\-U>$_Z*]**B>4HVK*#>UFP:-_'5_\NC9U?YS9S ?<"H)]CI
MPRDNO[KZ&D4VAD(89K2+DW!^@DNC4NBZ76\)^F\L3Y3'49WXHJ^W_B16"K09
MZ6T. -BT1A"'_VDEN3,.5+$A)$%JDC^7>@'G[0LQZ::!7044'__UL_GJ-V\G
M]SG1T1^WT1.1S#.@"5UDJ.,8T?;J(";/@+,NP'=;A:\ #IC#K ZMN)!'9-;'
M$OCG!L&N;N8'BN95_G#>.GZM[3!-W.7[WU/WSUH?TBFS?OO=P64XO\YDW?&I
M;9NPKS:_F*)XHY,]WO0Y>EOJKXB6N3ZB8'//1.-N0<YEQ DVY&T7"9DWM?BE
MYA[-&/^8,VS_PHN?WS9'3R31CUO 3^$7'1D":.(:XR@S:0->=6J4L-CI4S<+
MI+JG[XF&FGXM#N#Z. YW^A$ 'UR_WI^PY43'#2!@L1@IDO^B\LYG*SD/6F%@
M4<\JS6G=L, :8=WK XVJ37U#>B_N>*-/<N#Q#3:D2_-Q_(5-NTBSRB)X)D"V
M5 J&D4L!)[YENC^B =9FV4P^<CYG5D?Z1R!J_/M64A_R" NOX 5FC9/N8J8O
MNC[YI]X)DND2XRQ//-)4]^?TT'WZ1W0)0/Q"V ^;=&)UX4>2Z_6>YDT>,"CB
MYY@]_[K:9R? ,8 -*;W2B%=NO1KN^?Q& ?IE]&A<NDW^>@R^4$])H1DG^?L\
MI8 \^.;VFKM!X^V*#<<9JY?X/_5[T/XYW:4JW4)6_:X#OY[:VFJ>OH3=%_U%
M2D,JSN.>X(X'F.[ K1.M^F%+C[ZS(3W'-[=K#DV7=7M@[B9]OYO1@"[;,3SJ
MJ-Q)!FRB [)ZJY:_;U=P!?M$H?E+XXXG%A@55>P[?M9YV=,ZFM35MD3*?%1K
M=H35C3I2+Y67L6SQ@Z7PM>*N8I_9I]_Q;5RW6TJ%**W(1$8@;97<3A6C^!:@
M[9VV1,)B=)XO^IRS_!+G)WT]ZNC,Z%X-P]0?OTW<-#2DO=F0\M3EK$GW$?S-
M?EC99'V?CZZ24^W7>I[9?6[']9](*R=P+UU>V&^ K.'[L1W8HL-[WX8Z,G+6
M>Q[0=AX8J-_2,ZX1=1@4=W!Z"//*FR;89=6C<WS]UH88@:MP,Z#I0J,  <[J
MV]&?*)LL*J@,[5N1C709UTP?2I0PQVHMXZ3VO:188HA%\(JV5+([22*U])EO
M-57$/8J88ED9JAN/]3IP^>Q=,<Z'TJZO&;9Q+W=<J&+,.H0LQ1+;##O\7(7
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MFA0PTUV(BVP(7 BS<U<!Z8L<AJWY8/AA2S _-B37!@-"'&(*8>W);H\_.HK
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M][ GD3B%7S5'3,1&(9MK;[O9$ AZ&!VA=X0-"0DF+\+_Z/50S9:[U4AFZ]2
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M61N=!(]ACOB*.V3&7OFPSW_DI2W&(=/PI-!GZ$)R,$!#]P*]]-9 96K8^-(
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MI_[KISV1&Q++837\/W2G_,^Z\T=R[NE6 GR#EL$=M8"#%TSI);3D'[!W=OV
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M\H_!0S=%9/TK8M:&-=CZ+EBUL7R_5.07I;IQS<VF0UMQ&X432Q?=H+E;S!>
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M^1J:]J@+=GB\FM$4=HI\;D[,O-L7$#X5(4%[_Z5-^$ ;\?;841-&Y;]@#?(
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M$V:$W?:%-RV-76E\J9J?/5^K,1ST[)C&3H1X$N4YN5[W7D"VOQ*]M\=*Q]9
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M-<A0/1>E'.GF=_LM86EX'MIEPE&9]*ZLB_F$XZ+7W:]?0KYKOI8J<,*5\T2
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MPYH8<\"_+.%#VJ+EYZK?%1SCJ0_-C=>^XWEJJWGV'4A3F2L"]"+8=0VP="_
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M5<P^JP3E)O\-@?CE-JI17L@I''V]>R"$EM!M+8FA=\!<;:/T@<[)JH6\&?7
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M[J;R<\TLI01_;;.FZL8TJ:#T>E;-Q0#A;P_?;"TU#<"Z['# P,JL@S5["=B
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MQD]>5]L)Z14S?Q\$]]PE=M3KD](<NZW>+?_Q=]: ESJ@.M@>=>+&JA]6X\4
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M5;%N:WG( $1LMA(KO74AAJL&]$1B56/G2&@QMW%J=Z'KE^-*CRR^/GSXY(3
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M*<W+*;/5!^K:L<6A(PY-$]N^&%KN.#LO^.S8'J.AB6".N/9R,= S9\D.Y)B
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MYZEEN3J9WZ:Z8G<F!RK6NR=*W!'80*F"@WN'WN+OK: V<(*AJ"FY&15E:CK
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MEHI59>^'WY\%W)L,QQ&A\/*+OM)W+NK..IZ]1@W(9*.SM;;\OA_W_CSP_+P
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M%BT,BV ),_$Q&GU3K=2"&+WXNQ8NUKLV+!MTJ=5U;+PPDMKT.+R[R?X(?.K
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MWK1-(S6Z<JH1R],\(7-"1PHX@B *;;C:J:\M,;-]*O^3)*G8G2N 00K!.$V
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M!AH\"X5#M!4/[/(9+"S5;.O:V^ZP]ZQY^TEFCH?87GX\TY$CB5I^ C86=X=
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M$L$C'%P_H3T,^8(W]DYY^36+,L_#E77E+,-6I(0O>3_+/CGVEXGNU+F!_*4
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MV/E17>>WJW?UA&0FA+).TFY\4O9]<[SR_<Z]#_ASX<NK'$$EUCW0F2,PR3H
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M#S0NT+9^8$6E]@']D_+QZHL?+786'[%0WG%&?L\_/"QK2,O,V;NW84^CF*_
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M=='1#K]QLM(;/N=G)6MCBB0:3RR,6WR-"Y5XX3![Q^R!?1CR^01GC$B.=SU
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M^?TN5@*?_B^R>>VEHCM:=^<2GBA7-#[[_+EU[YF/!UNR_Y-T+_^WI+M%B^$
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MWFU8A!P4<GF (?_%(E52H)0Z^T-Z/S9D9&1D[A=FW:$@:!NVE$._A!@G,%U
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M!$7KM%$Q3C4/&4G'\W5_TC)RHTM1OAZ7B/S6=X6A,A.T#;LVT'R"C@#Y(V>
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MHS94/U==\  R>MQWY&2\W0?NIZC6EJ)2#0V-XN+T@JRK#XXCB,-_L5HJF&(
MA]5R)OX,-3 Y_V8^4T>JBS[3/JG:M3)!>(D CSE.+3$UX4Q)[RF)EJ,A1.#A
MX@)3V:.J]SE=%CV9#E /7$& $F&0Y]Y6Q28B9.H/LD?*[R)CV:KHY14RJ8$
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MZ&1**T[\9[5)G(%UGO>4<8WKP)T/%3J7S"-*J^SW)7R_6G7&!L:5>-\!5Y[
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MWJ+B@B%-M1GR C&>F:&>J<<DWB1I'_K8+)@5R&,[@V2*'J7/L+(!3XO147H
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MW(F$O'><<70//@.<D9HTFR(R@GBTN3J0GI_EL6'!W.=\0')H^D2V\=/N ,]
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MTU.5U/J@Q9/D>\!^ O7\7*%8.YM?BRH\U9(B,@)BX8^J>5(?KARV>WT_<*=
MR=.&XUQC%B>>HL;DR@KM07^3FH% V1HGI,6'B$4_/[_]=ID5_^Q-OWX<=H/P
M !Z+VLZTI,I2M LG$=(_]7(B,>:OQK0*V6FYCJ52DL7J-ZR^KO&XBIS@"1<*
MU8%47QFUH$R+(@L" DQSVIMVA_;[E\9]%?I^$'2K[QO_/Q4,4_7Q_(5C=Q7O
MZVV1G&WKT;JO)/W#YQ/^< </W_&&5NP+SOC=$J=YMBXX3 NG')/O7_!1Q>R^
MMM<BF6+O*A5\'&$W)'L^8<-'>3F8S3?*:5$$JZ ?UP;;KTVB(MFR]6D6WL]C
MK6F[6VMCW_P\LN:IIL3ML?>6S>'S\6AK+0CV-1HBK^'Y@<9C@"NPG;F?BIV+
MA0L[/@W.-16)#W->/E5/F3W.UWSVVY,J_1W[MIR,@;&M /(W5>Q*"T!U1"18
MH?B2SVHYZML-G>H[4#IW=JJ]Z,PEH[*-O;\-L(,RF$"/KT\D&^V+&3T>/FYW
M?Q_QJ)?00<N!O,2]XS^M#<^@HYAR'$H%DZ;>A!AMK-?_.K->,<$+%KIY[O[.
MM)F_VE?VIXE_O&U@Y5JDM$C1UMX_8/I\^$_^(\'T6O E0P)C"B'6YDG4XS4\
M#QA=2.PSJ].[: #:A5]/W+DCD<]:W^GLQ[RVXWNX-SCL.TX0_[K:8A[R6SS@
M@)'83.KS$C1CZK"3KGW[X97YTL"PX6"U-T^2?"3G:KAJ1X[@5(N8>'O[KERG
M5G\>7\W^RGA-R^0@)1C7V%/G%<8%M-)43KMZ1#*AM**U:TG$^RX0O_8F<Z9Z
MD:!?-E2E8*E?56ZS4_OS0]'O06T%C2*[WXOKL/DX SAB2%1+Q'TCF9<\R<0?
M+;OY/P8:&N0,[+%'TIH&N%BG(%FQXM![]:#CC@'2:.?N(3X#5>KP!>H.XZ-=
M=1\=/2\TK%]7#%;"6Z$ZW !7'#4 /O^% B?6L+=#4 )H-I(HPEVF2:1GOZUQ
M=X=K7(F5[?![>\:RJRK\8/FK[VD>T@JVM$IC(HQ- JX1X&@7.J<*X<X\6#2H
M%2=_EMI[G\G]UB@S_\I8EG; .WOCE;':K(?\GYRZW!%:P $$]0H!/%"*I%KA
MP0,)L49[/9$>*%[/HG8H@A!0($>Q>\K5RR_ER&)FG#WIB<]7RO]XWIG-,/!&
MEN&9$A<0 M@>K!C-O<4?@?8WC]]96"H;YQ#TY8[WV9B"VTYBF,J%2:Z3+X^6
M\!<]?FZU@FO#1;E,\K8A)4'3P.V!;M3ZDI L@9]OCK3?5?V!KAV\9'J1H0,S
M;8" '6=:[+:+G(F!#YOI7\$\FHP'I@O@!B^H'I*4?_0^4.#)QX:-7S96^"_=
MP3@JQFD"0JGB2'>S$'EYTX3SPUGE&&I_:?F6:^ AR'2%V=9![_\I(-!_FO40
MJXQN:).<:G$^)N,\?XMF_W6TFBV+5T!<]!Y#DG]:@/OQCY#D-X@BM93W:+A%
M[1!6'K._-NURWVJ^&TF[R/VFO%F7QW!>FNBI0UQ=(5MA*E,P3F.H;\HCC/XD
M#E3%-:3AQ*^<\G91?!/F[:O0(XDL[WX[WNQ!6-)J;HG1KU$%KK<1[LO6F)LU
M.BLD2;^I[PN,4_SVIGU?65WW'[3R[7LF$P>C3H5OGS\39OH.: Q"^@BA)C^"
M-OY$<8K&S$&1>P:V%%G*/=_&VC-2JNVW]RK>0Y9Z^+VN"I$\)I^8Z9NT]6J0
M-E?CJNX>\D8,^QJ!O-(;[SM% @^J/S00%ZPI8'*3.P03GZZK+2FE>L*G^(EL
MZXTUZ%6W8'8.U(M!;VF/ 6^>-\G/:!\8E>OEK#KPK4YE6+RNM;]]Q_ONE:.&
MM2+:4YWCI$+L8:"1#)14/,)*0U^Z/$T;_Q[70"6UI&]I"M-F\#2M.)PL+VG,
MZ,FXXF?;YV;X<XL%>!1'?@B($<@%4M@#E7'G >%:V5RO)\?8LFE1D:W'-UIO
M(XTFUE@6,FPQX :"^(."FD?1)"TDF<JTC"HR(&KN01>;\"SQ\5P8220>W!'^
M/N*-,;$AKB,G=QL!37!;(N(HP0\!\@ J 2%CM!_-:)TX3+-MJ2KS=E*_-!1H
M^OZ]ZM6:9-+)LPM=1<M?W.S'5-#\9B+;#G"ONK#Y.R$+<A6T@*SM+3#0W6U*
M=[$6.:6Z3=M<H/7N]8/U_8/%YS64,26CR;\>GS_!NU]:0 Q((8#*)DS1*$H.
M4PQ!44QQF3+5)(B@K5IZ#W_&F&4G,R O^;RT]I(QR4#\7?41XX]/2/*5-O*O
M6,E(,B6!N$X_^]EW-4R ,I1-$=HVN.54#OB:J.JY[^+A=TD]_[-Q$?A'W^(V
MU%]]BT?_6]_BN/P1V-6KXD_@>4CR # :VDHH(3 E>)L(PJIK9F^IB-;>TIF[
M]<^6CSK&9I4E>7N7GB>?5XAV48]W>=ZXD# '&UY!0:*0S,%,8104<=B4E56+
MFF2=:J[?0C5/_T+]5AV7?Y*]K[ZJ(C1 87N#5$7,P6R7P[_.9SB\I^S*6<T\
MOA5[!Y*& 9S<)FS2!&B4KM_C<$IG9*DV#,A!.PR6Q$WX-E2^#%MW=+P"S\1_
M\6**_DYO&;)P3:0M6*G1;ES9^*S104(4,OCCV05?1SEV("><9'SF)<,C,$=#
MIU [/*NUT_[D@MC8% D7=\D_/(.PN:K,J >W4A^8LW#8K:!.PUV#@-9L4.=T
MR1=5"2FO7S:?%93;*\^SM9A!T.FV&OUF@@"-*/86,&QR9<&GUASQ2.WR>ZN/
M_99+'7ZCCO.-(7,UN^<8AVD6T3ZU4I-A9G8#;QU]D:9ER?39&S,[+#.#758O
MFL. /03JK?5V/(@B4.U['XN?TDG/ 2],#S<-/3BV7-_NN^LVGKTU[!5;:QU@
M2O-2I18(8FP]S,6,W821NS=PDZ$''S$V81[)9FD1O"Q<,?$I&\2W),03)/RQ
M^AA?6DJ\EBJ)**<QK![85? '3GLZ^.6O35A(-V!)HGH$-UB EP'J64.=EDO-
MOSL9C7+PR==67KS^<W==Y"=>EJ92'0Q[&6C\EB%/&$*2"_6<TH?_*$^UN'>G
M0V4PX:/E>_7]-RP7%QMP]+!\$[9@2]\=QTT8>"@JQD]+\@'C7-?D1*;BLR01
MOF<D.X4(0[N3?8+"0249]X;[4-2[<$Z_:<:A(0PWPQ@=;%$_>"==EN.[S5JW
M$,<Z-'/[0OQ4U;*(PE]'WBO%I7]XUR3Z1R6^*>&_)-.=_RV9;K+5WM3&ZKF;
MPF]>'AX U0G_N4(%\9\K5-2=RK]4O4Q[]6?6/JYZPV6J=7B!4];@YXP^(AZE
M8.LH%CO1CHWB#C\M\'.W)<H9IY<CS&0/#)X.C9Q^/J1E;9E\7?HSLKM<\I*7
M[8?1IIKIRD27,^P5\7M(!QB[F\!9E +\7I1"XBK=%M591: .8/=6\5RK[3:=
M8$9NPCS/=#C?]>4NP_) )R4!@H1);LX">R\]?$H%6QRUW5.F9SZ,%:L:#RQ;
M("( *YQPK;0_=6J2'C$Y>CC?\]7,T,8=F"#L25O1>]XO9P!#)#5TO1DY3R#"
MR3J/'P++NZB+.:]+7\S1]5^\A>$86.3+5_ (I"L./'B:4 PP1=OI]T"+3%*:
MOR3F.DT[/<=8'F/JGRUK'_G/=HY;QQQ6U'\W:G3];M3 CCF+@JB<L-=_-6I4
M<QHU"@])6@6HW>7U*3#-$$QJ@_/\G<X!_I'.D0'_3N><^&<Z1_F?Z9R=B ,7
M>7\.-^.CJM6;+& >&1+4B73_-R#0''38,]4WKGHAIH>XPXX29_+ZW7W0E@K)
M]=:M?[5ID%B%T@G6D"AMPIP9U^7R=.B/V7]G=.K^SNA<8RAC_SVC<Y^3T:%P
M,CJ]OS,ZM[O3,$5%_\CH$/Z9T=F$_4M*Y_3_J/#_1TJ'\#NE,_]G2L? \>^4
M3K="1M?M@#T":X=U^@ARR.LX\,!26R^H%!RS)N1"_I&PYK^M-W]?-JLVH#G8
M#2NE?[Z\/^M)C9J=\K.QS#1/Z6-T_-\M%\8>&IYZO;];+@+_6\N%:-LQ32[6
M6:!1E_,,D.DBOYS8.J!I\= ($;G[Y,P0R7'87^W,8E%NQSV1%'&R+_?>VA>#
M\ELK>+9&(\_),#EQ%"=;T_U7MB;I7[(UDEYYF/@*3K8FZW]D:U:WW.-G8P#R
M>F\"R8/FWH"+*%]QF0]*38C!3_9.K#CK.]JT5SQ%(\G.@RQ>V^6#T+V<9V(W
M81$SO]=XQOH+0H:MG\GKG@/:?"E)KS>O[M9C^%975B(B8 %(JA]N_A=B <(5
M6Q- Y6PGA\*AM%>S2>@,JM[B:1F,F--IN[O24_>Q!<I0& C6T13;R<--P YT
M\V7?:O>(.[%UU^=_[(R<D.+8PT A0!])=:UH\ <A^^,-/$:(*49AC.#4LO(H
M@6+J4R\I(S];UJMD8<.'44,$>R3YFWH"ZO^P]^;A4+YO'_!(0I8A^SJ%HI"R
MEFVH;$E#A1 CLH<448:Q9(DL$8HR$E%HLF?)V*62+-F9&4K9[U'&G5F\]_3]
M;<_S_)[?/^_Q_O4^?XRCH^,^[N6ZSO-S?L[E.D^@GPB8!J;85UI])8;E626T
MCWQX+-%"#)*I>8]<F?X>6)@+8R+U;\Q)K26V:(WH&[^T_+YX>^771-P4[N>@
M3]'?VF.S&F6<9[(:^J5#RJ0!BFY=C.R/H'">'VZVN5[DBE._X<^#V*Q8<;V\
MW$[(T//S40MPCQ>?<7CNFIBH_JF3!-/+1$\G+-\ M)'C.51+T -8U321Y03J
M\IZV$.?"PR_.WE1L\+1S"\^ 3(TPH?[+].I36@C=]\WP@U?/=-*T>@]'KQP<
M5E3;AJ4)H3_GT"4L0PHAU<Z</2-:+]#2@A-4S+1.N/;3+;IFB2V@,V2L2W$"
M9>? Z4N'EBVV^*\CJ8P<[%6T,"88&$F^]0)S$'R*"?&;7+IX+[G =TAZJNM&
MVIOJ,XX7;K9G*BO:_B9 9.3*VF3R+'%9;4YJ)9RLF :A,KNOX^,=$QN_?IME
MA4MFV'K<[3 [,&CA_/YT1M ]:!VS"*3E;=@D\00C#TG*R\6W+T6<_H22P;AG
MRV@347L\9XEG4FU4OTRJ>?<_>+WC=DV/Q-@8T\E0-HSG OABC@%OWY(I(_I%
M*@SO'?Q%NX+0ZNI<5[$IV#S\'BGY(U(+<Q.\2W.EN^1USARG(!+I$7,&_H/$
M%?N?!M^&Z;/'W%VN%3Q6\=YQC\2&;D("5^WI4L39M#M(@5^XB9-SV0E!Y)7S
M9RRDVEJ$AOWOA=:M-SY@#C2E &X>YV:5'@9R-'>\?AD 8^@Q:C?>84GY2,!4
M3::G9+HR,![)@SLQN!HYOY18SI%51O,\+]BZ@9]]9T]] 0EU+0.GM0:9<VXK
M"J%-5JPZSX:RJX0\%W+9"[XUV>OOF;1\(K:)<+_6['IK*'ZVRMMEPBO5Q/MK
M2E+5ZXZ#T@)F%3"L'QHPP493F)^(P&EXE*%8JE:2.5W*X^6E H@N?Z4%SP'9
MWWZOH:V#\5_KF5PYM&#F(+$&O[)".X;A0Z<@!!/^W3F<??S4;9A7K3>]WBTZ
M#+:;65,*PS]FC2/=AK$(VR-6FDM&WSLS(G_M#!#!>'NOH2?GU@V)VCKD)M.;
M6?O+(](3VS:>G:]+X:3O.7GA<S.<C!4 'VGA]RQT=+*?KLKXL;!U5=9_Z-+I
MRA@[K7P>UXOW^%HSE-A_:^-74$RN9)K>29HJMDW)D .T\;<;7&E6]2]?Y*[G
M/;S6]O:Q3IE*#B_!!':- RMRQZT%H"!9W7"\PO+(NT$UINC/A=NN5<X&KX(K
M>,Z^'N;==Q-6+VA4=:KMFDZG3?RQXWVP"!\(A-(@TWNR!O( :KQB(W>%V9]+
ML*D$SU.3MV%[K (/@]C:5SOD)J6#6F:$]2H'7CGS2XC#<[&DT;7QW30JJW+Y
M#<AYWH_[L/YQH*9WCL]Q+K W@+IH\K#?JIM2L.]VEMG>RQ8(>>8'7!6B*W!R
M;4X_4@3T)SN']\@J#3__^>K*7<N>P+<M?LEE\;_ESF2<R7B]<U,A"EM! .6P
M]#T\'1!?2QM/1?%/SIC@(?_$GV\SN;;S1.7TE-Q]F698E$FSWM2!M4?)3>E-
MU%+.GP[0]R#^=.)>9AIB?4P'IK!^#LN<S<CQNGP+NMMZ_YP#%A(.4 [5":'H
M1OT]#S!\%C*A3,1_;)J4RQ!@!2:1K(.+;\#);1B?,2E%=M,%^%3Q?'(,_*(J
MKV'U[)+3WGBI49O^\1F.)/6Q3G_^B]%R<Y0>J@VCRE IL@,G/$?!MV,E?9G<
M%(4@J="&JBO>JVX*0L*?WU4(#WQ5OGI?XOK+H'0N&.,^J %Y%,9A59LV]9FS
MB!XLW*<N:3R?V-$H/%IE;B#J\/7.P7_3-&EBGM4TZ<*_-$WJN56N@LJL_&?3
M)--9FC&BK[\+"Q[WHXZ !'+\8&"DMJ^C5?G]Y?N_5.4Z+!HS[P703)JY#_V]
M:=(6JVF2,E4.3*$X=:?]IZ9)K_XT3<J%T8>@M7K'JAU<U<5.RGO4LPHJ+&EL
MR![XA-IU,T;M3S,R6AIZ\\-84G:+-FO #>;JB#X'"2$4)M;1.)]<I%V[EZ*Z
MTM<X-5E>V<DTC^%^-.UX04'@&>=Q_!0"U,MA<JO.P2?Z6UM$P!6 :-8,@9BA
MS,+@@JS\X-4Y#><I'Q=WE$CGT53TN_O?9U[RB.1=$T\I^ST,RE"(W;AJ1)>!
M<G<^&^5 )1DAZGWND<J&JNX-7D!:Q,/@$42D35EL>N<>)7:J'QE-E^"A(,ZW
MI#&%TE)=N ?\Z^%'O&]KC91^"X_^KO6:L^YL9$)Q9"ZV38- FB:.]S"Y\^::
MD((^UV; S=FX&E6#5PVS#H79$09A]AF#7T3<$S(X']I^=>[DAKG!?])FB>#Q
M[]092AI$VZH.@ .JCZ\V[6]\#<QG^80J;<->54[N.K^:AQ+98E4.7@<U>M!2
M+8H0>#,H4K84^[L;_J?[4<"G)_BE48T95&F9I>:F;_5'"]<4D=)6A1UC<\)L
MBTC@-KIG#31&LKIE,Q%MR)Q0"GO74HBZ%R/D25Q3<ZSL4+\W%F(MT 7;,#;.
M%0M:$$8>#%5 >M=2TI)KIM4I08,CE@^$*JD7,=V&[80S!-(O0AH1>,(J;XA$
MT)'U>7TU();,QKJEU3=&!W1+P&D"T3/1G,GDVP_R;<-XTI@\(N0^7W,,:Y(M
M8IAN<8"\GG"41_SGJNS&Q;_"Z F!@3)%@EW"/L(VI:=.2=G"(#O/MH#N&*4+
M]\^-TC6W871AM3FSM'.!-8YAF=VZ65W)WY$__*Y1)GDW.[G%Z<HT!4B,$C&W
M(55V8=PQ/((Q=FA.QG.#)\\/JTP>ZQN<1(X/(^P>=C^;&@4&C!!#G'0)&T",
M*4 8.S_KU7GPZ?JKYI#9C:%"M^/9HZ@ZYQ0<2G?U6^1+2 .*,:%_*KYXMF&\
MK.&&MT#XTUYX9LB+L!",R8W["6HOS#>W83JTT_6[F]=WL$VT=!;L(&0C0/U8
MVDFF[%P)HTJ];AL&1/E@715!,LUD%?++ZEJ\Z<I;^?BN?E O\W\(L]@_A+G\
M[\(L\R_"C(.$N90=H#&Y;T"O4TNIIXODS'E6DM1@8%YKB\RHIO/^VA><=P,#
M5$<6ISU2%=<QB0>\0GRLTT_<DYXGG#$489V/(@AN*/^ S-<Q\!OIB>CDM9_(
MU[_\*FS>;[)_\G.%-WPR@)^F>_Q#7ZS4_N@+_K_HRY[=5?D?RXO*Y'= ?W9P
MBU"]DK&D[[C)\&[9/<QW>7.GLH.JKF8O=G3DVA9//6,V]ER5@#?Z0[2<#5(7
M+&EZ[2]U^<!2%V(8I"[E5O])768:J7'NLT_X?UH.+Z^$\.F<BUX)J AP<[C<
M<'>XK/M':[S=.>-S7'O3_8 R)N\W(#"5J8.Q E<HM%GMLEF\T.)$5CZ._$3/
M9?255S/.VB[;+[G685ZA\9F)[Q%NV..@I-\$)JL%2<P3NATH"/&1NA'6$-93
M%+.80$,9T,OB\WYF+R&L8M5ASM_XSN>O74?Z%F,4["2,CJX#;*M$P'8-U/@X
MX[R4K\_("3%_]I,W)P.#_#(_4;#>;6"X\D8V6:2'G1GNSH..?CF!BVX^*^%(
M,QL)#B^//S>RJ6TOB'3O4$A<6C:62<0/0)2<M(R://N=3-^2!Y<ZT'[Y0G#J
M>]#EDX&Q^M&W-PONZ!"RNC :@!Y)K!,U*3^W'Q]'YR$3!<*6NEWV-JA1PX^Y
MS/O($+_G>OU(Y/'XEAYG;>')?B *B4>!>W56,F?5)LN8W.>!GA[9HTW^)[L^
M=]TH]-W$/]D<<IBRV/'I*V-!X:Y<J,'T%&60\( ('B+T:#.*D:0BHC3&?_Y1
M12U>8O%$;^\G?[DG!77T@M2CH/W&-T@2\QEWKT#K=Q/;9F@H29=K;*QM^=)\
MM*0YM[;O#6-X=%.C-^3&ZW0>N0\:A96P!R:D8$2/V0J9-4*8BF)4,A7H2(I!
M2E=\!9D@X#RY\A#Q*_%,^>=/)6"&^2,%N]57?#"L$1;P0+2"=$4:#\::0NLN
MNS6'DCB<#0^M?UV3\NPXA)@Y]>RR/2,$(R2I9D:> )30]Z"I2<U#F &(<G/Q
ME\&\4T=.94_/WH]>N7,3<B>_FE']_YQ*O<U(9\HLS@B :,C(Y7,"JV^O!ZPN
M:R;/1\O>O&#ZB.OWL_1R[^*Y0YUR,6$BC$0PE&K7 F9"']U5#2K/I?C909]J
M#/3IR^"7Q(9JO_T:%?*)&9F=-TO/SG!>7LL^KCH3A4Q89$XA2>FY=LF%V#9E
MK)=?Q YSA2$DV?E'!F=B#%YYK/-GYH]NS_37RY,)ODP-K ]QO*0;6<79$[@'
M<YPRGQ;Z%,QKWZQRO-2F?R;YB-T^S\374N3[1L%!'64[CFDM$%E>[E-TS0@.
M"""2X!V$NPB(LY"%*2H]9ZN!5VEZS3FJUT _;VUV]?+RK^+/7%\Y5Y4$O>,<
MP@'!6+JPO3FCF4!ZML?'17"X8B-P!WU_)62V;YQ]6_O ,K!T.D?=9<JT(^:Y
MU>OX2_&B;='[XOP@&"DDLIEU0=ZF"G\:O@_^B#64U1&7:'%YG5M&M/WH0I-.
M<4*C5VUD1.0@H;K^+N'*6LK$9@=!PMC/;Q;'VRLL^:2VN=VCYLE3"\<]<_%A
MF\MN#<[OQSS%W6F7(8.GBT&FKG5C:^R3BHSGQ\:]'2_ B5<'T99[MV'O!",?
ML/W2H<NF4=:8 BA0L22*SAZHDW.+PM[-'019(O\G*<T9YD=7]$<2 /SW,NIN
MD WB;+:TJW1%\!I%<V1&D^*95S0=U]_KK_I>9:W'(SE<^J8C(Q B+N,J]-!9
M^(0R604')(-Q+=)A7AWGQ6O)'O(^S\XU-5[6(CS>U95NXN=[LW)GO#BG"#A)
MTV8.M!QAW&<> T-G=:*T+@SH7R8[Q3<,J3D.2A5'CTMJ'SA^?^[JL]>_'\P=
M%]\KP,:8\)VHRR$A>2X1T9<N_M@ZG.P[-(72*!<=T:;L\[SI'F<^()QQ%L8^
MR.H6KDI<F818.@<KUYV%.06F/.M5R!>FG;JMD\#S-7!H1>"D=(&TB)!ZK^'0
M^T?O5NR15_O!PVLK5K3;F..9;=LP@18E%RNR<@;?R/VB,2<?[<VQE>/U*;)7
M?MPT__C(^N97SW)LVWY(=)((HEA2&5)4DQ;!8S&LCP0F9K[RA7;GW"RZ>+&3
M$+%7-3KHFAG/'J&8]Y<*OT5Q+B+I$AJT?6@?7;4N8JKCDSNO'1?;B6U;?!VO
MB#6'="8"D[9*@SR?)DC=[['=&PDM;-M[G.17D A]20'8%S0OH4+7"?<C-YU2
ME-M?79MTT&CKTX' ,ON-1S0EY@>F ".9X(7=C5$#9&)]F") 1'I55:HI4:5D
M_]=<T]9IE0R-=RO1V3>/R2C_%H;V+)HU,U:0^0D'V >F9#/W5C;6)G3-R#=2
M[#*##C%7MSYMV;TQ2VE4+]/K#AHH]-"/-4(\A6SR%7@K6(M((LH:[C^3=&#@
MUQ.=#KN4M(<5PX-3GPQ>7UUA-E#QS["D7]NPE(PP'2;W;^!G*W7]UO6PR6Z_
MD&.<#/_:K/+R#]LP;$E]( C#?Z^G.C)J(H\RWS7&5\#;D8FR1P"#GF1192?P
ME_+W>MW4P?:];;<;'TDKPQ^%UG'UXJ<"03TLU93R'MNFLPWSA/RM2U9E8'&+
M@"(5D;3A\-RO+"%[\=,GM;JIX_OS,-0KFO?.NH3T?M@-HQNQ"A\P\#1J-J.!
M":<CW]CZ(<7#>DX/KG8$BZY/=U=+AYM>FFM1ICWIYL#N:.&GI%8 K-)W0L&B
M_81AP]/I+FP)<?SCYRF'2Z?(<]DZET2"/7C%I6/8\%.XL?/4[V _'MJQ9G1=
M:/<V+ DKI.\QQS/M\PQ03"#:#1?E+?.I''6TV%_U7;!:^V73(YC"9,S9\WO9
M-W+^+RGT)RE4AF0% ;%^E.^MN#CJ3W]F_^MAS/D(_LAM&$[AYLA'L_KQU1XZ
MURCG_XO$T4<D$%S?TP^Z8 $'0B(5Z/N^P-Q9.T17];[!"AU^T*6YS8='@]:<
MK'E%<Y']-I&L[A$.B%A=_^F7TS[Y,L.>%).QD*G*9"Z%ACOW%ZAW_L0.?_\5
M.NS_>^@0':>9QPH=!NRKCYN/#,>4^OTFLV9RL$X&MYO1SD,L,4M3[QF B_?'
M(-E?_SY5OWG 4YGYV7('M\Q.W(K]XG>Z="QEB2FQR>3JH[RD'FPN6Q/R>0TZ
M?KD1JS.Y*E_W" O(_-?@H?:_! ]3IA*8CE::*?+ULQ^ML)#O[IO0B@;/(0'3
MP!U$2_CX6LO>Q=LY28<OW!.:/^O_U'VI<69DE^Q'Y=_R=749U/ECEU.^Y=IQ
M)28W/+G;"@L]0&B"CWTG!6.KU9:S@'[RE'>B/ISLKW,R@M!-I59V+J.N?RSO
MW%2 7N80EE1 F$  ,T0I0NTS[PT4B-H@UNW3+R=.:/R.!:Z.#B/^.9,KG&3R
MSYE<"_]U)I?T/V9R%?6R@N-+!" XA[[G?#>BJGZE>+8_94(V+?P%_2#XHO2)
M2\3I&0TY[]SRJ:G)J?N;^N/U'Z2T1>X4LZDD(+DCNY" 37\*#CA+%/&5[&GK
M3Y2LCPW0NG)Q@R=L+G[U/?WPS4?^)1;[;EYZ;7^PX:3VH/IU-IH@(,_DC6GR
M/SLS-QO:DQQ2?>D6U5#LLZ6%8JE3WET8^D5T2]86B[W-LLK(,7^5/HK];Z6/
M5M$UL).WS%^(J[[9JV+!=&(-A6_KA/P9^Q69@MZB);14LW&Q3_6KGMB.[.S_
M,@?L:+?REL)_+8',"(L9^A-47_M3 ADA5?RA-^CZ@E O85Z%^GFRSBFSB> (
M8[+Z;/]?N<W_Q^4V19'OL9P52 _<N!J9&#6^LE)AB #M40/%#UY?'%VNJ^Q<
MUPC^^M2M9SAW! RAG<(@04+9] )S#V4TMMDFHB0FH*(FQ7-BR\^5B_/VJ67[
MG='O9$PB69-K%W"B="P)/=9#3DN@Z]UX,08J=LWL:XSM$G*L-I/YT+7#H+C\
MXUMWS)3%Z\<:3B_:)H[2&<QVV:.4[]'(J_AXW;0.J91SQ)Z[LT[B-=C7 1I6
M>I\2Y28($8@@TY-9'IX[!<P+X*M)L2;",)O!)"58P8 )3#BX, FFI&ECQ"&C
M5!BUFT_XK[FJ._[OHO__7B2D:?-[P(C'!+H4^G$^P00QT@WW,(=R)B+Z._%Q
M1/Z6?9<6E"@7/\P&\HTO#CK(ISN[Z0@V&'5=2'_3RVZ@S$/.H0OU4+'@P;D\
MA'"8#BFP;8T+S+$\/.)8ETSJTVW?^MBH&>">JV0[=%WOX(2I;:*^D$N7"4P$
MA?ZL@G$H(/K<+DYY7ER\:&WA=\LK='<?Q[#Z0?O44ZZV P_2+\1P*<@>^B;,
M]G,;1M<-I3ILPY[Y,'"0M9[Q0=#37/H &KD_H65/F 8*(,9IRB Z#&4&W=:O
M!K\]\%Y/65EI_>R[IRFV@M<MVJ/4K?QMC&3]*$U431!).^.G?3NG,RT.R1>Y
MUU?RZH&)P:7.%O&J+\]K$RO=I0.#A*I>N)W];-3;9PV:T79B>$"V.7.,!0D9
MLPWC;A::50Z;$:^U8F^7C,P+ESS6\;*/]S3YXC6C8_(5M_N$8?9/F .(*E3[
M-FR"V"'X8QLFU(( S7IR(UKF F7KB[O"1N(JL^.F+4_UL,^?*$FM_?' FK-;
M&P$$*BX[/U\D^J=1L4"XU1OM<<^F;.FTK2M#PCUU4_9#"':(">,3L-7(!"=S
M,(2$Y@H3L\2(U7T.3M0$O\DW)6:%ZC1=&?6'=MC&!.8%EK7KHE+I!B%%?KDN
MN/(%G=YO4^-HI_U=;Z$7"YF[9IM0N:O%'DR&T%>2D<H\Z'O.>1%73>QX<^!!
M=N!RTX%!ZTQF7]DI0G%$D D,4PV$,[DR:?OIG*.D+_HZ  _YHVY6F4KZ)?0"
M8>*Z4^/CLJ>-ZE==;_&^D1]I*;;E>GK!5:F5O595&.:NM>[5&0CN,UM.H*![
MAL \)Y"#=+ V^45*Y[KCI(4'[[I0=F@\I_G#2H4,ZZ\99ZTBO$Q@M];N;,.N
MX.-:.$"$3H>!/+D_1B529OK$YTMAO@9[B+1#"U)2G74T_08=5]'#W.Z]O:\X
MF3(&-)5MV$ -';8-Z[A5A%TWB&"#[H1<L:>863+N;</<4(FRAX>N+FM&*)-Q
ML7C\KR5E[ST\X1XUU3=CN)Y9B]@K)986L+6RB]#5IJ9Z;P4I#)FO?U 6"[W1
M\"A-(7,JESF_#0O8AHV+63&:"5<($ACY$:T5KPY'^Y0*<DW3L"9>;>5:=X[@
MF??Y;E67.R.=KB"R)L6/:?T.@ES-TW3N;5AA \6/^7MH&P9VP2)2(+O\C0YQ
MQ?A;$+70P@@-?4OH;:'(9BHF!5Q\)>E>BMH_?"8R>]V(8")"W;A,UP"Q)9@#
M8"#$,7?_H#RLP?$NU$W89B!(,5S92CW2UTJ5KT<=;<8"2QW;,%%]^7#H.A%O
M7>3=&AD+_::W.K95J>N?%FX\J3*1JSKR[H?Q EHQ+);)M\JXIV]5H?WT!@T9
M=NCX^(>L&K\\\^L1<DFV]^"N;T2HML)L<\AJ'%VHB81:3@NNAQ1&D(X$ @K*
MJFDGSPZXIC)R!EZ=?O0P7,S ;[RT,.K8-BP56_T]&NM#2-B4%0'ODA'\X&1'
MZ.&JWA(_.\$9I]_)FY>48T1&%7F/=.A+_NY@-8 W2AN;;)=<HZ;@ES<!IE\*
MC>HR^2%BUPW<AD933YK_&RH>_Z, ?N@S4Y<N!$J47<)H##4[ !_:0O/AM7>_
M LVZ*=FY$R;-+Z_<8SQ0OQ7T>G_T;N&ON736B<M2 JG)10S<((T1O) QD0<K
M*8H)\V\L^Z66MB[,^BD/"27$GHWQ>/\^QL3A2O#^4(73XK,F>-:!E6;<+J86
MAM5VIY)^E7*S!"B9=7X;7SQKH1(<_JA9*VP?H;+F0E5MKM@ZM?FZ24!J>5&,
M9 -RS(_)Q4.SCIQN4:^O'F!*+K7P #2! (S%+.W@KQ3M&7U2E82 Q;5P_VCI
M[Z\&,F!'"*1[".",OQ]S=S$MP-N0/>YP1;-,<=87.OI%-Y>HY-4 G<)Z8\W.
MQ&>+)X]?%3'MH0:2^CE]L/ST?<5AV).OZP9_.?-_4D6BJNJMTB><.F..S9HL
MOTQZR>G*@6&%Y(N@][>G(Z&_*&9?-I,;P/B]\&O,R0F9#13LX[(D"+@<NO^V
M<3E.1[U+0$$N\X.>7OW0,,P&,A>V_NYFU131^R$EBZ)UFR-BG]^^[:OM/'$Q
M0/Z:[?V!:-YR[IV",?R'^H39*(PUNH \59M 25ZJBNS'PD>VS Z[I\Y<7%X_
M&U9K+\"V+-^*+V@VH2ECU"@);4OHA-N$CC2VQ1G8:\'D0#Z7'Z+UD@:$[!NR
M'^SO=3:AY'G:OMI'F,#"9/#T/<^HSI4-J=Y83V+4M3X>3@LA,C6C_!Z_\4ZG
MKP+AHZ\QIJ /F7#/A7M87V-V#?XC_Q P4QZCMZ)\L3)IJYMR<A>/@GJ9?-3[
MHEV<69RU 39&"&@I.DJP'K@M;=PXJY:%;_[^-NS=QNJ$;(([.46TWVKHZDHP
M0P\5K5KA[U]X\7+=7>%#IHD%AUZ6PI1@,)B(;Q)L'9V,?6W62DAC:N9UYNN#
MJD!>]XS<FY1].1=&Z?M*%NVK"OE**S0_5V?9M.XD\6<]!4[^L3D:?CJ-:1U8
MR.:T('PE'\A-K"YUN$A4#7HV)FJ3I=-V>G]\&J5G(2^OM7#!FLV%AV8#D40U
MI!=^$G7)WVDVH1VQ$VQRS%"(V_!+9N,OHA2T[VM,+.JZ<(T-P_]E[8(U9SKS
M _*U6AMV+/O](B(.R4N7)]TD6.?8Z_K'5$P/WKM\Y4FU<FFWD>=>Z?RB$<-J
M2#KJ&(\P9F73OI()R]^! UO,+:\W#0UO /XLE=$]3:*AH=[<GIX*&18*&7[3
MI07\*-)H*VH'\Y/+'BR<;@"@[] Y"WJO;:8\!T/-ZP=7)&_NKCB8M//4X1-*
MJO?2G^5SA#R *(8P9'0%:5;8MB.L!M.3\HZZ)9W]L4P.BF=5J[)OCJZ;6>F[
M E?E2SUUGM;'=E^*GFB>:T4#1O@Q(KFE3&;^"<V CGR3J_&&[]R,LYT*K2=X
M?1_=) (2#P]0K\U1IX/ [_B#B1C4? LWKW3.INI&O'2<=,(7FD8=2G-5IN@P
MX3? WXPXVG&Z".C.2T3>;3YY:];RX?#ZGNXI8]DU3[_O\I5'<:<9W?AH+*F<
M" 2N16%9]0N2^CIS:I(8(PHQ_BO0G:CI9,DG[LC(D\54:_;TW<T+OY54PBE^
M-^S3=39Z/[1-(I%LV(XST#_L#=E!DP*:5?F,:NWPFISR?=6*NSI#+ZA'G=X8
M=A-J7]*G(57T@"ZL)G!C20]QM0:XKC0^<++'\-"HYK3A8OO@I(,HSBMJ2BGE
MF^R%TY/M@3:?CLP3S$O9?S= :#;18HAMMZ(Y8!"@'^_D4R A_G#(P@"*!\+O
M;S#BRL[7YS0^6ZRAM;!M+Q P CD4>I!'LU"I)7P"LIX+NG^B :4'.<<ONS-7
MNJ94#(;M5P+IP@E,OG30:QO&<911H;66G*\&YE"DS+Z$-(5;F@S5#'CZJSRK
MKS>W=?^YSZM#Q.NXXOS]RFZ.VYST/99,+A&@G\G-0Y'O:CD$8).:G6<KG+IR
MKSI>2*M(=E4A.6!&!'_;E! ORT)8[A9EN/JR<3[.?39"=,UJN'PEA,^0*5K?
M4-MPUS-^5EO*049<Q,/5?&\,EQ:D9;_5;*&E$HSLR>U/E#J71PT#?>MY:>^-
MG_\6_;T->Z5TZB)U,FE+C?2]=8V#^8G)40_T1&$4R?T<X/4O$^8U??"S2>T#
M,BT_?P<=>C7?;>FNL'&@,5>)/0&DT33I!HR7^OPSDF F"<\;MF2L-E^175]B
M$BY\SC5:X7+;^E=8NLPUEG7JZ8!$HG_9BYSB4\L3.+[9.GBV9W_ R.PZHOW@
M%>\>4BU52Y@M%A@E!\9'\H49CG;," "K"63G79W^=4/!R5SE_JH]-$'3E\G@
M[IDE$V&V?\.$)$+^)Q/*L-B?#C$AE-:JH1 CHT44%"-AB+R_TA(,N2O!T! >
MXR!RZ2\G[')9T=7 /9,/UK].1UU\LS^QMQ=_HC#*$+L-2T!%?D#^\D="2LZ4
MZI/?AMU?FM8_3IY&MC$1E8/!>5(&:A:#*W/5554UT:[U-?%:W-(VW06'Y$IW
MORR 4,[ME8V1!/,0\#QG#L]'])Z8R2M9DC1\P>/D<I'H5-Q5.W7FR$"O5,RK
M(FD15V.1=9>W$)5A,KLCY2D:OJ,(R/J[-_KPQJF>"W>ZBMNZ+)PL:E#G>MM^
M#**YCR/[$96;[?AQ9=,\%.@.++6UL-<VSI.\;Y_2#@PV.ZE<&)^>9G_@->O(
M]--M&-O52%ET6!4:(F\\HQVYE^\'X+=AY /51XTH&:]2:!_7>'<O=R\#N\)>
MX:@EE/RWP!+U"G@7#]J?'JXE"GNW2 X'UD3HH.K]DBM.4/4<9+G<4HR]0M/E
MXF 9YOA9O7.,>X8:#F%)5MH_R<C.'R'^7PW*9\1;G%+&OPH?#?@446V$L,>V
MM>, >U8Q3SES=$DQ/N!P)EFM8R/'"BA2?W9J]-M[QC/KL$G>"CTY#CM8N8TI
ME]UAY444J!G(Y%956V&C+&S#?."2"TW-8L#,<AO9.T#^=XBS-RSR<P'CQXIM
M+,3I#7+UI3MGF\N8W) .[JJD!S.J]#V*EPBBFL[G26L=X@&":ZG5[(Y+6X^-
M8@:<'!K7$E_/]3VQL;_YS>&(':$4&;4-VZ$O3SM*1P#;L"@,]]-Q,+#=1:S&
M254'57M./N9HAH7B_B</JS4J598_?K102.=O3()\0NBW>ZLNTP^_$"JJ,U*W
M66=_OT9']&>W0E+PY7A3NYWJZ>9[ 1-,#D6(R;6/)DVW&2T>KD5!.B P?89&
MI*G/.!^6FVEQ+NM^3%/3VH!\-#*BVHPNQ$,-9Z1NU'Z)E,3( H@[&Z5?LK2<
M_%45AMWMR%D!5Z;57ZRR1_E-_RB,0O)C29O(--P8NAK7AHX_TO<3S.O4R5=H
M2$'M4_'O%%RE>A*N&YSQ&B1(_DG"0(#VG$ JP[$URP&,YR.!HA.+H?<%[^__
M5X1]#@>5=>A2-!("5*[OAI#U0S=.0#^$W*"O5L@G.H0:Z'I1UX-3Z3_ZT^WF
MS(S;B[9NN;.ZWW/^.RCGL$!YM,?E( 3*NBQ0OO@7*)L]N&6C#.T'"Y2CD.:E
M+$<:^OVNG\/1!7]2T8QB_<!;LVA).A\87A$6>^Y!_ZU2R&E3K?VRG%#V$7C@
M([X-N]6K.-($CT8"J+1H7#4B02M%L17)Q42$V?5TVJ64+"ZX/YTL\QWYR.5]
M^-(+G[F]Z>=.O+\>]G6T\N_LA? _V,LRD9\I!8:2X3$UT/^!*.,!C!IY^H"&
M2&I6T<4N#X\K<<DB2>)?;,2"%'?#>A7?_MT3UF!YPDO_T1/6#WC?=%?/F%U1
M"P>D4;E ,8"]^WY89BN6@RD$*G;:49J/^N9RWM%D:%,U@Q)L<\6SVE^3HJZ9
M.6Z\5(*]XIE+6\8#'=3\^J'+8!9 ;,4*D <FS(:&.F<0-5^RNXHF%([R)!(_
MJ%:JVTM,-'SB"*VQYHR>9,U*(GA,ZB7.)U#]04[A@2/!P6!$49D\B_@!9A7A
M\ZSH1MDK[YN&B@.O:E9.?QJU'EHK]#[L'^#F\/1-2KR$C+C >^.],4=,'"%
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MHB,P7E82U" EPWFA6TP@[M!UBI7W9V<^&S-Q=_<L[QHSXSU=&E6M(5!PI=+
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M"0K!(;ZGG< >><AWR&K0!.B;NOG#P,7+)(6SZ8@(C1MZ!]8Y"M,- ASR#TS
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MD]Q;@XM'PIL1)&6>PHH@V83BDYX!XZ;LI]\]+78]-O45=_O7:0C%OBXQ^:?
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M45@6'<6%TMML%.=H9C@PGS5),B(I[]-? TNDTFBT3]X?#=D+@U5K4$=?N^Q
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M-BZ#/'C+938H ?*U!1]:N(*CA&4Q).K62-#HY5V()XS#U_5B_8RU,IY:-=R
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MP#W$LLIP8U(V+DFLVUK<_L(B#^*)9=0'3MJ>IR_/)?TX\RDI+=)>DV([@WV
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M!DNY7@H8\-#L*4B&F"TYM(8"\F@F_C[:@4)HK9E6&M0K]#^_ZO/>3];KBW>
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M:-K.=H#;<1W.E_<C0P3CPK^>@4J7+NE'PZ7@1!("4!I=?DJ7 @5& QTUTRN
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MZQL@*4CH?NS,$],V;W%TA$#T(5PFL%@$$$A@[G5G!+%>XRB9!Q3!"J"H59<
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MZ'B_-2L9[H7GL+1PL-6U&#O . J97_+D7NFJY3ZQKP_=K/6ZVU==/Z^8P)3
M4;9(!.L)!D'1RC,#0H)UK3+U==3UVO>G(";*]ZT9?58)5-R3>^Y#'5M\H $*
M*H<RQ0DM9, 4/M9/._Y:+[YHI%$#^=[?6&]H?<KT<\!<97GBB,+/;M$7\%21
M\L//5;V]%:3U\17OUY#L/<W@3#%FIWZ:'KJMW[8>:9@DOVB BKYJKA\:;;V?
M=I./5;O\&OJN8L\?+C"97C.CTKD"&DBS!;,\J0AH[T-/JE-#UA:W;6V/'UOP
MN^ASF[ [Q?=>OKPG S/,3YMY8G7 +6G2;CR2+>+'2C;>A5&I^L:TI&B KNR#
M*7OKDV)UMB;2LG]?F%6]GN998V)-VGN;F^MU]R0N&P<J:3"E/-L)@&6O>]>#
MHL<8+LHV1!IY0+^FLE*O?G#R6";FA':I9]*7D"_= XHG]$]%W<=_:'3DL)84
MKO4L'/7P=*5&U 'NAR(A.IK'R%"FZ/V':'O *OM>G2B &SEHVG3&PSO<>*<*
M_6=L7_8.!SC@6CW65Z!,Z*B.K!"<9\HODY%H/I^]2!P-D' ^1.[K8ZR.E5R:
MPX[8=\0>PY7;[F('.)A^JJ]]5.9=^^APBOB(LA=/R:9X'/L^@9)$!I Y'4FQ
MVY#*Z%3Z6\:'DWX& 8F%S0=1>\CD!#-WN@X%I^.V:7Y/U.(FL3;4[^;?Y+23
M;H0W;A!5;6?Q+6OFC2I6-MP'=0!D;_F,,<6I$ZP'U^:XTD=(UMWP*R^8OMS@
M"F?(8QA<+2L?3OF(DS-RO*YX51M[(L-RT%6\5]RR:.EC^!M*M'#U%Y,NP_H@
M1!4!L+8#=9ZV9,*(CF#"EO-\#4RL^2AZD*U<8Z##8K54?<M$39^<E @)RVIS
M>>EF>M$ES;X#T\ELXXCV-?C-;0@8D .J,6+P8.:43H(:=:II-+'*KK(XI*[!
MTF79NG]WU"3=-I%MX[Q>9@+KV88PY7>\)Q<0Q?D_.V3$35>D,%["8XQ@,\B2
M/P_M3)&?;U\;Q'LF>,59[;\TP)/&,Y'\*LJW<Y*71*C@@!2]9;52[% .8(E[
M_& T%N]N/UII@\2+3$UJ]G17ZYV<F,A02=F&>%OI:?[,4EK'1Q(H&_CX>U)P
M'BPO$^XJN6[KX$&@"QUL];U>7>,>HE*[9]0V":'>I+:T,PG4AQM$.'BHABBC
MPW^S.J>]YD%A=3D!<=1]/D5YTRCP;9(/7Q/'.K(G#%#,$S$<(U'L/[8EGYU%
MCSQ'O_D8\VZ$%-51G7<"MO2\+AD]W[V,&(DYQ[Z&HZS!(S]AC#@+DX6&=Z;'
M?B/.H':3NM<TOKBM#LRB/2*7H>.X/K6-M2XR8 \58'*T9D2 ._O[U>-UEP$:
M^F1/AW#Y1^?FE%G2D8,U3XWNI]H<"RP*&!"F>(?#-3G0!,"!1T.91Q&1]:BE
M?@K+QB>V\;Z@?_:)= %CI/H1Q E2BH%.>TE==-!/LPC!KVHC!,K0"JBTP=1T
M7DHA[S.Z7LC*H3EWREI].)B(INLFO)&S1O%"CZZ]KN@^;11U4-N;H$Z@).(^
M\<41* 0RX R3P-P JX3\L4+?ULWI=D^?EB#=:]2?BAPPFMLPOW&9],!]PN"'
M6/XVY#*]L]SB'>?O!&0?Q)Z[>'XG 7H7KO47^0"!NC,=T:!XR[VU^^G9$."N
MW4D?ENW/]?84*\T5'MT8.MZ!0W ?USI&X,==QX\]I6:T.8*&,SU_&Z%Y9ZZ'
MAJ)POL^FIM8.?RT6Z'9^^>,:5/]Z-I)&F/B((_9RYN0'0@P=K#4]/ZT!EOA1
M>KN[4&/J*C&V]R423?_J+BM;WLJN8O'@VK5Q']GP'Y'S"-#>G\.;&28PF0E<
MZS)9\/AOQ3AX!$Q,*<6"_UUF5):6> O$)W4942VEIQ[J)=POG+Y\5*WRDB?F
M;/SR+;&3!G)BIWLQ#M0<4$^6H0;@GFBSW.U Z?S68K]0S6EWJY!>IS-RY1^#
M;Y0%.WYLD3MQ<(/'F52?_A;UUF]4.N-2%PJ)E+75_G"G_$U\A?@OB'(X/-4.
M/&5)X\W;\L2UAC9>I(I(-H\K)^DF4=05@E[U_NR\HKE\/\2 +<ER8YX 'UX'
M,J@Y,9@C!1H9!:#/^>J!6Z/[)H1%CUEI+A6K_=7F3*7)? 8,N)@$ZC>T88\W
M1UOGC30^+&%:-)P4CMW=,.E_\>:#^Y\%N;Y)<1?@KDA .,K&QE^JWF[I)WW7
MPE;/EDA-]+K,;3T663W@IGK.+>XK55B.[6WM0]1$9VWMU,E6;_1ZTW5?$"30
M6(W->[X'\.2>!_JR4$43&]66M_H*8KAF'\O=EN#: 4"\3WQ'W8J84@YGLLG&
M%[*H 3=FY]AU+YP4MB%)W:^1FP0=YAJN-87\Z3(IIAWVE"R'OYX<$-RS#R.9
M7P=3&OA*GYK&M21?KX!9]U_8AA3A (0=>/0T@2E&9NP=T5D^OB ))L_8:9D"
M(0W77Q]_";^/=JYWM\!\?7:Y^[H9\1O?3 93/G7G7E8]Z\,VQ+_)D!$$B QW
M%E#AT0_"DQQMCGUFU="DOEH<=OR,J^ ]4<QM?"LU7NX(?IP *D@SQ<5&=\KR
M[OYE+#FDG@O;B[E8<Y6>\(7Z@FP5&5!\?<00S6@_<2]=3+_K!?+O658$_):-
MW5@_HP.8ZY0/:TTGB%=!A::LW[GY;1;F N;*N7=O-"2W&1I:_.CF>+'I<?%V
M^^"E<+H<+)&#6)2W(50X\\@'.-@!P11QACPICNT@ X$Q3XU\?&3;,Q%QP5!Y
MUT_Q6H14GQ!%**Y2Z2V 7S1M8\M?ZI3-NB^&#'LQXI)OEA9R_9EE.9\.TXEC
MRG8"W4-S "<H*;.?EIY':3)LV?CV2XJDQ' *[4=G*,OX!)ZZ9ZX0][4D/CA6
M;JUKG?.]/"]!CN86X>)\^@)":2-9_?5#3-&"@A\O^[:* P:$DI@)<L^Y_NC\
M3\V*\8_H']$_HG]$_\.(SG^WG#.'J$MP2+'^N%:24X8T'##'R1K!%Y;7IZ1L
MDH*W;OG#Z8QS+#7\<X[>KD54%'0M[QSCOP+G*(NR3LU#A<!D9MEC?BVE#5VQ
MPW^L<I:U)J(.%)1/AQO;<O"YGD; ;P(E9?_S.^%*-71VB1S[=T"I"VXF/FU3
M9NLN6G"15K1TD1[9QC!&36"L*0E(FYK51QJS=M>U;6K(QS01"7#@IMVR0D @
M)2F!S'_[>/555[(K2+2K46'=NMO%L"GB9D6*O("O?T=NO F'I^%!K45&-##7
M"@./%C">TM06K^@T*Z)-5XBD\Q7UG9\03]_;%%,GVR$W;>X[6CH]C.,ZMAMW
MGE"YLFQ)@8^1*<T5=&Z:Y1/M%2$081:5G[GPV[Y,BY(6+;$U\!5LLPBO. #1
MV8EYW<WQ.B(MC0)G4"3#*V#JEL[B53EV#UV'2>H8C5IWKRCL?SOU6>5%VQ='
M,UG3*R_>G8KO:(N829N!>R>!.H:,7%8)]O O/7B51OMB@E[K?DV+]-Y&6[W8
MD">*/-[3Y$!?=:*JXM?I"?U#>O,FL!<["6@(H*I%#>>+3[-JC5SISI>C:5UV
MA)"/ /NE&F^ FDW,H6GN1+W7O8H4RN=CC^^8XVZ2RT=;?;<A/K!Q-6H2$7PK
MJA'1J%;H&Y\;@@QSH=UXV/-?6@RF,ZN"0!FTBX/)X"AOI(T-P+#W&!F@OW4B
MK%=*1,.T;BAD'[Y,>T+6T- [MK/ZDL7-0U-]Y]OK KZVOBS?.K7EQQYC\W(@
MAO<V1 QC#T:]LRP$<<3JGR,G+$DZLA'0-.2NU+5>-<R[)KYC5H[>$%@Z ;@/
M94H<(%.A2UD[I0KW'V;B@!3,I;JDRZ.'+%@_JQ.0JL'"!OB<X%B)#7?71XM7
MZ1S 5HYMTX.5%S'%-BQ&=1I.J6.<Z1&+;+&)L9^VG]Q)!L?N:1X 5R5L([OU
MCADZ_TABBH<R7.ES3+FWG"F[35?IS(E+#[($^LV&W@PUFN1J5K@<ZAJKE+VG
M^*S[G9(B7X]8G<*/*^2AJ*K*>_?H1&$_"4W5LV>OO(O3A^P)AYZ#I,2IYD)[
M":#!V@R9><0.5'1.T!Z;W3J]TFZ+L 6:&KBC%8JV/+[ IR,&O(R_(G_"P9.*
M%#V&94M2(DR\,&:6SMO@2<UR=;G[WH?;X[ST>,*?4QOQ#YR'.4 JB2GF/"/-
ME.RBYA!A@LP3=.EP;7F]MLR"W^]+BY[@\>K-@UKF$DZ%L(H)NP;_JI'EB<"F
MP%>OPGR8HK)L 6HIKO4$G)(]O0]TIB&G^"[1 YK6V45ET[X#/>H)[6N3=?&=
M UURC]5K'PG<=*C;H]^:"RTKY@B^&KC.BC!6\24 YV"@QL-X\MY2-F<(7."$
M,]!972/*YV[CVCQXX[C+WB"YJ[>"?MX]UY769X'[^([YGH/DYSAPNS(3QI18
MZUS%7 0#\?/9W&"->OV9$A%3E0"5]C<Z N(7OD>GR"1#$#J7;+_$%9SDAD"'
MH+SH2$LZ*BJ8Y4X<)=TN>.-_Y_!PPFS.25MDB%#X9Z7;C]\K[N+W4MJ+[&5K
M8:<1? 0?\M-F,1!'(\?NY\V8P<O[.Y&<GE#7TSZ$&'[^+:?D&G%PP%)6D[OW
MV3'/!D%V"(:;PRHSG,%9-@M;JT0S832_1KW<\ZX';*5I-F/S??D_4L4,ZGC6
MDM2,W^HPG)FB$VP1!'UN*6_K"N@^D]&Y\F0_;QD>/+=I>Z[?]#O/9GACK>]K
M,?>LSR,G962(RU;DPY9]IWBX&0WM;*4* !5=)>)YZ65 )>LHR;VG)"O_HD7!
M5-+W,_ HG"H,0*W$:,!1=J"^Y1GZ;+F0;0+*'4QX%_TW_B[M_IM;6U<FW=<0
M@QG+\P"N@URILN1,MVLQYB9\_T.01D\0I4E[LNZ_LSFFF]X?(F1Z95H[>51P
MZ<SE&WOT\7W]H)XG6V033.9HX0QPC<[=A1-?WX;$U/_<AL1J[ZM4ET-[,U;G
M<Q,^2(7E:$^ZM=8H"SUL"/41>77M)O=Z/6'/SE&"1A)\#%Z!:$5$W^E]8F1+
M,^P7G3R4;>HRP2\>6J&S);K@R<!/GF.&_9>'AA(!.T"@?(!5A3YFNE-@4ACU
M[Q@%*DJH*]_<AR9_CCV]N.R]0'/]*;3[U>>J9(I]:.1610OE&92C%"(=C'?A
MVI)WDN:C#VRZ8/L?TH4N#S4ZW,V_]GHMR\5E\W=-Y:.8"D&F,X<6SU2\#TRP
MA4)H"7>M?MRD[TG(6W2*<#24.529.)KDN*8.,]YZOQG.>M;,3=Q29W_)$6'+
MFHZL:H0SM8I\U8^=6IT+0_K2[O.:J(2IZ5KQ_/XLN0IC2F>P^?UV2C]=:Y;V
MK2$95R&I\+AL_CCT'_5S"X=&]( OCIE]*]=.\F\4WTPVV]=SBG\K]B#,%]N?
M<\!(9^L"<R] :-?@6W#:+(INO%)(+!F;-#]4.WXH6G7"6NB0W-N2GU=<+_ ?
M(N1L0T!#%;:0 W4EZ1F)W8L3#%D,0)D,:*3:TZO+B_HJW*Y.G0WBS9&+.]==
M#E\YK*C8Z_)<KI/6B&\A [>@RQP_R[(!.)!!2X 1FP6&E#HFTYM/9\I+_= D
M&DY8&'7-I-8+9VX.SN0P]\N4<,3V0@Z4J0,ZT/"[%V"2^$;G !IL'[JH?27H
M>D HCU3&LPX?WX]F=^@=LE,^2.'NNTO$6X&YO$E,&7' [;0LXP8X3A=]<R T
MMO&B#W7H6:+I&.GO#^B-$*Y7(:33:H,XRII=O/.!W3O)A-#(-D;IE^E3]([7
M3=_ZH0$!J*"[EBRV31"X?S.&S:^Q$UY.1S'%"(R]VY HKYD$F[;-FB>WC<P?
MEDU._I(6[_>F>47MY<W<A[AC=5FN\+1 &0Q4[V**%9+9@C^W9&$Q /(9Z--A
M<*!$JHFZ?(&FG$(R+)Y)4918(.BE*MVM3ZD[.@&#UGA",)PIYO7&Z X:[6S?
MU=%58M6+:FJ'C1QF&D::5,^$>4601E3S<*:\\Y#317RU91J@D?O,"O/H"GC8
M/.?QP?_J:DF-^7UJWR-$FA#0>-W4DCD]]M##N1U6#F?N_[YUG<G'RL<HDS*2
M,(I4<DRZL=+@NH:H"+1C@_ZAQ&]W^]US8A*/SJ>\&$[CR;.PZE']\7!Q&\(G
MBVN59NOB6A%5Y"A[C!Y=CY@@1)S>%7DQK!9C77R5U!,8$CQ".2D4YCJ<=FE2
MN/R24#57+R20 'C;M<!!YQS %B6)IM'D,W)$C3SO?/N<M)Y^S[X+!1L5SR+T
M+R+P:1088(,8FYUC0#BK@<-H@&:XP,)I_VF1@?-NKS;##$EV8=J?/#PJS_]*
M_/ZR,-7OYB4+ 7LT_D&3EM"IYCY%9$+,%S&QO=7ZDY;Z_1Y!)K#/*LO-<.HL
M# @Z7D>ELE\7@JFTLHQ(,NSDPXA.W^"_'M#?]W4'K+LNIDX3BK<A$[@6/80D
M_$;_TVGI\K7F"9H=SZ*!(^$Y].6LG2<'I,FO$O>M())S "L[4-=]!O=?(6X=
M8*,+]73Z!.A(4Q,173]M3OU6);N5U9-@NC#MZV2:.FZ:=>8UV7!5QAG"8+7G
M0G_ZL(69K#=&A@"<+5@2]@8=MSEJ"Q<S4@RE+A]U_>$R8D,/0@9)&+YX]%)L
MVO'B\*LWX=:["(4($HY1"$@O^0$(%_ 17:4],S2*J?&F_2HRJV1797^$TSZ'
M%1LMRN,$+F\C+D0L#'!"@=IA70<,6/DZ_4]P%5>KJ!V#&%N<;GDH-<%M:7YP
M7CK%>O;$IS3[SF\9WD<3/37OY-9V3DLS.+\I\O(VQ ]/0M&N)A1CAQ'BR@-&
M0GD284_],';*A/>]@JQ?![U](J;.10A'37B?$24<A&!WTI-<@J-R1'&M',1\
MFR".L6VL;*BI&?%).@],)_;.&K\LLCCG[BY\Q^.W#^:.5Z:I_B'")_RX&24?
M7N&SU 3,49?K<V-:V#*#E7L=WLHB?:GJV3^>*V7_F"4\1XQ94CA*'T[)@P%W
M4(^#<=R^U9L^1!?,71UUW4Y)95D<E(/^FB+TU%-L2.,=LEIBKC\_'\XDX-_]
M=RN,'8JC;."3<"2$-)87HQ$=0!@C6>31GG8_VMJ&^+]4SU7"53 ,XW'-R'5#
MM@@%%-B&"*]PQ.XV*%M@#4V]_\$WIGWCF,5^L^+>PTM>3>U:9PEG)0$\4VH;
MPA9I9KV!4XH)@/U4$"TF&N,')-D MS)OY^3/2Y%&BHJ[BMW/\ C-KB2J'5&<
MI?Z6,7GVTS4HP@I62=C#%+H.$*CL*.KKHW 5&^#W:U2A:U=2G;!FJ2]\M[TJ
M-WV"#?4 .=:.'[=D#M10)[7N.QOKTV]EEKZ#GISP8WPMS7]POR9]>?W,U5Z.
MMDA@\G!TTFG.N,.^K<\KK'YH/HQ.<J"+I\-.)2BY\[,8:9\F^=[.-07"@4 -
MYM[W,S5,23(C$MA3!VQT((2U$0)H+6+_#76,=0EB8DIV_L.5N60GH5/?.F^X
M7Q.X-FXQ Q'?U-D28/>^99QFQ6.EF!HGW?H#*0AA%]^-5%+ZB<DI\UU/GSC<
M<:B:79.[R;UVE^\<9#V.:<)AIZ\<*YR= Y0;[P8M&?$ *Y'EWG)2):;QPO>B
M7N67@4=T!S7_1,]_"6-5?$<RV+7;$)(0!17#X<&<1]/J8!CM/:(:'=J9:=N9
M5'S6>"--VTOH"%O:X[?30FENHCD$)X&H0BSWT_"D"2I?*UP G6)]7 '4H#H#
M3?$KRK-UL5.]2K<L ])G25SLWD^9["\X2C:,"T[-@%_?"?"%NL$JIM V;?MO
MYZ!K.V^GCQM_:W]0V6EA/$O@,^;#M;Y$',"(;UFBS1SI>HG-0@O8W0-&UCZA
M[[I0)?X(5,/@VSK+EY>4RT7_EO%?V_M%.K 5@QEF*7[C6]LY8&W"8-C?P2I
MBXK1"F!W#:"8%\/VPG'+#H>K&D39_>/'.=.#&9V?8\K.4W!0=A\<L$0]>G",
M5)VT^W=9[C:DS3JD?O7$TF;\)\3QWP]*@SI?+.W=,TSG6'I9MD@+ZRV']7(
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MS"2=DLRWZW\K"@!@U-<*_9FTC?_E@> !@!)&!8#NBX]&/_N"':  5<Q]W00
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MV1C%&6>.H=QO3H/)*6@)KJH+^@6PY3&$ALAKCH\C4TK,)[ITVSR!^]1=2\7
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MFSM_%HL:O_V]V,0(S_MBBDM/;0XQGZYO9W@4*S/2H]T-851W\X41)4B[ R*
M9#!A4IS]C#(R%Y&;^?\WD],7@CQ$+*/D@FXI,;5DP+;D<MPM+OU.II'#1E0"
MV[ZJ$FS$=,)O:C>SC>,\<Z-MO<<.+^/H?X#.XJY"?,2T]1TA%Z^)7;4@&4+-
M\]>Y!UM5V#+T7/XKS$)X#/6^&M0;2'%1T<P^^XOZ?4;.N_4M/_/20T,M=D/\
M,G/_ +G4_.D6B#-\JK5ZKCPNVEMWU2NHJ*RH6#1N_5!>B]\\-_75)#1K=IC%
M>U*I9UV]6":]WJK9C;-^I\CYLQ3XDXDKF&>H( >Z3OQ B>2+VM^R#_9/V2]!
M0_@(W#XUHM\MHQ]P,T-GC93'$])6M-FT/Y5G(O]FTCH5U= [MEV'7(U<[*G"
MBH<?5"88S%':0Y&-+ >;WT]'HJ.*4GR2-^8'XO6-CK%EF9IJ%)D)NN:;Y1 S
MC3\-5:V'_L_Q%+2O$F_(&92*4X-.@".N_;7Q+#R^1X((-,,,7@79KI_),Q*.
M0<BL?1R7)@1?0C8Z0"07>#Q$MZ#D1UAB3RQP?ACM- VC/1[2&)=RY?I+FQ""
M1%+_ @@&DF*"2R127?2_EPUSI]X 7ZG4%Y+;*7)VIZ"A$1FA ="N@PU.#&)
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MFC@L9SKOJ_.6,2RV"ULHY#M+)Z>Q?Y+:PXNB\2Y9P.).%UM+@E1?6L,P+?#
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MU# \$VPHLD*D]HK74K?S)9Z).D5\?<[ET/20J4?5MQ)39A>^^<Y:Y&%JR,#
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M\:#9?4?:ENO&79 ?A+A>LUZQJ,TCGY=\76\>^#JKX>(5_&.GJ*C;C%^+X6"
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MDH"[X'ERC76?AAY=$;<Z=F2IA7D<+9?"/W B 6/N$A+$?FQAM1[8$(]%+:*
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MIV-+_.5M=P/X0N0KQ4UL;J)N9.F2D*!L;M.O;B8V#[VB0$F/[_]QS<7W;X'
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MY9& L$'QCI3 _SLY_J9%9W/A%4FNBV7;(_ %HC:K&]W1<@VP,0"^9_<PXGB
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M ,Y=9>=S*DVQ4847:P"-Q(U/8)[#R9]T$"LSGBDM>AH^MPT8+5W,Q7SZ9!-
M+"PK('S9V=!BWY!0(,=F6AV%W!GM/S0'J4S_Y=K#=#J/YMH])[C,$3!\$>3/
MS6>-H'/UE/7!T\ATLMA6N;R$RI56!&NN5[J&]5E+18X;ZYD!4KOHIS*K$)++
MKT3,YGTF)JDCX#4T1%_NTQ=EM+Y5 ]Q(Y]KGJYLK3AU&B=GA;S/*GV/73/^R
MI@R09RF56!\[@ !AX\.KB?GRD0NJCAXS2Y/O"$H$DYDN>G$:#=/5Y9%X9B@<
M \'E0M=%T*Q=L'?$,,:9D$*GGK%^=T*%+:R#4Z.BI(-"&=(<6=AU/Z%*04/
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M^/6JUG^V>\@6R,;ES>";VN)NRV-).J*>]JA=,:CRV=_@H&X0'ZO2WQT<7]+
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MV#2%+,Q(N]9]>#J??QUU)MOEM#ZB#K;*7-^[R'^?CC[)(!V\F<)3'1SDG?V
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MB3$VFVP>+?LA+,X*86R<6%%5N7=B:&;<\<-HRKDIB_-PKYFJ.S:I+_+$P/G
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M]^RY7AM@J>%8XR +/G)E83T\G#W[E#6T%TH)-2KEH[#O>@D>JTLA<VS2<,<
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ML^*[:QMY!8=ZD01^(X:8MU4[>*!M=O'.2)'EB86/;M<"?,L)PQ7]_MG'NK:
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MZOCX@:5-@W;CA08V#%)B"// .FK$,M6R$):^'G3TK?;4Q)&:'N6=T;TEB^:
M+#?ZA,V*;G#7XT^*FMKCM',R"S=MV ]0T\FL04*9&:K@C*-R8+U%;N9+LMO"
M=P4V#QWO=K!HN>[>N<2S>^>JB.P8!/*\A/Q#$A\*3!OTX:<\T:&Q*(QH^NLZ
MI&\2!94(LNBC&-X\4:']-B&2?,=(MP,=AG=L1 4S\C;$L^ -NT]@<^M,$MB=
MC[>K*PJ<110C-2>P+&I(/XEM<@6U1=?12O?+YXXZVBZ*$EU7SR^@=!".E2'R
M-+0IRZIA"L0RA-(CM?JM!>E9\TSX#'H=NM262BS$DMPX#C/\\KD"UK!$G"(
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M'IEWQV](1WJ' Q\>*V0O,N[AR1G (YO R-*G29@=;&=#SU 445_C\PW1Q>J
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M3X:01+1=$.;E^C]=,RVC28^[H\0Y!:;:?SGI 2(IGA=)CT?QR[RH3+#P8$R
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M^UX"K8B6-F'\$RA%9_^O8KY@74J$_N<_@-/=.#\2'%&2.N4DQ#\ (%( !<Q
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M1Q+^O?[N!MO6U2 DK\75$:?OPM3$-H62JEAIY VQWOI4TS#9+;(6V?_#S=
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MZI]>7(91>B$8O"#+B*JM "NQ%DSVP4CPG,.MO1VT(&6&I\1$D#A,132\!Y3
MD$ILH72$1@$T!F,MYG8D.@$.A7.>1_R?>$[/6(46]0DF<D.P%*Z2SD;7)9Z+
M1$ZQH5$5/GPV*A.&2CN;4#%3T2E<$'=-U)>(GL8H%*'T^0GS)Q=N]-4Z'A$=
M1AZOC')X[WQP!JQ*MRU[J'#$S\^*F-)K-?+:2^O:%9>GX0$+#?+R;):%C2(M
M)DG3X.3*SJKF?P"8ED[B#VEDE](EQB^07F(%5C-#+&"+^1^ ^_^,$D'^WU&B
MFH(E,_PH>OEBV6S)2-6771Y\>*_&</Q*?^[& OY!N^86U':1R0'#8E6M=QLG
MKP7</D-:GJ:P#@(D%E&76Q:D7[0K1Y8%=O%']/-0J?Z=U9O WNW#BHLG;_^6
M&C18S4'UU+(*1SIS+VNN4= W4<^.",V8+4^KW>@ \/(!@!]!6E1/R[R))E1Q
MK%"3C>,MQ=HA,43I:@O_9Q?C=)#%S2E'H.,CZMEV[1"#H#Y:[Q*"0M_+J$SJ
M+M ]A?#,&ZU8]?%<BQWJBS?NEU3+<5_(7N"+Q%)W9,.5A^[%<,59M)Z%:%>R
M[R!AQ#W(@F)D@/<?@ 9,!3ANYKED%GQ3V #C,GA&GKDHP<>&6 D%Q:UNTP$H
MZDXQ]>%S!=("':Y:6;[#ZG^A5+FHS!$[0EVOZ-=NMJ ZXOT(JA:G8L+A2]0O
M;P6R,1TXLMA_ELF&2#]_[L^6\?T#*">H[G50'CMW']^%] I"RTB#+/S30OL$
MK@6-9J)5 $':E#%V0G";#8Q&XZAW1SC("*][UV*YFVK"'E$#GZRE8?H#J$W?
MG8<.])H?/3E?=Y)P*222"*,J+C0B&.J^I+]?E:EAP]6S1W#;O'?%;.HQ2!7Y
MCUYAFU9?(J_YDX'7=L"9BJDBQ*T6Y%2S*#_<(33Z1?^@."'\GH)K^.'M+%*#
M5Z.N_IOU?$M:-^MY=7:+8?:4^NNC4$IA9;;YW=#/W=@:'OD0*H"XQEV\Z@8B
M2EEDQ0VQ17:]NZ[HY-,<ALH%H0XP^50>N8O:/K<GV@L'[TAX0;0[X@KOF'/]
M X7D2D6="B.ODDTHT%?S/R6(LYFF+V+%'S'B)@NJ67D66E_G!"IF.^_E@&3^
M 3)=EAD]_#;_ 3BCTC8D]M*T &QU0=5JKB#<_,*^E[BP-/%+"ZLY66?])+,;
MNANC]B3GTN=]+*[][L_/^L*M_.>922+?I9 T_;'AJ<]R$.8"IT'RW$LN/\^*
M76?"*S(^((F0/#EU>F;"Z85HW//::A0'>G>'[_FT'3:P(2!P)R\>Q_B)9#5L
MO5L@KC>P']V&4?>H+V[*<2 R?>R^7UW9T18!AGRRF:@-,6S'OSLGF$Y]WSU=
MF9^MP'Z0"X+\>CVC13:+2?D'>-$E%8@RO;_*S]BL0@XI@J^1O-9M_N)Y[.CC
M.>1_Q=L/5XH'H(#]Y?D/D*7T#["#R"=ME8R%;Q"%&O?N=*82144WN.[(XV?S
MH-> BSD;+ZWVE?E%U26L_%/%SF=J;]-[ZFBP5U@2HTYS<B5CX^0? +6/8&!X
M-HS/USBJ+8/)E[$XKVT?(\-Y:ZE\N'(?S+5OT5_F+HZF#,RS:5V]=#YW<_6Q
MV*QAFG7IKH7+]J24J+JHW<C6LHI9@-F^,T00,MM?\2]>"S*I5G'XN9GT,"B_
MH*:Y8N.5^L)I)&D2E*%9]?P/P#]5[-RQN719CFAMOO4WEX/,Z.SKZ8Y7"I/R
M-2,W#LY,3GR<TSS[#9]7 J) <PO\-R1[C;O6U[' AZ1WQ;,"#JFGOQ:/!^M]
MH6SMB4L V""Z*/LR%X5@,J2F?_/7[(3DR*6/ZQ]@LS+!JX5,_:B="XF>%.-8
MB?1!_L'&!A-MGEIL/%M#5DRPP'-LZ@H.(/:3PK&K#4\#L97F"UJ8JJ[6%1 )
MK\'3X6V-XG?3=JBN"'?;X.ZBY;-%/.#;[0=CH8&&(XC*?_/$/Z\,V182D4=,
M<&N<\AEX3@P,CU+%\@U:?K'P\85H/7._X*TD!L)6JR3^@9A_M?2QQE&-,W(@
M+E>+-O+ K/'V^7&KWO\XL&%5-"SWY(4'&1DB0M: YBWV.&L+.$-2(Z@N.H)<
MH2$<P-,GV=*(XM8>#SFP@3RHY"8UR.D9B+'G;C-<ZX+V1,O_J7%A"-69=B$=
MHH_N;_N7Y_L#EFYU:)D:CC(_CZ]FL OQ_N=6&22%<Z= Y!>$^[ADHBFFA!WT
MO".",>D["Q,A+F29,_4Q"W>Z&!VF^F'VI6.7H1QT1VE.MY,SL[01)E1CR.DQ
MO_=^HYV3ZM1L7FQ3*4J&6PG9 U3EU="\ #JR5.A$U,*\NTHN] 23-'L-^J+W
M_DQJ]JZ.8LE%AR[)O.\<8O&/ALW5RT&EE!LQ/CD_0A129Q\J5S8_:SGM+_KJ
MEW/87%+Z,]'!,[UD2,/?[D^$G$TD*R32H6TX#&NK]>-G+JE9S(5D?Q*,B&7[
MFY.8(S_L[GL'YOH$?=SU!5^(/->>"J0!X#N2MY$_<] ]T F"_'0]FT[L+%,_
M0L+/7 *_:+&/]XJ'OE,:(Y7:L;9J^.'705Y7$N+"U;Q?$81V4%Z5ISY_1[;G
M$PAYEMF8<0T-W'$;%7E1N$3=$&##D64>,$C(U\@/*&9FDF;Z?_W;9(? *R:U
ML;W*^/TJA5.]9;KEGNE!H\%A1KW)8L7EIRO<2FC\<F49'B@>R:]XBU[M7PT-
M?7=WP'JJ2YZ?G9HZ-8>CXSW>>VS[K%K6K1>JYVK;$M3X0=QZRY"H?RY=V7D0
MD/+#&F2,_O)751/6D&!WY6GPXG)H0C_>&"1<1_+N9W/WW'OT#]!'/<']XD9Y
M3^(<24OUG]Q1L=R8/[)_)[PMAW#^_K!91WR3NAG0,M)?J1\:>\=GT<_2S,)/
M8[BL;A"<O2]$/L%]/]%B\9ISMO\_!AZW=K%%8Z"5C-(BI(;-X5YS6X#'#81G
M6Q(RLZB?,:=J[N9Y]L]O*)@"/RK4*W1NL#O\SMBHR0(5LO8OZ:?_ 83[R/\G
M%ONWA/81WQMGJV#?CA=AA.$$PNW\K)?-8,KC!Z1R!9)1?T\1AA]6E=IZN6B'
M*Z]0.F^B*XTZ%^6B6*KAW]: %V1_4V$6_.Y^;J&>ED<\*'[E9O\EO[XG]L\Y
MJ- D.]+WD%>P O%)GK7<>X#M\WQ5?Z G"'L^^* 9U91HR/S74+0^FV6/%)Z9
M!$5<(@F,+8W3F/CA/LXE[/.RUY/YW@+V1L_@[[S^OQCC"C6CEU7TH$&V0<$X
ME;_06;2F ;*6.HFB$A<@F2Q,>#$1).?GR1W&\6I12%0X)J<Z(S QKY>B7Y;_
M^I=/@N!,6<UX7[^P6.DZYQ^J7?33SM:''\8YA6J7<TPC]@^*?>1S[O9'?_LY
MQ:J)S NN@JG.&BDD.'"#2#-28$)1I,@&J%*O*9>AP15HZ.O0Q\'Y4#H87HA,
M8D^L4A=BF+.KG@&2R^*.%E8C18R9D1O,/!! IPWY5!;,@%_PV<VT'HW(,BY]
MF&B5'%Y<!G5PC;JC7P3$8?U_U/\/?4']+WVU!87QXQD%V4":]VSF#?C!V#59
M\\7]T<LCOA<&$.YRK_5B&/"@71'E6;Z7&-1DL,HH%2'929X*WGB*__5;1 X&
M$A^T"@/Y;+:X.07]O&TS(;5-RC&06T=/!E]89S/%(45M[*E.Z:E"C>^EW"K.
ML*_9/ HKT#&!^\54\BLVO'%_"53-O?F0X2C^6MS\T9(V-F;PY)&9B$B&)K(4
MA'+O[9D?\YQXE$SMD+,D.WILCDBS*TW9$LY)?/5./M[L'^MY=]$W29KY@?0L
MC*&Q:[Z8QX)'^.X2T5'GX?EL76'G@JO/_M#_0UP3Q'+:>6JJQ)Y'Y6NR%Q*V
M.;XV1\U1LC:4M\O%,6J*/M6JS[@ "K1%CQ <;68*A^6]:VQS_*^E)/]"R8FX
M7'A0A/25[$Y)63K:72@7BJ,K[?K=I&UT^'DJ48)$[.WVN+]G0 =,-K_;:"6_
M%6"<N;5^.[\6R4,$6=BQQ0!VS:>T%A=Y%&U*5M[M;YAL0\J*C@(:+ MG0>[>
M1O9><9"3+K!Z;D?GM7,=[[@(Y)[S)*K;.XW>V.F("8%[ZA8N$46C5C.Z_&TG
MJR]';;D@17?F_MUEQRV&>:$/.*ZN[]FP04M?17",X.T*H_LOC^^E)3IIH$,E
MO,R$8;A+Q3F>@CB&\C!*Y7=IMV;?>2IMXW BVJHNDL83+M]Y/A4BJ7+;1R@#
MP36E>7*M 3R]R!*Q/KBR[@<X^.ZA1^G+=T*2/P6.7_OXSE3"O?/EO-&2%:H?
MHRB_!?,PLW29>V<P4Z35\*4M"AI-!5[/O_"];I W WZ64S[OEWH("]=7;H9/
M]_DH+YC??]LX[A3^%3[1=/II.SYH7S=RB#=_.']V!PXIX H@O@JC'0U:8%\/
MZJCQ]'PRSS:$"YI:5\Y[O[E0JP8MO]7\<3XO%\J%6S3>E9-,\M9W^+./<:A'
MF25-9#V_^G:Z4J,[8U2,?D/2G,?M8A'P>?7B9)GSRG%YU _$>A"N*]_+AC:1
M08BHGB,/$2WG ,P+8[I<Z6=]\>A7&Q4'EJ\J$7Z(E[Z&;44$8GJ%E27L&E<W
MD)/!41:\H&K+<4& 66# )50[G'HH]E^CY-SW!?-NPENM>+YSJ[60#;1:WS)+
M=4E"G!Z\J@6X+>_N&KT=-Y_L_G88^&?X,KX\7U%WU/9^XMG29=#/1LGZ"/<B
MM1:E&[O^=1"5OL:*42W&RT?0RGX\/Q#CP EY+IO+=6EH%\SK3_-I0,TCI"JM
MFGR[]A6V.E"#(EV4V,WWZLN]V4I % <+G%EZ,&MGS/E.+8F;T(ID8#6M!J:\
MOV=7[!BBS\]Q^ZE0CG++\C[^=;M5P4<6T+L?MG@[46E$P$Q1N*&__2%%$D"-
M>.S\)JC@1^1#CU;JBQ6VMFG_[O9APJ.W^6-_9>K,9BE6+LNU'/DQP <SS)^5
M0F:9::PM1U%(%B1JM1!9* 3-CT%>@':,?<L[7_&Q'OGRH$:.8AL&KBM.L=Q-
MJUY%U_"+RR:-["3@R_^+@C^%/'=>BBIKR8Q']R-"VBU\<M/7AO=X.D5/9% F
M4QH9BAUB7,;C^Y3IWE[)4R3I,_'6#B87]DG]KC'4LGA2^^OG/O+EQ</KRVY_
MENT8)55B8=2*@F'<SNYPQ*X<#J68.^VWL->ML_2]I)$YSD2/G@^7QG:&!_UK
MQS?'J=/0:QP![-4$/>&TVR$33-4:A#\<"?H_?Y5#V_[FO560#1'LMQSV*_6,
M^7R3K_3;^GGX>CEHCK-K\.=X>.ZEGG-[C6#2C=ZF*"]@%SPZ_B/@4J[2[0VY
M,^!.#!;C4X@]ZK3['B$H SI&R08"R8>^$N.[0D"<[!_,I)/-W[A(#K#$6=[V
M0U<#'_C]<P_)3$@JZ!O/=B_#J;]'DLZYW^X61I&M2 QFY!QX4(A_M/K6W0SL
MJ"=)XR/CWE;M+'R45#)/$R.(RM:.M^[?YRHE_DGY,Z*"#-LO0Z_T%V,[0F#P
MYUR!18V QL."UGV7F^VI4 ][EE6!]$)(1M%AJN-!P#^ W:/A=E!/.?E(@#7F
M<=^G3/^;F^/'=QZCN:W-I=MR<\2YP;\^/X4W>E:]39QIQ^^!9NM/AP^[@:3&
M>G^=(E[!G;/;^N^J94Q\R6COE!OF(1I+'^6=Q#/D%C1&9D$' =(_KXWLN\'<
MA-23;@+Z >V[$5B<8]'P%^Z>MJ(%ZC1&#8<T#WHX=NIXSJ(#^$ :/S(^ACF]
MQ;=F:]6SS1*>_=/]^_]-FN0_WXX/NP&0U#-WA?)"PM;/MT,T,I-KC_F&]I"*
MV]-YQF;(=&K6J#+"5*E[E$\U5:7/5JTFC@TXW\5(%"M)%O?]79OW/_]ONF A
M]:2#S>.^MX#3,"HTY'+=?P#;&)1DIS\[^49V[/]/+^\9U=3WM8ONA 02:@B]
MAQ @]"*]:(#0:T*OAMX1$5 0-?2.$*J ]-Y!NJA4142D2Q<0$% 1"_9R]%?^
M[RGO&?=^N./N#VO,/<<SGUE6V67LM>T]0IF/%5%'ZZ([S=<$O)Z,'N?>J]9Z
M:Q*N4H7A/E<T0DZ[<O [IS::?S)B*GX+-C16WKRH+?1VHD-\PR59-;W)'\F:
MM,M1/V9JHR;[Y5-CK'7.Q,\ WS?;@W]RX;HFM+(AG)2=%/SEW%T!U2_!-(5'
M;\NNGHO[MO4[P],7WFU"Q&)?7YH^HSQ\Y?AOB)MZA]TK:OGACP8#"_M#T;G^
M!05V:5Z!#&9P3OBLE72,G!BTU7B,WZE5"15T-V:E@SC5<*7[+</(,TQG]HVG
M]HU/)WA'#%;#4MWCQ)Y%3Q^HOZ[QJK(Q+J=Y_$.D,_5FQ-<7OX#<,[\O]/14
M( #,3,4,  C@_X\#]:>!_27B_C3_A]>&/XTG^7=#U?1'M/HMPB!D )4) _YH
M0;?*   L,/@7X+<"\N"/B/G-3/Z=R6].K SO;T6G[V]/7FZ7?F-]?OZQ PP
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M2QD#^R?(OVO^CSLMX)_5X'>0_Y./& #R;P$Q_TPW$ K\Q\5?D?_N"ZU_)Q&
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MT3: @I:*I[)X0,TY)#>J^A&#ZH<S,D[5,=;XJR8><;0 =4?16E2L?UQ!H+*
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MJ!T8Z^93;^PK]@0ZYU!VI+%UR.2">>-+W9%'E=" 4'?-"?(">3;K*2A-[4<
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M,@THS##E\-PO=(QV"[*[;C@#U5&3_;A^9#FZW-D@_5#W>GH&RQV"E(P*A<]
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M2]1PV%"OV$EX )TN40MV684E)/9PK@\A(>Y"!AB5LL&@@J:O!;L".5O':K^
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MYV"8V))<(:IV:3-6VL:A/T:8$9' &F2 A'O@]?VXD9/.+L$\%/&MP77$U*L
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M)5.>^<RY5N1VZG8)\%1:0DH"@'0/ #!!_ %N=P!88J[&UAX ),!] .#7T"Z
M3M3$WL@48/(=,8*$#,"[C_SP,3H H$4"0'IL#4"RW@ @K1'?S@(^ 9#^]W+O
MWX+\+_EK[M<TTM]G_I=RVPK 0D760CI&1L("W,-"0L9"NFU'TD*$ T!!* ;\
M2^[=?_ 0!?41,M)CQ"C"T-_GD.XA/[A_-_L4 'B(<./^ \0_\CT4I+L9Q#X
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M/[*!04URZO1NMK)8\F%P)- !X'@??A B+T'6)"+\T)-E-!P-%][]SQU(?3A
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M(#1'[M/*D=M1P]6/X=23PVX DARW.>WSSYGL[V989P;6<?2^](Q.WOM];P)
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MT[=MH()M= </5P<.0G4@'0<-XHE/\=U]@MO*?"K%UZRG,;5IUE?O"M;@H8V
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MC"[9G+T7)4_,41 0*69CP.,B6]1D[(L+(D/&DX(O(UVA;0BRIMUWD?%OG:Y
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M'9F"<![]U<OLN>IY7Q$TWUT4JP5><\?J5ET38*YCO7J;T;3KQ6GMI^FF0=L
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MU'3Z#(T5,.0J"4ZU2_E?<C>56PG^X0PD0U>NBNEZ3E2.C-=+KWCQIZ SU71
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M&?U12HYOLG9%@LORT#2323E-RT01O\-XSIVAU7(5K6'V2,@%*A-*'U3B4/\
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MH,2E!D6/N]H>,MSXB06V'I;86&DJG2TPUM*4AMM>II0_.VP +E>WQD0QEGT
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M6S6\8';9:;E$E3:70X[+D2/#D28[[DMP'7([8!RI$JYZ(._#L&S6R^ZG!@U
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MU'?.$5I?:EW5BT7%N03P,DQ*>NCBA5Z.364Z'Q$\WM#6VG>FHC%X.WPRNS$
MW'(+-S*.VLYJ$X]ZUR(W*S(VI=I0I7PL/ZETMIW4#\5LF8SUZLUNN;L=HBSD
MVR<V.\3;9'M5$V5Q^C'Z+:=_1OV)Q?8'L:W^QN+^A_-<3V9R_)Y^9]97)7/M
MWX??TUI;3NGWY38LR7K+9K=;'9#0EG%MXX4=DG&Q/:B+LKBYWB4A+&M5NFW*
M0@)4U8@QG)3J"G261I:8U?WK]Y3?MX&;N,2#;)57+8[/-E)+K3S!JN>#9H+L
M=MB.M6\I[47*F(3C^@M,-N6Z5$F1'8-JC6UT'83POQP-VW!%-^*C@]IDU)DT
MV$*IB++?B.7>^WEYR+I^QLGPRFO-</COONH#A-0XO&#-E$C,S$43:I"QJK7_
M '466/HTGHZ2RM,PQN]N9EN"#!3/^6KJC+A9T3UD=L>)0"4"5$QJS4EE>5^U
MWG27/0W"3*YPWG6%5MX*EPWV#J#@U[)BJ8NO]0=X_P"VO>+_ /K_ '3^SNE<
M:OT%&]3ISO AG?;9$HH,LSN4=O8< /,;:CJ%PCBB;Q0.JG[%=P)/JB0OTB?V
MN$/!0DOND^:4LRT1.$H9E793'>%R&;C_ */OY\N>O)<9GVEYFW+[.XM>BF_9
MBVR>[KO"TK8].%-NHA:YUI@29T68$YU)7-/NZ;N#IF\M'!JZ5&R%-B;,2^\O
M6^IM.WF3<[;,B70K2V]%?ENO1XC#!<JU:K= $ Y,%*B)54KM7P3]0:4MP:^E
M:[LDMR?I&VNNA?K;#=]G2);SSB17XL8%F6D7F"+SVZ@J#V7"TEWBZMTBN@=+
MZ*2$[;[?/N#$V[W&3;)K]SC>K81%!3N9@IJ8-"+(T'.6WW/^S_\ ]$>#5=D9
M',]>--7VUM#51S.W"URHC8YA5"&I.[TVXU?H]PQ:NT'4/M_E'.Q(.)/@6^V.
MF($M2&))M2"YL["N#7SD\'=0S;9L:VN.Q+(%AN-P#C6Z%?RU7*3FI33K,F,<
M=@^4)U%;-%#SD5-F+CIZ^]YNBYUHNL=8LZ+['AL<9E5$LJ/1M)LR&ES"BHH$
M))C5.D+U,ASIMLL]Z/C0"?.)PI][.X-@TLAIAWL\SM[/G5Q=?Z@[Q_VU[Q?_
M -?[I_9W2N.Z3E5]:FG;9Q^&0H2#S^LU?1S;_P#HMZ+M4/V*BZDM0.%<]"W4
M+U5G:Z-J=#@W)UM$2M8K@,2"7T6V27%HOO#8E0=26;A7.$:(XR+[C10KS;'@
M7SA:DHZTJ+YP^)<7-SN7[RV+-9+M)YARQZAA!,:A]G*.5Q^)=HTMT4[*.<!I
MWAH*$14KBZ7CO'[P4U9(GPF(L6U0H?)VJVF#RO/260:&)&)URN2J1@7*F_H3
M4W>#<]9C.TI=O:BQ+2DJ<Y+<8FJ/L^URX3K(P8T6R)1&C!PR)&1V#F*FI>\7
MNFN7Z"1K VUII_4<F>^Z]J!UD2;;=9@1XY(RT[!:;S@1*&5&UVFI4@ZRN7>1
M;-56KVI%M\JVRHX$CIR ?=;;)B1%;<)EP8Y(1,.@\.]-E53NWU'HG57Z*Q6X
M<>[RX,J9<(9Q3NC,&:Q<8ZVUH^;N4%I5! -6T3T3',6.ZCN\TE?+G;+UJF]R
M.9EVR8] ?2.UR4 )$LH1,GRJ<X\\2)V/4JM-B8CQ0-UP(S#3 F^Z;SYBR MH
M;SSBJXZZ2#VB7:2[?!_UO>UH'LKV;R7LKA/\]F_1_P!CY^+^8IQ>U]7PO:\[
MM=5/Z%U+)><ERVV4D-PWYKU5D2XTF$ZU*@.2R55>&CH.*JK1*K6SR=7=\QG:
M;;=($^3 M;US<]IL0Y+4AR#*$1M#;C4H6\B\3B"E:Y5W8C6^?)=M5VM3KLBR
M7R.TC[L!U] &0T['4V>9AR>$"F&=LLS8JA)3 68.^6R^QVFTBMSG+2S(O/+B
M*")E(>LY3ED43SEF*?TL3.[U^_K<;U+TXS9Y&I+D#RK-FAP5>N,IOC2'ZR#!
M55,YKMWKB9W;2KE"E7"3;=4PAN##;PQ!._+/X!JV?K<K'-IF\F+EIRZ7.%='
MYNI)E[&1";>::!F1:[/!1DD?[7$$[:2]5"3&L^\^/F=TOHR.[8+!-VJS)EK#
M6S-K&-=AM/Q#F2EIM%'VZIVOV*=8?;!YAYLVGF711QIUIP5!QMP"11,#%:*B
M[%3#MLTO:V;/;WI1S7(<8G>!S3@-MN/"VXX8MD8-"BY:5I[B\7OND[S)^B(U
M]DG*G6&1;&[K;$=<)P_4B<AMGAQU=)&D<9<,!*B'BW7'O>[R[OKR+;'N9C:?
M8A!9K/QLR9D>!N2^A-/ -#X0,&J;,U, VV(@VV(@  B"  *4$1%-@B*)ABY.
MP8CEPB@3<:<Y':.7';-#$P8D$*NM"0NE5$7TE^Z2H,H%<BS([T62VAFWQ&'V
MR:=#.V0.#F E2J*BX&S:8M,2S6U'G9/*PPR@4A]4XKSA*I&XZ2"B5)57*B)N
M1/V4^T28[%=W&>;;K7=3.25KC*4X57^#:?<39],&E;^7&Q);OU&F]OB]8\WO
MQ_1+E_BX?_'L;8]P#ZS<;_!EECM2#:^NPZJ]'[T+G7A.'<(M2\T3=%HU\@.Y
M#7XOV6^U20 Z5X*=MY:UR^K&I(A4V*M$PHP(B(FRCLI:EX_4MDB"J="YR\F/
M6S7D';V&BX 47T2%G()IMZ:XW^[K'DO,[J\-PPK3YV54JF$20C4L.G,/#<IU
M";=!KXU0L"#I%#=6FQ[:UFZD>'91.LD#"&!(8DE1(50A5.M%38J?LAFE.T)?
M-9#MO'OW!T#V=ZT3!-Q/L3'T%]>2;-[N\=J>C3X<*1*I*N]56J_=<T608C6I
M-*N9H]U<S95&JHE*[TZ,"S.08CZ[,_\ Z,:[.E:DS55Z:I1/.PBHM47:BIN5
M.M/V,555$1$JJKL1$3>JKU8*-:U$S1:'+5$($ZT83<2HOI+L^_@G'G#<<):D
M9DI$J^-5JOO% KS$7ICN+L&JU56BVJV7R;=V.-%<S(FPP78XVN^AC^'=^Q3C
M[YHVTT*D9KN1$\FU5ZDWK@H\>K$*N[]T?HNQ7%3</T?N/3C<OQ8W+]Q%^,Z3
M;@]6XD^:2;B%?'B$O&50&T[T+DQ;: L4EQ2'X*&X4Z2E"6X! @4"%"WN;N5'
M<7>7-FA""0[!W:7%W=W="J6W_WGGON\[<S_<G3DS^VEG=_;L<Y[G[)X=JLP(
MRJV,/"D$;2CO/7VPOB?^AQ8+JK%F K/A><>W9UV.@DX&O#HKRE'W!VW*2"D&
M]^[X"[LP@]"OQJ6&!:TJ(#Z>(98]\C6AMECKO/M%WB<E9Q/?74J+3W?@><L;
MM4[QTFQ107ED>F04XIH$ 4E%;6'TS@&:&Q4'7Z]4DDXWIN!%81$L;]/.7:&>
M&S7WFO+;K5VV?VX9Q<_72-<<F0Y<:#*25BV.VE;62(6V,:7W7Y>_[S], CA"
MVV"Z2\^&,^L.;--?>2(VF'ZQ"4G7MGY57=1Y@"WG,%1,&89GS=#^,+TGPVGS
MI)N<1?N#RUXLGEE(<A,AHG;RPI^\A80X+*]@R00X$R\;,QX]?X2=K<']9^B%
ME]5($Q_:7(EQ:2=-BN<LIJ9_:8W9E79_/H/QO6DT&DTW$!-0%%,#: GX,J):
M("E^K5L-_"/OIZ/XRE>U%Q$MG/_Y6?'$F7Y0O,_*5;TC\@GHO!?A']L)K5+P
M_,K5T'C5-''IU[J9_C7EYH:L:<[:S[@U,T ]#>\R3'$&WYMZ9E6M0+VIGMK!
M-Z260U(0-! KY;S$O2O#UR2M>DN5>M-SK>PO0@.Y7QBY&\'D& ,PN,_F[7V)
MZB_F#?]B1;^=Z OT3OI@W_'A&=T@U_WSAWH95_KVAQME,Y/3M($P<TF]);?)
MX6;;FP1)$+@$R*D)U <"'6&PV?!TL8H(6>DQY\U9QRN$VU=CT'V_I<%R?U..
M.>J'HF-A?=9EV!9D/LNY+[J9D[MX?C4#V$);KYL?WL&S 3X_NL&Q\?N]& &[
MA5M(MKKXR528/:F]TKANN"P@M?^+1?E6$M6Z9@KAK7KB,<)U':3^$(\^;GF\
M--UX,F5_C=<B3D>DF@;AS"DF,RUZ;N>H<PIMJ*2P<3;>_ZTJKO2?6W$,H'/B
MB$>7BM\)L(<WL]Y%NK!X"D3Y=2U^:N7GG:4B_7E#.9D@[7QL)_-ZBNSY051&
MWZOH <^$S&W66Y@?ET.L(4*]]G5Y)E=#L%'59;.!Q)_#J4X!I.A=0T+INQ0J
MF&!=BUQR2?E[-F8XDUAL3^JXQ%BQYB&4Y5*U"D*J%J3^*LH:_1>KIO(<O^OT
MT#CN^OD;$N.?I*TGDXY5\[SA,; O@,Z->XJ>*SN\WVHIUK>("-CYI^@IA>'D
M\#2?!&Z8[F#KC>%;_I]5<%6U)Z2'EOXB53D?^+0>3-E'C5_I&1)(@MS*MZ.J
M]NT.['4IU)MX$CY#YQ<G2PX.RY+-@3_ES>1=#(Y.K>$C<E8Q 9&^=8Z9*.5#
M<)(0]YGL&],4-G QM?LCC3U>I(;>IPCM%++/AOQVDY36M%/H(Q)D15Z_*K)J
M'R8H8A7ZG*L2Z@GR']0=B4OE^(O%NO,7*U7SM/1=:Q&K/GVA2^L_QLS)>>J[
M2F<73FO7TSNL$_P</UU!]SM$B]C!5VR3%O=;7L.(:=!OK6_J)G%C0J>=SCH%
MW$YJ31=\J"G= \:9M?N:N&D"O3_AS;?<=?Y:9!K?ETP*9JO+KG?/R_97!#8_
M!^:('TKU17X+7LVW?>=DK3^!M6')([(:4;=*2OR:VI+LJ=)W7. AG'_IR],_
M,EHRT@L.QI_?1?]IB0"PI<=+>K-+I9%@$@J8XTKJX/R0Y1)DG/D*NW*6S]JS
M4?TW8YWFF)%&\73.X(VQ#;D-PDD*:39]2GV.:>$?;0KV FP*#D*>[/,=_=L'
MO=Q55&7G16TY?801^V>.OBW*D-$S$U<H. JW5,XMNV?VZ$9^WIO6P;^V=VX+
MV,PJ+S)%FJ/OLE%,=2V2>(VM5S==M!G3K^\=();<*;KT/*4.I98@9@@J##/I
M^</8DL^"J+9/W2;%3]XS&:@&2J][W5JEIQ&I*&!B.E\YN*BV[CB*5=&$QXGT
M,42.#03G]WAI9L,/#!<H<W>CFW]1L)[CP9PV"G<DUC!&6JRL]X^XI%+\K\J^
M4/N'/@+U[\A6M-ZHY2$;!(=[(8830" RG-U@S*;T0=/+4KY\.P\ E51_;MSZ
M<ZD@H,+FYR%DIWWKFHM6&1V1<!0Z*8?F_G[Y\J8N"5DT)[?%$,G#?5/ZH^##
M&.5>7=8%"JEC9HUIMCK)T4$5FJXFD-[U95$OM#0-N7]T'/4 YB@^O4$NQ<OQ
MCVA&4B[(DZ#L!GE#>?6[#*U%A46RFXS0,URN51DO3-L(C]%O<?N)6A<2\/RC
M%6E6\ZQ)6H.AD@8\.EP>N=SJ-OY1!1Q)W,YEF9'DX>"XF@U3CNR?/*I,Y;A]
M[P6F/$T[_@E V\?1_1\&;RA9>6WA335UPKB5_':%8L0;K14:(QHOY@EJ?MAK
MJ^O5:@'L:98MHSG2V'G08D?[JCE(K8\ JNAQ X=?6R*">J8\LOP:/^]^"H[K
MS><U6<V[F:TT.&%4*T0FF!C7N8Z%2//K BL+\(:!3(S/X/VE8VL_73&]$7.C
M,1AWO_]$.$5I!5O7=;<CUS3)K<DXP)*Z,1@[GM&!NM(>4=(6O$!,HA]'M'[9
M43F5V=>,G/CS\;<@1\Z[;\%*WU6797"Z)TS/X_!X8SK6BI7LD5ZF79"5S \1
MFU?V7T).2BU^<7T4-.MG45?]YBPVXDUG@VAE;<=@!S_G^*2("4Y$**YKGRI_
MONG/>*3,P59/F+JOG='8%U^SJS:X>EZPPRZV</R5=CFQX7V<SH;0Q59W"LNS
M3^4Y4W&_?5\\VK?^Q3K^@=,YQY0UFMW6E=K>U.7U.H>@)^!5W122H.K\"4<Z
M-X1_1=T-M+'X=C/*[?4X_A=V:J\!7(5<*U]'U>'\+%$0NZR9VGMO-,7HZ<P>
MZQ)G\MU0N]"!JD14+5V8_?/7+'<C:%X?G;N \9,&.\RBW4R42-'',0-<CSF'
M[N1E@XI:ZG?.'_6)28#%/3%O_F*YZ,HM-2FX9RCCJZLK9]NZG['S'P;7]5NM
M$+[I([IX:LZ40!JA;Z9VI@%=F1B2)WF*>KFSNXP<#2RME1<YM/*'!"16'%$>
M,13CV158]V$(^E\ZX_38)X@J0.:>P4M*55PE0J^^.W GNZXNPIL6CF[2R^[V
M*Y?8\Y>84W^*9/E4EME+Z-N5QH8Y4)SJ&&0D1,2;+%.;J2[FTL;4B>*^*O]<
MQ1J_. <V?C9\1FL;/1'CK"=L/WT;F-]MU6<E1H'BE5V'4SG2%"T&C?!WLW(2
M2#9L#.)(%.D]:RO93^F!.RVR[K%JPO47G 2&<E=JMMW/6!%D'Z8SF+?4N9T.
MD6I1_'.TQXVPP=GIC,CP)E),VE.<L0PR6KDJH=FF^??>Q;3?DZSFQVJ,\E[%
M%D'KM,[>D[<-DMZ?J _ AC]@ :DOD0O]JZ1I:J9;!ZOVTKY$<3<9UX_R2VB)
MH*NB0</I R8+M?@TY7Q)W0%B[5N5H>=?/UT"S1XC\AXNO/]BQ9D^SPY\H&%%
M3-%-15!;=,M_?;T2H%R$'OD2J7J6+3Q<&LYGIU(MJJH_OD)]XOQ)2K5WK#B\
MT+!(<MU[C>?#0Q2/_; D3QSVPE)O^Z5OX:#6Q&?%NL6B3D7- C%'1?]I&M]4
M77-)&SD]FP*,S8GI1*>NI4S^HH-F 7Q33H+XS-3506Q2UX6ZR+);)SW.8JKN
MJL$ L4C=*-"IF 1X,VTV&+[0K("N6A^+0+-RJ6(<95ML+.52;9;HIT60+!M'
M+E Q6ZHJT5<Y0/,Y4EG82+IMK(">0\QS<];8I>N=#L-:Z)&T6GCJ44AU/K[-
MN([5=#J:E#;(\6UB(88S&9[!O^ZB4HSM <S@)L,!PD/-^.A=RS'<0:!CE>Z2
MC A/MJONM[!0B1$/..9,TV!7M0_BO_U5T.[0:SRT29D-ICJ8[J*BX[ID/R*F
MRGAWON[]$W*&$1J=F5#R48ZBS_5HLVWJ-NE9^KBH+0I7!V#!G((XWY.#P:K]
M$94DDNDB1D^<BR'O>T= ;-C)4!;#761XE4F&+YZ5"L=ZOA'^_A@OFYIF:QF%
MMH2"-&JF@_MG'NOY[2*K.A&U8H&.Q,^?O(SH0RAFYTVK;^E[8VK@S F;%)P#
MD2MDW(Z,5*RO0EYDS2(WE&:>_JDJ?T*I:?&/M[1J&L71<UUKGY'U&"<4JN@H
M8S/=[U[/&_>JKA!(;1Z VGX=7[P&[S^S?%-P2[[)&P085^1H58.>W^^=X,,Z
MSWS:]'-J/P3@FUBYO*ZY5V_IA?E9@.-1L@9(U?0 MO1@O\ECAAKT!'R;1^M6
M<;^GKP0X\:2%VOY)#2NL4'<)A!HCLT$=@P_@XJ23_[GE4LA*KGSZE*!3XH#W
M71JI_L%RY2W>YER8^&1)^ R+CI8%F ;O^6*3"P*(7C0P]*V);@!I'AX&]D7Z
M@=CO.HB".GZ4E;WL^.GJLM[/&,?-?V#^ZP5$!!8A0"M[ )"$5'<P645UN8@C
M4-ZH\F?N](7?)]9.45>H\KY5Q?'Q@K:QV;NA7TIYQT6"C<;:9,/8^^#3?-^P
M48%]!D",$W<-!V,.[LU,F6[[-]-_>\/$4O+O?",VIK[(Q4?:_<%1ERKO1O\D
MO>^]74&(BL1(%I-KM,I-=##LUC/YY1:$G=Y/X4&="QM9*K^+('M<L@0SC^3T
M1ZI*V[Y31LDYUK,-\1O\*;KGIV%_I>>D\TYHR,@[GD\AQS9,W[ZS5J\.3\ZN
M%&AD6%*."6>Q@>P6XG#DO'5"2"/CTJ-JVJ)Y\EI6TWCRTFLVSVGG8C!16P-T
M6HN++Y"Q[+=)@ "57 K(<A: 0F:X*EO>IR0KP:_-%SL@R$.?_MOCGF^8<J$B
MV;K2(X/3+AYLN\65SKO+B_WL/^WS?PMQ.RP;2( <,$5&*IXR%?>MNOW%\@E=
M?^07ZR_N+SWY$-T5T^3%!R$V6G#JOA'[K6M;()-%%.+[=J,@+-M[+_%]Y:B2
M4C'36.Q\BD_*440#WRLLA-""Z:\X^5<X3UX,I/!M32\/%N;ZIC@_ 8DT_3>E
M&9YKKCLSL@N!MP#310Q5BN:@6B<@]^_L04=LN;YUN^Y_L80B'4!?'MJ<Z1DX
MJ@LD!Z1->?,EG^]_&R]'N4I@9)O>OB4C_3&17XV?&[NAH?BRQ(',G*4+!2XI
ML&K)U'(768]JD23-^G/\H>..A_13A.1=[.8#&,7;,6L<1PY&H;O!\Z@6A1RN
M8%$%8.3Q!XBH-#&%2AN]%+P=N,^6#/U"A6L=5\.G(--*9%_.X[:8J_\IZ^Y>
M:S#K4=W%6S-ZH/3(G55W^JG_ASL*2=J0LLI#/'$V950^/1>LR%,1A"IHPM:R
MYNW$?%0_.##S%#I,\F:.8EQW?"J;DD'!V:!*B?%4\-612&+GP-N@*W1/Y*@<
MN'AOK:)3\B'!XY"EJT*^F49,W7HB%KK)Q[WEG[^&&4I))Q<2TCY??=THA#UT
ME\IRNR]/JD1X)JL-L5^#S..?ZI*4SRR965=U9G3+O6:H48'9#53)8T>3OWKE
M$?G$;J]SWQ?GFJV@LDY6 &Y.4K^^S>@H#J3"#XH5"U=\SUAFK8Y1]-:R:QHN
MQO%9<! 2(9&TBA4RP@^.=-31HSC_+*CTR'<_LDM,;W>\N5+F:H*#P14A82_D
M:,&ZU254C#\(R^[_8\))BG04Q?7;P2]TZMH7SPR,59$!\"S1&-]JAS:3,JI:
M&4=Q(BRVHYR?% +ZD6.3&+8^P<-$LNDY/8_A,,,?#>"AD9XRRJR;R[6Z1]]
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M?9+<@RN1Y@ :,#?.-)!?-=R+^PC*E5IO(VK0OFUN)7'.9UND*$DGC6!/T'+
M*0UB'96P0Z(5%7+9/1DV3+H"U[<N;@G9=#-'FK5]P,H66IV,;V<VS^[X@G(C
MM5[^@X3%]-)2V%U^)=G:7F_WG=.B-TE( P^/FL4XJ=UDB%Q4;@9T<()G<D0U
M:TKJPFYB!)!ED#T)V8,??L!!7+(3IP!^..TA?OV<$IU)_ZVU'Z.[K*V-<N>A
MV$[B,1;3&AD:+\DAOY%F/F)?N_-OEQ[8=*Y%\:Y0'%!TTQRUW%H3NCF8'1&6
M. D@L0.=.YX2:1R8@UK?<"@DT8(I(U5 +5G[93C\<MGPH>814.F9FVGS>2DR
MK3J%HX551Z.G6PE&5C]F.&N?W@E7H_=\E=KJT8VENIN"PXTJG5]18L>PT;-R
MBIS+18<GA\])E#Y'-=G.01^,_?YWBE4MI6?Z0+^>3>_\_AIB&0U1;4I+L[/=
M:)=7%_X/^>7U]DH\Y]F?7K']KM2EI##F=#&0-7-$A[0Q+U$MQ"?ES/3&JZZM
M)#ND.)^\*:$!I&RYP$0/+M3IT$3SXO&;A(QI\A(N>6^/G6'(]G]6WWG#8?3L
MGZ.&G5KQUJ]<)F/;Z/ML' 1I=8PYYHJ'W 5^KT$.*WY=)]U">\;[:2&10T%_
MFI?@W9NXC''RR,-U,@6X@%$23D_5"'6S;?+L&78"5Y>\*DE?VB[?DJJ?8OA-
M#M]A<4:,F\N$-V S&8V_^?)'ZN25I.@S3O?2K\<4 )="0/\_-!TSCI$ K*D[
M%>2Z^I=_';^3&FE=7(B-=*UG%BXC"]9$$3R]Z\_69M5WOWV_G1J*;TSZAU0M
M >X\,6Z-*N24?0=F0<R,WP# Z%&]%.U=F+Q.U*GN"B#BJ9Y1?%_UQM%W9W9>
M'A3^1:9Y^%\L !ZXYCV$U:@ C%J;B?(MDM]$'=^2'1L>_\724/R+!5UNIN06
M-:D>S7*9U,QJ6FF0FWA+0(T]9KV?9+/P/97+>(!2R*,J#W?7TP,H^'GR53.Y
M%ZT0T+Z/!!3T:]1^L>F+)ZV1NUE"=OQR7GWC(EL6->9/KP$/YRN?0_90&G/R
M1SK^9<KLJ6GOZ<O)@JMCVHR8\ I Q M=<JO/:K2I&^G%6K9A'[UPZS.<YMVK
ME,@<1)2>8^=@LR0;._$43_*>ZBYF^;^L92AITNHBG7,TWQS)OG?.KZ+17G0J
MR=/6\N994RVM?F9J=QMA=\__5LDYEP(6?R5%[GT%+(;XSZ\?:\]'=RM=68I.
M::T-G431I2O_%#UVC%,OI=<!W0$B;WK"&I?RF6\?/>^$C!MND/3:LY4%*I7]
M#LQ$K1-J \+51D^>! K(NB6/D$:,8ZHZ&A1B*.>K>B$=<XXB7;398#U> 36Q
M$HXJ")K4ZR?@9:/1;V>[ZTM+,BZB8'M%[V\C(#D+,MG[#\$OD95@,NH^A0/E
MQ0 ;;6B"38ZK=_AZ:$GX[,Z;_ZZI#@7VV:Z&,97SEW^F@3:^B]UYSBZO0EED
M\,,YV>3)0HL8+U1?>0T9_OFAM]2R8JY<XUHFZFRRZ1@V*+-/Y^X2Q&V&GPT^
MBV57J1D.$R#8?;H?@O=!\PE2'8F]':,/'%P;M,HIULI=_5HF;11R>_8_Z?9%
M&P[=>R^%CU7?WRC&H&I%1 4FFK6MS^:#X"6'"Q-!GLI+S(O,)![ 10K@H+V$
MS5^L;5JPX4(:%IE4FJ.)3NB=BB*MT%Q]T/AG[C^O]12,QELE5P@6DCK47H+8
M2<)5CU;K(,W-YZJWG%9<0W!B0S*$A7RW!KT#<J):=,.WMN<0656W"3EW'42>
M%[>R!W$;U M2+J^<VSLOW1;T"W5;2C<5Y!&_N#5V78Q2G5VH[Z@E\</,AN>"
M3^W ZJY9_WBM_<39?=1<HL8R1IZ7'AS;0!( N_7OJEA^+ZL]W#4HS$:OSM^Q
MV&I4T_5KLT@W'U.6"9P"Y0!;@(JUDIR;IVB>OE_EO>0/.DNP/VVM//5X,SD8
ME>0\V!ZA&.?F>SAUP"5!_;DS8$O&%^II5L87(R0>XR.IV!+PBCDQ!5?+1DC:
M/B#Q]\?&!M5"]X&LLJ>T[N '(_:A8_]B<IAE%^$LEJ4>28)-_IS*_@8,Y56Z
M1E0BX]N)P>2-9C.KH]IY;P-N6D8@WR&U< 8<U0>Y]4;5B=YB=>S\ _]Y?VW6
M]W=D*WAMPF& ^U6&TV8BAI.;"(<'Z%IE]8-ZXW6PAO'G8>EQ(-+E7-<:;\;F
M65-?G_;^J>C#Q\<IOE:<[LX]@_S\.WY34,#*\LUZN?4THI>!05!"D"UO?<"I
MH"F$(H ; S,\J%\A)=JN8;[[;'PJ29EB>)*\,W-6K$!\/E6A[G8IKIH?W0P"
M1>;:_&;#;U8!V/#0!SY.V=LL1#1L*U\X>*%RZ/ #?W^]2>K$!$A!Z7=RW>4+
MNC,_N;(;"F@MWW'] 1WAQ.8TR*IDLAM?^BGQ9M%MW6;Q^@VX[H@]N7M:^A<K
M^=3ZFH+C@W607(Z:9+OD>H!!U/&%<)6;D"@0Q>J5E3S+G;&[SC;H\Q&\#U;'
M6RN>AY'*&R[M$=H0ET$UHP+]&W_]IDR!J.XV:"<M3X>Z!KA<QFX=K':D"C\8
MR0Q%?.E.]/.5.L>_W\/L#"5(O^OV*GMT43[B6YGQZJF\4R:HPGUG]:1"[?N3
M]^2W24N)5\#R@6/ J]NIJ;]8(.M;_OB92<F2$"UMRJ'//XK&RLC^7-[4Y=CD
M^LWU&:%I7L5(T_.P^K]_=)(ZJWY5?;_PB6OK_7P;WOK@?*SEAK3N"Y\0QCI-
M&LVS-X'8MP&KYU=".T>ZBSROU<O/,;:KF\O\H_/LSRS(N[:G:X#J+3,GAL*/
MSJZ/#I2L_M!_0YZV_V9L-CL7K9461'CQBG:I!G'/;Z1%5PVF;2+P91@66;]D
MM3S,^:9J[3Y2G#XK2XP*+)%5_(6\Y>,IU BK6.<QEB(!M>2&W$KF7D[([ !D
MMM=,=2<9$MJ-_<0YDFR'XF6B<.;;HK_X=M@&FJ7*5H^HS*9L%_Z^>8?<X:)*
M:+QZL<CV%RNS-8_&/"^LL_7YQ&YQ".WRG(?AJ^YPY"_#S".\*Q[L#HW@L9>*
M(@C$$43=>Y:(-\LEGJJQN@>M_X>'82 BXN%9R!UGUJGO4MVS4:=XOX@]TMM@
MCU5J@L#9;T0),GCK0#&J;POD#H(V.8ERJN(> %/$V:8F<OREL7/&P_OBONK3
M^V1U)WO03.#1B^X7"^HGI2=BCD6W]?T%;3U-I*Y<CQIAA/7W&Y8,R2"9L.4#
M_NZCQ@P]R*7^'N\68//\EEJ<X-OB<0/;B+['PE.&JF[8XY-"5/&'4&/GM"L2
M:4'R&TE<K&_>[[OW19;(188!XZ04-T2-)37N^T31!G1[M]VM%Y,$"(^-/@>O
M,BXUV0\".=KG%6/L7:N)*_(4*@&EN14!++P^UTF'1U CH]:BB5YCWY<1E20<
MX5D)9"XF/$DT(]8U$H2DE'M:2?5TD3[OQA%4MR4Y,BZI7]L8R]MYG@!ND,=F
M#;2Z\\1F0MSNS;^"/IN'%31J9MF&V*^R_<]#M&3MOUB^[6\JDNF.)5IM/^4Z
MNZ=()!4Z37J,$>N3TT4HE1<8OE7TWV&CV<O(<%Z./KVJN3>?B#B-,'5OE(7>
MDFZ"W45]^H^3(&W?M9V&:U2C]N'GA8JUMYIM@!:<U*3>S[MU4BP?GU.K]9\8
M)?$D\5*O"Z->7B^#&L^ IQM\>3GQ1U*4??F%'J:L12\M3+F\7:'$N>X>C?<Y
M#A*VL/L$$>OT5]J*$F.:44'6W7,MU<NA=.3Z;)-[IQ5X,A:?QN[,D7,Z"]H\
M@!A#?:+(UA<LB\S/W1A^QED,HJ&0Q6^?WX$A4-:B[OW.9(]<XEUYH]%"=842
M( =D/*)2@K\K>DV QI?[VEI[$,4FY(2K50 #O.P9@>GQ]+>T&.CC$9K"?B99
M3K&R(AW!*D#$% 4H,BL%X%+<O-!<A3]HG"%/X$^, 1-;OG-G)\FENAU0)NSC
M77H>WB94_U\ YZ=Y9X$L<X3BAGI[Z[E<!@/:=EM$1BSMY83!#6;];A2@_XB]
MVT5Y[_L"J)WTSK[B3B'-*;!HRBB:F3GE(+O@!8\69\TB>+9+N=F,WVC0#;W2
MZ%2 5X+85@)%'FO?0J$^?DUC #S[@4^OB8'N,\-=K,];4A/20,('+B4Y7MJZ
M%SB>@2C+A[+9=U'I^G,Y!5L:<.@>.R65(NS!?Q\CMP1]46\'(>$5R4G46D-2
MCY'Q%QW5LJ@(4[>$=H4CZVW#M.>SFH!9DJWKX!>*"D>;M*SZY7/+(\D@5%LF
MG_8N0FO9E3LH*,F@H,DL!#P@GOPFJ*#52@%'9PB)U_+:.:P]TSN-H-A Z'O=
MACGBD^(O6<58Z^"KD;@?Y,L'UE.775OJ7M^Y]>/&]]ASUNVE6._X8OBHY(MW
M2!_6C5*Z*!?,79-XWFM@>>+YJ$D$V-J+9"FDF7XR?%/ER%NOZ"KQ3)@\OT\=
M\EU[I27@,'5Z,(8OT''+6&H<S$<ZUU"YT.)1'M7)AI\<8A/U>+07*^[=3? =
MRI$1;%6CTE.]"/^+-:+_Z+L<>X OJ)<:<82)B5WN1[#VU)#?(>5;GQZ<DJ=;
MA1_?4"W&>G65/!B*05F@3/H<B5"HWQ?W_B[S]=MZ]N@H%S:2@<@X\;;@O$R&
M'ZUYRYU ._#L/T%,UIWS>LU@=H"B5LW2=^KU,!"%\*C/0,-FA0W3MXY6T0K.
M9)FY^^S\3%H#=W4'N\5+QQD'VNGK]G?("NE7R?<AB\B&] CC'XZ'MR[WOP*[
M55YIJ^ 2!P<G!K-P54*T2,M_FZ3XO+"^2VV?/Q2:5VNB$FUX[8GR[LQ5 7%#
MM4P1A]I&A2H^8X,GB%,[H?-+:F^G@GE7[H?MATOU@N4_Z0@$X@H$#6"]#\$A
M3RO1+#TW+?GY4MIW*?B6S&<-3RORSJ_C4/@O5K1B= Q6'>YN$%1FI<OY4Z^/
M=IC"^[J/.$[],1H0CAQSC(U'J32-_U=\K1<'A(A21;7'+<C0G!+Z4M^DQ,FL
MEE(0R+CP)O)E)!YC<71D1*VNS7V[0TS$&^_PIV=NHJR5 ZI78.=OZJ&M1\Z^
M(#M8/9 W1GS_SS\$$I>8_6[91#G%UG4HH.XP]RIP$M=VYX7.(9FG@>](360#
M:QWH4![*T?#?:HD#2[GFK90O0<,&]"A 4Z-R?V!;,C*6J#U$Q0>I6CY#"KD#
MI<^URVQI!#Q*]FK=.?593]/<:K?9I%^-S]S]BS:X6C0&HFFW6C#U 24M>F3J
MPN_ \+:4'2^24L,J>*V^1Z;Y) F%=89:ADNQTN4GALD)64&%DE(\W/SR'/R:
MY_\H:18I7;=X6D^PY=B3](,TSGX$;;$''BGF]W63-PF,]*M1G+<4H093S2G*
M?AEG%X._F\ZSU?6+Q9XMK<)ZNW'\T;Y[?S0/$"*92]$S^YOBMNN.N['T_HMO
MD@"5]35\UEYRMG&LT%;6;@Q<5T0P^^DH%6H)/Y,R]]M44OI,U0DQ+,6H:*8#
M:Y5#7!VEL,CO=,_]=L3NJ,O#84Y^2Z'KC,LWH6]#!P_++295PD[-IN7\V] 3
M7V_Z/$1N.0C$;"<9P6U ,];6"6D]G0S]6 O(OF$6 ,O"X35W A TXO7:B6R'
M['G)$=E ]$S4*@&%%/RY8C<+>EWT%H27/Z7/@]-=3[X3 @X9^HJZU@07M=/3
MV'!-*B@&6PJ^ZK,6%>KZ-&%M>/G\%T3JH-N"4_IU1I\V]9F\=Q]W1IH$^^<]
M,TY@!%Y)?&J/K&ID9 Y>U.K_P5#O[^%B56VCS#4W%X$?U>^>COX[5L\7B*$B
MJ&/*!%&TS#5!_J-CS%^LK![3>6[G%!%$WW\D*>B1UK+O^_=1$/>&]KJH?87!
MT=1N;7?9C+%:ORZ)6/,RB5,MP_@NC0[TIRVQ76QG,YX ?DFEF'P]C^TRSJ $
MNSS"]7:Q'TF_"JHYOWN!7V6R4PF2.S_IT'=$%#=3WN"V:>[Y-[]P)!@W&@Y6
M"W1U=@>DM:^<F=QKGZ+9 $I+= R!IMW:?^J;90^^U]Y:EW+,FX*YG-4QO;#,
MH?&8.UJQRB7'Z6??4LI\Q:INOCB?\&RQ[?A>B_+RL$Y_85FI0Q,:Y)^E3"^X
MBSG4:WX[[FE4&;W.#&#Q'F-([JMU9.V-G3C"7.@I4>,ZTU"H-O&A6P_LZJ1=
M8]/KGFT):I-W]L0%5+>Q4D _VFP1]*%8$[1">3EAN-:K'H("&V^9(L_2K:]C
MMJT:="-_)6:Y<6=IX=M;'MA[K&:D?*H7X1]2B4A_'.7A:DF8;Q)A$YO8[@Z:
M7C'@^0!=.#PRFNC&K<:S,SY$1_+ V([C(P2AE"GR]6-.Z*X4>@-3I?D&JNT5
M;"$P*XY(> @N=H+U1B?WZ(YC_?:%]US"^O;OYL]/,?)K2G'\(8N7NEG^A7NS
M&^ /4<LE]X+U+X?K1A#D80(7]53JM12!<K\2^@Q,C-8;TF[XX-8M\MX9G[]Z
M-O,S;G98FC'&B"UUPG4"J;V7!3CK^LL A7X PP]>_LP&;T[S\OB/]J,K\)2X
M8V_HW7T9.6MBH&0!/$Z70CLU 7'U&/%%F_>=EN2>^&^,K1?-OBMGN?GCJ ?W
M=BL=(BRU&ZS15\:-<+WO+ (M1LQ<H3D$*0-]W_+.,YQ-(I#L]^H:@C:AHAEW
M!M@)+JN1PTR4P33]<2@$E+0D_5V#X5$\@2?VP%@^]2&ZP[N=>U8^7W(R-&K$
M/>S)]%#_IP*NV..TOUC&DWF[UU^.S32^S'E_*:'I^8MU];CW)V>\]=0Y; &@
MYZ9-:S>.D&T:T\*ATA7RE+*3EW8%M5K[B\R8KDI_^_-/*]*':P,H#<IQ/)Q!
MKX+&;&N20'8W:9XKAT37N;I!W<-E\IZ5D%H9SL^5C@(Z/!6;=?.GQK%JT0&"
MO'P9M$QO$)]GHD8+Q@$+!;;7.1%')@[V\RS)Z9.:I/%8!+54NR?X'')S.+X?
M5)ZE#:BK912?5%^NJB7:'&9 F3_4P4V3PY1K#J*%W5:WC<:CK/71BYXYA4+8
MW^N7A4<NH-;U: JVZ04'KB9/VYB>^DR(\U=3UMKA7F')4#U?;UUB]X3]C)NA
M9J_J>>\&8CT;<1GGV!_2]PYG2PG9KKGCJ$3*19MMX9'!=7U758)UU<8!:MF*
M6?!_GI83]D'/8)12\%B6,(@@QEHUH\[:MC4%EW]U>3F/U+T*7.C_9/<]R71N
M^$8X.EQRHILM2IL4;)1MZ"Z=6"=%2C8]VYCY!C^ZV*+QZ$+C0\W"*G8Q 8TP
M/:@/0*SARUBJ K_O/?D,6V05=VE0CK,/G1J7E.__"%4D'3 ":+[1CD=-J-0]
MC>B"+:E8][J-YB>Y__*),7LK/7OY+9X9YZ[T^6K7ZN IGMN3P7M>QJ#$,8"E
M3>4RKEJ3N,=U65'W)(#M<W5?^*'>L<2FE](*,GZOE[8[9+XW:D:72G2M66G$
MQ1US81;,(XG?7#0'MOJ><3II2J E&@BL4F+RF_*PU4;Y0!=B7)N_E4>EUXC&
M\-UC<0*OKY9/G)P\6UB.J]:$(!,ZWV0MVKI/#=U?T3/4L;RE_FF^7F39NR4C
MQ<!T>2=FUWA.N*ZSV\1'?=_"#7/+\9I$]R=1!#;WF7X@>?KAQ]<+^D12N*C%
M:Y(HJR""NOP-<-V-)[Y&F_^OQBH(FIDDVY_!OMRQ$6H_'E(WG!XE3;!2L89#
M,@TJ2-$>6EJY"LW_BR5?8Z;Q%VONOR\ES_[?$N3[[@V Q6EII2'"@P&L#YRY
M$5S\W^K9@/79BVQ&EC/ 8#I LT1QSAG K3$F<M?RY472LM3*EPJ9>6\C[&./
M":2EM:H4_;K'8(=[+\'*9WW#)L//@SJTUG/JZ7R[%=/.CI^ 1S"XC;WFT876
M2/,"]]J 8L,RS=:FFL\'_HVJR@8+=K'1E@K!R_]?A;MM3$35&MIZW0A4J(6T
M:L5O#EA#<V3F;/.(<JL2KKZI-@U]2(X1.7!<E_AB'_Z0]F0<&[PF;<6\[6$W
M8_3;'2=3.+&_L+-BKQN$(908&[0O5*JE^QSUE$<"384 6JC8I'*?[8N<F*IL
MS1&-=/SG55^Z/XNG81!%6=3R<I9'JIH7NKR^; *W?->XL-KRVB"ZQ,]*#=\2
M>X<0+(_CRM,CQ++;R=68IN5( A$U<?R?*SDVSP2>G_3,M[7^F:V\E88W&^^A
MT( .)]4LC\+S/>WSXJ!CIWGVS;VYZS\*W$\M!2P!U"P7#!>^[ATSNKM!:S&T
MFZ%9K=:<@AE;K\884FSR!""C;Z9#/-*%-HM?@[R;6<JSTU&'X'E44P(_GK;&
M>J7M-*5O<C7AKWJ2!?O]6<(I4 :EX<#W\O&>-*W'I)5.U_4'WQJQN)YW_SE'
M,?7FQ'7I]"_(VD$ZT*="1MGZO*K[W.#-+-@H3B^?@@>;O/%_K TQ0D9(7'!$
M3LV"BJ?G'Y.2OUAC1Z\G9:X_&>]C_7^H=\:Z#S%.6N2A.BMM&TT,>,5T8G?/
M$VL*+G[O85O#-8DAPY$E!3.QS$=&U5( EJD=F\5F;HE-/_[S.Z_4FXU^EP^/
MW8U-SJ[,,;\K-_ S-)O2VNG6K0B4EC,GT6\IP1V)532?<T+[Y1W6GJOP.4_3
MNZ>&T.)0/-.&E5MK$?'Z_=E4G.+/".,N5<V=15<ZFOJECU;TC%J\#B22<A05
MK),41CJ"M)4VBG:6@$O+625;R[TJ<CD6%0ZJ56-/7D-]:XI8[6'H?4K>/WM-
M_E_9*-;5OODW&3BO4*D4;EZ(L.WY%*Y>3@3PS"S\1_RN:N&S8?'K6)?7J;OH
MX419SAWBJL'#WOP3+<4&0),5EY.RHP  =T?:[1HHW.LE3F(UYVTBUL=@(U)D
MF#V4!3 T8VAIF'DR44G;J! MFO-NJ+O;KFB_<KAU\[-JW;X>8082C"KC6RS3
M)X!;8F<5939)'*B>EO//6Y0;LOX'MJEB4I5;4M+H5[1**6(Q\LV;.;$N,D>;
M_B>^%T/#G.'2MVWR=>2GR8_!_%X'I'&(V^.WDQ<MGNCX0T"4ZBZWAC&F=7*F
M#/"<79A>F:?@M>E"X6LM$2T6-,^\W/Y&Y1SFJUQW+PGNKB"B48!IZ F(.5OT
M/\'GPZLH8:497(OJFU+"A2+Q98O^BI5&O"SS \N_6,\E>K1C#SJS-.#O1[9.
M:=0",0M!JO\LE/!)D=:SIR7Q\644 $(;^H-:Z!XGH>1&AX/?MM#P4T\!C,A!
M]E.]'Q4-)=PE:.A<AA-)[0L_O-1+?;$WAKP_J6I\:=7PL.669M]&(\/G@:><
M7K7/\R**BUR94C[S4^)KI)S3]G1ZW>J-06U>U%(B(UR:BD[XAX3KH!DNGB^*
MY/VP9RH6%K,$&$?9# [S"V89(OBMIJ76/+,?OUUSH15CK"*/.L'RRSZTZ;DM
MK"X)Z6NNXB@"TC+.&$'J%9^0SP:OHK*.DWL9O!D4CSJ?O%N]0ZV :LN->/0I
M&J*KV3R2#"4$HU^EO]!9Y&L(LO.U638O$UW_O[D6H-E(>]?ZYWPY!LZ79[SE
M-'-Z*\Z>5M7T$8XJS? ,2G1S.U(/6YXQH.M6'/+?7I"8$L.JHNK"]'JP)) M
M)$>DI4:-1473'SI<$R@6[0RY:,@VT;QAS  *D!I'<?8O4@W1??N@8Z0!8M>A
M'$#7/L\:]W$^MW @+@,1NMK7[:(A#B2#SELJ#;\(SNQU [@;-;O9!Q;:)U=\
MHH!V]2.&*2*R1:/,QZE'G4+DL[E_L9+;?C>MC*0U6$O'K1D_!8$0_]/&H%HN
MB!.(BD=IGTWXD<MU8PRQ-=B8O>^&4S]S?7S8W\@&!S%+R*P&1[L0#Q21],BN
MU2RHTJ I*&."Q@O!!L++=]8T%*,[N,@J[J=WBA]QV:<KZ784BW337V]*OA_,
M(,P?NZ'Z':4Q:K-D75?=F\(Z7Z[T/S\,3?5M2J\QBLPB$A(1;*Q?IF;<TD94
M;2,+0L1G6)^@8446-MA4974AK9'>":)%O/%H:H&C0@<)S]3K,#&]M3.+K-5A
MRYCI?,5MSM<#4 ,$T/&^=%Y>X>/V08LJU7H4:Y0S\;LX[I;8KFUJ2^5Q<P$#
MHN"YEZ0@T!0%OT6ES>,.[[5PFWJ4?> &H2(S)QF#S5NE[]*O1#"?'";3I#M.
MEZYT\C:G]_!@A:F:OCAL(HKU'&?TP[\D!E&G2_H>]:OW@](?+A.$X/>_@7)"
M]:Z5G>]%LLOIU+_NCR/SR-R;ZIK<=[3[$KQ?>X3[*<-M@PP4:U_&)/X8QU6O
MSWCBR94,0=BW[[^$3J^("!7;SV0IQSK#Z]6LB7]!A[^A^_R_DCT;S)J27#-N
M'/F+)>PO+3(@R;6*?<8>S$!0,_L!IK+:ZL0MLP07N;")Y,&C["E/$05. 8ZE
M?MVX_<4JKUXPL/F+)0$L-/#O#' ?]%4G*IK3KSDE"H>_@;N+52V61DCVH =(
MME@L(=..)/H;%@N=,71AQBQSZ?I#VF7.9(8*)RE#<M^;.FPNK"9&\@D6,F,X
MT38KU/IU)=V>=":3AZ?P@0SBZ1),@W!)EI6P=&KV4N/^!E,7;G3_"[Q7Z]9O
MW_0[Y3<N!.5DCU@J60ZF3Y\;S,P8OBBX[+XV,>#V\4\5KV](^UQ@EGB'HA)+
M6+-T2T[6C@SD2.D9:CAH\Y/(_E@KK^C$ P7V>J&Y<1I7?$V%BC9!+MT>2)98
M.L/\#C"*V[_/XS<I\P,;KRZNZU:]/GZBUR][CWS76Q$=\Y!]U&VE_40=1TQ7
MW?R&*%5H%@F%9%"X"[TV>'T@WK^8P".!VZD@/!RB,J1:J#IEE&EZQO)VB9LW
M/V7U[1M\;1:J'_5#=7("4^)N1C1W8:*TU9&6@\)%^ TQUB43>@8.Q'D!/[V<
MY&-7G@]?787]MYF/FN.GV#:R'W[$V+""CZR&1*+3-P,;K7V=Y"<<-<K2N+;V
MSY _*ND2YQDQYCRG%&1B4_JT\+<]GBT3F)_5^*[''NG?5+I>=M\*K<O:[^Z1
MG$;S($JR3#0@A3KA99ZE7TQP[OUSUX_FA<S7HDMSBK2N#Q,T4-R%TUJ,W[*@
MM3[_"S% SK^*NS$K7"]X2Z'L$F;-9L-KMS;@MF,9S@.$WP$!PXK3P$TKCAD9
M. 6Q$QJ.^]YFI?TRN=D*;/9E-IP@<8<2)!LMH!U8S+N:5/5$4S%5$G^E!3"]
MX$_O7+1;%R>F'IJQVQL$C Q&DN1LTAL'6G&HRRHZB/$XSI".;<J8UCW:Z^>C
MSM5Z)?>0;O'04]JPHLU;=+-[AB#1DQ*)I0=%!XK;R;$4:KWF=W&CIQW*;<KY
M<K?8G[D3/(Z.MUNG2#EW)L594/5Q%1L,^;MY=A%02U"7>!K1-8RKK(@/03!R
M4;<!&!F++$$DLL9.8=DCYJ4H";L:TU!#/A3;7IN[2(+O[W/Y1P(+FW?DE&"^
M/%UUQ(8;D7Z]WN; ;GNT=D,6R"W'166W#J;929SCI.JGGH@5W83,B+14)*I6
MA)N5.I4QI3NL[O76(FK=7JPX_=WT!4M,&7+.%$5GB";(..N,/...$B\)IK8*
MYZB/>##[V"UE&MTF!^DEDN;8+%-N;+:B"K &ZZ;D?G9(@O#X+J(:+N1<%JN&
MVK+%];TG/X"EF6,Z[>(*28JG1,ZQ9(DW7IRX<_[,+M_,S,0OU@OO\^UCO1T.
MQF9M&IX97V+&%*,\Z00K_'X24H+4:/=IC24ZJ='W69_$&GQ[/P^YI[AYI55>
M$ZBCU(CB5HGXPJOW'0,Z6J Q=-/_ &<]R*<FP:IL;+=5V*9301/QDQ#GPQ<<
M9L&J+?<;B 540A/P[C;$E$B?O,N<T/B1Q<6#44'6NL*S;9$*=%8U*P"6ZXBP
M"7"WDTL3,UR<I"!$7T4JFS&ICT?=IMU]KR+='O!S+A$G\M*M+4N0TSFBL,\)
MY6KUF-"JM%'%Q:TQJ&UWMRTNBS<0M\H'RBFYQ$;XB#^YN*T2"7FDHK1=F.]>
MW]RNJ[1I*VP)O"OMOUIDY*7>&[A<6)3=GAM Y(=@VZ6+W"<[.0#1%JA JWOO
M#U/J]C6NO+Y'*/)EQ.$W!@,'P!=&,V)DX?J8S+0*J C;0Y$3;B#I*=J&UQ=2
M7(!<@V9Z4 SI N9T:R-=;W#+(B[2ILQ!MEYOUJMEPNBB-NA39K,>3-(WDC@D
M9EPD-Y3?)!2GI>#16O+6V9II6XRHL\@#/RPSW(,FW3'*;18:F0%;)=V9X,0;
MU:[Q :?=C-%<;5(ELM3K5,44YB))9<,3]4[5!/S7!H2;%3&H)%DN-OO4G3\)
MZ3,B0);4DFG4C2)$9A_@$YPBD\L2#Y,:IU3WD=X.HDY.X#"9TY9;RMEBL,O,
MI)1_EQSM-P,IJRVB!F+AKF-53%DL^CY\BY62V^V(K<N3<#NAE+#0-Y6X-)-/
M\Z,>:1AU(HJF.YK_ ##1WR:PU*J?$N.\+^H'?Y]C%Y@P =<DHU>K@@,_G#9L
M^KTN\H11-I5BP3JG2FS%CLX3H3%STV[=(-SA&\TRZVLB[3KC%D\,C0B:E1I@
MKGW*XAIT8UVQIR6S='+=R<J2%O?"2/\ R'<[==;E&<5E33B1X#:NY=]13%LN
MKFKM4P[W'61$OEI@Z@9C-0);4E[A<.*<52;9EQ<CH[T[=*U1<7:^:9OETNM[
M<LZVRY-3[K#N"LQ+E-C3&WG@8CMO-O//66@*2[4$L=\FS= U@J>)?TOTVE4^
M!?!JO331(#]\T_=K;&,O-"5*A/-Q3/Z 2%%5\6+WW6ZOE-Z?OD"_2Y=N;NI)
M#!]7A8C3[5G>40;G0ID53R*J*8NKEKD+$.&_?K0U+N,AJ+!C%<(O'ER7CX;3
M+#2.9W''#V(B;UQHNXZLESK=H_4=MM<*1>8C_*G;N5DRX4SA2E!U&4@K(9D.
M+E\QU<*Y(UIJUV X"&1O:G@G$-OST-2.(K1!LKA[3NGY+TRRV]VP+;I3[S<A
MR1'FZC8GBZKS0-MN":RJBJ)3+3#G_9A=OYF9B%^L%]_GVL7AZ(O$"QZ<S3"3
MM"/_ ,*6Z"253=PY%S %ZBJGW67]1$^,Q3\/A7P-M/IL=9:D,.IYCK3HH51^
MJNQ?<./+^[N]GQ@VF6OY=?N.EN]#2S!/:@[MKHU<76F04WG[4DN++1WA@BF\
M-MFQA-13]Q==5=V(%U2*,BTZDM7VJW3F<V5'VU9GVV:RX-"..]G9<2E*BN)$
MJW2-56%F4:D];[1>^%"RU_-MH_%D/B"(JHF8SP]IK33,H;=)F2+A+*;**5)E
M3)4>-$>?==HVB*4>(V- $4[..\75ND6[G=KC[!N5R9B7&0+HHS98<RX0[:UP
M&6R)#?\ //:9)2B==P[Q^\/4\B5JN]W:9[0M]FDVRR-VH8KBQHS+T;E'B=)^
M*V#@GL50)*J19BQW9P.YS4MUGWNZ7B,U>[+[2:GY(Q7"W@RU-<A-1VEB7".X
M^CK;B=@&\^S>EG[SYKER&]6EVVR4BM/@,"5,LRB5KDO"K:NB4<FPJ@EE/(GC
MKIZ]7&RSFM&:"L$*7'N<B,8VVY7>,X[<HK<.078=D,W*Z-$2)T0R3P2;?<(K
M$V#,9./*B26Q>8D,.CE<:=;-%$P)%PY+C#?[.+I$7)6^YMK#;KN%D9D24\ I
M]=<7&%I9J=ENSK#T]^XR^;??**+P,(JHTRT(-B^6Q!3?B7=(I:DL@3C,Y-ML
MMW&) 5'%S&RT!1'G6HY%Z&?*G13&E=6V2VOVJXZ0M4BT6QB&^(07V)3%U8>?
MN31,F]-FD-Y>7BJXA*N6NP43&G>\2YG=DO\ IAJW,VT8LQIJ HVRX3+G&YF.
M45QQU>9G'FH8U&B8NVF+NLE+;>8JPYBQ'19D\(B$UX+I-NB!5#YJXBZ3L/.'
M:H;DQUKVB\$J0JSI+DI]'' 98 AXCJT[.[$BZ1V;SI\Y1$;T2QW!MBWYC7,X
MK4:1&D\!#/;E$D;3H%$Q^C&FVI*6U94B:\L]_FY$B3*%MMYQX\C8+F;9$:(*
M)1,/W: -]TQ(E*I/,:<NG)0E4US.9([L>0K*&>W*!("= XNS>F!N1NWQR(Y<
MYEUF\[*DK!YKE44A:8:%&>==W BKFVUQJ+O$MAW9;_J=JXLW(94QIV @W.X0
M[G)Y:.,5MQI>9@AEJ94&J>$KK>K8_"O)HB/7:S2$@RY64<K?."33\:2H)Z2A
MGILKNQ;=1PRO\ZY6B8U.@>T+BT4=J2P0FPZK,>''5PFG!JE2IA;)JNUM7*%G
MXS"JI-28DC*HI(B26U%UAVB]&PNE%3 M.W/6DBW@2$%M=OK7*)0LR#D& /9W
M[J+MWX'0%Q"9&T\VQ:HS+=ODHS)98LQ1R@M ^\U([(<L*+5%54PO=H!7#]'%
MLK]AS+)!;CR,A'!<7F>!P^/1U:+PZ>+%R:@'<BL%C&X7IQ);HS9[KKU"6,SP
MF&$<=DO(+;09=IDB8UGWPZIBE$O/>%<91VV,ZAB[&M!3G9<DD%Q$,(\N9D!H
M51%X442W$GW66@[^%F^ "0U^0?"O@8B$O#E160Y5]?0<1L1('$Z6W,NWJP;$
MMAQDVR45S"65:+2HE2A"O0O2FW"80LBMQD)$<>/8G6J(F\BHN[Q_#@&FTR@V
M* *=2"E$^ZJ)(A"2*A"J51478J*B[%14P[</8<RT.OFXX\W9+G(@1C-TLYJD
M?UK;0YMPAE!.A,<YIC3L>-<E;)I;K)<=FW#AG5"%M^09\OF$E1>&@9AV+^PZ
MHNY4HOD7"[/4'4F2K7LU\U>FHU3X_"W)=!4@0S%YTU1:/. J*# JE-Y;_%X$
M&5'9D"-<O&;!S(I#E50S(J@2BN]-N"(+<QVO.1S.\"U2BIPW2-NBHO5A !$$
M11!$12@B*;$1$38B(G[,*T\"&!5V+XT5*B24("HN]-N*L/$Q5554(.,GD%!<
M8RHGPXS2GCDT5%00#@#XT.KC^9%^# ,1VQ::;%! !W(B?*JKTJNU?_Q5U#IV
M'HA+JU9+S<K0W.&]JWSOLV4[$*2#0VYY!!PF55.TNS$/3-QMDO3%[N)<&!S+
MS4JVS)=.Q";EBC3C<EVBH".-BAE047,J)[N!HO0ZVQ<UJM7-!-@\V\=XNDJ3
MPF6R1]O*'*%'HE-Y+AD7W$=>%IL7G1'ABXZ@HCC@A4LB&6VE=GN8]UU==0M4
M.7+2%&)6GY#CTA6W'LC;$9MUXD%MM5):4'IWXB3XRD4:;&8EQR,#:(F)+0O-
M*3;B"XV2@:;%1%3P,S=1/NO39JDELLD% <N=PX=.*X &0-LQF:]IUQ1"NS:2
MHF"=A=WD/D!/]UN\LW2;0UVD\W;N$T9!XB05Z\7"[AIZ;8EM<MJWR%>>:E0)
M,PV>8=:M\H4:==6*T3:N9VPIQ1]WIHM,%#"\7R[2A4IT?FFO9MNAUEH+.=OU
MBRIL?M5V(B]>(>MKM#;O&JY.F;QJ&-;(,<HH7%P1GR[' 8:%7C0IL5M@:I6I
M'7&I?T[L3$"TP6F%@36[3,M5+BX\2.V]M)+KJ2FPC]I?2;V55<_@TG:])';Q
MF7.+=)]SY^)S=(S;L2/;N$/&;R9W4D9OJIC2]QU K:WNX6&U7"Z<%GEV@FS8
M;4I]D&<QY$8-W)O]'PPY^K[N%JCSY*Q(?J9$EU]X&U=<R,16GGE!L$[14RC5
M.M,,R&\W#?:;>;S@39Y'00QS :(8%1=R[4]]WJ^R/Z/9;3<;L_79ZFW0WI;F
MWZC.-2:GU&< HEHT_,D//7-8_!]IWB>P@O+S/J_Z*U)VXB_]6C<=R!*U9I88
M#EG;1J$]<(ZVWVE/A(RB-C'&8TXX3@H@+E)S=MQI*P:/O/L9V1:YEUO#B0X<
MTG8\F8$.W=B6P]EX)0)*]FF;-C3EYL=NONF.[&5J.W"A1K>P+!6!J=]LE2Y\
MEAPYCKD1LT-6UX*'04ZU<[M>Z=K-=(\T;1,NK$4+A/E7M31MRV6B,X+K \F[
MZIPS U)Q"1$1!S%9E[PI3ERAW(%F>R;BY:)<2XQ&G@;F-L7&U@9PYC*$GI>K
MSB1 2*E2[RWR<<LKEC@7FWM40),[VNRP=IA .W(_+=E-@O0%55=B+B[Z@T,X
M^S;;,7%.VVYFUL6J..7.%O KF'%NLYQD=H(1.%6HB-4QIB^7:*+$R7>;3=KG
M&"JQVRTA98[[PH)[6X[[MDH@%7+GRU)=JZ<T[HR[^RC.QN7:Z*,2%+5]9LYV
M)!;7FV'^&K"6YQ=E*\3;T8GZ@D3O_BR!IRRQ%GDS'0W-13EM]M>EI%4.7S)+
MD&\H9<J(*[*)C56I=<7SVC&C7=FV6\W8T&$W$2! 2;<G:Q6(]1,;BS52JB</
M9TX+1_<LT_#@\9YJ%)BQHY76ZLL5%^Y2Y$\3C6JVEYP[ (!HIFBKE27&[Q7G
MIM@B6"XSVF92V28%QN>QNWVV+=;:J<O(<?=SEQ")$;;I1*UQ#TCJZ+'#4<*>
MQ9+5IJVDPD"#,O'*$+8/))?;-Z2AL\5TW:)EVY42F+Z?>X_PX+,*!'L,(1L6
M0WG'7UE/(MG','*,QVQ1"6B\79NP;KA"VVV!..&:Y1  3,1$2[$$13#SMU=D
M)9)$F5<) ":H=OT?9RR0K?'S?F3D\1IHB%/ST@G:5KANRVRP6B':FVA92 S
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M^*,R)9[);E??<C.NN,-/<>0<:(H&\R8T$S-,J]G=6'I>]V74FBKK<G6V;?\
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M B:JEG2[=@%)I16]DR.5[M<[=0_G+5.+]]M:_VRUI;ENAO43 J@H7VCC76C
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MI_889:8R!ERD-6TIRZRLY_(QY!F*HLH!@'ZBH@+<#^*PK^GK\=8</4K9ZH*
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M1VQ!S\JO/U! USTY0]*0G%_7<N3M<*+$41,>[HK=6L!$M ,:0$ E0!.E']>
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M^A<6Q^V\-+*-=KGWPA,$>=$1RY0EWE^A+A@FB-M?C;TXN(ITS_+"0="9@H1
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M.TZ./KL;V",$%<'P'[KQ(:3J!6DI]HAUD>% ?XN^O#+9N!O7V=% &_V84'^
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M O\>_B]K QY %WUQD]I?]+_PEST!^N\I)L=\F=__<@H:\_<QM;_L'[/VMQ4
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MQ[#CU$TQC5,M=4UO?NR3;6X??B3#$E]X5'2(RJ^@;Z^YI?T%$!=T/BI#58G
M#4]M)LSM/'(JA_ IEZV$\^769"/":!(XF*'(!?O?,ZR'>A!6AR&]+R_TE2[]
M6A.VCZ>SG6G7B\7G* D"]!K@!35-@G$)4G8X06<"(S^>S7)?'/=!"\LZ>J:M
M_SZEG;"Z\(CE&ZV^]OS*;SXC8,?Z;-#VPH>@H/OSK0CT  38\#%JWR86/FB7
M-=U;/C6V)&HAG(X[B7J+'J.;7B'*Y S"9\GFYCFPMEPXFMQ:$1\I3,7#%FC
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M^P7_M41*#INF+8Q^X@@7>',(=9'!-CRW-"*F(CYBENSZRWX,I2T-A\6]WJ2
MUM0QD_=]_?!(0-]-2V>/QCT3-V/Z0A":%Z/53;S7:<D<%ASK%)U,FR=1/7/I
MWH :>=UA0ILU,(W,PEG@1PO4H.V6]7(XN+06^*T50Y Z"8>NGQ"=RN3X*=CK
M,93W,6B7]/"PC^HS^M)A;T&%6V #RX?>()S3!7]?!WJ<& )!M\$>VV$(.1=Q
M6;B>'->OB[1A4BFGME\#7+^W4<-%0B*9+3)\<_T]<K9%;J87'AF_%V2'][@?
MY69XZ-1ETY0M#M=\CZ*!+<1SL DW:/=Y",O)8A4^4=L!$NC"Z3ZXN611M[--
MVD=G5"TLB5_&\?P%#!ESF6"VSA,LY<I:%YHP /3NE2UOC_,RQZS=_,23'T)V
MA:?11:*$__P%. MU?>R]O ]-7(OW1VJ5B(^(&AOLPY#S-ZIQ+>G,\;MSV.DV
MA'Y!1#3NAP,DK&B/TWG&U)&+Q&HE+<Q ^<7:L<_E_S.*;INY9X&<\';W=U.,
MVW<=!5NJ@A8*RCQ(96\/,V_*^C6AXV7&KWKYE]." "(6Y%:J1K&@X%O,.NI,
MPXDFA3YS-&A <BRBX05BJD^% O-4)PV!3UOZN);&\D;\G@$^6_ @.F^"L\CO
MWW!.1RW\?1,3_B+*MR)J*1_[^\7 FPL$@I_C90UD=QAGS&+$T/@H<%'2U#&Z
M*<72BW)P""I(M/[Q*2$%0=*K4+Q:MDVPL(6!:#51M4/JF16J_)R,AVD%4IGD
M=NM(SE:=0HR_V.^/_[#C(^V#NC0=;+^%!@7(,HZ]6=XX) VW+6NK3"@V A#4
M-TV<-?WGV2J@;#BP 7#M:PV#CQ#MX40*$[+FL4/3*"!B390>@L89;)AMM3@X
MA].I^@]5IR8R$@T^ZAZZ]%C>O[F,D2!^T,+?4S3^L=?UQL;Z]A9Z<@&U^0NM
M+X642&SW\#-O?/ :) L>8(C\%0MM#@,;2QHD ,U3RU]3K:66#L'1"9R$,B%/
MA=PR!((.IQNK=/>C69 MWW%_7!B>G="@9;G5RB'99J"E2NC72LC@(B&+RL,)
MS1RO+<DQ19&1IZ2A@PMY<QBP\K5*O&_\MHVF1V:_S%XS/2#2QA?BPA/:7=94
M2OOSC.8JXL)3!Q=JLO,H2T76TB@@,+7E[)F3'\IC#M)@$D<-%; =V16_A6P%
MNQL/PN]@^/RK(C_O$QCK]Z3CITC&LSOQX>"37X *-BHO.U3=\._I>;^ME[)\
M 7/47W] R@C;HO@=8'QZ3'1K)3)+)8PF_ZBXQB4[LY&#*Q:9#7U%*H"98WR(
M%JJ%%*"2L$H859[&Y'%[>,F>NMHOJ2]9GX?&L[H_*G^Q7&_?F%TQ#JE@^WU7
M24&M#C9+G_Z3G7#L)>[^>E^QD"2=.(I19&I4-\<J0RD%WVX=$?_M0PA$XCRX
MN04JH4P9ZO\#OGQG^SVG((C$75L:RCZZI%$7;?Q1QBS3*7?X8J[<J N D0_C
M@@M_6H_SDF1$8H]6AGR<-P>>N,(7,'8)2XX6H25OM#R%GR(#:O<>O!+GRE,*
ML."%O_HI[&A&W B*G;?Z&;4$GLO>CJ@M45!BP$+5,=/#U*B73(_]*L9PI= >
M>[("ON)G.4P#$.V;H98$2(V92\1TY%SBH"8FB>?0XOCO=XAKO?YL#SA^_0 9
MD)%%L=W_T92X7[7Q^632]N[+5^2U86(205Z1US7^LF<##JM-S[+HD76,F[>'
MM96!/<9Q0<2PTJR[M</HW$2]99N'K-7?)[D]5]GQ-3); # >'-V?TWHN;I(N
M[NE1,V-_]/@H%4*3Z"T_Q\[[G>B$,L,O?DR)8DM7<6GF16XB_\Q;QE/_J8QD
MQJ4OP^>C"=42C?2@.(L?X[:\0\DPP<T,3;2^/O@+,KH22_&*DQ&7JL,S]7JJ
MH=_COI#W&(%.O)3@63TI;-ZZ&[W!F>"LR>XCZHUDTV,PZ4/NBFN/(:!K#ZSL
M4?=REKJ\;_OCQ#'BAY :(@I;B#((\@"(JV!<X8 ?$+A5OW-%.18T%9)S5)I$
MY4%IR8$H#AS<GJO;EEIMRAAKG4;985SC]"Z?OO\%F)H>S(\'<DP91/Z^8?<4
M3AOB+[>,,)DH6@K8@J,>UR!3[A<(JT*JS"0X[.=;0@'2]@FH4>.;F(>'5KE0
MZ[6:MNB8((FZCIR((5%:4G0 :S":I@A=V3SM2ICNYBK6BN[-EJ)OD3L99(,<
M([(KY1'XD:#8,AEP;8/$ND;<RLH4J)V)\2YSZK2+Y-8D'=N191'3\)[:I. J
M6G9PCL,(CV7N=CR#)&IE9%M66XSS;O*;CQOG5[3J7W"1C]A9_@).BKB5RA6@
M?UP);'9=W]:*0^-(,N-$^>?532*GC=;J3ZJ&A[1:%.%:_P1EE:IJR=L[#C6B
M_/^_7)#U[U$ZD44,4\3KD&;WQT$*-?"L+8F[DL! 0;IPSO?'DD2F,"WL7&P@
M+DE=P:7F<@9#5;=&J]21.]USL,&51],Q&;OJ^-&5-<8QKFI5*.\3W%XZ72/5
MMRS8_/IC6DIJ'0&9%ME35QD[C#E&^.Q@@GF8'D1SHSI<IKU/;*LAE<K'P  L
M<LD\"8:-.^[AD"U"X$\5(FAHVV:0#"T?20+HAKUC);1;39*K=3P*-B2D/ OQ
MY A87#Q)EPUK,$SF@%<24RNEC+)$N8><)G4R823JNDB^5Q\DBTJ$G]Q(,9]I
MW]4Q1SP<IKMJDP45C,I<AL[2U4SH95@U;J8"N1-+@2FE_(X9& FU,#^\KN"'
M&<-NRJ2NB.T*6OH$0DJBH]-B>,-)SY(^1Y7.2@N*"L5><S''P)XYK>D$(A8J
MM2 8/HR$SKPKZ+^08<%GW?_PMU2I'XT'%Q4ZH6\(,!PPX!,(N-1&]VB)](F7
MDA6GBK^W8S3.Q)N;<U+.)IU:R]$]]&X:1IN;KPB-68I&)I]?3,B</65 3W*W
M:4&A(N,1_^1R5V_1#8 ?,)\WCG3KYOM-!%$8^]RZ0)><DT%:V$A+Y_A^0E$*
MB!!CR0>H3*1#)CL>5L]=B&69FP8&3 ];+O/%%6$PMOA]P[1U%Y Z64V#'U./
MV -M(EN-N^5;4\ M"H)=F"D2XYU2*?<*G^/[R@)HR'M)[U&Y9V>[7?(MS D=
MV(YD*%(U,84[='S&@Y.$IZ0:N#B!J@X:3!NX]BDFM\Y0 ]JGZ1M)%,78/(1T
M(_H9R)+&GB\2(77(J)'%;E,&@G$/J;CEX-]!6+A_U#$6_^ADY-:$T&L/ "YD
M8,68X_B0<&'\1F-05=D!#1+.<TAQ(5QY>,K;47&3'3898:UR</U_?E6%*1LI
M(U3W7VA!(<P%4-^!)HC4;+P5#;1X>;@U$?!$8$(96KYV4A=8H=L.SZ/,31"
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M&6ML1RX'K X1FXP@550##-D((N6DJ&08OVJ,9QF5")2O4*3D95^2R5;B^6N
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M04LT!;\MI@T*UHGT/#(F\2?++ GF 2$<%ZA"=UF:IOT7A4&<2=O3 $<YD)-
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M%X=RQNA>J_9?>S7=HPH!\."!I[9FPN$<<@2_&;1=KYM^]&,/J^K>1LVDG3G
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M]4"JPM9&0@00B'&]IC=&@Q!5F/@J!E&<5X\Y058:1@&PT@A@C,\04IR0%PU
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MH7@AJ(B>3G@&62WO+)VA&"'D@KZ$K4OT'<-65_))_P!1Z0F$;"C_ 'NYED*
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M_;.G!CPH5O$IIUX6=O[A*>-STX(.&= _NJ2N\ ,'_P!M_P#_V5!+ P04
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M"P$%!@[Y'U,HJ,3OT-Z^)T%G9F%EP^ DY>#BUB=CQ\3")O\<F6DG3$DEA0H
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MB+=+#V\H A]]R&05A=XN):7R23S7I<>LY@.GZ\;.?(JY\B[4534;ZBWC8LY
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MHW$I,+\T0_QD)[= )0/K]5M"&':%]_]>)HAO?Q][F3>7!C__?ZZH_QR^+PL
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M?4(T$,=T;))[!Y@@#JK'JR<>*4RIRV2N6'-C+K^8S(Q#D*2VT J'!O]BV(H
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M*INY60Y<S9U>2VFTDS,AJ7FZNFJY_N;&[4;(A8ZZD$;YF?FO5Z=O?K\ZG?M
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M^D?.@\<*9G6<-@GL0K?L@8+ I-_3T$!<FIV3*2EAD'])L]?[),/^M?\#1$N
M%X>,C+0#0D=2AO]T-.$ZLI-G$>%!4%/6R0_/KF4I,K(SDIE,DJOB=04I4BC3
MG#T+4J@]-K8'5GLQV V"AVOK;6(*<PTO#!GRF A<4%(4)+?/N]!^BI-<TQCS
M#;T.S"IA!M/JO3P7.,%G>5KVK]PR!U-/SQ"UT;"6'!GB3$-9*R6M9Y XY/'5
M&E=*340)UBLE? >7ISR'@M_54LQ',^S,Q^P%'433OF=E&.[YF.>!@CG;1=I>
M )QY'M(2%H+?!'=W81YP%:=%>!^7XAY!U ]8HI>AY95?A*1SG\1W7GN#[<0;
MTU<(A\0"3F02EC+G)NW,XZ/)%DJYDIB)>Q+MO9-0E)/06SCV[M"'\#)>:=:E
M6)".7KZ<W6S]X2UL?YMPG%<GQKY:HKMN 2_/K?=71VEQ4 UQUN.JYV7B,TQI
M/DW6F#!#QI7NNXC*IR<<M<)V^IRC]#+OM<=/WC3AV';)=JO?E_?A/(N(9(SN
M,16;((PN3C-,0>7G;JVT#R82WQ:TOV78\"$V?3'$[1HNC(-2U^JCY<51#/#?
M&[AQ')(1>M-V>1 XO?Y SRI82D.DN0:JH<9W27\]M_B:D,2UK!I^QV4"&9#=
M;7@RO;$WEQL;.*N^ZU2LO#<7BBAJ>PYCMRGLBQ[P?H89[O?>96F&7DC1805[
M"NUBM1(E4X;]LI]:'RU8)GR5="^(^0(@$GN<VC;V,1.KR_,WB$7^2 J1: -)
M(E>M)VY@&--EXI(F;:0K'!__4!L7"I1@OI1O6VZU!PX]@"O%C<?F^FO.K'%0
M/TH]>N,]MM.^ '8@V'7BSQ,=SV&"KWG>+Q0L4%6B//2*AL>8A$A260T3R17Q
M\$ /YIQ?65X\ED0,FQ#FV(]I!'F0]&0:FHKSAV*I.\L))^J#C/4&!7M@M+X]
M$4Y-)BHA/(?E1F3+^$>EV_;.;N[-;M]K"(6^ /S2PY^6:;>?T*=_A 9W.#-[
M,[7'/@6H*-=%B/AA@ALST"Y6A6^@+W0I$UC1Y.>1]_<_(O@P!C\2JDI[;7D_
M$9R]7XH&PR:#G!&?PVY[5MX403\X),YNHQ+!(1.;&1/CSI\&*?\? '! C[\A
MKP,%\O,2?P/ODH_<,$LC#O@5]U!>>Z",$?@6GL+O^5>/%J_W'00($+]\I%N1
M&8-"T](3GI<>;]MWJ@O2D-%W<\M,7_#U,S/P*_"7R%#=_5D1@NOWB]3Z:OQ1
MV')3\.,W#C]"#Q/&S$Q& T;$:-%2++':^>F1'>@2IY?Q]&T^I72,7\?EIA?/
MJ?@/\(2I254=TF>@C!'UE1FYD>TK'ZN3X<5KNQ DF"3X>X[C+$14//?3FDX:
M%DM"D&RGL72.GLCRS[?N(ZGX#^[HVXMI=+;HLFB,%UL*^/91[" _6R>M?2S[
M!;$1##1)(O!W'<=QW'<91+*783_O2I2#;<1+2I'H,$7<R+L7EY#'?JKP?_;K
MB/\ -#+TF1@NMK5L6L;]"M?J8>&.J$.CJX7A[CN.X[CN#5V%OD+;:3,*^?1I
M/H+\YL1T]U>9D-^E85]WCQ#^:J+N/N!&"\?<=QW'<=QW$NWKX0E9<9B38S9?
M@;;[F&5>E;J?2MI'H1YEU'K09!7W>/$C[6QA7S'W C">O<=QW'<=QW$JPAPR
MEY<TD2[NRF=&D^%'R3T-'J<\V^WZ367RZEX,3_FY@P?1)_+N.X[CN._0D&8R
MJR.(@S,SZ)+N?W>!)>H^A%W,O.*22B=2:.I @?3MW&+&:;DP8,/K-MJ#DE=)
M)#S;I=QW'S!)!"0^W$8FRW)TKJVGL7@2I*2]T@2B,,-]B\Z^WZT=2!]<=?)N
MV,&#%FZ3->&W7658ZY8SI0($"&867<^J$]S^PC.^XGSI_=T($#ZI4IM=;/;L
M89@QE=@1-],89)NKZ$)\QNOAO/.2'NG8)+TEX.W@A?C\]]Q@@7AK+"17N-9%
M'6B=D*_0M2G5&T@P; QU7>J($"&66"I,GTF/2.P20/P$7@[!AOVT>>D(]#W0
MAV\$5KLGH^WT2A2A1S%07$*2LON%UDK;"34I77MX2^8[=4QW%!IA+?P"2Q[R
M3(TF08CFL.-*0.P]()/S+Y%T,NY-,]^I2)3"9=A,D%X"!^!"3"8SB@F(@@E"
M4_ U-H6"893U7'(PI"D!'XOL%E_']A&8]Y2$)07PHR(PJ.GOXS/L2B[_ &!$
M:C9;)I'Q1]?R'8$CN/:623\$)GXMZ$&/0@=B+HX7J;ZM-FZM)$DOC4B,KN&X
M[K@992RG_P""^7_L8=O_ (ZG_]H " $" @8_ O\  4W0T8-$MG:IJFJH@2T"
MU7*6ZV^6@,9O!MV#:1R:Y+/7$LX58$ T7-$MGHSM EH%M+1P(UL\13R4^94S
MDU4[H;YA;=&,W8LXTO$%,Y7(SDUL\Q72Y+/F1.0.+/0SC0Y53/'!R(X,X4VE
M00SDU9'%M5-N75R%9#64TVYO5D]I%5-M'(%D5LX4^;,KS93:13;3PY>\\9I\
MQ?#E=M-#C4SLV6VS4*;.9G"K+'CAH=G9QKRNR&LBJF/$<M<6<:/,&5^8:7GA
M&7VLXHLFIK)RFR&<*J7YSB'+4D'66<A23L+6ED -QHZQ@6"1;T9"ZBWE-O12
M$:3B4(7PD#O;SI.ZH'2R5JK-EDJ*=XI&<Z&%W>^2NJCY#O,:6%FTLQ/;D-K1
M04Y2*;6@8E*4%RW#O9]ZF%0T,X5/#2_@'H:7+36'>+$24),OG[S S0Z8TO8/
M2<A<SJ#DX3@%6O$IO (LBCRTUO:QYH"&M<4S32F\ BRD>.2!63[, 8=8QRDR
MDH+N>EO(O";*RR9<H E6G^;6ILL6=7\RUI%#U<6AE!8 =A T')R<!.S M3"S
MKJFRC3S[F?>)A)YZ6K7V>#/N\P@M8O8W=/.MK:(IQ<SS,Y9,R6#Y:>Z+2=H]
M-$Q X(^EN-/6&$Q0WPT[;WG$$9.3KP$[*;:J\P;^YO=68<\S.%6 9M_4E%WT
MGG7LBQEH,U=U.>SXD'L9]QF!2A6*E#H,>FK%37Z?&B4HU#Q;Y;U*94^=QK9X
M3':?&B=M[SA&DC7E,:V"+M+@,_.#14!U>#6E@*3T=SF"[S!&C,WDSE%=Y]A$
M2-M0'6_4V]=YUG:EO+NLUUX]A>ZKHS'[)-"[S.+I*$DG8&-XFO$@<",R1XG.
M>YU";Q=U%$Y)@0PO%5X3!8][P-8ZLV)W0!1O %MT 8#P _".RE6W)A1Y<KB9
MZXJ8#119%:H,9SOW9<E)]Y7@']36E14:'BMD_2OJZGS3"7,.?W5:]"L]1C6+
MNBN?- /PC>/:!@*NOJ3I?:F([+63'92=N3N'$6]Z@I:+ S \BII2APB\#\*\
M&[W*][TV03O>T" ZUK&G/MKIN_V__6O%>9-4$RQG)<&L?W4E_P 4.NIK2%!8
M/LQ[:F^7*+NEOFRR&<#'7AFD[<FZ6?F%.IU,VZ)_5(>GXA$==72Q2J"AB+M\
M1_"K$VU[UY5P)TZSJ#>=?%E6@>J-@YG30)O%=2=Y.K2-"M![F3.EE\M0!!U&
MJB&ZK4WEWB,O2UH58+J3MR8AB:5' 5]7^GIWZYB1^,?FZ].%KHNWQ'\*L0J;
M,+I:0\G4&7>U\%21H3F'CK?@7<JK3:3U*('8ZFPNIO[6;PFKGK]."!E-G2&^
M:7-!19]:65@J^J?3D_MZUI'J^\/=T^SLJP=;79W_ )/'$#Z5)/S)D5_#F'2>
MP:\&[2E<11:^^2KO9ZJF<E0)VT>:.)+!>? )H)U9.J<?5JP"I'K8+C4Q^H7$
M?L%&(]@_TGLJT8+PUVT^9AKO4\NE(2\\];3+Y._46I^S0.@0P$*O04;L%;P%
M9&CIJ;R[@A%VE:MY768=26\R]S%S%^\26>*V"9BS/N>="B_[JJQZ-3)O5V+Y
M$Q/\P=8J+*0<QI?2[2<G6G7BC+6 4$.(+?W5U>?IRS]PZ#J]D]!C7@(OMW=Y
MLM3P^IA>)$)HXT9TGPT'/M>,)/TB28#>F;?53^;JQ4^ZR5.EH6E7W@?Z67Y'
M$*^9:S>4.:T@O#6=%+M&3O5P&!Q:I$X!4I0<1J:W+>JX+.Z='NG7HTCIP1>[
MH?B&90T'G!A?+H=TUC.DZ#SC@*\R:A5Z @@%Y?F!=P]+F5>)D9JU$D[6CB3>
M9H(7/-K[(X>N)V$,M9SGGZ6LK#PWG2/T]#6J'EK64>1.X<Q[L6E6<7A/X5MK
MP1>9$91XT9E#Q&8YMCPR;\N\(3+6*O7V6 \O#%'TN25GVEP'W1$]:6=/GJ$K
MV4;H[*^E^*<*V3??JR;%V$1+/$KXM"=59U,X5-KH=ZK>X:+.<Y5Y<RL8H?\
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M91;F5,Y$!2_,&$L_H5G8/&#.%5#C4QOUP&YZR-&M.K2,V:#&:JJ6@GI,/0_
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M'2,(_49@B8([SW=>*E3YHWU)(^Z[^ID^=5F:U=U/:RN!:U2_3D\*\6)DLNF
MP:RN%Z36.\<X8)N\\;#G!TAC=KQ7F.8C2,!-B6H2"8J, [IKZ&3*1!"0X8H2
M9?!*%G[6?PZ&2C0&>F!;RIWZC6:',[*+:*\61F\E7I2VK!\F;"8.%7LGPTAE
M75,I16DU^K]XP:U?I@2-"8GK,.PL^5*!7I5O'MJZ'8IYJ8W>XFU-]K,-FD]F
M _UF]\46M&5/%1Q1_P!I7I&0_/F)MZ!$]0:S<I?2KP'BW[B82-%0ZA@6C51M
MH=GRK7BG:9:L<^\S$I]/56UFYRRHZ50'57Z&=,F$(T)@/X]+Z+6("LPRRT*C
MB1\"L9%DW*[*(GJBHBL)T=/H&MGFNEV(=EKBQ2</6R!I2KT8"I@K"26=,5Y4
MS0JK[U7H:U*4%#47X2KS.A+0'LN]3>-9_D.@0P'Y\'73;->7:\1)MYR1U@CT
MX$Z8<TL^B';1:DJ4E6HN:W.G3#=I8C$Q.8=^"/IDHP&\O\H[^K U8ERN(<C!
M:(+!>&3>$<7K#0K/_#52/I\OB,5;,P[^C72E>>8HGML]V N]S*DCK.8=;*GS
M2^8HO/3@.Q)V<C^9(.T9BSYLM:5]![QZ&=<D%^E6;H8KF14:(%I:?62\=I[G
M8 N,G]&57K7_ *:MK\!^*CQ'+R,V(MFNFV*(!C*G_P#'7V'3XM:07I9YJ8W;
MZ>;4_.K,G9I/8&>K&5.9]:N0(<89QKHM+X6]W =2YGKI_;S%)V'N:Q.FK4G;
M#JQ6MM#;T6W1R'OA[/"12],"V\PVXDXF/"&<GDN+/3#$/9^(<*VL<JV!3!K3
MH8/G'HY6B U0I(U8%@-9%7+=N7514X,Y-?\ F,G_V@ ( 0$!!C\"_P"#5QI6
MTIM9OV%),*%*>@5]&[#<=$1-2CN2-117B;P/YS8KYMO_  #7_P#\KT[_ /56
MT&N8HM=B]/F1H3).UFGT:%V4\##9.*&IS)&T(]^"*N'1X2@7EL[-N@1".BHV
M1L+-I"%#'M.9Z/"A$0JBH+[S9$BXHF&_;ER=/:SBL+N21V2F?R[TP5QH+D20
M<O'+G7S+LSJ/2TUR=5O/.Q^:[$EPG DQ\O/8)F8RR>9I2P51Q!>A5\.JM3PF
M6),NAH["TCL2N9V=YV''-T&WN4;;G+)1WX*B[:AL;NLJJQVGLHL)@*OM?+<;
M?BJ^1.]KD2"SH7DPV8[IF:6C<IG;S3%6MDZD_P!YHU>553/D.)EF#%YC3E@2
M![/#!$Q^Z<BQM-!:,LK"6YS94Z?I>CF3)+JX(KDB3(@N//.*B<255VB:;C4-
M+'TZ6J="QRH6*N"U2DQ+H=/O2F%JP8&"K,EUXR<')@9$JKQV;?8[N=",O,N
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M]C*5,GD"1P'_ $B;O3AX&9+*X.,N"X/I%>"_5)-R^;9B4UZC[:&GU5^<"_6
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M+[P<EM35P2C0U14>4D_)CN3;6G]8SO\ 8*3[19?#UF7 <3\ D7#T+L#H;P<
M7!7RB:(0_(O@BDJXFPBQ7/2SN#'SJSE7[7DR5_,,.N^E0!51/A792)<5)555
M\JKO5?#40,<1B5AR<.A')LDP+X<D(?L-WHQV'-<G6;TMQJ4WR.R-I(&(@\S,
M\+V[LZ\!7P-W,V/(DL!$E1U:B\OFYGQ1!7VIMA@F'EVDVBZ"E2[&3(>EO%--
MDV7Y,AU7GG'6W)DECKN$J_DE3S;,PNSLU5+%(3C5<5<R9@%0:*0]E;YJL@N
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M(C,MY$2J1*OE55WKMK6#&%#D3&9,5@5)!0GI%6^TT*D6 BBF:;UV'WH4.KA
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MCMXKRVT54%.E2527[GR)II[/D12#Z[J-(WCZ&T;^/Q?>$D,8, Q5$5.J_+3
MFV_(0M>L7P)T_=EQ]S@";DZ2)?5!/.2[./NKB;A9E_>1/,*;D\1B#&3,](<0
M$\@IQ)P_(#8IBOF3:/!CIU& P4L,"=<7>X\?UW"W_=GD-K[".JINX&[P(_0/
M!/%8E.I[62+HCC\QI6C)/A<5$^3[L\IM?;R$5$PXMM\"/TKP3_B\7$T]@U@3
MGUOHA^%^YM#7A[81_'ZG[_W8<><7 &Q4B_Q)YU7ALY(<XFO5'Z )ZH)Z$\1
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M5)H7'CP5%R)FWS='ZR2,YJ*'!*SK[>*RW#&VALN,M2V9<1K)';L(Y/B8JR(
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MDUO3Q(]_W;UT=R-K.@C112XC(^\BK>A+)2)68K0B@Y<C;:YN;B)\QJETAW%
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MMXYEI, %S V[*<_)L"N_EM"VWCORX[]M)_U!(_N/J7:;?ZBL(\8([#APX*O
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M1UVT[+S0=[+'B<MOLD>.'+R1T7>F./@/6%AJ+4E38G"BPN74N0&V@;B-FT)
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M\U0S+%U9E1%99+=R7>6-,$XG;)INSL0X,=GE21RI^!>P068B++8.(RKV7X"
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M>;#LLI!Z,!7/'+'6:N3JN:^N9]!G32FWKS /(Q=L@I;6894W.F WP+5[6D@
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MO9#1DH$CNAM4P]IB46S+!\!^9<2V@Y&;"^X"ZF21\464];Z,K?878+0?,(2
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M)<&N&. LBK8EK&GRFBQA*O?HG[-#AUR/K"C / "!(AB$$L*-$KZJ"'GR /%
M[)2H7,TD.'GI8$MLCK*[)@J(!A[;[S/L'[W2> %V,DH@"\ 3=:JF].<O@#'N
M>JN5=+CIQC4,>LQZM@VU>N@R;"*!%K%&Y_K"E]YTA@T%L9\\<H\^K\D9_^P(
M)81$O <C-V@55IJ07Z'Y)%5+O&6VJMXU%SS*RM,E+JGH%I)8IC305;0%FA?P
MC%Q;HVE2"G[N.+GF%Q8\_L>.;2121IVQ_[<JWN)CVMJL1SV_4GU-F]#TOOU
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M>R(=B>S^C= UJ@]=-7@Y6W(AI_YSV"E09Q0-<4$=OTW^S40XEL5MM,I9G%(
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MBVK/C#7#2^(?M$>E7,$84G,$9CH4J'Z8)C(R?I2W#DZ,J+TVB/W2A\,AN!<
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M)^#..BR)2T^?.CFBSD+' 4UB'!;M*.@&;(K=_1>=I$^J8"$SSSJ;0I?;*'[
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M&K=5.%GK]<&/QRT_>O%$SY:4G=1CRT[:ISIUUAI\ 4:\941(0ED%ZI=A6"M
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M00I0]KQ Q5EA@4/+@&Q_*2QLV(I<D$90^;+(9\ML$#$:AD9)*Z+1<T0 4>R
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M<D4<8]-R2KU"=GV#BAV4HH.KB+!E=DD6[(R*_%/&:A6/VC#BQH)0+452J2]
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M+GB(Z=K,V!SR@4V0H+'J3HUA?:H?P;2 6!_BZ%P4#Y=MU4-DY>YMH:2B%+\
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M?2(@%FOFJ7<!0TUR!6[NRX('J,I5,H5$[(WL'T>1#X)-.6.R$4ERV  S5 1
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M+CL>NRH?C$;M?)QJ#*2%\!@C;ITJZ'LX-F@[DKCO>/STU7R'#UY(X%KR[#.
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M_*#^GS@B3!P4-2 .QA('O^SHI4*_$ MHN;\83)S87\9 Y,"0?U 9##%J+#D
M^A\VO.#0<C QK\$ODA QF#BQOS1A_.^=_G\=OO_Z:S2,9V G?:P4$:.W,-(_
MB0ECM6?'@;_+*AEY&_Q1]GO]M]B$2!:$>\Y7&'F3H6/XLS_T"@QI$G>@*9S.
MC_-'$+O0#5?AO]3M\%4.C.<V1)][35Y*7)4V]4!T$7Y\V==MZ)=]"_4(_&);
M$LB"#] 7APYD(\K&LK%*)4[MKZ)0*Q*L8WW9OXI<YMQ1CW2]_6MTAKRV=W+<
M(2:P2/ 7,E30-W411AW,T'EM$'WVV4AE8ZB%' UCB_K4T^0ZI!(*S$!BJ18.
M[LNWL<%0+K9,7@&I_)29=._55R?\(RF@0!=X'3YH4JO8M<0E#A<)B =BZCX4
MS'VA.Y5"B+I#JE70OEP- _13L@:J.6]K82WC4#K+)3.J%@*H=9$"@3@<")->
MY4ZY#YRJF@_L!)I<HK/:';T%,\MX2;%Y_<:0[GO/I'C9TBK3M R"U[&'(>0B
MF+ $B-7M"(0D)^P4TDWY2WW6J!^Q4Q9X]P3<O9R?@;,4CKCT4Q:(LW7,)'4.
M:=E66.JL!/(8"_=\2EF*A?A[1O&S&98=Z;$U=#HZ8S 1V&(,CJZ=V>ZPI)N4
M<NB0-T (XH>(%^N(U%(3Y:+A/1#;+Z[C*M*&J)&C'@6%Z9>P7IK0J6D]#5NC
M8F+A\CH7>H-?S'0PC2C<:''T.UN1T?<X44$P7-W.8M0D9R+&&TA$W'DDP:&J
MK<3L[!Q+#JTS$K+$+(O1;0L.9CU=SZT5JERY-,)4=_<2$<[,@)\^%[\M+C+(
M?P831DH!FU* :O@LI1L[*X@.&2\U"T<JZ,WON-"CH[, /.+)CU.7*+ 3Q@,X
MBEL 7A" K"6725J7B#<L)KT8;$[)*TUES#?:&<D<H,.0#NG4#J;,,Z\#TUMU
M_V "3TP+Y/M4D&S(8.FZE"-Q65)[D'"J&<ZO0L;X:<E4OJ&<#F>5MLF/D:N0
M%=30;3F;5VG.P1>/:M#V;E]R6+"TN&)X97]L@RF[V!8#0H$Z$_O? <\ 3G1I
MIX(6%-=I*7VS3 < J$1RYJ"4AK7WZT/U7Q!07FA+F*2$]H5B23$,8QC%"62I
M<7QPAG)5\4A!L3UCJ92\'D5QKIQ_G;])?C1UYD.8Y7%:Z_X]341(OTQ8>RK'
M+2GF&!/+!D[(!P0/4-GA>J>%0+/QGXF-H",EI7624"%6!?1IZC$0U0/U?,H)
MP7QI72;6*I@J4D8_(TRW&8.&Q)KH;8+032S\\ \HT]Y"#2CP:?7O1ND-1Q+0
M^1M[<Z"01+4_+CXVN&D2U4 &6"_RVH3,MIK-7;L>'X= I(C9FZT39XO6O\^D
M]@\+K1/V?UI\9<45;3S->,P?CR:@V=]_&A9?NHO0270+L9HUUJ;&.]8,T;42
MEBK!,TG$' V->H/G;FZUET"D$J(2,(MH,)-25_ZNY@E#7)HY ;HS+IW9WF]Z
MJ\JFD\'/N&73&"O#U2U,9&@1NPY/O@&G-Z(ZAI2L@YPP65/0[1G0"4T9L3WK
M*)NZ?+H?17%+(Q,<15'"'O#E-_P83:1$3L:B258V?99\RXA.VF*A[DW>8';R
M,XFM$T<"B:'R$H!#T@[@M1FHER6THN6F@VHWI0$[A2YT,[_&Q80(L5+Y=_BK
M!YCV!9@J]Y>55UFJ*;^R';-O:Y/VH,,!2K( W5((XA#%I0T8#]MM/;3"9X,F
M_^5:GR;\D?-MA6A-5F][01!)0'^F1;  MF2_[V#V9J-.X68?MD]]UZ)51KM[
M<N';L$?R2:Z3 7Z7S7Y$KP\#]Z*QB][Q<E?'PB>A<F9#X%@)\&=Q?9[^O4@$
M/+;$,]:,[A@F6S&R1B.(^6HZX0?ON&!5)F:F7BW#K[#JU8-GU4L&[0=]RJUS
MJ)$TKB],MK\@53_Y:AYFLK]^,Z&>?7.74]Z4O;+_J?;6]]-.R%NRHXF;QU$F
M)<X!K3G'N13!$>H\8:.MR;.-?)/-1L7Q+?=53?>!:_W3BHO?SX#)*HD1'Y>P
M&7OYI^S2 K^D<Z[0, M92JL8%4PI.T5*JVB^N>ZY7X?F=IYUNN1>81D0Z(DL
MJ"1VB6@X8]-3NZRI-XC2XG/3Z$1<BLY%.(>;'X?VW<<O9M/XAG^F.29,]+8)
MB]9*1(EO9J<J>_E:A'Q^,$XC8__+70]=7&<39V73_!]/6-]\06O^NO1;291T
M-Z)LC*25Z0D>^D!(_48$/!$P$3 @Q[Y*1R7I)W.7$6Q@/QW<_,%$%98SG123
MJGY2L24K^Y-NA7J'!SPG)9SN,+:>\D9C:[(RP=<HX[= 9D<C"O.=>B? ]<4Q
M(HWO<"DYF^O]HN$7=D84C]]=[ 3S\-8IEX(G)UP"'@+;?YTPII<39N1I:*M(
MNA,==1[#OYTFPODDW[E[UEA6.KRC[OK^,34J@]5E\S'$PWT7+I!,0(*-PP]&
MHI<><Y)F,'";S]O^+=>-$&S;^5'- 0%E@NF,YAM2FV14QC=*%S=60*M?\B^<
M/O?02E*WXIRI8Z]7+W=&90!Z5A]0U"-XFH]&H?.#56][<%"TX!Y>2F:JE27\
MZ$X;K4_&E49P=I%D9/CU1_86^=IRT8M+)?M]V)30R3BY6GU3.'D?HDD+PH9W
M'Y(+HZ;[3M_>G)4U=Y#2&F]?T/WFPU?9*$![!C"LQ(_A.WH)3D!6.+*Z%_9B
M@3*_H?.I%/L:<#3%N,06@"KMO6,'#8YY77Q%UF_?>5;Q^POYDR)[S35$:F5J
M9I!L4J%;.BKB7^^,BC(^8LL.N!6X3-__TXUD7_2N4C]_$#R9LOJ01B8Z\/!B
M;O6857K3T^]]QHJTM^@C>0*'+S7E2!ZRN[F2:-E7.W#!0<IGN-O+=C*&FG4V
MA7$"VXK]3DFLQDK<ADC\I]G481$7W*987[ A*9C0K9,3FMPY;F+/TA[%O#FN
MW:CIAX>K)H!"(FUZG4]-%SH[3!MW8Y&9:3@M^S6:$_OM2V+&2Y*TNB1K%5Y;
M:8F=56H7#]FW=*7@0/ VT*YJ\W&0IC[WS/U*IL>0C[=JMMZ4-T.J3L!7X> O
M"U&<0 Q^R5_?06_\9K 7%F6JFY\/.>FKB,V\$9)V<W*83B6JOK<N;R9>7 GS
M#T>*2^$-/$8B$_AMT$HEL&$ M@$H1'OU[>@F5V(J2$@EY3;XOS2_VN)9F>FE
MLX;IO8*Y>B%"=?TT$RC2JC_JF*:T:(X;=0HTZYX!-#59TH*0PJO$.7YYOW-1
M%P52H9O+C)9=^C&,9L/UI.N-<S9F=S&LTO[CNL\!61J4@71D,P="17@V(9^5
M2>0,H)$NO7Y;\,J@'B1(0 )OR)^!8L=9><, ;8^!NZ':C6W+:!YKI[*+WZL$
M[@$.3A[[".[^J]!1:-T41!PDMJ55]'V*38<';'!],B5!@3QT>V)780AI7YV6
M+_3YKBEC3-#= Y@,=%'<TEUI4]LD+I._;=YSS1QN^7Y(8^7/C0J)BD>,)N>X
M''"XO^R=*"\2LIU3)Q,=G,4?='0_1W!:S.$;VFZ>8\K+T;L^#V(H=DWUF6\F
MT_G-3(&F5')<O:A:I$._C%OUW6"4;/+H'$>%29;+;.-WFB5KZI'QNC7)[JF@
M>#9\'8;WZ5_./I/:P]IK$K C4*4GS')X:X++GFF([O1;Q0B?>H!A>_[XUX1L
M4KZT?'I=U&1I@Y5#S97'@J:UZ7%L)/-A'%?B\/16&HWSY5+>Y(!D?ZW"]-V0
M)&F'@;G&GL^.)-''4339:#?&9CNF2\&*DF3N_,U^,/.7E,@E!XLTE,*--X3(
MC'#K3AD^<-T$9_H8E#&'1[XO%75AFTQ?C!>\J!55CFZ[8WK8>&U-PL@YOD'@
M?@Y>RG@I#\0.R-Y..)^0S>GT<.--5C-X*S6X- LVR&272E1A9NE=#@;O\.UU
M0_@)A]XAE MR_UZ;?YUSD<9WS,6^.<!?&$U\IYBLWX(T;84\+6'.3I&VA3CW
MK>A!;-#Y,R8Q*6'VYD.:H:#K(>]#6(Y'1ZJ7QYG=U%GTM9&AD*G%V387.K+P
M9_)5O%CF*8H]?Q84"(YD?L)#G/0[VF).>2 ,?,X4P$S8U!/S;AY. (?3! G/
M+C%?-F P?:NGG)&!B4%U[BLJ 3]GOI\DNR.VOYZF(U))ZPR30,/ZV-SVEMDX
M0V-EHW=H[Z&PF4)J[3<ASR)>+%LV&5",2G:!9OV>-=='WZ9D6J[;M0(*[0\1
M55/BSNS!Y ]*-L$1$)FV?M0I2!9+ J[M5E*:_.R83-#;!5L)JV\YN,Y"Q?3U
M]!3;PF/!=Y4\"+JDXQFO9%DJPBGI+ L^CI*3/M)0S"^D^0AB91W^O$GT6'M(
M;V=]H$T&+7<M>2S8S+E <6]TVKX_7G5P]2S(.H<?CS:FEY-2D9%2#.UFW_CZ
M7?,;WAP4/<GO/)"P)E "H]07V-Y+/1DK1!U$+H\L 3OKGF3-F@R+*"#7K/ :
M;(7UM'J :ISB/9$*FX-"V,[3*"H[E\8J"O_ZY<Q'6ESZ%@S32"-4I:&ZLU5I
M6Z*6LZ]^97WG:)!OZ%RR?S%F9=;?.Y7:KQ8A)F :2<97<WO.6ZJ:]/T7;$S8
M081RU.+W5*F65M]XA7[THWHACQQKC^.7<-&=KUN3"8ZO2X^%R&-$BMLRS";/
M#3Z I"_4JR;]?J'< O99> 1)!)VB%%)L51C\5/-@DP5K\0;O5*5;OC*;B6E8
MTO6.4FH"RW"$OD"[":OR][UV7@3#J'$C@I\:Q'>[4-IS!LH3!W!PM$$TD1B2
MTF^<XP].1E.#7*!+L&.K>ZUR32NB:H8QUKA$CR])4 HX&IB0]A']W@V+;&I:
MPW[F-7^GV@1[ICM)Y2$JYZ>2P(+\X&^3U_12\)>Q51<THYHQ</HB_-60?_(4
M\;WOLNKR&4]B[HQ20B;YC!0(#F"_9N.)0\()AA6+'YA^3,A\X"C[W7'N\+OC
M-$T6:5R(-/OZ<\QZ\8>:(/$LY33S+@]G3"045/'"T6 K/Q2P@(VD?6=CD.+W
M.V1L&A)IX!GP#_&5VX8:E^9U-/.\]TO2K.[6&JK:QURCVBZWH;)/&VLV+!;'
MP3 *^SEAQK]J=3G=7Y4L.$,;S,2*(VC*.ZIE9W&K#&9XN2:_7,[9H/)H(Q(F
M.S819K]CQ88G8\+8QYAC"$"%&5($T$M4JH43?G^_<W8BA':$O_NX=@!"I:5)
MH-+Z.I?[=B#\5?5Z&JSO26_N\*Y?GCRZ*2H"%[\X/)04CKO_6OE/"HJ[SL2]
M3V/P*O##=5A=)>]K))6E/3$*D'B/U:@%D-N83^VFFBLLP9$KJ-:#BL&[^V+*
M=T"G,B=$^XIT[2A&)3*+0NHUJHSE3C0"H73$6R@6I@UKY!^/;+!<87)[O-AR
M'O=H\V #*U9OI?6+Z)5[RY/''C/H^(Y@;YV+18VO>,\ 8IX3TWCLO<GUB[>$
M=YB7=%*M<ZO9XZ5P#:HY]Q-&_:C?Y/'$<:O>2%]>V8Q/]9=+S<4: "IO LS#
M%5=_;;)S%"G)H<<\VL8S-HH/Q4Z0JI[US2#U8J"$M<D67X\HLS<19QZZ8BRD
MOPD;$Q%,GMF,#+SS_TWGE,&WX'HV1"RT*KP=^W'XO6(@;!FJDFB\$P0\Q:,
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M^I%M,X?$W:> -P!K#I;[8.5LR) <ZS4*WP<KG*0R;YG3^.KVQ]MA$)M?QL,
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MS2.::IG(VT44;D<-IF (L("+A;Q]8(<Y X1R#NQDOAGD&8-AZDR@,ED=J#)
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M<)UT3(MQ9G?M$_7!1 H< O 5XR790"HP &55H M<1%^RDF2_-U4:;'D@H
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M;%MK-UQ_&3M7*435)Y:OH6^T<8!$DS9A60:A&-]:R'Y $Z(2G1P"HM !:JX
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M-#ZB C%Z)BQ@3"H*#D2$5@NB-.=F*ZRC#F&'>2%ZMQK(.DMF7QS<[ZN+048
M#\?I9JWMP(>\J4:OYD+:G1QJ*"W2(K?S(I>[ ]>!P5H/S-V72&6^!"+1UCH_
MF MHE5AQ)I%O,=^WY@47O KOP"$7!U_+F6&<\"'!X.T=?RV7$'%X.DU?EAIO
M@'#:0R7&,=(Z_E@7!!V(G9,(8.%W,(QBH_+UNO!E633@ ;,,T9UGF(JK?RQL
M$8QTB7 "W6'-X8N;\OIQC'2&DU>G B6NWY?1C'@XP0*X!%3_ "^ [QC'$.?
M.%ZC0_,LU>G A.X/YF\#%M K@$<%ND16_F='M#GP"$O:?F;G.DU>G A.]?F=
M<2J*:P*X5-.T=+_,FBT#??@0CVGR?F!;TFKTX$(M'#4_,!16\. ?0=^WY?5
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M#OR7?.P9?D*BO!6%/UV/67OD4'@(#_@/V':/13S=-0!DI4A$NF@0     !0
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MM<)1@M<(($-FI&B74+R.KOA'M>_WV"[M%=S@Y)EP9$3@--##48'4 D18 )J
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M>7]AB[_H+_J+_J*_Z"_Z7YO87K-R\;WFY6/CI7C\?LW&Q\G[;Z\]HA# #K
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M5)5=$NHY>L12HN8[G;<X&=[C:WYNV>J7?0!:5'R@?<(K+I#0>Z_*EIMSN@<
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M::-$2-=K-)(8U9'1=/:J,'54R\*BA,:)@"P!]+-OY&]1@U2*V)#75;C<J@-
M\N^[+C9E/<$3&V'+>4=GYX43B4;?9L!3%7IS4E4;._?=/XKY'*ONQM+1]VH_
MW$^=H-)G1(WBN PA132JF!<;C)R#G?5U0-.X>I3$:PYQ49[Y.!.E^:E2]*VU
MH/((*<O+TD_7.'QVGS*;X;GQ'X!&US,E>Z2K\\)9H<0583PPMB77M7QRD?_F
M4PI"XEJ>(WW.N+CF='/2XA0K'&SF<8GMC :P\KK75-W5H4/*G6W"#V4'\-X)
MW>-JS[IZEQ%"#_SFS,=,11+9L<!RH_BSID'5N1J6)L0FB2F<8]5[*W@\IC\5
M96;1&5[V ,3'A#T73"CV1A4Q\F,3W 7%QNQ'AWJY9R/+';-'@!A4PC9</7E>
MK6'[?]L>K2ZY],9,.&\ >7/K-917QN6$+(H11 4M4OOY"$P0G=_1+<^;F=5"
M,:YJ76G#E.Q1A(K<.=<O)P?,\_5UW]UO:BJD!>&VJZ1D%@J+_#138S5L^%2R
M&K?D^!B^"L%_6)X1PU$)*$O@_,&4/'LB:$IZVKH+^]ROLY*)'0\)6_-]!YB(
MHNB['"KCAC\:9S/A*&EIX+78%"L*UHV:J85KV9$B"^6.:QS@K%[I#WI)(!HD
MY\P9)&&WT6!]^QH8 ^\ #R1%AS 09YO^5DJ@NN8';B<PBA9I@63$1)8P?!V"
MC]DQ%/<2.F[\0'K\2X:-H:'NB?8<X7H$_C%N,9_7/O14;Y#7FQ:DWQ2U^@'[
M> Z6WA$%_G6 [BG;M^Q8("AXC7H!:<:#:;\:1?K!ADO29_+NX)QB2B,^'OK+
M- (Y_LUK?:4G4I,Y)3TJ89I.*PY7D]2XRF\Q6IF#4QZ H$;27-A[]^2WGI\B
MC$[;3FSEKI<O2Q[W@5JTAE2X2M9N?Y+M_N-Q9F8D@:,$]W<6W1G Z37@"$@R
M4X\D9S7V#0%.(TF\G(XC_69E[2JY<O-8R,TJ**O3)6W]KR9;? ]IH$&^WR==
M4ME&9^65=;16(P0.@BMJ:,YIG-(]3NT^"S_9@NIO7&3G:&N![4@['+3G9O.4
M!21:W%]]PFP:%-G'7VP:DB\+DAL]L+;1M.8:><4:*:'L>YO'R.;@)@<E:,:$
M1$AY#X!1G[@>QD9+V?HUGNJF>@F8Z:L1&.#3]W@<GN&>C^P8LGK)^DWI07-*
M$E@+N[>LR;Y]?"JUH><";D-A/W1,F2(.3]G9<:X\?_VJ]-TXDX:G)B:Q,W5-
ME58>$Q-5>;4TTS"-Q6L@?R]J]IK<2#$]RE/^.H"6B?9ID'!>:W'-9QN#00F\
M$'?"98]#W&%45A&"G UG)^7V I64&+O$)8,TOQ$)G(@HC"?YNU/X>/4FHS.=
MF[\*X_3NF\]5VS6G$J[?]ON030WBMC0+.JCW7;E': 9_<D##-'<M7;?6<*TQ
M=?+)Z45,;?436[I9G,B4TI&9F9\LYIG(V>DW,[>(=\/CT[-?E#.+=:'9(FNK
M!",R82S,,ZB&,UJFN#YB7!5.8DH0,2[Q9T+ K4@03:MEW(XYHZ'B1.7E2KW-
M V R>63Y)( 70#_O]LB:J.8M&,WG^Y%B;E*CWYD1PJ^62BF3M"B$/D4L[J]>
M4\&-%_/R>#BU4ZIVSZ!TV0>P@,+>#ZZIC[U/.X'<]J+WIYA_>>WAH-,6F[4/
MF9Y?P_B4._3!QL8$HJ%X?'Y@J+8C-Y2EW>!7-$Q)<8YD4>*H&"A$Y/V6N*?H
M%PN.GR(3R?Y[?MRSDD9T -%E)&?%,QT_U:RR A'3+*GJ\G'7U@@Y_SV[_I,+
M#0VRP\NB0NSLXFG<G[A'SH@*#@!BQ;OX1 8QG OQJ4+9',8;U36,I$.WR+Z&
MS)A$D)95MRX;.I')Q@&N0?Z537 4+VHAX?P<]'+H$9KLR<("S(LM8R!6VI5-
MQXL5C&R=&(-PL<9'XFN,'>H+W"N3OEF[.H)W<66RQ2]1*",,N-^2'^$+=W2L
M;XTG ;L_?SYN<3C,MU?)VB-5A +F/KE9S_4,B..OE%ZDI/B?M9;F%"!4U$3L
MRG[RXTR2L_M"@3Z]$Z.MECL8+6A=P1YOR/"6M6DB$C-R^0'XC/$Y3::8VLN6
ME3TEL@-=$Z'=BBW-7GK 6[9$#TW^R?4R=&.NP7P[I]EU3("P:%='O2NK>I-8
M%I*D^JJ%^19]1<ICLU &1)^YY^BUF T9A.33Q&CLU 5):#VFS&*=>Q (60>\
MP:-NN'56V$P[(KQ",IDLYRX^VDZ4J.UA2\U#[HL[U'?@M*/O85F0Z>->.-?3
MEQ'R5G+-)(HJ/$VL2LTT>)\Q/J%8Q[)-S*+CRAR=X-V=Y2F]"^-/+ __Q<*9
MG<EJN,XL$);9O&M$3EK\*>]F(5^9O55"J>,D&T/!=Q%4@/1CKK+TDLCO(_'W
MT:M"I/,6:*T8/V<O7.QV,=E<Y")&?1?W6*].AEA.9E?W#*"1C>8;;NG;^7,0
M-,J4"B6R6[/-]1C['-82/BVO"J=:DQS?&JLBJ.Y'>^<_$O1>,%RO2F]2((DM
MEK&1+]^=R46?W.Y-M"R)/_WNDEB2JR6/LT1+>E]E^:DI1365'A>2:J<RQ-C/
MU0^T$_W.8</N%%E8+$8V_H:4O8//=JQFZ=Y\3!B=I/?X4F%AFN]>P:H8'G<M
M[064^_,9TY.V?L7R^\5P(P0)W$^3^T7N%#TS;]PO2I6&74AE5<M.J[Q)SQ(]
MWYR^^A19<%:J((PJ_+)31A&;ERG9)W']GA,6)Y0 ?4]I4_2*R#92L*EX(_ (
M=L6.=TI^#Z#[%#OS!74RO1GJX(X?V1[NS=6V' 97Z-WE/I/[B6NJWU0QQ/G=
MSGA%4/(!Z/1 2-+S,0L1Y<IU84<7J,#HL!7P U0/ND *<ZWW>$V5T;+2U+6!
MJ[N@FJB7S&1:'Y%GAJQ1,[^>>AH200HNK%1+)=--#?'N?$TJ&EGYOD#"8U^2
M"9CG;U8Q?>#05[@.GQE9M>%JFUU=-2;Y91+:[Q@2?G(PWYV&\G,HVT4))MM:
MHY,]-?V+Q9-VNP626<]4OL(>S&4.;$1 MIJ<TI[#A)V^+QEKCJ\TCHF_:*<M
MDMYE00CBC9.-6Z,C%MG\2(C?12I[0YN;T#Z36G+P+@B3QD&:CN>GN6A?6N/[
MK 9818&VA:.>WO:73L&28N9D;Y:4(SN[,GCW@#@T&_Z/@SQ'XL\A9%-MRHO>
M$?>ZN),9E>));E'1J[RNE,1?5\0^Q"$D+#Z?+*TJYH&XZ7#]6-*7R=-OTZ=P
M5Q?V(/1']\-"=]X1(<LWM6=YQ72HEHF2J?F4:SZ76H!L;3&W5.AXJ),)7JDF
MHF](;MP:CXG_P/6+C%4DWP) W@#/NP_DBD*=9&M'7?A;<PU;F6,X9#RMG,@3
M:&0H 9F(9?CTMH_\UPRX_O1&/=04(R)HOY.G@164:T@]39W;0YSO,DC@AUE%
M#:V=39;>_37UK3C\6"GNMD[ 775"KJ*W#UN[C1UAM#;!<<%3F=(74\831UXN
M5JL$E;(+AG)-SHUC9M6(9J'61AKX&M3O\?E[MZB+ =F5 :&][GIV,#=W;^F.
M=.G+Q%6L5A;GF00$F@)W=$R'\6=64XV"9+F80=;OIQ89.&D"-#96>37L7TOO
M3!9 9"5B)(>_XT-UPE6<-5N29FE%.6K74^#2Y28W !QEB;\QFX4*)(DA2I_
MZ+'JP%55+^?VH%U(@1.3A9?T_X80AMHD@<C 4SG2!P&UXJ6]^($0D'0O>K,7
MYK.6.:P9#%L].FCFG<A!HCY 1+I%VKB/.VL&A4(S(&YM'N+-%.EB-76-VNH4
MXL%B\NS5..;S:57A;RV5E77(-@V3!;BH("&]?2H: O@K#T"( (/3FDR1EW1T
MI7+')DEI+W4>3> A#XEZHA=_,<1OI%$T,U1>""W@M)BC*;N"_/C0:>3SV6H#
MHNP1RMX8K+1+"&<8,?OD,XLMQ\ !9T&UY"K!NPC[#J?SO+,>PS:^K5NJ*2?W
M"W;*VA$6]KBDI7OWF+N-H=775GV_S%7BB6>-BO;/SS@S$]^#5E,*!@H/;+"W
M7+FMW.U:P#*X(3+$SY2[U87?5NBD"0P;2H]C?JX\>S*JQ_S]^07OSUC,[J2=
M\\@@]ITTQ)H)2N?:E _7RQUN<(1="[FUI/($EE&=*NK@@RMW<L.@@1W'KE0W
M<(T=C Z>G>_- (Z9%/R&Z$1DMHF%VW7V1.<\7U6H3N-S',KQ?-6[>?*W9\)!
M1/@71V'%DVI+-C8W5XX\/[>%!31+( ] ZS D4C1V]F>P#\ F1I6'&.E"M]C
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MW*D)!?#Y9I)AL&2<,YGT(578\2XTA;S#1-/-N&3'(\QRTFU8)JVU2VI%5#(
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M2K.L,X_#*:6=[/(@/8;ZM%1%GUIR9-9;$D-H=F&2R]U,^J/--Y.SBQSPK$:
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M_QEJUP.;L^Y_M/]J_ZO3MW^_]3_#HPR0Z>&_PO_\B:N_G_V?X<C%_PQ<_QF
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M[B<9T.1V76$:3?]&96_IQV7$C8(AB5#IW-135<J>Z_H/H1\S.ZH8!9^Y4&%
M'<=8&RR5)C BA^,>__K'2D(ZO2:X7CO)]+JL6T_+&PVNMU&"\:;1]Q7U5"]_
MWT:2+J4PP<8 U_<5RTM/SO[I$NOB@MAS F>:.'."6NR#V+-RJ>_5&5N!8AT\
M_[Z[HI _Z5Q1!.BG)&AQ-*X/C"TYO_3PG T4M-XI<BMQ1>H%XQ4A^3M7)VB%
M9_Y3VOS9SJ";KODSMWR&C4[<EJJ>UTO[>%\L'_WM*_(!K$-NLYNEPNU;Y6G
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M>6F@#.@DA@.X?AN+62OUYUX ZM*L_W6'UK;9SQTNQRH_9%5(TL+K)/Y]QC<
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ML%<'*-S,6>EP>@BC*;.BC.$%/J-[WU&B)(>_*>KP?9Q(Q]-M&P$MQ# ^@2L
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MI5N<GFQT[/Q81 :/:4V"<FMYDFDSNZPD:W^H\MFARAB:-,\ZLL5PTYUEQAV
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M[5XQM&$_0<+J"LLG>$<1EA%6_]WD,>+$^TAE9YVK^*B">?NY92YQV)^[@3-
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M[4.S;#M4S8E;.6]BGV\HY9H5>R6$=<3S9RV>K-[1T+L,FX;1[%A^V'%X<_+
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M"</H8+_B375W.V'-TI9FB;(1535O+^23CYF!=?20-+8>@[][OS,.+?'&/:!
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M!4-Q3P4/VDT&&T3?(;H?IJW?RSCWM7'$.]+_3M9(H,D!GY,.[KO%!0[B!Q#
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MZ3-R2W$SU6%/5?0:^Y>B#B#?R1TUUUD1I/+XI%[KX;CX0/Y"N<(@B^+SXZ3
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MUTP4?[H74W['==LU/-$-7[>."W,_:6PTI1;7<=T" AL%A[&=8^\!\0ZYG-3
MWRN60*)? 0FJ\T2;9=3=T'*V D/L04.&-DHKN+CA13[+W%%^]2HGTR!#]2;N
MMC>\Y]= +P+0!JG.#PHNA>U!(4F@?0DM#4!4N?E+M@7#*(G\U?W2%S.]2(.B
M*^%;?W.KZO,:/]W\L\\ WQJL-H/,A=)M_F .FN\L6()3R1VFYZJ%R*CG9Q3V
M: D,/CT=6,O!AQ *ZY1^=V*[#A9>@-,#X:L-6*HSZ?4@%2M>Q?*4]#F&O>$/
M<[@SE[?YA%$4X=L.P;2 0<4%?*)J+!^!7 "MR>:.R5Z$RB_##M?,TD?'SJ:L
MW3)T3[DAQM?;%,HK[?3XWL,.^DU/U;F!#"2@$<*6#J3(#6Q#IGF[2?5R?=#4
M37<2X$L)CW_-=F48IYH91SZ?<2?9O2QI<A8V_-HF;B^1>RCDV%R;RVQ\XGFN
M%CN\D!I-8LL_H?=QU71F7#J.O "BJWDVX;7]I:^2[V_6F7;[9L3J;ZQ6/R>0
MFS#*C.]X]GX\RV0)P]-12(N 20$^1<=3)R\47/93IQZ+W89H$YD*IP7)[S*I
M,? KW%W@LYV'>V&)EM0+670<I:DWPTI/')7?8]GK*3;&MJ.<LK,*D?0_L TI
M\^_GSDM$[95NO*$=+@I,6^XGU$^Q9;28ASC99HYO4% P4?4I,"?-M)X-O$'U
M(.@#"88ZP8B]2YD_TR)?1<?-7_>6URV)+'5]M.;HO=AA"AQF2?O!&Q>S6/([
M<VB[S,+X/W1A'W\[*A933Q(&5!0$UD6GZQ.#9"-%OU6.!B=4R3N:6_CPH0ZB
M^\#\H,? Q7;H8;NNP,G/"#70U1Y_F:WDCN.!SI-;1*.Z.U]@Q=Z^T>6S7V<L
MNG([9;<^UPJ\ORZM,+;++$;LSC8D'H2]_NW0?CQHW[Q<D$/6$%8%*RQ#7J,M
MQJP3V?YD/>FOTYSR_L5YNKV485NRBUPLK_7!.9S$;BTMH2W\M!=7V Z<!#N)
M,D#[S5)#6W(J5)J!4FIU(D:AP6I<NWHQ_N($"=%DJS-[V2^C/M_JSI?:)VF"
M=0HW+.O9.2 &T>!^@M<A:3N[9 3H)-HPZ]#TK!OJ>!=)GE:Y6OELTI.S^J:0
M=2&P),]5<6[PQZ"RMU>N3I,0A/<' =!I2,131N*@=-L<"FN?]AE/B5I40HG=
M/JL-,\T_/*<'AH9(3AJ@W<YPQ^'T*R/3IDQMH(&R'@=MT!MX0$<FMSE_QXM9
M5J!"+K-T?D8Z'73:,/5IY/%X=/(8CQ(9Z7>R<F2FF"NT"4[M-Z<:ZY?ARW0$
M^%FGP1XK9VH#/]QSK]K[=V U;UFZOK'6PWR_QT%GYZ'SLUD/TEI@ >SWH'#+
M?JV:@@X35\#M+KA0?9UOHG0J?<C8:4J?/]-OUFU4)FLB5J1$4L!,W![!4,^H
M9BM1Z'^"N(AZE.QUV+SQ0M??O.,K6\X;TCQ_RQ@@D--A:7)'H')!!%^2/&H$
M#"71=U_85D%W ZK=)OG)AG9!QXXGM1>1+L3Y-#WP3<P)WCAMWQOK>9T5Q/VR
M#=E%" 2)C7,_B8A@N@/C!=R4('I4+W$D$>U,40R@CD:=LAJP;VY.:.K],AQB
M<-DJX45TI7[#U.YX.I(MD<#&1H+*.H69G<+*BVQ#Z \'KE?TO12>^Q-OO7\B
MN6:V"$VHT<F<GPV/<AXAT,_8C2CMG'S9B3W%I]-.T/?1K9/5Z--=K!.$(+FK
M+&3N;,3#=QA:^,8KWG60!\DQ,Z<,D8"J-EX)'J"7:;SU^>?\T:D?DVT>"S@)
M6_B,]K.-Z?HF8]US_6G-&].\AK^-NY& 5AE-BH'OQ^RE6R=TZ"X;2;&M-PD4
MMV6E(W2?BF(7%.'C[6S18VM_B9K!T\</"F2Z;CT_W14+CS?1&>E3P +'XR]"
M]PY_'BL!_E[N]YDZL=^UQ<)L",O3*GOZ1WJ69P48.A>R6?;@$ZA@NTP(%$?Y
M@>1B^C8D\29]J. B/(!UFK[ZY/)>4N'0\7VX ^L#]R&<3DXQ@?P,6EM&JV:H
M=N/Y8%KL,T_;(A;RKE.@NU!W+=HF?C]U< [UOS3Z\?!-EQA;P=SN 5;3GX[+
MF<(4 ELV@BOX@1'1>_]''%<1?7?"T#ZBYZCG!ZK.+A)EDL!<-9@I;A^_[%X(
MU3^4?O;0SW-_GECQV.ZK3H'[B\WD+VAT@0012JY>W63Z LEAI,2ZLE08%+B$
M>F.X#1$]*YMC],3H15[F\MZGS+3'V/N5Q]5&GUV:M?S;Q); <@5_L!S8XIP6
M0@ "T)0;&!%%D(,4%O+3WP2WJ=*7-[B"U7E#RW)R^B1D57VVI4B?^L6:I(C+
MVEV-C&;>9>R,%%<HAR7"G;_OF_(;/R.UH$[*U$$K!M0!J=%Z707=.F^]?6RF
M/M4C3'P$OE_'H3/J*?;W]6@4EAW[ *<*MJ\')!\PPJN #H66]N;ZQO$0]DGL
MR\B-SL63X=;1NX^95,8^?/?:_N?*T_>=F'TH$VPZDFX)!_3*^A SIF2Y![[Y
MW80&W9A1ML;;N-FPTLQJU*;1D^//R.XS),/O=9GALX3'<T*<!4"#GM^-Y\&(
M 4AR62PUZQY.R,_HG5.13]"H[0$)[1NV"D!)4.L3G/:0[;?/_-]\V4KJ5+P2
MFY=3R-V'#@+D&(A^)1&&T>N%K=&&4];=17J$,>Z4/P>O'7=2-<[;NL?B@63+
M 3)[ ![ '8;7XVE3+ BV2P,C@0%]KWZ@US[$^K,A/ FVKYWAG![F'HWTR+:W
MVD(TZH2&:?N':F-N;?#M95U&)\?SY2)Z0 >+N@ZE]\ %$K&+E7!NH6[%9P*Y
M8AI.]QLF<+*@B<B_'L\^\X^9E+$/2(!^EC0:!N=;VH(VRO[S&?A[QI[_"D(L
M 'O=^LZNTHFN1HD9PM"#$EIZBHII@I4SC,'RV#E45KM%@]*KN7+P50]&>$^W
MR>[\U[Z^AD/'1DZMCL4Y"4>A)!:;'R9X-1K<V)5W I+%7L=V7:I_J@4Z1/Q5
M^ VO,O]&)HOM;H#[9O&ZY5O2%?]]Y#NN'3ZG;+]-?<'3;V.3T>9R;&D\5W!\
M&R(5C.3*?+O?F!!Q>ZN*FSH%G=WORXP_"3^L,N<>/'(VY#XDC;G :0AJB]XY
MW,/]F$>J'>E?3_ZKD8B^_.HG+U4L]K?6U[MGMR$I\0%;1QCS2W+SET^/! =]
MFDRX9//QQ%SE/NY'-I;32/!%S%3T=R@![@S5OJDI)7W&+6<IE&\73([.6:NK
M7#[:F;Z)4,Q-OS2D?-9)1^M(OU%6JYGS-V>V[!M[33#WCD)K+A';"<2\J1X+
MFI7S$)1Q$4DC9=[WE6<?*:IF6%([P#3%GPAL=KMM0_H]C+OV)R5W0-V ",JG
M*FJ(&)A)W2+%2OVW0F?=^Z?$^?R]4VE[Q(9&U*[;P31Y?X>O<X6B6*)$[@<)
M[M?;Z-MR)"$WI.Y*7P$\R5#KV]O;??+!Y,;&2-K'$]-<="C-QS&H]-$!!"^V
M"PDGXTE2'3( =B&D!YOV=Y% P<H ;8![S_TW:?217F?+2Y.[@S2FJ38TD4R6
MQ(AP_'?"2:<!//A$)^#D?"0_]D8(+QO%>=IFR3JMUR>J0$4FETVV15*J$#:I
MHV-VT58SDXN\DN<HLB@CR4I+@='C7Q[A!\4 9=\,M#)H72!!CQL*0+Z%]XDB
MG0B [T)+@XXS,XBQMVU$IF3]_AFG^Y421A(%W/[/Q-+W"H]CLBC!:B(\'(G9
MJ]8108KCYRC>IY?54[)B5,TJ(%=8X@+KB!>I$,W_P<8@$:%,$4X!/ "7 A,'
MFAC5IQFGF.UDK9%&%&S%%LBJ]M?WCX ?-9;HNAXE @MUNGFL5DZS3U!K8\J.
ML1,CS5D7T KC<-]M2(:;4W4Y"N'T-E#1_7P]PZ?TVA9S6#Z#4A1EE_SRB;R@
MR)MOL#LS9E-19R'H =9Q;)<B@8R'U@S$MWG06<R;P%FJ&/_/(M,QXDB?B<\3
MAEUOHM;[CZNZLO;F;4\:OY]AW'IT^,B!76>]T<=!04*Q7<>XHFP^1AFMB]Y#
M/E3W N"G*IR9/T;OP_=!)=.BSP_$&$N]RCL?(],HLRECT?$=XCQI<)'_0S[T
MW^/K]B1:4PA+^BJ:;Y)$\7C31IP@Q.'ZX)*<++T+MCE<"U/FF@]6+[R3A@RF
MNK4+7P2'#,'T%9!H$?PT86I(7-8*4C!(N[B^AEZ6;#C+L:2%6MT53UQ>C-2]
MKK\-&32R-4^'B+^BMO>G0NB(.#C='C%C27;N+\02K6WHGUJIB&0CF*(]KPT#
MCS-SQ[Y9WN_Y*#9NAO@A2CONZ]$-[V(>TE T;;;PI#.2;JLWK;+)'$("FF<'
MND_=8M]P7V_0R,BG6B?+7@DY./LG4("P(2MV\'%;+#3W>W:A$0-IXW ::H !
M <0YQ+0O4Q,@4 G$,N9U0+YJ&FW.T&F@=1PD8%-,OM,*V'6F")4Y=0[[K9U:
M#KK;5CHW_.O#.X$,/>:EG0+8*$M7P#>J&BCC"N4R\$Q'AM)SJOVE[]Q=\T"$
M2R!)S)A8XG+#U6S%:>*?WK<$XL$'D;'C=\PU_MJ]B($=!O] !,7/7  "65++
M,$E."T8=P/=--1(D#%%<Q4#NB?KFILGJ-FV0>3G+/?R:<S=XX]W5\V^O2ADX
MV.W75[# 10&;++&=G7WU3;UP(?85H/TEZLV*.]VJF+D-$;JZL[7T]^HA':/U
M050ZXU_SO)YJJZI[L<964?#(D%C5E],'&JOHSI1@ D.X>QLB&[:^QXV$RN]R
MDIOTE)W2D__>,O:\S>72DL-T]OF*W>9/:GOU/-UA_"PW;)<<EOP/O G16XA,
MPS?@.CF!_6Z<!SJRA1'1#-/>VP->\@\_7IK?9RA ;?*@75 ]JVC*@WOM]TSL
M'VP "5 CT,18MP'C;B4^3@57V!-%'>EL.CY,*:RZVW^_K8G)#;4\=FJ=V#%F
M L]7^I9GS7_C%U'_R<XI\BVVE%0GH3XD$?R;7=SW7.CG-G\R!S8_TC-U7Z=O
MHK2T]G2A\EUOZ8H@M5?-O3@%F$6->J[-W\14R!\]9@<H;R5L%^@<P<@,)J$>
MN\K+.E6(5S#_EE8M[@=3(8SZCLNJ"^]K-KIKO5A;7IZR5TVHO)7YBK<&V('F
M;SAQ!'_DS%0/MA;1-Q+S^BY]MMM9&)9 7E7H?5>4Y2U2OD]0S0.V*&7Z_6O3
MN:OK6233IX\Y_&<AH=L0'LQN]''.DPY)/^PNKNB2\U]L0IMA6=_UY_[O,@E1
MKPUS*VTD-24#9TKS!\\X7K'X[G"%#R+BG(QV *=LQNTBR; ]%@BR :2]ANV*
MF"-F>@S$63H^(^R4JCTCZLSWB>K5(%W55&?M3Q[C6A\68<R@57S9SV<BR*1M
MR-XV?GI9YWWG[O7$#K&Q>KV]?O?1X2:PE%*BMM%D^)=75U)/C$/*(?U:/[["
MN8(RK/TH5:IN$\..B1UM0])S'!D&\R$IUP'[A6%K\[<3ZO*]V=/N0SIF77D]
ME>=(^C]RD!= 5SJ%&2;1SX&,VY?I!/2]YGXA"7-%&J9ZJX)*H[VH>FF&*ZLA
M[N\BK69<OI*&M?H];I=8OY7Y$YJIE<NI(9!3L'3[]=FFA5.X52G6:;1@ ?*
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M:,\PRJ5/7?FLJRH!>UKNX3]&FO/?>!?W*=O-W6;R>*VT/TGDA6,6 4OPT3O
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M0+E3DE(Q4$".\GVVJP)(&D#X'Y#<5V4_,59A;A"C)O[XZ4Q-[)&%$R<6ZO4
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MR6Z:)?4^!/8F)$N]LE(D5<2[56]@I\Z5-+W^@' V2K@[243*3V*!>!2MAG"
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M#73\M\37_G-=7 4!9277SHK-1F6E%(PHC_RR@*+P1 L$17IK0YYZ!888AG/
M-(FXF/-#<T,;OB5!7E0A=-V;2Z_.J._\XW**77!3['3X6+=]!J :@1P7I6P%
M7D81F*!XN$R=I/AZ,\^@S?3K,!:/DXCVE(BUSG;W=_8"3KHV"Y4#X-1E^!7B
MC-F[X>_Z:?95GR3/Y GXNJ[O!9@<*'_HGWS?,Z6C.;$5Q%G[,>9JYN6LZT5Y
MPZG?,==(8QMUU(LTM9D<!7HN[1+7-R:HI+IZ5+PN$_[MNA-N$?H&+D9/@_BB
M)D/:-_)^KTPNU10;\-7FX#MT)>.U"ERX!/(?;RZ?BCX^S%]3?&1XK#Q4D,%F
M137W:I DX9"-XA_;\6'*=3F;@+Q^_MDSEIA2-__>A<2Y?S9DE0G*/\AQ,CM)
MNX[KR5#X(:-_B+;-O)S3?V_(A@FJR=R#)F-GJU#?U%[NHV.#%$]1,C,NF"(_
M*1OAUI[^>JU#A*?-Z_Y=%4T[C_<C#I'])1G/IM?J&1#UAPE,D*=E:"J#K9 (
MG46T8D[2'"AM)%0'_&(EL2\VJ @_3G$PKBY/O_<Q+O_I+:T[[)-H(7'=D>T-
M]$8@4/%_B&=X(['W35S:A]"'#?ASL!MI5S=_W1!*:GX'MM_Q/ZB&'!OLL$Z2
M74U[CXA\0]:6)J '4]M73+^8Z2=)Z>5?SC<,J,9X=?4[!".4]I;)^A1"$/4V
MHT_W-&6LP,[!P<FKFF<_G1S>6(!.MHW1,VG/9DVJ3_$:6".5]S,X\T@-W^&"
ML=^Q1P >@XIA\ SXA-!36O%F=6]OU25<-4_5SY0SE"CLDLBJHZHC6H"<]\'&
M8ZO4VI@@-@I^3C0E-/P>*3HZ'9/_)T>T2B]EQF-0K>?=I#5(=SV6-7XPX^RB
M[J)LMV6PK;'Q1H3]+T91#R,I1_K!-0&':VEG^])D>^N3ZHRN-M;=%;_T3'G]
MO;'3P!Z$)J#%8-\CH<DUE&\$\#G:N:^#XY,K 7\..T;1!7+L')]G7+7O5[CW
M96P6=LZ$)1Z 7R!F7Z#XMZHA[5CD(4_FS.U='1FOH5UNZ2BP(S@?GF/A/.V(
M8G%N+!HVJ5E&SR(N+3D+$.'^V2,_OU4N:@Q[5/4-^Z;82VTW^804CRXO+4"(
M9EC*)=Z6"3NX,F.BNCYIHT&@=@C?:7.&EORQA<WC13\XK Z/S!JCG62,S2Y]
M(_83(,A2Y0CXP?TS,Y>&:&I%:VIGFIW: ^IN:5T\M9(D-'5Q]G;XDR?-$H@6
M5B;( _,**]P(G=M0Q.6P#VI#"BEH\X9!O9&]GQD0M_0E@X2KN"/FP=<6_&8'
M0[<8;+8$Q L(^]Y6(B#[$5Y\/!F$:07CGBD?<"M6^;U!SRE#^>\' -0G95>\
M@%ZP>3:9."+')2X07A>\%2)!AA1M(T#P^+..\MJJDN=6ATL%Q(SN;JDNE?[X
M7&B=%1)<GVT?KMR?P%!RI($'JF1ES2(1IU3P?-_S<P[7[(@E8>8VQ[SOC?AN
M<CU/FI"O.'N651+\!4(T@5 NXV*U9><48Z'5^R\!%O&F[)Y97E?$F3@@+[X^
MCZDKSYHF>$1/18?FV'!OBU3^XY^-_/&'ZY'^56GKKDFA\NO[ZD*TXMUE!ALG
M%1!P/[S(.B0XF@G244&Q'F!VJ4[ERPR6:P5,T)?.QF0AW$!I=L&<;8>OT_KG
MZK6QOL-Q*E*P.5Y7$!#W%#EW'K??J=U+J]*!O<-OW54TC *6Z/,OAUWK-O..
M2Z38@]'6<Y"_^U7FXLL%UWM)(C1IRC1)WX3?[LQ5IP/(N&V-]*)A@P?>C_,Y
MW KGG+8Q0K+=& #J\EDUO1*NX03S8X)BHC/:4G][C(XFH-6B.^8NMKX/Q&Y<
MS3&41 MA!I7L,S_(*:J>X BL']CP;;)=@LM^?Z? CEOVS3@]YWZ+\P=>1?EW
MW6:=S=M5#R_\])^Z/Z,0XETD11(1+WZ2"6HS?,P52PGB%'YG@*951WNYF-'+
ML+,Y8I?TXL%(/(?CU>[\I9H'9\P&;41VH%Q_K^K[8MI# ^E15-.5#,@TU3WV
M<A1D_V?YPSH?%P;W!KU$?E\UFA1(V/@E>KQW<5<N[-"^MA_@_4FPJ5[U<G![
M2\<AA#&!^FK<AL_KU**(W%)AJ",^2($+=<\ [&Y]C:1E".6G2/Y#M'WES?EN
MR&*PM%2!(*<A(Y%X;<'5/V?O(>(YY*CO+?G^%C/VV^"M6.)TX?3>3]A8!D -
M5;!N0)(R?B#*-S):\'%J]JZ3[?8=&]/#]7IM/2SL$@<<%;G\VS++,K)XKU5B
MXPCQZP=/SVL>J@VZN)W^DPMU/*Q:[0^>F*JLM 8DR@1@X-(3QDM5Z@[("03Y
M<0/("=['./Y6<?I4J%'OMX,.Z\OTUQ#7AK\+D,NWV@I%]MR))B\D25=M^Z!$
M.WPLHDJQ'1&;PS:$>,3+&YI[N#ID7U\[@FK=/V4@=_NB-3*XT_*&W+C(KLK!
M#CT:Z'VOB(JT\$G&P)DW&&AY<R6)MZS5%@O?VSG(><;5("BCR"E]R>^9O(KM
MQB$*3?1[?B H1*3+X:BWV/4# YR[/S_X6><Z]W[T<')M>@)5!>8!X!3[ L)6
M95>%CT:PPI0(/5/O X]WS,3EMOA(O#G#_2U+Y5C9HE5R)LM@ P=-$LBQ2J"Y
M?*,(?C"88^T(=VI"5.TVQ.+&^E\=,D&*GE0'!EL+]1YC%%H9FTP+RH/_8H+X
M,%7OY7D-*\*%O38N3D[G9MFY'J\QX-""?7L3>9N<)S^7>$9)@$M.JIO'P4G6
M!\YP0AK'P9$3F.-/1F"CZ8K<FJ>]?WO473[XG)=KOMBT4/.8BNMHYB=N)=,4
M"T(5.R;OADPZ%[M?*LMS4PTVXRRTO17)PR;A[ZP$:*5C/^@O%<PE4!7)R2 -
M^O3((+C736!S;PE1#<&)NI.]Z9DP**FM;=+MP^)^;.5BSN H32U5MK+PK.UX
M]_@!E0^J%Y]\1CG?IM+*PJ2A>*7*G?":D,C+OW3W2MJ5X=610JFA6&T7>3>)
ME,;4<I_L?X"D-\*/GR+0NB#N"5?\D=-K]I'(+E]0D160=.) ;:.49(]33KC(
MTPSG2FW%5[A'(484K &@0^)TK[744!'DI\3>_OUF7+'CC9P/:NQ79^J3Q!D\
MRJ\(*EL3HK'[^16D9@1IM )\* #[&1KU<ADKLQ<%<#^S01+DGQP9 )BN<6G3
M=4L/*_O1"I!9).JKW/=G"+:M!SBH8OO^,F1_N+.P%XB*)_VE6\"?69U'5\)D
M0E.6678>>B70WR%FJU%<6 ^_)%TQR@47HE+[.9N\.=DV/[^GAXG\M_CX*M*]
MCWL_X+T!];7%1#(Z?A;6OPOM--2"J8XMO3G(X*<H93R)456_LWPY7_]SWL_4
M:,G0Z6)JC<.7FA58#W&-P2X+2'!Y$CF!)-NJJ8\]4_C1\S5T7'MR_G;DXVS-
M3<O&Q!=OH"864 U>BBR4QC^AXI#$LT6.JZYNJ*P-5;A8_TOE;.OM$NN8I9K)
M9Z(WQ&?JL[?7JRY)ZZ/4@M,VUNI&6G]SV@T5F\66_S&2Z?-,DC8:JS=UC)LD
M!_N%@_7'< @^Q"R ^A6"[0CA-<A)%<57S3J13)#3R&:0\'"L1?E5N52C0?7K
M/M=.*XFXQ>$LP\:*5X#YM 2/&SCBQK&>2-8OFRCOD>-81A)G<M4P\%[5UOJ'
M.6[L.*)RJVVJ?/H,OC-88;KV>\;Y;?7]@F(KV<[/:/5N_ QT2>0&H5E1#7WN
M6:>MI1%W)=HHMR)\UZ"G DB*$Y!'U; IF!.I54%3>]0;<=57YBTPZ@W>%S\3
MY9LU0DN%*<:34U? YJ<?-9,B0WT?&+_W2+^]8#[P(Y&C_,WK&Z)ZFAED?7LF
M:'&2AOA)8S@+$OG#9L7WNQ ;N.^"8.)U3'0ILAS^J_X0$?YS8-:;<>>J-5#$
MD4<H5S\DU6PH%ET$&B&"J[,]XG;V(^S-@L_;WE5,4 ^V@PG*3&R4(AXZS-HR
M6('T385H (HB"J%,ON, 'TD5=R^F2%RA1<]BFAF"H9?@YV" MFA[.PP?UX9\
MLO?(W>K:IC%!%T\GP']63T\%)F:["^EX!<>OM-V_\DY#35\5^YYNMP'@^(DG
M8YS6A;:RG]87E=\V_>G^X]DL;8077P9R $'+P\^QTEL1NQONT'AK.A?,D6)
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M Z,9/!ZOD/EA"<0EW<<40"<>>T='PD$PZ$"S*DSI5]64B<O-=$,YRPC_I:C
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M'<SI'E\0E1TF<R>2=Z*1WYW5&;LZ[Q@>%HPI+%1DN:I\(+.P-U<S6 )=JCI
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MUY@@K##OG9U#&\Y69_%[00E]GE;?S1&>C<.N3-#_P=Z;1S71K?G"410$A8B
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MNWS3CWH[JS,^2JY?%)V,M@F[0NM^$;]" 14ACC08U'C#OGG0.^=EV"=YG8N
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M'_F"YHKRH)TR%P+I6A#M!)B<7,&;W[_G;ZGGUI,^Q.^Y=G*Q QYQ^5)?0K#
MV .$%IDZJ#GBSTKA5I&O=48KZG(+>(>\%-68OQ.9Z9>JDA=L;Q>B?=<#PEO1
M\GX/DAGOR#=;_-Z^G7RJ98G9V%+[ 23](L:*&[T"<AI7Q8?,M;-1&"03,6]
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M[7AF%CK5(9KF]FLF> 6E2M:ES.KUF68O2^V/_1$$^<^A0ULC2:EVBT*(8'2
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MO7N]OONW\_"?^<8/3?6_9:+JUV:O2=_?'ZC0UJ;I$A/ZO\L]3,*UV6..<5P
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MLP<<F*^<Z\:>WIR?]CT6(NJBM/UHU$*3E63X[S[C^V.-T/NS3*>/QZFE7.D
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MVL=[I)9AN^2&[\B^5G.!?/Z[][1/#PI*?NXZ6><QLSRQEZ%5Q9?'M1E'P$3
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MBWN0]Q1CSS?9I5_51Y_\T_?1UJY1P7UGBN] 3=;<$KOGR/%T*+ /GPJ[EBF
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M];-*<?M=D?.8%F7[<;>G SL^OZG_%%&,,=/[Z]R6.D_;G>L&S:EA8M@<W M
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M56XTQAKUYAZ+#+L<L/ Q4)^SDV;3=#>QO7[_L9TE[=VBJR@C*K-*_)H.0W)
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MW$6?I$.=G7&M.]-?'%0*R7&JU3J?_:E8X?U2P>,0M^_P;@#:,7<K:A'::0>
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M_X#OX[_;?[?_^P9?G?H/4$L#!!0    ( +2 6%3%2#(#IO0  $U:"@ 5
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MW82'!+$@%+Z6U:[9W]PHII8/+#<"&L3D:J#;3R0C8#;^WKX6$OS 6G'_K*Z
M+<=%T2!^V2Z:$T4I7XRJ60RR/D:]D<8:S4P73ZROTT[4L,%KPSRKM:?VC6R2
MO<T?GWA6-EZ7HE 6I/JTWKQL'KG%+^I'UW_@@KW_^ZI>&<JJJ#_!\G/UP(L[
M:7E^?JJCU3_DA>!I)??BY:]<G41Q=OW,"WS/_RH;K][)560=YK.(B9,$/L60
MA4DD-X:Q@(DK$N@B1HC+$Q)BQ\2).P^UYK:8M+*K6P8%X-^>4G6HHLZA6+Y<
MXJ($3[QHSJ0,CZ3F ;>FEWH>PLYHT:RUA2I]D;HNM($$;&$"R O8?J[%!=3
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M@.MGQ$OA&)G)#) P*O-^2N7!9=X/&IRLS/LI5;;+O)]\9F!@>GW.L#[ICH-
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MT/5B:0!YF,,X3D(8\(2B&/MN(O0+H5TJS=SLI+4^G454.^.5V[U8JP0>.YW
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MO;!7OEMQM=O\D#[S!4N$(&Z"(>4J.ZWKA&KG%T(:L-@-G1"'OE%:*5,!YD8
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M$#DN@HDG]YN>BZ@;,A'XV.C@X51'<]MOML[J^B/O) 6_-;(:UB ^B:T>(]A
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MC ,&2>PECF"$!X[6L6-O+W-CAU-R#K 0#@ U,*<N@6DB6TH;H6$VP"D$M R
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MA?T-0[0W&-"PR>E"!(?INA,X.+")@;E$*,U7F2KG4J]'ZCI\%^\>)L0) ^;
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M9>T)W/Z]NCG\*:_^G5=?UD7G&Z_LA[S82H7F+KPX2(CO!I 'V%&7]@C$OA=
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MYIP[-W2":\=*'B$+3$5;M,P!LI'U!FQ_^;';QAS26L$&%]^]$SK''+LY@@T
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M"%/1-J$91RI""2'.T19!1)W:EMT1;K&GQ(!PBS 3[1!O\>K3]V\4<+&G<.B
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M^O]2085@3ATD!\@P-4M&R_:@CUEMI&%31Q24M4I75!8=,#>6)^2PB(]QRJU
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M"[IV'WIJI*V%!WJ(03Y6-\PM*#L8DH$9O 6Q @>2U\U16]FO\\RZ >W \<$
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M7BVCN$_I'I>'M][UIK+"2M[+154^RX]U.Y[/<OU%_:"_9@6)DXC&'"(4:7)
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MHH+10A.0_]H<9R69&B>=E.JX :W<X*$5W']-B?-SU$U9HR(?F,Q<*DR<SD?
M8A_G)\9_[8^K)VB"I4 <%DZ0XB"=F/JH%7)^@,F5#NG$84@ED>X7>LWQ_U N
MZ((?II&G4983R2CD*&8019A JNUEB#C#/(]$I@_E'G+\SPP]-9]>3];Y5H-
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M ]@IX3B>><@(]1O",7#W; D'0#XDRGD(]A;!SI['8*289Y>/OUWL\PWX]89
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M%(E8+10X1'%.U=J!8YA'60H9CWB2\R#FH64MZF[S4[,QS3%Y)2)H9+0-(CB
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M 80^XG9SD_KSJK%+)A1*K8@32)$4K'@A)G*RD-8]9JV(43U4_KTO<FZ1,RZ
M]M'OO5#91]@=(.9E6'X]F.7ZU^O_.IE^#T<U.W^P>AD6B]/I[,O?P]$)3I0.
M5GIK ;-4M4R50U"U2YQ-A;-@$WNP:&MW!&U%7@^(V@L&\]8ZZ0!H;V??<;E:
MG_U,1#*6V9)!!,5J%R!:?[0,H20>R*-CNK@V6]DU(L8)D=J!9E?Y=@"-@Y1J
MBZCE1TQ(:(]'^!Y7%Z7/R1GTHMZA8+%::*TA""$@!"%9]$(;V<;T/$35.&%5
M._ ,IH$.T%07PHP^<DHL3+S"J)0M('7AM56=@MI "I0HPG&FE,0V <)U*L9I
M&=O6U.PDX0[0\6&!W\(TO_[S&\Z6> 'QZ#+76D=POHYBR#R10\@=$/6)"6L9
M9P]=4-@=)O>2,TXCV79XV5_F'0#GAE@FD1>E'"*PA+3#&A9K>[H,FK$BK591
MV2<(J<;I,]MP&]I9QKL#9+X*1P-9EODW7*Q./QR%VH0_5]?]6_7'JI64&$-B
M4D(R/)"+GLE9]RQ!%ABU))],AX>J4_<Q,)NIZL$%'B02'TST'=B9P]577)S)
MYOU\EL[7@@D^!2,D:$O.O JF,F$%N)2"<,I(F]IL4/>2TX/[.PAP]A=V!X@Y
MHW_"M.<,F0&.JH!"E< 3VL'P)+DL)2O3<DOJP<D=,*WW*'%VL/N\FX8X/9JN
MIK@D [BNT/XZ/R*A+ZLQ7)U>BB:PB)%$ +)0#*=J6_](L(;"-?>QJ.#Y0\,S
M=H?)MA2.NRLU/V!HHJ@.K- UOFZ[A.@<4DQH %&1?Q\"@ZA)>DY%3(5QE*J-
M\[.9IG%3QFTPL!EH^RBD VA=9*<^A-.:FKJ(#P3JE#,WH-;7U5RI]<!H(<KB
M;%+2J499Y/OIZ092>VE[0V)P#]'W :#%";WUCHPF7'(*"(C\5"HWMB XHQ",
MMS[)PKTM;7;#C22-N_VU@]$ "N@ 2:_.7_L1O^/LY&H]B,"8,!%X$;0><B)_
MD[Q,D"EAXN04.-WFD.)^>L:-SQIA: #1=P"@PV]81Z/,OKS#0(\\%]5%>ZA)
M$$49A@JTJQN^L1Y"G;O$3="RQ&*E>ZA:>(\X_T&ZQ@WN&@%J0%5T *Q[;*N*
M(B1A'3")6#DPX/*:#?I>Q(3./S0-;TB_>]PCC48 VE/D'60-;MG4:SDPC9)A
MW9>9$A*4KJ<SV1G(WGMR[U+,ODTV:2-)W3A&[4*V8=2Q,ZZ^XR+.V^YSUUCB
M9=W[T(.0/M#&;<CS$U$0+GC *)D*[J%R^,&WNE[2VT^"M&'5T\'VM\[D7Q/=
M-4YB3#:R(,'7<;:J, ^^-F5UFKY76; <VSCGFVGJQI]JB+!A%-(!M*XQ,<G2
M:RW1@_*,2 _9@!>>@U$^9"$<-[+-MGB-B&Y\J2?)73Y*Y!VX5 ](Q&NC,O<&
M1&*TB9.+"#&O>1)H6>(Y^8=:E>US6V6OPY9F%21/@J6!%-*!(;K6?>FL!-Q'
MY)$S 2G7<RBI:R/0(H'D(Y7WJ<[F;E.6?XN2L2\%#:/AVV7X^XB[ [@<Y+P^
MM@Q''\(TOYV]#-^F9.6NL36QF6G/,H*56*<=H0)?"V0*4R5;@RK'-AF"'],V
M]C%P$T@-K)(>0);2R?')46WCM?;X:B_)!7[%V7+Z'6N3KV-\-U\N#[Z'Z5$]
M07HS7WP*1W@^;Z4:_OQ_3L[N+;S'U6'Y'/Z<)*:XT*J.3:BA1RTX]]Y(D*B2
MUZXXQQ\:F[O7H<S0S(P;2[:"\<A*[P#W'W$5IC/,K\-B1F'T\II(7F&9IBDY
M+=D'ETJ"(FPA"9L,P;D"B94<E0BH>1MW[\>TC1M_-D+EP"KI &1W!37!2&LA
M2 ?6I_5UBP).5!]$ITC"L3:6-EFSN[2,&X<V M&>(N\@ /U14%7+6WF,C(&7
MBMS8H@4$KA58BYYA\879AYK1M*L W I0@[?4'BNQL;]R!@/;$[4T^;#6PU=<
M35,XNLG$GOU-;CZY:;.3!YAXRLXG3JIZ IUI)Z. 5,G:I3N9 +PDQ0.J6.Q#
M'4;[[GQR+1XB<1\NUN_,ZR#\ R[6G:<G.=/.K0*#@E+6)'(B(^\$9%[01*XR
MPS:AZQ;$C9T.&1@_#R1&!E%/!Y[6G<;F!R>KK_/%]+\Q3T1DP9A,-E@*7X?L
M2'#9)2!!Q62%]ZAL:Z3=)FKL[,C3(6PO=?2(K.LM\X-G.3+:Z&VI+4I+X>#0
M&M#)"YV*CT&V<<7VGE70,&7QU-C:52'/H*/<I\_TYZ^OWW_^=/CF\,/KCP>?
MW])O#]Z_>GGXZX>/K__V^OVGMW]__>[PT][MYA[QIJ'=LUV9',A=.\MW7<+V
M$J-%1I$%[7NZB-J0.E,4RBEV+.B2P:2,;]9ZXEZ"]D]&G#_P<TWI38H+,60E
M0#L30651!XQI"K*M52E+'81MLRO>I&-<5VL(W=_-0.PLYQ&WN^5B5:]AYY.T
M(H<0%]^G"0_^G"XG(0AZC[ 0-86Q2FL#0>@ *'(6A3DA\U;)?'K!-8S0=[?Q
ML8F"3ISQ';0Y'U"T?4!CG?0XXV#Y:GX<IK-)28XE$VN#B"H15Q "<@V>^>B$
M"%KRK:JS'H./NV2, Y)A-'L7)GN*>42LK#L'GY>_OB$YO9P?T6_KF*#I=SSX
MLL#U6EK^BL<1%Q-OA.7::7"Q3HKQR4$( 2$7D2TF\M9N%[AO: 2_[1M'A\F^
MFIVW%G-'V/FESI:8K??EVQRAL9)%+"!LJA6(QH)39"H$5U$Q70L0Q6.!L_EU
MXP3K[5$SD( ["-+/Y71.?/&\%M4[R"+6VZV\SAB*$5+617*%V:0VE[!ND#%.
M&#X\:O:7<0< N73C*$K%M_3E<B)"<B5["580\:HH2[)()!!MN"'+B%JUN7Y^
MEY9.LH&[N[@#B;D#H)R;QZM6-,GKDA@Y<,[5^ZE*1O"<<$_"0$/A(?VWS4'-
M;4HZB8-VU.R=6H\]Q-P13"9(^V2IDY9ULOJL.UGT!D$X(Z0,L@C3)HUR0<&X
ML-A/CQM \2BA=@"&E_/E>K,];Y!Y)0PT6!22'(1S<=W8&Z*U=3R[T<'9E$.C
M0LA-%'6RT0QC0P81>R?P.2R_S.?YNL?V:7Z4)TP@K2 10&J5Z@4:DDSM!EZL
M-<XK^J5KDX/>3-.X]F88G=\#I $4T &4/I(VB( Z?> 5&=.C^;J+YKFPR+,3
M.AOTP%1EQN2:GS(!0E2&.VU*X6U.*Q\D:UR;U 10PZFA TS]@C-<A"/BY2 ?
M3V?3*I^:9KI@Q]=VC"X0.[IV8.!DQX,,"E@.P3F-6F*;3>X'A(U[#-X$5T.J
MH@-DW9;1Q)HD)%E6L+&0\U@LR<85#L078Y%9T>X^W$U*QJVO;[;)[2SL#LJB
M+SL>7-U/F3@20<@Z0RF>@1)!@JL7^FSR00ADGEAL@I=[B.FDZF88UWI?8?>
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M+JI\ZR;9AM[_&UXP'@0&TMM\8"&.#83_+\R6I(,7T_D*TU?BZ.+BI+56!XH
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M,[:D-K,=[J>G1ULU#)P&D']W*/HX_?)U=5A^6^(!"6XU(>0+5<B!B[86>8G
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M@OY1BMO8@_PQ4NP@S?619$T$?#V8Y5?X'8_FZSFY!XM%%<S93CE;GY9^GG_
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M\W?+:6XWPE)55-_Z^C,KVO- @1"$ 8%!&K+,@R3FI0*/D3)S"S\P%H=2A4&
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M43NLX(XJ%?&J^?UWN7M_M2]I\'3$3JN-EY+8G]AYI"4F*9)K]>^ELB]@=$G
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MUF ZM43M#ILIKY3V$-E]H>_ OXG%_MMBV5KG;#=N8D4EE0/)KBX8EP+'<I6
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M)_DC4Y6ZF@1)MAD\CAQL?!*3JV";5K.>JN'>P)0>]^/?"]#;,9%Y#)H[4-1
MK3  =0"A30%#ID(2&#AJ2*:(K,BJF77U&R%ZG>V3XQ'HZ00X?'GOED\']K:E
M#54"';)FGT,YMF'20N(H0?L@7(GS?(CI2.!QOW$>OXJ.@<,7<((^_YKU)+=:
MJK?.Q4*,Q%Y&,1G0N HEY>PH>I_D/&MG]J/[N!]5CU^9#XC:%Z#CKTI9M"_P
M]%OKIV_]G$0ISI'.$*IA89)H3W9!0C+:)EN-)#?1A?$^9!WIC=,\7E*' \Q<
MM"<]SXS4V[=_1ZT>G?_^]6JY8<TEGK9.K.I$6)UDR-2\^]KR4RJ@KQ;(DK <
MB6O,(\:;AR7VN%].!X3Z4#U-#X2[%Z":C_OTC[%(GF@3V)$W'G(5'(*+Y/GL
M+XXC\IB]"E$)-T_5W('8XWXGG:]JCHV[%Z":O3WTQSE7BDZ1; %K,;&WK@P+
MF55,:VNM]#9:.T^-'8X'1^K-SEZ1)T+I7/1[F!OO-\R)Q?)BD3?3"4Z,0^5D
M:26?+-365@E090T"K6#^R!3K/"O?'R7IN%]!1]:^R3$T%V4:QI^XRPAY@CI+
ME9, QR0WCUY#JE:!=SH87803-&(^_"@T'?=CY7P/LX%0-!=]&O5Z^-7'C^>;
M<NA[AB=X;P-I"[;4-CXD"(B9O\I2.,0JBZ)Y'EX[DWS<[Y+S/=P.@\%C5M9?
M_O-RL?[Z9LG"NMSD0OVQ_D3G'S[A<LO"WU?++QLNWB[]BPEEB2)"PB93'PHD
M%Q-DGU2U)F6<V[#;G>@\4I]SXO>+\2'U]U"X;06K]:Y0K 1!.HYI?6(9HB,.
M<6-653I)<F:SUON2>*2/%P? ^>%5<@?0'4^%U\[LN=<P3I$6R2<-VB@VIA(E
M1,$LTD83N>R0QAI^=2 *C_3-XB5IY!Z0F\]8T5TXPS*Z8L%W+/K6X"XIZ:LS
M$E2L%8R-GOT:]*!LL$4EF[,=J9_AB%0=Z?O"$2G=T- Z[BYPSPINFZ)(Y<8*
M5?)&&.?!([+4*L?'(6@-,JMHLV=C)&=6PM&?R",-^HY(#4<&W@O7RONNNJ-<
M(V4)I;;NQ8;E&$24[*I7EX)(6N#,4D='B0_G]U;QDC1R'] =>PU5=^;<RU/8
MN/ _LTGY%1?GFVOEVX)V*$01*4!PNN7OAPH8?82H#!LZ*<C)H[U#[<.((]7N
MH[ED'0V4?X];V&?9=Y(IDZQ%@VJIOJ:*-@6-__ VF8B%Z9YJ6.\!J'_Q=[?C
MJ<\,34$O+/_M[GV?9Y^P(6Y&AT2K(QA7D=TB_L-D60.:DK68627FT"QX\3?'
M+\ >C(GJ%^T47*63=&><QU -FE:\7IAQQ56(22<PY(34%"N&F?7K')H%+_Y.
M^P68@S%1_:+-P:T2_N>YACE3M3Z#4HIE'UI3J%I;<PL;I,-BQ=QZW ]*_XN_
M57\!AF T/+]H*] CND)1@F^3IH4*S#.7,P,@6+ DDS$R.AUG-BSFT#<%\[OG
M^UM9@)&P/)<7@"<G*3[(U)/ EDUAR5!LN]*UND*JE4!4+8NC0KF.]+K6?[-'
M6D4PT$WZR,*=P1GV]GR5B<K%K\S[AP=_ZNRR32J""I1:\HJ"2&Q5)!:V-SIX
M4_TH:'UV:T?:K&L8; XKN!D@<=^ZG+XW4*F46E2[EBZYA9R"#\J4-4AE@R'6
M6>UFYCB->'L:7JB6S!E4+T#GONL^_V&UQM-[96^I1&F"(,BNVE:CREZ=P0"V
M4"Q"II3LS-XR>U#72;OB#^TZ#'SFHE+I>9ZD)\M+KQER8UGD2:XE>9,,D-"%
MQ>,\!)("E))D<R87QIP*.P)%W9[YQ4O6G:EQ,@-]^>7L\^GJ*]%[.O^RR/2P
M5&[N$#8<N-B8B=L_?[VZ6/^^6O]/6K^CO/JX7/P?]G^M%NSA5@'>Q0K&&6+#
M$0*TO-Z4JC>^CE/0,1I)W31F?IDQPVC,/)#RDE5F:TM6Y]N_:K\G3VHD42D4
M8'O"DM*5XTBO%?NTRH7((C1^G%>FP]+93;GFEV8R<^7:'U,ST+B#E60&&;R6
M'#IJ= ),Y$@R6G9[(V$*285:Q,PN)<:H I;SR]Z8>VKV'CB:@7Z-9GV^?=+5
M/[K/MI,0%169%7CK(YAJ$$)U 0**)"EG&?,XV963D=Q- ^>7-C'S<VY0I+UD
ME7S8(?"1)$910,:DFN,M "V;KHQ"5Y2R^)'2&J=P,O^?__Z=[C&Z_[WYT>8G
M39;OJ/ZW]K]_OGMS(_4S9%7[2,M%OOB_\^KL2N9OEOPE?<"_Z.(N?BX63-L]
M=^'LX_*O#2NDVC+B]C__[]^V<']SVT^Y8POZ;8?^6M.R<!2['S!O/O];8[AO
MHVM<23(E#<7%TCI:>(@2$5KF@!"YMJ9QHZ#HB4WMJX@/?/0'9N5/_#O_/E%"
MLO)[!S8E!\;SB9]49#]:YR)"2-*.]#C[U*ZFK=\9"A_W3X[!Y#"8<1_-C'QH
MK4;W-2;;#QG8I#RTM0,8%FVU"$D0>&<U&*,]A"!:DA5Y62H2'UW'9EC>YT]4
M+D_IC_KS%H6\S*N+"UI?O%JRNX5I<<JGUI;GW["NC:*J30"78VA9FA&"0P[@
MM51DB@TBVG%BU-TV/%]SU =5WX62!Y#>#-S0;V3^4BOE]>(+W7#T':ZI.5?+
MS*1N!'J/UEPQ6]O>X(MLN5A60-"5G4HJ#HW4;)K%R$CMO^MIJ]W&A^O(<IP5
M9O]<GM_$ TSH3[2DNEA?W$K:O4>I4X:"H\J4!@NFM# H2(YT6P5M$%I+-S9B
M^^YYVG*L\?$ZJ@SG[PM^:\3]9EE7YV>;C_Z9UK@XW==#?/*C!_8;NY-Q &^2
MD$]@:1@77E0.0TA!D+E"1A>C\L8ACG/I.*(W^<=G:L-FEQ__N;JX>(WGYU_K
ME79<.2 GSMA0@T*H.856\,M^!Y$$Q&I)1V-J#J/0_,S&YNL=]D')??,UI#1F
M<*+>L.G5Y?K3ZGRQ_OKJK\7%"9&-,L0VD,EP.%]5;/6CBAD6;8Q):F7'B40>
MWL^T4!I4Y(_=?>S._UFBZ.=5F_IU0L''FC$#^9S Y.0@8NM!II$/ J?(U9&C
M^WL[FHE1VD/:SP)H!]9/"*'FQYSPENEBO<BWR<!E:SJS)O[??_*_/OT?E^>+
MB[+(35:_4>MK=_7G20Y"Q5(RR& 5&%'HZH&CVA0)B_ YY.=\I[UW,3=<[0*"
MU102F8'UNJ;U]>IRN3[_>D-$BCE[;/U+6XP3/6")NG5.K-'$2GZD[D /;F<F
M=Q=#X&LXML\ .\R3J^?(C2%W-M>:7&'SG2(897C?VCAP0<:*U6 :Z0+WSC:F
MQ<J8WM+NW)X35+:Z4[,KK"+M4<MYCD)$ E1,#85<9+LY)C-.]<Z]C4Q[=.TA
MTL? L0-_IW: >.__D_"<!68_K)30?FL-4>N4--M7F8G 8&:GT D"::HA%*7H
MHCKY-H\L,!/9[R*QU<#LFQH";Y:%ZF*Y6--V\R+)W'HS &;9JHR%@&#:(/14
M9%*MVCV[3K*__\G3G@^#"7TOADTH[8OS]<F[EI.WL7@E:$&)+ AT9IMR1QA!
M.'3>!E6+[#2=B#_UU@G W]VW_G>6G?9I80P787>NS@$*6P3S\8>&6B?YTBHR
M5;$0M4TLRH1>5E=DZ500TAT,4QX#>XCLOM!WX-_$8O^-+=?9Y=GU0>5$=D8'
M4 $Y]'%.00R\<9U"5"V?((E.V6:=!']GZ8E%OXO@5D-P<6KQXU^W-EZ(LHNY
M28G_,"490,L\"#GG*JT-'3MF=!/_[:6G\04&$__.7)Q!/'ASJ?++7WBV6%X_
MPFY3\;4P"1,ZR-57,(+#H: H@>7_A)@L1CU.O=*3VYJV,>1!'F+VEL8,H/7Z
M\KSQ\Q9-+:&>MAD6)R;9)$I*$'V2K9.6:87L["@;YU4[:HT<I^[TZ7W-Y Y]
M?P"L1I/&#+#U75+DXUKY_C+];\KK#RNF>'%^U<6-BH[9%,]N'K:0/'"XQE$Z
MB(JJD#(ZBG$*"?;;]TSNWP?'Y@&E.0/L,I6O>=7%^C9AK\[: \2)E=YF(G8>
M=6V/L"%!2IE]$$N!M);"Y'$*/I[8U$PR  ='W5!RF/K.[G%E^>?B;'$EJ8L_
MEG]>T)8XCF&S4LRO8C&QOJ"&%&,"CUI(JCFS&G6ZT^N[\K2.V_!(&I_]\\76
MJ^7R$D^_D;@E#C-[N4%+4"6R+0Y8(,0J-J-QM:\:(\8]L?7PRM/VBCXXM@9@
M_WRQ]?MJ?7/.?R/Q)+'I9=U@DD0;*B.SAQA,@)1U4"D)YV/9$UL/KSQME^2#
M8VL ]L_ S7HDL?_#)US_Q^KRM+PY^XQY?5.NLBU4.?$U1U)!0DFAMIX#!=#I
M"CH5-"BB#]CI*:2W![;;?J=MDCR><W8 Z<T7HS=L?4M+/&U5?J^6Y<V2UZ6+
M]39P/_'*>*>=@J2HQ>E>L#JJEO^4I3=5^C32=)@]-CUML^*#HW5P.<Z_GJBU
MS5@M6PNC55U_HO8M+K]>?!?AWZI@':;::(^%!ZY%&HH%!ZA4"L864QE[&ME)
M9'-)$%5!$$5YI;UU&=.X]_O#5RI]8_]#M=/7E&-!JXIUH#R?%B;("MBND$*4
M%(12TI5Q7C8Z;6\FE]![(N:[*^C!)3.#([S'W>5UKO%)S3+X&"6XL'DBXB@-
MV[=):)]+3AK-..#;8;/30G$$R.Q^][R3_(X+HIO2BE?;THH3YI]/[/R R+FE
M,K1A-T*R[OMDG) >DQPGDWS7'4_[0#(KL.XNR3DB]L&[^HMW+%_>YZ<3210-
ME0#H+3%Y44%H65S!&M9.EX4/XXS<ZKG1:9]2)L#G@'(['EAN>D.>N,H$>&=!
M5\&TU>HAE1)!*W*V45?,@8SG$[N<]D5F-H#L+[&I+\^?. D(>8%OL>4)8C!4
MF:PJ-'LK4A<(6AHP)M50JT%YOS7#8Z6IG=><]C%F/%B-R?HYVK?KO[B*"$],
M"$:E9(%I8@4I*""Q*PRY<#!H8A9$(U6C/KVQ:=]G)K!B>\AECC"[,K])&EVE
MLB KNP"L+ J05-R,AXU4J\Q5'BC:Z'PTCO:R,D4LT5L*<\32/\XY$F(J@N?S
MNPU';M=47K59R>QBHG=DBY48TSBO> _O9]IWCPFPU%\*NV.I=>L>!TMMY-:5
ME$Y/5_^%RTPGV8>2JR+P&)DDU7H-9,N65U@?4LFFQ'$Z^'78W+3#"B= V9[R
MZ0^Y> 6Y)7W$-0TS8?P[HGZG]8FSM1@9-IT%%7.IZ-:[)("M7HKJI/,X3L>B
MAW8S\2"_"7#55P0SL%V/<.E6,'+#*J786S0V@.+XH]T%!HBN5 @%%:98.3(9
M)_F]^QYGDNA^F/>O?64T+R_L%C5OSU<<&:^_OCW%Y?K5<C/EZ',;^'(27"TY
M4V-;<S(I1G8,LH3*VFI4M,[BZ'=C738ZR\>OO?'RN/D;7'B3'K'W;VMN47?W
MRN9=F_O]1VTIVAO[?^)M%HFP@$.![+CRD8+MX:2$I&I,J&WNEB&_R^JS?,0:
M"G2'D<G</+L[>D6?<5&VV5\<(SFI9&4W-6V&DU)1$&/D&"G*X#AZ8IT:)P6G
MT_9F^6!U* .XNZ!FA;\;=^;VS70N142JEM4GVU;@I#E.R@%\87>7O=TH1XYC
M']K5+%^CQD+;WF+9%V0?QKLXN452BZ5$CL@L(\B-((/"<%P6F%W\;=&U:ED.
M]#Q_=V.S?*8:T;KM+9S! MW1\H_O#AI9U7?T>77.8/_E8KTX:ZB_^=UMDO8P
MV<<[+SMP[O$PY!\@\[B2KHEC9I!H&-'*5< V_25D+[7!U,9H'%OF\;>)-W>D
M\$C+A5?K7XD-#)ZV3*U+_N2O=R;FG%@==1(R05+&M?[%$J)%PV&64>T'QNN1
MN]\/0<9\,YG[(/#1/BT'E_0,+GL>(?Y.PN$MDW3BM!:428%SV%X4;;QZ!3+&
M>(\Y:*?5(8'\V$;G>^DX E0'D=;425!=9HW==G_*_[Z\6&_FJU^7XJ=:A/("
MJL$"AIUO"*$0L.,C9,V>U/T)<H_<\^R[DYGTV!@(>X<7SGS-XDW"X;>LUZ1]
M"LDY<'Z38K&93& JY$PRE=#ZAHT\U?>Y+<ZD4<=A3.&>$IK%7<^SI%TE]VAA
M,*9L(6:?VLRI $%Q'.DS(=6DR81Q4JRZ[6\F/3P.#;O^LIDSYC;4W/S5\N-5
M=;53M4W.8#V2[=W4.@]88P2=-[,_G=%RY-'M'78YDSX?A\'?_G*:[Z'[^ZI=
M7URR^Y%.:1N,O?_$4O@)+ZBTBS?^F\UOOEY=K$^<8UYF%:#4V&Y=I8"$.D!.
M.5=M!*8TSOWD(-N?20N0PZ!V1,G.%\ZO/[4VQ6^671+@7&:W.R:&FJB*%9A=
MET150W$^:.4<_W?DDOZ=]SZ3[B"' ?)8,IT3BN_UF-4JQZJCXUC.Y];X#H'5
M, .[VL4D)LVKD><P[M#J=[1\V='QM@?WC^^=AYV9G^CC8KED3P:7Y9=EX2^N
M+A)6=9.-_DB/GG'>?_;>SLCO0L.RZP#O19ILUE9'B $KF&!8&53(P,>ZT(HC
M))='OD0>_KWHGC_^V"CZ7_[*IY??Y'/QELY9!DURK0MRZV2U^?5WM+X\7]X>
M7,]F)*%HB2I6M*==/D4@&.\@NU1L%;&0'2?<'YNR^;XJ]<'I?<L]*SS,P(]X
MA'XFHSAGK0+)K.:3S!2(T17(42H^)LDH&N?^])$-38O&>:&F6V.\7B+<&8F?
M-Q/>WJ_Q?#URM\;SEK':KH\O3UL"ZZ\LI.V\A:LI<_S;;U<7BTTKZ!.'(25K
M"S@AF/;$K PI,MZBREJ'I((:Y[9AF/U/^TQZC&@?$R!3/\$^0_+/=/6_=RA_
MRQ2?/T!WM&WZHDZM935'/6T44PCH6!(1H_-$*?GG?/*A-S7MP^PLT3ZIW&?L
MEJ!23DM%(%E%66V=AY0XRHXR>B'11>O'\;;W<4M&>\2=)72'%.&>;@F'W*/=
MD[QF-F%:78W'X?!^\]3SZN,YT2:_8I>[CN<^<HC[BE[;WO/.86/$[BS8DJ$6
MN=V8?5OR)JQ+OI3:,E!LI 3MW0!2M);#.AVS"N38:'4ZFCHON=>I_.PJWR+7
M#\S(G_@?_OO$>6-1$P+[Y8%#5VL G>=O6R^9&ERQOMN8[UU6GR:&&A$%=T[+
MT>4QT\;@SV@T>PM?U_1Z=?YY^RM[7,;NNM0!#%<W,@]KT(+) EM#%NTW4VJC
MAB!M@*+1DXW:6V7F8="NS^SW^1.5RU/ZH]Y:\@N].C]O#VE72RW+[^QT//+C
M#_S5!6^D^9Q7HSI1"!]"L2!J;N]JP4*LRK$^1\*LHY%QG#[,P]-R%/:S#^CN
MNVP3BW_B2<UOSU<MZ>&/\_=T_H7YNQE6CLE(1,J0M#)\0&@)6(.!Z()S1=NB
M:Z>G_DX#FQ_:P;07GU,C8C6@>.8!K\:O+06MV3G'82=**E5R<E!<92?$M$'&
M0MLV&B5Z5F,.PCJU?.R#L>^W,=U\^/TE^SU,]F3SU%=^[^@++2_IHEWI?&?K
MMU/0JXG990ZDL^:0W+20.G@44%WPTBKIG>PVJJW#8I.#8U]YKD9D[L2&Y5VS
MM1N=D=Z;D)@%_ N1=:86B"V;248A5,2<4[<$X$Z&Y&;9:1\K9G1"[2:(.:!G
M"WI4LE1*K$*N#7FFDB&P*H%U&C5[CSZE3@7#W?$SM779463WA;X#_R86^V^+
MY>+L\NQZX]:I9*H#3ZWW@0D%4A06JJE&5PI.U^$$?V?IB46_B^!60W!Q:O'C
M7[<V;D2I*F0^W:@P^<H:WK@1D)6C%-!6K8<+<NXL/<W9,9CX=^;B#)[8K@OQ
M^'3\F1VBT]6F\]RM@_'U:KFY4OBP>DOG=75^]NOJ?'/K=O'3UP^\R,9L,K*Q
M,-W,*\-.6#'LA)&LD*S-(>H451FG@\(@VY_VY7DFKLMT@#AN+6@D;T,1DLG'
MR!RWQ3+1)!5@(59]1*S5QBK5.)V^!MG^U+EU!X?=<,#?$0-37R]<O9;\]H]7
M0JJ;T'=[C*6H@W!)@(_>-SK8)2Y\+"9KM-$I>(/=^G(^L<C1(FY7>:]&8/X\
M0/1Z=79&YWF!I^\O/W\^_?H=1;YDI=@I=C$E,-&W\3S&0"TR$Y$VXGY^_)-P
M>F:YJ1,G9P"L(04R$XCQSQ;Y,7K(.LRU#?/6?#X:;P5@S1X2,<.2+0GO7WH]
M#;"G%ILZ4W$.\!I,&!.'P*];+AR=,^O77W_'LRLW(E15/?L,4%"P_6TM&Q-J
M \%2]J78Z+H-A>@4"3^T@VD3"F<2D0PBGJGO5>GS)>LJWGI;N$_25B&%ULD4
M/NYUQ#;!AY@>4PO4C+JB$5YT:]/8[=:UZ[:FNYC;7_*KL<4PDW/Q6[;3UOP&
M+W76/H'$UM\FR\PTH /A/+$:\M$N8B]GZ]X"$][6CB/'A]RG?9@Z@QN- 2SW
M/Q=+NFI54RBAL;DP1"*VJ8<., 8$Q7%*S,*4Y,:91CDD%=.VO)K)F3HY/*:V
MF4S<.ZJ7R])8^.=G%M1R_2O1Q0D%22D$#:A;S%UD@"0I0[0F%J-D5*[;A<=C
M*TP]X68J@:^&YO[4$'J[6C-G.+*^%7[ALKRCCY>G[=]]_6UQ2A?KU9+>XM<-
MC_]<EEM9RB<&4XJI9/#":HZ]V9\),196X21]KJUT/76"VKX[F7K^S1P@>5!I
MS@:ZWZZ'GB//,S]]=AJ2J:R9OA@^95)KF2V9YT4[HWJ"M?/:4X_$F14\QY'8
MU("\?8/50^G>W=04GFR20&VIX"PSU:#ED-"D# J%<R(99/>\$S[WWLK4,W7F
M -?#RG-J]+X]7V6B<M&D\6[U%4\WTZQ82YL:6@Q*)"\A!8>MLW& H)F0Z"N&
M:%P(OEN-_5.K3#U79PZ8&TP*4\/I+CNO=>,6M]Z>+S*=))4-DI;L8=0-H]A7
M+B(W(Y^%LCG;T"U2Z;;>M*UZYP&Q$20S-=BVZ>^_M:81GT_I9SIETLY;7':;
MRS\3+W>V6&Y;"[RG4_ZPCQMJM[,#O*A)2)DA.=&&]4G74N0MI"RE55%A"MBG
M_F#?#4W;HW<><)U"MC.X\[RNZ#@)+0H340)YXD#,N0P!180@M1.:L,0\5C>^
MJQU,VU]W<A#N)9#C++#_7[C@I<>KJK_[^0<HI7^"H,/6SV/-2?A@P7EIP:C"
M %1$X#%K4[Q0)+NE#AUS_;Q%'U5B+0RJM2G.2;9+)F0F>*FM0&G<.)WL_J;U
M\WU =X#Z^3[BG\5!/$0R+^:DI0H>O"BM!PPIB"9;4*2B=#&68,9I1'RXHH)C
MJMCOA<%1B@KZ .*XM>!6HE[R3OJD'=3:$C5UJX57J-@)0R&2(9]HG+?W'T4%
MN\!NE**"/AB8^E[ARF^\>.ZHO:Z6"SFF5B.'67FF3 G 4#FZ2"24U2BSSIV<
MNU[+'BTJ=\7$ZB ".A;HX?E'6E_^M3C#M*72^TK*%PFVM Z7H62(.@:(*5=G
MG=:I=+O$VGD++Z%D871([B>X(X'GAW=O?O[E]P^_\<J9/;CK3B0:K3%*@Z5$
MK5^J@4 8@5@C8]+*"].MS<L^NW@)A0]C@W1_\<T#IX]4>%QWQD&J2A0A0(C6
MH+,D#\$)!2)K%5PUT=RO=7T2CT^O-G5_Y1G@;D!QS 1?W?P/WGL(PE0PL1;^
M S4@LB\>I>?_8BBE='OL[+/JM*_J\\#;\.*9&G>OE)"A%W6D3::@'*0<)%MM
M3!!\3!!#L396LJG43N#KO?2TC^X3(W!<0<T ADI>4?>=&1=.1!D-;SS6-M/*
M*W83C  9HLV)?'8B= 7<8XM,^T ^/;0&8?X<JU:+UE+64D"*S#YF) E!H(>J
M8\PZ60[8AVL@NG/5ZC&U -SERGL0\1Q-U2KO316I VCA(ACC$4(H'DAZK;&8
M;%P<#'/'6K7:2_([5:WV$</4Y]\VCMX:7>F2T-8GJ&8S*[<-7-;9@Z+D5?3:
M8.YU\W8\%:J]9/; 1<0.#)R'Z*\WKCR?JNRDE>A9*TRTD$0Q0$5A%2H2WB]X
M?U+RDW<2/)3@=V#?U,?)37O5I BU$@0628&IH0 &R;!M]=0B"U]2I\2\$5H3
M'U-_OUW]DMT$,0?T7%]S"<IHM $?2YM?IS)O.Q50EN5O975NP#D,,VM-W$MD
MC[4F[L&_6?6FK4$8:Z*'Z$.+S:QL]<&!S[N$)A:VFF8XP]&_-^WXK8G[".[1
MWK1]N#B#!)KWS.>-!?SE/R\7ZZ^O5V>?5\N-O=ST>A1)Q=),GVYECJDX2,H'
MH*R<*]G%W*W-??^4R*>V]>(Z-^V3]C6< &> QGLT;)TY'4EK$144K9HMU@Y0
M9,7:F9-A2EHOCE%0^.!V)DXZ'$[<JZ%Y/P, O2IE,X873]_BHKQ9OL;/BS6>
M;FVS+N0-8N6H@ VT<2&W7AAMZ(A'2ZWQU?VF30,!Z<EM30NH <2^&DL&,P#4
M^\MT0?]YV13N2[/=-UV0"SIG=82L.+8T0G)HZ)P$&=$9*[6H:9QN[(]LZ,5U
M7MKK3!Q ://$WE8]J[&6F#N,C];\D_^$@)MW816T3RJ1[12C#8&^69R*0PC\
M>1#MP/WYP>@ZJ\"''(TJP$;7,!&%0UV;$X0DO$C&*Z/'::3_X'9F!Y]=1/TT
M@';@^PS ,VB=JT@Y!ZT2J-2\"J4TNZ>! V0,0J'+Y.PXA^;!>QR.EC8RLY-V
M,GA,_<SR:)>]8I@,J3Q4T68393* R;#[G)S/P7A-U.W)Y6_0X["7P#OU..S#
M_1E Z/PA(GZG]1_U _[U'XOUIT^KT[)8?CR1R1A?-9]#==,9UPE(05MFG,FY
M6EF+[E:@W6/1%]2Y<!^@C2*C66%OVR_L'CD40G#.1!#!LN_L'?LH5A:(BO]T
MJHU][=RL]9FU7E 3PF&0MK]$I@;8 "T_-=F@"'QN5YF%_>1(3+&E3#'YB)0Z
MMG8[1 /7XV@YN#,X#RK-&40]-TUU4$2KK/905([,,6$X_C,9$FF=V&>.VH[S
M]-"KR]%Q-!_<!7U["61J&_@+J\SZE,ISRJ$T^J(M^PRFLM,JH^-0+%:0PC@=
M)#NNKMM<I8X+OJ!N@SM;M#%D,S7>KI7DGMO@18M]"D))TK=AR0E2R[ZWRDM3
M@R^8NW67?OCS7U SP)W1- #GIP;/DQU>#:/<88I,")_<1K2!RU4&B$XKA2+G
MV+6;_KY]=H^CH=_NCM904I@:3M<:\5"@7 B1(F:0V5@P(2= PRX0"BV"4T[E
M^Y.LGS%(NUY>Q)<-IJ%D, .'_+IBK9'P^I(/[#,Z_^<"T^)TL?YZHBR%#4N,
M9)TPBC*@] B(DLEAUIG[C1L&>U=X8EO=+FK%B\7@\+*;VJC]<K%>G.&:./!=
MG*5+_LS&L5]7YP]77'XXD2@IAL@<*VU2)P<GD&2-$)(/4J78GONZ>?8]5^Z&
MO1?^2C"JN*;&XA^?UV^6OQ*=1#[Z8WNYLU0<&&868' 1(MJ,.9+WM=M%V?4G
M=L/."[_XWXF]4V/B[3F=+2[/WE$F9D[Y8_E^O<K_?KNMF3JIE*/,S@$[D97]
MQUQ;#PD+@H1@A/O \._HQ3^U3C?\O/#K_ %%,3FJ^H]'JL8(1*O ZLB&E,D!
MYF+EZ'<SG#JW%)A^E_?##K22?Y?[^G%$-C4B.XX*P51L1$WL4'+0;+(M$"J[
MEJ1*%IZ,%+%;:YD!A[C(EWM7/Y9HCG-8P?]@BGF9\:85W%O@ .,*GB)ISWD%
MUR#^P)_S$__%OV^ZQ!N=$+71P,$@@D&A()CD(1;=!O!AP-QI9GOOV/Z[K<QP
M9$&IQ>@V;XM<8XY'WR9O82O8" ZMT[Z$49CS4D86#(.[ TPGZ"/I.39.4BX(
M(:N#2,J <4I S)*C*NTK,[1F>7^$Y!2-DXYI5D O1#S7.*F/>*;N5="Y"8BT
M"LFC!'9K:^NK'5LIMN+0'4EI6Z,MPV'N6!LG]9+\3HV3^HAAZLABZ^+\M.
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MPW 2FL4\3L/3T6443L/AGL!O!X.+C^-H-#Z%D]'T_+&!/E%85Q1BP94M!RU
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M*Z)RO+D.U!5G.:A]0 6R4<TN7>.H:*W29IGT_0.8S'-A+='?9(58H:QP[:F
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M,C,Q+FAT;5!+ 0(4 Q0    ( +2 6%08T@E$8!0  *;6   1
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M &UG;G@M,C R,3$R,S%?9S(N:G!G4$L! A0#%     @ M(!85#)>^'*=U@$
M'.0! !0              ( !$:42 &UG;G@M,C R,3$R,S%?9S,N:G!G4$L!
M A0#%     @ M(!85)_;,DT3=@$ LH ! !0              ( !X'L4 &UG
M;G@M,C R,3$R,S%?9S0N:G!G4$L! A0#%     @ M(!85'O6/#IU0@  P%\
M !0              ( !)?(5 &UG;G@M,C R,3$R,S%?9S4N:G!G4$L! A0#
M%     @ M(!85!I(_[A8J $ VQL" !0              ( !S#06 &UG;G@M
M,C R,3$R,S%?9S8N:G!G4$L! A0#%     @ M(!85,5(,@.F]   35H* !4
M             ( !5MT7 &UG;G@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( +2 6%1N#C:H>ID   XI!P 5              "  2_2& !M9VYX+3(P
M,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " "T@%A4DX-/[0L$   A$0  &P
M            @ '<:QD ;6=N>&5X:&EB:70R,RTQ,C R,3$P>&LN:'1M4$L!
M A0#%     @ M(!85(VL'P?Q!P  ]"4  !L              ( !(' 9 &UG
M;GAE>&AI8FET,S$M,3(P,C$Q,'AK+FAT;5!+ 0(4 Q0    ( +2 6%0M=?>E
MW@<  /(E   ;              "  4IX&0!M9VYX97AH:6)I=#,Q+3(R,#(Q
M,3!X:RYH=&U02P$"% ,4    " "T@%A4)23(+_ #  "N#   &P
M    @ %A@!D ;6=N>&5X:&EB:70S,BTQ,C R,3$P>&LN:'1M4$L! A0#%
M  @ M(!85/);#U[Y P  )@T  !L              ( !BH09 &UG;GAE>&AI
I8FET,S(M,C(P,C$Q,'AK+FAT;5!+!08     $0 1 (,$  "\B!D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
